Susan Beggs, RN, MSN
Associate Professor, Nursing Faculty
Austin Community College
Austin, Texas

MaryAnn Cosgarea, RN, BSN, BA
Nurse Administrator, Practical Nursing
Health Coordinator, Adult Education
Portage Lakes Career Center
W. Howard Nicol School of Practical Nursing
Green, Ohio

Nancy T. Hatfield, RN, BSN, MA
Director/Department Chairperson
Health Occupations/Practical Nursing
Albuquerque Public Schools
Career Enrichment Center
Albuquerque, New Mexico

Debra Menshouse, RN, BSN
Nursing Faculty
Ashland Technical College
Ashland, Kentucky

Esther Salinas, RN, MSN, MS Ed
Associate Professor, Nursing
Vocational Nursing and Registered Nursing Departments
Del Mar College
Corpus Christi, Texas

Julie A. Slack, RN, MSN
Nursing Faculty
Mohave Community College
Colorado City, Arizona

Bonnie J. Smith, RN, BSN
Coordinator, Practical Nurse Program
Sikeston Public Schools—Health Occupations
Hayti, Missouri

Ginger White, RN, ADN
Instructor, Vocational Nursing Program
Wharton County Junior College
Wharton, Texas
The seventh edition of Introductory Clinical Pharmacology reflects the ever-changing science of pharmacology and the nurse’s responsibilities in administering pharmacologic agents. All information has been updated and revised according to the latest available information to prepare nurses to meet the challenges of safely administering medications. The text prepares the nurse to meet the challenges of the 21st century by promoting critical thinking and problem solving when administering medications.

**PURPOSE**

This text is designed to provide students with a clear, concise introduction to pharmacology. The basic explanations presented in this text are not intended to suggest that pharmacology is an easy subject. Drug therapy is one of the most important and complicated treatment modalities in modern health care. Because of its importance and complexity and the frequent additions and changes in the field of pharmacology, it is imperative that health care professionals constantly review and update their knowledge.

**CURRENT DRUG INFORMATION**

The student and practitioner should remember that information about drugs, such as dosages and new forms, is constantly changing. Likewise, there may be new drugs on the market that were not approved by the Federal Drug Administration (FDA) at the time of publication of this text. The reader may find that certain drugs or drug dosages available when this textbook was published may no longer be available. For the most current drug information and dosages, the practitioner is advised to consult references such as the most current Physician’s Desk Reference or Facts and Comparison and the package inserts that accompany most drugs. If reliable references are not available, the hospital pharmacist or physician should be contacted for information concerning a specific drug, including dosage, adverse reactions, contraindications, precautions, interactions, or administration.

**SPECIAL FEATURES**

A number of features have proven useful for students in their study of basic pharmacology. The following features appear in the seventh edition:

- **Key Terms**—lists the important words defined in the chapter
- **Nursing Process**—used as a framework in most chapters for presenting care of the patient as it relates to the drug and the drug regimen. Preadministration and Ongoing Assessments are included in the assessment phase of the nursing process. These assessments are divided in order to highlight the important assessments to perform before administering a specific drug and those important during the entire time the drug is being administering. In the implementation phase of the nursing process, most chapters contain sections Promoting an Optimal Response to Therapy and Monitoring and Managing Adverse Reactions. These sections provide invaluable information needed to ensure that the drug is properly administered and nursing interventions to use when certain adverse reactions occur.
- **Nursing Alerts**—short segments that identify urgent nursing considerations in the management of the patient receiving a specific drug or drug category
- **Gerontologic Alerts**—short segments to alert the nurse about specific problems for which the older adult is at increased risk. As the number of the older adults in our society increases, it becomes imperative that nurses recognize the necessity of specialized care.
- **Contraindications, Precautions, and Interactions**—of the most commonly used drugs in the category under discussion. While space prevents every contraindication, precaution, and interaction to be listed, the more common ones are included in the text. Pregnancy categories are identified for many drugs discussed within the chapter.
- **Home Health Care Checklists**—highlight specific issues that the patient or family may
Preface

encounter while undergoing drug therapy in the home setting. As more and more patients are cared for outside the hospital, it becomes increasingly important for the nurse to know what information the patient or family needs to obtain an optimal response the drug regimen.

- **Patient and Family Teaching Checklists**—highlight teaching points relating to specific pharmacologic techniques and most-know information for the patient undergoing drug therapy. This empowers the family to participate knowledgeably and accurately in the patient’s drug regimen.

- **Summary Drug Tables**—contain commonly used drugs representative of the class of drugs discussed in the chapter. Important drug information is provided, including the generic name, pronunciation guide for generic names, trade names, adverse reactions, and dosage ranges. In these tables, generic names are followed by trade names; when a drug is available under several trade names, several of the available trade names are given. The more common or serious adverse reactions associated with the drug are listed in the table’s adverse reaction section. It should be noted that any patient may exhibit adverse reactions not listed in this text. Because of this possibility, the nurse, when administering any drug, should consider any sign or symptom as a possible adverse reaction until the cause of the problem is determined by the primary health care provider.

  The adverse reactions are followed by the dose ranges for the drug. In most cases, the adult dose ranges are given in these tables because space does not permit the inclusion of all possible dosages for various types of disorders. Likewise, space limitation does not permit an inclusion of pediatric dose ranges due to the complexity of determining the pediatric dose of many drugs. Many drugs given to children are determined on the basis of body weight or body surface area and have a variety of dosage scheduling. When drugs are given to the pediatric patient, the practitioner is encouraged to consult references that give complete and extensive pediatric dosages.

- **Critical Thinking Exercises**—realistic patient care situations that help the student apply the material contained in the chapter by exploring options and making clinical judgments related to the administration of drugs

- **Abbreviations**—important pharmacologic and general medical abbreviations the nurse needs to know when caring for the patient undergoing drug therapy are spelled out in the back of the text.

- **Glossary**—key terms and other drug-related terms are listed and defined in the back of the text.

NEW FEATURES

- **Four-Color Illustrations**—the text is beautifully illustrated throughout with new four-color illustrations. Each illustration highlights and explains an important pharmacologic concept, technique, or idea.

- **New Chapters**—new chapters are included, such as Chapter 33, Cholinesterase Inhibitors, and Chapter 18, Nonsteroidal Anti-Inflammatory Drugs. Several of the chapters in previous editions have been divided. For example, the chapter on antiviral and antifungal drugs was divided into two chapters: Chapter 14, Antiviral Drugs, and Chapter 15, Antifungal Drugs.

- **Drug Lists**—replacing the chapter outline is a listing of the classifications and drugs discussed in the chapter. This new format allows the student to quickly identify the important drugs discussed in the chapter.

- **Herbal or Health Supplement Alerts**—provide important information on common herbs and supplements not regulated under the auspices of the Federal Drug Administration. Appendix B gives a listing of select herbs with examples of their common and scientific name(s). While not all of the common or scientific names are given, the more common names (both common and scientific) are included. With more and more individuals using herbs as part of their health care regimen, it is critical that the nurse be aware of the more common herbs currently in use. The nurse must consult appropriate sources when patients indicate they are using herbs as part of their health care regimen.

- **Review Questions**—several questions, reviewing important information covered in the chapter, can be found at the end of each chapter. The questions are written in PN-NCLEX format and provide the student an opportunity to answer questions specifically about the drugs covered in the chapter. Space does not permit more questions of this type, but provides the student practice in answering questions concerning medication therapy and administration of drugs.

- **Medication Dosage Problems**—Calculation of medication dosage is an important aspect of medication administration. Chapter 3 reviews the mathematics involved in dosage calculation and formulas used in the calculate medication dosages. To ensure the student’s understanding and application of this type of problem, two or more medication dosage problems are included at the end of most chapters dealing with specific medications discussed in the chapter. This provides
the student an opportunity for immediate application in medication administration. As an added benefit, several current medication labels are used throughout the text to help the student learn to read these labels and solve medication dosage problems using the information found on these labels.

- Drug and Health Care Information Sources on the World Wide Web—The inside back cover provides a listing of websites dealing with pharmacology and medication administration. The student can use these sites as valuable resources to identify new drugs and important new information on current drugs.

**Organization**

The text contains 58 chapters, which are divided into 11 units. Organization of the text in this manner allows the student to move about the text when these general areas are covered in the curriculum. While pharmacologic agents are presented in specific units, a disease may be treated with more than one type of drug, which may require consulting one or more units.

**Unit I** presents a foundation for the study of pharmacology and covers general principles of pharmacology, the administration of drugs, a review of arithmetic and calculation of drug dosages, a discussion of the nursing process as applicable to pharmacology, and a review of the teaching learning process and general nursing process as applicable to pharmacology, and covers general principles of pharmacology, the administration of drugs, a review of arithmetic and calculation of drug dosages, a discussion of the nursing process as applicable to pharmacology, and a review of the teaching learning process and general areas of consideration when educating the patient and family.

**Unit II** contains 11 chapters that present the anti-infective drugs, grouped according to classification. These shorter chapters allow for more inclusive coverage of the different types of anti-infectives and the appropriate nursing considerations for each classification.

**Unit III** includes four chapters covering the various types of drugs used to manage pain: the nonnarcotic analgesics (Salicylates, Nonsalicylates, and Nondiagnostic Anti-Inflammatory Drugs), the narcotic analgesics, and the narcotic antagonists.

**Unit IV** has been expanded to 15 chapters covering the many classifications of drugs that affect the nervous system and the neuromuscular system. These chapters include the following types of drugs: drugs that affect the musculoskeletal system, adrenergic drugs, adrenergic blocking drugs, cholinergic drugs, cholinergic blocking drugs, sedatives and hypnotics, central nervous system stimulants, anticonvulsants, antiparkinsonism drugs, antianxiety drugs, antidepressant drugs, antipsychotic drugs, cholinesterase inhibitors, antiemetic and antiinertive drugs, and anesthetic drugs.

**Unit V** has three chapters concerning drugs that affect the respiratory system. The first chapter in this unit discusses antihistamines and decongestants, the second chapter in the unit covers bronchodilators and antiasthma drugs, and the last chapter of the unit deals with antitussives, mucolytics, and expectorants.

**Unit VI** covers drugs that affect the cardiovascular system. This unit is divided into five chapters: cardioselective and miscellaneous inotropic drugs, antiarhythmic drugs, antianginal and peripheral dilating drugs, antihypertensives, and antihyperlipidemics.

**Unit VII** consists of two chapters dealing with drugs that affect the hematological system: anticoagulants and thrombolytic drugs, and agents used in the treatment of anemia.

**Unit VIII** has been expanded to cover drugs that affect both the gastrointestinal and urinary systems. The unit consists of three chapters: uretics, urinary anti-infectives and miscellaneous urinary drugs, and drugs that affect the gastrointestinal system.

**Unit IX** discusses drugs that affect the endocrine system and consists of five chapters: antidiabetic drugs, pituitary and andrenocortical hormones, thyroid and antithyroid drugs, male and female hormones, and drugs acting on the uterus.

**Unit X** discusses drugs that affect the immune system. The unit consists of two chapters: immunologic agents and antineoplastic drugs.

**Unit XI** consists of three chapters that discusses types of drugs not previously discussed or that are not members of a particular class or group. Chapters in this unit include topical drugs used in the treatment of skin disorders, otic and ophthalmic preparations, and fluids and electrolytes.

**Chapter Content**

Each chapter opens with learning objectives and a listing of key terms used and defined in the chapter. Less commonly used medical terms are also defined within the chapter and may be found in the Glossary. Chapters 1 to 5 provide introductory information concerning general principals of pharmacology, medication administration, a review of arithmetic and calculation of drug dosages, the nursing process, and patient and family teaching. Each chapter ends with critical thinking questions and several chapter review questions.

The remaining chapters discuss specific drug classifications and contain a common format. In addition to the learning objectives and key terms, the remaining chapters contain a table indicating the drug classifications and drugs discussed in the chapter. The body of each chapter contains the actions, uses, adverse reactions, contraindications, precautions and interactions of
the class or type of drug being discussed, followed by a section devoted to the nursing process. These chapters end with critical thinking questions, several chapter review questions, and two or more medication dosage problems. To promote easy retrieval of information, each area is identified by a large type heading.

- Actions—a basic explanation of how the drug accomplishes its intended activity
- Uses—the more common uses of the drug class or type are provided. No unlabeled or experimental uses of drugs are given in the text (unless specifically identified as an unlabeled use) because these uses are not approved by the FDA. Students should be reminded that, under certain circumstances, some physicians may prescribe drugs for a condition not approved by the FDA or may prescribe an experimental drug.

When discussing the use of antibiotics, this text does not list specific microorganisms. Microorganisms can become resistant to antibiotic drugs very rapidly. Because of this, the author feels that listing specific microorganisms or types of infections for an antibiotic may be misleading to the user of the text. Instead, when antibiotics are needed, the author recommends consulting culture and sensitivity studies to indicate which antibiotic has the most potential for controlling the infection.

- Adverse Reactions—the most common adverse drug reactions are listed under this heading
- Contraindications—contraindications for administration of the drug or drugs discussed in the chapter
- Precautions—precautions to take before, during, or after administration
- Interactions—more common interactions between the drug(s) discussed in the chapter and other drugs
- Nursing Process—with a few exceptions, the nursing process is used in every chapter of the test and geared specifically to the administration of the drugs discussed in the chapter. The assessment phase is divided into two distinct parts to include a preadministration and ongoing assessment. This assists the reader in determining what assessments to perform before administration of specific drugs of drug categories and what important assessments to perform during the entire time the drug is administered. Nursing diagnoses related to the administration of the drug are highlighted in a nursing diagnoses checklist. Under “Implementation,” three sections are included when applicable: “Promoting an Optimal Response to Therapy,” “Monitoring and Managing Adverse Reactions,” and “Educating the Patient and Family.”

- Critical Thinking Questions—each chapter includes critical thinking questions that provide the student with the challenge of applying chapter content to specific clinical situations
- Review Questions—several PN-NCLEX review questions are found at the end of each chapter
- Medication Dosage Problems—when applicable, the chapter contains real medication dosage prescriptions and the medication available for dispensing. The student solves medication dosage problems using the information provided. Several current medication labels are used to help the student learn to read these labels and solve medication dosage problems using the information found on these labels.

APPENDICES

Seven appendices containing important pharmacologic information are located at the back of the text.

- Appendix A contains a MedWatch form, which is used by health care professionals for voluntary reporting of adverse reactions and problems with the drug product. It also contains advice about voluntary reporting. This form is a part of the FDA medical products reporting program.
- Appendix B is a table of Select Herbs and Natural Products Used for Medicinal Purposes.
- Appendix C contains a United States Pharmacopeia (USP) medication errors reporting program form, which is used by health care professionals for sharing information of medication errors to prevent them from occurring again. Also included is text explaining medication error and the USP.
- Appendix D provides metric–apothecary equivalents and conversions. This guide covers liquid measurements; weights; Celsius and Fahrenheit temperatures; and a comparative scale of measures, weights, and temperatures.
- Appendix E contains two body surface area nomograms—one for infants and young children and one for older children and adults.
- Appendix F is a Vaccine Adverse Event Reporting Form.
- Appendix G contains answers to the review and dosage calculation exercises appearing at the end of the chapters.
- Appendix H lists examples of combination drugs.

TEACHING/ LEARNING PACKAGE

- Student Study Guide—the Student Study Guide to Accompany Introductory Clinical Pharmacology, 7th Edition, correlates with the textbook chapter
by chapter. For each chapter in the textbook, the Study Guide contains a corresponding chapter and includes three or more of the following components: a crossword puzzle featuring important terms of the chapter, multiple-choice questions, short-answer questions, word search puzzles, and critical thinking exercises derived from the textbook. Multiple-choice question have been written using the same format as currently used in the NCLEX-PN examinations. The Study Guide also features activities designed around specific drug-related websites. These activities promote use of the World Wide Web as an important learning tool in the study and practice of nursing pharmacology.

• Instructor’s Manual—the Instructor’s Manual to Accompany Introductory Clinical Pharmacology, 7th Edition, contains a variety of testing items as well as tips for classroom teaching. Multiple-choice questions and critical thinking exercises are provided. Answers are given for the multiple-choice questions. No answers are supplied for the critical thinking exercises, to encourage the students to use their creative abilities rather than be confined to a predetermined answer. Also included is a computer disk contain PN-NCLEX-style test items in multiple-choice format.

ACKNOWLEDGMENTS

I wish to thank everyone involved in the creation of this 7th Edition of Introductory Clinical Pharmacology. A special thanks to Lisa Stead, Acquisitions Editor, for her guidance and support during the preparation of the manuscript. My heartfelt gratitude goes to Joe Morita, Managing Editor, for his support and editorial assistance with manuscript preparation and development. His input was invaluable. A special thank-you to Brenda Shaffer, RPh, for her assistance with the Summary Drug Tables and to Tom Robinson for his assistance in obtaining drug labels. My gratitude to all those who worked in any way in the design, production, and preparation of this book: Debra Schiff, Senior Production Editor; Helen Ewan, Senior Production Manager; and Brett MacNaughton, Art Director.

Although not a part of the professional development of this textbook, I wish to express my love and gratitude to those who made my contribution to this book possible, my family. Their unwavering support and encouragement saw me through many difficult days, nights, and weekends of manuscript preparation.

Sally Roach, MSN, RN, CHN
# Contents

## UNIT I  FOUNDATIONS OF CLINICAL PHARMACOLOGY  
1 General Principles of Pharmacology  
2 The Administration of Drugs  
3 Review of Arithmetic and Calculation of Drug Dosages  
4 The Nursing Process  
5 Patient and Family Teaching  

## UNIT II  ANTI-INFECTIVES  
6 Sulfonamides  
7 Penicillins  
8 Cephalosporins and Related Antibiotics  
9 Tetracyclines, Macrolides, and Lincosamides  
10 Fluoroquinolones and Aminoglycosides  
11 Miscellaneous Anti-infectives  
12 Antitubercular Drugs  
13 Leprostatic Drugs  
14 Antiviral Drugs  
15 Antifungal Drugs  
16 Antiparasitic Drugs  

## UNIT III  DRUGS USED TO MANAGE PAIN  
17 Nonnarcotic Analgesics: Salicylates and Nonsalicylates  
18 Nonnarcotic Analgesics: Nonsteroidal Anti-inflammatory Drugs  
19 Narcotic Analgesics  
20 Narcotic Antagonists  

## UNIT IV  DRUGS THAT AFFECT THE NEUROMUSCULAR SYSTEM  
21 Drugs That Affect the Musculoskeletal System  
22 Adrenergic Drugs  
23 Adrenergic Blocking Drugs  
24 Cholinergic Drugs  
25 Cholinergic Blocking Drugs  
26 Sedatives and Hypnotics  
27 Central Nervous System Stimulants  
28 Anticonvulsants  
29 Antiparkinsonism Drugs  
30 Antianxiety Drugs  
31 Antidepressant Drugs  
32 Antipsychotic Drugs  
33 Cholinesterase Inhibitors  
34 Antiemetic and Antivertigo Drugs  
35 Anesthetic Drugs  

## UNIT V  DRUGS THAT AFFECT THE RESPIRATORY SYSTEM  
36 Antihistamines and Decongestants  
37 Bronchodilators and Antiasthma Drugs  
38 Antitussives, Mucolytics, Expectorants  

## UNIT VI  DRUGS THAT AFFECT THE CARDIOVASCULAR SYSTEM  
39 Cardiotonics and Miscellaneous Inotropic Drugs  
40 Antiarrhythmic Drugs  
41 Antianginal and Peripheral Dilating Drugs  
42 Antihypertensives  
43 Antihyperlipidemic Drugs
UNIT VII  DRUGS THAT AFFECT THE HEMATOLOGICAL SYSTEM  417
44 Anticoagulant and Thrombolytic Drugs  417
45 Agents Used in the Treatment of Anemia  433

UNIT VIII  DRUGS THAT AFFECT THE GASTROINTESTINAL AND URINARY SYSTEMS  443
46 Diuretics  443
47 Urinary Anti-infectives and Miscellaneous Urinary Drugs  456
48 Drugs That Affect the Gastrointestinal System  466

UNIT IX  DRUGS THAT AFFECT THE ENDOCRINE SYSTEM  487
49 Antidiabetic Drugs  487
50 Pituitary and Adrenocortical Hormones  510
51 Thyroid and Antithyroid Drugs  530
52 Male and Female Hormones  538
53 Drugs Acting on the Uterus  559

UNIT X  DRUGS THAT AFFECT THE IMMUNE SYSTEM  567
54 Immunologic Agents  567
55 Antineoplastic Drugs  583

UNIT XI  DRUGS THAT AFFECT OTHER BODY SYSTEMS  603
56 Topical Drugs Used in the Treatment of Skin Disorders  603
57 Otic and Ophthalmic Preparations  616
58 Fluids and Electrolytes  633
Abbreviations  647
Glossary  651
Appendices:
A: MedWatch  657
B: Select Herbs and Natural Products Used for Medicinal Purposes  659
C: USP Medication Errors Reporting Program  662
D: Metric–Apothecary Equivalents and Conversions  664
E: Body Surface Area Nomograms  667
F: Vaccine Adverse Event Reporting System  669
G: Multiple Choice Answers  671
H: Combination Drugs  679
Index  685
General Principles of Pharmacology

**Key Terms**

<table>
<thead>
<tr>
<th>Term</th>
<th>Term</th>
<th>Term</th>
<th>Term</th>
<th>Term</th>
<th>Term</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>additive drug reaction</td>
<td>macromolecule</td>
<td>nonprescription drugs</td>
<td>pharmacodynamic disorder</td>
<td>pharmacogenetic disorder</td>
<td>pharmacokinetics</td>
<td>pharmacology</td>
</tr>
<tr>
<td>adverse reaction</td>
<td></td>
<td></td>
<td>physical dependency</td>
<td>polypharmacy</td>
<td>prescription drugs</td>
<td>psychological dependency</td>
</tr>
<tr>
<td>agonist</td>
<td></td>
<td></td>
<td>receptor</td>
<td>synergism</td>
<td>toxic</td>
<td>teratogen</td>
</tr>
<tr>
<td>allergic reaction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>anaphylactic shock</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>angioedema</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>antagonist</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>antibodies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>antigen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>biotransformation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>botanical medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>controlled substances</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cumulative drug effect</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>drug idiosyncrasy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>drug tolerance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>half-life</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hypersensitivity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Chapter Objectives**

On completion of this chapter, the student will:
- Define pharmacology.
- Discuss drug development in the United States.
- Identify the different names assigned to drugs.
- Distinguish between prescription drugs, nonprescription drugs, and controlled substances.
- Discuss the laws governing the manufacture, distribution, and sale of drugs.
- Discuss the various types of drug reactions produced in the body.
- Identify factors that influence drug action.
- Define drug tolerance, cumulative drug effect, and drug idiosyncrasy.
- Discuss the types of drug interactions that may be seen with drug administration.
- Discuss the nursing implications associated with drug actions, interactions, and effects.
- Discuss the use of botanical medicines.

Pharmacology is the study of drugs and their action on living organisms. A sound knowledge of basic pharmacologic principles is essential if the nurse is to safely administer medications and to monitor patients who receive these medications. This chapter gives a basic overview of pharmacologic principles that the nurse must understand when administering medications. The chapter also discusses drug development, federal legislation affecting the dispensing and use of drugs, and the use of botanical medicines as they relate to pharmacology.

**DRUG DEVELOPMENT**

Drug development is a long and arduous process, taking anywhere from 7 to 12 years, and sometimes even longer. The United States Food and Drug Administration (FDA) has the responsibility of approving new drugs and monitoring drugs currently in use for adverse or toxic reactions. The development of a new drug is divided into the pre-FDA phase and the FDA phase (Fig. 1-1). During the pre-FDA phase, a manufacturer discovers a drug that looks promising. In vitro testing (testing in an artificial environment, such as a test tube) using animal and human cells is done. This testing is followed by studies in live animals. The manufacturer then makes application to the FDA for Investigational New Drug (IND) status.

With IND status, clinical testing of the new drug begins. Clinical testing involves three phases, with each phase involving a larger number of people. All effects, both pharmacologic and biologic, are noted. Phase I lasts 4 to 6 weeks and involves 20 to 100 individuals who are either “normal” volunteers or individuals in the intended treatment population. If Phase I studies are successful, the testing moves to Phase II, and if those results are positive, to Phase III. Each successive phase has a larger subject population. Phase III studies offer additional information on dosing and safety. The three phases last anywhere from 2 to 10 years, with the average being 5 years.

A New Drug Application (NDA) is submitted after the investigation of the drug in Phases I, II, and III is complete.
complete and the drug is found to be safe and effective. With the NDA, the manufacturer submits all data collected concerning the drug during the clinical trials. A panel of experts, including pharmacologists, chemists, physicians, and other professionals, reviews the application and makes a recommendation to the FDA. The FDA then either approves or disapproves the drug for use. This process of review takes approximately 2 years. After FDA approval, continued surveillance is done to ensure safety.

Postmarketing surveillance occurs after the manufacturer places the drug on the market. During this surveillance, an ongoing review of the drug occurs with particular attention given to adverse reactions. Health care professionals are encouraged to help with this surveillance by reporting adverse effects of drugs to the FDA by using MedWatch (see Display 1-1).

**SPECIAL FDA PROGRAMS**

Although it takes considerable time for most drugs to get FDA approval, the FDA has special programs to meet different needs. Examples of these special programs include the orphan drug program, accelerated programs for urgent needs, and compassionate use programs.

**Orphan Drug Program**

The Orphan Drug Act of 1983 was passed to encourage the development and marketing of products used to treat rare diseases. The act defines a “rare disease” as a condition affecting fewer than 200,000 individuals in the United States. The National Organization of Rare Disorders reports that there are more than 6000 rare disorders that affect approximately 25 million individuals. Examples of rare disorders include Tourette’s syndrome, ovarian cancer, acquired immunodeficiency syndrome (AIDS), Huntington’s disease, and certain forms of leukemia.

The act provides for incentives, such as research grants, protocol assistance by the FDA, and special tax credits, to encourage manufacturers to develop orphan drugs. If the drug is approved, the manufacturer has 7 years of exclusive marketing rights. More than 100 new drugs have received FDA approval since the law was passed. Examples of orphan drugs include thalidomide for leprosy, triptorelin pamoate for ovarian cancer, tetrabenazine for Huntington’s disease, and zidovudine for AIDS.

**Accelerated Programs**

Accelerated approval of drugs is offered by the FDA as a means to make promising products for life-threatening diseases available on the market, based on preliminary evidence before formal demonstration of patient benefit.
The approval that is granted is considered a “provisional approval,” with a written commitment from the pharmaceutical company to complete clinical studies that formally demonstrate patient benefit. This program seeks to make life-saving investigational drugs available before granting final approval to treat diseases that pose a significant health threat to the public. One example of a disease that qualifies as posing a significant health threat is AIDS. Because AIDS is so devastating to the individuals affected and because of the danger the disease poses to public health, the FDA and pharmaceutical companies are working together to shorten the IND approval process for some drugs that show promise in treating AIDS. This accelerated process allows primary care providers to administer medications that indicate positive results in early Phase I and II clinical trials, rather than wait until final approval is granted. If the drug continues to prove beneficial, the process of approval is accelerated.

Compassionate Access to Unapproved Drugs

The compassionate access program allows patients to receive drugs that have not yet been approved by the FDA. This program provides experimental drugs for patients who could benefit from new treatments but whose conditions are such that they most probably would die before the drug is approved for use. These patients are often too sick to participate in the controlled studies. Drug manufacturers make a proposal to the FDA to target patients with the disease and, at the pharmaceutical company’s expense, provide the drug free to patients. The pharmaceutical company analyzes and presents to the FDA data on the treatment. This program is not without problems. Because the drug is not in full production, quantities may be limited, so the number of patients may be limited, and patients may be selected at random. Because patients receiving compassionate access are often sicker, they are at increased risk for toxic reactions. This results in the newly developed drug running the risk of obtaining a “bad reputation,” even before marketing begins.

DRUG NAMES

Throughout the process of development, drugs may have several names assigned to them: a chemical name, a generic (nonproprietary) name, an official name, and a trade or brand name. This is confusing unless the nurse has a clear understanding of the different names used. Table 1-1 identifies the different names and provides an explanation of each.

DRUG CATEGORIES

After approval of a drug, the FDA assigns the drug to one of the following categories: prescription, nonprescription, or controlled substance.

Prescription Drugs

Prescription drugs are drugs that the federal government has designated to be potentially harmful unless their use is supervised by a licensed health care provider, such as a nurse practitioner, physician, or dentist. Although these drugs have been tested for safety and therapeutic effect, prescription drugs may cause different reactions in some individuals.

In institutional settings the nurse administers the drug and monitors the patient for therapeutic effect and adverse reactions. Some drugs have the potential to be toxic (harmful). The nurse plays a critical role in evaluating the patient for toxic effects. When these drugs are prescribed to be taken at home, the nurse provides patient and family education about the drug.

<table>
<thead>
<tr>
<th>DRUG NAME AND EXAMPLE</th>
<th>EXPLANATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical name</td>
<td>Gives the exact chemical makeup of the drug and placing of the atoms or molecular structure; it is not capitalized.</td>
</tr>
<tr>
<td>Generic name (nonproprietary)</td>
<td>Name given to a drug before it becomes official; may be used in all countries, by all manufacturers; it is not capitalized.</td>
</tr>
<tr>
<td>Example: loratadine</td>
<td></td>
</tr>
<tr>
<td>Official name</td>
<td>Name listed in The United States Pharmacopeia-National Formulary; may be the same as the generic name.</td>
</tr>
<tr>
<td>Example: loratadine</td>
<td></td>
</tr>
<tr>
<td>Trade name (brand name)</td>
<td>Name that is registered by the manufacturer and is followed by the trademark symbol; the name can be used only by the manufacturer; a drug may have several trade names, depending on the number of manufacturers; the first letter of the name is capitalized.</td>
</tr>
<tr>
<td>Example: Claritin©</td>
<td></td>
</tr>
</tbody>
</table>
Prescription drugs, also called legend drugs, are the largest category of drugs. Prescription drugs are prescribed by a licensed health care provider. The prescription (see Fig. 1-2) contains the name of the drug, the dosage, the method and times of administration, and the signature of the licensed health care provider prescribing the drug.

### Nonprescription Drugs

Nonprescription drugs are drugs that are designated by the FDA to be safe (if taken as directed) and obtained without a prescription. These drugs are also referred to as over-the-counter (OTC) drugs and may be purchased in a variety of settings, such as a pharmacy, drugstore, or in the local supermarket. OTC drugs include those given for symptoms of the common cold, headaches, constipation, diarrhea, and upset stomach.

These drugs are not without risk and may produce adverse reactions. For example, acetylsalicylic acid, commonly known as aspirin, is potentially harmful and can cause gastrointestinal bleeding and salicylism (see Chap. 17). Labeling requirements give the consumer important information regarding the drug, dosage, contraindications, precautions, and adverse reactions. Consumers are urged to read the directions carefully before taking OTC drugs.

### Controlled Substances

Controlled substances are the most carefully monitored of all drugs. These drugs have a high potential for abuse and may cause physical or psychological dependence. Physical dependency is a compulsive need to use a substance repeatedly to avoid mild to severe withdrawal symptoms; it is the body’s dependence on repeated administration of a drug. Psychological dependency is a compulsion to use a substance to obtain a pleasurable experience; it is the mind’s dependence on the repeated administration of a drug. One type of dependency may lead to the other type.

The Controlled Substances Act of 1970 regulates the manufacture, distribution, and dispensing of drugs that have abuse potential (see information under “Federal Drug Legislation and Enforcement” in this chapter). Drugs under the Controlled Substances Act are divided into five schedules, based on their potential for abuse and physical and psychological dependence. Display 1-2 describes the five schedules.

Prescriptions for controlled substances must be written in ink and include the name and address of the patient and the Drug Enforcement Agency number of the primary health care provider. Prescriptions for these drugs cannot be filled more than 6 months after the prescription.

---

**DISPLAY 1-2** Schedules of Controlled Substances

**SCHEDULE I (C-I)**
- High abuse potential
- No accepted medical use in the United States
- Examples: heroin, marijuana, LSD (lysergic acid diethylamide), peyote

**SCHEDULE II (C-II)**
- Potential for high abuse with severe physical or psychological dependence
- Examples: narcotics such as meperidine, methadone, morphine, oxycodone; amphetamines; and barbiturates

**SCHEDULE III (C-III)**
- Less abuse potential than schedule II drugs
- Potential for moderate physical or psychological dependence
- Examples: nonbarbiturate sedatives, nonamphetamine stimulants, limited amounts of certain narcotics

**SCHEDULE IV (C-IV)**
- Less abuse potential than schedule III drugs
- Limited dependence potential
- Examples: some sedatives and anxiety agents, nonnarcotic analgesics

**SCHEDULE V (C-V)**
- Limited abuse potential
- Examples: small amounts of narcotics (codeine) used as antitussives or antidiarrheals

*Under federal law, limited quantities of certain schedule V drugs may be purchased without a prescription directly from a pharmacist if allowed under state law. The purchaser must be at least 18 years of age and must furnish identification. All such transactions must be recorded by the dispensing pharmacist.
was written or be refilled more than five times. Under federal law, limited quantities of certain schedule C-V drugs may be purchased without a prescription, with the purchase recorded by the dispensing pharmacist. In some cases state laws are more restrictive than federal laws and impose additional requirements for the sale and distribution of controlled substances. In hospitals or other agencies that dispense controlled substances, the scheduled drugs are counted every 8 to 12 hours to account for each ampule, tablet, or other form of the drug. Any discrepancy in the number of drugs must be investigated and explained immediately.

**FEDERAL DRUG LEGISLATION AND ENFORCEMENT**

Many laws have been enacted over the last century that affect drug distribution and administration. Those included here are the Pure Food and Drug Act; Harrison Narcotic Act; Pure Food, Drug, and Cosmetic Act; and the Comprehensive Drug Abuse Prevention and Control Act. These laws control the use of the three categories of drugs in the United States (prescription, nonprescription, and controlled substances).

**Pure Food and Drug Act**

This act, passed in 1906, was the first attempt by the government to regulate and control the manufacture, distribution, and sale of drugs. Before 1906, any substance could be called a drug, and no testing or research was required before placing the drug on the market. Before this time, drug potency and the purity of many drugs were questionable, and some were even dangerous for human use.

**Harrison Narcotic Act**

This law, passed in 1914, regulated the sale of narcotic drugs. Before the passage of this act, any narcotic could be purchased without a prescription. This law was amended many times. In 1970, the Harrison Narcotic Act was replaced with the passage of the Comprehensive Drug Abuse Prevention and Control Act.

**Pure Food, Drug, and Cosmetic Act**

In 1938, Congress passed this law that gave the FDA control over the manufacture and sale of drugs, food, and cosmetics. Before the passage of this act, some drugs, as well as foods and cosmetics, contained chemicals that were often harmful to humans. This law requires that these substances are safe for human use. It also requires pharmaceutical companies to perform toxicology tests before a new drug is submitted to the FDA for approval. Following FDA review of the tests performed on animals and other research data, approval may be given to market the drug (see sections on “Drug Development”).

**Comprehensive Drug Abuse Prevention and Control Act**

Congress passed this act in 1970 because of the growing problem of drug abuse. It regulates the manufacture, distribution, and dispensation of drugs that have the potential for abuse. Title II of this law, the Controlled Substances Act, deals with control and enforcement. The Drug Enforcement Agency within the US Department of Justice is the leading federal agency responsible for the enforcement of this act.

**Drug Enforcement Administration**

The Drug Enforcement Administration (DEA) within the US Department of Justice is the chief federal agency responsible for enforcing the Controlled Substances Act. Failure to comply with the Controlled Substances Act is punishable by fine and/or imprisonment. With drug abuse so prevalent, nurses must diligently adhere to the regulation imposed by the FDA and the Nurse Practice Act of their state. Any violation may result in the loss of the nurse’s license to practice. Nurses must also report any misuse or abuse of these substances by other nurses to their State Board of Nursing. Most states have provisions within their Nurse Practice Act to assist nurses who have problems with drug abuse.

**DRUG USE AND PREGNANCY**

The use of any medication—prescription or nonprescription—carries a risk of causing birth defects in the developing fetus. Drugs administered to pregnant women, particularly during the first trimester (3 months), may cause teratogenic effects. A teratogen is any substance that causes abnormal development of the fetus leading to a severely deformed fetus. Drugs are one type of teratogen.

In an effort to prevent teratogenic effects, the FDA has established five categories suggesting the potential of a drug for causing birth defects (Display 1-3). Information regarding the pregnancy category of a specific drug is found in reliable drug literature, such as the inserts accompanying drugs and approved drug references. In general, most drugs are contraindicated during pregnancy or lactation unless the potential benefits of taking the drug outweigh the risks to the fetus or the infant.
Drugs act in various ways in the body. Oral drugs go through three phases: the pharmaceutic phase, pharmacokinetic phase, and pharmacodynamic phase. Liquid and parenteral drugs (drugs given by injection) go through the later two phases only.

**Pharmaceutic Phase**

The pharmaceutic phase of drug action is the dissolution of the drug. Drugs must be in solution to be absorbed. Drugs that are liquid or drugs given by injection (parenteral drugs) do not go through the pharmaceutic phase. A tablet or capsule (solid forms of a drug) goes through this phase as it disintegrates into small particles and dissolves into the body fluids within the gastrointestinal tract. Tablets that are enteric-coated do not disintegrate until reaching the alkaline environment of the small intestine.

**Pharmacokinetic Phase**

Pharmacokinetics refers to activities within the body after a drug is administered. These activities include absorption, distribution, metabolism, and excretion (A D M E). Another pharmacokinetic component is the half-life of the drug. Half-life is a measure of the rate at which drugs are removed from the body.

**Absorption**

Absorption follows administration and is the process by which a drug is made available for use in the body. It occurs after dissolution of a solid form of the drug or after the administration of a liquid or parenteral drug. In this process, the drug particles within the gastrointestinal tract are moved into the body fluids. This movement can be accomplished in several ways: active absorption, passive absorption, and pinocytosis. In active absorption, a carrier molecule such as a protein or enzyme actively moves the drug across the membrane. Passive absorption occurs by diffusion (movement from a higher concentration to a lower concentration). In pinocytosis, cells engulf the drug particle causing movement across the cell.

As the body transfers the drug from the body fluids to the tissue sites, absorption into the body tissues occurs. Several factors influence the rate of absorption, including the route of administration, the solubility of the drug, and the presence of certain body conditions. Drugs are most rapidly absorbed when given by the intravenous route, followed by the intramuscular route, the subcutaneous route, and lastly, the oral route. Some drugs are more soluble and thus are absorbed more rapidly than others. For example, water-soluble drugs are readily absorbed into the systemic circulation. Bodily conditions, such as the development of lipodystrophy (atrophy of the subcutaneous tissue) from repeated subcutaneous injections, inhibit absorption of a drug given in the site of lipodystrophy.

**Distribution**

The systemic circulation distributes drugs to various body tissues or target sites. Drugs interact with specific receptors (see Fig. 1-3) during distribution. Some drugs travel by binding to protein (albumin) in the blood. Drugs bound to protein are pharmacologically inactive. Only when the protein molecules release the drug can the drug diffuse into the tissues, interact with receptors, and produce a therapeutic effect.
As the drug circulates in the blood, a certain blood level must be maintained for the drugs to be effective. When the blood level decreases below the therapeutic level, the drug will not produce the desired effect. Should the blood level increase significantly over the therapeutic level, toxic symptoms develop. Specific therapeutic blood levels are discussed in the subsequent chapters when applicable.

**Metabolism**

Metabolism, also called biotransformation, is the process by which a drug is converted by the liver to inactive compounds through a series of chemical reactions. Patients with liver disease may require lower dosages of a drug detoxified by the liver, or the primary care provider may select a drug that does not undergo a biotransformation by the liver. Frequent liver function tests are necessary when liver disease is present. The kidneys, lungs, plasma, and intestinal mucosa also aid in the metabolism of drugs.

**Excretion**

The elimination of drugs from the body is called excretion. After the liver renders drugs inactive, the kidney excretes the inactive compounds from the body. Also, some drugs are excreted unchanged by the kidney without liver involvement. Patients with kidney disease may require a dosage reduction and careful monitoring of kidney function. Children have immature kidney function and may require dosage reduction and kidney function tests. Similarly, older adults have diminished kidney function and require careful monitoring and lower dosages. Other drugs are eliminated by sweat, breast milk, breath, or by the gastrointestinal tract in the feces.

**Pharmacokinetics**

- **Half-Life**
  - Half-life refers to the time required for the body to eliminate 50% of the drug. Knowledge of the half-life of a drug is important in planning the frequency of dosing. For example, drugs with a short half-life (2–4 hours) need to be administered frequently, whereas a drug with a long half-life (21–24 hours) requires less frequent dosing. It takes five to six half-lives to eliminate approximately 98% of a drug from the body. Although half-life is fairly stable, patients with liver or kidney disease may have problems excreting a drug. Difficulty in excreting a drug increases the half-life and increases the risk of toxicity. For example, digoxin (Lanoxin) has a long half-life (36 hours) and requires once-daily dosing. However, aspirin has a short half-life and requires frequent dosing. Older patients or patients with impaired kidney or liver function require frequent diagnostic tests measuring renal or hepatic function.

**Pharmacodynamic Phase**

Pharmacodynamics deals with the drug's action and effect within the body. After administration, most drugs enter the systemic circulation and expose almost all body tissues to possible effects of the drug. All drugs produce more than one effect in the body. The primary effect of a drug is the desired or therapeutic effect. Secondary effects are all other effects, whether desirable or undesirable, produced by the drug.

Most drugs have an affinity for certain organs or tissues and exert their greatest action at the cellular level on those specific areas, which are called target sites. There are two main mechanisms of action:

1. Alteration in cellular environment
2. Alteration in cellular function

**Alteration in Cellular Environment**

Some drugs act on the body by changing the cellular environment, either physically or chemically. Physical changes in the cellular environment include changes in osmotic pressures, lubrication, absorption, or the conditions on the surface of the cell membrane. An example of a drug that changes osmotic pressure is mannitol, which produces a change in the osmotic pressure in brain cells, causing a reduction in cerebral edema. A
drug that acts by altering the cellular environment by lubrication is sunscreen. An example of a drug that acts by altering absorption is activated charcoal, which is administered orally to absorb a toxic chemical ingested into the gastrointestinal tract. The stool softener docusate is an example of a drug that acts by altering the surface of the cellular membrane. Docusate has emulsifying and lubricating activity that causes a lowering of the surface tension in the cells of the bowel, permitting water and fats to enter the stool. This softens the fecal mass, allowing easier passage of the stool.

Chemical changes in the cellular environment include inactivation of cellular functions or the alteration of the chemical components of body fluid, such as a change in the pH. For example, antacids neutralize gastric acidity in patients with peptic ulcers.

**Alteration in Cellular Function**

Most drugs act on the body by altering cellular function. A drug cannot completely change the function of a cell, but it can alter its function. A drug that alters cellular function can increase or decrease certain physiologic functions, such as increase heart rate, decrease blood pressure, or increase urine output.

**Receptor-Mediated Drug Action**

The function of a cell alters when a drug interacts with a receptor cell. A receptor is a specialized macromolecule (a large group of molecules linked together) that attaches or binds to the drug molecule. This alters the function of the cell and produces the therapeutic response of the drug. For a drug–receptor reaction to occur, a drug must be attracted to a particular receptor. Drugs bind to a receptor much like a piece of a puzzle. The closer the shape, the better the fit, and the better the therapeutic response. The intensity of a drug response is related to how good the “fit” of the drug molecule is and the number of receptor sites occupied.

**Agonists** are drugs that bind with a receptor to produce a therapeutic response. Drugs that bind only partially to the receptor will most probably have some, although slight, therapeutic response. Figure 1-3 identifies the different drug–receptor interactions. Partial agonists are drugs that have some drug receptor fit and produce a response but inhibit other responses.

**Antagonists** join with a receptor to prevent the action of an agonist. When the antagonist binds more tightly than the agonist to the receptor, the action of the antagonist is strong. Drugs that act as antagonists produce no pharmacologic effect. An example of an antagonist is Narcan, a narcotic antagonist that completely blocks the effects of morphine, including the respiratory depression. This drug is useful in reversing the effects of an overdose of narcotics.

**Receptor-Mediated Drug Effects**

The number of available receptor sites influences the effects of a drug. If only a few receptor sites are occupied, although many sites are available, the response will be small. If the drug dose is increased, more receptor sites are used and the response increases. If only a few receptor sites are available, the response does not increase if more of the drug is administered. However, not all receptors on a cell need to be occupied for a drug to be effective. Some extremely potent drugs are effective even when the drug occupies few receptor sites.

**DRUG REACTIONS**

Drugs produce many reactions in the body. The following sections discuss adverse drug reactions, allergic drug reactions, drug idiosyncrasy, drug tolerance, cumulative drug effect, and toxic reactions. Pharmacogenetic reactions can also occur. A pharmacogenetic reaction is a genetically determined adverse reaction to a drug.

**Adverse Drug Reactions**

Patients may experience one or more adverse reactions (side effects) when they are given a drug. Adverse reactions are undesirable drug effects. A diverse reaction may be common or may occur infrequently. They may be mild, severe, or life threatening. They may occur after the first dose, after several doses, or even after many doses. An adverse reaction often is unpredictable, although some drugs are known to cause certain adverse reactions in many patients. For example, drugs used in the treatment of cancer are very toxic and are known to produce adverse reactions in many patients receiving them. Other drugs produce adverse reactions in fewer patients. Some adverse reaction is predictable, but many adverse drug reactions occur without warning.

Some texts use both terms side effect and adverse reactions. These texts distinguish between the two terms by using side effects to explain mild, common, and nontoxic reactions; adverse reaction is used to describe more severe and life-threatening reactions. For the purposes of this text only the term adverse reaction is used, with the understanding that these reactions may be mild, severe, or life threatening.

**Allergic Drug Reactions**

An allergic reaction also is called a hypersensitivity reaction. Allergy to a drug usually begins to occur after more than one dose of the drug is given. On occasion, the nurse may observe an allergic reaction the first time a drug is given because the patient has received or taken the drug in the past.
A drug allergy occurs because the individual’s immune system views the drug as a foreign substance or **antigen**. The presence of an antigen stimulates the antigen–antibody response that in turn prompts the body to produce **antibodies**. If the patient takes the drug after the antigen–antibody response has occurred, an allergic reaction results.

Even a mild allergic reaction produces serious effects if it goes unnoticed and the drug is given again. Any indication of an allergic reaction is reported to the primary health care provider before the next dose of the drug is given. Serious allergic reactions require contacting the primary health care provider immediately because emergency treatment may be necessary.

Some allergic reactions occur within minutes (even seconds) after the drug is given; others may be delayed for hours or days. Allergic reactions that occur immediately are the most serious.

Allergic reactions are manifested by a variety of signs and symptoms observed by the nurse or reported by the patient. Examples of some allergic symptoms include itching, various types of skin rashes, and hives (urticaria). Other symptoms include difficulty breathing, wheezing, cyanosis, a sudden loss of consciousness, and swelling of the eyes, lips, or tongue.

**Anaphylactic shock** is an extremely serious allergic drug reaction that usually occurs shortly after the administration of a drug to which the individual is sensitive. This type of allergic reaction requires immediate medical attention. Symptoms of anaphylactic shock are listed in Table 1-2.

All or only some of these symptoms may be present. A naphylactic shock can be fatal if the symptoms are not identified and treated immediately. Treatment is to raise the blood pressure, improve breathing, restore cardiac function, and treat other symptoms as they occur.

**TABLE 1-2** Symptoms of Anaphylactic Shock

<table>
<thead>
<tr>
<th>Category</th>
<th>Symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory</td>
<td>Bronchospasm, Dyspnea (difficult breathing), Feeling of fullness in the throat, Cough, Wheezing</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Extremely low blood pressure, Tachycardia (heart rate &gt; 100 bpm), Palpations, Syncope (fainting), Cardiac arrest</td>
</tr>
<tr>
<td>Integumentary</td>
<td>Urticaria, Angioedema, Pruritus (itching), Sweating</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Nausea, Vomiting, Abdominal pain</td>
</tr>
</tbody>
</table>

Epinephrine (adrenalin) 0.1 to 0.5 mg may be given by subcutaneous or intramuscular injection. Hypotension and shock may be treated with fluids and vasopressors. Bronchodilators are given to relax the smooth muscles of the bronchial tubes. Antihistamines may be given to block the effects of histamine.

**Angioedema** (angioneurotic edema) is another type of allergic drug reaction. It is manifested by the collection of fluid in subcutaneous tissues. Areas that are most commonly affected are the eyelids, lips, mouth, and throat, although other areas also may be affected. Angioedema can be dangerous when the mouth is affected because the swelling may block the airway and asphyxia may occur. Difficulty in breathing or swelling to any area of the body is reported immediately to the primary health care provider.

**Drug Idiosyncrasy**

Drug **idiosyncrasy** is a term used to describe any unusual or abnormal reaction to a drug. It is any reaction that is different from the one normally expected of a specific drug and dose. For example, a patient may be given a drug to help him or her sleep (eg, a hypnotic). Instead of falling asleep, the patient remains wide awake and shows signs of nervousness or excitement. This response is an idiosyncratic response because it is different from what the nurse expects from this type of drug. Another patient may receive the same drug and dose, fall asleep, and after 8 hours be difficult to awaken. This, too, is abnormal and describes an overresponse to the drug.

The cause of drug idiosyncrasy is not clear. It is believed to be due to a genetic deficiency that makes the patient unable to tolerate certain chemicals, including drugs.

**Drug Tolerance**

Drug **tolerance** is a term used to describe a decreased response to a drug, requiring an increase in dosage to achieve the desired effect. Drug tolerance may develop when a patient takes certain drugs, such as the narcotics and tranquilizers, for a long time. The individual who takes these drugs at home increases the dose when the expected drug effect does not occur. The development of drug tolerance is a sign of drug dependence. Drug tolerance may also occur in the hospitalized patient. When the patient receives a narcotic for more than 10 to 14 days, the nurse suspects drug tolerance (and possibly drug dependence). The patient may also begin to ask for the drug at more frequent intervals.

**Cumulative Drug Effect**

A **cumulative drug effect** may be seen in those with liver or kidney disease because these organs are the major sites for the breakdown and excretion of most
Drugs. This drug effect occurs when the body is unable to metabolize and excrete one (normal) dose of a drug before the next dose is given. Thus, if a second dose of this drug is given, some drug from the first dose remains in the body. A cumulative drug effect can be serious because too much of the drug can accumulate in the body and lead to toxicity.

Patients with liver or kidney disease are usually given drugs with caution because a cumulative effect may occur. When the patient is unable to excrete the drug at a normal rate the drug accumulates in the body, causing a toxic reaction. Sometimes, the primary health care provider lowers the dose of the drug to prevent a toxic drug reaction.

**Toxic Reactions**

Most drugs can produce toxic or harmful reactions if administered in large dosages or when blood concentration levels exceed the therapeutic level. Toxic levels build up when a drug is administered in dosages that exceed the normal level or if the patient’s kidneys are not functioning properly and cannot excrete the drug. Some toxic effects are immediately visible; others may not be seen for weeks or months. Some drugs, such as lithium or digoxin, have a narrow margin of safety, even when given in recommended dosages. It is important to monitor these drugs closely to avoid toxicity.

Drug toxicity can be reversible or irreversible, depending on the organs involved. Damage to the liver may be reversible because liver cells can regenerate. However, hearing loss due to damage to the eighth cranial nerve caused by toxic reaction to the anti-infective streptomycin may be permanent. Sometimes drug toxicity can be reversed by the administration of another drug that acts as an antidote. For example, in serious instances of digitalis toxicity, the drug Digibind may be given to counteract the effect of digoxin toxicity.

Nurses must carefully monitor the patient’s blood levels of drugs to ensure that they remain within the therapeutic range. Any deviation should be reported to the primary health care provider. Because some drugs can cause toxic reactions even in recommended doses, the nurse should be aware of the signs and symptoms of toxicity of commonly prescribed drugs.

**Pharmacogenetic Reactions**

A pharmacogenetic disorder is a genetically determined abnormal response to normal doses of a drug. This abnormal response occurs because of inherited traits that cause abnormal metabolism of drugs. For example, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency have abnormal reactions to a number of drugs. These patients exhibit varying degrees of hemolysis (destruction of red blood cells) if these drugs are administered. More than 100 million people are affected by this disorder. Examples of drugs that cause hemolysis in patients with a G6PD deficiency include aspirin, chloramphenicol, and the sulfonamides.

**DRUG INTERACTIONS**

It is important for the nurse administering medications to be aware of the various drug interactions that can occur, most importantly drug-drug interactions and drug-food interactions. The following section gives a brief overview of drug interactions. Specific drug-drug and drug-food interactions are discussed in subsequent chapters.

**Drug—Drug Interactions**

A drug–drug interaction occurs when one drug interacts with or interferes with the action of another drug. For example, taking an antacid with oral tetracycline causes a decrease in the effectiveness of the tetracycline. The antacid chemically interacts with the tetracycline and impairs its absorption into the bloodstream, thus reducing the effectiveness of the tetracycline. Drugs known to cause interactions include oral anticoagulants, oral hypoglycemics, anti-infectives, antiarrhythmics, cardiac glycosides, and alcohol. Drug–drug interactions can produce effects that are additive, synergistic, or antagonistic.

**ADDITIVE DRUG REACTION.** An additive drug reaction occurs when the combined effect of two drugs is equal to the sum of each drug given alone. For example, taking the drug heparin with alcohol will increase bleeding. The equation one + one = two is sometimes used to illustrate the additive effect of drugs.

**SYNERGISTIC DRUG REACTION.** Drug synergism occurs when drugs interact with each other and produce an effect that is greater than the sum of their separate actions. The equation one + one = four may be used to illustrate synergism. An example of drug synergism is when a person takes both a hypnotic and alcohol. When alcohol is taken simultaneously or shortly before or after the hypnotic is taken, the action of the hypnotic increases. The individual experiences a drug effect that is greater than if either drug was taken alone. On occasion, the occurrence of a synergistic drug effect is serious and even fatal.

**ANTAGONISTIC DRUG REACTION.** An antagonistic drug reaction occurs when one drug interferes with the action of another, causing neutralization or a decrease in
the effect of one drug. For example, protamine sulfate is a heparin antagonist. This means that the administration of protamine sulfate completely neutralizes the effects of heparin in the body.

**Drug–Food Interactions**

When a drug is given orally, food may impair or enhance its absorption. A drug taken on an empty stomach is absorbed into the bloodstream at a faster rate than when the drug is taken with food in the stomach. Some drugs (eg, captopril) must be taken on an empty stomach to achieve an optimal effect. Drugs that should be taken on an empty stomach are administered 1 hour before or 2 hours after meals. Other drugs, especially drugs that irritate the stomach, result in nausea or vomiting, or cause epigastric distress, are best given with food or meals. This minimizes gastric irritation. The nonsteroidal anti-inflammatory drugs and salicylates are examples of drugs that are given with food to decrease epigastric distress. Still other drugs combine with a drug forming an insoluble food–drug mixture. For example, when tetracycline is administered with dairy products, a drug–food mixture is formed that is unabsorbable by the body. When a drug is unabsorbable by the body, no pharmacologic effect occurs.

**FACTORS INFLUENCING DRUG RESPONSE**

Certain factors may influence drug response and are considered when the primary health care provider prescribes and the nurse administers a drug. These factors include age, weight, gender, disease, and route of administration.

**Age**

The age of the patient may influence the effects of a drug. Infants and children usually require smaller doses of a drug than adults do. Immature organ function, particularly the liver and kidneys, can affect the ability of infants and young children to metabolize drugs. An infant’s immature kidneys impair the elimination of drugs in the urine. Liver function is poorly developed in infants and young children. Drugs metabolized by the liver may produce more intense effects for longer periods. Parents must be taught the potential problems associated with administering drugs to their children. For example, a safe dose of a nonprescription drug for a 4-year-old child may be dangerous for a 6-month-old infant.

Elderly patients may also require smaller doses, although this may depend on the type of drug administered. For example, the elderly patient may be given the same dose of an antibiotic as a younger adult. However, the same older adult may require a smaller dose of a drug that depresses the central nervous system, such as a narcotic. Changes that occur with aging affect the pharmacokinetics (absorption, distribution, metabolism, and excretion) of a drug. Any of these processes may be altered because of the physiologic changes that occur with aging. Table 1-3 summarizes the changes that occur with aging and the possible pharmacokinetic effect.

**Polypharmacy** is the taking of numerous drugs that can potentially react with one another. When practiced by the elderly, polypharmacy leads to an increase in the number of potential adverse reactions. Although multiple drug therapy is necessary to treat certain disease states, it always increases the possibility of adverse reactions. The nurse needs good assessment skills to detect any problems when monitoring the geriatric patient’s response to drug therapy.

<table>
<thead>
<tr>
<th>AGE-RELATED CHANGES</th>
<th>EFFECT ON DRUG THERAPY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decreased gastric acidity; decreased gastric motility</td>
<td>Possible decreased or delayed absorption</td>
</tr>
<tr>
<td>Dry mouth and decreased saliva</td>
<td>Difficulty swallowing oral drugs</td>
</tr>
<tr>
<td>Decreased liver blood flow; decreased liver mass</td>
<td>Delayed and decreased metabolism of certain drugs; possible increased effect, leading to toxicity</td>
</tr>
<tr>
<td>Decreased lipid content of the skin</td>
<td>Possible decrease in absorption of transdermal drugs</td>
</tr>
<tr>
<td>Increased body fat; decreased body water</td>
<td>Possible increase in toxicity of water-soluble drugs; more prolonged effects of fat-soluble drugs</td>
</tr>
<tr>
<td>Decreased serum proteins</td>
<td>Possible increased effect and toxicity of highly protein-bound drugs</td>
</tr>
<tr>
<td>Decreased renal mass, blood flow, and glomerular filtration rate</td>
<td>Possible increased serum levels, leading to toxicity of drugs excreted by the kidney</td>
</tr>
<tr>
<td>Changes in sensitivity of certain drug receptors</td>
<td>Increase or decrease in drug effect</td>
</tr>
</tbody>
</table>

Weight

In general, dosages are based on a weight of approximately 150 lb, which is calculated to be the “average” weight of men and women. A drug dose may sometimes be increased or decreased because the patient’s weight is significantly higher or lower than this average. With narcotics, for example, higher or lower than average dosages may be necessary to produce relief of pain, depending on the patient’s weight.

Gender

The gender of an individual may influence the action of some drugs. Women may require a smaller dose of some drugs than men. This is because many women are smaller than men and have a body fat-and-water ratio different from that of men.

Disease

The presence of disease may influence the action of some drugs. Sometimes disease is an indication for not prescribing a drug or for reducing the dose of a certain drug. Both hepatic (liver) and renal (kidney) disease can greatly affect drug response.

In liver disease, for example, the ability to metabolize or detoxify a specific type of drug may be impaired. If the average or normal dose of the drug is given, the liver may be unable to metabolize the drug at a normal rate. Consequently, the drug may be excreted from the body at a much slower rate than normal. The primary health care provider may then decide to prescribe a lower dose and lengthen the time between doses because liver function is abnormal.

Patients with kidney disease may exhibit drug toxicity and a longer duration of drug action. The dosage of drugs may be reduced to prevent the accumulation of toxic levels in the blood or further injury to the kidney.

Route of Administration

Intravenous administration of a drug produces the most rapid drug action. Next in order of time of action is the intramuscular route, followed by the subcutaneous route. Giving a drug orally usually produces the slowest drug action.

Some drugs can be given only by one route; for example, antacids are given only orally. Other drugs are available in oral and parenteral forms. The primary health care provider selects the route of administration based on many factors, including the desired rate of action. For example, the patient with a severe cardiac problem may require intravenous administration of a drug that affects the heart. A another patient with a mild cardiac problem may experience a good response to oral administration of the same drug.

NURSING IMPLICATIONS

Many factors can influence drug action. The nurse should consult appropriate references or the hospital pharmacist if there is any question about the dosage of a drug, whether other drugs the patient is receiving will interfere with the drug being given, or whether the oral drug should or should not be given with food.

Drug reactions are potentially serious. The nurse should observe all patients for adverse drug reactions, drug idiosyncrasy, and evidence of drug tolerance (when applicable). It is important to report all drug reactions or any unusual drug effect to the primary health care provider.

The nurse must use judgment about when adverse drug reactions are reported to the primary health care provider. Accurate observation and evaluation of the circumstances are essential; the nurse should record all observations in the patient’s record. If there is any question regarding the events that are occurring, the nurse can withhold the drug but must contact the primary health care provider.

HERBAL THERAPY AND NUTRITIONAL SUPPLEMENTS

Botanical medicine or herbal therapy is a type of complementary/alternative therapy that uses plants or herbs to treat various disorders. Individuals worldwide use both herbal therapy and nutritional supplements extensively. According to the World Health Organization (WHO), 80% of the world’s population relies on herbs for a substantial part of their health care. Herbs have been used by virtually every culture in the world throughout history, from the beginning of time until now. For example, Hippocrates prescribed St. Johns Wort, currently a popular herbal remedy for depression. Native Americans used plants such as coneflower, ginseng, and ginger for therapeutic purposes. Herbal therapy is part of a group of nontraditional therapies commonly known as complementary/alternative medicine (CAM). Unfortunately, CAM therapies are not widely taught in medical schools. A 1998 survey revealed that 75 of 117 US medical schools offered elective courses in CAM or included CAM topics in required courses. Complementary therapies are therapies such as relaxation techniques, massage, dietary supplements, healing touch, and herbal therapy that can be used to “complement” traditional health care. Alternative therapies, on the other hand, are therapies used in place of or instead of conventional or Western medicine. The term complementary/alternative therapy often is used as an umbrella term for many therapies from all over the world.
Although herbs have been used for thousands of years, most of what we know has been from observation. Most herbs have not been scientifically studied for safety and efficacy (effectiveness). Much of what we know about herbal therapy has come from Europe, particularly Germany. During the last several decades, European scientists have studied botanical plants in ways that seek to identify how they work at the cellular level, what chemicals are most effective, and adverse effects related to their use. Germany has compiled information on 300 herbs and made recommendations for their use.

**Dietary Supplement Health and Education Act**

Because herbs cannot be sold and promoted in the United States as drugs, they are regulated as nutritional or dietary substances. Nutritional or dietary substances are terms used by the federal government to identify substances not regulated as drugs by the FDA but that are purported to be effective for use to promote health. Herbs, as well as vitamins and minerals, are classified as dietary or nutritional supplements. Because natural products cannot be patented in the United States, it is not profitable for drug manufacturers to spend the millions of dollars and the 8 to 12 years to study and develop these products as drugs. In 1994, the US government passed the Dietary Supplement Health and Education Act (DSHEA). This act defines substances such as herbs, vitamins, minerals, amino acids, and other natural substances as “dietary supplements.” The act permits general health claims such as “improves memory” or “promotes regularity” as long as the label also has a disclaimer stating that the supplements are not approved by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. The claims must be truthful and not misleading and be supported by scientific evidence. Some have abused the law by making exaggerated claims, but the FDA has the power to enforce the law, which it has done, and these claims have decreased.

**Center for Complementary and Alternative Health**

In 1992, the National Institutes of Health established an Office of Alternative Medicine to facilitate the study of alternative medical treatments and to disseminate the information to the public. In 1998, the name was changed to National Center for Complementary and Alternative Medicine (NCCAM). This office was established partly because of the increased interest and use of these therapies in the United States. It has been estimated that approximately 40% of all individuals in the United States use some form of complementary/alternative therapy. In 1997, Americans spent more that $27 billion on these therapies. A mong the various purposes of the NCCAM, one is to evaluate the safety and efficacy of widely used natural products, such as herbal remedies and nutritional and food supplements. Although the scientific study of CAM is relatively new, the Center is dedicated to developing programs and encouraging scientists to investigate CAM treatments that show promise. The NCCAM budget has steadily grown from $2 million in 1993 to more than $68.7 million in 2000. This funding increase reflects the public’s interest and need for CAM information that is based on rigorous scientific research.

**Educating the Client on the Use of Herbs and Nutritional Supplements**

The use of herbs and nutritional supplements to treat various disorders is common. Herbs are used for various effects, such as to boost the immune system, treat depression, and for relaxation. Individuals are becoming more aware of the benefits of herbal therapies and nutritional supplements. Advertisements, books, magazines, and Internet sites abound concerning these topics. People, eager to cure or control various disorders, take herbs, teas, megadoses of vitamins, and various other natural products. Although much information is available on nutritional supplements and herbal therapy, obtaining the correct information sometimes is difficult. Medicinal herbs and nutritional substances are available at supermarkets, pharmacies, health food stores, specialty herb stores, and through the Internet. The potential for misinformation abounds. Because these substances are “natural products,” many individuals may incorrectly assume that they are without adverse effects. When any herbal remedy or dietary supplement is used, it should be reported to the nurse and the primary health care provider. Many of these botanicals have strong pharmacological activity, and some may interact with prescription drugs or be toxic in the body. For example, comfrey, an herb that was once widely used to promote digestion, can cause liver damage. Although it may still be available in some areas, it is a dangerous herb and is not recommended for use as a supplement.

When obtaining the drug history, the nurse must always question the patient about the use of herbs, teas, vitamins, or other nutritional or dietary supplements. Many patients consider herbs as natural and therefore safe. It is also difficult for some to report the use of an herbal tea as a part of the health care regimen. Display 1-4 identifies teaching points to consider when discussing the use of herbs and nutritional supplements with patients. Although a complete discussion about the use of herbs is beyond the scope of this book, it is important to remember that the use of herbs and nutritional supplements is commonplace in many areas of the country. To help the student become more aware of herbal therapy and nutritional supplements, Appendix B gives
Ms. James, an 80-year-old woman, is receiving a lower dose of Demerol, a narcotic analgesic, postoperatively for pain. Her family questions the use of a lower dose. Determine what information you would give her family when they voice concerns that the dosage will not adequately relieve their mother’s pain. Analyze what patient assessment, if any, you would need to make before talking with the family.

### Critical Thinking Exercises

1. Judy Martin, a student nurse, has just administered an antibiotic to Mr. Green. When she returns to the room about 30 minutes later, she finds Mr. Green flushed, reporting a lump in his throat, and experiencing difficulty breathing. Determine what actions the student nurse should take.

2. Jenny Davis, age 25, is pregnant. Jenny’s primary health care provider tells her that she may not take any medication without first checking with the health care provider during the pregnancy. Jenny is puzzled and questions you about this. Discuss how you would address Jenny’s concerns.

3. Ms. James, an 80-year-old woman, is receiving a lower dose of Demerol, a narcotic analgesic, postoperatively for pain. Her family questions the use of a lower dose. Determine what action her best choice is to select an herbal product manufactured by a reputable company. Check the label for the word “standardized.” This means that the product has a specific percentage of a specific chemical. Some herbal tinctures are 50% alcohol, which could pose a problem to individuals with a history of alcohol abuse. Use products with more than six herbs cautiously. It is generally better to use the single herb than to use a diluted product with several herbs. Do not overmedicate with herbs. The adage “if one is good, two must be better” is definitely not true. Take only the recommended dosage. Herbs are generally safe when taken in recommended dosages. However, if you experience any different or unusual symptoms, such as heart palpitations, headaches, rashes, or difficulty breathing, stop taking the herb and contact your health care provider. Inform your primary health care provider of any natural products that you take (eg, herbs, vitamins, minerals, teas, etc.). Certain herbs can interact with the medications that you take, causing serious adverse reactions or toxic effects. Allow time for the herb to work. Generally, 30 days is sufficient. If your symptoms have not improved within 30 to 60 days, discontinue use of the herb.

### Review Questions

1. Mr. Carter has a rash and pruritus. You suspect an allergic reaction and immediately assess him for other more serious symptoms of an allergic reaction. What question would be most important to ask Mr. Carter?
   A. Are you having any difficulty breathing?
   B. Have you noticed any blood in your stool?
   C. Do you have a headache?
   D. Are you having difficulty with your vision?

2. Mr. Jones, a newly admitted patient, has a history of liver disease. In planning Mr. Jones’ care the nurse must consider that liver disease may result in a (an) _______.
   A. increase in the excretion rate of a drug
   B. impaired ability to metabolize or detoxify a drug
   C. necessity to increase the dosage of a drug
   D. decrease in the rate of drug absorption

3. Oxycodone is prescribed for a patient on the unit where you work. To safely administer oxycodone the nurse knows that this drug is regulated by the Controlled Substance Act, which classifies this drug as a Schedule _______.
   A. drug with a high abuse potential
   B. drug with the potential for high abuse with severe dependency
   C. drug with moderate abuse potential
   D. drug with limited abuse potential

4. A patient asks the nurse to define a hypersensitivity reaction. The nurse begins by telling the patient that a hypersensitivity reaction is also called a _______.
   A. synergistic reaction
   B. antagonistic reaction
   C. drug idiosyncrasy
   D. drug allergy

5. If a patient takes a drug on an empty stomach, the nurse is aware that the drug will be _______.
   A. absorbed more slowly
   B. neutralized by pancreatic enzymes
   C. affected by enzymes in the colon
   D. absorbed more rapidly

6. In monitoring drug therapy, the nurse is aware that a synergistic drug effect may be defined as _______.
   A. an effect greater than the sum of the separate actions of two or more drugs
   B. an increase in the action of one of the two drugs being given
   C. a neutralizing drug effect
   D. a comprehensive drug effect
The Administration of Drugs

Key Terms

| buccal       | parenteral       |
| drug errors  | standard precautions |
| extravasation| subcutaneous      |
| infiltration | sublingual        |
| inhalation   | transdermal      |
| intradermal  | unit dose        |
| intramuscular| Z-track          |

Chapter Objectives

On completion of this chapter, the student will:

- Name the six rights of drug administration.
- Identify the different types of medication orders.
- Discuss once-a-week dosing of certain drugs.
- Describe the various types of medication dispensing systems.
- List the various routes by which a drug may be given.
- Discuss the administration of oral and parenteral drugs.
- Discuss Occupational Safety and Health Administration (OSHA) guidelines concerning needle stick injuries and precautions.
- Discuss the administration of drugs through the skin and mucous membranes.
- Discuss nursing responsibilities before, during, and after a drug is administered.

THE SIX RIGHTS AND DRUG ADMINISTRATION

The administration of a drug is a fundamental responsibility of the nurse. An understanding of the basic concepts of administering drugs is critical if the nurse is to perform this task safely and accurately.

In addition to administering the drug, the nurse monitors the therapeutic response (desired response) and reports adverse reactions. In the home setting, the nurse is responsible for teaching the patient and family members the necessary information to administer drugs safely in an outpatient setting.

Right Patient

When administering a drug, the nurse must be certain that the patient receiving the drug is the patient for whom the drug has been ordered. This is accomplished by checking the patient’s wristband containing the patient’s name (see Fig. 2-1). If there is no written identification verifying the patient’s name, the nurse obtains a wristband or other form of identification before administering the drug. In some instances the nurse may ask the patient to identify himself. However, the nurse should not ask, “Are you Mr. Jones?” Some patients, particularly those who are confused or have difficulty hearing, may respond by answering yes even though that is not their name.

Some nursing homes or extended care facilities have pictures of the patient available, which allows the nurse to verify the correct patient. If pictures are used to identify patients, it is critical that they are recent and bear a good likeness of the individual.
Right Drug

Drug names are often confused, especially when the names sound similar or the spellings are similar. Nurses who hurriedly prepare a drug for administration or who fail to look up questionable drugs are at increased risk for administering the wrong drug. Table 2-1 identifies examples of drugs that can easily be confused. The nurse should compare medication, container label, and medication record (see Fig. 2-2).

Right Dose, Route, and Time

The nurse should obtain a primary care provider’s written order for the administration of all drugs. The primary care provider’s order must include the patient’s name, the drug name, the dosage form and route, the dosage to be administered, and the frequency of administration. The primary care provider’s signature must follow the drug order. In an emergency, the nurse may administer a drug with a verbal order from the primary care provider. However, the primary care provider must write and sign the order as soon as the emergency is over.

It is important to question any order that is unclear. This includes unclear directions for the administration of the drug, illegible handwriting on the primary care provider’s order sheet, or a drug dose that is higher or lower than the dosages given in approved references.

Right Documentation

After the administration of any drug, the nurse records the process immediately (see Fig. 2-3). Immediate documentation is particularly important when drugs are given on an as-needed basis (PRN drugs). For example, most analgesics require 20 to 30 minutes before the drug begins to relieve pain. A patient may forget that he or she received a drug for pain, may not have been told that the administered...
The Administration of Drugs

CONSIDERATIONS IN DRUG ADMINISTRATION

Drug Errors

Drug errors can be defined as any occurrence that can cause a patient to receive the wrong dose, the wrong drug, an incorrect dosage of the drug, a drug by the wrong route, or a drug given at the incorrect time. Errors may occur in transcribing drug orders, when the drug is dispensed, or in administration of the drug. Nurses serve as the last defense against detecting drug errors. When a drug error occurs, it must be reported immediately so that any necessary steps to counteract the action of the drug or any observation can be made as soon as possible. In most institutions, the nurse must complete an incident report and notify the primary care provider. It is important to report errors even if the patient suffers no harm.

Drug errors occur when one or more of the six “rights” has not been followed. Each time a drug is prepared and administered, the six rights must be a part of the procedure. In addition to consistently practicing the six rights, the nurse should adhere to the following precautions to help prevent drug errors:

- Confirm any questionable orders.
- When calculations are necessary, verify them with another nurse.
- Listen to the patient when he or she questions a drug, the dosage, or the drug regimen. Never administer the drug until the patient’s questions have been adequately researched.
- Concentrate on only one task at a time.

Most errors are made during administration of the drug. Errors most commonly occur because of a failure to administer a drug that has been ordered, administration of the wrong dose or strength of a drug, or administration of the wrong drug. Two drugs often associated with errors are insulin and heparin.

The United States Pharmacopeia (USP) in cooperation with the Institute for Safe Medication Practices instituted a program called Medication Errors Reporting Program. This program is designed to identify the number and type of drug errors occurring around the country. The goal of this voluntary reporting system is to collect data and disseminate information that will prevent such errors in the future. A copy of the report form is included in Appendix C. Nurses are urged to participate in this important program as a means of protecting the public by identifying ways to make drug administration safer.

The Medication Order

Before a medication can be administered in a hospital or other agency the nurse must have a physician’s order. Medications are ordered by the primary health care provider such as a physician, dentist, or in some cases a nurse practitioner.

Common orders include the standing order, the single order, the PRN order, and the STAT order. See Display 2-1 for an explanation of each.

DISPLAY 2-1  •  Types of Medication Orders

- **Standing Order:** This type of order is given when the patient is to receive the drug as prescribed on a regular basis. The drug is administered until the physician discontinues the drug’s use. Occasionally a drug may be ordered for a specified number of days, or in some cases a drug can only be given for a specified number of days before the order needs to be renewed.
  - **Example:** Lanoxin 0.25 mg PO QD.
- **Single order:** An order to administer the drug one time only.
  - **Example:** Valium 10 mg IVP @ 10:00 AM.
- **PRN order:** An order to administer the drug as needed.
  - **Example:** Demerol 100 mg IM q4h PRN for pain.
- **STAT order:** A one-time order given as soon as possible.
  - **Example:** Morphine 10 mg IV STAT.
Once-a-Week Drugs

Soon many drugs will be available for once-a-week, or even twice-a-month, administration. The doses are designed to replace daily doses of drugs. One of the first is alendronate (Fosamax), a drug used to treat osteoporosis (see Chapter 21). In 2001, the FDA approved two new strengths for this drug to be given once a week: 70-mg and 35-mg tablets. The 70-mg tablet is used to treat postmenopausal osteoporosis, and the 35-mg tablet for prevention of osteoporosis in postmenopausal osteoporosis. In clinical trials the once-a-week dosing showed no greater adverse reactions than the once-daily regimen. Once-a-week dosing may prove beneficial for those experiencing mild adverse reactions in that the reactions would be experienced once a week, rather than every day.

Drug Dispensing Systems

There are a number of drug dispensing systems for the nurse to use to dispense medication after it has been ordered for the patient. A brief description of three methods is given below.

Computerized Dispensing System

Automated or computerized dispensing systems are used in many hospitals or agencies dispensing drugs. Drugs are dispensed in the pharmacy from drug orders that are sent from the individual floors or units. Each floor or unit has a medication cart in which medications are placed for individual patients. Medication orders are filled in the hospital pharmacy and placed in the drug dispensing cart. When orders are filled, the cart is delivered to the unit. To administer the drugs, nurses enter the patient's name and the drug to be administered. The drug is dispensed and automatically recorded into the computerized system. After drugs are dispensed and the cart is almost empty, it goes back to the pharmacy to be refilled and for new drug orders to be placed.

Unit Dose System

The unit dose system is a method of dispensing medications in which drug orders are filled and medications dispensed to fill each patient's medication order(s) for a 24-hour period. The pharmacist dispenses each dose (unit) in a package that is labeled with the drug name and dosage. The drug(s) are placed in drawers in a special portable medication cart with a drawer for each patient. Many drugs are packaged by their manufacturers in unit doses. That is, each package is labeled by the manufacturer and contains one tablet or capsule, a premeasured amount of a liquid drug, a prefilled syringe, or one suppository. Hospital pharmacists also may prepare unit doses. The pharmacist restocks the cart each day with the drugs needed for the next 24-hour period. The nurse takes the drug cart into each patient's room (Figure 2-4).

Some hospitals are using a bar code scanner in the administration of unit dose drugs. To use this system, a bar code is placed on the patient's hospital identification band when the patient is admitted to the hospital. The bar codes, along with bar codes on the drug unit dose packages, are used to identify the patient and to record and charge routine and PRN drugs. The scanner also keeps an ongoing inventory of controlled substances, which eliminates the need for narcotic counts at the end of each shift.

Floor Stock

Some agencies, such as nursing homes or small hospitals, use a floor stock method to dispense drugs. Some special units in hospitals, such as the emergency department, may use this method. In this situation, drugs most frequently prescribed are kept on the unit in containers in a designated medication room or at the nurses' station. The nurse takes the medication from the appropriate container and administers the drug to the patient and records the drug in the patient's administration record.

General Principles of Drug Administration

The nurse must have factual knowledge of each drug given, the reasons for use of the drug, the drug's general action, the more common adverse reactions associated
with the drug, special precautions in administration (if any), and the normal dose ranges.

Some drugs may be given frequently; the nurse becomes familiar with pharmacologic information about a specific drug. Other drugs may be given less frequently, or a new drug may be introduced, requiring the nurse to obtain information from reliable sources, such as the drug package insert or the hospital department of pharmacy. It is of utmost importance to check current and approved references for all drug information.

It also is important for the nurse to take patient considerations, such as allergy history, previous adverse reactions, patient comments, and change in patient condition, into account before administering the drug. Before giving any drug for the first time, the nurse should ask the patient about any known allergies and any family history of allergies. This not only includes allergies to drugs but also to food, pollen, animals, and so on. Patients with a personal or family history of allergies are more likely to experience additional allergies and must be monitored closely.

If the patient makes any statement about the drug or if there is any change in the patient, these situations are carefully considered before the drug is given. Examples of situations that require consideration before a drug is given include:

- Problems that may be associated with the drug, such as nausea, dizziness, ringing in the ears, and difficulty walking. Any comments made by the patient may indicate the occurrence of an adverse reaction. The nurse should withhold the drug until references are consulted and the primary caregiver contacted. The decision to withhold the drug must have a sound rationale and must be based on knowledge of pharmacology.
- Comments stating that the drug looks different from the one previously received, that the drug was just given by another nurse, or that the patient thought the primary care provider discontinued the drug therapy.
- A change in the patient’s condition, a change in one or more vital signs, or the appearance of new symptoms. Depending on the drug being administered and the patient’s diagnosis, these changes may indicate that the drug should be withheld and the primary care provider contacted.

**Preparing a Drug for Administration**

When preparing a drug for administration, the nurse should observe the following guidelines:

- Always check the health care provider’s written orders and verify any questions with the primary health care provider.
- Prepare drugs for administration in a quiet, well-lit area.
- Always check the label of the drug three times: (1) when the drug is taken from its storage area, (2) immediately before removing the drug from the container, and (3) before returning the drug to its storage area.
- Never remove a drug from an unlabeled container or from a container whose label is illegible.
- Wash hands immediately before preparing a drug for administration.
- Do not let hands touch capsules or tablets. To remove an oral drug from the container, the correct number of tablets or capsules is shaken into the cap of the container and from there into the medicine cup.
- Always observe aseptic technique when handling syringes and needles.
- Be alert for drugs with similar names. Some drugs have names that sound alike but are very different. To give one drug when another is ordered could cause serious consequences. For example, digoxin and digitoxin sound alike but are different drugs.
- Replace the caps of drug containers immediately after the drug is removed.
- Return drugs requiring special storage to the storage area immediately after they are prepared for administration. This rule applies mainly to the refrigeration of drugs but may also apply to drugs that must be protected from exposure to light or heat.
- Never crush tablets or open capsules without first checking with the pharmacist. Some tablets can be crushed or capsules can be opened and the contents added to water or a tube feeding when the patient cannot swallow a whole tablet or capsule. Some tablets have a special coating that delays the absorption of the drug. Crushing the tablet may destroy this drug property and result in problems such as improper absorption of the drug or gastric irritation. Capsules are gelatin and dissolve on contact with a liquid. The contents of some capsules do not mix well with water and therefore are best left in the capsule. If the patient cannot take an oral tablet or capsule, consult the primary care provider because the drug may be available in liquid form.
- Never give a drug that someone else has prepared. The individual preparing the drug must administer the drug.
- When using a unit dose system, do not remove the wrappings of the unit dose until the drug reaches the bedside of the patient who is to receive it. After administering the drug, the nurse charts immediately on the unit dose drug form. The method of administering drugs by the unit dose system is widely used.
ADMINISTRATION OF DRUGS BY THE ORAL ROUTE

The oral route is the most frequent route of drug administration and rarely causes physical discomfort in patients. Oral drug forms include tablets, capsules, and liquids. Some capsules and tablets contain sustained-release drugs, which dissolve over an extended period of time. Administration of oral drugs is relatively easy for patients who are alert and can swallow.

**Nursing Responsibilities**

The nurse should observe the following points when giving an oral drug:

- Place the patient in an upright position. It is difficult, as well as dangerous, to swallow a solid or liquid when lying down.
- Make sure that a full glass of water is readily available.
- Assess the patient’s need for assistance in removing the tablet or capsule from the container, holding the container, holding a medicine cup, or holding a glass of water. Some patients with physical disabilities cannot handle or hold these objects and may require assistance.
- Advise the patient to take a few sips of water before placing a tablet or capsule in the mouth.
- Instruct the patient to place the pill or capsule on the back of the tongue and tilt the head back to swallow a tablet or slightly forward to swallow a capsule. Encourage the patient first to take a few sips of water to move the drug down the esophagus and into the stomach, and then to finish the whole glass.
- Give the patient any special instructions, such as drinking extra fluids or remaining in bed, that are pertinent to the drug being administered.
- Never leave a drug at the patient’s bedside to be taken later unless there is a specific order by the primary care provider to do so. A few drugs (eg, antacids and nitroglycerin tablets) may be ordered to be left at the bedside.
- Patients with a nasogastric feeding tube may be given their oral drugs through the tube. Dilute and flush liquid drugs through the tube. However, crush tablets and dissolve them in water before administering them through the tube. Before administration, check the tube for placement. Flush the tube with water after the drugs are placed in the tube to completely clear the tubing.
- Instruct the patient to place **buccal** drugs against the mucous membranes of the cheek in either the upper or lower jaw. These drugs are given for a local, rather than systemic, effect. They are absorbed slowly from the mucous membranes of the mouth. Examples of drugs given buccally are lozenges and troches.
- Certain drugs are also given by the **sublingual** (placed under the tongue) route. These drugs must not be swallowed or chewed and must be dissolved completely before the patient eats or drinks. Nitroglycerin is commonly given sublingually.

ADMINISTRATION OF DRUGS BY THE PARENTERAL ROUTE

**Parenteral** drug administration means the giving of a drug by the subcutaneous (SC), intramuscular (IM), intravenous (IV), or intradermal route (Fig. 2-5). Other routes of parenteral administration that may be used by the primary care provider are intralesional (into a lesion), intra-arterial (into an artery), intracardiac (into the heart), and intra-articular (into a joint). In some instances, intra-arterial drugs are administered by a nurse. However, administration is not by direct arterial injection but by means of a catheter that has been placed in an artery.

**Figure 2-5.** Needle insertion for parenteral drug: (A) Intradermal injection: a 26-gauge, ¾-inch long needle is inserted at a 10-degree angle. (B) Subcutaneous injection: a 25-gauge, ½-inch long needle is inserted at an angle that depends on the size of the patient. (C) Intramuscular injection: a 20-gauge to 23-gauge, 1-inch to 3-inch long needle is inserted into the relaxed muscle at a 90-degree angle with a dart-throwing type of hand movement. (D) Intravenous injection: the diameter and length of the needle used depend on the substance to be injected and on the site of injection.
Nursing Responsibilities

The nurse should observe the following points when giving a drug by the parenteral route:

- Wear gloves for protection from the potential of a blood spill when giving parenteral drugs. The risk of exposure to infected blood is increasing for all health care workers. The Centers for Disease Control and Prevention (CDC) recommends that gloves be worn when touching blood or body fluids, mucous membranes, or any broken skin area. This recommendation is referred to as Standard Precautions, which combine the Universal Precautions for Blood and Body Fluids with Body Substance Isolation guidelines.

- After selecting the site for injection, cleanse the skin. Most hospitals have a policy regarding the type of skin antiseptic used for cleansing the skin before parenteral drug administration. Cleanse the skin with a circular motion, starting at an inner point and moving outward.

- After inserting the needle for IM administration, pull back the syringe barrel to aspirate the drug. If blood appears in the syringe, remove the needle so the drug is not injected. Discard the drug, needle, and syringe and prepare another injection. If no blood appears in the syringe, inject the drug. Aspiration is not necessary when giving an intradermal or SC injection.

- After inserting a needle into a vein for IV drug administration, pull back the syringe barrel. Blood should flow back into the syringe. After a backflow of blood is obtained, it is safe to inject the drug.

- After removing the needle from an IM, SC, or IV injection site, place pressure on the area. Patients with bleeding tendencies often require prolonged pressure on the area.

- Do not recap syringes and dispose of them according to agency policy. Discard needles and syringes into clearly marked, appropriate containers. Most agencies have a “sharp” container located in each room for immediate disposal of needles and syringes after use.

- Most hospitals use needles designed to prevent sticks. This needle has a plastic guard that slips over the needle as it is withdrawn from the injection site. The guard locks in place and eliminates the need to recap. Other models are available as well. These newer types of methods for administering parenteral fluids provide a greater margin of safety for nurses. (See OSHA Guidelines below.)

Occupational Safety and Health Administration Guidelines

Each year between 600,000 and 1 million health care workers experience sticks from conventional needles and sharps. Needle exposures can transmit hepatitis B, hepatitis C, and human immunodeficiency virus. Other infections, such as tuberculosis, syphilis, and malaria, also can be transmitted through needle sticks. More than 80% of needle stick injuries could be prevented with the use of safer needle devices. Nurses working at the bedside are the largest group of health care workers sustaining needle stick and sharps injuries.

Effective April 2001, the Occupational Safety and Health Administration (OSHA) announced new guidelines on needle stick prevention. Under the theory that “prevention is the best medicine,” revisions were made in the Bloodborne Pathogens Standard. The revisions clarify the need for employers to select safer needle devices as they become available and to involve employees in identifying and choosing the devices. Employers with 11 or more employees must also maintain a Sharps Injury Log to include (at least) the following components:

- Type and brand of device involved in the incident (if known)
- Location of the incident
- Description of the incident

The needle stick log will help both employees and employers track all needle sticks to help identify problem areas. The log must be maintained to protect the confidentiality of the injured employee. In addition, employers must have a written Exposure Control Plan that is updated annually. During the annual review, inquiries must be made about new or prospective safer options. If new safer devices are available, they should be adopted for use in the agency. The new guidelines will help reduce needle stick injuries among health care workers and others who handle medical sharps. Safety engineered devices such as self-sheathing needles and needleless systems can be used.

Administration of Drugs by the Subcutaneous Route

A subcutaneous (SC) injection places the drug into the tissues between the skin and the muscle (see Fig. 2-5B). Drugs administered in this manner are absorbed more slowly than are intramuscular injections. Heparin and insulin are two drugs most commonly given by the SC route.

Nursing Responsibilities

The nurse should observe the following points when giving a drug by the SC route:

- A volume of 0.5 to 1 mL is used for SC injection. Larger volumes (eg, >1 mL) are best given as IM
injections. If a volume larger than 1 mL is ordered through the SC route, the injection is given in two sites, with separate needles and syringes.

- The sites for SC injection are the upper arms, the upper abdomen, and the upper back (Fig. 2-6). Rotate injection sites to ensure proper absorption and to minimize tissue damage.
- When giving a drug by the SC route, insert the needle at a 45-degree angle. However, to place the drug in the SC tissue, select the needle length and angle of insertion based on the patient’s body weight. Obese patients have excess SC tissue, and it may be necessary to give the injection at a 90-degree angle. If the patient is thin or cachectic, there usually is less SC tissue. For such patients, the upper abdomen is the best site for injection. Generally, a syringe with a 23- to 25-gauge needle that is 1⁄2 to 5⁄8 inches in length is most suitable for an SC injection.

Administration of Drugs by the Intramuscular Route

An intramuscular (IM) injection is the administration of a drug into a muscle (see Fig. 2-5C). Drugs that are irritating to SC tissue can be given via IM injection. Drugs given by this route are absorbed more rapidly than drugs given by the SC route because of the rich blood supply in the muscle. In addition, a larger volume (1–3 mL) can be given at one site.

Nursing Responsibilities

The nurse should observe the following points when giving a drug by the IM route:

- If an injection is more than 3 mL, divide the drug and give it as two separate injections. Volumes larger than 3 mL will not be absorbed properly.
- A 22-gauge needle that is 1 1⁄2 inches in length is most often used for IM injections.
- The sites for IM administration are the deltoid muscle (upper arm), the ventrogluteal or dorsogluteal sites (hip), and the vastus lateralis (thigh; Fig. 2-7). The vastus lateralis site is frequently used for infants and small children because it is more developed than the gluteal or deltoid sites. In children who have been ambulating for more than 2 years the ventrogluteal site may be used.
- When giving a drug by the IM route, insert the needle at a 90-degree angle. When injecting a drug into the ventrogluteal or dorsogluteal muscles, it is a good idea to place the patient in a comfortable position, preferably in a prone position with the toes pointing inward. When injecting the drug into the deltoid, a sitting or lying down position may be used. Place the patient in a recumbent position for injection of a drug into the vastus lateralis.

Z-Track Technique

The Z-track method of IM injection is used when a drug is highly irritating to SC tissues or has the ability to permanently stain the skin. The nurse should adhere to the following procedure when using the Z-track technique (Fig. 2-8):

- Draw the drug up into the syringe.
- Discard the needle and place a new needle on the syringe. This prevents any solution that may remain in the needle (that was used to draw the drug into the syringe) from contacting tissues as the needle is put into the muscle.
- Pull the plunger down to draw approximately 0.1 to 0.2 mL of air into the syringe. The air bubble in the syringe follows the drug into the tissues and seals off the area where the drug was injected, thereby preventing oozing of the drug up through the extremely small pathway created by the needle.
- Place the patient in the correct position for administration of an IM injection.
- Cleanse the skin.
- Pull the skin, SC tissues, and fat (that are over the injection site) laterally, displacing the tissue to the side.
- While holding the tissues in the lateral position, insert the needle and inject the drug.
After the drug is injected, release the tissues and withdraw the needle. This technique prevents the backflow of drug into the SC tissue.

Administration of Drugs by the Intravenous Route

A drug administered by the intravenous (IV) route is given directly into the blood by a needle inserted into a vein. Drug action occurs almost immediately.

Drugs administered via the IV route may be given:

- Slowly, over 1 or more minutes
- Rapidly (IV push)
- By piggyback infusions (drugs are mixed with 50–100 mL of compatible IV fluid and administered during a period of 30–60 minutes piggybacked onto the primary IV line)
- Into an existing IV line (the IV port)
- Into an intermittent venous access device called a heparin lock (a small IV catheter in the patient’s vein connected to a small fluid reservoir with a rubber cap through which the needle is inserted to administer the drug)
- By being added to an IV solution and allowed to infuse into the vein over a longer period

When administering a drug into a vein by a venipuncture, the nurse should place a tourniquet above the selected vein. It is important to tighten the tourniquet so that venous blood flow is blocked but arterial blood flow is not. The nurse should allow the veins to fill (distend) and then should pull the skin taut (to anchor the vein and the skin) and insert the needle into the vein, bevel up, and at a short angle to the skin. Blood should immediately flow into the syringe if the needle is properly inserted into the vein.

Performing a venipuncture requires practice. A suitable vein for venipuncture may be hard to find, and some
veins are difficult to enter. The nurse should never repeatedly and unsuccessfully attempt a venipuncture. Depending on clinical judgment, three unsuccessful attempts on the same patient warrant having a more skilled individual attempt the procedure.

Some drugs are added to an IV solution, such as 1000 mL of dextrose 5% and water. The drug is usually added to the IV fluid container immediately before adding the fluid to the IV line. Whenever a drug is added to an IV fluid, the bottle must have a label attached indicating the drug and drug dose added to the IV fluid. In some hospitals, a pharmacist is responsible for adding specific drugs to IV fluids.

Intravenous Infusion Controllers and Pumps

Electronic infusion devices are classified as either infusion controllers or infusion pumps. The primary difference between the two is that an infusion pump adds pressure to the infusion, whereas an infusion controller does not. An infusion pump may be used to deliver the desired number of drops per minute. An alarm is set to sound if the IV is more than or less than the preset rate.

Controllers and pumps have detectors and alarms that alert the nurse to various problems, such as air in the line, an occlusion, low battery, completion of an infusion, or an inability to deliver the preset rate. When any problem is detected by the device, an alarm is activated to alert the nurse. Potential complications in IV therapy are the same as those with peripheral line.

**Nursing Responsibilities**

After the start of an IV infusion, the nurse records on the patient’s chart the type of IV fluid and, when applicable, the drug added to the IV solution. It is important to check the infusion rate every 15 to 30 minutes. At this time, the nurse also inspects the needle site for signs of redness, swelling, or other problems. Swelling around the needle may indicate one of two things: extravasation or infiltration. **Extravasation** refers to the escape of fluid from a blood vessel into surrounding tissues while the needle or catheter is in the vein. **Infiltration** is the collection of fluid in tissues (usually SC tissue) when the needle or catheter is out of the vein. Both events necessitate discontinuation of the infusion and insertion of an IV line in another vein. Some drugs are capable of causing severe tissue damage if extravasation or infiltration occurs.

If extravasation or infiltration occurs, the IV must be stopped and restarted in another vein. The primary

**Nursing Alert**

Use of an infusion pump or controller still requires nursing supervision and frequent monitoring of the IV infusion. Infiltration can progress rapidly because the increased pressure will not slow the infusion until considerable edema has occurred. Therefore, it is important to monitor frequently for signs of infiltration, such as edema or redness at the site. Careful monitoring of the pump or controller is also necessary to make sure the flow rate is correct.
care provider should be contacted if a drug capable of causing tissue damage (eg, norepinephrine [Levophed]) has escaped into the tissues surrounding the needle insertion site.

**Administration of Drugs by the Intradermal Route**

Drugs given by the intradermal route are usually those for sensitivity tests (eg, the tuberculin test or allergy skin testing) (see Fig. 2-5A). Absorption is slow and allows for good results when testing for allergies or administering local anesthetics.

**Nursing Responsibilities**

The nurse observes the following points when administering drugs by the intradermal route:

- The inner part of the forearm and the upper back may be used for intradermal injections. The area should be hairless; areas near moles, scars, or pigmented skin areas should be avoided. The nurse should cleanse the area in the same manner as for SC and IM injections.
- A 1-mL syringe with a 25- to 27-gauge needle that is 1/4 to 5/8 inch long is best suited for intradermal injections. Small volumes (usually <0.1 mL) are used for intradermal injections and administered with the bevel up.
- The nurse should insert the needle at a 15-degree angle between the upper layers of the skin. The nurse should not aspirate the syringe or massage the area. Injection produces a small wheal (raised area) on the outer surface of the skin. If a wheal does not appear on the outer surface of the skin, there is a good possibility that the drug entered the SC tissue, and any test results would be inaccurate.

**Other Parenteral Routes of Drug Administration**

The primary care provider may administer a drug by the intracardial, intralesional, intra-arterial, or intra-articular routes. The nurse may be responsible for preparing the drug for administration. The nurse should ask the primary care provider what special materials will be required for administration.

Venous access ports are totally implanted ports with a self-sealing septum that is attached to a catheter leading to a large vessel, usually the vena cava. These devices are most commonly used for chemotherapy or other long-term therapy and require surgical insertion and removal. Drugs are administered through injections made into the portal through the skin. These drugs are administered by the primary care provider or a registered nurse.

**DISPLAY 2-2 • Topical Applications and Locations of Use**

- Creams, lotions, or ointments applied to the skin with a tongue blade, gloved fingers, or gauze
- Sprays applied to the skin or into the nose or oral cavity
- Liquids inserted into body cavities, such as fistulas
- Liquids inserted into the bladder or urethra
- Solids (eg, suppositories) or jellies inserted into the urethra
- Liquids dropped into the eyes, ears, or nose
- Ophthalmic ointments applied to the eyelids or dropped into the lower conjunctival sac
- Solids (eg, suppositories, tablets), foams, liquids, and creams inserted into the vagina
- Continuous or intermittent wet dressings applied to skin surfaces
- Solids (eg, tablets, lozenges) dissolved in the mouth
- Sprays or mists inhaled into the lungs
- Liquids, creams, or ointments applied to the scalp
- Solids (eg, suppositories), liquids, or foams inserted into the rectum

**ADMINISTRATION OF DRUGS THROUGH THE SKIN AND MUCOUS MEMBRANES**

Drugs may be applied to the skin and mucous membranes using several routes: topically (on the outer layers of skin), transdermally through a patch on which the drug has been implanted, or inhaled through the membranes of the upper respiratory tract.

**Administration of Drugs by the Topical Route**

Most topical drugs act on the skin but are not absorbed through the skin. These drugs are used to soften, disinfect, or lubricate the skin. A few topical drugs are enzymes that have the ability to remove the superficial debris, such as the dead skin and purulent matter present in skin ulcerations. Other topical drugs are used to treat minor, superficial skin infections. The various forms of topical applications and locations of use are described in Display 2-2.

**Nursing Responsibilities**

The nurse considers the following points when administering drugs by the topical route:

- The primary care provider may write special instructions for the application of a topical drug. For example, to apply the drug in a thin, even layer or to cover the area after application of the drug to the skin.
- Other drugs may have special instructions provided by the manufacturer, such as to apply the drug to a
clean, hairless area or to let the drug dissolve slowly in the mouth. All of these instructions are important because drug action may depend on correct administration of the drug.

**Administration of Drugs by the Transdermal Route**

Drugs administered by the transdermal route are readily absorbed from the skin and provide systemic effects. This type of administration is called transdermal drug delivery system. The drug dosages are implanted in a small patch-type bandage. The backing is removed, and the patch is applied to the skin where the drug is gradually absorbed into the systemic circulation. This type of drug system maintains a relatively constant blood concentration and reduces the possibility of toxicity. In addition, the use of drugs transdermally causes fewer adverse reactions, and administration is less frequent than when the drugs are given by another route. Nitroglycerin (used to treat cardiac problems) and scopolamine (used to treat dizziness and nausea) are two drugs given frequently by the transdermal route.

**Nursing Responsibilities**

The nurse observes the following points when administering drugs by the transdermal route:

- Apply transdermal patches to clean, dry, nonhairy areas of intact skin.
- Remove the old patch when the next dose is applied in a new site.
- Rotate sites for transdermal patches to prevent skin irritation. The chest, flank, and upper arm are the most commonly used sites. Do not shave the area to apply the patch; shaving may cause skin irritation.
- Ointments are sometimes used and come with a special paper marked in inches. Measure the correct length (onto the paper), place the paper with the drug ointment side down on the skin, and secure it with tape. Before the next dose, remove the paper and tape and cleanse the skin.

**Administration of Drugs Through Inhalation**

Drug droplets, vapor, or gas are administered through the mucous membranes of the respiratory tract with the use of a face mask, a nebulizer, or a positive-pressure breathing machine. Examples of drugs administered through inhalation include bronchodilators, mucolytics, and some anti-inflammatory drugs. These drugs produce, primarily, a local effect in the lungs.

**Nursing Responsibilities**

The primary nursing responsibility is to provide the patient with proper instructions for administering the drug. For example, many patients with asthma use a metered-dose inhaler to dilate the bronchi and make breathing easier. Without proper instruction on how to use the inhaler, much of the drug can be deposited on the tongue, rather than in the respiratory tract. This decreases the therapeutic effect of the drug. Instructions may vary with each inhaler. To be certain that the inhaler is used correctly, the patient is referred to the instructions accompanying each device. Figure 2-9 illustrates the proper use of one type of inhaler.

**Nursing Responsibilities After Drug Administration**

After the administration of any type of drug, the nurse is responsible for the following:

- Recording the administration of the drug. The nurse should complete this task as soon as possible. This is particularly important when PRN drugs (especially narcotics) are given.
- Recording (when necessary) any information concerning the administration of the drug. This includes information such as the IV flow rate, the site used for parenteral administration, problems...
• Evaluating and recording the patient’s response to the drug (when applicable). Evaluation may include such facts as relief of pain, decrease in body temperature, relief of itching, and decrease in the number of stools passed.

• Observing the adverse reactions. The frequency of these observations will depend on the drug administered. The nurse must record all suspected adverse reactions and report them to the primary care provider. The nurse must immediately report serious adverse reactions to the primary care provider.

ADMINISTRATION OF DRUGS IN THE HOME

Many times drugs are not administered by the nurse but in the home setting by the patient or family members serving as caregivers. When this is the case, it is important that the patient or caregivers understand the treatment regimen and are given an opportunity to ask questions concerning the drug therapy, such as why the drug was prescribed, how to administer the drug, and adverse reactions of the drug (see Chap. 5 for information concerning patient and family education). The Home Care Checklist: Administering Drugs Safely in the Home gives some guidelines to follow when drugs are administered in the home by the patient or caregiver, rather than by the nurse.

Critical Thinking Exercises

1. Ms. Benson, a nurse on your clinical unit, tells you that the head nurse is upset with her because she has not been recording the administration of narcotics immediately after they are given. Discuss the rationales you could give to Ms. Benson to stress the importance of recording the administration of narcotics immediately after they are given.

2. A nurse is to give an SC injection of heparin to a patient. Determine what information the nurse needs to know about the patient before preparing the injection. Discuss how this information would affect the preparation of the injection and the technique used to give the SC injection.

3. After administering a drug to a patient you find that the incorrect dosage was given. The dose that you administered was two times the correct dosage. Analyze what action, if any, you would take.
4. Discuss why the sixth right, right documentation, is important in drug administration.
5. Discuss the importance in participating in the MedWatch programs and the Medication Errors Reporting Program.

**Review Questions**

1. The nurse correctly administers an intramuscular injection by _____.
   A. displacing the skin to the side before making the injection
   B. using a 1-inch needle
   C. inserting the needle at a 90-degree angle
   D. using a 25-gauge needle

2. When preparing a drug for SC administration, the nurse is aware that the usual volume of a drug injected by the SC route is _____.
   A. 2 to 5 mL
   B. 3 to 4 mL
   C. 0.5 to 1 mL
   D. <0.5 mL

3. The nurse explains to the patient receiving an IV injection that the action of the drug occurs _____.
   A. in 5 to 10 minutes
   B. in 15 to 20 minutes
   C. within 30 minutes
   D. almost immediately

4. When administering a drug the nurse _____.
   A. checks the drug label two times before administration
   B. is alert for any drugs with a similar name
   C. may administer a drug prepared by another nurse
   D. may crush any tablet that the patient is unable to swallow

5. When monitoring a patient with an IV, the nurse observes the area around the needle insertion site is swollen and red. The first action of the nurse is to _____.
   A. check the patient’s blood pressure and pulse
   B. check further for possible extravasation
   C. ask the patient if the IV site has been accidentally injured
   D. immediately notify the primary health care provider
Review of Arithmetic and Calculation of Drug Dosages

Key Terms

<table>
<thead>
<tr>
<th>Apothecaries’ System</th>
<th>Household Measurements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Celsius (C)</td>
<td>Imperial</td>
</tr>
<tr>
<td>Centigrade</td>
<td>Liter</td>
</tr>
<tr>
<td>Decimal</td>
<td>Metric System</td>
</tr>
<tr>
<td>Decimal Fraction</td>
<td>Minim</td>
</tr>
<tr>
<td>Denominator</td>
<td>Mixed Number</td>
</tr>
<tr>
<td>Diluent</td>
<td>Proper Fraction</td>
</tr>
<tr>
<td>Dimensional Analysis</td>
<td>Quotient</td>
</tr>
<tr>
<td>Dividend</td>
<td>Remainer</td>
</tr>
<tr>
<td>Divisor</td>
<td>Solute</td>
</tr>
<tr>
<td>Dram</td>
<td>Solvent</td>
</tr>
<tr>
<td>Fahrenheit (F)</td>
<td></td>
</tr>
<tr>
<td>Fluid Dram</td>
<td></td>
</tr>
<tr>
<td>Fluid Ounce</td>
<td></td>
</tr>
<tr>
<td>Grain</td>
<td></td>
</tr>
<tr>
<td>Gram</td>
<td></td>
</tr>
</tbody>
</table>

Chapter Objective

On completion of this chapter, the student will:
- Accurately perform mathematical calculations when they are necessary to compute drug dosages.

REVIEW OF ARITHMETIC

Fractions

The two parts of a fraction are the numerator and the denominator.

\[
\frac{2}{3} \quad \text{numerator} \quad \frac{1}{2} \quad \text{denominator}
\]

A proper fraction may be defined as a part of a whole or any number less than a whole number. An improper fraction is a fraction having a numerator the same as or larger than the denominator.

\[
\text{proper fraction} \quad \frac{1}{2} \quad \text{improper fraction} \quad \frac{7}{3}
\]

The numerator and the denominator must be of like entities or terms, that is:

Correct (like terms)
- 2 acres
- 3 acres
- 2 grams
- 3 grams

Incorrect (unlike terms)
- 2 acres
- 3 miles
- 2 grams
- 5 milliliters

Mixed Numbers and Improper Fractions

A mixed number is a whole number and a proper fraction. A whole number is a number that stands alone; 3, 25, and 117 are examples of whole numbers. A proper fraction is a fraction whose numerator is smaller than the denominator; 1/8, 2/5, and 3/7 are examples of proper fractions.

These are mixed numbers:
- 2 2/3 2 is the whole number and 2/3 is the proper fraction
3 1/4 3 is the whole number and 1/4 is the proper fraction

When doing certain calculations, it is sometimes necessary to change a mixed number to an improper fraction or change an improper fraction to a mixed number.

An improper fraction is a fraction whose numerator is larger than the denominator; 5/2, 16/3, and 12 3/2 are examples of improper fractions.

To change a mixed number to an improper fraction, multiply the denominator of the fraction by the whole number, add the numerator, and place the sum over the denominator.

EXAMPLE Mixed number 3 3/5

1. Multiply the denominator of the fraction (5) by the whole number (3) or 5 \times 3 = 15:

2. Add the result of multiplying the denominator of the fraction (15) to the numerator (3) or 15 + 3 = 18:

3. Then place the sum (18) over the denominator of the fraction:

To change an improper fraction to a mixed number, divide the denominator into the numerator. The quotient (the result of the division of these two numbers) is the whole number. Then place the remainder over the denominator of the improper fraction.

EXAMPLE Improper fraction 15/4

1. Divide the denominator (4) into the numerator (15) or 15 divided by 4 (15 ÷ 4):

2. The quotient (3) becomes the whole number:

3. The remainder (3) now becomes the numerator of the fraction of the mixed number:

4. And the denominator of the improper fraction (4) now becomes the denominator of the fraction of the mixed number:

Adding Fractions With Like Denominators

When the denominators are the same, fractions can be added by adding the numerators and placing the sum of the numerators over the denominator.

EXAMPLES

\[
\begin{align*}
2/7 + 3/7 &= 5/7 \\
1/10 + 3/10 &= 4/10 \\
2/9 + 1/9 + 4/9 &= 7/9 \\
1/12 + 5/12 + 3/12 &= 9/12 \\
2/13 + 1/13 + 3/13 + 5/13 &= 11/13
\end{align*}
\]

When giving a final answer, fractions are always reduced to the lowest possible terms. In the examples above, the answers of 5/7, 7/9, and 11/13 cannot be reduced. The answers of 4/10 and 9/12 can be reduced to 2/5 and 3/4.

To reduce a fraction to the lowest possible terms, determine if any number, which always must be the same, can be divided into both the numerator and the denominator.

4/10: the numerator and the denominator can be divided by 2

9/12: the numerator and the denominator can be divided by 3

For example: 4 ÷ 2 = 2

9/12 divided by 3

If when adding fractions the answer is an improper fraction, it may then be changed to a mixed number.

2/5 + 4/5 = 6/5 (improper fraction)

6/5 changed to a mixed number is 1 1/5

Adding Fractions With Unlike Denominators

Fractions with unlike denominators cannot be added until the denominators are changed to like numbers or numbers that are the same. The first step is to find the lowest common denominator, which is the lowest number divisible by (or that can be divided by) all the denominators.

EXAMPLE Add 2/3 and 1/4

\[
\begin{align*}
2/3 + 1/4 &= \frac{2}{3} \times \frac{4}{4} + \frac{1}{4} \times \frac{3}{3} \\
&= \frac{8}{12} + \frac{3}{12} \\
&= \frac{11}{12}
\end{align*}
\]

The lowest number that can be divided by these two denominators is 12; therefore, 12 is the lowest common denominator.
1. Divide the lowest common denominator (which in this example is 12) by each of the denominators in the fractions (in this example 3 and 4):

\[
\frac{2}{3} = \frac{12}{12} \quad (12 \div 3 = 4)
\]

\[
\frac{1}{4} = \frac{12}{12} \quad (12 \div 4 = 3)
\]

2. Multiply the results of the divisions by the numerator of the fractions (12/3 and 12/4) and place the results in the numerator:

\[
\frac{2}{3} \times \frac{12}{12} = \frac{24}{12} \quad 8
\]

\[
\frac{1}{4} \times \frac{12}{12} = \frac{12}{12} \quad 3
\]

3. Add the numerators (8 + 3) and place the result over the denominator (12):

\[
\frac{8}{12} + \frac{3}{12} = \frac{11}{12}
\]

### Adding Mixed Numbers or Fractions With Mixed Numbers

When adding two or more mixed numbers or adding fractions and mixed numbers, the mixed number is first changed to an improper fraction.

**EXAMPLE** Add 3 3/4 and 3 3/4

\[
3\frac{3}{4} \text{ changed to an improper fraction } \rightarrow \frac{15}{4}
\]

\[
3\frac{3}{4} \text{ changed to an improper fraction } \rightarrow \frac{15}{4}
\]

The numerators are added \(\frac{15}{4} + \frac{15}{4} = \frac{30}{4} = 7\frac{1}{2}\)

The improper fraction (30/4) is changed to a mixed number (7 2/4) and the fraction of the mixed number (2/4) changed to the lowest possible terms (1/2).

**EXAMPLE** Add 2 1/2 and 3 1/4

\[
2\frac{1}{2} \text{ changed to an improper fraction } \frac{5}{2}
\]

\[
3\frac{1}{4} \text{ changed to an improper fraction } \frac{13}{4}
\]

In the example above, 5/2 and 13/4 cannot be added because the denominators are not the same. It will be necessary to find the lowest common denominator first.
EXAMPLES

\[ \frac{1}{2} \times \frac{1}{2} = \frac{1}{4} \] (answer reduced to lowest possible terms)
\[ \frac{3}{8} \times \frac{6}{8} = \frac{3}{4} \] (answer reduced to lowest possible terms)
\[ 4 \times \frac{2}{3} = \frac{8}{3} = \frac{22}{3} \] (improper fraction changed to a mixed number)

Multiplying Mixed Numbers

To multiply mixed numbers, the mixed numbers are changed to improper fractions and then multiplied.

\[
\begin{align*}
2 \frac{1}{2} \times 3 \frac{1}{4} &= \frac{5}{2} \times \frac{13}{4} = \frac{65}{8} = \frac{81}{8} \\
3 \frac{1}{3} \times 4 \frac{1}{2} &= \frac{10}{3} \times \frac{9}{2} = \frac{90}{6} = 15
\end{align*}
\]

Multiplying a Whole Number and a Mixed Number

To multiply a whole number and a mixed number, both numbers must be changed to improper fractions.

\[
\begin{align*}
3 \times 2 \frac{1}{2} &= \frac{3}{1} \times \frac{5}{2} = \frac{15}{2} = 7 \frac{1}{2} \\
2 \times 4 \frac{1}{2} &= \frac{2}{1} \times \frac{9}{2} = \frac{18}{2} = 9
\end{align*}
\]

A whole number is converted to an improper fraction by placing the whole number over 1. In the above examples, 3 becomes 3/1 and 2 becomes 2/1.

Dividing Fractions

When fractions are divided, the second fraction (the divisor) is inverted (turned upside down) and then the fractions are multiplied.

\[
\begin{align*}
\frac{1}{3} \div \frac{3}{7} &= \frac{1}{3} \times \frac{7}{3} = \frac{7}{9} \\
\frac{1}{8} \div \frac{1}{4} &= \frac{1}{8} \times \frac{4}{1} = \frac{4}{2} \\
\frac{3}{4} \div \frac{1}{2} &= \frac{3}{4} \times \frac{2}{1} = \frac{6}{4} = \frac{1}{2}
\end{align*}
\]

In the above examples, the second answer was reduced to its lowest possible terms and the third answer, which was an improper fraction, was changed to a mixed number.

Dividing Fractions and Mixed Numbers

Some problems of division may be expressed as (1) fractions and mixed numbers, (2) two mixed numbers, (3) whole numbers and fractions, or (4) whole numbers and mixed numbers.

MIXED NUMBERS AND FRACTIONS. When a mixed number is divided by a fraction, the whole number is first changed to a fraction.

\[
\begin{align*}
2 \frac{1}{2} \div \frac{1}{3} &= \frac{5}{2} \div \frac{1}{3} = \frac{5}{2} \times \frac{3}{1} = \frac{15}{2} = \frac{9}{1} \\
2 \frac{1}{2} \div \frac{1}{2} &= \frac{5}{2} \div \frac{1}{2} = \frac{5}{2} \times \frac{2}{1} = 10 = 5
\end{align*}
\]

MIXED NUMBERS. When two mixed numbers are divided, they are both changed to improper fractions.

\[
\begin{align*}
3 \frac{3}{4} \div 1 \frac{1}{2} &= \frac{15}{4} \div \frac{3}{2} = \frac{15}{4} \times \frac{2}{1} = \frac{30}{2} = \frac{12}{2} \\
&= 2 \frac{6}{12} = \frac{21}{2}
\end{align*}
\]

WHOLE NUMBERS AND FRACTIONS. When a whole number is divided by a fraction, the whole number is changed to an improper fraction by placing the whole number over 1.

\[
\begin{align*}
2 \div \frac{1}{2} &= \frac{2}{1} \times \frac{2}{1} = \frac{2}{1} \times \frac{3}{2} = \frac{6}{2} = 3
\end{align*}
\]

WHOLE NUMBERS AND MIXED NUMBERS. When whole numbers and mixed numbers are divided, the whole number is changed to an improper fraction and the mixed number is changed to an improper fraction.

\[
\begin{align*}
4 \div 2 \frac{2}{3} &= \frac{4}{1} \div \frac{8}{3} = \frac{4}{1} \times \frac{3}{8} = \frac{12}{8} = \frac{14}{8} = \frac{11}{2}
\end{align*}
\]

Ratios

A ratio is a way of expressing a part of a whole or the relation of one number to another. For example, a ratio written as 1:10 means 1 in 10 parts, or 1 to 10. A ratio may also be written as a fraction; thus 1:10 can also be expressed as 1/10.

\[
\begin{align*}
1 \text{ : } 1000 &= 1 \text{ part in } 1000 \text{ parts, or } 1 \text{ to } 1000, \text{ or } 1/1000 \\
1 \text{ : } 250 &= 1 \text{ part in } 250 \text{ parts, or } 1 \text{ to } 250, \text{ or } 1/250
\end{align*}
\]

Some drug solutions are expressed in ratios, for example 1:100 or 1:500. These ratios mean that there is 1 part of a drug in 100 parts of solution or 1 part of the drug in 500 parts of solution.
Percentages

The term percentage or percent (%) means parts per hundred.

**EXAMPLES**
- 25% is 25 parts per hundred
- 50% is 50 parts per hundred
A percentage may also be expressed as a fraction.

**EXAMPLES**
- 25% is 25 parts per hundred or 25/100
- 50% is 50 parts per hundred or 50/100
- 30% is 30 parts per hundred or 30/100

The above fractions may also be reduced to their lowest possible terms:
- 25/100 = 1/4
- 50/100 = 1/2
- 30/100 = 3/10.

**Changing a Fraction to a Percentage**

To change a fraction to a percentage, divide the denominator by the numerator and multiply the results (quotient) by 100 and then add a percent sign (%).

**EXAMPLES**
- Change 4/5 to a percentage
  \[
  4 \div 5 = 0.8 \\
  0.8 \times 100 = 80\% 
  \]
- Change 2/3 to a percentage
  \[
  2 \div 3 = 0.666 \\
  0.666 \times 100 = 66.6\% 
  \]

**Changing a Ratio to a Percentage**

To change a ratio to a percentage, the ratio is first expressed as a fraction with the first number or term of the ratio becoming the numerator and the second number or term becoming the denominator. For example, the ratio 1:500 when changed to a fraction becomes 1/500. This fraction is then changed to a percentage by the same method shown in the preceding section.

**EXAMPLE**
- Change 1:125 to a percentage
  \[
  1 \div 125 = 0.008 \\
  0.008 \times 100 = 0.8 \\
  \text{adding the percent sign} = 0.8\% 
  \]

**Changing a Percentage to a Ratio**

To change a percentage to a ratio, the percentage becomes the numerator and is placed over a denominator of 100.

**EXAMPLES**
- Changing 5% and 10% to ratios
  \[
  5\% \text{ is } \frac{5}{100} = \frac{1}{20} \text{ or } 1:20 \\
  10\% \text{ is } \frac{10}{100} = \frac{1}{10} \text{ or } 1:10 
  \]

**Proportions**

A proportion is a method of expressing equality between two ratios. An example of two ratios expressed as a proportion is: 3 is to 4 as 9 is to 12. This may also be written as:

\[
3:4 \text{ as } 9:12 \\
\text{or} \quad 3:4::9:12 \\
\text{or} \quad \text{Proportions may be used to find an unknown quantity. The unknown quantity is assigned a letter, usually } X. \text{ An example of a proportion with an unknown quantity is } 5:10::15:X.

The first and last terms of the proportion are called the extremes. In the above expression 5 and X are the extremes. The second and third terms of the proportion are called the means. In the above proportion, 10 and 15 are the means.

To solve for X:

1. Multiply the extremes and place the product (result) to the left of the equal sign.
   \[
   5:10::15:X \\
   5X = 
   \]

2. Multiply the means and place the product to the right of the equal sign.
   \[
   5:10::15X \\
   5X = 150 
   \]

3. Solve for X by dividing the number to the right of the equal sign by the number to the left of the equal sign (150 ÷ 5).
   \[
   5X = 150 \\
   X = 30 
   \]
To prove the answer is correct, substitute the answer (30) for X in the equation.

\[
\frac{5}{10} : \frac{15}{X} = \frac{5}{10} : \frac{15}{30}
\]

Then multiply the means and place the product to the left of the equal sign. Then multiply the extremes and place the product to the right of the equal sign.

\[
\frac{5}{10} : \frac{15}{30} = \frac{150}{150} = 1
\]

If the numbers are the same on both sides of the equal sign, the equation has been solved correctly.

If the proportion has been set up as a fraction, cross multiply and solve for X.

\[
\frac{5}{X} = \frac{10}{15} = \frac{5X}{150} = \frac{10 \times 15}{150} = \frac{150}{150} = 1
\]

To set up a proportion, remember that a sequence must be followed. If a sequence is not followed, the proportion will be stated incorrectly.

**Examples**

If a man can walk 6 miles in 2 hours, how many miles can he walk in 3 hours?

- miles is to hours and miles is to hours
- or miles:hours::miles:hours
- or \[
\frac{\text{miles}}{\text{hours}} = \frac{\text{miles}}{\text{hours}}
\]

The unknown fact is the number of miles walked in 3 hours:

\[
\frac{6 \text{ miles}}{2 \text{ hours}} = \frac{X \text{ miles}}{3 \text{ hours}}
\]

\[
2X = 18
\]

X = 9 miles (he can walk 9 miles in 3 hours)

If there are 15 grains in 1 gram, 30 grains equals how many grams?

\[
\frac{15 \text{ grains}}{1 \text{ gram}} = \frac{30 \text{ grains}}{X \text{ grams}}
\]

\[
15X = 30
\]

X = 2 grams (30 grains equals 2 grams)

**Decimals**

Decimals are used in the metric system. A decimal is a fraction in which the denominator is 10 or some power of 10. For example, 2/10 (read as two tenths) is a fraction with a denominator of 10; 1/100 (read as one one hundredth) is an example of a fraction with a denominator that is a power of 10 (ie, 100).

A power (or multiple) of 10 is the number 1 followed by one or more zeros. Therefore, 100, 1000, 10,000 and so on are powers of 10 because the number 1 is followed by two, three, and four zeros, respectively. Fractions whose denominators are 10 or a power of 10 are often expressed in decimal form.

**Parts of a Decimal**

There are three parts to a decimal:

- number(s) d number(s)
- to the e the left of c right of i the decimal m decimal

**Types of Decimals**

A decimal may consist only of numbers to the right of the decimal point. This is called a decimal fraction. Examples of decimal fractions are 0.05, 0.6, and 0.002.

A decimal may also have numbers to the left and right of the decimal point. This is called a mixed decimal fraction. Examples of mixed decimal fractions are 1.25, 2.5, and 7.5.

Both decimal fractions and mixed decimal fractions are commonly referred to as decimals. When there is no number to the left of the decimal, a zero may be written, for example, 0.25. Although in general mathematics the zero may not be required, it should be used in the writing of drug doses in the metric system. Use of the zero lessens the chance of drug errors, especially when the dose of a drug is hurriedly written and the decimal point is indistinct. For example, a drug order for dexamethasone is written as dexamethasone .25 mg by one physician and written as dexamethasone 0.25 by another. If the decimal point in the first written order is indistinct, the order might be interpreted as 25 mg, which is 100 times the prescribed dose!

**Reading Decimals**

To read a decimal, the position of the number to the left or right of the decimal point indicates how the decimal is to be expressed.
Adding Decimals

When adding decimals, place the numbers in a column so that the whole numbers are aligned to the left of the decimal and the decimal fractions are aligned to the right of the decimal.

EXAMPLE

\[
\begin{array}{c}
20.45 \\
+2.56 \\
\hline
23.01
\end{array}
\]

Subtracting Decimals

When subtracting decimals, the numbers are aligned to the left and right of the decimal in the same manner as for the addition of decimals.

EXAMPLE

\[
\begin{array}{c}
20.45 \\
-2.56 \\
\hline
17.89
\end{array}
\]

Multiplying a Whole Number by a Decimal

To multiply a whole number by a decimal, move the decimal point of the product (answer) as many places to the left as there are places to the right of the decimal point.

EXAMPLE

\[
\begin{array}{c}
500 \\
\times0.05 \\
\hline
25.00
\end{array}
\]

After moving the decimal point, the answer reads 25.

Multiplying a Decimal by a Decimal

To multiply a decimal by a decimal, move the decimal point of the product (answer) as many places to the left as there are places to the right in both decimals.

EXAMPLE

\[
\begin{array}{c}
2.75 \\
\times0.5 \\
\hline
1.375
\end{array}
\]

After moving the decimal point, the answer reads 1.375.

Dividing Decimals

The divisor is a number that is divided into the dividend.

EXAMPLE

\[
\begin{array}{c}
0.69 \\
\div0.3 \\
\hline
2.3
\end{array}
\]

This may be written or spoken as 0.69 divided by 0.3. To divide decimals:

1. The divisor is changed to a whole number. In this example, the decimal point is moved one place to the right so that 0.3 now becomes 3, which is a whole number.

\[
0.3\overline{0.69}
\]

2. The decimal point in the dividend is now moved the same number of places to the right. In this example, the decimal point is moved one place to the right, the same number of places the decimal point in the divisor was moved.

\[
0.3\overline{0.69}
\]

3. The numbers are now divided.

\[
\frac{2.3}{3\overline{6.9}}
\]

When only the dividend is a decimal, the decimal point is carried to the quotient (answer) in the same position.

EXAMPLES

\[
\begin{array}{c}
0.375 \\
\div0.750 \\
\hline
0.500
\end{array}
\]

To divide when only the divisor is a decimal, for example,

\[
0.3\overline{66}
\]

1. The divisor is changed to a whole number. In this example the decimal point is moved one place to the right.

\[
0.3\overline{66}
\]

2. The decimal point in the dividend must also be moved one place to the right.

\[
0.3\overline{66.0}
\]

3. The numbers are now divided.

\[
\frac{2.3}{3\overline{66.0}}
\]

Whenever the decimal point is moved in the dividend it must also be moved in the divisor, and whenever the
Changing a Fraction to a Decimal
To change a fraction to a decimal, divide the numerator by the denominator.

**EXAMPLE**

\[ \frac{1}{5} = 0.2 \quad \frac{3}{4} = 0.75 \quad \frac{1}{6} = 0.166 \]

Changing a Decimal to a Fraction
To change a decimal to a fraction:

1. Remove the decimal point and make the resulting whole number the numerator: 0.2 = 2.
2. The denominator is stated as 10 or a power of 10. In this example, 0.2 is read as two tenths, and therefore the denominator is 10.

0.2 = \frac{2}{10}

reduced to the lowest possible number is \frac{1}{5}

**ADDITIONAL EXAMPLES**

0.75 = \frac{75}{100} = \frac{3}{4}
0.025 = \frac{25}{1000} = \frac{1}{40}

**CALCULATION OF DRUG DOSAGES**

Although most hospital pharmacies dispense drugs as single doses or in a unit dose system, on occasion the nurse must compute a drug dosage because it differs from the dose of the drug that is available. This is particularly true of small hospitals, nursing homes, physicians' offices, and outpatient clinics that may not have a complete range of all available doses for a particular drug. Because certain situations may require computing the desired amount of drug to be given, nurses must be familiar with the calculation of all forms of drug dosages.

**Systems of Measurement**

There are three systems of measurement of drug dosages: the metric system, the apothecaries' system, and household measurements. The metric system is the most commonly used system of measurement in medicine. A physician may prescribe a drug dosage in the apothecaries' system, but for the most part this ancient system of measurements is only occasionally used. The household system is rarely used in a hospital setting but may be used to measure drug dosages in the home.

**DISPLAY 3-1 ● Metric Measurements**

<table>
<thead>
<tr>
<th>WEIGHT</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The unit of weight is the gram.</td>
<td></td>
</tr>
<tr>
<td>1 kilogram (kg) = 1000 grams (g)</td>
<td></td>
</tr>
<tr>
<td>1 gram (g) = 1000 milligrams (mg)</td>
<td></td>
</tr>
<tr>
<td>1 milligram (mg) = 1000 micrograms (mcg)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VOLUME</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The unit of volume is the liter.</td>
<td></td>
</tr>
<tr>
<td>1 decaliter (dL) = 10 liters (L)</td>
<td></td>
</tr>
<tr>
<td>1 liter (L) = 1000 milliliters (mL)</td>
<td></td>
</tr>
<tr>
<td>1 milliliter (mL) = 0.001 liter (L)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LENGTH</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The unit of length is the meter.</td>
<td></td>
</tr>
<tr>
<td>1 meter (m) = 100 centimeters (cm)</td>
<td></td>
</tr>
<tr>
<td>1 centimeter (cm) = 0.01 meter (m)</td>
<td></td>
</tr>
<tr>
<td>1 millimeter (mm) = 0.001 meter (m)</td>
<td></td>
</tr>
</tbody>
</table>

**The Metric System**

The metric system uses decimals (or the decimal system). In the metric system, the gram is the unit of weight, the liter the unit of volume, and the meter the unit of length.

Display 3-1 lists the measurements used in the metric system. The abbreviations for the measurements are given in parentheses.

**The Apothecaries’ System**

The apothecaries’ system uses whole numbers and fractions. Decimals are not used in this system. The whole numbers are written as lowercase Roman numerals, for example, x instead of 10, or v instead of 5.

The units of weight in the apothecaries’ system are grains, drams, and ounces. The units of volume are minims, fluid drams, and fluid ounces. The units of measurement in this system are not based on exact measurements.

Display 3-2 lists the measurements used in the apothecaries’ system. The abbreviations (or symbols) for the measurements are given in parentheses.

**DISPLAY 3-2 ● Apothecaries’ Measurements**

<table>
<thead>
<tr>
<th>WEIGHT</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The units of weight are grains, drams, and ounces.</td>
<td></td>
</tr>
<tr>
<td>60 grains (gr) = 1 dram (d)</td>
<td></td>
</tr>
<tr>
<td>1 ounce (oz) = 480 grains (gr)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VOLUME</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>The units of volume are minims, fluid drams, and fluid ounces.</td>
<td></td>
</tr>
<tr>
<td>1 fluid dram = 60 minims (m)</td>
<td></td>
</tr>
<tr>
<td>1 fluid ounce = 8 fluid drams</td>
<td></td>
</tr>
</tbody>
</table>
Household Measurements

When used, household measurements are for volume only. In the hospital, household measurements are rarely used because they are inaccurate when used to measure drug dosages. On occasion, the nurse may use the pint, quart, or gallon when ordering, irrigating, or sterilizing solutions or stock solutions. For the ease of a patient taking a drug at home, the physician may order a drug dosage in household measurements.

Display 3-3 lists the more common household measurements, with abbreviations in parentheses.

Conversion Between Systems

To convert between systems, it is necessary to know the equivalents, or what is equal to what in each system. Table 3-1 lists the more common equivalents.

These equivalents are only approximate because the three systems are different and are not truly equal to each other.

Several methods may be used to convert from one system to another using an equivalent, but most conversions can be done by using proportion.

EXAMPLES

Convert 120 mg (metric) to grains (apothecaries')

Using proportion and the known equivalent 60 mg = gr i (1 grain)

\[
1 \text{ gr:} 60 \text{ mg:} X \text{ gr:} 120 \text{ mg} \\
60X = 120 \\
X = 2 \text{ gr (grains or gr ii)}
\]

Note the use of the abbreviations gr and mg when setting up the proportion. This shows that the proportion was stated correctly and helps in identifying the answer as 2 grains.

Convert gr 1/100 (apothecaries') to mg (metric)

Using proportion and the known equivalent 60 mg = 1 gr:

If there are 60 mg in 1 gr, there are X mg in 1/100 gr

\[
60 \text{ mg:} 1 \text{ gr:} X \text{ mg:} 1/100 \text{ gr} \\
X = 60 \times \frac{1}{100} = \frac{60}{100} = \frac{3}{5} \\
X = \frac{3}{5} \text{ mg}
\]

or

\[
\text{gr } \frac{1}{100} = X \text{ mg} \\
\frac{60 \text{ mg}}{1 \text{ gr}} = \frac{X \text{ mg}}{\frac{1}{100} \text{ gr}} \\
X = 60 \times \frac{1}{100} = \frac{60}{100} = \frac{3}{5} \\
X = \frac{3}{5} \text{ mg}
\]

Fractions are not used in the metric system; therefore, the fraction must be converted to a decimal by dividing the denominator into the numerator, or \( \frac{3}{5} = 0.6 \) or

\[
\frac{6}{5} = 1.2
\]

Therefore, gr 1/100 is equal to 0.6 mg.

When setting up the proportion, the apothecaries’ system was written in Arabic numbers instead of Roman numerals, and their order was reversed (1 gr instead of gr i) so that all numbers and abbreviations are uniform in presentation.

Convert 0.3 milligrams (mg) [metric] to grains (gr) [apothecaries’]

Using proportion and the known equivalent 1 mg = gr 1/60

\[
0.3 \text{ mg:} 1 \text{ mg:} X \text{ gr} \\
X = 0.3 \times \frac{1}{60} = \frac{0.3}{60} = \frac{0.1}{20} = \frac{1}{200} \\
X = \frac{1}{200} \text{ gr}
\]
Therefore, 0.3 mg equals gr 1/200.
There is no rule stating which equivalent must be used. In the above problem, another equivalent (60 mg/1 gr) also could have been used. If 60 mg = 1 gr is used, the proportion would be:

\[
\frac{60 \text{ mg}}{1 \text{ gr}} = \frac{X \text{ mg}}{0.3 \text{ mg}}
\]

or

\[
\frac{60}{1} = \frac{X}{0.3}
\]

or

\[
\frac{60 \text{ mg}}{1 \text{ gr}} = \frac{0.3 \text{ mg}}{X \text{ gr}}
\]

or

\[
60 = \frac{0.3}{X}
\]

Therefore, 0.3 mg equals 0.005 gr.
Because decimals are not used in the apothecaries’ system, this decimal answer must be converted to a fraction: 0.005 is 5/1000, which, when reduced to its lowest terms, is 1/200. The final answer is now 0.3 mg = gr 1/200.

**Converting Within a System**

Sometimes it is necessary to convert within the same system, for example, changing grams (g) to milligrams (mg) or milligrams to grams. Proportion and a known equivalent also may be used for this type of conversion.

**EXAMPLE**

Convert 0.1 gram (g) to milligrams (mg)

Using proportion and the known equivalent 1000 mg = 1 g

\[
\frac{1000 \text{ mg}}{1 \text{ g}} = \frac{X \text{ mg}}{0.1 \text{ g}}
\]

or

\[
\frac{1000}{1} = \frac{X}{0.1}
\]

\[
X = 1000 \times 0.1
\]

\[
X = 100 \text{ mg}
\]

Therefore, 0.1 gram (g) equals 100 milligrams (mg).

**Solutions**

A **solute** is a substance dissolved in a **solvent**. A solvent may be water or some other liquid. Usually water is used for preparing a solution unless another liquid is specified. Solutions are prepared by using a solid (powder, tablet) and a liquid, or a liquid and a liquid. Today, most solutions are prepared by a pharmacist and not by the nurse.

Examples of how solutions may be labeled include:

- 10 mg/mL—10 mg of the drug in each milliliter
- 1:1000—a solution denoting strength or 1 part of the drug per 1000 parts
- 5 mg/teaspoon—5 mg of the drug in each teaspoon (home use)

**Reading Drug Labels**

Drug labels give important information the nurse must use to obtain the correct dosage. The unit dose is the most common type of labeling seen in hospitals. The unit dose is a method of dispensing drugs in which each capsule or tablet is packaged separately. At times the drug will come to the nursing unit in a container with a number of capsules or tablets or as a solution. The nurse must then determine the number of capsules/tablets or the amount of solution to administer.

Drug labels usually contain two names: the trade (brand) name and the generic or official name (see Chap. 1). The trade name is capitalized, written first on the label, and identified by the registration symbol. The official or generic name is written in smaller print and usually located under the trade name. Although the drug has only one official name, several companies may manufacture the drug, with each manufacturer using a different trade name. Sometimes the generic or official name is so widely known that all manufacturers will simply use that name. For example, atropine sulfate is a widely used drug that is so well known that all manufacturers use the official name. In this case only the official name, atropine sulfate, will be found on the label. Drugs may be prescribed by either the trade name or the official or generic name. See Figure 3-1 for an example of a drug label showing the trade and generic names.

The dosage strength is also given on the container. The dosage strength is the average strength given to a patient as one dose. If necessary, the dosage strength is used to calculate the number of tablets or the amount of
solution to administer. In liquid drugs there is a specified amount of drug in a given volume of solution, such as 50 mg in 2 mL.

Look at Figure 3-2. In this example, the dosage strength of the Augmentin is 125 mg/5 mL solution. If the physician orders 125 mg Augmentin, the nurse would administer 5 mL. More information on calculating drug dosages is given in the following section.

**Oral Dosages of Drugs**

Under certain circumstances, it may be necessary to compute an oral drug dosage because the dosage ordered by the physician may not be available, or the dosage may have been written in the apothecaries’ system and the drug or container label is in the metric system.

**Tablets and Capsules**

To find the correct dosage of a solid oral preparation, the following formula may be used:

\[
\frac{\text{dose desired}}{\text{dose on hand}} = \text{dose administered (the unknown or X)}
\]

This formula may be abbreviated as

\[
\frac{D}{H} = X
\]

When the dose ordered by the physician (dose desired) is written in the same system as the dose on the drug container (dose on hand), these two figures may be inserted into the formula.

**EXAMPLE**

The physician orders ascorbic acid 100 mg (metric). The drug is available as ascorbic acid 50 mg (metric).

\[
\frac{D}{H} = X
\]

\[
\frac{100 \text{ mg (dose desired)}}{50 \text{ mg (dose on hand)}} = 2 \text{ tablets of 50-mg ascorbic acid}
\]

If the physician had ordered ascorbic acid 0.5 g and the drug container was labeled ascorbic acid 250 mg, a conversion of grams to milligrams (because the drug container is labeled in milligrams) would be necessary before this formula can be used. If the 0.5 g were not
converted to milligrams, the fraction of the formula would look like this:

\[
\frac{0.5 \text{ grams}}{250 \text{ milligrams}}
\]

A fraction must be stated in like terms; therefore, proportion may be used to convert grams to milligrams.

\[
\frac{1000 \text{ mg}}{1 \text{ g}} : X \text{ mg} : \frac{0.5 \text{ g}}{1 \text{ g}}
\]

\[
X = 1000 \times 0.5
\]

\[
X = 500 \text{ mg}
\]

After changing 0.5 g to mg, use the formula:

\[
\frac{D}{H} = X
\]

\[
\frac{500 \text{ mg}}{250 \text{ mg}} = 2 \text{ tablets of 250 mg ascorbic acid}
\]

As with all fractions, the numerator and the denominator must be of like terms, for example, milligrams over milligrams or grams over grams. Errors in using this and other drug formulas, as well as proportions, will be reduced if the entire dose is written rather than just the numbers.

\[
\frac{100 \text{ mg}}{50 \text{ mg}} \text{ rather than } \frac{100}{50}
\]

This will eliminate the possibility of using unlike terms in the fraction.

Even if the physician’s order was written in the apothecaries’ system, the drug container most likely would be labeled in the metric system. A conversion of apothecaries’ to metric will now be necessary because the drug label is written in the metric system.

**EXAMPLE**

The physician’s order reads: codeine sulfate gr 1/4 (apothecaries’). The drug container is labeled: codeine sulfate 15 mg (metric). Grains must be converted to milligrams or milligrams converted to grains.

Grains to milligrams:

\[
60 \text{ mg} : 1 \text{ gr} : X \text{ mg} : 1/4 \text{ gr}
\]

\[
X = 60 \times \frac{1}{4}
\]

\[
X = 15 \text{ mg}
\]

or

\[
\frac{60 \text{ mg}}{1 \text{ gr}} = X \text{ mg}
\]

\[
\frac{1/4 \text{ gr}}{1/4 \text{ gr}}
\]

\[
X = 60 \times \frac{1}{4}
\]

\[
X = 15 \text{ mg}
\]

Therefore, 1/4 grain is approximately equivalent to 15 mg.

**Milligrams to grains:**

\[
60 \text{ mg} : 1 \text{ gr} : X \text{ gr}
\]

\[
60X = 15
\]

\[
X = 1/4 \text{ gr}
\]

or

\[
\frac{60 \text{ mg}}{1 \text{ gr}} = X \text{ mg}
\]

\[
\frac{15 \text{ mg}}{15 \text{ mg}} = 1 \text{ tablet}
\]

\[
X = \frac{1}{4} \text{ grain}
\]

Therefore, 15 mg is approximately equivalent to 1/4 grain.

The formula \[
\frac{D}{H} = X
\]

can now be used

\[
\frac{15 \text{ mg}}{15 \text{ mg}} = 1 \text{ tablet}
\]

or

\[
\frac{1/4 \text{ gr}}{1/4 \text{ gr}} = 1 \text{ tablet}
\]

**Liquids**

In liquid drugs, there is a specific amount of drug in a given volume of solution. For example, if a container is labeled as 10 mg per 5 mL (or 10 mg/5 mL), this means that for every 5 mL of solution there is 10 mg of drug.

As with tablets and capsules, the prescribed dose of the drug may not be the same as what is on hand (or available). For example, the physician may order 20 mg of an oral liquid preparation and the bottle is labeled as 10 mg/5 mL.

The formula for computing the dosage of oral liquids is:

\[
\frac{\text{dose desired}}{\text{dose on hand}} \times \text{quantity} = \text{volume administered}
\]

This may be abbreviated as

\[
\frac{D}{H} \times Q = X
\]

The quantity (or Q) in this formula is the amount of liquid in which the available drug is contained. For example, if the label states that there is 15 mg/5 mL, 5 mL is the quantity (or volume) in which there is 15 mg of this drug.
EXAMPLE

The physician orders oxacillin sodium 125 mg PO oral suspension. The drug is labeled as 250 mg/5 mL. The 5 mL is the amount (quantity or Q) that contains 250 mg of the drug.

\[
\frac{D}{H} \times \frac{Q}{X} = \text{the liquid amount to be given}
\]

\[
\frac{125 \text{ mg}}{250 \text{ mg}} \times 5 = X
\]

\[
\frac{1}{2} \times 5 = 2.5 \text{ mL}
\]

Therefore, 2.5 mL contains the desired dose of 125 mg of oxacillin oral suspension.

Liquid drugs may also be ordered in drops (gtt) or minims. With the former, a medicine dropper is usually supplied with the drug and is always used to measure the ordered dosage. Eye droppers are not standardized, and therefore the size of a drop from one eye dropper may be different than one from another eye dropper.

To measure an oral liquid drug in minims, a measuring glass calibrated in minims must be used.

Parenteral Dosages of Drugs

Drugs for parenteral use must be in liquid form before they are administered. Parenteral drugs may be available in the following forms:

1. As liquids in disposable cartridges or disposable syringes that contain a specific amount of a drug in a specific volume, for example, meperidine 50 mg/mL. After administration, the cartridge or syringe is discarded.

2. In ampules or vials that contain a specific amount of the liquid form of the drug in a specific volume. The vials may be single-dose vials or multidose vials. A multidose vial contains more than one dose of the drug.

3. In ampules or vials that contain powder or crystals, to which a liquid (called a diluent) must be added before the drug can be removed from the vial and administered. Vials may be single dose or multidose vials.

Parenteral Drugs in Disposable Syringes or Cartridges

In some instances a specific dosage strength is not available and it will be necessary to administer less than the amount contained in the syringe.

EXAMPLE

The physician orders diazepam 5 mg IM. The drug is available as a 2-mL disposable syringe labeled 5 mg/mL.

\[
\frac{D}{H} \times \frac{Q}{X} = \text{the liquid amount to be given}
\]

\[
\frac{5 \text{ mg}}{10 \text{ mg}} \times 2 \text{ mL} = X
\]

\[
X = \frac{1}{2} \times 2 = 1 \text{ mL}
\]

Note that since the syringe contains 2 mL of the drug and that each mL contains 5 mg of the drug, there is a total of 10 mg of the drug in the syringe. Because there is 10 mg of the drug in the syringe, half of the liquid in the syringe (1 mL) is discarded and the remaining half (1 mL) is administered to give the prescribed dose of 5 mg.

Parenteral Drugs in Ampules and Vials

If the drug is in liquid form in the ampule or vial, the desired amount is withdrawn from the ampule or vial. In some instances, the entire amount is used; in others, only part of the total amount is withdrawn from the ampule or vial and administered.

Whenever the dose to be administered is different from that listed on the label, the volume to be administered must be calculated. To determine the volume to be administered, the formula for liquid preparations is used. The calculations are the same as those given in the preceding section for parenteral drugs in disposable syringes or cartridges.

EXAMPLES

The physician orders chlorpromazine 12.5 mg IM. The drug is available as chlorpromazine 25 mg/mL in a 1-mL ampule.

\[
\frac{D}{H} \times \frac{Q}{X} = \text{the liquid amount to be given}
\]

\[
\frac{12.5 \text{ mg}}{25 \text{ mg}} \times 1 \text{ mL} = X
\]

\[
\frac{1}{2} \times 1 \text{ mL} = \frac{1}{2} \text{ mL (or 0.5 mL) volume to be administered.}
\]

The physician orders hydroxyzine 12.5 mg. The drug is available as hydroxyzine 25 mg/mL in 10-mL vials.

\[
\frac{D}{H} \times \frac{Q}{X} = \text{the liquid amount to be given}
\]

\[
\frac{12.5 \text{ mg}}{25 \text{ mg}} \times 1 \text{ mL} = \frac{1}{2} \text{ mL (or 0.5 mL)}
\]

Therefore, 0.5 mL is withdrawn from the 10-mL multidose vial and administered. In this example, the amount
in this or any multidose vial is not entered into the equation. What is entered into the equation as quantity (Q) is the amount of the available drug that is contained in a specific volume.

When the dose is less than 1 mL, it may be necessary, in some instances, to convert the answer to minims. A conversion factor of 15 or 16 minims/mL may be used.

**EXAMPLES**

The physician orders chlorpromazine 10 mg IM. The drug is available as chlorpromazine 25 mg/mL.

\[
\frac{10 \text{ mg}}{25 \text{ mg}} \times 1 \text{ mL} = x
\]

\[
\frac{2}{5} \times 1 \text{ mL} = \frac{2}{5} \text{ mL}
\]

\[
\frac{2}{5} \times 15 \text{ minims} = 6 \text{ minims}
\]

In this example 15 minims = 1 mL is used because 15 can be divided by 5.

The physician’s order reads methadone 2.5 mg IM. The drug is available as methadone 10 mg/mL.

\[
\frac{2.5 \text{ mg}}{10 \text{ mg}} \times 1 \text{ mL} = x
\]

\[
\frac{1}{4} \times 1 \text{ mL} = x
\]

\[
\frac{1}{4} \times 16 \text{ minims} = 4 \text{ minims}
\]

Because 16 (and not 15) minims can be divided by 4, the conversion factor of 16 is used.

**WARNING:** ALWAYS CHECK DRUG LABELS CAREFULLY. Some may be labeled in a manner different from others.

**EXAMPLE**

a 2-mL ampule labeled: 2 mL = 0.25 mg

a 2-mL ampule labeled: 1 mL = 5 mg

In these two examples, one manufacturer states the entire dose contained in the ampule: 2 mL = 0.25 mg. The other manufacturer gives the dose per milliliter: 1 mL = 5 mg. In this 2-mL ampule, there is a total of 10 mg.

**Parenteral Drugs in Dry Form**

Some parenteral drugs are available as a crystal or a powder. Because these drugs have a short life in liquid form, they are available in ampules or vials in dry form and must be made a liquid (reconstituted) before they are removed and administered. Some of these products have directions for reconstitution on the label or on the enclosed package insert. The manufacturer may give either of the following information for reconstitution:

1. the name of the diluent(s) that must be used with the drug,
2. the amount of diluent that must be added to the drug.

In some instances, the manufacturer supplies a diluent with the drug. If a diluent is supplied, no other stock diluent should be used. Before a drug is reconstituted, the label is carefully checked for instructions.

**EXAMPLES**

Methicillin sodium: To reconstitute 1 g vial add 1.5 mL of sterile water for injection or sodium chloride injection. Each reconstituted mL contains approximately 500 mg of methicillin.

Mechlorethamine: Reconstitute with 10 mL of sterile water for injection or sodium chloride injection. The solution now contains 1 mg/mL of mechlorethamine.

If there is any doubt about the reconstitution of the dry form of a drug and there are no manufacturer’s directions, the hospital pharmacist should be consulted.

Once a diluent is added, the volume to be administered is determined. In some cases, the entire amount is given; in others, a part (or fraction) of the total amount contained in the vial or ampule is given.

After reconstitution of any multidose vial, the following information must be added to the label:

- Amount of diluent added
- Dose of drug in mL (500 mg/mL, 10 mg/2 mL, etc.)
- The date of reconstitution
- The expiration date (the date after which any unused solution is discarded)

**Calculating Intravenous Flow Rates**

When the physician orders a drug added to an intravenous (IV) fluid, the amount of fluid to be administered over a specified period, such as 125 mL/h or 1000 mL over 8 hours, must be included in the written order. If no infusion rate had been ordered, 1 L (1000 mL) of IV fluid should infuse over 6 to 8 hours.

To allow the IV fluid to infuse over a specified period, the IV flow rate must be determined. Before using one of the methods below, the drop factor must be known. Drip chambers on the various types of IV fluid administration sets vary. Some deliver 15 drops/mL and others deliver more or less than this number. This is called the drop factor. The drop factor (number of drops/mL) is given on the package containing the drip chamber and IV tubing. Three methods for determining the IV infusion rate follow. Methods 1 and 2 can be used when the known factors are the total amount of solution, the drop factor, and the number of hours over which the solution is to be infused.

**METHOD 1**

**Step 1.** Total amount of solution ÷ number of hours = number of mL/h
**Step 2.** mL/h ÷ 60 min/h = number of mL/min

**Step 3.** mL/min × drop factor = number of drops/min

**EXAMPLE**

1000 mL of an IV solution is to infuse over a period of 8 hours. The drop factor is 14.

**Step 1.** 1000 mL ÷ 8 hours = 125 mL/h

**Step 2.** 125 ÷ 60 minutes = 2.08 mL/min

**Step 3.** 2.08 × 14 = 29 drops/min

**METHOD 2**

**Step 1.** Total amount of solution ÷ number of hours = number of mL/h

**Step 2.** mL/h ÷ drop factor ÷ 60 = number of drops/min

**EXAMPLE**

1000 mL of an IV solution is to infuse over a period of 6 hours. The drop factor is 12.

**Step 1.** 1000 mL ÷ 6 = 166.6 mL/h

**Step 2.** 166.6 ÷ 12 ÷ 60 = 33.33 (33 to 34) drops/min

**METHOD 3**

This method may be used when the desired amount of solution to be infused in 1 hour is known or written as a physician’s order.

\[
\frac{\text{drops/mL of given set (drop factor)}}{60\text{ (minutes in an hour)}} \times \frac{\text{total hourly volume}}{\text{drops/min}}
\]

**EXAMPLE**

If a set delivers 15 drops/min and 240 mL is to be infused in 1 hour:

\[
\frac{15}{60} \times 240 = \frac{1}{4} \times 240 = 60\text{ drops/min}
\]

**Oral or Parenteral Drug Dosages Based on Weight**

The dosage of an oral or parenteral drug may be based on the patient’s weight. In many instances, references give the dosage based on the weight in kilograms (kg) rather than pounds (lb). There are 2.2 lb in 1 kg.

When the dosage of a drug is based on weight, the physician, in most instances, computes and orders the dosage to be given. However, errors can occur for any number of reasons. The nurse should be able to calculate a drug dosage based on weight to detect any type of error that may have been made in the prescribing or dispensing of a drug whose dosage is based on weight.

To convert a known weight in kilograms to pounds, multiply the known weight by 2.2.

**EXAMPLES**

Patient’s weight in kilograms is 54

\[54 \times 2.2 = 118.8\text{ (or 119) lb}\]

To convert a known weight in pounds to kilograms, divide the known weight by 2.2.

**EXAMPLES**

Patient’s weight in pounds is 142

\[142 \div 2.2 = 64.5\text{ kg}\]

Child’s weight in pounds is 43

\[43 \div 2.2 = 19.5\text{ kg}\]

Once the weight is converted to pounds or kilograms, this information is used to determine drug dosage.

**EXAMPLES**

A drug dose is 5 mg/kg/d. The patient weighs 135 lb, which is converted to 61.2 kg.

\[61.2\text{ kg} \times 5\text{ mg} = 306.8\text{ mg}\]

Proportions also can be used:

\[5\text{ mg:1 kg::X mg:61.2 kg}\]

\[X = 306.8\text{ mg}\]

A drug dose is 60 mg/kg/d IV in three equally divided doses.

The patient weighs 143 lb, which is converted to 65 kg.

\[65\text{ kg} \div 60\text{ mg} = 3900\text{ mg/day}\]

\[3900\text{ mg} \div 3\text{ (dosess per day)} = 1300\text{ mg each dose}\]

If the drug dose is based on body surface area (m²) the same method of calculation may be used.

**EXAMPLE**

A drug dose is 60 to 75 mg/m² as a single IV injection.

The body surface area (BSA) of a patient is determined by means of a nomogram for estimating BSA (see Appendix E) and is found to be 1.8 m². The physician orders 60 mg/m².

\[60\text{ mg} \times 1.8\text{ m²} = 108\text{ mg}\]

Proportion can also be used:

\[60\text{ mg:1 m²::X mg:1.8 m²}\]

\[X = 108\text{ mg}\]

**Dosage Calculation Using Dimensional Analysis (DA)**

When using DA to calculate dosage problems, dosages are written as common fractions. For example:

\[
\frac{1\text{ mL}}{4\text{ mg}} \quad \frac{5\text{ mL}}{10\text{ mg}} \quad \frac{1\text{ tablet}}{100\text{ mg}}
\]
When written as common fractions the numerator is the top number. In the example above, 1 mL, 5 mL, and 1 tablet are the numerators. The numbers on the bottom are called denominators. In the example above, 4 mg, 10 mg, and 100 mg are denominators.

**EXAMPLE**
The physician orders 10 mg of diazepam. The drug comes in dosage strength of 5 mg/mL. How many mL would the nurse administer?

**Step 1.** To work this problem using DA, always begin by identifying the unit of measure to be calculated. The unit to be calculated will be mL or cc if the drug is to be administered parenterally. A water drug form is the solid and the unit of measure would be a tablet or capsule. In the problem above, the unit of measure to be calculated is mL. If the drug is an oral liquid drug, the measurement might be ounces.

**Step 2.** Write the identified unit of measure to be calculated, followed by an equal sign. In the problem above, mL is the unit to be calculated, so the nurse writes:

\[ \text{mL} = \]

**Step 3.** Next, the dosage strength is written, with the numerator always expressed in the same unit that was identified before the equal sign. For example:

\[ \frac{1 \text{ mL}}{5 \text{ mg}} \]

**Step 4.** Continue by writing the next fraction with the numerator having the same unit of measure as the denominator in the previous fraction. For example, our problem continues:

\[ \frac{1 \text{ mL}}{5 \text{ mg}} \times \frac{10 \text{ mg}}{X \text{ mL}} \]

**Step 5.** The problem is solved by multiplication of the two fractions:

\[ \frac{1 \text{ mL}}{5 \text{ mg}} \times \frac{10 \text{ mg}}{X \text{ mL}} = \frac{10 \text{ mg}}{5X \text{ mL}} = 2 \text{ mL} \]

**NOTE:** Each alternate denominator and numerator cancel, with only the final unit remaining.

**EXAMPLE**
Ordered: 200,000 U
On hand: Drug labeled 400,000 U/mL

\[ \text{mL} = \frac{1 \text{ mL}}{400,000 \text{ U}} \times \frac{200,000 \text{ U}}{X \text{ mL}} = \frac{1}{2} \text{ mL or 0.5 mL} \]

**Metric Conversions Using Dimensional Analysis**
Occasionally the physician may order a drug in one unit of measure, whereas the drug is available in another unit of measure.

**EXAMPLE**
The physician orders 0.4 mg of atropine. The drug label reads 400 mcg per 1 mL. This dosage problem is solved by expanding the DA equation by adding one step to the equation.

**Step 1.** As above, begin by writing the unit of measure to be calculated, followed by an equal sign.

**Step 2.** Next, express the dosage strength as a fraction with the numerator having the same unit of measure as the number before the equal sign.

**Step 3.** Continue by writing the next fraction with the numerator having the same unit of measure as the denominator in the previous fraction.

\[ \frac{1 \text{ mL}}{400 \text{ mcg}} \times \frac{1000 \text{ mcg}}{1 \text{ mg}} \]

**Step 4.** Expand the equation by filling in the missing numbers using the appropriate equivalent. In this problem, the equivalent would be 100 mcg = 1 mg. This will convert mcg to mg.

\[ \text{mL} = \frac{1 \text{ mL}}{400 \text{ mcg}} \times \frac{1000 \text{ mcg}}{1 \text{ mg}} \times \frac{0.4 \text{ mg}}{X \text{ mL}} \]

When possible, cancel out the units, leaving only mL.

**Step 5.** Solve the problem by multiplication. Cancel out the numbers when possible.

\[ \text{mL} = \frac{1 \text{ mL}}{400 \text{ mcg}} \times \frac{1000 \text{ mcg}}{1 \text{ mg}} \times \frac{0.4 \text{ mg}}{X \text{ mL}} = \frac{400}{400X} = 1 \text{ mL} \]

Solve the following problems using DA. Refer to the equivalent table if necessary. (See Table 3-1.)

**EXAMPLE**
Ordered: 250 mg.
On hand: Drug labeled 1 gram per 1 mL

\[ \text{mL} = \frac{1 \text{ mL}}{1 \text{ g}} \times \frac{1 \text{ g}}{1000 \text{ mg}} \times \frac{250 \text{ mg}}{X \text{ mL}} = \frac{1 \text{ mL}}{4} \text{ or 0.25 mL} \]

**Temperatures**
Two scales used in the measuring of temperatures are Fahrenheit (F) and Celsius (C) (also known as centi-grade). On the Fahrenheit scale, the freezing point of water is 32°F and the boiling point of water is 212°F. On the Celsius scale, 0°C is the freezing point of water and 100°C is the boiling point of water.
To convert from Celsius to Fahrenheit, the following formula may be used: \( F = \frac{9}{5} C + 32 \) (9/5 times the temperature in Celsius, then add 32).

**EXAMPLE**
Convert 38°C to Fahrenheit:

\[
F = \frac{9}{5} \times 38 + 32 \\
F = 68.4 + 32 \\
F = 100.4^\circ
\]

To convert from Fahrenheit to Celsius, the following formula may be used: \( C = \frac{5}{9} (F - 32) \) (5/9 times the temperature in Fahrenheit minus 32).

**EXAMPLE**
Convert 100°F to Celsius:

\[
C = \frac{5}{9} \times (100 - 32) \\
C = \frac{5}{9} \times 68 \\
C = 37.77 \text{ or } 37.8^\circ
\]

(See Appendix D for Celsius (Centigrade) and Fahrenheit temperatures chart.)

**Pediatric Dosages**
The dosages of drugs given to children are usually less than those given to adults. The dosage may be based on age, weight, or BSA.

**Body Surface Area**
Charts are used to determine the BSA (see Appendix D) in square meters according to the child’s height and weight. Once the BSA is determined, the following formula is used:

\[
\frac{\text{surface area of the child in square meters}}{\text{surface area of an adult in square meters}} \times \text{usual adult dose} = \text{pediatric dose}
\]

(See Appendix E for Body Surface Area Nomograms.)

**Weight**
Pediatric as well as adult dosages may also be based on the patient’s weight in pounds or kilograms. The method of converting pounds to kilograms or kilograms to pounds is explained in a previous section.

**EXAMPLE**

\[
5 \text{ mg/kg} \\
0.5 \text{ mg/lb}
\]

Today, most pediatric dosages are clearly given by the manufacturer, thus eliminating the need for formulas, except for determining the dose of some drugs based on the child’s weight or BSA.

* The figure for the average BSA of an adult in square meters is 1.7.
The Nursing Process

**Key Terms**

<table>
<thead>
<tr>
<th>Assessment</th>
<th>Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expected Outcomes</td>
<td>Nursing Process</td>
</tr>
<tr>
<td>Implementation</td>
<td>Objective Data</td>
</tr>
<tr>
<td>Independent Actions</td>
<td>Ongoing Assessment</td>
</tr>
<tr>
<td>Initial Assessment</td>
<td>Planning</td>
</tr>
<tr>
<td>Subjective Data</td>
<td></td>
</tr>
</tbody>
</table>

**Chapter Objectives**

On completion of this chapter, the student will:

- List the five phases of the nursing process.
- Discuss assessment, nursing diagnosis, planning, implementation, and evaluation as they apply to the administration of drugs.
- Differentiate between objective and subjective data.
- Discuss how the nursing process may be used in daily life, as well as when administering drugs.
- Identify common nursing diagnoses used in the administration of drugs and nursing interventions related to each diagnosis.

**The Five Phases of the Nursing Process**

Although the nursing process can be described in various ways, it generally consists of five phases: assessment, nursing diagnosis, planning, implementation, and evaluation. Each part is applicable, with modification, to the administration of medications. Figure 4-1 relates the nursing process to administration of medications.

**Assessment**

Assessment involves collecting objective and subjective data. **Objective data** are facts obtained by means of a physical assessment or physical examination. **Subjective data** are facts supplied by the patient or the patient’s family.

Assessments are both initial and ongoing. A **initial assessment** is made based on objective and subjective data collected when the patient is first seen in a hospital, outpatient clinic, health care provider’s office, or other type of health care facility. The initial assessment usually is more thorough and provides a database (sometimes called baseline) from which later data can be compared and decisions made. The initial assessment provides information that is analyzed to identify...
problems that can be resolved or alleviated by nursing actions.

Objective data are obtained during an initial assessment through activities, such as examining the skin, obtaining vital signs, palpating a lesion, and auscultating the lungs. A review of the results of any recent laboratory tests and diagnostic studies also is part of the initial physical assessment. Subjective data are acquired during an initial assessment by obtaining information from the patient, such as a family history of disease, allergy history, occupational history, a description (in the patient's own words) of the current illness or chief complaint, a medical history, and a drug history. In addition to the prescription drugs that the patient may be taking, it is important to know any over-the-counter drugs, vitamins, or herbal therapies. For women of childbearing age the nurse needs to ask about the woman's pregnancy status and whether or not she is breastfeeding.

An ongoing assessment is one that is made at the time of each patient contact and may include the collection of objective data, subjective data, or both. The scope of an ongoing assessment depends on many factors, such as the patient's diagnosis, the severity of illness, the response to treatment, and the prescribed medical or surgical treatment.

The assessment phase (including the initial and ongoing assessment) of the nursing process can be applied to the administration of drugs, with objective and subjective data collected before and after to obtain a thorough baseline or initial assessment. This allows subsequent assessments to be compared with the baseline information. This comparison helps to evaluate the effectiveness of the drug and the presence of any adverse reactions. Ongoing assessments of objective and subjective data are equally important when administering drugs. Important objective data include blood pressure, pulse, respiratory rate,
temperature, weight, examination of the skin, examination of an intravenous infusion site, and auscultation of the lungs. Important subjective data include any statements made by the patient about relief or nonrelief of pain or other symptoms after administration of a drug.

The extent of the assessment and collection of objective and subjective data before and after a drug is administered will depend on the type of drug and the reason for its use.

Nursing Diagnosis

After the data collected during assessment are analyzed, the nurse identifies the patient’s needs (problems) and formulates one or more nursing diagnoses. A nursing diagnosis is not a medical diagnosis; rather, it is a description of the patient’s problems and their probable or actual related causes based on the subjective and objective data in the database. A nursing diagnosis identifies problems that can be solved or prevented by independent nursing actions—actions that do not require a physician’s order and may be legally performed by a nurse. Nursing diagnoses provide the framework for selections of nursing interventions to achieve expected outcomes.

The North American Nursing Diagnosis Association (NANDA) was formed to standardize the terminology used for nursing diagnosis. NANDA continues to define, explain, classify, and research summary health statements about health problems related to nursing. NANDA has approved a list of diagnostic categories to be used in formulating a nursing diagnosis. This list of diagnostic categories is periodically revised and updated. In some instances, nursing diagnoses may apply to a specific group or type of drug or a particular patient. One example is Deficient Fluid Volume related to active fluid volume loss (diuresis) secondary to administration of a diuretic. Specific drug-related nursing diagnoses are highlighted in each chapter. However, it is beyond the scope of this book to discuss all possible nursing diagnoses related to a drug or a drug class.

Some of the nursing diagnoses developed by NANDA may be used to identify patient problems associated with drug therapy and are more commonly used when administering drugs. The most frequently used nursing diagnoses related to the administration of drugs include:

- Effective Therapeutic Regimen Management
- Ineffective Therapeutic Regimen Management
- Deficient Knowledge
- Noncompliance
- Anxiety

Because the above nursing diagnoses are commonly used for the administration of all types of drugs, they will not be repeated for each chapter. The nurse should keep these nursing diagnoses in mind when administering any drug.

Planning

After the nursing diagnoses are formulated, the nurse develops expected outcomes, which are patient-oriented. An expected outcome is a direct statement of nurse-patient goals to be achieved. The expected outcome describes the maximum level of wellness that is reasonably attainable for the patient. For example, common expected patient outcomes related to drug administration, in general, include:

- The patient will effectively manage the therapeutic regimen.
- The patient will understand the drug regimen.
- The patient will comply with the drug regimen.

The expected outcomes define the expected behavior of the patient or family that indicates the problem is being resolved or that progress toward resolution is occurring.

The nurse selects the appropriate interventions on the basis of expected outcomes to develop a plan of action or patient care plan. Planning for nursing actions specific for the drug to be administered can result in greater accuracy in drug administration, patient understanding of the drug regimen, and improved patient compliance with the prescribed drug therapy after discharge from the hospital. For example, during the initial assessment interview, the patient may report an allergy to penicillin. This information is important, and the nurse must now plan the best methods of informing all members of the health care team of the patient’s allergy to penicillin.

The planning phase plans the steps for carrying out nursing activities or interventions that are specific and that will meet the expected outcomes. Planning anticipates the implementation phase or the carrying out of nursing actions that are specific for the drug being administered. If, for example, the patient is to receive a drug by the intravenous route, the nurse must plan the materials needed and the patient instruction for administration of the drug by this route. In this instance, the planning phase occurs immediately before the implementation phase and is necessary to carry out the technique of intravenous administration correctly. Failing to plan effectively may result in forgetting to obtain all of the materials necessary for drug administration.

Expected outcomes define the expected behavior of the patient or family that indicates that the problem is being resolved or that progress toward resolution is occurring. Expected outcomes serve as a basis for evaluating the effectiveness of nursing interventions. For example, if the nursing intervention is to “monitor the blood pressure every hour,” the expected outcome is that “the patient experiences no further elevation in blood pressure.”
Implementation

Implementation is the carrying out of a plan of action and is a natural outgrowth of the assessment and planning phases of the nursing process. When related to the administration of drugs, implementation refers to the preparation and administration of one or more drugs to a specific patient. Before administering a drug, the nurse reviews the subjective and objective data obtained on assessment and considers any additional data, such as blood pressure, pulse, or statements made by the patient. The decision of whether to administer the drug is based on an analysis of all information. For example, a patient is hypertensive and is supposed to receive a drug to lower the blood pressure. Objective data obtained at the time of admission included a blood pressure of 188/110. Additional objective data obtained immediately before the administration of the drug included a blood pressure of 182/110. A decision was made by the nurse to administer the drug because the change in the patient’s blood pressure was only minimal. However, if the patient’s blood pressure was 132/84, and this was only the second dose of the drug, the nurse could decide to withhold the drug and contact the primary health care provider. Giving or withholding a drug or contacting the patient’s health care provider are nursing activities related to the implementation phase of the nursing process.

The more common nursing diagnoses used when administering drugs are Effective Therapeutic Regimen Management, Ineffective Therapeutic Regimen Management, Deficient Knowledge, and Noncompliance. Nursing interventions applicable to each of these nursing diagnoses are discussed in the following sections. However, each patient is an individual, and nursing care must be planned on an individual basis after a careful collection and analysis of the data. In addition, each drug is different and may have various effects within the body. (For drugs discussed in subsequent chapters, some possible nursing diagnoses related to that specific drug are discussed.)

Effective Therapeutic Regimen Management

This nursing diagnosis takes into consideration that the patient is willing to regulate and integrate into daily living the treatment regimen such as the self-administration of medications. For this nursing diagnosis to be used the patient verbalizes the desire to manage the medication regimen. When the patient is willing and able to manage the treatment regimen, he or she may simply need information concerning the drug, method of administration, what type of reactions to expect, and what to report to the primary health care provider. A patient willing to take responsibility may need the nurse to develop a teaching plan that gives the patient the information needed to properly manage the therapeutic regimen (see Chap. 5 for more information on educating patients).

Ineffective Therapeutic Regimen Management

NANDA defines “ineffective therapeutic regimen management” as “a pattern of regulating and integrating into daily living a program for treatment of illness and the sequelae of illness that is unsatisfactory for meeting specific health goals.” In the case of medication administration, the patient may not be taking the medication correctly or following the medication regimen prescribed by the health care provider.

The reasons for not following the drug regimen vary. For example, some people do not fill their prescriptions. Other patients skip doses, take the drug at the wrong times, or take an incorrect dose. Some may simply forget to take the drug; others take a drug for a few days, see no therapeutic effect, and quit. Some find the adverse effects so bothersome that they discontinue taking the drug without notifying the health care provider. Display 4-1 identifies some reasons for this ineffective therapeutic regimen management.

When working with a patient who is not managing the drug regimen correctly, the nurse must ensure that the patient understands the drug regimen. It is essential to provide written instructions. If possible, the nurse should allow the patient to administer the drug before he or she is dismissed from the health care facility. The nurse should determine if adequate funds are available to obtain the drug and any necessary supplies. For example, when a bronchodilator is administered by inhalation, a spacer or extender may be required for proper administration. This device is an additional expense. A referral to the social services department of the institution may help when finances are a problem.

For those who forget to take the drug, the nurse should suggest the use of small compartmentalized boxes marked with the day of the week or time the drug

---

display 4-1: Possible Causes of Ineffective Management of Health Care Regimen

- Extended therapy for chronic illness causes patient to become discouraged
- Troublesome adverse reactions
- Lack of understanding of the purpose for the drug
- Forgetfulness
- Misunderstanding of oral or written instructions on how to take the drug
- Weak nurse-patient relationships
- Lack of funds to obtain drug
- Mobility problems
- Lack of family support
- Cognitive deficits
- Visual or hearing defects
- Lack of motivation

is to be taken (see Fig. 4-2). These containers can be obtained from the local pharmacy.

It is important to discuss the drug regimen with the patient, including the reason the drug is to be taken, the times, the amount, adverse reactions to expect, and reactions that should be reported. The patient needs a thorough understanding of the desired or expected therapeutic effect and the approximate time expected to attain that effect. For example, a patient may become discouraged after taking an antidepressant for 5 to 7 days and seeing no response. An explanation that 2 to 3 weeks is required before the depression begins to lift will, in many cases, promote compliance.

It is important to provide ways to minimize adverse reactions if possible. For example, many anticholinergic drugs cause dry mouth. The nurse instructs the patient to take frequent sips of water or suck on hard candy to help minimize the discomfort of a dry mouth.

Frequent follow-up sessions are needed to determine compliance with the drug regimen. If a follow-up visit is not feasible, the nurse considers a telephone call or home visit. It is vital that the nurse strive to develop a caring and nurturing relationship with the patient. Compliance is enhanced when a patient trusts the nurse and feels comfortable confiding any problem encountered during drug therapy.

**Deficient Knowledge**

Deficient knowledge is the absence or deficiency of cognitive information to a specific subject. In the case of self-administration of drugs the patient lacks sufficient knowledge to administer the drug regimen correctly. It may also relate to a lack of interest in learning, cognitive limitation, or the inability to remember.

Most patients, at least in the initial treatment stages, have a lack of knowledge about the drug, its possible adverse reactions, and the times and method of administration. At times, the patient may have a lack of knowledge about the disease condition. In these situations, the nurse addresses the specific deficient knowledge (i.e., adverse reactions, disease process, method of administration, and so on) in words that the patient can understand. It is important for the nurse to first determine what information the patient is lacking and then plan a teaching session that directly pertains to the specific area of need. (See Chap. 5 for more information on patient education.) If the patient lacks the cognitive ability to learn the information concerning self-administration of drugs, then one or more of the caregivers should be taught to administer the proper treatment regimen.

**Noncompliance**

Noncompliance is defined as behavior of the patient or caregiver that fails to coincide with the therapeutic plan agreed on by the patient and the health care provider. Patients are noncompliant for various reasons, such as a lack of information about the drug, the reason the drug is prescribed, or the expected or therapeutic results. Noncompliance also can be the result of anxiety or bothersome side effects. The nurse can relieve anxiety by allowing the patient to express feelings or concerns, by actively listening as the patient verbalizes feelings, and by providing information so that the patient can be fully informed about the drug. Many patients have a tendency to discontinue use of the drug once the symptoms have been relieved. It is important to emphasize the importance of completing the prescribed course of therapy. For example, failure to complete a course of antibiotic therapy may result in recurrence of the infection. To combat noncompliance the nurse finds out the exact reason for the noncompliance, if possible. Factors related to noncompliance are similar to those listed in Display 4-1.

**Anxiety**

Anxiety is a vague uneasiness or apprehension that manifests itself in varying degrees from expressions of concern regarding drug regimen to total lack of compliance with the drug regimen. When anxiety is high, the ability to focus on details is reduced. If the patient or caregiver is given information concerning the medication regimen during a high anxiety state, the patient may not remember the information. This could lead to noncompliance. The anxiety experienced during drug administration depends on the severity of the illness, the occurrence of adverse reactions, and the knowledge level of the patient. Anxiety is decreased with understanding of the therapeutic regimen. To decrease anxiety before discussing the treatment regimen with the patient, the nurse takes time to talk with and actively

**Figure 4-2.** Various types of drug containers may be used to help individuals remember to take their medication at the correct time.
listen to the patient. This helps to build a caring relationship and decrease patient anxiety. It is critical for the nurse to allow time for a thorough explanation and to answer all questions and concerns in language the patient can understand.

It is important to identify and address the specific fear and, if possible, reassure the patient that the drug will alleviate the symptoms or, if possible, cure the disorder. The nurse thoroughly explains any procedure. The nurse actively listens and provides encouragement as the patient expresses fears and concerns. Reassurance and understanding on the part of the nurse are required; the amount of reassurance and understanding depends on the individual patient.

**Evaluation**

Evaluation is a decision-making process that involves determining the effectiveness of the nursing interventions in meeting the expected outcomes. When related to the administration of a drug, this phase of the nursing process is used to evaluate the patient’s response to drug therapy. The evaluation is positive if the expected outcomes have been accomplished or if progress has occurred. If the outcomes have not been accomplished, different interventions are needed. During the administration of the drug the expected response is alleviation of specific symptoms or the presence of a therapeutic effect. Evaluation also may be used to determine if the patient or family member understands the drug regimen.

To evaluate the patient’s response to therapy, and depending on the drug administered, the nurse may check the patient’s blood pressure every hour, inquire whether pain has been relieved, or monitor the pulse every 15 minutes. After evaluation, certain other decisions may need to be made and plans of action implemented. For example, the nurse may need to notify the primary health care provider of a marked change in a patient’s pulse and respiratory rate after a drug was administered, or the nurse may need to change the bed linen because sweating occurred after a drug used to lower the patient’s elevated temperature was administered.

The nurse can evaluate the patient’s or family’s understanding of the drug regimen by noting if one or both appear to understand the material that has been presented. Facial expression may indicate that one or both do or do not understand what has been explained. The nurse also may ask questions about the information that has been given to further evaluate the patient’s or family’s understanding.

**Critical Thinking Exercises**

1. Mr. Hatfield, age 69 years, confides to you that he is not taking the drug prescribed by his primary health care provider. He states he took the drug for a while and then quit. Explain some possible reasons Mr. Hatfield could have for not taking his drug. Discuss questions you could ask to assess the reason for Mr. Hatfield’s noncompliance.

2. Ms. Heggan is 82 years old and lives alone. She is prescribed several drugs by the primary health care provider but is worried about taking the drugs and the side effects that might occur. She comes to the outpatient clinic after 1 week, and you learn that she has not filled her prescription and is not taking the drugs. Your nursing diagnosis is Ineffective Management of the Therapeutic Regimen related to anxiety about taking the prescribed drugs. Determine what information you would seek to obtain from Ms. Heggan. Identify important nursing interventions for this diagnosis.

3. Ms. Taylor is receiving three drugs for the treatment of difficulty breathing and swelling of her legs. You are giving these drugs for the first time. Discuss what questions you would ask Ms. Taylor to obtain subjective data.

**Review Questions**

1. A patient states that he does not understand why he had to take a specific medication. The most accurate nursing diagnosis for this man would be ______.
   A. ineffective management of therapeutic regimen
   B. anxiety
   C. noncompliance
   D. deficient knowledge

2. When the nurse enters subjective data in the patient’s record, this information is obtained from ______.
   A. the primary care provider
   B. other members of the health care team
   C. the patient or family
   D. laboratory and x-ray reports

3. During the evaluation phase of the nursing process the nurse makes ______.
   A. decisions regarding the effectiveness of nursing interventions
   B. sure nursing procedures have been performed
   C. notations regarding the patient’s response to medical treatment
   D. a list of all adverse reactions the patient has experienced while taking the drug
Patient teaching is an integral part of nursing. When a drug is prescribed, the patient and the family must be made aware of all information concerning the drug. The nurse is responsible for supplying the patient with accurate and up-to-date information about the drugs prescribed. The teaching/learning process is the means through which the patient is made aware of the drug regimen.

THE THREE DOMAINS OF LEARNING

Learning occurs in three domains: cognitive, affective, and psychomotor. When developing a teaching plan for the patient, the nurse must consider each domain.

Cognitive Domain

The cognitive domain refers to intellectual activities such as thought, recall, decision making, and drawing conclusions. In this domain the patient uses previous experiences, prior knowledge, and perceptions to give meaning to new information or to modify previous thinking. The nurse makes use of the patient’s cognitive abilities when information is given to the patient or caregivers about the disease process, medication regimen, and adverse reactions. The patient uses the cognitive domain to process the information, ask questions, and make decisions.

Affective Domain

The affective domain includes the patient/caregiver’s attitudes, feelings, beliefs, and opinions. Health care providers often ignore these aspects of patient teaching.

Psychomotor Domain

The psychomotor domain involves practical skills such as physical and manual dexterity, motor coordination, and body movements. The nurse uses the patient’s psychomotor abilities when teaching the patient how to give medications, perform self-care tasks, or perform procedures.

THE TEACHING/LEARNING PROCESS

Teaching is defined as an interactive process that promotes learning. Both the patient and the nurse must be actively involved if teaching is to be effective. Learning is acquiring new knowledge or skills. When learning occurs there is a change in the patient’s behavior, thinking, or both.

A patient must have motivation (having the desire or seeing the need) to learn. Motivation depends on the patient’s perception of the need to learn. Education concerning the disease process may be necessary for the patient to become motivated to learn. Encouraging patient participation in planning realistic and attainable goals also promotes motivation. If the patient has no motivation, he or she is likely to be noncompliant.

Creating an accepting and positive atmosphere also enhances learning. Physical discomfort negatively affects the patient’s concentration and, thus, the ability to learn. Making sure the patient is not in pain is vital to the teaching/learning process.

On completion of this chapter, the student will:
- Identify important aspects of the teaching/learning process.
- Discuss the three domains of learning.
- Discuss important aspects of adult learning.
- Explain how the nursing process can be used to develop a teaching plan.
- Identify basic information to consider when developing a teaching plan.
- Discuss suggestions the nurse can make to the patient to modify drug administration in the home.

Key Terms

<table>
<thead>
<tr>
<th>affective domain</th>
<th>motivation</th>
</tr>
</thead>
<tbody>
<tr>
<td>cognitive domain</td>
<td>psychomotor domain</td>
</tr>
<tr>
<td>learning</td>
<td>teaching</td>
</tr>
</tbody>
</table>
It is easy to pull a preprinted teaching outline off of the computer or obtain preprinted material. This type of material is often used as a checklist to teach the patient about a drug and the therapeutic regimen. Such checklists are useful in helping the nurse remember important aspects of the drug that should be covered when teaching the patients about the drug and to give to the patient for future reference. However, the use of such checklists fails to take into account the affective domain.

Perhaps the most important prerequisite to learning about the patient’s affective behavior is to develop a therapeutic relationship with the patient (one that is based on trust and caring). When the nurse takes the time to develop a therapeutic relationship, the patient/family has confidence in the nurse and more confidence in the information to be taught. The nurse approaches the patient with respect and encourages the expression of thoughts and feelings. Exploring the patient’s beliefs about health and illness enhances the nurse’s understanding of the patient’s affective behavior.

**Psychomotor Domain**

The psychomotor domain involves learning physical skills (such as injection of insulin) or tasks (such as performing a dressing change). The nurse teaches a task or skill using a step-by-step method. The patient is allowed hands-on practice under the supervision of the nurse. The nurse assesses the patient mastery of the skill by having the patient or caregiver perform a return demonstration under the watchful eye of the nurse.

**ADULT LEARNING**

Generally adults learn only what they feel they need to learn. Adults learn best when they have a strong inner motivation to learn a new skill or acquire new knowledge. They will learn less if they are passive recipients of “canned” educational content. Adults have a vast array of experiences and knowledge to bring to a new learning experience. Teachers who use this experience will bring about the greatest behavior change. While 83% of adults are visual learners, only 11% learn by listening. Most adults retain the information taught if they are able to “do” something with that new knowledge immediately. For example, in teaching a patient how to administer his/her own insulin, the nurse would demonstrate the technique, allow time for supervised practice, and as soon as the patient appears ready, allow the patient to prepare and inject the insulin. Most adults prefer an informal learning environment where there is mutual exchange and freedom of expression.

**THE NURSING PROCESS AS A FRAMEWORK FOR PATIENT TEACHING**

The nursing process is a systematic method of identifying patient health needs, devising a plan of care to meet the identified needs, initiating the plan, and evaluating its effectiveness. This process provides the necessary framework to develop an effective teaching plan. However, the teaching plan differs from the nursing process in that the nursing process encompasses all of the patient’s health care needs, whereas the teaching plan focuses primarily on the patient’s learning needs. Nurses must be actively involved in teaching if they are to educate their patients about the proper way to take their drugs, the possibility of adverse reactions, and the signs and symptoms of toxicity (if applicable).

**Assessment**

Assessment is the data-gathering phase of the nursing process. Assessment assists the nurse in choosing the best teaching methods and individualizing the teaching plan. To develop an effective teaching plan, the nurse must first determine the patient’s needs. Needs stem from three areas: (1) information the patient or family needs to know about a particular drug; (2) the patient’s or family member’s ability to learn, accept, and use information; and (3) any barriers or obstacles to learning.

Some drugs have simple uses and, therefore, relatively little patient teaching is needed. For example, applying a nonprescription ointment to the skin requires only minimal teaching. Other drugs, such as insulin, require detailed information that may need to be given over several days.

Assessing an individual’s ability to learn may be difficult. Not all adults have the same literacy level. The information to be taught should be geared to the patient’s educational and reading level. When assessing language and literacy skills, it is important to remember that some patients do not have the ability to read well. The nurse must carefully assess the patient’s ability to communicate. Without accurate communication, learning will not occur. If the patient has a learning impairment, a family member or friend should be included in the teaching process. Most people readily understand what is being taught, but some cannot. For example, a visually impaired patient may be unable to read a label or printed directions supplied by the primary health care provider, pharmacist, or nurse. Another means of teaching will have to be used.

Through assessment, the nurse determines what barriers or obstacles (if any) may prevent the patient or family member from fully understanding the material being presented. Taking into consideration the patient’s
cultural background is helpful when planning a teaching session. For example, for some patients an interpreter is needed. In other cultures a certain individual (for example, the mother or the grandmother) is the decision maker in the family. It is important for the nurse to include the decision maker and the patient in the teaching session.

Nursing Diagnosis Checklist

- Effective Therapeutic Regimen Management
- Risk for Ineffective Therapeutic Regimen Management related to lack of knowledge, indifference, other factors
- Noncompliance with drug regimen related to indifference, lack of knowledge, other factors
- Deficient Knowledge related to the drug regimen, possible adverse reactions, disease process, other factors

Nursing Diagnoses

The nursing diagnosis is formulated after analyzing the information obtained during the assessment phase. Most often, nursing diagnoses related to the administration of drugs are associated with a risk for ineffective management, deficit knowledge, or noncompliance. Examples of nursing diagnoses related to the administration of drugs are listed in the Nursing Diagnosis Checklist.

Planning

Planning is the actual development of strategies to be used in the teaching plan and the selection of information to be taught. Planning begins with an expected outcome statement. The nurse develops a teaching plan based on the expected outcome using the information gained during the assessment. Display 5-1 identifies important information that the nurse should include in the teaching plan.

Developing an Individualized Teaching Plan

Teaching plans are individualized because patients' needs are not identical. Areas covered in an individualized teaching plan vary depending on the drug prescribed, the primary health care provider’s preference for including or excluding specific facts about the drug, and what the patient needs to know to take the drug correctly. Teaching strategies must reflect individual learning needs and ability. For example, a patient who speaks and reads only Spanish will not benefit from discharge instructions given in English or from instructions written in English. Different strategies must be implemented, such as providing instructions written in Spanish or communicating through another nurse who is fluent in the Spanish language.

When developing an individualized teaching plan for patients and their families, the nurse must select information relevant to a specific drug, adapt teaching to the individual’s level of understanding, and avoid medical terminology unless terms are explained or defined. Figure 5-1 is a sample form to use when developing a teaching plan. It is important to remember that repetition enhances learning. Several teaching sessions help the nurse to better assess what the patient is actually learning and provides time for clarification. The patient should be encouraged to ask questions and express feelings.

Basic Information to Consider When Developing a Teaching Plan

General material to consider when developing a teaching plan includes information on the dosage regimen, adverse reactions, family members, and basic information about drugs, drug containers, and drug storage.

DOSAGE REGIMEN. The dosage regimen is an important aspect of the teaching plan. The nurse must consider the following general points when teaching about the dosage regimen:

- Capsules or tablets should be taken with water unless the primary health care provider or pharmacist directs otherwise (eg, take with food, milk, or an antacid). Some liquids, such as coffee, tea, fruit juice, and carbonated beverages, may interfere with the action of certain drugs.
- A full glass of water is used when taking an oral drug. In some instances, it may be necessary to drink extra fluids during the day while taking certain drugs.
- It is important not to chew capsules before swallowing; they must be swallowed whole. The patient also should not chew tablets unless labeled as “chewable.” Some tablets have special coatings that are required for specific purposes, such as
Patient: __________________________ Medical Diagnosis: __________________________

Nursing Diagnosis: __________________________

- Effective Therapeutic Regimen Management __________________________
- Ineffective Therapeutic Regimen Management related to __________________________
- Deficient Knowledge related to __________________________

Expected Outcome: Patient will __________________________

Identified obstacles to learning: __________________________

Primary Language: __________________________

Cultural Considerations: __________________________

Information to include in teaching session:

- Expected therapeutic drug response: __________________________

- Dosage and route: __________________________

- Possible adverse reactions: __________________________

- Adverse reactions to report: __________________________

- Special considerations: __________________________

Teaching session (s)

<table>
<thead>
<tr>
<th>Date(s)</th>
<th>Present</th>
<th>Evaluation*</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*return demonstration, verbalizes understanding of information, questioned by nurse, other (specify) __________________________

Figure 5-1. Patient and family teaching.
proper absorption of the drug or prevention of irritation of the lining of the stomach.

• The dose of a drug or the time interval between doses is never increased or decreased unless directed by the primary health care provider.

• A prescription drug or nonprescription drug recommended by a primary health care provider is not stopped or omitted except on the advice of the primary health care provider.

• If the symptoms for which a drug was prescribed do not improve, or become worse, the primary health care provider must be contacted as soon as possible because a change in dosage or a different drug may be necessary.

• If a dose of a drug is omitted or forgotten, the next dose must not be doubled or the drug taken at more frequent intervals unless advised to do so by the primary health care provider.

• All health care workers, including physicians, dentists, nurses, and health personnel must always be informed of all drugs (prescription and nonprescription) currently being taken on a regular or occasional basis.

• The exact names of all prescription and nonprescription drugs currently being taken should be kept in a wallet or purse for instant reference when seeing a physician, dentist, or other health care provider.

• Check prescriptions carefully when obtaining refills from the pharmacy and report any changes in the prescription (eg, changes in color, size, shape) to the pharmacist or primary health care provider before taking the drug because an error may have occurred.

• Wear a Medic-Alert bracelet or other type of identification when taking a drug for a long time. This is especially important for drugs such as anticoagulants, steroids, oral hypoglycemic agents, insulin, or digitalis. In case of an emergency, the bracelet ensures that medical personnel are aware of health problems and current drug therapy.

ADVERSE DRUG EFFECTS. Information about adverse drug effects of the prescribed drug must be included when the nurse develops a teaching plan for the patient. The nurse should teach the patient the following general points about adverse drug effects:

• All drugs cause adverse reactions (side effects). Examples of some of the more common adverse reactions are nausea, vomiting, diarrhea, constipation, skin rash, dizziness, drowsiness, and dry mouth. Some may be mild and disappear with time or when the primary health care provider adjusts the dosage. In some instances, mild reactions, such as dry mouth, may have to be tolerated. Some adverse reactions are potentially serious and even life threatening.

• Adverse effects are always reported to the primary health care provider as soon as possible.

• Medical personnel must be informed of all drug allergies before any treatment or drug is given.

FAMILY MEMBERS. The nurse considers the following points concerning family members when developing a teaching plan:

• A drug prescribed for one family member is never given to another family member, relative, or friend unless directed to do so by the primary health care provider.

• The nurse makes sure that all family members or relatives are aware of all drugs, prescription and nonprescription, that are currently being taken by the patient.

DRUGS, DRUG CONTAINERS, AND DRUG STORAGE. The following are important facts about drugs, drug containers, and the storage of drugs that the nurse must consider when developing a teaching plan:

• The term drug applies to both nonprescription and prescription drugs.

• A drug must be kept in the container in which it was dispensed or purchased. Some drugs require special containers, such as light-resistant (brown) bottles to prevent deterioration that may occur on exposure to light.

• If any drug changes color or develops a new odor, a pharmacist must be consulted immediately about continued use of the drug.

• The lid or cap of the container must be replaced immediately after removing the drug from the container. The lid or cap must be firmly snapped or screwed in place because exposure to air or moisture shortens the life of most drugs.

• Drugs requiring refrigeration are so labeled. The container must be returned to the refrigerator immediately after removing the drug.

• All drugs must be kept out of the reach of children.

• Unless otherwise directed, drugs must be stored in a cool, dry place.

• Do not expose a drug to excessive sunlight, heat, cold, or moisture because deterioration may occur.
• The entire label of the prescription or nonprescription drug container must be read, including the recommended dosage and warnings.

• All directions printed on the label (e.g., “shake well before using,” “keep refrigerated,” “take before meals”) must be followed to ensure drug effectiveness.

• In some instances, especially when an ointment or liquid drug is prescribed, some drug may remain after it is used or taken for the prescribed time. Some drugs have a short life (a few weeks to a few months) and may deteriorate or change chemically after a time. A prescription must never be saved for later use unless the primary health care provider so advises.

**Implementation**

Implementation is the actual performance of the interventions identified in the teaching plan. Teaching at an appropriate time for each patient fosters learning. For example, patient teaching is not done when there are visitors (unless they are to be involved in the administration of the patient’s drugs), immediately before discharge from the hospital, or if the patient has been sedated or is in pain. Teaching is begun a day or more before discharge, at a time when the patient is alone and alert, and continued each day until dismissal. The nurse gears teaching to the patient’s level of understanding and, when necessary, provides written as well as oral instructions. If much information is given, it is often best to present the material in two or more sessions. Drug administration modifications may be necessary once the patient is at home. The nurse keeps these modifications in mind when teaching the patient (see Home Care Checklist: Modifying Drug Administration in the Home).

**Evaluation**

To determine the effectiveness of patient teaching, the nurse evaluates the patient’s knowledge of the material presented. Evaluation can be done in several ways, depending on the nature of the information.
For example, if the patient is being taught to administer insulin, several demonstrations can be scheduled, followed by a return demonstration by the patient with the nurse observing to evaluate the patient's technique.

Questions such as “Do you understand?” or “Is there anything you don’t understand?” should be avoided because the patient may feel uncomfortable admitting a lack of understanding. When factual material is being evaluated, the nurse should periodically ask the patient to list or repeat some of the information presented.

**Critical Thinking Exercises**

1. Locate the clinical educator in any health care agency in your community whose job it is to do patient education. Discuss with that person his or her thoughts and feelings on patient education, as well as any problems or pitfalls he or she has identified.

2. Interview friends or relatives about their knowledge of the drug(s) prescribed by their primary health care provider. Discuss with them the teaching they received from nurses or other health care providers before they began taking the drugs. Determine what areas could have been included that were not discussed. Analyze how the teaching/learning process was evaluated. Identify any areas that could be improved.

3. Using the form in Figure 5-1, develop a teaching plan for a patient.

**Review Questions**

1. An interactive process that promotes learning is defined as ______.
   A. motivation
   B. cognitive ability
   C. the psychomotor domain
   D. teaching

2. When developing a teaching plan, the nurse assesses the affective learning domain, which means that the nurse considers the patient's ______.
   A. attitudes, feelings, beliefs, and opinions
   B. ability to perform a return demonstration
   C. intellectual ability
   D. home environment

3. Actual development of the strategies to be used in the teaching plan and selections of the information to be taught occur in the _____ phase of the nursing process.
   A. assessment
   B. planning
   C. implementation
   D. evaluation

4. Unless the primary health care provider or pharmacist directs otherwise, the nurse informs patient to take oral medications with ______.
   A. fruit juice
   B. milk
   C. water
   D. food
Sulfonamides

Key Terms

- agranulocytosis
- anorexia
- antibacterial
- anti-infective
- aplastic anemia
- bacteriostatic
- crystalluria
- leukopenia
- pruritus
- Stevens-Johnson syndrome
- stomatitis
- thrombocytopenia
- urticaria

Chapter Objectives

On completion of this chapter, the student will:

- Discuss the uses, general drug actions, and general adverse reactions, contraindications, precautions, and interactions of the sulfonamides.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking sulfonamides.
- Describe the signs and symptoms associated with Stevens-Johnson syndrome.
- List some nursing diagnoses particular to a patient taking sulfonamides.
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating patients about the use of the sulfonamides.

The sulfonamides (sulfa) drugs were the first antibiotic drugs developed that effectively treated infections. Although the use of sulfonamides began to decline after the introduction of more effective anti-infectives, such as the penicillins and other antibiotics, these drugs still remain important for the treatment of certain types of infections.

**USES**

The sulfonamides are often used to control urinary tract infections caused by certain bacteria such as Escherichia coli, Staphylococcus aureus, and Klebsiella-Enterobacter. Mafenide (Sulfamylon) and silver sulfadiazine (Silvadene) are topical sulfonamides used in the treatment of second- and third-degree burns. Additional uses of the sulfonamides are given in the Summary Drug Table: The Sulfonamides.

**ACTIONS**

The sulfonamides are primarily bacteriostatic, which means they slow or retard the multiplication of bacteria. This bacteriostatic activity is due to sulfonamide antagonism to para-aminobenzoic acid (PABA), a substance that some, but not all, bacteria need to multiply. Once the rate of bacterial multiplication is slowed, the body’s own defense mechanisms (white blood cells) are able to rid the body of the invading microorganisms and therefore control the infection.

**ADVERSE REACTIONS**

The sulfonamides are capable of causing a variety of adverse reactions. Some of these are serious or potentially
# SUMMARY DRUG TABLE
## THE SULFONAMIDES

<table>
<thead>
<tr>
<th>Single Agents</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GENERIC NAME</strong></td>
<td><strong>TRADE NAME</strong>*</td>
<td><strong>USES</strong></td>
<td><strong>ADVERSE REACTIONS</strong></td>
<td><strong>dosage ranges</strong></td>
<td></td>
</tr>
<tr>
<td>sulfadiazine</td>
<td>generic</td>
<td>urinary tract infections due to susceptible microorganisms, chancroid, acute otitis media, Hemophilus influenzae and meningococcal meningitis, rheumatic fever</td>
<td>hematologic changes, Stevens-Johnson syndrome, nausea, vomiting, headache, diarrhea, chills, fever, anorexia, crystalluria, stomatitis, urticaria, pruritus</td>
<td>loading dose: 2–4 g PO; maintenance dose: 2–4 g/d PO in 4–6 divided doses</td>
<td></td>
</tr>
<tr>
<td>sulfamethizole</td>
<td>Thiosulfil Forte</td>
<td>urinary tract infections due to susceptible microorganisms</td>
<td>same as sulfadiazine</td>
<td>0.5–1 g PO tid, qid</td>
<td></td>
</tr>
<tr>
<td>sulfamethoxazole</td>
<td>Gantanol, Urobak, generic</td>
<td>urinary tract infections due to susceptible microorganisms, meningococcal meningitis, acute otitis media</td>
<td>same as sulfadiazine</td>
<td>initial dose: 2 g PO, maintenance dose: 1 g PO bid, tid</td>
<td></td>
</tr>
<tr>
<td>sulfasalazine</td>
<td>Azulfidine, EN-tabs, generic</td>
<td>ulcerative colitis, rheumatoid arthritis</td>
<td>same as sulfadiazine; may cause skin and urine to turn orange-yellow</td>
<td>initial therapy: 1–4 g/d PO in divided doses; maintenance dose: 2 g/d in evenly spaced doses 500 mg qid</td>
<td></td>
</tr>
<tr>
<td>sulfisoxazole</td>
<td>generic</td>
<td>same as sulfadiazine</td>
<td>same as sulfadiazine</td>
<td>loading dose: 2–4 g PO; maintenance dose: 4–8 g/d PO in 4–6 divided doses</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Multiple Preparations</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>trimethoprim (TMP) and sulfamethoxazole (SMZ)</td>
<td>Bactrim, Bactrim DS, Septra, Septra DS, generic</td>
<td>urinary tract infections due to susceptible microorganisms, acute otitis media, traveler's diarrhea due to Escherichia coli</td>
<td>gastrointestinal disturbances, allergic skin reactions, hematologic changes, Stevens-Johnson syndrome, headache</td>
<td>160 mg TMP/800 mg SMZ PO q12h; 8–10 mg/kg/d (based on TMP) IV in 2–4 divided doses</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Miscellaneous Sulfonamide Preparations</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>mafenide</td>
<td>Sulfamylon</td>
<td>second- and third-degree burns</td>
<td>pain or burning sensation, rash, itching, facial edema</td>
<td>apply to burned area 1–2 times/d</td>
<td></td>
</tr>
<tr>
<td>silver sulfadiazine sil-'ver sul-fa-dye'-a-zeen</td>
<td>Silvadene, Thermazene, SSD (cream)</td>
<td>same as mafenide</td>
<td>leukopenia, skin necrosis, skin discoloration, burning sensation</td>
<td>same as mafenide</td>
<td></td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.*
serious; others are mild. The following hematologic changes may occur during sulfonamide therapy:

- Agranulocytosis—decrease in or lack of granulocytes, a type of white blood cell
- Thrombocytopenia—decrease in the number of platelets
- Aplastic anemia—anemia due to deficient red blood cell production in the bone marrow
- Leukopenia—decrease in the number of white blood cells

These are examples of a serious adverse reaction. If any of these occur, discontinuation of sulfonamide therapy may be required.

A norexia (loss of appetite) is an example of a mild adverse reaction. Unless it becomes severe and pronounced weight loss occurs, it may not be necessary to discontinue sulfonamide therapy.

Various types of hypersensitivity (allergic) reactions may be seen during sulfonamide therapy, including Stevens-Johnson syndrome, urticaria (hives), pruritus (itching), and generalized skin eruptions. Stevens-Johnson syndrome is manifested by fever, cough, muscular aches and pains, and headache, all of which are signs and symptoms of many other disorders. However, the appearance of lesions on the skin, mucous membranes, eyes, and other organs are diagnostically significant and may be the first conclusive signs of this syndrome. Any of these symptoms must be reported to the primary health care provider immediately.

Other adverse reactions that may occur during therapy include nausea, vomiting, diarrhea, abdominal pain, chills, fever, and stomatitis (inflammation of the mouth). In some instances, these may be mild. Other times they may cause serious problems requiring discontinuation of the drug. Sulfasalazine may cause the urine and skin to be an orange-yellow color; this is not abnormal.

Crystalluria (crystals in the urine) may occur during administration of a sulfonamide, although this problem occurs less frequently with some of the newer sulfonamide preparations. This potentially serious problem often can be prevented by increasing fluid intake during sulfonamide therapy.

The most frequent adverse reaction seen with the application of mafenide is a burning sensation or pain when the drug is applied to the skin. Other possible allergic reactions include rash, itching, edema, and urticaria. Burning, rash, and itching may also be seen with the use of silver sulfadiazine. It may be difficult to distinguish between an adverse reaction due to the use of mafenide or silver sulfadiazine and reactions that may occur from the severe burn injury or from other agents used at the same time for the management of the burns.

**CONTRAINDICATIONS**

The sulfonamides are contraindicated in patients with hypersensitivity to the sulfonamides, during lactation, and in children less than 2 years old. The sulfonamides are not used near the end (at term) of pregnancy (Pregnancy Category D). If the sulfonamides are given near the end of pregnancy, significant blood levels of the drug may occur, causing jaundice or hemolytic anemia in the neonate. Additionally, the sulfonamides are not used for infections caused by group A beta-hemolytic streptococci because the sulfonamides have not been shown to be effective in preventing the complications of rheumatic fever or glomerulonephritis.

**PRECAUTIONS**

The sulfonamides are used with caution in patients with renal or hepatic impairment and bronchial asthma. These drugs are given with caution to patients with allergies. Safety for use during pregnancy has not been established (Pregnancy Category C, except at term).

**INTERACTIONS**

When a sulfonamide is administered with an oral anticoagulant, the action of the anticoagulant may be enhanced. The risk of bone marrow suppression may be increased when a sulfonamide is administered with methotrexate. When a sulfonamide is administered with a hydantoin, the serum hydantoin level may be increased.

Sulfonamides may inhibit the (hepatic) metabolism of the oral hypoglycemic drugs tolbutamide (Orinase) and chlorpropamide (Diabinese). This would increase the possibility of a hypoglycemic reaction.

---

**Health Supplement Alert: Cranberry**

Cranberries and cranberry juice are a commonly used remedy for the prevention of urinary tract infections (UTIs) and for the relief of symptoms from UTIs. The use of cranberry juice in combination with antibiotics has been recommended by physicians for the long-term suppression of UTIs. Cranberries are thought to act by preventing the bacteria from attaching to the walls of the urinary tract. The suggested amount is 6 ounces of the juice two times daily. Extremely large doses can produce gastrointestinal disturbances such as diarrhea or abdominal cramping. Although cranberries may relieve the symptoms of a UTI or prevent the occurrence of a UTI, their use will not cure a UTI. If an individual suspects a UTI, medical attention is necessary.
The Patient Receiving a Sulfonamide

ASSESSMENT

Preadministration Assessment
Before the initial administration of the drug, it is important to assess the patient’s general appearance and take and record the vital signs. The nurse obtains information regarding the symptoms experienced by the patient and the length of time these symptoms have been present. Depending on the type and location of the infection or disease, the nurse reviews the results of tests, such as a urine culture, urinalysis, complete blood count, intravenous pyelogram, renal function tests, and examination of the stool.

Ongoing Assessment
During the course of therapy, the nurse evaluates the patient at periodic intervals for response to the drug, that is, a relief of symptoms and a decrease in temperature (if it was elevated before therapy started), as well as the occurrence of any adverse reactions.

The nurse monitors the temperature, pulse, respiratory rate, and blood pressure every 4 hours or as ordered by the primary health care provider. If fever is present and the patient’s temperature suddenly increases or if the temperature was normal and suddenly increases, the nurse contacts the primary health care provider immediately.

The ongoing assessment for patients receiving sulfasalazine for ulcerative colitis includes observation for evidence of the relief or intensification of the symptoms of the disease. The nurse inspects all stool samples and records their number and appearance.

When administering a sulfonamide for a burn, the nurse inspects the burned areas every 1 to 2 hours because some treatment regimens require keeping the affected areas covered with the mafenide or silver sulfadiazine ointment at all times. Any adverse reactions should be reported immediately to the primary health care provider.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to the drugs are discussed in depth in Chapter 4.

Nursing Diagnoses Checklist

- Risk for Infection related to adverse reactions of the sulfonamides
- Risk for Impaired Skin Integrity related to adverse drug reaction of the sulfonamides
- Impaired Urinary Elimination related to adverse drug reaction of the sulfonamides

PLANNING

The expected outcomes of the patient depend on the reason for administration of the sulfonamide but may include an optimal response to drug therapy, management of adverse drug reactions, and an understanding of and compliance with the prescribed treatment regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy
The patient receiving a sulfonamide drug almost always has an active infection. Some patients may be receiving one of these drugs to prevent an infection (prophylaxis) or as part of the management of a disease such as ulcerative colitis.

Unless the primary health care provider orders otherwise, the nurse gives sulfonamides to the patient whose stomach is empty, that is, 1 hour before or 2 hours after meals. If gastrointestinal irritation occurs, the nurse may give sulfasalazine with food or immediately after meals. It is important to instruct the patient to drink a full glass of water when taking an oral sulfonamide and to drink at least eight large glasses of water each day until therapy is finished.

Managing Burns
When mafenide or silver sulfadiazine is used in the treatment of burns, the treatment regimen is outlined by the primary health care provider or the personnel in the burn treatment unit. There are various burn treatment regimens, such as debridement (removal of burned or dead tissue from the burned site), special dressings, and cleansing of the burned area. The use of a specific treatment regimen often depends on the extent of the burned area, the degree of the burns, and the physical condition and age of the patient. Other concurrent problems, such as lung damage due to smoke or heat or physical injuries that occurred at the time of the burn injury, also may influence the treatment regimen.

When instructed to do so, the nurse cleans and removes debris present on the surface of the skin before each application of mafenide or silver sulfadiazine and applies these drugs with a sterile gloved hand. The drug is applied approximately 1/16 inch thick; thicker application is not recommended. The patient is kept away from any draft of air because even the slightest movement of air across the burned area can cause pain. It is important to warn the patient that stinging or burning may be felt during, and for a short time after, application of mafenide. Some burning also may be noted with the application of silver sulfadiazine.

Monitoring and Managing Adverse Drug Reactions
The nurse must observe the patient for adverse reactions, especially an allergic reaction (see Chap. 1). If one or more adverse reactions should occur, the nurse withholds the next dose of the drug and notifies the primary health care provider.
The nurse monitors the patient for leukopenia and thrombocytopenia. Leukopenia may result in signs and symptoms of an infection, such as fever, sore throat, and cough. The nurse protects the patient with leukopenia from individuals who have an infection. With severe leukopenia the patient may be placed in protective (reverse) isolation. Thrombocytopenia is manifested by easy bruising and unusual bleeding following moderate to slight trauma to the skin or mucous membranes. The extremities of the patient with thrombocytopenia are handled with care to prevent bruising. Care is taken to prevent trauma when the patient is moved. The nurse inspects the skin daily for the extent of bruising and evidence of exacerbation of existing ecchymotic areas. It is important to encourage the patient to use a soft-bristled toothbrush to prevent any trauma to the mucous membranes of the oral cavity. The nurse reports any signs of leukopenia or thrombocytopenia immediately because this is an indication to stop drug therapy.

**Nursing Alert**

Stevens-Johnson syndrome is a serious and sometimes fatal hypersensitivity reaction. The nurse must be alert for lesions on the skin and mucous membranes, a diagnostically important symptom of this syndrome. The lesions appear as red wheals or blisters, often starting on the face, in the mouth, or on the lips, neck, and extremities. This syndrome, which also may occur with the administration of other types of drugs, can be fatal. The nurse must notify the primary health care provider and withhold the next dose of the drug. In addition, the nurse must exercise care to prevent injury to the involved areas.

**Maintaining Adequate Fluid Intake and Output**

Because one adverse reaction of the sulfonamide drugs is altered elimination patterns, it is important that the nurse helps the patient maintain adequate fluid intake and output. The nurse can encourage patients to increase fluid intake to 2000 mL or more a day to prevent crystalluria and stone formation in the genitourinary tract, as well as to aid in the removal of microorganisms from the urinary tract. It is important to measure and record the intake and output every 8 hours and notify the primary health care provider if the urinary output decreases or the patient fails to increase his or her oral intake.

**Gerontologic Alert**

Because renal impairment is common in older adults, the nurse should give the sulfonamides with great caution. There is an increased danger of the sulfonamides causing additional renal damage when renal impairment is already present. An increase of fluid intake up to 2000 mL (if the older adult can tolerate this amount) decreases the risk of crystals and stones forming in the urinary tract.

**Educating the Patient and Family**

When a sulfonamide is prescribed for an infection, some outpatients have a tendency to discontinue the drug once symptoms have been relieved. When teaching the patient and the family, the nurse emphasizes the importance of completing the prescribed course of therapy to be sure all microorganisms causing the infection are eradicated. Failure to complete a course of therapy may result in a recurrence of the infection. The nurse should develop a teaching plan to include the following information:

- Take the drug as prescribed.
- Take the drug on an empty stomach either 1 hour before or 2 hours after a meal (exception: sulfasalazine is taken with food or immediately after a meal).
- Take the drug with a full glass of water. Do not increase or decrease the time between doses unless directed to do so by the primary health care provider.
- Complete the full course of therapy. Do not discontinue this drug (unless advised to do so by the primary health care provider) even though the symptoms of the infection have disappeared.
- Drink at least 8 to 10 8-oz glasses of fluid every day.
- Prolonged exposure to sunlight may result in skin reactions similar to a severe sunburn (photosensitivity reactions). When going outside, cover exposed areas of the skin or apply a protective sunscreen to exposed areas.
- Notify the primary health care provider immediately if the following should occur: fever, skin rash or other skin problems, nausea, vomiting, unusual bleeding or bruising, sore throat, or extreme fatigue.
- Keep all follow-up appointments to ensure the infection is controlled.
- When taking sulfasalazine, the skin or urine may turn an orange-yellow color; this is not abnormal. If the patient wears soft contact lenses, a permanent yellow stain of the lenses may occur. It is a good idea to seek the advice of an ophthalmologist regarding corrective lenses while taking this drug.

**EVALUATION**

- The therapeutic drug effect is achieved.
- No evidence of infection is seen.
- The skin is intact and free of inflammation, irritation, or ulcerations.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.
- The patient and family demonstrate an understanding of the drug regimen.
Critical Thinking Exercises

1. Ms. Bartlett, age 80, has been prescribed a sulfonamide for a urinary tract infection and is to take the drug for 10 days. You note that Ms. Bartlett seems forgetful and at times confused. Determine what problems might be associated with Ms. Bartlett's mental state and her possible noncompliance to her prescribed treatment regimen.

2. Mr. Garcia is receiving sulfisoxazole for a recurrent bladder infection. When keeping an outpatient clinic appointment, he tells you that he developed a fever and sore throat yesterday. Analyze the steps you would take to investigate his recent problem. Give a reason for your answers.

3. Ms. Watson has diabetes and is taking tolbutamide (Orinase). Her primary care provider prescribes the combination drug sulfamethoxazole and trimethoprim (Septra) for a bladder infection. Discuss any instructions/information you would give to Ms. Watson in the patient education session.

Review Questions

1. A nurse working in the clinic asks how the sulfonamides control an infection. The most correct answer is that these drugs ______.
   
   A. encourage the production of antibodies
   B. antagonize PABA, which some bacteria need to multiply
   C. reduce the urine output
   D. make the urine alkaline, which eliminates bacteria

2. Patients receiving sulfasalazine for ulcerative colitis are told that the drug ______.
   
   A. is not to be taken with food
   B. rarely causes adverse effects
   C. may cause hair loss
   D. may turn the urine orange-yellow in color

3. When mafenide (Sulfamylon) is applied to a burned area, the nurse ______.
   
   A. first covers the burned area with a sterile compress
   B. irrigates the area with normal saline
   C. warns the patient that stinging or burning may be felt
   D. instructs the patient to drink two to three extra glasses of water each day

4. The nurse can evaluate the patient's response to therapy by asking him if ______.
   
   A. he completed the entire course of therapy
   B. his symptoms have been relieved
   C. he has seen any evidence of blood in the urine
   D. has experienced any constipation

Medication Dosage Problems

1. The primary health care provider prescribed sulfasalazine oral suspension 500 mg every 8 hours. The nurse has sulfasalazine oral suspension 250 mg/5 mL on hand. What dosage would the nurse give?

2. The nurse orders sulfamethoxazole 2 g PO initially, followed by 1 g PO BID. The nurse has 1000-mg tablets on hand. How many tablets would the nurse give for the initial dose?
Penicillins

Key Terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Term</th>
</tr>
</thead>
<tbody>
<tr>
<td>anaphylactic shock</td>
<td>leukopenia</td>
</tr>
<tr>
<td>angioedema</td>
<td>nonpathogenic</td>
</tr>
<tr>
<td>bacterial resistance</td>
<td>normal flora</td>
</tr>
<tr>
<td>bactericidal</td>
<td>penicillinase</td>
</tr>
<tr>
<td>bacteriostatic</td>
<td>phlebitis</td>
</tr>
<tr>
<td>cross-allergenicity</td>
<td>prophylaxis</td>
</tr>
<tr>
<td>cross-sensitivity</td>
<td>pseudomembranous</td>
</tr>
<tr>
<td>culture and sensitivity tests</td>
<td>colitis</td>
</tr>
<tr>
<td>glossitis</td>
<td>stomatitis</td>
</tr>
<tr>
<td>hypersensitivity</td>
<td>superinfection</td>
</tr>
<tr>
<td></td>
<td>thrombocytopenia</td>
</tr>
</tbody>
</table>

Chapter Objectives

On completion of this chapter, the student will:

- Identify the uses, general drug actions, and general adverse reactions, contraindications, precautions, and interactions of the penicillins.
- Discuss hypersensitivity reactions and pseudomembranous colitis as they relate to antibiotic therapy.
- List some nursing diagnoses particular to a patient taking penicillin.
- Identify important preadministration and ongoing assessment activities the nurse should perform on the patient taking penicillin.
- Discuss ways to promote optimal response to therapy, nursing actions to minimize adverse effects, and important points to keep in mind when educating patients about the use of penicillin.

Summary Drug Table: Penicillins for a more complete listing of the penicillins. Display 7-1 gives examples of the various groups.

**DRUG RESISTANCE**

Because the natural penicillins have been used for many years, drug-resistant strains of microorganisms have developed, making the natural penicillins less effective than some of the newer antibiotics in treating a broad range of infections. Bacterial resistance has occurred within the penicillins. Bacterial resistance is the ability of bacteria to produce substances that inactivate or destroy the penicillin. One example of bacterial resistance is the ability of certain bacteria to produce penicillinase, an enzyme that inactivates penicillin. The penicillinase-resistant penicillins were developed to combat this problem.

The natural penicillins also have a fairly narrow spectrum of activity, which means that they are effective against only a few strains of bacteria. Newer penicillins have been developed to combat this problem. These penicillins are a result of chemical treatment of a biologic precursor to penicillin. Because of their chemical modifications, they are more slowly excreted.
# Anti-infectives

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Natural Penicillins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>penicillin G (aqueous)</td>
<td>Pfizerpen, generic</td>
<td>Infections due to susceptible microorganisms; syphilis, gonorrhea</td>
<td>Glossitis, stomatitis, gastritis, furry tongue, nausea, vomiting, diarrhea, rash, fever, pain at injection site, hypersensitivity reactions, hematopoietic changes</td>
<td>Up to 20—30 million U/d IV or IM; dosage may also be based on weight</td>
</tr>
<tr>
<td>penicillin G benzathine</td>
<td>Bicillin L-A, generic</td>
<td>Infections due to susceptible microorganisms, syphilis; prophylaxis of rheumatic fever or chorea</td>
<td>Same as penicillin G</td>
<td>Up to 2.4 million U/d IM</td>
</tr>
<tr>
<td>penicillin G procaine, IM</td>
<td>Wycillin</td>
<td>Infections due to susceptible organisms</td>
<td>Same as penicillin G</td>
<td>600,000—2.4 million U/d IM</td>
</tr>
<tr>
<td>penicillin V</td>
<td>Beepen VK, generic</td>
<td>Infections due to susceptible organisms</td>
<td>Same as penicillin G</td>
<td>125—500 mg PO q6h or q8h</td>
</tr>
<tr>
<td><strong>Semisynthetic Penicillins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cloxacillin sodium</td>
<td>Cloxapen, generic</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>250—500 mg PO q6h</td>
</tr>
<tr>
<td>dicloxacillin sodium</td>
<td>Dynapen, generic</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>250 mg—1 g PO, 500 mg IM q4—6h; 3–6 g/d IV for 24—48 h only</td>
</tr>
<tr>
<td>nafcillin</td>
<td>Unipen, Nallpen</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>250 mg—1 g PO q4—6h; 250 mg—1 g q4—6h IM, IV</td>
</tr>
<tr>
<td>oxacillin sodium</td>
<td>Bactocill, generic</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>500 mg—1 g PO q4—6h; 250 mg—1 g q4—6h IM, IV</td>
</tr>
<tr>
<td><strong>Aminopenicillins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amoxicillin</td>
<td>Amoxil, generic</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>250—500 mg PO q8h or 875 mg PO BID</td>
</tr>
<tr>
<td>amoxicillin and clavulanate acid</td>
<td>Augmentin</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>250—500 mg PO q8h or 875 mg q12h**</td>
</tr>
<tr>
<td>ampicillin, oral</td>
<td>Omnifen, generic</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>250—500 mg PO q6h</td>
</tr>
<tr>
<td>ampicillin sodium parenteral</td>
<td>Omnifen-N, generic</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>1–12 g/d IM, IV in divided doses of q4—6h</td>
</tr>
<tr>
<td>ampicillin/sulbactam</td>
<td>Unasyn</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>0.5–1 g Sulbactam with 1–2 g ampicillin IM or IV q6—8h</td>
</tr>
<tr>
<td>bacampicillin</td>
<td>Spectrobid</td>
<td>Same as penicillin G</td>
<td>Same as penicillin G</td>
<td>400–800 mg PO q12h, may also be given based on weight</td>
</tr>
</tbody>
</table>
by the kidneys and, thus, have a somewhat wider spectrum of antibacterial activity. Penicillin β-lactamase inhibitor combinations are a type of penicillin that have a wider spectrum of antibacterial activity. Certain bacteria have developed the ability to produce enzymes called β-lactamases, which are able to destroy a component of the penicillin called the β-lactam ring. Fortunately, chemicals were discovered that inhibit the activity of these enzymes. Three examples of these β-lactamase inhibitors are clavulanic acid, sulbactam, and tazobactam. When these chemicals are used alone, they have little antimicrobial activity. However, when combined with certain penicillins, they extend the spectrum of penicillin's antibacterial activity. The β-lactamase inhibitors bind with the penicillin and protect the penicillin from destruction. Examples of the combinations of penicillins with the β-lactamase inhibitors are seen in Display 7-2. See the Summary Drug Table: Penicillins for more information on these combinations.

**Herbal Alert: Goldenseal**

Goldenseal, also called Hydrastis canadensis, is an herb found growing in the certain areas of the northeastern United States, particularly the Ohio River Valley. Goldenseal has long been used alone or in combination with echinacea for colds and influenza. However, there is no scientific evidence to support the use of goldenseal for cold and influenza or as a stimulant as there is for the use of echinacea (see Chap. 54). Similarly, goldenseal is touted as an “herbal antibiotic,” although there is no scientific evidence to support this use either. Another myth surrounding goldenseal’s use is that taking the herb masks the presence of illicit drugs in the urine.

There are many traditional uses of the herb, such as an antiseptic for the skin, mouthwash for canker sores, wash for inflamed or infected eyes, and the treatment of sinus infections and digestive problems, such as peptic ulcers and gastritis. Some evidence supports the use of goldenseal to treat diarrhea caused by bacteria or intestinal parasites, such as Giardia. The herb is contraindicated during pregnancy and in patients with hypertension. Adverse reactions are rare when the herb is used as directed. However, this herb should not be taken for more than a few days to a week. Because of widespread use, destruction of its natural habitats, and renewed interest in its use as an herbal remedy, goldenseal was classified as an “endangered” plant in 1997 by the US government.
The penicillins have the same type of action against bacteria. Penicillins prevent bacteria from using a substance that is necessary for the maintenance of the bacteria's outer cell wall. Unable to use this substance for cell wall maintenance, the bacteria swell, rupture, assume unusual shapes, and finally die (Fig. 7-1).

The penicillins may be **bactericidal** (destroy bacteria) or **bacteriostatic** (slow or retard the multiplication of bacteria). They are bactericidal against sensitive microorganisms (ie, those microorganisms that will be affected by penicillin) provided there is an adequate concentration of penicillin in the body. An adequate concentration of any drug in the body is referred to as the blood level. An inadequate concentration (or inadequate blood level) of penicillin may produce bacteriostatic activity, which may or may not control the infection.

### Identifying the Appropriate Penicillin

To determine if a specific type of bacteria is sensitive to penicillin, **culture and sensitivity tests** are performed. A culture is performed by placing infectious material obtained from areas such as the skin, respiratory tract, and blood on a culture plate that contains a special growing medium. This growing medium is "food" for the bacteria. After a specified time, the bacteria are examined under a microscope and identified. The sensitivity test involves placing the infectious material on a separate culture plate and then placing small disks impregnated with various antibiotics over the area. After a specified time, the culture plate is examined. If there is little or no growth around a disk, the bacteria are considered sensitive to that particular antibiotic. Therefore, the infection will be controlled by this antibiotic (Fig. 7-2). If there is considerable growth around the disk, then the bacteria are considered resistant to that particular antibiotic, and the infection will not be controlled by this antibiotic.

After a culture and sensitivity report is received, the strain of microorganisms causing the infection is known, and the antibiotic to which these microorganisms are sensitive and resistant is identified. The primary healthcare provider then selects the antibiotic to which the microorganism is sensitive because that is the antibiotic that will be effective in the treatment of the infection.

### Uses

**Infectious Disease**

The natural and semisynthetic penicillins are used in the treatment of bacterial infections due to susceptible microorganisms. Penicillins may be used to treat infections such as urinary tract infections, septicemia, meningitis, intra-abdominal infection, gonorrhea, syphilis, pneumonia, and other respiratory infections. Examples of infectious microorganisms (bacteria) that may respond to penicillin therapy include gonococci, staphylococci,
streptococci, and pneumococci. Culture and sensitivity tests are performed whenever possible to determine which penicillin will best control an infection caused by a specific strain of bacteria. A penicillinase-resistant penicillin is used as initial therapy for any suspected staphylococcal infection until culture and sensitivity results are known.

**Prophylaxis**

Penicillin is of no value in the treatment of viral or fungal infections. However, the primary health care provider occasionally will prescribe penicillin as prophylaxis (prevention) against a potential secondary bacterial infection that can occur in a patient with a viral infection. In these situations the viral infection has weakened the body’s defenses and the person is susceptible to other infections, particularly a bacterial infection. Penicillin also may be prescribed as prophylaxis for a potential infection in high-risk individuals, such as those with a history of rheumatic fever. Penicillin is taken several hours or, in some instances days, before and after an operative procedure, such as dental, oral, or upper respiratory tract procedures that can result in bacteria entering the bloodstream. Taking penicillin before and after the procedure will usually prevent a bacterial infection in these high-risk patients. Penicillin also may be given prophylactically on a continuing basis to those with rheumatic fever and chronic ear infections.

**ADVERSE REACTIONS**

Common adverse reactions include mild nausea, vomiting, diarrhea, sore tongue or mouth, fever, and pain at injection site. Penicillin can stimulate a hypersensitivity (allergic) reaction within the body. Another adverse reaction that may be seen with penicillin, as well as with almost all antibiotics, is a superinfection (a secondary infection that occurs during antibiotic treatment).

**Hypersensitivity Reactions**

A hypersensitivity (or allergic) reaction to a drug occurs in some individuals, especially those with a history of allergy to many substances. Signs and symptoms of a hypersensitivity to penicillin are highlighted in Display 7-3. A naphylactic shock, which is a severe form of hypersensitivity reaction, also can occur (see Chap. 1). A naphylactic shock occurs more frequently after parenteral administration but can occur with oral use. This reaction is likely to be immediate and severe in susceptible individuals.

**DISPLAY 7-3**

---

<table>
<thead>
<tr>
<th>Signs and Symptoms of Hypersensitivity to Penicillin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin rash</td>
</tr>
<tr>
<td>Urticaria (hives)</td>
</tr>
<tr>
<td>Sneezing</td>
</tr>
<tr>
<td>Wheezing</td>
</tr>
<tr>
<td>Pruritus (itching)</td>
</tr>
<tr>
<td>Bronchospasm (spasm of the bronchi)</td>
</tr>
<tr>
<td>Laryngospasm (spasm of the larynx)</td>
</tr>
<tr>
<td><strong>Angioedema</strong> (also called angioneurotic edema)—swelling of the skin and mucous membranes, especially around and in the mouth and throat</td>
</tr>
<tr>
<td>Hypotension—can progress to shock</td>
</tr>
<tr>
<td>Signs and symptoms resembling serum sickness—chills, fever, edema, joint and muscle pain, and malaise</td>
</tr>
</tbody>
</table>

---
individuals. Signs of anaphylactic shock include severe hypotension, loss of consciousness, and acute respiratory distress. If not immediately treated, anaphylactic shock can be fatal.

Once an individual is allergic to one penicillin, he or she is most likely allergic to all of the penicillins. Those allergic to penicillin also have a higher incidence of allergy to the cephalosporins (see Chap. 8). Allergy to drugs in the same or related groups is called cross-sensitivity or cross-allergenicity.

### Superinfections

Antibiotics can disrupt the normal flora (nonpathogenic microorganisms within the body) causing a superinfection. This new infection is “superimposed” on the original infection. The destruction of large numbers of nonpathogenic bacteria (normal flora) by the antibiotic alters the chemical environment. This allows uncontrolled growth of bacteria or fungal microorganisms, which are not affected by the antibiotic being administered. A superinfection may occur with the use of any antibiotic, especially when these drugs are given for a long time or when repeated courses of therapy are necessary. A superinfection can develop rapidly and is potentially serious and even life threatening. Bacterial superinfections are commonly seen with the administration of the oral penicillins and occur in the bowel. Symptoms of bacterial superinfection of the bowel include diarrhea or bloody diarrhea, rectal bleeding, fever, and abdominal cramping.

Fungal superinfections commonly occur in the vagina, mouth, and anal and genital areas. Symptoms include lesions of the mouth or tongue, vaginal discharge, and anal or vaginal itching. Pseudomembranous colitis is a common bacterial superinfection; candidiasis or moniliasis is a common type of fungal superinfection.

### Nursing Alert

Pseudomembranous colitis may occur after 4 to 9 days of treatment with penicillin or as long as 6 weeks after the drug is discontinued.

### CANDIDIASIS OR MONILIASIS

Another type of superinfection may occur due to an overgrowth of the yeastlike fungi that usually exist in small numbers in the vagina. The multiplication rate of these microorganisms is normally slowed and kept under control because of the presence of a strain of bacteria (Döderlein’s bacillus) in the vagina. If penicillin therapy destroys these normal microorganisms of the vagina (Döderlein’s bacillus), the fungi are now uncontrolled, multiply at a rapid rate, and cause symptoms of a fungal infection called candidiasis (or moniliasis). Symptoms include vaginal itching and discharge.

Candida fungal superinfections also occur in the mouth and around the anal and genital areas. Signs and symptoms include lesions in the mouth or anal/genital itching.

### Other Adverse Reactions

Other adverse reactions associated with penicillin are hematopoietic changes such as anemia, thrombocytopenia (low platelet count), leukopenia (low white blood cell count), and bone marrow depression. When penicillin is given orally, glossitis (inflammation of the tongue), stomatitis (inflammation of the mouth), dry mouth, gastritis, nausea, vomiting, and abdominal pain occur. When penicillin is given intramuscularly (IM), there may be pain at the injection site. Irritation of the vein and phlebitis (inflammation of a vein) may occur with intravenous (IV) administration.

### CONTRAINDICATIONS

Penicillins are contraindicated in patients with a history of hypersensitivity to penicillin or the cephalosporins.

### PRECAUTIONS

Penicillins should be used cautiously in patients with renal disease, pregnancy (Pregnancy Category C), lactation (may cause diarrhea or candidiasis in the infant), and in those with a history of allergies. Any indication of sensitivity is reason for caution. The drug is also used with caution in patients with asthma, renal disease, bleeding disorders, and gastrointestinal disease.
INTERACTIONS

Some penicillins (ampicillin, bacampicillin, penicillin V) may interfere with the effectiveness of birth control pills that contain estrogen. There is a decreased effectiveness of the penicillin when it is administered with the tetracyclines. Large doses of penicillin can increase bleeding risks of patients taking anticoagulant agents. Some reports indicate that when oral penicillins are administered with beta-adrenergic blocking drugs (see Chap. 23), the patient may be at increased risk for an anaphylactic reaction. Absorption of most penicillins is affected by food. In general, penicillins should be given 1 hour before or 2 hours after meals.

Additional culture and sensitivity tests may be performed during therapy because microorganisms causing the infection may become resistant to penicillin, or a superinfection may have occurred. A urinalysis, complete blood count, and renal and hepatic function tests also may be performed at intervals during therapy.

NURSING PROCESS

The Patient Receiving Penicillin

ASSESSMENT

Preadministration Assessment
Before the administration of the first dose of penicillin, the nurse obtains or reviews the patient’s general health history. The health history includes an allergy history, a history of all medical and surgical treatments, a drug history, and the current symptoms of the infection. If the patient has a history of allergy, particularly a drug allergy, the nurse must explore this area to ensure the patient is not allergic to penicillin or a cephalosporin.

The nurse should take and record vital signs. When appropriate, it is important to obtain a description of the signs and symptoms of the infection from the patient or family. The nurse assesses the infected area (when possible) and records findings on the patient’s chart. It is important to describe accurately any signs and symptoms related to the patient’s infection, such as color and type of drainage from a wound, pain, redness and inflammation, color of sputum, or presence of an odor. In addition, the nurse should note the patient’s general appearance. A culture and sensitivity test is almost always ordered, and the nurse must obtain the results before giving the first dose of penicillin.

Ongoing Assessment
The nurse evaluates the patient daily for a response to therapy, such as a decrease in temperature, the relief of symptoms caused by the infection (such as pain or discomfort), an increase in appetite, and a change in the appearance or amount of drainage (when originally present). Once an infection is controlled, patients often look better and even state that they feel better. It is important to record these evaluations on the patient’s chart. The nurse notifies the primary health care provider if signs and symptoms of the infection appear to worsen.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in Chapter 4.

PLANNING

The expected outcomes of the patient depend on the reason for administration of penicillin but may include an optimal response to drug therapy, management of common adverse reactions, and an understanding of and compliance with the prescribed drug regimen.

IMPLEMENTATION

Promoting Optimal Response to Therapy
The results of a culture and sensitivity test take several days because time must be allowed for the bacteria to grow on the culture media. However, infections are treated as soon as possible. In a few instances, the primary health care provider may determine that a penicillin is the treatment of choice until the results of the culture and sensitivity tests are known. In many instances, the primary health care provider selects a broad-spectrum antibiotic (ie, an antibiotic that is effective against many types or strains of bacteria) for initial treatment because of the many penicillin-resistant strains of microorganisms.

Nursing Diagnoses Checklist

- Diarrhea related to adverse reaction to penicillin
- Risk for Impaired Skin Integrity related to adverse reaction to penicillin
- Risk for Impaired Oral Mucous Membrane related to adverse reaction to penicillin
- Risk for Imbalanced Body Temperature
Penicillin is ordered in units or milligrams. The exact equivalency usually is stated on the container or package insert. When preparing a parenteral form of penicillin, the nurse should shake the vial thoroughly before withdrawing the drug to ensure even distribution of the drug in the solution. Some forms of penicillin are in powder or crystalline form and must be made into a liquid (reconstituted) before being withdrawn from the vial. The manufacturer’s directions regarding reconstitution are printed on the label or package insert. The manufacturer indicates the type of diluent to be used when reconstituting a specific drug. Some powdered or crystalline drugs, when reconstituted with a given amount of diluent, may yield slightly more or less than the amount of the diluent added to the vial. If there is any question regarding the reconstitution of this or any drug, the nurse consults with a pharmacist. In some health care facilities the drug is prepared in the pharmacy and delivered to the nurse for administration.

Adequate blood levels of the drug must be maintained for the agent to be effective. An accidental omission or delay of a dose results in decreased blood levels, which will reduce the effectiveness of the antibiotic. It is best to give oral penicillins on an empty stomach, 1 hour before or 2 hours after a meal. Bacampicillin (Spectrobid), penicillin V (Pen-Vee K), and amoxicillin (Amoxil) may be given without regard to meals. Esampicillin is best to give oral penicillins on an empty stomach, which will reduce the effectiveness of the antibiotic. It or delay of a dose results in decreased blood levels, accidental omission of this or any drug, the nurse consults with a pharmacist. In some health care facilities the drug is prepared in the pharmacy and delivered to the nurse for administration.

When administering penicillin IM, the nurse warns the patient about allergy to penicillin before administering the first dose, even when an accurate drug history has been taken. It is important to tell patients that the drug they are receiving is penicillin because information regarding a drug allergy may have been forgotten at the time the initial drug history was obtained. If a patient states he or she is allergic to penicillin or a cephalosporin, the nurse withholds the drug and contacts the primary health care provider.

**Nursing Alert**

The nurse questions the patient about allergy to penicillin before administering the first dose, even when an accurate drug history has been taken. It is important to tell patients that the drug they are receiving is penicillin because information regarding a drug allergy may have been forgotten at the time the initial drug history was obtained. If a patient states he or she is allergic to penicillin or a cephalosporin, the nurse withholds the drug and contacts the primary health care provider.

The nurse also closely observes the patient for signs of a bacterial or fungal superinfection in the vaginal or anal area. It is important to report any signs and symptoms of a superinfection to the primary health care provider before administering the next dose of the drug. When symptoms are severe, additional treatment measures may be necessary, such as administration of an antipyretic drug for fever or an antifungal drug.

**DIARRHEA.** Diarrhea may be an indication of a superinfection of the gastrointestinal tract or pseudomembranous colitis. The nurse inspects all stools and notifies the primary health care provider if diarrhea occurs because it may be necessary to stop the drug. If diarrhea does occur and there appears to be blood and mucus in the stool, it is important to save a sample of the stool and test for occult blood using a test such as Hemoccult. If the stool tests positive for blood, the nurse saves the sample for possible further laboratory analysis.

**IMPAIRED SKIN INTEGRITY.** Dermatologic reactions such as hives, rashes, and skin lesions can occur with the administration of penicillin. In mild cases or where the benefit of the drug outweighs the discomfort of skin lesions, the nurse administers frequent skin care. Emollients, antipyretic creams, or a topical corticosteroid may be prescribed. An antihistamine may be prescribed. Harsh soaps and perfumed lotions are avoided. The nurse instructs the patient to avoid rubbing the area and not to wear rough or irritating clothing. It is important to report a rash or hives to the primary health care provider because this may be a precursor to a severe anaphylactic reaction (see Hypersensitivity Reactions). In severe cases, the primary health care provider may discontinue penicillin therapy.

**IMPAIRED ORAL MUCOUS MEMBRANES.** The administration of oral penicillin may result in a fungal superinfection in the oral cavity. With impaired oral mucous membranes there will be varying degrees of inflamed oral mucous membranes, swollen and red tongue, swollen gums, and pain in the mouth and throat. To detect this problem early, the nurse inspects the patient’s mouth...
daily for evidence of glossitis, sore tongue, ulceration, or a black, furry tongue. The nurse can explain that, if the diet permits, yogurt, buttermilk, or acidophilus capsules may be taken to reduce the risk of fungal superinfection.

The nurse inspects the mouth and gums often and gives frequent mouth care with a nonirritating solution. A soft bristled toothbrush is used when brushing is needed. A nonirritating soft diet may be required. The nurse monitors the dietary intake to assure the patient is receiving adequate nutrition. Antifungal agents and/or local anesthetics are sometimes recommended to soothe the irritated membranes.

FEVER. The nurse takes vital signs every 4 hours or more often if necessary. It is important to report any increase in temperature to the primary health care provider because additional treatment measures, such as administration of an antipyretic drug or change in the drug or dosage, may be necessary. An increase in body temperature several days after the start of therapy may indicate a secondary bacterial infection or failure of the drug to control the original infection. On occasion the fever may be caused from an adverse reaction to the penicillin. In these cases the fever can usually be managed by using an antipyretic drug.

Educating the Patient and Family

Any time a drug is prescribed for a patient, the nurse is responsible for ensuring that the patient has a thorough understanding of the drug, the treatment regimen, and adverse reactions. Some patients do not adhere to the prescribed drug regimen for a variety of reasons, such as failure to comprehend the prescribed regimen or failure to understand the importance of continued and uninterrupted therapy. The nurse describes the drug regimen and stresses the importance of continued and uninterrupted therapy when teaching the patient who is prescribed an antibiotic.

The nurse teaches the following information to patients prescribed an antibiotic:

- **Prophylaxis**—Take the drug as prescribed until the primary health care provider discontinues therapy.
- **Infection**—Complete the full course of therapy. Do not stop taking the drug, even if the symptoms have disappeared, unless directed to do so by the primary health care provider.
- Take the drug at the prescribed times of day because it is important to keep an adequate amount of drug in the body throughout the entire 24 hours of each day.
- **Penicillin** (oral)—Take the drug on an empty stom-ach either 1 hour before or 2 hours after meals (exceptions: bacampicillin, penicillin V, amoxicillin).
- Take each dose with a full glass of water.
- To reduce the risk of superinfection, take yogurt, buttermilk, or acidophilus capsules.
- Notify the primary health care provider immediately if any one or more of the following should occur: skin rash; hives (urticaria); severe diarrhea; vaginal or anal itching; sore mouth; black, furry tongue; sores in the mouth; swelling around the mouth or eyes; breathing difficulty; or gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Do not take the next dose of the drug until the problem is discussed with the primary health care provider.
- **Oral suspensions**—Keep the container refrigerated (if so labeled), shake the drug well before pouring (if so labeled), and return the drug to the refrigerator immediately after pouring the dose. Drugs that are kept refrigerated lose their potency when kept at room temperature. A small amount of the drug may be left after the last dose is taken. Discard any remaining drug because the drug (in suspension form) begins to lose its potency after a few weeks (7–14 days).
- **Women prescribed ampicillin, bacampicillin, and penicillin V who take birth control pills containing estrogen should use additional contraception measures.**
- **Never give this drug to another individual even though the symptoms appear to be the same.**
- **Notify the primary health care provider if the symptoms of the infection do not improve or if the condition becomes worse.**
- When a penicillin is to be taken for a long time for prophylaxis, you may feel well despite the need for long-term antibiotic therapy. There may be a tendency to omit one or more doses or even neglect to take the drug for an extended time. Never skip doses or stop therapy unless told to do so by the primary health care provider. (See Patient and Family Teaching Checklist: Preventing Antibiotic Resistance.)

EVALUATION

- The therapeutic drug effect is achieved and the infection is controlled.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
- The patient and family demonstrate understanding of the drug regimen.

Critical Thinking Exercises

1. Ms. Barker had a bowel resection 4 days ago. After a culture and sensitivity test of her draining surgical wound, the primary health care provider orders penicillin G aqueous IV as a continuous drip. Determine what questions you would ask Ms. Barker before the penicillin is added to the IV solution.
2. After administering penicillin to a patient in an outpatient setting, you request that the patient wait about 30 minutes before leaving. The patient is reluctant to stay, saying that she has a busy schedule. Discuss how you would handle this situation.

3. A 28-year-old married woman with three children is prescribed bacampicillin (Spectrobid) for an upper respiratory infection caused by Streptococcus pneumoniae. What information would be important for you to obtain from this woman? What special instructions would you give her because of her gender and age?

Review Questions

1. When reviewing Ms. Robertson’s culture and sensitivity test results, the nurse learns that the bacteria causing Ms. Robertson’s infection are sensitive to penicillin. The nurse interprets this result to mean that _____.
   A. Ms. Robertson is allergic to penicillin
   B. penicillin will be effective in treating the infection
   C. penicillin will not be effective in treating the infection
   D. the test must be repeated to obtain accurate results

2. Mr. Thomas, who is receiving oral penicillin, reports he has a sore mouth. Upon inspection the nurse notes a black, furry tongue and bright red oral mucous membranes. The primary care provider is notified immediately because these symptoms may be caused by _____.
   A. a vitamin C deficiency
   B. a superinfection
   C. dehydration
   D. poor oral hygiene

3. The nurse correctly administers penicillin V _____.
   A. 1 hour before or 2 hours after meals
   B. without regard to meals
   C. with meals to prevent gastrointestinal upset
   D. every 3 hours around the clock

4. After administering penicillin in an outpatient setting the nurse _____.
   A. asks the patient to wait 10 to 15 minutes before leaving the clinic
   B. instructs the patient to report any numbness or tingling of the extremities
   C. keeps pressure on the injection site for 10 minutes
   D. asks the patient to wait in the area for at least 30 minutes

Medication Dosage Problems

1. A patient is prescribed amoxicillin for oral suspension. The drug is reconstituted to a solution of 250 mg/5 mL. Answer the following questions: How much amoxicillin will 1 teaspoon contain? _____ The primary care provider prescribes 500 mg. How many milliliters (mL) will the nurse administer? _____

2. The primary care provider orders 500 mg of Augmentin oral suspension. Read the label below to answer the following questions:

   How much water will be required for reconstitution? _____ Describe the process you would go through to reconstitute this drug. _____ When reconstituted, what will be the strength of the solution? _____

Patient and Family Teaching Checklist

Preventing Antibiotic Resistance

The nurse:

✓ Reviews the reason for the drug and the prescribed drug regimen, including drug name, correct dose, and frequency of administration.
✓ Stresses the importance of continued and uninterrupted therapy, even if the patient feels better after a few doses.
✓ Instructs the patient to continue taking the drug until all the drug is finished or the prescriber discontinues therapy.
✓ Urges the patient and family to discard any unused drug once therapy is discontinued or completed.
✓ Warns the patient not to use any leftover antibiotic or to take another family member’s antibiotic as self-treatment for a suspected infection.
✓ Reviews the possible adverse reactions and the signs and symptoms of a new infection or of a worsening infection, both verbally and in writing.
✓ Instructs the patient and family to notify the health care provider at once should the patient experience any adverse reactions or signs and symptoms of infection.

UNIT II  Anti-infectives
The effectiveness of penicillin in the treatment of infections prompted research directed toward finding new antibiotics with a wider range of antibacterial activity. The cephalosporins are a valuable group of drugs that are effective in the treatment of almost all of the strains of bacteria affected by the penicillins, as well as some strains of bacteria that have become resistant to penicillin. The cephalosporins are structurally and chemically related to penicillin.

The cephalosporins are divided into first-, second-, and third-generation drugs. Particular cephalosporins also may be differentiated within each group according to the microorganisms that are sensitive to them. Generally, progression from the first-generation to the second-generation and then to the third-generation drugs shows an increase in the sensitivity of gram-negative microorganisms and a decrease in the sensitivity of gram-positive microorganisms. For example, a first-generation cephalosporin would have more use against gram-positive microorganisms than would a third-generation cephalosporin. This scheme of classification is becoming less clearly defined as newer drugs are introduced. Examples of first-, second-, and third-generation cephalosporins are listed in Display 8-1. For a more complete listing see the Summary Drug Table: Cephalosporins.

### ACTIONS

Cephalosporins affect the bacterial cell wall, making it defective and unstable. This action is similar to the action of penicillin. The cephalosporins are usually bactericidal (capable of destroying bacteria).

### USES

The cephalosporins are used in the treatment of infections caused by susceptible microorganisms. Examples of microorganisms that may be susceptible to the cephalosporins include streptococci, staphylococci, and...
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>First-Generation Cephalosporins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefadroxil</td>
<td>Duricef</td>
<td>Infections due to susceptible microorganisms</td>
<td>Nausea, vomiting, diarrhea, hypersensitivity reactions, superinfection, nephrotoxicity, headache, Stevens-Johnson syndrome, pseudomembranous colitis</td>
<td>1–2 g/d PO in divided doses</td>
</tr>
<tr>
<td>cefazolin sodium</td>
<td>Ancef, Kefzol, generic</td>
<td>Infections due to susceptible microorganisms; perioperative prophylaxis</td>
<td>Nausea, vomiting, diarrhea, hypersensitivity reactions, superinfection, nephrotoxicity, headache, Stevens-Johnson syndrome, pseudomembranous colitis</td>
<td>250 mg–1 g IM, IV 6–12h; perioperative, 0.5–1g IM, IV</td>
</tr>
<tr>
<td>cephalixin</td>
<td>Keflex, generic</td>
<td>Infections due to susceptible microorganisms</td>
<td>Same as cefadroxil</td>
<td>1–4 g/d PO in divided doses</td>
</tr>
<tr>
<td><strong>Second-Generation Cephalosporins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefaclor</td>
<td>Ceclor</td>
<td>Treatment of infections due to susceptible organisms</td>
<td>Nausea, vomiting, diarrhea, hypersensitivity reactions, nephrotoxicity, headache, hematologic reactions</td>
<td>250 mg PO q8h</td>
</tr>
<tr>
<td>cefamandole</td>
<td>Mandol</td>
<td>Same as cefaclor</td>
<td>Same as cefaclor</td>
<td>500 mg to 1 g IM, IV q4–6h</td>
</tr>
<tr>
<td>cefotetan</td>
<td>Cefotan</td>
<td>Same as cefaclor; perioperative prophylaxis</td>
<td>Same as cefaclor</td>
<td>1–6 g IM, IV in equally divided doses; perioperative: 1–2 g IV</td>
</tr>
<tr>
<td>cefoxitin</td>
<td>Mefoxin</td>
<td>Same as cefaclor; perioperative prophylaxis</td>
<td>Same as cefaclor</td>
<td>1–2 g IM q6–8h; 1–12 g/d IV in equally divided doses; perioperative, 1–2 g IV</td>
</tr>
<tr>
<td>cefpodoxime</td>
<td>Vantin</td>
<td>Same as cefaclor</td>
<td>Same as cefaclor</td>
<td>200–800 mg/d PO in equally divided doses</td>
</tr>
<tr>
<td>cefprozil</td>
<td>Cefzil</td>
<td>Same as cefaclor</td>
<td>Same as cefaclor</td>
<td>250–500 mg PO q12h</td>
</tr>
<tr>
<td>cefuroxime</td>
<td>Ceftin, Kefurox, Zinacef</td>
<td>Same as cefaclor; perioperative prophylaxis</td>
<td>Same as cefaclor</td>
<td>250 mg PO BID; 750 mg–1.5 g IM or IV q8h; perioperative, 1.5 g IV</td>
</tr>
<tr>
<td>loracarbef</td>
<td>Lorabid</td>
<td>Same as cefaclor</td>
<td>Same as cefaclor</td>
<td>200–400 mg PO q12h</td>
</tr>
<tr>
<td><strong>Third-Generation Cephalosporins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cefdinir</td>
<td>Omnicef</td>
<td>Same as cefaclor</td>
<td>Same as cefaclor</td>
<td>300 mg PO q12h or 600 mg q24h PO</td>
</tr>
<tr>
<td>cefepime hydrochloride</td>
<td>Maxipime</td>
<td>Same as cefaclor</td>
<td>Same as cefaclor</td>
<td>0.5 mg–2 g IV, IM q12h</td>
</tr>
<tr>
<td>cefixime</td>
<td>Suprax</td>
<td>Same as cefaclor</td>
<td>Same as cefaclor</td>
<td>400 mg/d as a single dose or divided doses</td>
</tr>
</tbody>
</table>
citrobacters, gonococci, shigella, and clostridia. Culture and sensitivity tests (see Chap. 7) are performed whenever possible to determine which antibiotic, including a cephalosporin, will best control an infection caused by a specific strain of bacteria. Pharyngitis, tonsillitis, otitis media, lower respiratory infections, urinary tract infections, septicemia, and gonorrhea are examples of the types of infections that may be treated with the cephalosporins.

The cephalosporins also may be used perioperatively, that is, during the preoperative, intraoperative, and postoperative periods, to prevent infection in patients having surgery on a contaminated or potentially contaminated area, such as the gastrointestinal tract or vagina. In some instances, a specific drug may be recommended for postoperative prophylactic use only.

**ADVERSE REACTIONS**

The most common adverse reactions seen with administration of the cephalosporins are gastrointestinal disturbances, such as nausea, vomiting, and diarrhea.

Hypersensitivity (allergic) reactions may occur with administration of the cephalosporins and range from mild to life threatening. Mild hypersensitivity reactions include pruritus, urticaria, and skin rashes. More serious hypersensitivity reactions include **Stevens-Johnson syndrome** (fever, cough, muscular aches and pains, headache, and the appearance of lesions on the skin, mucous membranes, and eyes), hepatic and renal dysfunction, **aplastic anemia** (anemia due to deficient red blood cell production), and **epidermal necrolysis** (death of the epidermal layer of the skin).

Because of the close relation of the cephalosporins to penicillin, a patient allergic to penicillin also may be allergic to the cephalosporins.

Other adverse reactions that may be seen with administration of the cephalosporins are headache, dizziness, **nephrotoxicity** (damage to the kidneys by a toxic substance), malaise, heartburn, and fever. Intramuscular (IM) administration often results in pain, tenderness, and inflammation at the injection site. Intravenous (IV) administration has resulted in thrombophlebitis and phlebitis.

Therapy with cephalosporins may result in a bacterial or fungal superinfection. Diarrhea may be an indication of pseudomembranous colitis, which is one type of bacterial superinfection. See Chapter 7 for a discussion of bacterial and fungal superinfections and pseudomembranous colitis.

**CONTRAINDICATIONS**

The nurse should not administer cephalosporins if the patient has a history of allergies to cephalosporins or penicillins.
PRECAUTIONS

The nurse should use cephalosporins cautiously in patients with renal or hepatic impairment and in patients with bleeding disorders. Safety of cephalosporin administration has not been established in pregnancy or lactation; these drugs are assigned to Pregnancy Category B.

INTERAKTIONS

The risk of nephrotoxicity increases when the cephalosporins are administered with the aminoglycosides (see Chap. 10). The risk for bleeding increases when the cephalosporins are taken with oral anticoagulants. A disulfiram-like reaction may occur if alcohol is consumed within 72 hours after cephalosporin administration. Symptoms of a disulfiram-like reactions include flushing, throbbing in the head and neck, respiratory difficulty, vomiting, sweating, chest pain, and hypotension. Severe reactions may cause arrhythmias and unconsciousness. When the cephalosporins are administered with the aminoglycosides, the risk for nephrotoxicity increases.

NURSING PROCESS

- The Patient Receiving a Cephalosporin

ASSESSMENT

As with most drugs, assessment depends on the drug, the patient, and the reason for administration.

Preadministration Assessment

Before the administration of the first dose of a cephalosporin, it is important to obtain a general health history. The health history includes an allergy history, a history of all medical and surgical treatments, a drug history, and the current symptoms of the infection. If the patient has a history of allergy, particularly a drug allergy, the nurse explores this area to ensure that the patient is not allergic to a cephalosporin. Patients with a history of an allergy to penicillin may also be allergic to a cephalosporin (see Chap. 7) even though they have never received one of these drugs. If an allergy to either of these drug groups is suspected, the nurse informs the primary health care provider of this before the first dose of the drug is given. Liver and kidney function tests may be ordered by the primary health care provider. The nurse should check to be sure any cultures for sensitivity testing are done before the first dose of the drug is administered.

Ongoing Assessment

An ongoing assessment is important in evaluating the patient’s response to therapy, such as a decrease in temperature, the relief of symptoms caused by the infection (eg, pain or discomfort), an increase in appetite, and a change in the appearance or amount of drainage (when originally present). The nurse notifies the primary health care provider if symptoms of the infection appear to worsen. The nurse checks the patient’s skin regularly for rash and is alert for any loose stools or diarrhea.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other, more general nursing diagnoses are discussed in Chapter 4.

PLANNING

The expected outcomes for the patient depend on the reason for administration but may include an optimal response to therapy (infectious process controlled), management of adverse drug reactions, and an understanding of and compliance with the prescribed treatment regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

The nurse must question the patient about allergy to cephalosporins or the penicillins before administering the first dose, even when an accurate drug history has been taken. Information regarding a drug allergy may have been forgotten at the time the initial drug history was obtained. If a patient gives a history of possible cephalosporin or penicillin allergy, the nurse withholds the drug and contacts the primary health care provider.

ORAL ADMINISTRATION. The nurse administers cephalosporins around the clock to the patient to provide adequate blood levels. Most cephalosporins may be taken with food to prevent gastric upset. Cefdinir may be taken without regard to food. The absorption of oral cefuroxime and cefpodoxime is increased when given with food. However, if the patient experiences gastrointestinal upset, the nurse can administer the drug with

Nursing Diagnoses Checklist

- Risk for Imbalanced Body Temperature: Hyperthermia related to infection
- Diarrhea related to superinfection secondary to cephalosporin therapy
- Risk for Impaired Skin Integrity related to adverse reactions secondary to cephalosporin therapy
food. The nurse should shake oral suspensions well before administering them.

Some cephalosporins are available as powder for a suspension and are reconstituted by a pharmacist or a nurse. It is important to keep this form of the drug refrigerated until it is used.

**PARENTERAL ADMINISTRATION.** The nurse should read the manufacturer’s package insert for each drug for instructions regarding reconstitution of powder for injection, storage of unused portions, life of the drug after it is reconstituted, methods of IV administration, and precautions to be taken when the drug is administered.

Some cephalosporins are given by direct IV, intermittent infusion, or continuous IV infusion. When the direct IV method is used, the nurse gives the dose directly into a vein. Intermittent IV infusion is given by means of Y tubing while another solution is being given on a continuous basis. When this method is used, the nurse clamps off IV fluid given on a continuous basis while the drug is allowed to infuse. Continuous IV infusion requires that the nurse add the drug to a specified amount of an IV solution at a drip rate or volume per hour prescribed by the primary health care provider.

**Nursing Alert**

When the drug is given IV, the nurse inspects the needle insertion site for signs of extravasation or infiltration (see Chap. 2). In addition, it is important to inspect the needle insertion site and the area above the site several times a day for signs of redness, which may indicate thrombophlebitis (inflammation of a vein with formation of a clot within the vein) or phlebitis (inflammation of a vein). If either problem occurs, the nurse contacts the primary health care provider and the IV must be discontinued and restarted in another vein, preferably in another extremity.

**Gerontologic Alert**

When a cephalosporin is given IM, the nurse injects the drug into a large muscle mass, such as the gluteus muscle or lateral aspect of the thigh. It is important to rotate injection sites. The nurse warns the patient that at the time the drug is injected into the muscle, there may be a stinging or burning sensation and the area may be sore for a short time. The nurse informs the primary health care provider if previously used areas for injection appear red or if the patient reports continued pain in the area.

**Monitoring and Managing Adverse Reactions**

The nurse observes the patient closely for any adverse drug reactions, particularly signs and symptoms of a hypersensitivity reaction. It is important to report a rash or hives to the primary health care provider because this may be a precursor to a severe anaphylactic reaction (see Chap. 7). In severe cases, the primary health care provider may discontinue the cephalosporin therapy. The nurse closely observes the patient for signs and symptoms of a bacterial or fungal superinfection (see Chap. 7). If any occur, the nurse contacts the primary health care provider before the next dose of the drug is due.

Rare cases of hemolytic anemia, including fatalities, have been reported with the administration of the cephalosporins. The patient should be monitored for anemia. If a patient experiences anemia within 2 to 3 weeks after the start of cephalosporin therapy, drug-induced anemia should be considered. If hemolytic anemia is suspected, the primary health care provider will discontinue the drug therapy. The patient may require blood transfusions to correct the anemia. Frequent hematological studies may be required.

**Nursing Alert**

Nephrotoxicity may occur with the administration of these drugs. Early signs of this adverse reaction may become apparent by a decrease in urine output. The nurse should measure and record the fluid intake and output and notify the primary health care provider if the output is less than 500 mL/d. Any changes in the fluid intake-and-output ratio or in the appearance of the urine may indicate nephrotoxicity. It is important that the nurse report these findings to the primary health care provider promptly.

**Gerontologic Alert**

The older adult is more susceptible to the nephrotoxic effects of the cephalosporins, particularly if renal function is already diminished because of age or disease. If renal impairment is present, a lower dosage and monitoring of blood creatinine levels are indicated. Blood creatinine levels greater than 4 mg/dL indicate serious renal impairment. In elderly patients with decreased renal function, a dosage adjustment may be necessary.

**FEVER.** The nurse takes vital signs every 4 hours or as ordered by the primary health care provider. It is important to report any increase in temperature to the primary health care provider because additional treatment measures, such as administration of an antipyretic drug or change in the drug or dosage, may be necessary.

**DIARRHEA.** Frequent liquid stools may be an indication of a superinfection or pseudomembranous colitis. If pseudomembranous colitis occurs, it is usually seen 4 to 10 days after treatment is started.
The nurse inspects each bowel movement and immediately reports to the primary health care provider the occurrence of diarrhea or loose stools containing blood and mucus because it may be necessary to discontinue the drug use and institute treatment for diarrhea, a superinfection, or pseudomembranous colitis.

If there appears to be blood and mucus in the stool, the nurse saves a sample of the stool and tests for occult blood using a test such as Hemoccult. If the stool tests positive for blood, the sample is saved for possible laboratory testing for blood.

**IMPARED SKIN INTEGRITY.** The nurse inspects the skin every 4 hours for redness, rash, or lesions that appear as red wheals or blisters. When a skin rash or irritation is present, the nurse administers frequent skin care. Emollients, antipyretic creams, or a topical corticosteroid may be prescribed. An antihistamine may be prescribed. Harsh soaps and perfumed lotions are avoided. The nurse instructs the patient to avoid rubbing the area and not to wear rough or irritating clothing.

**Nursing Alert**

The patient is at risk for Stevens-Johnson syndrome when taking the cephalosporins. Stevens-Johnson syndrome is manifested by fever, cough, muscular aches and pains, headache, and the appearance of lesions on the skin, mucous membranes, and eyes. The lesions appear as red wheals or blisters, often starting on the face, in the mouth, or on the lips, neck, and extremities. This syndrome, which also may occur with the administration of other types of drugs, can be fatal. The nurse should report any of these symptoms to the primary health care provider immediately.

**Educating the Patient and Family**

The nurse carefully reviews the dose regimen with the patient and family and teaches the patient the following information:

- Complete the full course of therapy. Do not stop the drug even if the symptoms have disappeared unless directed to do so by the primary health care provider.
- Take the drug at the prescribed times of day because it is important to keep an adequate amount of drug in the body throughout the entire 24 hours of each day.
- It is a good idea to take each dose with food or milk if gastrointestinal upset occurs after administration.
- Avoid drinking alcoholic beverages when taking the cephalosporins and for 3 days after completing the course of therapy because severe reactions may occur.
- Notify the primary health care provider immediately if any one or more of the following occurs: vomiting, skin rash, hives (urticaria), severe diarrhea, vaginal or anal itching, sores in the mouth, swelling around the mouth or eyes, breathing difficulty or gastrointestinal disturbances, such as nausea, vomiting, and diarrhea. Do not take the next dose of the drug until the problem is discussed with the primary health care provider (see Home Care Teaching Checklist: Teaching About Superinfection).
- Oral suspensions—keep the container refrigerated (if so labeled), shake the drug well before pouring (if so labeled), and return the drug to the refrigerator immediately after pouring the dose. Drugs that are kept refrigerated lose their potency when kept at room temperature. If a small amount of the drug is left after the last dose is taken, discard it because the drug (in suspension form) begins to lose potency after a few weeks.
- Never give this drug to another individual even though the symptoms appear to be the same.
- Notify the primary health care provider if the symptoms of the infection do not improve or if the condition becomes worse.

**EVALUATION**

- Therapeutic effect is achieved; infection is controlled.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully with nursing interventions.
- Patient and family demonstrate understanding of the drug regimen.
- Patient verbalizes importance of complying with the prescribed therapeutic regimen.

**Critical Thinking Exercises**

1. Mr. Jonas is receiving a cephalosporin IM. He tells you that he has had to get out of bed several times this morning because he has diarrhea. Determine what questions you would ask Mr. Jonas. Analyze what steps you would take to resolve this problem.

2. A patient who is a recent immigrant to the United States is seen in the outpatient clinic for a severe upper respiratory infection. The primary health care provider prescribes a cephalosporin and asks you to give the patient instructions for taking the drug. You note that the patient appears to understand very little English. Discuss how you would solve this problem. Determine what information you would include in a teaching plan.
and how you would evaluate the effectiveness of the teaching plan for this patient.

3. Analyze what assessments you would make if you suspect that a patient receiving a cephalosporin is experiencing Stevens-Johnson syndrome.

---

**Review Questions**

1. The nurse observes a patient taking a cephalosporin for common adverse reactions, which include_____.
   A. hypotension, dizziness, urticaria
   B. nausea, vomiting, diarrhea
   C. skin rash, constipation, headache
   D. bradycardia, pruritus, insomnia

2. When giving a cephalosporin by the intramuscular route, the nurse tells the patient that ______.
   A. a stinging or burning sensation and soreness at the site may be experienced

3. The nurse observes a patient taking a cephalosporin for common adverse reactions, which include_____.
   A. hypotension, dizziness, urticaria
   B. nausea, vomiting, diarrhea
   C. skin rash, constipation, headache
   D. bradycardia, pruritus, insomnia

4. The nurse observes a patient receiving a cephalosporin for the Stevens-Johnson syndrome. The signs and symptoms that might indicate this syndrome include_____.
   A. swelling of the extremities
   B. increased blood pressure and pulse rate
   C. lesions on the skin and/or mucous membranes
   D. pain in the joints
Medication Dosage Problems

1. Ceclor 500 mg is prescribed for a patient. Use the drug label below to determine the dosage.

The nurse would administer _____.

2. The physician prescribes 1 g of Mefoxin (cefoxitin) for parenteral administration. Mefoxin is available in a solution of 250 mg/1 mL. What amount of Mefoxin would the nurse prepare? _____
Tetracyclines, Macrolides, and Lincosamides

Key Terms

- bacteriostatic
- bactericidal
- myasthenia gravis
- photosensitivity
- reaction
- prophylaxis

Chapter Objectives

On completion of this chapter, the student will:

- Discuss the uses, general drug action, adverse reactions, contraindications, precautions, and interactions of the tetracyclines, macrolides, and lincosamides.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking a tetracycline, macrolide, or lincosamide.
- List some nursing diagnoses particular to a patient taking a tetracycline, macrolide, or lincosamide.
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating patients about the use of a tetracycline, macrolide, or lincosamide.

This chapter discusses three groups of broad-spectrum antibiotics: the tetracyclines, the macrolides, and the lincosamides. Examples of the tetracyclines include doxycycline (Vibramycin), minocycline (Minocin), and tetracycline (Sumycin). Examples of the macrolides include azithromycin (Zithromax), clarithromycin (Biaxin), and erythromycin (E-Mycin). The lincosamides include clindamycin (Cleocin) and lincomycin (Lincocin). The Summary Drug Table: Tetracyclines, Macrolides, and Lincosamides describes the types of broad-spectrum antibiotics discussed in this chapter.

**Tetracyclines**

The tetracyclines are a group of anti-infectives composed of natural and semisynthetic compounds. They are useful in select infections when the organism shows sensitivity (see Chap. 7) to the tetracyclines, such as in cholera, Rocky Mountain spotted fever, and typhus.

**Actions**

The tetracyclines exert their effect by inhibiting bacterial protein synthesis, which is a process necessary for reproduction of the microorganism. The ultimate effect of this action is that the bacteria are either destroyed or their multiplication rate is slowed. The tetracyclines are bacteriostatic (capable of slowing or retarding the multiplication of bacteria), whereas the macrolides and lincosamides may be bacteriostatic or bactericidal (capable of destroying bacteria).

**Uses**

These antibiotics are effective in the treatment of infections caused by a wide range of gram-negative and gram-positive microorganisms. The tetracyclines are used in infections caused by Rickettsiae (Rocky Mountain spotted fever, typhus fever, and tick fevers). Tetracyclines are also used in situations in which penicillin is contraindicated, in the treatment of intestinal amebiasis, and in some skin and soft tissue infections. Oral
### UNIT II

#### Anti-infectives

<table>
<thead>
<tr>
<th>Tetracyclines</th>
<th>Macrolides</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GENERIC NAME</strong></td>
<td><strong>TRADE NAME</strong></td>
</tr>
<tr>
<td>demeclocycline deh-meh-kloe-sye'-kleen</td>
<td>Declomycin</td>
</tr>
<tr>
<td>doxycycline dox-i-sye'-kleen</td>
<td>Doxychel Hyclate, Vibra-Tab, Vibramycin, generic</td>
</tr>
<tr>
<td>minocycline min-oh-sye'-kleen</td>
<td>Minocin, Minocin IV</td>
</tr>
<tr>
<td>oxytetracycline ox-i-tet-ra-sye'-kleen</td>
<td>Terramycin, Terramycin IM, Uri-Tet</td>
</tr>
<tr>
<td>tetracycline tet-ra-sye'-kleen</td>
<td>Panmycin, Sumycin, Tetracap, generic</td>
</tr>
<tr>
<td>azithromycin ay-zi-thro-my'-cin</td>
<td>Zithromax</td>
</tr>
<tr>
<td>clarithromycin klar-ith-ro-my'-cin</td>
<td>Biaxin</td>
</tr>
<tr>
<td>dirithromycin dir-ith-ro-my'-cin</td>
<td>Dynabac</td>
</tr>
<tr>
<td>erythromycin base er-th-ro-my'-sin</td>
<td>E-Mycin, Eryc, generic</td>
</tr>
<tr>
<td>erythromycin ethylsuccinate</td>
<td>EryPed, E.E.S., generic</td>
</tr>
<tr>
<td>erythromycin estolate</td>
<td>Ilosone, generic</td>
</tr>
<tr>
<td>erythromycin IV</td>
<td>Ilotycin Glucenate, generic</td>
</tr>
<tr>
<td>troleandomycin</td>
<td>Tao</td>
</tr>
</tbody>
</table>
Tetracyclines are used in the treatment of uncomplicated urethral, endocervical, or rectal infections caused by Chlamydia trachomatis and as adjunctive treatment in severe acne. Tetracycline in combination with metronidazole and bismuth subsalicylate is useful in treating Helicobacter pylori (a bacteria in the stomach that can cause peptic ulcer).

**ADVERSE REACTIONS**

Gastrointestinal reactions that may occur during tetracycline administration include nausea, vomiting, diarrhea, epigastric distress, stomatitis, and sore throat. Skin rashes also may be seen. A photosensitivity (phototoxic) reaction may be seen with this group of drugs, manifested by an exaggerated sunburn reaction when the skin is exposed to sunlight even for brief periods. Demeclocycline seems to cause the most serious photosensitivity reaction, whereas minocycline is least likely to cause this type of reaction.

The tetracyclines are not given to children younger than 9 years of age unless their use is absolutely necessary because these drugs may cause permanent yellow-gray-brown discoloration of the teeth. The use of the tetracyclines, especially prolonged or repeated therapy, may result in bacterial or fungal overgrowth of nonsusceptible organisms.

**CONTRAINDICATIONS**

The tetracyclines are contraindicated if the patient is known to be hypersensitive to any of the tetracyclines. Tetracyclines also are contraindicated during pregnancy because of the possibility of toxic effects to the developing fetus. The tetracyclines are classified Pregnancy Category D drugs. These drugs also are contraindicated during lactation and in children younger than 9 years (may cause permanent discoloration of the teeth).

**PRECAUTIONS**

It is important to use the tetracyclines cautiously in patients with renal function impairment. In addition, doses greater that 2 g/d can be extremely damaging to the liver. The nurse should carefully check the expiration dates of the tetracyclines before administration because degradation of the tetracyclines can occur; after degradation, the agents are highly toxic to the kidneys.

**INTERACTIONS**

Antacids containing aluminum, zinc, magnesium, or bismuth salts, or foods high in calcium impair absorption of the tetracyclines. When the tetracyclines are administered with oral anticoagulants, an increase in the effects of the anticoagulant may occur. When tetracyclines are administered to women using oral contraceptives, a decrease in the effect of the oral contraceptive may be seen. This may result in breakthrough bleeding or pregnancy. When digoxin is administered with the tetracyclines there is an increased risk for digitalis toxicity (see Chapter 39). The effects of this could last for months after tetracycline administration is discontinued. Tetracyclines may reduce insulin requirements. Blood glucose levels should be monitored frequently during tetracycline therapy.

**MACROLIDES**

The macrolides are effective against a wide variety of pathogenic organisms, particularly infections of the respiratory and genital tract.
**ACTIONS**

The macrolides are bacteriostatic or bactericidal in susceptible bacteria. The drugs act by binding to cell membranes and causing changes in protein function.

**USES**

These antibiotics are effective in the treatment of infections caused by a wide range of gram-negative and gram-positive microorganisms. In addition, the drugs are used to treat acne vulgaris and skin infections, in conjunction with sulfonamides to treat upper respiratory infections caused by *Hemophilus influenzae*, and as prophylaxis before dental or other procedures in patients allergic to penicillin.

**ADVERSE REACTIONS**

Most of the adverse reactions seen with the administration of azithromycin and clarithromycin are related to the gastrointestinal tract and include nausea, vomiting, diarrhea, and abdominal pain. Abdominal cramping, nausea, vomiting, diarrhea, and allergic reactions have been reported with the administration of erythromycin. However, there appears to be a low incidence of adverse reactions associated with normal oral doses of erythromycin. As with almost all antibacterial drugs, pseudomembranous colitis may occur ranging in severity from mild to life threatening.

**CONTRAINDICATIONS**

These drugs are contraindicated in patients with a hypersensitivity to the macrolides and patients with pre-existing liver disease.

**PRECAUTIONS**

It is important to use these drugs cautiously during pregnancy and lactation. Azithromycin and erythromycin are Pregnancy Category B drugs, and clarithromycin, dirithromycin, and troleandomycin are Pregnancy Category C drugs. Because azithromycin, erythromycin, and troleandomycin are primarily eliminated from the body by the liver, these drugs should be used with great caution in patients with liver dysfunction. There is a decreased gastrointestinal absorption of the macrolides when administered with kaolin, aluminum salts, or magaldrate.

**INTERACTIONS**

Use of the macrolides increases serum levels of digoxin and increases the effects of anticoagulants. Use of antacids decreases the absorption of most macrolides. The macrolides should not be administered with clindamycin, lincomycin, or chloramphenicol; a decrease in the therapeutic activity of the macrolides can occur. Concurrent administration of the macrolides with theophylline may increase serum theophylline levels.

**LINCOSAMIDES**

The lincosamides, another group of anti-infectives, are effective against many gram-positive organisms, such as streptococci and staphylococci. However, because of their high potential for toxicity, the lincosamides are usually used only for the treatment of serious infections in which penicillin or erythromycin (a macrolide) is not effective.

**ACTIONS**

The lincosamides act by inhibiting protein synthesis in susceptible bacteria, causing death.

**USES**

These antibiotics are effective in the treatment of infections caused by a wide range of gram-negative and gram-positive microorganisms. The lincosamides are used for the more serious infections. In serious infections they may be used in conjunction with other antibiotics.

**ADVERSE REACTIONS**

Abdominal pain, esophagitis, nausea, vomiting, diarrhea, skin rash, and blood dyscrasias may be seen with the use of the lincosamides. These drugs also can cause pseudomembranous colitis, which may range from mild to very severe. Discontinuing the drug may relieve mild symptoms of pseudomembranous colitis.

**CONTRAINDICATIONS**

The lincosamides are contraindicated in patients with hypersensitivity to the lincosamides, those with minor bacterial or viral infections, and during lactation and infancy.
PRECAUTIONS

It is important to use these drugs with caution in patients with a history of gastrointestinal disorders, renal disease, or liver impairment. The neuromuscular blocking action of the lincosamides poses a danger to patients with myasthenia gravis (an autoimmune disease manifested by extreme weakness and exhaustion of the muscles).

INTERACTIONS

When kaolin or aluminum is administered with the lincosamides, the absorption of the lincosamide is decreased. When the lincosamides are administered with the neuromuscular blocking drugs (drugs that are used as adjuncts to anesthetic drugs that cause paralysis of the respiratory system) the action of the neuromuscular blocking drug is enhanced, possibly leading to severe and profound respiratory depression.

NURSING PROCESS

The Patient Receiving a Tetracycline, Macrolide, or Lincosamide

ASSESSMENT

Preadministration Assessment

It is important to establish an accurate database before the administration of any antibiotic. The nurse should identify and record signs and symptoms of the infection. Signs and symptoms may vary and often depend on the organ or system involved and whether the infection is external or internal. Examples of some of the signs and symptoms of an infection in various areas of the body are pain, drainage, redness, changes in the appearance of sputum, general malaise, chills and fever, cough, and swelling.

The nurse obtains a thorough allergy history, especially a history of drug allergies. Some antibiotics have a higher incidence of hypersensitivity reactions in those with a history of allergy to drugs or other substances. If the patient has a history of allergies and has not told the primary health care provider, the nurse should not administer the first dose of the drug until this problem is discussed with the primary health care provider.

It also is important to take and record vital signs before the first dose of the antibiotic is given. The primary health care provider may order culture and sensitivity tests, and these should also be performed before the first dose of the drug is given. Other laboratory tests such as renal and hepatic function tests, complete blood count, and urinalysis may also be ordered by the primary health care provider.

Ongoing Assessment

An ongoing assessment is important during therapy with the tetracyclines, macrolides, and lincosamides. The nurse should take vital signs every 4 hours or as ordered by the primary health care provider. The nurse must notify the primary health care provider if there are changes in the vital signs, such as a significant drop in blood pressure, an increase in the pulse or respiratory rate, or a sudden increase in temperature.

Each day, the nurse compares current signs and symptoms of the infection against the initial signs and symptoms and records any specific findings in the patient’s chart.

When an antibiotic is ordered for the prevention of a secondary infection (prophylaxis), the nurse observes the patient for signs and symptoms that may indicate the beginning of an infection despite the prophylactic use of the antibiotic. If signs and symptoms of an infection occur, the nurse must report them to the primary health care provider.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to therapy, which includes control of the infectious process or prophylaxis of bacterial infection, an absence of adverse drug effects, and an understanding of and compliance with the prescribed treatment regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

Before therapy is begun, culture and sensitivity tests (see Chap. 7) are performed to determine which antibiotic will best control the infection. These drugs are of no value in the treatment of infections caused by a virus or fungus. There may be times when a secondary bacterial infection has occurred or potentially will occur when the patient has a fungal or viral infection. The primary health care provider may then order one of the

Nursing Diagnoses Checklist

- Risk for Imbalanced Body Temperature: Hyperthermia related to infection
- Diarrhea related to superinfection secondary to antibiotic therapy, adverse drug reaction
- Risk for Impaired Skin Integrity related to adverse drug reaction
broad-spectrum antibiotics, but its purpose is for the prevention (prophylaxis) or treatment of a secondary bacterial infection that could potentially develop after the primary fungal or viral infection.

**ORAL ADMINISTRATION.** To control the infectious process or prevent a bacterial infection, the nurse must keep several important things in mind when administering the tetracyclines, macrolides, and lincosamides.

**Tetracyclines.** It is important to give the tetracyclines on an empty stomach; tetracyclines are not to be taken with dairy products (milk or cheese). The exceptions are doxycycline (Vibramycin) and minocycline (Minocin), which may be taken with dairy products or food. The nurse should give clindamycin with food or a full glass of water. The nurse can give troleandomycin and clarithromycin without regard to meals. All tetracyclines should be given with a full glass of water (240 mL).

- **Nursing Alert**
  The nurse should not give tetracyclines along with dairy products (milk or cheese), antacids, laxatives, or products containing iron. When these drugs are prescribed, the nurse makes sure they are given 2 hours before or after the administration of a tetracycline. Food or drugs containing calcium, magnesium, aluminum, or iron prevent the absorption of the tetracyclines if ingested concurrently.

**Macrolides.** The nurse gives clarithromycin without regard to meals. Clarithromycin may be taken with milk, if desired. Azithromycin tablets may be given without regard to meals. However, azithromycin suspension is given 1 hour or more before a meal or 2 hours or more after a meal. Dirithromycin is given on an empty stomach (1 hour before or 2 hours after meals) and with 180 to 240 mL of water.

**Lincosamides.** Food impairs the absorption of lincomycin. The patient should take nothing by mouth (except water) for 1 to 2 hours before and after taking lincomycin. Clindamycin may be given without regard to food.

**PARENTERAL ADMINISTRATION.** When these drugs are given intramuscularly, the nurse inspects previous injection sites for signs of pain or tenderness, redness, and swelling. Some antibiotics may cause temporary local reactions, but persistence of a localized reaction should be reported to the primary health care provider. It is important to rotate injection sites and record the site used for injection in the patient’s chart.

When these drugs are given intravenously (IV), the nurse should inspect the needle site and area around the needle for signs of extravasation of the IV fluid or signs of tenderness, pain, and redness (which may indicate phlebitis or thrombophlebitis). If these symptoms are apparent, the nurse should restart the IV in another vein and bring the problem to the attention of the primary health care provider.

**Monitoring and Managing Adverse Drug Reactions**

The nurse observes the patient at frequent intervals, especially during the first 48 hours of therapy. It is important to report to the primary health care provider the occurrence of any adverse reaction before the next dose of the drug is due. The nurse should report serious adverse reactions, such as a severe hypersensitivity reaction, respiratory difficulty, severe diarrhea, or a decided drop in blood pressure, to the primary health care provider immediately because a serious adverse reaction may require emergency intervention.

The nurse observes the patient for the signs and symptoms of a bacterial or fungal superinfection, such as vaginal or anal itching, sore throat, sores in the mouth, diarrhea, fever, chills, and sore throat. It is important to report any new signs and symptoms occurring during antibiotic therapy to the primary health care provider, who must then decide if these problems are part of the original infection or if a superinfection has occurred.

**HYPERThERMIA.** The nurse monitors the temperature at frequent intervals, usually every 4 hours unless the patient has an elevated temperature. When the patient has an elevated temperature the nurse checks the temperature, pulse, and respirations every hour until the temperature returns to normal and administers an antipyretic if prescribed by the primary care provider.

**DIARRHEA.** Diarrhea may be an indication of a superinfection or pseudomembranous colitis, both of which can be serious. The nurse should inspect all stools for the presence of blood or mucus. If diarrhea does occur and there appears to be blood and mucus in the stool, the nurse saves a sample of the stool and tests for occult blood using a test such as Hemoccult. If the stool tests positive for blood, the nurse saves the stool for possible further laboratory analysis.

The nurse should encourage the patient with diarrhea to drink fluids to replace those lost with the diarrhea. It is important to maintain an accurate intake and output record to help determine fluid balance.

**Educating the Patient and Family**

The patient and family must understand the prescribed therapeutic regimen. It is not uncommon for patients to stop taking a prescribed drug because they feel better. A detailed plan of teaching helps to reduce the incidence of this problem.

The nurse should explain, in easy to understand terms, the adverse reactions associated with the specific
prescribed antibiotic. The nurse tells the patient to contact the primary health care provider if any potentially serious adverse reactions, such as hypersensitivity reactions, moderate to severe diarrhea, sudden onset of chills and fever, sore throat, or sores in the mouth, occur.

The nurse develops a teaching plan that includes the following information:

- Take the drug at the prescribed time intervals. These time intervals are important because a certain amount of the drug must be in the body at all times for the infection to be controlled.
- Do not to increase or omit the dose unless advised to do so by the primary health care provider.
- Complete the entire course of treatment. Never stop the drug, except on the advice of a primary health care provider, before the course of treatment is completed even if symptoms improve or disappear. Failure to complete the prescribed course of treatment may result in a return of the infection.
- Take each dose with a full glass of water. Follow the directions given by the pharmacist regarding taking the drug on an empty stomach, 1 hour before or 2 hours after a meal. In addition, the nurse teaches the patient to avoid the following foods before or after taking the drug:
  - Milk (whole, low-fat, skim, condensed, or evaporated)
  - Cream (half-and-half, heavy, light)
  - Sour cream
  - Coffee creamers
  - Creamy salad dressings
  - Eggnog
  - Milkshakes
  - Cheese (natural and processed)
  - Yogurt (regular, low-fat, or nonfat)
  - Cottage cheese
  - Ice cream
  - Frozen custard
  - Frozen yogurt
  - Ice milk

In some instances, drugs may be taken with food or milk to minimize the risk for gastrointestinal upset. However, most tetracyclines, when given with foods containing calcium, such as dairy products, are not absorbed as well as when they are taken on an empty stomach. So, if the patient is to receive tetracycline at home, it is important to be sure he or she knows to take the drug on an empty stomach, 1 hour before or 2 hours after a meal. In addition, the nurse teaches the patient to avoid the following foods before or after taking the drug:

- Milk (whole, low-fat, skim, condensed, or evaporated)
- Cream (half-and-half, heavy, light)
- Sour cream
- Coffee creamers
- Creamy salad dressings
- Eggnog
- Milkshakes
- Cheese (natural and processed)
- Yogurt (regular, low-fat, or nonfat)
- Cottage cheese
- Ice cream
- Frozen custard
- Frozen yogurt
- Ice milk

Home Care Checklist

AVOIDING DRUG–FOOD INTERACTIONS

In some instances, drugs may be taken with food or milk to minimize the risk for gastrointestinal upset. However, most tetracyclines, when given with foods containing calcium, such as dairy products, are not absorbed as well as when they are taken on an empty stomach. So, if the patient is to receive tetracycline at home, it is important to be sure he or she knows to take the drug on an empty stomach, 1 hour before or 2 hours after a meal. In addition, the nurse teaches the patient to avoid the following foods before or after taking the drug:

- Milk (whole, low-fat, skim, condensed, or evaporated)
- Cream (half-and-half, heavy, light)
- Sour cream
- Coffee creamers
- Creamy salad dressings
- Eggnog
- Milkshakes
- Cheese (natural and processed)
- Yogurt (regular, low-fat, or nonfat)
- Cottage cheese
- Ice cream
- Frozen custard
- Frozen yogurt
- Ice milk
wide-brimmed hat to protect the face and neck. Application of a sunscreen may or may not be effective. Therefore, consult the primary health care provider before using a sunscreen to prevent a photosensitivity reaction.

**EVALUATION**

- The therapeutic effect is achieved, and the infection is controlled or prevented.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
- The patient and family demonstrate understanding of the drug regimen.
- The patient verbalizes the importance of complying with the prescribed therapeutic regimen.

**Critical Thinking Exercises**

1. Ms. Jones has been prescribed tetracycline. She works nights and is home sleeping during the day. To decrease the possibility of noncompliance with the treatment regimen, discuss how and what you would teach Ms. Jones about her drug regimen.

2. Mr. Park, a patient in a nursing home, has been receiving clarithromycin (Biaxin) for an upper respiratory infection for 9 days. The nurse assistant reports that he has been incontinent of feces for the past 2 days. Analyze whether this matter should be investigated.

3. When taking the drug history of Mr. Woods, a patient in the outpatient clinic, you note that he has been taking 0.25 mg digoxin, one baby aspirin, and the tetracycline minocycline (Minocin). Based on your knowledge of the tetracyclines, determine whether there is any reason to be concerned about the drug regimen that Mr. Woods is on. Explain your answer.

4. Ms. Evans, age 75 years, is to be dismissed on a regimen of doxycycline (Vibramycin). You note that she is alert and has good communication skills. Because she lives alone, she will be responsible for administering her own drug. Devise a teaching plan for Ms. Evans. You may want to use the teaching plan form in Chapter 5.

**Review Questions**

1. A patient asks the nurse why the primary health care provider prescribed an antibiotic when she was told that she has a viral infection. The most correct response by the nurse is that the antibiotic may be used to prevent a ______.
   A. primary fungal infection
   B. repeat viral infection
   C. secondary bacterial infection
   D. breakdown of the immune system

2. A patient is receiving erythromycin for an infection. The patient’s response to therapy is best evaluated by ______.
   A. monitoring vital signs every 4 hours
   B. comparing initial and current signs and symptoms
   C. monitoring fluid intake and output
   D. asking the patient if he is feeling better

3. When asked to describe a photosensitivity reaction, the nurse correctly states that this reaction may be described as a(n) ______.
   A. tearing of the eyes on exposure to bright light
   B. aversion to bright lights and sunlight
   C. sensitivity to products in the environment
   D. exaggerated sunburn reaction when the skin is exposed to sunlight

4. When giving one of the macrolide antibiotics, the nurse assesses the patient for the most common adverse reactions, which are ______.
   A. related to the gastrointestinal tract
   B. skin rash and urinary retention
   C. sores in the mouth and hypertension
   D. related to the nervous system

**Medication Dosage Problems**

1. Mr. Baker is prescribed azithromycin for a lower respiratory tract infection. The nurse tells Mr. Baker to take the drug on an empty stomach. Azithromycin is available in 250-mg tablets. The primary health care provider has ordered 500 mg on the first day, followed by 250 mg on days 2 to 5. How many tablets would Mr. Baker take on the first day? On the last day of therapy?

2. A patient is prescribed 600 mg of lincomycin every 12 hours IM. The drug is available as 300 mg/mL. How many milliliters would the nurse administer?

3. A patient is prescribed 200 mg of minocycline oral suspension initially, followed by 100 mg PO every 12 hours. The minocycline is available as an oral suspension of 50 mg/5 mL. How many milliliters would the nurse administer as the initial dose?
As antibiotics became resistant to various microorganisms, researchers sought to develop more powerful drugs that would be effective against these resistant pathogens. The fluoroquinolones and aminoglycosides are two groups of broad-spectrum antibiotics that resulted from this research. The Summary Drug Table: Fluoroquinolones and Aminoglycosides lists the fluoroquinolones and aminoglycosides discussed in this chapter.

**FLUOROQUINOLONES**

The fluoroquinolones include ciprofloxacin (Cipro), enoxacin (Penetrex), gatifloxacin (Tequin), lomefloxacin (Maxaquin), moxifloxacin (Avelox), ofloxacin (Floxin), and sparfloxacin (Zagam).

**ACTIONS**

The fluoroquinolones exert their bactericidal (bacteria-destroying) effect by interfering with an enzyme (DNA gyrase) needed by bacteria for the synthesis of DNA. This interference prevents cell reproduction, leading to death of the bacteria.

**USES**

The fluoroquinolones are used in the treatment of infections caused by susceptible microorganisms. The fluoroquinolones are effective in the treatment of infections caused by gram-positive and gram-negative microorganisms. They are primarily used in the treatment of susceptible microorganisms in lower respiratory infections, infections of the skin, urinary tract infections, and sexually transmitted diseases. Ciprofloxacin, norfloxacin, and ofloxacin are available in ophthalmic forms for infections in the eyes.

**ADVERSE REACTIONS**

Bacterial or fungal superinfections and pseudomembranous colitis (see Chap. 7) may occur with the use of both of these drugs. The administration of any drug may result in a hypersensitivity reaction, which can
## SUMMARY DRUG TABLE  FLUOROQUINOLONES AND AMINOGLYCOSIDES

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fluoroquinolones</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ciprofloxacin</td>
<td>Cipro, Cipro IV</td>
<td>Treatment of infections due to susceptible microorganisms</td>
<td>Nausea, diarrhea, headache, abdominal discomfort, photosensitivity, superinfections, hypersensitivity reactions</td>
<td>250–750 mg PO q12h; 200–400 mg IV q12h</td>
</tr>
<tr>
<td>enoxacin</td>
<td>Penetrex</td>
<td>Same as ciprofloxacin</td>
<td>Same as ciprofloxacin</td>
<td>200–400 mg PO q12h</td>
</tr>
<tr>
<td>gatifloxacin</td>
<td>Tequin</td>
<td>Same as ciprofloxacin</td>
<td>Same as ciprofloxacin</td>
<td>200–400 mg qd PO or IV</td>
</tr>
<tr>
<td>levofloxacin</td>
<td>Levaquin</td>
<td>Same as ciprofloxacin</td>
<td>Same as ciprofloxacin</td>
<td>250–500 mg/d PO, IV</td>
</tr>
<tr>
<td>lomefloxacin</td>
<td>Maxaquin</td>
<td>Same as ciprofloxacin</td>
<td>Same as ciprofloxacin</td>
<td>400 mg PO once daily</td>
</tr>
<tr>
<td>moxifloxacin</td>
<td>Avelox</td>
<td>Same as ciprofloxacin</td>
<td>Same as ciprofloxacin</td>
<td>400 mg qd PO</td>
</tr>
<tr>
<td>norfloxacin</td>
<td>Noroxin</td>
<td>Same as ciprofloxacin</td>
<td>Same as ciprofloxacin</td>
<td>400 mg PO q12h; 800 mg as single dose for gonorrhea</td>
</tr>
<tr>
<td>ofloxacin</td>
<td>Floxin</td>
<td>Same as ciprofloxacin</td>
<td>Same as ciprofloxacin</td>
<td>200–400 mg PO, IV q12h</td>
</tr>
<tr>
<td>trovafloxacin</td>
<td>Trovan</td>
<td>Same as ciprofloxacin</td>
<td>Same as ciprofloxacin, serious liver toxicity</td>
<td>100–200 mg/d PO, IV</td>
</tr>
<tr>
<td>alatrofloxacin</td>
<td>Trovan IV</td>
<td>Same as ciprofloxacin</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aminoglycosides</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amikacin</td>
<td>Amikin, Amikacin, generic</td>
<td>Treatment of serious infections caused by susceptible strains of microorganisms</td>
<td>Nausea, vomiting, diarrhea, rash, ototoxicity, nephrotoxicity, hypersensitivity reactions, neuromuscular blockade</td>
<td>15 mg/kg IM, IV, in divided doses, not to exceed 1.5 g/d</td>
</tr>
<tr>
<td>gentamicin</td>
<td>Garamycin, generic</td>
<td>Same as amikacin</td>
<td>Same as amikacin</td>
<td>3 mg/kg/d q8h IM, IV, not to exceed 5 mg/kg/d in divided doses</td>
</tr>
<tr>
<td>kanamycin</td>
<td>Kantrex, generic</td>
<td>Same as amikacin; oral use for hepatic coma and for suppression of intestinal bacteria</td>
<td>Same as amikacin</td>
<td>7.5–15 mg/kg/d in divided doses IM; 15 mg/kg/d in divided doses IV; suppression of intestinal bacteria 1 g qh for 4h then 1 g q6h for 36–72 h PO; hepatic coma 8–12 g/d in divided doses PO</td>
</tr>
</tbody>
</table>
range from mild to severe and in some cases can be life threatening. Mild hypersensitivity reactions may only require discontinuing the drug, whereas the more serious reactions require immediate treatment. (Chapters 1 and 7 contain discussions of hypersensitivity reactions.)

The more common adverse effects seen with the administration of these drugs include nausea, diarrhea, headache, abdominal pain or discomfort, and dizziness. A more serious adverse reaction seen with the administration of the fluoroquinolones, especially lomefloxacin and sparfloxacin, is a photosensitivity reaction. This is manifested by an exaggerated sunburn reaction when the skin is exposed to the ultraviolet rays of sunlight or sunlamps.

**CONTRAINDICATIONS**

The fluoroquinolones are contraindicated in patients with a history of hypersensitivity to the fluoroquinolones, in children younger than 18 years, and in pregnant women (Pregnancy Category C). These drugs also are contraindicated in patients whose life-styles do not allow for adherence to the precautions regarding photosensitivity.

**PRECAUTIONS**

The fluoroquinolones are used cautiously in patients with renal impairment or a history of seizures, in geriatric patients, and in patients on dialysis.

**INTERACTIONS**

Concurrent use of the fluoroquinolones with theophylline causes an increase in serum theophylline levels. When used concurrently with cimetidine, the cimetidine may interfere with the elimination of the fluoroquinolones. Use of the fluoroquinolones with an oral anticoagulant may cause an increase in the effects of the oral coagulant. Administration of the fluoroquinolones with antacids, iron salts, or zinc will decrease absorption of the fluoroquinolones. There is a risk of seizures if fluoroquinolones are given with the NSAIDs. There is a risk of severe cardiac arrhythmias when the fluoroquinolones gatifloxacin and moxifloxacin are administered with drugs that increase the QT interval (eg, quinidine, procainamide, amiodarone, and sotalol).

**AMINOGLYCOSIDES**

The aminoglycosides include amikacin (Amikin), gentamicin (Garamycin), kanamycin (Kantrex), neomycin (Mycifradin), netilmicin (Netromycin), streptomycin, and tobramycin (Nebcin).

**ACTIONS**

The aminoglycosides exert their bactericidal effect by blocking a step in protein synthesis necessary for bacterial multiplication. They disrupt the functional
ability of the bacterial cell membrane causing cell death.

USES

The aminoglycosides are used in the treatment of infections caused by susceptible microorganisms. The aminoglycosides are used primarily in the treatment of infections caused by gram-negative microorganisms.

Because the oral aminoglycosides are poorly absorbed, they are useful to suppressing gastrointestinal bacteria. The oral aminoglycosides kanamycin (Kantrex) and neomycin (Mycifradin) are used preoperatively to reduce the number of bacteria normally present in the intestine (bowel prep). A reduction in intestinal bacteria is thought to lessen the possibility of abdominal infection that may occur after surgery on the bowel. Kanamycin, neomycin, and paromomycin are used orally in the management of hepatic coma. In this disorder, liver failure results in an elevation of blood ammonia levels. By reducing the number of ammonia-forming bacteria in the intestines, blood ammonia levels may be lowered, thereby temporarily reducing some of the symptoms associated with this disorder.

ADVERSE REACTIONS

The aminoglycosides are capable of causing nephrotoxicity (damage to the kidneys by a toxic substance) and ototoxicity (damage to the organs of hearing by a toxic substance). Signs and symptoms of nephrotoxicity may include protein in the urine (proteinuria), hematuria (blood in the urine), increase in the blood urea nitrogen level, decrease in urine output, and an increase in the serum creatinine concentration. Nephrotoxicity is usually reversible once the drug is discontinued. Signs and symptoms of ototoxicity include tinnitus, dizziness, roaring in the ears, vertigo, and a mild to severe loss of hearing. If hearing loss occurs, it is most often permanent. Ototoxicity may occur during drug therapy or even after the drug is discontinued. The short-term administration of kanamycin and neomycin as a preparation for bowel surgery rarely causes these two adverse reactions.

Neurotoxicity (damage to the nervous system by a toxic substance) may also be seen with the administration of the aminoglycosides. Signs and symptoms of neurotoxicity include numbness, skin tingling, circumoral (around the mouth) paresthesia, peripheral paresthesia, tremors, muscle twitching, convulsions, muscle weakness, and neuromuscular blockade (acute muscular paralysis and apnea).

Additional adverse reactions seen with administration of the aminoglycosides may include nausea, vomiting, anorexia, rash, and urticaria. When these drugs are given, individual drug references, such as the package insert, should be consulted for more specific adverse reactions.

Like the other anti-infectives, bacterial or fungal superinfections and pseudomembranous colitis (see Chap. 7) may occur with the use of these drugs. The administration of the aminoglycosides may result in a hypersensitivity reaction, which can range from mild to severe and in some cases can be life threatening. Mild hypersensitivity reactions may only require discontinuing the drug, whereas the more serious reactions require immediate treatment.

CONTRAINDICATIONS

The aminoglycosides are contraindicated in patients with hypersensitivity to aminoglycosides. The aminoglycosides should not be given to patients requiring long-term therapy because of the potential for ototoxicity and nephrotoxicity. One exception is the use of streptomycin for long-term management of tuberculosis. These drugs are contraindicated in patients with preexisting hearing loss, myasthenia gravis, parkinsonism, and during lactation or pregnancy. Neomycin, amikacin, gentamicin, kanamycin, netilmicin, and tobramycin are Pregnancy Category D drugs; the remainder are Category C.

PRECAUTIONS

The aminoglycosides are used cautiously in patients with renal failure (dosage adjustments may be necessary), in the elderly, and in patients with neuromuscular disorders.

INTERACTIONS

Administration of the aminoglycosides with the cephalosporins may increase the risks of nephrotoxicity. When the aminoglycosides are administered with loop diuretics there is an increased risk of ototoxicity (irreversible hearing loss). There is an increased risk of neuromuscular blockade (paralysis of the respiratory muscles) if the aminoglycosides are given shortly after general anesthetics (neuromuscular junction blockers).
NURSING PROCESS

The Patient Receiving a Fluoroquinolone or Aminoglycoside

ASSESSMENT

Preadministration Assessment
Before administering a fluoroquinolone or an aminoglycoside, the nurse identifies and records the signs and symptoms of the infection. It is particularly important for the nurse to obtain a thorough allergy history, especially a history of drug allergies. The nurse should take and record vital signs as well.

The primary health care provider may order culture and sensitivity tests, and the culture is obtained before the first dose of the drug is given. When an aminoglycoside is to be given, laboratory tests such as renal and hepatic function tests, complete blood count, and urinalysis also may be ordered.

When kanamycin or neomycin is given for hepatic coma, the nurse must evaluate the patient’s level of consciousness and ability to swallow.

Ongoing Assessment
During drug therapy with the aminoglycosides or the fluoroquinolones, it is important for the nurse to perform an ongoing assessment. In general, the nurse compares the initial signs and symptoms of the infection, which were recorded during the initial assessment, to the current signs and symptoms. The nurse then records these findings in the patient’s chart. When kanamycin or neomycin is given for hepatic coma, the nurse evaluates and records the patient’s general condition daily.

The nurse monitors the patient’s vital signs every 4 hours or as ordered by the primary health care provider. The nurse should notify the primary health care provider if there are changes in the vital signs, such as a significant drop in blood pressure, an increase in the pulse or respiratory rate, or a sudden increase in temperature.

When an aminoglycoside is being administered, it is important to monitor the patient’s respiratory rate because neuromuscular blockade has been reported with the administration of these drugs. The nurse reports any changes in the respiratory rate or rhythm to the primary health care provider because immediate treatment may be necessary.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in Chapter 4.

PLANNING

The expected outcomes for the patient may include an optimal response to therapy, which includes control of the infectious process, an absence of adverse drug effects, and an understanding of and compliance with the prescribed treatment regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy: Fluoroquinolones
The nurse encourages patients who receive the fluoroquinolones to increase their fluid intake. Norfloxacin and enoxacin are given on an empty stomach (eg, 1 hour before or 2 hours after meals). Ciprofloxacin and lomefloxacin can be given without regard to meals. However, the manufacturer recommends that the drug be given 2 hours after a meal. Moxifloxacin is given once a day for the period prescribed. If the patient is taking an antacid, moxifloxacin should be administered 4 hours before or 8 hours after the antacid.

Ciprofloxacin, gatifloxacin, and ofloxacin are the only fluoroquinolones given intravenously (IV). None of the fluoroquinolones are given intramuscularly (IM).

MONITORING FOR HYPERThERMIA. The infectious process is accompanied by an elevation in temperature. When the patient is being treated for the infection the nurse must monitor the vital signs, particularly the body temperature. As the anti-infective works to rid the body of the infectious organism, the body temperature should return to normal. The nurse monitors the vital signs (temperature, pulse, and respiration) frequently to monitor the drug’s effectiveness in eradicating the infectious process. The nurse checks the vital signs every 4 hours or more frequently if the temperature is elevated. The primary health care provider is notified if a temperature is greater than 101° Fahrenheit.

Promoting an Optimal Response to Therapy: Aminoglycosides
The oral aminoglycosides may be given without regard to meals. If there is any doubt about administration of
these drugs with or without food, consult the hospital pharmacist.

With the exception of paromomycin, all of the aminoglycoside drugs can be given intramuscularly (IM). For optimal results, the nurse should inspect previous injection sites for signs of pain or tenderness, redness, and swelling. The nurse informs the primary health care provider of any persistence in a localized reaction of pain, redness, or extreme tenderness. It is important to rotate injection sites and record the site used on the patient’s chart. With the exception of paromomycin and streptomycin, all of the aminoglycoside drugs can be given intravenously (IV).

**SUPPRESSION OF INTESTINAL BACTERIA.** When kanamycin or neomycin is given for suppression of intestinal bacteria before surgery, the primary health care provider’s orders regarding the timing of the administration of the drug are extremely important. Omission of a dosage or failure to give the drug at the specified time may result in inadequate suppression of intestinal bacteria. When neomycin is given, enteric-coated erythromycin (see Chap. 9) may be given at the same time as the aminoglycoside drug to prevent the emergence of resistant bacteria. The nurse may give the erythromycin by mouth.

When the aminoglycosides kanamycin or neomycin are given orally as treatment for hepatic coma, the nurse exercises care when giving the drug. During the early stages of this disorder, various changes in the level of consciousness may be seen. At times, the patient may appear lethargic and respond poorly to commands. Because of these changes in the level of consciousness, the patient may have difficulty swallowing, and a danger of aspiration is present. If the patient appears to have difficulty taking an oral drug, the nurse withholds the drug and contacts the primary health care provider.

**HEPATIC COMA.** When the aminoglycosides kanamycin or neomycin are given orally as treatment for hepatic coma, the nurse exercises care when giving the drug. During the early stages of this disorder, various changes in the level of consciousness may be seen. At times, the patient may appear lethargic and respond poorly to commands. Because of these changes in the level of consciousness, the patient may have difficulty swallowing, and a danger of aspiration is present. If the patient appears to have difficulty taking an oral drug, the nurse withholds the drug and contacts the primary health care provider.

The nurse always listens, evaluates, and reports any complaints the patient may have; certain complaints may be an early sign of an adverse drug reaction. The nurse should report all changes in the patient’s condition and any new problems that occur (eg, nausea or diarrhea) as soon as possible. It is then up to the primary health care provider to decide if these changes or problems are a part of the patient’s infectious process or the result of an adverse drug reaction.

**MONITORING FOR DIARRHEA.** Because superinfections and pseudomembranous colitis can occur during therapy with these drugs, the nurse checks the patient’s stools and reports any incidence of diarrhea immediately because this may indicate a superinfection or pseudomembranous colitis. If diarrhea does occur and blood and mucus appear in the stool, the nurse should save a sample of the stool and test it for occult blood using a test such as Hemoccult. If the stool tests positive for blood, it is important to save the sample for possible additional laboratory tests.

**MONITORING DRUGS GIVEN INTRAVENOUSLY.** For optimal results, the nurse inspects the needle site and the area around the needle every hour for signs of extravasation of the IV fluid. The nurse performs these assessments more frequently if the patient is restless or uncooperative. It is important to check the rate of infusion every 15 minutes and adjust it as needed. The nurse should inspect the vein used for the IV infusion every 4 hours for signs of tenderness, pain, and redness (which may indicate phlebitis or thrombophlebitis). If these are apparent, the nurse must restart the IV in another vein and bring the problem to the attention of the primary health care provider.

**Monitoring and Managing Adverse Drug Reactions: Fluoroquinolones**

All fluoroquinolone drugs can cause pain, inflammation, or rupture of a tendon. The Achilles tendon is particularly vulnerable. This problem can be so severe that prolonged disability results, and, at times, surgical intervention may be necessary to correct the problem. In addition, the fluoroquinolone drugs, particularly sparflloxacin and lomefloxacin, cause dangerous photosensitivity reactions. Patients have experienced severe reactions even when sunscreens or sunblocks were used.

**Monitoring and Managing Adverse Drug Reactions: Aminoglycosides**

The aminoglycosides are potentially neurotoxic, nephrotoxic, and ototoxic and are capable of causing permanent damage to these organs and structures. The nurse notifies the primary health care provider immediately when one or more signs and symptoms of these adverse reactions is suspected.

**MONITORING FOR NEUROTOXICITY.** The nurse should be alert for symptoms such as numbness or tingling of the skin, circumoral paresthesia, peripheral paresthesia (numbness or tingling in the extremities), tremors, and muscle twitching or weakness. The nurse reports any
symptom of neurotoxicity immediately to the primary health care provider. Convulsions can occur if the drug is not discontinued.

**Nursing Alert**

Neuromuscular blockade or respiratory paralysis may occur after administration of the aminoglycosides. Therefore, it is extremely important that any symptoms of respiratory difficulty be reported immediately. If neuromuscular blockade occurs, it may be reversed by the administration of calcium salts, but mechanical ventilation may be required.

**INEFFECTIVE TISSUE PERFUSION: RENAL.** The patient taking an aminoglycoside is at risk for nephrotoxicity. The nurse measures and records the intake and output and notifies the primary health care provider if the output is less than 750 mL/day. It is important to keep a record of the fluid intake and output as well as a daily weight to assess hydration and renal function. The nurse encourages fluid intake to 2000 mL/day (if the patient’s condition permits). Any changes in the intake and output ratio or in the appearance of the urine may indicate nephrotoxicity. The nurse reports these types of changes to the primary health care provider promptly. The primary health care provider may order daily laboratory tests (ie, serum creatinine and blood urea nitrogen [BUN]) to monitor renal function. The nurse reports any elevation in the creatinine or BUN level to the primary health care provider because an elevation may indicate renal dysfunction.

**DISTURBED SENSORY PERCEPTION: AUDITORY.** The patient taking aminoglycosides is at risk for ototoxicity. Auditory changes are irreversible, usually bilateral, and may be partial or total. The risk is greater in patients with renal impairment or those with preexisting hearing loss. It is important for the nurse to detect any problems with hearing and report them to the primary health care provider because continued administration could lead to permanent hearing loss.

**Nursing Alert**

To detect ototoxicity, the nurse carefully evaluates the patient's complaints or comments related to hearing, such as a ringing or buzzing in the ears or difficulty hearing. If hearing problems do occur, the nurse reports this problem to the primary health care provider immediately. To monitor for damage to the eighth cranial nerve, an evaluation of hearing may be done by audiometry before and throughout the course of therapy.

**SPECIFIC INSTRUCTIONS REGARDING FLUOROQUINOLONE THERAPY**

- When taking the fluoroquinolones, report any signs of tendinitis, such as pain or soreness in the leg, shoulder, or back of the heel. Periodic applications...
of ice may help relieve the pain. Until tendinitis or tendon rupture can be excluded, rest the involved area and avoid exercise.

• Do not take antacids or drugs containing iron or zinc because these drugs will decrease absorption of the fluoroquinolone.

SPECIFIC INSTRUCTIONS REGARDING AMINOGLYCOLYOSIDE THERAPY

• Notify the primary health care provider of any ringing in the ears or difficulty hearing, numbness or tingling around the mouth or in the extremities, and of any change in urinary patterns.

SPECIFIC INSTRUCTIONS FOR A PREOPERATIVE PREPARATION OF THE BOWEL

• When taking an aminoglycoside for preparation of the bowel before surgery, take the prescribed drug at the exact times indicated on the prescription container. Some bowel prep regimens are complex. For example, when kanamycin is prescribed for suppression of intestinal bacteria in preparation for bowel surgery, the drug is given orally every hour for 4 hours followed by 1 g every 6 hours for 36 to 72 hours.

EVALUATION

• The therapeutic effect is achieved, the infection is controlled, and the bowel is cleansed sufficiently.

• Adverse reactions are identified, reported to the primary health care provider, and managed successfully through nursing interventions.

• The patient and family demonstrate understanding of the drug regimen.

• The patient verbalizes the importance of complying with the prescribed therapeutic regimen.

Critical Thinking Exercises

1. Mr. Baker is receiving amikacin (Amikin) IV as treatment for a bacterial septicemia. When checking a drug reference you note that this drug is an aminoglycoside. Considering the most serious toxic effects associated with this group of drugs, determine what daily assessments you would perform to detect early signs and symptoms of these adverse drug effects.

2. Ms. Carson is seen in the outpatient clinic for a severe respiratory infection and is prescribed ciprofloxacin. Discuss what you would include in the teaching plan for this patient.

3. A patient is prescribed ciprofloxacin for a severe respiratory infection. What serious adverse reaction(s) should the nurse warn the patient to be especially observant for? What common adverse reactions should the patient be aware of? What important information should the nurse include in the teaching plan concerning adverse reactions?

Review Questions

1. Mr. Allison is taking gentamicin for a severe gram-negative infection. The nurse observes him for signs of neurotoxicity, which include _______

A. anorexia and abdominal pain
B. decreased urinary output and dark, concentrated urine
C. muscle twitching and numbness
D. headache and agitation

2. Patients taking a fluoroquinolone are encouraged to _______.

A. nap 1 to 2 hours daily while taking the drug
B. eat a high-protein diet
C. increase their fluid intake
D. avoid foods high in carbohydrate

3. Which of the following complaints by a patient taking tobramycin would be most indicative the patient is experiencing ototoxicity?

A. tingling of the extremities
B. complaints that he is unable to hear the television
C. changes in mental status
D. short periods of dizziness

4. A patient is prescribed moxifloxacin. The nurse notes that the patient is also taking an antacid. The nurse correctly administers moxifloxacin _______.

A. once daily PO, 4 hours before the antacid
B. twice daily PO, immediately following the antacid
C. once daily IM without regard to the administration of the antacid
D. every 12 hours IV without regard to the administration of the antacid

5. The nurse is asked why kanamycin is given as a “bowel prep” before gastrointestinal surgery. The nurse correctly replies _______.

A. abdominal surgery requires starting antibiotic therapy 4 days before surgery
B. the bacteria found in the bowel cannot be destroyed after surgery
C. a reduction of intestinal bacteria lessens the possibility of postoperative infection
D. anesthesia makes the bowel resistant to an antibiotic after surgery
Medication Dosage Problems

1. A patient is prescribed 40 mg of tobramycin IM. Use the drug label shown below to determine the amount of drug to administer. The nurse would administer ______.

2. The primary health care provider prescribed 400 mg gatifloxacin PO daily for 7 days. The drug is available in 200-mg tablets. How many tablets would the nurse administer each day?
Miscellaneous Anti-infectives

**Key Terms**
- anaerobic
- blood dyscrasias
- hypoglycemia
- hypotension

**Chapter Objectives**
On completion of this chapter, the student will:
- Discuss the uses, general drug actions, adverse reactions, contraindications, precautions, and interactions of the drugs presented in this chapter.
- Discuss preadministration and ongoing assessments necessary with the administration of the drugs presented in this chapter.
- Identify nursing assessments that are performed when a drug is potentially nephrotoxic or ototoxic.
- List some nursing diagnoses particular to a patient taking the anti-infective drugs presented in this chapter.
- Discuss ways to promote optimal response to therapy and important points to keep in mind when educating patients about the use of the anti-infectives presented in this chapter.

---

The anti-infectives discussed in this chapter (see Summary Drug Table: Miscellaneous Anti-infectives) are singular drugs, that is, they are not related to each other and do not belong to any one of the drug groups discussed in Chapters 6 through 10. Some of these drugs are used only for the treatment of one type of infection, whereas others may be limited to the treatment of serious infections not treatable by other anti-infectives.

**CHLORAMPHENICOL**

**ACTIONS AND USES**
Chloramphenicol (Chloromycetin) interferes with or inhibits protein synthesis, a process necessary for the growth and multiplication of microorganisms. This is a potentially dangerous drug (see below), and therefore its use is limited to serious infections when less potentially dangerous drugs are ineffective or contraindicated.

---

**ADVERSE REACTIONS**
Serious and sometimes fatal blood dyscrasias (pathologic condition of blood; disorder of cellular elements of blood) are the chief adverse reaction seen with the administration of chloramphenicol. In addition to blood dyscrasias, superinfection, hypersensitivity reactions, nausea, vomiting, and headache may be seen. It is recommended that patients receiving oral chloramphenicol be hospitalized so that patient observation and frequent blood studies can be performed during treatment with this drug.

**CONTRAINdications, PRECAUTIONS, AND INTERACTIONS**
Chloramphenicol is contraindicated in patients with known hypersensitivity to the drug. This drug is used cautiously in patients with severe liver or kidney disease, in geriatric patients, in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (see Chap. 1), and during pregnancy (Category C) or lactation. Newborns are at increased risk for experiencing adverse reactions due to their inability to metabolize and excrete chloramphenicol.
The effects of oral hypoglycemic drugs, oral anticoagulants, and phenytoin may be increased when administered with chloramphenicol. Phenobarbital or rifampin may decrease chloramphenicol blood levels.

**Linezolid**

**Actions and Uses**

Linezolid (Zyvox) is the first of a new classification, an oxazolidinone, that acts by binding to a site on a specific ribosomal RNA and preventing the formation of a component necessary for the bacteria to replicate. It is both bacteriostatic (ie, to enterococci and staphylococci) and bacteriocidal (ie, against streptococci). The drug is used in the treatment of vancomycin-resistant enterococcus (VRE), nosocomial (hospital acquired) and community acquired pneumonia, pneumonia, and in the treatment of skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA).

**Adverse Reactions**

The most common adverse reactions include nausea, vomiting, diarrhea, headache, and insomnia. The drug may also cause fatigue, depression, nervousness, and
photosensitivity. Pseudomembranous colitis and thrombocytopenia are the more serious adverse reactions caused by linezolid.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

The drug is contraindicated in the presence of an allergy to the drug, pregnancy (Category C), lactation, and phenylketonuria (oral form only). Linezolid is used cautiously in patients with bone marrow depression, hepatic dysfunction, renal impairment, hypertension, and hyperthyroidism.

When linezolid is used with antiplatelet drugs such as aspirin or the NSAIDs (see Chap. 18) there is an increased risk of bleeding and thrombocytopenia. When administered with the MAOIs (see Chap. 31) the effects of the MAOIs are decreased. There is a risk of severe hypertension if linezolid is combined with large amounts of food containing tyramine (eg, aged cheese, caffeinated beverages, yogurt, chocolate, red wine, beer, pepperoni).

**MEROPENEM**

**ACTION AND USES**

Meropenem (Merrem IV) inhibits synthesis of the bacterial cell wall and causes the death of susceptible cells. This drug is used for intra-abdominal infections caused by Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and other susceptible organisms. Meropenem also is effective against bacterial meningitis caused by Neisseria meningitidis, Streptococcus pneumoniae, and Hemophilus influenzae.

**ADVERSE REACTIONS**

The most common adverse reactions with meropenem include headache, nausea, vomiting, diarrhea, anorexia, abdominal pain, generalized pain, flatulence, rash, and superinfections. This drug also can cause an abscess or phlebitis at the injection site. An abscess is suspected if the injection site appears red or is tender and warm to the touch. Tissue sloughing at the injection site also may occur.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

Meropenem is contraindicated in patients who are allergic to cephalosporins and penicillins and in patients with renal failure. This drug is not recommended in children younger than 3 months or for women during pregnancy (Category B) or lactation. Meropenem is used cautiously in patients with central nervous system (CNS) disorders, seizure disorders, and in patients with renal or hepatic failure. When administered with probenecid, the excretion of meropenem is inhibited.

**METRONIDAZOLE**

**ACTIONS AND USES**

The mode of action of metronidazole (Flagyl) is not well understood, but it is thought to disrupt DNA and protein synthesis in susceptible organisms. This drug may be used in the treatment of serious infections, such as intra-abdominal, bone, soft tissue, lower respiratory, gynecologic, and CNS infections caused by susceptible anaerobic (able to live without oxygen) microorganisms.

**ADVERSE REACTIONS**

The most common adverse reactions seen with this drug are related to the gastrointestinal tract and may include nausea, anorexia, and occasionally vomiting and diarrhea. The most serious adverse reactions are associated with the CNS and include seizures and numbness of the extremities. Hypersensitivity reactions also may be seen. Thrombophlebitis may occur with intravenous (IV) use of the drug.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

This drug is contraindicated in patients with known hypersensitivity to the drug and during the first trimester of pregnancy (Category B). This drug is used cautiously in patients with blood dyscrasias, seizure disorders, and hepatic dysfunction. Safety in children (other than orally for amebiasis) has not been established.

The metabolism of metronidazole may decrease when administered with cimetidine. When administered with phenobarbital, the effectiveness of metronidazole may decrease. When metronidazole is administered with warfarin, the effectiveness of the warfarin is increased.

**PENTAMIDINE ISETHIONATE**

**ACTIONS AND USES**

Pentamidine isethionate (Pentam 300, the parenteral form; NebuPent, the aerosol form) is used in the treatment (parenteral form) or prevention (aerosol form) of
Pneumocystis carinii pneumonia, a pneumonia seen in those with acquired immunodeficiency syndrome. The mode of action of this drug is not fully understood.

**ADVERSE REACTIONS**

More than half of the patients receiving this drug by the parenteral route experience some adverse reaction. Severe and sometimes life-threatening reactions include leukopenia (low white blood cell count), hypoglycemia (low blood sugar), thrombocytopenia (low platelet count), and hypotension (low blood pressure). Moderate or less severe reactions include changes in some laboratory tests, such as the serum creatinine and liver function tests. Other adverse reactions include anxiety, headache, hypotension, chills, nausea, and anorexia. Aerosol administration may result in fatigue, a metallic taste in the mouth, shortness of breath, and anorexia.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

This drug is contraindicated in individuals who have had previous hypersensitivity reactions to pentamidine isethionate. Pentamidine isethionate is used cautiously in patients with hypertension, hypotension, hyperglycemia, renal impairment, diabetes mellitus, liver impairment, bone marrow depression, pregnancy (Category C), or lactation.

An additive nephrotoxicity develops when pentamidine isethionate is administered with other nephrotoxic drugs (eg, aminoglycosides, vancomycin, or amphotericin B). An additive bone marrow depression occurs when the drug is administered with antineoplastic drugs or when the patient has received radiation therapy recently.

**SPECTINOMYCIN**

**ACTIONS AND USES**

Spectinomycin (Trobicin) is chemically related to but different from the aminoglycosides (see Chap. 10). This drug exerts its action by interfering with bacterial protein synthesis. Spectinomycin is used for the treatment of gonorrhea.

**ADVERSE REACTIONS**

Soreness at the injection site, urticaria, dizziness, rash, chills, fever, and hypersensitivity reactions may be seen with the administration of this drug.
the symptoms of the infection. It is very important to take a thorough allergy history, especially a history of drug allergies. When culture and sensitivity tests are ordered, these procedures must be performed before the first dose of the drug is given. Other laboratory tests such as renal and hepatic function tests, complete blood count, and urinalysis also may be ordered before and during drug therapy for early detection of toxic reactions.

**Ongoing Assessment**
The nurse should monitor the patient’s vital signs every 4 hours or as ordered by the primary health care provider. It is important to notify the primary health care provider if there are changes in the vital signs, such as a significant drop in blood pressure, an increase in the pulse or respiratory rate, or a sudden increase in temperature.

The nurse observes the patient at frequent intervals, especially during the first 48 hours of therapy. It is important to report any adverse reaction to the primary health care provider before the next dose of the drug is due.

**NURSING DIAGNOSES**
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in Chapter 4.

**PLANNING**
The expected outcomes for the patient depend on the reason for administration of the anti-infective but may include an optimal response to drug therapy, management of adverse drug reactions, a decrease in anxiety, and an understanding of and compliance with the prescribed drug regimen.

**IMPLEMENTATION**
**Promoting an Optimal Response to Therapy**
Monitoring each patient for response to drug therapy and for the appearance of adverse reactions is an integral part of promoting an optimal response to therapy. The nurse immediately reports serious adverse reactions, such as signs and symptoms of a hypersensitivity reaction or superinfection, respiratory difficulty, or a marked drop in blood pressure.

**Nursing Diagnoses Checklist**
- **Anxiety** related to infection, seriousness of illness, route of administration, other factors (specify)
- **Diarrhea** related to adverse drug reaction, superinfection
- **Pain** related to intramuscular injection
- **Risk for Disturbed Sensory Perception: Auditory** related to adverse drug effects (ototoxicity)
- **Risk for Impaired Urinary Elimination** related to adverse drug effects (nephrotoxicity)

**Nursing Alert**
The blood dyscrasias may occur with the administration of chloramphenicol during either short- or long-term therapy. The nurse observes patients closely for signs and symptoms that may indicate a blood dyscrasia—fever, sore throat, sores in the mouth, easy bruising or bleeding (even several weeks after the drug regimen is completed) and extreme fatigue.

It is important to monitor closely serum blood levels of chloramphenicol, particularly in patients with impaired liver or kidney function or when administering chloramphenicol with other drugs metabolized by the liver. Blood concentration levels exceeding 25 mcg/mL increase the risk of the patient developing bone marrow depression.

**Linezolid.** The drug is given orally or intravenously (IV). When the drug is given orally, it is administered every 12 hours and may be taken with or without food. If nausea develops, the drug may be taken with food. Foods

**INTRAMUSCULAR ADMINISTRATION.** To promote an optimal response to therapy when giving these drugs intramuscularly (IM), the nurse inspects previous injection sites for signs of pain or tenderness, redness, and swelling. In addition, the nurse reports any persistent local reaction to the primary health care provider. It also is important to develop a plan for rotation of injection sites and to record the site used after each injection.

**INTRAVENOUS ADMINISTRATION.** When giving these drugs IV, the nurse inspects the needle site and area around the needle at frequent intervals for signs of extravasation of the IV fluid. More frequent assessments are performed if the patient is restless or uncooperative. The rate of infusion is checked every 15 minutes and adjusted as needed. This is especially important when administering vancomycin because rapid infusion of the drug can result in severe hypotension and shock. The nurse inspects the vein used for the IV infusion every 4 to 8 hours for signs of tenderness, pain, and redness (which may indicate phlebitis or thrombophlebitis). If these symptoms are apparent, the nurse restarts the IV in another vein and brings the problem to the attention of the primary health care provider.

**SPECIAL CONSIDERATIONS FOR SPECIFIC DRUGS.** To promote an optimal response to therapy, the nurse should know the following special considerations for specific drugs.

**Chloramphenicol.** When the drug is given orally, the nurse gives it to the patient whose stomach is empty, 1 hour before or 2 hours after meals. If gastrointestinal distress occurs, it is acceptable to give the drug with food. Chloramphenicol is also given IV. The drug should be administered around the clock to maintain therapeutic blood levels of the drug.
high in tyramine (see Chap. 31) are avoided because of the risk of hypertension. When given IV, the drug is infused during a period of 30 to 120 minutes. The nurse protects the drug from light by leaving the overwrap in place until ready to administer. It is important to monitor the patient’s platelet count regularly, particularly if the drug is used for longer than 2 weeks.

**Meropenem.** This drug is administered only by the IV route. The nurse gives meropenem every 8 hours over a period of 15 to 30 minutes if the drug is diluted or over a period of 3 to 5 minutes as a bolus injection (5–20 mL).

**Metronidazole.** When the nurse prepares the drug, the package insert should be consulted for reconstitution of the powder form because the directions for the order of preparation for IV administration must be followed. After reconstitution, the solution should be clear to pale yellow to pale green; do not use if the solution is cloudy or contains particulates. The drug should be used within 24 hours. When given orally, it is important to give the drug with meals to avoid gastrointestinal upset. The nurse informs the patient that an unpleasant metallic taste may be noted during therapy. When the drug is given on an outpatient basis, it is a good idea to advise the patient to avoid drinking alcoholic beverages during and for at least 1 day after treatment. When metronidazole is mixed with alcohol, the patient may experience flushing, nausea, vomiting, headache, and abdominal cramping.

The nurse informs patients being treated for gynecologic infections, such as trichomoniiasis, that sexual contact with infected partners may lead to reinfection, so sexual partners must be treated concurrently.

**Pentamidine Isethionate.** When the drug is given IM or IV, the nurse prepares the drug according to the manufacturer’s directions. When the drug is given by the IV route, it is important to infuse the drug over 1 hour. When the drug is given by aerosol, the nurse uses a special nebulizer (Respirgard II) and delivers the drug until the chamber is empty. It also is a good idea to explain or demonstrate the use of the nebulizer to the patient. The nurse monitors blood pressure frequently during administration because sudden, severe hypotension may occur after administration. Because hypotension can occur after a single dose, the nurse should always have the patient lying down when the drug is administered. The nurse assesses the patient for signs of hypoglycemia (weakness, diaphoresis, cool skin, shakiness) and hyperglycemia (flushed dry skin, fruity breath odor, increased thirst, and increased urination).

**Spectinomycin.** Spectinomycin may be given as a single dose, but multiple doses may be prescribed for complicated, widespread gonorrhea. The nurse warns the patient that the IM injection may be uncomfortable and that soreness at the injection site may be noted for a brief time. The nurse emphasizes the importance of following the primary health care provider’s recommendations regarding a follow-up examination to determine if the infection has been eliminated. In addition, the nurse explains to the patient that all sexual contacts need to receive treatment.

**Vancomycin.** The nurse can administer vancomycin orally or by intermittent IV infusion. This drug is not administered IM. Unused portions of reconstituted oral suspensions and parenteral solutions are stable for 14 days when refrigerated after reconstitution.

---

**Nursing Alert**

The nurse should administer each IV dose of vancomycin over 60 minutes. Too rapid an infusion may result in a sudden and profound fall in blood pressure and shock. When giving the drug IV, the nurse closely monitors the infusion rate and the patient’s blood pressure. The nurse reports any decrease in blood pressure or reports of throbbing neck or back pain. These symptoms could indicate a severe adverse reaction referred to as “red neck” or “red man” syndrome. Symptoms of this syndrome include a sudden and profound fall in blood pressure, fever, chills, paresthesias, and erythema (redness) of the neck and back.

The nurse reports patient complaints of difficulty hearing or tinnitus (ringing in the ears) to the primary health care provider before the next dose is due. In addition, the nurse monitors the fluid intake and output and brings any decrease in the urinary output to the attention of the primary health care provider.

---

**Monitoring and Managing Adverse Reactions**

**MANAGING ANXIETY.** Patients may exhibit varying degrees of anxiety related to their illness and infection and the necessary drug therapy. When these drugs are given by the parenteral route, patients may experience anxiety because of the discomfort or pain that accompanies an IM injection or IV administration. The nurse reassures the patient that every effort will be made to reduce pain and discomfort although complete pain relief may not always be possible.

**MANAGING DIARRHEA.** Diarrhea may be a sign of a superinfection or pseudomembranous colitis, both of which are adverse reactions that may be seen with the administration of any anti-infective. The nurse checks each stool and reports any changes in color or consistency. When vancomycin is given as part of the treatment for pseudomembranous colitis, it is important to record the color and consistency of each stool to determine the effectiveness of therapy.

**MANAGING PAIN.** Pain at the injection site may occur when these drugs are given IM. The nurse warns the patient that discomfort may be felt when it is injected and that additional discomfort may be experienced for a brief time afterward. The nurse places a warm moist compress over the injection site to help alleviate the discomfort.
MONITORING FOR NEPHROTOXICITY AND OTOTOXICITY.
It is important for the nurse to monitor for nephrotoxicity. The nurse measures and records intake and output during the time the patient is receiving these drugs. Any changes in the intake and output ratio or in the appearance of the urine must be reported immediately because these may indicate nephrotoxicity.

The nurse also closely monitors for ototoxicity in all patients receiving an anti-infective. It is important to report any ringing in the ears, difficulty hearing, or dizziness to the primary health care provider. Changes in hearing may not be noticed initially by the patient, but when changes occur they usually progress from difficulty in hearing high-pitched sounds to problems hearing low-pitched sounds.

Educating the Patient and Family
A nytime a drug is prescribed for a patient, the nurse is responsible to ensure that the patient has a thorough understanding of the drug, the treatment regimen, and the potential adverse reactions. Not all of the miscellaneous anti-infectives are prescribed for use within the clinical setting. Chloramphenicol, metronidazole, and vancomycin can be given orally and prescribed for outpatient use. However, patients requiring oral chloramphenicol are usually hospitalized so that blood studies can be done during treatment.

When pentamidine is prescribed for aerosol use at home, the nurse reviews the use of the special nebulizer, as well as directions for cleaning and maintaining the nebulizer equipment (see Home Care Checklist: Administering Pentamidine at Home).

When metronidazole is prescribed, the nurse warns the patient to avoid the use of alcoholic beverages because a severe reaction may occur.

To decrease the chance of noncompliance, the nurse emphasizes the following points when any of these drugs are prescribed on an outpatient basis:

- Take the drug at the prescribed time intervals. These time intervals are important because a certain amount of the drug must be in the body at all times for the infection to be controlled.
- Take the drug with food or on an empty stomach as directed on the prescription container.

Home Care Checklist
ADMINISTERING PENTAMIDINE AT HOME

The patient may be required to receive aerosol pentamidine at home. Before discharge, the nurse checks to make sure that arrangements have been made to deliver the specialized equipment and supplies, such as a Respirgard II nebulizer and diluent, to the home. The nurse also instructs the patient and caregiver on how to administer the drug:

- Prepare the solution immediately before its use.
- Dissolve the contents of one vial in 6 mL sterile water and protect the solution from light.
- Place the entire solution in the reservoir. Do not put any other drugs into the reservoir.
- Attach the tubing to the nebulizer and reservoir.
- Place the mouthpiece in your mouth and turn on the nebulizer.
- Breathe in and out deeply and slowly. The entire treatment should last 30 to 45 minutes.
- Tap the reservoir periodically to ensure that all of the drug is aerosolized.
- When the treatment is finished, turn off the nebulizer.
- Clean the equipment according to the manufacturer’s instructions.
- Allow tubing, reservoir, and mouthpiece to air dry.
- Store the equipment in a clean plastic bag and put it away for the next dose.
- Use a calendar to mark the days you are to receive the drug and check off each time you’ve done the treatment.
• Do not increase or omit the dose unless advised to do so by the primary health care provider.
• Complete the entire course of treatment. Do not stop the drug, except on the advice of a primary health care provider, before the course of treatment is completed even if symptoms have improved or have disappeared. Failure to complete the prescribed course of treatment may result in a return of the infection.
• Notify the primary health care provider if symptoms of the infection become worse or there is no improvement in the original symptoms after about 5 to 7 days.
• Contact the primary health care provider as soon as possible if a rash, fever, sore throat, diarrhea, chills, extreme fatigue, easy bruising, ringing in the ears, difficulty hearing, or other problems occur.
• Avoid drinking alcoholic beverages unless use has been approved by the primary health care provider.

**EVALUATION**

• The therapeutic drug effect is achieved and the infection is controlled.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully.
• Pain or discomfort following IM or IV administration is relieved or eliminated.
• Anxiety is reduced.
• The patient and family demonstrate understanding of the drug regimen.

**Critical Thinking Exercises**

1. The charge nurse asks you to discuss the drug metronidazole (Flagyl) at a team conference. Determine what specific points regarding administration and patient and family teaching you would discuss at the conference.

2. Mr. Stone is receiving vancomycin. One adverse reaction that may be seen with the administration of this drug is ototoxicity. Rather than ask Mr. Stone directly whether he is having any problem with his hearing, discuss how you might determine if ototoxicity might be occurring.

3. Mr. Reeves has a severe infection and is receiving chloramphenicol IV. The nurse notes several bruises on Mr. Reeves arm after 2 days of therapy. What action (if any) should the nurse take? Give a rationale for your answer.

**Medication Dosage Problems**

1. A patient is prescribed 500 mg of vancomycin PO every 6 hours. The drug is available in 500-mg tablets. The nurse administers _____.

2. Metronidazole 250 mg IV is ordered. The drug is available in a vial with 500 mg/2 mL. The nurse administers _____.

3. The primary health care provider prescribes linezolid 400 mg PO. The drug is available as an oral suspension in a strength of 100 mg/5 mL. The nurse administers _____.

**Review Questions**

1. When educating a patient about the drug linezolid the nurse instructs the patient _____.
   A. to avoid foods high in tyramine such as chocolate, coffee, and red wine
   B. to avoid alcohol for at least 10 days after taking the drug
   C. to take the drug without food to enhance absorption
   D. that frequent liver function tests will be necessary while taking the drug

2. When giving a drug that is potentially neurotoxic, the nurse reports which of the patient’s complaints related to neurotoxicity?
   A. light-headedness and abdominal pain
   B. severe headache and feeling chilly
   C. numbness of the extremities and dizziness
   D. blurred vision and tinnitus

3. When giving spectinomycin to Mr. Jackson for gonorrhea, the nurse advises him to _____.
   A. return for a follow-up examination
   B. limit his fluid intake to 1200 mL per day while taking the drug
   C. return the next day for a second injection
   D. avoid drinking alcohol for the next 10 days

4. When monitoring the IV infusion of vancomycin, the nurse makes sure the drug infuses over a period of 60 minutes because rapid infusion can result in a _____.
   A. fluid overload and respiratory distress
   B. sudden and profound fall in blood pressure
   C. fluid deficit and dehydration
   D. sudden and severe rise in blood pressure
Antitubercular Drugs

Key Terms

<table>
<thead>
<tr>
<th>anaphylactoid reactions</th>
<th>nephrotoxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>antitubercular drugs</td>
<td>optic neuritis</td>
</tr>
<tr>
<td>bacteriostatic</td>
<td>ototoxicity</td>
</tr>
<tr>
<td>circumoral</td>
<td>peripheral neuropathy</td>
</tr>
<tr>
<td>extrapulmonary</td>
<td>prophylactic</td>
</tr>
<tr>
<td>gout</td>
<td>tinnitus</td>
</tr>
<tr>
<td>Mycobacterium tuberculosis</td>
<td>tuberculosis</td>
</tr>
<tr>
<td></td>
<td>vertigo</td>
</tr>
</tbody>
</table>

Chapter Objectives

On completion of this chapter, the student will:

- Discuss the drugs used in the treatment of tuberculosis.
- Discuss the uses, general drug action, contraindications, precautions, interactions, and general adverse reactions associated with the administration of the antitubercular drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking an antitubercular drug.
- List some nursing diagnoses particular to a patient taking an antitubercular drug.
- Explain directly observed therapy (DOT).
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating patients about the use of the antitubercular drugs.

Tuberculosis is a major health problem throughout the world, infecting more than 8 million individuals each year. It is the world’s leading cause of death from infectious disease. Individuals living in crowded conditions, those with compromised immune systems, and individuals with debilitative conditions are especially susceptible to tuberculosis.

Tuberculosis is an infectious disease caused by the Mycobacterium tuberculosis bacillus. The pathogen is also referred to as the tubercle bacillus. The disease is transmitted from one person to another by droplets dispersed in the air when an infected person coughs or sneezes. These droplet nuclei are released into the air and inhaled by noninfected persons. Although tuberculosis primarily affects the lungs, other organs may also be affected. For example, if the immune system is poor, the infection can spread from the lungs to other organs of the body. Extrapulmonary (outside of the lungs) tuberculosis is the term used to distinguish tuberculosis affecting the lungs from infection with the M. tuberculosis bacillus in other organs of the body. Organs that can be affected include the liver, kidneys, spleen, and uterus. People with acquired immunodeficiency syndrome (AIDS) are at risk for tuberculosis because of their compromised immune systems. Tuberculosis responds well to long-term treatment with a combination of three or more antitubercular drugs.

Antitubercular drugs are used to treat active cases of tuberculosis and as a prophylactic to prevent the spread of tuberculosis. The drugs used to treat tuberculosis do not “cure” the disease, but they render the patient noninfectious to others. A nititubercular drugs are classified as primary and second-line drugs. Primary (first-line) drugs provide the foundation for treatment. Second-line or secondary drugs are less effective and more toxic than primary drugs. These drugs are used in various combinations to treat tuberculosis. Sensitivity testing may be done to determine the most effective combination treatment, especially in areas of the country showing resistance. Second-line drugs are used to treat extrapulmonary tuberculosis or drug-resistant organisms. The primary antitubercular drugs are discussed in this chapter. Both primary and second-line antitubercular drugs are listed in the Summary Drug Table: Antitubercular Drugs. Certain fluoroquinolones such as ciprofloxacin, ofloxacin, levofloxacin, and sparfloxacin have proven effective against tuberculosis and are considered second-line drugs. See Chapter 10 for a discussion of the fluoroquinolones.
### Primary Drugs

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>ethambutol</td>
<td>Myambutol</td>
<td>Pulmonary tuberculosis (TB)</td>
<td>Optic neuritis, fever, pruritis, headache, nausea, anorexia, dermatitis, hypersensitivity, psychic disturbances</td>
<td>15–25 mg/kg/d PO</td>
</tr>
<tr>
<td>isoniazid</td>
<td>INH, Laniazid, Nydrazid, generic</td>
<td>Active TB; prophylaxis for TB</td>
<td>Peripheral neuropathy, nausea, vomiting, epigastric distress, jaundice, hepatitis, pyridoxine deficiency, skin eruptions, hypersensitivity</td>
<td>Active TB: up to 300 mg/d PO or up to 300 mg/d IM, to 900 mg IM 2–3 times/wk First-line treatment: 300 mg INH and 600 mg rifampin PO in single dose TB prophylaxis: 30 mg/d PO</td>
</tr>
<tr>
<td>pyrazinamide</td>
<td>generic</td>
<td>Active TB</td>
<td>Hepatotoxicity, nausea, vomiting, diarrhea, myalgia, rashes</td>
<td>15–30 mg/kg/d maximum, 3 g/d PO; 50–70 mg/kg twice weekly PO</td>
</tr>
<tr>
<td>rifabutin</td>
<td>Mycobutin</td>
<td>Active TB</td>
<td>Nausea, vomiting, diarrhea, rash, discolored urine</td>
<td>300 mg PO as a single dose or BID</td>
</tr>
<tr>
<td>rifampin</td>
<td>Rifadin, Rimactane, generic</td>
<td>Active TB</td>
<td>Heartburn, drowsiness, fatigue, dizziness, epigastric distress, hematologic changes, renal insufficiency, rash</td>
<td>600 mg PO, IV</td>
</tr>
<tr>
<td>streptomycin</td>
<td>generic</td>
<td>TB; infections due to susceptible microorganisms</td>
<td>Nephrotoxicity, ototoxicity, numbness, tingling, paresthesia of the face, nausea, dizziness</td>
<td>Up to 1 g/d IM</td>
</tr>
<tr>
<td>isoniazid (150 mg) and rifampin 300 mg</td>
<td>Rifamate</td>
<td>TB</td>
<td>See individual drugs</td>
<td>1–2 tablets daily PO</td>
</tr>
</tbody>
</table>

### Second-line Drugs

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>aminosalicylate</td>
<td>Paser</td>
<td>TB</td>
<td>Nausea, vomiting, diarrhea, abdominal pain, hypersensitivity reactions</td>
<td>4 g (1 packet) PO TID</td>
</tr>
<tr>
<td>capreomycin sulfate</td>
<td>Capastat Sulfate</td>
<td>TB</td>
<td>Hypersensitivity reactions, nephrotoxicity, hepatic impairment, pain and induration at injection site, ototoxicity</td>
<td>1 g/d (maximum, 20 mg/kg/d) IM</td>
</tr>
<tr>
<td>cycloserine</td>
<td>Seromycin Pulvules</td>
<td>TB</td>
<td>Convulsions, somnolence, confusion, renal impairment, sudden development of congestive heart failure, psychoses</td>
<td>500 mg to 1 g PO in divided doses</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
**ACTIONS**

Most antitubercular drugs are **bacteriostatic** (slow or retard the growth of bacteria) against the *M. tuberculosis* bacillus. These drugs usually act to inhibit bacterial cell wall synthesis, which slows the multiplication rate of the bacteria. Only isoniazid is bactericidal, with rifampin and streptomycin having some bactericidal activity.

**USES**

Antitubercular drugs are used in combination with other antitubercular drugs to treat active tuberculosis. Isoniazid (INH) is the only antitubercular drug used alone. While isoniazid is used in combination with other drugs for the treatment of primary tuberculosis, a primary use is in preventive therapy (prophylaxis) against tuberculosis. For example, when a diagnosis of tuberculosis is present, family members of the infected individual must be given prophylactic treatment with isoniazid for 6 months to 1 year. Display 12-1 identifies prophylactic uses for isoniazid.

**RESISTANCE TO THE ANTITUBERCULAR DRUGS**

Of increasing concern is the development of mutant strains of tuberculosis that are resistant to many of the antitubercular drugs currently in use. Bacterial resistance develops, sometimes rapidly, with the use of antitubercular drugs. Treatment is individualized and based on laboratory studies identifying the drugs to which the organism is susceptible. To slow the development of bacterial resistance, the Centers for Disease Control (CDC) recommends the use of three or more drugs with initial therapy, as well as in retreatment. Using a combination of drugs slows the development of bacterial resistance.

Tuberculosis caused by drug-resistant organisms should be considered in patients who have no response to therapy and in patients who have been treated in the past.

**STANDARD TREATMENT**

Standard treatment for tuberculosis is divided into two phases: the initial phase followed by a continuing phase. During the initial phase, drugs are used to kill the rapidly multiplying *M. tuberculosis* and to prevent drug resistance. The initial phase lasts approximately 2 months and the continuing phase approximately 4 months, with the total treatment regimen lasting for 6 to 9 months, depending on the patient’s response to therapy.

The initial phase must contain three or more of the following drugs: isoniazid, rifampin, and pyrazinamide, along with either ethambutol or streptomycin. The CDC recommends treatment to begin as soon as possible after the diagnosis of tuberculosis. The treatment recommendation regimen is for the administration of rifampin, isoniazid, and pyrazinamide for a minimum of 2 months (8 weeks), followed by rifampin and isoniazid for 4 months (16 weeks) in areas with a low incidence of tuberculosis. In areas of high incidence of tuberculosis, the CDC recommends the addition of streptomycin or ethambutol for the first 2 months.

**DISPLAY 12-1 Prophylactic Uses for Isoniazid**

Isoniazid may be used in the following situations:
- Household members and other close associates of those recently diagnosed as having tuberculosis
- Those whose tuberculin skin test has become positive in the last 2 years
- Those with positive skin tests whose radiographic findings indicate nonprogressive, healed, or quiescent (causing no symptoms) tubercular lesions
- Those at risk of developing tuberculosis (eg, those with Hodgkin’s disease, severe diabetes mellitus, leukemia, and other serious illnesses and those receiving corticosteroids or drug therapy for a malignancy)
- All patients younger than 35 years (primarily children to age 7) who have a positive skin test
- Persons with acquired immunodeficiency syndrome or those who are positive for the human immunodeficiency virus and have a positive tuberculosis skin test or a negative tuberculosis skin test but a history of a prior significant reaction to purified protein derivative (a skin test for tuberculosis)

**RETREATMENT**

At times treatment fails due to noncompliance with the drug regimen or to inadequate initial drug treatment. When treatment fails, retreatment is necessary. Retreatment generally includes the use of four or more antitubercular drugs. Retreatment drug regimens most often consist of the secondary drugs ethionamide, aminosalicylic acid, cycloserine, and capreomycin. Ofloxacin and ciprofloxacin may also be used in retreatment. At times during retreatment, as many as seven or more drugs may be used, with the ineffective drugs discontinued when susceptibility test results are available.

This chapter will discuss the following primary antitubercular drugs: ethambutol, isoniazid, pyrazinamide, rifampin, and streptomycin. Other primary and secondary drugs are listed in the Summary Drug Table: Antitubercular Drugs.
**ETHAMBUTOL**

**ADVERSE REACTIONS**

Optic neuritis (a decrease in visual acuity and changes in color perception), which appears to be related to the dose given and duration of treatment, has occurred in some patients receiving ethambutol. Usually, this adverse reaction disappears when the drug is discontinued. Other adverse reactions are dermatitis, pruritus, anaphylactoid reactions (unusual or exaggerated allergic reactions), joint pain, anorexia, nausea, and vomiting.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

Ethambutol is contraindicated in patients with a history of hypersensitivity to the drug. Ethambutol is not recommended for children younger than 13 years. The drug is used with caution during lactation, in patients with hepatic and renal impairment, and during pregnancy (Category B). Because of the danger of optic neuritis, the drug is used cautiously in patients with diabetic retinopathy or cataracts.

**ISONIAZID**

**ADVERSE REACTIONS**

The incidence of adverse reactions appears to be higher when larger doses of isoniazid are prescribed. Adverse reactions include hypersensitivity reactions, hematologic changes, jaundice, fever, skin eruptions, nausea, vomiting, and epigastric distress. Severe, and sometimes fatal, hepatitis has been associated with isoniazid therapy and may appear after many months of treatment. Peripheral neuropathy (numbness and tingling of the extremities) is the most common symptom of toxicity.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

Isoniazid is contraindicated in patients with a history of hypersensitivity to the drug. The drug is used with caution during lactation, in patients with hepatic and renal impairment, and during pregnancy (Category C). Daily consumption of alcohol when taking isoniazid may result in a higher incidence of drug-related hepatitis. Aluminum salts may reduce the oral absorption of isoniazid. The action of the anticoagulants may be enhanced when taken with isoniazid. There is a possibility of increased serum levels of phenytoin with concurrent use of isoniazid. When isoniazid is taken with foods containing tyramine, such as aged cheese and meats, bananas, yeast products, and alcohol, an exaggerated sympathetic-type response can occur (eg, hypertension, increased heart rate, palpitations).

**PYRAZINAMIDE**

**ADVERSE REACTIONS**

Hepatotoxicity is the principal adverse reaction seen with pyrazinamide use. Symptoms of hepatotoxicity may range from none (except for slightly abnormal hepatic function tests) to a more severe reaction such as jaundice. Nausea, vomiting, diarrhea, myalgia, and rashes also may be seen.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

Pyrazinamide is contraindicated in patients with a history of hypersensitivity to the drug. The drug is also contraindicated in patients with acute gout (a metabolic disorder resulting in increased levels of uric acid) and in patients with severe hepatic damage. The drug is used with caution during lactation, in patients with hepatic and renal impairment, and during pregnancy (Category C). Pyrazinamide is used cautiously in patients infected with human immunodeficiency virus, who may require longer treatment, and in patients with diabetes mellitus, in whom management is more difficult. Pyrazinamide decreases the effects of allopurinol, colchicines, and probenecid.

**RIFAMPIN**

**ADVERSE REACTIONS**

Nausea, vomiting, epigastric distress, heartburn, fatigue, dizziness, rash, hematologic changes, and renal insufficiency may be seen with administration of rifampin. Rifampin may also cause a reddish-orange discoloration of body fluids, including urine, tears, saliva, sweat, and sputum.
CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Rifampin is contraindicated in patients with a history of hypersensitivity to the drug. The drug is used with caution during lactation, in patients with hepatic and renal impairment, and during pregnancy. Serum concentrations of digoxin may be decreased by rifampin. Isoniazid and rifampin administered concurrently may result in a higher risk of hepatotoxicity than when either drug is used alone. The use of rifampin with the oral anticoagulants or oral hypoglycemics may decrease the effects of the anticoagulant or hypoglycemic drug. There is a decrease in the effect of the oral contraceptives, chloramphenicol, phenytoin, and verapamil when these agents are administered concurrently with rifampin.

STREPTOMYCIN

ADVERSE REACTIONS

Nephrotoxicity (damage to the kidneys), ototoxicity (damage to the organs of hearing by a toxic substance), numbness, tingling, tinnitus (ringing in the ears), nausea, vomiting, vertigo (dizziness), and circumoral (around the mouth) paresthesia may be noted with the administration of streptomycin. Soreness at the injection site may also be noted, especially when the drug is given for a long time.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Streptomycin is contraindicated in patients with a history of hypersensitivity to the drug or any other aminoglycoside. Streptomycin is a Pregnancy Category D drug and can cause fetal harm when administered to a pregnant woman. This drug is used cautiously in patients with preexisting hearing difficulty or tinnitus and in patients with renal insufficiency. The ototoxic effects of streptomycin are potentiated when administered with ethacrynic acid, furosemide, and mannitol. (See Chapter 10 for additional information about streptomycin.)

Ongoing Assessment

When performing the ongoing assessment, the nurse observes the patient daily for the appearance of adverse reactions. These observations are especially important when a drug is known to be nephrotoxic or ototoxic. It is important to report any adverse reactions to the primary health care provider. In addition, the nurse carefully monitors vital signs daily or as frequently as every 4 hours when the patient is hospitalized.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. The nursing diagnoses Noncompliance and Ineffective Management of Therapeutic Regimen also are discussed in Chapter 4.

PLANNING

The expected outcomes for the patient may include an optimal response to antitubercular therapy, management of common adverse reactions, and an understanding of and compliance with the prescribed treatment regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

The diagnosis, as well as the necessity of long-term treatment and follow-up, is often distressing to the patient. The spread of the disease and make the patient noninfectious to others. Many laboratory and diagnostic tests may be necessary before starting antitubercular therapy. The diagnosis, as well as the necessity of long-term treatment and follow-up, is often distressing to the patient. Many laboratory and diagnostic tests may be necessary before starting antitubercular therapy, including radiographic studies, culture and sensitivity tests, and various types of laboratory tests, such as a complete blood count. It also is important to include a family history and a history of contacts, if the patient has active tuberculosis, as part of the assessment.

Depending on the severity of the disease, patients may be treated initially in the hospital and then discharged to their home for supervised follow-up care, or they may have all treatment instituted on an outpatient basis.
Patient. Patients with a diagnosis of tuberculosis may have many questions about the disease and its treatment. The nurse allows time for the patient and family members to ask questions. In some instances, it may be necessary to refer the patient to other health care workers, such as a social service worker or a dietitian.

When administering the antitubercular drug by the parenteral route, the nurse is careful to rotate the injection sites. At the time of each injection, the nurse inspects previous injection sites for signs of swelling, redness, and tenderness. If a localized reaction persists or if the area appears to be infected, it is important to notify the primary health care provider.

The nurse should give antitubercular drugs by the oral route and on an empty stomach, unless gastric upset occurs. If gastric upset occurs, it is important to notify the primary health care provider before the next dose is given.

**DIRECTLY OBSERVED THERAPY (DOT).** Because the antitubercular drugs must be taken for prolonged periods, compliance with the treatment regimen becomes a problem and increases the risk of the development of resistant strains of tuberculosis. To help prevent the problem of noncompliance, directly observed therapy (DOT) is used to administer these drugs. When using DOT, the patient makes periodic visits to the office of the primary care provider or the health clinic, where the drug is taken in the presence of the nurse. The nurse watches the patient swallow each dose of the medication regimen. In some cases, the nurse uses the direct observation method to administer the antitubercular drug in the patient’s home, place of employment, or school. DOT may occur daily or two to three times weekly, depending on the patient’s health care regimen. Studies indicate that the intermittent administration of antitubercular drugs does not cause a drop in the therapeutic blood levels of antitubercular drugs, even if the drugs were given only two or three times a week.

**MANAGING VARIOUS TREATMENT REGIMENS.** The nurse uses the following interventions in the management of patients receiving antitubercular drugs to promote an optimal response to therapy.

**Ethambutol.** The nurse administers ethambutol once every 24 hours at the same time each day. It is a good idea to give the drug with food to prevent gastric upset. If a dose is missed, the nurse should tell the patient not to double the dose the next day. The nurse should explain to the patient that the urine, feces, saliva, sputum, sweat, and tears may be colored reddish-orange or brownish-orange and that this is normal.

**Isoniazid.** The nurse gives isoniazid to the patient whose stomach is empty, at least 1 hour before or 2 hours after meals. If gastrointestinal upset occurs, the patient can take the drug with food. The nurse teaches the patient to minimize alcohol consumption because of the increased risk of hepatitis. To prevent pyridoxine (vitamin B₆) deficiency, 6 to 50 mg pyridoxine daily may be prescribed.

**Pyrazinamide.** This drug is given once a day with food to prevent gastric upset. An alternative dosing regimen of twice weekly dosing has been developed to promote patient compliance on an outpatient basis. When administered on an outpatient basis, this drug, as well as the other antitubercular drugs, is administered using DOT.

**Rifampin.** The nurse administers rifampin once daily to the patient with an empty stomach, at least 1 hour before or 2 hours after meals. It is a good idea to explain to patients that their urine, feces, saliva, sputum, sweat, and tears may be colored reddish-orange and that this is normal.

**Streptomycin.** Streptomycin is usually administered daily as a single IM injection. The preferred site is the upper outer quadrant of the buttock or the midlateral thigh. The deltoid area is used only if the area is well developed. In patients 60 years of age or older, the dosage is reduced because of the risk of increased toxicity.

**MONITORING AND MANAGING ADVERSE REACTIONS**

Managing adverse reactions in patients taking antitubercular drugs is an important responsibility of the nurse. The nurse must continuously observe for signs of adverse reactions and immediately report them to the primary health care provider. Some information specific to the different antitubercular drugs is provided below.

**Ethambutol.** The nurse monitors for any changes in visual acuity and promptly reports any visual changes to the primary health care provider. Vision changes are usually reversible if the drug is discontinued as soon as symptoms appear. The patient may need assistance with ambulation if visual disturbances occur. Psychiatric disturbances may occur. If the patient appears depressed, withdrawn, noncommunicative, or has other personality changes, the nurse must report the problem to the primary health care provider.

**Isoniazid.** Severe and sometimes fatal hepatitis may occur with isoniazid therapy. The nurse must carefully monitor all patients at least monthly for any evidence of liver dysfunction. It is important to instruct patients to report any of the following symptoms: anorexia, nausea, vomiting, fatigue, weakness, yellowing of the skin or eyes, darkening of the urine, or numbness in the hands and feet.
PYRAZINAMIDE. Patients should have baseline liver functions tests to use as a comparison when monitoring liver function during pyrazinamide therapy. The nurse should monitor the patient closely for symptoms of a decline in hepatic functioning (ie, yellowing of the skin, malaise, liver tenderness, anorexia, or nausea). The primary health care provider may order periodic liver function tests. Hepatotoxicity appears to be dose related and may appear at any time during therapy.

RIFAMPIN. The patient is informed about the reddish-orange or reddish-brown discoloration of body fluids (eg, tears, sweat, sputum, saliva). Advise the patient not to wear soft contact lenses during therapy because they may be permanently stained.

STREPTOMYCIN. This drug may cause ototoxicity, resulting in hearing loss. The nurse should monitor for any signs of hearing loss, including tinnitus, and vertigo. The patient may have hearing checked by audiometry before beginning therapy and periodically during therapy. Tinnitus, roaring noises, or a sense of fullness in the ears indicates the need for audiometric examination or termination of the drug. Hearing loss occurs most often for high-frequency sounds. These drugs must be discontinued if the patient reports any hearing loss or if tinnitus occurs. Prompt action by the nurse is critical in preventing permanent hearing loss.

Educating the Patient and Family
Antitubercular drugs are given for a long time, and careful patient and family education and close medical supervision are necessary. Noncompliance can be a problem whenever a disease or disorder requires long-term treatment. For this reason, the DOT method of administration is preferred. The patient and family must understand that short-term therapy is of no value in treating this disease. The nurse remains alert for statements made by the patient or family that may indicate future noncompliance with the drug regimen necessary in controlling the disease. (See Patient and Family Teaching Checklist: Increasing Compliance in Tubercular Drug Treatment Programs.)

Gerontologic Alert
Older adults are particularly susceptible to a potentially fatal hepatitis when taking isoniazid, especially if they consume alcohol on a regular basis. Two other antitubercular drugs, rifampin and pyrazinamide, can cause liver dysfunction in the older adult. Careful observation and monitoring for signs of liver impairment are necessary (eg, increased serum aspartate transaminase, increased serum alanine transferase, increased serum bilirubin, and jaundice).

Patient and Family Teaching Checklist

The nurse:
- Discusses tuberculosis, its causes and communicability, and the need for long-term therapy for disease control.
- Reinforces that short-term treatment is ineffective.
- Reviews the drug therapy regimen, including the prescribed drugs, doses, and frequency of administration.
- Reassures the patient that various combinations of drugs are effective in treating tuberculosis.
- Urges the patient to take the drugs exactly as prescribed and not to omit, increase, or decrease the dosage unless directed to do so by the health care provider.
- Instructs the patient about possible adverse reactions and the need to notify prescriber should any occur.
- Arranges for direct observation therapy with the patient and family.
- Instructs the patient in measures to minimize gastrointestinal upset.
- Advises the patient to avoid alcohol and the use of nonprescription drugs, especially those containing aspirin, unless use is approved by the health care provider.
- Reassures the patient and family that the results of therapy will be monitored by periodic laboratory and diagnostic tests and follow-up visits with the health care provider.

The nurse reviews the dosage schedule and adverse effects associated with the prescribed antitubercular drug with the patient and family. Information that applies to all patients taking these drugs includes:

- The results of antitubercular therapy will be monitored at periodic intervals. Laboratory and diagnostic tests and visits to the primary health care provider’s office or clinic are necessary.
- Take these drugs exactly as directed on the prescription container. Do not omit, increase, or decrease a dose unless advised to do so by the primary health care provider.
- Avoid the use of nonprescription drugs, especially those containing aspirin, unless use has been approved by the primary health care provider.
- Discuss the drinking of alcoholic beverages with the primary health care provider. A limited amount of alcohol may be allowed, but excessive intake should usually be avoided.
The nurse includes the following information in the teaching plan when a specific antitubercular drug is prescribed:

**Ethambutol:** Take this drug once a day at the same time each day. If a dose is missed, do not double the dose the next day. Notify the primary health care provider of any changes in vision or the occurrence of a skin rash.

**Isoniazid:** Take this drug 1 hour before or 2 hours after meals. However, if gastric upset occurs, take isoniazid with food. Notify the primary health care provider of weakness, yellowing of the skin, loss of appetite, darkening of the urine, skin rashes, or numbness or tingling of the hands or feet. Avoid tyramine-containing foods (see Chap. 31). To prevent pyridoxine (vitamin B₆) deficiency, 6 to 50 mg of pyridoxine daily may be prescribed.

**Pyrazinamide:** Notify the primary health care provider if any of the following occurs: nausea, vomiting, loss of appetite, fever, malaise, visual changes, yellow discoloration of the skin, or severe pain in the knees, feet, or wrists. (Note: Pain in these areas may be a sign of active gout.)

**Rifampin:** Take the drug once daily on an empty stomach (1 hour before or 2 hours after meals). A reddish-brown or reddish-orange discoloration of tears, sputum, urine, or sweat may occur. Soft contact lenses may be permanently stained if worn while the patient is taking the drug. Notify the primary health care provider of any yellow discoloration of the skin, fever, chills, unusual bleeding or bruising, and skin rash or itching. If taking an oral contraceptive, check with primary health care provider because reliability of the contraceptive may be affected.

**EVALUATION**

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully.
- The patient verbalizes an understanding of treatment modalities and the importance of continued follow-up care.
- The patient and family demonstrate understanding of the drug regimen.
- The patient complies with the prescribed drug regimen.

**Critical Thinking Exercises**

1. Ms. Burns has received a diagnosis of tuberculosis. She is concerned because her primary health care provider has informed her that the treatment regimen consists of three drugs, isoniazid, rifampin, and pyrazinamide, taken for the next 2 months, followed by a 4-month treatment regimen with two of the drugs. Determine what rationales the nurse can give Ms. Burns for the use of multiple drugs and the need for long-term therapy.

2. While Mr. Johnson is taking isoniazid, explain what instructions the nurse should give him concerning side effects.

**Review Questions**

1. The nurse explains to the patient that to slow bacterial resistance to an antitubercular drug the primary health care provider may prescribe ______.
   - at least three antitubercular drugs
   - an antibiotic to be given with the drug
   - vitamin B₆
   - that the drug be given only once a week

2. Which of the following drugs is the only antitubercular drug to be prescribed alone?
   - rifampin
   - pyrazinamide
   - streptomycin
   - isoniazid

3. The nurse monitors the patient taking isoniazid for toxicity. The most common symptom of toxicity is ______.
   - peripheral edema
   - circumoral edema
   - peripheral neuropathy
   - jaundice

4. Which of the following is a dose-related adverse reaction to ethambutol?
   - peripheral neuropathy
   - optic neuritis
   - hyperglycemia
   - fatal hepatitis

5. Which of the following antitubercular drugs is contraindicated in patients with gout?
   - rifampin
   - streptomycin
   - isoniazid
   - pyrazinamide

**Medication Dosage Problems**

1. A patient is prescribed isoniazid syrup 300 mg. The isoniazid is available as 50 mg/mL. The nurse should administer ______.

2. Rifampin 600 mg PO is prescribed. The drug is available in 150-mg tablets. The nurse should administer ______.
Leprosy is a chronic, communicable disease spread by prolonged, intimate contact with an infected person. Peripheral nerves are affected, and skin involvement is present. Lesions may be confined to a few isolated areas or may be fairly widespread over the entire body. Treatment with the leprostatic drugs provides a good prospect for controlling the disease and preventing complications.

Leprosy, also referred to as Hansen’s disease, is caused by the bacterium *Mycobacterium leprae*. Although rare in colder climates, this disease may be seen in tropical and subtropical zones. Dapsone and clofazimine (Lamprene) are the two drugs currently used to treat leprosy. The leprostatic drugs are listed in the Summary Drug Table: Leprostatic Drugs.

**CLOFAZIMINE**

**ACTIONS AND USES**

Clofazimine is primarily bactericidal against *M. leprae*. The exact mode of action of this drug is unknown. Clofazimine is used to treat leprosy.

**ADVERSE REACTIONS**

Clofazimine may cause pigmentation of the skin, abdominal pain, diarrhea, nausea, and vomiting.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

Clofazimine is used cautiously in patients with gastrointestinal disorders, diarrhea, and during pregnancy (Pregnancy Category C) and lactation. If clofazimine is used during pregnancy, the infant may be born with pigmented skin. No significant drug-drug interactions are associated with the use of clofazimine.

**DAPSONE**

**ACTIONS AND USES**

Dapsone is bactericidal and bacteriostatic against *M. leprae*. The drug is used to treat leprosy. Dapsone...
may also be used in the treatment of dermatitis herpetiformis, a chronic, inflammatory skin disease.

**ADVERSE REACTIONS**

Administration of dapsone may result in hemolysis (destruction of red blood cells), nausea, vomiting, anorexia, and blurred vision.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

Dapsone is used with caution in patients with anemia, severe cardiopulmonary disease, hepatic dysfunction, and during pregnancy (Pregnancy Category C). Dapsone is contraindicated during lactation. Substantial amounts of dapsone are excreted in breast milk and can cause hemolytic reactions in neonates. No significant drug-drug interactions are associated with the use of dapsone.

**ONGOING ASSESSMENT**

These drugs are often given on an outpatient basis. Each time the patient is seen in the clinic or primary health care provider’s office, the nurse performs a general physical examination, with particular attention given to the affected areas.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. More general nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes for the patient may include an optimal response to drug therapy and an understanding of and compliance with the prescribed treatment regimen.

**IMPLEMENTATION**

Promoting an Optimal Response to Therapy

Treatment with a leprostatic drug may require many years. These patients are faced with long-term medical and drug therapy and possibly severe disfigurement. The nurse must spend time with these patients, allowing them to verbalize their anxieties, problems, and fears.

It is important to give the leprostatic drugs orally and with food to minimize gastric upset. The nurse can give antitubercular drugs, such as rifampin, concurrently.
during initial therapy to minimize bacterial resistance to the leprostatic drug.

**Educating the Patient and Family**
The nurse is alert to patient statements regarding compliance with the long-term treatment regimen. It is important to note factors, such as depression or indifference, that may be indicative of treatment noncompliance. The nurse uses a positive approach when doing patient and family teaching. The nurse informs the patient that changes in skin pigmentation may occur, ranging from red to brownish-black. Skin discoloration may take months to years to reverse after use of the drug is discontinued.

To ensure compliance with the treatment regimen, the nurse explains the dosage schedule, possible adverse effects, and the importance of scheduled follow-up visits to the patient and family members. In particular, the nurse emphasizes the importance of adhering to the prescribed dosage schedule.

**EVALUATION**
- The therapeutic drug effect is achieved.
- The patient verbalizes an understanding of treatment modalities and the importance of continued follow-up care.
- The patient and family demonstrate understanding of the drug regimen.
- The patient complies with the prescribed drug regimen.

**Critical Thinking Exercises**
1. Mr. Winters is very anxious about his newly diagnosed leprosy and his treatment regimen with dapsone. Discuss what you could do to decrease his anxiety. Determine what information you would include when educating Mr. Winters about the treatment regimen.
2. Mr. York has been prescribed clofazimine daily to manage his leprosy. Discuss what preadministration assessments the nurse should make. Explain what information you would include in a teaching plan for Mr. York.

**Review Questions**
1. Before administration of the initial dose of a leprostatic drug, it is most important for the nurse to assess ________.
   A. range of motion  
   B. mental ability  
   C. vital signs  
   D. affected areas on the patient’s body
2. Which of the following adverse reactions would the nurse expect with the administration of clofazimine?
   A. hypotension  
   B. blurred vision  
   C. pigmentation of the skin  
   D. jaundice
3. Which of the following hematologic changes may result from the administration of dapsone?
   A. hemolysis  
   B. leukopenia  
   C. decreased platelets  
   D. increase in the hematocrit
4. When educating the patient about taking a leprostatic drug, the nurse would include which of the following information?
   A. This drug regimen will require that you take the drug faithfully for at least 3 months.  
   B. Take the drug with food to minimize gastric upset.  
   C. Skin lesions should clear within 3 days.  
   D. The drug should be taken on an empty stomach at bedtime to minimize gastric upset.

**Medication Dosage Problems**
1. The patient is prescribed 150 mg of dapsone. On hand are 50-mg tablets. The nurse administers ________.
2. A patient with leprosy is prescribed clofazimine 100 mg daily PO. The drug is available in 200-mg tablets. The nurse administers ________.
Antiviral Drugs

Key Terms

<table>
<thead>
<tr>
<th>anticholinergic effects</th>
<th>remissions</th>
</tr>
</thead>
<tbody>
<tr>
<td>exacerbations</td>
<td></td>
</tr>
<tr>
<td>granulocytopenia</td>
<td>retinitis</td>
</tr>
</tbody>
</table>

Chapter Objectives

On completion of this chapter, the student will:

- Discuss the uses, general drug action, adverse reactions, contraindications, precautions, and interactions of antiviral drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient receiving an antiviral drug.
- List some nursing diagnoses particular to a patient taking an antiviral drug.
- List possible goals for a patient taking an antiviral drug.
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and special considerations to keep in mind when educating the patient and the family about the antiviral drugs.

More than 200 viruses have been identified as capable of producing disease. Acute viruses, such as the common cold, have a rapid onset and quick recovery. Chronic viral infections, such as acquired immunodeficiency syndrome (AIDS), have recurrent episodes of exacerbations (increases in severity of symptoms of the disease) and remissions (periods of partial or complete disappearance of the signs and symptoms). Display 14-1 describes the viruses discussed in this chapter.

Although viral infections are common, for many years only a limited number of drugs were available for their treatment. Over the past several years, the number of antiviral drugs has increased significantly. Several of the antiviral drugs will be discussed in greater detail than others. These include acyclovir (Zovirax), amantadine (Symmetrel), didanosine (Videx), ribavirin (Virazole), zanamivir (Relenza), and zidovudine (AZT, Retrovir). The Summary Drug Table: Antiviral Drugs presents a more complete listing of the antiviral drugs currently in use.

ACTIONS

Viruses can reproduce only within a living cell. A virus consists of either DNA or RNA surrounded by a protein shell. The virus is capable of reproducing only when it uses the body’s cellular material (Fig. 14-1). Most antiviral drugs act by inhibiting viral DNA or RNA replication in the virus, causing viral death.

USES

Although infections caused by a virus are common, antiviral drugs have limited use because they are effective against only a small number of specific viral infections. General uses of the antiviral drugs include the treatment of:

- Initial and recurrent mucosal and cutaneous herpes simplex virus (HSV) 1 and 2 infections
DISPLAY 14-1 • Description of Viral Infections

| CYTOMEGALOVIRUS (CMV) | • CMV, a virus of the herpes family, is a common viral infection. Healthy individuals may become infected yet have no symptoms. However, immunocompromised patients (such as those with HIV or cancer) may have the infection. Symptoms include malaise, fever, pneumonia, and superinfection. Infants may acquire the virus from the mother while in the uterus, resulting in learning disabilities and mental retardation. CMV can infect the eye, causing retinitis. Symptoms of CMV retinitis are blurred vision and decreased visual acuity. Visual impairment is irreversible and can lead to blindness if untreated. |
| HERPES SIMPLEX VIRUS (HSV) | • HSV is divided into HSV-1, which causes oral, ocular, or facial infections, and HSV-2, which causes genital infection. However, either type can cause disease at either body site. HSV-1 causes painful vesicular lesions in the oral mucosa, face, or around the eyes. HSV-2 or genital herpes is usually transmitted by sexual contact and causes painful vesicular lesions on the mucous membranes of the genitalia. Vaginal lesions may appear as mucous patches with grayish ulcerations. The patient may appear irritable, lethargic, and jaundiced, and may have difficulty breathing or experience seizures. The lesions usually heal within 2 weeks. Immunosuppressed patients may develop a severe systemic disease. |
| HERPES ZOSTER | • Herpes zoster (shingles) is caused by the varicella (chickenpox) virus. It is highly contagious. The virus causes chickenpox in the child and is easily spread via the respiratory system. Recovery from childhood chickenpox results in the infection lying dormant in the nerve cells. The virus may become reactivated later in life as the older adult’s immune system weakens or the individual becomes ill with other disorders. The lesions of herpes zoster appear as pustules along a sensory nerve route. Pain often continues for several months after the lesions have healed. |

HUMAN IMMUNODEFICIENCY VIRUS (HIV)
• HIV or AIDS is a type of viral infection transmitted through an infected person’s bodily secretions, such as blood or semen. HIV destroys the immune system, causing the body to develop opportunistic infections such as Kaposi’s sarcoma, *Pneumocystis carinii* pneumonia, or tuberculosis. Symptoms include chills and fever, night sweats, dry productive cough, dyspnea, lethargy, malaise, fatigue, weight loss, and diarrhea.

INFLUENZA
• Influenza, commonly called the “flu,” is an acute respiratory illness caused by influenza viruses A and B. Symptoms include fever, cough, sore throat, runny or stuffy nose, headache, muscle aches, and extreme fatigue. Most people recover within 1 to 2 weeks. Influenza may cause severe complications such as pneumonia in children, the elderly, and other vulnerable groups. The viruses causing influenza continually change over time, which enables them to evade the immune system of the host. These rapid changes in the most commonly circulating types of influenza virus necessitate annual changes in the composition of the “flu” vaccine.

RESPIRATORY SYNCYTIAL VIRUS (RSV)
• RSV infection is highly contagious and infects mostly children, causing bronchiolitis and pneumonia. Infants younger than 6 months are the most severely affected. In adults, RSV causes colds and bronchitis, with fever, cough, and nasal congestion. When RSV affects immunocompromised patients, the consequences can be severe and sometimes fatal.

Unlabeled Uses
Because there are a limited number of antiviral drugs and more than 200 viral diseases, the primary health care provider may decide to prescribe an antiviral drug for an unlabeled use even though documentation of its effectiveness is lacking. Approval by the Food and Drug Administration (FDA) is necessary for a drug to be prescribed. On occasion, the use of a drug for a specific disorder or condition may be under investigation or may be approved for use in another country. In this instance, the drug may be prescribed by the primary health care provider for the condition under investigation. The use of the drug for a specific disorder or condition that is not officially approved by the FDA is called an “unlabeled use.” Examples of unlabeled uses of the antiviral drugs include treatment of CMV and HSV infections after transplant and varicella pneumonia; the treatment of CMV retinitis in immunocompromised patients; and the use of ribavirin for influenza A and B (aerosol form), acute and chronic hepatitis, herpes genitalis, and measles (oral form).

General Adverse Reactions
Antiviral drugs are given systemically or as topical drugs. When used systemically these drugs may be administered orally or intravenously (IV). Rapid IV administration can result in crystalluria (presence of crystals in the urine). The most common adverse reactions when these drugs are administered systemically...
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>abacavir sulfate</td>
<td>Ziagen</td>
<td>HIV infection</td>
<td>Nausea, vomiting, diarrhea, anorexia, liver dysfunction</td>
<td>300 mg BID</td>
</tr>
<tr>
<td>acyclovir</td>
<td>Zovirax</td>
<td>Herpes simplex, herpes zoster</td>
<td>Nausea, vomiting, diarrhea, headache, dizziness, lethargy, confusion, rashes, crystalluria, phlebitis</td>
<td>Oral, 200 mg q4h while awake for a total of 5 capsules/d; IV, 5–10 mg/kg q8h; topical, apply to lesions q3h</td>
</tr>
<tr>
<td>amantadine</td>
<td>Symmetrel, generic</td>
<td>Prevention and treatment of influenza A; Parkinson’s disease</td>
<td>Nausea, vomiting, diarrhea, dizziness, hypotension, blurred vision, psychosis, urinary retention</td>
<td>200 mg/d PO or 100 mg PO BID; up to 400 mg/d</td>
</tr>
<tr>
<td>amprenavir</td>
<td>Agenerase</td>
<td>HIV infection, in combination with other antivirals</td>
<td>Asthenia, peripheral and circumoral paresthesias, nausea, vomiting, diarrhea, anorexia, abdominal pain, rash, hyperglycemia, hypertriglyceridemia</td>
<td>1200 mg PO BID</td>
</tr>
<tr>
<td>cidofovir</td>
<td>Vistide</td>
<td>Retinitis in patients with AIDS</td>
<td>Headache, nausea, vomiting, diarrhea, anorexia, dyspnea, alopecia, rash, neutropenia, nephrotoxicity</td>
<td>5 mg/kg IV once a wk for 2 wk, then once every 2 wk for maintenance</td>
</tr>
<tr>
<td>delavirdine</td>
<td>Rescriptor</td>
<td>Same as amprenavir</td>
<td>Headache, asthenia, malaise, paresthesia, nausea, diarrhea, rash</td>
<td>400 mg PO TID</td>
</tr>
<tr>
<td>didanosine</td>
<td>Videx</td>
<td>HIV infection</td>
<td>Headache, rhinitis, cough, nausea, rash, vomiting, anorexia, hepatotoxicity, pancreatitis, peripheral neuropathy</td>
<td>For patients with creatinine clearance (CrCl) ≥ 60 mL/min and weighing ≥ 60 kg, 400 mg/d or 200 mg BID; weighing &lt; 60 kg, 250 mg/d or 125 mg BID; weighing ≥ 60 kg, 250 mg BID in buffered powder; weighing &lt; 60 kg, 167 mg BID in buffered powder</td>
</tr>
<tr>
<td>docosanol</td>
<td>Abreva</td>
<td>HSV types 1 and 2</td>
<td>Headache, skin irritation</td>
<td>Apply to lesions 5 times/d</td>
</tr>
<tr>
<td>efavirenz</td>
<td>Sustiva</td>
<td>HIV infection</td>
<td>Erythema, pruritus, dizziness, fatigue, nausea, vomiting</td>
<td>200–600 mg/d PO</td>
</tr>
<tr>
<td>famciclovir</td>
<td>Famvir</td>
<td>Acute herpes zoster, HSV type 2</td>
<td>Fatigue, fever, nausea, vomiting, diarrhea, sinusitis, constipation, headache</td>
<td>Herpes zoster: 500 mg PO q8h for 7 d; HSV-2: 125 mg PO BID for 5 d</td>
</tr>
<tr>
<td>foscarnet</td>
<td>Foscavir</td>
<td>cytomegalovirus (CMV) retinitis; acyclovir-resistant HSV types 1 and 2</td>
<td>Headache, seizures, nausea, vomiting, diarrhea, anemia, abnormal renal function tests</td>
<td>CMV retinitis: 60 mg/kg IV q8h for 2–3 wk; maintenance dose, 90–120 mg/kg IV; HSV: 40 mg/kg IV q8–12h</td>
</tr>
<tr>
<td>ganciclovir</td>
<td>Cytovene, Vitarset</td>
<td>CMV retinitis</td>
<td>Hematologic changes, fever, rash, anemia</td>
<td>5 mg/kg IV q12h for 14–21 d, then QD</td>
</tr>
<tr>
<td>imiquimod</td>
<td>Aldara</td>
<td>External genitalia and perianal warts</td>
<td>Local skin irritation, itching, excoriation/flaking</td>
<td>Apply externally 3 times/wk</td>
</tr>
<tr>
<td>indinavir</td>
<td>Crizivan</td>
<td>HIV infection</td>
<td>Headache, nausea, vomiting, diarrhea, hyperbilirubinemia, cough, dysuria, acne</td>
<td>800 mg PO q8h</td>
</tr>
<tr>
<td>lamivudine</td>
<td>3TC, Epivir</td>
<td>HIV infection (combined with zidovudine)</td>
<td>Headache, asthenia, nausea, diarrhea, agranulocytopenia, nasal congestion, cough, fever, rash, pancreatitis, hepatomegaly</td>
<td>150 mg PO BID</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>lopinavir/ritonavir</td>
<td>Kaletra</td>
<td>Same as amprenavir</td>
<td>Same as amprenavir</td>
<td>400 mg lopinavir/100 mg ritonavir PO BID; 533 mg lopinavir/133 mg ritonavir PO BID</td>
</tr>
<tr>
<td>low-pin'-ah-veer/ritonavir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nevirapine</td>
<td>Viramune</td>
<td>Same as amprenavir</td>
<td>Diarrhea, nausea, GI pain, rash, dermatitis</td>
<td>750–1250 mg PO BID</td>
</tr>
<tr>
<td>neh-vear'-ah-pee</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>oseltamivir</td>
<td>Tamiflu</td>
<td>Treatment of influenza A and B</td>
<td>Nausea, vomiting, diarrhea, abdominal pain, headache, cough</td>
<td>75–150 mg/d PO</td>
</tr>
<tr>
<td>oh-sell-tam'-ih-veer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>penciclovir</td>
<td>Denavir</td>
<td>HSV types 1 and 2</td>
<td>No significant adverse reactions reported; headache, taste perversion</td>
<td>Apply q2h while awake for 4 d</td>
</tr>
<tr>
<td>pen-sye'-kloe-ver</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ribavirin</td>
<td>Virazole</td>
<td>Severe lower respiratory tract infections (infants and young children)</td>
<td>Worsening of pulmonary status, bacterial pneumonia, hypotension</td>
<td>Administered by aerosol with special aerosol generator</td>
</tr>
<tr>
<td>rye-ba-vye'-rin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rimantadine HCL</td>
<td>Flumadine</td>
<td>Influenza A virus</td>
<td>Light-headedness, dizziness, insomnia, nausea, anorexia</td>
<td>100 mg/d PO BID</td>
</tr>
<tr>
<td>ri-man'-ta-deen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ritonavir</td>
<td>Norvir</td>
<td>HIV infection</td>
<td>Peripheral and circumoral paresthesias, nausea, vomiting, diarrhea, anorexia, dysuria</td>
<td>600 mg PO BID</td>
</tr>
<tr>
<td>ri-ton'-ah-ver</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>saquinavir, saquinavir</td>
<td>Fortovase,</td>
<td>HIV infection in combination with other drugs</td>
<td>Headache, nausea, GI pain, diarrhea, asthenia, elevated CPK</td>
<td>Fortovase: Six 200-mg capsules PO TID invirase: Three 200-mg capsules PO TID</td>
</tr>
<tr>
<td>mesylate</td>
<td>Invirase</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sa-kwen'-a-veer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>stavudine</td>
<td>Zerit</td>
<td>HIV infection</td>
<td>Headache, nausea, diarrhea, fever, agranulocytopenia</td>
<td>40 mg PO q12h</td>
</tr>
<tr>
<td>stay-vew'-den</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>valacyclovir</td>
<td>Valtrex</td>
<td>HSV type 2; herpes zoster</td>
<td>Nausea, dizziness, headache, vomiting, anorexia, diarrhea</td>
<td>HSV type 2: 500 mg PO BID for 5 d; herpes zoster: 1 g PO TID for 7 d</td>
</tr>
<tr>
<td>val-ah-sye'-kloe-ver</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>valganciclovir</td>
<td>Valcyte</td>
<td>CMV retinitis</td>
<td>Headache, insomnia, diarrhea, nausea, vomiting, neutropenia, fever</td>
<td>900 mg PO BID</td>
</tr>
<tr>
<td>val-gan-si'-klo-veer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>vidarabine</td>
<td>Ara-A, Vira-A</td>
<td>Keratitis, keratoconjunctivitis caused by HSV types 1 and 2</td>
<td>Burning, itching, irritation, tearing, sensitivity to light</td>
<td>Ophthalmic ointment: 0.5 inch into lower conjunctival sac 2–5 times daily</td>
</tr>
<tr>
<td>vy-dare'-ah-been</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>zalcitabine</td>
<td>Hivid</td>
<td>Combination therapy with zidovudine in advanced HIV</td>
<td>Nausea, vomiting, oral ulcers, peripheral neuropathy, headache, diarrhea, congestive heart failure</td>
<td>0.75 mg with 200 mg zidovudine q8h</td>
</tr>
<tr>
<td>zal-ye'-tay-been</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>zanamivir</td>
<td>Relenza</td>
<td>Influenza virus</td>
<td>Nausea, headache, diarrhea, anorexia, rhinitis, flulike symptoms, rash, bronchospasm</td>
<td>2 inhalations BID q12h</td>
</tr>
<tr>
<td>zan-am'-ah-ver</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>zidovudine (AZT)</td>
<td>Retrovir</td>
<td>HIV infection</td>
<td>Asthenia, malaise, weakness, headache, anorexia, diarrhea, nausea, abdominal pain, dizziness, insomnia, anemia, agranulocytosis</td>
<td>100 mg q4h PO; 1–2 mg/kg IV q4h</td>
</tr>
<tr>
<td>zid-o-vew'-den</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
are gastrointestinal disturbances, such as nausea, vomiting, diarrhea, and anorexia. When administered topically, the antiviral drugs can cause transient burning, stinging, and pruritus at the application site. The Summary Drug Table: Antiviral Drugs lists adverse reactions associated with other antiviral drugs.

**ADVERSE REACTIONS FOR SPECIFIC DRUGS**

**Acyclovir**

Acyclovir is available for use orally, topically, and parenterally (for IV use). When given IV, acyclovir can cause phlebitis, lethargy, confusion, tremors, skin rashes, nausea, and crystalluria. Side effects when given orally include nausea, vomiting, diarrhea, headache, dizziness, and skin rashes. Topical administration causes transient burning, stinging, and pruritus.

**Amantadine**

Adverse reactions of amantadine include gastrointestinal upset with nausea and vomiting, anorexia, asthenia (weakness, loss of strength), constipation, depression, visual disturbances, psychosis, urinary retention, and orthostatic hypotension.

**Didanosine**

Adverse reactions reported with didanosine include headache, peripheral neuropathy, rhinitis, cough, diarrhea, nausea, vomiting, anorexia, hepatotoxicity, and pancreatitis.

**Ribavirin**

Ribavirin is given by inhalation and can cause worsening of respiratory status, hypotension, and ocular irritation, including erythema (redness of skin), conjunctivitis, and blurred vision.

**Zanamivir**

Common adverse effects include headache, nausea, diarrhea, anorexia, rhinitis, and flu-like symptoms. The most serious adverse reactions are related to respiratory effects and include severe bronchospasm that may lead to death.

**Zidovudine**

Adverse reactions associated with zidovudine include headache, weakness, malaise, nausea, abdominal pain, and diarrhea. Hematologic changes include anemia and granulocytopenia (low levels of granulocytes, a type of white blood cell, in the blood).

**GENERAL CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

All antiviral drugs are contraindicated in patients with previous hypersensitivity to the individual antiviral drug. The antiviral drugs are also contraindicated in patients with congestive heart failure, seizures, renal disease, and during lactation. The antiviral drugs are given with caution in patients with renal impairment and require dosage adjustments. Antivirals are used with caution in children, during pregnancy (except ribavirin, a Pregnancy Category X drug), and during lactation.
Other contraindications and precautions are listed below, according to the specific drug. Numerous interactions are possible with the antiviral drugs. Only the most significant interactions are listed for selected drugs. The nurse should consult an appropriate source for a more extensive listing of interactions.

**Acyclovir**

This drug is used cautiously in patients with pre-existing neurologic, renal, hepatic, respiratory, or fluid and electrolyte abnormalities. The nurse gives the drug with caution to patients with a history of seizures. Acyclovir is a Pregnancy Category C drug and is used cautiously during pregnancy and lactation. Incidences of extreme drowsiness have occurred when acyclovir is given with zidovudine. There is an increased risk of nephrotoxicity when acyclovir is administered with other nephrotoxic drugs. When administered with amphotericin B, the risk of nephrotoxicity is increased. Administration with probenecid causes a decrease in the renal excretion of acyclovir, prolonging the effects of acyclovir and increasing the risk of drug toxicity.

**Amantadine**

Amantadine is used cautiously in patients with seizure disorders, psychiatric problems, renal impairment, and cardiac disease. Amantadine is a Pregnancy Category B drug and is used cautiously during pregnancy and lactation. Concurrent use of antihistamines, phenothiazines, tricyclic antidepressants, disopyramide, and quinidine may increase the *anticholinergic effects* (dry mouth, blurred vision, constipation) of amantadine.

**Didanosine**

This drug is used cautiously in patients with peripheral vascular disease, neuropathy, chronic pancreatitis, or impaired liver function. Didanosine is a Pregnancy Category B drug and is used cautiously during pregnancy and lactation. There may be a decrease in the effectiveness of dapsone in preventing *Pneumocystis carinii* pneumonia when didanosine is administered with dapsone. Use of didanosine with zalcitabine may cause additive neuropathy. Absorption of didanosine is decreased when it is administered with food.

**Ribavirin**

Ribavirin may be teratogenic and embryotoxic (Pregnancy Category X) and is contraindicated during pregnancy, in patients with chronic obstructive pulmonary disease (COPD), and during lactation. Ribavirin is used cautiously at all times during administration of the drug. Ribavirin may antagonize the antiviral action of zidovudine and potentiate the hematologic toxic effects of zidovudine. When ribavirin is used concurrently with digitalis, the risk of digitalis toxicity increases.

**Zanamivir**

Zanamivir is used cautiously with pregnancy (Category C), lactation, asthma, COPD, or other underlying respiratory diseases. No significant drug interactions have been reported with the use of zanamivir.

**Zidovudine**

This drug is used cautiously in patients with bone marrow depression or severe hepatic or renal impairment. Zidovudine is a Pregnancy Category C drug and is used cautiously during pregnancy and lactation. There is an increased risk of bone marrow depression when zidovudine is administered with antineoplastic drugs, other drugs causing bone marrow depression, and in patients having or recently taking radiation therapy. An additive neurotoxicity may occur when zidovudine is administered with acyclovir. Clarithromycin decreases blood levels of zidovudine. The blood levels of zidovudine are increased when it is given with lamivudine.

---

**NURSING PROCESS**

### The Patient Receiving an Antiviral Drug

#### ASSESSMENT

**Preadministration Assessment**

Preadministration assessment of the patient receiving an antiviral drug depends on the patient’s symptoms or diagnosis. These patients may have a serious infection that causes a decrease in their natural defenses against disease. Before administering the antiviral drug, the nurse determines the patient’s general state of health and resistance to infection. The nurse then records the patient’s symptoms and complaints. In addition, the nurse takes and records the patient’s vital signs. Additional assessments may be necessary in certain types of viral infections or in patients who are acutely ill. For example, in patients with HSV 1 or 2 the nurse inspects the areas of the body affected with the lesions (e.g., the mouth, face, eyes, or genitalia) before treatment for comparison during treatment.

**Ongoing Assessment**

The ongoing assessment depends on the reason for giving the antiviral drug. It is important to make a daily assessment for improvement of the signs and symptoms
ACYCLOVIR. Treatment with acyclovir is begun as soon as symptoms of herpes simplex appear. The drug may be given topically, orally, or intravenously. When the drug is given orally, the nurse may give the drug without regard to food. However, if GI upset occurs, acyclovir is administered with food. Patients with a history of congestive heart failure may not be able to tolerate an increase in fluids, so it is important to monitor them closely to prevent fluid overload. Neurologic symptoms such as seizures may occur with the administration of acyclovir. When the drug is administered topically, the nurse should use a finger cot or glove to prevent spread of infection.

AMANTADINE. The nurse administers this drug for the prevention or treatment of respiratory tract illness caused by influenza A virus. Some patients are prescribed this drug to manage extrapyramidal effects caused by drugs used to treat Parkinsonism (See Chaps. 29 and 32). The nurse should protect the capsules from moisture to prevent deterioration. When the drug is administered for symptoms of influenza, it is important to start therapy within 24 to 48 hours after symptoms begin.

DIDANOSINE. For patients with HIV infection who cannot tolerate zidovudine or who have exhibited decreased therapeutic effect with zidovudine, the nurse should administer this drug to the patient with an empty stomach (at least 1 hour before or 2 hours after meals). The tablets are not swallowed whole; the patient should chew them or crush and mix them thoroughly with at least 1 oz of water. The nurse mixes buffered powder with 4 oz of water (not juice), stirs until dissolved, and gives it to the patient to drink immediately. The nurse avoids generating dust when preparing the medication. When cleaning up powdered products, a wet mop or damp sponge is used. The surface is cleaned with soap and water.

RIBAVIRIN. The nurse gives ribavirin by inhalation using a small particle aerosol generator (SPAG-2 aerosol generator). It is important to discard and replace the solution every 24 hours. Treatment with ribavirin lasts for at least 3 days, but not more than 7, for 12 to 18 h/d. Women of childbearing age should not take this drug because evidence links it to birth defects.

ZANAMIVIR. This drug is available as a powder blister for inhalation. The usual dose is 2 inhalations (one 5-mg blister per inhalation) administered with a Diskhaler device. The drug should be started within 2 days’ onset of flu symptoms. The drug is taken every 12 hours.

ZIDOVUDINE. The nurse assesses the patient for an increase in severity of symptoms of HIV and for symptoms identified in the initial assessment. The nurse monitors for and reports any adverse reactions from the antiviral drug. It also is important to inspect the IV site several times a day for redness, inflammation, or pain. The nurse should report any signs of phlebitis (inflammation of the vein).

NURSING DIAGNOSES
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other, more general nursing diagnoses applicable to the antiviral drugs are discussed in Chapter 4.

PLANNING
The expected outcomes for the patient depend on the reason for administration of the antiviral drug but may include an optimal response to therapy, management of adverse reactions, and an understanding of and compliance with the prescribed treatment regimen.

IMPLEMENTATION
Promoting an Optimal Response to Therapy
Because these drugs may be used in the treatment of certain types of severe and sometimes life-threatening viral infections, the patient may be concerned about the diagnosis and prognosis. The nurse should allow the patient time to talk and ask questions about methods of treatment, especially when the drug is given IV. It is important to explain the treatment methods to the patient and family members.

The antiviral drugs are not given intramuscularly or subcutaneously. It is important to prepare the antiviral drugs according to the manufacturer’s directions. The administration rate is ordered by the primary health care provider. The nurse takes care to prevent trauma because even slight trauma can result in bruising if the platelet count is low. If injections are given, pressure is applied at the injection site to prevent bleeding. Occasionally, headache or a slight fever may occur in patients taking antiviral drugs. An analgesic may be prescribed to manage these effects.
of opportunistic infections. Capsules and syrup should be protected from light.

**Monitoring and Managing Adverse Reactions**

Serious adverse reactions can occur in patients taking antiviral drugs. The nurse must notify the primary health care provider of any adverse reactions to these drugs.

**ACYCLOVIR.** When given IV, acyclovir can cause crystalluria (presence of crystals in the urine) and mental confusion. The nurse helps the patient maintain adequate hydration to prevent crystalluria by encouraging the patient to drink 2000 to 3000 mL of fluid each day (if the disease condition permits). In addition, the nurse should give careful attention to assessing the mental status of the patient.

**AMANTADINE.** The nurse should monitor the patient for the occurrence of drowsiness, dizziness, light-headedness, or mood changes (irritability or mood change).

**DIDANOSINE.** Although rare, pancreatitis and peripheral neuropathy are possible adverse reactions seen with didanosine. The nurse must be alert for symptoms of pancreatitis (nausea, vomiting, abdominal pain, jaundice, elevated enzymes) and for signs of peripheral neuropathy (numbness, tingling, or pain in the feet or hands). It is important to immediately report these signs to the primary health care provider.

**RIBAVIRIN.** This drug can cause worsening of the respiratory status. Sudden deterioration of respiratory status can occur in infants receiving ribavirin. It is important to monitor respiratory function closely throughout therapy. The nurse should immediately report any worsening of respiratory function to the primary health care provider.

**ZANAMIVIR.** There is a risk for bronchospasm in patients with asthma or COPD. A fast-acting bronchodilator should be on hand in case bronchospasm occurs. Zanamivir use should be discontinued and the primary health care provider notified promptly if respiratory symptoms worsen.

**ZIDOVUDINE.** With zidovudine, bone marrow depression may occur, making the patient susceptible to infection and easy bruising. The patient is protected against individuals with upper respiratory infection. All caregivers are reminded to use good handwashing technique. The nurse takes care to prevent trauma because even slight trauma can result in bruising if the platelet count is low. If injections are given, pressure is applied at the injection site to prevent bleeding.

**NUTRITIONAL IMBALANCE.** The antiviral drugs may cause anorexia, nausea, or vomiting. These effects range from mild to severe. The patient may be able to tolerate small, frequent meals with soft, nonirritating foods if nausea is mild. Frequent sips of carbonated beverages or hot tea may be helpful for others. It is important to keep the atmosphere clean and free of odors. The nurse provides good oral care before and after meals. If nausea is severe or the patient is vomiting, the nurse notifies the primary health care provider.

**IMPAIRED SKIN INTEGRITY.** The nurse monitors the skin lesions carefully for worsening or improvement. Should the lesions not improve, the nurse informs the primary health care provider. Accurate observation and documentation is essential. If an antiviral drug is administered topically, the nurse uses gloves when applying to avoid spreading the infection. These drugs may also cause a rash as an adverse reaction. The nurse notes and reports any rash to the primary health care provider. When administering the drug by the IV route, the nurse must closely observe the injection site for signs of phlebitis, and depending on the patient’s symptoms, the nurse monitors vital signs every 4 hours or as ordered by the primary health care provider.

**RISK FOR INJURY.** Some patients with a viral infection are acutely ill. Others may experience fatigue, lethargy, dizziness, or weakness as an adverse reaction to the antiviral agent. The nurse monitors these patients carefully. Call lights are placed in a convenient place for the patient and are answered promptly by the nurse. If fatigue, dizziness, or weakness is present, the patient may require assistance with ambulation or activities of daily living. The nurse plans activities so as to provide adequate rest periods.

**RISK FOR INFECTION IN IMMUNOSUPPRESSED PATIENTS.** When patients are immunosuppressed, they are at increased risk for bacterial or other infection. The patient is protected against individuals with upper respiratory infection. All caregivers are reminded to use good handwashing technique.

---

**Nursing Alert**

Patients receiving antiviral drugs for HIV infections may continue to develop opportunistic infections and other complications of HIV. The nurse monitors all patients closely for signs of infection such as fever (even low-grade fever), malaise, sore throat, or lethargy.

---

**Educating the Patient and Family**

When an antiviral drug is given orally, the nurse explains the dosage regimen to the patient and family.
The nurse instructs the patient to take the drug exactly as directed and for the full course of therapy. If a dose is missed, the patient should take it as soon as remembered but should not double the dose at the next dosage time. Any adverse reactions should be reported to the primary health care provider or the nurse. The patient must understand that these drugs do not cure viral infections but should decrease symptoms and increase feelings of well-being.

The nurse instructs patients to report any symptoms of infection such as an elevated temperature (even a slight elevation), sore throat, difficulty breathing, weakness, or lethargy. The patient must be aware of possible signs of pancreatitis (nausea, vomiting, abdominal pain, jaundice [yellow discoloration of the skin or eyes]) and peripheral neuritis (tingling, burning, numbness, or pain in the hands or feet). Any indication of pancreatitis or peripheral neuritis must be reported at once.

The nurse includes the following information in the teaching plan for specific antiviral drugs:

- **Acyclovir:** This drug is not a cure for herpes simplex, but it will shorten the course of the disease and promote healing of the lesions. The drug will not prevent the spread of the disease to others. Topical application should not exceed the frequency prescribed. Apply this drug with a finger cot or gloves and cover all lesions. Do not have sexual contact while lesions are present. Notify the primary health care provider if burning, stinging, itching, or rash worsens or becomes pronounced.

- **Amantadine:** Do not drive a car or do work for which mental alertness is necessary until the effect of the drug is apparent because vision and coordination can be affected. Rise slowly from a prone to a sitting position to decrease the possibility of lightheadedness caused by orthostatic hypotension. Report changes such as nervousness, tremors, slurred speech, or depression. Some patients are on an alternate dosage schedule. If this is the situation, it is important to mark the calendar to designate the days the drug is to be taken.

- **Didanosine:** Take this drug on an empty stomach because food decreases absorption. Follow the instructions for administration carefully. Crush the drug and mix it with water. Discontinue use of the drug and notify the primary health care provider if any numbness or tingling of the extremities is experienced. Report any signs of abdominal pain, nausea, or vomiting. Didanosine is not a cure for AIDS and does not prevent the spread of the disease, but it may decrease the symptoms of AIDS.

- **Ribavirin:** The patient is told that this drug is given with a small-particle aerosol generator. Any worsening of respiratory function, dizziness, confusion, or shortness of breath should be reported. If a child is taking this drug it is important for any female caregivers to know that the drug is a Pregnancy Category X drug and women of childbearing age should take care not to inhale the drug. It may be necessary for the mother or other females of childbearing age who have direct contact with the child to observe respiratory precautions while the child is taking the drug.

- **Zanamivir:** This drug is taken every 12 hours for 5 days using a Diskhaler delivery system. If a bronchodilator is also prescribed, the bronchodilator is used before the zanamivir if both are prescribed at the same time. The drug may cause dizziness. The patient should use caution if driving an automobile or operating dangerous machinery. Treatment with this drug does not decrease the risk of transmission of the “flu” to others.

- **Zidovudine:** This drug may cause dizziness. Avoid activities requiring alertness until the drug response is known. This drug does not cure AIDS and does not prevent transmission to others. Notify the primary health care provider if fever, sore throat, or signs of infection occur. The primary health care provider may prescribe frequent blood tests to monitor for a decrease in the immune response indicating the need to decrease the dosage or to discontinue use of the drug for a period of time.

**EVALUATION**

- The therapeutic effect is achieved and symptoms of disease process subside or diminish.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through nursing interventions.
- The patient and family demonstrate an understanding of the drug regimen.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.

**Critical Thinking Exercises**

1. A young mother is concerned because her 2-month-old daughter has received a diagnosis of RSV. The infant is receiving inhalation treatments with ribavirin. The mother questions this treatment. Describe how the nurse could explain treatment with ribavirin to the mother. Discuss what possible effects the drug could have on the infant and on the mother.

2. Ms. Jenkins, age 77 years, has herpes zoster. The primary health care provider prescribes acyclovir 200 mg every 4 hours while awake. Discuss what information you would give Ms. Jenkins concerning herpes zoster, the drug regimen, and the possible adverse reactions.
3. Jim, age 25 years, has recently received a diagnosis of HIV infection and is placed on a treatment regimen of zidovudine and lamivudine. Determine what information you would give him concerning the drugs he will be taking. What adverse reactions would you discuss with Jim?

**Review Questions**

1. Which of the following adverse reactions would the nurse expect in a patient receiving acyclovir by the oral route?
   - A. nausea and vomiting
   - B. constipation and urinary frequency
   - C. conjunctivitis and blurred vision
   - D. nephrotoxicity

2. Which of the following would the nurse report immediately in a 3-month-old patient receiving ribavirin?
   - A. any worsening of the respiratory status
   - B. refusal to take foods or fluids
   - C. drowsiness
   - D. constipation

3. The nurse is administering didanosine properly when _______.
   - A. tablets are crushed and mixed thoroughly with 1 oz of water
   - B. the drug is prepared for subcutaneous injection
   - C. the drug is given with meals
   - D. the drug is given mixed with orange juice or apple juice

4. Intravenous administration of acyclovir can result in _______.
   - A. shock
   - B. crystalluria
   - C. cardiac arrest
   - D. hypertensive crisis

**Medication Dosage Problems**

1. The patient is prescribed amantadine 200 mg. The drug is available in 100-mg tablets. The nurse administers _______.

2. A patient is prescribed 2 inhalations of zanamivir. The drug is available as one 5-mg blister per inhalation and is to be given with a Diskhaler device. How many milligrams will the nurse administer with 2 inhalations?

3. The nurse is to administer 100 mg of zidovudine PO. The drug is available as syrup 50 mg/5 mL. The nurse administers _______.

Antifungal Drugs

Key Terms

| fungicidal | onychomycosis |
| fungistatic | tinea corporis |
| fungus | tinea cruris |
| mycotic infections | tinea pedi |

Chapter Objectives

On completion of this chapter, the student will:

- Distinguish between superficial and systemic fungal infections
- Discuss the uses, general drug action, adverse reactions, contraindications, precautions, and interactions of antifungal drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient receiving an antifungal drug.
- List some nursing diagnoses particular to a patient taking an antifungal drug.
- List possible goals for a patient taking an antifungal drug.
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating the patient and the family about the antifungal drugs.

Fungal infections range from superficial skin infections to life-threatening systemic infections. Systemic fungal infections are serious infections that occur when fungi gain entrance into the interior of the body.

A fungus is a colorless plant that lacks chlorophyll. Fungi that cause disease in humans may be yeastlike or moldlike; the resulting infections are called mycotic infections or fungal infections.

Mycotic (fungal) infections may be one of two types:

1. Superficial mycotic infections
2. Deep (systemic) mycotic infections

The superficial mycotic infections occur on the surface of, or just below, the skin or nails. Superficial infections include tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), onychomycosis (nail fungus), and yeast infections, such as those caused by Candida albicans. Yeast infections or those caused by C. albicans affect women in the vulvovaginal area and can be difficult to control. Women who are at increased risk for vulvovaginal yeast infections are those who have diabetes, are pregnant, or are taking oral contraceptives, antibiotics, or corticosteroids.

Deep mycotic infections develop inside the body, such as in the lungs. Treatment for deep mycotic infections is often difficult and prolonged. The Summary Drug Table: Antifungal Drugs identifies drugs that are used to combat fungal infections.

**ACTIONS**

Antifungal drugs may be fungicidal (able to destroy fungi) or fungistatic (able to slow or retard the multiplication of fungi). Amphotericin B (Fungizone IV), miconazole (Monistat), nystatin (Mycostatin), and ketoconazole (Nizoral) are thought to have an effect on the cell membrane of the fungus, resulting in a fungicidal or fungistatic effect. The fungicidal or fungistatic effect of these drugs appears to be related to their concentration in body tissues. Fluconazole (Diflucan) has fungistatic activity that appears to result from the depletion of sterols (a group of substances related to fats) in the fungus cells.

Griseofulvin (Grisactin) exerts its effect by being deposited in keratin precursor cells, which are then gradually lost (due to the constant shedding of top skin cells), and replaced by new, noninfected cells. The mode of action of flucytosine (Ancobon) is not clearly understood. Clotrimazole (Lotrimin, Mycelex) binds with phospholipids in the fungal cell membrane,
increasing permeability of the cell and resulting in loss of intracellular components. (See Tables 15-1 and 15-2.)

USES

Antifungal drugs are used to treat superficial and deep fungal infections. The antifungal drugs specifically discussed in this chapter are: amphotericin B (Fungizone), fluconazole (Diflucan), flucytosine (Ancobon), griseofulvin (Grisactin), ketoconazole (Nizoral), and miconazole (Monistat). The specific uses of antifungal drugs are given in the Summary Drug Table: Antifungal Drugs. Miconazole is an antifungal drug used to treat vulvovaginal “yeast” infections and is representative of all of the vaginal antifungal agents. (See Table 15-2.) Fungal infections of the skin or mucous membranes may be treated with topical or vaginal preparations. A listing of the topical antifungal drugs appears in
ADVERSE REACTIONS

When topical antifungal drugs, such as clotrimazole (see Table 15-1), are applied to the skin or mucous membranes, few adverse reactions are seen. On occasion, a local reaction, such as irritation or burning, may occur with topical use. The vulvovaginal antifungal drugs may cause local irritation, redness, stinging, or abdominal pain. Few adverse reactions are seen with the use of the vulvovaginal antifungal drugs.

Amphotericin B

Amphotericin B is the most effective drug available for the treatment of most systemic fungal infections. Administration often results in serious reactions,
including fever, shaking, chills, headache, malaise, anorexia, joint and muscle pain, abnormal renal function, nausea, vomiting, and anemia. This drug is given parenterally, usually for a period of several months. Its use is reserved for serious and potentially life-threatening fungal infections. Some of these adverse reactions may be lessened by use of aspirin, antihistamines, or antiemetics.

**Fluconazole**
Administration may result in nausea, vomiting, headache, diarrhea, abdominal pain, and skin rash. Abnormal liver function tests may be seen and may require follow-up tests to determine if liver function has been affected.

**Flucytosine**
Administration may result in nausea, vomiting, diarrhea, rash, anemia, leukopenia, and thrombocytopenia. Signs of renal impairment include elevated blood urea nitrogen (BUN) and serum creatinine levels. Periodic renal function tests are usually performed during therapy.

**Griseofulvin**
Administration may result in a hypersensitivity-type reaction that includes rash and urticaria. Nausea, vomiting, oral thrush, diarrhea, and headache also may be seen.

**Itraconazole**
The most common adverse reactions are nausea, vomiting, and diarrhea. On occasion, severe hypokalemia (low potassium level) has occurred in patients receiving 600 mg or more of the drug on a daily basis. Hepatotoxicity is a possibility with itraconazole administration.

**Ketoconazole**
This drug is usually well tolerated, but nausea, vomiting, headache, dizziness, abdominal pain, and pruritus may be seen. Most adverse reactions are mild and transient. On rare occasions, hepatic toxicity may be seen, and use of the drug must be discontinued immediately. Periodic hepatic function tests are recommended to monitor for hepatic toxicity.

**Miconazole**
Administration of miconazole for a vulvovaginal fungal infection may cause irritation, sensitization, or vulvovaginal burning. Skin irritation may result in redness, itching, burning, or skin fissures. Other adverse reactions with miconazole include cramping, nausea, and headache. Adverse reactions associated with topical use are usually not severe.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Amphotericin B**
Amphotericin B is contraindicated in patients with a history of allergy to the drug and during lactation. It is used cautiously in patients with renal dysfunction, electrolyte imbalances, and in combination with antineoplastic drugs (because it can cause severe bone marrow suppression). This drug is a Pregnancy Category B drug and is used during pregnancy only when the situation is life threatening. When given with the corticosteroids, severe hypokalemia may occur. There may be an increased risk of digitalis toxicity if digoxin is administered concurrently with amphotericin B. Administration with nephrotoxic drugs (eg, aminoglycosides or cyclosporine) may increase the risk of nephrotoxicity in patients also taking amphotericin B. Amphotericin B decreases the effects of miconazole. Amphotericin B is given only under close supervision in the hospital setting.

**Fluconazole**
Fluconazole is contraindicated in patients with known hypersensitivity to the drug. The drug is used cautiously in patients with renal impairment and during pregnancy (Category C) and lactation. The drug is given during pregnancy only if the benefit of the drug clearly outweighs any possible risk to the infant. When fluconazole is administered with oral hypoglycemics, there is an increased effect of the oral hypoglycemics.
Fluconazole may decrease the metabolism of phenytoin and warfarin.

Flucytosine
Flucytosine is contraindicated in patients with known hypersensitivity to the drug. Flucytosine is used cautiously in patients with bone marrow depression and with extreme caution in those with renal impairment. The drug is also used cautiously during pregnancy (Category C) and lactation. When flucytosine and amphotericin B are administered concurrently, the risk of flucytosine toxicity is increased.

Griseofulvin
Griseofulvin is contraindicated in patients with known hypersensitivity to the drug and in those with severe liver disease. This drug is used cautiously during pregnancy (Category C) and lactation. It is important to use caution when administering concurrently with penicillin because there is a possibility of cross-sensitivity. When griseofulvin is administered with warfarin, the anticoagulant effect may be decreased. When administered with the barbiturates the effect of griseofulvin may be decreased. A decrease in the effects of oral contraceptives may occur with griseofulvin therapy, causing breakthrough bleeding, pregnancy, or amenorrhea. Blood salicylate concentrations may be decreased when the salicylates are administered with griseofulvin.

Itraconazole
Itraconazole is contraindicated in patients with a known hypersensitivity to the drug. The drug is used cautiously in patients with hepatitis, those with human immunodeficiency virus, impaired liver function, and in pregnant women (Pregnancy Category C). In patients with hypochlorhydria, the absorption of itraconazole is decreased. Multiple drug interactions occur with itraconazole. Itraconazole elevates blood concentrations of digoxin and cyclosporine. Phenytoin decreases blood levels of itraconazole and alters the metabolism of phenytoin. Histamine antagonists, isoniazid, and rifampin decrease plasma levels of itraconazole. There is an increased anticoagulant effect when warfarin is administered concurrently with itraconazole.

Ketoconazole
Ketoconazole is contraindicated in patients with known hypersensitivity to the drug. Ketoconazole is used cautiously in patients with hepatic impairment, those who are pregnant (Category C), and during lactation. The absorption of ketoconazole is impaired when the drug is taken with histamine antagonists and antacids. Ketoconazole enhances the anticoagulant effect of warfarin and causes an additive hepatotoxicity when given with other hepatotoxic drugs and alcohol. Administration of ketoconazole with rifampin or isoniazid may decrease the blood levels of ketoconazole.

Miconazole
Miconazole is contraindicated in patients with known hypersensitivity to the drug. The drug is given cautiously in cases of chronic or recurrent candidiasis. With recurrent or chronic candidiasis the patient may have underlying diabetes. Recurrent or chronic candidiasis requires an evaluation for diabetes. The drug is used cautiously during pregnancy (Category C). If used during pregnancy, a vaginal applicator may be contraindicated. Manual insertion of the vaginal tablets may be preferred. Because small amounts of these drugs may be absorbed from the vagina, the drug is used during the first trimester only when essential.

Nursing Process

The Patient Receiving an Antifungal Drug

Assessment

Preadministration Assessment

Information gathered before the administration of the first dose establishes a database for comparison during therapy. In performing the preadministration assessment before giving the first dose of an antifungal drug, the nurse assesses the patient for signs of the infection. The nurse inspects for superficial fungal infections of the skin or skin structures (eg, hair, nails) and describes them on the patient's record. The nurse carefully documents any skin lesions, such as rough itchy patches, cracks between the toes, and sore and reddened areas, to obtain an accurate database. It also is important to describe any vaginal discharge or white plaques or sore areas of the mucous membranes. The nurse takes and records vital signs. The nurse weighs the patient scheduled to receive amphotericin or flucytosine because the dosage of the drug is determined according to the patient’s weight.

Ongoing Assessment

The ongoing assessment involves careful observation of the patient every 2 to 4 hours for adverse drug reactions when the antifungal drug is given by the oral or parenteral route. When these drugs are applied topically to the skin, the nurse inspects the area at the time of each application for localized skin reactions. When these drugs are administered vaginally, the nurse questions the patient regarding any discomfort or other sensations...
experienced after insertion of the antifungal preparation. The nurse notes improvement or deterioration of lesions of the skin, mucous membranes, or vaginal secretions in the chart. It is important for the nurse to evaluate and chart the patient’s response to therapy daily.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. More general nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes for the patient depend on the reason for administration of the antifungal drug but may include a therapeutic response to the antifungal drug, management of adverse reactions, and an understanding of and compliance with the prescribed treatment regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

Superficial and deep fungal infections respond slowly to antifungal therapy. Many patients experience anxiety and depression over the fact that therapy must continue for a prolonged time. Depending on the method of treatment, patients may be faced with many problems during therapy and therefore need time to talk about problems as they arise. Examples of problems are the cost of treatment, hospitalization (when required), the failure of treatment to adequately control the infection, and loss of income. The nurse must help the patient and the family to understand that therapy must be continued until the infection is under control. In some cases, therapy may take weeks or months.

DISTURBED BODY IMAGE. The lesions caused by the fungal infections may cause the patient to feel negatively about the body or a body part. It is important for the nurse to develop a therapeutic nurse-patient relationship that conveys an attitude of caring and develops a sense of trust. The nurse listens to the patient’s concerns and assists the patient in accepting the situation as temporary. The nurse encourages the patient to verbalize any feelings or anxiety about the effect of the disorder on body image. The nurse explains the disorder and the treatment regimen in terms the patient can understand and discusses the need at times for long-term treatment to eradicate the infection.

RISK FOR INEFFECTIVE TISSUE PERFUSION: RENAL. When the patient is taking a drug that is potentially toxic to the kidneys, the nurse must carefully monitor fluid intake and output. In some instances, the nurse may need to perform hourly measurements of the urinary output. Periodic laboratory tests are usually ordered to monitor the patient’s response to therapy and to detect toxic drug reactions. Serum creatinine levels and BUN levels are checked frequently during the course of therapy to monitor kidney function. If the BUN exceeds 40 mg/dL or if the serum creatinine level exceeds 3 mg/dL, the primary health care provider may discontinue the drug therapy or reduce the dosage until renal function improves.

IMPAIRED SKIN INTEGRITY AND RISK FOR INFECTION. Many fungal infections are associated with lesions that are at risk for infection. The nurse monitors the patient’s temperature, pulse, respirations, and blood pressure every 4 hours or more often if needed. The nurse inspects for superficial fungal infections of the skin or skin structures (eg, hair, nails) and describes them on the patient’s record. The nurse carefully documents any skin lesions, such as rough itchy patches, cracks between the toes, and sore and reddened areas. The nurse checks the skin for localized signs of infection (ie, increased redness or swelling). The nurse monitors the skin lesions daily, describing lesions and any changes observed. It is important that the nurse note any improvement or healing of the lesions. Gloves are used when caring for open lesions to minimize autoinoculation or transmission of the disease.

Nursing Diagnoses Checklist

<table>
<thead>
<tr>
<th>Drug-specific nursing diagnoses are listed below. Depending on the drug, dose, and reason for administration, one or more of the following nursing diagnoses may apply to a person receiving an antifungal drug:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Disturbed Body Image</strong> related to changes in skin and mucous membranes</td>
</tr>
<tr>
<td><strong>Risk for Ineffective Tissue Perfusion: Renal</strong> related to adverse reactions of the antifungal drug</td>
</tr>
<tr>
<td><strong>Risk for Infection</strong> related to the presence of skin lesions</td>
</tr>
<tr>
<td><strong>Impaired Skin Integrity</strong> related to the presence of skin lesions</td>
</tr>
</tbody>
</table>

Administering Specific Antifungal Drugs

AMPHOTERICIN B. The nurse administers this drug daily or every other day over several months. The patient is often acutely ill with a life-threatening deep fungal infection. The nurse should reconstitute the drug according to the manufacturer’s instructions. Sterile water is used for reconstitution because any other diluent may cause precipitation. Immediately after the drug is reconstituted, the nurse administers the IV infusion over a period of 6 hours or more.

The manufacturer recommends that the IV solution be protected from exposure to light. It is a good idea to wrap a brown paper bag or aluminum foil around the
infusion bottle after reconstitution of the powder and during administration of the solution. Although solutions of amphotericin B are light sensitive, research indicates that if used within 8 hours, there is negligible loss of drug activity. Because the solution decomposes slowly, it is probably not necessary to protect the container from light if the drug is used within 8 hours of reconstitution.

The nurse should consult the primary health care provider or hospital pharmacist regarding whether or not to use a protective covering for the infusion container. The nurse checks the IV infusion rate and the infusion site frequently during administration of the drug. This is especially important if the patient is restless or confused.

On occasion amphotericin B may be administered as an oral solution for oral candidiasis. The patient is instructed to swish and hold the solution in the mouth for several minutes (or as long as possible) before swallowing. The oral solution may be used for as long as 2 weeks.

**FLUCONAZOLE.** The drug may be administered orally or intravenously. Initially the patient receives 200 to 400 mg, followed by 100 to 200 mg per day for at least 14 days. When given as a continuous infusion, the drug is infused at a maximum rate of 200 mg per hour. When administering IV do not remove the overwrap until ready to use. The nurse tears the overwrap down the side at the slit and removes the solution container. When administering IV, the nurse must follow the manufacturer's directions regarding removal of the wrapping around the container. It is important not to administer solution that is cloudy or contains precipitate. The nurse then checks the bag for minute leaks by squeezing firmly. The solution is discarded if any leaks are found.

**FLUCYTOSINE.** The nurse gives flucytosine orally. The prescribed dose may range from 2 to 6 capsules/dose. To decrease or avoid nausea and vomiting, the capsules may be taken a few at a time during a 15-minute period.

**GRISEOFULVIN.** This drug is given orally as a single dose or in two to four divided doses. Prolonged therapy is usually needed to eradicate the fungus.

**KETOCONAZOLE.** This drug is given with food to minimize gastrointestinal irritation. Tablets may be crushed. Ketoconazole is absorbed best in an acid environment. Do not administer antacids, anticholinergics, or histamine blockers until at least 2 hours after ketoconazole is given.

**ITRACONAZOLE.** Give the drug orally with food to increase absorption. When administering IV, use only components provided by the manufacturer for reconstitution. Do not dilute with any other diluent. The drug is infused during a period of 60 minutes. Doses greater than 200 mg are given in 2 divided dosages.

**MICONAZOLE.** This drug is self-administered on an outpatient basis. See Patient and Family Education for information to give to the patient concerning this drug.

**Monitoring and Managing Adverse Reactions**

**AMPHOTERICIN B.** Fever (sometimes with shaking chills) may occur within 15 to 20 minutes of initiation of the treatment regimen. It is important to monitor the patient’s temperature, pulse, respirations, and blood pressure carefully during the first 30 minutes to 1 hour of treatment. The nurse should monitor vital signs every 2 to 4 hours during therapy, depending on the patient’s condition.

The nurse must carefully monitor fluid intake and output because this drug may be nephrotoxic (harmful to the kidneys). In some instances, the nurse may need to perform hourly measurements of the urinary output. Periodic laboratory tests are usually ordered to monitor the patient’s response to therapy and detect toxic drug reactions.

**Nursing Alert**

Renal damage is the most serious adverse reaction with the use of amphotericin B. Renal impairment usually improves with modification of dosage regimen (reduction of dosage or increasing time between dosages). Serum creatinine levels and BUN levels are checked frequently during the course of therapy to monitor kidney function. If the BUN exceeds 40 mg/dL or if the serum creatinine level exceeds 3 mg/dL, the primary health care provider may discontinue the drug or reduce the dosage until renal function improves.

**Gerontological Alert**

Before administering this drug to an elderly patient or one that has renal impairment, the primary health care provider may order a creatinine clearance. The initial dose is 50 to 100 mg PO or IV, depending on the results of the creatinine clearance. The nurse reports the laboratory results to the primary health care provider because dosage adjustments may be made on the results of the creatinine clearance.

**FLUCYTOSINE.** To reduce the incidence of gastrointestinal distress, the nurse may give the capsules one or two at a time during a 15-minute period. If gastrointestinal distress still occurs, the nurse should notify the primary health care provider. Before therapy is begun, electrolytes, hematological status, and renal status are
Renal impairment can cause accumulation of the drug.

**ITRACONAZOLE.** Although rare, the patient may develop hepatitis during itraconazole administration. The nurse closely monitors the patient for signs of hepatitis, including anorexia, abdominal pain, unusual tiredness, jaundice, and dark urine. The primary health care provider may order periodic liver function tests.

**Educating the Patient and Family**

If the patient is being treated with topical antifungal drugs, the nurse includes the following points in the teaching plan (see Home Care Checklist: Using Topical Antifungal Drugs):

- Clean the involved area and apply the ointment or cream to the skin as directed by the primary health care provider.
- Do not increase or decrease the amount used or the number of times the ointment or cream should be applied unless directed to do so by the primary health care provider.
- During treatment for a ringworm infection, keep towels and facecloths used for bathing separate from those of other family members to avoid the spread of the infection. It is important to keep the affected area clean and dry.

Drug-specific teaching points include:

- **Flucytosine:** Nausea and vomiting may occur with this drug. Reduce or eliminate these effects by taking a few capsules at a time during a 15-minute period. If nausea, vomiting, or diarrhea persists, notify the primary health care provider as soon as possible.
- **Griseofulvin:** Beneficial effects may not be noticed for some time; therefore, take the drug for the full course of therapy. Avoid exposure to sunlight and sunlamps because an exaggerated skin reaction (which is similar to a severe sunburn) may occur even after a brief exposure to ultraviolet light. Notify the primary health care provider if fever, soar throat, or skin rash occurs.
- **Ketoconazole:** Complete the full course of therapy as prescribed by the primary health care provider. Do not take this drug with an antacid. In addition, avoid the use of nonprescription drugs unless use of a specific drug is approved by the primary health care provider. This drug may produce headache.
dizziness, and drowsiness. If drowsiness or dizziness should occur, observe caution while driving or performing other hazardous tasks. Notify the primary health care provider if abdominal pain, fever, or diarrhea becomes pronounced.

- **Itraconazole:** The drug is taken with food. Therapy will continue for at least 3 months until infection is controlled. Report unusual fatigue, yellow skin, darkened urine, anorexia, nausea, and vomiting.
- **Miconazole:** If the drug (cream or tablet) is administered vaginally, insert the drug high in the vagina using the applicator provided with the product. Wear a sanitary napkin after insertion of the drug to prevent staining of the clothing and bed linen. Continue taking the drug during the menstrual period if vaginal route is being used. Do not have intercourse while taking this drug, or advise the partner to use a condom to avoid reinfection. To prevent recurrent infections, avoid nylon and tight-fitting garments. If there is no improvement in 5 to 7 days, stop using the drug and consult a primary care provider because a more serious infection may be present. If abdominal pain, pelvic pain, rash, fever, or offensive-smelling vaginal discharge is present, do not use the drug, but notify the primary health care provider.

### EVALUATION

- The therapeutic effect occurs and signs and symptoms of infection improve.
- Optimal skin integrity is maintained.
- Adverse reactions are identified, reported to the primary health care provider, and managed through appropriate nursing interventions.
- The patient and family demonstrate an understanding of the drug regimen.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.

### Critical Thinking Exercises

**1.** A nurse is preparing to administer amphotericin B to a patient with a systemic mycotic infection. This is the first time the nurse has administered amphotericin B. Determine what information the nurse should be aware of concerning the administration of this drug. Explain your answer.

**2.** Mr. Harding, age 35 years, has received a diagnosis of a fungal infection. The primary health care provider has prescribed a topical antifungal drug. Develop a teaching plan concerning the application of a topical antifungal drug.

### Review Questions

1. Mr. Carr is receiving amphotericin B for a systemic fungal infection. Which of the following would most likely indicate to the nurse that Mr. Carr is experiencing an adverse reaction to amphotericin B?
   - A. fever and chills
   - B. abdominal pain
   - C. drowsiness
   - D. flushing of the skin

2. Which of the following laboratory tests would the nurse monitor in patients receiving fluconazole?
   - A. liver function tests
   - B. complete blood count
   - C. renal functions tests
   - D. prothrombin levels

3. The nurse monitors a patient taking itraconazole for the most common adverse reaction, which is .
   - A. nausea
   - B. hypokalemia
   - C. irregular pulse
   - D. confusion

4. The nurse would withhold griseofulvin if the patient has .
   - A. anemia
   - B. respiratory disease
   - C. had a recent myocardial infarction
   - D. severe liver disease

### Medication Dosage Problems

1. A patient weighs 140 pounds. If amphotericin B 1.5 mg/kg per day is prescribed, what is the total daily dosage of amphotericin B for this patient?

2. The primary care provider has prescribed fluconazole 200 mg PO initially, followed by 100 mg PO daily. On hand are fluconazole 100-mg tablets. What would the nurse administer as the initial dose?
A parasite is an organism that lives in or on another organism (the host) without contributing to the survival or well-being of the host. Helminthiasis (invasion of the body by helminths [worms]), malaria (an infectious disease caused by a protozoan and transmitted to humans through a bite from an infected mosquito), and amebiasis (invasion of the body by the ameba Entamoeba histolytica) are worldwide health problems caused by parasites.

Pinworm is a helminth infection that is universally common; most other helminth infections are predominantly found in countries or areas of the world that lack proper sanitary facilities. Malaria is rare in the United States, but it is sometimes seen in individuals who have traveled to or lived in areas where this disease is a health problem. The first antimalarial drug, quinine, is derived from the bark of the cinchona tree. Amebiasis is seen throughout the world, but it is less common in developed countries where sanitary facilities prevent the spread of the causative organism.

### ANTHelmINTIC DRUGS

An anthelmintic (against helminths) drugs are used to treat helminthiasis. Roundworms, pinworms, whipworms, hookworms, and tapeworms are examples of helminths. Table 16-1 lists the organisms that cause helminth infections. The anthelmintic drugs are listed in the Summary Drug Table: Anthelmintic Drugs.

### ACTION, USES, AND ADVERSE REACTIONS

Although the actions of anthelmintic drugs vary, their prime purpose is to kill the parasite. Adverse reactions associated with the anthelmintic drugs, if they do occur, are usually mild when the drug is used in the recommended dosage.

**Albendazole**

Albendazole (Albenza) interferes with the synthesis of the parasite’s microtubules, resulting in death of susceptible larva. This drug is used to treat larval forms of pork tapeworm and to treat liver, lung, and peritoneum disease caused by the dog tapeworm.

**Mebendazole**

Mebendazole (Vermox) blocks the uptake of glucose by the helminth, resulting in a depletion of the helminth’s...
own glycogen. Glycogen depletion results in a decreased formation of adenosine triphosphate, which is required by the helminth for reproduction and survival. This drug is used to treat whipworm, pinworm, roundworm, American hookworm, and the common hookworm. Treatment with mebendazole may cause transient abdominal pain and diarrhea.

**Pyrantel**

The activity of pyrantel (Antiminth) is probably due to its ability to paralyze the helminth. Paralysis causes the helminth to release its grip on the intestinal wall; it is then excreted in the feces. Pyrantel is used to treat roundworm and pinworm. Some patients receiving pyrantel may experience gastrointestinal side effects, such as nausea, vomiting, abdominal cramps, or diarrhea.

**Thiabendazole**

The exact mechanism of action of thiabendazole (Mintezol) is unknown. This drug appears to suppress egg or larval production and therefore may interrupt the life cycle of the helminth. Thiabendazole is used to treat threadworm. Thiabendazole may cause hypersensitivity reactions, drowsiness, and dizziness.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Albendazole**

Albendazole is contraindicated in patients with known hypersensitivity to the drug and during pregnancy (Category C). The drug has exhibited embryotoxic and teratogenic effects in experimental animals. Albendazole is used cautiously in patients with hepatic impairment and during lactation. The effects of albendazole are increased with dexamethasone and cimetidine.

**Mebendazole**

Mebendazole is contraindicated in patients with known hypersensitivity. Mebendazole is also contraindicated during pregnancy (Category C). The drug, like albendazole, has exhibited embryotoxic and teratogenic effects in experimental animals. Administration of mebendazole with the hydantoins and carbamazepine may reduce plasma levels of mebendazole.

---

**TABLE 16-1  Common Names and Causative Organisms of Parasitic Infections**

<table>
<thead>
<tr>
<th>COMMON NAME</th>
<th>CAUSATIVE ORGANISM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roundworm</td>
<td>Ascaris lumbricoides</td>
</tr>
<tr>
<td>Pinworm</td>
<td>Enterobius vermicularis</td>
</tr>
<tr>
<td>Whipworm</td>
<td>Trichuris trichiura</td>
</tr>
<tr>
<td>Threadworm</td>
<td>Strongyloides stercoralis</td>
</tr>
<tr>
<td>Hookworm</td>
<td>Ankylostoma duodenale, Necator americanus</td>
</tr>
<tr>
<td>Beef tapeworm</td>
<td>Taenia saginata</td>
</tr>
<tr>
<td>Pork tapeworm</td>
<td>Taenia solium</td>
</tr>
<tr>
<td>Fish tapeworm</td>
<td>Diphyllobothrium latum</td>
</tr>
</tbody>
</table>

---

**SUMMARY DRUG TABLE  ANTHELMINTIC DRUGS**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>albendazole</td>
<td>Albenza</td>
<td>Parenchymal neurocysticerosis due to pork tapeworm, hydatid disease (caused by the larval form of the dog tapeworm)</td>
<td>Abnormal liver function tests, abdominal pain, nausea, vomiting, headache, dizziness</td>
<td>≥60 kg: 400 mg BID; &lt;60 kg: 15 mg/kg/d</td>
</tr>
<tr>
<td>mebendazole</td>
<td>Vermox, generic</td>
<td>Treatment of whipworm, pinworm, roundworm, common and American hookworm</td>
<td>Transient abdominal pain, diarrhea</td>
<td>100 mg PO morning and evening for 3 consecutive d; pinworm: 100 mg PO as a single dose</td>
</tr>
<tr>
<td>pyrantel</td>
<td>Reese’s Pinworm</td>
<td>Treatment of pinworm and roundworm</td>
<td>Anorexia, nausea, vomiting, abdominal cramps, diarrhea, rash</td>
<td>11 mg/kg PO as a single dose</td>
</tr>
<tr>
<td>thiabendazole</td>
<td>Mintezol</td>
<td>Treatment of threadworm</td>
<td>Hypersensitivity reactions, drowsiness, dizziness</td>
<td>&lt;150 lb: 10 mg/lb per dose PO &gt;150 lb: 1.5 g/dose PO Maximum daily dose, 3g</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
Pyrantel

Pyrantel is contraindicated in patients with known hypersensitivity. Pyrantel is used with caution in individuals with liver dysfunction, malnutrition, or anemia. Pyrantel is a Pregnancy Category C drug and is used during pregnancy only if the potential benefit outweighs the risk to the fetus. Pyrantel and piperazine are antagonists and should not be given together.

Thiabendazole

Thiabendazole is contraindicated in patients with known hypersensitivity. Thiabendazole is used with caution in patients with hepatic or renal disease. Thiabendazole is a Pregnancy Category C drug and is used during pregnancy only if the potential benefit outweighs the risk to the fetus. When thiabendazole is administered with the xanthine derivatives, the plasma level of the xanthine may increase to toxic levels. It is important to monitor xanthine plasma levels closely in case a dosage reduction is necessary.

The Patient Receiving an Anthelmintic Drug

ASSESSMENT

Preadministration Assessment
During the preadministration assessment, the nurse obtains vital signs before the first dose of the anthelmintic drug is given. The nurse also may need to weigh the patient if the drug's dosage is determined by weight or if the patient is acutely ill.

Ongoing Assessment
Unless ordered otherwise, the nurse should save all stools that are passed after the drug is given. It is important to visually inspect each stool for passage of the helminth. If stool specimens are to be saved for laboratory examination, the nurse follows hospital procedure for saving the stool and transporting it to the laboratory. If the patient is acutely ill or has a massive infection, it is important to monitor vital signs every 4 hours and measure and record fluid intake and output. The nurse observes the patient for adverse drug reactions, as well as severe episodes of diarrhea. It is important to notify the primary health care provider if these occur.

NURSING DIAGNOSSES
The nursing diagnoses depend on the patient and the type of helminth infection. Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses are discussed in depth in Chapter 4.

NURSING PROCESS

PLANNING
The expected outcomes for the patient may include a reduction in anxiety, an optimal response to therapy, management of adverse reactions, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION
Promoting an Optimal Response to Therapy
The diagnosis of a helminth infection is made by examination of the stool for ova and all or part of the helminth. Several stool specimens may be necessary before the helminth is seen and identified. The patient history also may lead to a suspicion of a helminth infection, but some patients have no symptoms.

When a pinworm infection is suspected, the nurse takes a specimen from the anal area, preferably early in the morning before the patient gets out of bed. Specimens are taken by swabbing the perianal area with a cellophane tape swab.

Patients with massive helminth infections may or may not be acutely ill. The acutely ill patient requires hospitalization, but many individuals with helminth infections can be treated on an outpatient basis.

The diagnosis of a helminth infection is often distressing to patients and their family. The nurse should allow time to explain the treatment and future preventive measures, as well as to allow the patient or family members to discuss their concerns or ask questions.

Depending on hospital policy, as well as the type of helminth infection, linen precautions may be necessary. The nurse wears gloves when changing bed linens, emptying bedpans, or obtaining or handling stool specimens. It is important to wash hands thoroughly after removing the gloves. The nurse instructs the patient to wash the hands thoroughly after personal care and use of the bedpan.

ADMINISTERING AN ANTHELMINTIC DRUG. The method of administration of an anthelmintic drug may vary somewhat from the administration of other drugs. To achieve an optimal response to therapy, it is most important that the drug be given as directed by the primary health care provider, drug label, or package insert. Display 16-1 provides specific instructions for administering anthelmintic drugs.

Monitoring and Managing Adverse Reactions
The nurse monitors the patient taking an anthelmintic drug closely for adverse reactions.

Nursing Diagnoses Checklist

- Imbalanced Nutrition: Less Than Body Requirements related to infestation with helminths or anthelmintic adverse drug reactions
RISK FOR IMBALANCED NUTRITION. Gastrointestinal upset may occur, causing nausea, vomiting, abdominal pain, and diarrhea. Taking the drug with food often helps to alleviate the nausea. The patient may require frequent, small meals of easily digested food. The nurse considers the patient’s food preferences and encourages the patient to eat nutritious, balanced meals. If vomiting is present, the primary health care provider may prescribe an antiemetic or a different anthelmintic agent. If diarrhea is present, the nurse notifies the primary health care provider because a change in the drug regimen may be needed. The nurse keeps a record of the number, consistency, color, and frequency of stools. The nurse monitors the fluid intake and output. It is important to keep the patient clean and the room free of odor.

Educating the Patient and Family
When an anthelmintic is prescribed on an outpatient basis, the nurse gives the patient or a family member complete instructions about taking the drug, as well as household precautions that should be followed until the helminth is eliminated from the intestine. The nurse develops a patient education plan to include the following:

• Report any symptoms of infection (low-grade fever or sore throat) or thrombocytopenia (easy bruising or bleeding).
• Follow the dosage schedule exactly as printed on the prescription container. (See Administering an Anthelmintic Drug for the directions specific for each drug.) It is absolutely necessary to follow the directions for taking the drug to eradicate the helminth.
• Follow-up stool specimens will be necessary because this is the only way to determine the success of drug therapy.
• To prevent reinfection and the infection of others in the household, change and launder bed linens and undergarments daily, separately from those of other members of the family.
• Daily bathing (showering is best) is recommended. Disinfect toilet facilities daily, and disinfect the bathtub or shower stall immediately after bathing. Use the disinfectant recommended by the primary health care provider or use chlorine bleach. Scrub the surfaces thoroughly and allow the disinfectant to remain in contact with the surfaces for several minutes.
• Wash the hands thoroughly after urinating or defecating and before preparing and eating food. Clean under the fingernails daily and avoid putting fingers in the mouth or biting the nails.
• Albendazole can cause serious harm to a developing fetus. Use a barrier contraceptive during the course of therapy and for 1 month after discontinuing the therapy.

EVALUATION
• The therapeutic effect is achieved.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully using appropriate nursing interventions.
• The infection is resolved.
• Stool specimens or perineal swabs are negative for parasites.
• The patient verbalizes an understanding of the therapeutic regimen modalities and the importance of continued follow-up testing.
• The patient describes or lists measures used to prevent the spread of infection to others.
• The patient verbalizes the importance of complying with the prescribed treatment regimen and preventive measures.

ANTIMALARIAL DRUGS

Malaria is transmitted from person to person by a certain species of the Anopheles mosquito. The four different protozoans causing malaria are Plasmodium falciparum, P. malariae, P. ovale, and P. vivax. Drugs used to treat or prevent malaria are called antimalarial drugs. Three antimalarial drugs are discussed in the chapter: chloroquine, doxycycline, and quinine sulfate. Other examples of antimalarial drugs in use today are listed in the Summary Drug Table: Antimalarial Drugs.

ACTIONS

The plasmodium causing malaria must enter the mosquito to develop, reproduce, and be transmitted. When the mosquito bites a person infected with malaria, it ingests the male and female forms (gametocytes) of the plasmodium. The gametocytes mate in the mosquito’s
### SUMMARY DRUG TABLE  ANTIMALARIAL DRUGS

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>atovaquone and proguanil HCl</td>
<td>Malarone</td>
<td>Prevention and treatment of malaria</td>
<td>Headache, fever, myalgia, abdominal pain, diarrhea</td>
<td>Prevention: 1–2 d before travel 1 tablet PO per day during period of exposure and for 7 days after exposure. Treatment: 4 tablets PO daily for 3 d</td>
</tr>
<tr>
<td>chloroquine klor'-oh-kwin</td>
<td>Aralen</td>
<td>Treatment and prevention of malaria</td>
<td>Hypotension, electrolydiographic changes, headache, nausea, vomiting, anorexia, diarrhea, abdominal cramps, visual disturbances</td>
<td>Treatment: Dose expressed as base. 160–200 mg (4–5 mL) IM and repeat in 6 h if necessary. Prevention: 300 mg PO weekly; treatment: initially 600 mg PO and 300 mg PO 6 h later, then 300 mg/d PO for 2 d</td>
</tr>
<tr>
<td>doxycycline dox-i-sye'-kleen</td>
<td>Monodox, Vibramycin, Vibra-Tab, generic</td>
<td>Short-term prevention of malaria</td>
<td>Photosensitivity, anorexia, nausea, vomiting, diarrhea, superinfection, rash</td>
<td>100 mg PO QD</td>
</tr>
<tr>
<td>halofantrine hay'-low-fan-trin</td>
<td>Halan</td>
<td>Treatment of malaria</td>
<td>Abdominal pain, nausea, vomiting, anorexia, diarrhea, dizziness</td>
<td>500 mg PO q6h for 3 doses, repeat dose regimen in 7 days</td>
</tr>
<tr>
<td>hydroxychloroquine sulfate hye-drox-ee-klor'-oh-kwin</td>
<td>Plaquenil Sulfate</td>
<td>Prevention and treatment of malaria</td>
<td>Same as chloroquine</td>
<td>Dose expressed as base. Prevention: 310 mg PO weekly; treatment: initially 620 mg PO, and 310 mg 6 h later, then 310 mg/d PO for 2 d</td>
</tr>
<tr>
<td>mefloquine hydrochloride me'-flow-kwin</td>
<td>Lariam</td>
<td>Prevention and treatment of malaria</td>
<td>Vomiting, dizziness, disturbed sense of balance, nausea, fever, headache, visual disturbances</td>
<td>Prevention: 250 mg/wk PO for 4 wk, then 250 mg PO every other week; treatment: 5 tablets PO as a single dose</td>
</tr>
<tr>
<td>primaquine phosphate prim'-a-kween</td>
<td>generic</td>
<td>Treatment of malaria</td>
<td>Nausea, vomiting, epigastric distress, abdominal cramps</td>
<td>Dose expressed as base. 15 mg/d PO for 14 d</td>
</tr>
<tr>
<td>pyrimethamine peer-i-meth'-a-mine</td>
<td>Daraprim</td>
<td>Prevention and treatment of malaria</td>
<td>Nausea, vomiting, hematologic changes, anorexia</td>
<td>Prevention: 25 mg PO once weekly; treatment: 50 mg/d for 2 days</td>
</tr>
<tr>
<td>quinine sulfate kw'i'-nine</td>
<td>generic</td>
<td>Treatment of malaria</td>
<td>Cinchonism, vertigo, hematologic changes, skin rash, visual disturbances</td>
<td>260–650 mg TID for 6–12 days</td>
</tr>
<tr>
<td>sulfadoxine and pyrimethamine sul-fa-dox'-een peer-i-meth'-a-meen</td>
<td>Fansidar</td>
<td>Prevention and treatment of malaria</td>
<td>Hematologic changes, nausea, emesis, headache, hypersensitivity reactions, Stevens-Johnson syndrome</td>
<td>Prevention: 1 tablet PO weekly or 2 tablets every 2 wk; treatment: 2–3 tablets PO as a single dose</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
stomach and ultimately form *sporozoites* (an animal reproductive cell) that make their way to the salivary glands of the mosquito. When the mosquito bites a non-infected person, the sporozoites enter the person’s bloodstream and lodge in the liver and other tissues. The sporozoites then undergo asexual cell division and reproduction and form *merozoites* (cells formed as a result of asexual reproduction). The merozoites then divide asexually and enter the red blood cells of the person, where they form the male and female forms of the plasmodium. The symptoms of malaria (shaking, chills, and fever) appear when the merozoites enter the individual’s red blood cells.

Antimalarial drugs interfere with, or are active against, the life cycle of the plasmodium, primarily when it is present in the red blood cells. Destruction at this stage of the plasmodium life cycle prevents the development of the male and female forms of the plasmodium. This in turn keeps the mosquito (when the mosquito bites an infected individual) from ingesting the male and female forms of the plasmodium, thus effectively ending the plasmodium life cycle (Fig. 16-1).

**USES**

Two terms are used when discussing the uses of antimalarial drugs:

1. Suppression—the prevention of malaria
2. Treatment—the management of a malarial attack

Not all antimalarial drugs are effective in suppressing or treating all four of the *Plasmodium* species that cause malaria. In addition, resistant strains have developed, and some antimalarial drugs are no longer effective against some of these strains. The primary health care provider must select the antimalarial drug that reportedly is effective, at present, for the type of malaria the individual either has (treatment) or could be exposed to (prevention) in a specific area of the world.

Chloroquine (*Aralen*) is also used in the treatment of extraintestinal amebiasis (see section on *Amebicides*). Doxycycline is also used to treat infections caused by *Neisseria gonorrhoeae*, *Treponema pallidum*, *Listeria monocytogenes*, *Clostridium*, and *Bacillus anthracis* when penicillin is contraindicated. Quinine also may be used for the prevention and treatment of nocturnal leg cramps.

**ADVERSE REACTIONS**

**Chloroquine**

The adverse reactions associated with the administration of chloroquine (*Aralen HCl and phosphate*) and hydroxychloroquine include hypotension, electrocardiographic changes, visual disturbances, headache, nausea, vomiting, anorexia, diarrhea, and abdominal cramps.

**Doxycycline**

Doxycycline (*Vibramycin*) is an antibiotic belonging to the tetracycline group of antibiotics. The adverse reactions associated with this drug are discussed in Chapter 9 and include photosensitivity, anorexia, nausea, and vomiting.

**Quinine**

The use of quinine can cause cinchonism at full therapeutic doses. *Cinchonism* is a group of symptoms associated with quinine, including tinnitus, dizziness, headache, gastrointestinal disturbances, and visual disturbances. These symptoms usually disappear when the dosage is reduced. Other adverse reactions include hematologic changes, vertigo, and skin rash.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Chloroquine**

Chloroquine is contraindicated in patients with known hypersensitivity. It is a good idea to use chloroquine cautiously in patients with hepatic disease or bone marrow depression and during pregnancy. Children are very sensitive to chloroquine, and the drug should be used with extreme caution in children.
Because the effects of chloroquine during pregnancy (Pregnancy Category C) are unknown, this drug is given only when clearly needed and the potential benefits outweigh potential hazards to the fetus. There is an increased risk of hepatotoxicity when chloroquine is administered with other hepatotoxic drugs.

Foods that acidify the urine (cranberries, plums, prunes, meats, cheeses, eggs, fish, and grains) may increase excretion and decrease the effectiveness of chloroquine.

**Doxycycline**

Doxycycline is contraindicated in patients with known hypersensitivity. Because the effects of doxycycline during pregnancy (Category D) are unknown, this drug is contraindicated during pregnancy. The drug is used cautiously in patients with renal or hepatic impairment and during lactation. There is a decreased absorption of the drug when administered with antacids or iron. There is a decrease of the therapeutic effects of doxycycline when the drug is administered with barbiturates, phenytoins, and carbamazepine. There is an increased risk of digoxin toxicity when digoxin is administered with doxycycline.

**Quinine**

Quinine is contraindicated in patients with known hypersensitivity. The drug is also contraindicated in pregnant women (Pregnancy Category X) and in patients with myasthenia gravis (may cause respiratory distress and dysphagia). Quinine absorption is delayed when administered with antacids containing aluminum. Plasma digitalis levels may increase when digitalis preparations and quinine are given concurrently. Plasma levels of warfarin are increased when administered with quinine.

---

**NURSING DIAGNOSES**

The specific nursing diagnoses for a patient receiving an antimalarial depend on the reason for administration (prevention or treatment) of the antimalarial drug. Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist.

**PLANNING**

The expected outcomes for the patient may include an optimal response to therapy, maintenance of adequate nutrition, management of common adverse reactions, and an understanding of and compliance with the prescribed therapeutic or prevention regimen.

**IMPLEMENTATION**

Promoting an Optimal Therapeutic Response

When administering an antimalarial drug such as chloroquine for prophylaxis (prevention), therapy should begin 2 weeks before exposure and continue for 6 to 8 weeks after the client leaves the area where malaria is prevalent. Initial treatment with quinine may be given parenterally. When administered intravenously (IV), quinine should be well diluted and administered slowly. The nurse must frequently examine the injection site and areas along the vein because quinine is irritating to the vein. Parenteral injection of chloroquine is avoided because the drug can cause respiratory distress, shock, and cardiovascular collapse when given intramuscularly or IV. If chloroquine must be given parenterally, the route should be changed to oral as soon as possible.

**RISK FOR IMBALANCED NUTRITION.** Patients receiving an antimalarial drug may experience nausea. Good nutrition
is essential in the healing process. The nurse assists patients to identify food preferences and aversions and helps them in planning a nutritious diet. The nurse can consult a registered dietitian if necessary. If the patient is hospitalized with an active case of malaria, the nurse keeps the room environment clean and pleasant during mealtime. Meals should be nutritious and attractively served. Several small meals may be preferable to three large meals.

**Monitoring and Managing Adverse Reactions**

The nurse monitors for adverse reactions associated with the antimalarial drugs, such as dizziness, hypoten- sion, and visual disturbances. Other adverse reactions are listed in the Summary Drug Table: Antimalarial Drugs.

**RISK FOR INJURY.** Some patients experience dizziness and hypotensive episodes when taking antimalarial drugs. The nurse should frequently monitor blood pressure if the patient is hospitalized. If dizziness occurs, the nurse may need to assist the patient with ambulation. The nurse instructs the patient to rise slowly from a reclining position, sit a few minutes before standing, and stand a few minutes before beginning to walk. When the patient is taking these drugs on an outpatient basis, the nurse instructs the patient to avoid driving or performing hazardous tasks if dizziness occurs.

**DISTURBED SENSORY PERCEPTION: VISUAL.** The patient taking chloroquine may experience a number of visual disturbances, such as disturbed color vision, blurred vision, night blindness, diminished visual fields, or optic atrophy. The nurse questions the patient about visual disturbances.

### Nursing Alert

The nurse reports any visual disturbance in patients taking chloroquine to the primary health care provider. Irreversible retinal damage has occurred in patients on long-term therapy with these drugs.

Frequent ophthalmic examinations are necessary for patients receiving long-term or high-dose regimens of chloroquine. When vision is affected, the patient is assessed for the extent of visual impairment. If treated outside the hospital, it is important to instruct the patient not to drive until assessed by an ophthalmologist. Environmental safety is accomplished by measures such as positioning doors and furniture so they are out of walkways, removing scatter rugs, placing items frequently used in convenient places, and strategically placing grab bars to aid in maintaining balance. Assistance with ambulation may be necessary.

### Educating the Patient and Family

When an antimalarial drug is prescribed for the prevention (suppression) of malaria, the nurse thoroughly reviews the drug regimen with the patient. When the drug is to be taken once a week, the nurse advises patients to select a day of the week that will best remind them to take the drug. The nurse emphasizes the importance of taking the drug exactly as prescribed because failure to take the drug on an exact schedule will not give protection against malaria.

The patient must have a complete understanding of the therapeutic regimen. The nurse reviews the drug dosage schedule with the patient and stresses the importance of adhering to the prescribed dosage schedule.

When an antimalarial drug is used for prevention of malaria and taken once a week, the patient must take the drug on the same day each week. The program of prevention is usually started 1 week before departure to an area where malaria is prevalent.

The following additional information is relevant to specific antimalarial drugs:

- **Chloroquine:** Take this drug with food or milk. Avoid foods that acidify the urine (cranberries, plums, prunes, meats, cheeses, eggs, fish, and grains). This drug may cause diarrhea, loss of appetite, nausea, stomach pain, or vomiting. Notify the primary health care provider if these symptoms become pronounced. Chloroquine may cause a yellow or brownish discoloration to the urine; this is normal and will go away when the drug therapy is discontinued. Notify the primary health care provider if any of the following occur:
  - Visual changes
  - Ringing in the ears
  - Difficulty in hearing
  - Fever
  - Sore throat
  - Unusual bleeding or bruising
  - Unusual color (blue-black) of the skin
  - Skin rash
  - Unusual muscle weakness

- **Doxycycline:** This drug can cause photosensitivity. Even relatively brief exposure to sunlight may cause sunburn. Avoid exposure to the sun by wearing protective clothing (eg, long-sleeved shirts and wide-brimmed hats) and by using a sunscreen.

- **Quinine:** Take this drug with food or immediately after a meal. Do not drive or perform other hazardous tasks requiring alertness if blurred vision or dizziness occurs. If the tablet or capsule is difficult to swallow, do not chew the tablet or open the capsule because the drug is irritating to the stomach. If itching, rash, fever, difficult breathing, or vision problems occur, stop taking the drug and notify the primary health care provider.
EVALUATION

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the health care provider, and managed using appropriate nursing interventions.
- The patient verbalizes the importance of complying with the prescribed therapeutic or prophylactic regimen.
- The patient verbalizes an understanding of the prophylaxis or treatment schedule.

AMEBICIDES

Amebicides (drugs that kill amebas) are used to treat amebiasis caused by the parasite E. histolytica. An ameba is a one-celled organism found in soil and water. Examples of amebicides are listed in the Summary Drug Table: Amebicides.

ACTIONS AND USES

These drugs are amebicidal (ie, they kill amebas). There are two types of amebiasis: intestinal and extraintestinal.

In the intestinal form, the ameba is confined to the intestine. In the extraintestinal form, the ameba is found outside of the intestine, such as in the liver. The extraintestinal form of amebiasis is more difficult to treat.

Iodoquinol (Yodoxin) and metronidazole (Flagyl) are used to treat intestinal amebiasis. Metronidazole is also used to treat infections caused by susceptible microorganisms and is discussed in Chapter 11. Paromomycin is an aminoglycoside with amebicidal activity and is used to treat intestinal amebiasis. Chloroquine hydrochloride (Aralen) is used to treat extraintestinal amebiasis.

ADVERSE REACTIONS

Chloroquine

Hypotension, electrocardiographic changes, headache, nausea, vomiting, anorexia, diarrhea, abdominal cramps, and psychic stimulation can occur with the use of chloroquine hydrochloride or phosphate.

Iodoquinol

Various types of skin eruptions, nausea, vomiting, fever, chills, abdominal cramps, vertigo, and diarrhea can occur with administration of iodoquinol.

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>chloroquine</td>
<td>Aralen</td>
<td>Extraintestinal amebiasis when oral therapy not feasible</td>
<td>Hypotension, electrocardiographic (ECG) changes, headache, nausea, vomiting, anorexia, diarrhea, abdominal cramps, psychic stimulation, visual disturbances</td>
<td>Dose expressed as base. 160–200 mg/d IM for 10–12 d</td>
</tr>
<tr>
<td>hydrochloride</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>klor'-oh-kwin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chloroquine</td>
<td>Aralen</td>
<td>Extraintestinal amebiasis when oral therapy not feasible</td>
<td>Hypotension, ECG changes, headache, nausea, vomiting, anorexia, diarrhea, abdominal cramps, psychic stimulation</td>
<td>1 g (600 mg base)'/d for 2 d, then 500 mg (300 mg base)'/d for 2–3 wk</td>
</tr>
<tr>
<td>phosphate</td>
<td>Phosphate,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>klor'-oh-kwin</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>iodoquinol</td>
<td>Yodoxin</td>
<td>Treatment of intestinal amebiasis</td>
<td>Skin eruptions, nausea, vomiting, fever, chills, abdominal cramps, vertigo, diarrhea</td>
<td>650 mg PO TID after meals for 20 d</td>
</tr>
<tr>
<td>eye-oh-doe-kwin'-ole</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>metronidazole</td>
<td>Flagyl,</td>
<td>Treatment of intestinal amebiasis</td>
<td>Headache, nausea, peripheral neuropathy, disulfiram-like interaction with alcohol</td>
<td>750 mg PO TID for 5–10 d</td>
</tr>
<tr>
<td>me-troe-ni'-da-zole</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>paromomycin</td>
<td>Humatin</td>
<td>Treatment of intestinal amebiasis</td>
<td>Nausea, vomiting, diarrhea</td>
<td>25–35 mg/kg/d in 3 divided doses with meals for 5–10 d</td>
</tr>
<tr>
<td>par-oh-moe-mye'-sin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
**Metronidazole**
Convulsive seizures, headache, nausea, and peripheral neuropathy (numbness and tingling of the extremities) have been reported with the use of metronidazole.

**Paromomycin**
This drug has relatively few adverse reactions. The most common include nausea, vomiting, and diarrhea. The more serious adverse reactions, although rare, are nephrotoxicity and ototoxicity.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Chloroquine**
Chloroquine is contraindicated in patients with known hypersensitivity. Precautions and interactions for chloroquine are provided in the discussion of the drug in the Antimalarial Drugs section.

**Iodoquinol**
Iodoquinol is contraindicated in patients with known hypersensitivity. Iodoquinol is used with caution in patients with thyroid disease and during pregnancy and lactation. Iodoquinol may interfere with the results of thyroid function tests. This interference not only occurs during therapy, but may last as long as 6 months after iodoquinol therapy is discontinued.

**Metronidazole**
Metronidazole is contraindicated in patients with known hypersensitivity. Metronidazole is contraindicated during the first trimester of pregnancy (Category B). Metronidazole is given during the second and third trimesters of pregnancy. Metronidazole is used cautiously in patients with blood dyscrasias, seizure disorders, and severe hepatic impairment. The patient must avoid alcohol while taking metronidazole.

When metronidazole is administered with cimetidine, the metabolism of metronidazole is decreased; when it is administered with phenobarbital, the metabolism is increased, possibly causing a decrease in the effectiveness of metronidazole. Metronidazole increases the effects of warfarin.

**Paromomycin**
Paromomycin is contraindicated in patients with known hypersensitivity. Paromomycin is given with caution during pregnancy. Paromomycin is used with caution in patients with bowel disease. High doses and prolonged therapy are avoided because the drug may be absorbed in large amounts by patients with bowel disease, causing ototoxicity and renal impairment.

**NURSING PROCESS**

*The Patient Receiving an Amebicide*

**ASSESSMENT**

**Preadministration Assessment**
Diagnosis of amebiasis is made by examining the stool, as well as by considering the patient’s symptoms. Once the patient has received a diagnosis of amebiasis, local health department regulations often require investigation into the source of infection. A thorough history of foreign travel is necessary. If the patient has not traveled to a foreign country, further investigation of the patient’s lifestyle, such as local travel, use of restaurants, and the local water supply (especially well water) may be necessary to identify the source of the infection. In addition, it is common practice to test immediate family members for amebiasis.

Before the first dose of an amebicide is given, the nurse records the patient’s vital signs and weight. The nurse evaluates the general physical status of the patient and looks for evidence of dehydration, especially if severe vomiting and diarrhea have occurred.

**Ongoing Assessment**
If the patient is acutely ill or has vomiting and diarrhea, the nurse measures the fluid intake and output and observes the patient closely for signs of dehydration. If dehydration is apparent, the nurse notifies the primary health care provider. If the patient is or becomes dehydrated, oral or IV fluid and electrolyte replacement may be necessary. The nurse takes vital signs every 4 hours or as ordered by the primary health care provider.

**NURSING DIAGNOSES**
The specific nursing diagnoses used depend on the type of amebiasis and the condition of the patient. Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. More general nursing diagnoses are discussed in greater depth in Chapter 4.

**Nursing Diagnoses Checklist**
- Diarrhea related to amebiasis
- Risk for Deficient Fluid Volume related to amebiasis
- Imbalanced Nutrition: Less Than Body Requirements related to adverse effects of drug therapy
PLANNING

The expected outcomes for the patient may include an optimal response to therapy, management of common adverse reactions, an absence of diarrhea, maintenance of an adequate intake of fluids, maintenance of adequate nutrition, an understanding of the therapeutic regimen (hospitalized patients), and an understanding of and compliance with the prescribed therapeutic regimen (outpatients).

IMPLEMENTATION

Promoting an Optimal Response to Therapy

The patient with amebiasis may or may not be acutely ill. Nursing management depends on the condition of the patient and the information obtained during the initial assessment.

Isolation is usually not necessary, but hospital policy may require isolation procedures. Stool precautions are usually necessary. The nurse washes the hands thoroughly after all patient care and the handling of stool specimens.

Monitoring and Managing Adverse Reactions

The nurse monitors the patient for adverse reactions associated with the amebicides such as diarrhea and gastrointestinal upsets. Other adverse reactions are listed on the Summary Drug Table: Amebicides.

DIARRHEA AND DEFICIENT FLUID VOLUME. The nurse records the number, character, and color of stools passed. Daily stool specimens may be ordered to be sent to the laboratory for examination. The nurse immediately delivers all stool specimens saved for examination to the laboratory because the organisms die (and therefore cannot be seen microscopically) when the specimen cools. The nurse should inform laboratory personnel that the patient has amebiasis because the specimen must be kept at or near body temperature until examined under a microscope.

The nurse observes the patient with severe or frequent episodes of diarrhea for symptoms of a fluid volume deficit. The primary health care provider is notified if signs of dehydration become apparent because IV fluids may be necessary.

IMBALANCED NUTRITION. Because most amebicides cause gastrointestinal upsets, particularly nausea, the maintenance of adequate nutrition is important. A discussion of eating habits, food preferences, and food aversions will assist in meal planning. The nurse monitors body weight daily to identify any changes (increase or decrease). The nurse should make sure that meals are well balanced nutritionally, appetizing, and attractively served. Small frequent meals (five to six daily) may be more appealing than three large meals. The nurse may consult the dietitian if necessary.

Educating the Patient and Family

The nurse stresses the importance of completing the full course of treatment. The nurse should provide the following information to patients receiving an amebicide on an outpatient basis:

- Follow directions: Take the drug exactly as prescribed. Complete the full course of therapy to eradicate the ameba. Failure to complete treatment may result in a return of the infection.
- Prevention: Follow measures to control the spread of infection. Wash hands immediately before eating or preparing food and after defecation.
- Chef/waitstaff: Food handlers should not resume work until a full course of treatment is completed and stools do not contain the ameba.
- Chloroquine: Notify the primary health care provider if any of the following occurs: ringing in the ears, difficulty hearing, visual changes, fever, sore throat, or unusual bleeding or bruising.
- Iodoquinol: Notify the primary health care provider if nausea, vomiting, or other gastrointestinal distress becomes severe.
- Metronidazole: This drug may cause gastric upset. Take this drug with food or meals. Avoid the use of alcohol, in any form, until the course of treatment is completed. The ingestion of alcohol may cause a mild to severe reaction, with symptoms of severe vomiting, headache, nausea, abdominal cramps, flushing, and sweating. These symptoms may be so severe that hospitalization may be required.
- Paromomycin: Take this drug three times a day with meals. Report any ringing in the ears, dizziness, severe gastrointestinal upset, decrease in urinary output, or other urinary difficulties.

EVALUATION

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through nursing interventions.
- Bowel elimination is normal.
- The patient verbalizes an understanding of the therapeutic modalities and importance of continued follow-up care.
- The patient verbalizes the importance of complying with the prescribed therapeutic regimen.

Critical Thinking Exercises

1. While he was living outside the country for 3 years, Mr. Evans became infected with a helminth. The parasite has been identified and the appropriate drug prescribed. Discuss the points you would include in a teaching plan for this patient.
2. A child in a family of four children is found to have pinworms. Determine what you would include in a teaching plan to prevent the spread of pinworms to other family members.

3. Explain what precautions should be taken when administering paromomycin.

4. Mr. Adkins, age 68 years, is being treated with metronidazole for intestinal amebiasis. He tells you that he lives alone, eats out for most of his meals, and likes to have a glass of wine before retiring. Analyze what information would be most important for you to give Mr. Adkins before he begins taking metronidazole.

**Review Questions**

1. When discussing the adverse reactions of the anthelmintic, the nurse correctly states that ______.
   A. patients must be closely observed for 2 hours after the drug is given
   B. adverse reactions are usually mild when recommended doses are used
   C. most patients experience severe adverse reactions and must be monitored closely
   D. there are no adverse reactions associated with these drugs

2. A patient asks how antimalarial drugs prevent or treat malaria. The nurse correctly responds that this group of drugs ______.
   A. kills the mosquito that carries the protozoa
   B. interferes with the life cycle of the protozoa causing malaria
   C. ruptures the red blood cells that contain merozoites
   D. increases the body’s natural immune response to the protozoa

3. When explaining the drug regimen to a patient who will be taking chloroquine for the prevention of malaria the nurse instructs the patient ______.
   A. to take the drug on an empty stomach
   B. to protect the skin from the sun because the drug can cause a severe sunburn
   C. therapy should begin 2 weeks before exposure
   D. to take the drug with a citrus drink to enhance absorption

4. While administering paromomycin, the nurse monitors the patient for which of the following adverse reactions?
   A. ototoxicity
   B. cinchonism
   C. convulsions
   D. hypertension

**Medication Dosage Problems**

1. Pyrantel 360 mg is prescribed. The drug is available in 180-mg capsules. The nurse administers ______.

2. Hydroxychloroquine 0.4 g is ordered. The drug is available in 200-mg tablets. The nurse administers ______.
Nonnarcotic Analgesics: Salicylates and Nonsalicylates

Key Terms

- acute pain
- aggregation
- analgesic
- antipyretic
- chronic pain
- jaundice
- pain
- pancytopenia
- prostaglandin
- Reye’s syndrome
- salicylate
- salicylism
- tinnitus

Chapter Objectives

On completion of this chapter, the student will:

- Discuss the types, uses, general drug actions, common adverse reactions, contraindications, precautions, and interactions of the salicylates and acetaminophen.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking salicylates or acetaminophen.
- List some nursing diagnoses particular to a patient taking the salicylates or acetaminophen.
- Discuss the ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating patients about the use of the salicylates or acetaminophen.

Pain can be defined as an unpleasant sensory and emotional experience that is associated with actual or potential tissue damage. Pain is subjective, and the patient’s report of pain should always be taken seriously. Pain management in acute and chronic illness is an important responsibility of the nurse. Many nurses consider pain as the fifth vital sign and assessment of pain just as important as the assessment of temperature, pulse, respirations, and blood pressure. Accurate assessment of pain is necessary if pain management is to be effective. Patients with pain are often undertreated.

Basically there are three types of pain: acute pain, chronic pain associated with malignant disease, and chronic pain not associated with malignant disease. Acute pain is of short duration and lasts less than 3 to 6 months. Intensity of acute pain is from mild to severe. Causes of acute pain include postoperative pain, procedural pain, and traumatic pain. Acute pain usually subsides when the injury heals.

Chronic pain lasts longer than 6 months and ranges in intensity from mild to severe. Chronic pain associated with malignancy includes the pain of cancer, acquired immunodeficiency syndrome (AIDS), multiple sclerosis, sickle cell disease, and end-stage organ system failure.

The exact cause of chronic pain of a nonmalignant nature may or may not be known. This type of pain includes the pain associated with various neuropathic and musculoskeletal disorders such as headaches, fibromyalgia, rheumatoid arthritis, and osteoarthritis.

The next three chapters deal with drugs used in the management of pain: the nonnarcotic analgesics (salicylates, nonsalicylates [acetaminophen], and the nonsteroidal anti-inflammatory drugs) and the narcotic analgesics.

The nonnarcotic analgesics are a group of drugs used to relieve pain without the possibility of causing physical dependency, which can occur with the use of the narcotic analgesics. The nonnarcotic analgesics can be divided into the salicylates, nonsalicylates (acetaminophen), and the nonsteroidal anti-inflammatory drugs (NSAIDs). There are a number of combination nonnarcotic analgesics that are available over the counter and by prescription. The NSAIDs have emerged as important drugs in the treatment of the
chronic pain and inflammation associated with disorders such as rheumatoid arthritis or osteoarthritis. Examples of NSAIDs include celecoxib (Celebrex) and rofecoxib (Vioxx). This chapter deals with the nonnarcotic analgesics: the salicylates and acetaminophen. Subsequent chapters cover the NSAIDs and the narcotic analgesics.

**SALICYLATES**

The salicylates include aspirin (acetylsalicylic acid) and related drugs, such as magnesium salicylate and sodium salicylate. The salicylates have analgesic (relieves pain), antipyretic (reduces elevated body temperature), and anti-inflammatory effects. All the salicylates are similar in pharmacologic activity; however, aspirin has a greater anti-inflammatory effect than the other salicylates. Specific salicylates are listed in the Summary Drug Table: Nonnarcotic Analgesics: Salicylates and Nonsalicylates.

**USES**

The salicylate nonnarcotic analgesics are used for the following reasons:

- Relief of mild to moderate pain;
- Reduction of elevated body temperature (except for diflunisal which is not used as an antipyretic);
- Treatment of inflammatory conditions, such as rheumatoid arthritis, osteoarthritis, and rheumatic fever;
- Reduction of the risk of myocardial infarction in those with unstable angina or previous myocardial infarction (aspirin only); and
- Reduction of the risk of transient ischemic attacks or strokes in men who have had transient ischemia of the brain due to fibrin platelet emboli (aspirin only). This use has been found to be effective only in men (not women).

**ADVERSE REACTIONS**

Gastric upset, heartburn, nausea, vomiting, anorexia, and gastrointestinal bleeding may occur with salicylate use. Although these drugs are relatively safe when taken as recommended on the label or by the primary health care provider, their use can occasionally result in more serious reactions. Some individuals are allergic to aspirin and the other salicylates. Allergy to the salicylates may be manifested by hives, rash, angioedema, bronchospasm with asthma-like symptoms, and anaphylactoid reactions.

Loss of blood through the gastrointestinal tract occurs with salicylate use. The amount of blood lost is to increase the sensitivity of peripheral pain receptors. The inhibitory action of the salicylates on the prostaglandins is also thought to account for the anti-inflammatory activity. Salicylates lower an elevated body temperature by dilating peripheral blood vessels, which in turn cools the body.

Aspirin more potently inhibits prostaglandin synthesis and has greater anti-inflammatory effects than the other salicylates. In addition, aspirin also prolongs the bleeding time by inhibiting the aggregation (clumping) of platelets. When the bleeding time is prolonged, it takes a longer time for the blood to clot after a cut, surgery, or other injury to the skin or mucous membranes. The other salicylates do not have as great an effect on platelets as does aspirin. This effect of aspirin on the platelets is irreversible and lasts for the life of the platelet (7–10 days).

**ACTIONS**

The manner in which salicylates relieve pain and reduce inflammation is not fully understood. It is thought that the analgesic action of the salicylates is due to the inhibition of prostaglandins. Prostaglandins are fatty acid derivatives found in almost every tissue of the body and body fluid. Release of prostaglandin is thought to increase the sensitivity of peripheral pain receptors. The inhibitory action of the salicylates on the prostaglandins is also thought to account for the anti-inflammatory activity. Salicylates lower an elevated body temperature by dilating peripheral blood vessels, which in turn cools the body.

A spirin more potently inhibits prostaglandin synthesis and has greater anti-inflammatory effects than the other salicylates. In addition, aspirin also prolongs the bleeding time by inhibiting the aggregation (clumping) of platelets. When the bleeding time is prolonged, it takes a longer time for the blood to clot after a cut, surgery, or other injury to the skin or mucous membranes. The other salicylates do not have as great an effect on platelets as does aspirin. This effect of aspirin on the platelets is irreversible and lasts for the life of the platelet (7–10 days).

**USES**

The salicylate nonnarcotic analgesics are used for the following reasons:

- Relief of mild to moderate pain;
- Reduction of elevated body temperature (except for diflunisal which is not used as an antipyretic);
- Treatment of inflammatory conditions, such as rheumatoid arthritis, osteoarthritis, and rheumatic fever;
- Reduction of the risk of myocardial infarction in those with unstable angina or previous myocardial infarction (aspirin only); and
- Reduction of the risk of transient ischemic attacks or strokes in men who have had transient ischemia of the brain due to fibrin platelet emboli (aspirin only). This use has been found to be effective only in men (not women).

**ADVERSE REACTIONS**

Gastric upset, heartburn, nausea, vomiting, anorexia, and gastrointestinal bleeding may occur with salicylate use. Although these drugs are relatively safe when taken as recommended on the label or by the primary health care provider, their use can occasionally result in more serious reactions. Some individuals are allergic to aspirin and the other salicylates. Allergy to the salicylates may be manifested by hives, rash, angioedema, bronchospasm with asthma-like symptoms, and anaphylactoid reactions.

Loss of blood through the gastrointestinal tract occurs with salicylate use. The amount of blood lost is
The salicylates are contraindicated in patients with known hypersensitivity to the salicylates or the NSAIDs and during pregnancy. Aspirin is a Pregnancy Category D drug and may produce adverse maternal effects (e.g., anemia, postpartum hemorrhage, and prolonged gestation or labor). Maternal aspirin used may insignificant when one normal dose is taken. However, use of these drugs over a long period, even in normal doses, can result in a significant blood loss.

Salicylate toxicity produces a condition called salicylism. The symptoms of this condition are listed in Display 17-1. Mild salicylism usually occurs with repeated administration of large doses of a salicylate. This condition is reversible with reduction of the drug dosage.
also cause adverse fetal effects, such as low birth weight, intracranial hemorrhage in premature infants, stillbirths, and neonatal death. Other salicylates (ie, sal-salate and magnesium salicylate) are Pregnancy Category C drugs. Because the salicylates prolong bleeding time, they are contraindicated in those with bleeding disorders or bleeding tendencies. These include patients with gastrointestinal bleeding (due to any cause), blood dyscrasias, and those receiving anticoagulant or antineoplastic drugs. Children or teenagers with influenza or chickenpox should not take the salicylates, particularly aspirin, because their use appears to be associated with Reye’s syndrome (a life-threatening condition characterized by vomiting and lethargy, progressing to coma).

PRECAUTIONS

The salicylates are used cautiously in patients with hepatic or renal disease, preexisting hypoprothrombinemia, or vitamin K deficiency and during lactation. The drugs are also used with caution in patients with gastrointestinal irritation such as peptic ulcers and in patients with mild diabetes or gout.

INTERACTIONS

Food containing salicylate (curry powder, paprika, licorice, prunes, raisins, and tea) may increase the risk of adverse reactions. Coadministration of the salicylates with activated charcoal decreases the absorption of the salicylates. Antacids may decrease the effects of the salicylates. Coadministration with the carbonic anhydrase inhibitors increases the risk of salicylism. Aspirin may increase the risk of bleeding during heparin administration. Coadministration with the NSAIDs may increase NSAID blood levels.

NONSALICYLATES

The major drug classified as a nonsalicylate is acetaminophen (Tylenol, Dafrol, Panadol). Acetaminophen is the only drug of its kind available in the United States at this time. It is the most widely used aspirin substitute for patients who are allergic to aspirin or who experience extreme gastric upset when taking aspirin. Acetaminophen is also the drug of choice for treating children with fever and flu-like symptoms.

ACTIONS

Acetaminophen is a nonsalicylate nonnarcotic analgesic whose mechanism of action is unknown. Like the salicylates, acetaminophen has analgesic and antipyretic activity. However, acetaminophen does not possess anti-inflammatory action and is of no value in the treatment of inflammation or inflammatory disorders.

USES

Acetaminophen is used to relieve mild to moderate pain and to reduce elevated body temperature (fever). This drug is particularly useful for those with aspirin allergy and bleeding disorders, such as bleeding ulcer or hemophilia, those receiving anticoagulant therapy, and those who have recently had minor surgical procedures. Although acetaminophen has no anti-inflammatory action, it may be used to relieve the pain and discomfort associated with arthritic disorders.

ADVERSE REACTIONS

Acetaminophen causes few adverse reactions when used as directed on the label or recommended by the primary health care provider. Adverse reactions associated with the use of acetaminophen usually occur with chronic use or when the recommended dosage is exceeded. Adverse reactions to acetaminophen include skin eruptions, urticaria (hives), hemolytic anemia, pancytopenia (a reduction in all cellular components of the blood), hypoglycemia, jaundice (yellow discoloration of the skin), hepatotoxicity (damage to the liver), and hepatic failure (seen in chronic alcoholics taking the drug).
Acute acetaminophen poisoning or toxicity can occur after a single 10- to 15-g dose of acetaminophen. Dosages of 20 to 25 g may be fatal. With excessive dosages the liver cells necrose or die. Death can occur due to liver failure. The risk of liver failure increases in patients who are chronic alcoholics.

Signs of acute acetaminophen toxicity include the following:

- Nausea
- Vomiting
- Confusion
- Liver tenderness
- Hypotension
- Arrhythmias
- Jaundice
- Acute hepatic and renal failure

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Hypersensitivity to acetaminophen is a contraindication.

Hepatotoxicity has occurred in chronic alcoholics after therapeutic dosages. The individual taking acetaminophen should avoid alcohol if taking more than an occasional dose of acetaminophen and avoid taking acetaminophen concurrently with the salicylates or the NSAIDs. Acetaminophen is classified as Pregnancy Category B and is used cautiously during pregnancy and lactation. If an analgesic is necessary, it appears safe for short-term use. The drug is used cautiously in patients with severe or recurrent pain or high or continued fever because this may indicate a serious illness that is untreated. If pain persists for more than 5 days or if redness or swelling is present, the primary health care provider should be consulted.

Gerontologic Alert

If liver damage is present, the older adult should use acetaminophen with caution.

Acetaminophen may alter blood glucose test results, causing falsely lower blood glucose values. Use with the barbiturates, hydantoins, isoniazid, and rifampin may increase the toxic effects and possibly decrease the therapeutic effects of acetaminophen. The effects of the loop diuretics may be decreased when administered with acetaminophen. Hepatotoxicity has occurred in chronic alcoholics who are taking moderate doses of acetaminophen.

The Patient Receiving a Salicylate or a Nonsalicylate (Acetaminophen)

ASSESSMENT

Preadministration Assessment

Before giving a nonnarcotic analgesic to a patient, the nurse assesses the type, onset, and location of the pain. It is important to determine if this problem is different in any way from previous episodes of pain or discomfort. If the patient is receiving a nonnarcotic analgesic for an arthritic or musculoskeletal disorder or soft tissue inflammation, the nurse should examine the joints or areas involved. The appearance of the skin over the joint or affected area or any limitation of motion is documented. The nurse evaluates the patient's ability to carry out activities of daily living. This important information is used to develop a care plan, as well as to evaluate the response to drug therapy.

Nursing Alert

When administering acetaminophen, the nurse assesses the overall health and alcohol usage of the patient before administration. Patients who are malnourished or abuse alcohol are at risk of developing hepatotoxicity (damage to the liver) with the use of acetaminophen.

Ongoing Assessment

During the ongoing assessment, the nurse monitors the patient for relief of pain. If pain recurs it is important to assess its severity, location, and intensity. The nurse monitors the vital signs every 4 hours or more frequently if necessary. Hot, dry, flushed skin and a decrease in urinary output may develop if temperature elevation is prolonged and dehydration occurs. The nurse assesses the joints for decrease in inflammation and greater mobility.

The nurse reports to the primary care provider any adverse reactions, such as unusual or prolonged bleeding or dark stools.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient depend on the reason for administration of a nonnarcotic analgesic but may include an optimal response to drug therapy, which
includes relief of pain and fever, management of adverse reactions, and an understanding of and compliance with the prescribed treatment regimen.

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**

**PAIN.** The nurse notifies the primary health care provider if the salicylate or acetaminophen fails to relieve the patient’s pain or discomfort.

**IMBALANCED BODY TEMPERATURE.** If the patient is receiving the analgesic for reduction of elevated body temperature, the nurse checks the temperature immediately before and 45 to 60 minutes after administration of the drug. If a suppository form of the drug is used, it is important to check the patient after 30 minutes for retention of the suppository. If the drug fails to lower an elevated temperature, the nurse notifies the primary health care provider because other means of temperature control, such as a cooling blanket, may be necessary.

However, some health care providers may not prescribe an antipyretic for the patient with an elevated temperature because evidence suggests that fever activates the immune system to produce disease-fighting antibodies. The decision to treat an elevated temperature with an antipyretic is an individual one, based on the cause of the fever and the patient’s physical condition.

**IMPAIRED PHYSICAL MOBILITY.** The patient may have an acute or chronic disorder with varying degrees of mobility. The patient may be in acute pain or have longstanding mild to moderate pain. Along with the pain there may be skeletal deformities, such as the joint deformities seen with advanced rheumatoid arthritis. Considering the nature of the patient’s condition, the nurse’s assistance with ambulation may be required. The nurse determines the degree of immobility of the patient and assists the patient as needed.

**SALICYLATES.** The nurse gives the salicylates with food, milk, or a full glass of water to prevent gastric upset. If gastric distress occurs, the nurse notifies the primary health care provider because other drug therapy may be necessary. An antacid may be prescribed to minimize gastrointestinal distress.

The patient should avoid salicylates for at least 1 week before any type of major or minor surgery, including dental surgery, because of the possibility of postoperative bleeding. In addition, the patient should not use the salicylates after any type of surgery until complete healing has occurred. The patient may use acetaminophen or an NSAID after surgery or a dental procedure, when relief of mild pain is necessary.

**ACETAMINOPHEN.** The nurse administers acetaminophen with a full glass of water. The patient may take this drug with meals or on an empty stomach. Symptoms of overdose include nausea, vomiting, diaphoresis, and generalized malaise. Acute overdose may be treated with the administration of the drug acetylcysteine (Mucomyst) to prevent liver damage.

**Monitoring and Managing Adverse Reactions**

**SALICYLATES.** The nurse observes the patient for adverse drug reactions. When high doses of salicylates are administered (eg, to those with severe arthritic disorders), the nurse observes the patient for signs of salicylism. Should signs of salicylism occur, the nurse should notify the primary health care provider before the next dose is given because a reduction in dose or determination of the plasma salicylate level may be necessary. Therapeutic salicylate levels are between 100 and 300 mcg/mL. Symptoms associated with certain salicylate levels are:

- Levels greater than 150 mcg/mL may result in symptoms of mild salicylism, namely tinnitus (ringing sound in the ear), difficulty in hearing, dizziness, nausea, vomiting, diarrhea, mental confusion, central nervous system depression, headache, sweating, and hyperventilation (rapid, deep breathing).
- Levels greater than 250 mcg/mL may result in symptoms of mild salicylism plus headache, diarrhea, thirst, and flushing.
- Levels greater than 400 mcg/mL may result in respiratory alkalosis, hemorrhage, excitement, confusion, asterixis (involuntary jerking movements especially of the hands), pulmonary edema, convulsions, tetany (muscle spasms), fever, coma, shock, and renal and respiratory failure.
The nurse checks the color of the stools. Black or dark stools or bright red blood in the stool may indicate gastrointestinal bleeding. The nurse reports to the primary care provider any change in the color of the stool.

The nurse monitors the patient for signs and symptoms of acute salicylate toxicity or salicylism (see Display 17-1). Initial treatment includes induction of emesis or gastric lavage to remove any unabsorbed drug from the stomach. Activated charcoal diminishes salicylate absorption if given within 2 hours of ingestion. Further therapy is supportive (reduce hyperthermia and treat severe convulsions with diazepam). Hemodialysis is effective in removing the salicylate but is used only in patients with severe salicylism.

DISTURBED SENSORY PERCEPTION: AUDITORY. The nurse should also assess the patient for tinnitus or impaired hearing. Tinnitus or impaired hearing probably indicates high blood salicylate levels. If this is suspected, the nurse should withhold the drug and report any sensory alterations immediately. It is a good idea to explain to the patient that hearing loss disappears gradually after the drug therapy is discontinued.

Nursing Alert
The nurse immediately reports any signs of acetaminophen toxicity, such as nausea, vomiting, anorexia, malaise, diaphoresis, abdominal pain, confusion, liver tenderness, hypotension, arrhythmias, jaundice, and acute hepatic and renal failure. Early diagnosis is important because liver failure may be reversible. Toxicity is treated with gastric lavage, preferably within 4 hours of ingestion of the acetaminophen. Liver function studies are performed frequently. Acetylcysteine (Mucomyst) is an antidote to acetaminophen toxicity and acts by protecting liver cells and destroying acetaminophen metabolites. It is administered by nebulization within 24 hours after ingestion of the drug and after the gastric lavage. The primary health care provider may prescribe syrup of ipecac to induce vomiting in lieu of the gastric lavage.

Educating the Patient and Family
In some instances, a nonnarcotic analgesic may be prescribed for a prolonged period, such as when the patient has arthritis. Some patients may discontinue use of the drug, fail to take the drug at the prescribed or recommended intervals, increase the dose, or decrease the time interval between doses, especially if there is an increase or decrease in their symptoms. The patient and family must understand that the drug is to be taken even though symptoms have been relieved. The nurse develops a teaching plan to include the following:

GENERAL POINTS
• Take the drug exactly as prescribed by the primary health care provider. Do not increase or decrease the dosage, and do not take any over-the-counter (OTC) drugs without first consulting the primary health care provider. Notify the primary health care provider or dentist if the pain is not relieved.
• Take the drug with food or a full glass of water unless indicated otherwise by the primary health care provider. If gastric upset occurs, take the drug with food or milk. If the problem persists, contact the primary health care provider.
• Inform all health care providers, including dentists, when these drugs are taken on a regular or occasional basis.
• If the drug is used to reduce fever, contact the primary health care provider if the temperature continues to remain elevated for more than 24 hours.
• Do not consistently use an OTC nonnarcotic analgesic to treat chronic pain without first consulting the primary health care provider.
• Severe or recurrent pain or high or continued fever may indicate serious illness. If pain persists more than 10 days in adults, or if fever persists more than 3 days, consult the primary health care provider.

Gerontologic Alert
The salicylates are prescribed for the pain and inflammation associated with arthritis. Because older adults have a higher incidence of both rheumatoid arthritis and osteoarthritis and may use the nonnarcotic analgesics on a long-term basis, they are particularly vulnerable to gastrointestinal bleeding. The nurse should encourage the patient to take the drug with a full glass of water or with food because this may decrease the gastrointestinal effects.

Nursing Alert
Studies suggest that the use of salicylates (especially aspirin) may be involved in the development of Reye’s syndrome in children with chickenpox or influenza. This rare but life-threatening disorder is characterized by vomiting and lethargy, progressing to coma. Therefore, use of salicylates in children with chickenpox, fever, or flu-like symptoms is not recommended. Acetaminophen is recommended for the management of symptoms associated with these disorders.

ACETAMINOPHEN. Acetaminophen is usually well tolerated, and few adverse reactions are seen if the drug is given in recommended amounts. It is important not to exceed the recommended dosage of acetaminophen. If the patient is an alcoholic or chronic user of alcohol, acetaminophen intake is limited to no more than 2 g/d.
Home Care Checklist
DETECTING GASTROINTESTINAL BLEEDING

The patient with a musculoskeletal disorder commonly receives salicylates or NSAIDs (see Chap. 17) to help control inflammation and pain. In addition, these drugs are readily available over the counter (OTC). So a patient who is prescribed one drug, such as NSAIDs, may also take an OTC salicylate, such as aspirin, for headaches or additional pain relief. When taken alone, these drugs may cause gastrointestinal (GI) irritation, possibly leading to GI bleeding. If taken in combination or with high doses, or for long periods of time, your patient’s risk for GI bleeding increases dramatically. Be sure to teach your patient how to look for signs and symptoms of GI bleeding. Instruct the patient to report any of the following:

- Abdominal pain or distention, especially any sudden increases
- Vomiting that appears bright red or blood streaked (indicates fresh or recent bleeding)
- dark red, brown, or black, similar to the consistency of coffee grounds (indicates partial digestion of retained blood)
- Stools that appear black, loose and tarry
- bright red, red streaked, maroon, or dark mahogany colored

Also instruct your patient how to check the stools for occult blood (guaiac) by doing the following:

- Gather necessary supplies, including chemical testing solution, testing card, applicator, and watch with second hand.
- After passing stool and opening the flap of the testing card, obtain a sample of stool and place a thin smear on the first window or slot marked as “1” or “A.”
- Then, obtain a second sample from another area of the same stool and place a thin smear on the second window or slot marked as “2” or “B.”
- Close the flap of the test card.

If the health care provider or laboratory will be checking the test results, inform the patient to return the test card to them.
If the patient will be checking the sample, then instruct as follows:

- Turn the test card over and open the flap.
- Open the bottle of chemical testing solution.
- Place two drops of the solution onto each area of the paper with a sample.
- Wait 30 to 60 seconds.
- Then observe the paper for a color change. If there is no color change, the results are negative. If either area of the paper turns blue, the results are positive for blood and the patient should contact his or her health care provider as soon as possible.

SALICYLATES
- If taking a salicylate, notify the primary health care provider if any of the following symptoms occur: ringing in the ears, gastrointestinal pain, nausea, vomiting, flushing, sweating, thirst, headache, diarrhea, episodes of unusual bleeding or bruising, or dark stools. (See Home Care Checklist: Detecting Gastrointestinal Bleeding.)
- All drugs deteriorate with age. Salicylates often deteriorate at a more rapid rate than many other drugs. If there is a vinegar odor to the salicylate, discard the entire contents of the container. Purchase salicylates in small amounts when used on an occasional basis. Keep the container tightly closed at all times because salicylates deteriorate rapidly when exposed to air, moisture, and heat.
- The ingredients of some OTC drugs contain aspirin. The name of the salicylate may not appear in the name of the drug, but it is listed on the label. Do not
use these products while taking a salicylate, especially during high-dose or long-term salicylate therapy. Consult the pharmacist about the product’s ingredients if in doubt.
- If surgery or a dental procedure, such as tooth extraction or gum surgery, is anticipated, notify the primary health care provider or dentist. Salicylates may be discontinued 1 week before the procedure because of the possibility of postoperative bleeding.

ACETAMINOPHEN
- In the case of arthritis, do not change from aspirin to acetaminophen without consulting the primary health care provider. Acetaminophen lacks the anti-inflammatory properties of aspirin.
- Notify the primary health care provider if any of the following adverse reactions occur: dyspnea, weakness, dizziness, bluish discoloration of the nailbeds, unexplained bleeding, bruising, or sore throat.
- Avoid the use of alcoholic beverages.

EVALUATION
- Pain is relieved, and discomfort is reduced or eliminated.
- Body temperature is normal.
- Adverse reactions are identified, reported to the primary health care provider, and managed through nursing interventions.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.
- The patient demonstrates an understanding of the treatment regimen and adverse effects of the drug.

Critical Thinking Exercises
1. On a visit to an outpatient clinic, Ms. Cain tells you that she takes aspirin daily for the minor aches and pains she experiences. Determine what you might want to discuss with Ms. Cain to explore her use of this drug. Discuss what you might incorporate into the teaching plan to increase her knowledge of the drug and to prevent any complications.
2. Jim, a 49-year-old man, is at the outpatient clinic with complaints of muscular aches and pain. He is currently taking an over-the-counter aspirin product but states he is experiencing some gastric upset. He tells you that he plans to begin taking Tylenol because he has heard that it does not cause an upset stomach. What assessments would be important for the nurse to make? What information would you give Jim concerning the Tylenol?

Review Questions
1. At a team conference the nurse explains that the anti-inflammatory actions of the salicylates is most likely due to ______.
   A. a decrease in the prothrombin time
   B. a decrease in the productions of endorphins
   C. the inhibition of prostaglandins
   D. vasodilation of the blood vessels
2. Which of the following symptoms would the nurse expect in a patient experiencing salicylism?
   A. dizziness, tinnitus, mental confusion
   B. diarrhea, nausea, weight loss
   C. constipation, anorexia, rash
   D. weight gain, hyperglycemia, urinary frequency
3. When administering a salicylate the nurse most correctly administers the drug ______.
   A. between meals
   B. with a carbonated beverage
   C. with food or milk
   D. dissolved in juice
4. A nurse instructs the patient taking aspirin to avoid foods containing salicylates because this increases the risk of adverse reactions. Which foods should the patient avoid?
   A. salt, soft drinks
   B. broccoli, milk
   C. prunes, tea
   D. liver, pepper
5. The nurse monitors the alcoholic patient taking acetaminophen for symptoms of toxicity, which include ______.
   A. hypertension
   B. visual disturbances
   C. liver tenderness
   D. skin lesions
6. Which of the following drugs would the nurse most likely administer to a child with an elevated temperature?
   A. baby aspirin
   B. acetaminophen
   C. fenoprofen
   D. diflunisal

Medication Dosage Problems
1. The physician orders acetaminophen elixir 180 mg PO. Acetaminophen elixir is available in a 120-mg/mL solution. The nurse administers ______.
2. A aspirin 650 mg PO is prescribed. On hand is aspirin in 325-mg tablets. The nurse administers ______.
Nonnarcotic Analgesics: Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

Key Terms
- cyclooxygenase
- cyclooxygenase-1 (COX-1)
- cyclooxygenase-2 (COX-2)
- prostaglandin

Chapter Objectives
On completion of this chapter, the student will:
- Discuss the types, uses, general drug actions, common adverse reactions, contraindications, precautions, and interactions of the NSAIDs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking the NSAIDs.
- List some nursing diagnoses particular to a patient taking an NSAID.
- Discuss the ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating patients about the use of the NSAIDs.

The nonsteroidal anti-inflammatory drug (NSAID) group contains a large number of drugs. There are more than 70 drugs in this category, with new drugs continually becoming available. Some texts include the salicylates in the NSAID group, whereas others do not. Although the chemical and physiologic effects are similar, this text discusses the salicylates in a separate chapter (see Chap. 17). The NSAIDs are another type of nonnarcotic analgesic. This chapter covers general information on the NSAID group and discusses four of the more commonly used NSAIDs specifically. The four NSAIDs discussed in this chapter are celecoxib (Celebrex), ibuprofen (Advil), naproxen (Naprosyn), and rofecoxib (Vioxx). Other NSAIDs are listed in the Summary Drug Table: Nonsteroidal Anti-inflammatory Drugs. Like the salicylates, the NSAIDs have anti-inflammatory, antipyretic, and analgesic effects.

ACTIONS

The NSAIDs are so named because they do not belong to the steroid group of drugs and thus do not possess the adverse reactions associated with the steroids (see Chap. 50), and yet they have anti-inflammatory effects. In addition, NSAIDs have analgesic and antipyretic properties. Although the exact mechanisms of actions are not known, the NSAIDs are thought to act by inhibiting prostaglandin (a group of naturally occurring fatty acids that act within the body to regulate acid secretion of the stomach, regulate body temperature and platelet aggregation, and control inflammation) synthesis by inhibiting the action of the enzyme cyclooxygenase, the enzyme responsible for prostaglandin synthesis. The NSAIDs act to inhibit the activity of two related enzymes:

1. cyclooxygenase-1 (COX-1), the enzyme that helps to maintain the stomach lining; and
2. cyclooxygenase-2 (COX-2), the enzyme that triggers pain and inflammation.

The anti-inflammatory effects of the NSAIDs are carried out by inhibition of COX-2. The gastrointestinal adverse reactions are caused by inhibition of COX-1. The newer NSAIDs (celecoxib and rofecoxib) appear to work by specifically inhibiting the COX-2 enzyme, without inhibiting the COX-1 enzyme. Celecoxib and rofecoxib relieve pain and inflammation with less potential for gastrointestinal adverse
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>celecoxib</td>
<td>Celebrex</td>
<td>Acute and long-term treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis; reduction of the number of colorectal polyps in familial adenomatous polyposis</td>
<td>Headache, dizziness, somnolence, insomnia, dyspepsia, rash, fatigue, ophthalmic changes</td>
<td>100–200 mg PO BID as needed</td>
</tr>
<tr>
<td>diclofenac</td>
<td>Voltaren, generic</td>
<td>Signs and symptoms of rheumatoid arthritis and osteoarthritis, ankylosing spondylitis</td>
<td>Nausea, gastric or duodenal ulcer formation, gastrointestinal (GI) bleeding</td>
<td>Osteoarthritis: 100–150 mg/d PO in divided doses; rheumatoid arthritis: 150–200 mg/d PO in divided doses; ankylosing spondylitis: 100–125 mg/d PO in divided doses</td>
</tr>
<tr>
<td>sodium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>potassium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>diclofenac</td>
<td>Cataflam, generic</td>
<td>Signs and symptoms of rheumatoid arthritis and osteoarthritis, ankylosing spondylitis</td>
<td>Nausea, gastric or duodenal ulcer formation, gastrointestinal (GI) bleeding</td>
<td>Osteoarthritis: 50 mg PO BID–TID; Rheumatoid arthritis: 50 mg PO BID–TID; Ankylosing spondylitis: 25 mg PO QID with 25 mg hs PRN</td>
</tr>
<tr>
<td>potassium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>etodolac</td>
<td>Lodine, Lodine XL, generic</td>
<td>Osteoarthritis, mild to moderate pain, rheumatoid arthritis</td>
<td>Dizziness, tiredness, nausea, dyspepsia, rash, constipation, bleeding, diarrhea</td>
<td>Osteoarthritis, rheumatoid arthritis: Maintenance, 600–1200 mg/d in divided doses. Maximum dose 1200 mg/d</td>
</tr>
<tr>
<td>calcium</td>
<td>Nalfon, generic</td>
<td>Signs and symptoms of rheumatoid arthritis and osteoarthritis, long-term management of mild to moderate pain</td>
<td>Dizziness, visual disturbances, jaundice, nausea, vomiting, peptic ulcer</td>
<td>Rheumatoid arthritis and osteoarthritis: 300–600 mg PO TID, QID; pain: 200 mg PO q4–8h</td>
</tr>
<tr>
<td>fenoprofen</td>
<td>Ansaid, generic</td>
<td>Signs and symptoms of rheumatoid arthritis and osteoarthritis</td>
<td>Nausea, vomiting, diarrhea, constipation, gastric or duodenal ulcer formation, GI bleeding, headache</td>
<td>Up to 300 mg/d PO in divided doses</td>
</tr>
<tr>
<td>calcium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fenoprofen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>flurbiprofen</td>
<td>Ansaid, generic</td>
<td>Signs and symptoms of rheumatoid arthritis and osteoarthritis</td>
<td>Nausea, vomiting, diarrhea, constipation, gastric or duodenal ulcer formation, GI bleeding, headache</td>
<td>Arthritis disorders: 12–32 g/d PO in divided doses; pain: 400 mg PO q4–6h; dysmenorrhea: 400 mg PO q4h</td>
</tr>
<tr>
<td>flur-bi'-proe-fen</td>
<td>Ansaid, generic</td>
<td>Signs and symptoms of rheumatoid arthritis and osteoarthritis</td>
<td>Nausea, vomiting, diarrhea, constipation, gastric or duodenal ulcer formation, GI bleeding, headache</td>
<td>Arthritis disorders: 12–32 g/d PO in divided doses; pain: 400 mg PO q4–6h; dysmenorrhea: 400 mg PO q4h</td>
</tr>
<tr>
<td>ibuprofen</td>
<td>Advil, Genpril, Nuprin, Motrin, generic</td>
<td>Mild to moderate pain, rheumatoid disorders, painful dysmenorrhea</td>
<td>Nausea, dizziness, somnolence, dyspepsia, gastric or duodenal ulcer formation, GI bleeding, headache</td>
<td>Anti-inflammatory and analgesic: 25–50 mg PO BID–TID not to exceed 200 mg/d</td>
</tr>
<tr>
<td>eye-byoo'-proe-fen</td>
<td>Advil, Genpril, Nuprin, Motrin, generic</td>
<td>Mild to moderate pain, rheumatoid disorders, painful dysmenorrhea</td>
<td>Nausea, dizziness, somnolence, dyspepsia, gastric or duodenal ulcer formation, GI bleeding, headache</td>
<td>Anti-inflammatory and analgesic: 25–50 mg PO BID–TID not to exceed 200 mg/d</td>
</tr>
<tr>
<td>indomethacin</td>
<td>Indocin, generic</td>
<td>Rheumatoid arthritis, ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder, acute gouty arthritis</td>
<td>Nausea, constipation, gastric or duodenal ulcer formation, GI bleeding, headache, hematologic changes</td>
<td>Arthritis disorders: 12–32 g/d PO in divided doses; pain: 400 mg PO q4–6h; dysmenorrhea: 400 mg PO q4h</td>
</tr>
<tr>
<td>in-doe-meth'-a-sin</td>
<td>Indocin, generic</td>
<td>Rheumatoid arthritis, ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder, acute gouty arthritis</td>
<td>Nausea, constipation, gastric or duodenal ulcer formation, GI bleeding, headache, hematologic changes</td>
<td>Arthritis disorders: 12–32 g/d PO in divided doses; pain: 400 mg PO q4–6h; dysmenorrhea: 400 mg PO q4h</td>
</tr>
<tr>
<td>ketoprofen</td>
<td>Orudis, Oruvail, generic</td>
<td>Mild to moderate pain, rheumatoid disorders, painful dysmenorrhea</td>
<td>Dizziness, visual disturbances, nausea, constipation, vomiting, diarrhea, gastric or duodenal ulcer formation, GI bleeding, headache</td>
<td>Arthritis: 150–300 mg/d in divided doses; Primary dysmenorrhea: 25–50 mg q6–8h PRN; 30–60 mg IM initially, followed by half the initial dose q6h PRN; 10 mg q4–6h PO, PRN; maximum dose, 40 mg/d</td>
</tr>
<tr>
<td>kee-to-proe-fen</td>
<td>Orudis, Oruvail, generic</td>
<td>Mild to moderate pain, rheumatoid disorders, painful dysmenorrhea</td>
<td>Dizziness, visual disturbances, nausea, constipation, vomiting, diarrhea, gastric or duodenal ulcer formation, GI bleeding, headache</td>
<td>Arthritis: 150–300 mg/d in divided doses; Primary dysmenorrhea: 25–50 mg q6–8h PRN; 30–60 mg IM initially, followed by half the initial dose q6h PRN; 10 mg q4–6h PO, PRN; maximum dose, 40 mg/d</td>
</tr>
<tr>
<td>ketorolac</td>
<td>Toradol, generic</td>
<td>Short-term management of pain; osteoarthritis, rheumatoid arthritis</td>
<td>Dyspepsia, nausea, GI pain, pain at injection site, drowsiness</td>
<td>10 mg q4–6h PO, PRN; maximum dose, 15 mg q4–6h PRN; maximum dose, 40 mg/d</td>
</tr>
<tr>
<td>kee'-toe-role-ak</td>
<td>Toradol, generic</td>
<td>Short-term management of pain; osteoarthritis, rheumatoid arthritis</td>
<td>Dyspepsia, nausea, GI pain, pain at injection site, drowsiness</td>
<td>10 mg q4–6h PO, PRN; maximum dose, 15 mg q4–6h PRN; maximum dose, 40 mg/d</td>
</tr>
</tbody>
</table>

SUMMARY DRUG TABLE NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>meclofenamate mekloe-fen-am'-ate</td>
<td>generic</td>
<td>Rheumatoid arthritis; mild to moderate pain; dysmenorrhea</td>
<td>Headache, dizziness, tiredness, insomnia, nausea, dyspepsia, constipation, rash, bleeding</td>
<td>Rheumatoid arthritis: 200–400 mg/d PO in 3–4 doses; pain: 50 mg q4–6h, maximum dose, 400 mg/d; dysmenorrhea: 100 mg PO TID</td>
</tr>
<tr>
<td>mefenamic acid me-fe-nam'-ik</td>
<td>Ponstel</td>
<td>Moderate pain that does not exceed 1 wk</td>
<td>Dizziness, tiredness, nausea, dyspepsia, rash, constipation, bleeding, diarrhea</td>
<td>500 mg followed by 250 mg q6h PO PRN, maximum dose, 1 wk of therapy</td>
</tr>
<tr>
<td>meloxicam mel-ox'-i-kam</td>
<td>Mobic</td>
<td>Osteoarthritis</td>
<td>Nausea, dyspepsia, GI pain, headache, dizziness, somnolence, insomnia, rash</td>
<td>7.5–15 mg PO QD</td>
</tr>
<tr>
<td>nabumetone nah-byew'-meh-tone</td>
<td>Relafen</td>
<td>Rheumatoid arthritis and osteoarthritis</td>
<td>Dizziness, tiredness, nausea, dyspepsia, rash, constipation, bleeding, diarrhea</td>
<td>1000–2000 mg/d PO</td>
</tr>
<tr>
<td>naproxen na-prox'-en</td>
<td>Aleve, Anaprox, Naprosyn, Naprelan, generic</td>
<td>Management of inflammatory disorders including rheumatoid arthritis and osteoarthritis, management of mild to moderate pain, treatment of dysmenorrhea</td>
<td>Dizziness, visual disturbances, headache, nausea, vomiting, gastric or duodenal ulcer formation, GI bleeding</td>
<td>Pain, primary dysmenorrhea: 500 mg initially then 250 mg q6–8h; arthritic disorders: 250–500 mg PO BID</td>
</tr>
<tr>
<td>oxaprozin oks-a-pro'-zin</td>
<td>Daypro</td>
<td>Rheumatoid arthritis and osteoarthritis</td>
<td>Dizziness, tiredness, nausea, dyspepsia, rash, constipation, bleeding, diarrhea</td>
<td>1200 mg PO QD</td>
</tr>
<tr>
<td>piroxicam peer-ox'-i-kam</td>
<td>Feldene, generic</td>
<td>Mild to moderate pain, rheumatoid arthritis and osteoarthritis</td>
<td>Nausea, vomiting, diarrhea, drowsiness, gastric or duodenal ulcer formation, GI bleeding</td>
<td>20 mg/d PO as a single dose or 10 mg PO BID</td>
</tr>
<tr>
<td>rofecoxib roh-fah-cox'-ib</td>
<td>Vioxx</td>
<td>Signs and symptoms of osteoarthritis, management of acute pain, primary dysmenorrhea</td>
<td>Same as celecoxib</td>
<td>Osteoarthritis: 12.5 mg or 25 mg/d PO Dysmenorrhea and acute pain: 50 mg PO QD for no more than 5 days</td>
</tr>
<tr>
<td>sulindac sul-in'-dak</td>
<td>Clinoril, generic</td>
<td>Mild to moderate pain, rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, gouty arthritis</td>
<td>Nausea, vomiting, diarrhea, constipation, gastric or duodenal ulcer formation, GI bleeding</td>
<td>150–200 mg PO BID for 1–2 wk, then reduce dose (not to exceed 400 mg/d)</td>
</tr>
<tr>
<td>tolmetin sodium tole-met-in</td>
<td>Tolectin</td>
<td>Mild to moderate pain, rheumatoid arthritis and osteoarthritis</td>
<td>Nausea, vomiting, diarrhea, constipation, gastric or duodenal ulcer formation, GI bleeding</td>
<td>400 mg PO TID or BID, not to exceed 2 g/d</td>
</tr>
<tr>
<td>valdecoxib val-dah-cox'-ib</td>
<td>Bextra</td>
<td>Osteoarthritis, rheumatoid arthritis, primary dysmenorrhea</td>
<td>Headache, nausea, dyspepsia, abdominal pain, anemia</td>
<td>Arthritis 10 mg/d PO; primary dysmenorrhea, 20 mg BID PRN</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.*
reactions. The traditional NSAIDs, such as ibuprofen and naproxen, are thought to regulate the pain and inflammation by blocking COX-2. Unlike celecoxib and rofecoxib, these drugs also inhibit COX-1, the enzyme that helps maintain the lining of the stomach. This inhibition of COX-1 causes the unwanted gastrointestinal reactions, such as stomach irritation and ulcers.

USES

The NSAIDs have a variety of uses that vary depending on the drug selected. NSAIDs are used for the following conditions:

- Relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and other musculoskeletal disorders (see Chap. 19 for more information on these disorders)
- Mild to moderate pain relief
- Primary dysmenorrhea
- Fever reduction

The uses of individual NSAIDs are given in the Summary Drug Table: Nonsteroidal Anti-inflammatory Drugs.

ADVERSE REACTIONS

Many adverse reactions are associated with the use of the NSAIDs. However, many patients take these drugs and experience few, if any, side effects. Some of the adverse reactions associated with the use of these drugs are listed here.

- Gastrointestinal tract—nausea, vomiting, diarrhea, constipation, epigastric pain, indigestion, abdominal distress or discomfort, intestinal ulceration, stomatitis, jaundice, bloating, anorexia, and dry mouth
- Central nervous system—dizziness, anxiety, light-headedness, vertigo, headache, drowsiness, insomnia, confusion, depression, and psychic disturbances
- Cardiovascular—congestive heart failure, decrease or increase in blood pressure, and cardiac arrhythmias
- Renal—hematuria, cystitis, elevated blood urea nitrogen, polyuria, dysuria, oliguria, and acute renal failure in those with impaired renal function
- Special senses—visual disturbances, blurred or diminished vision, diplopia, swollen or irritated eyes, photophobia, reversible loss of color vision, tinnitus, taste change, and rhinitis
- Hematologic—neutropenia, eosinophilia, leukopenia, pancytopenia, thrombocytopenia, agranulocytosis, and aplastic anemia
- Skin—rash, erythema, irritation, skin eruptions, exfoliative dermatitis, Stevens-Johnson syndrome, ecchymosis, and purpura
- Metabolic/endocrinologic—decreased appetite, weight increase or decrease, hyperglycemia, hypoglycemia, flushing, sweating, menstrual disorders, and vaginal bleeding
- Other—thirst, fever, chills, and vaginitis

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The NSAIDs are contraindicated in patients with known hypersensitivity. There is a cross-sensitivity to other NSAIDs. Therefore, if a patient is allergic to one NSAID, there is an increased risk of an allergic reaction with any other NSAID. Hypersensitivity to aspirin is a contraindication for all NSAIDs. In general, the NSAIDs are contraindicated during the third trimester of pregnancy and during lactation.

The NSAIDs are used cautiously in patients with bleeding disorders, renal disease, cardiovascular disease, or hepatic impairment and in the elderly. There is an increased risk of ulcer formation in patients older than 65 years. Most NSAIDs are classified as Pregnancy Category B. In general, the NSAIDs are used with extreme caution during pregnancy, especially in large doses or during the third trimester (see above).

The NSAIDs prolong bleeding time and increase the effects of anticoagulants, lithium, cyclosporine, and the hydantoins. These drugs may decrease the effects of diuretics or antihypertensive drugs. Long-term use of the NSAIDs with acetaminophen may increase the risk of renal impairment.

COMMON ADVERSE REACTIONS OF SELECT NSAIDs

Celecoxib

The most common adverse reactions seen with celecoxib include dyspepsia, abdominal pain, diarrhea, nausea, and headache. Like other NSAIDs, celecoxib may compromise renal function. Elevation of aminotransferase levels also occurs.
**Ibuprofen**

This drug is available to individuals as an over-the-counter drug and may be purchased without a prescription. The drug is used in children with juvenile arthritis and for fever reduction in children 6 months to 12 years. Common adverse reactions seen with ibuprofen include headache, dizziness, somnolence, nausea, dyspepsia, gastrointestinal pain, and rash.

**Naproxen**

Common adverse reactions seen with naproxen include headache, vertigo (dizziness), somnolence, insomnia, nausea, dyspepsia, gastrointestinal pain, and rash.

**Rofecoxib**

Common adverse reactions seen with rofecoxib include headache, dizziness, somnolence, insomnia, dyspnea, hemoptysis, and rash.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Celecoxib**

Celecoxib is contraindicated in patients who are allergic to the drug itself, the sulfonamides, other NSAIDs, or aspirin; it also is contraindicated during pregnancy (Category C) and lactation.

The drug is used cautiously in patients with a history of peptic ulcer, individuals older than 60 years, and those taking an anticoagulant or steroids. In rare instances, serious stomach problems such as bleeding can occur without warning. When celecoxib is given with the anticoagulants, there is an increased risk for bleeding.

**Ibuprofen**

Ibuprofen is contraindicated in individuals who are allergic to the drug or other NSAIDs; those who have hypertension, peptic ulceration, or gastrointestinal bleeding; and during pregnancy (Category B) and lactation. The drug is used cautiously in patients with renal or liver dysfunction. When ibuprofen is used with lithium, there is an increased risk of lithium toxicity. A decreased effect of the diuretic may occur when administered with ibuprofen. When ibuprofen is administered with the beta-adrenergic blocking drugs there is a risk for a decrease in the antihypertensive effect of the beta-adrenergic blocking drug.

**Naproxen**

Naproxen is contraindicated in patients who are allergic to the drug or other NSAIDs and during pregnancy (Category B) and lactation. The drug is used cautiously in patients with asthma, hypertension, cardiac problems, peptic ulcer disease, and impaired liver or kidney function. Like ibuprofen, naproxen increases the risk of lithium toxicity when the drug is administered with naproxen. When naproxen is administered with the anticoagulants there is an increased risk for bleeding. When naproxen is administered with the antihypertensives, there is a decrease in the antihypertensive effect. Coadministration of naproxen with the diuretics decreases the diuretic effect.

**Rofecoxib**

Rofecoxib is contraindicated in patients who are allergic to the drug, any of the NSAIDs, or the sulfonamides. The drug is not used during pregnancy (Category C) or lactation. Rofecoxib is used cautiously in patients with impaired renal or hepatic function, in those with a history of gastrointestinal bleeding or peptic ulcer disease, and in patients with congestive heart failure, asthma, or hypertension. Interactions with rofecoxib are similar to those with the other NSAIDs, such as an increased risk of bleeding when taken with anticoagulants and possible risk of lithium toxicity when taken concurrently with lithium.

**NURSING PROCESS**

**The Patient Receiving a Nonsteroidal Anti-inflammatory Drug**

**ASSESSMENT**

*Preadministration Assessment*

Before administering an NSAID, it is important for the nurse to determine if the patient has any history of allergy to aspirin or any other NSAID. The nurse determines if the patient has a history of gastrointestinal bleeding, hypertension, peptic ulceration, or impaired hepatic or renal function. If so, the nurse notifies the primary health care provider before administering an NSAID.

In addition, before giving an NSAID to a patient, the nurse assesses the type, onset, and location of the pain. It is important to determine if this problem is different in any way from previous episodes of pain or discomfort. If the patient is receiving an NSAID for arthritis, a musculoskeletal disorder, or soft tissue inflammation, the nurse should examine the joints or areas involved. The appearance of the skin over the joint or affected area or any limitation of motion is documented. The
nurse evaluates the patient’s ability to carry out activities of daily living. This important information is used to develop a care plan, as well as to evaluate the response to drug therapy.

**Ongoing Assessment**
During the ongoing assessment, the nurse monitors the patient for relief of pain. If pain recurs it is important to assess its severity, location, and intensity. The nurse monitors the vital signs every 4 hours or more frequently if necessary. Hot, dry, flushed skin and a decrease in urinary output may develop if temperature elevation is prolonged and dehydration occurs. The nurse assesses the joints for a decrease in inflammation and greater mobility. The nurse reports adverse reactions, such as unusual or prolonged bleeding or dark-colored stools, to the primary health care provider.

**NURSING DIAGNOSES**
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**
The expected outcomes for the patient depend on the reason for administration of the NSAID but may include an optimal response to drug therapy, which includes relief of pain and fever, management of adverse reactions, and an understanding of and compliance with the prescribed treatment regimen.

**IMPLEMENTATION**
**Promoting an Optimal Response to Therapy**
The nurse should give the NSAIDs with food, milk, or antacids. Patients who do not experience a therapeutic response to one NSAID may have such a response to another NSAID. However, several weeks of treatment may be necessary to receive full therapeutic response.

The NSAIDs are prescribed for the pain and inflammation associated with arthritis. Because older adults have a higher incidence of both rheumatoid arthritis and osteoarthritis and may use the NSAID on a long-term basis, they are particularly vulnerable to gastrointestinal bleeding. The nurse should encourage the patient to take the drug with a full glass of water or with food because this may decrease the gastrointestinal effects.

![Gerontologic Alert]
Age appears to increase the possibility of adverse reactions to the NSAIDs. The risk of serious ulcer disease in adults older than 65 years is increased with higher doses of the NSAIDs. Use greater care and begin with reduced dosages in the elderly, increasing the dosage slowly.

**Pain and Impaired Physical Mobility**
The nurse provides comfort measures to the patient with pain from the limbs or joints affected by the various musculoskeletal disorders. Limbs are supported by proper positioning, in the use of heat or cold, joint rest, and avoidance of joint overuse. Various orthodontic devices, such as splints and braces, may be used to support inflamed joints. The use of braces, splints, and assistive mobility devices such as canes, crutches, and walkers eases pain by limiting movement or stress from weight bearing on painful joints. The nurse may need to assist the patient while ambulating or help the patient when using assistive devices to walk. Patients with osteoarthritis should exhibit an increased range of motion and a reduction in tenderness, pain, stiffness, and swelling.

**Monitoring and Managing Adverse Reactions**
It is important to observe the patient receiving an NSAID for adverse drug reactions throughout therapy. Because these drugs have many adverse reactions, the nurse notifies the primary health care provider of any complaints the patient may have. Gastrointestinal reactions are the most common and can be severe and sometimes fatal, especially in those prone to upper gastrointestinal disease.

![Nursing Alert]
The nurse withholds the next dose and notifies the primary health care provider immediately if any gastric symptoms, especially nausea, vomiting, diarrhea, evidence of bleeding (blood in stool, tarry stools), or abdominal pain occurs.

**Nursing Diagnoses Checklist**
- **Acute or Chronic Pain** related to physical disorder (name of specific disorder)
- **Impaired Physical Mobility** related to muscle and joint stiffness

The NSAIDs may cause visual disturbances. The nurse reports any complaints of blurred or diminished vision or changes in color vision to the primary health care provider. Corneal deposits and retinal disturbances may also occur. The primary health care provider may discontinue therapy if ocular changes are noted. Blurred vision may be significant and warrants thorough examination.
Because the visual changes may be asymptomatic, patients on long-term therapy require periodic eye examinations.

**Educating the Patient and Family**

In many instances, an NSAID may be prescribed for a prolonged period, such as when the patient has arthritis. Some patients may discontinue their drug use, fail to take the drug at the prescribed or recommended intervals, increase the dose, or decrease the time interval between doses, especially if there is an increase or decrease in their symptoms. The patient and family must understand that the drug is to be taken even though symptoms have been relieved. The nurse develops a teaching plan to include the following information.

- Take the drug exactly as prescribed by the primary health care provider. Do not increase or decrease the dosage, and do not take any over-the-counter (OTC) drugs without first consulting the primary health care provider. Notify the primary health care provider or dentist if the pain is not relieved.
- Take the drug with food or a full glass of water unless indicated otherwise by the primary health care provider. If gastric upset occurs, take the drug with food or milk. If the problem persists, contact the primary health care provider.
- Inform all health care providers, including dentists, when these drugs are taken on a regular or occasional basis.
- If the drug is used to reduce fever, contact the primary health care provider if the temperature continues to remain elevated for more than 24 hours.
- Do not consistently use an OTC nonnarcotic analgesic to treat chronic pain without first consulting the primary health care provider.
- Severe or recurrent pain or high or continued fever may indicate serious illness. If pain persists more than 10 days in adults, or if fever persists more than 3 days, consult the primary health care provider.
- Avoid the use of aspirin or other salicylates when taking an NSAID.
- The drug may take several days to produce an effect (relief of pain and tenderness). If some or all of the symptoms are not relieved after 2 weeks of therapy, continue taking the drug, but notify the primary health care provider.
- These drugs may cause drowsiness, dizziness, or blurred vision. Use caution while driving or performing tasks that require alertness.
- Notify the primary health care provider if any of the following adverse reactions occur: skin rash, itching, visual disturbances, weight gain, edema, diarrhea, black stools, nausea, vomiting, or persistent headache. See Home Care Checklist: Using Over-the-Counter Nonsteroidal Anti-inflammatory Drugs.
EVALUATION

- Pain is relieved, and discomfort is reduced or eliminated.
- Body temperature is normal.
- Adverse reactions are identified, reported to the primary health care provider, and managed.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.
- The patient demonstrates an understanding of the treatment regimen and adverse effects of the drug.

Critical Thinking Exercises

1. Mr. Nunn, age 68 years, has been prescribed an NSAID for the treatment of arthritis and has been taking the drug for 2 weeks. When keeping an outpatient appointment, Mr. Nunn tells you that he has noticed very little, if any, improvement in his arthritis and complains of nausea, difficulty hearing, constipation, and bloating. Analyze what steps you might take to investigate this problem. Give a reason for your answers.

2. Ms. Parker, age 72 years, is prescribed celecoxib for osteoarthritis. She is confused at times and has difficulty hearing. In developing a teaching plan for Ms. Parker, discuss what assessments would be important. Identify points to include in her teaching plan.

Review Questions

1. The nurse observes a patient for which of the common adverse reactions when administering naproxen?
   A. headache, dyspepsia
   B. blurred vision, constipation
   C. anorexia, tinnitus
   D. stomatitis, confusion

2. An elderly patient is receiving sulindac. The nurse is aware that older adults taking NSAIDs are at increased risk for ______.
   A. ulcer disease
   B. stroke
   C. myocardial infarction
   D. gout

3. When a patient is receiving a nonsteroidal anti-inflammatory drug, the nurse must monitor the patient for ______.
   A. agitation, which indicates nervous system involvement
   B. urinary retention, which indicates renal insufficiency
   C. decrease in WBC count, which increases the risk for infection
   D. gastrointestinal symptoms, which can be serious and sometimes fatal

4. Which of the following statements would the nurse be certain to include in a teaching plan for the patient taking a NSAID?
   A. If gastrointestinal upset occurs, take this drug on an empty stomach.
   B. Avoid the use of aspirin or other salicylates when taking these drugs.
   C. These drugs can cause extreme confusion and should be used with caution.
   D. Relief from pain and inflammation should occur within 30 minutes after the first dose.

Medication Dosage Problems

1. Naprosyn oral suspension 250 mg is prescribed. The dosage on hand is oral suspension 125 mg/5 mL. The nurse administers ______.

2. The physician orders celecoxib 200 mg PO. The nurse has celecoxib 100-mg tablets on hand. The nurse administers ______.
Pain is a complex occurrence that is uniquely experienced by each individual. It has been defined as the emotional and sensory perceptions associated with real or potential tissue damage (see Chap. 17 for a discussion on pain). Acute pain is a warning that something is not right in the body. Chronic pain is pain that persists beyond the expected time for healing. Analgesics are drugs that relieve pain. The narcotic analgesics are controlled substances (see Chap. 1) used to treat moderate to severe pain. Nurses must be knowledgeable concerning pain assessment and management if the patient’s pain is to be adequately managed. Despite advances in technology and pharmacologic measures, evidence exists indicating that for many, pain is not managed adequately.

Drugs that counteract the effects of the narcotic analgesics are the narcotic antagonists. These drugs compete with the narcotics at the receptor sites and are used to reverse the depressant effects of the narcotic analgesics. Both types of drugs are discussed in this chapter.

**NARCOTIC ANALGESICS**

Opioid analgesics are the narcotic analgesics obtained from the opium plant. More than 20 different alkaloids are obtained from the unripe seed of the opium poppy plant. The analgesic properties of opium have been known for hundreds of years. The narcotics obtained from raw opium (also called the opiates, opioids, or opiate narcotics) include morphine, codeine, hydrochlorides of opium alkaloids, and camphorated tincture of opium.

Morphine, when extracted from raw opium and treated chemically, yields the semisynthetic narcotics hydromorphone, oxymorphone, oxycodone, and heroin. Heroin is an illegal narcotic in the United States and is not used in medicine. Synthetic narcotics are those man-made analgesics with properties and actions similar to the natural opioids. Examples of synthetic narcotic analgesics are methadone, levorphanol, remifentanil, and meperidine. Additional narcotics are listed in the Summary Drug Table: Narcotic Analgesics.

**ACTIONS**

Narcotic analgesics are classified as agonists, partial agonists, and mixed agonists-antagonists. The agonist binds to a receptor and causes a response. A partial agonist binds to a receptor, but the response is limited (ie, is not as great as with the agonist). Antagonists bind to a receptor and cause no response. A narcotic antagonist can reverse the effects of the agonist. This reversal is possible because the antagonist competes with the agonist for a receptor site.
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>alfentanil HCL</td>
<td>Alfenta</td>
<td>Analgesic, anesthetic</td>
<td>Respiratory depression, skeletal muscle rigidity, light-headedness, sedation, constipation, dizziness, nausea, vomiting</td>
<td>Individualize dosage and titrate to obtain desired effect</td>
</tr>
<tr>
<td>codeine</td>
<td>generic</td>
<td>Analgesic, antitussive</td>
<td>Sedation, sweating, headache, dizziness, lethargy, confusion, light-headedness</td>
<td>Analgesic: 15–60 mg q4–6h PRN PO, IV, SC, IM; antitussive: 10–20 mg PO q4–6h; maximum dose, 120 mg/24 h</td>
</tr>
<tr>
<td>fentanyl</td>
<td>Sublimaze, generic</td>
<td>Analgesic, anesthesia before, during, and after surgery</td>
<td>Sedation, sweating, headache, vertigo, lethargy, confusion, light-headedness, nausea, vomiting, respiratory depression</td>
<td>Preanesthesia: 0.05–0.1 mg IM; postoperative: 0.05–0.1 mg IM; anesthesia: administered by anesthesiologist</td>
</tr>
<tr>
<td>fentanyl transmucosal system</td>
<td>Actiq, Fentanyl Oralet</td>
<td>Fentanyl Oralet: only as anesthetic premedication Actiq: only as management of breakthrough cancer pain</td>
<td>Sedation, sweating, headache, vertigo, lethargy, confusion, light-headedness, nausea, vomiting, respiratory depression</td>
<td>Individualize dosage: Oralet up to 5 mcg/kg/dose (lozenges) Actiq: 200 mcg/dose (lozenge on a stick)</td>
</tr>
<tr>
<td>hydromorphone</td>
<td>Dilaudid</td>
<td>Analgesic</td>
<td>Sedation, vertigo, lethargy, confusion, light-headedness, nausea, vomiting, respiratory depression</td>
<td>2–4 mg PO, IM, SC q4–6h; 3 mg q6–8h rectally</td>
</tr>
<tr>
<td>levomethadyl acetate</td>
<td>Orlaam</td>
<td>Opioid dependence</td>
<td>Sedation, lethargy, nausea, vomiting, clamminess, sweating, vertigo, unusual dreams, respiratory depression</td>
<td>Individualized dosage of 60–90 mg PO 3 times a wk</td>
</tr>
<tr>
<td>levorphanol tartrate</td>
<td>Levo-Dromoran</td>
<td>Analgesic, preoperative medication</td>
<td>Dizziness, sedation, nausea, vomiting, dry mouth, sweating, respiratory depression</td>
<td>2–3 mg PO, SC, IM q4h PRN; 1 mg IV q3–8 h PRN</td>
</tr>
<tr>
<td>meperidine</td>
<td>Demerol</td>
<td>Analgesic, preoperative medication, support of anesthesia</td>
<td>Light-headedness, sedation, constipation, dizziness, nausea, vomiting, respiratory depression</td>
<td>50–150 mg PO, IM, SC, q3–4h PRN</td>
</tr>
<tr>
<td>methadone</td>
<td>Dolophine</td>
<td>Analgesic, detoxification and temporary maintenance treatment of narcotic abstinence syndrome</td>
<td>Light-headedness, dizziness, sedation, nausea, vomiting, constipation, respiratory depression</td>
<td>Analytical: 2.5–10 mg PO, IM, SC q4h PRN; detoxification: 10–40 mg PO, IV</td>
</tr>
<tr>
<td>morphine sulfate</td>
<td>MS Contin, Roxanol</td>
<td>Analgesic, preoperative sedation, adjunct to anesthesia, dyspnea due to pulmonary edema, pain associated with MI</td>
<td>Sedation, hypotension, increased sweating, constipation, dizziness, drowsiness, nausea, vomiting, dry mouth, somnolence, respiratory depression</td>
<td>10–30 mg PO q4h PRN; 10–20 mg rectally q4h; 5–20 mg IM SC q4h PRN; 2.5–15 mg/70 kg IV</td>
</tr>
<tr>
<td>opium</td>
<td>Camphorated tincture of opium, Paregoric</td>
<td>Analgesic, anti-diarrheal</td>
<td>Light-headedness, dizziness, sedation, nausea, vomiting, constipation, suppression of cough reflex, dry mouth</td>
<td>Paregoric: 5–10 mL PO QID: 10% liquid: 0.6 mL PO QID</td>
</tr>
<tr>
<td>oxycodone</td>
<td>OxyContin, OxyIR, Roxicodone</td>
<td>Analgesic</td>
<td>Light-headedness, sedation, constipation, dizziness, nausea, vomiting, sweating, respiratory depression</td>
<td>OxyContin: 10–20 mg PO q12h; OxyIR: 5 mg for breakthrough pain</td>
</tr>
</tbody>
</table>
Drugs that act as antagonists are discussed at the end of this chapter. An agonist-antagonist has properties of both the agonist and antagonist. These drugs have some agonist activity at the receptor sites and some antagonist activity at the receptor sites.

Classification of the narcotic analgesics is based on their activity at the opioid receptor sites. Although five categories of opioid receptors have been identified, only three of these receptors affect the action of the narcotic analgesics:

- mu
- kappa
- delta

Table 19-1 identifies the responses in the body associated with each of these receptors. The narcotic agonists

<table>
<thead>
<tr>
<th>RECEPTOR</th>
<th>BODILY RESPONSE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mu</strong></td>
<td>Morphone-like supraspinal analgesia, respiratory and physical depression, miosis, reduced G1 motility</td>
</tr>
<tr>
<td><strong>Delta</strong></td>
<td>Dysphoria, psychotomimetic effects (eg, hallucinations), respiratory and vasomotor stimulations caused by drugs with antagonist activity</td>
</tr>
<tr>
<td><strong>Kappa</strong></td>
<td>Sedation and miosis</td>
</tr>
</tbody>
</table>
is the most widely used opioid and an effective drug for the management of moderate to severe acute and chronic pain. The major use of the narcotic analgesic is to relieve or manage moderate to severe acute and chronic pain.

**Nursing Alert**

If transferring from levomethadyl to methadone, the nurse should wait 48 hours after the last dose of levomethadyl before administering the first dose of methadone or other narcotic.

**Uses in Management of Opioid Dependence**

Two opioids are used in the treatment and management of opiate dependence: levomethadyl and methadone. Levomethadyl is given in an opiate dependency clinic to maintain control over the delivery of the drug. Because of its potential for serious and life-threatening proarrhythmic effects, levomethadyl is reserved for use in the treatment of addicted patients who have no response to other treatments. Levomethadyl is not taken daily; the drug is administered three times a week (Monday/Wednesday/Thursday or Tuesday/Thursday/Saturday). Daily use of the usual dose will cause serious overdose.

**Uses**

The major use of the narcotic analgesic is to relieve or manage moderate to severe acute and chronic pain. The ability of a narcotic analgesic to relieve pain depends on several factors, such as the drug, the dose, the route of administration, the type of pain, the patient, and the length of time the drug has been administered. Morphine is the most widely used opioid and an effective drug for moderately severe to severe pain. Morphine is considered the prototype or “model” narcotic. Morphine’s actions, uses, and ability to relieve pain are the standards to which other narcotic analgesics are often compared. Other narcotics, such as meperidine and levorphanol, are effective for the treatment of moderate to severe pain. For mild to moderate pain, the primary health care provider may order a narcotic such as codeine or pentazocine.

In addition to the relief or management of moderate to severe acute and chronic pain, the narcotic analgesics may be used for the following reasons:

- To lessen anxiety and sedate the patient before surgery. Patients who are relaxed and sedated when anesthesia is given are easier to anesthetize (requiring a smaller dose of an induction anesthetic), as well as easier to maintain under anesthesia
- Support of anesthesia (i.e., as an adjunct during anesthesia)
- Obstetrical analgesia
- Relief of anxiety in patients with dyspnea associated with pulmonary edema
- Intrathecally or epidurally for pain relief for extended periods without apparent loss of motor, sensory, or sympathetic function
- Relief of pain associated with a myocardial infarction (morphine)
- Management of opiate dependence (levomethadyl)
- Detoxification of and temporary maintenance of narcotic addiction (methadone)
- To induce conscious sedation before a diagnostic or therapeutic procedure in the hospital setting
- Treatment of severe diarrhea and intestinal cramping (camphorated tincture of opium)
- Relief of severe, persistent cough (codeine, although the drug’s use has declined)

**Use of the Narcotic Analgesic**

The prototype or “model” narcotic is morphine. Its actions, uses, and ability to relieve pain are the standards to which other narcotic analgesics are often compared. Meperidine and levorphanol are effective for the treatment of moderate to severe pain. For mild to moderate pain, the primary health care provider may order a narcotic such as codeine or pentazocine.

**DISPLAY 19-1**

**Secondary Pharmacological Effects of the Narcotic Analgesics**

- **Cardiovascular**—peripheral vasodilation, decreased peripheral resistance, inhibition of baroreceptors (pressure receptors located in the aortic arch and carotid sinus that regulate blood pressure), orthostatic hypotension and fainting
- **Central nervous system**—euphoria, drowsiness, apathy, mental confusion, alterations in mood, reduction in body temperature, feelings of relaxation, dysphoria (depression accompanied by anxiety), nausea, and vomiting are caused by direct stimulation of the emetic chemoreceptors located in the medulla. The degree to which these occur usually depends on the drug and the dose.
- **Dermatologic**—histamine release, pruritus, flushing, and red eyes
- **Gastrointestinal**—decrease in gastric mobility (prolonged emptying time); decrease in biliary, pancreatic, and intestinal secretions; and delay in digestion of food in the small intestine; increase in resting tone, with the potential for spasms, epigastric distress, or biliary colic (caused by constriction of the sphincter of Oddi). These drugs can cause constipation and anorexia.
- **Genitourinary**—urinary urgency and difficulty with urination, caused by spasms of the ureter. Urinary urgency may also occur because of the action of the drugs on the detrusor muscle of the bladder. Some patients may experience difficulty voiding because of contraction of the bladder sphincter.
- **Respiratory**—depressant effects on respiratory rate (caused by a reduced sensitivity of the respiratory center to carbon dioxide)
- **Cough**—suppression of the cough reflex (antitussive effective) by exerting a direct effect on the cough center in the medulla. Codeine has the most noticeable effect on the cough reflex.
- **Medulla**—Nausea and vomiting may occur when the chemoreceptor trigger zone located in the medulla is stimulated. To a varying degree, narcotic analgesics also depress the chemoreceptor trigger zone. Therefore, nausea and vomiting may or may not occur when these drugs are given.
Methadone, a synthetic narcotic, may be used for the relief of pain, but it also is used in the detoxification and maintenance treatment of those addicted to narcotics. Detoxification involves withdrawing the patient from the narcotic while preventing withdrawal symptoms.

Maintenance therapy is designed to reduce the patient’s desire to return to the drug that caused addiction, as well as to prevent withdrawal symptoms. The dosages used vary with the patient, the length of time the individual has been addicted, and the average amount of drug used each day. Patients enrolled in an outpatient methadone program for detoxification or maintenance therapy on methadone must continue to receive methadone when hospitalized.

**ADVERSE REACTIONS**

The adverse reactions differ according to whether the narcotic analgesic acts as an agonist or as an agonist-antagonist.

**Agonists**

One of the major hazards of narcotic administration is respiratory depression, with a decrease in the respiratory rate and depth. The most common adverse reactions include light-headedness, dizziness, sedation, constipation, anorexia, nausea, vomiting, and sweating. When these effects occur, the primary health care provider may lower the dose in an effort to eliminate or decrease the intensity of the adverse reaction. Other adverse reactions that may be seen with the administration of an agonist narcotic analgesic include:

- Central nervous system—euphoria, weakness, headache, pinpoint pupils, insomnia, agitation, tremor, and impairment of mental and physical tasks
- Gastrointestinal—dry mouth and biliary tract spasms
- Cardiovascular—flushing of the face, peripheral circulatory collapse, tachycardia, bradycardia, and palpitations
- Genitourinary—spasms of the ureters and bladder sphincter, urinary retention or hesitancy
- Allergic—pruritus, rash, and urticaria
- Other—physical dependence, pain at injection site, and local tissue irritation

**Agonist-Antagonists**

Administration of a narcotic agonist-antagonist may result in symptoms of narcotic withdrawal in those addicted to narcotics. Other adverse reactions associated with the administration of a narcotic agonist-antagonist include sedation, nausea, vomiting, sweating, headache, vertigo, dry mouth, euphoria, and dizziness.

**CONTRAINDICATIONS**

All narcotic analgesics are contraindicated in patients with known hypersensitivity to the drugs. These drugs are contraindicated in patients with acute bronchial asthma, emphysema, or upper airway obstruction and in patients with head injury or increased intracranial pressure. The drugs are also contraindicated in patients with convulsive disorders, severe renal or hepatic dysfunction, acute ulcerative colitis, and increased intracranial pressure. The narcotic analgesics are Pregnancy Category C drugs (oxycodone, Category B) and are not recommended for use during pregnancy or labor (may prolong labor or cause respiratory depression of the neonate). The use of narcotic analgesics is recommended during pregnancy only if the benefit to the mother outweighs the potential harm to the fetus.

**PRECAUTIONS**

These drugs are used cautiously in the elderly and in patients with undiagnosed abdominal pain, liver disease, history of addiction to the opioids, hypoxia, supraventricular tachycardia, prostatic hypertrophy, and renal or hepatic impairment. The obese must be monitored closely for respiratory depression while taking the narcotic analgesics. The drug is used cautiously during lactation (wait at least 4 to 6 hours after taking the drug to breastfeed the infant). The narcotics are used cautiously in patients undergoing biliary surgery because the drug may cause spasm of the sphincter of Oddi.

**INTERACTIONS**

The narcotic analgesics potentiate the central nervous system (CNS) depressant properties of other CNS depressants, such as alcohol, antihistamines, antidepressants, sedatives, phenothiazines, and monoamine oxidase inhibitors. Use of the narcotic analgesics within 14 days of the MAO inhibitors (see Chap. 31) may potentiate the effect of either drug. Patients taking the agonist-antagonist narcotic analgesics may experience withdrawal symptoms if the patient has been abusing or using narcotics.

The agonist-antagonists drugs can cause opioid withdrawal symptoms in those who are physically dependent on the opioids. There is an increased risk of respiratory
depression, hypotension, and sedation when narcotic analgesics are administered too soon after barbiturate general anesthesia.

**Herbal Alert: Passion Flower**

The term “passion flower” is used to denote many of the approximately 400 species of the herb. Passion flower has been used in medicine to treat pain, anxiety, and insomnia. Some herbalists use the herb to treat symptoms of parkinsonism. Passion flower is often used in combination with other herbs, such as valerian, chamomile, and hops, for promoting relaxation, rest, and sleep. Although no adverse reactions have been reported, large doses may cause CNS depression. The use of passion flower is contraindicated in pregnancy and in patients taking the monoamine oxidase inhibitors (MAOIs). Passion flower contains coumarin, and the risk of bleeding may be increased when used in patients taking warfarin and passion flower.

The following are recommended dosages for passion flower:

- **Tea:** 1–4 cups per day (made with 1 tablespoon of the crude herb per cup)
- **Tincture (2 g/5 mL):** 2 teaspoons (10 mL) 3–4 times daily
- **Dried herb:** 2 g 3–4 times daily

**Nursing Process**

**The Patient Receiving a Narcotic Analgesic for Pain**

**Assessment**

**Preadministration Assessment**

As part of the preadministration assessment, the nurse reviews the patient’s health history, allergy history, and past and current drug therapies. This is especially important when a narcotic is given for the first time because data may be obtained during the initial history and physical assessment that require the nurse to contact the primary health care provider. For example, the patient may state that nausea and vomiting occurred when he or she was given a drug for pain several years ago. Further questioning of the patient is necessary because this information may influence the primary health care provider regarding administration of a specific narcotic drug. Guidelines for the initial pain assessment are listed in Display 19-2. Questions to include in the assessment of pain include the following:

- Does the pain keep you awake at night? Prevent you from falling asleep or staying asleep?
- What makes your pain worse?
- Does the pain affect your mood? Are you depressed? Irritable? Anxious?
- What over-the-counter or herbal remedies have you used for the pain?
- Does the pain affect your activity level? Are you able to walk? Perform self-care activities?

**Ongoing Assessment**

The nurse obtains the blood pressure, pulse, and respiratory rate 20 to 30 minutes after the drug is administered intramuscularly or subcutaneously, 30 or more minutes if the drug is given orally, and in 5 to 10 minutes if the drug is given intravenously (IV).

During the ongoing assessment, it is important for the nurse to ask about the pain regularly and believe the patient and family in their reports of pain. The nurse determines the exact location of the pain, a description of the pain (eg, sharp, dull, or stabbing), and an estimate of when the pain began, each time the patient requests a narcotic analgesic. Further questioning and more detailed information about the pain are necessary if the pain is of a different type than the patient had been experiencing previously or if it is in a different area. Nursing judgment must be exercised because not all instances of a change in pain type, location, or intensity require notifying the primary health care provider. For example, if a patient recovering from recent abdominal surgery experiences pain in the calf of the leg, the nurse should immediately notify the primary health care provider. However, it is not important to contact the primary health care provider for pain that is slightly worse because the patient has been moving in bed.

**Display 19-2  ● Guidelines for the Initial Pain Assessment**

- Patient’s subjective description of the pain (What does the pain feel like?)
- Location(s) of the pain
- Intensity, severity, and duration
- Any factors that influence the pain
- Quality of the pain
- Patterns of coping
- Effects of previous therapy (if applicable)
- Nurses’ observations of patient’s behavior

The nurse may request that the patient evaluate the pain using a standardized pain scale measurement tool. The pain is rated using a scale of 1 to 10, with 10 being the most severe pain and 1 being the least discomfort. Failure to adequately assess pain is a major factor in the undertreatment of pain.

It is especially important for the nurse to assess the type, location, and intensity of pain before administering the narcotic analgesic. Immediately before preparing a narcotic analgesic for administration, the nurse assesses the patient’s blood pressure, pulse, and respiratory rate.

In addition, a thorough drug history, as well as physical assessment, may raise a question of drug dependency. The nurse must notify the primary health care provider of any suspicion of drug dependency.

**Herbal Alert: Passion Flower**

The term “passion flower” is used to denote many of the approximately 400 species of the herb. Passion flower has been used in medicine to treat pain, anxiety, and insomnia. Some herbalists use the herb to treat symptoms of parkinsonism. Passion flower is often used in combination with other herbs, such as valerian, chamomile, and hops, for promoting relaxation, rest, and sleep. Although no adverse reactions have been reported, large doses may cause CNS depression. The use of passion flower is contraindicated in pregnancy and in patients taking the monoamine oxidase inhibitors (MAOIs). Passion flower contains coumarin, and the risk of bleeding may be increased when used in patients taking warfarin and passion flower.

The following are recommended dosages for passion flower:

- **Tea:** 1–4 cups per day (made with 1 tablespoon of the crude herb per cup)
- **Tincture (2 g/5 mL):** 2 teaspoons (10 mL) 3–4 times daily
- **Dried herb:** 2 g 3–4 times daily
In addition, the nurse determines if any controllable factors (eg, uncomfortable position, cold room, drafts, bright lights, noise, thirst) may be decreasing the patient’s tolerance to pain. If these factors are present, the nurse corrects them as soon as possible. However, the nurse should not deny pain drugs or make the patient wait for the drug. Pain medication is delivered in a timely manner.

Narcotic analgesics can produce serious or potentially fatal respiratory depression if given too frequently or in an excessive dose. Respiratory depression may occur in patients receiving a normal dose if the patient is vulnerable (ie, in weakened state or debilitated state). Elderly, cachectic, or debilitated patients may have a reduced initial dose until the response of the drug is known. If the respiratory rate is 10/min or below, the nurse must monitor the patient at frequent intervals and notify the primary health care provider immediately.

When an opiate is used as an antidiarrheal drug, the nurse records each bowel movement, as well as its appearance, color, and consistency. The nurse should notify the primary health care provider immediately if diarrhea is not relieved or becomes worse; if the patient has severe abdominal pain; or if blood in the stool is noted.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes of the patient may include a relief of pain, an understanding of the use of the patient-controlled analgesia device (when applicable), an absence of injury, an adequate nutrition intake, an absence of drug dependence, and an understanding of and compliance with the prescribed treatment regimen.

**Figure 19-1.** Patient-controlled analgesia allows the client to self-administer medication, as necessary, to control pain.
subcutaneously, intramuscularly, IV, and rectally in the form of a suppository allows tremendous versatility. Medication for chronic pain should be scheduled around the clock and not given on a PRN (as needed) basis. Most patients with cancer can be treated with 30 to 60 mg morphine orally every 4 hours. The oral route is preferred as long as the patient is able to swallow or can tolerate sublingual administration. Respiratory depression is less likely to occur when the drug is given orally.

OxyContin is a controlled-release form of oxycodone and indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is not intended for use as a PRN analgesic. The patient may experience fewer adverse reactions with oxycodone than morphine, and the drug is effective and safe for the elderly. The tablets are to be swallowed whole and are not to be broken, chewed, or crushed.

Fentanyl transdermal is a transdermal system that is effective in the management of the severe pain associated with cancer. The transdermal system allows for a timed-release patch containing the drug fentanyl to be activated over a 72-hour period. A small number of patients may require systems applied every 48 hours. The nurse monitors for adverse effects in the same manner as for other narcotic analgesics (eg, the nurse notifies the primary health care provider if the respiratory rate is 10/min or less).

On rare occasions, when pain is not relieved by the narcotic analgesics alone, a mixture of an oral narcotic and other drugs may be used to obtain relief. Brompton’s mixture is commonly used to identify these solutions. In addition to the narcotics, such as morphine or methadone, other drugs may be used in the solution, including antidepressants, stimulants, aspirin, acetaminophen, and tranquilizers. The pharmacist prepares the solution according to the primary health care provider’s instructions.

It is necessary to monitor for the adverse reactions of each drug contained in the solution. The time interval for administration varies. Some primary health care providers may order the mixture on an as-needed basis; others may order it given at regular intervals.

When narcotics are administered for severe pain, the goal is to prevent or control the pain, not to prevent addiction. Patients taking the narcotics for severe pain rarely become addicted. Although some dependence may occur in rare instances, if the patient recovers from the illness, he or she may be gradually weaned from the drug.

When long-acting forms of the narcotic are used, a fast-acting form may be given for breakthrough pain. Patients should be given the drug as ordered and on time. Oral transmucosal fentanyl (Actiq) is used to treat breakthrough pain. Making the patient wait for the drug may result in withdrawal symptoms, which will only add to the pain of the illness.

Tolerance results over a period of time in the patient taking a narcotic analgesic. The rate the patient develops tolerance varies according to the dosage, the route or administration, and the individual. Patients taking oral or transdermal morphine develop tolerance more slowly than those taking the drug parenterally. Some patients develop tolerance quickly and need larger doses every few weeks, whereas others are maintained on the same dosage schedule throughout the course of the illness.

The risk of respiratory depression is a concern for many nurses administering a narcotic and may cause some nurses to hesitate to administer the drug. However, respiratory depression rarely occurs in patients using a narcotic for pain. In fact, these patients usually develop tolerance to the respiratory depressant effects of the drug very quickly. Naloxone (see Chap. 20) can be administered to reverse the narcotic effects if absolutely necessary.

**Gerontologic Alert**

The use of the transdermal route in the elderly is questionable because the amount of subcutaneous tissue is reduced in the aging process.

**Nursing Alert**

Naloxone should be administered with great caution and only when necessary in patients receiving a narcotic for severe pain. Naloxone removes all of the pain-relieving effects of the narcotic and may lead to withdrawal symptoms or the return of pain.

**Using Epidural Pain Management**

Administration of certain narcotic analgesics, specifically morphine and fentanyl, by the epidural route has provided an alternative to the intramuscular or oral route. **Epidural** administration is performed when a catheter is placed into the epidural space, which is the space outside of the dura matter of the brain and spinal cord. The analgesic effect is produced by the direct effect on the opiate receptors in the dorsal horn of the spinal cord. This approach was introduced with the idea that very small doses of narcotic would provide long-lasting pain relief with systemic adverse reactions. Epidural administration offers several advantages over other routes. Lower total dosages of the drug used, fewer adverse reactions, and greater patient comfort are all benefits seen with epidural administration.

Access to the epidural route is made through the use of a percutaneous epidural catheter. The placement of the catheter requires strict aseptic technique by a skilled physician. The epidural catheter is placed into the space...
between the dura mater and the vertebral column (Fig. 19-2). Drug injected through the catheter spreads freely throughout all the tissues in the space, interrupting pain conduction at the points where sensory fibers exit from the spinal cord. The administration of the narcotic is either by bolus or by continuous infusion pump.

This type of pain management is used for postoperative pain, labor pain, and cancer pain. The most serious adverse reaction associated with the administration of narcotics by the epidural route is respiratory depression. The patient may also experience sedation, confusion, nausea, pruritus, or urinary retention. Fentanyl is increasingly used as an alternative to morphine sulfate because patients experience fewer adverse reactions.

Policies and procedures for administering, monitoring, and documenting drugs given through the epidural route must be specific to the Nurse Practice Act in each state and in accordance with federal and state regulations. This type of analgesia is most often managed by registered nurses with special training in the care and management of epidural catheters.

**Monitoring and Managing Adverse Drug Reactions**

The nurse immediately reports to the primary health care provider any significant change in the patient’s vital signs. Narcotic analgesics can cause hypotension. Particularly vulnerable are postoperative patients and individuals whose ability to maintain blood pressure has been compromised.

Nursing care includes close monitoring of the patient immediately after insertion of the epidural catheter and throughout therapy for respiratory depression. Vital signs are taken every 30 minutes, apnea monitors are used, and a narcotic antagonist, such as naloxone, is readily available.

**Nursing Alert**

Sufentanil, fentanyl, remifentanil, alfentanil, and morphine sulfate should be administered only by those specifically trained in the use of IV and epidural anesthetics. Oxygen, resuscitative, and intubation equipment should be readily available.

The nurse should withhold the narcotic analgesic and contact the primary health care provider immediately if any of the following are present:

- A significant decrease in the respiratory rate or a respiratory rate of 10/min or below
- A significant increase or decrease in the pulse rate or a change in the pulse quality
- A significant decrease in blood pressure (systolic or diastolic) or a systolic pressure below 100 mm Hg
Patients receiving long-term opioid therapy rarely have problems with respiratory depression. In instances where respiratory depression occurs, administration of a narcotic antagonist (see Chap. 20) may be ordered by the primary health care provider if the respiratory rate continues to fall.

Gerontologic Alert

The older adult is especially prone to adverse reactions of the narcotic analgesics, particularly respiratory depression, somnolence (sedation), and confusion. The primary health care provider may order a lower dosage of the narcotic for the older adult.

Narcotics may depress the cough reflex. The nurse should encourage patients receiving a narcotic on a regular basis, even for a few days, to cough and breathe deeply every 2 hours. This task prevents the pooling of secretions in the lungs, which can lead to hypostatic pneumonia and other lung problems. If the patient experiences nausea and vomiting, the nurse should notify the primary health care provider. A different analgesic or an antiemetic may be necessary.

RISK FOR INJURY. Narcotics may produce orthostatic hypotension, which in turn results in dizziness. The nurse should assist the patient with ambulatory activities and with rising slowly from a sitting or lying position. Miosis (pinpoint pupils) may occur with the administration of some narcotics and is most pronounced with morphine, hydromorphone, and hydrochlorides of opium alkaloids. Miosis decreases the ability to see in dim light. The nurse keeps the room well lit during daytime hours and advises the patient to seek assistance when getting out of bed at night.

CONSTIPATION. The nurse checks the bowel elimination pattern daily because constipation can occur with repeated doses of a narcotic. The nurse keeps a daily record of bowel movements and informs the primary health care provider if constipation appears to be a problem. Most patients should begin taking a stool softener or laxative with the initial dose of a narcotic analgesic. Many patients need to continue taking a laxative as long as the narcotic analgesic is taken. If the patient is constipated despite the use of a stool softener, the primary health care provider may prescribe an enema or another means of relieving constipation.

IMBALANCED NUTRITION. When a narcotic is prescribed for a prolonged time, anorexia (loss of appetite) may occur. Those receiving a narcotic for the relief of pain caused by terminal cancer often have severe anorexia from the disease and the narcotic. The nurse assesses food intake after each meal. When anorexia is prolonged, the nurse weighs the patient weekly or as ordered by the primary health care provider. It is important for the nurse to notify the primary health care provider of continued weight loss and anorexia.

**NARCOTIC DRUG DEPENDENCE.** Most patients receiving the narcotic analgesics for medical purposes do not develop dependence. However, drug dependence can occur when a narcotic is administered over a long period. For some patients, such as those who are terminally ill and in severe pain, drug dependence is not considered a problem because the most important task is to keep the patient as comfortable as possible for the time he or she has remaining (see “Relieving Chronic Severe Pain”).

When a patient does not have a painful terminal illness, drug dependence must be avoided. Signs of drug dependence include occurrence of withdrawal symptoms (acute abstinence syndrome) when the narcotic is discontinued, requests for the narcotic at frequent intervals around the clock, personality changes if the narcotic is not given immediately, and constant complaints of pain and failure of the narcotic to relieve pain. Although these behaviors can have other causes, the nurse should consider drug dependence and discuss the problem with the primary health care provider. Specific symptoms of the abstinence syndrome are listed in Display 19-3.

Drug dependence can also occur in a newborn whose mother was dependent on opiates during pregnancy. Withdrawal symptoms in the newborn usually appear during the first few days of life. Symptoms include irritability, excessive crying, yawning, sneezing, increased respiratory rate, tremors, fever, vomiting, and diarrhea.

Educating the Patient and Family

The nurse informs the patient that the drug he or she is receiving is for pain. It also is a good idea to include additional information, such as how often the drug can be given and the name of the drug being given. If a patient is receiving drugs through a PCA infusion pump, the nurse discusses the following points:

- The location of the control button that activates the administration of the drug;

**DISPLAY 19-3  ■ Symptoms of the Abstinence Syndrome**

**EARLY SYMPTOMS**
Yawning, lacrimation, rhinorrhea, sweating

**INTERMEDIATE SYMPTOMS**
Mydriasis, tachycardia, twitching, tremor, restlessness, irritability, anxiety, anorexia

**LATE SYMPTOMS**
Muscle spasm, fever, nausea, vomiting, kicking movements, weakness, depression, body aches, weight loss, severe backache, abdominal and leg pains, hot and cold flashes, insomnia, repetitive sneezing, increased blood pressure, respiratory rate, and heart rate.
In some situations, narcotic analgesics may be ordered for pain relief using patient-controlled analgesia (PCA). If the patient will be receiving PCA at home, the nurse makes sure to review the following steps with the patient and the caregiver:

- How the pump works
- What drug is being given
- When to administer a dose
- What the power source is (battery or electricity)
- What to do if the battery fails or a power failure occurs
- How to check the insertion site
- How to change the cartridge or syringe

If the patient or caregiver will be responsible for changing the drug cartridge or syringe, the nurse teaches the following steps:

- Gather new syringe with drug (if refrigerated, remove it at least 30 minutes before using).
- Attach pump specific tubing to the drug.
- Prime the tubing.
- Turn off the pump and clamp the infusion tubing.
- Remove the tubing from the infusion site.
- Flush the site (if ordered).
- Remove used cartridge or syringe from the pump.
- Insert the new cartridge or syringe into the pump.
- Connect the new infusion tubing to the infusion site.
- Turn on the pump and have the patient provide a drug dose when needed.

Home Care Checklist

USING A PATIENT-CONTROLLED ANALGESIA PUMP

In some situations, narcotic analgesics may be ordered for pain relief using patient-controlled analgesia (PCA). If the patient will be receiving PCA at home, the nurse makes sure to review the following steps with the patient and the caregiver:

- The difference between the control button and the button to call the nurse (when both are similar in appearance and feel);
- The machine regulates the dose of the drug as well as the time interval between doses;
- If the control button is used too soon after the last dose, the machine will not deliver the drug until the correct time;
- Pain relief should occur shortly after pushing the button;
- Call the nurse if pain relief does not occur after two successive doses.

Narcotics for outpatient use may be prescribed in the oral form or as a timed-release transdermal patch. In certain cases, such as when terminally ill patients are being cared for at home, the nurse may give the family instruction in the parenteral administration of the drug or use of PCA (see Home Care Checklist: Using a Patient Controlled Analgesia Pump). When a narcotic has been prescribed, the nurse includes the following points in the teaching plan:

- This drug may cause drowsiness, dizziness, and blurring of vision. Use caution when driving or performing tasks requiring alertness.
- Avoid the use of alcoholic beverages unless use has been approved by the primary health care provider. Alcohol may intensify the action of the drug and cause extreme drowsiness or dizziness.
In some instances, the use of alcohol and a narcotic can have extremely serious and even life-threatening consequences that may require emergency medical treatment.

- Take the drug as directed on the container label and do not exceed the prescribed dose. Contact the primary health care provider if the drug is not effective.
- If gastrointestinal upset occurs, take the drug with food.
- Notify the primary health care provider if nausea, vomiting, and constipation become severe.
- To administer the transdermal system, remove the system from the package and immediately apply it to the skin of the upper torso. To ensure complete contact with the skin surface, press for 10 to 20 seconds with the palm of the hand. After 72 hours, remove the system and, if continuous therapy is prescribed, apply a new system. Use only water to cleanse the site before application because soaps, oils, and other substances may irritate the skin. Rotate site of application. The used patch should be folded carefully so the system adheres to itself.

EVALUATION

- The therapeutic effect occurs and pain is relieved.
- The patient demonstrates the ability to effectively use PCA.
- Adverse reactions are identified, reported to the primary health care provider, and managed through appropriate nursing interventions.
- No evidence of injury is seen.
- Body weight is maintained.
- Diet is adequate.
- The patient is free of drug dependence.
- The patient and family demonstrate understanding of the drug regimen.

**Critical Thinking Exercises**

1. Ms. Taylor is receiving meperidine for postoperative pain management. In assessing Ms. Taylor approximately 20 minutes after receiving an injection of meperidine, the nurse discovers Ms. Taylor’s vital signs are blood pressure 100/50 mm Hg, pulse rate 100 bpm, and respiratory rate 10/min. Determine what action, if any, the nurse should take.

2. Mr. Talley, a 64-year-old retired schoolteacher, has cancer and is to receive morphine through a PCA infusion pump. His wife is eager to help, but Mr. Talley is very independent and refuses any assistance from her. Formulate a teaching plan for Mr. Talley that includes the use of PCA, adverse reactions to expect, and what adverse reactions to report. Discuss what methods the nurse might use to include Mrs. Talley in the care of her husband.

3. Roger Baccus, age 23 years, is prescribed Demerol for postoperative pain. You discover in his health history on the chart that he has a history of alcohol and drug use. Determine what further assessments you would need to make. Explain how Roger’s answers would influence the actions that you as a nurse would take.

4. Discuss the important preadministration assessments that must be made on the patient receiving a narcotic analgesic.

5. Joe Thompson, age 48 years, is taking morphine to manage severe pain occurring as the result of cancer. The primary health care provider has prescribed an around-the-clock dosage regimen. Joe is asking for the pain drug 1 to 2 hours before the next dose is due. One of your co-workers feels that Joe is becoming addicted to the narcotic analgesic. Analyze this situation. What signs and symptoms would you look for in Joe? What information (if any) would you discuss with your co-worker. Discuss the actions you would take in providing the best possible care for this patient.

**Review Questions**

1. The nurse explains to the patient that some narcotics may be used as part of the preoperative medication regimen to _____.
   - A. increase intestinal motility
   - B. facilitate passage of an endotracheal tube
   - C. enhance the effects of the skeletal muscle relaxant
   - D. lessen anxiety and sedate the patient

2. Each time the patient requests a narcotic analgesic, the nurse must _____.
   - A. check the patient’s diagnosis
   - B. talk to the patient to be sure he or she is not becoming addicted to the narcotic
   - C. determine the exact location of the pain, a description of the pain, and when the pain began
   - D. administer the narcotic with food to prevent gastric upset

3. Which of the following findings requires that the nurse withhold a narcotic and immediately contact the health care provider?
   - A. a pulse rate of 80 bpm
   - B. a significant decrease in blood pressure or a systolic pressure below 100 mm Hg
   - C. a respiratory rate of 20/min
   - D. blood pressure with a systolic pressure of 140 mm Hg

4. When administering narcotic analgesics to an elderly patient, the nurse monitors the patient closely for _____.
   - A. an increased heart rate
   - B. euphoria
C. confusion  
D. a synergistic reaction 

5. When monitoring a patient receiving a narcotic agonist-antagonist, the nurse must be aware that_____. 

A. symptoms of narcotic withdrawal may occur in those addicted to narcotics  
B. severe respiratory depression may occur  
C. serious cardiac arrhythmias may develop  
D. CNS stimulation is possible

<table>
<thead>
<tr>
<th>Medications Dosage Problems</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. A patient is prescribed oral morphine 12 mg. The dosage available is 10 mg/mL. The nurse administers_____.</td>
</tr>
<tr>
<td>2. A patient is prescribed fentanyl (Sublimaze) 50 mcg IM 30 minutes before surgery. The nurse has available a vial with a dosage strength of 0.05 mg/1 mL. The nurse calculates the dosage and administers_____.</td>
</tr>
</tbody>
</table>
Key Terms

antagonist

Chapter Objectives

On completion of this chapter, the student will:

- Discuss the uses, general drug action, general adverse reactions, contraindications, precautions, and interactions of the narcotic antagonists.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking the narcotic antagonists.
- List some nursing diagnoses particular to a patient taking a narcotic antagonist.
- Discuss ways to promote optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating patients about the use of narcotic antagonists.

An antagonist is a substance that counteracts the action of something else. A drug that is an antagonist has an affinity for a cell receptor, and by binding to it, prevents the cell from responding. Thus, a narcotic antagonist reverses the actions of a narcotic. Specific antagonists have been developed to reverse the respiratory depression associated with the opiates. The two narcotic antagonists in use today are naloxone (Narcan) and naltrexone (ReVia; see the Summary Drug Table: Narcotic Antagonists). Naloxone is capable of restoring respiratory function within 1 to 2 minutes after administration. Naltrexone is used primarily for the treatment of narcotic dependence to block the effects of the opiates, especially the euphoric effects experienced in opiate dependence.

Naloxone has no drug activity.

**USES**

This drug is used for complete or partial reversal of narcotic depression, including respiratory depression. Narcotic depression may be due to intentional or accidental overdose (self-administration by an individual), accidental overdose by medical personnel, and drug idiosyncrasy. Naloxone also may be used for diagnosis of a suspected acute opioid overdosage.

**ADVERSE REACTIONS**

Although not a true adverse reaction, abrupt reversal of narcotic depression may result in nausea, vomiting, sweating, tachycardia, increased blood pressure, and tremors.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

Naloxone is contraindicated in those with a hypersensitivity to the narcotic antagonists. Naloxone is used cautiously in those with a narcotic addiction. Naloxone...
is used cautiously in patients with cardiovascular disease; those who are pregnant (Pregnancy Category B); and in infants of opioid-dependent mothers. These drugs may produce withdrawal symptoms in those physically dependent on the narcotics. The patient must not have taken any opiate for the last 7 to 10 days. Naloxone may prevent the action of opioid antidiarrheals, antitussives, and analgesics. This drug is used cautiously during lactation.

**NAITREXONE**

**ACTIONS**

Naltrexone completely blocks the effects of IV opiates, as well as drugs with agonist-antagonist actions (butorphanol, nalbuphine, and pentazocine). The mechanism of action appears to be the same as that for naloxone.

**USES**

Naltrexone is used to treat persons dependent on opioids. Patients receiving naltrexone have been detoxified and are enrolled in a program for treatment of narcotic addiction. Naltrexone, along with other methods of treatment (counseling, psychotherapy), is used to maintain an opioid-free state. Patients taking naltrexone on a scheduled basis will not experience any narcotic effects if they use an opioid.

**ADVERSE REACTIONS**

Administration of naltrexone may result in anxiety, difficulty sleeping, abdominal cramps, nasal congestion, joint and muscle pain, nausea, vomiting, dizziness, irritability, depression, fatigue, and drowsiness.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

Naltrexone is contraindicated in those with a hypersensitivity to the narcotic antagonists. Naltrexone is contraindicated during pregnancy (Category C). Naltrexone is used cautiously in those with a narcotic addiction; in patients with cardiovascular disease, acute hepatitis, liver failure, or depression; and in patients who are suicidal. Naltrexone is used cautiously during lactation.

Naltrexone may produce withdrawal symptoms in those physically dependent on narcotics. The patient must not have taken any opiate for the last 7 to 10 days. Concurrent use of naltrexone with thioridazine may cause increased drowsiness and lethargy. Naltrexone may prevent the action of opioid antidiarrheals, antitussives, and analgesics.
**UNIT III**

**Drugs Used to Manage Pain**

---

**NURSING PROCESS**

**The Patient Receiving a Narcotic Antagonist for Respiratory Depression**

**ASSESSMENT**

**Preadministration Assessment**

Before the administration of naloxone, the nurse obtains the blood pressure, pulse, and respiratory rate and reviews the record for the drug suspected of causing the overdosage. If there is sufficient time, the nurse also should review the initial health history, allergy history, and current treatment modalities.

**Ongoing Assessment**

As part of the ongoing assessment during the administration of naloxone, the nurse monitors the blood pressure, pulse, and respiratory rate at frequent intervals, usually every 5 minutes, until the patient responds. After the patient has shown response to the drug, the nurse monitors vital signs every 5 to 15 minutes. The nurse should notify the primary health care provider if any adverse drug reactions occur because additional medical treatment may be needed. The nurse monitors the respiratory rate, rhythm, and depth; pulse; blood pressure; and level of consciousness until the effects of the narcotics wear off.

---

**Nursing Alert**

The effects of some narcotics may last longer than the effects of naloxone. A repeat dose of naloxone may be ordered by the primary health care provider if results obtained from the initial dose are unsatisfactory. The duration of close patient observation depends on the patient’s response to the administration of the narcotic antagonist.

---

**NURSING DIAGNOSIS**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

---

**Nursing Diagnoses Checklist**

- **Ineffective Airway Clearance** related to administration of a narcotic (specify overdose, drug idiosyncrasy, or other cause)
- **Risk for Impaired Gas Exchange** related to decreased respiratory rate

---

**PLANNING**

The expected outcome for the patient with respiratory depression is an optimal response to therapy, which essentially is a return to normal respiratory rate, rhythm, and depth.

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**

Depending on the patient’s condition, the nurse may use cardiac monitoring, artificial ventilation (respirator), and other drugs during and after the administration of naloxone. It is important to keep suction equipment readily available because abrupt reversal of narcotic depression may cause vomiting. The nurse must maintain a patent airway and should suction the patient as needed.

If naloxone is given by IV infusion, the primary health care provider orders the IV fluid and amount, the drug dosage, and the infusion rate. Giving the drug by IV infusion requires use of a secondary line or IV piggyback.

---

**Nursing Alert**

When naloxone is used to reverse respiratory depression and the resulting somnolence, the drug is given slow IV push until the respiratory rate begins to increase and somnolence abates. Giving a rapid bolus will cause withdrawal and return of intense pain.

---

The nurse monitors fluid intake and output and notifies the primary health care provider of any change in the fluid intake-output ratio. The nurse should notify the primary health care provider if there is any sudden change in the patient’s condition.

**EVALUATION**

- The therapeutic effect is achieved.
- The patient’s respiratory rate, rhythm, and depth are normal.
- A clear airway is maintained.

---

**NURSING PROCESS**

**The Patient Receiving a Narcotic Antagonist for Treatment of Opioid Dependency**

**ASSESSMENT**

**Preadministration Assessment**

During the preadministration assessment, the nurse obtains a complete drug history. In addition, the nurse
performs a complete physical examination and psychological evaluation before initiating therapy. The extent of the pretreatment assessment is usually based on the guidelines set up by the clinic or agency dispensing the drug.

Ongoing Assessment
Each time the patient visits the outpatient clinic, the nurse evaluates the patient's response to therapy and looks for any signs that drug dependency might again be a problem.

NURSING DIAGNOSES
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

Nursing Diagnoses Checklist

- Ineffective Coping related to difficulty staying drug free
- Noncompliance related to anxiety, difficulty in staying drug free, other factors (specify)
- Risk of Ineffective Therapeutic Regimen Management related to indifference, requirements of treatment program, other factors (specify)

PLANNING
The expected outcomes of the person formerly dependent on opioids may include an optimal response to therapy, which includes compliance with the treatment program, remaining drug free, and an understanding of the drug rehabilitation program.

IMPLEMENTATION
Promoting an Optimal Response to Drug Therapy
Entering a program for drug dependency may cause great anxiety due to many factors. Examples of possible causes of anxiety include the socioeconomic impact of drug dependency, the effectiveness of the treatment program, and concern over remaining drug free. Individuals vary in their ability to communicate their fears and concerns. At times, the nurse may be able to identify those situations causing anxiety and explore possible solutions to the many problems faced by these patients.

One of the greatest problems associated with former drug dependency is remaining drug free. The nurse must follow precisely the administration techniques of the drug treatment program. Some people find it difficult to break away from situations, individuals, or pressures that promote drug use. Because of this, some opioid users entering a drug rehabilitation program may, in time, not report to the program or agency to receive their drug and thus are more apt to return to the use of an opiate.

All staff members of the rehabilitation program should work to encourage adherence to the regimen and attempt to identify situations that may encourage a return to drug use.

Educating the Patient and Family
The nurse instructs patients under treatment for narcotic addiction to wear or carry identification indicating that they are receiving naltrexone. If the patient is taking naltrexone and requires hospitalization, it is important that all medical personnel be aware of therapy with this drug. Narcotics administered to these patients have no effect and therefore do not relieve pain. Patients receiving naltrexone may pose a problem if they experience acute pain. The primary health care provider must decide what methods must be used to control pain in these patients.

The nurse should teach the patient taking naltrexone the impact of therapy. While taking the drug, any use of heroin or other opiate by the patient results in no effect. In fact, large doses of heroin or other opiates can overcome the drug's effect and result in coma or death.

EVALUATION

- The therapeutic effect is achieved, and the patient remains drug free.
- The patient complies with the prescribed treatment regimen.
- The patient demonstrates an understanding of the therapeutic regimen and requirements of the rehabilitation program.

Critical Thinking Exercises
1. Jerry Jones is to begin receiving methadone for the treatment of heroin dependency. Jerry asks why methadone, a narcotic, is effective in the treatment of narcotic dependency. How would you explain this to the patient? What information would be important to give this patient while he is in the methadone program?

2. Discuss important preadministration and ongoing nursing assessments you would make when giving a patient naloxone for severe respiratory depression caused by morphine.

Review Questions
1. Which narcotic antagonist would most likely be prescribed for treatment of a patient who is experiencing an overdose of a narcotic?
   A. naltrexone
   B. naloxone
2. When given a narcotic analgesic for acute pain, a patient taking naltrexone for narcotic addiction _____.
   A. may have an acute hypersensitivity reaction
   B. is at increased risk for respiratory arrest
   C. will not have pain relief
   D. will have additive effects of the narcotic

3. When naltrexone is administered with thioridazine, the nurse monitors the patient for
   A. elevated temperature
   B. severe occipital headache
   C. increased blood pressure
   D. increased drowsiness

### Medications Dosage Problems

1. A patient is prescribed 0.8 mg naloxone IM for an overdose of morphine. Available is a vial with 1 mg/mL. The nurse administers _____.

2. The physician prescribes naltrexone (ReVia) 25 mg PO initially. The nurse is to observe the patient carefully and if no withdrawal signs appear, 100 mg PO of the drug is prescribed every other day. On hand is naltrexone 50-mg tablets. The nurse administers _____ as the initial dose.
A variety of drugs are used in the treatment of musculoskeletal (bone and muscle) disorders. Examples of the musculoskeletal disorders discussed in this chapter include osteoarthritis, rheumatoid arthritis, gout, and Paget's disease. A description of these and other musculoskeletal disorders is given in Table 21-1. The drug selected is based on the musculoskeletal disorder being treated, the severity of the disorder, and the patient's positive or negative response to past therapy. For example, early cases of rheumatoid arthritis may respond well to the salicylates, whereas advanced rheumatoid arthritis not responding to other drug therapies may require the use of one of the gold compounds.

The salicylates and nonsteroidal anti-inflammatory drugs (NSAIDs) are important in the treatment of arthritic conditions. For example, the salicylates and NSAIDs are used in the treatment of rheumatoid arthritis (a chronic disease characterized by inflammatory changes within the body's connective tissue) and osteoarthritis (a noninflammatory joint disease resulting in degeneration of the articular cartilage and changes in the synovial membrane), as well as relief of pain or discomfort resulting from musculoskeletal injuries such as sprains. The reader is referred to Chapters 17 and 18, where these drugs are discussed in detail.

**GOLD COMPOUNDS**

Gold suppresses or prevents but, but does not cure, arthritis and synovitis. The therapeutic effects from gold compounds occur slowly. Early improvement is often limited to reduction in morning stiffness. The full effects of gold therapy are not known for 6 to 8 weeks or in some cases after 6 months of therapy.

**ACTIONS**

The exact mechanism of action of the gold compounds (for example, gold sodium thiomalate, aurothioglucose, and auranofin) in the suppression or prevention of
inflammation is unknown. Gold compounds decrease synovial inflammation and retard cartilage and bone destruction. Gold decreases the concentration of rheumatoid factor and immunoglobulins.

**USES**

Gold compounds are used to treat active juvenile and adult rheumatoid arthritis not controlled by other anti-inflammatory drugs. It is important to note that when cartilage and bone damage has already occurred, gold cannot reverse structural changes to the joints. The greatest benefit appears to occur in patients in the early stages of disease.

**ADVERSE REACTIONS**

Adverse reactions to the gold compounds may occur any time during therapy, as well as many months after therapy has been discontinued. Dermatitis (inflammation of the skin) and stomatitis (inflammation of mucosa of the mouth, gums, and possibly the tongue) are the most common adverse reactions seen. Pruritus (itching) often occurs before the skin eruption becomes apparent. Photosensitivity reactions (exaggerated sunburn reaction when the skin is exposed to sunlight or ultraviolet light) may also occur. Chrysiasis (grey to blue pigmentation of the skin) may occur and is caused by gold deposits in tissues. Gold dermatitis is exacerbated by exposure to sunlight.

**CONTRAINDICATIONS**

The gold compounds are contraindicated in patients with known hypersensitivity to any component of the drug. Parenteral administration is contraindicated in patients with uncontrolled diabetes, hepatic disease, uncontrolled hypertension, uncontrolled congestive heart failure, systemic lupus erythematosus, and blood dyscrasias and in those with recent radiotherapy. Oral administration is contraindicated in patients with necrotizing enterocolitis, pulmonary fibrosis, and hematologic disorders and during pregnancy (Category C) and lactation.

**PRECAUTIONS**

The gold compounds are used cautiously in patients with a history of hypersensitivity to other drugs, previous kidney or liver disease, diabetes, or hypertension.
Concurrent administration of auranofin with phenytoin may increase phenytoin blood levels.

**DRUGS USED IN THE TREATMENT OF GOUT**

**Gout** is a form of arthritis in which uric acid accumulates in increased amounts in the blood and often is deposited in the joints. The deposit or collection of urate crystals in the joints causes the symptoms (pain, redness, swelling, joint deformity) of gout.

**ACTIONS**

Allopurinol (Zyloprim) reduces the production of uric acid, thus decreasing serum uric acid levels and the deposit of urate crystals in joints. The exact mechanism of action of colchicine is unknown, but it does reduce the inflammation associated with the deposit of urate crystals in the joints. This probably accounts for its ability to relieve the severe pain of acute gout. Colchicine has no effect on uric acid metabolism.

In those with gout, the serum uric acid level is usually elevated. Sulfinpyrazone increases the excretion of uric acid by the kidneys, which lowers serum uric acid levels and consequently retards the deposit of urate crystals in the joints. Probenecid (Benemid) works in the same manner and may be given alone or with colchicine as combination therapy when there are frequent, recurrent attacks of gout. Probenecid also has been used to prolong the plasma levels of the penicillins and cephalosporins.

**USES**

Drugs indicated for treatment of gout may be used to manage acute attacks of gout or in preventing acute attacks of gout (prophylaxis).

**ADVERSE REACTIONS**

One adverse reaction associated with allopurinol is skin rash, which in some cases has been followed by serious hypersensitivity reactions such as exfoliative dermatitis and Stevens-Johnson syndrome (see Chap. 6 for a description of this syndrome). Other adverse reactions include nausea, vomiting, diarrhea, abdominal pain, and hematologic changes.

Colchicine administration may result in nausea, vomiting, diarrhea, abdominal pain, and bone marrow depression. When this drug is given to patients with an acute attack of gout, the primary health care provider may order the drug given at frequent intervals until gastrointestinal symptoms occur. Probenecid administration may cause headache, gastrointestinal symptoms, urinary frequency, and hypersensitivity reactions. Upper gastrointestinal disturbances may be seen with the administration of sulfinpyrazone. Even when the drug is given with food, milk, or antacids, gastrointestinal distress may persist and the drug therapy may need to be discontinued. The adverse reactions seen with other agents used in the treatment of gout are listed in the Summary Drug Table: Drugs Used to Treat Musculoskeletal Disorders.

**CONTRAINDICATIONS**

The drugs used for gout are contraindicated in patients with known hypersensitivity. Probenecid is contraindicated in patients with blood dyscrasias or uric acid kidney stones and in children younger than 2 years. Sulfinpyrazone is contraindicated in patients with peptic ulcer disease and gastrointestinal inflammation. Colchicine is contraindicated in patients with serious gastrointestinal, renal, hepatic, or cardiac disorders and those with blood dyscrasias.

**PRECAUTIONS**

Allopurinol is used cautiously in patients with liver and renal impairment and during pregnancy (Pregnancy Category C) and lactation. Probenecid is used cautiously in patients with renal impairment, previous hypersensitivity to sulfa drugs, peptic ulcer disease, and those who are pregnant (Pregnancy Category B). Sulfinpyrazone is used cautiously in patients with renal function impairment and those who are pregnant (category unknown). Colchicine is used with caution in older adults and during pregnancy (Pregnancy Category C) and lactation.

**INTERACTIONS**

There is an increased incidence of skin rash when allopurinol and ampicillin are administered concurrently. Concurrent administration of allopurinol and theophylline...
## Drugs Used to Treat Osteoporosis

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bisphosphonates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>alendronate sodium</td>
<td>Fosamax</td>
<td>Treatment and prevention of postmenopausal osteoporosis;</td>
<td>Headache, abdominal pain, arthralgia, recurrent bone</td>
<td>Postmenopausal osteoporosis, osteoporosis in men:</td>
</tr>
<tr>
<td>ah-len'-drew-nate</td>
<td></td>
<td>glucocorticoid-induced osteoporosis; osteoporosis in men;</td>
<td>pain, nausea, diarrhea, esophageal ulceration, dysphagia</td>
<td>35–70 mg/wk or 10 mg/d PO; in glucocorticoid-induced</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paget’s disease</td>
<td></td>
<td>osteoporosis: 5–10 mg/d PO; Paget’s disease: 40 mg/d</td>
</tr>
<tr>
<td>etidronate</td>
<td>Didronel,</td>
<td>Paget’s disease, postoperative treatment after total hip</td>
<td>Headache, abdominal pain, arthralgia, recurrent bone</td>
<td>5–10 mg/kg/d PO (not to exceed 6 months) or 11 mg/d</td>
</tr>
<tr>
<td>e-tid'-ro-nate</td>
<td>Didronel IV</td>
<td>replacement</td>
<td>pain, nausea, diarrhea</td>
<td>PO, if retreatment is necessary wait at least 90</td>
</tr>
<tr>
<td>risedronate sodium</td>
<td>Actonel</td>
<td>Treatment and prevention of postmenopausal osteoporosis;</td>
<td>Headache, abdominal pain, arthralgia, recurrent bone</td>
<td>Osteoporosis: 5 mg/d PO; Paget’s disease: 30 mg/d PO</td>
</tr>
<tr>
<td>rah-sed'-dro-nate</td>
<td></td>
<td>glucocorticoid-induced osteoporosis, Paget’s disease</td>
<td>pain, nausea, diarrhea</td>
<td>for 2 months</td>
</tr>
<tr>
<td>Gold Compounds</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>auranofin</td>
<td>Ridaura</td>
<td>Rheumatoid arthritis</td>
<td>Dermatitis, stomatitis, photosensitivity, pruritus,</td>
<td>6–9 mg/d PO (may give 3 mg BID or 6 mg QD)</td>
</tr>
<tr>
<td>au-rane'-oh-fin</td>
<td></td>
<td></td>
<td>hematologic changes, nausea, vomiting, anorexia, rash,</td>
<td></td>
</tr>
<tr>
<td>aurothioglucose</td>
<td>Solganal</td>
<td>Rheumatoid arthritis</td>
<td>urticaria, metallic taste</td>
<td></td>
</tr>
<tr>
<td>aur-oh-thye-oh-gloo'-kose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gold sodium thiomalate</td>
<td>Aurolate,</td>
<td>Rheumatoid arthritis</td>
<td>Dermatitis, stomatitis, photosensitivity, pruritus,</td>
<td>10–50 mg IM; initial dose: 10 mg IM; 2nd &amp; 3rd</td>
</tr>
<tr>
<td>thi-oh-ma'-late</td>
<td>generic</td>
<td></td>
<td>hematologic changes, nausea, vomiting, anorexia, rash,</td>
<td>doses: 25 mg IM; 4th &amp; subsequent doses, 50 mg IM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>urticaria, metallic taste</td>
<td>until 0.8–1 g is given; dosage may be</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>continued at 50 mg IM q3–4wk</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Generic Name | Trade Name* | Uses | Adverse Reactions | Dosage Ranges
--- | --- | --- | --- | ---
**Baclofen**
bac'-loe-fen | bak'-loe-fen | Management of symptoms of gout | Rash, exfoliative dermatitis, Stevens-Johnson syndrome, nausea, vomiting, diarrhea, abdominal pain, hematologic changes | 100–800 mg/d PO
**Colchicine**
col'-chi-seen | generic | Relief of acute attacks of gout, prevention of gout attacks | Nausea, vomiting, diarrhea, abdominal pain, bone marrow depression | Acute attack: Initial dose 0.5–1.2 mg PO or 2 mg IV then 0.5–1.2 mg PO q1–2h or 0.5 mg IV q6h until attack aborted or adverse effects occur; prophylaxis: 0.5–0.6 mg/d PO
**Probenecid**
proe'-ben'-e-sid | Benemid, generic | Treatment of hyperuricemia of gout and gouty arthritis | Headache, anorexia, nausea, vomiting, urinary frequency, flushing, dizziness | 0.25 mg PO BID for 1 wk then 0.5 mg PO BID
**Sulfinpyrazone**
sul-fin-peer'-a-zone | generic | Treatment of gouty arthritis | Upper GI disturbances, rash, blood dyscrasias | 200–400 mg/d PO in 2 divided doses

### Skeletal Muscle Relaxants

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
</table>
**Allopurinol**
al-oh-pure'-i-nole | Zyloprim, generic | Management of symptoms of gout | Rash, exfoliative dermatitis, Stevens-Johnson syndrome, nausea, vomiting, diarrhea, abdominal pain, hematologic changes | 100–800 mg/d PO in divided doses
**Colchicine**
col'-chi-seen | generic | Relief of acute attacks of gout, prevention of gout attacks | Nausea, vomiting, diarrhea, abdominal pain, bone marrow depression | Acute attack: Initial dose 0.5–1.2 mg PO or 2 mg IV then 0.5–1.2 mg PO q1–2h or 0.5 mg IV q6h until attack aborted or adverse effects occur; prophylaxis: 0.5–0.6 mg/d PO
**Probenecid**
proe'-ben'-e-sid | Benemid, generic | Treatment of hyperuricemia of gout and gouty arthritis | Headache, anorexia, nausea, vomiting, urinary frequency, flushing, dizziness | 0.25 mg PO BID for 1 wk then 0.5 mg PO BID
**Sulfinpyrazone**
sul-fin-peer'-a-zone | generic | Treatment of gouty arthritis | Upper GI disturbances, rash, blood dyscrasias | 200–400 mg/d PO in 2 divided doses

### Dosage Ranges

- **Baclofen**: 15–80 mg/d PO in divided doses
- **Colchicine**: Initial dose 0.5–1.2 mg PO then 0.5–1.2 mg PO q1–2h or 0.5 mg IV q6h until attack aborted or adverse effects occur; prophylaxis: 0.5–0.6 mg/d PO
- **Probenecid**: 0.25 mg PO BID for 1 wk then 0.5 mg PO BID
- **Sulfinpyrazone**: 200–400 mg/d PO in 2 divided doses

### Summary

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
</table>
**Baclofen**ac'-loe-fen | bak'-loe-fen | Management of symptoms of gout | Rash, exfoliative dermatitis, Stevens-Johnson syndrome, nausea, vomiting, diarrhea, abdominal pain, hematologic changes | 100–800 mg/d PO
**Colchicine**
col'-chi-seen | generic | Relief of acute attacks of gout, prevention of gout attacks | Nausea, vomiting, diarrhea, abdominal pain, bone marrow depression | Acute attack: Initial dose 0.5–1.2 mg PO or 2 mg IV then 0.5–1.2 mg PO q1–2h or 0.5 mg IV q6h until attack aborted or adverse effects occur; prophylaxis: 0.5–0.6 mg/d PO
**Probenecid**
proe'-ben'-e-sid | Benemid, generic | Treatment of hyperuricemia of gout and gouty arthritis | Headache, anorexia, nausea, vomiting, urinary frequency, flushing, dizziness | 0.25 mg PO BID for 1 wk then 0.5 mg PO BID
**Sulfinpyrazone**
sul-fin-peer'-a-zone | generic | Treatment of gouty arthritis | Upper GI disturbances, rash, blood dyscrasias | 200–400 mg/d PO in 2 divided doses

### Skeletal Muscle Relaxants

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
</table>
**Allopurinol**
al-oh-pure'-i-nole | Zyloprim, generic | Management of symptoms of gout | Rash, exfoliative dermatitis, Stevens-Johnson syndrome, nausea, vomiting, diarrhea, abdominal pain, hematologic changes | 100–800 mg/d PO in divided doses
**Colchicine**
col'-chi-seen | generic | Relief of acute attacks of gout, prevention of gout attacks | Nausea, vomiting, diarrhea, abdominal pain, bone marrow depression | Acute attack: Initial dose 0.5–1.2 mg PO or 2 mg IV then 0.5–1.2 mg PO q1–2h or 0.5 mg IV q6h until attack aborted or adverse effects occur; prophylaxis: 0.5–0.6 mg/d PO
**Probenecid**
proe'-ben'-e-sid | Benemid, generic | Treatment of hyperuricemia of gout and gouty arthritis | Headache, anorexia, nausea, vomiting, urinary frequency, flushing, dizziness | 0.25 mg PO BID for 1 wk then 0.5 mg PO BID
**Sulfinpyrazone**
sul-fin-peer'-a-zone | generic | Treatment of gouty arthritis | Upper GI disturbances, rash, blood dyscrasias | 200–400 mg/d PO in 2 divided doses

### Dosage Ranges

- **Baclofen**: 15–80 mg/d PO in divided doses
- **Colchicine**: Initial dose 0.5–1.2 mg PO then 0.5–1.2 mg PO q1–2h or 0.5 mg IV q6h until attack aborted or adverse effects occur; prophylaxis: 0.5–0.6 mg/d PO
- **Probenecid**: 0.25 mg PO BID for 1 wk then 0.5 mg PO BID
- **Sulfinpyrazone**: 200–400 mg/d PO in 2 divided doses
## SUMMARY DRUG TABLE  
**DRUGS USED TO TREAT MUSCULOSKELETAL DISORDERS**  
(Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>methocarbamol meth-oh-kar’-ba-mol</td>
<td>Robaxin, generic</td>
<td>Discomfort due to musculoskeletal disorders</td>
<td>Drowsiness, dizziness, light-headedness, confusion, headache, rash, blurred vision, GI upset</td>
<td>1–1.5 g QID PO; up to 3 g/d IM, IV</td>
</tr>
<tr>
<td>orphenadrine citrate or-fen’-a-dreen</td>
<td>Banflex, Flexojet, Flexon, Norflex, generic</td>
<td>Discomfort due to musculoskeletal disorders</td>
<td>Drowsiness, dizziness, light-headedness, confusion, headache, rash, blurred vision, GI upset</td>
<td>100 mg BID PO; 60 mg IV or IM q12h</td>
</tr>
</tbody>
</table>

### Corticosteroids

| prednisolone pred-niss'-oh-lone | Delta-Cortef, generic | Ankylosing spondylitis, bursitis, acute gouty arthritis, rheumatoid arthritis | See Chap. 50 | 5–60 mg/d PO |
| prednisone pred’ni-sone | Deltasone, Orasone, generic | Ankylosing spondylitis, bursitis, acute gouty arthritis, rheumatoid arthritis | See Chap. 50 | 5–60 mg/d PO |

### Miscellaneous Drugs

| etanercept ee-tah-ner’-sept | Enbrel | Rheumatoid arthritis | Congestion, abdominal pain, dyspepsia, irritation at injection site, increased risk of infections, optic neuritis, pancytopenia | 25 mg SC twice weekly |
| hylan G-F 20 (hyaluronic acid derivatives) | Synvisc, Hylagan | Treatment of osteoarthritic knee pain in patients with no response to other treatment | Temporary pain, swelling and/or fluid accumulation in the injected knee, nausea, rash | 2 mL by intra-articular injections once weekly for 3 wk |
| hydroxychloroquine sulfate hye-drox-ee-klor’-oh-kwin | Plaquinil Sulfate, generic | Rheumatoid arthritis-antimalarial | Irritability, nervousness, retinal and corneal changes, anorexia, nausea, vomiting, hematologic effects | 200-600 mg/d PO |
| leflunomide le-flu’-no-mide | Arava | Rheumatoid arthritis | Hypertension, alopecia, rash, nausea | Initial dose: 100 mg for 3d; maintenance dose: 20 mg/d |
| methotrexate meth-oh-trex’-ate | Rheumatrex Dose Pak, generic | Rheumatoid arthritis, antineoplastic | Nausea, vomiting, anorexia, severe bone marrow depression, nephrotoxicity, leukopenia, stomatitis, blurred vision | 7.5 mg PO once a wk or 2.5 mg at 12-h intervals for 3 doses once a week |
| penicillamine pen-i-sill’-a-meen | Cuprimine, Depen | Rheumatoid arthritis | Pruritus, rash, anorexia, nausea, vomiting, epigastric pain, bone marrow depression, proteinuria, hematuria, increased skin friability, tinnitus | Initial dose: 125–250 mg/d PO and increased to obtain remission. Maximum daily dose is 1.0 g PO |
| sulfasalazine sul-fa-sal’-a-zeen | Azulfidine, generic | Rheumatoid arthritis, ulcerative colitis | Nausea, emesis, abdominal pains, crystalluria, hematuria, Stevens-Johnson syndrome, rash, headache, drowsiness, diarrhea | 2–4 g/d PO in divided doses |

*The term generic indicates the drug is available in generic form.*
increases the risk of theophylline toxicity. When angiotensin-converting enzyme inhibitors or the thiazide diuretics are administered with allopurinol, there is an increased risk of hypersensitivity reactions. Administration of allopurinol with aluminum salts may decrease the effectiveness of allopurinol.

Salicylates antagonize probenecid's uricosuric action. Concurrent administration of probenecid increases the effects of acyclovir, barbiturates, benzodiazepines, dapsone, methotrexate, NSAIDs, rifampin, and the sulfonamides.

Sulfinpyrazone may increase the anticoagulant activity of oral anticoagulants. There is an increased risk of hypoglycemia when sulfinpyrazone is administered with tolbutamide. Concurrent administration of sulfinpyrazone with verapamil may decrease the effectiveness of verapamil.

SKELETAL MUSCLE RELAXANTS

ACTIONS

The mode of action of many skeletal muscle relaxants, for example carisoprodol (Soma), baclofen (Lioresal), and chlorzoxazone (Paraflex), is not clearly understood. Many of these drugs do not directly relax skeletal muscles, but their ability to relieve acute painful musculoskeletal conditions may be due to their sedative action. Cyclobenzaprine (Flexeril) appears to have an effect on muscle tone, thus reducing muscle spasm.

The exact mode of action of diazepam (Valium), an antianxiety drug (see Chap. 30), in the relief of painful musculoskeletal conditions is unknown. The drug does have a sedative action, which may account for some of its ability to relieve muscle spasm and pain.

USES

Skeletal muscle relaxants are used in various acute, painful musculoskeletal conditions, such as muscle strains and back pain.

ADVERSE REACTIONS

Drowsiness is the most common reaction seen with the use of skeletal muscle relaxants. Additional adverse reactions are given in the Summary Drug Table: Drugs Used to Treat Musculoskeletal Disorders. Some of the adverse reactions that may be seen with the administration of diazepam include drowsiness, sedation, sleepiness, lethargy, constipation or diarrhea, bradycardia or tachycardia, and rash.

CONTRAINDICATIONS

The skeletal muscle relaxants are contraindicated in patients with known hypersensitivity. Baclofen is contraindicated in skeletal muscle spasms caused by rheumatic disorders. Carisoprodol is contraindicated in patients with a known hypersensitivity to meprobamate. Cyclobenzaprine is contraindicated in patients with a recent myocardial infarction, cardiac conduction disorders, and hyperthyroidism. In addition, cyclobenzaprine is contraindicated within 14 days of the administration of a monoamine oxidase inhibitor. Oral dantrolene is contraindicated in patients with active hepatic disease and muscle spasm caused by rheumatic disorders and during lactation. See Chapter 30 for information on diazepam.

PRECAUTIONS

The skeletal muscle relaxants are used with caution in patients with a history of cerebrovascular accident, cerebral palsy, parkinsonism, or seizure disorders and during pregnancy (Pregnancy Category C) and lactation. Carisoprodol is used with caution in patients with severe liver or kidney disease and during pregnancy (category unknown) and lactation. Cyclobenzaprine is used cautiously in patients with cardiovascular disease and during pregnancy (Pregnancy Category B) and lactation. Dantrolene is a Pregnancy Category C drug and is used with caution during pregnancy. See Chapter 25 for information on diazepam.

INTERACTIONS

There is an increased central nervous system (CNS) depressant effect when the skeletal muscle relaxants are administered with other CNS depressants, such as alcohol, antihistamines, opiates, and sedatives. There is an additive anticholinergic effect when cyclobenzaprine is administered with other drugs with anticholinergic effects (eg, antihistamines, antidepressants, atropine, haloperidol). See Chapter 30 for information on diazepam.

BISPHOSPHONATES

The bisphosphonates are drugs used to treat musculoskeletal disorders such as osteoporosis and Paget's disease. This chapter will discuss the use of these drugs in the treatment of osteoporosis.
ACTIONS

Alendronate, etidronate, and risedronate act primarily on the bone by inhibiting normal and abnormal bone resorption. This results in increased bone mineral density, reversing the progression of osteoporosis.

USES

The bisphosphonates are used to treat osteoporosis in postmenopausal women, Paget’s disease of the bone, and postoperative treatment after total hip replacement (etidronate).

ADVERSE REACTIONS

Adverse reactions with the bisphosphonates include nausea, diarrhea, increased or recurrent bone pain, headache, dyspepsia, acid regurgitation, dysphagia, and abdominal pain.

CONTRAINDICATIONS

These drugs are contraindicated in patients who are hypersensitive to the bisphosphonates. Alendronate and risedronate are contraindicated in patients with hypocalcemia. Alendronate is a pregnancy Category C drug and is contraindicated during pregnancy. These drugs are contraindicated in patients with renal impairment with serum creatinine less than 5 mg/dL. Concurrent use of these drugs with hormone replacement therapy is not recommended.

PRECAUTIONS

These drugs are used cautiously in patients with gastrointestinal disorders, renal function impairment and those who are pregnant or lactating.

INTERACTIONS

When administered with ranitidine, alendronate bioavailability is increased. When calcium supplements or antacids are administered with risedronate or alendronate, absorption of the bisphosphonates is decreased. In addition, risedronate absorption is inhibited when the drug is administered with magnesium and aluminum. There is an increased risk of gastrointestinal effects when the bisphosphonates are administered with aspirin.

CORTICOSTEROIDS

ACTIONS

Corticosteroids are hormones secreted from the adrenal cortex. These hormones arise from the cortex of the adrenal gland and are made from the crystalline steroid alcohol cholesterol. Synthetic forms of the natural adrenal cortical hormones are available. The potent anti-inflammatory action of the corticosteroids makes these drugs useful in the treatment of many types of musculoskeletal disorders. The corticosteroids are discussed in Chapter 50.

USES

The corticosteroids may be used to treat rheumatic disorders such as ankylosing spondylitis, rheumatoid arthritis, gout, bursitis (inflammation of the bursa, usually the bursa of the shoulder), and osteoarthritis.

ADVERSE REACTIONS

Corticosteroids may be given in high doses for some arthritic disorders. Many adverse reactions are associated with high-dose and long-term corticosteroid therapy. Chapter 50 discusses some of the adverse reactions associated with corticosteroid therapy. A comprehensive list of adverse reactions is provided in Display 50-2. Contraindications, precautions, and interactions of the corticosteroids are discussed in Chapter 50.

MISCELLANEOUS DRUGS

The miscellaneous drugs are used to treat a variety of musculoskeletal disorders. Penicillamine, methotrexate (MTX), and hydroxychloroquine are used to treat rheumatoid arthritis in patients who have had an insufficient therapeutic response to or are intolerant of other antirheumatic drugs such as the salicylates and NSAIDs. The Summary Drug Table: Drugs Used to Treat Musculoskeletal Disorders provides additional information about these and other drugs. One compound, hylan G-F 20, listed in the Summary Drug Table is not used for rheumatoid arthritis, but rather, for osteoarthritis knee pain. It is a viscous, elastic
A sterile mixture made of hylan A fluid, hylan B gel, and salt water that is administered directly into the knee.

**ACTIONS**

The mechanism of action of penicillamine, MTX, and hydroxychloroquine in the treatment of rheumatoid arthritis is unknown.

**USES**

Penicillamine, MTX, and hydroxychloroquine are used in the treatment of rheumatoid arthritis. The administration of MTX is reserved for severe, disabling disease that is not responsive to other treatment.

**ADVERSE REACTIONS**

Hydroxychloroquine administration may result in irritability, nervousness, anorexia, nausea, vomiting, and diarrhea. This drug also may have adverse effects on the eye, including blurred vision, corneal edema, halos around lights, and retinal damage. Hematologic effects, such as aplastic anemia and leukopenia, may also be seen.

The adverse reactions seen with penicillamine include pruritus, rash, anorexia, nausea, vomiting, epigastric pain, bone marrow depression, proteinuria, hematuria, increased skin friability, and tinnitus. Penicillamine is capable of causing severe toxic reactions.

MTX is a potentially toxic drug that is also used in the treatment of malignancies and psoriasis. Nausea, vomiting, a decreased platelet count, leukopenia (decreased white blood cell count), stomatitis (inflammation of the oral cavity), rash, pruritus, dermatitis, diarrhea, alopecia (loss of hair), and diarrhea may be seen with the administration of this drug.

**CONTRAINDICATIONS**

These drugs are contraindicated in patients with known hypersensitivity. Hydroxychloroquine is contraindicated in patients with porphyria (a group of serious inherited disorders affecting the bone marrow or the liver), psoriasis (chronic skin disorder), and retinal disease (may cause irreversible retinal damage). MTX is contraindicated during pregnancy because it is a Pregnancy Category X drug and may cause birth defects in the developing fetus. Penicillamine is contraindicated in patients with a history of allergy to penicillin.

**PRECAUTIONS**

Hydroxychloroquine is used cautiously in patients with hepatic disease or alcoholism and during pregnancy (Pregnancy Category C) and lactation. MTX is used cautiously in patients with renal impairment, women of childbearing age, and older adults or individuals who are chronically ill or debilitated. Penicillamine is used with extreme caution during pregnancy (Pregnancy Category C) and lactation.

**INTERACTIONS**

There is an increased risk of toxicity of MTX when administered with the NSAIDs, salicylates, oral antidiabetic drugs, phenytoin, tetracycline, and probenecid. There is an additive bone marrow depressant effect when administered with other drugs known to depress the bone marrow or with radiation therapy. There is an increased risk for nephrotoxicity when MTX is administered with other drugs that cause nephrotoxicity. When penicillamine is administered with digoxin, decreased blood levels of digoxin may occur. There is a decreased absorption of penicillamine when the drug is administered with food, iron preparations, and antacids.

---

**Health Supplement Alert: Glucosamine and Chondroitin**

Both glucosamine and chondroitin are used, in combination or alone, to treat arthritis, particularly osteoarthritis. Chondroitin acts as the flexible connecting matrix between the protein filaments in cartilage. Chondroitin can be produced in the laboratory or can come from natural sources (eg, shark cartilage). Some studies suggest that if chondroitin sulfate is available to the cell matrix, synthesis of the matrix can occur. For this reason it is used to treat arthritis. Although there is not much information on chondroitin’s long-term effects, it is generally not considered to be harmful.

Glucosamine is found in mucopolysaccharides, mucoproteins, and chitin. Chitin is found in various marine invertebrates and other lower animals and members of the plant family. In osteoarthritis there is a progressive degeneration of cartilage glycosaminoglycans. Oral glucosamine theoretically provides a building block for regeneration of damaged cartilage. The absorption of oral glucosamine is 90% to 98%, making it widely accepted for use. However, chondroitin molecules are very large (50-300 times larger than glucosamine), and only 0% to 13% of chondroitin is absorbed. There is speculation that these larger molecules are undeliverable to cartilage cells. Glucosamine is generally well tolerated, and no adverse reactions have been reported with its use.
The Patient Receiving a Drug for a Musculoskeletal Disorder

ASSESSMENT

Preadministration Assessment
The nurse obtains the patient’s history, that is, a summary of the disorder, including onset, symptoms, and current treatment or therapy. In some instances, it may be necessary to question patients regarding their ability to carry out activities of daily living, including employment when applicable.

For the physical assessment, the nurse generally appraises the patient’s physical condition and limitations. If the patient has arthritis (any type), the nurse examines the affected joints in the extremities for appearance of the skin over the joint, evidence of joint deformity, and mobility of the affected joint. Patients with osteoporosis are assessed for pain particularly in the upper and lower back or hip. Vital signs and weight are taken to provide a baseline for comparison during therapy. If the patient has gout, the nurse examines the affected joints and notes the appearance of the skin over the joints and any joint enlargement.

Ongoing Assessment
Periodic evaluation is an important part of therapy for musculoskeletal disorders. With some disorders such as acute gout, the patient can be expected to respond to therapy in hours. Therefore, it is important for the nurse to inspect the joints involved every 1 to 2 hours to identify immediately a response or nonresponse to therapy. At this time, the nurse questions the patient regarding the relief of pain, as well as adverse drug reactions. In other disorders, response is gradual and may take days, weeks, and even months of treatment. Depending on the drug administered and the disorder being treated, the evaluation of therapy may be daily or weekly. These recorded evaluations help the primary health care provider plan current and future therapy, including dosage changes, changes in the drug administered, and institution of physical therapy.

Some of these drugs are toxic. The nurse closely observes the patient for the development of adverse reactions. Should any one or more adverse reactions occur, the nurse notifies the primary health care provider before the next dose is due.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

Nursing Diagnoses Checklist

- Risk for Injury related to adverse drug reactions (dizziness, drowsiness)
- Risk for Impaired Skin Integrity related to adverse drug reactions (dermatitis, rash)
- Altered Oral Mucous Membranes related to adverse reactions (stomatitis)
- Diarrhea related to adverse drug reaction
- Constipation related to adverse drug reaction

PLANNING

The expected outcomes for the patient depend on the reason for administration but may include an optimal response to therapy, management of common adverse drug reactions, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy
The patient with a musculoskeletal disorder may be in acute pain or have longstanding mild to moderate pain, which can be just as difficult to tolerate as severe pain. Along with pain, there may be skeletal deformities, such as the joint deformities seen with advanced rheumatoid arthritis. For many musculoskeletal conditions, drug therapy is a major treatment modality. Therapy with these drugs may keep the disorder under control (e.g., therapy for gout), improve the patient's ability to carry out the activities of daily living, or make the pain and discomfort tolerable.

Patients on bed rest require position changes and good skin care every 2 hours. The patient with an arthritis disorder may experience much pain or discomfort and may require assistance with activities, such as ambulating, eating, and grooming. Patients with osteoporosis may require a brace or corset when out of bed.

Patients with a musculoskeletal disorder often have anxiety related to the symptoms and the chronicity of their disorder. In addition to physical care, these patients often require emotional support, especially when a disorder is disabling and chronic. The nurse explains to the patient that therapy may take weeks or longer before any benefit is noted. When this is explained before therapy is started, the patient is less likely to become discouraged over the slow results of drug therapy.

GOLD COMPOUNDS. Aurothioglucose and gold sodium thiomolate are given intramuscularly, preferably in the upper outer quadrant of the gluteus muscle. The nurse gives auranofin orally.
DRUGS USED FOR GOUT. The nurse gives allopurinol, probenecid, and sulfipyrazone with, or immediately after, meals to minimize gastric distress. Colchicine usually can be given with food or milk. When this drug is used for the treatment of an acute gout attack, the nurse may give it every 1 to 2 hours until the pain is relieved. The primary health care provider writes specific orders for administration of the drug and when the drug is to be stopped. The nurse evaluates the patient carefully for relief of pain or the occurrence of nausea, vomiting, or diarrhea. After this evaluation, the nurse decides whether to administer or withhold the drug. Colchicine may be given intravenously for severe gout.

SKELETAL MUSCLE RELAXANTS. The nurse gives these drugs with food to minimize gastrointestinal distress. In addition to drug therapy, rest, physical therapy, and other measures may be part of treatment.

BISPHOSPHONATES. When administering alendronate or risedronate the nurse gives the drug orally in the morning before the first food or drink of the day. Risedronate and etidronate are administered once daily. Etidronate is not administered within 2 hours of food, vitamin and mineral supplements, or antacids.

When alendronate and risedronate are administered, serum calcium levels are monitored before, during, and after therapy. To facilitate delivery of the drug to the stomach and minimize adverse gastrointestinal effects, the nurse administers the drug with 6 to 8 oz of water while the patient is in an upright position. The patient is instructed to remain upright (avoid lying down) for at least 30 minutes after taking the drug.

CORTICOSTEROIDS. When the patient is receiving one of these drugs on alternate days (alternate-day therapy), the drug must be given before 9 A.M. It is extremely important that these drugs not be omitted or discontinued suddenly.

MISCELLANEOUS DRUGS. The nurse administers hydroxychloroquine with food or milk to help prevent gastrointestinal upset. The nurse administers MTX orally. A therapeutic response usually begins within 3 to 6 weeks of therapy, and improvement may continue for another 12 weeks. Treatment with this drug may continue for as long as 2 years. Penicillamine must be given to a patient with an empty stomach, 1 hour before or 2 hours after a meal.

Monitoring and Managing Adverse Drug Reactions

GOLD COMPOUNDS. The nurse observes the patient closely for evidence of dermatitis. Itching may occur before a skin reaction and should be reported to the primary health care provider immediately. If itching occurs, the nurse may apply a soothing lotion or an antiseptic cream. The nurse also keeps the environment free of irritants that aggravate itching, such as rough fabrics, excessive warmth, or excessive dryness.

The nurse inspects the patient’s mouth daily for ulceration of the mucous membranes. A metallic taste may be noted before stomatitis becomes evident. The nurse advises the patient to inform the primary health care provider or nurse if a metallic taste occurs. Good oral care is necessary. The teeth should be brushed after each meal and the mouth rinsed with plain water to remove food particles. Mouthwash may also be used, but excessive use may result in oral infections due to the destruction of the normal bacteria present in the mouth.

When corticosteroid use is discontinued, the dosage must be tapered gradually over several days. If high dosages have been given, it may take a week or more to taper the dosage.

Gerontologic Alert

Gold compounds are given cautiously to older adults. Tolerance for gold therapy decreases with advancing age.

While taking gold compounds the patient is monitored closely for thrombocytopenia (abnormally low numbers of platelets in the blood). The primary health care provider orders frequent blood studies (usually once a month or more frequently).

Nursing Alert

If the platelet count falls below 100,000/mm³ or if the patient experiences signs and symptoms of thrombocytopenia (eg, easy bruising, bleeding gums, epistaxis, melena), the nurse notifies the physician immediately.
The nurse closely observes severe diarrhea. Adverse reactions such as the return of bone pain or for headache. Notify the primary health care provider of gia, and abdominal pain. Analgesic may be administered pain, headache, dyspepsia, acid regurgitation, dyspha-gia, and increased or recurrent bone. Particular attention is paid to easy bruising because irreversible retinal damage may occur. The nurse immediately reports adverse reactions to the attention of the primary health care provider.

Administration of allopurinol may result in skin rash. This rash may precede a serious adverse reaction, Stevens-Johnson syndrome (see Chaps. 6 and 8). The nurse immediately reports to the primary health care provider the presence of any rash.

These drugs may cause drowsiness. Because of the risk of injury, the nurse evaluates the patient carefully before allowing the patient to ambulate alone. If drowsiness occurs, assistance with ambulatory activities is necessary. If drowsiness is severe, the nurse notifies the primary health care provider before the next dose is due.

The nurse monitors the patient taking the bisphosphonates for any adverse reactions such as nausea, diarrhea, increased or recurrent bone pain, headache, dyspepsia, acid regurgitation, dysphagia, and abdominal pain. A nalgesic may be administered for headache. Notify the primary health care provider of adverse reactions such as the return of bone pain or severe diarrhea.

The nurse closely observes the patient taking hydroxychloroquine for adverse reactions. It is important for the nurse to be alert to skin rash, fever, cough, easy bruising, or unusual bleeding, or the patient’s complaints of sore throat, visual changes, mood changes, loss of hair, tinnitus, or hearing loss. The nurse immediately reports adverse reactions. Particular attention is paid to visual changes because irreversible retinal damage may occur. The nurse observes the patient for signs of easy bruising and infection, which may indicate bone marrow depression, an adverse reaction related to the platelets and white blood cells. A decreased platelet count may cause the patient to bleed easily. The nurse applies pressure to all venipuncture puncture sites for at least 10 minutes and avoids intramuscular injections. The mouth is inspected daily for signs of inflammation or ulceration. The nurse also inspects each stool for diarrhea or signs of gastrointestinal bleeding.

Administration of allopurinol may result in skin rash. This rash may precede a serious adverse reaction, Stevens-Johnson syndrome (see Chaps. 6 and 8). The nurse immediately reports to the primary health care provider the presence of any rash.

These drugs may cause drowsiness. Because of the risk of injury, the nurse evaluates the patient carefully before allowing the patient to ambulate alone. If drowsiness occurs, assistance with ambulatory activities is necessary. If drowsiness is severe, the nurse notifies the primary health care provider before the next dose is due.

The nurse monitors the patient taking the bisphosphonates for any adverse reactions such as nausea, diarrhea, increased or recurrent bone pain, headache, dyspepsia, acid regurgitation, dysphagia, and abdominal pain. A nalgesic may be administered for headache. Notify the primary health care provider of adverse reactions such as the return of bone pain or severe diarrhea.

The nurse closely observes the patient taking hydroxychloroquine for adverse reactions. It is important for the nurse to be alert to skin rash, fever, cough, easy bruising, or unusual bleeding, or the patient’s complaints of sore throat, visual changes, mood changes, loss of hair, tinnitus, or hearing loss. The nurse immediately reports adverse reactions. Particular attention is paid to visual changes because irreversible retinal damage may occur. The nurse observes the patient for signs of easy bruising and infection, which may indicate bone marrow depression, an adverse reaction related to the platelets and white blood cells. A decreased platelet count may cause the patient to bleed easily. The nurse applies pressure to all venipuncture puncture sites for at least 10 minutes and avoids intramuscular injections. The mouth is inspected daily for signs of inflammation or ulceration. The nurse also inspects each stool for diarrhea or signs of gastrointestinal bleeding.

GOLD COMPOUNDS

- Toxic reactions are possible when taking gold compounds. Report adverse reactions to the primary health care provider as soon as possible.
- Contact the primary health care provider if a metallic taste is noted.
- Arthralgia (pain in the joints) may be noted for 1 or 2 days after the parenteral form is given.
- Chrysiasis may occur, especially on areas exposed to sunlight. Avoid exposure to sunlight or ultraviolet light.
DRUGS USED FOR GOUT

• Drink at least 10 glasses of water a day until the acute attack has subsided.
• Take this drug with food to minimize gastrointestinal upset.
• If drowsiness occurs, avoid driving or performing other hazardous tasks.
• Acute gout—Notify the primary health care provider if pain is not relieved in a few days.
• Colchicine for acute gout—Take this drug at the intervals prescribed by the primary health care provider and stop taking the drug when the pain is relieved or when diarrhea or vomiting occurs. If the pain is not relieved in about 12 hours, notify the primary health care provider.
• Allopurinol—Notify the primary health care provider if a skin rash occurs.
• Colchicine—Notify the primary health care provider if skin rash, sore throat, fever, unusual bleeding or bruising, unusual fatigue, or weakness occurs.

SKELETAL MUSCLE RELAXANTS

• This drug may cause drowsiness. Do not drive or perform other hazardous tasks if drowsiness occurs.
• This drug is for short-term use. Do not use the drug for longer than 2 to 3 weeks.
• Avoid alcohol or other depressants while taking this drug.

BISPHOSPHONATES

Alendronate and risedronate. These drugs are taken with 6 to 8 oz of water first thing in the morning. Do not lie down for at least 30 minutes after taking the drug and wait at least 30 minutes before taking any other food or drink. The drugs are taken exactly as prescribed. The primary care provider may prescribe alendronate as a once weekly dose or to be taken daily. Risedronate is taken daily. Take supplemental calcium and vitamin D if dietary intake is inadequate. Take all medication, including vitamin and mineral supplements, at a different time of the day to prevent interference with absorption of the drug.

MISCELLANEOUS DRUGS

Penicillamine. The primary health care provider will explain the treatment regimen and adverse reactions before therapy is started. You must know which toxic reactions require contacting the primary health care provider immediately. Take penicillamine on an empty stomach, 1 hour before or 2 hours after a meal. If other drugs are prescribed, penicillamine is taken 1 hour apart from any other drug. Observe skin areas over the elbows, shoulders, and buttocks for evidence of bruising, bleeding, or break in the skin (delayed wound healing may occur). If these occur, do not self-treat the problem, but notify the primary health care provider immediately. An alteration in taste perception may occur. Taste perception should return to normal within 2 to 3 months.

Methotrexate. Take MTX exactly as directed. If a weekly dose is prescribed, use a calendar or some other method to take the drug on the same day each week. Never increase the prescribed dose of this drug. Mistaken daily use has led to fatal toxicity. Notify the primary health care provider immediately if any of the following occur: sore mouth, sores in the mouth, diarrhea, fever, sore throat, easy bruising, rash, itching, or nausea and vomiting. Women of childbearing age should use an effective contraceptive during therapy with MTX and for 8 weeks after therapy.

Hydroxychloroquine. Take hydroxychloroquine with food or milk. Contact the primary health care provider immediately if any of the following occur: hearing or visual changes, skin rash or severe itching, hair loss, change in the color of the hair (bleaching), changes in the color of the skin, easy bruising or bleeding, fever, sore throat, muscle weakness, or mood changes. It may be several weeks before symptoms are relieved.

EVALUATION

• The therapeutic drug effect is achieved.
• Adverse reactions are identified, reported to the primary health care provider, and managed using appropriate nursing interventions.
• The patient verbalizes the importance of complying with the prescribed therapeutic regimen.
• The patient and family demonstrate an understanding of the drug regimen.

Critical Thinking Exercises

1. Mary is a nurse who has returned to nursing after 15 years absence to raise a family. Mary asks you what should be included in a teaching plan for a patient with rheumatoid arthritis now taking high doses of salicylates. Discuss what information you would suggest Mary emphasize in a teaching plan.

2. Ms. Leeds is prescribed methotrexate for rheumatoid arthritis not responding to other therapies. She is nervous about starting the drug after she was told that the drug can cause many serious adverse reactions. Discuss what you could say to Ms. Leeds to relieve her anxiety. Identify specific instructions you would give her before she begins therapy with this drug.

3. Discuss important points the nurse should consider when administering colchicine to a patient with an acute attack of diarrhea.

4. Discuss the important points to include when educating a patient prescribed alendronate 35 mg once weekly.
What suggestions could you give the patient to help him remember when to take the drug?

**Review Questions**

1. When a patient is taking gold compound therapy on an outpatient basis, the nurse advises the patient to inform the primary care provider if _____.
   - A. the appetite decreases
   - B. a severe headache occurs
   - C. a metallic taste is noted
   - D. hair loss occurs

2. When administering a skeletal muscle relaxant, the nurse observes the patient for the most common adverse reaction, which is _____.
   - A. drowsiness
   - B. gastrointestinal bleeding
   - C. vomiting
   - D. constipation

3. When a patient is prescribed a corticosteroid for arthritis and alternate-day therapy is used, the nurse administers the drug _____.
   - A. with food or milk
   - B. on an empty stomach
   - C. before 9:00 AM
   - D. at bedtime

4. When allopurinol (Zyloprim) is used for the treatment of gout, the nurse _____.
   - A. administers the drug with juice or milk
   - B. administers the drug after the evening meal
   - C. restricts fluids during evening hours
   - D. encourages a liberal fluid intake

5. What teaching points would the nurse include when educating the patient prescribed risedronate?
   - A. The drug is administered once weekly.
   - B. Take a daily laxative because the drug will likely cause constipation.
   - C. Take the drug in the morning before breakfast and immediately lie down for 30 minutes to facilitate absorption.
   - D. After taking the drug, remain upright for at least 30 minutes.

**Medication Dosage Problems**

1. A patient is to receive allopurinol 300 mg PO for gout. The nurse has 100-mg tablets available. How many tablets would the nurse administer?

2. The physician prescribes 1.5 g methocarbamol (Robaxin) PO for a musculoskeletal disorder. Available for administration are 500-mg tablets. The nurse administers _____.
Adrenergic Drugs

Key Terms

- autonomic nervous system
- central nervous system
- neurotransmitter
- parasympathetic nervous system
- peripheral nervous system
- shock
- somatic nervous system
- sympathetic nervous system
- vasopressor

Chapter Objectives

On completion of this chapter, the student will:

- Discuss the activity of the central nervous system and the peripheral nervous system.
- Discuss the types of shock, physiologic responses of shock, and the use of adrenergic drugs in the treatment of shock.
- Discuss the uses, general drug actions, contraindications, precautions, interactions, and adverse reactions associated with the administration of adrenergic drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking adrenergic drugs.
- List some nursing diagnoses particular to a patient taking the adrenergic drugs.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating patients about the use of adrenergic drugs.

The adrenergic drugs produce pharmacologic effects similar to the effects that occur in the body when the adrenergic nerves and the medulla are stimulated. The primary effects of these drugs occur on the heart, the blood vessels, and the smooth muscles, such as the bronchi. A basic knowledge of the nervous system is necessary to understand these drugs and how they work in the body.

THE NERVOUS SYSTEM

The nervous system is a complex part of the human body concerned with the regulation and coordination of body activities such as movement, digestion of food, sleep, and elimination of waste products. The nervous system has two main divisions: the central nervous system (CNS) and the peripheral nervous system (PNS). Figure 22-1 illustrates the divisions of the nervous system.

The CNS consists of the brain and the spinal cord and receives, integrates, and interprets nerve impulses.

The PNS is the term used to describe all nerves outside of the brain and spinal cord. The PNS connects all parts of the body with the CNS.

Peripheral Nervous System

The PNS is further divided into the somatic nervous system and the autonomic nervous system. The somatic branch of the PNS is concerned with sensation and voluntary movement. The sensory part of the somatic nervous system sends messages to the brain concerning the internal and external environment, such as sensations of heat, pain, cold, and pressure. The voluntary part of the somatic nervous system is concerned with the voluntary movement of skeletal muscles, such as walking, chewing food, or writing a letter.

Autonomic Branch of the Peripheral Nervous System

The autonomic branch of the PNS is concerned with functions essential to the survival of the organism. Functional activity of the autonomic nervous system...
is not consciously controlled (i.e., the activity is automatic). This system controls blood pressure, heart rate, gastrointestinal activity, and glandular secretions. Table 22-1 describes the action of the autonomic nervous system on the body.

The autonomic nervous system is divided into the sympathetic and the parasympathetic nervous system. The sympathetic nervous system tends to regulate the expenditure of energy and is operative when the organism is confronted with stressful situations, such as danger, intense emotion, or severe illness. The parasympathetic nervous system helps conserve body energy and is partly responsible for such activities as slowing the heart rate, digesting food, and eliminating body wastes.

Neurotransmitters

Neurotransmitters are chemical substances called neurohormones. These are released at the nerve endings that facilitate the transmission of nerve impulses. The two neurotransmitters (neurotransmitters) of the sympathetic nervous system are epinephrine and norepinephrine. Epinephrine is secreted by the adrenal medulla. Norepinephrine is secreted mainly at nerve endings of sympathetic (also called adrenergic) nerve fibers (Fig. 22-2).

ADRENERGIC DRUGS

Adrenergic drugs mimic the activity of the sympathetic nervous system. These drugs also are called sympathomimetic drugs. Epinephrine and norepinephrine are neurohormones produced naturally by the body. Synthetic preparations of these two neurohormones, which are identical to those naturally produced by the body, are used in medicine. Adrenergic drugs such as metaraminol (Aramine), isoproterenol (Isuprel), and ephedrine are synthetic adrenergic drugs.

ACTIONS

Generally, adrenergic drugs produce one or more of the following responses in varying degrees:

- CNS—wakefulness, quick reaction to stimuli, quickened reflexes
- PNS—relaxation of the smooth muscles of the bronchi; constriction of blood vessels, sphincters of the stomach; dilatation of coronary blood vessels; decrease in gastric motility
- Heart—increase in the heart rate
- Metabolism—increased use of glucose (sugar) and liberation of fatty acids from adipose tissue

Adrenergic Nerve Receptors

Adrenergic nerve fibers have either alpha (α) or beta (β) receptors. Adrenergic drugs may act on α receptors only, β receptors only, or on both α and β receptors. For example, phenylephrine (Neo-Synephrine) acts chiefly on α receptors; isoproterenol acts chiefly on β receptors; and epinephrine acts on both α and β receptors. Whether an adrenergic drug acts on α, β, or α and β receptors accounts for the variation of responses for this group of drugs. See Table 22-1 for a list of the type of adrenergic nerve fiber receptors that corresponds with each action of the autonomic nervous system on the body.

The α and β receptors can be further divided into α1- and α2-adrenergic receptors and β1- and β2-adrenergic
CHAPTER 22  Adrenergic Drugs

TYPES OF SYMPATHETIC (ADRENERGIC) ORGANS OR STRUCTURES (ADRENERGIC) EFFECTS RECEPTOR (CHOLINERGIC) EFFECTS

**Heart**
- Increase in heart rate, heart muscle contractility, increase in speed of atrioventricular conduction
- Decrease in heart rate, decrease in heart muscle contractility
- \( \beta \)

**Blood vessels**
- 1. Skin, mucous membranes: Constriction
- 2. Skeletal muscle: Usually dilatation
- Bronchial muscles: Relaxation
- Gastrointestinal
  - 1. Muscle motility, tone decrease
  - 2. Sphincters: Usually contraction
  - 3. Gallbladder: Relaxation

**Urinary bladder**
- 1. Detrusor muscle: Relaxation
- 2. Trigone, sphincter muscles: Contraction
- Eye
  - 1. Radial muscle of iris: Contraction (pupil dilates)
  - 2. Sphincter muscle of iris: Contraction (pupil constricts)
  - 3. Ciliary muscle: Contraction

**Skin**
- 1. Sweat glands: Increased activity in localized areas
- 2. Pilomotor muscles: Contraction (gooseflesh)
- Uterus: Relaxation
- Salivary glands: Thickened secretions
- Liver: Glycogenolysis
- Lacrimal and nasopharyngeal glands
- Male sex organs: Emission

**Receptors.** Table 22-2 indicates the effects in the body when stimulation of these receptors occurs.

### USES

Adrenergic drugs have a wide variety of uses and may be given as all or part of the treatment for:

- Hypovolemic and septic shock;
- Moderately severe to severe episodes of hypotension;
- Control of superficial bleeding during surgical and dental procedures of the mouth, nose, throat, and skin;
- Bronchial asthma;
- Cardiac decompensation and arrest;
- Allergic reactions (anaphylactic shock, angioneurotic edema);
- Temporary treatment of heart block;
- Ventricular arrhythmias (under certain conditions);
- Nasal congestion (applied topically); and
- In conjunction with local anesthetics to prolong anesthetic action in medicine and dentistry.

Other adrenergic drugs have specific uses. Isoproterenol may be used in the treatment of some cardiac arrhythmias, cardiac arrest, Adams-Stokes syndrome, or as a systemic bronchodilator (see Chap. 37 for a more detailed discussion of the bronchodilators). Midodrine is used to treat orthostatic hypotension. The uses of various adrenergic drugs are given in the Summary Drug Table: Adrenergic Drugs.
## Summary Drug Table: Adrenergic Drugs

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>dobutamine HCl</td>
<td>Dobutrex, generic</td>
<td>Cardiac decompensation due to depressed contractility caused by organic heart disease or cardiac surgical procedures</td>
<td>Headache, nausea, increased heart rate, increase in systolic blood pressure, palpitations, anginal and nonspecific chest pain</td>
<td>2.5—15 mcg/kg/min IV (up to 40 mcg/kg/min); titrate to patient’s hemodynamic and renal status</td>
</tr>
<tr>
<td>dopamine</td>
<td>Intropin, generic</td>
<td>Shock due to MI, trauma, open-heart surgery, renal failure, and chronic cardiac decompensation in CHF</td>
<td>Nausea, vomiting, ectopic beats, tachycardia, anginal pain, palpitations, hypotension, dyspnea</td>
<td>2—50 mcg/kg/min IV (infusion rate determined by patient’s response)</td>
</tr>
<tr>
<td>ephedrine sulfate</td>
<td>generic</td>
<td>Hypotension, relief of acute bronchospasm, allergic disorders, nasal and nasopharyngeal mucosal congestion, adjunctive treatment of middle ear infection</td>
<td>Anxiety, insomnia, tenseness, restlessness, headache, light-headedness, dizziness, nausea, dysuria, pallor</td>
<td>Hypotension and allergic disorders, asthma: 25/mg—50 mg IM, SC, or IV; topical nasal decongestant: instill in each nostril q4h</td>
</tr>
<tr>
<td>epinephrine</td>
<td>Adrenalin chloride, Bronkaid, generic</td>
<td>Ventricular standstill; treatment and prophylaxis of cardiac arrest, heart block; mucusosal congestion of hay fever, rhinitis, and acute sinusitis; relief of bronchial asthmatic paroxysms; simple open-angle glaucoma</td>
<td>Anxiety, insomnia, tenseness, restlessness, headache, light-headedness, dizziness, nausea, dysuria, pallor</td>
<td>Cardiac arrest: 0.5—1.0 mg IV; respiratory distress (eg, asthma, anaphylaxis): 0.3—0.5 mL of 1:1000 solution, SC or IM q20 min for 4h or 0.1—0.3 mL SC of 1:200 suspension; 1 inhalation q3h; 1—3 deep inhalation by nebulizer 4—6 times/day; ophthalmic, 1—2 gtts times daily</td>
</tr>
<tr>
<td>isoproterenol</td>
<td>Isuprel, Medihaler-Iso</td>
<td>Injection: shock, bronchospasm during anesthesia, cardiac standstill and arrhythmias Inhalation: acute bronchial asthma, emphysema, bronchitis, bronchiectasis</td>
<td>Anxiety, insomnia, tenseness, restlessness, headache, light-headedness, dizziness, nausea, dysuria, pallor</td>
<td>Injection shock: 2 mcg/mL diluted solution IV; bronchospasm during anesthesia: 0.01—0.02 mg of diluted solution IV; cardiac arrhythmias, cardiac standstill: 0.02—0.06 mg of diluted solution IV, 5 µg/min IV infusion; 0.2 mg of undiluted 1:5000 solution IM, SC; inhalation bronchial spasm: hand bulb nebulizer 1:200 solution 5—15 deep inhalations or 1:100 solution in 3—7 inhalations; for metered-dose inhaler, 1—2 inhalations 4—6 times a day</td>
</tr>
<tr>
<td>levальнуterol</td>
<td>Xopenex</td>
<td>Treatment or prevention of bronchospasm in adults and adolescents 12 years and older with reversible obstructive airway disease</td>
<td>Restlessness, apprehension, anxiety, fear, CNS stimulation, cardiac arrhythmias, sweating, pallor, flushing, nausea</td>
<td>0.63—1.25 mg TID by nebulization</td>
</tr>
</tbody>
</table>
**Shock**

The adrenergic drugs are important in the care and treatment of patients in shock. Shock is defined as a life-threatening condition of inadequate perfusion. In shock, there is an inadequate supply of arterial blood flow and oxygen delivery to the cells and tissues. The body initiates compensatory mechanisms to counteract the symptoms of shock (e.g., the release of epinephrine and norepinephrine). In some situations, the body is able to compensate and blood pressure is maintained. However, if shock is untreated and compensatory mechanisms of the body fail, irreversible shock occurs and death follows. There are five types of shock: hypovolemic shock, cardiogenic shock, septic shock, obstructive shock, and neurogenic shock. Table 22-3 describes the various types of shock.

Various clinical manifestations may be present in a patient in shock. For example, in the early stages of shock the extremities may be warm because compensatory mechanisms are initiated and the blood flow to the skin and extremities is maintained. If the condition is untreated, the skin and extremities become cool and clammy because of the failure of the compensatory mechanisms and the progression of shock. Thus, more advanced shock may be referred to as

---

### Table 22-2

**Effects of the Adrenergic Receptors**

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Site</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\alpha_1$</td>
<td>Peripheral blood vessels</td>
<td>Vasoconstriction of peripheral blood vessels</td>
</tr>
<tr>
<td>$\alpha_2$</td>
<td>Presynaptic neuron</td>
<td>Regulates release of neurotransmitters; decreases tone, motility, and secretions of gastrointestinal tract</td>
</tr>
<tr>
<td>$\beta_1$</td>
<td>Myocardium</td>
<td>Increased heart rate, increased force of myocardial contraction</td>
</tr>
<tr>
<td>$\beta_2$</td>
<td>Peripheral blood vessels</td>
<td>Vasodilation of peripheral vessels</td>
</tr>
<tr>
<td></td>
<td>Bronchial smooth muscles</td>
<td>Bronchodilation</td>
</tr>
</tbody>
</table>

alpha, $\alpha$; beta, $\beta$. **Summary Drug Table** ADRENERGIC DRUGS (Continued)

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>metaraminol</td>
<td>Aramine</td>
<td>Hypotension with spinal</td>
<td>Headache, flushing sinus or ventricular tachycardia,</td>
<td>2—10 mg IM, SC; 15—100 mg in 250— or 500–mL solution IV</td>
</tr>
<tr>
<td>met-a-ram-i-</td>
<td></td>
<td>anesthesia, hypotension due to</td>
<td>arrhythmias, nausea, apprehension, palpitation</td>
<td></td>
</tr>
<tr>
<td>nole</td>
<td></td>
<td>hemorrhage, drug reactions,</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>surgical complication, shock</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>associated with brain damage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>midodrine</td>
<td>ProAmatine</td>
<td>Orthostatic hypotension</td>
<td>Paresthesias, headache, pain, dizziness, supine</td>
<td>10 mg PO TID during daylight hours when</td>
</tr>
<tr>
<td>mid'-oh-dryn</td>
<td></td>
<td></td>
<td>hypertension, bradycardia, piloerection, pruritus, dysuria,</td>
<td>upright</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>chills</td>
<td></td>
</tr>
<tr>
<td>norepinephrine</td>
<td>Levophed</td>
<td>Shock, hypotension, cardiac</td>
<td>Restlessness, headache, dizziness, bradycardia, hypertension</td>
<td>1 mg/mL in 1000 mL 5% dextrose solution,</td>
</tr>
<tr>
<td>nor-ep-i-ner</td>
<td></td>
<td>arrest</td>
<td></td>
<td>2—3 mL/min IV, rate adjusted to maintain desired blood pressure; average dose, 2—4 $\mu$g/min</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
“cool” or “cold” shock. Regardless of the type, shock results in a decrease in cardiac output, decrease in arterial blood pressure (hypotension), reabsorption of water by the kidneys (causing a decrease in urinary output), decrease in the exchange of oxygen and carbon dioxide in the lungs, increase in carbon dioxide in the blood and decrease in oxygen in the blood, hypoxia (decreased oxygen reaching the cells), and increased concentration of intravascular fluid. This scenario compromises the functioning of vital organs such as the heart, brain, and kidneys. The various physiologic responses caused by shock within the body are listed in Table 22-4.

The adrenergic drugs are useful in improving hemodynamic status by improving myocardial contractility and increasing heart rate, which results in increased cardiac output. Peripheral resistance is increased by vasoconstriction. In cardiogenic shock or advanced shock associated with low cardiac output, the adrenergic drug may be used with a vasodilating drug. A vasodilator such as nitroprusside (Chap. 42) or nitroglycerin (Chap. 41) improves myocardial performance as the adrenergic drug maintains blood pressure.

### ADVERSE REACTIONS

The adverse reactions associated with the administration of adrenergic drugs depend on the drug used, the dose administered, and individualized patient response. Some of the more common adverse reactions include cardiac arrhythmias, such as bradycardia and tachycardia, headache, insomnia, nervousness, anorexia, and an increase in blood pressure (which may reach dangerously high levels). Additional adverse reactions for specific adrenergic drugs are listed in the Summary Drug Table: Adrenergic Drugs.

### CONTRAINDICATIONS

Adrenergic drugs are contraindicated in patients with known hypersensitivity. Isoproterenol is contraindicated in patients with tachyarrhythmias, tachycardia or heart block caused by digitalis toxicity, ventricular arrhythmias, and angina pectoris. Dopamine is contraindicated in those with pheochromocytoma (tumor of adrenal gland), unmanaged arrhythmias, and ventricular fibrillation. Epinephrine is contraindicated in patients with narrow-angle glaucoma, cerebral arteriosclerosis, and cardiac insufficiency. Norepinephrine and ephedrine are contraindicated in patients who are hypotensive from blood volume deficits. Midodrine is contraindicated in those with severe organic heart disease, acute renal disease, pheochromocytoma, and supine hypertension.

<table>
<thead>
<tr>
<th>TABLE 22-3</th>
<th>Types of Shock</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TYPE</strong></td>
<td><strong>DESCRIPTION</strong></td>
</tr>
<tr>
<td>Hypovolemic</td>
<td>Occurs when the volume of extracellular fluid is significantly diminished. Examples include hemorrhage, fluid loss caused by burns, diarrhea, vomiting, or excess diuresis</td>
</tr>
<tr>
<td>Cardiogenic</td>
<td>Occurs when the heart is unable to deliver an adequate cardiac output to maintain perfusion to the vital organs. Examples include: as the result of an acute myocardial infarction, ventricular arrhythmias, congestive heart failure (CHF), or severe cardiomyopathy.</td>
</tr>
<tr>
<td>Septic</td>
<td>Occurs as a result of circulatory insufficiency associated with overwhelming infection</td>
</tr>
<tr>
<td>Obstructive</td>
<td>Occurs when obstruction of blood flow results in inadequate tissue perfusion. Examples include a severe reduction of blood flow as the result of massive pulmonary embolism, pericardial tamponade, restrictive pericarditis, and severe cardiac valve dysfunction</td>
</tr>
<tr>
<td>Neurogenic</td>
<td>Occurs as a result of blockade of neurohumoral outflow. Examples include: from a pharmacological source (ie, spinal anesthesia) or direct injury to the spinal cord. This type of shock is rare.</td>
</tr>
</tbody>
</table>

*Other causes of shock include anaphylaxis, hypoglycemia, hypothyroidism, or Addison’s disease.

<table>
<thead>
<tr>
<th>TABLE 22-4</th>
<th>Physiologic Manifestations of Shock</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BODY SYSTEM</strong></td>
<td><strong>POSSIBLE SIGNS AND SYMPTOMS</strong></td>
</tr>
<tr>
<td>Integumentary (skin)</td>
<td>Pallor, cyanosis, cold and clammy, sweating</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>Agitation, confusion, disorientation, coma</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Hypotension, tachycardia, arrhythmias, wide pulse pressure, gallop rhythm</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Tachypnea, pulmonary edema</td>
</tr>
<tr>
<td>Renal</td>
<td>Urinary output &lt; 20 mL/h</td>
</tr>
<tr>
<td>Metabolic</td>
<td>Acidosis</td>
</tr>
</tbody>
</table>
**PRECAUTIONS**

These drugs are used cautiously in patients with coronary insufficiency, cardiac arrhythmias, angina pectoris, diabetes, hyperthyroidism, occlusive vascular disease, or prostatic hypertrophy, and in those taking digoxin. Patients with diabetes may require an increased dosage of insulin. Epinephrine is used cautiously in patients with Parkinson’s disease (may temporarily increase rigidity and tremor) or ventricular fibrillation and in the elderly. Ephedrine is used cautiously in patients with acute-closure glaucoma. Midodrine is used cautiously in patients with urinary problems or hepatic disease and during lactation. Adrenergic drugs are classified as Pregnancy Category C and are used with extreme caution during pregnancy.

**INTERACTIONS**

There is an increased risk of hypertension when dobutamine is administered with the β-adrenergic blocking drugs. When dopamine is administered with the monoamine oxidase inhibitors (see Chap. 31) or the tricyclic antidepressants (see Chap. 31), there is a risk for increased effects of dopamine. There is an increased risk of seizures, hypotension, and bradycardia when dopamine is administered with phenytoin. When epinephrine is administered with the tricyclic antidepressants, there is an increased risk of sympathomimetic effects. Excessive hypertension can occur when epinephrine is administered with propranolol. A decreased bronchodilating effect occurs when epinephrine is administered with the β-adrenergic drugs. Metaraminol is used cautiously in patients taking digoxin because of an increased risk for cardiac arrhythmias. When midodrine is administered with cardiac glycosides, psychotropic drugs, or β blockers, bradycardia, heart block, or arrhythmias can occur.

**Herbal Alert: Ephedra**

Many members of the Ephedra family have been used medicinally (i.e., *E. sinica* and *E. intermedia*). Ephedra preparations have traditionally been used to relieve cold symptoms, improve respiratory function, as an adjunct in weight loss, and to treat a variety of conditions from headaches to sexually transmitted disease. Large doses may cause a variety of adverse reactions, such as hypertension, irregular heart rate, tremors, epigastric pain, nausea, vomiting, sweating, weakness, and possible dependence. Ephedra is contraindicated in patients with hypertension, glaucoma, hypertrophy of the prostate, urinary tract problems, clotting disorders, anxiety, anorexia, colitis, thyroid disease, or diabetes. Ephedra should not be used with the cardiac glycosides, halothane, guanethidine, MAOIs, oxytocin, and in patients taking St. John’s wort. Weight loss preparations containing ephedra should be avoided.

Before taking this herb the patient should consult the primary care provider. When taking a standardized extract, 12 to 25 mg total alkaloids (calculated as ephedrine) two to three times daily is the normal dosage. When taking the capsules or tablets, the normal dosage is 500 to 1000 mg two to three times daily.

The FDA warns the public not to take ephedrine-containing dietary supplements with labels that portray the products as an alternative to illegal street drugs such as Ecstasy because these products may pose serious health risks to consumers.

**Preadministration Assessment**

When a patient is to receive an adrenergic agent for shock, the nurse obtains the blood pressure, pulse rate and quality, and respiratory rate and rhythm. The nurse assesses the patient’s symptoms, problems, or needs before administering the drug and records any subjective or objective data on the patient’s chart. In emergencies, the nurse must make assessments quickly and accurately. This information provides an important database that is used during treatment.

A general survey of the patient also is necessary. It is important to look for additional symptoms of shock, such as cool skin, cyanosis, diaphoresis, and a change in the level of consciousness. Other assessments may be necessary if the hypotensive episode is due to trauma, severe infection, or blood loss.

In patients taking midodrine for orthostatic hypotension, the nurse checks the blood pressure with the patient supine and sitting before therapy is begun. This is important because midodrine is contraindicated in patients with supine hypertension.

When a patient is to have nose drops instilled for nasal congestion, the nurse examines the nasal passages and describes the type of secretions present in the nose. The nurse also should obtain the blood pressure because nose drops that contain adrenergic drugs are not given to those with high blood pressure.

**NURSING PROCESS**

**The Patient Receiving an Adrenergic Drug**

**ASSESSMENT**

Assessment of the patient receiving an adrenergic drug differs depending on the drug, the patient, and the reason for administration. For example, assessment of the patient in shock who is to be treated with norepinephrine is different from that for the patient receiving nose drops containing phenylephrine. Both are receiving adrenergic drugs, but the circumstances are much different.
Management of shock is aimed at providing basic life support (airway, breathing, and circulation) while attempting to correct the underlying cause. Antibiotics, inotropes, hormones (eg, insulin, thyroid), and other drugs may be used to treat the underlying disease. However, the initial pharmacologic intervention is aimed at supporting the circulation with vasopressors.

MAINTAINING ADEQUATE TISSUE PERFUSION. When a patient is in shock and experiencing ineffective tissue perfusion there is a decrease in oxygen resulting in an inability of the body to nourish its cells at the capillary level. If the patient has marked hypotension the administration of a vasopressor (a drug that raises the blood pressure because of its ability to constrict blood vessels) is required. The primary health care provider determines the cause of the hypotension and then selects the best method of treatment. Some hypotensive episodes require the use of a less potent vasopressor, such as metaraminol, whereas at other times a more potent vasopressor, such as dobutamine (Dobutrex), dopamine (Intropin), or norepinephrine (Levophed) is necessary. The nurse considers the following points when administering the potent vasopressors dopamine and norepinephrine:

- Use an electronic infusion pump to administer these drugs.
- Do not mix dopamine with other drugs, especially sodium bicarbonate or other alkaline intravenous (IV) solutions. Check with the hospital pharmacist before adding a second drug to an IV solution containing this drug.
- Administer norepinephrine and dopamine only via the IV route. Do not dilute these drugs in an IV solution before administration. The primary health care provider orders the IV solution, the amount of drug added to the solution, and the initial rate of infusion.
- Monitor blood pressure every 2 minutes from the beginning of therapy until the desired blood pressure is achieved, then monitor the blood pressure and pulse rate at frequent intervals, usually every 5 to 15 minutes, during the administration of these drugs.
- Adjust the rate of administration according to the patient’s blood pressure. The rate of administration of the IV solution is increased or decreased to maintain the patient’s blood pressure at the systolic level ordered by the primary health care provider.
- Readjustment of the rate of flow of the IV solution is often necessary. The frequency of adjustment will depend on the patient’s response to the vasopressor.
- Inspect the needle site and surrounding tissues at frequent intervals for leakage (extravasation, infiltration) of the solution into the subcutaneous tissues surrounding the needle site. If either situation occurs, establish another IV line immediately, discontinue the IV containing the vasopressor, and reinsert catheter. As soon as possible, report the adverse reaction to the primary health care provider.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient will depend on the reason for administration of an adrenergic agent but may include an optimal response to drug therapy, management of common adverse reactions, an absence of infection, and an understanding of the reason the drug is being given.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

Management of the patient receiving an adrenergic agent varies and depends on the drug used, the reason for administration, and the patient’s response to the drug. In most instances, adrenergic drugs are potent and potentially dangerous. The nurse must exercise great care in the calculation and preparation of these drugs for administration. Although adrenergic drugs are potentially dangerous, proper supervision and management before, during, and after administration will minimize the occurrence of any serious problems. Management of shock is aimed at providing basic life support (airway, breathing, and circulation) while attempting to correct the underlying cause. Antibiotics, inotropes, hormones (eg, insulin, thyroid), and other drugs may be used to treat the underlying disease. However, the initial pharmacologic intervention is aimed at supporting the circulation with vasopressors.

MAINTAINING ADEQUATE TISSUE PERFUSION. When a patient is in shock and experiencing ineffective tissue perfusion there is a decrease in oxygen resulting in an inability of the body to nourish its cells at the capillary level. If the patient has marked hypotension the administration of a vasopressor (a drug that raises the blood pressure because of its ability to constrict blood vessels) is required. The primary health care provider determines the cause of the hypotension and then selects the best method of treatment. Some hypotensive episodes require the use of a less potent vasopressor, such as metaraminol, whereas at other times a more potent vasopressor, such as dobutamine (Dobutrex), dopamine (Intropin), or norepinephrine (Levophed) is necessary. The nurse considers the following points when administering the potent vasopressors dopamine and norepinephrine:

- Use an electronic infusion pump to administer these drugs.
- Do not mix dopamine with other drugs, especially sodium bicarbonate or other alkaline intravenous (IV) solutions. Check with the hospital pharmacist before adding a second drug to an IV solution containing this drug.
- Administer norepinephrine and dopamine only via the IV route. Do not dilute these drugs in an IV solution before administration. The primary health care provider orders the IV solution, the amount of drug added to the solution, and the initial rate of infusion.
- Monitor blood pressure every 2 minutes from the beginning of therapy until the desired blood pressure is achieved, then monitor the blood pressure and pulse rate at frequent intervals, usually every 5 to 15 minutes, during the administration of these drugs.
- Adjust the rate of administration according to the patient’s blood pressure. The rate of administration of the IV solution is increased or decreased to maintain the patient’s blood pressure at the systolic level ordered by the primary health care provider.
- Readjustment of the rate of flow of the IV solution is often necessary. The frequency of adjustment will depend on the patient’s response to the vasopressor.
- Inspect the needle site and surrounding tissues at frequent intervals for leakage (extravasation, infiltration) of the solution into the subcutaneous tissues surrounding the needle site. If either situation occurs, establish another IV line immediately, discontinue the IV containing the vasopressor, and
The patient taking midodrine will need frequent monitoring of blood pressure and heart rate. Bradycardia is common at the beginning of therapy. Persistent bradycardia should be reported to the primary health care provider for evaluation. Because the drug can cause dysuria, the patient is asked to void before administration of the drug.

Monitoring and Managing Adverse Reactions
The nurse reports and documents any complaint the patient may have while taking the adrenergic drugs. However, nursing judgment is necessary when reporting adverse reactions. The nurse must report some adverse effects, such as the development of cardiac arrhythmias immediately, regardless of the time of day or night. The nurse should report other adverse effects, such as anorexia, but this is usually not an emergency.

Nursing Alert
Regardless of the actual numerical reading of the blood pressure, a progressive fall of the blood pressure is serious. The nurse reports to the primary health care provider any progressive fall of the blood pressure, a fall in systolic blood pressure below 100 mm Hg, or any fall of 20 mm Hg or more of the patient’s normal blood pressure.

Nursing Alert
Supine hypertension is a potentially dangerous adverse reaction when taking midodrine. The nurse can minimize this reaction by administering the medication during the day while the patient is in an upright position. Keeping the patient in an upright position can sometimes control supine hypertension. This requires that the patient sleep with the head of the bed elevated.

The following is a suggested dosing schedule for the administration of midodrine: shortly before arising in the morning, midday, and late afternoon (not after 6:00 pm). The nurse should continue drug therapy only in the patient whose orthostatic hypotension improves during the initial treatment.

Gerontologic Alert
The older adult is particularly vulnerable to adverse reactions of the adrenergic drugs, particularly epinephrine. In addition, older adults are more likely to have preexisting cardiovascular disease that predisposes them to potentially serious cardiac arrhythmias. The nurse closely monitors all elderly patients taking an adrenergic drug. It is important to report any changes in the pulse rate or rhythm immediately. In addition, epinephrine may temporarily increase tremor and rigidity in older adults with Parkinson’s disease.
MAINTAINING ADEQUATE TISSUE PERFUSION AND CARDIAC OUTPUT. Administration of an adrenergic drug may cause hypertension or tachycardia. These adverse reactions may cause a decrease in oxygenation at the cellular level. It is important for the nurse to monitor the pulse and blood pressure during the administration of an adrenergic drug. If the patient is being given the adrenergic drug for hypotension, there is already a potential problem with tissue perfusion. Administration of the adrenergic drug may correct the problem or, if the blood pressure becomes too high, tissue perfusion may again be a problem. Maintaining the blood pressure at the systolic rate prescribed by the primary health care provider will maintain tissue perfusion. If the pulse rate increases to a rate of 100 bpm or more or a change in rhythm occurs, the primary health care provider is notified.

Nursing Alert

Prolonged high-dose therapy of the adrenergic drugs can produce cyanosis and tissue necrosis of distal extremities. It is important to remember to use the lowest possible dose that produces an adequate response for the shortest period of time. The nurse monitors the patient’s extremities closely for any signs of cyanosis.

MANAGING ANOREXIA. Administration of an adrenergic drug may cause anorexia in the patient. Management of this adverse reaction requires diligence on the part of the nurse. The nurse discusses food preferences and aversions with the patient and makes modifications in the diet when possible. An easily digested diet high in carbohydrate and protein and low in fat is usually well tolerated. Several small meals may be better tolerated than three large meals. The nurse weighs the patient daily or weekly and keeps an accurate dietary record. Foods that cause increased gastric motility, such as gas-forming foods, spicy foods, and caffeinated beverages, are avoided. Good oral care is provided. The dietitian may be consulted if necessary. The nurse provides a pleasant, odor-free, relaxing environment for eating.

MANAGING SLEEP DISTURBANCES. The patient taking an adrenergic drug may experience insomnia and nervousness. This can cause a great deal of stress in the patient. It is important to inform the patient that this is an effect of the drug. It is helpful to identify circumstances that disturb sleep, such as the nurse taking vital signs during the night or turning the overhead light on during the night. The nurse plans care with as few interruptions as possible or makes modifications. For example, instead of turning the overhead light on during the night, a night light may be used. However, monitoring vital signs is an important nursing intervention when administering the adrenergic drugs. A thorough explanation of the reason for close monitoring of the vital signs by the nurse is necessary. In addition, caffeinated beverages are avoided, especially after 5:00 PM. Other sleep aids may be used (eg, warm milk, back rub, progressive relaxation, or bedtime snack). The patient is assured that sleeplessness and nervousness will pass when the drug therapy is discontinued.

Educating the Patient and Family

Only medical personnel give some adrenergic drugs, such as the vasopressors. The nurse’s responsibility for teaching involves explaining the drug to the patient or family. Depending on the situation, the nurse may include facts such as how the drug will be given (eg, the route of administration) and what results are expected. The nurse must use judgment regarding some of the information given to the patient or family regarding administration of an adrenergic drug in life-threatening situations because certain facts, such as the seriousness of the patient’s condition, are usually best given by the primary health care provider.

EDUCATING THE PATIENT USING A NASAL DECONGESTANT. When a nasal decongestant (drops or spray) containing an adrenergic drug has been recommended or prescribed, the nurse shows the patient or family member the correct method of instillation. The nurse explains possible adverse effects and the importance of adherence to the dose regimen prescribed by the primary health care provider. Because many nasal decongestants are over-the-counter (OTC) drugs, the nurse advises patients using them that these drugs are contraindicated in those with high blood pressure and that overuse can increase nasal congestion (rebound congestion).

EDUCATING THE PATIENT PRESCRIBED A BRONCHODILATOR. If an adrenergic drug, such as ephedrine or isoproterenol, has been prescribed as a bronchodilator, the nurse explains the drug regimen to the patient (see Chap. 37 for additional information). It is important to stress the importance of reporting adverse reactions to the primary health care provider as soon as possible. If the drug is prescribed in sublingual form, the nurse demonstrates the technique of placing the drug under the tongue. The nurse warns the patient not to use any OTC drug unless use has been approved by the primary health care provider. The nurse encourages patients receiving a bronchodilator to contact their primary health care provider if the drug fails to produce at least partial relief of their symptoms.

EDUCATING THE PATIENT PRESCRIBED MIDODRINE. When midodrine is given to patients with severe orthostatic hypotension, the nurse explains the importance of
taking the drug during daytime hours when the patient is upright. The patient can take doses in 3-hour intervals, if needed to control symptoms. The drug should not be taken within 4 hours of bedtime. In addition, to control supine hypertension, a potentially fatal adverse reaction, the patient should not become fully supine. The nurse explains that it may be necessary to sleep with the head of the bed elevated. If urinary retention is a problem, the patient is instructed to urinate before taking the drug. The nurse stresses the importance of returning for regular medical evaluation. The patient is instructed to report any changes in vision, pounding in the head when lying down, slow heart rate, or difficulty urinating.

**EVALUATION**

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully.
- The patient verbalizes an understanding of treatment modalities and the importance of continued follow-up care.

**Critical Thinking Exercises**

1. Mr. Cole is receiving dopamine for the treatment of severe hypotension. In planning the care for Mr. Cole, determine what would be the most important aspects of nursing management. Explain your answers.
2. Plan a teaching program to explain the nervous system to a group of nurses at a staff education meeting.
3. Discuss the preadministration assessment for a patient requiring an adrenergic drug for hypotension.
4. Describe what information is important to include in an education session for a patient taking an adrenergic drug for nasal congestion.

**Review Questions**

1. The physician prescribes norepinephrine, a potent vasopressor, to be administered to a patient in shock. The rate of the administration of the IV fluid containing the norepinephrine is
   - **A.** maintained at a set rate of infusion
   - **B.** adjusted accordingly to maintain the patient’s blood pressure
   - **C.** given at a rate not to exceed 5 mg/min
   - **D.** discontinued when the blood pressure is 100 mm Hg systolic

2. At what intervals would the nurse monitor the blood pressure of a patient taking norepinephrine?
   - **A.** every 5 to 15 minutes
   - **B.** every 30 minutes
   - **C.** every hour
   - **D.** every 4 hours

3. Which of the following are the common adverse reactions the nurse would expect with the administration of the adrenergic drugs?
   - **A.** bradycardia, lethargy, bronchial constriction
   - **B.** increase in appetite, nervousness, drowsiness
   - **C.** nausea, vomiting, hypotension
   - **D.** insomnia, nervousness, anorexia

4. When dobutamine is administered with the β-adrenergic blocking drugs the nurse is aware of an increased risk for ______.
   - **A.** seizures
   - **B.** arrhythmias
   - **C.** hypotension
   - **D.** hypertension

5. Epinephrine is administered cautiously in patients with Parkinson’s disease because the drug may ______.
   - **A.** precipitate congestive heart failure
   - **B.** temporarily increase rigidity and tremor
   - **C.** decrease the response to antiparkinsonism drugs
   - **D.** cause confusion

**Medication Dosage Problems**

1. Midodrine 2.5 mg is prescribed. The drug is available in 5-mg tablets. The nurse would administer ______.
2. The physician orders 0.5 mg of 1:1000 epinephrine solution IV. The drug is available in 1:1000 solution 1 mg/mL. The nurse administers ______.
Adrenergic blocking drugs, also called sympathomimetic blocking drugs, may be divided into four groups:

- **Alpha (α)-adrenergic blocking drugs**—drugs that block α-adrenergic receptors. These drugs produce their greatest effect on α receptors of adrenergic receptors of adrenergic nerves that control the vascular system.

- **Beta (β)-adrenergic blocking drugs**—drugs that block β-adrenergic receptors. These drugs produce their greatest effect on β receptors of adrenergic nerves, primarily the β receptors of the heart.

- **Antiadrenergic drugs**—drugs that block adrenergic nerve fibers. These drugs block the adrenergic nerve fibers within the central nervous system (CNS) or within the peripheral nervous system.

- **α/β-Adrenergic blocking drugs**—drugs that block both α- and β-adrenergic receptors. These drugs act on both α and β nerve fibers.

Each of these groups will be discussed individually followed by information concerning the use of the nursing process for the group as a whole. See the Summary Drug Table: the Adrenergic Blocking Drugs for a more complete listing of these drugs.

### Summary Drug Table: the Adrenergic Blocking Drugs

<table>
<thead>
<tr>
<th>Key Terms</th>
<th>Chapter Objectives</th>
</tr>
</thead>
<tbody>
<tr>
<td>α-adrenergic blocking drugs</td>
<td>On completion of this chapter, the student will:</td>
</tr>
<tr>
<td>α/β-adrenergic blocking drugs</td>
<td>- List the four types of adrenergic blocking drugs.</td>
</tr>
<tr>
<td>β-adrenergic blocking drugs</td>
<td>- Discuss the uses, general drug actions, general adverse reactions, contraindications, precautions, and interactions of the adrenergic blocking drugs.</td>
</tr>
<tr>
<td>Antiadrenergic drugs</td>
<td>- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking adrenergic blocking drugs.</td>
</tr>
<tr>
<td>Postural hypotension</td>
<td>- List some nursing diagnoses particular to a patient taking adrenergic blocking drugs.</td>
</tr>
<tr>
<td>Orthostatic hypotension</td>
<td>- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, nursing actions that may be taken to minimize orthostatic or postural hypotension, and important points to keep in mind when educating patients about the use of adrenergic blocking drugs.</td>
</tr>
</tbody>
</table>

Stimulation of α-adrenergic fibers results in vasoconstriction (see Table 22-1 in Chap. 22). If stimulation of these α-adrenergic fibers is interrupted or blocked, the result will be vasodilation. This is the direct opposite of the effect of an adrenergic drug having mainly α activity. Phentolamine (Regitine) is an example of an α-adrenergic blocking drug.

### Actions

Stimulation of α-adrenergic fibers results in vasoconstriction (see Table 22-1 in Chap. 22). If stimulation of these α-adrenergic fibers is interrupted or blocked, the result will be vasodilation. This is the direct opposite of the effect of an adrenergic drug having mainly α activity. Phentolamine (Regitine) is an example of an α-adrenergic blocking drug.

### Uses

Phentolamine (Regitine) is used for its vasodilating effect on peripheral blood vessels and therefore may be beneficial in the treatment of hypertension caused by
## Adrenergic Blocking Drugs

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>α-Adrenergic Blocking Agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>phentolamine</td>
<td>Regitine</td>
<td>Diagnosis of pheochromocytoma, hypertensive episodes before and during surgery, prevention/treatment of dermal necrosis after IV administration of norepinephrine or dopamine</td>
<td>Weakness, dizziness, flushing, nausea, vomiting, orthostatic hypotension</td>
<td>5 mg IV, IM for tissue necrosis: 5–10 mg in 10 mL saline infiltrated into affected area</td>
</tr>
<tr>
<td>acebutolol HCl</td>
<td>Sectral, generic</td>
<td>Hypertension, ventricular arrhythmias</td>
<td>Bradycardia, dizziness, weakness, hypotension, nausea, vomiting, diarrhea, nervousness</td>
<td>Hypertension: 400 mg PO in 1–2 doses; arrhythmias: 400–1200 mg/d PO in divided doses</td>
</tr>
<tr>
<td>atenolol</td>
<td>Tenormin, generic</td>
<td>Hypertension, angina, acute MI</td>
<td>Bradycardia, dizziness, fatigue, weakness, hypotension, nausea, vomiting, diarrhea, nervousness</td>
<td>50–200 mg/d PO; 5 mg IV</td>
</tr>
<tr>
<td>betaxolol HCl</td>
<td>Kerlone</td>
<td>Hypertension</td>
<td>Bradycardia, dizziness, hypotension, bronchospasm, nausea, vomiting, diarrhea, nervousness</td>
<td>5–20 mg/d PO</td>
</tr>
<tr>
<td>bisoprolol</td>
<td>Zebeta</td>
<td>Hypertension</td>
<td>Bradycardia, dizziness, weakness, hypotension, nausea, vomiting, diarrhea, nervousness</td>
<td>5 mg PO QD; maximum dose, 20 mg PO QD</td>
</tr>
<tr>
<td>carteolol</td>
<td>Cartrol</td>
<td>Hypertension</td>
<td>Bradycardia, dizziness, weakness, hypotension, nausea, vomiting, diarrhea, nervousness</td>
<td>2.5 mg–10 mg/d PO</td>
</tr>
<tr>
<td>esmolol HCl</td>
<td>Brevibloc</td>
<td>Supraventricular tachycardia, noncompensatory tachycardia</td>
<td>Hypotension, weakness, light-headedness, urinary retention</td>
<td>25–500 mcg/kg/min IV</td>
</tr>
<tr>
<td>metoprolol</td>
<td>Lopressor, Toprol-XL, generic</td>
<td>Hypertension, angina, MI</td>
<td>Dizziness, hypotension, CHF, arrhythmia, nausea, vomiting, diarrhea</td>
<td>100–450 mg/d PO; 5 mg IV; extended release: 50–100 mg/d PO</td>
</tr>
<tr>
<td>nadolol</td>
<td>Corgard, generic</td>
<td>Angina, hypertension</td>
<td>Dizziness, hypotension, nausea, vomiting, diarrhea, CHF, cardiac arrhythmias</td>
<td>40–320 mg/d PO</td>
</tr>
<tr>
<td>penbutolol</td>
<td>Levatol</td>
<td>Hypertension</td>
<td>Bradycardia, dizziness, hypotension, nausea, vomiting, diarrhea</td>
<td>20 mg PO QD</td>
</tr>
<tr>
<td>pindolol</td>
<td>Visken, generic</td>
<td>Hypertension</td>
<td>Bradycardia, dizziness, hypotension, nausea, vomiting, diarrhea</td>
<td>5–60 mg/d PO in divided doses</td>
</tr>
</tbody>
</table>

### SUMMARY DRUG TABLE ADRENERGIC BLOCKING DRUGS

* (continued)
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>propranolol</td>
<td>Inderal,</td>
<td>Cardiac arrhythmias, MI, angina, hypertension, migraine prophylaxis</td>
<td>Bradycardia, dizziness, hypotension, nausea, vomiting, diarrhea, bronchospasm, hyperglycemia, pulmonary edema</td>
<td>Arrhythmias: 10–30 mg PO TID, QID; hypertension: 40–640 mg/d PO in divided doses; angina: 10–320 mg/d PO in divided doses; life-threatening arrhythmias: up to 1–3 mg IV; migraine: 80–240 mg/d PO in divided doses</td>
</tr>
<tr>
<td>sotalol HCl</td>
<td>Betapace,</td>
<td>Ventricular arrhythmias</td>
<td>Dizziness, hypotension, nausea, vomiting, diarrhea, respiratory distress</td>
<td>Hypertension: 80–320 mg/d PO in divided doses</td>
</tr>
<tr>
<td>timolol maleate</td>
<td>Bloocadren,</td>
<td>Hypertension, MI, migraine prophylaxis</td>
<td>Dizziness, hypotension, nausea, vomiting, diarrhea, pulmonary edema</td>
<td>Hypertension: 10–60 mg/d PO in divided doses; MI: 10 mg PO BID; migraine: 10–30 mg/d PO</td>
</tr>
<tr>
<td>labetalol</td>
<td>Normodyne,</td>
<td>Hypertension</td>
<td>Fatigue, drowsiness, insomnia, hypotension, impotence, diarrhea</td>
<td>Hypertension: 6.25–50 mg PO BID; CHF: dose individualized based on patient response; initial dose 3.125 mg PO BID, increased gradually to a maximum dose of 50 mg PO BID</td>
</tr>
</tbody>
</table>

**α/β-Adrenergic Blocking Agents**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>carvedilol</td>
<td>Coreg</td>
<td>Hypertension, CHF</td>
<td>Bradycardia, hypotension, cardiac insufficiency, fatigue, dizziness, diarrhea</td>
<td></td>
</tr>
<tr>
<td>clonidine HCl</td>
<td>Catapres,</td>
<td>Severe pain in patients with cancer, hypertension</td>
<td>Drowsiness, dizziness, sedation, dry mouth, constipation, syncope, dreams, rash</td>
<td>100–2400 mg/d PO; transdermal: 0.1–0.3 mg/24h</td>
</tr>
<tr>
<td>guanabenz acetate</td>
<td>Wytensin, generic</td>
<td>Hypertension</td>
<td>Dry mouth, sedation, dizziness, headache, weakness, arrhythmias</td>
<td>4–32 mg BID</td>
</tr>
<tr>
<td>guanfacine HCL</td>
<td>Tenex</td>
<td>Hypertension</td>
<td>Dry mouth, somnolence, asthenia, dizziness, headache, constipation, fatigue</td>
<td>1–3 mg/d PO at hs</td>
</tr>
<tr>
<td>methyl dopa OR methyldopate HCL</td>
<td>Aldomet, generic</td>
<td>Hypertension, hypertensive crisis</td>
<td>Bradycardia, aggravation of angina pectoris, heart failure, sedation, headache, rash, nausea, vomiting, nasal stuffiness</td>
<td>250 mg PO BID–TID; maintenance dose, 3 g/d; 250–500 mg q6h IV</td>
</tr>
</tbody>
</table>
Adrenergic Blocking Drugs

Pheochromocytoma, a tumor of the adrenal gland that produces excessive amounts of epinephrine and norepinephrine. The drug is used to control hypertension during preoperative preparation and surgical excision of pheochromocytoma.

Some drugs such as norepinephrine or dopamine are particularly damaging to the surrounding tissues if extravasation (infiltration) occurs during intravenous administration. Phentolamine is used to prevent or treat tissue damage caused by extravasation of these drugs.

Adverse Reactions

Administration of an \(\alpha\)-adrenergic blocking drug may result in weakness, orthostatic hypotension, cardiac arrhythmias, hypotension, and tachycardia.

Contraindications, Precautions, and Interactions

\(\alpha\)-Adrenergic blocking drugs are contraindicated in patients who are hypersensitive to the drugs and in patients with coronary artery disease. These drugs are used cautiously during pregnancy (Pregnancy Category C) and lactation, after a recent myocardial infarction, and in patients with renal failure or Raynaud’s disease. When phentolamine is administered with epinephrine or ephedrine there is a decreased vasoconstrictor and hypertensive effects.

β-Adrenergic Blocking Drugs

β-Adrenergic blocking drugs, also called β blockers, decrease the activity of the sympathetic nervous system on certain tissues. β-Adrenergic receptors are found mainly in the heart. Stimulation of β receptors of the heart results in an increase in the heart rate. If stimulation of these β-adrenergic fibers is interrupted or blocked, the heart rate decreases and the vessels dilate (Fig. 23-1). These drugs decrease the excitability of the heart, decrease cardiac workload and oxygen consumption, and provide membrane-stabilizing effects that contribute to the antiarrhythmic activity of the β-adrenergic blocking drugs. Examples of β-adrenergic blocking drugs are esmolol (Brevibloc), metoprolol (Lopressor), nadolol (Corgard), and propranolol (Inderal).

β-Adrenergic blocking drugs, such as betaxolol (Betoptic) and timolol (Timoptic), when used topically...
as ophthalmic drops, appear to reduce the production of aqueous humor in the anterior chamber of the eye.

**USES**

These drugs are primarily used in the treatment of hypertension (see the Summary Drug Table: Adrenergic Blocking Drugs; also see Chap. 39) and certain cardiac arrhythmias (abnormal rhythm of the heart), such as ventricular arrhythmias or supraventricular tachycardia. They are used to prevent reinfarction in patients with a recent myocardial infarction (1–4 weeks after MI). Some of these drugs have additional uses, such as the use of propranolol for migraine headaches and nadolol for angina pectoris.

β-Adrenergic blocking drugs also can be used topically as ophthalmic eye drops. For example, betaxolol (Betoptic) and timolol (Timoptic) are used in the treatment of glaucoma. **Glaucoma** is a narrowing or blockage of the drainage channels (canals of Schlemm) between the anterior and posterior chambers of the eye. This results in a build-up of pressure (increased intraocular pressure) in the eye. Blindness may occur if glaucoma is left untreated.

**ADVERSE REACTIONS**

Some of the adverse reactions observed with the administration of β-adrenergic blocking drugs include orthostatic hypotension, bradycardia, dizziness, vertigo, bronchospasm (especially in those with a history of asthma), hyperglycemia, nausea, vomiting, and diarrhea. Many of these reactions are mild and may disappear with therapy. More serious adverse reactions include symptoms of congestive heart failure (dyspnea, weight gain, peripheral edema). Examples of adverse reactions associated with the use of β-adrenergic ophthalmic preparations include headache, depression, cardiac arrhythmias, and bronchospasm.

**Gerontologic Alert**

Older adults are at increased risk for adverse reactions when taking the β-adrenergic blocking drugs. The nurse should monitor the older adult closely for confusion, heart failure, worsening of angina, shortness of breath, and peripheral vascular insufficiency (eg, cold extremities, paresthesia of the hands, weak peripheral pulses).

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

These drugs are contraindicated in patients with an allergy to the β blockers, in patients with sinus bradycardia, second- or third-degree heart block, heart failure, and those with asthma, emphysema, or hypotension. The drugs are used cautiously in patients with diabetes, thyrotoxicosis, and peptic ulcer.

When used with verapamil, the effects of the β blockers are increased. When the β blockers are used with indomethacin, ibuprofen, sulindac, or barbiturates, a decrease in the effects of the β blockers may occur. Diuretics may increase the hypotensive effects of the β-adrenergic blocking drugs. There is a paradoxical hypertensive effect when clonidine is given with the β-adrenergic blocking drugs. There is a risk of increased serum levels and toxic effects of the β-adrenergic blocking drugs when given with lidocaine and cimetidine.

**ANTIADRENERGIC DRUGS**

**ACTIONS**

One group of antiadrenergic drugs inhibits the release of norepinephrine (a neurohormone of the sympathetic nervous system, see Chap. 22) from certain adrenergic
nerve endings in the peripheral nervous system. This group is composed of peripherally acting (i.e., acting on peripheral structures) antiadrenergic drugs. An example of a peripherally acting antiadrenergic drug is guanethidine (Ismelin). The other antiadrenergic drugs are called centrally acting antiadrenergic drugs because they act on the CNS, rather than on the peripheral nervous system. This group affects specific CNS centers, thereby decreasing some of the activity of the sympathetic nervous system. Although the action of both types of antiadrenergic drugs is somewhat different, the results are basically the same. An example of a centrally acting antiadrenergic drug is clonidine (Catapres-TTS).

**USES**

Antiadrenergic drugs are used mainly for the treatment of certain cardiac arrhythmias and hypertension (see the Summary Drug Table: Adrenergic Blocking Drugs).

**ADVERSE REACTIONS**

Some of the adverse reactions associated with the administration of centrally acting antiadrenergic drugs include dry mouth, drowsiness, sedation, anorexia, rash, malaise, and weakness. Adverse reactions associated with the administration of the peripherally acting antiadrenergic drugs include hypotension, weakness, light-headedness, and bradycardia.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

The centrally acting antiadrenergic drugs are contraindicated in active hepatic disease such as acute hepatitis or active cirrhosis and in patients with a history of hypersensitivity to these drugs. The centrally acting antiadrenergic drugs are used cautiously in patients with a history of liver disease, renal function impairment, and during pregnancy and lactation. If methyldopa is administered with anesthetics, there is an increased effect of the anesthetic. The centrally acting antiadrenergic drugs increase the activity of sympathomimetics, possibly causing hypertension. Clonidine decreases the effectiveness of levodopa. When clonidine is administered with β-adrenergic blocking drugs, a potentially life-threatening hypertensive episode may occur.

The peripherally acting antiadrenergic drugs are contraindicated in patients with a hypersensitivity to any of the drugs. Reserpine is contraindicated in patients who have an active peptic ulcer or ulcerative colitis and in patients who are mentally depressed. Reserpine is used cautiously in patients with a history of depression, in patients with renal impairment or cardiovascular disease, and during pregnancy and lactation. Guanethidine, another peripherally acting antiadrenergic drug, is contraindicated in patients with pheochromocytoma and congestive heart failure. The drug is used cautiously in patients with bronchial asthma and renal impairment and during pregnancy and lactation. Anorexiants, haloperidol, the monoamine oxidase inhibitors, tricyclic antidepressants, and phenothiazines decrease the hypotensive effects of guanethidine.

### α/β-ADRENERGIC BLOCKING DRUGS

**ACTIONS**

α/β-Adrenergic blocking drugs block the stimulation of α- and β-adrenergic receptors, resulting in peripheral vasodilation. The two drugs in this category are carvedilol (Coreg) and labetalol (Normodyne).

**USES**

Labetalol is used in the treatment of hypertension, either alone or in combination with another drug such as a diuretic. Carvedilol is used to treat essential hypertension and in congestive heart failure to reduce progression of the disease.

**ADVERSE REACTIONS**

Most adverse effects of labetalol are mild and do not require discontinuation of therapy. Examples of the adverse reactions include fatigue, drowsiness, insomnia, weakness, hypotension, diarrhea, dyspnea, and skin rash. Adverse reactions of carvedilol include fatigue, hypotension, cardiac insufficiency, chest pain, bradycardia, dizziness, diarrhea, hypotension, and fatigue.

### CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Both carvedilol and labetalol are contraindicated in patients with hypersensitivity to the drug, bronchial asthma, decompensated heart failure, and severe bradycardia. The drugs are used cautiously in patients with drug-controlled congestive heart failure, chronic bronchitis, impaired hepatic or cardiac function, in those with diabetes, and during pregnancy (Category C) and lactation.
When either drug is administered with diuretics and other hypotensives, an increased hypotensive effect may occur. When labetalol is administered with cimetidine, the effects of labetalol are increased. Halothane increases the effects of labetalol. When carvedilol is administered with the antidiabetic drugs, there is an increased effectiveness of the antidiabetic drugs. There is an increased effectiveness of clonidine when carvedilol is administered with clonidine. There is an increased serum level of digoxin when digoxin is administered with carvedilol.

**NURSING PROCESS**

*The Patient Receiving an Adrenergic Blocking Drug*

**ASSESSMENT**

An assessment depends on the drug, the patient, and the reason for administration.

**Preadministration Assessment**

The nurse establishes an accurate database before any adrenergic blocking drug is administered for the first time. If, for example, the patient has a peripheral vascular disease, the nurse notes the subjective and objective symptoms of the disorder during the initial assessment. If the drug is given for anginal pain, the nurse records the onset, type (eg, sharp, dull, squeezing), radiation, location, intensity, and duration of anginal pain. The nurse also questions the patient regarding any precipitating factors of the anginal pains, such as exertion or emotional stress. Once drug therapy is started, evaluation of the effects of therapy can be made by comparing the patient's current symptoms with the symptoms experienced before therapy was initiated.

Patients with hypertension must have their blood pressure and pulse taken on both arms in sitting, standing, and supine positions before therapy is begun. If the patient has a cardiac arrhythmia, the initial assessment includes taking the pulse rate, determining the pulse rhythm, and noting the patient's general appearance.

Subjective data (ie, the patient's complaints or description of symptoms) also are obtained at this time. The primary health care provider usually orders an electrocardiogram. Additional diagnostic studies and laboratory tests also may be ordered.

If the drug is given is given to treat congestive heart failure (ie, carvedilol), the patient is assessed for evidence of the disease, such as dyspnea (especially on exertion), peripheral edema, distended neck veins, and cough.

**Ongoing Assessment**

It is important for the nurse to perform ongoing assessment of the patient receiving adrenergic drug therapy. This assessment often depends on the reason the drug is administered. For all adrenergic blocking drugs, it is important for the nurse to continually observe these patients for the appearance of adverse reactions. Some adverse reactions are mild, whereas others, such as diarrhea, may cause a problem, especially if the patient is elderly or debilitated.

During therapy with an adrenergic blocking drug for hypertension, the nurse should take the patient's blood pressure before each dose is given. Some patients have an unusual response to the drugs. In addition, some drugs may, in some individuals, decrease the blood pressure at a more rapid rate than other drugs. It is important to monitor the patient's blood pressure on both arms and in the sitting, standing, and supine position for the first week or more of therapy. Once the patient's blood pressure has stabilized, the nurse should take the blood pressure before each drug administration using the same arm and position for each reading. It is a good idea to make a notation on the medication administration record or care plan about the position and arm used for blood pressure determinations. Measuring the blood pressure near the end of the dosing interval or near the end of the day after the last dose of the day helps to determine if the blood pressure is controlled throughout the day.

Ongoing assessment of patients receiving adrenergic blocking drugs for cardiac arrhythmias depends on the type of arrhythmia and the method of treatment. Some cardiac arrhythmias, such as ventricular fibrillation, are life threatening and require immediate attention. Other arrhythmias are serious and require treatment but are not life threatening. The patient with a life-threatening arrhythmia may receive an adrenergic blocking drug, such as propranolol, by the intravenous (IV) route. When these drugs are administered IV, cardiac monitoring is necessary. Patients not in a specialized unit, such as a coronary care unit, are usually transferred to one as soon as possible. When administering these drugs for a life-threatening arrhythmia, it is important for the nurse to continually supervise the patient, frequently monitor the blood pressure and respiratory rate, and perform cardiac monitoring.

When propranolol is administered orally for a less serious cardiac arrhythmia, cardiac monitoring is usually not necessary. The nurse should monitor the patient's blood pressure and pulse rate and rhythm at varying intervals, depending on the length of treatment and the patient's response to the drug.

**Nursing Alert**

When administering a β-adrenergic blocking drug, such as propranolol (Inderal), the nurse should take an apical pulse rate and blood pressure before giving the drug. If pulse is below 60 bpm or if systolic blood pressure is less than 90 mm Hg, the nurse should withhold the drug and contact the primary health care provider.
If propranolol is given for angina, the nurse should ask the patient about the relief of symptoms and should record responses on the patient’s chart.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes for the patient depend on the reason for administration of an adrenergic blocking drug but may include an optimal response to drug therapy, management of common adverse drug reactions (diarrhea, constipation, anorexia, fatigue, ineffective tissue perfusion), decreased risk for injury, and an understanding of and compliance with the prescribed drug regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

Most adrenergic blocking drugs may be given without regard to food. However, the nurse should administer propranolol and metoprolol at the same time each day because food may enhance bioavailability. Sotalol is given on an empty stomach because food may reduce absorption of the drug.

Nursing Alert

The nurse should withhold the administration of a β-adrenergic drug, such as propranolol (Inderal), and contact the primary health care provider if the patient has a heart rate of less than 60 bpm or if there is any irregularity in the patient's heart rate or rhythm.

When adrenergic blocking drugs are given to patients to control hypertension, angina, or cardiac arrhythmias, it is important to communicate with the primary care provider about the patient’s response to therapy. When given for a cardiac arrhythmia, these drugs can provoke new or worsen existing ventricular arrhythmias. If angina worsens or does not appear to be controlled by the drug, the nurse should contact the primary care provider immediately. When the drug is administered for hypertension, the nurse monitors the patient for a decrease in the blood pressure. If there is a significant rise in the blood pressure, the nurse administers the dose and notifies the primary care provider immediately because additional drug therapy may be necessary.

When a β-adrenergic blocking ophthalmic preparation, such as timolol, is administered to patients with glaucoma, it is important to insist that they have periodic follow-up examinations by an ophthalmologist. At these examinations, the intraocular pressure should be measured to determine the effectiveness of drug therapy.

Monitoring and Managing Common Adverse Reactions

Some patients may experience one or more adverse drug reactions during treatment with adrenergic blocking drugs. As with any drug, the nurse must report adverse reactions to the primary care provider and record the reactions on the patient’s chart. Nursing judgment in this matter is necessary because some adverse reactions are serious or potentially serious in nature. In these cases, the nurse should withhold the next dose of the drug and contact the primary care provider immediately. The nurse also reports to the primary care provider any adverse reactions that pose no serious threat. Adverse reactions that pose no serious threat to the patient’s well-being, such as dry mouth or mild constipation, may have to be tolerated by the patient. It is important to assure the patient that, in some instances, these less serious reactions disappear or lessen in intensity after a time.

However, even minor adverse drug reactions can be distressing to the patient, especially when they persist for a long time. Therefore, when possible, the nurse should relieve minor adverse reactions with simple nursing measures. For example, the nurse can assist the patient with dry mouth by giving frequent sips of water or by allowing the patient to suck on a piece of hard candy (provided that the patient does not have diabetes or is not on a special diet that limits sugar intake) to relieve a dry mouth. The nurse can help relieve a patient’s constipation by encouraging increased fluid intake, unless extra fluids are contraindicated. The primary care provider also may order a laxative or stool softener. It is important for the nurse to maintain a daily record of bowel elimination. The nurse can help the patient minimize certain gastrointestinal side effects, such as anorexia, diarrhea, and constipation by administering drugs at a specific time in relation to meals, with food, or with antacids.

MANAGING HYPOTENSION. Administration of the adrenergic blocking drugs may cause hypotension. If the
drug is administered for hypertension, then a decrease is expected.

**Nursing Alert**

If a significant decrease in the blood pressure (a drop of 20 mm Hg systolic or a systolic below 90 mm Hg) occurs after a dose of an adrenergic blocking drug, the nurse should withhold the drug and notify the primary care provider immediately. A dosage reduction or discontinuation of the drug may be necessary. Some adrenergic blocking drugs (eg, prazosin or terazosin) may cause a “first dose effect.” A first dose effect occurs when the patient experiences marked hypotension (or postural hypotension) and syncope with sudden loss of consciousness with the first few doses of the drug.

The first dose effect may be minimized by decreasing the initial dose and administering the dose at bedtime. The dosage can then be slowly increased every 2 weeks until a full therapeutic effect is achieved. If the patient experiences syncope, the nurse places the patient in a recumbent position and treats supportively. This effect is self-limiting and in most cases does not recur after the initial period of therapy. Light-headedness and dizziness are more common than loss of consciousness. The section below discusses these effects and provides interventions for management.

**DECREASING THE PATIENT'S RISK FOR INJURY.** On occasion, patients receiving an adrenergic blocking drug may experience postural or orthostatic hypotension. **Postural hypotension** is characterized by a feeling of light-headedness and dizziness when the patient suddenly changes from a lying to a sitting or standing position, or from a sitting to a standing position. **Orthostatic hypotension** is characterized by similar symptoms as postural hypotension and occurs when the patient changes or shifts position after standing in one place for a long period. The nurse can help to minimize these adverse reactions as follows:

- Instruct the patient to avoid standing in one place for prolonged periods. This is rarely a problem in the hospital but should be included in the patient and family discharge teaching plan.
- Teach the patient to avoid taking hot showers or baths, which tend to increase vasodilation.

Symptoms of postural or orthostatic hypotension often lessen with time, and the patient may be allowed to get out of bed or chair slowly without assistance. The nurse must exercise good judgment in this matter. Allowing the patient to rise from a lying or sitting position without help is done only when the determination has been made that the symptoms have lessened and ambulation poses no danger of falling.

**Educating the Patient and Family**

Some patients do not adhere to the prescribed drug regimen for a variety of reasons, such as failure to comprehend the prescribed regimen, the cost of drug therapy, and failure to understand the importance of continued and uninterrupted therapy. If the nurse detects failure to adhere to the prescribed drug regimen, he or she should investigate the possible cause of the problem. In some instances, financial assistance may be necessary; in other instances, patients need to know why they are taking a drug and why therapy must be continuous to attain and maintain an optimal state of health and well-being.

The nurse should describe the drug regimen and stress the importance of continued and uninterrupted therapy when teaching the patient who is prescribed an adrenergic blocking drug. Patient education will differ according to the reason the adrenergic blocking drug is prescribed.

**EDUCATING THE PATIENT WITH HYPERTENSION, CARDIAC ARRHYTHMIA, OR ANGINA.** If a β-adrenergic blocking drug has been prescribed for hypertension, cardiac arrhythmia, angina, or other cardiac disorders, the patient must have a full understanding of the treatment regimen. In some instances, the primary care provider may advise the hypertensive patient to lose weight or eat a special diet, such as a low-salt diet. A special diet also may be recommended for the patient with angina or a cardiac arrhythmia. When appropriate, the nurse should stress the importance of diet and weight loss in the therapy of hypertension.

It is important to include the following additional points in the teaching plan for the patient with hypertension, angina, or a cardiac arrhythmia:

- Do not stop taking the drug abruptly, except on the advice of the primary care provider. Most of these drugs require that the dosage be gradually decreased to prevent precipitation or worsening of adverse effects.
CHAPTER 23

Adrenergic Blocking Drugs

219

• Notify the primary health care provider promptly if adverse drug reactions occur.
• Observe caution while driving or performing other hazardous tasks because these drugs (β-adrenergic blockers) may cause drowsiness, dizziness, or light-headedness.
• Immediately report any signs of congestive heart failure (weight gain, difficulty breathing, or edema of the extremities).
• Do not use any nonprescription drug (eg, cold or flu preparations or nasal decongestants) unless use of a specific drug has been approved by the primary care provider.
• Inform dentists and other primary care providers of therapy with this drug.
• Keep all primary care provider appointments because close monitoring of therapy is essential.
• Check with a primary health care provider or pharmacist to determine if the drug is to be taken with food or on an empty stomach.

In addition, when an adrenergic blocking drug is prescribed for hypertension, the primary care provider may want the patient to monitor his or her own blood pressure between office visits. This may enable the number of visits to the primary care provider office to be reduced and will help the patient learn to manage his or her own health (see Patient and Family Teaching Checklist: Monitoring Blood Pressure).

EDUCATING THE PATIENT WITH GLAUCOMA. When an adrenergic blocking drug has been prescribed for glaucoma, the nurse demonstrates the technique of eye drop instillation and explains the prescribed treatment regimen to the patient. Adherence to the instillation schedule is stressed because omitting or discontinuing the drug without approval of the primary care provider may result in a marked increase in intraocular pressure, which can lead to blindness. The nurse should tell patients with glaucoma who are using adrenergic blocking eye drops to contact their primary health care provider if eye pain, excessive tearing, or any change in vision occurs.

EVALUATION

• The therapeutic effect is achieved and hypertension, cardiac arrhythmia, or glaucoma is controlled.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
• No evidence of injury related to orthostatic or postural hypotension is seen.
• The patient and family demonstrate an understanding of the drug regimen.

Critical Thinking Exercises

1. Ms. Martin has been prescribed propranolol (Inderal) for hypertension. She arrives at the outpatient clinic and tells you that she is having episodes of dizziness and at times feels as if she is going to faint. Discuss how you would investigate this problem and what information you could give Ms. Martin that might help her.

2. Mr. Garcia was prescribed labetalol (Normodyne) 100 mg orally twice daily for hypertension. The health care provider wants him to monitor his blood pressure once daily. Determine what assessments you would make. Develop a teaching plan for Mr. Garcia that would help him in monitoring his blood pressure and taking labetalol.

3. A new nurse says that she is unsure about how the adrenergic blocking drugs work. Discuss the four types of adrenergic blocking drugs and how each one works within the body.

Review Questions

1. A patient is to receive a β-adrenergic drug for hypertension. Before the drug is administered the most important assessment the nurse performs is _______.
   A. weighing the patient
   B. obtaining blood for laboratory tests
   C. taking a past medical history
   D. taking the blood pressure on both arms
2. When an adrenergic blocking drug is given for a life-threatening cardiac arrhythmia, which of the following activities would the nurse expect to be a part of patient care?
   A. daily ECGs
   B. fluid restriction of 1000 mL per day
   C. daily weights
   D. cardiac monitoring

3. To prevent complications when administering a β-adrenergic blocking drug to an elderly patient, the nurse would be particularly alert for ______.
   A. vascular insufficiency (e.g., weak peripheral pulses and cold extremities)
   B. complaints of an occipital headache
   C. insomnia
   D. hypoglycemia

4. The patient with glaucoma will likely receive a(n) ______.
   A. α/β-adrenergic blocking drug
   B. α-adrenergic blocking drug
   C. β-adrenergic blocking drug
   D. antiadrenergic drug

Medication Dosage Problems

1. The primary health care provider prescribes 60 mg propranolol oral solution. The drug is available in an oral solution with a strength of 4 mg/mL. The nurse administers ______.

2. A patient is prescribed 12.5 mg of carvedilol. The drug on hand is 3.125-mg tablets. The nurse administers ______.
Key Terms
- acetylcholine
- acetylcholinesterase
- cholinergic crisis
- glaucoma
- micturition
- myasthenia gravis
- parasympathomimetic drugs

Chapter Objectives
On completion of this chapter, the student will:
- Discuss important aspects of the parasympathetic nervous system.
- Discuss the uses, drug actions, general adverse reactions, contraindications, precautions, and interactions of the cholinergic drugs.
- Identify important preadministration and ongoing assessment activities the nurse should perform on the patient taking cholinergic drugs.
- List some nursing diagnoses particular to a patient taking cholinergic drugs.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating the patient about the use of cholinergic drugs.

Cholinergic drugs mimic the activity of the parasympathetic nervous system (PNS). They also are called parasympathomimetic drugs. An understanding of the PNS is useful in understanding the cholinergic drugs.

PARASYMPATHETIC NERVOUS SYSTEM

The PNS is a part of the autonomic nervous system (see Chap. 22). It helps conserve body energy and is partly responsible for activities such as slowing the heart rate, digesting food, and eliminating body wastes.

Electron microscopic study reveals an incalculably small space between nerve endings and the effector organ (e.g., the muscle, cell, or gland) that is innervated (or controlled) by a nerve fiber. For a nerve impulse to be transmitted from the nerve ending (motor end plate) across the space to the effector organ, a neurohormone is needed.

The PNS has two neurohormones (neurotransmitters): acetylcholine (ACh) and acetylcholinesterase (AChE). ACh is a neurotransmitter responsible for the transmission of nerve impulses to effector cells of the parasympathetic nervous system. ACh plays an important role in the transmission of nerve impulses at synapses and myoneural junctions. ACh is quickly destroyed by the enzyme AChE, thereby allowing the nerve impulse to pass, but not remain in an excited state.

These two neurohormones are released at nerve endings of parasympathetic nerve fibers, at some nerve endings in the sympathetic nervous system, and at nerve endings of skeletal muscles. These parasympathetic neurohormones are believed to be manufactured by special cells located in the nerve ending. When a parasympathetic nerve fiber is stimulated, the nerve fiber releases ACh, and the nerve impulses pass (travel) from the nerve fiber to the effector organ or structure. After the impulse has crossed over to the effector organ or structure, ACh is inactivated (destroyed) by the neurohormone AChE. When the next nerve impulse is ready to travel along the nerve fiber, ACh is again released and then inactivated by AChE.

CHOLINERGIC DRUGS

Cholinergic drugs have limited usefulness in medicine, partly because of the adverse reactions that may occur during administration. However, in some diseases or conditions cholinergic drugs are either definitely indicated or may be of value.
ACTIONS

Cholinergic drugs may act like the neurohormone ACh or they may inhibit the release of the neurohormone AChE. Cholinergic drugs that act like ACh are called direct-acting cholinergics. If a cholinergic drug inhibits the body’s release of AChE, it prolongs the activity of the ACh produced by the body. Cholinergic drugs that prolong the activity of ACh by inhibiting the release of AChE are called indirect-acting cholinergics. Although a specific cholinergic drug may act in either of these two ways, the results of drug action are basically the same.

USES

The major uses of the cholinergic drugs are in the treatment of glaucoma, myasthenia gravis, and urinary retention.

Glaucoma is a disorder of increased pressure within the eye caused by an obstruction of the outflow of aqueous humor through the canal of Schlemm. In the normal eye the aqueous humor flows from the ciliary body to the posterior chamber of the eye, through the pupil, and out the canal of Schlemm into the venous circulation (Fig. 24-1). This flow of aqueous humor keeps the pressure within the eye within normal limits. Glaucoma may be treated by topical application (eg, eye drops) of a cholinergic drug, such as carbachol or pilocarpine (Isopto Carpine). Treatment of glaucoma with a cholinergic drug produces miosis (constriction of the iris). This opens the blocked channels and allows the normal passage of aqueous humor, thus reducing intraocular pressure.

Myasthenia gravis is a disease that involves rapid fatigue of skeletal muscles because of the lack of ACh released at the nerve endings of parasympathetic nerve fibers. Drugs used to treat this disorder include ambenonium (Mytelase) and pyridostigmine (Mestinon).

Urinary retention (not caused by a mechanical obstruction, such as a stone in the bladder or an enlarged prostate) results when micturition (voiding of urine) is impaired. Micturition is both a voluntary and involuntary act. The PNS partly controls the process of micturition by constricting the detrusor muscle and relaxing the bladder sphincter (see Table 22-1). Treatment of urinary retention with cholinergic drugs, such as ambenonium, bethanechol chloride (Urecholine), or pyridostigmine results in the spontaneous passage of urine.

ADVERSE REACTIONS

Unless applied topically, as in the treatment of glaucoma, cholinergic drugs are not selective in action. Therefore, they may affect many organs and structures of the body, causing a variety of adverse effects. Oral or parenteral administration can result in nausea, diarrhea, abdominal cramping, salivation, flushing of the skin, cardiac arrhythmias, and muscle weakness. Topical administration usually produces few adverse effects, but a temporary reduction of visual acuity (sharpness) and headache may occur. The Summary Drug Table: Cholinergic Drugs lists the adverse reactions that may be seen with specific cholinergic drugs.

CONTRAINDICATIONS

These drugs are contraindicated in patients with known hypersensitivity to the drugs, asthma, peptic ulcer disease, coronary artery disease, and hyperthyroidism. Bethanecol is contraindicated in those with mechanical obstruction of the gastrointestinal or genitourinary tracts. Patients with secondary glaucoma, iritis, corneal abrasion, or any acute inflammatory disease of the eye should not use the ophthalmic cholinergic preparations.

PRECAUTIONS

These drugs are used cautiously in patients with hypertension, epilepsy, cardiac arrhythmias, bradycardia, recent coronary occlusion, and megacolon. The safety of these drugs has not been established for use during pregnancy (Pregnancy Category C), lactation, or in children.
INTERACTIONS

When the cholinergic drugs are administered with other cholinergics, there is an increase in the effects of the drugs and greater risk for toxicity. Concurrent use of the anticholinergic drugs antagonizes the effects of the cholinergic drugs. Because of this property, atropine is considered an antidote for overdosage of the cholinergic drugs. Carbachol and pilocarpine produce an additive effect when used concurrently. The effects of the cholinergic drugs, particularly edrophonium, neostigmine, and pyridostigmine, are decreased with possible muscular depression when administered with the corticosteroids.

NURSING PROCESS

The Patient Receiving a Cholinergic Drug

ASSESSMENT

Preadministration Assessment
The preadministration assessment depends on the drug and the reason for administration.

GLAUCOMA. Before therapy for glaucoma is started, the primary health care provider thoroughly examines the eye. The nurse reviews the primary health care provider’s diagnosis and comments, takes a general patient health
history, and evaluates the patient’s ability to carry out the activities of daily living, especially if the patient is elderly or has limited vision.

**MYASTHENIA GRAVIS.** Before the nurse gives a cholinergic drug to a patient with myasthenia gravis, the primary health care provider performs a complete neurologic assessment. The nurse assesses for signs of muscle weakness, such as drooling (ie, the lack of ability to swallow), inability to chew and swallow, drooping of the eyelids, inability to perform repetitive movements (eg, walking, combing hair, using eating utensils), difficulty breathing, and extreme fatigue.

**URINARY RETENTION.** If a patient receives a cholinergic drug for the treatment of urinary retention, the nurse palpates the abdomen in the pelvis area to determine if distention is present. A rounded swelling over the pelvis usually indicates retention and a distended bladder. The patient may also complain of discomfort in the lower abdomen. In addition, the nurse takes the patient’s blood pressure and pulse rate.

**Ongoing Assessment**
While the patient is receiving a cholinergic drug it is important for the nurse to monitor for drug toxicity or cholinergic crisis.

**Nursing Alert**
Symptoms of *cholinergic crisis* (cholinergic drug toxicity) include severe abdominal cramping, diarrhea, excessive salivation, muscle weakness, rigidity and spasm, and clenching of the jaw. Patients exhibiting these symptoms require immediate medical treatment and their condition must be immediately reported to the primary health care provider. In the case of overdosage, an antidote such as atropine and other treatment also may be prescribed. The usual dosage of atropine is 0.4 to 0.6 mg IV.

**GLAUCOMA.** When a cholinergic drug is used to treat glaucoma, the nurse checks the eye and the area around the eye daily for evidence of redness, inflammation, and excessive secretions, particularly if the ocular system is used. If secretions are present around the eye, the nurse removes them with a cotton ball or gauze soaked in normal saline or other cleansing solution recommended by the primary health care provider.

**MYASTHENIA GRAVIS.** Once therapy is under way, the nurse must document any increase in the symptoms of the disease or adverse drug reactions before giving each dose of the drug. The nurse assesses the patient for the presence or absence of the symptoms of myasthenia gravis before each drug dose. In patients with severe myasthenia gravis, the nurse can carry out these assessments between drug doses, as well as immediately before drug administration. The nurse documents each symptom, as well as the patient’s response or lack of response to drug therapy.

Assessment is important because the dosage frequently has to be increased or decreased early in therapy, depending on the patient’s response. Regulation of dosage is important in keeping the symptoms of myasthenia gravis from incapacitating the patient. For many patients, the symptoms are fairly well controlled with drug therapy once the optimal drug dose is determined.

**URINARY RETENTION.** The ongoing assessment for a patient with urinary retention includes measuring and recording the fluid intake and output. The nurse must notify the primary health care provider if the patient fails to void after drug administration.

If a cholinergic drug is ordered for the prevention of urinary retention, the nurse measures and records the fluid intake and output. If the amount of each voiding is insufficient or the patient fails to void, the nurse palpates the bladder to determine its size and notifies the primary health care provider.

**NURSING DIAGNOSES**
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**
The expected outcomes of the patient depend on the reason for administration of the cholinergic drug but may include an optimal response to therapy, management of common adverse drug effects, and an understanding of and compliance with the prescribed therapeutic regimen.

**IMPLEMENTATION**
Promoting an Optimal Response to Therapy
The care of a patient receiving a cholinergic drug depends on the drug used, the reason for administration, and the patient’s response to the drug.

**Nursing Diagnoses Checklist**
- Disturbed Sensory Perception: Visual related to adverse drug reactions or increased pressure within the eye
- Risk for Injury related to muscular weakness, rigidity, or spasms due to drug overdose
- Diarrhea related to adverse drug reaction
MANAGING GLAUCOMA. The nurse checks the primary health care provider’s order and the drug label carefully when instilling any ophthalmic preparation. The drug label must indicate that the preparation is for ophthalmic use. In addition, the nurse should check the name of the drug and the drug dosage or strength as stated on the label against the primary health care provider’s orders. The nurse instills the drug in the lower conjunctival sac unless the primary health care provider orders a different method of instillation. The nurse supports the hand holding the dropper against the patient’s forehead. The tip of the dropper must never touch the eye.

In some instances, the patient may have been using an ophthalmic preparation for glaucoma for a long time, and the primary health care provider may allow the hospitalized patient to instill his or her own eye drops. When this is stated on the patient’s order sheet, the nurse can leave the drug at the patient’s bedside. Even though the drug is self-administered, the nurse checks the patient at intervals to be sure that the drug is instilled at the prescribed time using the correct technique for ophthalmic instillation.

Pilocarpine Ocular System. If the pilocarpine ocular system is prescribed for the hospitalized patient, the nurse checks the cheek and eye area several times a day because the system can become displaced from the eye.

Gerontologic Alert
Most patients are usually aware of displacement of the pilocarpine ocular system, but some patients, the elderly in particular, may not realize that the system has come out of the eye. If displacement does occur, the nurse inserts a new system and informs the primary health care provider of the problem.

On occasion, patients cannot insert the system by themselves or cannot retain the system in the eye for the required time. When this occurs, the nurse notifies the primary health care provider because the ocular system should remain in place until it is time for it to be changed. The nurse changes the pilocarpine ocular system every 7 days unless the primary health care provider orders otherwise (Display 24-1).

If patients have a problem retaining the system, placing the system in the upper conjunctival cul-de-sac is preferable. The nurse can manipulate the system from the lower to the upper conjunctival cul-de-sac using gentle massage through the eyelid. The nurse contacts the primary health care provider if the symptoms of glaucoma increase, if the patient is unable to retain the ocular system, or if redness, eye irritation, or excessive secretions are noted.

MANAGING MYASTHENIA GRAVIS. In the beginning, determining the dosage that will control symptoms may be difficult. In many cases, the dosage must be adjusted upward or downward until optimal drug effects are obtained. Patients with severe symptoms of the disease require the drug every 2 to 4 hours even during the night. Sustained-released tablets are available that allow less frequent dosing and help the patient to have longer undisturbed periods during the night.

Nursing Alert
Because of the need to make frequent dosage adjustments, the nurse should observe the patient closely for symptoms of drug overdosage or underdosage. Signs of drug overdosage include muscle rigidity and spasm, salivation, and clenching of the jaw. Signs of drug underdosage are signs of the disease itself, namely, rapid fatigability of the muscles, drooping of the eyelids, and difficulty breathing. If symptoms of drug overdosage or underdosage develop, the nurse should contact the primary health care provider immediately because a change in dosage is usually necessary.

MANAGING URINARY RETENTION. Voiding usually occurs in 5 to 15 minutes after subcutaneous drug administration and 30 to 90 minutes after oral administration. The nurse should place the call light and any other items the patient might need, such as the urinal or the bedpan, within easy reach. However, some patients are not able to reach or handle these aids easily, so the nurse must promptly answer their call light.

Monitoring and Managing Adverse Reactions
When a cholinergic drug is given by the oral or parenteral route, adverse drug reactions may affect many systems of the body, such as the heart, respiratory and gastrointestinal tracts, and the central nervous system. The nurse observes the patient closely for the appearance of adverse drug reactions, such as a change in vital signs or an increase in symptoms. The nurse documents any complaints the patient may have and notifies the primary health care provider.

DISTURBED SENSORY PERCEPTION: VISUAL. Because drug-induced myopia (nearsightedness) may occur after instillation of a cholinergic ophthalmic drug for the treatment of glaucoma, the nurse assists the patient in getting out of bed or ambulating. Keeping the patient’s room dimly lit at night is helpful because night vision may be decreased. Obstacles that may hinder ambulation or result in falls, such as slippers, chairs, and tables, are placed out of the way, especially during the night.
1. Wash hands and put on gloves. Press the disk with the fingertip until it remains on the finger as shown.

2. Have the patient look up. Pull the lower conjunctiva away from the eye and gently place the disk in the lower conjunctival sac. The disk should float on the sclera.

3. Pull the lower conjunctiva over the disk. Check for correct position. The disk should not be visible. If the disk is still seen, the eyelid must be repositioned by pulling the lower conjunctiva out and over the disk again.

4. Use gloves when removing the disk. Pull the lower eyelid down and use the thumb and first finger of the free hand to lift the disk out of the eye as shown.

(Adapted from Nursing94, June, Intraocular Drug Administration, pp. 44-45, which was adapted from Giving drugs by advanced techniques [1993]. Springhouse, PA: Springhouse Corp.)
DIARRHEA. When these drugs are used orally they occasionally result in excessive salivation, abdominal cramping, flatus, and sometimes diarrhea. The patient is informed that these reactions will continue until tolerance develops, usually within a few weeks. Until tolerance develops, the nurse ensures that proper facilities, such as a bedside commode, bedpan, or bathroom, are readily available. The patient is encouraged to ambulate to assist the passing of flatus. If needed, a rectal tube may be used to assist in the passing of flatus. The nurse keeps a record of the fluid intake and output and the number, consistency, and frequency of stools if diarrhea is present. The primary health care provider is informed if diarrhea is excessive because this may be an indication of toxicity.

Educating the Patient and Family

Patients required to take a drug over a long period may incur lapses in their drug schedule. For some, it is a matter of occasionally forgetting to take a drug; for others, a lapse may be caused by other factors, such as failure to understand the importance of drug therapy, inability to instill an eye drug (when the drug is prescribed for glaucoma), the cost of the drug, or unfamiliarity with the consequences associated with discontinuing the drug therapy.

When developing a teaching plan for the patient and family, the nurse emphasizes the importance of uninterrupted drug therapy. The nurse allows the patient and family time to ask questions. The nurse explores any problems that appear to be associated with the prescribed drug regimen and then reports them to the primary health care provider. The nurse reviews the purpose of the drug therapy with the patient and family, as well as the adverse reactions that may occur.

GLAUCOMA. When a cholinergic drug is prescribed for glaucoma, the nurse instructs the patient and a family member in instillation of the eye drops (see Patient and Family Teaching Checklist: Instilling Liquid Eye Medications).

If a family member is to instill the drug, the nurse allows time for instruction as well as supervised practice of the procedure. The nurse warns the patient that the eye drops may sting when instilled into the eye and that this is a normal, but often temporary, discomfort. The nurse advises the patient to observe caution while driving or performing any task that requires visual acuity.

Local irritation and headache may occur at the beginning of therapy. The patient is instructed to notify the primary health care provider if abdominal cramping, diarrhea, or excessive salivation occurs.

PILOCARPINE OCULAR SYSTEM. If the pilocarpine ocular system is prescribed, the primary health care provider must evaluate the patient’s ability to insert and remove the system. A package insert is provided with the system and the nurse reviews this with the patient. The nurse instructs the patient to remove and replace the system every 7 days or as instructed by the primary health care provider. Replacement is best done at bedtime (unless the primary health care provider orders otherwise) because there is some impairment of vision for a short time after insertion. The nurse tells the patient to check for unit placement before retiring at night and in the morning on arising. The nurse notifies the primary health care provider if eye secretions are excessive or irritation occurs.

MYASTHENIA GRAVIS. Many patients with myasthenia gravis learn to adjust their drug dosage according to their needs because dosages may vary slightly from day to day. The nurse teaches the patient and family members to recognize symptoms of overdosage and underdosage, as well as what steps the primary health care provider wishes them to take if either occurs. The dosage regimen is explained and instruction is given in how to adjust the dosage upward or downward.

The nurse gives the patient a written or printed description of the signs and symptoms of drug overdosage or underdosage. The nurse instructs the patient...
to keep a record of the response to drug therapy (eg, time of day, increased or decreased muscle strength, fatigue) and to bring this to each primary health care provider or clinic visit until the symptoms are well controlled and the drug dosage is stabilized. These patients must wear or carry identification (such as a Medic-Alert tag) indicating that they have myasthenia gravis.

**EVALUATION**

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.
- The patient complies with the prescribed drug regimen.
- The patient and family demonstrate understanding of the drug regimen.

**Critical Thinking Exercises**

1. Mr. Johnson, age 78 years, has glaucoma and is prescribed the pilocarpine ocular system. On a visit to the outpatient clinic, Mr. Johnson tells you that he is having problems retaining the ocular system. You notice that his right eye is very red and inflamed. Determine how you can investigate this problem further with Mr. Johnson. Provide suggestions that will help Mr. Johnson to retain the system.

2. Mr. Hopkins, aged 32 years, has myasthenia gravis. Explain to Mr. Hopkins the symptoms he should be aware of that would indicate toxicity.

3. Discuss the types of ongoing assessments made when a patient takes a cholinergic drug for urinary retention.

**Review Questions**

1. A patient with glaucoma is prescribed pilocarpine eye drops. One adverse reaction that the nurse will expect with the use of this drug is _____.

2. The primary care provider allows the patient to keep pilocarpine eye drops at the bedside and to self-administer the eye drops 4 times daily. The nurse _____.

   - A. need not check with the patient concerning the eye drops because the patient is a responsible adult
   - B. must check the patient to be sure the medication is used properly and at the right time
   - C. is not responsible for monitoring the patient’s response to the medication
   - D. does not record the administration of the drug in the patient’s chart

3. Ms. Martin has received a diagnosis of myasthenia gravis and begins a regimen of ambenonium. The nursing assessment is important because the dose of the drug _____.

   - A. usually must be increased every 4 hours early in therapy
   - B. frequently is increased or decreased early in therapy
   - C. is titrated according to the patient’s blood pressure
   - D. is gradually decreased as a therapeutic response is achieved

**Medication Dosage Problems**

1. The dosage of neostigmine is 0.022 mg/kg. What dosage would the nurse expect the primary care provider to prescribe for a patient who weighs 150 pounds?

2. The primary care provider prescribes 2.5 mg of bethanechol subcutaneously. The drug is available in a solution of 5 mg/mL. The nurse administers _____.
Like adrenergic blocking drugs, the cholinergic blocking drugs have an effect on the autonomic nervous system. These drugs block the action of the neurotransmitter acetylcholine in the parasympathetic nervous system. Because parasympathetic nerves influence many areas of the body, the effects of the cholinergic blocking drugs are numerous.

Cholinergic blocking drugs also are called anticholinergics or parasympathomimetic blocking drugs. Examples of cholinergic blocking drugs include atropine, scopolamine, and propantheline.

**ACTIONS**

Cholinergic blocking drugs inhibit the activity of acetylcholine in parasympathetic nerve fibers (see Chap. 24 for a description of the role of acetylcholine in the transmission of nerve impulses across parasympathetic nerve fibers). When the activity of acetylcholine is inhibited, nerve impulses traveling along parasympathetic nerve fibers cannot pass from the nerve fiber to the effector organ or structure.

Because of the wide distribution of parasympathetic nerves, these drugs affect many organs and structures of the body, including the eyes, the respiratory and gastrointestinal tracts, the heart, and the bladder (see Display 25-1).
However, responses to administration of a cholinergic blocking drug vary and often depend on the drug and the dose used. For example, scopolamine may occasionally cause excitement, delirium, and restlessness. This reaction is thought to be a drug idiosyncrasy (an unexpected or unusual drug effect).

**USES**

Because of their widespread effect on many organs and structures of the body, cholinergic blocking drugs have a variety of uses. Some of the uses of atropine include treatment of pylorospasm, peptic ulcer, ureteral and biliary colic, vagal-induced bradycardia, parkinsonism, and preoperatively to reduce secretions of the upper respiratory tract before the administration of a general anesthetic. Other cholinergic blocking drugs have a more selective action, that is, they affect principally one structure of the body. An example of this type of drug is clidinium bromide (Quarzan), which is used only in the treatment of peptic ulcer. The Summary Drug Table: Cholinergic Blocking Drugs lists the uses of specific cholinergic blocking drugs.

**ADVERSE REACTIONS**

Dryness of the mouth with difficulty in swallowing, blurred vision, and photophobia (aversion to bright light) are commonly seen with the administration of a cholinergic blocking drug. The severity of many adverse reactions is often dose dependent, that is, the larger the dose, the more intense the adverse reaction. Even in normal doses, some degree of dryness of the mouth almost always occurs.

Constipation, caused by a decrease in intestinal motility, may occur in those taking one of these drugs on a regular basis. Drowsiness may occur with the use of these drugs, but at times this adverse reaction is desirable. For example, when atropine is preoperatively used to reduce the production of secretions in the respiratory tract, drowsiness is part of the desired response.

Other adverse reactions that may be seen with the administration of a cholinergic blocking drug include:

- **Central nervous system**—headache, flushing, nausea, drowsiness, weakness, insomnia, nasal congestion, fever
- **Eyes**—blurred vision, mydriasis, photophobia, cycloplegia, increased ocular tension
- **Gastrointestinal tract**—nausea, vomiting, difficulty in swallowing, heartburn
- **Urinary tract**—urinary hesitancy and retention, dysuria
- **Cardiovascular system**—palpitations, bradycardia (after low doses of atropine), tachycardia (after higher doses of atropine)
- **Other**—urticaria, anaphylactic shock, other skin manifestations

**CONTRAINDICATIONS**

Cholinergic blocking drugs are contraindicated in those with glaucoma because use of these drugs may lead to an attack of acute glaucoma. Unfortunately, glaucoma in its early stages may have few, if any, symptoms, and the individual may be unaware of this disorder until he or she has an eye examination. The lack of symptoms of early glaucoma combined with individuals failing to read drug labels can have serious consequences.

Other contraindications for the anticholinergics include tachyarrhythmias, myocardial infarction, and congestive heart failure (unless bradycardia is present).

**PRECAUTIONS**

Administration of these drugs can result in urinary retention. The nurse should give these drugs with great caution to patients with an enlarged prostate because urinary retention may occur. This caution applies to some over-the-counter preparations available for the relief of allergy and cold symptoms and as aids to induce sleep. Some of these products contain atropine, scopolamine, or other cholinergic blocking drugs. Although this warning is printed on the container or package, many users fail to carefully read drug labels.

The nurse should use these drugs with caution in patients with gastrointestinal infections, benign prostatic hypertrophy, hyperthyroidism, hepatic or renal disease, and hypertension. The nurse should use atropine with caution in patients with asthma. The anticholinergic drugs are classified as Pregnancy Category C drugs and are used only when the benefit to the woman outweighs the risk to the fetus.
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>atropine generic</td>
<td>Pylorospasm, reduction of bronchial and oral secretions, excessive vagal-induced bradycardia, ureteral and biliary colic</td>
<td>Drowsiness, blurred vision, tachycardia, dry mouth, urinary hesitancy</td>
<td>0.4–0.6 mg PO IM, SC, IV</td>
<td></td>
</tr>
<tr>
<td>belladonna alkaloids generic</td>
<td>Adjunctive therapy for peptic ulcer, digestive disorders, diverticulitis, pancreatitis, diarrhea</td>
<td>Drowsiness, blurred vision, tachycardia, dry mouth, urinary hesitancy</td>
<td>0.25–0.5 mg PO TID</td>
<td></td>
</tr>
<tr>
<td>clidinium bromide Quarzan</td>
<td>Adjunctive therapy for peptic ulcer</td>
<td>Drowsiness, blurred vision, tachycardia, dry mouth, urinary hesitancy</td>
<td>2.5–5 mg PO 3–4 times/d</td>
<td></td>
</tr>
<tr>
<td>dicyclomine HCl Bentyl</td>
<td>Functional bowel/irritable bowel syndrome</td>
<td>Drowsiness, blurred vision, tachycardia, dry mouth, urinary hesitancy</td>
<td>80–160 mg PO QID</td>
<td></td>
</tr>
<tr>
<td>flavoxate Urispas</td>
<td>Relieves dysuria, urgency, frequency, and pain of cystitis and prostatitis</td>
<td>Nausea, vomiting, dry mouth, nervousness, vertigo, headache, drowsiness, blurred vision</td>
<td>100–200 mg PO 3–4 times/d</td>
<td></td>
</tr>
<tr>
<td>glycopyrrolate Robinul</td>
<td>Oral: peptic ulcer Parenteral: in conjunction with anesthesia to reduce bronchial and oral secretions, to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation; protection against the peripheral muscarinic effects of cholinergic agents (eg, neostigmine)</td>
<td>Blurred vision, dry mouth, altered taste perception, nausea, vomiting, dysphagia, urinary hesitancy and retention</td>
<td>PO: 1–2 mg BID, TID Parenteral: peptic ulcer, 0.1–0.2 mg IM, IV TID, QID: preanesthesia, 0.002 mg/lb IM Intraoperative: 0.1 mg IV</td>
<td></td>
</tr>
<tr>
<td>l-hyoscyamine sulfate Levbid</td>
<td>Aids in control of gastric secretions, visceral spasm, hypermotility in spastic colitis, spastic bladder, pylorospasm, relief of symptoms in functional intestinal disorders, biliary and renal colic, peptic ulcer, irritable bowel syndrome, neurogenic colon, pancreatitis</td>
<td>Drowsiness, blurred vision, tachycardia, dry mouth, urinary hesitancy</td>
<td>0.125–0.25 mg PO or sublingually 3 or 4 times/d; 0.375–0.75 mg sustained-release form q12h; 0.25–0.5 mg SC, IM, or IV 2–4 times/d</td>
<td></td>
</tr>
<tr>
<td>mepenzolate bromide Cantil</td>
<td>Adjunctive treatment of peptic ulcer</td>
<td>Drowsiness, blurred vision, tachycardia, dry mouth, urinary hesitancy</td>
<td>25–50 mg PO TID–QID with meals and at bedtime</td>
<td></td>
</tr>
<tr>
<td>methantheline bromide Banthine</td>
<td>Adjunctive treatment for peptic ulcer, hypertonic neurogenic bladder</td>
<td>Drowsiness, blurred vision, tachycardia, dry mouth, urinary hesitancy</td>
<td>50–100 mg PO q6h</td>
<td></td>
</tr>
<tr>
<td>methscopolamine meths-coe-pol`a-meen Pamine</td>
<td>Adjunctive therapy for peptic ulcer</td>
<td>Drowsiness, blurred vision, tachycardia, dry mouth, urinary hesitancy</td>
<td>2.5 mg 30 minutes AC and 2.5–5 mg HS PO</td>
<td></td>
</tr>
<tr>
<td>propantheline bromide Pro-Banthine, generic</td>
<td>Adjunctive therapy for peptic ulcer</td>
<td>Dry mouth, constipation, hesitancy, urinary retention, blurred vision</td>
<td>15 mg PO 30 minutes AC and HS</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
administration of atropine with meperidine (Demerol), flurazepam (Dalmane), diphenhydramine (Benadryl), phenothiazines, and the tricyclic antidepressants may increase the effects of atropine. There is a decreased effectiveness of haloperidol when administered with the anticholinergic drugs.

**ASSESSMENT**

**Preadministration Assessment**
Before administering a cholinergic blocking drug to a patient for the first time, the nurse obtains a thorough health history as well as a history of the signs and symptoms of the current disorder. The focus of the initial physical assessment depends on the reason for administering the drug. In most instances, the nurse obtains the blood pressure, pulse, and respiratory rate. The nurse also may include additional assessments, such as checking the stool of the patient who has a peptic ulcer for color and signs of occult blood, determining visual acuity in the patient with glaucoma, or looking for signs of dehydration and weighing the patient if prolonged diarrhea is one of the patient’s symptoms.

**Ongoing Assessment**
When administering a cholinergic blocking drug, the daily ongoing assessment requires that the nurse closely observes the patient. The nurse checks vital signs, observes for adverse drug reactions, and evaluates the symptoms and complaints related to the patient’s diagnosis. For example, the nurse questions the patient with a peptic ulcer regarding current symptoms, then makes a comparison of these symptoms to the symptoms present before the start of therapy. The nurse reports any increase in the severity of symptoms to the primary health care provider immediately.

**PLANNING**
The expected outcomes for the patient depend on the reason for administration of a cholinergic blocking drug but may include an optimal response to therapy, management of common adverse drug reactions, maintenance of oral mucous membrane integrity, and an understanding of and compliance with the prescribed therapeutic regimen.

---

### Nursing Diagnoses Checklist

- Disturbed Sensory Perception: Visual related to adverse drug reaction
- Impaired Oral Mucous Membranes related to drug action on mucous membranes
- Risk for Injury related to effect of drug
- Constipation related to slowing of peristalsis in the gastrointestinal tract
IMPLEMENTATION

Promoting an Optimal Response to Therapy
THE PATIENT WITH HEART BLOCK. The patient receiving atropine for third-degree heart block is placed on a cardiac monitor during and after administration of the drug. The nurse watches the monitor for a change in pulse rate or rhythm. Tachycardia, other cardiac arrhythmias, or failure of the drug to increase the heart rate must be reported to the primary health care provider immediately because other drugs or medical management may be necessary.

THE PATIENT RECEIVING A PREOPERATIVE DRUG. If a cholinergic blocking drug is administered preoperatively, the nurse instructs the patient to void before the drug is given. The nurse informs the patient that his or her mouth will become extremely dry, that this is normal, and that fluid is not to be taken. The side rails of the bed are raised, and the patient is instructed to remain in bed after administration of the preoperative drug.

Nursing Alert
The nurse must administer the preoperative drug at the exact time prescribed because the cholinergic blocking drug must be allowed to produce the greatest effect (ie, the drying of upper respiratory and oral secretions) before the administration of a general anesthetic. The anesthesiologist must be notified if the preoperative drug is given late.

Gerontologic Alert
Cholinergic blocking drugs are usually not included in the preoperative drugs of patients older than 60 years because of the effects of these drugs on the eye and the central nervous system.

Monitoring and Managing Adverse Reactions
Because this group of drugs may have widespread effects, the nurse must closely observe all patients for the appearance of adverse drug reactions. In hot weather, sweating may decrease and may be followed by heat prostration. The nurse observes the patient at frequent intervals for signs of heat prostration (see Adverse Reactions), especially if the patient is elderly or debilitated. The nurse withholds the next dose of the drug and contacts the primary health care provider immediately if heat prostration is suspected. The nurse observes the elderly patient receiving a cholinergic blocking drug at frequent intervals for excitement, agitation, mental confusion, drowsiness, urinary retention, or other adverse effects. If any of these should occur, it is important to withhold the next dose of the drug and contact the primary health care provider. The nurse ensures patient safety until these adverse reactions disappear.

Gerontologic Alert
The nurse observes the elderly patient receiving a cholinergic blocking drug at frequent intervals for excitement, agitation, mental confusion, drowsiness, urinary retention, or other adverse effects. If any of these should occur, it is important to withhold the next dose of the drug and contact the primary health care provider. The nurse ensures patient safety until these adverse reactions disappear.

MANAGING ALTERATION IN VISUAL ACUITY. Blurred vision and photophobia are commonly seen with the administration of a cholinergic blocking drug. The severity of this adverse reaction is often dose dependent, that is, the larger the dose, the more intense the adverse reaction. The nurse monitors the patient for any disturbance in vision. The patient may need assistance when ambulating. If photophobia is a problem, the patient may need to wear shaded glasses when going outside, even on cloudy days. The rooms are kept dimly lit and curtains or blinds closed to eliminate bright sunlight in the room.

Gerontologic Alert
For elderly patients, as well as those experiencing visual difficulties, the nurse places against the walls any items of furniture (eg, footstools, chairs, stands) that obstruct ambulatory areas. Throw rugs should be removed.

MANAGING IMPAIRED ORAL MUCOUS MEMBRANES. When taking these drugs on a daily basis, mouth dryness may be severe and extremely uncomfortable in some patients. The patient may have moderate to extreme difficulty swallowing oral drugs and food. The nurse encourages the patient to take a few sips of water before and while taking an oral drug and to sip water at intervals during meals. If allowed, hard candy slowly dissolved in the mouth and frequent sips of water during the day may help relieve persistent oral dryness. The nurse checks the oral cavity daily for soreness or ulcerations.

MINIMIZING RISK FOR INJURY. These drugs may cause drowsiness, dizziness, and blurred vision. Patients (especially the elderly) may require assistance with ambulation. For elderly patients, as well as those experiencing visual difficulties, the nurse places items of furniture (eg, footstools, chairs, stands) that obstruct ambulatory areas against the wall. Those with photophobia may be more comfortable in a semi-darkened room, especially on sunny days. It is a
good idea to use overhead lights as little as possible. Mydriasis and cycloplegia, if they occur, may interfere with reading, watching television, and similar activities. If these drug effects upset the patient, the nurse discusses the problem with the primary health care provider. At times, these visual impairments will have to be tolerated because drug therapy cannot be changed or discontinued. The nurse attempts to find other forms of diversional therapy, such as interaction with other patients or listening to the radio.

MANAGING CONSTIPATION. Constipation caused by decreased gastric motility can be a problem with cholinergic drugs. The nurse urges the patient to increase fluid intake up to 2000 mL daily (if health conditions permit), eat a diet high in fiber, and obtain adequate exercise. The primary health care provider may prescribe a stool softener, if necessary, to prevent constipation.

Educating the Patient and Family
A cholinergic blocking drug may be prescribed for a prolonged period. Some patients may discontinue drug use, especially if their original symptoms have been relieved. The nurse must make sure that the patient and family understand the prescribed drug is to be taken even though symptoms have been relieved.

When a cholinergic blocking drug is prescribed for outpatient use, the nurse informs the patient about the more common adverse reactions associated with these drugs, such as dry mouth, drowsiness, dizziness, and visual impairments. The nurse warns the patient that if drowsiness, dizziness, or blurred vision occurs, caution must be observed while driving or performing other tasks requiring alertness and good vision.

Some of the adverse reactions associated with the cholinergic blocking drugs may be uncomfortable or distressing. The nurse encourages the patient to discuss these problems with the primary health care provider. The nurse makes suggestions to lessen the intensity of some of these adverse reactions.

The following is a list of adverse reactions that can be included in the teaching plan, along with the measures that may lessen their intensity or allow the patient to perform tasks at times when these adverse reactions are least likely to occur.

- Photophobia—Wear sunglasses when outside, even on cloudy days, keep rooms dimly lit, and close curtains or blinds to eliminate bright sunlight in the room; soft indirect lighting is usually more comfortable. Schedule outdoor activities (when necessary) before the first dose of the drug is taken, such as early in the morning.
- Dry mouth—Take frequent sips of cool water during the day, before taking the drug orally, and during meals. In addition, if allowed, chew gum or dissolve hard candy in the mouth (see Home Care Checklist: Combating Dry Mouth).
- Constipation—It is a good idea to drink plenty of fluids during the day, exercise if approved by the primary health care provider, and eat foods high in fiber.

<table>
<thead>
<tr>
<th>Home Care Checklist</th>
<th>COMBATING DRY MOUTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perform frequent mouth care, including brushing, rinsing, and flossing.</td>
<td>• Photophobia—Wear sunglasses when outside, even on cloudy days, keep rooms dimly lit, and close curtains or blinds to eliminate bright sunlight in the room; soft indirect lighting is usually more comfortable. Schedule outdoor activities (when necessary) before the first dose of the drug is taken, such as early in the morning.</td>
</tr>
<tr>
<td>Keep a glass or sports bottle filled with fluid on hand at all times.</td>
<td>- Dry mouth—Take frequent sips of cool water during the day, before taking the drug orally, and during meals. In addition, if allowed, chew gum or dissolve hard candy in the mouth (see Home Care Checklist: Combating Dry Mouth).</td>
</tr>
<tr>
<td>Sip small amounts of cool water or fluids throughout the day and with meals.</td>
<td>- Constipation—It is a good idea to drink plenty of fluids during the day, exercise if approved by the primary health care provider, and eat foods high in fiber.</td>
</tr>
<tr>
<td>Take a few sips of water before taking any oral drugs.</td>
<td></td>
</tr>
<tr>
<td>Suck on ice chips or frozen ices, such as Popsicles.</td>
<td></td>
</tr>
<tr>
<td>Chew gum.</td>
<td></td>
</tr>
<tr>
<td>Suck on sugar-free hard candies.</td>
<td></td>
</tr>
<tr>
<td>Avoid alcohol-based mouthwashes.</td>
<td></td>
</tr>
</tbody>
</table>
Heat prostration—Avoid going outside on hot, sunny days; use fans to cool the body if the day is extremely warm; sponge the skin with cool water if other cooling measures are not available; and wear loose-fitting clothes in warm weather.

Drowsiness—Schedule tasks requiring alertness during times when drowsiness does not occur, such as early in the morning before the first dose of the drug is taken.

The patient complies with the prescribed drug regimen.

No evidence of injury is seen.

The patient and family demonstrate an understanding of the drug regimen.

The patient verbalizes the importance of complying with the prescribed therapeutic regimen.

Critical Thinking Exercises

1. Mr. Anthony is prescribed a cholinergic blocking drug for the treatment of peptic ulcer. In planning patient teaching for Mr. Anthony before dismissal from the hospital, determine what information must be included to prevent complications of therapy.

2. A nurse assistant asks you what is the purpose of preoperative drugs and why patients cannot get out of bed after receiving a preoperative drug. Describe how you would explain this to the nurse assistant.

3. Mr. Salinas is prescribed a cholinergic blocking drug for a gastric ulcer. You note in the admission interview that he states that he has a history of enlarged prostate. Discuss how Mr. Salinas' history of enlarged prostate relates to the drug therapy for a gastric ulcer.

4. Develop a teaching plan for Ms. Likens, age 54 years, who will be taking glycopyrrolate (Robinul) for a peptic ulcer. Ms. Likens is alert, well oriented, and teaches school at a local high school.

Review Questions

1. A patient taking clidinium for a peptic ulcer complains of dry mouth. The nurse should _____.
   A. consider this to be unusual and contact the primary care provider
   B. encourage the patient to take frequent sips of water
   C. give the patient salt-water mouth rinses
   D. ignore this reaction because it is only temporary

2. Which of the following adverse reactions would the nurse expect after the administration of atropine as part of a patient’s preoperative medication regimen? The nurse expect after the administration of atropine as part of a patient’s preoperative medication regimen?
   A. enhance the action of anesthesia
   B. reduce secretions of the upper respiratory tract
   C. prolong the action of the preoperative narcotic
   D. increase gastric motility

3. Because of the effect of cholinergic blocking drugs on intestinal motility, the nurse must monitor the patient taking these drugs for the development of _____.
   A. esophageal ulcers
   B. diarrhea
C. heartburn
D. constipation

4. Anticholinergic drugs are contraindicated in patients with _____.
   A. gout
   B. glaucoma
   C. diabetes
   D. bradycardia

---

**Medication Dosage Problems**

1. A patient is prescribed glycopyrrolate 0.1 mg. The drug is available in a solution of 0.2 mg/mL. The nurse administers _____.

2. Trihexyphenidyl 4 mg PO is ordered. The drug is available as an elixir with a strength of 2 mg/5 mL. The nurse administers _____.
Sedatives and Hypnotics

**Key Terms**
- ataxia
- detoxified
- hypnotic
- sedative
- soporifics

**Chapter Objectives**

On completion of this chapter, the student will:

- Differentiate between a sedative and a hypnotic.
- Discuss the uses, general drug actions, adverse reactions, contraindications, precautions, and interactions of the barbiturates and miscellaneous sedatives and hypnotics.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking a sedative or hypnotic.
- List some nursing diagnoses particular to a patient taking a sedative or hypnotic.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating patients about the use of a sedative or hypnotic.

A **sedative** is a drug that produces a relaxing, calming effect. Sedatives are usually given during daytime hours, and although they may make the patient drowsy, they usually do not produce sleep. A **hypnotic** is a drug that induces sleep, that is, it allows the patient to fall asleep and stay asleep. Hypnotics also may be called **soporifics**. Hypnotics are given at night or hour of sleep (HS).

Sedatives and hypnotics may be divided into two classes: barbiturates and miscellaneous sedatives and hypnotics. The barbiturates are divided into several groups, depending on their duration of action:

- **Ultrashort-acting** (eg, thiamylal [Surital], thiopental [Pentothal]). The ultrashort-acting barbiturates are used as anesthetics (see Chap. 35). Single doses have a duration of 20 minutes or less.
- **Short-acting** (eg, secobarbital [Seconal], pentobarbital [Nembutal]). The average duration of action of the short-acting barbiturates is 3 to 4 hours.
- **Intermediate-acting** (eg, amobarbital [Amytal], aprobarbital [Aurat], butabarbital [Butisol]). The average duration of action of the intermediate-acting barbiturates is 6 to 8 hours.
- **Long-acting** (eg, phenobarbital, mephobarbital [Mebaral]). The average duration of action of the long-acting barbiturates is 10 to 16 hours.

The Summary Drug Table: Sedatives and Hypnotics: Barbiturates gives examples of the short-, intermediate-, and long-acting barbiturate sedatives and hypnotics.

The miscellaneous sedatives and hypnotics consist of a group of nonrelated drugs and a second group called the benzodiazepines. Examples of the nonrelated group of drugs include ethchlorvynol (Placidyl), zaleplon (Sonata), and zolpidem (Ambien). The benzodiazepines are also called antianxiety drugs (see Chap. 30). Examples of the benzodiazepines include estazolam (Prosom), flurazepam (Dalmane), and quazepam (Doral). The miscellaneous sedatives and hypnotics are listed in the Summary Drug Table: Miscellaneous Sedatives and Hypnotics.

**ACTIONS**

**Barbiturates**

All barbiturates have essentially the same mode of action. Depending on the dose given, these drugs are capable of producing central nervous system (CNS) depression and mood alteration ranging from mild excitation to mild sedation, hypnosis (sleep), and deep coma. These drugs also are respiratory depressants; the degree of depression...
usually depends on the dose given. When these drugs are used as hypnotics, their respiratory depressant effect is usually similar to that occurring during sleep.

The sedative or hypnotic effects of the barbiturates diminishes after approximately 2 weeks. Persons taking these drugs for periods longer than 2 weeks may have a tendency to increase the dose to produce the desired effects (e.g., sleep, sedation). Physical and psychological dependence may occur, especially after prolonged use of high doses. Discontinuing use of a barbiturate after prolonged use may result in severe, and sometimes fatal, withdrawal symptoms.

### Effect of the Barbiturates on Sleep

Sleep occurs in four stages that include varying degrees of wakefulness followed by deeper sleep throughout the sleep cycle. The stages in the sleep cycle fall into two areas: rapid eye movement (REM) sleep and nonrapid eye movement (NREM) sleep. NREM sleep occurs mostly in the early hours of sleep; REM sleep tends to lengthen progressively during the later hours of sleep.

Dreaming occurs mostly during the REM stage of sleep. Dreams appear to be a necessary part of sleep, and when an individual is deprived of dreaming for a prolonged period, a psychosis can develop. Sleep induced by a barbiturate reduces the amount of time spent in the REM stage (the dreaming stage) of sleep. A brunt discontinuation of the barbiturates can cause increased dreaming, nightmares, or insomnia.

### Miscellaneous Sedatives and Hypnotics

Miscellaneous or nonbarbiturate sedatives and hypnotics have essentially the same mode of action as the barbiturates, that is, they depress the CNS. However,
the miscellaneous sedatives and hypnotics have a lesser effect on the respiratory rate. Like the barbiturates, the miscellaneous drugs’ sedative or hypnotic effects diminish after approximately 2 weeks. Persons taking these drugs for periods longer than 2 weeks may have a tendency to increase the dose to produce the desired effects (e.g., sleep, sedation). Physical and psychological dependence may occur, especially after prolonged use of high doses. However, their addictive potential appears to be less than that of the barbiturates. Discontinuing use of a miscellaneous sedative or hypnotic after prolonged use may result in mild to severe withdrawal symptoms.

**USES**

According to the National Sleep Foundation, insomnia affects nearly 84 million people. It may be caused by lifestyle changes, such as a new job or moving to a new
town, returning to school, jet lag, pain from arthritis or headaches, stress, or anxiety. The sedatives and hypnotics are primarily used to treat insomnia.

During hospitalization, helping the patient sleep is an important part of the management of illness. Hospitalized patients are in unfamiliar surroundings that are unlike the home situation. There are noises and lights at night, which often interfere with or interrupt sleep. Sleep deprivation may interfere with the healing process; therefore, a hypnotic may be given. These drugs also may be prescribed for short-term use as hypnotics after discharge from the hospital.

Zaleplon, a miscellaneous sedative, is the first prescription sleep preparation that the patient can take, later in the night, if you have at least 4 hours in bed before you become active again. With zaleplon the patient will fall asleep quickly and wake up with little or no aftereffects of the drug.

A hypnotic may be given the night before the operation to prepare the patient for surgery. On the day of surgery, a barbiturate or miscellaneous sedative and hypnotic may be used either alone or with other drugs as part of the preoperative regimen. The anesthesiologist or surgeon selects a drug that is tailored to the patient's needs. When a barbiturate or miscellaneous sedative and hypnotic is used as a hypnotic, a dose larger than that required to produce sedation is given.

Gerontologic Alert

Elderly patients may require a smaller hypnotic dose, and, in some instances, a sedative dose produces sleep.

Although the use of barbiturates and miscellaneous sedatives and hypnotics for sedation has largely been replaced by the antianxiety drugs (see Chap. 30), they occasionally may be used to provide sedation before certain types of procedures, such as cardiac catheterization or the administration of a local or general anesthesia. Sedative doses, usually given during daytime hours, may be used to treat anxiety and apprehension. Patients with chronic disease may require sedation, not only to reduce anxiety, but also as an adjunct in the treatment of their disease.

Paraldehyde, a miscellaneous sedative and hypnotic, may be used to treat delirium tremens and other psychiatric conditions. In addition, some barbiturates are used as anticonvulsants (see Chap. 28).

ADVERSE REACTIONS

Barbiturates

Adverse reactions associated with barbiturate administration include:

- CNS—somnolence, agitation, confusion, CNS depression, ataxia, nightmares, lethargy, residual sedation (drug hangover), hallucinations, paradoxical excitement
- Respiratory—hypoventilation, apnea, respiratory depression, bronchospasm, laryngospasm
- Gastrointestinal—nausea, vomiting, constipation, diarrhea, epigastric pain
- Cardiovascular—bradycardia, hypotension, syncope
- Hypersensitivity—rash, angioneurotic edema, fever, urticaria
- Other—headache and liver damage.

Miscellaneous Sedatives and Hypnotics

Adverse reactions associated with administration of the miscellaneous sedatives and hypnotics vary depending on the drug used. Common adverse reactions include dizziness, drowsiness, headache, and nausea. Other adverse reactions that may be seen with the administration of miscellaneous sedatives and hypnotics are listed in the Summary Drug Table: Miscellaneous Sedatives and Hypnotics.

CONTRAINDICATIONS

These drugs are contraindicated in patients with known hypersensitivity to the sedatives or hypnotics. The nurse should not administer these drugs to comatose patients, those with severe respiratory problems, those with a history of drug and alcohol abuse, or to pregnant or lactating women. The barbiturates (eg, amobarbital, butabarbital, secobarbital) are classified as Pregnancy Category D drugs. Most miscellaneous sedatives and hypnotics (eg, zolpidem, chloral hydrate, zaleplon) are Pregnancy Category C drugs. Some benzodiazepines (eg, estazolam, quazepam, temazepam, triazolam) are classified as Pregnancy Category X drugs and can cause damage to the developing fetus if administered during pregnancy.

Nursing Alert

Women taking the barbiturates or the benzodiazepines should be warned of the potential risk to the fetus so that contraceptive methods may be instituted, if necessary. A child born to a mother taking benzodiazepines may develop withdrawal symptoms during the postnatal period.

PRECAUTIONS

All drugs entering the body ultimately leave the body. Some leave virtually unchanged, whereas others are transformed into other, less-potent chemicals or compounds detoxified (to make nontoxic or not harmful) before they are eliminated. Barbiturates and miscellaneous sedatives and hypnotics are detoxified by the liver
and ultimately excreted by the kidney. These drugs are given with great caution to patients with liver or kidney disease because their diseased organs will not be able to detoxify or eliminate the drug, and a drug build-up will occur. The barbiturates should be administered with extreme caution to patients with a history of drug abuse (eg, alcoholics and opiate abusers) or mental illness. If the drugs are prescribed on an outpatient basis, the amount dispensed is limited to the amount needed until the next appointment. These drugs should be used with great caution during lactation. Drowsiness in infants of breastfeeding mothers who have taken the barbiturates has been reported.

**INTERACTIONS**

The sedatives and hypnotics have an additive effect when administered with alcohol, antidepressants, narcotic analgesics, antihistamines, or phenothiazines.

**Gerontologic Alert**

The nurse uses these drugs cautiously in older adults or in those who are debilitated because these patients are more sensitive to the effects of the sedatives or hypnotics.

**Nursing Alert**

Because narcotic analgesics depress the CNS (see Chap. 19), the nurse should not administer a barbiturate or miscellaneous sedatives and hypnotics approximately 2 hours before or after administration of a narcotic analgesic or other CNS depressant. If the time interval between administration of a narcotic analgesic and a sedative or hypnotic is less than 2 hours, the patient may experience severe respiratory depression, bradycardia, and unresponsiveness.

**Health Supplement Alert: Melatonin**

Melatonin is a hormone produced by the pineal gland in the brain. The use of melatonin obtained from animal pineal tissue is not recommended because of the risk of contamination. The synthetic form of melatonin does not carry this risk. However, melatonin is an over-the-counter dietary supplement and has not been evaluated for safety, effectiveness, and purity by the FDA. All of the potential risks and benefits may not be known. Supplements should be purchased from a reliable source to minimize the risk of contamination. Melatonin has been used in treating insomnia, overcoming jet lag, improving the effectiveness of the immune system, and as an antioxidant. The most significant use is for the short-term treatment of insomnia at low doses. Individuals wishing to use melatonin should consult with their primary health care provider or a pharmacist before using the supplement. Possible adverse reactions include headache and depression. Drowsiness may occur within 30 minutes after taking the herb. The drowsiness may persist for an hour or more, affecting any activity that requires mental alertness, such as driving. Although uncommon, allergic reactions to melatonin have been reported. The supplement should be stopped and emergency care sought if symptoms of an allergic reaction (eg, difficulty breathing, hives, or swelling of lips, tongue, or face) occur.

**Herbal Alert: Valerian**

Valerian was originally used in Europe and was brought on the Mayflower to North America. The herb is widely used for its sedative effects in conditions of mild anxiety or restlessness. It is particularly useful in individuals with insomnia. Valerian improves overall sleep quality by shortening the length of time it takes to go to sleep and decreasing the number of nighttime awakenings. It does not cause the adverse reactions common with sedative drugs, such as addiction and “drug hangovers” the morning after taking the herb. Valerian is classified as generally recognized as safe (GRAS) for use in the United States. Valerian is used as a tea, tablet, capsule, or tincture. When valerian is used as an aid to sleep, the herb is taken approximately 1 hour before bedtime. The dose is less if used for anxiety, and the herb can be used in combination with other calming herbs, such as lemon balm or chamomile. It may take 2 to 4 weeks before the full therapeutic effect (ie, improvement of mood and sleep patterns) of the herb occurs. Dosages include the following:

- **Tea:** 1 to 2 cups/day
- **Capsules/tablets:** 300 to 500 mg daily
- **Tincture:** ½ to 1 teaspoon daily
- **Standardized extract:** 300 to 400 mg daily

**NURSING PROCESS**

- **The Patient Receiving a Sedative or Hypnotic**

**ASSESSMENT**

A assessment of the patient receiving a sedative or hypnotic drug depends on the reason for administration and whether the drug is given routinely or as needed.

**Preadministration Assessment**

Before administering a barbiturate or miscellaneous sedative and hypnotic, the nurse takes and records the patient’s blood pressure, pulse, and respiratory rate. In addition to the vital signs, the nurse assesses the following patient needs.

- Is the patient uncomfortable? If the reason for discomfort is pain, an analgesic, rather than a hypnotic, may be required.
- Is it too early for the patient to receive the drug? Is a later hour preferred?
- Does the patient receive a narcotic analgesic every 4 to 6 hours? A hypnotic may not be necessary because a narcotic analgesic is also capable of causing drowsiness and sleep.
• Are there disturbances in the environment that may keep the patient awake and decrease the effectiveness of the drug?

Barbiturates have little or no analgesic action, so the nurse does not give these drugs if the patient has pain and cannot sleep. Barbiturates, when given in the presence of pain, may cause restlessness, excitement, and delirium.

If the patient is receiving one of these drugs for daytime sedation, the nurse assesses the patient's general mental state and level of consciousness. If the patient appears sedated and difficult to awaken, the nurse withholds the drug and contacts the primary health care provider as soon as possible.

**Ongoing Assessment**

Before administering the drug each time, the nurse should perform an assessment to include the patient's vital signs (temperature, pulse, respirations, and blood pressure) and level of consciousness (is the patient alert, confused, or lethargic). This is especially important when the drug is ordered to be given as needed. After assessing the patient, the nurse makes a decision regarding administration of the drug.

The nurse checks to see if the drug helped the patient sleep on previous nights. If not, a different drug or dose may be needed, and the nurse should consult the primary health care provider regarding the drug's ineffectiveness.

If the patient has an order for a PRN narcotic analgesic or other CNS depressant and a hypnotic, the nurse should consult the primary health care provider regarding the time interval between administration of these drugs. Usually at least 2 hours should elapse between administration of a hypnotic and any other CNS depressant, but this interval may vary, depending on factors such as the patient's age and diagnosis.

**Nursing Alert**

The nurse withholds the drug and notifies the primary health care provider if any one or more vital signs significantly varies from the database, if the respiratory rate is 10/min or below, or if the patient appears lethargic. In addition, it is important to determine if there are any factors (eg, noise, lights, pain, discomfort) that would interfere with sleep and whether these may be controlled or eliminated.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes for the patient depend on the reason for administration of a sedative or hypnotic but may include an optimal response to drug therapy (eg, sedation or sleep), management of adverse drug reactions, an absence of drug dependence, and an understanding of and compliance with the postdischarge drug regimen (when applicable).

**IMPLEMENTATION**

Promoting an Optimal Response to Therapy

**ENHANCING SLEEP PATTERNS.** To promote the effects of the sedative or hypnotic the nurse provides supportive care, such as back rubs, night lights or a darkened room, and a quiet atmosphere. The patient is discouraged from drinking beverages containing caffeine, such as coffee, tea, or cola drinks, which can contribute to wakefulness.

The nurse never leaves hypnotics and sedatives at the patient's bedside to be taken at a later hour; hypnotics and sedatives are controlled substances (see Chap. 1). In addition, the nurse never leaves these drugs unattended in the nurses' station, hallway, or other areas to which patients, visitors, or hospital personnel have direct access. If these drugs are prepared in advance, it is important to place them in a locked cupboard until the time of administration.

When giving these drugs orally, the nurse encourages the patient to drink a full glass of water with the drug. When barbiturates are administered intramuscularly, the nurse gives the drug in the gluteus maximus, vastus lateralis, or other areas where there is little risk of encountering a nerve trunk or major artery. Injection near or into peripheral nerves results in permanent nerve damage. When giving oral paraldehyde, the nurse mixes the drug with cold orange or tomato juice to eliminate some of the pungent taste. When paraldehyde is ordered for rectal administration, the nurse dissolves the dose of the drug (usually 10–20 mL) in one to two parts of oil or isotonic sodium chloride and gives it as a retention enema.

**PREVENTING INJURY.** After administration of a hypnotic, the nurse raises the side rails and advises the patient to remain in bed and to call for assistance if it is necessary to get out of bed. Patients receiving sedative doses may or may not require this safety measure, depending on the patient's response to the drug. The nurse assesses the
patient receiving a sedative dose and determines what safety measures must be taken. The nurse assesses the patient receiving a hypnotic 1 to 2 hours after the drug is given to evaluate the effect of the drug.

**Monitoring and Managing Adverse Drug Reactions**  
It is important that the nurse observes the patient for adverse drug reactions. During periods when the patient is excited or confused, the nurse protects the patient from harm and provides supportive care and a safe environment. The nurse notifies the primary health care provider if the patient fails to sleep, awakens one or more times during the night, or develops an adverse drug reaction. In some instances, supplemental doses of a hypnotic may be ordered if the patient awakens during the night.

Excessive drowsiness and headache the morning after a hypnotic has been given (drug hangover) may occur in some patients. The nurse reports this problem to the primary health care provider because a smaller dose or a different drug may be necessary. The nurse assists the patient with ambulation, if necessary. When getting out of bed the patient is encouraged to rise to a sitting position first, wait a few minutes, then rise to a standing position.

**Gerontologic Alert**  
The older adult is at greater risk for oversedation, dizziness, confusion, or ataxia (unsteady gait) when taking a sedative or hypnotic. The nurse checks elderly and debilitated patients for marked excitement, CNS depression, and confusion. If excitement or confusion occurs, the nurse observes the patient at frequent intervals (as often as every 5-10 minutes may be necessary) for the duration of this occurrence and institutes safety measures to prevent injury. If oversedation, extreme dizziness, or ataxia occurs, the nurse notifies the primary health care provider.

**MONITORING AND MANAGING RESPIRATORY DEPRESSION.** These drugs depress the CNS and can cause respiratory depression. The nurse carefully assesses respiratory function (rate, depth, and quality) before administering a sedative, ½ to 1 hour after administering the drug, and frequently thereafter. Toxic reaction of the barbiturates can cause severe respiratory depression, hypoventilation, and circulatory collapse.

**Nursing Alert**  
The onset of symptoms of barbiturate toxicity may not occur until several hours after the drug is administered. Symptoms of acute toxicity include CNS and respiratory depression, constriction or paralytic dilation of the pupils, tachycardia, hypotension, lowered body temperature, oliguria, circulatory collapse, and coma. The nurse should report any symptoms of toxicity to the primary health care provider immediately.

Treatment of barbiturate toxicity is mainly supportive (ie, maintaining a patent airway, oxygen administration, monitoring vital signs and fluid balance). The patient may require treatment for shock, respiratory assistance, administration of activated charcoal, and in severe cases of toxicity, hemodialysis.

**MANAGING DRUG DEPENDENCY.** Sedatives and hypnotics are best given for no more than 2 weeks and preferably for a shorter time. However, a barbiturate or miscellaneous sedative and hypnotic can cause drug dependency. The nurse must never suddenly discontinue use of these drugs when there is a question of possible dependency. Patients who have been taking a sedative or hypnotic for several weeks should be gradually withdrawn from the drug to prevent withdrawal symptoms. Symptoms of withdrawal include restlessness, excitement, euphoria, and confusion. Withdrawal can result in serious consequences, especially in those with existing diseases or disorders.

**Educating the Patient and Family**  
In educating the patient and family about barbiturates and miscellaneous sedatives and hypnotics, several general points must be considered, as well as teaching about two common abuses of these drugs.

The nurse gives the patient and family an explanation of the prescribed drug and dosage regimen, as well as situations that should be avoided. The nurse develops a teaching plan to include one or more of the following items of information:

**GENERAL TEACHING POINTS**

- Do not drink any alcoholic beverage 2 hours before, with, or 8 hours after taking the drug.
- If the drug appears to be ineffective, contact the primary health care provider. Do not increase the dose unless advised to do so by the primary health care provider.
- Notify the primary health care provider if any adverse drug reactions occur.
- The primary health care provider usually prescribes these drugs for short-term use only.
- When taking the drug as a sedative, be aware that the drug can impair the mental and physical abilities required for performing potentially dangerous tasks, such as driving a car or operating machinery.
- Observe caution when getting out of bed at night after taking a drug for sleep. Keep the room dimly lit and remove any obstacles that may result in injury when getting out of bed. Never attempt to drive or perform any hazardous task after taking a drug intended to produce sleep.
- Do not use these drugs if you are pregnant, considering becoming pregnant, or breastfeeding.
• Do not use over-the-counter (OTC) cold, cough, or allergy drugs while taking this drug unless their use has been approved by the primary health care provider. Some of these products contain antihistamines or other drugs that also may cause mild to extreme drowsiness. Others may contain an adrenergic drug, which is a mild stimulant, and therefore will defeat the purpose of the drug.

ZALEPLON
• Zaleplon may be taken at bedtime or later in the night if the you have at least 4 hours of bedtime left. You will still wake up naturally without excessive drowsiness in the morning.
• Zaleplon should not be given with a high fat meal or snack because fat interferes with absorption of the drug.

TEACHING ABOUT ABUSE. Sedatives and hypnotics are subject to abuse when taken on an outpatient basis. The most common abuses are increasing the dose of the drug and drinking an alcohol beverage shortly before or after taking the sedative or hypnotic. The nurse emphasizes the importance of not increasing the dosage of the drug and the dangers of consuming alcohol while taking a sedative or hypnotic.

Increasing the Dosage. Sedatives and hypnotics can become less effective after they are taken for a period of time. Thus, there may be a tendency to increase the dose without consulting the primary health care provider. To ensure compliance with the treatment regimen, the nurse emphasizes the importance of not increasing the dosage of the drug and the dangers of consuming alcohol while taking a sedative or hypnotic.

Use With Alcohol. Alcohol is a CNS depressant, as are the sedatives and hypnotics. When alcohol and a sedative or hypnotic are taken together, there is an additive effect and an increase in CNS depression, which has, on occasion, resulted in death. The nurse must emphasize the importance of not drinking alcohol while taking this drug and stress that the use of alcohol and any one of these drugs can result in serious effects.

EVALUATION
• The therapeutic effect is achieved and the sleep pattern improved.
• Adverse drug reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
• The patient is free of drug dependence.
• The patient and family demonstrate an understanding of the drug regimen.
• The patient verbalizes the importance of complying with the prescribed therapeutic regimen.
• The patient verbalizes an understanding of what to avoid while taking the drug.

Critical Thinking Exercises
1. Ms. Parker's husband was killed in an automobile accident, and she has had trouble coping with her loss. She complains of being unable to sleep for more than an hour before she wakes. The primary health care provider prescribes a hypnotic, one capsule per night for use during the next 3 weeks. In 2 weeks, she calls the primary health care provider's office and asks for a refill of her prescription. Determine what questions you would ask Ms. Parker. Explain why you would ask them.
2. Mr. Davidson, who is 67 years old, is to be discharged after major bowel surgery. The primary health care provider gives him a prescription for 24 tablets of zolpidem (Ambien). When reading Mr. Davidson's chart you note that he works part time on weekends as a bartender. Discuss what you would emphasize when explaining the prescription to Mr. Davidson.
3. Mr. Allen, who is hospitalized in the coronary care unit with a myocardial infarction, is restless and tells you that although he has been able to sleep other nights while in the hospital, he is unable to sleep tonight. Although he has an order for flurazepam (Dalmane) 30 mg HS, analyze what you would investigate before making a decision regarding administration of the hypnotic.
4. Discuss and give a rationale for situations or conditions in which sedatives would be contraindicated.
5. Explain why sedatives or hypnotics must be given cautiously in older adults.

Review Questions
1. Ms. Brown has arthritis in her lower back, and the pain keeps her awake at night. She asks if she can have a “sleeping pill.” In considering her request the nurse must take into account that _____.
   A. barbiturates, if given in the presence of pain, may cause excitement or delirium
   B. a hypnotic may be given instead of an analgesic to relieve her pain
   C. hypnotics often increase the pain threshold
   D. a hypnotic plus an analgesic is best given in this situation
2. Which of these drugs can be given at bedtime or later during the night if the patient is unable to sleep and has at least 4 hours left to sleep?
   A. temazepam
   B. estazolam
   C. zaleplon
   D. zolpidem

3. When giving a hypnotic to Ms. Green, age 82 years, the nurse is aware that _____.
   A. smaller doses of the drug are usually given to older patients
   B. elderly patients usually require larger doses of a hypnotic
   C. older adults excrete the drug faster than younger adults
   D. dosages of the hypnotic may be increased each night until the desired effect is achieved

4. Which of the following points should be included in a teaching plan for a patient taking a sedative or hypnotic?
   A. An alcoholic beverage may be served 1 to 2 hours before a sedative is taken without any ill effects.

5. Which of the following sedatives/hypnotics is a Pregnancy Category X drug?
   A. zolpidem
   B. amobarbital
   C. temazepam
   D. chloral hydrate

**Medication Dosage Problems**

1. Triazolam (Halcion) 0.125 mg is prescribed. The drug is available in 0.25-mg tablets. The nurse administers _____.

2. Chloral hydrate (Noctec) 500 mg is prescribed for insomnia. The drug is available in 250-mg tablets. The nurse administers ______.
The central nervous system (CNS) includes the brain and the spinal cord. The CNS processes information to and from the peripheral nervous system and is the center of coordination and control for the entire body. Many drugs stimulate the CNS, but only a few are used therapeutically. This chapter discusses the drugs that stimulate the CNS and the nursing implications related to their administration.

The CNS stimulants include the **analeptics**, drugs that stimulate the respiratory center of the CNS; the amphetamines, drugs with a high abuse potential because of their ability to produce euphoria and wakefulness; and the **anorexiants**, drugs used to suppress the appetite.

**ACTIONS**

**Analeptics**

Doxapram (Dopram) and caffeine (combination of caffeine and sodium benzoate) are two analeptics used in medicine. Doxapram increases the depth of respirations by stimulating special receptors located in the carotid arteries and upper aorta. These special receptors (called chemoreceptors) are sensitive to the amount of oxygen in arterial blood. Stimulation of these receptors results in an increase in the depth of the respirations. In larger doses, doxapram increases the respiratory rate by stimulating the medulla.

Caffeine is a mild to potent CNS stimulant, with the degree of its stimulating effect dependent on the dose administered. Caffeine stimulates the CNS at all levels, including the cerebral cortex, the medulla, and the spinal cord. Caffeine has mild analeptic (respiratory stimulating) activity. Other actions include cardiac stimulation (which may produce tachycardia), dilatation of coronary and peripheral blood vessels, constriction of cerebral blood vessels, and skeletal muscle stimulation. Caffeine also has mild diuretic activity.

Modafinil is an analeptic used to treat **narcolepsy** (disorder causing an uncontrollable desire to sleep during normal waking hours even though the individual has a normal nighttime sleeping pattern). The exact mechanism of action is not known, but the drug is thought to bind to dopamine reuptake carrier sites, increasing alpha activity and decreasing delta, theta, and beta activity,
thereby reducing the number of sleepiness episodes. It is
not associated with cardiac and other systemic stimula-
tory effects of the other CNS stimulants.

Amphetamines
The amphetamines, such as amphetamine, dextroamphet-
amine (Dexedrine), and methamphetamine (Desoxyn),
are sympathomimetic (ie, adrenergic) drugs that stimu-
late the CNS (see Chap. 22). Their drug action results in
an elevation of blood pressure, wakefulness, and an
increase or decrease in pulse rate. The ability of these
drugs to act as anorexians and suppress the appetite is
thought to be due to their action on the appetite center in
the hypothalamus.

Anorexians
The anorexians, such as phentermine and phendime-
trazine, are nonamphetamine drugs pharmacologically
similar to the amphetamines. Like the amphetamines,
their ability to suppress the appetite is thought to be due
to their action on the appetite center in the hypothalamus.

USES
The CNS stimulants have limited use in medicine.
Examples of CNS stimulants are given in the Summary
Drug Table: Central Nervous System Stimulants.

Analeptics
Doxapram is used to treat drug-induced respiratory
depression and to temporarily treat respiratory depres-
sion in patients with chronic pulmonary disease. This
drug also may be used during the postanesthesia period
when respiratory depression is caused by anesthesia. It
also is used to stimulate deep breathing in patients after
anesthesia.
Caffeine and sodium benzoate are administered intra-
muscularly or intravenously as part of the treatment of
respiratory depression caused by CNS depressants, such
as narcotic analgesics and alcohol. Because caffeine also
has other effects, such as constriction of cerebral arteries
and stimulation of skeletal muscles, the use of caffeine
for this purpose has largely been replaced by narcotic
antagonists for respiratory depression caused by narcotic
overdose or other drugs with greater analeptic activity
(eg, doxapram). Orally, caffeine, either as a beverage
(coffee, tea) or in nonprescription tablet form, may be
used by some individuals to relieve fatigue. Caffeine also
may be included in some nonprescription analgesics.
Modafinil is use to treat narcolepsy to decrease the num-
ber of sleepiness episodes during the day.

Amphetamines
A mphetamine may be used in the short-term treat-
mant of exogenous obesity (obesity caused by a persistent
calorie intake that is greater than needed by the body). How-
ever, their use in treating exogenous obesity has
depended because the long-term use of the amphet-
amines for obesity carries the potential for addiction and
abuse.
These drugs may also be helpful in the management
of narcolepsy, a disorder manifested by an uncontrol-
lable desire to sleep during normal waking hours even
though the individual has a normal nighttime sleeping
pattern. The individual with narcolepsy may fall asleep
from a few minutes to a few hours many times in one
day. This disorder begins in adolescence or in the young
adult and persists throughout life.
A mphetamine is used to manage attention deficit
hyperactivity disorder (ADHD) in children. Children
with this disorder exhibit a short attention span, hyper-
activity, impulsiveness, and emotional lability. The con-
dition is more prevalent in boys than in girls and poses
a problem with school and learning, although these chil-
dren are usually of normal or above average intelligence.
How amphetamines, which are CNS stimulants, calm
the hyperactive child is unknown. These drugs reduce
motor restlessness, increase mental alertness, provide
mood elevation, produce a mild sense of euphoria, and
reduce the sense of fatigue. In addition to taking a CNS
stimulant, the child with ADHD may also need psy-
chotherapeutic counseling.

Anorexians
Phendimetrazine and phentermine are chemically related
to the amphetamines and are used for short-term treat-
mant of exogenous obesity. These drugs are available only
by prescription and have addiction and abuse potential.
Some nonprescription diet aids contain phenyl-
propanolamine, an adrenergic drug that has actions simi-
lar to the adrenergic drug ephedrine. These diet aids are
not true anorexians, and those containing phenyl-
propanolamine have limited appetite-suppressing ability
when compared to the anorexians. Phenylpropanolamine
also has little abuse potential and has no addiction
potential.

ADVERSE REACTIONS
The adverse reactions associated with the administra-
tion of doxapram include excessive CNS stimulation,
symptoms of which may include headache, dizziness,
apprehension, disorientation, and hyperactivity. Other
adverse reactions include nausea, vomiting, cough,
### UNIT IV
Drugs That Affect the Neuromuscular System

#### SUMMARY DRUG TABLE  CENTRAL NERVOUS SYSTEM STIMULANTS

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAMES*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Analeptics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>caffeine</td>
<td>Caffedrine,</td>
<td>Fatigue, drowsiness, as adjunct in analgesic formulation, respiratory depression</td>
<td>Palpitations, nausea, vomiting, insomnia, tachycardia, restlessness</td>
<td>100–200 mg PO q3–4h; caffeine and sodium benzoate: 500 mg–1g IM, IV</td>
</tr>
<tr>
<td>kaf-een'</td>
<td>Stay Awake, generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>doxapram HCL</td>
<td>Dopram</td>
<td>Drug-induced postanesthesia, drug-induced respiratory depression, acute respiratory insufficiency superimposed on COPD</td>
<td>Dizziness, headache, apprehension, disorientation, nausea, cough, dyspnea, urinary retention</td>
<td>0.5–1 mg/kg IV</td>
</tr>
<tr>
<td>docks'-a-pram</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>modafinil</td>
<td>Provigil</td>
<td>Narcolepsy</td>
<td>Insomnia, nervousness, headache, tachycardia, anorexia, dizziness, excitement</td>
<td>200–400 mg/d PO</td>
</tr>
<tr>
<td>moe-daf'-in-ill</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Amphetamines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amphetamine</td>
<td>generic</td>
<td>Narcolepsy, attention deficit hyperactivity disorder (ADHD), exogenous obesity</td>
<td>Insomnia, nervousness, headache, tachycardia, anorexia, dizziness, excitement</td>
<td>Narcolepsy: 5–60 mg/d PO in divided doses; ADD: 5 mg BID, increase by 10 mg/wk until desired effect; Obesity: 5–30 mg/d PO in divided doses 2.5 mg PO BID; maximum dosage, 20 mg/d</td>
</tr>
<tr>
<td>sulfate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>am-fet'-a-meen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethylphenidate</td>
<td>Focalin</td>
<td>ADHD</td>
<td>Nervousness, insomnia, loss of appetite, abdominal pain, weight loss, tachycardia, skin rash</td>
<td>Narcolepsy: 5–60 mg/d PO in divided doses, ADD: up to 40 mg/d PO; obesity: 5–30 mg/d PO in divided doses</td>
</tr>
<tr>
<td>dex-meth-thyl-fen-i-date</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dextroamphetamine sulfat e</td>
<td>DEXEDRINE, generic</td>
<td>Narcolepsy, ADHD, exogenous obesity</td>
<td>Insomnia, nervousness, headache, tachycardia, anorexia, dizziness, excitement</td>
<td>Narcolepsy: 5–60 mg/d PO in divided doses, ADD: up to 40 mg/d PO; obesity: 5–30 mg/d PO in divided doses</td>
</tr>
<tr>
<td>dex-troe-am-fet'-a-meen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>methamphetamine</td>
<td>Desoxyn</td>
<td>ADHD</td>
<td>Insomnia, nervousness, headache, tachycardia, anorexia, dizziness, excitement</td>
<td>Up to 25 mg/d PO</td>
</tr>
<tr>
<td>meth-am-fet'-a-meen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>methylphenidate HCL</td>
<td>Concerta, Metadate ER, Ritalin, generic</td>
<td>ADHD, narcolepsy</td>
<td>Nervousness, insomnia, anorexia, dizziness, drowsiness, headache</td>
<td>5–60 mg/day PO</td>
</tr>
<tr>
<td>meh-thyl-fen'-ih-date</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pemoline</td>
<td>Cylert</td>
<td>ADHD</td>
<td>Insomnia, nervousness, headache, tachycardia, anorexia, dizziness, excitement</td>
<td>37.5–112.5 mg/d PO</td>
</tr>
<tr>
<td>pem'-oh-leen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anorexiants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>benzphetamine HCL</td>
<td>Didrex</td>
<td>Obesity</td>
<td>Insomnia, nervousness, headache, dry mouth, palpitations, tachycardia, anorexia, dizziness, excitement</td>
<td>25–50 mg PO 1–3 times/d</td>
</tr>
<tr>
<td>benz-fe-ta-meen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
dyspnea, urinary retention, and variations in the heart rate. Administration of caffeine and sodium benzoate may result in tachycardia, palpitations, nausea, and vomiting.

One of the chief adverse reactions associated with the amphetamines and anorexiants is overstimulation of the CNS, which may result in a variety of adverse reactions, including insomnia, tachycardia, nervousness, headache, anorexia, dizziness, and excitement. In some instances, the intensity of these reactions is dose dependent, but some individuals may experience an intense degree of these symptoms even with low doses. Other individuals experience few symptoms of CNS stimulation.

The amphetamines and anorexiants are recommended only for short-term use in selected patients for the treatment of exogenous obesity. When used for treatment of children with ADHD, long-term use must be followed by gradual withdrawal of the drug.

**CONTRAINDICATIONS**

The CNS stimulants are contraindicated in patients with known hypersensitivity or severe hypertension, in newborns, and in patients with epilepsy or convulsive states, pneumothorax, acute bronchial asthma, head injury, or stroke. In addition, the amphetamines are contraindicated in patients with hyperthyroidism and glaucoma. The anorexiants are classified as Pregnancy Category X and should not be used during pregnancy.

**PRECAUTIONS**

The CNS stimulants are given cautiously in all patients, particularly because the use of these drugs can lead to physical dependence. Some individuals are especially sensitive to the effects of the CNS stimulants. The analeptics and amphetamines are Pregnancy Category B drugs and are not recommended during pregnancy, except when clearly needed. These drugs are used with extreme caution in patients with cardiovascular disease and in women during the early stages of pregnancy.

**INTERACTIONS**

The amphetamines and the anorexiants should not be given during or within 14 days after administration of monoamine oxidase inhibitors (see Chap. 31) because the patient may experience hypertensive crisis and intracranial hemorrhage. When guanethidine is administered with the amphetamines or the anorexiants, the antihypertensive effect of guanethidine may decrease. Coadministration of the amphetamines or the anorexiants with the tricyclic antidepressants may decrease the effects of the amphetamines or the anorexiants.
The Patient Receiving a Central Nervous System Stimulant

ASSESSMENT

Assessment of the patient receiving a CNS stimulant depends on the drug, the patient, and the reason for administration.

Preadministration Assessment

The preadministration assessment depends on the type of CNS used and the reason for administration.

ANALEPTICS. When a CNS stimulant is prescribed for respiratory depression, initial patient assessments will include the blood pressure, pulse, and respiratory rate. It is important to note the depth of the respirations and any pattern to the respiratory rate, such as shallow respirotions or alternating deep and shallow respirations. The nurse reviews recent laboratory tests (if any), such as arterial blood gas studies. Before administering the drug, the nurse ensures that the patient has a patent airway. Oxygen is usually administered before, during, and after drug administration.

AMPHETAMINES. When an amphetamine is prescribed for any reason, the nurse weighs the patient and takes the blood pressure, pulse, and respiratory rate before starting drug therapy. The nurse should initially observe the child with ADD for the various patterns of abnormal behavior. The nurse records a summary of the behavior pattern in the patient's chart to provide a comparison with future changes that may occur during therapy.

ANOREXIANTS. When an anorexiant or amphetamine is used as part of the treatment of obesity, the drug is usually prescribed for outpatient use. The nurse obtains the patient’s weight and vital signs at the time of each outpatient visit.

Ongoing Assessment

The ongoing assessment depends on the type of CNS stimulant used and the reason for administration.

ANALEPTICS. After administration of an analeptic, the nurse carefully monitors the patient’s respiratory rate and pattern until the respirations return to normal. The nurse monitors the level of consciousness, the blood pressure, and pulse rate at 5- to 15-minute intervals or as ordered by the primary health care provider. The nurse may draw blood for arterial blood gas analysis at intervals to determine the effectiveness of the analeptic, as well as the need for additional drug therapy. It is important to observe the patient for adverse drug reactions and to report their occurrence immediately to the primary health care provider.

ATTENTION DEFICIT DISORDER. If the child is hospitalized, the nurse enters a daily summary of the child’s behavior in the patient’s record. This provides a record of the results of therapy.

NARCOLEPSY. The nurse observes the patient with narcolepsy during daytime hours. If periods of sleep are noted, the nurse records the time of day they occur and their length.

WEIGHT LOSS. When an amphetamine or anorexiant is prescribed for obesity, the nurse obtains the patient’s weight and vital signs at the time of each outpatient visit.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes for the patient depend on the reason for administration of a CNS stimulant but may include an optimal response to therapy, management of adverse drug reactions, and an understanding of the drug regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

Respiratory depression can be a serious event requiring administration of a respiratory stimulant. When an analeptic is administered, the nurse notes and records the rate, depth, and character of the respirations before the drug is given to provide a database for evaluation of the effectiveness of drug therapy. Oxygen is usually ordered for before and after administration of a respiratory stimulant. After administration, the nurse monitors respirations closely and records the effects of therapy.

When a CNS stimulant such as dextroamphetamine is administered to treat a child with ADD, the drug regimen will be periodically interrupted to determine if the child still exhibits the symptoms of ADD.

Nursing Diagnoses Checklist

- Risk for Sleep Pattern Disturbance related to hyperactivity, nervousness, insomnia, other (specify)
- Risk for Injury related to adverse drug effects (CNS stimulation, drug dependency, other [specify])
Monitoring and Managing Adverse Drug Reactions

The adverse drug reactions that may occur with the use of an amphetamine, such as insomnia and a significant increase in blood pressure and pulse rate, may be serious enough to require discontinuation of the drug. In some instances, the adverse drug effects are mild and may even disappear during therapy. The nurse informs the primary care provider of all adverse reactions.

When use of the CNS stimulants causes insomnia, the nurse administers the drug early in the day (when possible) to diminish sleep disturbances. The patient is encouraged not to nap during the day. Other stimulants, such as coffee, tea, or cola drinks, are avoided. In some patients, nervousness, restlessness, and palpitations may occur. The vital signs are checked every 6 to 8 hours or more often if tachycardia, hypertension, or palpitations occur. Many times these adverse reactions will diminish with continued use as tolerance develops. If tolerance develops, the dosage is not increased.

Gerontologic Alert

Older adults are especially sensitive to the effects of the CNS stimulants and may exhibit excessive anxiety, nervousness, insomnia, and mental confusion. Cardiovascular disorders, common in the older adult, may be worsened by the CNS stimulants. Careful monitoring is important because the presence of these reactions may result in the need to discontinue use of the drug.

Nausea and vomiting may occur with the administration of an analeptic; therefore, the nurse should keep a suction machine nearby should vomiting occur. Urinary retention may be seen with the administration of doxapram; therefore, the nurse measures intake and output and notifies the primary health care provider if the patient is unable to void or the bladder appears distended on palpation.

Long-term treatment with the CNS stimulants can retard growth in children. Children on long-term treatment with the CNS drugs require frequent height and weight measurements to monitor growth. Intermittent therapy is usually advised to prevent tolerance to the drug and to minimize the effect on growth and the development of tolerance.

Educating the Patient and Family

The nurse explains the therapeutic regimen and adverse drug reactions to the patient and family. The type of information included in the teaching plan will depend on the drug and the reason for its use. It is important to emphasize the importance of following the recommended dosage schedule. The nurse may include the following additional teaching points:

- Attention deficit disorder: Give the drug in the morning 30 to 45 minutes before breakfast and before lunch. Do not give the drug in the afternoon. Pemoline is given once daily in the morning. Therapeutic response of pemoline may take 3 to 4 weeks. Insomnia and anorexia usually disappear during continued therapy. Write a daily summary of the child’s behavior, including periods of hyperactivity, general pattern of behavior, socialization with others, and attention span. Bring this record to each primary health care provider or clinic visit because this record may help the primary health care provider determine future drug dosages or additional treatment modalities. The primary health care provider may prescribe that the drug be given only on school days when high levels of attention and performance are necessary.
- Narcolepsy: Keep a record of the number of times per day that periods of sleepiness occur, and bring this record to each visit to the primary health care provider or clinic.
- Amphetamines and anorexiants: These drugs are taken early in the day to avoid insomnia. Do not increase the dose or take the drug more frequently, except on the advice of a primary health care provider. These drugs may impair the ability to drive or perform hazardous tasks and may mask extreme fatigue. If dizziness, light-headedness, anxiety, nervousness, or tremors occur, contact the primary care provider. Avoid or decrease the use of coffee, tea, and carbonated beverages containing caffeine (see Patient and Family Teaching Checklist: Using Anorexiants for Weight Loss).
- Caffeine (oral, nonprescription): Avoid the use of oral caffeine-containing products to stay awake if there is a history of heart disease, high blood pressure, or stomach ulcers. These products are intended for occasional use and should not be used if heart palpitations, dizziness, or light-headedness occurs.

EVALUATION

- The parent or child reports that the child’s behavior and school performance are improved.
- The patient reports fewer episodes of inappropriate sleep patterns.
- Adverse reactions are identified and managed through appropriate nursing interventions.
- The patient complies with the prescribed drug regimen.
- The patient and family demonstrate an understanding of the drug regimen.
- The patient verbalizes the importance of complying with the prescribed therapeutic regimen.
**Critical Thinking Exercises**

1. Ms. Stone is given a special diet and prescribed an anorexiant to help her lose 20 lb before she has reconstructive knee surgery. Determine what instructions you would include in a teaching plan for this patient.

2. Mr. Trent has narcolepsy and is prescribed amphetamine 10 mg/d. Develop questions you would ask Mr. Trent when he returns to the clinic for evaluation after 1 month of therapy.

3. Ms. Allison is prescribed an analeptic for respiratory depression. Discuss what preadministration and ongoing assessments you would make when caring for Ms. Allison.

4. Discuss precautions that should be taken when administering the CNS stimulants.

**Review Questions**

1. Initial assessment of the child with attention deficit disorder includes ______.
   - A. assessing to which stimuli the child responds the most
   - B. determining the child’s intelligence
   - C. obtaining a summary of the child’s behavior pattern
   - D. obtaining vital signs

2. When assessing the patient receiving doxapram for chronic pulmonary disease, the nurse observes the patient for adverse drug reactions, which may include ______.
   - A. headache, dizziness, variations in heart rate
   - B. diarrhea, drowsiness, hypotension
   - C. decreased respiratory rate, weight gain, bradycardia
   - D. fever, dysuria, constipation

3. When teaching a patient with narcolepsy who is receiving an amphetamine, the nurse instructs the patient to ______.
   - A. record the times of the day the medication is taken
   - B. take the medication at bedtime as well as in the morning
   - C. take the drug with meals
   - D. keep a record of how often periods of sleepiness occur

4. When administering an amphetamine, the nurse first checks to see if the patient is taking or has taken a monoamine oxidase (MAO) inhibitor because ______.
   - A. a lower dosage of the amphetamine may be needed
   - B. a higher dosage of the amphetamine may be needed
   - C. if the amphetamine is administered within 14 days of the MAO inhibitor, cardiac arrest may occur
   - D. if the amphetamine is administered within 14 days of the MAO inhibitor, an intracranial hemorrhage may occur

**Medication Dosage Problems**

1. Phentermine hydrochloride 8 mg three times a day PO is prescribed as an adjunct for weight loss. The total amount of drug the patient will receive daily is ______. Is this an appropriate dose for this drug? ______

2. Modafinil 400 mg is prescribed. The drug is available in 200-mg tablets. The nurse administers ______.
Anticonvulsants

The terms *convulsion* and *seizure* are often used interchangeably and basically have the same meaning. A *seizure* may be defined as a periodic attack of disturbed cerebral function. A seizure may also be described as an abnormal disturbance in the electrical activity in one or more areas of the brain. Seizures may be classified as partial (focal) or generalized. Each different type of seizure disorder is characterized by a specific pattern of events, as well as a different pattern of motor or sensory manifestation.

Partial or focal seizures arise from a localized area in the brain and cause specific symptoms. A partial seizure can spread to the entire brain and cause a generalized seizure. Partial seizures include simple seizures in which consciousness is not impaired, *jacksonian seizures* (a focal seizure that begins with an uncontrolled stiffening or jerking in one part of the body such as finger, mouth, hand, or foot that may progress to a generalized seizure), and psychomotor seizures.

*Psychomotor seizures* occur most often in children 3 years of age through adolescence. The individual may experience an aura with perceptual alterations, such as hallucinations or a strong sense of fear. Repeated coordinated but inappropriate movements, such as clutching, kicking, picking at clothes, walking in circles, and licking are characteristic. The most common motor symptom is drawing or jerking of the mouth and face.

Generalized seizures include absence, myoclonic, and tonic-clonic. Manifestations of a generalized *tonic-clonic seizure* include alternate contraction (tonic phase) and relaxation (clonic phase) of muscles, a loss of consciousness, and abnormal behavior. *Myoclonic seizures* involve sudden, forceful contractions involving the musculature of the trunk, neck, and extremities. *Absence seizures*, previously referred to as petit mal seizures, are seizures characterized by a brief loss of consciousness during which physical activity ceases. The seizures typically last a few seconds, occur many times a day, and may go unnoticed by others.

Seizure disorders are generally categorized as idiopathic or acquired. Idiopathic seizures have no known cause; acquired seizure disorders have a known cause, including high fever, electrolyte imbalances, uremia, hypoglycemia, hypoxia, brain tumors, and some drug withdrawal reactions. Once the cause is removed (if it can be removed), the seizures theoretically cease.
Epilepsy may be defined as a permanent, recurrent seizure disorder. Examples of the known causes of epilepsy include brain injury at birth, head injuries, and inborn errors of metabolism. In some patients, the cause of epilepsy is never determined.

Drugs used for the management of convulsive disorders are called anticonvulsants. Most anticonvulsants have specific uses, that is, they are of value only in the treatment of certain types of seizure disorders. There are five types of drugs used as anticonvulsants: barbiturates, benzodiazepines, hydantoins, oxazolidinediones, and the succinimides. In addition, several miscellaneous drugs are used as anticonvulsants. All possess the ability to depress abnormal neural discharges in the central nervous system (CNS), resulting in an inhibition of seizure activity. Drugs that control generalized tonic-clonic seizures are not effective for absence (petit mal) seizures. If both conditions are present, combined drug therapy is required.

**ACTIONS**

Generally, anticonvulsants reduce the excitability of the neurons (nerve cells) of the brain. When neuron excitability is decreased, seizures are theoretically reduced in intensity and frequency of occurrence or, in some instances, are virtually eliminated. For some patients, only partial control of the seizure disorder may be obtained with anticonvulsant drug therapy.

**USES**

The more common types of seizures, which respond to a specific anticonvulant, are given in the Summary Drug Table: Anticonvulsants. In some cases, the patient does not respond well to one drug, and another drug or a combination of anticonvulsants must be tried. Dosage increases and decreases are often necessary during the initial period of treatment. Dosage adjustment also may be necessary during times of stress, severe illness, or when other drugs are being taken for treatment of conditions other than a seizure disorder. The miscellaneous anticonvulsants are adjuncts to the more widely used anticonvulsants. They are used in patients who have an inadequate response to other anticonvulsants.

Occasionally, status epilepticus (an emergency situation characterized by continual seizure activity with no interruptions) can occur. Diazepam (Valium) is most often the initial drug prescribed for this condition. However, because the effects of diazepam last less than 1 hour, a longer-lasting anticonvulsant, such as phenytoin or phenobarbital, also must be given to control the seizure activity.

**ADVERSE REACTIONS**

**Barbiturates**

The most common adverse reaction associated with phenobarbital is sedation, which can range from mild sleepiness or drowsiness to somnolence. These drugs may also cause nausea, vomiting, constipation, bradycardia, hypoventilation, skin rash, headache, fever, and diarrhea. Agitation, rather than sedation, may occur in some patients. Some of these adverse effects may be reduced or eliminated as therapy continues. Occasionally, a slight dosage reduction, without reducing the ability of the drug to control the seizures, will reduce or eliminate some of these adverse reactions.

**Benzodiazepines**

As with the barbiturates, the most common adverse reaction seen with the use of clonazepam (Klonopin), clorazepate (Tranxene), and diazepam (Valium) is sedation in varying degrees. Additional adverse effects may include anorexia, constipation, or diarrhea. Some adverse reactions are dose dependent, whereas others may diminish in intensity or cause few problems after several weeks of therapy.

**Hydantoins**

Phenytoin is the most commonly prescribed anticonvulsant. Many adverse reactions are associated with the use of phenytoin (Dilantin). The most common adverse reactions associated with the hydantoins are related to the CNS and include nystagmus (constant, involuntary movement of the eyeball), ataxia (loss of control of voluntary movements, especially gait), slurred speech, and mental changes. Other adverse reactions that may be seen include various types of skin rashes, nausea, vomiting, gingival hyperplasia (overgrowth of gum tissue), hematologic changes (changes relating to the blood or blood-forming tissue), and hepatotoxicity. Some of these adverse reactions diminish with continuous use of the hydantoins.

**Nursing Alert**

Research suggests an association between the use of anticonvulsants by pregnant women with epilepsy and an increased incidence of birth defects in children born to these women. The use of anticonvulsants generally is not discontinued in pregnant women with a history of major seizures because of the danger of precipitating status epilepticus. However, when seizure activity poses no serious threat to the pregnant woman, the primary health care provider will consider discontinuing use of the drug during pregnancy.
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Barbiturates</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>phenobarbital</td>
<td>generic</td>
<td>Status epilepticus, cortical focal seizures, tonic-clonic seizures</td>
<td>Somnolence, agitation, confusion, ataxia, CNS depression, nervousness, nausea, vomiting, constipation, diarrhea, rash</td>
<td>30–200 mg/d PO BID, TID</td>
</tr>
<tr>
<td>phenobarbital sodium</td>
<td>Luminal Sodium, generic</td>
<td>Status epilepticus, cortical focal seizures, tonic-clonic seizures</td>
<td>Somnolence, agitation, confusion, ataxia, CNS depression, nervousness, nausea, vomiting, constipation, diarrhea, rash</td>
<td>30–320 mg IM, IV; may repeat in 6 h</td>
</tr>
<tr>
<td><strong>Hydantoins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ethosuximide</td>
<td>Zarontin, generic</td>
<td>Absence seizures</td>
<td>Drowsiness, ataxia, dizziness, irritability, hematologic changes, mental confusion, nervousness, blurred vision, nausea, vomiting, gastric cramps, urinary frequency, anorexia, pruritus, urticaria</td>
<td>Up to 15 g/d PO in divided doses; children, 250 mg/d PO</td>
</tr>
<tr>
<td>methsuximide</td>
<td>Celontin Kapseals</td>
<td>Absence seizures</td>
<td>Drowsiness, ataxia, mental confusion, dizziness, irritability, nervousness, blurred vision, nausea, vomiting, gastric cramps, anorexia, pruritus, urticaria</td>
<td>300 mg/d – 12 g/d PO</td>
</tr>
<tr>
<td>phenosuximide</td>
<td>Milontin Kapseals</td>
<td>Absence seizures</td>
<td>Drowsiness, ataxia, mental confusion, dizziness, irritability, nervousness, blurred vision, nausea, vomiting, gastric cramps, anorexia, pruritus, urticaria</td>
<td>1–3 g/d PO in divided doses</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxazolidinedione</td>
<td>trimethadione</td>
<td>Tridione</td>
<td>Absence seizures</td>
<td>Precipitation of clonic-tonic seizure, diplopia, drowsiness, vomiting, photosensitivity, blurred vision, personality changes, increased irritability, headache, fatigue, exfoliative dermatitis, skin rash, nephrosis, hematologic effects</td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>clonazepam</td>
<td>Klonopin, generic</td>
<td>Absence seizures, myoclonic and akinetic seizures</td>
<td>Drowsiness, depression, lethargy, apathy, diarrhea, constipation, dry mouth, bradycardia, tachycardia, fatigue, visual disturbances, urticaria, anorexia, rash, pruritus</td>
</tr>
<tr>
<td></td>
<td>clorazepate</td>
<td>Tranxene SD, generic</td>
<td>Partial seizures, anxiety disorders</td>
<td>Drowsiness, depression, lethargy, apathy, diarrhea, constipation, dry mouth, bradycardia, tachycardia, fatigue, visual disturbances, urticaria, anorexia, rash, pruritus</td>
</tr>
<tr>
<td></td>
<td>diazepam</td>
<td>Valium, generic</td>
<td>Status epilepticus, convulsive disorders (all forms), anxiety disorders</td>
<td>Drowsiness, depression, lethargy, apathy, diarrhea, constipation, dry mouth, bradycardia, tachycardia, fatigue, visual disturbances, urticaria, anorexia, rash, pruritus</td>
</tr>
<tr>
<td>Miscellaneous Preparations</td>
<td>carbamazepine</td>
<td>Tegretol, Tegretol-XR, generic</td>
<td>Tonic-clonic, mixed seizures, psychomotor seizures</td>
<td>Dizziness, nausea, drowsiness, vomiting, aplastic anemia and other blood cell abnormalities</td>
</tr>
<tr>
<td></td>
<td>felbamate</td>
<td>Felbatol</td>
<td>Partial seizures (adults)</td>
<td>Insomnia, headache, anxiety, acne, rash, dyspepsia, vomiting, constipation, diarrhea, upper respiratory tract infection, fatigue, rhinitis</td>
</tr>
<tr>
<td></td>
<td>gabapentin</td>
<td>Neurontin</td>
<td>Partial seizures (adults)</td>
<td>Somnolence, dizziness, ataxia, Stevens-Johnson syndrome, nystagmus, tremor, rhinitis, diplopia</td>
</tr>
<tr>
<td></td>
<td>lamotrigine</td>
<td>Lamictal, Lamictal Chewable Dispersible Tablets</td>
<td>Partial seizures (adults)</td>
<td>Dizziness, insomnia, rash, somnolence, ataxia, nausea, vomiting, diplopia, headache</td>
</tr>
<tr>
<td></td>
<td>magnesium sulfate</td>
<td>Epsom Salt, generic</td>
<td>Hypomagnesemia, toxemia, evacuation</td>
<td>High magnesium levels, flushing, sweating, depressed</td>
</tr>
</tbody>
</table>
### SUMMARY DRUG TABLE  ANTICONVULSANTS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>oxcarbazepine</td>
<td>Trileptal</td>
<td>Epilepsy</td>
<td>Headache, dizziness, somnolence, ataxia, nystagmus, abnormal gait, insomnia, abdominal pain, diarrhea, dyspepsia, nausea, vomiting</td>
<td>up to 1000 mg PO BID</td>
</tr>
<tr>
<td>primidone</td>
<td>Mysoline</td>
<td>Grand mal, psychomotor or focal epileptic seizures</td>
<td>Somnolence, agitation, confusion, ataxia, CNS depression, nervousness, nausea, vomiting, constipation, diarrhea, rash</td>
<td>up to 500 mg PO QID</td>
</tr>
<tr>
<td>valproic acid</td>
<td>Depakene, Depakote, generic</td>
<td>Absence seizures</td>
<td>Nausea, vomiting, rash, sedative effects, indigestion, nystagmus, diplopia</td>
<td>10–60 mg/kg/d PO; if dosage is &gt;250 mg/d, give in divided doses &gt;16 years 100–600 mg/d PO</td>
</tr>
<tr>
<td>zonisamide</td>
<td>Zonegran</td>
<td>Epilepsy</td>
<td>Agitation, somnolence, anorexia, nausea, dizziness, headache, diplopia, tiredness, abdominal pain</td>
<td></td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.

### Oxazolidinediones

Administration of trimethadione (Tridione) may result in hematologic changes, such as pancytopenia (decrease in all the cellular components of the blood), leukopenia, aplastic anemia, and thrombocytopenia. Also reported are various types of skin rashes, diplopia (double vision), vomiting, changes in blood pressure, CNS depression, photosensitivity, and fatal nephrosis. Because these drugs have been associated with serious adverse reactions and fetal malformations, they should be used only when other less toxic drugs are not effective in controlling seizures. The oxazolidinediones may precipitate a tonic-clonic seizure.

### Succinimides

Gastrointestinal symptoms occur frequently with the administration of ethosuximide (Zarontin), methsuximide (Celontin Kapseals), and phensuximide (Milontin Kapseals). Mental confusion and other personality changes, pruritus, urticaria, urinary frequency, weight loss, and hematologic changes may also be seen.

### Miscellaneous Anticonvulsants

The adverse reactions seen with the various miscellaneous anticonvulsants are given in the Summary Drug Table: Anticonvulsants.

### CONTRAINDICATIONS, PRECAUTIONS, INTERACTIONS

#### Barbiturates

The barbiturates are contraindicated in patients with known hypersensitivity to the drugs. The barbiturates are used cautiously in patients with liver or kidney disease and those with neurological disorders. The barbiturates (eg, phenobarbital) are used with caution in patients with pulmonary disease and in hyperactive children. When barbiturates are used with other CNS depressants (eg, alcohol, narcotic analgesics, and antidepressants), an additive CNS depressant effect may occur. See Chapter 26 for additional information on the barbiturates.

#### Benzodiazepines

The benzodiazepines are contraindicated in patients with known hypersensitivity to the drugs. The benzodiazepines are used cautiously during pregnancy (Category D) and in patients with psychoses, acute narrow angle glaucoma, liver or kidney disease, and neurologic disorders. The benzodiazepines are used cautiously in elderly or debilitated patients. When the benzodiazepines are used with other CNS depressants (eg, alcohol, narcotic analgesics, and antidepressants),
an additive CNS depressant effect may occur. Increased effects of the benzodiazepines are seen when the drugs are administered with cimetidine, disulfiram, and oral contraceptives. When the benzodiazepines are administered with theophylline, there is a decreased effect of the benzodiazepines. See Chapter 30 for additional information on the benzodiazepines.

Hydantoins

The hydantoins are contraindicated in patients with known hypersensitivity to the drugs. Phenytoin is contraindicated in patients with sinus bradycardia, sinoatrial block, second and third degree AV block, and Adams-Stokes syndrome; it also is contraindicated during pregnancy (ethotoin and phenytoin are Pregnancy Category D) and lactation. Ethotoin is contraindicated in patients with hepatic abnormalities.

When the hydantoins are used with other CNS depressants (eg, alcohol, narcotic analgesics, and antidepressants), an additive CNS depressant effect may occur. The hydantoins are used cautiously in patients with liver or kidney disease and neurologic disorders. Phenytoin is used cautiously in patients with hypertension, severe myocardial insufficiency, and hepatic impairment.

Phenytoin interacts with many different drugs. For example, isoniazid, chloramphenicol, sulfonamides, benzodiazepines, succinimides, and cimetidine all increase phenytoin blood levels. The barbiturates, rifampin, theophylline, and warfarin decrease phenytoin blood levels. When administering the hydantoins with meperidine, the analgesic effect of meperidine is decreased.

Oxazolidinediones

The oxazolidinediones are contraindicated in patients with known hypersensitivity to the drugs. Trimethadione is classified as a Pregnancy Category D drug and is contraindicated during pregnancy and lactation. Trimethadione is used with caution in patients with eye disorders (eg, retinal or optic nerve disease), liver or kidney disease, and neurologic disorders. When trimethadione is used with other nervous system (CNS) depressants (eg, alcohol, narcotic analgesics, and anti-depressants), an additive CNS depressant effect may occur.

Succinimides

The succinimides are contraindicated in patients with known hypersensitivity to the drugs. The succinimides are contraindicated in patients with bone marrow depression or hepatic or renal impairment and during lactation. Ethosuximide is classified as a Pregnancy Category C drug and is used with caution during pregnancy. As with all anticonvulsants, when the succinimides are used with other CNS depressants (eg, alcohol, narcotic analgesics, and antidepressants), an additive CNS depressant effect may occur.

When the hydantoins are administered with the succinimides there may be an increase in the hydantoin blood levels. Concurrent administration of valproic acid and the succinimides may result in either a decrease or an increase in succinimide blood levels. When primidone in administered with the succinimides, lower primidone levels may occur.

Miscellaneous Anticonvulsants

The miscellaneous anticonvulsants are contraindicated in patients with known hypersensitivity to any of the drugs. Carbamazepine is contraindicated in patients with bone marrow depression or hepatic or renal impairment and during pregnancy (Category D). Valproic acid is not administered to patients with renal impairment or during pregnancy (Category D). Oxcarbazepine (Trileptal), a miscellaneous anticonvulsant, may exacerbate dementia.

The miscellaneous anticonvulsants are used cautiously in patients with glaucoma or increased intraocular pressure; a history of cardiac, renal or liver dysfunction; and psychiatric disorders. When the miscellaneous anticonvulsants are used with other CNS depressants (eg, alcohol, narcotic analgesics, and antidepressants), an additive CNS depressant effect may occur.

When carbamazepine is administered with primidone, decreased primidone levels and higher carbamazepine serum levels may result. Cimetidine administered with carbamazepine may result in an increase in plasma levels of carbamazepine that can lead to toxicity. Blood levels of lamotrigine increase when the agent is administered with valproic acid, requiring a lower dosage of lamotrigine.
Additional patient information should include a family history of seizures (if any) and recent drug therapy (all drugs currently being used). Depending on the type of seizure disorder, other information may be needed, such as a history of a head injury or a thorough medical history.

The nurse obtains the vital signs at the time of the initial assessment to provide baseline data. The primary health care provider may order many laboratory and diagnostic tests, such as an electroencephalogram, computed tomographic scan, complete blood count, and hepatic and renal function tests to confirm the diagnosis and identify a possible cause of the seizure disorder, as well as to provide a baseline during therapy with anticonvulsants.

Ongoing Assessment
Anticonvulsants control, but do not cure, epilepsy. An accurate ongoing assessment is important to obtain the desired effect of the anticonvulsant. The dosage of the anticonvulsant may require frequent adjustments during the initial treatment period. Dosage adjustments are based on the patient’s response to therapy (eg, the control of the seizures), as well as the occurrence of adverse reactions. Depending on the patient’s response to therapy, a second anticonvulsant may be added to the therapeutic regimen, or one anticonvulsant may be changed to another. Regular serum plasma levels of the anticonvulsant are taken to monitor for toxicity.

The patient’s seizures, as well as response to drug therapy, must be observed when a hospitalized patient is receiving an anticonvulsant. The nurse must carefully document each seizure with regard to the time of occurrence, the length of the seizure, and the psychic or motor activity occurring before, during, and after the seizure. Most seizures occur without warning, and the nurse may not see the patient until after the seizure begins or after the seizure is over. However, any observations made during and after the seizure are important and may aid in the diagnosis of the type of seizure, as well as assist the primary health care provider in evaluating the effectiveness of drug therapy.

DISPLAY 28-1  General Assessment of Seizure Activity

- A description of the seizures (the motor or psychic activity occurring during the seizure)
- The frequency of the seizures (approximate number per day)
- The average length of a seizure
- A description of an aura (a subjective sensation preceding a seizure) if any has occurred
- A description of the degree of impairment of consciousness
- A description of what, if anything, appears to bring on the seizure

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

NURSING DIAGNOSES

The expected outcomes for the patient depend on the type and severity of the seizure but may include an optimal response to therapy (control of seizure), management of common adverse drug reactions (includes minimizing injury and maintaining normal oral mucous membranes), reduction in anxiety, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

When administering an anticonvulsant, the nurse must not omit or miss a dose (except by order of the primary health care provider). An abrupt interruption in therapy by omitting a dose may result in a recurrence of the seizures. In some instances, abrupt withdrawal of an anticonvulsant can result in status epilepticus.

The nurse aids continuity of anticonvulsant administration by making a notation on the care plan, as well as by informing all health care team members of the importance of the drug. If the primary health care provider discontinues the anticonvulsant therapy, the dosage is gradually withdrawn or another drug is gradually substituted.

To prevent gastric upset, the nurse gives oral anticonvulsants with food or soon after eating. Oral suspensions are shaken well before measuring. If the

Nursing Diagnoses Checklist

- Risk for Injury related to seizure disorder, adverse drug reactions (drowsiness, ataxia)
- Impaired Oral Mucous Membranes related to adverse drug reactions (hydantoins)
- Disturbed Sensory Perception: Visual related to adverse drug reactions
- Risk for Impaired Skin Integrity related to adverse reactions (rash)

Nursing Alert

Status epilepticus may result from abrupt discontinuation of the drug, even when the anticonvulsant is being administered in small daily doses.
patient appears drowsy, the nurse must use caution when giving an oral preparation because aspiration of the tablet, capsule, or liquid may occur. The nurse tests the swallowing ability of the patient by offering small sips of water before giving the drug. If the patient has difficulty swallowing, the nurse withholds the drug and notifies the primary health care provider as soon as possible. A different route of administration may be necessary. Injury may occur when the patient has a seizure. The nurse takes precautions to prevent falls and other injuries until seizures are controlled by the drug.

**BARBITURATES.** The barbiturate phenobarbital (Luminal) is commonly used to treat convulsive disorders. When administering the barbiturates by the intravenous (IV) route, it is important not to exceed a rate of 60 mg/min and to administer the drug within 30 minutes of preparation. The nurse monitors the patient carefully during administration of a barbiturate. The blood pressure and respirations are taken frequently. Resuscitation equipment and artificial ventilation equipment are kept nearby.

**BENZODIAZEPINES.** The dosage of the benzodiazepines is highly individualized, and the nurse must increase the dosage cautiously to avoid adverse reactions, particularly in elderly and debilitated patients. IV diazepam may bring seizures under control quickly. However, patients may have a return of seizure activity because of the short duration of the effects of the drug. The nurse must be prepared to administer another dose of the drug. The nurse must not mix diazepam with other drugs. When used to control seizures, the drug is administered by IV push. The nurse injects IV diazepam slowly, allowing at least 1 minute for each 5 mg of drug.

**HYDANTOINS.** Phenytoin is the most commonly prescribed anticonvulsant because of its effectiveness and relatively low toxicity. However, a genetically linked inability to metabolize phenytoin has been identified. For this reason, it is important to monitor serum concentrations of the drug on a regular basis to detect signs of toxicity. Phenytoin is administered orally and parenterally. If the drug is administered parenterally, the IV route is preferred over the intramuscular route because erratic absorption of phenytoin causes pain and muscle damage at the injection site.

**OXAZOLIDINEDIONES.** The oxazolidinediones are used only when other, less-toxic drugs have not been effective in controlling the seizure disorder because they have been associated with fetal abnormalities and serious adverse reactions.

**SUCCINIMIDES.** The succinimides are easily absorbed in the gastrointestinal tract and are effective in controlling absence or petit mal seizures. These drugs are given with food to prevent gastrointestinal upset.

**MISCELLANEOUS ANTICONVULSANTS.** Valproic acid (Depakene) is unrelated chemically to the other anticonvulsants. This drug is absorbed rapidly when taken orally. Tablets should not be chewed but swallowed whole to avoid irritation to the mouth and throat. The capsules may be opened and the drug sprinkled on a small amount of food, such as pudding or applesauce. This mixture must be swallowed whole immediately and not chewed. Zonisamide is administered orally once a day or in divided doses. The dose may be increased by 100 mg/day every 1 to 2 weeks until control of the seizures is obtained or the patient reaches the maximum dosage of 600 mg/d.

The nurse may give lamotrigine without regard to meals. However, it is important to give carbamazepine with meals to decrease gastric upset. The nurse can crush the tablets if the patient has difficulty swallowing. However, it is important not to crush or chew extended-release carbamazepine.

**Monitoring and Managing Adverse Reactions**
Drowsiness is a common adverse reaction of the anticonvulsant drugs, especially early in therapy. Therefore, the nurse should assist the patient with all ambulatory activities. The nurse helps the patient to arise from the bed slowly and sit for a few minutes before standing. Drowsiness decreases with continued use.

**BARBITURATES.** The barbiturates can produce a hypersensitivity rash. Should a skin rash occur, the nurse must notify the primary health care provider immediately because the primary health care provider may discontinue the drug. The nurse carefully examines all affected areas and provides an accurate description. If pruritus is present, the nurse keeps the patient’s nails short, applies an antiseptic cream (if prescribed), and tells the patient to avoid the use of soap until the rash subsides.

### Gerontologic Alert

The barbiturates may produce marked excitement, depression, and confusion in the elderly. In some individuals the barbiturates produce excitement, rather than depression. The nurse should monitor the older adult carefully during therapy with the barbiturates and report any unusual effects to the primary health care provider.

**BENZODIAZEPINES.** Carbamazepine may cause aplastic anemia and agranulocytosis. During treatment blood studies are performed frequently. If evidence of bone marrow depression is obtained (eg, the patient’s platelet...
count and white blood cell count decrease significantly), the primary health care provider is notified because the drug may be discontinued. The nurse reports any unusual bruising or unusual bleeding, fever, sore throat, rash, or mouth ulcers.

**Gerontologic Alert**

Older or debilitated adults may require a reduced dosage of diazepam to reduce ataxia and oversedation. The nurse observes these patients carefully. Apnea and cardiac arrest have occurred when diazepam is administered to older adults, very ill patients, and individuals with limited pulmonary reserve.

**HYDANTOINS.** The nurse must also be alert for the signs of blood dyscrasias, such as sore throat, fever, general malaise, bleeding of the mucous membranes, epistaxis (bleeding from the nose), and easy bruising. These are serious reactions that the nurse must report to the primary health care provider immediately. Routine laboratory tests, such as complete blood counts and differential counts, should be performed periodically. When a blood dyscrasia is present, the skin and mucous membranes are protected from bleeding and easy bruising by using a soft-bristled toothbrush, and the extremities are protected from trauma or injury.

**Nursing Alert**

Phenytoin can cause hematologic changes (eg, aplastic anemia, leukopenia, and thrombocytopenia). The nurse should immediately report any of the following: signs of thrombocytopenia (eg, bleeding gums, easy bruising, increased menstrual bleeding, tarry stools) or leukopenia (eg, sore throat, chills, swollen glands, excessive fatigue, or shortness of breath).

Hypersensitivity reactions and Stevens-Johnson syndrome (a serious, sometimes fatal inflammatory disease) have been reported with the use of phenytoin.

**Nursing Alert**

The nurse informs the primary health care provider immediately if a skin rash occurs. The use of phenytoin is usually discontinued if a skin rash occurs. If the rash is exfoliative (red rash with scaling of the skin), purpuric (small hemorrhages or bruising on the skin), or bullous (skin vesicle filled with fluid, ie, blister) use of the drug is not resumed. If the rash is milder (eg, measles-like), therapy may be resumed after the rash has completely disappeared.

The hydantoins may affect the blood glucose levels. In some patients these drugs have an inhibitory effect on the release of insulin in the body, causing hyperglycemia. The nurse closely monitors blood glucose levels, particularly in patients with diabetes. The nurse reports any abnormalities to the primary health care provider.

Long-term administration of the hydantoins can cause gingivitis and gingival hyperplasia (overgrowth of gum tissue). It is important to periodically inspect the teeth and gums of patients in a hospital or long-term clinical setting who are receiving one of these drugs. The nurse reports any changes in the gums or teeth to the primary health care provider. It is important that oral care be given after each meal and that the mouth and gums be inspected routinely.

The nurse monitors vital signs every 4 hours or as ordered. Any adverse drug reactions or signs of toxicity are reported to the primary health care provider immediately.

**Nursing Alert**

When administering phenytoin, the nurse closely monitors the patient for the following signs of drug toxicity: slurred speech, ataxia, lethargy, dizziness, nausea, and vomiting. Phenytoin plasma levels between 10 and 20 mcg/mL give optimal anticonvulsant effect. However, many patients achieve seizure control at lower serum concentration levels. Levels greater than 20 mcg/mL are associated with toxicity. Patients with plasma levels greater than 20 mcg/mL may exhibit nystagmus, and at concentrations greater than 30 mcg/mL, ataxia and mental changes are usually seen.

**OXAZOLIDINEDIONES.** Drowsiness is the most common adverse reaction and, as with the other anticonvulsants, tends to subside with continued use. Visual disturbances may also occur. The patient with a visual disturbance is assisted with ambulation and oriented carefully to the environment. The nurse ensures that the environment is safe. The patient may be especially sensitive to bright lights and may want the room light to be kept dim. Because photosensitivity can occur, the nurse must keep the patient out of the sun. The nurse instructs the patient to use sunscreens and protective clothing until the individual effects of the drug are known.

**SUCCINIMIDES.** The succinimides are particularly toxic. The nurse must be alert for signs of blood dyscrasias, such as the presence of fever, sore throat, and general malaise. The nurse reports any of these symptoms immediately because fatal blood dyscrasias have occurred. Routine blood tests may be performed, such as complete blood counts and differential counts.

**MISCELLANEOUS ANTICONVULSANTS.** A severe and potentially fatal rash can occur in patients taking lamotrigine. The nurse must immediately report any rash in
a patient taking lamotrigine to the primary health care provider before the next dose is due. Discontinuation of the drug may be required.

**Educating the Patient and Family**

When the patient receives a diagnosis of epilepsy, the nurse must assist the patient and the family to adjust to the diagnosis. The nurse should instruct family members in the care of the patient before, during, and after a seizure. The nurse explains the importance of restricting some activities until the seizures are controlled by drugs. Restriction of activities often depend on the age, sex, and occupation of the patient. For example, the nurse should advise a mother with a seizure disorder who has a newborn infant to have help when caring for her child. The nurse also would warn a carpenter about climbing ladders or using power tools. For some patients, the restriction of activities may create problems with such things as employment, management of the home environment, or child care. If a problem is recognized, a referral may be needed to a social worker, discharge planning coordinator, or public health nurse.

The nurse reviews adverse drug reactions associated with the prescribed anticonvulsant with the patient and family members. The patient and family members are instructed to contact the primary health care provider if any adverse reactions occur before the next dose of the drug is due. The patient must not stop taking the drug until the problem is discussed with the primary health care provider.

Some patients, once their seizures are under control (eg, stop occurring or occur less frequently), may have a tendency to stop the drug abruptly or begin to omit a dose occasionally. The drug must never be abruptly discontinued or doses omitted. If the patient experiences drowsiness during initial therapy, a family member should be responsible for administration of the drug.

The nurse should include the following points in a patient and family teaching plan.

- Do not omit, increase, or decrease the prescribed dose.
- Anticonvulsant blood levels must be monitored at regular intervals, even if the seizures are well controlled.

**Nursing Alert**
The nurse must report symptoms of succinimide overdosage immediately. Symptoms of overdosage include confusion, sleepiness, unsteadiness, flaccid muscles, slow shallow respirations, nausea, vomiting, hypotension, absent reflexes, and CNS depression leading to coma. It is important to report symptoms to the primary health care provider immediately. Therapeutic serum blood levels of ethosuximide (Zarontin) range from 40 to 100 mcg/mL.

- This drug should never be abruptly discontinued, except when recommended by the primary health care provider.
- If the primary health care provider finds it necessary to stop the drug, another drug usually is prescribed. Start taking this drug immediately (at the time the next dose of the previously used drug was due).
- These drugs may cause drowsiness or dizziness. Observe caution when performing hazardous tasks. Do not drive unless the adverse reactions of drowsiness, dizziness, or blurred vision are not significant. Driving privileges will be given by the primary health care provider based on seizure control.
- Avoid the use of alcohol unless use has been approved by the primary health care provider.
- Carry identification, such as a Medic-Alert tag, indicating drug use and the type of seizure disorder.
- Do not use any nonprescription drug unless use of a specific drug has been approved by the primary health care provider.
- Keep a record of all seizures (date, time, length), as well as any minor problems (eg, drowsiness, dizziness, lethargy), and bring this information to each clinic or office visit.
- Contact the local branches of agencies, such as the Epilepsy Foundation of America, for information services, and job training or retraining.

**HYDANTOINS**

- Inform the dentist and other primary health care providers of use of this drug.
- Brush and floss the teeth after each meal and make periodic dental appointments for oral examination and care.
- Take the medication with food to reduce gastrointestinal upset.
- Phenytoin suspension must be thoroughly shaken immediately before use.
- Do not use when capsules are discolored.
- Notify the primary health care provider if any of the following occurs: skin rash, bleeding, swollen or tender gums, yellowish discoloration of the skin or eyes, unexplained fever, sore throat, unusual bleeding or bruising, persistent headache, malaise, or pregnancy.

**SUCCINIMIDES**

- If gastrointestinal upsets occurs, take the drug with food or milk.
- Phensuximide may discolor the urine pink, red, or red-brown. This is not abnormal and will cause no harm.
- Notify the primary health care provider if any of the following occurs: skin rash, joint pain, unexplained fever, sore throat, usual bleeding or bruising, drowsiness, dizziness, blurred vision, or pregnancy.
OXAZOLIDINEDIONES
- This drug may cause photosensitivity. Take protective measures (eg, use sunscreens, wear protective clothing) when exposed to ultraviolet light or sunlight until tolerance is determined.
- Notify the primary care provider if the following reactions occur: visual disturbances, excessive drowsiness or dizziness, sore throat, fever, skin rash, pregnancy, malaise, easy bruising, epistaxis, or bleeding tendencies.
- Avoid pregnancy while taking trimethadione; the drug has caused serious birth defects.

EVALUATION
- The therapeutic effect is achieved, and convulsions are controlled.
- No evidence of injury is seen.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
- Oral mucous membranes appear normal.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.
- The patient verbalizes an understanding of treatment modalities and the importance of continued follow-up care.
- The patient and family demonstrate an understanding of the drug regimen.

Critical Thinking Exercises
1. Ms. Taylor tells you that since she has been taking phenytoin she has had no seizures. In fact, she states that she has omitted one or two doses over the last month because she is “doing so well.” Explain your response to Ms. Taylor’s statement.
2. Mr. Parks, age 32 years, has recently received a diagnosis of epilepsy. He has been taking the anticonvulsant carbamazepine, but his seizures are not yet under control. Mr. Parks asks you how long it will take to “cure” his epilepsy. Determine how you would respond to Mr. Parks.
3. Develop a teaching plan educating the family members on what to do when the patient has a seizure.

Review Questions
1. A patient is prescribed phenytoin for a recurrent convulsive disorder. The nurse informs the patient that the most common adverse reactions are _______.
   A. related to the gastrointestinal system
   B. associated with the reproductive system
   C. associated with kidney function
   D. related to the CNS

2. Which of the following adverse reactions, if observed in a patient prescribed phenytoin, would indicate that the patient may be developing phenytoin toxicity?
   A. severe occipital headache
   B. ataxia
   C. hyperactivity
   D. somnolence

3. When administering phenobarbital to an elderly patient the nurse should monitor the patient for unusual effects of the drug such as _______.
   A. marked excitement
   B. excessive sweating
   C. insomnia
   D. agitation

4. When caring for a patient taking a succinimide for absent seizures, the nurse monitors the patient for blood dyscrasias. Which of the following symptoms would indicate that the patient may be developing a blood dyscrasia?
   A. constipation, blood in the stool
   B. diarrhea, lethargy
   C. sore throat, general malaise
   D. hyperthermia, excitement

5. Which statement would be included when educating the patient taking trimethadione for absence seizures?
   A. Take this drug with milk to enhance absorption.
   B. Wear a sunscreen and protective clothing when exposed to sunlight.
   C. To minimize adverse reactions, take this drug once daily at bedtime.
   D. Visit a dentist frequently because this drug increases the risk of gum disease.

Medication Dosage Problems
1. The nurse is preparing to administer an anticonvulsant for status epilepticus. The primary care provider prescribes Luminal 200 mg IV. The drug is available in a dosage of 60 mg/mL. The nurse administers _______.

2. Zonisamide 200 mg is prescribed. The drug is available in 100-mg tablets. The nurse administers _______.

3. The primary care provider prescribes ethosuximide syrup 500 mg for a patient with absence seizures. The drug is available in a strength of 250 mg/5 mL. The nurse administers _______.
Antiparkinsonism Drugs

**Key Terms**

<table>
<thead>
<tr>
<th>Blood–Brain Barrier</th>
<th>On-off Phenomenon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choreiform Movements</td>
<td>Parkinson’s Disease</td>
</tr>
<tr>
<td>Dystonic Movements</td>
<td>Parkinsonism</td>
</tr>
</tbody>
</table>

**Chapter Objectives**

On completion of this chapter, the student will:

- Define the terms Parkinson’s disease and parkinsonism.
- Discuss the uses, general drug action, adverse drug reactions, contraindications, precautions, and interactions of the antiparkinsonism drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking antiparkinsonism drugs.
- List some nursing diagnoses particular to a patient taking antiparkinsonism drugs.
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating patients about the use of the antiparkinsonism drugs.

**Parkinson’s Disease**

Also called paralysis agitans, is a degenerative disorder of the central nervous system (CNS). The disease is thought to be caused by a deficiency of dopamine and an excess of acetylcholine within the CNS. Parkinson’s disease affects the part of the brain that controls muscle movement, causing such symptoms as trembling, rigidity, difficulty walking, and problems in balance. It is characterized by fine tremors and rigidity of some muscle groups and weakness of others. Parkinson’s disease is progressive, that is the symptoms become worse over time. As the disease progresses, speech becomes slurred, the face has a masklike and emotionless expression, and the patient may have difficulty chewing and swallowing. The patient may have a shuffling and unsteady gait, and the upper part of the body is bent forward. Fine tremors begin in the fingers with a pill-rolling movement, increase with stress, and decrease with purposeful movement. Depression or dementia may occur, causing memory impairment and alterations in thinking.

Parkinson’s disease has no cure, but the antiparkinsonism drugs are used to relieve the symptoms and assist in maintaining the patient’s mobility and functioning capability as long as possible. For years, levodopa was the drug that provided the mainstay of treatment. Now, there are new drugs that are used either alone or in combination with levodopa. Entacapone (Comtan), pramipexole (Mirapex), and ropinirole (Requip) are newer drugs used in the treatment of Parkinson’s disease. Drug-induced parkinsonism is treated with the anticholinergics benzotropine (Cogentin) and trihexyphenidyl (Artane).

**Parkinsonism** is a term that refers to the symptoms of Parkinson’s disease, as well as the Parkinson-like symptoms that may be seen with the use of certain drugs, head injuries, and encephalitis. Drugs used to treat the symptoms associated with parkinsonism are called antiparkinsonism drugs. As with some other types of drugs, it may be necessary to change from one antiparkinsonism drug to another or to increase or decrease the dosage until maximum response is obtained. The Summary Drug Table: Antiparkinsonism Drugs provides a listing of the drugs used to treat Parkinson’s disease. Antiparkinsonism drugs discussed in the chapter are classified as dopaminergic agents, anticholinergic drugs, COMT inhibitors, and dopamine receptor agonists (non-ergot).

**Dopaminergic Drugs**

Dopaminergic drugs are drugs that affect the dopamine content of the brain. These drugs include levodopa (Larodopa), carbidopa (Lodosyn), amantadine (Symmetrel),...
and pergolide mesylate (Permax). (See Summary Drug Table: Antiparkinsonism Drugs).

**ACTIONS**

The symptoms of parkinsonism are caused by a depletion of dopamine in the CNS. Dopamine, when given orally, does not cross the blood–brain barrier and therefore is ineffective. The body’s **blood–brain barrier** is a meshwork of tightly packed cells in the walls of the brain’s capillaries that screen out certain substances. This unique meshwork of cells in the CNS prohibits large and potentially harmful molecules from crossing into the brain. This ability to screen out certain substances has important implications for drug therapy because some drugs are able to pass through the blood–brain barrier more easily than others.

Levodopa is a chemical formulation found in plants and animals that is converted into dopamine by nerve cells in the brain. Levodopa does cross the blood–brain barrier, and a small amount is then converted to dopamine. This allows the drug to have a pharmacologic effect in patients with Parkinson’s disease (Fig. 29-1). Combining levodopa with another drug (carbidopa) causes more levodopa to reach the brain. When more levodopa is available, the dosage of levodopa may be reduced. Carbidopa has no effect when given alone. Sinemet is a combination of carbidopa and levodopa and is available in several combinations (eg, Sinemet 10/100 has 10 mg of carbidopa and 100 mg of levodopa; Sinemet CR is a time-released version of the combined drugs).

The mechanism of action of amantadine (Symmetrel) and selegiline (Eldepryl) in the treatment of parkinsonism is not fully understood.

**USES**

The dopaminergic drugs are used to treat the signs and symptoms of parkinsonism. As with some other types of drugs, it may be necessary to change from one antiparkinsonism drug to another or to increase or decrease the dosage until maximum response is obtained.

Levodopa has been considered the gold standard drug therapy for Parkinson’s disease since it was first used in the 1960s. Carbidopa is always given with levodopa, combined either as one drug or as two separate drugs. When it is necessary to titrate the dose of carbidopa, both carbidopa and levodopa may be given at the same time, but as separate drugs. Sometimes the response with these two drugs can be enhanced by the addition of another drug. For example, selegiline or pergolide may be added to the drug regimen of those being treated with carbidopa and levodopa but who have had a decreased response to therapy with these two drugs.

A mantadine is less effective than levodopa in the treatment of Parkinson’s disease but more effective than the anticholinergics. A mantadine may be given alone or in combination with an antiparkinsonism drug with anticholinergic activity. A mantadine is also used as an antiviral drug (see Chap. 14).

**ADVERSE REACTIONS**

During early treatment with levodopa and carbidopa, adverse reactions are usually not a problem. But as the disease progresses, the response to the drug may become less, and the period of time that each dose is effective begins to decrease, leading to more frequent doses, and more adverse reactions.

The most serious and frequent adverse reactions seen with levodopa include **choreiform movements**
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dopaminergic Agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amantadine</td>
<td>Symmetrel, generic</td>
<td>Parkinson's disease/ drug-induced extrapyramidal reactions, prevention and treatment of influenza A virus</td>
<td>Light-headedness, dizziness, insomnia, confusion, nausea, constipation, dry mouth, orthostatic hypotension, depression</td>
<td>100–400 mg/d PO in divided doses</td>
</tr>
<tr>
<td>bromocriptine</td>
<td>Parlodel, Parlodel Snap Tabs</td>
<td>Parkinson's disease</td>
<td>Drowsiness, sedation, dizziness, faintness, epigastric distress, anorexia</td>
<td>1.25–100 mg/d PO</td>
</tr>
<tr>
<td>carbidopa</td>
<td>Lodosyn</td>
<td>Used with levodopa in the treatment of Parkinson's disease</td>
<td>None when given alone; when administered with levodopa, adverse reactions of levodopa</td>
<td>Up to 200 mg/d PO</td>
</tr>
<tr>
<td>carbidopa/levodopa</td>
<td>Sinemet CR, Sinemet 10/100, Sinemet 25/100, Sinemet 25/250, generic</td>
<td>Parkinson's disease</td>
<td>Same as levodopa</td>
<td>Dosages individualized to obtain therapeutic effect; average dose is 1 tablet PO TID</td>
</tr>
<tr>
<td>levodopa</td>
<td>Dopar, Larodopa, generic</td>
<td>Parkinson's disease</td>
<td>Choreiform or dystonic movements, anorexia, nausea, vomiting, abdominal pain, dysphagia, dry mouth, mental changes, headache, dizziness, increased hand tremor</td>
<td>0.5–8 g/d</td>
</tr>
<tr>
<td>pergolide</td>
<td>Permax</td>
<td>As adjunct to levodopa/carbidopa in Parkinson's disease</td>
<td>Nausea, dyskinesia, dizziness, hallucinations, somnolence, insomnia, peripheral edema, constipation</td>
<td>0.05–3 mg/d PO TID</td>
</tr>
<tr>
<td>selegiline</td>
<td>Carbex, Eldepryl, generic</td>
<td>As adjunct to levodopa/carbidopa in Parkinson's disease</td>
<td>Nausea, hallucinations, confusion, depression, loss of balance, dizziness, nausea</td>
<td>10 mg/d PO in divided doses</td>
</tr>
<tr>
<td><strong>Anticholinergic Agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>benztropine mesylate</td>
<td>Cogentin, generic</td>
<td>Adjunct therapy in Parkinson's disease</td>
<td>Dry mouth, blurred vision, dizziness, nausea, nervousness, skin rash, urinary retention, dysuria, tachycardia, muscle weakness, disorientation, confusion</td>
<td>0.5–6 mg/d PO, IM, IV</td>
</tr>
<tr>
<td>biperiden</td>
<td>Akineton</td>
<td>Adjunct therapy in Parkinson's disease</td>
<td>Same as benztropine mesylate</td>
<td>2 mg PO 3–4 times/d; maximum dose, 16 mg/24h; 2 mg IM or IV</td>
</tr>
<tr>
<td>diphenhydramine</td>
<td>Benadryl, generic</td>
<td>Drug-induced extrapyramidal reactions in Parkinson's disease, allergies</td>
<td>Same as benztropine mesylate</td>
<td>25–50 mg PO q4–6h; 10–400 mg IM, IV</td>
</tr>
<tr>
<td>procyclidine</td>
<td>Kemadrin</td>
<td>Parkinson's disease</td>
<td>Same as benztropine mesylate</td>
<td>2.5–5 mg PO TID</td>
</tr>
<tr>
<td>trihexyphenidyl</td>
<td>Artane, Trihexy-2, generic</td>
<td>Adjunct in the treatment of Parkinson's disease</td>
<td>Same as benztropine mesylate</td>
<td>1–15 mg/d PO in divided doses</td>
</tr>
</tbody>
</table>
### COMT Inhibitors

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>entacapone</td>
<td>Comtan</td>
<td>As adjunct to levodopa/carbidopa in Parkinson’s disease</td>
<td>Orthostatic hypotension, dyskinesia, sleep disorders, dystonia, excessive dreaming, somnolence, confusion, dizziness, nausea, anorexia, diarrhea, muscle cramps</td>
<td>200–1600 mg/d PO</td>
</tr>
<tr>
<td>tolcapone</td>
<td>Tasmar</td>
<td>As adjunct to levodopa/carbidopa in Parkinson’s disease</td>
<td>Orthostatic hypotension, dyskinesia, sleep disorders, dystonia, excessive dreaming, somnolence, confusion, dizziness, nausea, anorexia, diarrhea, muscle cramps</td>
<td>100–200 mg PO TID</td>
</tr>
</tbody>
</table>

### Dopamine Receptor Agonists, Non-Ergot

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>pramipexole</td>
<td>Mirapex</td>
<td>Parkinson’s disease</td>
<td>Dizziness, somnolence, insomnia, hallucinations, confusion, nausea, dyspepsia, syncope</td>
<td>0.125–1.5 mg PO TID</td>
</tr>
<tr>
<td>ropinirole HCL</td>
<td>Requip</td>
<td>Parkinson’s disease</td>
<td>Dizziness, somnolence, insomnia, hallucinations, confusion, nausea, dyspepsia, syncope</td>
<td>0.25–1 mg PO TID; maximum dose, 24 mg/d</td>
</tr>
</tbody>
</table>

* The term generic indicates the drug is available in generic form.

... (involuntary muscular twitching of the limbs or facial muscles) and dystonic movements (muscular spasms most often affecting the tongue, jaw, eyes, and neck). Less common but serious reactions include mental changes, such as depression, psychotic episodes, paranoia, and suicidal tendencies. Common and less serious adverse reactions include anorexia, nausea, vomiting, abdominal pain, dry mouth, difficulty in swallowing, increased hand tremor, headache, and dizziness. Carbidopa is used with levodopa and has no effect when given alone.

The most common serious adverse reactions to amantadine are orthostatic hypotension, depression, congestive heart failure, psychosis, urinary retention, convulsions, leukopenia, and neutropenia. Less serious reactions include hallucinations, confusion, anxiety, anorexia, nausea, and constipation. Adverse reactions with selegiline include nausea, hallucinations, confusion, depression, loss of balance, and dizziness.

### CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The dopaminergic drugs are contraindicated in patients with known hypersensitivity to the drugs. Levodopa is contraindicated in patients with narrow-angle glaucoma, those receiving a monoamine oxidase inhibitor (see Chap. 31), and during lactation. Levodopa is used cautiously in patients with cardiovascular disease, bronchial asthma, emphysema, peptic ulcer disease, renal or hepatic disease, and psychosis. Levodopa and combination antiparkinsonism drugs (eg, carbidopa/levodopa) are classified as Pregnancy Category C and are used with caution during pregnancy and lactation.

Levodopa interacts with many different drugs. When levodopa is used with phenytoin, reserpine, and papaverine, there is a decrease in response to levodopa. The risk of a hypertensive crisis increases when levodopa is used with the monoamine oxidase inhibitors (see Chap. 31). Foods high in pyridoxine (vitamin B6) or vitamin B6 preparations reverse the effect of levodopa. However, when carbidopa is used with levodopa, pyridoxine has no effect on the action of levodopa. In fact, when levodopa and carbidopa are given together, pyridoxine may be prescribed to decrease the adverse effects associated with levodopa.

Selegiline is used cautiously in patients with psychosis, dementia, or excessive tremor. When selegiline is administered with levodopa, the effectiveness of levodopa increases. This effect allows for a decrease in the dosage of levodopa. If selegiline is given in doses greater than 10 mg/d there is an increased risk of hypertension, particularly if tyramine-containing foods (eg, beer, wine, aged cheese, yeast products, chicken livers, and pickled herring) are ingested. A potentially serious reaction...
confusion, agitation, hypertension, and seizures) can occur when fluoxetine is administered with selegiline. Fluoxetine therapy is discontinued for at least 1 week before treatment with selegiline is initiated.

A mantadine is used cautiously in patients with seizure disorders, hepatic disease, psychosis, cardiac disease, and renal disease. The antihistamines, phenothiazines, disopyramide, and alcohol increase the risk of adverse reactions when administered with amantadine.

**ANTICHOLINERGIC DRUGS**

**ACTIONS**

Drugs with anticholinergic activity inhibit acetylcholine (a neurohormone produced in excess in Parkinson's disease) in the CNS. Drugs with anticholinergic activity are generally less effective than levodopa.

**USES**

Drugs with anticholinergic activity are used as adjunctive therapy in all forms of parkinsonism and in the control of drug-induced extrapyramidal disorders. Examples of drugs with anticholinergic activity include benztropine mesylate (Cogentin), biperiden (Akineton), diphenhydramine, procyclidine (Kemadrin), and trihexyphenidyl (Artane). See Summary Drug Table: Antiparkinsonism Drugs for specific uses of these drugs.

**ADVERSE REACTIONS**

Frequently seen adverse reactions to drugs with anticholinergic activity include dry mouth, blurred vision, dizziness, mild nausea, and nervousness. These may become less pronounced as therapy progresses. Other adverse reactions may include skin rash, urticaria (hives), urinary retention, dysuria, tachycardia, muscle weakness, disorientation, and confusion. If any of these reactions are severe, the drug may be discontinued for several days and restarted at a lower dosage, or a different antiparkinsonism drug may be prescribed.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

These drugs are contraindicated in those with a hypersensitivity to the anticholinergic drugs, those with glaucoma (angle-closure), pyloric or duodenal obstruction, peptic ulcers, prostatic hypertrophy, achalasia (failure of the muscles of the lower esophagus to relax causing difficulty swallowing), myasthenia gravis, and megacolon.

These drugs are used with caution in patients with tachycardia, cardiac arrhythmias, hypertension, hypotension, those with a tendency toward urinary retention, those with decreased liver or kidney function, and those with obstructive disease of the urinary system or gastrointestinal tract. The anticholinergic drugs are given with caution to the older adult.

**Gerontologic Alert**

Individuals older than 60 years frequently develop increased sensitivity to anticholinergic drugs and require careful monitoring. Confusion and disorientation may occur. Lower doses may be required.

When the anticholinergic drugs are administered with amantadine, there is an increased anticholinergic effect. When digoxin is administered with an anticholinergic drug, digoxin blood levels may be increased, leading to an increased risk for digitalis toxicity. Haloperidol and anticholinergic co-administration may result in worsening of schizophrenic symptoms, decreased haloperidol blood levels, and development of tardive dyskinesia (see Chap. 32). When the anticholinergic drugs are administered with the phenothiazines, there is a decrease in the therapeutic effects of the phenothiazines and an increase in anticholinergic adverse reactions.

**COMT INHIBITORS**

A newer classification of antiparkinson drugs is the catechol-O-methyltransferase (COMT) inhibitors. Examples of the COMT inhibitors are entacapone (Comtan) and tolcapone (Tasmar).

**ACTIONS**

These drugs are thought to prolong the effect of levodopa by blocking an enzyme, catechol-O-methyltransferase (COMT), which eliminates dopamine. When given with levodopa, the COMT inhibitors increase the plasma concentrations and duration of action of levodopa.

**USES**

The COMT inhibitors are used as adjuncts to levodopa/carbidopa in Parkinson’s disease. Tolcapone is a potent COMT inhibitor that easily crosses the blood–brain barrier. However, the drug is associated with liver damage.
ADVERSE REACTIONS

The adverse reactions most often associated with the administration of the COMT inhibitors include disorientation, confusion, light-headedness, dizziness, dyskinesias, hyperkinesias, nausea, vomiting, hallucinations, and fever. Other adverse reactions are orthostatic hypotension, sleep disorders, excessive dreaming, somnolence, and muscle cramps. A serious and possibly fatal adverse reaction that can occur with the administration of tolcapone is liver failure.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

These drugs are contraindicated in patients with a hypersensitivity to the drugs and during pregnancy (Category C) and lactation. Tolcapone is contraindicated in patients with liver dysfunction. The COMT inhibitors are used with caution in patients with hypertension, hypotension, and decreased hepatic or renal function.

The COMT inhibitors should not be administered with the monoamine oxidase (MAO) inhibitors (see Chap. 31) because there is an increased risk of toxicity. If the COMT inhibitors are administered with norepinephrine, dopamine, dobutamine, methyldopa, or epinephrine, there is a risk of increased heart rate, arrhythmias, and excessive blood pressure changes.

DOPAMINE RECEPTOR AGONISTS (NON-ERGOT)

ACTIONS

The exact mechanism of action of these drugs is not understood. It is thought that these drugs act directly on postsynaptic dopamine receptors of nerve cells in the brain, mimicking the effects of dopamine in the brain.

USES

The dopamine receptor agonists, such as pramipexole (Mirapex) and ropinirole (Requip), are used for the treatment of the signs and symptoms of Parkinson’s disease.

ADVERSE REACTIONS

The most common adverse reactions seen with pramipexole and ropinirole include nausea, dizziness, postural hypotension, hallucinations, somnolence, vomiting, confusion, visual disturbances, abnormal involuntary movements, and headache.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The dopamine receptor agonists are contraindicated in patients with known hypersensitivity to the drugs, severe ischemic heart disease, or peripheral vascular disease. The dopamine receptor agonists are used with caution in patients with dyskinesia, orthostatic hypotension, and hepatic or renal impairment. The dopamine receptor agonists are used cautiously in patients with a history of hallucinations or psychosis, cardiovascular disease, and renal impairment. Both ropinirole and pramipexole are Pregnancy Category C drugs, and safety during pregnancy has not been established.

There is an increased risk of CNS depression when the dopamine receptor agonists are administered with other CNS depressants. When administered with levodopa, the dopamine receptor agonists increase the effects of levodopa (a lower dosage of levodopa may be required). In addition, when the dopamine receptor agonists are administered with levodopa, there is an increased risk of hallucinations. When administered with ciprofloxacin, there is an increased effect of the dopamine receptor agonist.

The phenothiazines may decrease the effectiveness of the dopamine receptor agonists. When pramipexole is administered concurrently with cimetidine, ranitidine, verapamil, and quinidine, there is an increased effect of pramipexole. When ropinirole is administered with the estrogens, particularly estradiol, there may be an increased effect of ropinirole.

NURSING PROCESS

The Patient Receiving an Antiparkinsonism Drug

ASSESSMENT

Preadministration Assessment

Because of memory impairment and alterations in thinking in some patients with parkinsonism, a history obtained from the patient may be unreliable. When necessary, the nurse obtains the health history from a family member. Important data to include is information regarding the symptoms of the disorder, the length of
time the symptoms have been present, the ability of the patient to carry on activities of daily living, and the patient’s current mental condition (eg, impairment in memory, signs of depression, or withdrawal).

Before starting the drug therapy, the nurse performs a physical assessment of the patient to provide a baseline for future evaluations of drug therapy. It is also important to include an evaluation of the patient’s neurologic status. Display 29-1 describes the assessments the nurse would make when evaluating the neurological status.

**Ongoing Assessment**
The nurse evaluates the patient’s response to drug therapy by neurologic observations (see Display 29-1) and compares these observations with the data obtained during the initial physical assessment. For example, the patient is assessed for clinical improvement of the symptoms of the disease, such as improvement of tremor of head and/or hands at rest, muscular rigidity, mask-like facial expression, and ambulation stability. Although drug response may occur slowly in some patients, these observations aid the primary health care provider in adjusting the dosage of the drug upward or downward to obtain the desired therapeutic results.

**NURSING DIAGNOSES**
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**
The expected outcomes for the patient may include an optimal response to drug therapy, management of common adverse drug reactions, absence of injury, and an understanding of and compliance with the prescribed therapeutic regimen.

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**
Effective management of the patient with parkinsonism requires that the nurse carefully monitor the drug therapy, provide psychological support, and place a strong emphasis on patient and family teaching.

The drugs used to treat parkinsonism also may be used to treat the symptoms of parkinsonism that occur with the administration of some of the psychotherapeutic drugs (see Chap. 32). When used for this purpose, the antiparkinsonism drugs may exacerbate mental symptoms and precipitate a psychosis. The nurse must observe the patient’s behavior at frequent intervals. If sudden behavioral changes are noted, the nurse withhold the next dose of the drug and immediately notifies the primary health care provider.

**Monitoring and Managing Adverse Drug Reactions**
The nurse observes the patient daily for the development of adverse reactions. All adverse reactions are reported to the primary health care provider because a dosage adjustment or change to a different antiparkinsonism drug may be necessary with the occurrence of the more serious adverse reactions.

**Nursing Alert**
The nurse observes patients receiving levodopa or carbidopa and levodopa for the occurrence of choreiform and dystonic movements, such as facial grimacing, protruding tongue, exaggerated chewing motions and head movements, and jerking movements of the arms and legs. If these occur, the nurse should withhold the next dose of the drug and notify the primary health care provider because it may be necessary to reduce the dosage of levodopa or discontinue use of the drug.

Some adverse reactions, although not serious, may be uncomfortable. An example of a less serious but uncomfortable adverse reaction is dryness of the mouth. The nurse can help relieve dry mouth by offering frequent

**DISPLAY 29-1  Neurologic Evaluation**
The neurologic evaluation includes observation for the following:
- Tremors of the hands or head while the patient is at rest
- A masklike facial expression
- Changes (from the normal) in walking
- Type of speech pattern (halting, monotone)
- Postural deformities
- Muscular rigidity
- Drooling, difficulty in chewing or swallowing
- Changes in thought processes
- Ability of the patient to carry out any or all of the activities of daily living (eg, bathing, ambulating, dressing)
sips of water, ice chips, or hard candy (if allowed). If dry mouth is so severe that there is difficulty in swallowing or speaking, or if loss of appetite and weight loss occurs, the dosage of the antiparkinsonism drug may be reduced. Some patients taking the antiparkinsonism drugs experience gastrointestinal disturbances such as nausea, vomiting, or constipation. This can affect the patient's nutritional status. It is a good idea for the nurse to create a calm environment, serve small frequent meals, and serve foods the patient prefers to help improve nutrition. The nurse also may monitor the patient's weight daily. Gastrointestinal disturbances are sometimes helped by taking the drug with meals. Severe nausea or vomiting may necessitate discontinuing the drug and changing to a different antiparkinsonism drug. With continued use of the drug, nausea usually decreases or is resolved. If constipation is a problem, the nurse stresses the need for a diet high in fiber and increasing fluids in the diet. A stool softener may be needed to help prevent constipation.

Minimizing the risk for injury is an important aspect in the care of the patient with parkinsonism. These patients may have difficulty ambulating. Adverse reactions, such as dizziness, muscle weakness, and ataxia (lack of muscular coordination) may further increase difficulty with ambulatory activities. These individuals are especially prone to falls and other accidents because of their disease process and possible adverse drug reactions. The nurse assists the patient in getting out of the bed or a chair, walking, and other self-care activities. In addition, assistive devices such as a cane or walker may be helpful with ambulation. The nurse may suggest that the patient wear shoes with rubber soles to minimize the possibility of slipping. Patients are prone to orthostatic hypotension as a result of the drug regimen. These patients are instructed to arise slowly from a sitting or lying position, especially after sitting or lying for a prolonged time.

The on-off phenomenon may occur in patients taking levodopa. In this condition, the patient may suddenly alternate between improved clinical status and loss of therapeutic effect. This effect is associated with long-term levodopa treatment. Low doses of the drug, reserving the drug for severe cases, or the use of a “drug holiday” may be prescribed. Should symptoms occur, the primary health care provider may order a drug holiday that includes complete withdrawal of levodopa for 5 to 14 days, followed by gradually restarting use of the drug at a lower dose.

Visual difficulties (eg, adverse reactions of blurred vision and diplopia) may be evidenced by the patient's sudden refusal to read or watch television or by the patient bumping into objects when ambulating. The nurse carefully evaluates any sudden changes in the patient's behavior or activity and reports them to the primary health care provider. The patient with visual difficulties may need assistance with ambulation. The room should be kept well lighted, the use of scatter or throw rugs should be avoided, and any small pieces of furniture or objects that might increase the risk of falling should be removed. The nurse carefully assesses the environment and makes the necessary adjustments to ensure the patient's safety.
Educating the Patient and Family
The nurse evaluates the patient’s ability to understand the therapeutic drug regimen, ability to care for himself or herself in the home environment, and ability to comply with the prescribed drug therapy. If any type of assistance is needed, the nurse provides a referral to the discharge planning coordinator or social worker.

If the patient requires supervision or help with daily activities and the drug regimen, the nurse encourages the family to create a home environment that is least likely to result in accidents or falls. Changes such as removing throw rugs, installing a handrail next to the toilet, and moving obstacles that can result in tripping or falling can be made at little or no expense to the family.

The nurse should include the following information in the patient and family teaching plan:

• Take this drug as prescribed. Do not increase, decrease, or omit a dose or stop taking the drug unless advised to do so by the primary health care provider. If gastrointestinal upset occurs, take the drug with food.
• If dizziness, drowsiness, or blurred vision occurs, avoid driving or performing other tasks that require alertness.
• Avoid the use of alcohol unless use has been approved by the primary health care provider.
• Relieve dry mouth by sucking on hard candy (unless the patient has diabetes) or frequent sips of water. Consult a dentist if dryness of the mouth interferes with wearing, inserting, or removing dentures or causes other dental problems.
• Inform patients that orthostatic hypotension may develop with or without symptoms of dizziness, nausea, fainting, and sweating. Caution the patient against rising rapidly after sitting or lying down.
• Notify the primary health care provider if any of these problems occur: severe dry mouth, inability to chew or swallow food, inability to urinate, feelings of depression, severe dizziness or drowsiness, rapid or irregular heartbeat, abdominal pain, mood changes, and unusual movements of the head, eyes, tongue, neck, arms, legs, feet, mouth, or tongue.
• Keep all appointments with the primary health care provider or clinic personnel because close monitoring of therapy is necessary.
• When taking levodopa, avoid vitamin B6 (pyridoxine) because this vitamin may interfere with the action of levodopa (see Home Care Checklist: Avoiding Certain Foods While Taking Levodopa).
• Patients with diabetes: Levodopa may interfere with urine tests for glucose or ketones. Report any abnormal result to the primary care provider before adjusting the dosage of the antidiabetic medication.
• Tocapone: Keep all appointments with the primary care provider. Liver function tests are performed periodically and are an important part of therapy. Report any signs of liver failure, such as persistent nausea, fatigue, lethargy, anorexia, jaundice, dark urine, pruritus, and right upper quadrant tenderness.

EVALUATION
• The therapeutic effect is achieved and the symptoms of parkinsonism are controlled.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
• No evidence of injury is seen.
• The patient verbalizes an understanding of the treatment modalities, adverse reactions, and importance of continued follow-up care.
• The patient and family demonstrate an understanding of the drug regimen.

Critical Thinking Exercises
1. Ms. Dennis, age 89 years, has Parkinson’s disease and is taking amantadine daily. In discussing her care with the family, determine what information you would include in the teaching plan and what information would be most important for the family to understand. Explain your answer.
2. Ms. Whitman is taking two drugs for Parkinson’s disease: levodopa and carbidopa. Ms. Whitman questions you as to why she received two drugs while her friend with Parkinson’s disease is taking only one drug. Discuss how you would explain this to Ms. Whitman.
3. Discuss the special considerations the nurse should be aware of when administering tocapone.
4. Explain what adverse reaction would be more likely to occur in the older adult prescribed a non-ergot dopamine receptor agonist drug. Describe how you would assess for this adverse reaction.

Review Questions
1. The most serious adverse reactions seen with levodopa include ________.
   A. choreiform and dystonic movements
   B. depression
   C. suicidal tendencies
   D. paranoia
2. Elderly patients prescribed one of the dopamine receptor agonists are monitored closely for which of the following adverse reactions?
   A. occipital headache
   B. hallucinations
   C. paralytic ileus
   D. cardiac arrhythmias
3. When taking an anticholinergic drug for parkinsonism, the patient would mostly experience which of the following adverse reactions?
   A. constipation, urinary frequency
   B. muscle spasm, convulsions
   C. diarrhea, hypertension
   D. dry mouth, dizziness

4. The patient taking tolcapone for Parkinson’s disease is monitored closely for _____.
   A. kidney dysfunction
   B. liver dysfunction
   C. agranulocytosis
   D. the development of an autoimmune disease

---

**Medication Dosage Problems**

1. Levodopa 0.75 g PO is prescribed. The drug is available in 100-mg tablets, 250-mg tablets, and 500-mg tablets. The nurse administers _____.

2. Ropinirole 6 mg PO is prescribed. The drug is available in 2-mg tablets. The nurse administers _____.
Antianxiety Drugs

Key Terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>antianxiety drugs</td>
<td>Drugs used to treat anxiety disorders</td>
</tr>
<tr>
<td>anxiety</td>
<td>A feeling of apprehension, worry, or</td>
</tr>
<tr>
<td>anxiolytics</td>
<td>&quot;Antianxiety drugs&quot; is another term</td>
</tr>
<tr>
<td>benzodiazepine</td>
<td>Drugs included under the antianxiety</td>
</tr>
<tr>
<td>withdrawal</td>
<td>drugs. They include alprazolam (Xanax),</td>
</tr>
<tr>
<td></td>
<td>chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam (Valium), lorazepam (Ativan), and oxazepam (Serax). All benzodiazepines are classified as Schedule IV in the Controlled Substances Act by the Drug Enforcement Agency (DEA) regulations (see Chap. 1). Nonbenzodiazepines useful as antianxiety drugs are buspirone (BuSpar), hydroxyzine (Atarax), and zolpidem (Ambien).</td>
</tr>
<tr>
<td>psychotherapeutic drug</td>
<td>A drug used to treat mental illnesses</td>
</tr>
<tr>
<td>psychotropic drug</td>
<td>The types of psychotherapeutic drugs used to treat mental illness include:</td>
</tr>
<tr>
<td></td>
<td>• Antianxiety drugs (tranquilizers);</td>
</tr>
<tr>
<td></td>
<td>• Antidepressant drugs; and</td>
</tr>
<tr>
<td></td>
<td>• Antipsychotic drugs.</td>
</tr>
</tbody>
</table>

By definition, a psychotherapeutic drug or a psychotropic drug is one that is used to treat disorders of the mind. The types of psychotherapeutic drugs used to treat mental illness include:

- Antianxiety drugs (tranquilizers);
- Antidepressant drugs; and
- Antipsychotic drugs.

The antianxiety drugs are discussed in this chapter. Antidepressant drugs and antipsychotic drugs are discussed in Chapters 31 and 32, respectively.

Anxiety is a feeling of apprehension, worry, or uneasiness that may or may not be based on reality. Anxiety may be seen in many types of situations, ranging from the anxiety that may accompany one’s employment to the acute anxiety that may be seen during withdrawal from alcohol. Although a certain amount of anxiety is normal, excess anxiety interferes with day-to-day functioning and can cause undue stress in the lives of certain individuals. Drugs used to treat anxiety are called antianxiety drugs. Another term that refers to the antianxiety drugs is anxiolytics.

Antianxiety drugs include the benzodiazepines and the nonbenzodiazepines. Examples of the benzodiazepines include alprazolam (Xanax), chlordiazepoxide (Librium), clorazepate (Tranxene), diazepam (Valium), lorazepam (Ativan), and oxazepam (Serax). All benzodiazepines are classified as Schedule IV in the Controlled Substances Act by the Drug Enforcement Agency (DEA) regulations (see Chap. 1). Nonbenzodiazepines useful as antianxiety drugs are buspirone (BuSpar), hydroxyzine (Atarax), and zolpidem (Ambien).

Chapter Objectives

On completion of this chapter, the student will:

- Name the three types of psychotherapeutic drugs.
- Discuss the uses, general drug actions, general adverse reactions, contraindications, precautions, and interactions associated with the administration of the antianxiety drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking antianxiety drugs.
- List some nursing diagnoses particular to a patient taking antianxiety drugs.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating patients about the use of antianxiety drugs.
Antianxiety drugs are used in the management of anxiety disorders and short-term treatment of the symptoms of anxiety. Long-term use of these drugs is usually not recommended because prolonged therapy can result in drug dependence and serious withdrawal symptoms. Some of these drugs may have additional uses as sedatives, muscle relaxants, anticonvulsants, and in the treatment of alcohol withdrawal. For example, clorazepate (Tranxene) and diazepam (Valium) are used as anticonvulsants (see Chap. 28). Additional uses of the individual antianxiety drugs are given in the Summary Drug Table: Antianxiety Drugs.

**USES**

Transient, mild drowsiness is commonly seen during the first few days of treatment with antianxiety drugs. Discontinuation of therapy because of the undesirable effects of the antianxiety agent is rare. Depending on the severity of anxiety or other circumstances, it may be desirable to allow some degree of sedation to occur during early therapy. Other adverse reactions include lethargy, apathy, fatigue, disorientation, anger, restlessness, constipation, diarrhea, dry mouth, nausea, visual disturbances, and incontinence. Some adverse reactions may be seen only when higher dosages are used.

**ADVERSE REACTIONS**

Transients, mild drowsiness is commonly seen during the first few days of treatment with antianxiety drugs. Discontinuation of therapy because of the undesirable effects of the antianxiety agent is rare. Depending on the severity of anxiety or other circumstances, it may be desirable to allow some degree of sedation to occur during early therapy. Other adverse reactions include lethargy, apathy, fatigue, disorientation, anger, restlessness, constipation, diarrhea, dry mouth, nausea, visual disturbances, and incontinence. Some adverse reactions may be seen only when higher dosages are used.

**SUMMARY DRUG TABLE: ANTIANXIETY DRUGS**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benzo diazepines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>alprazolam al-prah-zoe-lam</td>
<td>Xanax, generic</td>
<td>Anxiety disorders, short-term relief of anxiety</td>
<td>Transient mild drowsiness, sedation, nausea, depression, lethargy, apathy, confusion, constipation, diarrhea, dry mouth, incontinence, visual disturbances</td>
<td>0.25–0.5 mg PO TID, may be increased to 4 mg/d in divided doses</td>
</tr>
<tr>
<td>clorazepate klor-az‘eh-pate</td>
<td>Traxene SD, Traxene T, generic</td>
<td>Anxiety disorders, short-term relief of anxiety, acute alcohol withdrawal</td>
<td>Transient mild drowsiness, sedation, nausea, depression, lethargy, apathy, confusion, constipation, diarrhea, dry mouth, incontinence, visual disturbances</td>
<td>Anxiety: 5–25 mg PO 3 or 4 times/d, 50–100 mg IM, IV, then 25–50 mg IM, IV 3 or 4 times/d; acute alcohol withdrawal: up to 300 mg/d PO in divided doses, 50–100 mg IM, IV may repeat in 2–4h</td>
</tr>
<tr>
<td>diazepam dye-az‘e-pam</td>
<td>Valium, generic</td>
<td>Anxiety disorders, short-term relief of anxiety, acute alcohol withdrawal</td>
<td>Transient mild drowsiness, sedation, nausea, depression, lethargy, apathy, confusion, constipation, diarrhea, dry mouth, incontinence, visual disturbances</td>
<td>Individualize dosage: 2–10 mg PO 2–4 times/d (15–30 mg/d), 2–10 mg IM or IV; may repeat in 3–4h if needed</td>
</tr>
<tr>
<td>halazepam hal-az‘e-pam</td>
<td>Paxipam</td>
<td>Anxiety disorders, short-term relief of anxiety</td>
<td>Transient mild drowsiness, sedation, nausea, depression, lethargy, apathy, confusion, constipation, diarrhea, dry mouth, incontinence, visual disturbances</td>
<td>20–40 mg PO 3–4 times/d; increase dosage according to need and tolerance</td>
</tr>
</tbody>
</table>

(continued)
Long-term use of antianxiety drugs may result in physical drug dependence (addiction) and tolerance (increasingly larger dosages required to obtain the desired effect). Withdrawal syndrome has occurred after as little as 4 to 6 weeks of therapy with a benzodiazepine. Withdrawal syndrome is more likely to occur when the benzodiazepine is taken for 3 months or more and is abruptly discontinued. The antianxiety drugs must never be discontinued abruptly because withdrawal symptoms, which can be extremely severe, may occur. The onset of withdrawal symptoms is usually within 1 to 10 days after discontinuing the drug, with the duration of withdrawal symptoms from 5 days to 1 month. Symptoms of withdrawal are identified in Display 30-1.

Dependence

Some antianxiety drugs, such as buspirone (BuSpar), seem to have less abuse potential and less effect on motor ability and cognition than that of the other antianxiety drugs.

### Nursing Alert

When discontinuing use of an antianxiety drug in patients who have used these drugs for prolonged periods, the physician will prescribe a decrease of dosage gradually for a period of 4 to 8 weeks to avoid the possibility of withdrawal symptoms.
CONTRAINDICATIONS

The antianxiety drugs are contraindicated in patients with known hypersensitivity, psychoses, acute narrow-angle glaucoma, and shock. These drugs are also contraindicated in patients in a coma or with acute alcoholic intoxication with depression of vital signs.

The benzodiazepines are Pregnancy Category D drugs, and the drug metabolite freely crosses the placenta. Use of these drugs during pregnancy is contraindicated because of the risk of birth defects or neonatal withdrawal syndrome manifested by irritability tremors and respiratory problems. The benzodiazepines are contraindicated during labor because of reports of floppy infant syndrome manifested by sucking difficulties, lethargy, and hypotonia. Lactating women should also avoid the benzodiazepines because of the effect on the infant, who becomes lethargic and loses weight.

PRECAUTIONS

Antianxiety drugs are used cautiously in patients with impaired liver or kidney function and in elderly and debilitated patients. The metabolism of the benzodiazepines is slowed in the liver, increasing the risk of benzodiazepine toxicity. Lorazepam and oxazepam are the only benzodiazepines whose elimination is not significantly affected by liver metabolism. Two nonbenzodiazepines are Pregnancy Category B drugs (buspirone and zolpidem); hydroxyzine is a Pregnancy Category C drug. No adequate studies have been performed in pregnant women. These drugs should be used during pregnancy only when clearly needed and when the potential good would outweigh any harm to the fetus.

INTERACTIONS

Central nervous system (CNS) depressants such as alcohol, narcotic analgesics, tricyclic antidepressants (see Chap. 31), and the antipsychotic drugs (see Chap. 32), increase the sedative effects of the antianxiety drugs. Combination of any of these drugs with the antianxiety drugs is dangerous and can cause serious respiratory depression and profound sedation. Ingestion of alcohol with the antianxiety drugs can cause convulsions and coma.

Buspirone causes less additive CNS depression than do the other antianxiety drugs. However, it is recommended that concurrent use with a CNS depressant be avoided. Buspirone may increase serum digoxin levels, which increases the risk of digitalis toxicity.

ASSESSMENT

Preadministration Assessment

A patient receiving an antianxiety drug may be treated in the hospital or in an outpatient setting. Before starting therapy for the hospitalized patient, the nurse obtains a complete medical history, including mental status and anxiety level. In the case of mild anxiety, patients may (but sometimes may not) give a reliable history of their illness.

When severe anxiety is present, it is important to obtain the history from a family member or friend. During the time the history is taken, the nurse observes the patient for behavioral symptoms indicating anxiety (e.g., psychomotor agitation [extreme restlessness], facial grimaces, tense posture). Physiologic manifestations of anxiety include increased blood
pressure and pulse rate, increased rate and depth of respiration, and increased muscle tension. An anxious patient will have cool and pale skin. Physical assessments include the blood pressure on both arms and in a sitting position, pulse, respiratory rate, and weight.

In addition, if possible, the nurse obtains a history of any past drug or alcohol abuse. Individuals with a history of previous abuse are more likely to abuse other drugs, such as the antianxiety drugs. Some patients, such as those with mild anxiety or depression, do not necessarily require inpatient care. These patients are usually seen at periodic intervals in the primary health care provider’s office or in a psychiatric outpatient setting. The preadministration assessments of the outpatient are the same as those for the hospitalized patient.

**Ongoing Assessment**

An ongoing assessment is important for the patient taking an antianxiety drug. The nurse checks the patient’s blood pressure before drug administration. If systolic pressure drops 20 mm Hg, the nurse withholds the drug and notifies the primary health care provider. The nurse periodically monitors the patient’s mental status and anxiety level during therapy. The nurse assesses for improvement or worsening of behavioral and physical symptoms identified in the preadministration assessment.

The patient is monitored for adverse reactions. The sedation and drowsiness that sometimes occur with the use of an antianxiety drug may decrease as therapy continues. Prolonged therapy (>3–4 months) may lead to dependence.

When the patient is an outpatient, the nurse observes the patient for a response to therapy at the time of each clinic visit. In some instances, the nurse may question the patient or a family member about the response to therapy. The type of questions asked depends on the patient and the diagnosis and may include questions such as: “How are you feeling?” “Do you seem to be less nervous,” or “Would you like to tell me how everything is going?” Many times the nurse may need to rephrase questions or direct the conversation toward other subjects until these patients feel comfortable and are able to discuss their therapy.

The nurse can ask the patient or a family member about adverse drug reactions or any other problems occurring during therapy. The nurse then brings these reactions or problems to the attention of the primary health care provider. The nurse documents a general summary of the patient’s outward behavior and any complaints or problems in the patient’s record. The nurse then compares notations to previous notations and observations.

---

**Nursing Diagnoses Checklist**

- Anxiety related to (individual manifestations)
- Risk for Injury related to an adverse drug reaction (eg, drowsiness or ataxia)

---

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes of the patient may include an optimal response to drug therapy, management of common adverse drug reactions, and a knowledge of and compliance with the prescribed therapeutic regimen.

**IMPLEMENTATION**

Promoting an Optimal Response to Therapy

The antianxiety drugs are not recommended for long-term use. When the antianxiety drugs are used for short periods (1–2 weeks), tolerance, dependence, or withdrawal symptoms usually do not develop. The nurse reports any signs of tolerance or dependence, such as the patient requesting larger doses of drug or increased anxiety and agitation (see Display 30-1).

When the patient is hospitalized, the nurse develops a nursing care plan to meet the patient’s individual needs. Vital signs are monitored at frequent intervals, usually 3 to 4 times daily. In some instances, such as when hypotensive episodes occur, the vital signs are taken more often. The nurse reports any significant change in the vital signs to the primary health care provider.

Parenteral administration is indicated primarily in acute states. When these drugs are given intramuscularly, the nurse gives them in a large muscle mass, such as the gluteus muscle. The nurse observes the patient closely for at least 3 hours after parenteral administration. The patient is kept lying down (when possible) for 30 minutes to 3 hours after the drug is given.

---

**Gerontologic Alert**

Parenteral (IV or IM) administration to older adults, the debilitated, and those with limited pulmonary reserve requires that the nurse exert extreme care because the patient may experience apnea and cardiac arrest. Resuscitative equipment should be readily available during parenteral (particularly IV) administration.
The nurse may administer oral antianxiety drugs with food or meals to decrease the possibility of gastrointestinal upset. However, the nurse should use great care when administering these drugs orally because some patients have difficulty swallowing (due to a dry mouth or other causes). The patient may chew sugarless gum, suck on hard candy, or take frequent sips of water to reduce discomfort from dry mouth.

**Gerontologic Alert**

Benzodiazepines are excreted more slowly in older adults, causing a prolonged drug effect. The drugs may accumulate in the blood, resulting in an increase in adverse reactions or toxicity. For this reason, the initial dose should be small, and the nurse should increase dosages gradually until a therapeutic response is obtained.

However, lorazepam and oxazepam are relatively safe for older adults when given in normal dosages. Buspirone (BuSpar) also is a safe choice for older adults with anxiety because it does not cause excessive sedation, and the risk of falling is not as great. Before buspirone therapy is begun, benzodiazepines and sedatives and hypnotics are gradually withdrawn. Buspirone, unlike most of the benzodiazepines, must be taken regularly and is not effective on an as-needed basis.

**Monitoring and Managing Adverse Drug Reactions**

During initial therapy the nurse observes the patient closely for adverse drug reactions. Some adverse reactions, such as dry mouth, episodes of postural hypotension, and drowsiness, may need to be tolerated because drug therapy must continue. Nursing interventions to relieve some of these reactions may include offering frequent sips of water, assisting the patient out of the bed or chair, and supervising all ambulatory activities. The nurse should provide total assistance with activities of daily living to the patient experiencing extreme sedation, confusion, seizures, and in some cases, symptoms of benzodiazepine withdrawal. Adverse reactions of flumazenil related to the symptoms of benzodiazepine withdrawal are relieved by the administration of the benzodiazepine.

**Educating the Patient and Family**

The nurse evaluates the patient’s ability to assume responsibility for taking drugs at home. The nurse explains any adverse reactions that may occur with a specific antianxiety drug and encourages the patient or family members to contact the primary health care provider immediately if a serious drug reaction occurs.

The nurse should include the following points in a teaching plan for the patient or family member:

- Take the drug exactly as directed. Do not increase, decrease, or omit a dose or discontinue use of this drug unless directed to do so by the primary health care provider.
- Do not discontinue use of the drug abruptly because withdrawal symptoms may occur.
- Do not drive or perform other hazardous tasks if drowsiness occurs.
- Do not take any nonprescription drug unless use of a specific drug has been approved by the primary health care provider.
- Inform physicians, dentists, and other health care providers of therapy with this drug.
- Do not drink alcoholic beverages unless approval is obtained from the primary health care provider.
- If dizziness occurs when changing position, rise slowly when getting out of bed or a chair. If dizziness is severe, always have help when changing positions.
- If dryness of the mouth occurs, relieve it by taking frequent sips of water, sucking on hard candy, or chewing gum (preferably sugarless).
- If constipation occurs, relieve it by eating foods high in fiber, increasing fluid intake, and exercising if condition permits.
- Keep all appointments with the primary health care provider because close monitoring of therapy is essential.
- Report any unusual changes or physical effects to the primary health care provider.

Although rare, benzodiazepine toxicity may occur from an overdose of the drug. Benzodiazepine toxicity causes sedation, respiratory depression, and coma. Flumazenil (Romazicon) is an antidote (antagonist) for benzodiazepine toxicity and acts to reverse the sedation, respiratory depression, and coma within 6 to 10 minutes after intravenous administration. The dosage is individualized based on the patient’s response, with most patients responding to doses of 0.6 to 1 mg. However, the drug’s action is short, and additional doses may be needed. Adverse reactions of flumazenil include agitation, confusion, seizures, and in some cases, symptoms of benzodiazepine withdrawal. Adverse reactions of flumazenil related to the symptoms of benzodiazepine withdrawal are relieved by the administration of the benzodiazepine.

**Nursing Alert**

Benzodiazepine withdrawal may occur when use of the antianxiety drugs is abruptly discontinued after 3 to 4 months of therapy. Occasionally, withdrawal symptoms may occur after as little as 4 to 6 weeks of therapy. Symptoms of benzodiazepine withdrawal include increased anxiety, concentration difficulties, tremor, and sensory disturbances, such as paresthesias, photophobia, hypersomnia, and metallic taste. To help prevent withdrawal symptoms, the nurse must make sure the dosage of the benzodiazepine is gradually decreased over a period of time, usually 4 to 6 weeks.
EVALUATION

• The therapeutic effect is achieved, and the patient reports a decrease in feelings of anxiety.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
• The patient verbalizes the importance of complying with the prescribed therapeutic regimen.
• The patient and family demonstrate an understanding of the drug regimen.

Critical Thinking Exercises

1. Ms. Stovall, age 66 years, is hospitalized for congestive heart failure. She is improving, but has been complaining of feelings of anxiety. Her respirations are 32 min, heart rate 88 bpm, and blood pressure 118/60 mm Hg. The primary health care provider prescribes alprazolam 0.25 mg PO TID. What precautions would the nurse expect to be taken because of Ms. Stovall’s age? Discuss what assessment findings would indicate increased anxiety.

2. The primary health care provider prescribes lorazepam for short-term management of anxiety. What information would be included in a teaching plan for this patient?

3. A patient is prescribed buspirone 5 mg PO TID to be taken on an outpatient basis. What assessments would be important for the nurse to make when the patient comes to the clinic for a visit?

Review Questions

1. Alprazolam is contraindicated in patients with _____.
   A. a psychotic disorder  
   B. congestive heart failure  
   C. diabetes  
   D. hypertension

2. The three types of psychotherapeutic drugs include _____.
   A. antianxiety drugs, tranquilizers, and anxiolytics  
   B. antidepressants, psychotropic drugs, and anticonvulsants  
   C. antipsychotic drugs, benzodiazepines, and tranquilizers  
   D. antianxiety drugs, antidepressants, and antipsychotic drugs

3. Which antianxiety drug must be taken regularly and is not effective on a PRN basis?
   A. lorazepam  
   B. buspirone  
   C. oxazepam  
   D. hydroxyzine

4. The benzodiazepines are pregnancy category _____ drugs that should not be taken while lactating because the infant may _____.
   A. B; seizure  
   B. C; develop the floppy infant syndrome  
   C. D; become lethargic and lose weight  
   D. X; become hypoglycemic

Medication Dosage Problems

1. Hydroxyzine 100 mg IM is prescribed. Available is a vial with 100 mg hydroxyzine per mL. The nurse administers _____.

2. The patient is prescribed 30 mg oxazepam TID orally. The drug is available in 15-mg tablets. The nurse administers _____.
Antidepressant Drugs

Chapter Objectives
On completion of this chapter, the student will:
- Define depression and identify symptoms of a major depressive episode.
- Name the different types of antidepressant drugs.
- Discuss the uses, general drug actions, general adverse reactions, contraindications, precautions, and interactions of the antidepressant drugs.
- Discuss important preadministration and ongoing assessment activities that the nurse should perform on the patient taking antidepressant drugs.
- List some nursing diagnoses particular to a patient taking antidepressant drugs.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating patients about the use of antidepressant drugs.

Key Terms
- antidepressant drugs
- depression
- dysphoric
- orthostatic
- hypotension
- priapism
- Selective serotonin reuptake inhibitors (SSRIs)
- A group of miscellaneous, unrelated drugs

Depression is one of the most common psychiatric disorders. It is characterized by feelings of intense sadness, helplessness, worthlessness, and impaired functioning. Those experiencing a major depressive episode exhibit physical and psychological symptoms, such as appetite disturbances, sleep disturbances, and loss of interest in job, family, and other activities usually enjoyed. A major depressive episode is a depressed or dysphoric (extreme or exaggerated sadness, anxiety, or unhappiness) mood that interferes with daily functioning and includes five or more of the symptoms listed in Display 31-1.

To be classified as a major depression, these symptoms should occur daily or nearly every day for a period of 2 weeks or more. The symptoms of major depression should not be the result of normal bereavement, such as the loss of a loved one, or disease, such as hypothyroidism.

Depression is treated with the use of antidepressant drugs. Psychotherapy is used in conjunction with the antidepressant drugs in treating major depressive episodes. The four types of antidepressants are:
- Tricyclic antidepressants (TCAs)
- Monoamine oxidase inhibitors (MAOIs)
- Selective serotonin reuptake inhibitors (SSRIs)
- A group of miscellaneous, unrelated drugs

ACTIONS

For several years it was thought that the antidepressants blocked the reuptake of the endogenous neurotransmitters norepinephrine and serotonin, which resulted in stimulation of the central nervous system (CNS). Although the exact mechanism of action is unknown, this theory is now being questioned. New research indicates that the effects of the antidepressants are related to the slower adaptive changes in norepinephrine and serotonin receptor systems. Treatment with the antidepressants is thought to produce complex changes in the sensitivities of both presynaptic and postsynaptic receptor sites. The antidepressants increase the sensitivity of postsynaptic alpha (α)-adrenergic and serotonin receptors and decrease the sensitivity of the presynaptic receptor sites. This enhances the recovery from the depressive episode by normalizing neurotransmission activity.
The TCAs, such as amitriptyline (Elavil) and doxepin (Sinequan), inhibit reuptake of norepinephrine or serotonin at the presynaptic neuron. Drugs classified as MAOIs inhibit the activity of monoamine oxidase, a complex enzyme system that is responsible for breaking down amines. This results in an increase in endogenous epinephrine, norepinephrine, and serotonin in the nervous system. An increase in these neurohormones results in stimulation of the CNS. The action of the SSRIs is linked to their inhibition of CNS neuronal uptake of serotonin (a CNS neurotransmitter). The increase in serotonin levels is thought to act as a stimulant to reverse depression.

The mechanism of action of most of the miscellaneous antidepressants is not clearly understood. Examples of this group of drugs include fluoxetine (Prozac) and bupropion (Wellbutrin).

USES

Antidepressant drugs are used to manage depressive episodes such as major depression or depression accompanied by anxiety. These drugs may be used in conjunction with psychotherapy in severe depression. The SSRIs also are used to treat obsessive-compulsive disorders. The uses of individual antidepressants are given in the Summary Drug Table: Antidepressants. Treatment is usually continued for 9 months after recovery from the first major depressive episode. If the patient, at a later date, experiences another major depressive episode, treatment is continued for 5 years, and with a third episode, treatment is continued indefinitely.

ADVERSE REACTIONS

The Summary Drug Table: Antidepressants gives a more complete listing of the antidepressant drugs.

TCAs

Sedation and dry mouth are the most common adverse reactions seen with the use of TCAs. Tolerance to these effects develops with continued use. Orthostatic hypotension can occur with the administration of the TCAs. Orthostatic hypotension is a drop in blood pressure of 20 to 30 points when a person changes position, such as going from a lying position to a standing position. Mental confusion, lethargy, disorientation, rash, nausea, vomiting, constipation, urinary retention, visual disturbances, photosensitivity, and nasal congestion also may be seen. Sexual dysfunction may occur with administration of clomipramine.

MAOIs

Orthostatic hypotension is a common adverse reaction seen with the administration of the MAOIs. Other common adverse reactions include dizziness, vertigo, nausea, constipation, dry mouth, diarrhea, headache, and overactivity.

One serious adverse reaction associated with the use of the MAOIs is hypertensive crisis (extremely high blood pressure), which may occur when foods containing tyramine (an amino acid present in some foods) are eaten (see Home Care Checklist: Avoiding Drug–Food Interactions With MAOIs).

One of the earliest symptoms of hypertensive crisis is headache (usually occipital), followed by a stiff or sore neck, nausea, vomiting, sweating, fever, chest pain, dilated pupils, and bradycardia or tachycardia. If a hypertensive crisis occurs, immediate medical intervention is necessary to reduce the blood pressure. Strokes (cerebrovascular accidents) and death have been reported.

SSRIs

Some of the more common adverse reactions associated with the administration of the SSRIs include headache, nervousness, dizziness, insomnia, nausea, vomiting, weight loss, sweating, rash, pharyngitis, and painful menstruation.

Miscellaneous Antidepressants

Adverse reactions with administration of bupropion include agitation, dry mouth, insomnia, headache, nausea, constipation, anorexia, weight loss, and seizures. Fluoxetine administration may result in headache, activation of mania or hypomania, insomnia, anxiety, nervousness, nausea, vomiting, and sexual dysfunction. Trazodone administration may cause the following adverse reactions: drowsiness, skin disorders, anger, hostility, anemia, priapism, nausea, and vomiting. Additional
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tricyclics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amitriptyline</td>
<td>Elavil, generic</td>
<td>Depression</td>
<td>Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention, nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea)</td>
<td>Up to 300 mg/d PO in divided doses; 20–30 mg IM QID</td>
</tr>
<tr>
<td>amoxapine</td>
<td>Asendin, generic</td>
<td>Depression accompanied by anxiety</td>
<td>Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention, nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea)</td>
<td>Up to 600 mg/d PO in divided doses</td>
</tr>
<tr>
<td>clomipramine</td>
<td>Anafranil</td>
<td>Obsessive compulsive disorder (OCD)</td>
<td>Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention, nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea)</td>
<td>25–250 mg/d PO in divided doses</td>
</tr>
<tr>
<td>desipramine</td>
<td>Norpramin, generic</td>
<td>Depression</td>
<td>Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention, nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea)</td>
<td>100–300 mg/d PO</td>
</tr>
<tr>
<td>doxepin</td>
<td>Sinequan, generic</td>
<td>Anxiety or depression, emotional symptoms accompanying organic disease</td>
<td>Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention, nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea)</td>
<td>25–300 mg/d PO in divided doses</td>
</tr>
<tr>
<td>imipramine</td>
<td>Tofranil, generic</td>
<td>Depression</td>
<td>Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention, nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea)</td>
<td>75–300 mg/d PO in divided doses</td>
</tr>
<tr>
<td>nortriptyline</td>
<td>Aventyl, generic</td>
<td>Depression</td>
<td>Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention, nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea)</td>
<td>25 mg PO TID, QID; do not exceed 150 mg/d</td>
</tr>
<tr>
<td>protriptyline</td>
<td>Vivactil, generic</td>
<td>Depression</td>
<td>Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention, nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea)</td>
<td>15–60 mg/d PO in 3–4 doses</td>
</tr>
</tbody>
</table>

(continued)
### Drugs That Affect the Neuromuscular System

#### Generic Name | Trade Name | Uses | Adverse Reactions | Dosage Ranges
--- | --- | --- | --- | ---
trimipramine | Surmontil | Depression | Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention), nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea | 100–300 mg/d PO in divided doses

### Monoamine Oxidase Inhibitors

<table>
<thead>
<tr>
<th>Name</th>
<th>Trade Name</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>phenelzine</td>
<td>Nardil</td>
<td>Neurotic or atypical depression</td>
<td>Orthostatic hypotension, vertigo, dizziness, nausea, constipation, dry mouth, diarrhea, headache, restlessness, blurred vision, hypertensive crisis</td>
<td>Up to 90 mg/d PO in divided doses</td>
</tr>
<tr>
<td>tranylcypromine</td>
<td>Parnate</td>
<td>Neurotic or atypical depression</td>
<td>Orthostatic hypotension, vertigo, dizziness, nausea, constipation, dry mouth, diarrhea, headache, restlessness, blurred vision, hypertensive crisis</td>
<td>Up to 60 mg/d PO in divided doses</td>
</tr>
</tbody>
</table>

### Selective Serotonin Reuptake Inhibitors

<table>
<thead>
<tr>
<th>Name</th>
<th>Trade Name</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>citalopram</td>
<td>Celexa</td>
<td>Depression</td>
<td>Nausea, dry mouth, postural hypotension, sweating, somnolence, dizziness, insomnia, tremor, ejaculatory disorders</td>
<td>20–40 mg/d PO</td>
</tr>
<tr>
<td>fluoxetine</td>
<td>Prozac, Prozac Weekly, Sarafem, generic</td>
<td>Depression, bulimia, OCD, premenstrual dysphoric disorder (Sarafem only)</td>
<td>Anxiety, nervousness, insomnia, drowsiness, fatigue, asthenia, tremor, sweating, dizziness, headache, sexual dysfunction, nausea, diarrhea, constipation, light-headedness, anorexia</td>
<td>20 mg/d PO in the morning or 40–80 mg/d PO in divided doses; weekly dose: 1 capsule weekly; premenstrual dysphoric disorder: 20–60 mg/d PO 50–300 mg/d PO in divided doses</td>
</tr>
<tr>
<td>fluvoxamine</td>
<td>Luvox, generic</td>
<td>OCD, depression</td>
<td>Headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, light-headedness, nausea, vomiting, diarrhea, dry mouth, anorexia, constipation, dyspepsia, sweating, rash, pharyngitis, sexual dysfunction, urinary frequency</td>
<td>20–50 mg/d PO</td>
</tr>
<tr>
<td>paroxetine</td>
<td>Paxil</td>
<td>Depression, OCD, panic disorder, general anxiety disorder, social anxiety disorder, post-traumatic stress disorder</td>
<td>Headache, tremors, nervousness, dizziness, insomnia, nausea, diarrhea, visual disturbances, sweating</td>
<td>20–200 mg/d PO</td>
</tr>
<tr>
<td>sertraline</td>
<td>Zoloft</td>
<td>Depression, OCD, panic disorder, post-traumatic stress disorder</td>
<td>Headache, nervousness, drowsiness, anxiety, tremor, dizziness, insomnia, vision changes, fatigue, nausea, diarrhea, dry mouth, rhinitis, painful menstruation, sweating</td>
<td>20–200 mg/d PO</td>
</tr>
</tbody>
</table>

### SUMMARY DRUG TABLE

<table>
<thead>
<tr>
<th>ADVERSE REACTIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sedation, anticholinergic effects (dry mouth, dry eyes, urinary retention), nausea, nasal congestion, blurred vision, orthostatic hypotension, lethargy, confusion, constipation, diarrhea</td>
</tr>
<tr>
<td>Orthostatic hypotension, vertigo, dizziness, nausea, constipation, dry mouth, diarrhea, headache, restlessness, blurred vision, hypertensive crisis</td>
</tr>
<tr>
<td>Nausea, dry mouth, postural hypotension, sweating, somnolence, dizziness, insomnia, tremor, ejaculatory disorders</td>
</tr>
<tr>
<td>Anxiety, nervousness, insomnia, drowsiness, fatigue, asthenia, tremor, sweating, dizziness, headache, sexual dysfunction, nausea, diarrhea, constipation, light-headedness, anorexia</td>
</tr>
<tr>
<td>Headache, nervousness, insomnia, drowsiness, anxiety, tremor, dizziness, light-headedness, nausea, vomiting, diarrhea, dry mouth, anorexia, constipation, dyspepsia, sweating, rash, pharyngitis, sexual dysfunction, urinary frequency</td>
</tr>
<tr>
<td>Headache, tremors, nervousness, dizziness, insomnia, nausea, diarrhea, visual disturbances, sweating</td>
</tr>
<tr>
<td>Headache, nervousness, drowsiness, anxiety, tremor, dizziness, insomnia, vision changes, fatigue, nausea, diarrhea, dry mouth, rhinitis, painful menstruation, sweating</td>
</tr>
</tbody>
</table>
## Antidepressant Drugs

### Miscellaneous Drugs

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>bupropion HCL</td>
<td>Wellbutrin, Wellbutrin SR, generic Zyban (smoking cessation)</td>
<td>Depression, smoking cessation (Zyban)</td>
<td>Agitation, dry mouth, insomnia, headache, nausea, vomiting, tremor, constipation, weight loss, anorexia, seizures</td>
<td>100–450 mg/d PO in divided doses; sustained release, 1 tablet twice daily PO</td>
</tr>
<tr>
<td>maprotiline</td>
<td>Ludiomil, generic</td>
<td>Depression</td>
<td>Sedation, anticholinergic effects, confusion, disturbed concentration, dry mouth, constipation, orthostatic hypotension</td>
<td>75–225 mg/d PO</td>
</tr>
<tr>
<td>mirtazapine</td>
<td>Remeron</td>
<td>Depression</td>
<td>Sedation, anticholinergic effects, confusion, disturbed concentration, dry mouth, constipation, orthostatic hypotension</td>
<td>15–45 mg/d PO</td>
</tr>
<tr>
<td>nefazodone</td>
<td>Serzone</td>
<td>Depression</td>
<td>Somnolence, insomnia, dizziness, nausea, dry mouth, constipation, blurred vision</td>
<td>200–600 mg/d PO in divided doses</td>
</tr>
<tr>
<td>trazodone</td>
<td>Desyrel generic</td>
<td>Depression</td>
<td>Drowsiness, skin disorders, tinnitus, anger, hostility, anemia, priapism, hypertension, blurred vision, hypotension, dry mouth, nausea, vomiting, diarrhea</td>
<td>150–600 mg/d PO in divided doses</td>
</tr>
<tr>
<td>venlafaxine</td>
<td>Effexor, Effexor XR</td>
<td>Depression, anxiety disorders</td>
<td>Headache, abnormal dreams, dizziness, anxiety, nervousness, weakness, visual disturbances, rhinitis, anorexia, nausea, constipation, hypertension, diarrhea, abnormal taste, weight loss, paresthesia, chills</td>
<td>75–225 mg/d PO in divided doses</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.

Adverse reactions and adverse reactions associated with the use of other miscellaneous antidepressant drugs are listed in the Summary Drug Table: Antidepressants.

### Contraindications, Precautions, and Interactions

#### TCAs

The TCA s are contraindicated in patients with known hypersensitivity to the drugs. Doxepin is contraindicated in patients with glaucoma or in those with a tendency for urinary retention. The TCA s are not given within 14 days of the MAOIs, in patients with a recent myocardial infarction, or during pregnancy or lactation. These drugs are Pregnancy Category C drugs (except imipramine, which is Pregnancy Category B), and the safety of their use during pregnancy has not been established. TCA s are contraindicated in patients scheduled to have a myelogram (x-ray of the spinal cord and associated nerves) during the next 48 hours or within 24 hours of having a myelogram.

As with all antidepressants, the TCA s are used cautiously in patients with hepatic or renal impairment. The tricyclics are used cautiously in patients with heart disease, angina, paroxysmal tachycardia, increased intraocular pressure, prostatic hypertrophy, or a history of seizures.

If the tricyclics are administered with the MAOIs, the patient is at risk for hypertensive episodes, severe convulsions, and hyperpyretic episodes. Use of the MAOIs must be discontinued at least 2 weeks before treatment with the tricyclics begins. The tricyclics may prevent the therapeutic effect of many antihypertensives. When the tricyclics are administered with dicumarol, the risk for bleeding increases.
If your patients are taking MAOIs, they need to avoid foods containing tyramine. Otherwise they may experience a life-threatening reaction, hypertensive crisis. Be sure to instruct your patients to avoid the following foods:

- Aged cheese
- Blue Camembert
- Cheddar
- Mozzarella
- Parmesan
- Romano
- Stilton
- Sour cream
- Yogurt
- Beef or chicken livers
- Pickled herring
- Fermented meats
  - Bologna
  - Pepperoni
  - Salami
  - Dried fish
- Undistilled alcoholic beverages
  - Imported beer
  - Ale
  - Red wine, especially Chianti
- Coffee
- Tea
- Colas containing caffeine
- Chocolate drinks
- Fruits and vegetables
  - Avocado
  - Fava beans
  - Figs
  - Raisins
  - Bananas
- Sauerkraut
- Yeast extracts
- Soy sauce
- Chocolate
Arrhythmias and hypertension have been reported when the TCA’s are administered with the adrenergic drugs. There is a risk of severe hypertension when the TCA’s are administered with clonidine.

**MAOIs**

The MAOI antidepressant drugs are contraindicated in patients with known hypersensitivity to the drugs, liver and kidney disease, cerebrovascular disease, hypertension, or congestive heart failure and in the elderly. These drugs are given cautiously to patients with impaired liver function, history of seizures, parkinsonian symptoms, diabetes, or hyperthyroidism.

Foods containing tyramine must not be eaten by patients taking MAOIs because a hypertensive crisis can occur (see Home Care Checklist: Avoiding Drug–Food Interactions With MAOIs). Use of the MAOIs should be discontinued several weeks before surgery because they can cause unpredictable reactions in patients undergoing surgery. Serious adverse reactions (hypertension or hypotension, coma, and death) have been reported when the MAOIs are administered with the opiates. Concurrent use of the MAOIs with the thiazide diuretics may result in exaggerated hypotensive effect. Administration of the MAOIs with the adrenergic drugs increases the sympathomimetic effects, possibly resulting in hypertensive crisis.

**SSRIs**

The SSRIs are contraindicated in patients with a hypersensitivity to the drugs and during pregnancy. The SSRIs are Pregnancy Category C drugs (except for fluoxetine, which is Pregnancy Category B). SSRIs are used cautiously in patients with diabetes mellitus or impaired liver or kidney function and during lactation.

Use of the MAOIs must be discontinued 2 weeks before the administration of the SSRIs. When the SSRIs are administered with the tricyclic antidepressants, there is an increased risk of toxic effects and an increased therapeutic effect. When sertraline is administered with a MAOI, a potentially fatal reaction can occur. Symptoms of a serious reaction include hyperthermia, rigidity, autonomic instability with fluctuating vital signs and agitation, delirium, and coma. Sertraline blood levels are increased when administered with cimetidine.

There is a decreased effectiveness of fluoxetine in patients who smoke cigarettes during administration of the drug. Fluoxetine is not administered with lithium because this combination can increase lithium levels. The SSRIs are not administered with herbal preparations containing St. John’s wort because there is an increased risk for severe reactions.

**Miscellaneous Antidepressants**

The miscellaneous antidepressant drugs are contraindicated in patients with known hypersensitivity to the drugs. Among the miscellaneous antidepressants, bupropion and maprotiline are Pregnancy Category B drugs. Other miscellaneous antidepressants discussed in this chapter are Pregnancy Category C drugs. Safe use of the antidepressants during pregnancy has not been established. They should be used during pregnancy only when the potential benefits outweigh the potential hazards to the developing fetus. These drugs are used cautiously in patients with liver or kidney impairment and during lactation. The miscellaneous antidepressants are given with caution to patients taking alcohol or other CNS depressants.

The effects of buspirone are decreased when the drug is administered with fluoxetine. Increased serum levels of buspirone occur if the drug is taken with erythromycin or itraconazole. Should any of these combinations be required, the dosage of buspirone is decreased to 2.5 mg BID, and the patient is monitored closely. Venlafaxine blood levels increase with a risk of toxicity when administered with MAOIs or cimetidine. There is an increased risk of toxicity when trazodone is administered with the phenothiazines and decreased effectiveness of trazodone when it is administered with carbamazepine. Increased serum digoxin levels have occurred when digoxin is administered with trazodone. There is a risk for increased phenytoin levels when phenytoin is administered with trazodone.

None of the antidepressants should be administered with herbal preparations containing St. John’s wort because of the potential for adverse reactions.
## INSTRUCTIONS

This is a questionnaire. On the questionnaire are groups of statements. Please read the entire group of statements in each category. Then pick out the one statement in that group that best describes the way you feel today, that is, right now! Circle the number beside the statement you have chosen. If several statements in the group seem to apply equally well, circle each one.

**Be sure to read all the statements in each group before making your choice.**

### A. Sadness
1. I am so sad or unhappy that I can't stand it.
2. I am blue or sad all the time and I can't snap out of it.
3. I feel sad or blue.
4. I do not feel sad.

### B. Pessimism
1. I feel that the future is hopeless and that things cannot improve.
2. I feel I have nothing to look forward to.
3. I feel discouraged about the future.
4. I am not particularly pessimistic or discouraged about the future.

### C. Sense of failure
1. I feel I am a complete failure as a person (parent, husband, wife).
2. As I look back on my life, all I can see is a lot of failures.
3. I feel I have failed more than the average person.
4. I do not feel like a failure.

### D. Dissatisfaction
1. I am dissatisfied with everything.
2. I don't get satisfaction out of anything anymore.
3. I don't enjoy things the way I used to.
4. I am not particularly dissatisfied.

### E. Guilt
1. I feel as though I am very bad or worthless.
2. I feel quite guilty.
3. I feel bad or unworthy a good part of the time.
4. I don't feel particularly guilty.

### F. Self-dislike
1. I hate myself.
2. I am disgusted with myself.
3. I am disappointed in myself.
4. I don't feel disappointed in myself.

### G. Self-harm
1. I would kill myself if I had the chance.
2. I have definite plans about committing suicide.
3. I feel I would be better off dead.
4. I don't have any thought of harming myself.

### H. Social withdrawal
1. I have lost all of my interest in other people and don't care about them at all.
2. I have lost most of my interest in other people and have little feeling for them.
3. I am less interested in other people than I used to be.
4. I have not lost interest in other people.

### I. Indecisiveness
1. I can't make any decisions at all anymore.
2. I have great difficulty in making decisions.
3. I try to put off making decisions.
4. I make decisions about as well as ever.

### J. Self-image change
1. I feel that I am ugly or repulsive-looking.
2. I feel that there are permanent changes in my appearance and they make me look unattractive.
3. I am worried that I am looking old or unattractive.
4. I don't feel that I look any worse than I used to.

### K. Work difficulty
1. I can't do any work at all.
2. I have to push myself very hard to do anything.
3. It takes extra effort to get started at doing something.
4. I can work about as well as before.

### L. Fatigability
1. I get too tired to do anything.
2. I get tired from doing anything.
3. I get tired more easily than I used to.
4. I don't get any more tired than usual.

### M. Anorexia
1. I have no appetite at all anymore.
2. My appetite is much worse now.
3. My appetite is not as good as it used to be.
4. My appetite is no worse than usual.

**Scoring:**
- 0–4 = None or minimal depression
- 5–7 = Mild depression
- 8–15 = Moderate depression
- 16+ = Severe depression

---

feelings as well as slowness to answer questions, a monotonous speech pattern, and any sadness or crying.

It is important for the nurse to note the presence of suicidal thoughts. The nurse accurately documents in the patient’s record and reports to the primary health care provider any statements concerning suicide and the ability of the patient to carry out any suicide intentions. The nurse performs a physical assessment, which includes obtaining blood pressure measurements on both arms with the patient in a sitting position, pulse, respiratory rate, and weight.

The preadministration assessments of the outpatient are basically the same as those for the hospitalized patient. The nurse obtains a complete medical history and a history of the symptoms of the depression from the patient, a family member, or the patient’s hospital records. During the initial interview, the nurse observes the patient for symptoms of depression and the potential for suicide. The initial physical assessment also should include the patient’s vital signs and weight.

Ongoing Assessment
The nurse monitors vital signs at least daily as part of the ongoing assessment. In some instances, such as when hypotensive episodes occur, the nurse monitors the vital signs more frequently. The nurse reports any significant change in the vital signs to the primary health care provider. Initially, the patient may need assistance with self-care because patients with depression often do not have the physical or emotional energy to perform self-care activities. Some antidepressants cause excessive drowsiness during the initial stages of treatment, and patients may need assistance with ambulation and self-care activities. These reactions usually subside as the depression lifts and with continued use of the antidepressant. Patients with a high suicide potential require protection from suicidal acts and a well-supervised environment.

OUTPATIENT ASSESSMENT. The hospitalized patient may ultimately be discharged from the acute care setting. Some patients, such as those with mild depression, do not require inpatient care. These patients are usually seen at periodic intervals in the primary health care provider’s office or in a psychiatric outpatient setting.

At the time of each visit to the primary health care provider or clinic visit, the nurse observes the patient for a response to therapy. In some instances, the nurse may question the patient or a family member about the response to therapy. The type of questions asked depends on the patient and the diagnosis and may include questions such as

- How are you feeling?
- Do you seem to be less depressed?
- How would you rate your depression?
- Would you like to tell me how everything is going?

Many times the nurse may need to rephrase questions or direct conversation toward other subjects until these patients feel comfortable and are able to discuss their therapy.

The nurse should ask the patient or a family member about adverse drug reactions or any other problems occurring during therapy. It is important to bring these reactions or problems to the attention of the primary health care provider. The nurse documents in the patient’s record a general summary of the patient’s outward behavior and any complaints or problems. Then the nurse compares these notations with previous notations and observations.

NURSING DIAGNOSES
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING
The expected outcomes of the patient depend on the reason for administration of an antidepressant but may
include an optimal response to drug therapy, management of common adverse drug reactions, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

When caring for hospitalized patients with depression, the nurse must develop a nursing care plan to meet the patient’s individual needs. When the antidepressants are given parenterally, the nurse gives these drugs intramuscularly in a large muscle mass, such as the gluteus muscle. The nurse keeps the patient lying down (when possible) for about 30 minutes after the drug is given.

Oral administration requires great care because some patients have difficulty swallowing (because of a dry mouth or other causes). Other patients may refuse to take the drug. If the patient refuses to take the drug, the nurse contacts the primary health care provider regarding this problem because parenteral administration of the drug may be necessary.

After administration of an oral drug, the nurse inspects the patient’s oral cavity to be sure the drug has been swallowed. If the patient resists having his or her oral cavity checked, the nurse reports this refusal to the primary health care provider. Patients planning suicide may try to keep the drug on the side of the mouth or other causes). Other patients may refuse to take the drug. If the patient refuses to take the drug, the nurse contacts the primary health care provider regarding this problem because parenteral administration of the drug may be necessary.

After administration of an oral drug, the nurse inspects the patient’s oral cavity to be sure the drug has been swallowed. If the patient resists having his or her oral cavity checked, the nurse reports this refusal to the primary health care provider. Patients planning suicide may try to keep the drug on the side of the mouth or other causes). Other patients may refuse to take the drug. If the patient refuses to take the drug, the nurse contacts the primary health care provider regarding this problem because parenteral administration of the drug may be necessary.

If the drug is prescribed on an outpatient basis, the primary health care provider may prescribe only a week’s supply of the antidepressant to reduce the risk of suicide.

TCAs. Once-a-day dosing may be prescribed for maintenance therapy. When the nurse administers the total daily dosage at night, the sedative effects promote sleep, and the adverse reactions appear less troublesome. Because protriptyline may produce a mild stimulation in some patients, it is usually not given as a single bedtime dose.

MAOIs. The MAOIs are less frequently prescribed than other antidepressants, probably because of the risk of hypertensive crisis when food containing tyramine is ingested during MAOI therapy. Patients receiving MAOIs require strict dietary control because foods containing tyramine should not be eaten. The nurse asks family members and visitors not to bring food to the patient and explains why this is important. Close observation of the patient when eating in a community setting may be necessary so that food is not taken or accepted from other patients.

SSRIs. It is best to administer SSRIs in the morning. The nurse should give dosages greater than 20 mg/d in two divided doses.

MISCELLANEOUS ANTIDEPRESSANTS. Bupropion is administered in equally divided doses 3 or 4 times a day to minimize the risk of seizure. Seizure activity is associated with doses greater than 150 mg. When administering the sustained release form of bupropion (Wellbutrin SR), the drug is given in two doses with at least 8 hours between doses. Trazodone may cause drowsiness or sedation, especially early in treatment. This may require the administration of the major portion of the dosage at bedtime. The drug is taken shortly after a meal or light snack. Fluoxetine may take as long as 4 weeks to attain a full therapeutic effect. For patients with severe depression, suicide precautions are important until a therapeutic effect is achieved.

Monitoring and Managing Adverse Drug Reactions

During initial therapy or whenever the dosage is increased or decreased, the nurse observes the patient closely for adverse drug reactions and any behavioral changes. The nurse reports to the primary health care provider any change in behavior or the appearance of adverse reactions because a further increase or decrease in dosage may be necessary or use of the drug may need to be discontinued.

Some adverse reactions, such as dry mouth, episodes of orthostatic hypotension, and drowsiness, may need to be tolerated because drug therapy must continue. Nursing interventions to relieve some of these reactions may include offering frequent sips of water, assisting the patient out of the bed or chair, and supervising all ambulatory activities.

With orthostatic hypotension, the nurse instructs the patient to rise from a lying position to a sitting position. The patient remains in a sitting position for a few minutes before rising to a standing position. Position changes
are made slowly, with the nurse at the bedside to offer assistance, if necessary.

To minimize the risk for injury, the nurse assists the patient when necessary and makes the environment as safe as possible. If the patient has a difficult time with self-care because of the depression or sedative effects of the antidepressants, the nurse provides total assistance with activities of daily living, including help with eating, dressing, and ambulating. Because of the depression, the patient may not have the mental or physical energy to provide self-care activities such as bathing, hygiene, dressing, and grooming. The nurse assists the patient when necessary with self-care. However, the nurse encourages self-care, whenever possible, allowing sufficient time for the patient to accomplish tasks to the fullest extent of his or her ability. It is important for the nurse to provide positive feedback when appropriate.

As a therapeutic effect of the drug is attained, the patient will be able to resume self-care (if there are no other physical conditions that would interfere).

**SSRIs.** The SSRIs can cause weight loss. The nurse monitors dietary intake and helps the dietitian in providing nutritious meals, taking into consideration foods that the patient likes and dislikes. Weighing the patient weekly is important for monitoring weight loss or gain. To minimize the dry mouth that frequently accompanies administration of the SSRIs, the nurse provides good oral hygiene, frequent mouthwashes, and sugarless gum or hard candy.

**MISCELLANEOUS ANTIDEPRESSANTS.** An uncommon but potentially serious adverse reaction of trazodone is priapism (a persistent erection of the penis). If not treated within a few hours, priapism can result in impotence. The nurse instructs the patient to report any prolonged or inappropriate penile erection. Use of the drug is discontinued immediately and the primary care provider notified. Injection of $\alpha$-adrenergic stimulants (eg, norepinephrine) may be helpful in treating priapism. In some cases, surgical intervention may be required. Venlafaxine may cause an increase in the blood pressure. A sustained increase in the blood pressure may indicate that the dosage of venlafaxine needs to be decreased.

**Educating the Patient and Family**

Noncompliance with drug therapy is a problem with some patients once they are discharged to the home setting. The nurse evaluates the patient’s ability to assume responsibility for taking drugs at home (see Patient and Family Teaching Checklist: Promoting Patient Responsibility for Antidepressant Drug Therapy). The administration of antidepressant drugs becomes a family responsibility if the outpatient appears to be unable to manage his or her own drug therapy.

The nurse explains any adverse reactions that may occur with a specific antidepressant drug and encourages the patient or family member to contact the primary health care provider immediately if a serious drug reaction occurs.

The nurse includes the following points in a teaching plan for the patient or family member.

- Take the drug exactly as directed. Do not increase, decrease, or omit a dose or discontinue use of this drug unless directed to do so by the primary health care provider.
- Do not drive or perform other hazardous tasks if drowsiness occurs.
- Do not take any nonprescription drug unless use of a specific drug has been approved by the primary health care provider.
- Inform the primary health care provider, dentist, and other medical personnel of therapy with this drug.
• Keep all clinic appointments or appointments with the primary health care provider because close monitoring of therapy is essential.
• Do not take the antidepressants during pregnancy. Notify the primary health care provider if you are pregnant or wish to become pregnant.
• Report to the primary health care provider any unusual changes or physical effects.
• Avoid prolonged exposure to sunlight or sunlamps because an exaggerated reaction to the ultraviolet light may occur (photosensitivity), resulting in sunburn.
• Remember that a high incidence of sexual dysfunction is associated with clomipramine therapy.
• Remember that male patients taking trazodone who experience prolonged, inappropriate, and painful erections should stop taking the drug and notify the primary care provider.

EVALUATION
• The therapeutic effect is achieved.
• No evidence of injury is apparent.
• The patient is able to provide self-care.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
• The patient verbalizes an understanding of treatment modalities and importance of continued follow-up care.
• The patient verbalizes the importance of complying with the prescribed therapeutic regimen.
• The patient and family demonstrate understanding of the drug regimen.

Critical Thinking Exercises

1. Mr. Hopkins has been severely depressed for several months. Two weeks ago the primary care provider prescribed amitriptyline 30 mg orally four times a day. His family is concerned because he is still depressed. They are requesting that the dosage be increased. Discuss what information you would give Mr. Hopkins and his family and what assessments you could make.

2. Ms. Jefferson has been taking phenelzine for depression. She reports having a "bad headache" at the back of her head. Determine what assessment would be most important to make. Explain what action, if any, you would take.

3. Mr. Jones is prescribed trazodone, and the nurse is preparing discharge instructions. What would be the most important points to cover at the teaching session.
1. When administering an antidepressant to a patient contemplating suicide, it is most important for the nurse to ______.
   A. have the patient remain upright for at least 30 minutes after taking the antidepressant
   B. assess the patient in 30 minutes for a therapeutic response to the drug
   C. monitor the patient for an occipital headache
   D. inspect the patient’s oral cavity to be sure the drug was swallowed

2. Which of the following adverse reactions would the nurse expect to find in a patient taking amitriptyline?
   A. constipation and abdominal cramps
   B. bradycardia and double vision
   C. sedation and dry mouth
   D. polyuria and hypotension

3. The nurse instructs the patient taking a monoamine oxidase inhibitor not to eat foods containing ______.
   A. glutamine
   B. sugar
   C. tyramine
   D. large amounts of iron

4. Which of the following antidepressants would be most likely to cause the patient to have a seizure?
   A. amitriptyline
   B. bupropion
   C. sertraline
   D. venlafaxine

### Medication Dosage Problems

1. The primary care provider prescribes trazodone 150 mg PO. Available are 50-mg tablets. The nurse administers ______.

2. The primary care provider prescribes paroxetine 50 mg/d PO. The drug is available as oral suspension with a strength of 10 mg/5 mL. The nurse administers ______.
Antipsychotic drugs are also called neuroleptic drugs. These drugs are given to patients with a psychotic disorder, such as schizophrenia. A psychotic disorder is characterized by extreme personality disorganization and the loss of contact with reality. Hallucinations (a false perception having no basis in reality) or delusions (false beliefs that cannot be changed with reason) are usually present. Other symptoms include disorganized speech, behavior disturbance, social withdrawal, flattened affect (absence of an emotional response to any situation or condition), and anhedonia (finding no pleasure in activities that are normal pleasurable).

Although lithium is not a true antipsychotic drug, it is considered with the antipsychotics because of its use in regulating the severe fluctuations of the manic phase of bipolar disorder (a psychiatric disorder characterized by severe mood swings of extreme hyperactivity to depression). During the manic phase, the person experiences altered thought processes, which can lead to bizarre delusions. The drug diminishes the frequency and intensity of hyperactive (manic) episodes.

**ACTIONS**

The exact mechanism of action of antipsychotic drugs is not well understood. These drugs are thought to act by inhibiting or blocking the release of the neurotransmitter dopamine in the brain and possibly increasing the firing of nerve cells in certain areas of the brain. These effects may be responsible for the ability of these drugs to suppress the symptoms of certain psychotic disorders. Examples of antipsychotic drugs include chlorpromazine (Thorazine), haloperidol (Haldol), and lithium. Lithium is an antimanic drug; although its exact mechanism is unknown, it appears to alter sodium transport in nerve and muscle cells and inhibits the release of norepinephrine and dopamine. Haloperidol may act to block postsynaptic dopamine receptors in the brain and depress the RAS, including those parts of the brain involved with wakefulness and emesis. The Summary Drug Table: Antipsychotic Drugs gives a more complete listing of the antipsychotic drugs.
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>chlorpromazine HCL</td>
<td>Thorazine, generic</td>
<td>Psychotic disorders, nausea, vomiting, intractable hiccups</td>
<td>Hypotension, postural hypotension, tardive dyskinesia, photophobia, urticaria, nasal congestion, dry mouth, akathisia, dystonia, pseudoparkinsonism, behavioral changes, headache, photosensitivity</td>
<td>Psychotic disorders: up to 2000 mg/d PO in divided doses, 25 IM; nausea and vomiting: 10—25 mg PO, 25—50 mg IM, 50—100 rectal; hiccups: 25—50 mg PO, IM, IV TID—QID</td>
</tr>
<tr>
<td>clozapine</td>
<td>Clozaril, generic</td>
<td>Severely ill schizophrenic patients with no response to other therapies</td>
<td>Drowsiness, sedation, akathisia, seizures, dizziness, syncope, tachycardia, hypotension, nausea, vomiting</td>
<td>Up to 900 mg/d PO in divided doses</td>
</tr>
<tr>
<td>fluphenazine HCL</td>
<td>Permitil, Prolixin, generic</td>
<td>Psychotic disorders</td>
<td>Drowsiness, extrapyramidal effects, dystonia, akathisia, hypotension</td>
<td>0.5—10 mg/PO in divided doses up to 20 mg/d; 2.5—10 mg/d IM in divided doses</td>
</tr>
<tr>
<td>haloperidol</td>
<td>Haldol</td>
<td>Psychotic disorders; Tourette's syndrome, behavior problems in children</td>
<td>Extrapyramidal symptoms, akathisia, dystonia, tardive dyskinesia, drowsiness, headache, dry mouth, orthostatic hypotension</td>
<td>0.5—5 mg PO BID, TID with dosages up to 100 mg/d in divided doses; 2—5 mg IM; children 0.05—0.075 mg/kg/d PO</td>
</tr>
<tr>
<td>lithium</td>
<td>Eskalith, Lithobid, Lithonate, generic</td>
<td>Manic episodes of bipolar disorder</td>
<td>Headache, drowsiness, tremors, nausea, polyuria (see Table 32-1)</td>
<td>Based on lithium serum levels; average dose range is 900—1800 mg/d PO in divided doses</td>
</tr>
<tr>
<td>loxapine</td>
<td>Loxitane</td>
<td>Psychotic disorders</td>
<td>Extrapyramidal symptoms, akathisia, dystonia, tardive dyskinesia, drowsiness, headache, dry mouth, orthostatic hypotension</td>
<td>60—250 mg/d PO in divided doses; 12.5—50 mg IM</td>
</tr>
<tr>
<td>olanzapine</td>
<td>Zyprexa</td>
<td>Schizophrenia, short-term treatment of manic episodes of bipolar disorder</td>
<td>Agitation, dizziness, nervousness, akathisia, constipation, fever, weight gain</td>
<td>5—20 mg/d PO</td>
</tr>
<tr>
<td>perphenazine</td>
<td>Trilafon, generic</td>
<td>Psychotic disorders</td>
<td>Hypotension, postural hypotension, tardive dyskinesia, photophobia, urticaria, nasal congestion, dry mouth, akathisia, dystonia, pseudoparkinsonism, behavioral changes, headache, photosensitivity</td>
<td>Psychotic disorders: 4—16 mg PO BID to QID, 5—10 mg IM</td>
</tr>
<tr>
<td>pimozide</td>
<td>Orap</td>
<td>Tourette's syndrome</td>
<td>Parkinson-like symptoms, motor restlessness, dystonia, oculogyric crisis, tardive dyskinesia, dry mouth, diarrhea, headache, rash, drowsiness</td>
<td>Initial dose: 1—2 mg/d PO; maintenance dose: up to 10 mg/d PO</td>
</tr>
</tbody>
</table>

(continued)
**SUMMARY DRUG TABLE  ANTIPSYCHOTIC DRUGS (Continued)**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>prochlorperazine</td>
<td>Compazine, generic</td>
<td>Psychotic disorders, nausea, vomiting, anxiety</td>
<td>Extrapiramidal effects, sedation, tardive dyskinesia, dry eyes, blurred vision, constipation, dry mouth, photosensitivity</td>
<td>Up to 150 mg PO, 10–20 mg IM; nausea, vomiting: 15–40 mg/d PO in divided doses; anxiety: 5 mg TID, PO</td>
</tr>
<tr>
<td>promazine HCL</td>
<td>Sparine, generic</td>
<td>Psychotic disorders</td>
<td>Drowsiness, extrapyramidal effects, dystonia, akathisia, hypotension</td>
<td>10–200 mg PO, IM q4–6h QID</td>
</tr>
<tr>
<td>quetiapine fumarate</td>
<td>Seroquel</td>
<td>Psychotic disorders</td>
<td>Orthostatic hypotension, dizziness, vertigo, nausea, constipation, dry mouth, diarrhea, headache, restlessness, blurred vision</td>
<td>Up to 800 mg/d PO in divided doses</td>
</tr>
<tr>
<td>risperidone</td>
<td>Risperdal</td>
<td>Psychotic disorders</td>
<td>Agitation, dizziness, nervousness, akathisia, constipation, fever, weight gain</td>
<td>1–3 mg BID PO</td>
</tr>
<tr>
<td>trifluoperazine HCL</td>
<td>Stelazine, generic</td>
<td>Psychotic disorders, anxiety</td>
<td>Drowsiness, pseudoparkinsonism, dystonia, akathisia, tardive dyskinesia, photophobia, blurred vision, dry mouth, salivation, nasal congestion, nausea, urine discolored pink to red-brown</td>
<td>Psychosis: 4–20 mg/d PO in divided doses; anxiety: 1–2 mg BID PO</td>
</tr>
<tr>
<td>ziprasidone HCL</td>
<td>Geodon</td>
<td>Schizophrenia</td>
<td>Somnolence, drowsiness, sedation, headache, arrhythmias, dyspepsia, fever, constipation, extrapyramidal effects</td>
<td>80 mg BID PO</td>
</tr>
</tbody>
</table>

*The term generic indicates that the drug is available in generic form.

**USES**

Antipsychotic drugs are used to manage acute and chronic psychoses. In addition to its antipsychotic properties, chlorpromazine (Thorazine) is used to treat uncontrollable hiccoughs. Clozapine (Clozaril) is used only in patients with schizophrenia that is unresponsive to other antipsychotic drugs. Lithium is effective in the management of bipolar (manic-depressive) illness. Some of these drugs, such as chlorpromazine (Thorazine) and prochlorperazine (Compazine), are used as antiemetics (see Chap. 34). When given in small doses, neuroleptics are effective in the control of acute agitation in the elderly. More specific uses of these drugs are given in the Summary Drug Table: Antipsychotic Drugs.

**ADVERSE REACTIONS**

Administration of these drugs may result in a wide variety of adverse reactions. The adverse reactions seen with the use of some of these drugs may include sedation, hypotension, postural hypotension, dry mouth, nasal congestion, photophobia (an intolerance to light), urticaria, photosensitivity (abnormal response or sensitivity when exposed to light), behavioral changes, and headache. Photosensitivity can result in severe sunburn when patients taking antipsychotic drugs are exposed to the sun or ultraviolet light.

Behavioral changes may also occur with the use of the antipsychotic drugs. These changes include an increase in the intensity of the psychotic symptoms, lethargy, hyperactivity, paranoid reactions, agitation, and confusion. A
decrease in dosage may eliminate some of these symptoms, but it also may be necessary to try another drug.

**Extrapyramidal Effects**

Among the most significant adverse reactions associated with the antipsychotic drugs are the extrapyramidal effects. The term **extrapyramidal effects** refers to a group of adverse reactions occurring on the extrapyramidal portion of the nervous system as a result of antipsychotic drugs. This part of the nervous system affects body posture and promotes smooth and uninterrupted movement of various muscle groups. Antipsychotics disturb the function of the extrapyramidal portion of the nervous system, causing abnormal muscle movement. Extrapyramidal effects include Parkinson-like symptoms (see Chap. 29), akathisia, and dystonia (see Display 32-1).

Extrapyramidal effects usually diminish with a reduction in the dosage of the antipsychotic drug. The primary health care provider may also prescribe an antiparkinsonism drug, such as benztropine (see Chap. 29) to reduce the incidence of Parkinson-like symptoms.

**Tardive Dyskinesia**

**Tardive dyskinesia** (TD) is a syndrome consisting of potentially irreversible, involuntary dyskinetic movements. TD is characterized by rhythmic, involuntary movements of the tongue, face, mouth, or jaw and sometimes the extremities (see Fig. 32-1). The tongue may protrude, and there may be chewing movements, puckering of the mouth, and facial grimacing. TD may be observed in patients receiving an antipsychotic drug or after discontinuation of antipsychotic drug therapy. When symptoms of TD occur during the course of therapy, use of the drug must be discontinued. Depending on the severity of the condition being treated, the primary health care provider may slowly taper the drug dose because abrupt discontinuation may result in a return of the psychotic symptoms. There is no known treatment of TD, although partial or complete remission may occur if the antipsychotic drugs are withdrawn. The risk of TD and the likelihood that it will become irreversible increase as the duration of treatment and total cumulative dosage administered increase. It is best to use the smallest dose and the shortest duration of treatment that produces a satisfactory clinical response. The highest incidence of TD is found in patients receiving an antiparkinson drug for extrapyramidal effects along with an antipsychotic drug. Although any patient taking an antipsychotic can experience TD, elderly women are at highest risk.

**Neuroleptic Malignant Syndrome**

**Neuroleptic malignant syndrome** (NMS) is a rare reaction characterized by a combination of extrapyramidal effects, hyperthermia, and autonomic disturbance. It may occur hours to months after the antipsychotic drug regimen is begun. Once NMS begins, it progresses rapidly during the next 24 to 72 hours. The syndrome most often occurs in patients taking haloperidol, but has occurred with administration of thiothixene, thioridazine, and clozapine. NMS is potentially fatal and requires intensive symptomatic treatment and immediate discontinuation of use of the causative drug.

**Lithium**

Lithium carbonate is rapidly absorbed after oral administration. The most common adverse reactions include tremors, nausea, vomiting, thirst, and polyuria. Toxic reactions may be seen when serum lithium levels are greater than 1.5 mEq/L (Table 32-1). Because some of these toxic reactions are potentially serious, lithium blood levels are usually obtained during therapy, and the dosage of lithium is adjusted according to the results.

**TABLE 32-1 Lithium Toxicity**

<table>
<thead>
<tr>
<th>LITHIUM LEVEL</th>
<th>SIGNS OF TOXICITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.5–2 mEq/L</td>
<td>Diarrhea, vomiting, nausea, drowsiness, muscular weakness, lack of coordination (early signs of toxicity)</td>
</tr>
<tr>
<td>2–3 mEq/L</td>
<td>Giddiness, ataxia, blurred vision, tinnitus, vertigo, increasing confusion, slurred speech, blackouts, myoclonic twitching or movement of entire limbs, choreoathetoid movements, urinary or fecal incontinence, agitation or manic-like behavior, hyperreflexia, hypertonia, dystarthritis</td>
</tr>
<tr>
<td>&gt; 3 mEq/L</td>
<td>May produce a complex clinical picture involving multiple organs and organ systems, including seizures (generalized and focal), arrhythmias, hypotension, peripheral vascular collapse, stupor, muscle group twitching, spasticity, coma</td>
</tr>
</tbody>
</table>

**DISPLAY 32-1 Extrapyramidal Effects**

- Parkinson-like symptoms—fine tremors, muscle rigidity, mask-like appearance of the face, slowness of movement, slurred speech, and unsteady gait
- Akathisia—extreme restlessness and increased motor activity
- Dystonia—facial grimacing and twisting of the neck into unnatural positions
### CONTRAINDICATIONS

The antipsychotics are contraindicated in patients with known hypersensitivity to the drugs, in comatose patients, and in those who are severely depressed, have bone marrow depression, blood dyscrasias, Parkinson's disease (haloperidol), liver impairment, coronary artery disease, or severe hypotension or hypertension.

Antipsychotic drugs are classified as Pregnancy Category C drugs (except for clozapine, which is Pregnancy Category B). Safe use of these drugs during pregnancy and lactation has not been clearly established. They should be used only when clearly needed and when the potential good outweighs any potential harm to the fetus.

Lithium is contraindicated in patients who have hypersensitivity to tartrazine, renal or cardiovascular disease, sodium depletion, dehydration, patients receiving diuretics, and those who are dehydrated. Lithium is a Pregnancy Category D drug and is contraindicated during pregnancy and lactation. For women of childbearing age, contraceptives may be prescribed while they are taking lithium.

---

**Figure 32-1.** A simple method to determine tardive dyskinesia symptoms: Abnormal Involuntary Scale examination procedure. (From Clayton & Stock [1997]. Basic pharmacology for nurses 11th ed., p. 580, St Louis: Mosby.)

<table>
<thead>
<tr>
<th>Patient Identification</th>
<th>Rated By</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Either before or after completing the examination procedure, observe the patient unobtrusively at rest (e.g., in waiting room).

The chair to be used in this examination should be a hard, firm one without arms.

After observing the patient, he/she may be rated on a scale of 0 (none), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe) according to the severity of symptoms.

Ask the patient whether there is anything in his/her teeth (i.e., gum, candy, etc.) and if there is to remove it.

Ask patient about the current condition of his/her teeth. Ask patient if he/she wears dentures. Do teeth or dentures bother patient now?

Ask patient whether he/she notices any movement in mouth, face, hands, or feet. If yes, ask to describe and to what extent they currently bother patient or interfere with his/her activities.

*Abnormal Involuntary Movement Scale
From Novartis Pharmaceuticals, East Hanover, NJ 07936.

<table>
<thead>
<tr>
<th>0 1 2 3 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 1 2 3 4</td>
</tr>
<tr>
<td>0 1 2 3 4</td>
</tr>
<tr>
<td>0 1 2 3 4</td>
</tr>
<tr>
<td>0 1 2 3 4</td>
</tr>
<tr>
<td>0 1 2 3 4</td>
</tr>
<tr>
<td>0 1 2 3 4</td>
</tr>
<tr>
<td>0 1 2 3 4</td>
</tr>
</tbody>
</table>

Have patient sit in chair with hands on knees, legs slightly apart, and feet flat on floor. (Look at entire body for movements while in this position.)

Ask patient to sit with hands hanging unsupported, if male, between legs, if female and wearing a dress, hanging over knees. (Observe hands and other body areas.)

Ask patient to open mouth. (Observe tongue at rest within mouth.) Do this twice.

Ask patient to protrude tongue. (Observe abnormalities of tongue movement.) Do this twice.

Ask patient to extend both arms outstretched in front with palms down. (Observe trunk, legs, and mouth.)

Have patient walk a few paces, turn, and walk back to chair. (Observe hands and gait.) Do this twice.
PRECAUTIONS

The antipsychotic drugs are used cautiously in patients exposed to extreme heat or phosphorous insecticides and in those with respiratory disorders, glaucoma, prostatic hypertrophy, epilepsy, decreased renal function, lactation, or peptic ulcer. The antipsychotic drugs are used cautiously in elderly and debilitated patients because these patients are more sensitive to the antipsychotic drugs. Lithium is used cautiously in patients who are in situations in which they may sweat profusely and those who are suicidal, have diarrhea, or who have an infection or fever.

INTERACTIONS

Administering the antipsychotic drugs with alcohol may result in additive central nervous system (CNS) depression. Anticholinergics (see Chap. 25) may reduce the therapeutic effects of the antipsychotics, causing worsening of the psychotic symptoms and an increase in the risk of tardive dyskinesia. Clozapine acts synergistically with other drugs that suppress bone marrow, resulting in an increase in the severity of bone marrow suppression. When lithium is administered with other antipsychotic drugs, lithium renal clearance may be reduced, making a decreased dosage necessary to prevent lithium toxicity. There may be a decreased effectiveness of lithium when the agent is administered with antacids. When thiazide or loop diuretics are administered with lithium, there is an increase in serum lithium levels, resulting in an increased risk for lithium toxicity.

NURSING PROCESS

The Patient Receiving an Antipsychotic Drug

ASSESSMENT

Preadministration Assessment
A patient receiving an antipsychotic drug may be treated in the hospital or in an outpatient setting. The nurse assesses the patient’s mental status before and periodically throughout therapy. The nurse must note the presence of hallucinations or delusions and document them accurately in the patient’s record.

Before starting therapy for the hospitalized patient, the nurse obtains a complete psychiatric and medical history. In the case of psychosis, patients often are unable to give a reliable history of their illness. When a psychosis is present, the nurse obtains the psychiatric history from a family member or friend. During the time the history is taken, the nurse observes the patient for any behavior patterns that appear to be deviations from normal. Examples of deviations include poor eye contact, failure to answer questions completely, inappropriate answers to questions, a monotone speech pattern, and inappropriate laughter, sadness, or crying.

Physical assessments include obtaining blood pressure measurements on both arms with the patient in a sitting position, pulse, respiratory rate, and weight. The hospitalized patient may ultimately be discharged from the psychiatric setting. Some patients, such as those with mild schizophrenia, do not require inpatient care. The nurse usually sees these patients at periodic intervals in the psychiatric outpatient setting.

The initial assessments of the outpatient are basically the same as those for the hospitalized patient. The nurse obtains a complete medical history and a history of the symptoms of the mental disorder from the patient, a family member, or the patient’s hospital records. During the initial interview, the nurse observes the patient for what appear to be deviations from a normal behavior pattern. The nurse also should assess the patient’s vital signs and body weight.

Ongoing Assessment

Many antipsychotic drugs are administered for a long time, which makes the ongoing assessment an important part of determining therapeutic drug effects and monitoring for adverse reactions, particularly extrapyramidal effects and tardive dyskinesia (see Display 32-1 and Fig. 32-1). The role of the nurse is important in the administration of these drugs in both the psychiatric and nonpsychiatric setting for the following reasons:

- The patient’s response to drug therapy on an inpatient basis requires around-the-clock assessments because frequent dosage adjustments may be necessary during therapy.
- Accurate assessments for the appearance of adverse drug effects assume a greater importance when the patient may not be able to verbalize physical changes to the primary health care provider or nurse.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient depend on the reason for drug administration but may include an optimal response to drug therapy, management of common adverse drug reactions, an absence of injury, and compliance with the prescribed therapeutic regimen.
IMPLEMENTATION
Promoting an Optimal Response to Therapy

The nurse develops a nursing care plan to meet the patient's individual needs. It is important to monitor vital signs at least daily. In some instances, such as when hypotensive episodes occur, the nurse should monitor vital signs more frequently. The nurse should report any significant change in the vital signs to the primary health care provider.

Behavioral records should be written at periodic intervals (frequency depends on hospital or unit guidelines). An accurate description of the patient's behavior aids the primary health care provider in planning therapy and thus becomes an important part of nursing management. Patients with poor response to drug therapy may require dosage changes, a change to another psychotherapeutic drug, or the addition of other therapies to the treatment regimen. However, it is important for the nurse to know that full response to antipsychotic drugs takes several weeks.

The nurse may give antipsychotic drugs orally as a single daily dose or in divided doses several times a day. Divided daily doses are recommended when beginning drug therapy, but once-daily dosing may be used with continued therapy. Administration at bedtime helps to minimize the postural hypotension and sedation associated with these drugs. The exact dosage (milligram to milligram) has not been precisely identified. The primary care provider may prescribe small incremental dosage increases until the patient's symptoms are controlled.

Gerontologic Alert
Dosages in older adults are usually in the lower range. Because older adults are more susceptible to cardiovascular and neuromuscular reactions to the antipsychotic drugs, the nurse must closely monitor them. It is important to increase the dosages gradually.

Oral liquid concentrates are available for use in patients who can more easily swallow a liquid. These concentrates are light sensitive and dispensed in amber or opaque bottles to help protect the concentrate from light. They are administered mixed in liquids such as juice, tomato juice, milk, or carbonated beverages. Semisolid foods, such as soups or puddings, may also be used. Perphenazine (Trilafon) concentrate should not be mixed with beverages containing caffeine (coffee, cola), tea, or apple juice because of the risk of incompatibility.

When these drugs are given parenterally, the nurse should give the drugs intramuscularly in a large muscle mass, such as the gluteus muscle. The nurse keeps the patient lying down (when possible) for about 30 minutes after the drug is given.

Nursing Alert
In combative patients or those who have serious manifestations of acute psychosis (eg, hallucinations or loss of contact with reality), parenteral administration may be repeated every 1 to 4 hours until the desired effects are obtained or until cardiac arrhythmias or rhythm changes, or hypotension occur.

Managing Care of the Outpatient. At the time of each visit of the patient to the primary health care provider's office or clinic, the nurse observes the patient for a response to therapy. In some instances, the nurse may question the patient or a family member about the response to therapy. The questions asked depend on the patient and the diagnosis and may include questions such as:

- How are you feeling?
- Do you seem to be less nervous?
- Would you like to tell me how everything is going?
Many times the nurse may need to rephrase questions or direct conversation toward other subjects until these patients feel comfortable and are able to discuss their therapy.

The nurse asks the patient or a family member about adverse drug reactions or any other problems occurring during therapy. The nurse brings these reactions or problems to the attention of the primary health care provider. The nurse should document in the patient’s record a general summary of the patient’s outward behavior and any complaints or problems. The nurse then compares these notations to previous notations and observations.

**LITHIUM.** The dosage of lithium is individualized according to serum levels and clinical response to the drug. The desirable serum lithium levels are 0.6 to 1.2 mEq/L. Blood samples are drawn immediately before the next dose of lithium (8–12 hours after the last dose) when lithium levels are relatively stable. During the acute phase the nurse monitors serum lithium levels twice weekly or until the patient’s manic phase is under control. During maintenance therapy, the serum lithium levels are monitored every 2 to 4 months.

### Monitoring and Managing Adverse Drug Reactions

During initial therapy or whenever the dosage is increased or decreased, the nurse observes the patient closely for adverse drug reactions, including tardive dyskinesia (see Fig. 32-1) and any behavioral changes. It is important to report to the primary health care provider any change in behavior or the appearance of adverse reactions. A further increase or decrease in dosage may be necessary, or use of the drug may need to be discontinued.

**Nursing Alert**

When administering the antipsychotic drugs, the nurse observes the patient for extrapyramidal effects, which include muscular spasms of the face and neck, the inability to sleep or sit still, tremors, rigidity, or involuntary rhythmic movements. The nurse notifies the primary health care provider of the occurrence of these symptoms because they may indicate a need for dosage adjustment.

The patient may need to tolerate some adverse reactions, such as dry mouth, episodes of orthostatic hypotension, and drowsiness because drug therapy must continue. Nursing interventions to relieve some of these reactions may include offering frequent sips of water, assisting the patient out of the bed or chair, and supervising all ambulatory activities. The nurse provides total assistance with activities of daily living to the patient experiencing extreme sedation, including help with eating, dressing, and ambulating. However, the nurse must protect extremely hyperactive patients from injury to themselves or others.

**Nursing Alert**

The antipsychotic drugs may cause extreme drowsiness and sedation, especially during the first or second weeks of therapy. This reaction may impair mental or physical abilities. Drowsiness usually diminishes after 2–3 weeks of therapy. However, if the patient continues to be troubled by drowsiness and sedation, the physician may prescribe a lower dosage.

Tardive dyskinesia can occur in patients taking the antipsychotics. The nurse must remain alert for any signs and symptoms of this condition.

**Nursing Alert**

Because there is no known treatment for tardive dyskinesia and because it is irreversible in some patients, the nurse must immediately report symptoms. These include rhythmic, involuntary movements of the tongue, face, mouth, jaw, or the extremities.

**CLOzapine.** This drug is available only through the Clozaril Patient Management System (a program that combines WBC testing, patient monitoring, and pharmacy and drug distribution services). Only 1 week of this drug is dispensed at a time. Patients taking clozapine are at increased risk for bone marrow suppression. A weekly WBC count is done throughout therapy and for 4 weeks after therapy is discontinued. In addition, the nurse monitors the patient for adverse reactions that indicate bone marrow suppression: lethargy, weakness, fever, sore throat, malaise, mucous membrane ulceration, or “flu-like” complaints.

**LITHIUM.** Lithium toxicity is closely related to serum lithium levels and can occur even when the drug is administered at therapeutic doses. Adverse reactions are seldom observed at serum lithium levels of less than 1.5 mEq/L, except in the patient who is especially sensitive to lithium. Toxic symptoms may be seen with serum lithium levels of 1.5 mEq/L or greater. Levels should not exceed 2 mEq/L (see Table 32-1). Therefore, the nurse must continually monitor patients taking lithium for signs of toxicity, such as diarrhea, vomiting, nausea, drowsiness, muscular weakness, and lack of coordination. For early symptoms, the primary health care provider may order a dosage reduction or discontinue the drug for 24 to 48 hours and then gradually restart the drug therapy at a lower dosage.
For patients receiving lithium, the nurse increases the oral fluid intake to about 3000 mL/d. It is important to keep fluids readily available and to offer extra fluids throughout waking hours. If there is any question regarding the oral fluid intake, the nurse monitors intake and output.

**Educating the Patient and Family**

Noncompliance is a problem with some patients once they are discharged to the home setting. It is important for the nurse to accurately evaluate the patient’s ability to assume responsibility for taking drugs at home. The administration of antipsychotic drugs becomes a family responsibility if the outpatient appears to be unable to manage his or her own drug therapy.

The nurse explains any adverse reactions that may occur with a specific antipsychotic drug and encourages the patient or family members to contact the primary health care provider immediately if a serious drug reaction occurs.

The nurse includes the following points in a teaching plan for the patient or family member:

- Keep all primary care provider and clinic appointments because close monitoring of therapy is essential.
- Report any unusual changes or physical effects to the primary health care provider.
- Take the drug exactly as directed. Do not increase, decrease, or omit a dose or discontinue use of this drug unless directed to do so by the primary health care provider.
- Do not drive or perform other hazardous tasks if drowsiness occurs.
- Do not take any nonprescription drug unless use of a specific drug has been approved by the primary health care provider.
- Inform physicians, dentists, and other medical personnel of therapy with this drug.
- Do not drink alcoholic beverages unless approval is obtained from the primary health care provider.
- If dizziness occurs when changing position, rise slowly when getting out of bed or a chair. If dizziness is severe, always have help when changing positions.
- If dryness of the mouth occurs, relieve it by taking frequent sips of water, sucking on hard candy, or chewing gum (preferably sugarless).
- Notify your primary care provider if you become pregnant or intend to become pregnant during therapy.
- Immediately report the occurrence of the following adverse reactions: restlessness, inability to sit still, muscle spasms, masklike expression, rigidity, tremors, drooling, or involuntary rhythmic movements of the mouth, face, or extremities. Inform all patients about the risks of extrapyramidal symptoms and tardive dyskinesia. Avoid exposure to the sun. If exposure is unavoidable, wear sunblock, keep arms and legs covered, and wear a sun hat.
- Note that only a 1-week supply of clozapine is dispensed at a time. The drug is obtained through a special program designed to ensure the required blood monitoring. Weekly WBC laboratory tests are required. Immediately report any signs of weakness, fever, sore throat, malaise, or “flu-like” symptoms to the primary care provider.
- Note that olanzapine is available as a tablet to swallow or as an orally disintegrating tablet. When using the orally disintegrating tablet, peel back the foil on the blister. Using dry hands, remove the tablet and place the entire tablet in the mouth. The tablet will disintegrate with or without liquid.
- Remember to take lithium with food or immediately after meals to avoid stomach upset. Drink at least 10 large glasses of fluid each day and add extra salt to food. Prolonged exposure to the sun may lead to dehydration. If any of the following occurs, do not take the next dose and immediately notify the primary health care provider: diarrhea, vomiting, fever, tremors, drowsiness, lack of muscle coordination, or muscle weakness.

**EVALUATION**

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
- No evidence of injury is seen.
- The patient verbalizes an understanding of treatment modalities and the importance of continued follow-up care.
- The patient verbalizes the importance of complying with the prescribed therapeutic regimen.
- The patient and family demonstrate understanding of the drug regimen.

**Critical Thinking Exercises**

1. Ms. Brown comes to the mental health clinic for a follow-up visit. She is taking lithium to control a bipolar disorder. Ms. Brown tells you that she is concerned because her “hands are always shaking” and “sometimes I walk like I have been drinking alcohol.” Explain how you would explore this problem with Ms. Brown.
2. As a nurse on the psychiatric unit, you are assigned to discuss extrapyramidal effects at a team conference. Discuss how you would present and explain this topic. Describe the points you would stress.

3. Your patient is prescribed clozapine for schizophrenia that has not responded to other drugs. You must discuss this new therapy with the family. Discuss what points to include in this family teaching session.

**Review Questions**

1. A patient taking chlorpromazine (Thorazine) for schizophrenia is also prescribed the antiparkinson drug benztropine. What is the best explanation for adding an antiparkinson drug to the drug regimen?
   - A. Antiparkinson drugs prevent symptoms of tardive dyskinesia, such as involuntary movements of the face and tongue.
   - B. Antiparkinson drugs promote the effects of chlorpromazine.
   - C. Antiparkinson drugs are given to reduce the possibility of symptoms such as fine tremors, muscle rigidity, and slow movement.
   - D. Antiparkinson drugs help to decrease hallucinations and delusions in patients with schizophrenia.

2. Which of the following reactions would the nurse expect to see in a patient experiencing tardive dyskinesia?
   - A. Muscle rigidity, dry mouth, insomnia
   - B. Rhythmic, involuntary movements of the tongue, face, mouth, or jaw
   - C. Muscle weakness, paralysis of the eyelids, diarrhea
   - D. Dyspnea, somnolence, muscle spasms

3. Which of the following symptoms would indicate to the nurse that a patient taking lithium is experiencing toxicity?
   - A. Constipation, abdominal cramps, rash
   - B. Stupor, oliguria, hypertension
   - C. Nausea, vomiting, diarrhea
   - D. Dry mouth, blurred vision, difficulty swallowing

4. In giving discharge instructions to a patient taking lithium the nurse stresses that the patient should ______.
   - A. eat a diet high in carbohydrates and low in proteins
   - B. increase oral fluid intake to approximately 3000 mL/day
   - C. have blood drawn before each dose of lithium is administered
   - D. avoid eating foods high in amines

**Medication Dosage Problems**

1. A patient is prescribed haloperidol 3 mg IM. The drug is available in solution of 2 mg/mL. The nurse would administer ______.

2. Thorazine 50 mg PO is prescribed. Use the drug label below to determine the correct dosage. The nurse administers ______.

3. Lithium 600 mg is prescribed. Use the drug label below to determine the correct dosage. The nurse administers ______.
Cholinesterase Inhibitors

Key Terms

| acetylcholine | Alzheimer’s disease |
| alanine aminotransferase | dementia |
| ginkgo biloba |

Chapter Objectives

On completion of this chapter, the student will:

- Discuss the clinical manifestations of Alzheimer’s disease.
- List the uses, general drug actions, general adverse reactions, contraindications, precautions, and interactions associated with the administration of the cholinesterase inhibitors.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking a cholinesterase inhibitor.
- List some nursing diagnoses particular to a patient taking a cholinesterase inhibitor.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating patients about the use of the cholinesterase inhibitors.

Alzheimer’s disease (AD) is a progressive deterioration of mental, physical, and cognitive abilities from which there is no recovery. About 2 million Americans have the disease. Almost 50% of individuals in nursing homes and almost half of all people older than 85 years experience the devastating effects of AD. Currently it is the fourth leading cause of death in adults. Specific pathologic changes occur in the cortex of the brain thought to be associated with deficiencies of one or more of the neurohormones, such as acetylcholine or norepinephrine.

Drugs that are used to treat AD do not cure the disease but are aimed at slowing the progression. These drugs are the cholinesterase inhibitors. Examples of the cholinesterase inhibitors include donepezil (Aricept), galantamine hydrobromide (Reminyl), rivastigmine tartrate (Exelon), and tacrine hydrochloride (Cognex). These drugs are used to treat mild to moderate dementia (decrease in cognitive functioning) of AD. Other drugs are used for symptomatic relief. For example, wandering, irritability, and aggression in people with AD are treated with the antipsychotics, such as risperidone and olanzapine (see Chap. 32). Other drugs, such as the antidepressants or antianxiety drugs, may be helpful in AD for symptoms of depression and anxiety.

Several herbal remedies are thought to be helpful in AD. Ginkgo biloba is a common herb that appears to increase blood flow to the brain and has antioxidant properties. The herb is available over the counter, but there are no standards in the United States to regulate its quality of effectiveness. No one should take this or any other herb for AD without first consulting with the primary care provider. When ginkgo biloba is used with other drugs, such as with warfarin or high doses of vitamin E, there is a risk for increased bleeding.

**ACTIONS**

Acetylcholine, a natural chemical in the brain, is required for memory and thinking. Individuals with AD slowly lose this chemical, and as the levels of the chemical decrease, the patient experiences problems with memory and thinking. The cholinesterase inhibitors act to increase the level of acetylcholine in the CNS by inhibiting its breakdown and slowing neuronal destruction. However, the disease is progressive, and although these drugs alter the progress of the disease, they do not cure the disease. The life span of a
patient with A D is usually decreased, although a patient may live from 3 to 20 years after diagnosis.

**USES**

Cholinesterase inhibitors are used to treat the dementia associated with A D. The effectiveness of these drugs varies from individual to individual. The drugs may noticeably diminish the symptoms of A D, the symptoms could improve only slightly, or the symptoms could continue to progress (only at a slower rate).

Donepezil has the advantage of once-daily administration and appears to be better tolerated than tacrine. Tacrine is particularly harmful to the liver and can result in hepatotoxicity. Because tacrine is more likely to cause adverse reactions and drug interactions, it must be administered more frequently (4 times a day) and is rarely used in current therapy. Donepezil has fewer and milder side effects than tacrine. It is considered the agent of first choice. However, some patients may achieve a better response with one drug than another. Additional adverse reactions are listed in the Summary Drug Table: Cholinesterase Inhibitors.

**CONTRAINDICATIONS**

The cholinesterase inhibitors are contraindicated in patients with a hypersensitivity to the drugs and during pregnancy (Pregnancy Category B) and lactation.

**PRECAUTIONS**

These drugs are used cautiously in patients with renal or hepatic disease, bladder obstruction, seizure disorders, sick sinus syndrome, gastrointestinal bleeding, and asthma. Individuals with a history of ulcer disease may have a recurrence of the bleeding.
INTERACTIONS

When the cholinesterase inhibitors are administered with the anticholinergic drugs, there is a potential decrease in activity of the anticholinergic drug. There is an increased risk of toxicity of theophylline when the cholinesterase inhibitors are administered with tacrine. There is a synergistic effect when tacrine is administered with succinylcholine, cholinesterase inhibitors, or cholinergic agonists (eg, betahanechol).

HERBAL ALERT: Ginseng

Ginseng has been called the "king of herbs" because of its wide use and the benefits attributed to the herb. In early times in China, ginseng was valued as high as gold. Hundreds of ginseng products (eg, gum, teas, chewing gum, juices) are sold throughout the US. Ginseng is the fourth best selling herb in the US. The primary use of ginseng is to improve energy and mental performance. The benefits of ginseng include improving endurance during exercise, reducing fatigue, boosting stamina and reaction times, and increasing feelings of well-being.

Adverse reactions are rare, but sleeplessness, nervousness, and diarrhea have been reported in individuals taking large amounts of the herb. The herb should not be taken in combination with stimulants including those containing caffeine. Dosage is 200 to 500 mg/day of the standardized extract or 1 to 4 g of powdered root a day. Ginseng is contraindicated in individuals with high blood pressure and during pregnancy.

HERBAL ALERT: Ginkgo

Ginkgo is one of the oldest herbs in the world and has many beneficial effects. Ginkgo is taken to improve memory and brain function and to enhance circulation to the brain, heart, limbs, and eyes. Most of the research done on ginkgo has been done on standardized extract ginkgo. The recommended dose is 40 mg standardized extract ginkgo three times a day. The effects of ginkgo may not be seen until after 4 to 24 weeks of treatment. The most common adverse reactions include mild gastrointestinal discomfort, headache, and rash. Excessively large doses have been reported to cause diarrhea, nausea, vomiting, and restlessness. Ginkgo is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) because of the risk of a toxic reaction. Individuals taking anticoagulants should take ginkgo only on the advice of a primary care provider.

NURSING PROCESS

The Patient Receiving a Cholinesterase Inhibitor for Mild-to-Moderate Dementia of Alzheimer's Disease

ASSESSMENT

Preadministration Assessment

A patient receiving a cholinesterase inhibitor may be treated in the hospital, nursing home, or in an outpatient setting. The patient's cognitive ability and functional ability are assessed before and during therapy. The baseline or initial assessment depends on the stage of AD. The nurse assesses the patient for confusion, agitation, and impulsive behavior. Speech, ability to perform activities of daily living, and self-care ability also are assessed. These assessments will be used by the nurse in the ongoing assessment in monitoring the patient's improvement (if any) after taking the cholinesterase inhibitors. These drugs may slow the progression of the disease but are not a cure for AD.

Before starting therapy for the hospitalized patient, the nurse obtains a complete psychiatric and medical history. With AD, patients often are unable to give a reliable history of their illness. A family member or primary caregiver will be able to verify or give information needed for an accurate assessment. During the time the history is taken, the nurse observes the patient for any behavior patterns that appear to be deviations from normal. Examples of deviations include poor eye contact, failure to answer questions completely, inappropriate answers to questions, a monotone speech pattern, and inappropriate laughter, sadness, or crying. These patients are in varying stages of decline. Display 33-1 identifies the stages of AD and the associated clinical manifestations. The nurse documents the patient's cognitive ability using Display 33-1 as a guide.

Late dementia or the final phase of AD may last from a few months to several years while the patient becomes increasingly immobile and dysfunctional.

Physical assessments include obtaining blood pressure measurements on both arms with the patients in a sitting position, pulse, respiratory rate, and weight. The functional ability of the patient is also important.

DISPLAY 33-1  Clinical Manifestations of Alzheimer's Disease

EARLY PHASE—MILD COGNITIVE DECLINE

- Increased forgetfulness
- Decreased performance in social settings
- Evidence of memory deficit when interviewed
- Mild to moderate anxiety

EARLY DEMENTIA PHASE—MODERATELY SEVERE COGNITIVE DECLINE

- Needs assistance for activities of daily living
- Unable to recall important aspects of current life
- Difficulty making choices (ie, what clothes to wear, what to eat)
- Able to recall major facts (ie, their name and family member's names)
- Need assistance for survival

LATE DEMENTIA PHASE—SEVERE COGNITIVE DECLINE

- Incontinent of urine
- No verbal ability
- No basic psychomotor skills
- Needs assistance when bathing, toileting, and feeding
The initial assessments of the outpatient are basically the same as those for the hospitalized patient. The nurse obtains a complete medical history and a history of the symptoms of AD from the patient (if possible), a family member, or the patient’s hospital records. During the initial interview, the nurse observes the patient for what appear to be deviations from a normal behavior pattern. The nurse also should assess the patient’s vital signs and body weight.

**Ongoing Assessment**

Ongoing assessment of patients taking the cholinesterase inhibitors includes both mental and physical assessments. Cognitive and functional abilities are assessed using Display 33-1 as a guide. Initial assessments will be compared with the ongoing assessments to monitor the patient’s improvement (if any) after taking the cholinesterase inhibitors.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes for the patient may include an optimal response to drug therapy, management of common adverse drug reactions, an absence of injury, and compliance with the prescribed therapeutic regimen.

**IMPLEMENTATION**

Promoting an Optimal Response to Therapy

The nurse develops a nursing care plan to meet the patient’s individual needs. It is important to monitor vital signs at least daily. The nurse should report any significant change in the patient’s vital signs to the primary health care provider.

Behavioral records should be written at periodic intervals (frequency depends on hospital or unit guidelines). An accurate description of the patient’s behavior and cognitive ability aids the primary health care provider in planning therapy and thus becomes an important part of nursing management. Patients with poor response to drug therapy may require dosage changes, discontinuation of the drug therapy, or the addition of other therapies to the treatment regimen. However, it is important for the nurse to know that response to these drugs may take several weeks. The symptoms that the patient is experiencing may get better or remain the same, or the patient may experience only a small response to therapy. It is important to remember that a treatment that slows the progression of symptoms in AD is a successful treatment.

Donepezil is administered orally once daily at bedtime. It can be taken with or without food. Galantamine is administered orally twice daily, preferably with morning and evening meals.

Rivastigmine is administered as a tablet or oral solution twice daily. When rivastigmine is administered as an oral solution, the nurse removes the oral dosing syringe provided in the protective container. The syringe provided is used to withdraw the prescribed amount. The dosage may be swallowed directly from the syringe or first mixed with a small glass of water, cold fruit juice, or soda.

Tacrine is administered orally 3 or 4 times a day, preferably on an empty stomach 1 hour before or 2 hours after meals. For best results the drug should be administered around the clock.

**Monitoring and Managing Adverse Reactions**

When taking the cholinesterase inhibitors, patients may experience nausea and vomiting. Although this can occur with all of the cholinesterase inhibitors, patients taking rivastigmine appear to have more problems with nausea and severe vomiting. Nausea and vomiting should be reported to the primary health care provider because the primary care provider may discontinue use of the drug and then restart the drug therapy at the lowest dose possible. Restarting therapy at the lower dose helps to reduce the nausea and vomiting.

Weight loss and eating problems related to the inability to swallow are two major problems in the late stage of AD. These problems coupled with the anorexia and nausea associated with administration of the cholinesterase inhibitors present a challenge for the nurse or the caregiver. Mealtime should be simple and calm. The patient should be offered a well-balanced diet with foods that are easy to chew and digest. Frequent, small meals may be tolerated better than three regular meals. Offering foods of different consistency and flavor is important in case the patient can handle one form better than another. Fluid intake of 6 to 8 glasses of water daily is encouraged to prevent dehydration. In later stages, the patient may be fed through a feeding syringe, or the caregiver can encourage chewing action by pressing gently on the bottom of the patient’s chin and on the lips.
Physical decline and the adverse reactions of dizziness and syncope place the patient at risk for injury. The patient may require assistance by the nurse when ambulating. Assistive devices such as walkers or canes may reduce falls. To minimize the risk of injury, the patient's environment should be controlled and safe. Encouraging the use of bedrails, keeping the bed in low position, using night lights, and frequenting monitoring by the nurse or caregiver will reduce the risk of injury. The patient should wear an identification tag, such as a medical alert bracelet.

When administering tacrine, the nurse must monitor the patient for liver damage. This is best accomplished by monitoring alanine aminotransferase (ALT) levels. ALT is an enzyme found predominately in the liver. Disease or injury to the liver causes a release of this enzyme into the bloodstream, resulting in elevated ALT levels. In patients taking tacrine, ALT levels should be obtained weekly from at least week 4 to week 16 after the initiation of therapy. After week 16, transaminase levels are monitored every 3 months.

The nurse includes the following points in a teaching plan for the patient or family member:

- Keep all appointments with the primary care provider or clinic because close monitoring of therapy is essential. Dose changes may be needed to achieve the best results.
- Report any unusual changes or physical effects to the primary health care provider.
- Take the drug exactly as directed. Do not increase, decrease, or omit a dose or discontinue use of this drug unless directed to do so by the primary health care provider.
- Do not drive or perform other hazardous tasks if drowsiness occurs. As soon as the diagnosis of AD is made, patients should not be permitted to drive.
- Do not take any nonprescription drug unless use of a specific drug has been approved by the primary health care provider.
- Inform physicians, dentists, and other medical personnel of therapy with this drug.
- Keep track of when the drug is taken. In the early stages of forgetfulness, a mark on the calendar each time the medicine is taken or use of a pill counter that holds the medicine for each day of the week may be used to help the patient remember to take the medication or if the medication has been taken for the day.
- Notify the primary health care provider if the following adverse reactions are experienced for more than a few days: nausea, diarrhea, difficulty sleeping, vomiting, or loss of appetite.
- Immediately report the occurrence of the following adverse reactions: severe vomiting, dehydration, changes in neurologic functioning, or yellowing of the skin or eyes.
- Notify the primary health care provider if you have a history of ulcers, feel faint, experience severe stomach pains, vomit blood or material that resembles coffee grounds, or have bloody or black stools.
- Remember that these drugs do not cure AD but slow the mental and physical degeneration associated with the disease.
- Remember that during tacrine therapy the ALT level must be monitored at intervals prescribed by the primary health care provider.

**EVALUATION**

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
- No evidence of injury is seen.
- The patient (if possible), family member, or caregiver demonstrates understanding of the drug regimen.
Critical Thinking Exercises

1. A patient is prescribed tacrine (Cognex) for mild dementia related to AD. The nurse has a meeting with the patient and family. What patient assessments would you need to make before discussing the drug regimen with the patient? What would you include in a teaching plan for the patient and family?

2. A patient with AD is taking donepezil (Aricept). She attends an adult day care center during the day. She is not eating well and recently has lost 5 pounds. If you are the nurse at the center, what actions would you take and why would you take these particular actions?

Review Questions

1. Adverse reactions that the nurse would assess for in a patient taking rivastigmine (Exelon) include _____.
   A. occipital headache
   B. vomiting
   C. hyperactivity
   D. hypoactivity

2. When administering tacrine (Cognex) to a patient with AD the nurse would expect which of the laboratory examinations most likely to be prescribed _____.
   A. a complete blood count
   B. cholesterol levels
   C. transaminase levels
   D. electrolytes

3. Which of the following nursing diagnoses would the nurse most likely place on the care plan of a patient with AD that is related to adverse reactions of the cholinesterase inhibitors?
   A. Imbalanced nutrition
   B. Confusion
   C. Risk for suicide
   D. Bowel incontinence

4. The nurse correctly administers donepezil (Aricept) _____.
   A. three times daily around the clock.
   B. twice daily 1 hour before meals or 2 hours after meals.
   C. once daily in the morning.
   D. once daily at bedtime.

Medication Dosage Problems

1. Rivastigmine (Exelon) oral solution 6 mg PO is prescribed. The drug is available as an oral solution of 2 mg/mL. The nurse administers _____.

2. Galantamine (Reminyl) 4 mg PO is prescribed for a patient with AD. On hand are 8-mg tablets. The nurse administers _____.
Chapter 34

**Antiemetic and Antivertigo Drugs**

### Key Terms

- **antiemetic**: used to treat or prevent nausea or vomiting.
- **antivertigo**: used to treat or prevent vertigo.
- **chemoreceptor trigger zone (CTZ)**: a group of nerve fibers located on the surface of the fourth ventricle of the brain.
- **nausea**: an unpleasant gastric sensation usually preceding vomiting.
- **vomiting**: forceful expulsion of gastric contents through the mouth.
- **vertigo**: a feeling of a spinning or rotation-type motion.
- **vestibular neuritis**: inflammation of the vestibular nerve.

### Chapter Objectives

On completion of this chapter, the student will:

- Define the terms nausea, vomiting, antiemetic, and antivertigo.
- Discuss the general drug actions, uses, adverse reactions, contraindications, precautions, and interactions of antiemetic and antivertigo drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient receiving an antiemetic or antivertigo drug.
- List nursing diagnoses particular to a patient receiving an antiemetic or antivertigo drug.
- Use the nursing process when administering an antiemetic or antivertigo drug.

### Antiemetic Drug Use

An **antiemetic** drug is used to treat or prevent nausea (unpleasant gastric sensation usually preceding vomiting) or vomiting (forceful expulsion of gastric contents through the mouth). An **antivertigo** drug is used to treat or prevent vertigo (a feeling of a spinning or rotation-type motion) that may occur with motion sickness, Ménière's disease of the ear, middle and inner ear surgery, and other disorders.

Vomiting caused by drugs, radiation, and metabolic disorders usually occurs because of stimulation of the **chemoreceptor trigger zone (CTZ)**, a group of nerve fibers located on the surface of the fourth ventricle of the brain. When these fibers are stimulated by chemicals, such as drugs or toxic substances, impulses are sent to the vomiting center located in the medulla. The vomiting center may also be directly stimulated by disorders such as gastrointestinal irritation, motion sickness, and vestibular neuritis (inflammation of the vestibular nerve).

### Actions

These drugs appear to act primarily by inhibiting the CTZ or by depressing the sensitivity of the vestibular apparatus of the inner ear. Those that act on the CTZ are more effective for vomiting caused by stimulation of the CTZ, whereas those that act on the vestibular apparatus of the inner ear are more effective for vertigo associated with motion sickness and middle and inner ear surgeries.

### Uses

**Antiemetic Drugs**

An antiemetic is used to prevent (prophylaxis) or treat nausea and vomiting. An example of prophylactic use is the administration of an antiemetic before surgery to prevent vomiting during the immediate postoperative period when the patient is recovering from anesthesia. Another example is giving an antiemetic before administration of one or a combination of antineoplastic drugs (drugs used in the treatment of cancer; see Chap. 55), which have a high incidence of causing vomiting.

Dronabinol is the only currently available derivative of THC, which is a derivative of the active substance found in marijuana. Dronabinol is a second-line antiemetic and is used after treatment with other antiemetics has failed.
Other causes of nausea and vomiting that may be treated with an antiemetic include radiation therapy for a malignancy, bacterial and viral infections, nausea and vomiting caused by drugs, Ménière's disease and other ear disorders, and neurological diseases and disorders. Some of these drugs also are used to treat the nausea and vomiting seen with motion sickness. Some antiemetics also are antivertigo drugs (see the Summary Drug Table: Antiemetic and Antivertigo Drugs).

Antivertigo Drugs

An antivertigo drug is used to treat vertigo, which is usually accompanied by light-headedness, dizziness, and weakness. The individual often has difficulty walking. Some of the causes of vertigo include high alcohol consumption during a short time, certain drugs, inner ear disease, and postural hypotension. Motion sickness (seasickness, carsickness) has similar symptoms but is caused by repetitive motion (eg, riding in an airplane, boat, or car). Both vertigo and motion sickness may result in nausea and vomiting.

It is important to note that antivertigo drugs are essentially antiemetics because many of these preparations, whether used for motion sickness or vertigo, also have direct or indirect antiemetic properties. They prevent the nausea and vomiting that occur because of stimulation of the vestibular apparatus in the ear. Stimulation of this apparatus results in vertigo, which is often followed by nausea and vomiting.

ADVERSE REACTIONS

The most common adverse reactions seen with these drugs are varying degrees of drowsiness. Additional adverse reactions for each drug are listed in the Summary Drug Table: Antiemetic and Antivertigo Drugs.

CONTRAINDICATIONS

The antiemetic and antivertigo drugs are contraindicated in patients with known hypersensitivity to these drugs, those in a coma, or those with severe central nervous system (CNS) depression. In general, these drugs are not recommended during pregnancy, lactation, or for uncomplicated vomiting in young children. Metoclopramide is contraindicated in patients with a seizure disorder, breast cancer, pheochromocytoma, or gastrointestinal obstruction. Prochlorperazine is contraindicated in patients with bone marrow depression, blood dyscrasia, Parkinson’s disease, or severe liver or cardiovascular disease. Thiethylperazine is classified as Pregnancy Category X and is contraindicated during pregnancy.

PRECAUTIONS

Severe nausea and vomiting should not be treated with antiemetic drugs alone. The cause of the vomiting must be investigated. Antiemetic drugs may hamper the diagnosis of disorders such as brain tumors, appendicitis, intestinal obstruction, or drug toxicity (eg, digitalis toxicity). Delayed diagnosis of any of these disorders could have serious consequences for the patient.

Antiemetics and antivertigo drugs are used cautiously in patients with glaucoma or obstructive disease of the gastrointestinal or genitourinary system, those with renal or hepatic dysfunction, and in older men with possible prostatic hypertrophy. Promethazine is used cautiously in patients with hypertension, sleep apnea, or epilepsy. Trimethobenzamide is used cautiously in children with a viral illness because it may increase the risk of Reye's syndrome.

Perphenazine, prochlorperazine, promethazine, scopolamine, chlorpromazine, and trimethobenzamide are Pregnancy Category C drugs. The pregnancy category of diphenidol is unknown. Other antiemetics and antivertigo drugs are classified as Pregnancy Category B (except for thiethylperazine, which is classified as Pregnancy Category X).

INTERACTIONS

The antiemetics and antivertigo drugs may have additive effects when used with alcohol and other CNS depressants such as sedatives, hypnotics, antianxiety drugs, opiates, and antidepressants. There may be additive anticholinergic effects (see Chap. 25) when administered with drugs that have anticholinergic activity such as the antihistamines, antidepressants, phenothiazines, and disopyramide. The antacids decrease absorption of the antiemetics.

When ondansetron is administered with rifampin, blood levels of ondansetron may be reduced, decreasing the antiemetic effect. Dimenhydrinate may mask the signs and symptoms of ototoxicity when administered with ototoxic drugs, such as the aminoglycosides (see Chap. 10), causing irreversible hearing damage. When lithium is administered with prochlorperazine, the risk of extrapyramidal reactions increases (see Chap. 32).
### Summary Drug Table: Antiemetic and Antivertigo Drugs

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>buclizine</td>
<td>Bucladin-S</td>
<td>Nausea and vomiting, motion sickness</td>
<td>Drowsiness, confusion, dry mouth, headache, jitteriness, anorexia, nausea, urinary frequency, difficulty urinating</td>
<td>50 mg PO q4—6 hours; maximum dose, 150 mg/d</td>
</tr>
<tr>
<td>byoo'-kli-zeen</td>
<td>Softabs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chlorpromazine</td>
<td>Thorazine,</td>
<td>Control of nausea and vomiting, intractable postural hypotension, hiccoughs</td>
<td>Drowsiness, hypotension, postural hypotension, hypertension, bradycardia, hypersensitivity reactions, dry mouth, nasal congestion</td>
<td>Nausea and vomiting: 10—25 mg PO q4—6h PRN; 50—100 mg rectal suppository q6—8h PRN; 25—50 mg IM q3—4h PRN; hiccoughs: 25—50 mg PO, IM, slow IV infusion</td>
</tr>
<tr>
<td>klor-proe'-ma-zeen</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cyclizine</td>
<td>Marezine</td>
<td>Nausea and vomiting, motion sickness</td>
<td>Same as buclizine</td>
<td>50 mg PO ½ hour before exposure to motion, may repeat q4—6h; maximum dose, 200 mg/d</td>
</tr>
<tr>
<td>sye'-kli-zeen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dimenhydrinate</td>
<td>Dinate,</td>
<td>Prevention and treatment of nausea, vomiting, dizziness, vertigo of motion sickness</td>
<td>Dizziness, confusion, nervousness, restlessness, nausea, vomiting, diarrhea, blurred vision, palpitations</td>
<td>50—100 mg PO q4—6h PRN, maximum dose, 400 mg/d, 50 mg IM as needed, 50 mg IV</td>
</tr>
<tr>
<td>dye-men-hye'-dri-nate</td>
<td>Dramamine,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>drame-anate</td>
<td>Triptone,</td>
<td>Prevention and treatment of motion sickness, antihistamine</td>
<td>Dizziness, sedation, epigastric distress, faintness, allergic reactions, urinary frequency, thickening of bronchial secretions</td>
<td>25—50 mg PO q4—6h 10—50 mg IM, IV</td>
</tr>
<tr>
<td>diphenhydramine</td>
<td>Benadryl,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dye-fen-hye'-dra-meen</td>
<td>generic</td>
<td>Prevention and treatment of nausea and vomiting, control of nausea in postoperative period, malignancies, inner ear disturbances</td>
<td></td>
<td></td>
</tr>
<tr>
<td>diphenidol</td>
<td>Vontrol</td>
<td>Vertigo and associated nausea and vomiting, Ménière's disease, middle and inner ear surgery, control of nausea and vomiting in postoperative period, inner ear disturbances</td>
<td>Auditory and visual hallucinations, disorientation, drowsiness, dry mouth, nausea, skin rash</td>
<td>25—50 mg PO q4h</td>
</tr>
<tr>
<td>di-phen'-i-dol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dolasetron mesylate</td>
<td>Anzemet</td>
<td>Prevention of chemotherapy-induced nausea, vomiting, and postoperative nausea and vomiting</td>
<td>Hypotension, hypertension, electrocardiographic changes, headache, dizziness, light-headedness, fatigue, sedation, hunger, constipation</td>
<td>Before chemotherapy: 100 mg within 1 h before chemotherapy; PO nausea and vomiting: 100 mg or 1.8 mg/kg IV</td>
</tr>
<tr>
<td>doe-laz-e'-tron</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dronabinol</td>
<td>Marinol</td>
<td>Treatment of nausea and vomiting due to antineoplastic drug therapy, appetite stimulant in AIDS patients with weight loss</td>
<td>Palpitations, drowsiness, diarrhea, euphoria, dizziness, paranoid reaction, somnolence, irritability, hallucinations</td>
<td>Antiemetic: 5—15 mg/m² 1—3 h before chemotherapy, then q2—4h after chemotherapy, for a total of 4—6 doses/d; appetite stimulant: 2.5 mg PO BID AC lunch and supper</td>
</tr>
<tr>
<td>droe-nab'i-nol</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>granisetron</td>
<td>Kytril</td>
<td>Prevention and treatment of nausea and vomiting due to antineoplastic drug therapy</td>
<td>Headache, weakness, somnolence, diarrhea, constipation</td>
<td>10 μg/kg infused IV over 5 min, 30 min before chemotherapy, or 1 mg PO BID</td>
</tr>
<tr>
<td>hydrochloride</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gran-iz'e-tron</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SUMMARY DRUG TABLE

#### ANTIEMETIC AND ANTIVERTIGO DRUGS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>meclizine</td>
<td>Antivert, Antivert/25, Antivert/50, generic</td>
<td>Vertigo, prevention and treatment of nausea and vomiting due to motion sickness</td>
<td>Drowsiness, restlessness, rash, urticaria, anorexia, hypotension, dry mouth, nose, and throat</td>
<td>Vertigo: 25–100 mg/d PO in divided doses; nausea and vomiting: 25–50 mg PO 1 h before travel and repeat 24h PRN</td>
</tr>
<tr>
<td>metoclopramide</td>
<td>Reglan, generic</td>
<td>Prevention of nausea and vomiting due to antineoplastic drug therapy</td>
<td>Restlessness, drowsiness, fatigue, lassitude, dizziness, nausea, diarrhea</td>
<td>Chemo therapy: 3 doses of 0.15 mg/kg IV or 32 mg PO 30 min before chemotherapy; postoperative nausea and vomiting: 4 mg IV</td>
</tr>
<tr>
<td>ondansetron hydrochloride</td>
<td>Zofran</td>
<td>Prevention of nausea and vomiting due to antineoplastic drug therapy, prevention of postoperative nausea and vomiting</td>
<td>Diarrhea, headache, fever, weakness, dry mouth, drowsiness, sedation</td>
<td>8–16 mg/d PO in divided doses, 5–10 mg IM, IV q6h PRN</td>
</tr>
<tr>
<td>perphenazine</td>
<td>Trilafon, generic</td>
<td>Control of nausea and vomiting, intractable hiccoughs</td>
<td>Same as chlorpromazine hydrochloride</td>
<td>5–10 mg PO TID, QID; 10–20 mg IM, IV; 25 mg rectal suppository BID; 10–15 mg sustained release</td>
</tr>
<tr>
<td>prochlorperazine hydrochloride</td>
<td>Compazine, generic</td>
<td>Control of nausea and vomiting</td>
<td>Same as chlorpromazine hydrochloride</td>
<td></td>
</tr>
<tr>
<td>promethazine hydrochloride</td>
<td>Phenergan, generic</td>
<td>Treatment of motion sickness, prevention of nausea and vomiting associated with anesthesia and surgery</td>
<td>Same as diphenhydramine hydrochloride</td>
<td>Motion sickness: Initial dose 25 mg PO ½ h before travel and repeat in 8–12 h, then 25 mg PO BID, 12.5–25 mg IM, IV; nausea and vomiting: 12.5–25 mg PO, IM, IV</td>
</tr>
<tr>
<td>thiethylperazine maleate</td>
<td>Torecan</td>
<td>Nausea and vomiting</td>
<td>Same as chlorpromazine hydrochloride</td>
<td>10 mg PO, IM, PRN 1–3 times a day; maximum dose, 30 mg/d</td>
</tr>
<tr>
<td>transdermal scopolamine</td>
<td>Transderm-Scop, Scopace</td>
<td>Prevention of nausea and vomiting due to motion sickness</td>
<td>Drowsiness, dry mouth, blurred vision</td>
<td>One system applied at least 4 h before effect is required, repeat in 3 d if needed; orally, 0.4–0.8 mg PO</td>
</tr>
<tr>
<td>triflupromazine trye-flu-proe'-ma-zeen</td>
<td>Vesprin</td>
<td>Severe nausea and vomiting</td>
<td>Drowsiness, insomnia, vertigo, dry mouth, salivation, nausea, vomiting, anorexia, constipation, urinary retention, extrapyramidal effects (see Chap. 30)</td>
<td>5–15 mg IM q4h, maximum dose, 60 mg/d; 1 mg IV up to 3 mg/d</td>
</tr>
<tr>
<td>trimethobenzamide hydrochloride</td>
<td>Tebamide, T-Gen, Tigan, generic</td>
<td>Control of nausea and vomiting</td>
<td>Hypersensitivity reactions, hypotension (IM use), Parkinson-like symptoms, blurred vision, drowsiness, dizziness</td>
<td>250 mg PO TID, QID: 200 mg IM, rectal suppository TID, QID</td>
</tr>
</tbody>
</table>

---

*The term generic indicates the drug is available in generic form.

AIDS, acquired immunodeficiency syndrome.
The Patient Receiving an Antiemetic or Antivertigo Drug

**ASSESSMENT**

**Preadministration Assessment**
As part of the preadministration assessment for a patient receiving a drug for nausea and vomiting, the nurse documents the number of times the patient has vomited and the approximate amount of fluid lost. Before starting therapy, the nurse takes vital signs and assesses for signs of fluid and electrolyte imbalances (see Chap. 58).

**Ongoing Assessment**
If vomiting is severe, the nurse observes the patient for signs and symptoms of electrolyte imbalance. The nurse monitors the blood pressure, pulse, and respiratory rate every 2 to 4 hours or as ordered by the primary health care provider. The nurse carefully measures the intake and output (urine, emesis) until vomiting ceases and the patient is able to take oral fluids in sufficient quantity. The nurse documents in the patient's chart each time the patient has an emesis. The nurse informs the primary health care provider if there is blood in the emesis or if vomiting suddenly becomes more severe.

The nurse also may need to measure the patient’s weight daily to weekly in those with prolonged and repeated episodes of vomiting (eg, those receiving chemotherapy for malignant disease). The nurse assesses the patient at frequent intervals for the effectiveness of the drug to relieve symptoms (eg, nausea, vomiting, or vertigo). The nurse notifies the primary health care provider if the drug fails to relieve or diminish symptoms.

**NURSING DIAGNOSSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

### Nursing Diagnoses Checklist

- Risk for Fluid Volume Deficit related to nausea and vomiting
- Risk for Injury related to adverse drug effects of drowsiness
- Altered Nutrition: Less than Body Requirements related to impaired ability to ingest and retain food and fluids

**PLANNING**

The expected outcomes for the patient depend on the reason the antiemetic or antivertigo drug is administered but may include an optimal response to drug therapy, management of symptoms, absence of injury, and an understanding of the drug regimen.

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**
If the patient is unable to retain the oral form of the drug, the nurse may give it parenterally or as a rectal suppository (if the prescribed drug is available in these forms). If only the oral form has been ordered and the patient is unable to retain the drug, the nurse contacts the primary health care provider regarding an order for a parenteral or suppository form of this or another antiemetic drug.

Buclizine may be taken without water. The patient is instructed to place the tablet in the mouth and allow it to dissolve or to chew or swallow the tablet whole. When given for motion sickness, one 50-mg dose is usually effective. For more extensive travel, a second 50-mg dose may be taken after 4 to 6 hours. When administering scopolamine, one transdermal system is applied behind the ear approximately 4 hours before the antiemetic effect is needed. About 1 g of scopolamine will be administered every 24 hours for 3 days. If the disk detaches from the body, discard it and place a fresh one behind the opposite ear. (See Patient and Family Teaching Checklist: Applying Transdermal Scopolamine.)

**PREVENTION OF NAUSEA IN PATIENTS WITH CANCER.**
Granisetron (Kytril), ondansetron (Zofran), dolasetron (Anzemet), and dronabinol (Marinol) are examples of antiemetics used to prevent nausea and vomiting after cancer (antineoplastic) chemotherapy. The nurse administers these drugs on the day the chemotherapy is given. The nurse may give granisetron and ondansetron intravenously. The nurse mixes the drug according to the manufacturer’s directions and administers it about 30 minutes before administration of an antineoplastic drug. The nurse may give ondansetron orally 30 minutes before antineoplastic therapy, as well as for 1 to 2 days after, to prevent or relieve nausea and vomiting. The nurse gives dolasetron orally within 1 hour before chemotherapy. It is important to give dronabinol, which has abuse potential, orally 1 to 3 hours before administration of an antineoplastic drug, then every 2 to 4 hours after chemotherapy. These drugs have been effective in relieving or eliminating nausea and vomiting after antineoplastic therapy.

**Managing Patient Symptoms**
Dehydration is a serious concern in the patient experiencing nausea and vomiting. It is important to observe
the patient for signs of dehydration, which include poor skin turgor, dry mucous membranes, decrease in or absence of urinary output, concentrated urine, restlessness, irritability, increased respiratory rate, and confusion. If the patient is able to take and retain small amounts of oral fluids, the nurse offers sips of water at frequent intervals. In addition, it is important to observe the patient for signs of electrolyte imbalance, particularly sodium and potassium deficit (see Chap. 58). If signs of dehydration or electrolyte imbalance are noted, the nurse contacts the primary health care provider because parenteral administration of fluids or fluids with electrolytes may be necessary.

Nausea, vomiting, vertigo, and dizziness are disagreeable sensations. The nurse changes the patient’s bedding and patient’s clothing or gown as needed because the odor of vomitus may only intensify these sensations. The nurse provides the patient with an emesis basin and checks the basin at frequent intervals. If an emesis occurs, the nurse empties the basin and measures and documents the vomitus in the patient’s chart. The nurse may give the patient a damp washcloth and a towel to wipe the hands and face as needed. It also is a good idea to give the patient mouthwash or frequent oral rinses to remove the disagreeable taste that accompanies vomiting.

Many of these drugs cause variable degrees of drowsiness. The nurse advises the patient to seek help when getting out of bed if drowsiness occurs.

Administration of these drugs may result in varying degrees of drowsiness. To prevent accidental falls and other injuries, the nurse assists the patient who is allowed out of bed with ambulatory activities. If extreme drowsiness is noted, the nurse instructs the patient to remain in bed and provides a call light for assistance.

When an antiemetic or antivertigo drug is prescribed for outpatient use, the nurse includes the following information in a patient teaching plan:

- A void driving or performing other hazardous tasks when taking this drug because drowsiness may occur with use.
- Contact the primary health care provider if nausea, vomiting, or vertigo persists or worsens.
- Use only as directed. Do not increase the dose or frequency of use unless told to do so by the primary health care provider.
- Avoid the use of alcohol and other sedative-type drugs unless use has been approved by the primary health care provider.
- Avoid driving or performing other hazardous tasks when taking this drug because drowsiness may occur with use.
- Contact the primary health care provider if nausea, vomiting, or vertigo persists or worsens.
- Use only as directed. Do not increase the dose or frequency of use unless told to do so by the primary health care provider.
- Avoid the use of alcohol and other sedative-type drugs unless use has been approved by the primary health care provider.
- A void driving or performing other hazardous tasks when taking this drug because drowsiness may occur with use.
- Contact the primary health care provider if nausea, vomiting, or vertigo persists or worsens.
- Use only as directed. Do not increase the dose or frequency of use unless told to do so by the primary health care provider.
- Avoid the use of alcohol and other sedative-type drugs unless use has been approved by the primary health care provider.
- Take the drug about 1 hour before travel for motion sickness. Buclizine may be taken without water. Place the tablet in the mouth and allow it to dissolve or chew or swallow the tablet whole.
- Take granisetron (Kytril), dronabinol (Marinol), or ondansetron (Zofran) before antineoplastic chemotherapy (oral, intravenous) about 30 minutes before the chemotherapy treatment. Take dolasetron mesylate (Anzemet) orally at least 1 hour before
chemotherapy. After the treatment, take the prescribed antiemetic at the time recommended by the primary health care provider or printed on the drug container.

- Follow the directions for application of transdermal scopolamine that are supplied with the drug (see Patient and Family Teaching Checklist: Applying Transdermal Scopolamine).

**EVALUATION**

- The therapeutic effect is achieved; nausea or vertigo is controlled.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
- No evidence of a fluid volume deficit or electrolyte imbalance is seen.
- No evidence of injury is apparent.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.
- The patient or family demonstrates an understanding of the drug regimen.

**Critical Thinking Exercises**

1. Ms. Davis was prescribed meclizine (Antivert-50) 50 mg for motion sickness. On return from a long car ride she tells you that the medicine did not help. Explain what questions you would ask to determine if Ms. Davis followed the prescribed drug regimen.

2. Mr. Collins is prescribed transdermal scopolamine to relieve motion sickness. Discuss the rationale you would give him to stress the importance of washing his hands after applying or removing the transdermal system.

3. Discuss the ongoing assessment needs of a patient receiving an antiemetic before chemotherapy for cancer.

4. In assessing Ms. Potter, age 52 years, in the emergency department you find that she has a decreased urinary output, concentrated urine, and poor skin turgor and is confused. She reports nausea and states she has been “vomiting all morning.” Explain what is the most important information obtained from your assessment of Ms. Potter. Determine what action you would take first.

**Review Questions**

1. What is the most common adverse reaction the nurse would expect in a patient receiving an antiemetic?
   - A. Occipital headache
   - B. Drowsiness
   - C. Edema
   - D. Nausea

2. When explaining how to use transdermal scopolamine the nurse tells the patient to apply the system to ______.
   - A. a nonhairy region of the chest
   - B. on the upper back
   - C. behind the ear
   - D. on the forearm

3. When an antivertigo drug is prescribed for a patient experiencing motion sickness, the nurse advises the patient to ______.
   - A. avoid driving or performing hazardous tasks
   - B. administer the drug at least 6 hours before travel
   - C. take the drug with food immediately before traveling
   - D. take the drug at the first sign of motion sickness

4. Which of these drugs is a Pregnancy Category X drug and should not be administered to a pregnant woman?
   - A. Dimenhydrinate
   - B. Scopolamine
   - C. Promethazine
   - D. Thiethylperazine

**Medication Dosage Problems**

1. Ondansetron 4 mg is prescribed. The drug is available as a solution of 2 mg/mL. The nurse administers ______.

2. Diphenhydramine 50 is prescribed. The drug is available in 25-mg tablets. The nurse administers ______.

3. Compazine 2.5 mg PO is prescribed. Use the drug label below to prepare the correct dosage. The nurse would administer ______.

- [Drug Label Image]
Aesthetic Drugs

### Key Terms

- analgesia
- anesthesia
- anesthesiologist
- anesthetist
- brachial plexus block
- conduction block
- epidural block
- general anesthesia
- local anesthesia
- local infiltration anesthesia
- neuroleptanalgesia
- preanesthetic drug
- regional anesthesia
- spinal anesthesia
- transsacral block
- volatile liquid

### Chapter Objectives

On completion of this chapter, the student will:

- State the uses of local anesthesia, methods of administration, and nursing responsibilities when administering a local anesthetic.
- Describe the purpose of a preanesthetic drug and the nursing responsibilities associated with the administration of a preanesthetic drug.
- List several drugs used in local and general anesthesia.
- List and briefly describe the four stages of general anesthesia.
- Discuss important nursing responsibilities associated with caring for a patient receiving a preanesthesia drug and during the postanesthesia recovery room period.

### Anesthesia

Anesthesia is a loss of feeling or sensation. Anesthesia may be induced by various drugs that are able to bring about partial or complete loss of sensation. There are two types of anesthesia: local anesthesia and general anesthesia. **Local anesthesia**, as the term implies, is the provision of a pain-free state in a specific area (or region). With a local anesthetic, the patient is fully awake but does not feel pain in the area that has been anesthetized. However, some procedures done under local anesthesia may require the patient to be sedated. Although not fully awake, sedated patients may still hear what is going on around them. **General anesthesia** is the provision of a pain-free state for the entire body. When a general anesthetic is given, the patient loses consciousness and feels no pain. Reflexes, such as the swallowing and gag reflexes, are lost during deep general anesthesia (Fig. 35-1). A **anesthesiologist** is a physician with special training in administering anesthesia. A **nurse anesthetist** is a nurse with special training who is qualified to administer anesthetics.

### Local Anesthesia

The various methods of administering a local anesthetic include topical application, local infiltration, or regional anesthesia.

#### Topical Anesthesia

Topical anesthesia involves the application of the anesthetic to the surface of the skin, open area, or mucous membrane. The anesthetic may be applied with a cotton swab or sprayed on the area. This type of anesthesia may be used to desensitize the skin or mucous membrane to the injection of a deeper local anesthetic. In some instances, topical anesthetics may be applied by the nurse.

#### Local Infiltration Anesthesia

**Local infiltration anesthesia** is the injection of a local anesthetic drug into tissues. This type of anesthesia may be used for dental procedures, the suturing of small wounds, or making an incision into a small area, such as that required for removing a superficial piece of tissue for biopsy.

#### Regional Anesthesia

**Regional anesthesia** is the injection of a local anesthetic around nerves so that the area supplied by these nerves will not send pain signals to the brain. The anesthetized area is usually larger than the area affected by
Spinal Anesthesia

Spinal anesthesia is a type of regional anesthesia that involves the injection of a local anesthetic drug into the subarachnoid space of the spinal cord, usually at the level of the second lumbar vertebra. There is a loss of feeling (anesthesia) and movement in the lower extremities, lower abdomen, and perineum.

Conduction Blocks

A conduction block is a type of regional anesthesia produced by injection of a local anesthetic drug into or near a nerve trunk. Examples of a conduction block include an epidural block (injection of a local anesthetic into the space surrounding the dura of the spinal cord); a transsacral (caudal) block (injection of a local anesthetic into the epidural space at the level of the sacrococcygeal notch); and a brachial plexus block (injection of a local anesthetic into the brachial plexus). Epidural, especially, and transsacral blocks are often used in obstetrics. A brachial plexus block may be used for surgery of the arm or hand.

Preparing the Patient for Local Anesthesia

Depending on the procedure performed, preparing the patient for local anesthesia may or may not be similar to preparing the patient for general anesthesia. For example, administering a local anesthetic for dental surgery or for suturing a small wound may require that the nurse explain to the patient how the anesthetic will be administered, take a patient's allergy history, and when applicable, prepare the area to be anesthetized, which may involve cleaning the area with an antiseptic or shaving the area. Other local anesthetic procedures may require the patient to be in a fasting state because a sedative may also be administered. The nurse may administer an intravenous sedative such as the antianxiety drug diazepam (Valium) (see Chap. 30) during some local anesthetic procedures, such as cataract surgery or surgery performed under spinal anesthesia.

Administering Local Anesthesia

The physician or dentist administers a local injectable anesthetic. Table 35-1 lists the more commonly used local anesthetics.
Nursing Responsibilities When Caring for a Patient Receiving Local Anesthesia

When applicable, the nurse may be responsible for applying a dressing to the area. Depending on the reason for using local anesthesia, the nurse also may be responsible for observing the area for bleeding, oozing, or other problems after the administration of the anesthetic.

PREANESTHETIC DRUGS

A preanesthetic drug is one given before the administration of anesthesia. The nurse usually gives a preanesthetic drug before the administration of general anesthesia but on occasion may give it before injection of the local anesthetic to sedate the patient. The preanesthetic may consist of one drug or a combination of drugs.

Purpose of Preanesthetic Drugs

The general purpose of the preanesthetic drug is to prepare the patient for anesthesia. The more specific purposes of these drugs include the following:

- Narcotic or antianxiety drug—to decrease anxiety and apprehension immediately before surgery. The patient who is calm and relaxed can be anesthetized more quickly, usually requires a smaller dose of an induction drug, may require less anesthesia during surgery, and may have a smoother anesthesia recovery period (awakening from anesthesia).
- Cholinergic blocking drug—to decrease secretions of the upper respiratory tract. Some anesthetic gases and volatile liquids are irritating to the lining of the respiratory tract and thereby increase mucous secretions. The cough and swallowing reflexes are lost during general anesthesia, and excessive secretions can pool in the lungs, resulting in pneumonia or atelectasis during the postoperative period. The administration of a cholinergic blocking drug, such as glycopyrrolate (Robinul) dries up secretions of the upper respiratory tract and lessens the possibility of excessive mucous production.

Selection of Preanesthetic Drugs

The preanesthetic drug is usually selected by the anesthesiologist and may consist of one or more drugs (Table 35-2). A narcotic (see Chap. 19), antianxiety drug (see Chap. 30), or barbiturate (see Chap. 26) may be given to

TABLE 35-1 EXAMPLES OF LOCAL ANESTHETICS

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
</tr>
</thead>
<tbody>
<tr>
<td>articaine HCl</td>
<td>Septocaine</td>
</tr>
<tr>
<td>bupivacaine HCl</td>
<td>Marcaine HCl, generic</td>
</tr>
<tr>
<td>chloroprocaine HCl</td>
<td>Nesacaine, Nesacaine-MPF</td>
</tr>
<tr>
<td>lidocaine HCl</td>
<td>Dilocaine, Xylocaine, generic</td>
</tr>
<tr>
<td>mepivacaine HCl</td>
<td>Carbocaine, Isocaine HCl</td>
</tr>
<tr>
<td>prilocaine HCl</td>
<td>Citanest HCl</td>
</tr>
<tr>
<td>procaine HCl, injectable</td>
<td>Novocain, generic</td>
</tr>
<tr>
<td>ropivacaine</td>
<td>Naropin</td>
</tr>
<tr>
<td>tetracaine HCl</td>
<td>Pontocaine HCl</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.

TABLE 35-2 EXAMPLES OF PREANESTHETIC DRUGS

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Narcotics</td>
<td></td>
</tr>
<tr>
<td>droperidol</td>
<td>Inapsine</td>
</tr>
<tr>
<td>fentanyl</td>
<td>Sublimaze, generic</td>
</tr>
<tr>
<td>meperidine hydrochloride</td>
<td>Demerol, generic</td>
</tr>
<tr>
<td>morphine sulfate</td>
<td>Duramorph, generic</td>
</tr>
<tr>
<td>Barbiturates</td>
<td></td>
</tr>
<tr>
<td>pentobarbital</td>
<td>Nembutal Sodium, generic</td>
</tr>
<tr>
<td>secobarbital</td>
<td>generic</td>
</tr>
<tr>
<td>Cholinergic-Blocking Drugs</td>
<td></td>
</tr>
<tr>
<td>atropine sulfate</td>
<td>generic</td>
</tr>
<tr>
<td>glycopyrrolate</td>
<td>Robinul, generic</td>
</tr>
<tr>
<td>scopolamine</td>
<td>generic</td>
</tr>
<tr>
<td>Antianxiety Drugs With Antiemetic Properties</td>
<td></td>
</tr>
<tr>
<td>hydroxyzine</td>
<td>Atarax, Vistaril, generic</td>
</tr>
<tr>
<td>Antianxiety Drugs</td>
<td></td>
</tr>
<tr>
<td>chlordiazepoxide</td>
<td>Librium, generic</td>
</tr>
<tr>
<td>diazepam</td>
<td>Valium, generic</td>
</tr>
<tr>
<td>midazolam</td>
<td>Versed</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
relax or sedate the patient. Barbiturates are used only occasionally; narcotics are usually preferred for sedation. A cholinergic blocking drug (see Chap. 25) is given to dry secretions in the upper respiratory tract. Scopolamine and glycopyrrolate also have mild sedative properties, and atropine may or may not produce some sedation. Antianxiety drugs have sedative action; when combined with a narcotic, they allow for a lowering of the narcotic dosage because they also have the ability to potentiate the sedative action of the narcotic. Diazepam (Valium), an antianxiety drug, is one of the more commonly used drugs for preoperative sedation.

**Nursing Responsibilities When Caring for a Patient Receiving a Preanesthetic Drug**

The nurse evaluates the patient’s physical status and gives an explanation of the anesthesia. In some hospitals, the anesthesiologist examines the patient the day or evening before surgery, although this may not be possible in emergency situations. Some hospitals use members of the operating room or postanesthesia recovery room staff to visit the patient the night before or the morning of surgery to explain certain facts, such as the time of surgery, the effects of the preanesthetic drug, preparations for surgery, and the postanesthesia recovery room. Proper explanation of anesthesia, the surgery itself, and the events that may occur in preparation for surgery, as well as care after surgery, require a team approach. The nurse’s responsibilities include the following:

- The nurse describes or explains the preparations for surgery ordered by the physician. Examples of preoperative preparations include fasting from midnight (or the time specified by the physician), enemas, shaving of the operative site, use of a hypnotic for sleep the night before, and the preoperative injection about 30 minutes before going to surgery.
- The nurse describes or explains immediate postoperative care, such as the postanesthesia recovery room or a special postoperative surgical unit and the activities of the physicians and nurses during this period. The nurse tells the patient that his or her vital signs will be monitored frequently and that other equipment, such as intravenous fluids and monitors, may be used.
- The nurse describes, explains, and demonstrates postoperative patient activities, such as deep breathing, coughing, and leg exercises.
- The nurse tailors the preoperative explanations to fit the type of surgery scheduled. Not all of these teaching points may be included in every explanation.

**GENERAL ANESTHESIA**

The administration of general anesthesia requires the use of one or more drugs. The choice of anesthetic drug depends on many factors, including:

- The general physical condition of the patient
- The area, organ, or system being operated on
- The anticipated length of the surgical procedure

The anesthesiologist selects the anesthetic drugs that will produce safe anesthesia, analgesia (absence of pain), and in some surgeries, effective skeletal muscle relaxation. General anesthesia is most commonly achieved when the anesthetic vapors are inhaled or administered intravenously (IV). Volatile liquid anesthetics produce anesthesia when their vapors are inhaled. Volatile liquids are liquids that evaporate on exposure to air. Examples of volatile liquids include halothane, desflurane, and enflurane. Gas anesthetics are combined with oxygen and administered by inhalation. Examples of gas anesthetics are nitrous oxide and cyclopropane.

**Drugs Used for General Anesthesia**

**Methohexital and Thiopental**

Methohexital (Brevital) and thiopental (Pentothal), which are ultrashort-acting barbiturates, are used for:

- Induction of anesthesia
- Short surgical procedures with minimal painful stimuli
- In conjunction with or as a supplement to other anesthetics
- Control of convulsive states (thiopental)

These drugs have a rapid onset and a short duration of action. They depress the central nervous system (CNS) to produce hypnosis and anesthesia but do not produce analgesia. Recovery after a small dose is rapid.

**Etomidate**

Etomidate (Amidate), a nonbarbiturate, is used for induction of anesthesia. Etomidate also may be used to supplement other anesthetics, such as nitrous oxide, for short surgical procedures. It is a hypnotic without analgesic activity.

**Propofol**

Propofol (Diprivan) is used for induction and maintenance of anesthesia. It also may be used for sedation during diagnostic procedures and procedures that use a local anesthetic. This drug also is used for continuous sedation of intubated or respiratory-controlled patients in intensive care units.
Midazolam

Midazolam (Versed), a short-acting benzodiazepine CNS depressant, is used as a preanesthetic drug to relieve anxiety; for induction of anesthesia; for conscious sedation before minor procedures, such as endoscopic procedures; and to supplement nitrous oxide and oxygen for short surgical procedures. When the drug is used for induction anesthesia, the patient gradually loses consciousness during a period of 1 to 2 minutes.

Sevoflurane

Sevoflurane (Ultane) is an inhalational analgesic. It is used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgical procedures.

Ketamine

Ketamine (Ketalar) is a rapid-acting general anesthetic. It produces an anesthetic state characterized by profound analgesia, cardiovascular and respiratory stimulation, normal or enhanced skeletal muscle tone, and occasionally mild respiratory depression. Ketamine is used for diagnostic and surgical procedures that do not require relaxation of skeletal muscles, for induction of anesthesia before the administration of other anesthetic drugs, and as a supplement to other anesthetic drugs.

Cyclopropane

An anesthetic gas, cyclopropane has a rapid onset of action and may be used for induction and maintenance of anesthesia. Skeletal muscle relaxation is produced with full anesthetic doses. Cyclopropane is supplied in orange cylinders. Disadvantages of cyclopropane are difficulty in detecting the planes of anesthesia, occasional laryngospasm, cardiac arrhythmias, and postanesthesia nausea, vomiting, and headache. Cyclopropane and oxygen mixtures are explosive, which limits the use of this gas anesthetic.

Ethylene

Ethylene is an anesthetic gas with a rapid onset of action and a rapid recovery from its anesthetic effects. It provides adequate analgesia but has poor muscle-relaxant properties. The advantages of ethylene include minimal bronchospasm, laryngospasm, and postanesthesia vomiting. A disadvantage of ethylene is hypoxia. This gas is supplied in red cylinders. Mixtures of ethylene and oxygen are flammable and explosive.

Nitrous Oxide

Nitrous oxide is the most commonly used anesthetic gas. It is a weak anesthetic and is usually used in combination with other anesthetic drugs. It does not cause skeletal muscle relaxation. The chief danger in the use of nitrous oxide is hypoxemia. Nitrous oxide is nonexplosive and is supplied in blue cylinders.

Enflurane

Enflurane (Ethrane) is a volatile liquid anesthetic that is delivered by inhalation. Induction and recovery from anesthesia are rapid. Muscle relaxation for abdominal surgery is adequate, but greater relaxation may be necessary and may require the use of a skeletal muscle relaxant. Enflurane may produce mild stimulation of respiratory and bronchial secretions when used alone. Hypotension may occur when anesthesia deepens.

Halothane

Halothane (Fluothane) is a volatile liquid given by inhalation for induction and maintenance of anesthesia. Induction and recovery from anesthesia are rapid, and the depth of anesthesia can be rapidly altered. Halothane does not irritate the respiratory tract, and an increase in tracheobronchial secretions usually does not occur. Halothane produces moderate muscle relaxation, but skeletal muscle relaxants may be used in certain types of surgeries. This anesthetic may be given with a mixture of nitrous oxide and oxygen.

Isoflurane

Isoflurane (Forane) is a volatile liquid given by inhalation. It is used for induction and maintenance of anesthesia.

Methoxyflurane

Methoxyflurane (Penthrane), a volatile liquid, provides analgesia and anesthesia. It is usually used in combination with nitrous oxide but may also be used alone. It does not produce good muscle relaxation, and a skeletal muscle relaxant may be required.

Desflurane

Desflurane (Suprane), a volatile liquid, is used for induction and maintenance of anesthesia. A special vaporizer is used to deliver this anesthetic because delivery by mask results in irritation of the respiratory tract.

Fentanyl and Droperidol

The narcotic analgesic fentanyl (Sublimaze) and the neuroleptic (major tranquilizer) droperidol (Inapsine) may be used together as a single drug called Innovar. The combination of these two drugs results in neuroleptanalgesia, which is characterized by general quietness, reduced motor activity, and profound analgesia. Complete loss of consciousness may not occur unless
other anesthetic drugs are used. A combination of fentanyl and droperidol may be used for the tranquilizing effect and analgesia for surgical and diagnostic procedures. It may also be used as a preanesthetic for the induction of anesthesia and in the maintenance of general anesthesia.

Droperidol may be used alone as a tranquilizer, as an antiemetic to reduce nausea and vomiting during the immediate postanesthesia period, as an induction drug, and as an adjunct to general anesthesia. Fentanyl may be used alone as a supplement to general or regional anesthesia. It may also be administered alone or with other drugs as a preoperative drug and as an analgesic during the immediate postoperative (recovery room) period.

**Remifentanil Hydrochloride**

Remifentanil (Ultiva) is used for induction and maintenance of general anesthesia and for continued analgesia during the immediate postoperative period. This drug is used cautiously in patients with a history of hypersensitivity to fentanyl.

**Skeletal Muscle Relaxants**

The various skeletal muscle relaxants that may be used during general anesthesia are listed in Table 35-3. These drugs are administered to produce relaxation of the skeletal muscles during certain types of surgeries, such as those involving the chest or abdomen. They may also be used to facilitate the insertion of an endotracheal tube. Their onset of action is usually rapid (45 seconds to a few minutes), and the duration of action is 30 minutes or more.

**Stages of General Anesthesia**

General surgical anesthesia is divided into the following stages:

- Stage I — analgesia
- Stage II — delirium
- Stage III — surgical analgesia
- Stage IV — respiratory paralysis

Display 35-1 describes the stages of general anesthesia more completely.

With newer drugs and techniques, the stages of anesthesia may not be as prominent as those described in Display 35-1. In addition, movement through the first two stages is usually very rapid.

Aesthesia begins with a loss of consciousness. This is part of the induction stage (stage I). The patient is now relaxed and can no longer see or hear what is going on. After consciousness is lost, additional anesthetic drugs are administered. Some of these drugs are also used as part of the induction phase, as well as for deepening anesthesia. Depending on the type of surgery, an endotracheal tube also may be inserted into the trachea to provide an adequate airway and to assist in the administration of oxygen and other anesthetic drugs. The endotracheal tube is removed during the postanesthesia period once the gag and swallowing reflexes have returned. If an intravenous line was not inserted before the patient’s

**TABLE 35-3 Examples of Muscle Relaxants Used During General Anesthesia**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
</tr>
</thead>
<tbody>
<tr>
<td>atracurium besylate</td>
<td>Tracrium</td>
</tr>
<tr>
<td>cisatracurium besylate</td>
<td>Nimbox</td>
</tr>
<tr>
<td>doxacurium chloride</td>
<td>Nuromax</td>
</tr>
<tr>
<td>metocurine iodide</td>
<td>Metubine iodine, generic</td>
</tr>
<tr>
<td>mivacurium chloride</td>
<td>Mivacron</td>
</tr>
<tr>
<td>pancuronium bromide</td>
<td>Pavulon, generic</td>
</tr>
<tr>
<td>pipecuronium bromide</td>
<td>Arduan</td>
</tr>
<tr>
<td>rapacuronium bromide</td>
<td>Raplon</td>
</tr>
<tr>
<td>rocuronium bromide</td>
<td>Zemuron</td>
</tr>
<tr>
<td>succinylcholine chloride</td>
<td>Anectine, generic</td>
</tr>
<tr>
<td>tubocurarine chloride</td>
<td>Norcuron, generic</td>
</tr>
</tbody>
</table>

*The term generic indicates that the drug is available in generic form.
arrival in surgery, it is inserted by the anesthesiologist before the administration of an induction drug.

Nursing Responsibilities During the Administration of General Anesthesia

Preanesthesia

Before surgery, the nurse has the following responsibilities:

- Performing the required tasks and procedures as prescribed by the physician and hospital policy the day or evening before or the morning of surgery and recording these tasks on the patient’s chart. Examples of these tasks include administration of a hypnotic the night before surgery, shaving the operative area, taking vital signs, seeing that the operative consent is signed, checking to see if all jewelry or metal objects are removed, administering enemas, inserting a catheter, inserting a nasogastric tube, and teaching.
- Checking the chart for any recent, abnormal laboratory tests. If a recent, abnormal laboratory test was attached to the patient’s chart shortly before surgery, the nurse must make sure that the surgeon and the anesthesiologist are aware of the abnormality. The nurse can attach a note to the front of the chart and contact the surgeon or anesthesiologist by telephone.
- Placing a list of known or suspected drug allergies or idiosyncrasies on the front of the chart.
- Administering the preanesthetic (preoperative) drug.
- Instructing the patient to remain in bed and placing the side rails up once the preanesthetic drug has been given.
- Positioning the patient to prevent aspiration of vomitus and secretions.
- Checking blood pressure, pulse, intravenous lines, catheters, drainage tubes, surgical dressings, and casts.
- Reviewing the patient’s surgical and anesthesia records.
- Monitoring the blood pressure, pulse, and respiratory rate every 5 to 15 minutes until the patient is discharged from the area.
- Checking the patient every 5 to 15 minutes for emergence from anesthesia. Suctioning is provided as needed.
- Exercising caution in administering narcotics. The nurse must check the patient’s respiratory rate, blood pressure, and pulse before these drugs are given and 20 to 30 minutes after administration (see Chap. 20). The physician is contacted if the respiratory rate is below 10 before the drug is given or if the respirations fall below 10 after the drug is given.
- Discharging the patient from the area to his or her room or other specified area. The nurse must record all drugs administered and nursing tasks performed before the patient leaves the postanesthesia recovery room.

Critical Thinking Exercises

1. Mr. Cantu’s family asks you why a drug is being given before he goes to surgery for a bowel resection. When checking the chart, you note that Mr. Cantu has an order for meperidine HCl (Demerol) 50 mg IM and glycopyrrolate (Robinul) 0.35 mg IM 30 minutes before surgery. Describe how you would explain to the family the purpose of the preanesthetic drugs that are to be given to Mr. Cantu.

2. A nurse you are working with complains she was reprimanded and asked to fill out an incident report for not giving a preanesthetic drug on time. She states that she feels she is being unfairly accused of an error because the drug was given 10 minutes before the patient was taken to surgery. Justify why this is a potentially serious error.

3. Discuss the most important responsibilities of the nurse in the recovery room after a patient has undergone general anesthesia.

Review Questions

1. When planning preoperative care, the nurse expects that a preanesthetic medication usually is given _______ before the patient is transported to surgery.
   A. 20 minutes  
   B. 30 minutes  
   C. 40 minutes  
   D. 60 minutes
2. Which of the following drugs is the most commonly used gas for general anesthesia?
   A. Ethylene
   B. Eflurane
   C. Nitrous oxide
   D. Sevoflurane

3. Neuroleptanalgesia is used to promote general quietness, reduced motor activity, and profound analgesia. Which of the following two drugs are used in combination to accomplish neuroleptanalgesia?
   A. Fentanyl and droperidol
   B. Morphine and glycopyrrolate
   C. Atropine and meperidine
   D. Fentanyl and midazolam

4. One use of skeletal muscle relaxants as part of general anesthesia is to _____.
   A. prevent movement during surgery
   B. facilitate insertion of the endotracheal tube
   C. allow for deeper anesthesia
   D. produce additional anesthesia

Medication Dosage Problems

1. As a preoperative medication for a patient going to surgery, the anesthesiologist prescribes meperidine HCl (Demerol) 50 mg IM. Meperidine is available in solution of 50 mg/mL. The nurse prepares to administer _____.

2. Glycopyrrolate (Robinul) is prescribed for a patient as part of the preoperative preparation for surgery. The drug dose recommendation is 0.002 mg/lb. The patient weighs 150 pounds. The nurse expects the primary care provider to prescribe _____.
The respiratory system consists of the upper and lower airways, the lungs, and the thoracic cavity. The function of the respiratory system is to provide a mechanism for the exchange of oxygen and carbon dioxide in the lungs. Any change in the respiratory status has the potential to affect every other body system because all cells need an adequate supply of oxygen for optimal functioning. This chapter focuses on drugs used to treat some of the more common disorders affecting the respiratory system, particularly allergies and the congestion associated with certain respiratory disorders.

ANTIHISTAMINES

Histamine is a substance present in various tissues of the body, such as the heart, lungs, gastric mucosa, and skin (Fig. 36-1). The highest concentration of histamine is found in the basophil (a type of white blood cell) and mast cells that are found near capillaries. Histamine is produced in response to injury. It acts on areas such as the vascular system and smooth muscle, producing dilatation of arterioles and an increased permeability of capillaries and venules. Dilatation of the arterioles results in localized redness. An increase in the permeability of small blood vessels produces an escape of fluid from these blood vessels into the surrounding tissues, which produces localized swelling. Thus, the release of histamine produces an inflammatory response. Histamine is also released in allergic reactions or hypersensitivity reactions, such as anaphylactic shock.

Antihistamines are drugs used to counteract the effects of histamine on body organs and structures. Examples of antihistamines include diphenhydramine (Benadryl), loratadine (Claritin), fexofenadine (Allegra), and cetirizine (Zyrtec). A new antihistamine, desloratadine (Clarinex), is the active metabolite of loratadine and is intended to eventually replace loratadine (Claritin). Topical corticosteroid nasal sprays such as fluticasone propionate (Flonase) or triamcinolone acetonide (Nasacort AQ) are also used for nasal allergy symptoms. See Chapter 56 for more information on the topical corticosteroids.

ACTIONS

Antihistamines block most, but not all, of the effects of histamine. They do this by competing for histamine at histamine receptor sites, thereby preventing histamine...
from entering these receptor sites and producing an effect on body tissues. Some antihistamines have additional effects, such as antipruritic, antiemetic, and sedative effects.

**USES**

The general uses of the antihistamines include:

- Relief of the symptoms of seasonal and perennial allergies
- Allergic and vasomotor rhinitis
- Allergic conjunctivitis
- Mild and uncomplicated angioneurotic edema and urticaria
- Relief of allergic reactions to drugs, blood, or plasma
- Relief of coughs caused by colds or allergy
- Adjunctive therapy in anaphylactic shock
- Treatment of parkinsonism
- Relief of nausea and vomiting
- Relief of motion sickness
- Sedation
- Adjuncts to analgesics

Each antihistamine may be used for one or more of these reasons. The more specific uses of the various antihistamine preparations are given in the Summary Drug Table: Antihistamines.

**ADVERSE REACTIONS**

Drowsiness and sedation are common adverse reactions seen with the use of many of the antihistamines. Some antihistamines appear to cause more drowsiness and sedation than others. These drugs may also have varying degrees of anticholinergic (cholinergic blocking) effects, which may result in dryness of the mouth, nose, and throat and a thickening of bronchial secretions. Several newer preparations (e.g., loratadine) cause little, if any, drowsiness and fewer anticholinergic effects than some of the other antihistamines. Photosensitivity may occur with the use of the antihistamines.

Some antihistamines may cause dizziness, disturbed coordination, fatigue, hypotension, headache, epigastric distress, and photosensitivity (exaggerated response to brief exposure to the sun, resulting in moderately severe to severe sunburn).

Although these drugs are sometimes used to treat allergies, a drug allergy can occur with the use of an antihistamine. Symptoms that may indicate an allergy to these drugs include skin rash, urticaria, and anaphylactic shock.

**CONTRAINDICATIONS**

Antihistamines are contraindicated in patients with known hypersensitivity to the drugs and during pregnancy. Although the antihistamines are classified in Pregnancy Category B (chlorpheniramine, dexchlorpheniramine, clemastine, diphenhydramine, and loratadine) and C (fexofenadine, hydroxyzine, and promethazine), they are generally contraindicated during pregnancy. Several possible associations with malformations have been reported along with jaundice, hyperreflexia, and prolonged extrapyramidal symptoms in infants whose mothers have received antihistamines (particularly promethazine) during pregnancy. Use of antihistamines during the third trimester of pregnancy has been associated with severe reactions (convulsions) in the infant. The antihistamines are contraindicated in lactating women; these drugs pass readily into breast milk and may adversely affect newborns.

**PRECAUTIONS**

The antihistamines are used cautiously in patients with bronchial asthma, cardiovascular disease, narrow-angle glaucoma, symptomatic prostatic hypertrophy, hypertension, impaired kidney function, peptic ulcer, urinary
### SUMMARY DRUG TABLE  
#### ANTIHISTAMINES

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>brompheniramine maleate</td>
<td>Bromphen, Dimetane, generic</td>
<td>Allergic symptoms; allergic reactions to blood or plasma; adjunctive therapy in anaphylactic reactions</td>
<td>Drowsiness, sedation, dizziness, disturbed coordination, hypotension, headache, blurred vision, thickening of bronchial secretions</td>
<td>4 mg PO q4–6h; 8–12 mg PO of sustained-release form q12h; maximum dosage, 40 mg/d IM, SC, IV in divided doses</td>
</tr>
<tr>
<td>cetirizine HCl</td>
<td>Zyrtec</td>
<td>Seasonal rhinitis, chronic urticaria</td>
<td>Sedation, diarrhea, somnolence</td>
<td>5–10 mg daily PO; maximum dosage, 20 mg/d</td>
</tr>
<tr>
<td>chlorpheniramine maleate</td>
<td>Aller-Chlor, Chlor-Trimeton, generic</td>
<td>Allergic symptoms, hypersensitivity reactions, including anaphylaxis and transfusion reactions</td>
<td>Drowsiness, sedation, hypotension, palpitations, blurred vision, dry mouth, urinary hesitancy</td>
<td>4 mg PO q4–6h; sustained-release form: 8–12 mg PO q8–12h; 5–20 mg IM, SC, IV</td>
</tr>
<tr>
<td>clemastine fumarate</td>
<td>Tavist</td>
<td>Allergic rhinitis, urticaria</td>
<td>Drowsiness, sedation, hypotension, palpitations, blurred vision, dry mouth, urinary hesitancy</td>
<td>1.34 mg PO BID to 8.04 mg/d</td>
</tr>
<tr>
<td>desloratadine</td>
<td>Clarinex</td>
<td>Seasonal or perennial allergic rhinitis</td>
<td>Headache, fatigue, drowsiness, dry mouth, nose, and throat</td>
<td>Adults and children 12 years and older: 5 mg once daily PO; 25–50 mg PO q4–6h; 10–400 mg IM, IV</td>
</tr>
<tr>
<td>diphenhydramine hydrochloride</td>
<td>Benadryl, Hyrexin, Tusstat, generic</td>
<td>Allergic symptoms, hypersensitivity reactions, including anaphylaxis and transfusion reactions, motion sickness, sleep aid, antitussive, parkinsonism</td>
<td>Drowsiness, dry mouth, anorexia, blurred vision, urinary frequency</td>
<td></td>
</tr>
<tr>
<td>fexofenadine</td>
<td>Allegra</td>
<td>Seasonal rhinitis, urticaria</td>
<td>Drowsiness, nausea, headache, back pain, upper respiratory infection</td>
<td>30–60 mg PO BID; maximum dosage, 180 mg/d</td>
</tr>
<tr>
<td>hydroxyzine</td>
<td>Atarax, Vistaril, generic</td>
<td>Pruritus, sedation (oral only), adjunctive therapy for analgesia (parenteral only), antiemetic (parenteral)</td>
<td>Drowsiness, dry mouth, dizziness, wheezing, chest tightness</td>
<td>25 mg 3–4 times a day PO; 25–100 mg IM; sedation, 50–100 mg PO</td>
</tr>
<tr>
<td>loratadine</td>
<td>Claritin, Claritine, Reditabs</td>
<td>Allergic rhinitis</td>
<td>Dizziness, migraine headache, tremors, conjunctivitis, altered salivation</td>
<td>PO 10 mg/d</td>
</tr>
<tr>
<td>promethazine HCl</td>
<td>Anergan, Phenergan, generic</td>
<td>Allergic symptoms, motion sickness, nausea and vomiting associated with anesthesia and surgery, adjunct to analgesics, sedation and apprehension, preoperative and postoperative sedation</td>
<td>Excessive sedation, confusion, disorientation, dizziness, fatigue, blurred vision, dry mouth</td>
<td>Allergy: 12.5–25 mg PO, 25 mg IM, IV; motion sickness, 25 mg BID; nausea, vomiting: 12.5–25 mg PO, IM, IV; preoperative: 50 mg IM or PO the night before surgery</td>
</tr>
<tr>
<td>triptolennamine HCl</td>
<td>PBZ, PBZ-SR</td>
<td>Seasonal allergic rhinitis</td>
<td>Moderate sedation, mild gastrointestinal distress, paradoxical excitation</td>
<td>25–50 mg q4–6h; SR: 1 (100-mg) tablet in AM and 1 tablet in PM</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.*
retention, pyloroduodenal obstruction, or hyperthyroidism.

INTERACTIONS

There is an increase in anticholinergic effects when antihistamines are administered with the monamine oxidase inhibitors (MAOIs) and additive sedative effects if administered with central nervous system depressants (eg, narcotic analgesics or alcohol). When cimetidine and loratadine are administered together there is a risk for increased loratadine levels.

The Patient Receiving an Antihistamine

ASSESSMENT

Preadministration Assessment
The preadministration assessment of the patient receiving these drugs depends on the reason for use. Examples of assessments the nurse may perform include an assessment of the involved areas (eyes, nose, and upper and lower respiratory tract) if the patient is receiving an antihistamine for the relief of symptoms of an allergy. If promethazine (Phenergan) is used with a narcotic to enhance the effects and reduce the dosage of the narcotic, the nurse should take the patient’s blood pressure, pulse, and respiratory rate before giving the drug.

Ongoing Assessment
The nurse usually gives these drugs in the outpatient setting. If the patient is in the hospital or clinic, the nurse observes the patient for the expected effects of the antihistamine and for adverse reactions. The nurse reports adverse reactions to the primary health care provider. In some instances, drowsiness or sedation may occur. When the drug is given to relieve preoperative anxiety, these adverse reactions are expected and are allowed to occur.

If the antihistamine is given for a serious situation, such as a blood transfusion reaction or a severe drug allergy, the nurse assesses the patient at frequent intervals until the symptoms appear relieved and for about 24 hours after the incident.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

NURSING PROCESS

PLANNING
The expected outcomes of the patient vary according to the reason the drug was administered and may include an optimal response to drug therapy, management of common adverse drug reactions, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy
Most antihistamines are given orally with food to prevent gastrointestinal upset. The nurse gives loratadine to the patient whose stomach is empty, at least 2 hours after meals or 1 hour before meals. Loratadine disintegrating tablets can be administered with or without water and are placed on the tongue where the tablet disintegrates rapidly. When administering the antihistamines parenterally, the nurse should give the drug deep intramuscularly, rather than subcutaneously, because many of the antihistamines are irritating to subcutaneous tissue.

Nursing Diagnoses Checklist

- Impaired Oral Mucous Membranes related to adverse drug effects (dry mouth, nose, and throat)
- Risk for Injury related to adverse drug reactions (drowsiness, dizziness, disturbed coordination)

Nursing Alert

The nurse must not administer antihistamines to patients with lower respiratory tract diseases. If the nurse administers these drugs to patients with disorders such as asthma, the drying effect on the respiratory tract may cause thickening of the respiratory secretions and make expectoration more difficult.

Monitoring and Managing Adverse Reactions
Dryness of the mouth, nose, and throat may occur. The nurse offers the patient frequent sips of water to relieve these symptoms.

Gerontologic Alert

Older adults are more likely to experience anticholinergic effects (eg, dryness of the mouth, nose, and throat), dizziness, sedation, hypotension, and confusion from the antihistamines. A dosage reduction may be necessary if these symptoms persist.
If the patient experiences dizziness or drowsiness, it is important to provide assistance with ambulation. If drowsiness is severe or if other problems such as dizziness or a disturbance in muscle coordination occur, the patient may require assistance with ambulation and other activities. The nurse places the call light within easy reach and instructs the patient to call before attempting to get out of bed or ambulate. The nurse informs the patient that this adverse reaction may lessen with continued use of the drug.

**Educating the Patient and Family**

The nurse reviews the dosage regimen and possible adverse drug reactions with the patient. The following points are included in the patient teaching plan:

- Do not drive or perform other hazardous tasks if drowsiness occurs. This effect may diminish with continued use.
- Avoid the use of alcohol, as well as other drugs that cause sleepiness or drowsiness, while taking these drugs.
- These drugs may cause dryness of the mouth and throat. Frequent sips of water, hard candy, or chewing gum (preferably sugarless) may relieve this problem.
- If gastric upset occurs, take this drug with food or meals. Loratadine should be taken on an empty stomach, if possible. If the gastric upset is not relieved, discuss this with the primary health care provider.
- Avoid ultraviolet light or sunlight because of the possibility of photosensitivity. Wear sunglasses, protective clothing, and a sunscreen when exposed to sunlight.
- Do not crush or chew sustained-release preparations.

**EVALUATION**

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through nursing interventions.
- No evidence of injury is seen.
- Mucous membranes are kept moist.
- The patient demonstrates an understanding of the drug regimen and adverse effects of the drug.

---

**DECONGESTANTS**

A decongestant is a drug that reduces swelling of the nasal passages, which, in turn, opens clogged nasal passages and enhances drainage of the sinuses. These drugs are used for the temporary relief of nasal congestion caused by the common cold, hay fever, sinusitis, and other respiratory allergies.

**ACTIONS**

The nasal decongestants are sympathomimetic drugs, which produce localized vasoconstriction of the small blood vessels of the nasal membranes. Vasoconstriction reduces swelling in the nasal passages (decongestive activity). Nasal decongestants may be applied topically, and a few are available for oral use. Examples of nasal decongestants include phenylephrine (Neo-Synephrine) and oxymetazoline (Afrin), which are available as nasal sprays or drops, and pseudoephedrine (Sudafed), which is taken orally. Additional nasal decongestants are listed in the Summary Drug Table: Systemic and Topical Nasal Decongestants.

**USES**

Decongestants are used to treat the congestion associated with rhinitis, hay fever, allergic rhinitis, sinusitis, and the common cold. In addition, they are used in adjunctive therapy of middle ear infections to decrease congestion around the eustachian tube. Nasal inhalers may relieve ear block and pressure pain during air travel. Many can be administered orally as well as topically, but topical application is more effective than the oral route.

**ADVERSE REACTIONS**

When used topically in prescribed doses, there are usually minimal systemic effects in most individuals. On occasion, nasal burning, stinging, and dryness may be seen. When the topical form is used frequently or if the liquid is swallowed, the same adverse reactions seen with the oral decongestants may occur.

Use of oral decongestants may result in tachycardia and other cardiac arrhythmias, nervousness, restlessness, insomnia, blurred vision, nausea, and vomiting.

**CONTRAINDICATIONS**

The decongestants are contraindicated in patients with known hypersensitivity, hypertension, and severe coronary artery disease. These drugs are also contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). Naphazoline is contraindicated in patients with glaucoma.

**PRECAUTIONS**

The decongestants are used cautiously in patients with hyperthyroidism, diabetes mellitus, prostatic hypertrophy, ischemic heart disease, and glaucoma. Safe use of the
### SUMMARY DRUG TABLE  
**SYSTEMIC AND TOPICAL NASAL DECONGESTANTS**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>ephedrine</td>
<td>Pertz-D</td>
<td>Nasal congestion</td>
<td>Nasal burning, stinging, dryness, rebound nasal congestion</td>
<td>2–3 drops or small amount of jelly in each nostril q4h; maximum use, 3–4 d</td>
</tr>
<tr>
<td>epinephrine HCl</td>
<td>Adrenalin Chloride</td>
<td>Nasal congestion</td>
<td>Same as ephedrine</td>
<td>2–3 drops or spray in each nostril q4–6h</td>
</tr>
<tr>
<td>naphazoline HCl</td>
<td>Privine</td>
<td>Nasal congestion</td>
<td>Same as ephedrine</td>
<td>1–2 drops in each nostril PRN maximum dosage, q3h for drops and q4–6h for spray</td>
</tr>
<tr>
<td>oxymetazoline HCl</td>
<td>Afrin, Dristan 12-hour Nasal, generic</td>
<td>Nasal congestion</td>
<td>Same as ephedrine</td>
<td>2–3 drops or sprays q10–12h</td>
</tr>
<tr>
<td>phenylephrine HCl</td>
<td>Alconefrin, Neo-Synephrine</td>
<td>Nasal congestion</td>
<td>Same as ephedrine</td>
<td>1–2 sprays of 0–25% solution q3–4h</td>
</tr>
<tr>
<td>phenylpropanolamine HCl</td>
<td>Propagest, generic</td>
<td>Nasal congestion</td>
<td>Anxiety, restlessness, anorexia, arrhythmias, nervousness, nausea, vomiting, blurred vision</td>
<td>25 mg PO q4h; maximum dosage, 150 mg/d; discontinued in US</td>
</tr>
<tr>
<td>pseudoephedrine HCl</td>
<td>Sudafed, generic</td>
<td>Nasal congestion</td>
<td>Same as phenylpropanolamine HCl</td>
<td>60 mg PO q4–6h</td>
</tr>
<tr>
<td>tetrahydrozoline HCl</td>
<td>Tyzine</td>
<td>Nasal congestion</td>
<td>Same as phenylpropanolamine HCl</td>
<td>2–4 drops in each nostril 3–4 times/d</td>
</tr>
<tr>
<td>xylometazoline HCl</td>
<td>Otrivin</td>
<td>Nasal congestion</td>
<td>Same as ephedrine</td>
<td>2–3 drops or sprays in each nostril q8–10h</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.

---

**NURSING PROCESS**

**The Patient Using a Nasal Decongestant**

**ASSESSMENT**

**Preadministration Assessment**

As part of the preadministration assessment, the nurse assesses the patient’s blood pressure, pulse, and congestion before administering a decongestant. The nurse assesses lung sounds and bronchial secretions, which are noted in the patient’s record. It is important to obtain a history of the use of these products, including the name of the product used and the frequency of use.

**Ongoing Assessment**

The ongoing assessment usually occurs when the patient comes to an outpatient clinic for follow-up.

---

**INTERACTIONS**

Additive sympathomimetic effects may develop when decongestants are administered with other sympathomimetic drugs (see Chap. 22). Use of the nasal decongestants with the MAOIs may cause hypertensive crisis. Use of a decongestant with beta-adrenergic blocking drugs may cause hypertension or bradycardia. When ephedrine is administered with theophylline, the patient is at increased risk for theophylline toxicity.

---

**decongestants during pregnancy (Pregnancy Category C) and lactation has not been established. Pregnant women should consult with their primary health care provider before using these drugs.**
treatment with the primary health care provider. The nurse assesses the patient’s blood pressure, pulse, and congestion. The nurse questions the patient about attaining a therapeutic effect and the presence of any adverse reactions to the drug.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes of the patient may include an optimal response to therapy and an understanding of the use of the nasal decongestants.

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**

Decongestants are used only occasionally in the clinical setting. Because some of these products are available without a prescription, their use may be discovered during a patient history for other medical disorders. Nonprescription nasal decongestants should not be used by those with hypertension or heart disease unless such use is approved by the primary health care provider. After administering a topical nasal decongestant, some patients may experience a mild, transient stinging sensation. This usually disappears with continued use. To minimize the occurrence of rebound nasal congestion, the drug therapy should be discontinued gradually by initially discontinuing the medication in one nostril, followed by withdrawal from the other nostril.

**EVALUATION**

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through nursing interventions.
- No evidence of injury is seen.
- Swelling of the nasal passages is reduced.
- The patient demonstrates an understanding of the drug regimen and adverse effects of the drug.

---

**Critical Thinking Exercises**

1. A number of the antihistamines have anticholinergic effects. Discuss this term and identify nursing interactions important when caring for a patient experiencing anticholinergic effects while taking an antihistamine.
2. Discuss important teaching points that should be included in developing a teaching plan for a patient taking a nasal decongestant. Determine what teaching points would be the most important. Provide a rationale for your answer.

**Review Questions**

1. Which of the following is a common adverse reaction seen when administering an antihistamine?
   - A. Sedation
   - B. Blurred vision
   - C. Headache
   - D. Hypertension

2. Antihistamines are not routinely given to patients with lower respiratory disorders because ______.
   - A. the depressant effects may cause a hypotensive crisis
   - B. stimulation of the central nervous system may occur, resulting in paradoxical excitement
   - C. the effects of these drugs on the respiratory tract may cause secretions to thicken
   - D. antihistamines may irritate the bronchi, causing bronchospasm

3. When antihistamines are administered to patients receiving central nervous system depressants, the nurse monitors the patient for ______.
   - A. an increase in anticholinergic effects
   - B. excessive sedation
   - C. seizure activity
   - D. loss of hearing

4. A patient receives a prescription for phenylephrine (Neo-Synephrine). The nurse explains that overuse of this drug may ______.
   - A. result in hypotensive episodes
   - B. decrease sinus drainage
   - C. cause rebound nasal congestion
   - D. dilate capillaries in the nasal mucosa

**Medication Dosage Problems**

1. Loratadine (Claritin) 10 mg is prescribed. The drug is available in a syrup containing 1 mg/mL. The nurse prepares to administer ______.

2. A patient is to receive 50 mg of diphenhydramine hydrochloride orally. The drug is available in 25-mg tablets. The nurse administers ______.
### Key Terms

- asthma
- bronchodilator
- leukotriene
- sympathomimetic
- theophyllinization
- xanthine derivatives

### Chapter Objectives

On completion of this chapter, the student will:

- Describe the uses, general drug action, general adverse reactions, contraindications, precautions, and interactions of the bronchodilators and antiasthma drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking the bronchodilators or antiasthma drugs.
- List some nursing diagnoses particular to a patient taking a bronchodilator or an antiasthma drug.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating a patient about the use of a bronchodilator or an antiasthma drug.

### Key Concepts

**Extrinsic or allergic asthma** causes the IgE inflammatory response. With exposure, the IgE antibodies are produced and attach to mast cells in the lung. Re-exposure to the antigen causes them to bind to the IgE antibody, releasing histamine and other mast cell products. The release of these products causes bronchospasm, mucous membrane swelling, and excessive mucous production. Gas exchange is impaired, causing carbon dioxide to be trapped in the alveoli so that oxygen is unable to enter. Figure 37-2 identifies the asthmatic pathway from both intrinsic and extrinsic stimulus.

Other disorders of the lower respiratory tract include emphysema (lung disorder in which the terminal bronchioles or alveoli become enlarged and plugged with mucus) and chronic bronchitis (chronic inflammation and possibly infection of the bronchi). Chronic obstructive pulmonary disease (COPD) is the name given collectively to emphysema and chronic bronchitis because the obstruction to the airflow is present most of the time. A sthma that is persistent and present for most of the time may also be referred to as COPD.
A bronchodilator is a drug used to relieve bronchospasm associated with respiratory disorders, such as bronchial asthma, chronic bronchitis, and emphysema. These conditions are progressive disorders characterized by a decrease in the inspiratory and expiratory capacity of the lung. Collectively, they are often referred to as COPD. The patient with COPD experiences dyspnea (difficulty breathing) with physical exertion, has difficulty inhaling and exhaling, and may exhibit a chronic cough.

The two major types of bronchodilators are the sympathomimetics and the xanthine derivatives. The anticholinergic drug ipratropium bromide (Atrovent) is used for bronchospasm associated with COPD, chronic bronchitis, and emphysema. Ipratropium is included in the Summary Drug Table: Bronchodilators. Chapter 25 provides specific information concerning the anticholinergic drugs (cholinergic blocking drugs).

**BRONCHODILATORS**

Examples of sympathomimetic bronchodilators include albuterol (Ventolin), epinephrine (Adrenalin), salmeterol (Serevent), and terbutaline (Brethine). Many of the sympathomimetics used as bronchodilators have the subclassification of beta-2 (β₂) receptor agonists (eg, albuterol, salmeterol, and terbutaline). Additional information concerning the various sympathomimetic drugs is given in the Summary Drug Table: Bronchodilators.

**ACTIONS**

When bronchospasm occurs, there is a decrease in the lumen (or inside diameter) of the bronchi, which decreases the amount of air taken into the lungs with
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sympathomimetics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>albuterol sulfate</td>
<td>Proventil, Ventolin,</td>
<td>Bronchospasm, prevention of exercise-</td>
<td>Palpitations, tachycardia, hypertension, tremor,</td>
<td>2—4 mg TID, QID PO; 1—2 inhalations q4—6h; 2</td>
</tr>
<tr>
<td>al-byoo'-ter-ole</td>
<td>Volmax, generic</td>
<td>induced bronchospasm (EIB)</td>
<td>dizziness, shakiness, nervousness, nausea, vomiting</td>
<td>inhalations q4—6h; may also be given by nebulization</td>
</tr>
<tr>
<td>bitolterol mesylate</td>
<td>Tornalate</td>
<td>Asthma, bronchospasm</td>
<td>Palpitations, hypertension, dizziness, vertigo,</td>
<td>2 inhalations q8h; inhalation solution; 2.5 mg</td>
</tr>
<tr>
<td>bye-tole'-ter-ole</td>
<td></td>
<td></td>
<td>tremor, nervousness, headache, throat irritation</td>
<td>over 10–15 mins with continuous flow system or</td>
</tr>
<tr>
<td>ephedrine sulfate</td>
<td>generic</td>
<td>Asthma, bronchospasm</td>
<td>Palpitations, tachycardia, hypertension, arrhythmias,</td>
<td>25–50 mg PO q3–4 h PRN; 25–50 mg IM, SC, IV</td>
</tr>
<tr>
<td>e-fed'-rin</td>
<td></td>
<td></td>
<td>dizziness, vertigo, shakiness, nervousness, headache,</td>
<td></td>
</tr>
<tr>
<td>epinephrine</td>
<td>Adrenalin, Epinephrine</td>
<td>Asthma, bronchospasm</td>
<td>noseua, nausea, vomiting</td>
<td></td>
</tr>
<tr>
<td>ep-i-nef-rin</td>
<td>Mist, Primatene Mist,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>formoterol</td>
<td>Foradil Aerolizer</td>
<td>Maintenance treatment of asthma, prevention</td>
<td>Palpitations, tachycardia, dizziness, nervousness</td>
<td>12-µg capsule q12h using Aerolizer Inhaler; EIB 1</td>
</tr>
<tr>
<td>for-moh'-te-rol</td>
<td></td>
<td>of EIB</td>
<td></td>
<td>12-µg capsule 15 min before exercise using the</td>
</tr>
<tr>
<td>isoetharine</td>
<td>generic</td>
<td>Asthma, bronchospasm</td>
<td>Palpitations, tachycardia, hypertension, tremor,</td>
<td>Hand-held nebulizer: 3–7 inhalations 1:3 dilution</td>
</tr>
<tr>
<td>eye-soe-eth'-a-</td>
<td></td>
<td></td>
<td>dizziness, weakness, restless, hyperactivity,</td>
<td>or 4 inhalations undiluted</td>
</tr>
<tr>
<td>reen</td>
<td></td>
<td></td>
<td>headache, insomnia, nausea, vomiting</td>
<td></td>
</tr>
<tr>
<td>isoproterenol HCl</td>
<td>Isuprel, generic</td>
<td>Bronchospasm during anesthesia, vasopressor</td>
<td>Palpitations, tachycardia, chest tightness, angina,</td>
<td>0.01–0.02 mg IV, repeat if necessary; dilute 1 mL</td>
</tr>
<tr>
<td>eye-soe-proe-</td>
<td></td>
<td>during shock</td>
<td>shakiness, nervousness, weakness, hyperactivity,</td>
<td>of a 1:5000 solution to 10 mL with sodium chloride</td>
</tr>
<tr>
<td>ter'-a-nole</td>
<td></td>
<td></td>
<td>headache, nausea, vomiting, flushing, sweating</td>
<td>injections of 5% dextrose IV</td>
</tr>
<tr>
<td>levalbuterol HCl</td>
<td>Xopenex</td>
<td>Bronchospasm</td>
<td>Tachycardia, nervousness, anxiety, pain, dizziness,</td>
<td>0.63 mg TID, every 6–8 h by nebulization; if no</td>
</tr>
<tr>
<td>lev-al-byoo'-ter-</td>
<td></td>
<td></td>
<td>rhinitis, cough, cardiac arrhythmias</td>
<td>response, dose may be increased to 1.25 mg TID by</td>
</tr>
<tr>
<td>al-ole</td>
<td></td>
<td></td>
<td></td>
<td>nebulization</td>
</tr>
<tr>
<td>metaproterenol</td>
<td>Alupent, generic</td>
<td>Asthma, bronchospasm</td>
<td>Tachycardia, tremor, nervousness, shakiness, nausea,</td>
<td>Aerosol 2–3 inhalations q3–4 h; do not exceed 12</td>
</tr>
<tr>
<td>sulfate</td>
<td></td>
<td></td>
<td>vomiting</td>
<td>inhalations</td>
</tr>
<tr>
<td>met-a-proe-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pirbuterol acetate</td>
<td>Maxair Autohaler,</td>
<td>Asthma, bronchospasm</td>
<td>Shakiness, nervousness, nausea, tachycardia</td>
<td>2 inhalations q4—6 h; do not exceed 12 inhalations</td>
</tr>
<tr>
<td>peer-byoo'-ter-ole</td>
<td>Maxair Inhaler</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>salmeterol</td>
<td>Serevent</td>
<td>Asthma, bronchospasm</td>
<td>Palpitations, tachycardia, tremor, nervousness,</td>
<td>Asthma/bronchospasm: aerosol, 2 inhalations BID</td>
</tr>
<tr>
<td>sal-mee'-ter-ol</td>
<td></td>
<td></td>
<td>headache, nausea, vomiting, heartburn, GI distress,</td>
<td>morning and evening; inhalation powder, 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>diarrhea, cough, rhinitis</td>
<td>(50 mcg) inhalation BID</td>
</tr>
</tbody>
</table>

(continued)
SUMMARY DRUG TABLE  BRONCHODILATORS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>terbutaline sulfate</td>
<td>Brethine,</td>
<td>Asthma, bronchospasm</td>
<td>Palpitations, tremor, dizziness, vertigo, shakiness, nervousness, drowsiness,</td>
<td>2.5–5 mg q6h PO TID during waking hours; 0.25 mg SC (may repeat one time if needed)</td>
</tr>
<tr>
<td>ter-byoo'-ta-leen</td>
<td>generic</td>
<td></td>
<td>headache, nausea, vomiting, GI upset</td>
<td></td>
</tr>
<tr>
<td>Xanthine Derivatives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aminophylline</td>
<td>Phyllocontin, Truphylline, generic</td>
<td>Symptomatic relief or prevention of bronchial asthma and reversible bronchospasm of chronic bronchitis and emphysema</td>
<td>Nausea, vomiting, diarrhea, headache, insomnia, irritability, hyperglycemia, hypotension, cardiac arrhythmias, tachycardia, tachypnea, seizures</td>
<td>Individualize dosage: base adjustments on clinical responses, monitor serum theophylline levels, maintain therapeutic range of 10–20 mcg/mL; base dosage on lean body mass up to 15 mg/kg PO QID; 250–500 mg IM</td>
</tr>
<tr>
<td>oxtriphylline</td>
<td>Choledyl, generic</td>
<td>Same as aminophylline</td>
<td>Same as aminophylline</td>
<td>4.7 mg/kg q8h PO; sustained action: 1 tablet q12h PO</td>
</tr>
<tr>
<td>theophylline</td>
<td>Theo-24, Theo-dur, Theolair, Slo-bid, Uniphyl, generic</td>
<td>Same as aminophylline</td>
<td>Same as aminophylline</td>
<td>Long-term therapy: 16 mg/kg/24h or 400 mg/24h in divided doses. Monitor serum theophylline levels.</td>
</tr>
</tbody>
</table>

Anticholinergic

| ipratropium bromide   | Atrovent, generic | Bronchospasm associated with chronic obstructive pulmonary disease, chronic bronchitis and emphysema, rhinorrhea | Dryness of the oropharynx, nervousness, irritation from aerosol, dizziness, headache, GI distress, dry mouth, exacerbation of symptoms, nausea, palpitations | Aerosol: 2 inhalations (36 µg) QID, not to exceed 12 inhalations; solution: 500 µg (1 unit dose vial) TID, QID by oral nebulization; nasal spray: 2 sprays per nostril BID, TID of 0.03% or 2 sprays per nostril TID, QID of 0.06% |
| ih-prah-trow'-pea-um  |              |                             |                                                                                    |                                                   |

*The term generic indicates the drug is available in generic form.

SUMMARY DRUG TABLE  BRONCHODILATORS (Continued)

Each breath. A decrease in the amount of air taken into the lungs results in respiratory distress. Use of a bronchodilating drug opens the bronchi and allows more air to enter the lungs, which in turn, completely or partially relieves respiratory distress.

USES

Sympathomimetics (drugs that mimic the sympathetic nervous system) are used primarily to treat reversible airway obstruction caused by bronchospasm associated with acute and chronic bronchial asthma, exercise-induced bronchospasm, bronchitis, emphysema, bronchiectasis (abnormal condition of the bronchial tree), or other obstructive pulmonary diseases.

ADVERSE REACTIONS

Administration of a sympathomimetic bronchodilator may result in restlessness, anxiety, increase in blood pressure, palpitations, cardiac arrhythmias, and insomnia. When these drugs are used by inhalation, excessive use (eg, over the recommended times) may result in paradoxical bronchospasm.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The sympathomimetic bronchodilators are contraindicated in patients with known hypersensitivity to the drug, cardiac arrhythmias associated with tachycardia,
ADVERSE REACTIONS

Adverse reactions associated with administration of the xanthine derivatives include nausea, vomiting, restlessness, nervousness, tachycardia, tremors, palpitations, increased respirations, fever, hyperglycemia, and electrocardiographic changes.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The xanthine derivatives are contraindicated in those with known hypersensitivity, peptic ulcers, seizure disorders (unless well controlled with appropriate anticonvulsant medication), serious uncontrolled arrhythmias, and hyperthyroidism.

The xanthine derivatives are used cautiously in patients older than 60 years, those with cardiac disease, hypoxemia, hypertension, congestive heart failure, or liver disease. Aminophylline, dyphylline, oxtriphylline, and theophylline are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation.

When xanthine bronchodilators are administered with sympathomimetic drugs (see Chap. 22), additive CNS and cardiovascular effects may occur. If a patient eats large amounts of charcoal-broiled foods while taking the xanthines, a decrease in the therapeutic effect of the xanthines may occur. Certain foods contain xanthine (eg, coffee, colas, or chocolate) and may increase the risk of cardiac and CNS adverse reactions. Cigarettes, nicotine gum and patches, barbiturates, phenytoin, loop diuretics, isoniazid, and rifampin may decrease the effectiveness of the xanthines. There is an increased risk of xanthine toxicity when the drugs are administered with influenza vaccination, oral contraceptives, glucocorticoids, β-adrenergic blockers, cimetidine, macrolides, thyroid hormones, or allopurinol.

ANTIASTHMA DRUGS

Asthma is a respiratory condition characterized by recurrent attacks of dyspnea (difficulty breathing) and wheezing caused by spasmodic constriction of the bronchi. With asthma, the body responds with a massive inflammation. During the inflammatory process, large amounts of histamine are released from the mast cells of the respiratory tract, causing symptoms such as increased mucous production and edema of the airway and resulting in bronchospasm and inflammation. With asthma the airways become narrow, the muscles around the airway tighten, the inner lining of the bronchi swell, and extra mucus clogs the smaller airways. (See Fig. 37-1.)
Along with the bronchodilators, several types of drugs are effective in the treatment of asthma. These include corticosteroids, leukotriene formation inhibitors, leukotriene receptor agonists, and mast cell stabilizers.

Antiasthma drugs are used in various combinations to treat and manage asthma. Using several drugs may be more beneficial than using a single drug. A multidrug regimen allows smaller dosages of each drug, decreasing the number and severity of adverse reactions. Various combinations of these drugs are used depending on the patient’s response.

### Antiasthma Drugs: Corticosteroids

**ACTIONS**

Corticosteroids, such as beclomethasone (Beclovent), flunisolide (AeroBid), and triamcinolone (Azmacort), are given by inhalation and act to decrease the inflammatory process in the airways of the patient with asthma. In addition, the corticosteroids increase the sensitivity of the \( \beta_2 \)-receptors. With increased sensitivity of the \( \beta_2 \)-receptors, the \( \beta_2 \)-receptor agonist drugs are more effective.

**USES**

The corticosteroids are used in the management and prophylactic treatment of the inflammation associated with chronic asthma or allergic rhinitis.

**ADVERSE REACTIONS**

When used to manage chronic asthma, the corticosteroids are most often given by inhalation. Adverse reactions to the corticosteroids are less likely to occur when the drugs are given by inhalation rather than taken orally. Occasionally, patients may experience throat irritation causing hoarseness, cough, or fungal infection of the mouth and throat. Vertigo or headache also may occur. See Chapter 50 for adverse reactions after oral administration of the corticosteroids. A more complete listing of the adverse reactions associated with the corticosteroids is found in the Summary Drug Table: Antiasthma Drugs.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

The corticosteroids are contraindicated in patients with hypersensitivity to the corticosteroids, acute bronchospasm, status asthmaticus, or other acute episodes of asthma. Vanceril is contraindicated for the relief of symptoms that can be controlled by a bronchodilator and other nonsteroidal medications and in the treatment of nonasthmatic bronchitis. The corticosteroids are used cautiously in patients with compromised immune systems, glaucoma, kidney or liver disease, convulsive disorders, or diabetes, those taking systemic corticosteroids, and during pregnancy (Pregnancy Category C) and lactation. Ketoconazole may increase plasma levels of budesonide and fluticasone.

### Antiasthma Drugs: Leukotriene Receptor Antagonists and Leukotriene Formation Inhibitors

**ACTIONS**

Leukotrienes are bronchoconstrictive substances released by the body during the inflammatory process. When leukotriene production is inhibited, bronchodilation is facilitated. Zileuton acts by decreasing the formation of leukotrienes. Although the result is the same, montelukast and zafirlukast work in a manner slightly differently from that of zileuton. Montelukast and zafirlukast are considered leukotriene receptor antagonists because they inhibit leukotriene receptor sites in the respiratory tract, preventing airway edema and facilitating bronchodilation.

**USES**

Zafirlukast and zileuton are used in the prophylaxis and treatment of chronic asthma in adults and children older than 12 years. Montelukast is used in the prophylaxis and treatment of chronic asthma in adults and in children older than 2 years.

**ADVERSE REACTIONS**

Adverse reactions of zafirlukast (Accolate) include headache, dizziness, myalgia, pain, nausea, diarrhea, abdominal pain, vomiting, and fever. Montelukast (Singulair) administration may cause headache, dizziness, dyspepsia, flu-like symptoms, cough, abdominal pain, and fatigue. Adverse reactions seen with the
### Corticosteroids

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>beclomethasone dipropionate</td>
<td>Beconase AQ, Vanceril, Double Strength</td>
<td>Respiratory inhalant use: asthma Intranasal use: seasonal or perennial rhinitis, prevention of recurrence of nasal polyps after surgical removal</td>
<td>Oral, laryngeal, pharyngeal irritation, fungal infections, suppression of hypothalamic-pituitary-adrenal (HPA) function</td>
<td>Respiratory inhalation use: 2 inhalations (84–168 μg) TID, QID; maximum dosage, 20 inhalations (840 mcg/d). Intranasal therapy: 1 inhalation (42–84 mcg) in each nostril BID, QID (168–336 mcg/d)</td>
</tr>
<tr>
<td>budesonide</td>
<td>Vanceril, Intranasal use: suppression of hypothalamic-pituitary-adrenal (HPA) function</td>
<td>Turbuhaler: management of chronic asthma in adults and children over age 6; Respules: maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years; Additional indication: improvement of symptoms of mild to moderate acute laryngotraecho-bronchitis (croup), seasonal or perennial rhinitis (nasal spray)</td>
<td>Oral, laryngeal, pharyngeal irritation, fungal infections, suppression of HPA function</td>
<td>Individualized dosage by oral inhalation Adults: 200–800 mcg BID; children 6 years and older: 200–400 mcg BID; children 12 months to 8 years: 0.5–1 mcg total daily dose administered one or twice daily in divided doses</td>
</tr>
<tr>
<td>flunisolide</td>
<td>AeroBid, AeroBid-M</td>
<td>Chronic asthma Respiratory inhalant: asthma Intranasal: rhinitis</td>
<td>Oral, laryngeal, pharyngeal irritation, fungal infections, suppression of HPA function</td>
<td>Adults: 2 inhalations BID; maximum dose, 4 inhalations BID; Intranasal: 2 sprays each nostril BID (maximum dosage, 8 sprays/d)</td>
</tr>
<tr>
<td>fluticasone propionate</td>
<td>Flovent, Flovent Rotadisk</td>
<td>Prophylactic maintenance and treatment of asthma</td>
<td>Oral, laryngeal, pharyngeal irritation, fungal infections, suppression of HPA function</td>
<td>Aerosol: 88–880 mcg BID; powder: adults and adolescents 100–1000 mcg BID; children 4–11 years, 500–600 mcg BID</td>
</tr>
<tr>
<td>triamcinolone acetonide</td>
<td>Azmacort</td>
<td>Maintenance and prophylactic treatment of asthma; for asthma patients who require systemic corticosteroid administration when adding an inhaled corticosteroid may reduce or eliminate the need for systemic corticosteroids</td>
<td>Oral, laryngeal, pharyngeal irritation, fungal infections, suppression of HPA function</td>
<td>Adults: 2 inhalations TID, QID; maximum daily dosage 16 inhalations; children 6–12 years: 1–2 inhalations TID, QID; maximum daily dosage, 12 inhalations</td>
</tr>
</tbody>
</table>

### Leukotriene Receptor Antagonists

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>montelukast sodium</td>
<td>Singulair</td>
<td>Prophylaxis and treatment of chronic asthma in adults and children older than 2 years</td>
<td>Headache, dizziness, dyspepsia, gastroenteritis, influenza symptoms, cough, abdominal pain, fatigue</td>
<td>Adults and children older than 15 years: 10 mg PO in the evening; children 6–14 years: 1.5 mg chewable tablet daily, in the evening; children 2–5 years: 1.4 mg chewable tablet daily, in the evening (continued)</td>
</tr>
</tbody>
</table>
administration of zileuton (Zyflo) include dyspepsia, nausea, abdominal pain, and headache. Liver enzyme elevations may occur with the administration of zileuton. These elevations may continue to rise, remain unchanged, or resolve with continued therapy. Alanine aminotransferase (ALT) is an enzyme produced by the liver that acts as a catalyst in the transamination reaction necessary for amino acid production. ALT is found in liver cells in high concentration. When liver damage occurs, ALT levels increase, which makes ALT testing a valuable test for monitoring liver function.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

These drugs are contraindicated in patients with a known hypersensitivity to the drugs. Montelukast, zafirlukast, and zileuton are not used in the reversal of bronchospasm in acute asthma attacks. Zileuton is contraindicated in active liver disease. The drugs are used cautiously in patients with hepatic dysfunction and during pregnancy (zafirlukast and montelukast are Pregnancy Category B drugs, and zileuton is Pregnancy Category C) and lactation.

Administration of zafirlukast and aspirin increases plasma levels of zafirlukast. When zafirlukast is administered with warfarin, there is an increased effect of the anticoagulant. Administration of zafirlukast and theophylline or erythromycin may result in a decreased level of zafirlukast. Administration of montelukast with other drugs has not revealed any adverse responses. Administration of montelukast with aspirin and NSAIDs is avoided in patients with known aspirin sensitivity. Administration of zileuton with propranolol increases the activity or the propranolol, with theophylline increases serum theophylline levels; and with warfarin may increase prothrombin time (PT). A prothrombin blood test should be done regularly in the event dosages of warfarin need to be decreased.
Antiasthma Drugs: Mast Cell Stabilizers

Mast cell stabilizers include cromolyn sodium (Intal) and nedocromil sodium (Tilade).

**ACTIONS**

These drugs inhibit the release of substances that cause bronchoconstriction and inflammation from the mast cells in the respiratory tract.

**USES**

The mast cell stabilizers are used in combination with other drugs in the treatment of asthma and other allergic disorders, including allergic rhinitis (nasal solution), and in the prevention of exercise-induced bronchospasm. When the mast cell stabilizers are used in conjunction with other antiasthma drugs, a reduction in dosage of the drugs may be possible after using the mast cell stabilizer for 3 or 4 weeks. These drugs may be given by nebulization, aerosol spray, or as an oral concentrate.

**ADVERSE REACTIONS**

The more common adverse reactions associated with the mast cell stabilizers include headache, dizziness, nausea, fatigue, hypotension, or unpleasant taste in the mouth. These drugs may cause nasal or throat irritation when given intranasally or by inhalation. A more complete listing of the adverse reactions associated with the mast cell stabilizers is found in the Summary Drug Table: Antiasthma Drugs.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

The mast cell stabilizers are contraindicated in patients with known hypersensitivity to the drugs. The mast cell stabilizers are contraindicated in patients during attacks of acute asthma because they may worsen bronchospasm during the acute asthma attack.

It is important to use the mast cell stabilizers cautiously in patients with impaired renal or hepatic function and during pregnancy (Pregnancy Category B) and lactation. No significant drug interactions have been reported.

---

**ASSESSMENT**

**Preadministration Assessment**

Because the bronchodilators or antiasthma drugs may be given for asthma, emphysema, or chronic bronchitis, the preadministration assessment of the patient requires careful observation and documentation. The nurse takes the blood pressure, pulse, and respiratory rate before therapy with a bronchodilator or antiasthma drug is initiated. Respiratory rates below 12/min or above 24/min are considered abnormal. It is important to assess the lung fields and carefully document the sounds heard before therapy is begun. The nurse notes any dyspnea, cough, wheezing (a musical sound of the respiratory tract caused by air passing through a narrowed bronchial tube), "noisy" respirations, or use of accessory muscles when breathing. If the patient is raising sputum, the nurse records a description of the sputum. The nurse notes and records the patient's general physical condition. It is important to record any signs of hypoxia (eg, mental confusion, restlessness, anxiety, and cyanosis [bluish discoloration of the skin and mucous membranes]). In some instances the primary health care provider may order arterial blood gas analysis or pulmonary function tests.

In patients with chronic asthma, question the patient concerning allergies, frequency of attacks, severity of attacks, factors that cause or relieve attacks, and any antiasthma drugs used currently or taken previously.

**Ongoing Assessment**

During the ongoing assessment, the nurse assesses the respiratory status every 4 hours and whenever the drug is administered. The nurse notes the respiratory rate, lung sounds, and use of accessory muscles in breathing. In addition, the nurse keeps a careful record of the intake and output and reports any imbalance, which may indicate a fluid overload or excessive diuresis. It is important to monitor any patient with a history of cardiovascular problems for chest pain and changes in the electrocardiogram. The primary health care provider may order periodic pulmonary function tests, particularly for patients with emphysema or bronchitis, to help monitor respiratory status.

After administration of the drug, the nurse observes the patient for the effectiveness of drug therapy. Breathing should improve, and the patient will appear less anxious. If relief does not occur, the nurse notifies the primary health care provider because a different drug or an increase in dosage may be necessary.
The nurse observes the patient for adverse drug reactions. If adverse reactions occur, the nurse withholds the next dose and contacts the primary health care provider.

Occasionally the patient may experience an acute bronchospasm either as a result of the disease, after exposure to an allergen, or as an adverse reaction to some antiasthma drugs, such as cromolyn inhalation. An inhaled sympathomimetic, such as albuterol, may be prescribed initially. Salmeterol, a long-acting β-agonist, is contraindicated because of its slowed onset of action. During an acute bronchospasm, the nurse checks the blood pressure, pulse, respiratory rate, and response to the drug every 15 to 35 minutes until the patient’s condition stabilizes and respiratory distress is relieved.

**Nursing Alert**

Acute bronchospasm causes severe respiratory distress and wheezing from the forceful expiration of air and is considered a medical emergency. It is characterized by severe respiratory distress, dyspnea, forceful expiration, and wheezing. The nurse must report these symptoms to the primary health care provider immediately.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes for the patient depend on the specific reason for administering the drug but may include an optimal response to therapy, management of common adverse drug reactions, and an understanding of and compliance with the prescribed treatment regimen.

**PATIENTS TAKING SYMPATHOMIMETICS.** Some of the sympathomimetics are extremely potent drugs. The nurse exercises great care in reading the primary health care provider’s order when preparing these drugs for administration. Doses of drugs such as epinephrine are measured in tenths of a milliliter. A tuberculin syringe is used for measuring and administering these drugs by the parenteral route.

The nurse may administer epinephrine subcutaneously for an acute bronchospasm. Therapeutic effects occur within 5 minutes after administration and last as long as 4 hours.

Salmeterol is a long-acting inhaled bronchodilator and is not used to treat acute asthma symptoms. It does not replace the fast-acting inhalers for sudden symptoms. Salmeterol should not be used more frequently than twice daily (morning and evening).

Formoterol fumarate (Foradil Aerolizer) is administered only by oral inhalation using the Aerolizer Inhaler.
The usual dosage is one 12-μg capsule of formoterol every 12 hours. When using the Aerolizer Inhaler, the patient must not exhale into the device. When beginning treatment with this drug, the patient is instructed to discontinue the regular use of the short-acting β₂-agonist and use that agent only for relief of acute asthma symptoms.

**PATIENTS TAKING XANTHINE DERIVATIVES.** For acute respiratory symptoms, rapid theophyllinization using one of the xanthine derivatives may be required. **Theophyllinization** is accomplished by giving the patient a higher initial dose, called a loading dose, to bring blood levels to a therapeutic range more quickly than waiting several days for the drug to exert a therapeutic effect. The nurse may give loading doses orally or intravenously (IV) during a period of 12 to 24 hours. It is important to closely monitor the patient for signs of theophylline toxicity. See “Monitoring and Managing Adverse Reactions.”

For patients receiving a xanthine derivative such as theophylline, the dosage is individualized and based on improvement of the patient’s condition and serum theophylline drug levels.

The nurse can give some of these drugs (for example, aminophylline or theophylline) IV, either direct IV or as an IV infusion. When giving theophylline or aminophylline IV, the nurse monitors the patient for hypotension, cardiac arrhythmias, and tachycardia. If a bronchodilator is given IV, the nurse administers it through an infusion pump. The nurse checks the IV infusion site at frequent intervals because these patients may be extremely restless, and extravasation can occur.

If theophylline or another xanthine derivative is given as a rectal suppository, the nurse checks the patient every 15 to 30 minutes to be sure the suppository has been retained. If the patient is unable to retain the suppository, the nurse contacts the primary health care provider because another route of administration may be necessary.

When immediate-release products are used, the nurse administers the drug every 6 hours. In some adults, intervals of 8 hours between dosing may be satisfactory.

**PATIENTS TAKING LEUKOTRIENE RECEPTOR ANTAGONISTS AND LEUKOTRIENE FORMATION INHIBITORS.** The nurse should never administer these during an acute asthma attack. These agents are used for the management of chronic asthma and are not bronchodilators. If used during an acute attack, these drugs may worsen the attack.

These drugs are administered orally. Montelukast is administered once daily in the evening; zafirlukast is administered twice daily 1 hour before meals or 2 hours after meals. Zileuton is administered four times daily.

**PATIENTS TAKING CORTICOSTEROID INHALANTS.** If the patient is receiving a sympathomimetic bronchodilator by inhalation and a corticosteroid such as triamcinolone by inhalation, the nurse administers the bronchodilator first, waits several minutes, then administers the corticosteroid inhalant. When administering two inhalations of the same drug, it is advisable to wait at least 1 minute between puffs.

**PATIENTS TAKING MAST CELL STABILIZERS.** The mast cell stabilizers, such as cromolyn (Intal), may be added to the patient’s existing treatment regimen (eg, bronchodilators). When added to the existing regimen, the other medications (ie, corticosteroids) are decreased gradually when the patient experiences a therapeutic response to cromolyn (2–4 weeks) and asthma is under good control. The corticosteroids or other antiasthma drugs may be reinstated based on the patient’s symptoms. If use of the mast cell stabilizers must be discontinued for any reason, the dosage is gradually tapered.

When administered orally, cromolyn is given 1/2 hour before meals and at bedtime. The oral form of the drug comes in an ampule. The ampule is opened and the contents poured into a glass of water. The nurse stirs the mixture thoroughly. The patient must drink all of the mixture. The drug may not be mixed with any other substance (eg, fruit juice, milk, or foods).

The drugs may be administered by a metered-dose inhaler (see Patient and Family Teaching Checklist: Teaching the Patient to Use a Metered-Dose Inhaler). If an aerosol inhalator is used for administration, the nurse teaches the patient how to use this method of delivering the drug to the lungs.

When a therapeutic response occurs, the dosage may be reduced to a maintenance dose.

**Monitoring and Managing Adverse Reactions**

**SYMPATHOMIMETIC DRUGS.** Patients who have difficulty breathing and are receiving a sympathomimetic drug may experience extreme anxiety, nervousness, and restlessness, which may be caused by their breathing difficulty or the action of the sympathomimetic drug. In these patients, it may be difficult for the primary health care provider to determine if the patient is having an adverse drug reaction or if the problem is related to the respiratory disorder. The nurse can reassure the patient that the drug being administered will most likely relieve the respiratory distress in a short time. Patients who are extremely apprehensive are observed more frequently until their respirations are near normal. The nurse closely monitors the patient’s blood pressure and pulse during therapy and reports any significant changes. The nurse speaks and acts in a calm manner, being careful not to increase the anxiety or nervousness caused by the sympathomimetic drug. Explaining the effects of the
To monitor the amount of drug in a metered-dose inhaler, you can periodically place the canister in a container of water. The figure shows the positioning of the canister with various amounts of medication remaining in the canister. (Adapted from the American Lung Association. [1993]. Understanding lung medications: How they work—how to use them, p. 4)

**Drug dispersion using a metered dose-inhaler with and without a spacer. (Adapted from the American Lung Association. [1993]. Understanding lung medications: How they work—how to use them, p. 5)**

---

**Patient and Family Teaching Checklist**

**Teaching the Patient to Use a Metered-Dose Inhaler**

To properly instruct the patient in administration of drug via a metered-dose inhaler, the nurse must be aware of general instructions for use for all metered-dose inhalers and three common methods of use: holding the lips around the mouthpiece, holding the inhaler away from the mouth, and using a spacer or extender.

**General Instructions for Use for All Metered-Dose Inhalers**

The nurse teaches the patient to:

- Shake the inhaler well, with the canister in place, for 5 to 10 seconds immediately before use.
- Remove the cap from the mouthpiece.
- Breathe out to the end of a normal breath.
- Hold the inhaler system upright.
- Place the mouthpiece into the mouth, close the lips tightly or position the mouthpiece 2 to 3 finger-widths from open mouth and tilt the head back.
- Activate the inhaler while taking a slow, deep breath for 3 to 5 seconds.
- Hold the breath for about 10 seconds and exhale slowly.
- If more than one inhalation is required, wait about 1 minute between inhalations (see manufacturer’s directions for specific times). Two minutes are allowed between inhalations for metaproterenol.
- Gargle or rinse the mouth after each dose to relieve dry mouth and throat irritation.
- Rinse the extender and mouthpiece, if applicable, daily in warm water and store them away from heat.
- To monitor the amount of drug remaining in the canister, test the canister by placing it in a container of water.

**Holding the Inhaler Away From the Mouth.** This method involves the use of a device called an extender or spacer attached to the inhaler. Use of the extender allows more drug to reach the lung. The nurse teaches the patient to:

- Place the extender over the mouth (see manufacturer’s directions for specific directions).
- Press the chamber.
- When the drug passes through the extender, take four to six deep breaths to deliver the drug to the lower respiratory passages.

**Patient and Family Teaching Checklist**

**Teaching the Patient to Use a Metered-Dose Inhaler**

To properly instruct the patient in administration of drug via a metered-dose inhaler, the nurse must be aware of general instructions for use for all metered-dose inhalers and three common methods of use: holding the lips around the mouthpiece, holding the inhaler away from the mouth, and using a spacer or extender.

**General Instructions for Use for All Metered-Dose Inhalers**

The nurse teaches the patient to:

- Shake the inhaler well, with the canister in place, for 5 to 10 seconds immediately before use.
- Remove the cap from the mouthpiece.
- Breathe out to the end of a normal breath.
- Hold the inhaler system upright.
- Place the mouthpiece into the mouth, close the lips tightly or position the mouthpiece 2 to 3 finger-widths from open mouth and tilt the head back.
- Activate the inhaler while taking a slow, deep breath for 3 to 5 seconds.
- Hold the breath for about 10 seconds and exhale slowly.
- If more than one inhalation is required, wait about 1 minute between inhalations (see manufacturer’s directions for specific times). Two minutes are allowed between inhalations for metaproterenol.
- Gargle or rinse the mouth after each dose to relieve dry mouth and throat irritation.
- Rinse the extender and mouthpiece, if applicable, daily in warm water and store them away from heat.
- To monitor the amount of drug remaining in the canister, test the canister by placing it in a container of water.

**Holding the Inhaler Away From the Mouth.** This method involves the use of a device called an extender or spacer attached to the inhaler. Use of the extender allows more drug to reach the lung. The nurse teaches the patient to:

- Place the extender over the mouth (see manufacturer’s directions for specific directions).
- Press the chamber.
- When the drug passes through the extender, take four to six deep breaths to deliver the drug to the lower respiratory passages.
drug may help the patient to tolerate these uncomfortable adverse reactions.

**Gerontologic Alert**

Older adults taking the sympathomimetic bronchodilators are at increased risk for adverse reactions related to the cardiovascular system (tachycardia, arrhythmias, palpitations, and hypertension) as well as adverse reactions related to the central nervous system (restlessness, agitation, insomnia).

**Nursing Alert**

Large doses of IV albuterol or IV terbutaline may aggravate diabetes mellitus. Diabetic patients may require an increase in insulin dosage or oral hypoglycemic drug.

**XANTHINE DERIVATIVES**. The patient taking theophylline may report heartburn because the drug relaxes the lower esophageal sphincter, allowing gastroesophageal reflex. Heartburn is minimized if the patient remains in an upright position and sleeps with the head of the bed elevated.

When the patient is taking theophylline, the nurse must monitor frequently for signs of toxicity. A daily plasma theophylline level is useful in monitoring for toxicity. The nurse should arrange to obtain serum blood samples to measure theophylline levels at the time of peak absorption, 1 to 2 hours after administration for immediate-release products and 5 to 9 hours after the morning dose for most sustained-released preparations. The patient should not have missed any doses during the previous 48 hours. The nurse should discourage the patient from drinking coffee before blood is drawn to determine the blood theophylline level because this can cause a false elevation of drug concentration levels.

The therapeutic range of theophylline blood levels is 10 to 20 μg/mL. Levels greater than 20 μg/mL may cause toxicity. In some patients, toxicity may occur with levels between 15 and 20 μg/mL. Toxicity is more likely to occur in patients requiring high doses or during prolonged therapy.

Display 37-1 identifies symptoms observed in patients with various serum theophylline levels.

The nurse reports any serum theophylline levels greater than 20 μg/mL or any symptoms associated with toxicity.

**Nursing Alert**

Notify the primary health care provider immediately if any of the following signs of theophylline toxicity develop: anorexia, nausea, vomiting, diarrhea, confusion, abdominal cramping, headache, restlessness, insomnia, tachycardia, arrhythmias, or seizures.

**DISPLAY 37-1 Symptoms Associated With Serum Theophylline Levels**

- Levels less than 20 mcg/mL—adverse reactions are rare
- Levels greater than 20 mcg/mL—nausea, vomiting, diarrhea, headache, insomnia, irritability
- Levels greater than 35 mcg/mL—hyperglycemia, hypotension, cardiac arrhythmias, tachycardia, seizures, brain damage
- Levels greater than 40 mcg/mL—seizures and cardiopulmonary arrest

**ANTIASTHMA DRUGS**. Some antiasthma drugs may cause an unpleasant taste in the mouth. Having the patient take frequent sips of water, suck on sugarless candy, or chew gum helps to alleviate the problem. If dizziness occurs, the patient may require assistance with ambulation. For nausea, the nurse provides frequent small meals, rather than three larger meals.

**CORTICOSTEROID INHALANTS**. The inhalers, particularly the corticosteroid or mast cell aerosols, may cause throat irritation and infection with *Candida albicans*. The nurse instructs the patient to use strict oral hygiene, cleanse the inhaler as directed in the package directions, and use the proper technique when taking an inhalation. These interventions will decrease the incidence of candidiasis and help to soothe the throat. Occasionally an antifungal drug may be prescribed by the primary health care provider to manage the candidiasis.

**Nursing Alert**

Bronchospasm may occur after administration of the inhaled corticosteroids. If an immediate increase in wheezing indicating bronchospasm occurs after administration of a corticosteroid inhalant, the nurse immediately administers a short-acting inhaled bronchodilator. The inhaled corticosteroid is discontinued and an alternate treatment started.

**LEUKOTRIENE RECEPTOR AGONISTS AND LEUKOTRIENE FORMATION INHIBITORS**. The nurse carefully monitors hepatic transaminase levels at the beginning of treatment and during therapy with zileuton. ALT levels are taken before treatment begins, once a month for the first 3 months, then every 2 to 3 months for the remainder of the first year. After the first year, ALT levels are measured periodically. If symptoms of liver impairment (such as right upper quadrant pain, nausea, fatigue, lethargy, pruritus, jaundice, or “flu-like” symptoms) occur or the ALT elevation is greater than 5 times the upper limits of normal, use of the drug is discontinued. Transaminase levels are monitored until they return to normal.

**Educating the Patient and Family**

If the patient is to use an aerosol inhalator for administration of the bronchodilator, the nurse provides a
A thorough explanation of its use (see Patient and Family Teaching Checklist: Teaching the Patient to Use a Metered-Dose Inhaler).

**Nursing Alert**

The nurse should not assume that the patient understands how to use an aerosol inhaler correctly. Many patients, even with repeated instruction, do not use the proper technique to administer the drug by inhalation. Along with verbal instructions, the nurse should have the patient demonstrate the use of the inhaler to evaluate if he or she is using the proper technique. It is important to repeat instructions at each follow-up visit.

Because each brand is slightly different, the nurse carefully reviews any instruction sheets with the patient and provides information about how the unit is assembled, used, and cleaned.

In addition, the patient may use a peak flow meter at home to monitor the effectiveness of the drug regimen or breathing status. The nurse teaches the patient how to use the peak flow meter and when to notify the primary health care provider (see Home Care Checklist: Using a Peak Flow Meter). A commonly used method to interpret peak flow rates is to relate the three zones to the traffic light colors: green, yellow, and red. See Display 37-2 for information about the three-zone system. The physician may give the patient an action plan to determine what action to take for each of the three zones (see Fig. 37-3).

The nurse also includes the following general points in the patient teaching plan:

- Take the drug exactly as prescribed by the primary health care provider.
- If symptoms become worse, do not increase the dose or frequency of use unless directed to do so by the primary health care provider.
DISPLAY 37-2  Monitoring Peak Flow Readings

Many primary care health providers recommend a three-zone system. This system is based on your personal best peak flow rate—the highest peak flow measurement you can achieve on a day when your asthma is under good control—and it divides peak flow readings into three zones. The green zone ranges from 80% to 100%* of your personal best. The yellow zone, from 50% to 80%*: And the red zone is anything below 50%*.

*These percentages are given as an example. Your doctor will tailor your zones to your individual needs and peak flow patterns.

THINK OF THESE ZONES AS TRAFFIC SIGNALS
- Green means “go.” Continue your regular activities and follow your maintenance medication plan.
- Yellow means “caution.” Additional medication may be needed (either for an acute episode, or if your condition remains stable, as part of your maintenance plan).
- Red means “stop.” This is a danger zone. Notify the primary care health provider immediately. Use the medication prescribed when peak flow readings indicate that asthma is not in good control.

The goal is to stay in the green zone as long as possible and to take action whenever you enter the yellow zone, so you never enter the red zone. The primary care health provider will adjust the color-coded zone indicators on your personal best peak flow meter to remind you of your red, yellow, and green zones, as well as fill out your action plan with your medication instructions.

- If gastrointestinal upset occurs, take this drug with food or milk (oral form).
- Drink 6 to 8 glasses of water each day to decrease the thickness of secretions.
- Do not use nonprescription drugs (some may contain sympathomimetic drugs) unless use has been approved by the primary health care provider.
- Avoid smoking (when applicable). Smoking may make it difficult to adjust the dosage and may worsen breathing problems.
- Do not puncture metered dose inhalers or store them near heat or open flame; the contents of such inhalers are under pressure. Never throw the container into a fire or incinerator. If an unusual smell or taste is noted with use of the inhaler, discontinue use and contact the primary care provider.

SYMPATHOMIMETICS
- Do not exceed the recommended dosage.
- These drugs may cause nervousness, insomnia, and restlessness (especially the sympathomimetics). Contact the primary health care provider if the symptoms become severe.
- Contact the primary care provider if palpitations, tachycardia, chest pain, muscle tremors, dizziness, headache, flushing, or difficulty with urination or breathing occur.
- Salmeterol is not meant to relieve acute asthmatic symptoms. Notify the physician immediately if salmeterol becomes less effective for symptom relief, if more inhalations than usual are needed, or if more than the maximum number of inhalations of short-acting bronchodilators are needed.
- Formoterol fumarate (Foradil Aerolizer) is administered only by oral inhalation using the Aerolizer Inhaler. When using the Aerolizer Inhaler, do not exhale into the device. Always store formoterol capsules in the blister and remove immediately before use. Always discard the capsule and Aerolizer Inhaler by the expiration date included in the manufacturer’s instructions. When treatment with formoterol begins, discontinue the regular use of the short-acting β₂-agonist and use it only for relief of acute asthma symptoms. Do not substitute formoterol for inhaled oral corticosteroids and do not reduce the use of the corticosteroids.

XANTHINE DERIVATIVES
- Remember that frequent monitoring of theophylline serum levels is important.
- Avoid foods that contain xanthine, such as colas, coffee, chocolate, and charcoal-prepared foods.
- If gastrointestinal upset occurs, take the drug with food. Do not chew or crush coated or sustained-release tablets.
- Do not change from one brand to another without consulting your physician.

CORTICOSTEROID INHALANTS
- Corticosteroid Inhalant—Rinse mouth with water without swallowing after each dose to reduce the risk of oral candidiasis. Carry a warning card indicating the need for supplemental systemic steroids in the event of stress or severe asthmatic attack that is unresponsive to bronchodilators. Do not stop therapy abruptly. These drugs are not bronchodilators and do not contain medication to provide rapid relief of breathing difficulties during an asthma attack. If taking bronchodilators by inhalation, use the bronchodilator several minutes before the corticosteroid to enhance application of the steroid into the bronchial tract. See Patient and Family Teaching Checklist: Teaching the Patient to Use a Metered-Dose Inhaler.
- Corticosteroid Inhaled Powder—Hold the inhaler upright and twist off the cover. Twist the grip to the right as far as it will go, listen for the click, and then twist it back. Exhale and place the mouthpiece between lips; slightly tilt head back and inhale deeply and forcefully. Remove inhaler from the mouth and hold breath for about 10 seconds. Rinse the mouth with water after each use to help reduce dry mouth and hoarseness.
FIGURE 37-3. Example of an action plan for asthma.

**ASTHMA ACTION PLAN FOR**

**Doctor’s Name**

**Date**

**Doctor’s Phone Number**

**Hospital/Emergency Room Phone Number**

---

**GREEN ZONE: Doing well**

- No cough, wheeze, chest tightness, or shortness of breath during the day or night
- Can do usual activities

And, if peak flow meter is used,

**Peak flow: more than**

(80% or more of my best peak flow)

My best peak flow is:

**YELLOW ZONE: Asthma is getting worse**

- Cough, wheeze, chest tightness, or shortness of breath, or
- Waking at night due to asthma, or
- Can do some, but not all, usual activities

**First**

**Peak flow:** _____ to _____

(50%–80% of my best peak flow)

**SECOND**

If your symptoms (and peak flow, if used) return to **GREEN ZONE** after 1 hour of above treatment:

- Take the quick-relief medicine every 4 hours for 1 to 2 days.
- Double the dose of your inhaled steroid for _____ (7-10) days.
- Or—

If your symptoms (and peak flow, if used) do not return to **GREEN ZONE** after 1 hour of above treatment:

- Take: _____

(short-acting beta₂-agonist) 2 or 4 puffs or Nebulizer

- Add: _____ mg. per day For _____ (3-10) days

- Call the doctor before/within _____ hours after taking the oral steroid.

**RED ZONE: Medical Alert!**

- Very short of breath, or
- Quick-relief medicines have not helped, or
- Cannot do usual activities, or
- Symptoms are same or get worse after 24 hours in **YELLOW ZONE**

- Or—

**Peak flow:** less than _____

(50% of my best peak flow)

**Take this medicine:**

- _____

(short-acting beta₂-agonist) 4 or 6 puffs or Nebulizer

- _____

(oral steroid) mg.

Then call your doctor NOW. Go to the hospital or call for an ambulance if:

- You are still in the red zone after 15 minutes AND
- You have not reached your doctor.

---

**DANGER SIGNS**

- Trouble walking and talking due to shortness of breath
- Lips or fingernails are blue

- Go to the hospital or call for an ambulance ( _____ ) NOW!
LEUKOTRIENE RECEPTOR AGONISTS AND LEUKOTRIENE FORMATION INHIBITORS

- Zafirlukast—Take this drug regularly as prescribed, even during symptom-free times. Do not use to treat acute episodes of asthma.
- Montelukast—Take once daily in the evening, even when free of symptoms. Contact physician if the asthma is not well controlled. This drug is not for the treatment of an acute attack. Avoid taking aspirin and the NSAIDs while taking montelukast.
- Zileuton—This drug is not a bronchodilator, so do not use it for an acute episode of asthma. Contact the physician if bronchodilators are needed more often than usual or if more than the maximum number of inhalations for a 24-hour period is needed. This drug can interact with other drugs; consult a physician before starting or stopping any prescription or non-prescription drug. Have liver enzyme tests monitored on a regular basis. Immediately report any symptoms of liver dysfunction, such as upper right quadrant pain, nausea, fatigue, lethargy, pruritus, and jaundice.

MAST CELL STABILIZERS

- Inform the primary health care provider if asthma symptoms do not improve within 4 weeks of initiating treatment. The primary health care provider may discontinue the drug therapy.
- Cromolyn—When taken to prevent exercise-induced asthma, this drug should be taken approximately 15 minutes before activity but no earlier than 1 hour before the expected activity.
- Cromolyn—When taken orally, this drug should be taken at least 30 minutes before meals and at bedtime. The drug is prepared by opening the ampule and squeezing the liquid contents into a glass of water. The nurse stirs the solution, and the patient is instructed to drink the entire amount. Do not mix the drug with any other food or beverage.

EVALUATION

- The therapeutic effect is achieved, and breathing is easier and more effective.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully.
- The patient demonstrates an understanding of the drug regimen and use of the nebulizer or aerosol inhalator.

Critical Thinking Exercises

1. Mr. Potter, age 57 years, is admitted to the pulmonary unit in acute respiratory distress. The primary health care provider orders IV aminophylline. In developing a care plan for Mr. Potter, you select the nursing diagnosis Ineffective Airway Clearance. Suggest nursing interventions that would be most important in managing this problem.

Review Questions

1. Which of the following laboratory exams would the nurse expect to be ordered for a patient taking aminophylline?
   A. Thyroid levels
   B. Alanine aminotransferase
   C. Electrolytes
   D. Serum aminophylline levels

2. When the sympathomimetics are administered to older adults there is an increased risk of ______.
   A. gastrointestinal effects
   B. nephrotoxic effects
   C. neurotoxic effects
   D. cardiovascular effects

3. When zileuton is prescribed, the nurse expects which laboratory test to be checked periodically?
   A. Urine for culture and sensitivity (C&S)
   B. Complete blood count (CBC)
   C. Prothrombin test (PT)
   D. Alanine aminotransferase (ALT)

4. When administering aminophylline, a xanthine derivative bronchodilating drug, the nurse monitors the patient for adverse reactions, which include ______.
   A. restlessness, nervousness
   B. hypoglycemia, hypothyroidism
   C. bradycardia, bronchospasm
   D. somnolence, lethargy

5. The nurse correctly administers montelukast (Singulair) ______.
   A. once daily in the evening
   B. twice daily in the morning and evening
   C. three times a day with meals
   D. once daily in the morning

Medication Dosage Problems

1. A patient is to have 0.25 mg of terbutaline SC. The drug is available for injection in a solution of 1 mg/mL. The nurse administers ______.

2. The patient is prescribed zafirlukast 20 mg PO BID. The drug is available in 10-mg tablets. The nurse administers ______. How many milligrams of zafirlukast will the patient receive each day?
Antitussives, Mucolytics, and Expectorants

Key Terms

<table>
<thead>
<tr>
<th>antitussive</th>
<th>mucolytic</th>
</tr>
</thead>
<tbody>
<tr>
<td>coughing</td>
<td>nonproductive cough</td>
</tr>
<tr>
<td>expectorant</td>
<td>productive cough</td>
</tr>
</tbody>
</table>

Chapter Objectives

On completion of this chapter, the student will:

- Define the terms antitussive, mucolytic, and expectorant.
- Describe the uses, general drug actions, adverse reactions, contraindications, precautions and interactions of antitussive, mucolytic, and expectorant drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on patients receiving an antitussive, mucolytic, or expectorant drug.
- List some nursing diagnoses particular to a patient taking an antitussive, mucolytic, or expectorant drug.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating the patient about the use of an antitussive, mucolytic, or expectorant drug.

Upper respiratory infections are among the most common afflictions of humans. The drugs used to treat the discomfort associated with an upper respiratory infection include antitussives, mucolytics, and expectorants. Many of these drugs are available as nonprescription (over-the-counter) drugs, whereas others are available only by prescription.

**ANTITUSSIVES**

Coughing is the forceful expulsion of air from the lungs. A cough may be productive or nonproductive. With a **productive cough**, secretions from the lower respiratory tract are expelled. A **nonproductive cough** is a dry, hacking one that produces no secretions. An **antitussive** is a drug used to relieve coughing. Many antitussive drugs are combined with another drug, such as an antihistamine or expectorant, and sold as nonprescription cough medicine. Other antitussives, either alone or in combination with other drugs, are available by prescription only.

**ACTIONS**

Some antitussives depress the cough center located in the medulla and are called centrally acting drugs. Codeine and dextromethorphan are examples of centrally acting antitussives. Other antitussives are peripherally acting drugs, which act by anesthetizing stretch receptors in the respiratory passages, thereby decreasing coughing. An example of a peripherally acting antitussive is benzonatate (Tessalon).

**USES**

Antitussives are used to relieve a nonproductive cough. When the cough is productive of sputum, it should be treated by the primary health care provider who, based on a physical examination, may or may not prescribe or recommend an antitussive.
# SUMMARY DRUG TABLE  
## ANTITUSSIVE, MUCOLYTIC, AND EXPECTORANT DRUGS

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antitussives</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Narcotic</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>codeine sulfate</td>
<td>koe'-deen</td>
<td>Suppression of nonproductive cough, relief of mild to moderate pain</td>
<td>Sedation, nausea, vomiting, dizziness, constipation, CNS depression</td>
<td>10–20 mg PO q4–6h; maximum dosage 120 mg/d</td>
</tr>
<tr>
<td>benzonatate</td>
<td>generic</td>
<td>Symptomatic relief of cough</td>
<td>Sedation, headache, mild dizziness, constipation, nausea, GI upset, skin eruptions, nasal congestion</td>
<td>Adults and children older than 10 years: 100 mg TID (up to 600 mg/d)</td>
</tr>
<tr>
<td>dextromethorphan HBr</td>
<td>Liquid Caps, Robitussin Pediatric, Sucrets, Suppress, Trocal</td>
<td>Symptomatic relief of cough</td>
<td>Sedation, headache, mild dizziness, constipation, nausea, GI upset, skin eruptions, nasal congestion</td>
<td>Adults and children older than 12 years: 10–30 mg q4–8h, sustained release (SR) 60 mg q12h PO; children 6–12 years: 5–10 mg q4h or 15 mg q6–8h, SR 30 mg q12h PO; children 2–6 years: 2.5–7.5 mg q4–8h, SR 15 mg q12h PO</td>
</tr>
<tr>
<td>dextromethorphan HBr and benzoicaeine HCl</td>
<td>generic</td>
<td>Same as dextromethorphan HBr</td>
<td>Varies, depending on formulation; take as directed on package</td>
<td>Adults: 25 mg q4h PO not to exceed 150 mg/d; children (6–12 years): 25 mg PO q4h (not to exceed 75 mg/d); children 2–6 years old, 6.25 mg q4h (not to exceed 25 mg/d)</td>
</tr>
<tr>
<td>diphenhydramine HCI</td>
<td>Benadryl, generic</td>
<td>Symptomatic relief of cough</td>
<td>Sedation, headache, mild dizziness, constipation, nausea, GI upset, skin eruptions, postural hypotension</td>
<td></td>
</tr>
<tr>
<td>guaifenesin (glyceryl guaiacolate)</td>
<td>generic</td>
<td>Relief of dry, nonproductive cough, and in the presence of mucus in the respiratory tract</td>
<td>Nausea, vomiting, dizziness, headache, rash</td>
<td>Adults and children 12 years and older: 100–400 mg PO q4h; children 6–12 years: 100–200 mg q4h PO; children 2–6 years: 50–100 mg q4h</td>
</tr>
<tr>
<td>potassium iodide</td>
<td>Pima, SSKI, generic</td>
<td>Symptomatic relief of chronic pulmonary diseases for which tenacious mucus complicates the problem</td>
<td>Iodine sensitivity or iodinism (sore mouth, metallic taste, increased salivation, nausea, vomiting, epigastric pain, parotid swelling, and pain)</td>
<td>300–1000 mg PO after meals BID or TID, up to 1.5 g PO TID</td>
</tr>
<tr>
<td>terpin hydrate</td>
<td>generic</td>
<td>Symptomatic relief of dry, nonproductive cough</td>
<td>Drowsiness, nausea, vomiting or abdominal pain</td>
<td>85–170 mg TID or QID PO</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
ADVERSE REACTIONS

Use of codeine may result in respiratory depression, euphoria, light-headedness, sedation, nausea, vomiting, and hypersensitivity reactions. The more common adverse reactions associated with the antitussives are listed in the Summary Drug Table: Antitussive, Mucolytic, and Expectorant Drugs. When used as directed, nonprescription cough medicines containing two or more ingredients have few adverse reactions. However, those that contain an antihistamine may cause drowsiness.

CONTRAINDICATIONS

Antitussives are contraindicated in patients with known hypersensitivity to the drugs. The narcotic antitussives (those with codeine) are contraindicated in premature infants or during labor when delivery of a premature infant is anticipated. Codeine is a Pregnancy Category C drug except in the pregnant woman at term or when taken for extended periods, when it is considered a Pregnancy Category D drug.

PRECAUTIONS

All antitussives are given with caution to patients with a persistent or chronic cough or when the cough is accompanied by excessive secretion. Individuals with a high fever, rash, persistent headache, nausea, or vomiting should take antitussives only when advised to do so by the primary health care provider. Antitussives containing codeine are used with caution in patients having an acute asthmatic attack, those with COPD, and those with pre-existing respiratory disorders. Administration of codeine may obscure the diagnosis in patients with acute abdominal conditions.

Antitussives containing codeine are classified as Pregnancy Category C (during pregnancy) and Pregnancy Category D (during labor) drugs. Safe use of non-narcotic antitussives during pregnancy has not been established. They are used with caution and only when clearly needed during pregnancy and lactation.

The narcotic antitussives are used cautiously in patients with head injury and increased intracranial pressure, acute abdominal disorders, convulsive disorders, hepatic or renal impairment, prostatic hypertrophy, and asthma or other respiratory conditions.

INTERACTIONS

Other central nervous system (CNS) depressants and alcohol may cause additive depressant effects when administered with antitussives containing codeine. When dextromethorphan is administered with the monoamine oxidase inhibitors (see Chap. 31), patients may experience hypotension, fever, nausea, jerking motions to the leg, and coma.

NURSING PROCESS

The Patient Receiving an Antitussive Drug

ASSESSMENT

Preadministration Assessment

A hospitalized patient may occasionally have an antitussive preparation prescribed, especially when a nonproductive cough causes discomfort or threatens to cause more serious problems, such as raising pressure in the eye (increased intraocular pressure) after eye surgery or increasing intracranial pressure in those with CNS disorders. During the preadministration assessment, the nurse documents the type of cough (productive, nonproductive) and describes the color and amount of any sputum present. The nurse takes and records vital signs because some patients with a productive cough may have an infection.

Ongoing Assessment

During the ongoing assessment, the nurse observes for a therapeutic effect (eg, coughing decreases). The nurse auscultates lung sounds and takes vital signs periodically. When a patient has a cough, the nurse describes and records in the chart the type of cough (productive or nonproductive of sputum) and the frequency of coughing. The nurse also notes and records whether the cough interrupts sleep or causes pain in the chest or other parts of the body.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes for the patient may include an optimal response to therapy and an understanding of and compliance with the prescribed treatment regimen.

Nursing Diagnoses Checklist

- Ineffective Airway Clearance related to congestion or coughing
- Disturbed Sleep Pattern related to coughing at night
- Risk for Ineffective Therapeutic Regimen Management related to lack of knowledge of drug regimen, adverse drug effects
IMPLEMENTATION

Promoting an Optimal Response to Therapy

The nurse gives antitussives orally. When the nurse gives the drug as a tablet, the patient should swallow the drug whole and not chew it. Chewing of benzonatate tablets may result in a local anesthetic effect (oropharyngeal anesthesia) with possible choking.

One problem associated with the use of an antitussive is related to its drug action. Although not an adverse reaction, depression of the cough reflex can cause a pooling of secretions in the lungs. A pooling of the secretions that are normally removed by coughing may result in more serious problems, such as pneumonia and atelectasis. For this reason, using an antitussive for a productive cough is often contraindicated.

Another problem can arise from the use of nonprescription cough medicine for self-treatment of a chronic cough. Indiscriminate use of antitussives by the general public may prevent early diagnosis and treatment of serious disorders, such as lung cancer and emphysema.

**Nursing Alert**

The nurse should advise the patient taking a nonprescription cough medicine that if a cough lasts more than 10 days or is accompanied by fever, chest pain, severe headache, or skin rash, the patient should consult the primary health care provider.

**PROMOTING SLEEP.** The nurse notes whether coughing keeps the patient awake at night or if the patient has difficulty falling asleep after being awakened by coughing. If sleep is frequently interrupted by coughing, the problem is discussed with the primary health care provider.

**Educating the Patient and Family**

The nurse discourages the indiscriminate use of nonprescription cough medicines, especially when coughing produces sputum. The nurse advises the patient to read the label carefully, follow the dosage recommendations, and consult the primary health care provider if the cough persists for more than 10 days or if fever or chest pain occurs. If an antitussive is prescribed for use at home, the nurse includes the following information in a teaching plan:

- Do not exceed the recommended dose.
- If chills, fever, chest pain, or sputum production occurs, contact the primary health care provider as soon as possible.
- Drink plenty of fluids. A fluid intake of 1500 to 2000 mL is recommended.
- If taking oral capsules, do not chew or break open the capsules; swallow them whole.
- If the cough is not relieved or becomes worse, contact the primary health care provider.
- Avoid irritants such as cigarette smoke, dust, or fumes to decrease irritation to the throat. Take frequent sips of water, suck on sugarless hard candy, or chew gum to diminish coughing.
- Remember that codeine may impair mental or physical abilities required for the performance of potentially hazardous tasks. Observe caution when driving or performing tasks requiring alertness, coordination, or physical dexterity. Do not use with alcohol or other CNS depressants (eg, antidepressants, hypnotics, sedatives, tranquilizers). Codeine may cause orthostatic hypotension when rising too quickly from a sitting or lying position. Do not take for persistent or chronic cough, such as occurs with smoking, asthma, or emphysema or when the cough is accompanied by excessive secretions, except when under the supervision of a physician.

**EVALUATION**

- The therapeutic effect is achieved and coughing is relieved.
- The patient sleeps through the night.
- The patient and family demonstrate an understanding of the drug regimen.

**MUCOLYTICS AND EXPECTORANTS**

A **mucolytic** is a drug that loosens respiratory secretions. An **expectorant** is a drug that aids in raising thick, tenacious mucus from the respiratory passages.

**ACTIONS**

A drug with mucolytic activity appears to reduce the viscosity (thickness) of respiratory secretions by direct action on the mucus. An example of a mucolytic drug is acetylcysteine (Mucomyst).

Expectorants increase the production of respiratory secretions, which in turn appears to decrease the viscosity of the mucus. This helps to raise secretions from the respiratory passages. An example of an expectorant is guaifenesin.

**USES**

The mucolytic acetylcysteine may be used as part of the treatment of bronchopulmonary diseases such as emphysema. It is primarily given by nebulization but also may be directly instilled into a tracheostomy to liquefy (thin) secretions. The mucolytic drugs are effective as adjunctive therapy in chronic bronchopulmonary diseases, such as chronic emphysema, emphysema with...
bronchitis, chronic asthma, tuberculosis, and bronchiectasis, and acute bronchopulmonary diseases, such as pneumonia and tracheobronchitis. It is also used in pulmonary conditions of cystic fibrosis and in tracheostomy care. Acetylcysteine has an additional use in preventing liver damage caused by acetaminophen overdose.

Expectorants are used to help raise respiratory secretions. An expectorant may also be included along with one or more additional drugs, such as an antihistamine, decongestant, or antitussive, in some prescription and nonprescription cough medicines.

**ADVERSE REACTIONS**

The more common adverse reactions associated with mucolytic and expectorant drugs are listed in the Summary Drug Table: Antitussive, Mucolytic, and Expectorant Drugs.

**CONTRAINDICATIONS**

The expectorants and mucolytics are contraindicated in patients with known hypersensitivity. The expectorant potassium iodide is contraindicated during pregnancy (Pregnancy Category D).

**PRECAUTIONS**

The expectorants are used cautiously in patients with persistent cough that may be caused by a serious condition needing medical evaluation. Acetylcysteine is used cautiously in those with severe respiratory insufficiency or asthma and in older adults or debilitated patients. The expectorants are used cautiously during pregnancy and lactation. Acetylcysteine is a Pregnancy Category B drug; guaifenesin is a Pregnancy Category C drug.

**INTERACTIONS**

No significant interactions have been reported when the expectorants are used as directed. The exception is iodine products. Lithium and other antithyroid drugs may potentiate the hypothyroid effects of these drugs if used concurrently with iodine products. When potassium-containing medications and potassium-sparing diuretics are administered with iodine products, the patient may experience hypokalemia, cardiac arrhythmias, or cardiac arrest. Thyroid function tests may also be altered by iodine.

---

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes for the patient may include an optimal response to drug therapy and an understanding of and compliance with the drug regimen.

**NURSING PROCESS**

- **The Patient Receiving a Mucolytic or an Expectorant**

  **ASSESSMENT**
  
  **Preadministration Assessment**
  
  Before administering the drug, the nurse assesses the respiratory status of the patient. The nurse documents lung sounds, amount of dyspnea (if any), and consistency of sputum (if present). A description of the sputum is important as a baseline for future comparison.

  **Ongoing Assessment**
  
  After administering the drug, the nurse notes any increase in sputum or change in consistency. The nurse documents, on the patient’s chart, a description of the sputum raised. Patients with thick, tenacious mucus may have difficulty breathing. It is important to notify the primary health care provider if the patient has difficulty breathing because of an inability to raise sputum and clear the respiratory passages.

  Immediately before and after treatment with the mucolytic acetylcysteine, the nurse auscultates the lungs and records the findings of both assessments on the patient’s chart. Between treatments, the nurse evaluates the patient’s respiratory status and records these findings on the patient’s chart. These evaluations aid the primary health care provider in determining the effectiveness of therapy. If any problem occurs during or after treatment, or if the patient is uncooperative, the nurse discusses the problem with the primary health care provider.

  When expectorants are given to those with chronic pulmonary disease, the nurse evaluates the effectiveness of drug therapy (ie, the patient’s ability to raise sputum) and records this finding in the patient’s chart.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes for the patient may include an optimal response to drug therapy and an understanding of and compliance with the drug regimen.
The nurse remains with the patient during the first few treatments, especially when the patient is elderly or exhibits anxiety. The nurse supplies the patient with tissues and places a paper bag for disposal of the tissues within the patient's reach. If acetylcysteine is ordered to be inserted into a tracheostomy, the nurse must make sure suction equipment is at the bedside to be immediately available for aspiration of secretions.

When acetylcysteine is administered for acetaminophen overdosage, the drug is given as soon as the overdose is discovered. Treatment should begin as soon as possible after overdose and within 24 hours of ingestion.

Educating the Patient and Family
Acetylcysteine usually is administered in the hospital but may be prescribed for the patient being discharged and renting or buying respiratory therapy equipment for use at home (see Patient and Family Teaching Checklist: Using Respiratory Equipment at Home). The nurse gives the patient or a family member full instruction in the use and maintenance of the equipment, as well as the technique of administration of acetylcysteine.

When an expectorant is prescribed, the nurse instructs the patient to take the drug as directed and to contact the primary health care provider if any unusual symptoms or other problems occur during use of the drug or if the drug appears to be ineffective.

EVALUATION

• The therapeutic effect is achieved, and secretions are thinned and easily expectorated.
• The patient and family demonstrate an understanding of the drug regimen and use of equipment to administer the drug (mucolytic).

IMPLEMENTATION

Promoting an Optimal Response to Therapy
When the mucolytic acetylcysteine is administered by nebulization, the nurse explains the treatment to the patient and demonstrates how the nebulizer will be used. The nurse remains with the patient during the first few treatments, especially when the patient is elderly or exhibits anxiety. The nurse supplies the patient with tissues and places a paper bag for disposal of the tissues within the patient's reach. If acetylcysteine is ordered to be inserted into a tracheostomy, the nurse must make sure suction equipment is at the bedside to be immediately available for aspiration of secretions.

When acetylcysteine is administered for acetaminophen overdosage, the drug is given as soon as the overdose is discovered. Treatment should begin as soon as possible after overdose and within 24 hours of ingestion.

Educating the Patient and Family
Acetylcysteine usually is administered in the hospital but may be prescribed for the patient being discharged and renting or buying respiratory therapy equipment for use at home (see Patient and Family Teaching Checklist: Using Respiratory Equipment at Home). The nurse gives the patient or a family member full instruction in the use and maintenance of the equipment, as well as the technique of administration of acetylcysteine.

When an expectorant is prescribed, the nurse instructs the patient to take the drug as directed and to contact the primary health care provider if any unusual symptoms or other problems occur during use of the drug or if the drug appears to be ineffective.

EVALUATION

• The therapeutic effect is achieved, and secretions are thinned and easily expectorated.
• The patient and family demonstrate an understanding of the drug regimen and use of equipment to administer the drug (mucolytic).

Critical Thinking Exercises

1. Your neighbor, Mr. Peterson, tells you that he has had a chronic cough for the past several months and asks you what the best “cough medicine” to buy is. Describe the advice you would give to Mr. Peterson.
2. Ms. Moore, a patient in a nursing home, has had a cough for the past 3 weeks. Ms. Moore's physician is aware of her problem and has ordered an expectorant but told her that he wants her to cough and raise sputum. Ms. Moore's family asks you if something can be given to their mother to stop her from coughing. Explain how you would discuss this problem and explain the prescribed therapy with Ms. Moore's family.
3. Discuss any precautions the nurse would consider when the expectorants are administered. Give a rationale for your answer.
Review Questions

1. Antitussives are given with caution to patients with ______.
   A. an unproductive cough
   B. a chronic cough
   C. hypertension
   D. hypotension

2. Which of these drugs is classified as an expectorant?
   A. Guaifenesin
   B. Codeine
   C. Dextromethorphan
   D. Diphenhydramine

3. Which of the following statements is appropriate for the nurse to include in discharge instructions for a patient taking an antitussive?
   A. Increase the dosage if the drug does not relieve the cough.
   B. Limit fluids to less than 1000 mL each day.
   C. Expect the cough to worsen during the first few days of treatment.
   D. Frequent sips of water and sugarless hard candy may diminish coughing.

4. Which of these drugs would be prescribed for a patient with an acetaminophen overdose?
   A. Acetylcysteine
   B. Guaifenesin
   C. Benzonatate
   D. Dextromethorphan

Medication Dosage Problems

1. A patient is prescribed 200 mg of guaifenesin syrup. The drug is available in a syrup of 200 mg/5 mL. The nurse administers ______.

2. Codeine 10 mg is prescribed for a patient with a severe unproductive cough. The drug is available as an oral solution of 10 mg/5 mL. The nurse administers ______.
Cardiotonics and Miscellaneous Inotropic Drugs

Key Terms

- atrial fibrillation
- cardiac glycosides
- cardiac output
digitalis glycosides
digitalis toxicity
digitalization
heart failure
hypokalemia

left ventricular dysfunction
neurohormonal activity
positive inotropic action
right ventricular failure

Chapter Objectives

On completion of this chapter, the student will:

- Discuss heart failure in relationship to left ventricular failure, right ventricular failure, neurohormonal activity, and treatment options.
- Discuss the uses, general drug action, general adverse reactions, contraindications, precautions, and interactions of the cardiotonic and inotropic drugs.
- Discuss the use of other drugs with positive inotropic action.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking a cardiotonic or inotropic drug.
- List some nursing diagnoses particular to a patient taking a cardiotonic or inotropic drug.
- Identify the symptoms of digitalis toxicity.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when administering a cardiotonic drug.

The cardiotonics are drugs used to increase the efficiency and improve the contraction of the heart muscle, which leads to improved blood flow to all tissues of the body. The drugs have long been used to treat congestive heart failure (CHF), a condition in which the heart cannot pump enough blood to meet the tissue needs of the body. While the term “congestive heart failure” continues to be used by some, a more accurate term is simply “heart failure.”

About 4.5 million Americans have heart failure (HF). It is the most frequent cause of hospitalization for individuals older than 65 years. Some patients, with treatment, may lead nearly normal lives, whereas more than 50% of individuals with severe HF die each year. HF is a complex clinical syndrome that can result from any number of cardiac or metabolic disorders such as ischemic heart disease, hypertension, or hyperthyroidism. Any condition that impairs the ability of the ventricle to pump blood can lead to HF. In HF, the heart fails in its ability to pump enough blood to meet the needs of the body or can do so only with an elevated filling pressure. Recently it was discovered that HF causes a number of neurohormonal changes as the body tries to compensate for the increased workload of the heart. Display 39-1 discusses this neurohormonal response.

The sympathetic nervous system increases the secretions of the catecholamines (neurohormones epinephrine and norepinephrine), which results in increased heart rate and vasoconstriction. The activation of the renin-angiotensin-aldosterone (RAA) system occurs because of decreased perfusion to the kidneys. As the RAA system is activated, increased levels of angiotensin II and aldosterone occur, which increases the blood pressure, adding to the workload of the heart. These increases in neurohormonal activity cause a remodeling (restructuring) of the cardiac muscle cells, leading to hypertrophy of the heart, increased need for oxygen, and cardiac necrosis, which worsens the HF. The tissue of the heart is changed.
in a manner to increase the cellular mass of cardiac tissue, change the shape of the ventricle(s), and reduce the heart’s ability to contract effectively.

Heart failure is best described as denoting the area of initial ventricle dysfunction: left-sided (left ventricular) dysfunction and right-sided (right ventricular) dysfunction. Left ventricular dysfunction leads to pulmonary symptoms such as dyspnea and moist cough. Right ventricular dysfunction leads to neck vein distension, peripheral edema, weight gain, and hepatic engorgement. Because both sides of the heart work together, ultimately both sides are affected in HF. Typically the left side of the heart is affected first, followed by right ventricular involvement.

The most common symptoms associated with HF include:

**Left Ventricular Dysfunction**
- Shortness of breath with exercise or difficulty breathing when lying flat
- Dry, hacking cough or wheezing
- Orthopnea (difficulty breathing while lying flat)
- Restlessness and anxiety

**Right Ventricular Dysfunction**
- Swollen ankles, legs, or abdomen, leading to pitting edema
- Anorexia
- Nausea
- Nocturia (the need to urinate frequently at night)
- Weakness
- Weight gain as the result of fluid retention

Other symptoms include:
- Palpitations, fatigue, or pain when performing normal activities
- Tachycardia or irregular heart rate
- Dizziness or confusion

**Left ventricular dysfunction**, also called left ventricular systolic dysfunction, is the most common form of heart failure and results in decreased cardiac output and decreased ejection fraction (the amount of blood that the ventricle ejects per beat in relationship to the amount of blood available to eject). Typically, the ejection fraction should be greater than 60%. With, left ventricular systolic dysfunction, the ejection fraction in less than 40%, and the heart is enlarged and dilated.

Until recently, the cardiotonics and a diuretic were the treatment of choice for HF. However, other drugs such as the angiotensin-converting enzyme (ACE) inhibitors, and beta blockers have become the treatment of choice during the last several years. See Figure 39-1 for an example of a method of determining treatment for left ventricular systolic dysfunction. See Chapters 23, 42, and 46 for more information on the beta blockers, ACE inhibitors, and diuretics, respectively.

**CARDIOTONICS**

Digoxin (Lanoxin) is the most commonly used cardiotonic drug. Other terms used to identify the cardiotonics are cardiac glycosides or digitalis glycosides. The digitalis or cardiac glycosides are obtained from the leaves of the purple foxglove plant or the Digitalis purpurea and the Digitalis lanata.

Miscellaneous drugs with positive inotropic action such as inamrinone and milrinone (Primacor) are non-glycosides used in the short-term management of HF. Although in the past the cardiotonics were the mainstay in the treatment of HF, currently they are used as the fourth line of treatment for patients who continue to experience symptoms after using the ACE inhibitors, diuretics, and beta blockers. See the Summary Drug Table: Cardiotonics and Miscellaneous Inotropic Drugs for information concerning these drugs.

**ACTIONS**

Digitalis acts in two ways:

1. Increases cardiac output through positive inotropic activity
2. Decreases the conduction velocity through the atrioventricular (AV) and sinoatrial (SA) nodes in the heart

**Increased Cardiac Output**

Cardiotonic drugs increase the force of the contraction of the muscle (myocardium) of the heart. This is called a positive inotropic action. When the force of contraction of the myocardium is increased, the amount of blood leaving the left ventricle at the time of each contraction is increased. When the amount of blood leaving the left ventricle is increased, cardiac output (the amount of blood leaving the left ventricle with each contraction) is increased.
The most profound effect of a cardiotonic drug occurs in patients with HF. In HF, the heart, weakened by disease or age, cannot pump a sufficient amount of blood to meet the demands of the body. The weakened heart results in a decrease in the amount of oxygenated blood leaving the left ventricle during each myocardial contraction (a decrease in cardiac output). A marked decrease in cardiac output deprives the kidneys, brain, and other vital organs of an adequate blood supply. The weakened heart is unable to pump enough circulated blood back into the heart. The blood accumulates or congests in the body’s tissues. With congestion, legs and ankles swell. Fluid collects in the lungs, and the individual finds it increasingly hard to breathe, especially when lying down. When the kidneys are deprived of an adequate blood supply, they are unable to effectively remove water, electrolytes, and waste products from the bloodstream. Excess fluid (edema) may occur in the lungs or tissues, increasing the congestion. The body then attempts to make up for this deficit by increasing the heart rate, which in turn circulates more blood through the kidneys, brain, and other vital organs. In many instances, an increase in the heart rate ultimately fails to deliver an adequate amount of blood to the kidneys and other vital organs. An increased heart rate also places added strain on the heart’s muscle, which may further weaken the heart. Untreated, congestion worsens and may prevent the heart from pumping enough blood to keep the individual alive.

When a cardiotonic drug is administered, the positive inotropic action increases the force of the contraction, resulting in an increased cardiac output. When cardiac output is increased, the blood supply to the kidneys and other vital organs is increased. Water, electrolytes, and waste products are removed in adequate amounts, and the symptoms of inadequate heart action or HF are relieved. In most instances, the heart rate also decreases. This occurs because vital organs are now receiving an adequate blood supply because of the increased force of myocardial contraction.

**Depression of the Sinoatrial and Atrioventricular Nodes**

The cardiotonics affect the transmission of electrical impulses along the pathway of the conduction system of the heart. The conduction system of the heart is a group of specialized nerve fibers consisting of the SA node, the AV node, the bundle of His, and the branches of Purkinje (Fig. 39-2). Each heartbeat (or contraction of the ventricles) is the result of an electrical impulse that normally starts in the SA node, is then received by the AV node, and travels down the bundle of His and through the Purkinje fibers (see Fig. 39-2). The heartbeat can be felt as a pulse at the wrist and other areas of the body where an artery is close to the surface or lies near a bone. When the electrical impulse reaches the

---

*Figure 39-1. Management of left ventricular systolic dysfunction. (Adapted from Ammon, S. [2001]. Managing patients with heart failure, AJN 101 [12] 35.)

All therapies should be individualized to suit each patient.
Purkinje fibers, the ventricles contract. Normally, once the ventricles contract, another electrical impulse is generated by the SA node, and the cycle begins again. Cardiotonic drugs depress the SA node and slow conduction of the electrical impulse to and through the AV node. Slowing this part of the transmission of nerve impulses decreases the number of impulses and the number of ventricular contractions per minute, thereby decreasing the heart rate and allowing the heart to function more normally. The therapeutic effects of digoxin on atrial arrhythmias are thought to be related to the depressive action on the SA and AV nodes and baroreceptor sensitization.

**USES**

The cardiotonics are used to treat HF and atrial fibrillation. Atrial fibrillation is a cardiac arrhythmia characterized by rapid contractions of the atrial myocardium, resulting in an irregular and often rapid ventricular rate. See Chapter 40 for more information on various arrhythmias and treatment.

### Adverse Reactions

Adverse reactions are dose dependent. Dosages are individualized based on several factors, including the following:

- The ideal body weight of the patient;
- The patient’s renal function, evaluated on creatinine clearance;
- The patient’s age (infants and children require lower dosages, and advanced age may be indicative of decreased renal function, requiring a lower dosage); and
- Current medications, other medical problems, or other factors affecting the activity of digoxin.

Because some patients are more sensitive to side effects with digoxin, the dosage is selected carefully and adjusted as the clinical condition indicates. Adverse reactions were more common and severe in past years before careful attention to weight, renal function, and the concurrent administration of certain medications was given. The incidence and severity of digoxin toxicity has decreased significantly in recent years.
There is a narrow margin of safety between the full therapeutic effects and the toxic effects of cardiotonic drugs. Even normal doses of a cardiotonic drug can cause toxic drug effects. Because substantial individual variations may occur, it is important to individualize the dosage. The term digitalis toxicity (digitalis intoxication) is used when toxic drug effects occur when digoxin is administered. The signs of digitalis toxicity are listed in Display 39-2.

Digoxin has a rapid onset and a short duration of action. Once the drug is withheld, the toxic effects of digoxin will disappear rapidly. At times, the primary care provider may deem it necessary to administer digoxin immune fab (Digibind) when serious life-threatening digoxin overdosage occurs.

CONTRAINDICATIONS

The cardiotonics are contraindicated in patients with known hypersensitivity, ventricular failure, ventricular tachycardia, or AV block and in the presence of digitalis toxicity.

PRECAUTIONS

The cardiotonics are given cautiously in patients with electrolyte imbalance (especially hypokalemia, hypocalcemia, and hypomagnesemia), severe carditis, heart block, myocardial infarction, severe pulmonary disease, acute glomerulonephritis, and impaired renal or hepatic function. Digoxin and digoxin immune fab are classified as Pregnancy Category C drugs. Fetal toxicity and neonatal death have been reported from maternal digoxin overdosage. These drugs are used only when the potential benefit outweighs the potential harm to the fetus.

INTERACTIONS

When the cardiotonics are taken with food, absorption is slowed, but the amount absorbed is the same. However, if taken with high-fiber meals, absorption of the cardiotonics may be decreased. The cardiotonics react with many different drugs. Drugs that may increase plasma digitalis levels leading to toxicity include amiodarone, benzodiazepines, cyclosporine, diphenoxylate, indomethacin, itraconazole, macrolides (erythromycin, clarithromycin), propafenone, quindine, quinine, spironolactone, tetracyclines, and verapamil. Drugs that may decrease plasma digitalis levels include the oral aminoglycosides, antacids, antineoplastics (bleomycin, carmustine, cyclophosphamide, methotrexate, and vincristine), activated charcoal, cholestyramine, colesteipol, kaolin/pectin, neomycin, penicillamine, rifampin, St. John’s wort, and sulfasalazine. The thyroid hormones may decrease the effectiveness of digitalis glycosides, requiring a larger dosage of digoxin. Thiazide and loop diuretics may increase diuretic-induced electrolyte disturbances, predisposing the patient to digitalis-induced arrhythmias.

Patients taking a diuretic and a digitalis glycoside must be monitored closely. Thiazide and loop diuretics (see Chap. 46) may increase the risk and effects of toxicity.
Inamrinone and milrinone have inotropic actions and are used in the short-term management of severe HF that is not controlled by the digitalis preparations. Milrinone is used more often than inamrinone, appears to be more effective, and has fewer adverse reactions. Both drugs are given intravenously (IV), and close monitoring is required during therapy. The nurse must continuously monitor the patient's heart rate and blood pressure with administration of either drug. If hypotension occurs, use of the drug is discontinued or the rate of administration is reduced. Continuous cardiac monitoring is necessary because life-threatening arrhythmias may occur. These drugs do not cure, but rather control, the signs and symptoms of HF.

**Nursing Process**

### The Patient Receiving a Cardiotonic Drug

#### Assessment

**Preadministration Assessment**

The cardiotonics are potentially toxic drugs. Therefore, the nurse must observe the patient closely, especially during initial therapy. Before therapy is started, the physical assessment should include information that will establish a database for comparison during therapy. The physical assessment should include:

- Taking blood pressure, apical-radial pulse rate, respiratory rate;
- Auscultating the lungs, noting any unusual sounds during inspiration and expiration;
- Examining the extremities for edema;
- Checking the jugular veins for distention;
- Measuring weight;
- Inspecting sputum raised (if any), and noting the appearance (eg, frothy, pink-tinged, clear, yellow); and
- Looking for evidence of other problems, such as cyanosis, shortness of breath on exertion (if the patient is allowed out of bed) or when lying flat, and mental changes.

The primary care provider also may order laboratory and diagnostic tests, such as an electrocardiogram, renal and hepatic function tests, complete blood count, serum enzymes, and serum electrolytes. These tests should be reviewed before the first dose of the drug is given. Renal function is particularly important because a diminished renal function could affect the dosage of digoxin. When subsequent laboratory tests are ordered, they also should be reviewed when the results are recorded on the patient's record. Because digoxin reacts with many medications, the nurse must take a careful drug history.

**Ongoing Assessment**

Before administering each dose of a cardiotonic, the nurse takes the apical pulse rate for 60 seconds (see Fig. 39-3). The nurse records the apical pulse rate in the designated area on the chart or the medication administration record. The nurse withholds the drug and notifies the primary care provider if the pulse rate is below 60 bpm in adults (below 70 bpm in a child and below 90 bpm in an infant) or greater than 100 bpm, unless there is a written order giving different guidelines for withholding the drug.

**Nursing Alert**

The drug should also be withheld and the physician contacted if there are any signs of digitalis toxicity, there is any change in the pulse rhythm, there is a marked increase or decrease in the pulse rate since the last time it was taken, or the patient's general condition appears to have worsened.

**Nursing Alert**

Plasma digoxin levels are monitored closely. Blood for plasma levels may be drawn 6 to 8 hours after the last dose or immediately before the next dose. Plasma digoxin levels greater than 2 ng/mL are reported to the physician.

Digitalis toxicity can occur even when normal doses are being administered or when the patient has been receiving a maintenance dose. Many symptoms of toxicity are similar to the symptoms of the heart conditions for which the patient is receiving the cardiotonic. This makes careful assessment of the patient by the nurse a critical aspect of care.
Digitalization is a series of doses given until the drug begins to exert a full therapeutic effect. The digitalizing, or loading dose, is administered in several doses, with approximately half the total digitalization dose administered as the first dose. Additional fractions of the digitalis dose are administered at 6- to 8-hour intervals. Once a full therapeutic effect is achieved, the patient is usually prescribed a maintenance dose schedule. The ranges for digitalizing (loading) and maintenance doses are given in the Summary Drug Table: Cardiotonics and Miscellaneous Inotropic Drugs. Digoxin injections are usually used for rapid digitalization; digoxin tablets or capsules are used for maintenance therapy.

Digitalizing doses vary, and the primary care provider may decide to achieve full digitalization rapidly or slowly, depending on the patient’s diagnosis, age, current condition, and other factors.

During digitalization, the nurse takes the blood pressure, pulse, and respiratory rate every 2 to 4 hours or as ordered by the primary care provider. This time interval may be increased or decreased, depending on the patient’s condition and the route used for administration. Serum levels (digoxin) may be ordered daily during the period of digitalization and periodically during maintenance therapy. Periodic electrocardiograms, serum electrolytes, hepatic and renal function tests, and other laboratory studies also may be ordered.

PARENTERAL ADMINISTRATION. The nurse may give a cardiotonic orally, IV, or intramuscularly. When a cardiotonic is given IV, it is administered slowly. If the patient is receiving the drug IV, the nurse assesses the IV site for redness or infiltration. Extravasation can lead to tissue irritation and sloughing. When given intramuscularly, the nurse should rotate the injection sites. To rotate injection sites correctly, the nurse inserts a diagram showing the order of rotation in the chart or the medication administration record. Each time the drug is given, the injection site is recorded in the patient’s chart. However, intramuscular injection is not recommended for these drugs.

ORAL ADMINISTRATION. The nurse can administer oral preparations without regard to meals. Tablets can be crushed and mixed with food or fluids if the patient has difficulty swallowing. Do not alternate between the dosage forms (ie, the tablets and the capsules). Dosages are not the same. The recommended dosage of the capsules is 80% of the dosage for tablets and elixir.

Monitoring and Managing Adverse Drug Reactions
The nurse observes for signs of digitalis toxicity every 2 to 4 hours during digitalization and 1 to 2 times a day when a maintenance dose is being given. When digitalis toxicity develops, the primary care provider may
discontinue digitalis use until all signs of toxicity are gone. If severe bradycardia occurs, atropine (see Chap. 25) may be ordered. If digoxin has been given, the primary care provider may order blood tests to determine drug serum levels. The therapeutic serum level of digoxin is 0.8 to 2 ng/mL, and the toxic serum level is more than 2.5 ng/mL.

**Nursing Alert**

The nurse should withhold the drug and report any of the following signs of digitalis toxicity to the physician immediately: loss of appetite (anorexia), nausea, vomiting, abdominal pain, visual disturbances (blurred, yellow or green vision and white halos, borders around dark objects), and arrhythmias (any type). The nurse also must immediately report serum digoxin levels greater than 2.0 ng/mL.

**Gerontologic Alert**

Older adults are particularly prone to digitalis toxicity. All older adults must be carefully monitored for signs of digitalis toxicity.

The nurse must also closely observe the patient for other adverse drug reactions, such as anorexia, nausea, vomiting, and diarrhea. Some adverse drug reactions are also signs of digitalis toxicity, which can be serious. The nurse should carefully consider any patient complaint or comment, record it on the patient’s chart, and bring it to the attention of the primary care provider.

Diuretics (see Chap. 46) may be ordered for some patients receiving a cardiotonic drug. Diuretics, as well as other conditions or factors, such as gastrointestinal suction, diarrhea, and old age, may produce low serum potassium levels (hypokalemia). The primary care provider may order a potassium salt to be given orally or IV.

**Nursing Alert**

Hypokalemia makes the heart muscle more sensitive to digitalis, thereby increasing the possibility of developing digitalis toxicity. The nurse must closely, and at frequent intervals, observe patients with hypokalemia for signs of digitalis toxicity.

Patients with hypomagnesemia (low magnesium plasma levels) are at increased risk for digitalis toxicity. If low magnesium levels are detected, the primary care provider may prescribe magnesium replacement therapy.

Most often digoxin toxicity can be successfully treated by simply withdrawing the drug. However, severe life-threatening toxicity is treated with digoxin immune fab (Digibind). Digoxin immune fab, composed of digoxin-specific antigen-binding fragments (fab), is used as an antidote in the treatment of digoxin overdosage. The dosage varies with the amount of digoxin ingested and is administered by the IV route during a 30-minute period. Most life-threatening states can be adequately treated with 800 mg of digoxin immune fab (20 vials). Few adverse reactions have been observed with the use of immune fab. However, the nurse should be alert for the possibility of worsening of HF, low cardiac output, hypokalemia, or atrial fibrillation. Hypokalemia is of particular concern in patients taking digoxin immune fab, particularly because hypokalemia usually coexists with toxicity. (See the Summary Drug Table: Cardiotonics and Miscellaneous Inotropic Drugs.)

**Educating the Patient and Family**

In some instances, a cardiotonic may be prescribed for a prolonged period. Some patients may discontinue use of the drug, especially if they feel better and their original symptoms have been relieved. The patient and family must understand that the prescribed drug must be taken exactly as directed by the primary care provider.

The primary care provider may want the patient to monitor the pulse rate daily during cardiotonic therapy. The nurse shows the patient or a family member the correct technique for taking the pulse (see Home Care Checklist: Monitoring Pulse Rate). The primary care provider may also want the patient to omit the next dose of the drug and call him or her if the pulse rate falls below a certain level (usually 60 bpm in an adult, 70 bpm in a child, and 90 bpm in an infant). These instructions are emphasized at the time of patient teaching. The nurse includes the following points in a teaching plan for the patient taking a cardiac glycoside drug:

- Do not discontinue use of this drug without first checking with the primary care provider (unless instructed to do otherwise). Do not miss a dose or take an extra dose.
- Take this drug at the same time each day.
- Take your pulse before taking the drug, and withhold the drug and notify the primary care provider if your pulse rate is less than 60 bpm or greater than 100 bpm.
- Avoid antacids and nonprescription cough, cold, allergy, antidiarrheal, and diet (weight-reducing) drugs unless their use has been approved by the primary care provider. Some of these drugs interfere with the action of the cardiotonic drug or cause other, potentially serious, problems. (See Interactions.)
- Contact the primary care provider if nausea, vomiting, diarrhea, unusual fatigue, weakness, vision change (such as blurred vision, changes in colors of objects, or halos around dark objects), or mental depression occurs.
• Carry an identification card describing the disease process and your medication regimen.
• Keep the drug in its original container.
• Follow the dietary recommendations (if any) made by the primary care provider.
• The primary care provider will closely monitor therapy. Keep all appointments for primary care provider visits or laboratory or diagnostic tests.

EVALUATION

• The therapeutic effect is achieved.
• Adverse reactions are identified, reported to the primary care provider, and managed using appropriate nursing interventions.
• The patient verbalizes the importance of continued follow-up care.
• The patient verbalizes the importance of complying with the prescribed therapeutic regimen.
• The patient and family demonstrate an understanding of the drug regimen.
• The patient complies with the prescribed drug regimen.

Mr. Taylor during the interview to evaluate his knowledge of the drug regimen and to find out if he is experiencing any adverse reactions.

2. You are to participate in a team conference on the cardiac glycosides. Your topic to discuss is discharge teaching for the patient receiving a cardiac glycoside. Develop a teaching plan using the nursing process as a framework. Determine what points would be most important for you to include.

3. Discuss when you would expect the primary care provider to order digoxin immune fab. State the assessment you feel would be most important and give a rationale.

Review Questions

1. Which of the following is commonly associated with left ventricular systolic dysfunction?
   A. Ejection fraction of 60% or more
   B. Ejection fraction below 40%
   C. Increased cardiac output
   D. Normal cardiac output

2. Which of the following serum digoxin levels would be most indicative that a patient taking digoxin may be experiencing toxicity?
   A. 0.5 ng/mL
   B. 0.8 ng/mL
   C. 1.0 ng/mL
   D. 2.0 ng/mL
3. In which of the following situations would the nurse withhold a dosage of digoxin and notify the primary care provider?
   A. A pulse rate greater than 100 bpm
   B. A pulse rate less than 100 bpm
   C. A pulse rate of 60 bpm
   D. A pulse rate of 72 bpm

4. Which drug would the nurse expect to be prescribed for a patient with digoxin toxicity?
   A. Digoxin immune fab
   B. Milrinone
   C. Inamrinone lactate
   D. Any inotropic drug

5. During rapid digitalization the nurse expects the first dose to _____.
   A. be the smallest dose in case the patient is allergic to digoxin
   B. be given orally, with succeeding doses given intravenously
   C. be approximately half of the total digitalization dose
   D. be approximately three quarters of the total digitalization dose

Medication Dosage Problems

1. Digoxin (Lanoxin) is prescribed for a patient with HF, and digitalization is begun. The primary health care provider prescribes digoxin (Lanoxin) 0.75 mg PO as the initial dose. Available are digoxin tablets of 0.5 and 0.25 mg. The nurse administers _____.

2. Digoxin 0.5 mg IV is prescribed. The drug is available in a solution of 0.25 mg/mL. How many mL will the nurse prepare?
Antiarrhythmic Drugs

The antiarrhythmic drugs are primarily used to treat cardiac arrhythmias. A cardiac arrhythmia is a disturbance or irregularity in the heart rate, rhythm, or both, which requires administration of one of the antiarrhythmic drugs. Some examples of cardiac arrhythmias are listed in Table 40-1.

An arrhythmia may occur as a result of heart disease or from a disorder that affects cardiovascular function. Conditions such as emotional stress, hypoxia, and electrolyte imbalance also may trigger an arrhythmia. An electrocardiogram (ECG) provides a record of the electrical activity of the heart. Careful interpretation of the ECG along with a thorough physical assessment is necessary to determine the cause and type of arrhythmia. The goal of antiarrhythmic drug therapy is to restore normal cardiac function and to prevent life-threatening arrhythmias.

**Key Terms**
- action potential
- arrhythmia
- blockade effect
- cinchonism
- depolarization
- depolarization
- polarization
- proarrhythmic effect
- refractory period
- repolarization
- threshold

**Chapter Objectives**

On completion of this chapter, the student will:
- Describe various types of cardiac arrhythmias.
- Discuss the uses, general drug actions, general adverse reactions, contraindications, precautions, and interactions of the antiarrhythmic drugs.
- Discuss important preadministration and ongoing assessments the nurse should perform on a patient taking an antiarrhythmic drug.
- List some nursing diagnoses particular to a patient taking an antiarrhythmic drug.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating patients about the use of antiarrhythmic drugs.

**Class I Antiarrhythmic Drugs**

Class I antiarrhythmic drugs, such as moricizine, have a membrane-stabilizing or anesthetic effect on the cells of the myocardium, making them valuable in treating cardiac arrhythmias. Class I antiarrhythmic drugs contain the largest number of drugs of the four classifications. Because the actions differ slightly, they are subdivided into classes I-A, I-B, and I-C.

**Class I-A**

The drugs disopyramide, procainamide, and quinidine are examples of class I-A drugs. Quinidine depresses
myocardial excitability or the ability of the myocardium to respond to an electrical stimulus. By depressing the myocardium and its ability to respond to some, but not all, electrical stimuli, the pulse rate decreases and the arrhythmia is corrected. Quinidine also prolongs or lengthens the refractory (resting) period and decreases the height and rate of the action potential of the impulses traveling through the myocardium.

All cells are electrically polarized, with the inside of the cell more negatively charged than the outside. The difference in electrical charge is called the resting membrane potential. Nerve and muscle cells are excitable and can change the resting membrane potential in response to electrochemical stimuli. The action potential is an electrical impulse that passes from cell to cell in the myocardium, stimulating the fibers to shorten, causing muscular contraction (systole). After the action potential passes, the fibers relax and return to their resting length (diastole). A n action potential generated in one part of the myocardium passes almost simultaneously through all of the fibers, causing rapid contraction.

Only one impulse can pass along a nerve fiber at any given time. After the passage of an impulse, there is a brief pause, or interval, before the next impulse can pass along the nerve fiber. This pause is called the refractory period, which is the period between the transmission of nerve impulses along a nerve fiber. By lengthening the refractory period, the number of impulses traveling along a nerve fiber within a given time is decreased. For example, a patient has a pulse rate of 120 bpm. By lengthening the refractory period between each impulse and decreasing the height and rate of the rise of action potential, fewer impulses would be generated each minute, and the pulse rate would decrease. Procainamide is thought to act by decreasing the rate of diastolic depolarization in the ventricles, decreasing the rate and height of the action potential and increasing the fibrillation threshold. Disopyramide (Norpace) decreases the rate of depolarization of myocardial fibers during the diastolic phase of the cardiac cycle, prolongs the refractory period, and decreases the rate of rise of the action potential.

Nerve cells have positive ions on the outside and negative ions on the inside of the cell membrane when they are at rest (Fig. 40-1). This is called polarization. When a stimulus passes along the nerve, the positive ions move from outside the cell into the cell, and the negative ions move from inside the cell to outside the cell. This movement of ions is called depolarization. Unless positive ions move into and negative ions move out of a nerve cell, a stimulus (or impulse) cannot pass along the nerve fiber. Once the stimulus has passed along the nerve fiber, the positive and negative ions move back to their original place, that is, the positive ions on the outside and the negative ions on the inside of the nerve cell. This movement back to the original place is called repolarization. By decreasing the rate (or speed) of depolarization, the stimulus must literally wait for this process before it can pass along the nerve fiber. Thus, decreasing the rate of depolarization decreases the number of impulses that can pass along a nerve fiber during a specific time period.

### Class I-B Drugs

Lidocaine (Xylocaine), the representative class I-B drug, raises the threshold of the ventricular myocardium. Threshold is a term applied to any stimulus of the lowest intensity that will give rise to a response in a nerve fiber. A stimulus must be of a specific intensity (strength, amplitude) to pass along a given nerve fiber (Fig. 40-2).

To further illustrate the threshold phenomenon using plain figures instead of precise electrical values, a certain nerve fiber has a threshold of 10. If a stimulus rated as 9 reaches the fiber, it will not pass along the fiber because its intensity is lower than the fiber’s threshold of 10. If another stimulus reaches the fiber and is rated 14, it will pass along the fiber because its intensity is greater than the fiber’s threshold of 10. If the threshold of a fiber is raised from 10 to 15, only the stimuli greater than 15 can pass along the nerve fiber.
Some cardiac arrhythmias result from many stimuli present in the myocardium. Some of these are weak or of low intensity but are still able to excite myocardial tissue. Lidocaine, by raising the threshold of myocardial fibers, reduces the number of stimuli that will pass along these fibers and therefore decreases the pulse rate and corrects the arrhythmia. Mexiletine (Mexitil) and tocainide (Tonocard) are also antiarrhythmic drugs with actions similar to those of lidocaine.

**Class I-C Drugs**

Flecainide (Tambocor) and propafenone (Rythmol) are examples of class I-C drugs. These drugs have a direct stabilizing action on the myocardium, decreasing the height and rate of rise of cardiac action potentials, thus slowing conduction in all parts of the heart.

**Class II Antiarrhythmic Drugs**

Class II antiarrhythmic drugs include beta (β)-adrenergic blocking drugs, such as acebutolol (Sectral), esmolol (Brevibloc), and propranolol (Inderal). These drugs also decrease myocardial response to epinephrine and norepinephrine (adrenergic neurohormones) because of their ability to block stimulation of β receptors of the myocardial fibers.

---

**Figure 40-1.** Polarization, depolarization, and repolarization.

**Threshold**

A stimulus must reach the threshold to cause a response in a nerve fiber. Note that stimuli a, b, and d do not reach the threshold; therefore, they do not cause a response in a nerve fiber. Stimuli c, e, f, and g do reach and surpass the threshold, resulting in stimulation of nerve fiber.

**Threshold raised**

After receiving lidocaine hydrochloride (Xylocaine HCl), the threshold is raised to a higher level, allowing fewer stimuli to reach the threshold. This results in decreased stimulation of the nerve fiber and prevents conduction of the nerve impulses causing the arrhythmia.

---

**Figure 40-2.** The threshold phenomenon.
heart (see Chap. 23). Adrenergic neurohormones stimulate the β receptors of the myocardium and therefore increase the heart rate. Blocking the effect of these neurohormones decreases the heart rate. This is called a blockade effect.

Class III Antiarrhythmic Drugs

Bretylium (Bretylol) prolongs repolarization, prolongs refractory period, and increases the ventricular fibrillation threshold. A miidarone (Cordarone) appears to act directly on the cardiac cell membrane, prolonging the refractory period and repolarization and increasing the ventricular fibrillation threshold. Newer class III antiarrhythmic drugs include ibutilide (Corvert) and dofetilide (Tikosyn). These two drugs are used to convert atrial fibrillation or flutter to a normal sinus rhythm. Ibutilide acts by prolonging the action potential, producing a mild slowing of the sinus rate and atrioventricular conduction. Dofetilide selectively blocks potassium channels, widens the QRS complex, and prolongs the action potential. The drug has no effect on calcium channels or cardiac contraction.

Class IV Antiarrhythmic Drugs

Class IV antiarrhythmic drugs include verapamil (Calan) and the other calcium channel blockers. Calcium channel blockers produce their antiarrhythmic action by inhibiting the movement of calcium through channels across the myocardial cell membranes and vascular smooth muscle. Contraction of cardiac and vascular smooth muscle depends on the movement of calcium ions into these cells through specific ion channels. By reducing the calcium flow, conduction through the sinoatrial (SA) and atrioventricular (AV) nodes is slowed and the refractory period is prolonged, resulting in suppression of the arrhythmia. The calcium channel blockers are also called slow channel blockers or calcium antagonists. Two calcium channel blockers that have been approved as antiarrhythmics are verapamil and diltiazem. Dosage ranges for the antiarrhythmic drugs are given in the Summary Drug Table: Antiarrhythmic Drugs.

USES

The uses of the antiarrhythmic drugs are given in the Summary Drug Table: Antiarrhythmic Drugs. In general these drugs are used to prevent and treat cardiac arrhythmias, such as premature ventricular contractions (PVCs), ventricular tachycardia (VT), premature atrial contractions (PACs), paroxysmal atrial tachycardia (PAT), atrial fibrillation, and atrial flutter. Some of the antiarrhythmic drugs are used for other conditions. For example, propranolol, in addition to its use as an antiarrhythmic, may also be used for patients with myocardial infarction. This drug has reduced the risk of death and repeated myocardial infarctions in those surviving the acute phase of a myocardial infarction. An additional use includes control of tachycardia in those with pheochromocytoma (a tumor of the adrenal gland that secretes excessive amounts of norepinephrine), migraine headaches, angina pectoris caused by atherosclerosis, and hypertrophic subaortic stenosis.

ADVERSE REACTIONS

General adverse reactions common to most antiarrhythmic drugs include light-headedness, weakness, hypotension, bradycardia, and drowsiness. Adverse reactions associated with the administration of specific antiarrhythmic drugs are given in the Summary Drug Table: Antiarrhythmic Drugs. All antiarrhythmic drugs may cause new arrhythmias or worsen existing arrhythmias, even though they are administered to resolve an existing arrhythmia. This phenomenon is called the proarrhythmic effect. This effect ranges from an increase in frequency of premature ventricular contractions (PVCs), to the development of more severe ventricular tachycardia, to ventricular fibrillation, and may lead to death. Proarrhythmic effects may occur at any time but occur more often when excessive dosages are given, when the preexisting arrhythmia is life-threatening, or if the drug is given IV.

CONTRAINDICATIONS

The antiarrhythmic drugs are reserved for emergency situations and are contraindicated in patients with known hypersensitivity to the antiarrhythmic drugs and during pregnancy and lactation. Most antiarrhythmic drugs are Pregnancy Category B or C drugs, indicating that safe use of these drugs during pregnancy, lactation, or in children has not been established. The antiarrhythmic drug amiodarone is a Pregnancy Category D drug, indicating that fetal harm can occur when the agent is administered to a pregnant woman. It is used only if the potential benefits outweigh the potential hazards to the fetus. Antiarrhythmic drugs are contraindicated in patients with second- or third-degree AV block (if the patient has no artificial pacemaker), severe congestive heart failure (CHF), aortic stenosis, hypotension, and cardiogenic shock. Quinidine and procainamide are contraindicated in patients with myasthenia gravis (see Chap. 24).
### GENERIC NAME | TRADE NAME* | USES | ADVERSE REACTIONS | DOSAGE RANGES
---|---|---|---|---

#### Class I

| disopyramide | Norpace, Norpace CR, generic | Suppression and treatment of sustained ventricular tachycardia | Dry mouth, constipation, urinary hesitancy, blurred vision, nausea, fatigue, dizziness, headache, rash, hypotension, CHF | Ventricular arrhythmias: dosage individualized, 400–800 mg/d PO in divided doses |
| flecainide | Tambocor | Paroxysmal atrial fibrillation/flutter and supraventricular tachycardia | Dizziness, headache, faintness, unsteadiness, blurred vision, headache, nausea, dyspnea, CHF, fatigue, palpitations, chest pain | Initial dose: 50 mg PO q12h; maximum dosage, 300 mg/d |
| lidocaine HCl | Xylocaine, generic | Ventricular arrhythmias | Light-headedness, nervousness, bradyarrhythmia, hypotension, drowsiness, apprehension | 50–300 mg IV bolus; 1–4 mg/min IV infusion 20–50 µg/kg/min; 300 mg IM |
| mexiletine HCl | Mexitil | Ventricular arrhythmias | Palpitations, nausea, vomiting, chest pain, heartburn, dizziness, light-headedness, rash | Initial dose: 200 mg PO q8h; maximum dosage, 1200 mg/d PO |
| moricizine | Ethmozine | Life-threatening ventricular arrhythmias | Cardiac rhythm disturbances, existing arrhythmias worsened, palpitations, dizziness, headache, nausea, anxiety | 600–900 mg/d PO in 3 equally divided doses |
| procaainamide HCl | Pronestyl, Pronestyl SR, Procanbid | Life-threatening ventricular arrhythmias | Hypotension, disturbances of cardiac rhythm, urticaria, fever, chills, nausea, vomiting, rash, confusion, dizziness, weakness, anorexia | Oral: 50 mg/kg/d PO in divided doses q3h; IM: 0.5–1.0 g q4–8h; IV: 500–600 mg over 25–30 min then 2–6 mg/min |
| propafenone HCl | Rythmol | Life-threatening ventricular arrhythmias | Dizziness, nausea, vomiting, constipation, unusual taste, first-degree AV block | Initial dose: 150 mg PO q8h; may be increased to 300 mg PO q8h |
| quinidine gluconate | Quinaglute, generic | Premature atrial and ventricular contractions, atrial tachycardia and flutter, paroxysmal atrial fibrillation, chronic atrial fibrillation | Ringing in the ears, hearing loss, nausea, vomiting, dizziness, headache, rash, disturbed vision, proarrhythmias | Administer test dose of 1 tablet PO or 200 mg IM to test for idiosyncratic reaction. 200–300 mg TID, QID or 300–600 mg q8h or q/12h for SR; IM 600 mg quinidine gluconate, then 400 mg q2h; IV 300 mg quinidine gluconate slow IV at 1 mL/min of diluted solution |
| quinidine sulfate | Quinidex | Cardioquin | | |
| tocaainide HCl | Tonicard | Life-threatening ventricular arrhythmias | Light-headedness, nausea, vomiting, tremor, vertigo, paresthesia, numbness, hallucinations, restlessness, sedation, blurred vision, cardiac arrhythmias | Initial dose: 400 mg PO q8h; may be increased to 1800 mg/d PO in divided doses |

#### Class II

| acebutolol ah-see-byoo’toe-lol | Sectral, generic | Ventricular arrhythmias, hypertension | Hypotension, nausea, diaphoresis, headache, fatigue, weakness, dizziness, impotence, CHF | Arrhythmias: initially 200 mg q12h PO; may increase to 1200 mg/d in 2 divided doses; hypertension: 400 mg/d in 1 or 2 doses PO; maintenance, 200–1200 mg in divided doses |
| esmolol HCl ez’-moe-lol | Brevibloc | Rapid, short-term treatment of ventricular rate in supraventricular arrhythmia, sinus tachycardia | Dizziness, headache, hypotension, nausea, cold extremities, bradycardia | Loading dose: 500 µg/kg/min IV for 1 minute, followed by infusion of 50 µg/kg/min IV for 4 min; maintenance dose, 25 µg/kg/min IV |

(continued)
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>propranolol HCl</td>
<td>Inderal,</td>
<td>Cardiac arrhythmias, angina pectoris,</td>
<td>Fatigue, weakness, depression, bradycardia, dizziness,</td>
<td>Cardiac arrhythmias: 10–30 mg PO 3–4 times daily;</td>
</tr>
<tr>
<td>proe-pran'-oh-lole</td>
<td>generic</td>
<td>hypertension, essential tremor, myocardial infarction, migraine headache</td>
<td>vertigo, rash, decreased libido, hypotension, hyperglycemia</td>
<td>life-threatening arrhythmias: 1–3 mg IV, may repeat once in 2 min; angina pectoris: 80–320 mg/d PO in 2–4 divided doses; hypertension: initially, 40 mg PO BID or 80 mg sustained released once daily; maintenance dose: up to 640 mg/d PO in divided doses</td>
</tr>
<tr>
<td>amiodarone HCl</td>
<td>Cordarone,</td>
<td>Life-threatening ventricular arrhythmias</td>
<td>Malaise, fatigue, tremor, proarhythmias, nausea,</td>
<td>Loading dose: 800–1600 mg/d PO in divided doses; maintenance dose: 400 mg/d PO; up to 1000 mg/d over 24 h IV</td>
</tr>
<tr>
<td>a-mee-o-'da-rone</td>
<td>Pacerone,</td>
<td></td>
<td>vomiting, constipation, ataxia, anorexia, bradycardia, photosensitivity</td>
<td>Immediate treatment: 5–10 mg/kg (diluted) IV; maintenance: rate of 1–2 mg/min by continuous IV infusion or infuse intermittently at 5–10 mg/kg over 10–30 min q6h</td>
</tr>
<tr>
<td>bretyllium</td>
<td>generic</td>
<td>Prophylaxis and treatment of ventricular fibrillation</td>
<td>Hypotension, nausea, vomiting, vertigo, dizziness, postural hypotension, bradycardia</td>
<td>Dosage based on ECG response and Cr; range, 125–500 µg BID</td>
</tr>
<tr>
<td>tosylate</td>
<td>bre-til'-ee-um</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dofetilide</td>
<td>Tikosyn</td>
<td>Conversion of atrial fibrillation/flutter to normal sinus rhythm (NSR), maintenance of NSR</td>
<td>Headache, chest pain, dizziness, respiratory tract infection, dyspnea, nausea, flu syndrome, insomnia, proarhythmias</td>
<td></td>
</tr>
<tr>
<td>doe-fe'-li-yed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ibutilide</td>
<td>Convert</td>
<td>Atrial fibrillation/flutter</td>
<td>Headache, nausea, hypo- or hypertension, ventricular arrhythmias</td>
<td>Adults 60 kg and more: 1 mg infused over 10 min; may repeat 10 min &lt;60 kg: 0.1 mL/kg infused over 10 min; may repeat in 10 min</td>
</tr>
<tr>
<td>fumarate</td>
<td></td>
<td></td>
<td></td>
<td>Initially: 80 mg BID PO; may increase up to 240–320 mg/d (Betapace); up to 120 mg BID (Betapace AF)</td>
</tr>
<tr>
<td>eye-byoo'-li-yed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sotalol</td>
<td>Betapace,</td>
<td>Treatment of life-threatening ventricular arrhythmias, reduction and delay of atrial fibrillation and flutter for ventricular arrhythmias (Betapace AF)</td>
<td>Drowsiness, difficulty sleeping, unusual tiredness or weakness, depression, decreased sexual libido, bradycardia, CHF, cold hands and feet, nausea, vomiting, nasal congestion, anxiety, life-threatening arrhythmias (proarhythmias)</td>
<td></td>
</tr>
<tr>
<td>sew'-ta-lol</td>
<td>Betapace AF</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>verapamil</td>
<td>Calan,</td>
<td>Superventricular tachyarrhythmias, temporary control of rapid ventricular rate in atrial flutter/fibrillation, angina, unstable angina, hypertension</td>
<td>Constipation, dizziness, light-headedness, headache, asthenia, nausea, peripheral edema, hypotension, proarhythmias, CHF</td>
<td>Adults: oral—initial dose 80–120 mg TID; maintenance 320–480 mg/d</td>
</tr>
<tr>
<td>ver-ap'-ah-mill</td>
<td>Covera HS,</td>
<td></td>
<td></td>
<td>Hypertension: 240 mg PO daily; sustained release in AM 80 mg TID; ER capsules, 100–300 mg HS PO Parenteral: IV use only; initial dose 5–10 mg over 2 min; may repeat 10 mg 30 min later</td>
</tr>
<tr>
<td></td>
<td>Isoptin,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Verelan,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Verelan PM,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.*
PRECAUTIONS

All antiarrhythmic drugs are used cautiously in patients with renal or hepatic disease. When renal or hepatic dysfunction is present, a dosage reduction may be necessary. All patients should be observed for renal and hepatic dysfunction. Quinidine and procainamide are used cautiously in patients with CHF. Disopyramide is used cautiously in patients with CHF, myasthenia gravis, or glaucoma, and in men with prostate enlargement. Bretylium is used cautiously in patients with digitalis toxicity because the initial release of norepinephrine with digitalis toxicity may exacerbate arrhythmias and symptoms of toxicity. Verapamil is used cautiously in patients with a history of serious ventricular arrhythmias or CHF. Electrolyte disturbances such as hypokalemia, hyperkalemia, or hypomagnesemia may alter the effects of the antiarrhythmic drugs. Electrolytes are monitored frequently and imbalances corrected as soon as possible.

INTERACTIONS

When two antiarrhythmic drugs are administered concurrently the patient may experience additive effects and is at increased risk for drug toxicity. When quinidine and procainamide are administered with digitalis, the risk of digitalis toxicity is increased. Pharmacologic effects of procainamide may be increased when procainamide is administered with quinidine. When quinidine is administered with verapamil, there is an increased risk of hypotensive effects. When quinidine is administered with disopyramide, there is an increased risk of increased disopyramide blood levels and/or decreased serum quinidine levels.

Propranolol may increase procainamide plasma levels. Additive cholinergic effects may occur when procainamide is administered with other drugs with anticholinergic effects. There is the potential of additive cardiodepressant effects when procainamide is administered with lidocaine. When a beta blocker, such as Inderal, is administered with lidocaine, there is an increased risk of lidocaine toxicity.

Propranolol may alter the effectiveness of insulin or oral hypoglycemic drugs. Dosage adjustments may be necessary.

Dofetilide is not administered with cimetidine because dofetilide plasma levels may be increased by as much as 50%. When treatment for gastric disorders is necessary, patients receiving dofetilide should take omeprazole, ranitidine, or antacids as an alternative to cimetidine.

Verapamil may cause an additive hypotensive effect when administered with other antihypertensives, alcohol, or the nitrates. Verapamil increases plasma digoxin levels and may cause bradycardia or CHF.

NURSING PROCESS

The Patient Receiving an Antiarrhythmic Drug

ASSESSMENT

Preadministration Assessment

Antiarrhythmic drugs are used to treat various types of cardiac arrhythmias. There are initial preadministration assessments the nurse performs before starting therapy that are the same for all antiarrhythmic drugs. These assessments include:

- Taking and recording the blood pressure, apical and radial pulses, and respiratory rate. This provides a database for comparison during therapy.
- Assessing the patient's general condition and including observations such as skin color (pale, cyanotic, flushed), orientation, level of consciousness, and the patient's general status (such as appears acutely ill or appears somewhat ill). All observations must be recorded to provide a means of evaluating the response to drug therapy.
- Recording any symptoms (subjective data) described by the patient.

Because all antiarrhythmic drugs may produce proarrhythmic effects, a careful preadministration assessment is essential. It is often difficult to distinguish a proarrhythmic effect from the patient's underlying rhythm disorder, so it is important that the nurse assess each patient taking an antiarrhythmic drug through the use of cardiac monitoring before therapy begins and in the ongoing assessment to determine if the patient is experiencing a therapeutic response to the drug, developing another arrhythmia, or is experiencing worsening of the original arrhythmia.

The primary health care provider may also order laboratory and diagnostic tests, renal and hepatic function tests, complete blood count, serum enzymes, and serum electrolytes. The nurse reviews these test results before the first dose is given and reports any abnormalities to the primary health care provider. The patient is usually placed on a cardiac monitor before antiarrhythmic drug therapy is initiated. The primary health care provider may order an ECG to provide baseline data for comparison during therapy.

Ongoing Assessment

During ongoing therapy with the antiarrhythmic drugs, the nurse takes the patient's blood pressure, apical and radial pulses, and respiratory rate at periodic intervals, usually every 1 to 4 hours. Specific intervals depend on
the primary health care provider’s order or on nursing judgment and are based on the patient’s general condition. The nurse closely observes the patient for a response to drug therapy, signs of CHF, the development of a new cardiac arrhythmia, or worsening of the arrhythmia being treated.

The nurse should immediately report to the primary health care provider any significant changes in the blood pressure, the pulse rate or rhythm, respiratory difficulty, change in respiratory rate or rhythm, or change in the patient’s general condition.

Continual cardiac monitoring assists the nurse in assessing the patient for adverse drug reactions. If the patient is acutely ill or is receiving one of these drugs parenterally, the nurse measures and records the fluid intake and output. The primary health care provider may order subsequent laboratory tests to monitor the patient’s progress for comparison with tests performed in the predadministration assessment, such as an ECG, renal and hepatic function tests, complete blood count, serum enzymes, and serum electrolytes. The nurse reports to the primary care provider any abnormalities or significant interval changes of the ECG, such as prolongation of the PR or QT interval or widening of the QRS complex. (See Fig. 40-3 for a diagram of a normal QRS complex.) In addition, when subsequent laboratory tests are ordered, the nurse reviews the results and reports any abnormalities to the primary health care provider.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes for the patient may include obtaining an optimal therapeutic response to drug therapy, management of adverse drug reactions, and an understanding of and compliance with the postdischarge drug regimen.

**Nursing Diagnoses Checklist**

- Ineffective Tissue Perfusion: Peripheral related to adverse drug reactions (hypotension)
- Decreased Cardiac Output related to adverse drug reactions (drug-induced arrhythmias)
- Activity Intolerance related to weakness and fatigue
- Risk for Injury related to adverse drug reactions (dizziness, light-headedness)
IMPLEMENTATION

Promoting an Optimal Response to Therapy

ADMINISTERING QUINIDINE. When quinidine is administered orally the drug is not crushed or chewed. Gastrointestinal upset can be reduced if the drug is given with food. The nurse must monitor serum quinidine levels during administration of the drug. Normal therapeutic levels range between 2 and 6 μg/mL. Toxic effects of quinidine usually occur at levels greater than 8 μg/mL.

ADMINISTERING PROCAINAMIDE. If procainamide is given IV, the nurse maintains continuous and close cardiac monitoring. When the drug is given IV, the nurse discontinues the drug immediately if changes in the ECG pattern occur. IV administration is by IV piggy-back. Hypotension may be seen with IV administration; therefore, the blood pressure must be monitored every 15 minutes while the drug is being infused. The nurse keeps the patient supine during IV administration to minimize hypotension. If hypotension should occur, the drug therapy is discontinued, and the primary IV line is run at a rate to keep the vein open until the primary health care provider sees the patient. Although not the route of choice, the drug may be administered by IM injection. When the drug is given IM, the gluteus muscle is used and the injection sites are rotated.

When the drug is given orally, the nurse instructs the patient not to chew the capsule or tablet but to swallow it whole. For faster absorption, the drug is given with a full glass of water when the patient’s stomach is empty, either 1 hour before or 2 hours after meals. If gastrointestinal upset occurs, the nurse can administer the drug with or immediately after meals. Sustained-released tablets should not be crushed or divided.

ADMINISTERING DISOPYRAMIDE. Disopyramide is administered to the patient with a full glass of water either 1 hour before or 2 hours after meals. If patients are receiving procainamide or quinidine, the manufacturer suggests that disopyramide therapy not be started for 6 to 12 hours after the last dose of quinidine and 3 to 6 hours after the last dose of procainamide. When the patient is to switch from taking the regular capsules to taking extended-release capsules, 6 hours should lapse after the last capsule before therapy is begun with the extended-release capsules.

ADMINISTERING LIDOCAINE. Lidocaine is most often administered IV either continuously diluted in D5W or direct IV as a loading dose. When administered as a loading dose, the drug is given during a period of 1 minute with the dose repeated once after 5 minutes. The arrhythmia is usually controlled within 24 hours of continuous administration. The infusion is discontinued when the heart rhythm is stable or at the earliest sign of lidocaine toxicity. Blood lidocaine levels greater than 7 μg/mL are potentially toxic.

ADMINISTERING TOCAINIDE AND MEXILETINE. Tocainide and mexiletine are administered at 8-hour intervals and with food (or an antacid) to prevent gastrointestinal upset. In addition, administering tocainide with food may offer some protection against toxicity because the absorption rate is slowed in the presence of food.

ADMINISTERING FLECAINIDE AND PROPAFENONE. The nurse closely observes the patient for a response to drug therapy, signs of CHF, the development of a new cardiac arrhythmia, or worsening of the arrhythmia being treated. When flecainide is being administered, other antiarrhythmic drugs should be discontinued for at least two to four half-lives (time required for the blood level of a drug to decrease by 50%) of the drug being discontinued before flecainide therapy is begun. In general, when a drug therapy is discontinued, four to five half-lives are needed to eliminate the drug from the body. It is advisable to hospitalize the patient during withdrawal of the antiarrhythmic drug before initiating flecainide therapy because life-threatening arrhythmias may occur.

Propafenone is administered orally every 8 hours. Any previously given antiarrhythmic drug should be discontinued before propafenone therapy is started. Dosage changes are done 3 to 4 days apart because of the length of time the drug remains active in the body.

ADMINISTERING PROPRANOLOL. Cardiac monitoring is recommended when the drug is given IV because severe bradycardia and hypotension may be seen. The nurse obtains written instructions from the primary health care provider for propranolol administration. For example, the primary health care provider may want the drug to be withheld for a systolic blood pressure less than 90 mm Hg or a pulse rate less than 50 bpm.

ADMINISTERING BRETYLIUM. Bretylium is used in the emergency treatment of life-threatening ventricular arrhythmias. Because of its adverse reactions, bretylium is used when the arrhythmia is unresponsive to the other antiarrhythmic drugs. Baseline data will come from routine assessments made before the emergency. The nurse administers this drug IM or IV and uses continuous cardiac monitoring. The patient is placed in a supine position with suction equipment readily available in the event vomiting should occur.

Nursing Alert

A transient increase in arrhythmias and hypertension may occur within 1 hour after initial therapy with bretylium is begun. The nurse should take the blood pressure and respiratory rate every 5 to 15 minutes and obtain the pulse rate from the cardiac monitor. These activities are continued until the arrhythmia is corrected.
To discontinue use of the drug, the dosage should be gradually reduced during a period of 3 to 5 days. After administering the drug, the nurse observes the patient closely. An oral antiarrhythmic drug may be prescribed to provide continued stability to the cardiac muscle.

**ADMINISTERING VERAPAMIL.** This drug is used to manage supraventricular arrhythmias and rapid ventricular rates in atrial flutter or fibrillation. Continuous cardiac monitoring is necessary during IV administration. The nurse notifies the primary health care provider if bradycardia or hypotension occurs. Patients receiving a cardiac glycoside (eg, digoxin) concurrently with verapamil must be monitored for an increased risk of digitalis toxicity. Verapamil is administered orally with food to minimize gastric upset.

**Monitoring and Managing Adverse Reactions**
Nursing judgment is necessary in reporting other adverse reactions to the primary health care provider. For example, the patient with a dry mouth is in no danger, even though the condition is uncomfortable. Although the occurrence of this is reported to the primary health care provider, it is not of an emergency nature. In some instances, minor adverse reactions must be tolerated by the patient. However, the patient with severe bradycardia or prolonged nausea and vomiting is in a potentially dangerous situation. The nurse contacts the primary health care provider immediately because additional treatment may be necessary.

Proarrhythmic effects (worsening of the existing arrhythmia or causation of a new arrhythmia) may occur, such as severe ventricular tachycardia or ventricular fibrillation. It is often difficult to distinguish proarrhythmic effects from the patient’s preexisting arrhythmia.

**Gerontologic Alert**
When older adults take the antiarrhythmic drugs, they are at greater risk for adverse reactions such as the development of additional arrhythmias or aggravation of existing arrhythmias, hypotension, and congestive heart failure (CHF). A dosage reduction may be indicated. Careful monitoring by the nurse is necessary for early identification and management of adverse reactions. The nurse monitors the intake and output and reports any signs of CHF, such as increase in weight, decrease in urinary output, or shortness of breath.

Some of the antiarrhythmic drugs such as quinidine, procainamide, mexiletine, tocainide, or verapamil may cause agranulocytosis. The nurse reports any signs of agranulocytosis such as fever, chills, sore throat, or unusual bleeding or bruising. A complete blood count is usually ordered every 2 to 3 weeks during the first 3 months of therapy. If a decrease in the blood levels of leukocytes, platelets, or hematocrit occurs, use of the drug is discontinued. Blood levels usually return to normal within 1 month after use of the antiarrhythmic drug is discontinued.

**ADMINISTERING QUINIDINE.** The nurse monitors the patient for the most common adverse reactions seen with quinidine, which include nausea, vomiting, abdominal pain, diarrhea, or anorexia. **Cinchonism** is the term used to describe quinidine toxicity, and it occurs with high blood levels of quinidine ($> 8 \mu g/mL$). The nurse must report any quinidine levels greater than 8 $\mu g/mL$ and the occurrence of any of the following signs or symptoms of cinchonism: ringing in the ears (tinnitus), hearing loss, headache, nausea, dizziness, vertigo, and light-headedness. These symptoms may also appear after a single dose. The patient is kept in a supine position throughout IV administration to minimize hypotension. If a widening of the QRS complex of 50% or more occurs, the nurse immediately notifies the primary care provider, who may order that the drug therapy be discontinued.

**ADMINISTERING PROCAINAMIDE.** Adverse reactions with procainamide therapy include nausea, loss of appetite, and vomiting. Small meals eaten frequently may be better tolerated than three full meals. Administering the drug with meals may decrease gastrointestinal effects.

**ADMINISTERING DISOPYRAMIDE.** Because of the cholinergic blocking effects of disopyramide (see Chap. 25), urinary retention may occur. The nurse monitors the urinary output closely, especially during the initial period of therapy. If the patient’s intake is sufficient but the output is low, the lower abdomen is...
palpated for bladder distention. If urinary retention occurs, catheterization may be necessary.

Dryness of the mouth and throat caused by the cholinergic blocking action of this drug also may occur. The nurse provides an adequate amount of fluid and instructs the patient to take frequent sips of water to relieve this problem. In addition, postural hypotension may occur during the first few weeks of disopyramide therapy. The patient is advised to make position changes slowly. In some instances, the patient may require assistance in getting out of the bed or chair.

ADMINISTERING LIDOCAINE. Lidocaine is an emergency drug used in the treatment of life-threatening ventricular arrhythmias. Constant cardiac monitoring is essential when this drug is administered by the IV or intramuscular (IM) route. The administration of lidocaine is titrated to the patient's response and within institutional protocols. The nurse must observe the patient closely for signs of respiratory depression, bradycardia, change in mental status, respiratory arrest, convulsions, and hypotension. An oropharyngeal airway and suction equipment are kept at the bedside in case convulsions should occur.

If pronounced bradycardia occurs, the primary health care provider may order emergency measures, such as the administration of IV atropine (see Chap. 25) or isoproterenol (see Chap. 22). Any sudden change in mental state should be reported to the primary health care provider immediately because a decrease in the dosage may be necessary.

The nurse monitors the blood pressure and respiratory rate every 2 to 5 minutes when the drug is given IV and every 5 to 10 minutes when the drug is given IM. The pulse rate and rhythm are monitored continually by means of the cardiac monitor. The primary health care provider is contacted immediately if there are any changes in the vital signs or the ECG pattern or if respiratory problems or convulsions occur.

ADMINISTERING TOCAINIDE AND MEXILETINE. The dosage of these drugs must be individualized; therefore, the nurse monitors vital signs at frequent intervals during initial therapy. The nurse reports any changes in the pulse rate or rhythm to the primary health care provider. Onset of tremors is an indicator the maximum dosage of both tocainide and mexiletine has been reached. Adverse effects related to the central nervous system or gastrointestinal tract may occur during initial therapy and must be reported to the primary health care provider.

ADMINISTERING FLECAINIDE AND PROPAFENONE. When administering flecainide, the nurse must carefully monitor the patient for cardiac arrhythmias. Therapeutic serum levels fall between 0.2 and 1 μg/mL. Life support equipment, including pacemaker, should be kept on stand-by during administration.

During the initiation of therapy, patients taking propafenone must be monitored carefully. To minimize adverse reactions, dosage is increased slowly at a minimum of 3- to 4-day intervals. Periodic ECG monitoring is necessary to evaluate the effects on cardiac conduction.

ADMINISTERING PROPRANOLOL. The nurse monitors the ECG frequently for cardiac arrhythmias. Patients receiving IV propranolol must have continuous cardiac monitoring. The nurse must monitor the blood pressure and pulse frequently during the dosage adjustment period and periodically throughout therapy.

ADMINISTERING BRETYLIUM. The nurse monitors cardiac rhythm and blood pressure continuously during administration. Hypotension and postural hypotension occur in about 50% of the patients receiving bretylium. If systolic pressure is less than 75 mm Hg, the nurse should notify the primary health care provider. The patient is kept supine until tolerance of postural hypotension develops. The nurse instructs the patient to change position slowly. Most individuals adjust to blood pressure changes within a few days.

ADMINISTERING VERAPAMIL. The nurse monitors the patient's blood pressure and cardiac rhythm carefully while the drug is being titrated (dosage increased or decreased based on an established criteria by the primary care provider). Dosage may be increased more rapidly in a hospitalized setting. The nurse must assess the cardiac rhythm (ECG) regularly during stabilization of the dosage and periodically during long-term therapy.

Educating the Patient and Family

The nurse explains the adverse drug effects that may occur to the patient and family. To ensure compliance with the prescribed drug regimen, the nurse emphasizes the importance of taking these drugs exactly as prescribed. It may be necessary to teach the patient or a family member how to take the pulse rate. The nurse advises the patient to report any changes in the pulse rate or rhythm to the primary health care provider (see Patient and Family Teaching Checklist: Self-Monitoring Pulse Rate With Antiarrhythmic Therapy).

The nurse emphasizes the following points when teaching the patient and the family:

- Take the drug at the prescribed intervals. Do not omit a dose or increase or decrease the dose unless advised to do so by the primary health care provider.
- Do not stop taking the drug unless advised to do so by the primary health care provider.
- Do not take any nonprescription drug unless the use of a specific drug is approved by the primary health care provider.
• Keep all follow-up visits with the primary health care provider to monitor progress.

EVALUATION
• The therapeutic response is achieved and the arrhythmia is controlled.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully with appropriate nursing interventions.
• No evidence of injury is seen.
• The patient and family demonstrate an understanding of the drug regimen.
• The patient verbalizes the importance of continued follow-up care.
• The patient verbalizes the importance of complying with the prescribed treatment regimen.
• The patient complies with the prescribed drug regimen.

Critical Thinking Exercises

1. Mr. Parker is at an outpatient clinic for a follow-up visit. He has been taking quinidine for several months for a cardiac arrhythmia. Analyze what assessments you would make on Mr. Parker to determine the effectiveness of quinidine therapy. Discuss what questions you would ask to determine the presence of any adverse reactions.

2. Ms. Grady, age 48 years, will be discharged in 2 days. The primary health care provider has prescribed propranolol to treat her arrhythmia. Develop a patient educational handout for Ms. Grady to take home with her explaining the most important points for her to know when taking propranolol.

3. Mr. Summers has a ventricular arrhythmia and is placed on a cardiac monitor. The primary health care provider prescribes IV lidocaine. Discuss preadministration assessments you would perform on Mr. Summers. Analyze which adverse reactions would be most important to monitor for during the ongoing assessment. Determine what reactions should be reported immediately.

4. Ms. Watters is receiving bretylium for a ventricular arrhythmia. Discuss the ongoing assessments you would make when caring for Ms. Watters.

Review Questions

1. Which of the following adverse reactions of lidocaine (Xylocaine) should be reported immediately to the primary care provider?
   A. Sudden change in mental status
   B. Dry mouth
   C. Occipital headache
   D. Light-headedness
2. Which of the following drugs, when given with quinidine (Quinidex), would increase the risk for hypotension?
   A. Verapamil (Calan)
   B. Propranolol (Inderal)
   C. Encainide (Enkaid)
   D. Disopyramide (Norpace)

3. Common adverse reactions of the antiarrhythmic drugs include ______.
   A. light-headedness, hypotension, and weakness
   B. headache, hypertension, and lethargy
   C. weakness, lethargy, and hyperglycemia
   D. anorexia, gastrointestinal upset, and hypertension

4. When administering lidocaine (Xylocaine), the nurse reports a blood level greater than ______.
   A. 2 µg/mL
   B. 3 µg/mL
   C. 4 µg/mL
   D. 6 µg/mL

5. Which of the following statements would the nurse include in a teaching plan for the patient taking an antiarrhythmic drug on an outpatient basis?
   A. Take the drug without regard to meals.
   B. Limit fluid intake during the evening hours.
   C. Avoid drinking alcoholic beverages unless their consumption has been approved by the primary care provider.
   D. Eat a diet high in potassium.

---

**Medication Dosage Problems**

1. The primary care provider prescribed 75 mg of bretylium IV. The drug is available for injection in vials of 50 mg/mL. The nurse prepares ______.

2. Disopyramide 200 mg PO is prescribed. The pharmacy sends disopyramide (Norpace) 100 mg tablets. The nurse administers ______.
Diseases of the arteries can cause serious problems, namely coronary artery disease, cerebral vascular disease, and peripheral vascular disease. Drug therapy for vascular diseases may include drugs that dilate blood vessels and thereby increase blood supply to an area.

Atherosclerosis is a disease characterized by deposits of fatty plaques on the inner wall of arteries. These deposits result in a narrowing of the lumen (inside diameter) of the artery and a decrease in blood supply to the area served by the artery.

This chapter discusses two different types of drugs whose primary purpose is to increase blood supply to an area by dilating blood vessels: the antianginal and peripheral vasodilating drugs. Vasodilating drugs relax the smooth muscle layer of arterial blood vessels, which results in vasodilatation, an increase in the size of blood vessels, primarily small arteries and arterioles. Because peripheral, cerebral, or coronary artery disease usually results in decreased blood flow to an area, drugs that dilate narrowed arterial blood vessels will carry more blood, followed by an increase in blood flow to the affected area. Increasing the blood flow to an area may result in complete or partial relief of symptoms.

Vasodilating drugs sometimes relieve the symptoms of vascular disease, but in some cases drug therapy provides only minimal and temporary relief. Many of the vasodilating drugs are also used to treat hypertension. Their use as antihypertensives is discussed in Chapter 42.

**ANTIANGINAL DRUGS**

Angina is a disorder characterized by atherosclerotic plaque formation in the coronary arteries, which causes decreased oxygen supply to the heart muscle and results in chest pain or pressure. Any activity that increases the workload of the heart, such as exercise or simply climbing stairs, can precipitate an angina attack. Antianginal drugs relieve chest pain or pressure by dilating coronary arteries, increasing the blood supply to the myocardium.

The antianginal drugs include the nitrates and the calcium channel blockers. Chapter 23 and its Summary Drug Table: Adrenergic Blocking Drugs discuss the adrenergic blocking drugs that are also used to treat angina and other disorders.


**ACTIONS**

**Nitrates**

The nitrates, such as isosorbide (Isordil) and nitroglycerin, have a direct relaxing effect on the smooth muscle layer of blood vessels. The result of this effect is an increase in the lumen of the artery or arteriole and an increase in the amount of blood flowing through these vessels. An increased blood flow results in an increase in the oxygen supply to surrounding tissues.

**Calcium Channel Blockers**

Systemic and coronary arteries are influenced by movement of calcium across cell membranes of vascular smooth muscle. The contractions of cardiac and vascular smooth muscle depend on movement of extracellular calcium ions into these walls through specific ion channels. Calcium channel blockers, such as amlodipine (Norvasc), diltiazem (Cardizem), nicardipine (Cardene), nifedipine (Procardia), and verapamil (Calan), inhibit the movement of calcium ions across cell membranes. This results in less calcium available for the transmission of nerve impulses (Fig. 41-1). This drug action of the calcium channel blockers (also known as slow channel blockers) has several effects on the heart, including an effect on the smooth muscle of arteries and arterioles. These drugs dilate coronary arteries and arterioles, which in turn deliver more oxygen to cardiac muscle. Dilation of peripheral arteries reduces the workload of the heart. The end effect of these drugs is the same as that of the nitrates.

**USES**

**Nitrates**

The nitrates are used to treat angina pectoris. Some of these drugs, such as isosorbide dinitrate (Isordil), are used for prophylaxis (prevention) and long-term treatment of angina, whereas others, such as sublingual nitroglycerin (Nitrostat), are used to relieve the pain of acute anginal attacks when they occur. See the Summary Drug Table: Antianginal Drugs for additional uses of the nitrates. Intravenous nitroglycerin is used to control perioperative hypertension associated with surgical procedures.

**Calcium Channel Blockers**

Calcium channel blockers are primarily used to prevent anginal pain associated with certain forms of angina, such as vasospastic (Prinzmetal’s variant) angina and chronic stable angina. They are not used to abort (stop) anginal pain once it has occurred. When angina is caused by coronary artery spasm, these drugs are recommended when the patient cannot tolerate therapy with the beta (β)-adrenergic blocking drugs (see Chap. 23) or the nitrates. Calcium channel blockers used as antianginals are listed in the Summary Drug Table: Antianginal Drugs. Some calcium channel blocking drugs have additional uses. Verapamil affects the conduction system of the heart and may be used to treat cardiac arrhythmias. Diltiazem, nicardipine, nifedipine, and verapamil also are used in the treatment of essential hypertension (see Chap. 42).

**ADVERSE REACTIONS**

**Nitrates**

The nitrate antianginal drugs all have the same adverse reactions, although the intensity of some reactions may vary with the drug and the dose. A common adverse reaction seen with these drugs is headache, especially early in therapy. Hypotension, dizziness, vertigo, and weakness may also be associated with headache. Flushing caused by dilatation of small capillaries near the surface of the skin may also be seen.

The nitrates are available in various forms (eg, sublingual, transmucosal, translingual spray, and inhalation). Some adverse reactions are a result of the method of administration. For example, sublingual nitroglycerin may cause a local burning or tingling in the oral cavity. However, the patient must be aware that an absence of this effect does not indicate a decrease in the drug’s potency. Contact dermatitis may occur from use of the transdermal delivery system.

---

**FIGURE 41-1.** Calcium channel blockers inhibit the movement of calcium ions across the cell membrane. When calcium channels are blocked by drug molecules, muscle contraction is decreased, causing the smooth muscles of the arteries and arterioles to dilate.
## ANTANGINAL DRUGS

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>amyl nitrite, generic</td>
<td>am-il-nye-trite</td>
<td>Relief of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>Crush capsule and wave under nose, taking 1–6 inhalations; may repeat in 3–5 minutes</td>
</tr>
<tr>
<td>isosorbide mononitrate, ISMO, Imdur, Monoket, generic</td>
<td>Prevention of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>20 mg BID PO with the two doses given 7h apart; extended-release tablets: 30–60 mg once daily may be increased to 240 mg/d PO</td>
<td></td>
</tr>
<tr>
<td>isosorbide dinitrate sublingual and chewable</td>
<td>Isordil, Sorbitrate, generic</td>
<td>Treatment and prevention of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>Treatment: 2.5–5 mg sublingual; prevention: 2.5–5 mg SL, 5 mg chewable</td>
</tr>
<tr>
<td>isosorbide dinitrate oral, sublingual and chewable</td>
<td>Dilatrate SR, Isordil Tembids, Isordil Titradoose, Sorbitrate, generic</td>
<td>Treatment and prevention of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>Initial dose 5–20 mg PO; maintenance dose 10–40 mg BID, TID; sustained release: 40 mg/d; daily maximum dose, 160 mg/d PO</td>
</tr>
<tr>
<td>nitroglycerin, intravenous Nitro-Bid IV, Tridil, generic</td>
<td>Control of blood pressure in perioperative hypertension and in immediate postoperative period, CHF associated with acute MI, angina pectoris unresponsive to recommended doses of nitrates or beta blockers</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>Initially 5 mcg/min via IV infusion pump; may increase to 20 mcg/min</td>
<td></td>
</tr>
<tr>
<td>nitroglycerin, sublingual NitroQuick, Nitrostat</td>
<td>Acute relief of an attack of angina pectoris or prophylaxis of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>1 tablet under tongue or in buccal pouch at first sign of an acute anginal attack; may repeat q5 min until relief or 3 tablets have been taken</td>
<td></td>
</tr>
<tr>
<td>nitroglycerin, translingual Nitrolingual</td>
<td>Acute relief of an attack or prophylaxis of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>1–2 metered dose sprays onto or under the tongue; maximum of 3 metered doses in 15 min</td>
<td></td>
</tr>
<tr>
<td>nitroglycerin, transmucosal Nitrogard</td>
<td>Prevention of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>1 tablet q3–5h between lip and gum or between cheek and gum</td>
<td></td>
</tr>
<tr>
<td>nitroglycerin, sustained release Nitrogard, Nitrong, Nitro-Time, generic</td>
<td>Prevention of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>2.5–2.6 mg TID, QID PO up to 26 mg QID</td>
<td></td>
</tr>
<tr>
<td>nitroglycerin transdermal systems Nitrogard, Deponit, Minitran, Nitro-Dur, Transderm-Nitro, generic</td>
<td>Prevention of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>One system daily 0.2–0.8 mg/h</td>
<td></td>
</tr>
</tbody>
</table>

*Note: The trade names listed are for reference only and may vary by region.*
**Summary Drug Table: Antianginal Drugs**

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitroglycerin, topical</td>
<td>Nitrobid, Nitrol, generic</td>
<td>Prevention and treatment of angina pectoris</td>
<td>Headache, hypotension, dizziness, vertigo, weakness, flushing</td>
<td>1–5 inches q4–8h</td>
</tr>
</tbody>
</table>

### Calcium Channel Blocking Drugs

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amlodipine</td>
<td>Norvasc</td>
<td>Hypertension, chronic stable angina, vasospastic angina (Prinzmetal’s angina)</td>
<td>Dizziness, light-headedness, headache, nervousness, nausea, diarrhea, constipation, peripheral edema, angina, bradycardia, AV block, flushing, rash, nasal congestion, cough</td>
<td>Individualize dosage; 5–10 mg PO once daily</td>
</tr>
<tr>
<td>Bepridil HCl</td>
<td>Vascor</td>
<td>Chronic stable angina</td>
<td>Dizziness, light-headedness, headache, nervousness, nausea, diarrhea, constipation, peripheral edema, angina, bradycardia, AV block, flushing, rash, nasal congestion, cough</td>
<td>Individualize dosage; 200–400 mg/d PO</td>
</tr>
<tr>
<td>Diltiazem HCl</td>
<td>Cardizem, Cardizem CD, Dilacor XR, Tiamate, Tiazac, generic</td>
<td>Oral: Angina pectoris, essential hypertension Parenteral: atrial fibrillation or flutter, paroxysmal supraventricular tachycardia</td>
<td>Dizziness, light-headedness, headache, nervousness, nausea, diarrhea, constipation, peripheral edema, angina, bradycardia, AV block, flushing, rash, nasal congestion, cough</td>
<td>Tablets: 30–360 mg/d in divided doses; sustained-release: Cardizem SR 120–360 mg/d; Cardizem CD angina 120–240 mg once daily; Dilacor XR, 180–480 mg once daily PO; Tiazac, 120–240 mg/d for hypertension Parenteral: 0.25 mg/kg IV bolus; 5–15 mg/h IV</td>
</tr>
<tr>
<td>Nicardipine HCl</td>
<td>Cardene, Cardene IV, Cardene SR, generic</td>
<td>Chronic stable angina, hypertension, short-term treatment of hypertension when oral therapy is not desirable</td>
<td>Dizziness, light-headedness, headache, nervousness, nausea, diarrhea, constipation, peripheral edema, angina, bradycardia, AV block, flushing, rash, nasal congestion, cough</td>
<td>Angina: individualize dosage; immediate release only, 20–40 mg TID PO Hypertension: individualize dosage; immediate release, 20–40 mg/d TID PO; sustained release, 30–60 mg BID PO; 0.5–2.2 mg/h IV by infusion 10–20 mg TID PO; may increase to 120 mg/d; sustained release, 30–60 mg/d PO; may increase to 120 mg/d</td>
</tr>
<tr>
<td>Nifedipine</td>
<td>Adalat, Procardia, Procardia XL, generic</td>
<td>Vasospastic angina (Prinzmetal’s angina), chronic stable angina, hypertension (sustained-release only)</td>
<td>Dizziness, light-headedness, headache, nervousness, nausea, diarrhea, constipation, peripheral edema, angina, bradycardia, AV block, flushing, rash, nasal congestion, cough</td>
<td>Individualize dosage; do not exceed 480 mg/d; essential hypertension: 240 mg/d, sustained release 80 mg TID; ER capsules, 100–300 mg HS</td>
</tr>
</tbody>
</table>
| Verapamil HCl | Calan, Calan SR, Isotin, Isotin SR, Verelan, generic | Angina, arrhythmias, essential hypertension, supraventricular tachycardia (parenteral only), atrial flutter/fibrillation (parenteral only) | Dizziness, light-headedness, headache, nervousness, nausea, diarrhea, constipation, peripheral edema, angina, bradycardia, AV block, flushing, rash, nasal congestion, cough | *The term generic indicates the drug is available in generic form.*
In many instances, the adverse reactions associated with the nitrates lessen and often disappear with prolonged use of the drug. However, for some patients, these adverse reactions become severe, and the primary health care provider may lower the dose until symptoms subside. The dose may then be slowly increased if the lower dosage does not provide relief from the symptoms of angina.

**Calcium Channel Blockers**

Adverse reactions to the calcium channel blocking drugs usually are not serious and rarely require discontinuation of the drug therapy. The more common adverse reactions include dizziness, light-headedness, nausea, diarrhea, constipation, peripheral edema, headache, bradycardia, flushing, dermatitis, skin rash, and nervousness. See the Summary Drug Table: Antianginal Drugs for a more specific listing of the adverse reactions of the calcium channel blockers.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Nitrates**

The nitrates are contraindicated in patients with known hypersensitivity to the drugs, severe anemia, closed angle glaucoma, postural hypertension, head trauma, cerebral hemorrhage (may increase intracranial hemorrhage), allergy to adhesive (transdermal system), or constrictive pericarditis. Amyl nitrate is contraindicated during pregnancy (Pregnancy Category X).

The nitrates are used cautiously in patients with severe hepatic or renal disease, severe head trauma, acute myocardial infarction (MI), hypothyroidism, and during pregnancy (Pregnancy Category C, except for amyl nitrate) or lactation.

If the nitrates are administered with the antihypertensives, alcohol, calcium channel blockers, or the phenothiazines, there may be an increased hypotensive effect. When nitroglycerin is administered intravenously (IV), the effects of heparin may be decreased. Increased nitrate serum concentrations may occur when the nitrates are administered with aspirin.

**Calcium Channel Blockers**

Calcium channel blockers are contraindicated in patients who are hypersensitive to the drugs and those with sick sinus syndrome, second- or third-degree AV block (except with a functioning pacemaker), hypotension (systolic less than 90 mm Hg), ventricular dysfunction, or cardiogenic shock. The calcium channel blockers are used cautiously during pregnancy (Pregnancy Category C) and lactation and in patients with congestive heart failure (CHF), hypotension, or renal or hepatic impairment.

The effects of the calcium channel blockers are increased when administered with cimetidine or ranitidine. A decrease in effectiveness of the calcium channel blockers may occur when the agents are administered with phenobarbital or phenytoin. The calcium channel blockers have an antiplatelet effect (inhibition of platelet function) when administered with aspirin, causing easy bruising, petechiae (pinpoint purplish red spot caused by intradermal hemorrhage), and bleeding. There is an additive depressive effect on the myocardium when the calcium channel blockers are administered with the β-adrenergic blocking drugs. When the calcium channel blockers are administered with digoxin, there is an increased risk for digitalis toxicity.

**NURSING PROCESS**

**The Patient Receiving an Antianginal Drug**

**ASSESSMENT**

**Preadministration Assessment**

Before administering an antianginal drug, the nurse obtains and records a thorough description of the patient's anginal pain. The nurse includes the information in Display 41-1 in the preadministration assessment. The nurse obtains a history of allergy to the nitrates or calcium channel blockers and other disease processes that would contraindicate administration of the drug. The nurse assesses the physical appearance of the patient (ie, skin color, lesions), auscultates the lungs for adventitious sounds, and obtains a baseline ECG.

**DISPLAY 41-1 • Information Regarding Anginal Pain**

**HISTORY**
- Description of the type of pain (eg, sharp, dull, squeezing)
- Whether the pain radiates and to where
- Events that appear to cause anginal pain (eg, exercise, emotion)
- Events that appear to relieve the pain (eg, resting)

**PHYSICAL ASSESSMENT**
- Blood pressure
- Apical and radial pulse rates
- Respiratory rate (after the patient has been at rest for about 10 minutes)
- Weight
- Inspection of the extremities for edema
- Auscultation of the lungs

*These assessments may be appropriate, depending on the type of heart disease.
and vital signs. Any problem with orthostatic hypotension is noted.

**Ongoing Assessment**
As a part of the ongoing assessment, the nurse monitors the patient for the frequency and severity of any episodes of angina pain. With treatment, episodes of angina should be eliminated or decrease in frequency and severity. The nurse should report to the primary health care provider any chest pain that does not respond to three doses of nitroglycerin given every 5 minutes for 15 minutes.

The nurse takes the patient's vital signs before the drug is administered and frequently during administration of the antianginals or the calcium channel blockers. If the heart rate is below 50 bpm or the systolic blood pressure is below 90 mm Hg, the drug is withheld and the primary health care provider notified. A dosage adjustment may be necessary.

The nurse should assess patients receiving the calcium channel blockers for signs of CHF: dyspnea, weight gain, peripheral edema, abnormal lung sounds (crackles/rales), and jugular vein distention. Any symptoms of CHF are reported immediately to the primary health care provider.

The patient is monitored carefully; vital signs are taken frequently, and the patient is placed on a cardiac monitor while the drug is being titrated to a therapeutic dose. The dosage may be increased more rapidly in hospitalized patients under close supervision.

**NURSING DIAGNOSES**
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**
The expected outcomes for the patient depend on the reason for administration of an antianginal drug but may include an optimal response to drug therapy, management of common adverse drug reactions, and an understanding of the postdischarge drug regimen.

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**

**NITRATES.** The nitrates may be administered by the sublingual (under the tongue), buccal (between the cheek and gum), oral, IV, or transdermal route. Nitroglycerin may be administered by the sublingual, buccal, topical, transdermal, oral, or IV route. If the buccal form of nitroglycerin has been prescribed, the nurse instructs the patient to place the buccal tablet between the cheek and gum or between the upper lip and gum above the incisors and allow it to dissolve. The nurse shows the patient how and where to place the tablet in the mouth. Absorption of sublingual and buccal forms is dependent on salivary secretion. Dry mouth decreases absorption.

Nitroglycerin may also be administered by a metered spray canister that is used to abort an acute anginal attack. The spray is directed from the canister onto or under the tongue. Each dose is metered so that when the canister top is depressed, the same dose is delivered each time. The nurse instructs the patient not to inhale the spray. For some individuals, this is more convenient than the small tablets placed under the tongue.

**Nursing Alert**
The dose of sublingual nitroglycerin may be repeated every 5 minutes until pain is relieved or until the patient has received three doses in a 15-minute period. One to two sprays of translingual nitroglycerin may be used to relieve angina, but no more than three metered doses are recommended within a 15-minute period.

The nurse instructs the patient to call the nurse if the pain is not relieved after three doses. The primary health care provider is notified if the patient frequently has anginal pain, or if the pain worsens, or if the pain is not relieved after three doses within a 15-minute period because a change in the dosage of the drug or other treatment may be necessary.

**Administering Topical Nitroglycerin.** The dose of topical (ointment) nitroglycerin is measured in inches or millimeters (mm); 1 inch (25 mm) of ointment equals about 15 mg nitroglycerin. Before the drug is measured and applied and after the ambulatory patient has rested for 10 to 15 minutes, the nurse obtains the patient’s blood pressure and pulse rate and compares the results with the baseline and previous vital signs. If the blood pressure is appreciably lower or the pulse rate higher than the resting baseline, the nurse contacts the primary health care provider before the drug is applied. Applicator paper is supplied with the drug; one paper is used for each application. While holding the paper, the nurse expresses the prescribed amount of ointment from the tube onto the paper. The nurse must remove...
the paper from the previous application and cleanse the area as needed. The nurse uses the applicator or dose-measured paper to gently spread in a thin uniform layer over at least a 2½- by 3½-inch area. The ointment is usually applied to the chest or back. Application sites are rotated to prevent inflammation of the skin. Areas that may be used for application include the chest (front and back), abdomen, and upper arms and legs.

**Nursing Alert**

The nurse must not rub the nitroglycerin ointment into the patient’s skin because this will immediately deliver a large amount of the drug through the skin. Exercise care in applying topical nitroglycerin and do not allow the ointment to come in contact with the fingers or hands while measuring or applying the ointment because the drug will be absorbed through the skin of the person applying the drug. The nurse should wear disposable plastic gloves if drug contact is a problem. After application of the ointment, the nurse may secure the paper with nonallergenic tape.

**Administering Transdermal Nitroglycerin.** For most people, nitroglycerin transdermal systems are more convenient and easier to use because the drug is absorbed through the skin. Transdermal systems have the drug impregnated in a pad. The pad is applied to the skin once a day for 10 to 12 hours.

Tolerance to the vascular and anginal effects of the nitrates may develop, particularly in patients taking higher dosages, those prescribed longer-acting products, or those on more frequent dosing schedules. Patients using the transdermal nitroglycerin patches are particularly prone to tolerance because the nitroglycerin is released at a constant rate, and steady plasma concentrations are maintained. Research has shown that applying the patch in the morning and leaving it in place for 10 to 12 hours, followed by leaving the patch off for 10 to 12 hours, yields better results and delays tolerance to the drug.

When applying the transdermal system, the nurse inspects the skin site to be sure it is dry, free of hair, and not subject to excessive rubbing or movement. If needed, the nurse shaves the application site. The nurse applies the transdermal system to the same site each day and rotates the placement sites. Optimal sites include the chest, abdomen, and thighs. The system is not applied to distal extremities. The best time to apply the transdermal system is after morning care (bed bath, shower, tub bath) because it is important that the skin be thoroughly dry before applying the system. When removing the pad, the nurse cleanses the area as needed. To avoid errors in applying and removing the patch, the person applying the patch can use a fiber-tipped pen to write his or her name (or initials), date, and time of application on the top side of the patch. Patches should be removed before cardioversion or defibrillation to prevent patient burns.

**Administering Oral Nitroglycerin.** Nitroglycerin is also available as oral tablets that are swallowed. The nurse gives this form of nitroglycerin to the patient whose stomach is empty, unless the primary health care provider orders otherwise. If nausea occurs after administration, the nurse notifies the primary health care provider. Taking the tablet or capsule with food may be ordered to relieve nausea. The sustained released preparation may not be crushed or chewed.

Because of the risk of tolerance to oral nitrates developing, the primary care provider may prescribe the short-acting preparations 2 to 3 times daily, with the last dose no later than 7 PM and the sustained release preparations once daily or twice daily at 8 AM and 2 PM.

**Administering IV Nitroglycerin.** The nurse administers IV nitroglycerin diluted in normal saline or 5% dextrose by continuous infusion using an infusion pump to ensure an accurate rate. The nurse administers the drug by using the glass IV bottles and administration sets provided by the manufacturer. When the drug is administered IV, it should be protected from light and extremes in temperature. The nurse regulates the dosage according to the patient’s response and the primary health care provider’s instructions.

**Calcium Channel Blockers.** With a few exceptions, the calcium channel blockers may be taken without regard to meals. If gastrointestinal upset occurs, the drug may be taken with meals. Verapamil and bepridil frequently cause gastric upset, and the nurse should routinely give them with meals. Verapamil tablets may be opened and sprinkled on foods or mixed in liquids. Sometimes the tablet coverings of verapamil are expelled in the stool. This causes no change in the effect of the drug and should be of no concern to the patient.

For patients who have difficulty swallowing diltiazem, tablets can be crushed and mixed with food or liquids. However, the patient should swallow the sustained-released tablets whole and not chew or divide them. When nifedipine is ordered sublingually, the capsule is punctured with a sterile needle and the liquid squeezed under the tongue or in the buccal pouch.

**Monitoring and Managing Adverse Drug Reactions**

The nurse must carefully observe patients receiving these drugs for adverse reactions.

During initial therapy, headache and postural hypotension may occur, and the nurse must notify the primary health care provider because a dose change may be necessary. The nurse assists patients having episodes of postural hypotension with all ambulatory activities. The nurse instructs those with episodes of postural hypotension to take the drug in a sitting or supine position and to remain in that position until symptoms disappear. Hypotension may be accompanied by paradoxical
bradycardia and increased angina pectoris. Adverse reactions such as headache, flushing, and postural hypotension that are seen with the administration of the antianginal drugs often become less severe or even disappear after a period of time.

**Educating the Patient and Family**

The patient and family must have a thorough understanding of the treatment of chest pain with an antianginal drug. These drugs are used either to prevent angina from occurring or to relieve the pain of angina. The nurse explains the therapeutic regimen (dose, time of day the drug is taken, how often to take the drug, how to take or apply the drug) to the patient. The nurse adapts a teaching plan to the type of prescribed antianginal drug. The nurse should include the following general areas, as well as those points relevant to specific routes of administration of the drug, in a teaching plan.

- Avoid the use of alcohol unless use has been permitted by the primary health care provider.
- Notify the primary health care provider if the drug does not relieve pain or if pain becomes more intense despite use of this drug.
- Follow the recommendations of the primary health care provider regarding frequency of use.
- Take oral capsules or tablets (except sublingual) on an empty stomach unless the primary health care provider directs otherwise.
- Keep an adequate supply of the drug on hand for events, such as vacations, bad weather conditions, and holidays.
- Keep a record of the frequency of acute anginal attacks (date, time of the attack, drug, and dose used to relieve the acute pain), and bring this record to each primary health care provider or clinic visit.

**NITRATES**

- Headache is a common adverse reaction but should decrease with continued therapy. If headache persists or becomes severe, notify the primary health care provider because a change in dosage may be necessary. In patients who get headaches, the headaches may be a marker of the drug’s effectiveness. Patients should not try to avoid headaches by altering the treatment schedule because loss of headache may be associated with simultaneous loss of drug effectiveness. A aspirin or acetaminophen may be used for headache relief.
- Do not change from one brand of nitrates to another without consulting your pharmacist or primary care provider. Products manufactured by different companies may not be equally effective.

**ORAL NITRATES**

- When taking nitroglycerin for an acute attack of angina, sit or lie down. To relieve severe light-headedness or dizziness, lie down, elevate the extremities, move the extremities, and breathe deeply.
• Keep capsules and tablets in their original containers because nitroglycerin must be kept in a dark container and protected from exposure to light. Never mix this drug with any other drug in a container. Nitroglycerin will lose its potency in containers made of plastic or if mixed with other drugs.
• Always replace the cover or cap of the container as soon as the oral drug or ointment is removed from the container or tube. Replace caps or covers tightly because the drug deteriorates on contact with air.
• If chest pain persists, changes character, increases in severity, or is not relieved by following the recommended dosing regimen, seek prompt medical attention.

SUBLINGUAL OR BUCCAL ADMINISTRATION
• Do not handle the tablets labeled as sublingual any more than necessary.
• Check the expiration date on the container of sublingual tablets. If the expiration date has passed, do not use the tablets. Instead, purchase a new supply. Unused tablets should be discarded 6 months after the original bottle is opened.
• Do not swallow or chew sublingual or transmucosal tablets; allow them to dissolve slowly. The tablet may cause a burning or tingling in the oral cavity. Absence of this effect does not indicate a decrease in potency. Older adults are less likely to report a burning or tingling sensation on administration.

TRANSLINGUAL/TRANSMUCOSAL
• The directions for use of translingual nitroglycerin are supplied with the product. Follow the instructions regarding using and cleaning the canister.
• This drug may be used prophylactically 5 to 10 minutes before engaging in activities that precipitate an attack.
• At the onset of an anginal attack, spray 1 to 2 metered doses onto or under the tongue. Do not exceed three metered doses within 15 minutes.
• When using the transmucosal form, insert the tablet between the lip and gum above the incisors or between the cheek and gum.

TOPICAL OINTMENT OR TRANSDERMAL SYSTEM
• Instructions for application of the topical ointment or transdermal system are available with the product. Read these instructions carefully.
• A ply the topical ointment or transdermal system at approximately the same time each day.
• Be sure the area is clean and thoroughly dry before applying the topical ointment or transdermal system, and rotate the application sites. A ply the transdermal system to the chest (front and back), abdomen, and upper or lower arms and legs. Firmly press the patch to ensure contact with the skin. If the transdermal system comes off or becomes loose, apply a new system. A ply the topical ointment to the front or the back of the chest. If applying to the back, another person should apply the ointment.
• When using the topical ointment form or transdermal system, cleanse old application sites with soap and warm water as soon as the ointment or transdermal system is removed.
• To use the topical ointment, apply a thin layer on the skin using the paper applicator (the patient or family member may need instructions regarding this technique). Avoid finger contact with the ointment.
• Wash the hands before and after applying the ointment.

CALCIUM CHANNEL BLOCKERS
• Do not chew or divide sustainedreleased tablets. Swallow them whole.
• Notify the primary health care provider if any of the following occurs: increased severity of chest pain or discomfort, irregular heartbeat, palpitations, nausea, shortness of breath, swelling of the hands or feet, or severe and prolonged episodes of light-headedness and dizziness.
• If the primary health care provider prescribes one of these drugs plus a nitrate, take both drugs exactly as directed to obtain the best results of the combined drug therapy.
• Make position changes slowly to minimize hypotensive effects.
• These drugs can cause dizziness or drowsiness. Do not drive or engage in hazardous activities until response to the drug is known.

EVALUATION
• The therapeutic effect is achieved and pain is relieved.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully through nursing interventions.
• The patient verbalizes an understanding of the treatment modalities.
• The patient and family demonstrate an understanding of the drug regimen.

PERIPHERAL VASODILATING DRUGS
In contrast to the antianginal drugs, which are used primarily for angina, the peripheral vasodilating drugs are given for disorders that affect blood vessels of the extremities. Unfortunately, although these drugs increase blood flow to nonischemic areas (areas with adequate blood flow), they cause pooling of blood in the extremities, where tissues are supplied with adequate blood flow, but not in the ischemic areas.
flow), there is no conclusive evidence that blood flow is increased in ischemic areas (areas that lack adequate blood flow) that are in critical need of improved perfusion. Because of the lack of evidence of the effectiveness of the peripheral vasodilating drugs, most are labeled as “possibly effective” in the treatment of peripheral vascular disorders. These drugs are not as widely used today as they were in the past. Many of the peripheral dilating drugs are used for hypertension and are discussed in Chapter 40.

A new drug, cilostazol (Pletal), is a phosphodiesterase II inhibitor (drug that inhibits platelet aggregation and dilates vascular beds, particularly in the femoral area). The drug reduces the symptoms of intermittent claudication (increased pain when walking) associated with peripheral vascular disease. This drug increases the walking distance in those with intermittent claudication. This drug is listed under Miscellaneous Drugs in the Summary Drug Table: Peripheral Vasodilators and Miscellaneous Vasodilating Drugs.

Peripheral vasodilating drugs, such as isoxsuprine (Vasodilan), act on the smooth muscle layers of peripheral blood vessels, primarily by blocking alpha (α) -adrenergic nerves and stimulating β-adrenergic nerves. For a review of the effect of stimulation and blocking (or blockade) effects on adrenergic nerve fibers, see Chapters 22 and 23. Cilostazol (Pletal) inhibits platelet aggregation and dilates vascular beds, particularly in the femoral area. The exact mechanism of action is unknown.

**USES**

Peripheral vasodilating drugs are chiefly used in the treatment of peripheral vascular diseases, such as arteriosclerosis obliterans, Raynaud’s phenomenon, and spastic peripheral vascular disorders. Short-term use is rarely beneficial or permanent. Improvement, if it occurs, takes place gradually during weeks of therapy.

The peripheral vasodilating drugs also have other uses, such as the relief of symptoms associated with cerebral vascular insufficiency and circulatory disturbances of the inner ear. More specific uses of individual peripheral vasodilating drugs are given in the Summary Drug Table: Peripheral Vasodilators and Miscellaneous Vasodilating Drugs.

Intermittent claudication is a group of symptoms characterized by pain in the calf muscle of one or both legs, caused by walking and relieved by rest. It is a manifestation of peripheral vascular disease, in which atherosclerotic lesions develop in the femoral artery, diminishing blood supply to the lower leg. Cilostazol is used to treat intermittent claudication.

**ADVERSE REACTIONS**

Adverse reactions associated with these drugs are variable. Some of the more common adverse reactions are listed in the Summary Drug Table: Peripheral Vasodilators and Miscellaneous Vasodilating Drugs. Because these drugs dilate peripheral arteries, some degree of hypotension may be associated with their
administration. Along with hypotension, there is a physiologic increase in the pulse rate (tachycardia). Some of these drugs also cause flushing of the skin, which can range from mild to moderately severe. Nausea, vomiting, flushing, headache, and dizziness may also be seen with the use of these drugs. Adverse results associated with cilostazol include headache, diarrhea, palpitations, dizziness, pharyngitis, hypotension, and cardiac arrhythmias.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The peripheral vasodilating drugs are contraindicated in patients with known hypersensitivity to the drugs, women in the immediate postpartum period (isoxsuprine causes uterine relaxation), and in patients with arterial bleeding. Safe use during pregnancy has not been established (Pregnancy Category C). Cilostazol is contraindicated in patients with CHF and during pregnancy (Pregnancy Category C). These drugs are used cautiously in patients with bleeding tendencies, severe cerebrovascular or cardiovascular disease, and after a myocardial infarction. There are no significant drug–drug interactions.

Ongoing Assessment

Therapeutic results obtained from the administration of a peripheral vasodilating drug may not occur immediately. In some instances, results are minimal. The nurse assesses involved extremities daily for changes in color and temperature and records the patient’s comments regarding relief from pain or discomfort. The nurse should monitor the blood pressure and pulse one to two times per day because these drugs may cause a decrease in blood pressure. The anticipated result of therapy for cerebral vascular disease is an improvement in the patient’s mental status. When the drug is taken for intermittent claudication, the nurse assesses the patient for increased walking distance without pain.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes for the patient may include relief of pain, management of common adverse drug reactions, absence of injury, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

These drugs are often prescribed for outpatient use. Positive results of therapy for a peripheral vascular
disorder may include a decrease in pain, discomfort, and cramping; increased warmth in the extremities; and an increase in amplitude of the peripheral pulses. Patients taking these drugs for relief of symptoms associated with peripheral vascular disorders often become discouraged about the lack of effectiveness of drug therapy. The nurse encourages the patient to continue with the prescribed drug regimen and to follow the primary health care provider’s recommendations regarding additional methods of treating the disorder. The patient is reminded that although signs of improvement may be rapid, improvement usually occurs slowly during the course of many weeks. The nurse examines the patient’s affected areas at the time of each visit to a primary health care provider’s office or outpatient clinic and records the findings in the patient’s record. The nurse administers cilostazol at least 30 minutes before or 2 hours after meals. The drug is not administered with grapefruit juice because the juice may increase blood concentrations of the drug.

Monitoring and Managing Adverse Drug Reactions
If adverse reactions occur, the nurse should notify the primary health care provider. It is important to note the severity of the adverse reactions on the patient’s record. In some instances, adverse reactions are mild and the patient may need to tolerate them.

Some patients may experience dizziness and light-headedness, especially during early therapy. If these effects should occur, the nurse assists the patient with all ambulatory activities and instructs the patient to ask for help when getting out of bed or ambulating.

Educating the Patient and Family
To ensure compliance to the drug regimen, the nurse tells the patient and family that improvement will most likely be gradual, although some improvement may be noted in a few days. The nurse encourages the patient to continue with drug therapy and to follow the primary health care provider’s recommendations regarding care of the affected extremities, even though improvement may be slow. The nurse includes the following in a teaching plan:

- If nausea, vomiting, or diarrhea occurs, contact the primary health care provider. These drugs may also cause flushing, sweating, headache, tiredness, jaundice, skin rash, anorexia, and abdominal distress. Notify the primary health care provider if these effects become pronounced.
- Dizziness may occur. Avoid driving and other potentially dangerous tasks, as well as sudden changes in position. Dangle the legs over the side of the bed for a few minutes when getting up in the morning or after lying down. If dizziness persists, contact the primary health care provider.
- Use caution when walking up or down stairs or when walking on ice, snow, a slick pavement, or slippery floors.
- Stop smoking (if applicable).
- For peripheral vascular disease, follow the primary health care provider’s recommendations regarding exercise, avoiding exposure to cold, keeping the extremities warm, and avoiding injury to the extremities.
- Therapeutic effects when taking the drugs for peripheral vascular disease may not be seen for 2 weeks and may take up to 12 weeks.
- Take cilostazol (Pletal) 30 minutes before or 2 hours after meals. Do not take the drug with grapefruit juice.

EVALUATION
- The therapeutic effect is achieved and pain is relieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
- No evidence of injury is seen.
- The patient and family demonstrate an understanding of the drug regimen.
- The patient verbalizes the importance of complying with the prescribed therapeutic regimen.

Critical Thinking Exercises
1. Ms. Moore is admitted with severe chest pain and a possible myocardial infarction. After tests are done, her primary health care provider prescribes transdermal nitroglycerin for her angina. Develop a teaching plan that will show Ms. Moore how and when to apply the transdermal form of nitroglycerin.

2. Mr. Billings is prescribed sublingual nitroglycerin for his angina. Develop a teaching plan that incorporates when and how to take the drug and what precautions he should take regarding handling and storage of the drug.

3. Mr. Crawford has peripheral vascular disease and is prescribed isoxsuprine hydrochloride (Vasodilan). Discuss the important aspects of the preadministration and ongoing assessment for Mr. Crawford.

Review Questions
1. When administering the nitrates for angina pectoris, the nurse monitors the patient for the most common adverse reaction, which is ______.
   A. hyperglycemia
   B. headache
   C. fever
   D. anorexia

2. When teaching a patient about prescribed sublingual nitroglycerin, the nurse informs the patient that if
pain is not relieved, the dose can be repeated in _____ minute(s).

A. 1  
B. 5  
C. 15  
D. 30

3. When administering nitroglycerin ointment, the nurse _____.
   A. rubs the ointment into the skin  
   B. applies the ointment every hour or until the angina is relieved  
   C. applies the ointment to a clean, dry area  
   D. rubs the ointment between her palms and then spreads it evenly onto the patient’s chest

4. A patient taking a calcium channel blocker experiences orthostatic hypotension. The nurse instructs the patient with orthostatic hypotension to _____.
   A. remain in a supine position until the effects subside  
   B. make position changes slowly to minimize hypotensive effects  
   C. increase the dosage of the calcium channel blocker  
   D. discontinue use of the calcium channel blocker until the hypotensive effects diminish

5. When administering cilostazol (Pletal), the nurse instructs the patient _____.
   A. that drugs used to treat peripheral vascular disease may take 2 to 4 weeks before improvement is seen  
   B. to take the drug with food to enhance absorption  
   C. to increase the dose if no response is seen within the first week  
   D. the drug must be given for short periods only (up to 4 to 8 weeks)

6. The peripheral vasodilating drugs are contraindicated in patients _____.
   A. with arthritis  
   B. with hypertension  
   C. with elevated blood cholesterol levels  
   D. during the immediate postpartum period

---

**Medication Dosage Problems**

1. The primary care provider prescribed verapamil HCl (Calan) 120 mg TID PO. The drug is available in 40-mg tablets. The nurse administers _____.

2. The patient is prescribed isosorbide (Isordil) 40 mg PO BID. The drug form available is 20-mg tablets. The nurse administers _____.
Antihypertensive Drugs

**Key Terms**
- aldosterone
- angiotensin-converting enzyme
- blood pressure
- endogenous
- essential hypertension
- hypokalemia
- hyponatremia
- isolated systolic hypertension
- lumen
- malignant hypertension
- orthostatic hypotension
- postural hypotension
- secondary hypertension
- vasodilatation

**Chapter Objectives**
On completion of this chapter, the student will:
- Discuss the various types of hypertension and risk factors involved.
- Identify normal and abnormal blood pressure levels for adults.
- List the various types of drugs used to treat hypertension.
- Discuss the general drug actions, uses, adverse reactions, contraindications, precautions, and interactions of the antihypertensive drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking an antihypertensive drug.
- Explain why blood pressure determinations are important during therapy with an antihypertensive drug.
- List some nursing diagnoses particular to a patient taking an antihypertensive drug.
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating patients about the use of an antihypertensive drug.

**Blood pressure** is the force of the blood against the walls of the arteries. Blood pressure rises and falls throughout the day. When the blood pressure stays elevated over time, hypertension develops. A systolic pressure less than 120 mm Hg and a diastolic blood pressure of less than 80 mm Hg (120/80) are considered optimal. **Hypertension** is usually defined as a systolic pressure above 140 mm Hg and a diastolic pressure above 90 mm Hg. Table 42-1 identifies blood pressure levels for adults and implications of diagnosis. Patients in the high-normal range require frequent blood pressure monitoring; patients in stage 1, 2, or 3 should be under the care of a physician. Hypertension is serious because it causes the heart to work too hard and contributes to atherosclerosis. It increases the risk of heart disease, congestive heart failure, kidney disease, blindness, and stroke.

Most cases of hypertension have no known cause. When there is no known cause of hypertension, the term **essential hypertension** is used. Essential hypertension has been linked to certain risk factors, such as diet and lifestyle. Display 42-1 identifies the risk factors associated with hypertension.

In the United States, African-Americans are twice as likely as Caucasians to experience hypertension. After age 65 years, African-American women have the highest incidence of hypertension. Essential hypertension cannot be cured but can be controlled. Many individuals experience hypertension as they grow older, but hypertension is not a part of healthy aging. For many older individuals, the systolic pressure gives the most accurate diagnosis of hypertension. Display 42-2 discusses the importance of the systolic pressure.

Once essential hypertension develops, management of this disorder becomes a lifetime task. When a direct cause of the hypertension can be identified, the condition is described as **secondary hypertension**. Among the known causes of secondary hypertension, kidney disease ranks first, with tumors or other abnormalities of the adrenal glands following. In **malignant hypertension** the diastolic pressure usually exceeds 130 mm Hg. In secondary hypertension,
taking care of the medical condition causing the hypertension results in the patient regaining a normal blood pressure.

Malignant hypertension is a dangerous condition that develops rapidly and requires immediate medical attention. Patients with malignant hypertension experience organ damage as the result of hypertension. Target organs of hypertension include the heart, kidney, and eyes (retinopathy).

Most primary care providers will prescribe lifestyle changes to reduce risk factors before prescribing drugs. The primary care provider may recommend measures, such as weight loss (if the patient is overweight), reduction of stress, regular aerobic exercise, quitting smoking (if applicable), and dietary changes, such as a decrease in sodium (salt) intake. Most people with hypertension are “salt sensitive,” that is, any salt or sodium more than the minimal bodily need is too much for them and leads to an increase in blood pressure. Dietitians usually recommend the Dietary Approaches to Stop Hypertension (DASH) diet. Studies indicate that blood pressure was reduced by eating a diet low in saturated fat, total fat, and cholesterol and rich in fruits, vegetables, and low-fat dairy foods. The DASH diet includes whole grains, poultry, fish, and nuts and has reduced amounts of fats, red meats, sweets and sugared beverages. The diet is rich in potassium, calcium, magnesium, protein, and fiber. Stress-reducing techniques, such as relaxation techniques, meditation, and yoga, may also be a part of the treatment regimen.

When drug therapy is begun, the primary care provider may first prescribe a diuretic (Chap. 46) or beta (β) blocker (Chap. 23) because these drugs have been shown to be highly effective. However, as in many other diseases and conditions, there is no “best” single drug, drug combination, or medical regimen for treatment of hypertension. After examination and evaluation of the patient, the primary care provider selects the antihypertensive drug and therapeutic regimen that will probably be most effective. Figure 42-1 shows an algorithm for the treatment of hypertension. In some instances, it may be necessary to change to another antihypertensive drug or add a second antihypertensive drug when the patient does not experience a response to therapy. The primary care provider also recommends that the patient continue with stress reduction, dietary modification, and other lifestyle modifications important in the control of hypertension.

The types of drugs used for the treatment of hypertension include:

- Vasodilating drugs—for example, hydralazine (Apresoline) and minoxidil (Loniten)
- β-adrenergic blocking drugs—for example, atenolol (Tenormin), metoprolol (Lopressor), and propranolol (Inderal)
- Antiadrenergic drugs (centrally acting)—for example, guanabenz (Wytensin) and guanfacine (Tenex)
- Antiadrenergic drugs (peripherally acting)—for example, guanadrel (Hylorel) and guanethidine (Ismelin)
- Alpha (α)-adrenergic blocking drugs—for example, doxazosin (Cardura) and prazosin (Minipress)
- Calcium channel blocking drugs—for example, amlodipine (Norvasc) and diltiazem (Cardizem)

### TABLE 42-1 Blood Pressure Levels for Adults

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>SYSTOLIC* (in mm Hg)</th>
<th>DIASTOLIC* (in mm Hg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimal</td>
<td>less than 120</td>
<td>less than 80</td>
</tr>
<tr>
<td>Normal</td>
<td>less than 130</td>
<td>less than 85</td>
</tr>
<tr>
<td>High-normal</td>
<td>130–139</td>
<td>85–89</td>
</tr>
</tbody>
</table>

**HYPERTENSION**

| Stage 1          | 140–159 or 90–99    |
| Stage 2          | 160–179 or 100–109  |
| Stage 3          | 180 or higher or 110 or higher |

*if systolic and diastolic pressures fall into different categories, the patient’s status is the higher category.


### DISPLAY 42-1 Risk Factors in Hypertensive Patients

- Smoking
- Age (women older than 65 years and men older than 55 years of age)
- Obesity
- Diabetes
- Lack of physical activity
- Chronic alcohol consumption
- Family history of cardiovascular disease
- Sex (men and postmenopausal women)

### DISPLAY 42-2 Importance of the Systolic Blood Pressure

In most individuals, the systolic pressure increases sharply with age, whereas the diastolic pressure increases until about age 55 years and then declines. Older individuals with an elevated systolic pressure have a condition known as isolated systolic hypertension (ISH). When the systolic pressure is high, blood vessels become less flexible and stiffen, leading to cardiovascular disease and kidney damage. Research indicates that treating ISH saves lives and reduces illness. The treatment is the same for ISH as for other forms of hypertension.
**Figure 42-1. Algorithm for the treatment of hypertension.**

**Begin or Continue Lifestyle Modifications**

**Not at Goal Blood Pressure (< 140/90 mm Hg)**
Lower goals for patients with diabetes or renal disease

**Initial Drug Choices**

*Uncomplicated Hypertension* -
- Diuretics
- Beta blockers

*Specific Indications for the Following Drugs*
- ACE inhibitors
- Angiotensin II receptor blockers
- Alpha blockers
- Alpha/beta blockers
- Beta blockers
- Calcium antagonists
- Diuretics

*Compelling Indications* -
- Diabetes mellitus (type 1) with proteinuria
  - ACE inhibitors
- Heart failure
  - ACE inhibitors
  - Diuretics
- Isolated systolic hypertension (older persons)
  - Diuretics preferred
  - Long-acting dihydropyridine calcium antagonists
- Myocardial infarction
  - Beta blockers (nonISA)
  - ACE inhibitors (with systolic dysfunction)

- Start with a low dose of a long-acting once-daily drug, and titrate dose.
- Low-dose combinations may be appropriate.

**Not at Goal Blood Pressure**

- No response or troublesome side effects
- Inadequate response but well tolerated

* Substitute another drug from a different class.*

* Add a second agent from a different class (diuretic if not already used).*

*Not at Goal Blood Pressure*

- Continue adding agents from other classes.
- Consider referral to a hypertension specialist.

1. Goal blood pressure for patients with diabetes is < 130/85 mm Hg. Goal blood pressure for patients with renal disease is ≤ 130/85 mm Hg or ≤ 125/75 mm Hg in patients with proteinuria > 1 gram/24 hours.

2. Unless contraindicated. ACE, angiotensin-converting enzyme; ISA, intrinsic sympathomimetic activity.

3. Based on randomized controlled trials.
Angiotensin-converting enzyme (ACE) inhibitors—for example, captopril (Capoten), enalapril (Vasotec), and lisinopril (Prinivil)

Angiotensin II receptor antagonists—for example, irbesartan (Avapro), losartan (Cozaar), and valsartan (Diovan)

Diuretics—for example, furosemide (Lasix) and hydrochlorothiazide (HydroDIURIL)

For additional information concerning the antihypertensive drugs (both centrally and peripherally acting), and the α- and β-adrenergic blocking drugs, see Chapter 23. For more information on the calcium channel blockers see Chapter 41. Information on the vasodilating drugs and the diuretics can be found in Chapters 41 and 46, respectively. The angiotensin-converting enzyme (ACE) inhibitors and the angiotensin II receptor antagonists are discussed in this chapter.

In addition to these antihypertensive drugs, many antihypertensive combinations are available, such as Ser-Ap-Es, Timolide 10-25, Aldoril, and Lopressor (Table 42-2). Most combination antihypertensive drugs are a combination of an antihypertensive and a diuretic.

**ACTIONS**

Many antihypertensive drugs lower the blood pressure by dilating or increasing the size of the arterial blood vessels (vasodilatation). Vasodilatation creates an increase in the lumen (the space or opening within an artery) of the arterial blood vessels, which in turn increases the amount of space available for the blood to circulate. Because blood volume (the amount of blood) remains relatively constant, an increase in the space in which the blood circulates (ie, the blood vessels) lowers the pressure of the fluid (measured as blood pressure) in the blood vessels. Although the method by which antihypertensive drugs dilate blood vessels varies, the result remains basically the same. Antihypertensive drugs that have vasodilating activity include:

- Adrenergic blocking drugs
- Antiadrenergic blocking drugs
- Calcium channel blocking drugs
- Vasodilating drugs

Another type of antihypertensive drug is the diuretic. The mechanism by which the diuretics reduce elevated blood pressure is unknown, but it is thought to be based, in part, on their ability to increase the excretion of sodium from the body. The actions and uses of diuretics are discussed in Chapter 46.

The mechanism of action of the ACE inhibitors is not fully understood. It is believed that these drugs may prevent (or inhibit) the activity of angiotensin-converting enzyme, which converts angiotensin I to angiotensin II, a powerful vasoconstritor. Both angiotensin I and ACE normally are manufactured by the body and are called endogenous substances. The vasoconstricting activity of angiotensin II stimulates the secretion of the endogenous hormone aldosterone by the adrenal cortex. Aldosterone promotes the retention of sodium and water, which may contribute to a rise in blood pressure. By preventing the conversion of angiotensin I to angiotensin II, this chain of events is interrupted, sodium and water are not retained, and the blood pressure decreases. The angiotensin II receptor antagonists act to block the vasoconstrictor and aldosterone effects of angiotensin II at various receptor sites, resulting in a lowering of the blood pressure (Fig. 42-2).

**USES**

Antihypertensives are used in the treatment of hypertension. Although many antihypertensive drugs are available, not all drugs may work equally well in a given patient. In some instances, the primary care provider

---

**TABLE 42-2** Examples of Selected Antihypertensive Combinations

<table>
<thead>
<tr>
<th>TRADE NAME</th>
<th>DIURETIC CONSTITUENT</th>
<th>ANTIHYPERTENSIVE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aldoril-15</td>
<td>hydrochlorothiazide (15 mg)</td>
<td>methyldopa (250 mg)</td>
</tr>
<tr>
<td>Apresazide</td>
<td>hydrochlorothiazide (50 mg)</td>
<td>hydralazine (50 mg)</td>
</tr>
<tr>
<td>Combipres</td>
<td>chlorothalidone (15 mg)</td>
<td>clonidine (0.1 mg)</td>
</tr>
<tr>
<td>Hydropres-50</td>
<td>hydrochlorothiazide (50 mg)</td>
<td>reserpine (0.125 mg)</td>
</tr>
<tr>
<td>Lopressor 100/50</td>
<td>hydrochlorothiazide (50 mg)</td>
<td>metoprolol (100 mg)</td>
</tr>
<tr>
<td>Minizide 5</td>
<td>polythiazide (0.5 mg)</td>
<td>prazosin (5 mg)</td>
</tr>
<tr>
<td>Ser-Ap-Es</td>
<td>hydrochlorothiazide (15 mg)</td>
<td>reserpine (0.1 mg)</td>
</tr>
<tr>
<td>Tenoretic 100</td>
<td>chlorothalidone (25 mg)</td>
<td>atenolol (100 mg)</td>
</tr>
<tr>
<td>Timolide 10–25</td>
<td>hydrochlorothiazide (25 mg)</td>
<td>timolol maleate (10 mg)</td>
</tr>
<tr>
<td>Zestoretic</td>
<td>hydrochlorothiazide (12.5 mg)</td>
<td>lisinopril (20 mg)</td>
</tr>
</tbody>
</table>
may find it necessary to prescribe a different antihypertensive drug when the patient experiences no response to therapy. Some antihypertensive drugs are used only in severe cases of hypertension and when other less potent drugs have failed to lower the blood pressure. At times, two antihypertensive drugs may be given together to achieve a better response (see Fig. 42-1). Diazoxide (Hyperstat IV) and nitroprusside (Nitropress) are examples of intravenous (IV) drugs that may be used to treat hypertensive emergencies. A hypertensive emergency is a case of extremely high blood pressure that does not respond to conventional antihypertensive drug therapy.

ADVERSE REACTIONS

When any antihypertensive drug is given, postural or orthostatic hypotension may be seen in some patients, especially early in therapy. Postural hypotension is the occurrence of dizziness and light-headedness when the individual rises suddenly from a lying or sitting position. Orthostatic hypotension occurs when the individual has been standing in one place for a long time. These reactions can be avoided or minimized by having the patient rise slowly from a lying or sitting position and by avoiding standing in one place for a prolonged period.

Additional adverse reactions that may be seen when an antihypertensive drug is administered are listed in the Summary Drug Table: Antihypertensive Drugs. For the adverse reactions that may be seen when a diuretic is used as an antihypertensive drug, see the Summary Drug Table: Diuretics in Chapter 46.

CONTRAINDICATIONS

Antihypertensive drugs are contraindicated in patients with known hypersensitivity to the individual drugs. When an antihypertensive is administered by a transdermal system (eg, clonidine), the system is contraindicated if the patient is allergic to any component of the adhesive layer of the transdermal system. Use of the angiotensin II receptor antagonists during the second and third trimester of pregnancy is contraindicated.
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Peripheral Vasodilators</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hydralazine HCl</td>
<td>Apresoline, generic</td>
<td>Hypertension</td>
<td>Dizziness, drowsiness, headache, hypotension, diarrhea, nausea, rash, sodium retention, drug-induced lupus syndrome</td>
<td>10–50 mg QID PO up to 300 mg/d</td>
</tr>
<tr>
<td>minoxidil</td>
<td>Loniten, generic</td>
<td>Severe hypertension</td>
<td>Headache, hypotension, ECG changes, tachycardia, rash, sodium and water retention, hair growth</td>
<td>5–100 mg/d PO; dosage greater than 5 mg given in divided doses</td>
</tr>
<tr>
<td><strong>β-Adrenergic Blocking Drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>acebutolol HCl</td>
<td>Sectral, generic</td>
<td>Hypertension, ventricular arrhythmias</td>
<td>Fatigue, hypotension, weakness, impotence, blurred vision, hypotension, congestive heart failure (CHF), bradycardia, pulmonary edema</td>
<td>400–1200 mg/d in single or divided doses PO</td>
</tr>
<tr>
<td>atenolol</td>
<td>Tenormin, generic</td>
<td>Angina pectoris, hypertension, myocardial infarction (MI)</td>
<td>Fatigue, hypotension, weakness, blurred vision, stuffy nose, impotence, decreased libido, rash, CHF, bradycardia, pulmonary edema</td>
<td>50–100 mg/d PO in single dose; 5 mg IV; may repeat every 10 min up to 2 times</td>
</tr>
<tr>
<td>betaxolol HCl</td>
<td>Kerfune</td>
<td>Hypertension, glaucoma (ophthalmic)</td>
<td>Fatigue, hypotension, weakness, blurred vision, stuffy nose, rash, CHF, bradycardia, pulmonary edema</td>
<td>10–20 mg once daily PO</td>
</tr>
<tr>
<td>bisoprolol fumarate</td>
<td>Zebeta</td>
<td>Hypertension</td>
<td>Fatigue, hypotension, weakness, blurred vision, stuffy nose, rash, CHF, bradycardia, pulmonary edema</td>
<td>2.5–20 mg once daily PO</td>
</tr>
<tr>
<td>carvedilol HCl</td>
<td>Cartrol</td>
<td>Hypertension, glaucoma (ophthalmic)</td>
<td>Fatigue, orthostatic hypotension, weakness, blurred vision, stuffy nose, impotence, rash, CHF, bradycardia, pulmonary edema</td>
<td>2.5–10 mg/d once daily PO</td>
</tr>
<tr>
<td>labetalol HCl</td>
<td>Normodyne, Trandate, generic</td>
<td>Hypertension</td>
<td>Fatigue, weakness, orthostatic hypotension, diarrhea, hyperglycemia, weakness, impotence, CHF, bradycardia, pulmonary edema</td>
<td>200–400 mg BID up to 2400 mg/d; 20–80 mg IV; may give q 10 min up to 300 mg</td>
</tr>
<tr>
<td>metoprolol</td>
<td>Lopressor, Toprol XL, generic</td>
<td>Hypertension, angina pectoris, MI, heart failure (HF)</td>
<td>Fatigue, weakness, orthostatic hypotension, impotence, drowsiness, bradycardia, pulmonary edema, CHF</td>
<td>Hypertension angina, 100–400 mg/d PO; extended-release products are given once daily; MI: 25–100 mg BID PO; 5 mg q 2 min IV for 3 doses</td>
</tr>
<tr>
<td>nadolol</td>
<td>Corgard, generic</td>
<td>Angina pectoris, hypertension</td>
<td>Fatigue, weakness, orthostatic hypotension, impotence, drowsiness, bradycardia, pulmonary edema, CHF</td>
<td>Angina: 40–80 mg/d PO; up to 240 mg/d; hypertension: 40–80 mg’d once daily PO; may increase to 320 mg/d</td>
</tr>
</tbody>
</table>
### SUMMARY DRUG TABLE

#### ANTIHYPERTENSIVE DRUGS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>penbutolol sulfate</td>
<td>Levatol</td>
<td>Hypertension</td>
<td>Fatigue, weakness, orthostatic hypotension, impotence, drowsiness, bradycardia, pulmonary edema, CHF</td>
<td>20 mg once daily PO</td>
</tr>
<tr>
<td>pindolol</td>
<td>Visken, generic</td>
<td>Hypertension</td>
<td>Fatigue, weakness, orthostatic hypotension, impotence, drowsiness, bradycardia, pulmonary edema, CHF</td>
<td>5–60 mg/d, given twice daily PO</td>
</tr>
<tr>
<td>propranolol HCl</td>
<td>Inderal, Inderal LA, generic</td>
<td>MI, cardiac arrhythmias, angina pectoris, hypertension, migraine</td>
<td>Fatigue, weakness, orthostatic hypotension, impotence, drowsiness, bradycardia, pulmonary edema, CHF</td>
<td>MI: 180—240 mg/d PO; arrhythmias: 10–30 mg/d PO TID, QID; 1–3 mg IV, may repeat in 2 min and again in 4 h if needed; angina: 80–320 mg/d in 2–4 divided doses or once daily as extended release; hypertension: 80–240 mg/d PO in divided doses; doses up to 640 mg have been given; migraine: 20 mg QID PO or 80 mg as extended release</td>
</tr>
<tr>
<td>timolol maleate</td>
<td>Blocadren, generic</td>
<td>Hypertension, MI, migraine prophylaxis, glaucoma (ophthalmic)</td>
<td>Fatigue, weakness, orthostatic hypotension, impotence, drowsiness, bradycardia, pulmonary edema, CHF</td>
<td>Hypertension: 20 mg/d PO up to 60 mg/d; MI: 10 mg PO BID; migraine: 10–30 mg/d PO in one or divided dose</td>
</tr>
</tbody>
</table>

#### Antiadrenergics—Centrally Acting

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>clonidine HCl (oral)</td>
<td>Catapres, generic</td>
<td>Hypertension</td>
<td>Drowsiness, sedation dizziness, headache, fatigue that tends to diminish within 4–6 weeks, dry mouth, constipation, impotence, decreased sexual activity</td>
<td>Individualize dosage, 0.1–0.8 mg/d PO in divided doses; maximum dosage, 2.4 mg/d</td>
</tr>
<tr>
<td>clonidine HCl (transdermal)</td>
<td>Catapres-TTS1, Catapres-TTS2, Catapres-TTS3, generic</td>
<td>Hypertension</td>
<td>Drowsiness, dry mouth, transient localized skin reactions, fatigue, headache, constipation, nausea</td>
<td>0.1 mg system–0.3 mg system q7d, may increase up to 2 0.3-mg systems per 24 hours</td>
</tr>
<tr>
<td>guanabenz acetate</td>
<td>Wytensin, generic</td>
<td>Hypertension</td>
<td>Dizziness, weakness, lassitude, syncope, postural or exertional hypotension, diarrhea, bradycardia, fluid retention and edema, inhibition of ejaculation, CHF</td>
<td>Individualize dosage, 4–8 mg BID PO; may increase up to 64 mg/d</td>
</tr>
<tr>
<td>guanfacine HCl</td>
<td>Tenex</td>
<td>Hypertension</td>
<td>Sedation, weakness, dizziness, dry mouth, constipation, impotence</td>
<td>1–3 mg PO HS</td>
</tr>
<tr>
<td>methyl dopa and methyldopate HCl</td>
<td>Aldomet</td>
<td>Hypertension</td>
<td>Sedation, headache, asthenia, weakness, nausea, vomiting, distention, constipation, bradycardia</td>
<td>Metyldopa: 250 mg—3 g/d PO in divided doses; methyldopate: 250 mg-1g q6h IV</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antiadrenergics—Peripherally Acting</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>guanadrel</td>
<td>Hylorel</td>
<td>Hypertension</td>
<td>Fatigue, headache, faintness, drowsiness, visual disturbances, confusion, increased bowel movements, indigestion, constipation, anorexia, shortness of breath on exertion, palpitations, chest pain, coughing, nocturia, urinary urgency or frequency, peripheral edema, ejaculation disturbances, weight loss or gain</td>
<td>10—75 mg/d PO</td>
</tr>
<tr>
<td>guanethidine</td>
<td>Ismelin</td>
<td>Hypertension</td>
<td>Dizziness, weakness, lassitude, syncope, postural or exertional hypotension, diarrhea, bradycardia, fluid retention and edema, CHF, inhibition of ejaculation</td>
<td>10—50 mg/d PO</td>
</tr>
<tr>
<td>reserpine</td>
<td>Generic</td>
<td>Hypertension</td>
<td>Drowsiness, sedation, lethargy, respiratory depression, edema, orthostatic hypotension, nasal congestion</td>
<td>0.5—1 mg/d PO</td>
</tr>
<tr>
<td><strong>α-Adrenergic Blocking Drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>doxazosin mesylate</td>
<td>Cardura</td>
<td>Hypertension, benign prostatic hypertrophy (BPH)</td>
<td>Headache, fatigue, dizziness, postural hypotension, dizziness, lethargy, vertigo, nausea, dyspepsia, diarrhea, tachycardia, palpitations, edema, sexual dysfunction</td>
<td>Hypertension: 1—16 mg/d PO once a day; BPH: 1—8 mg/d PO</td>
</tr>
<tr>
<td>mecamylamine</td>
<td>Inversine</td>
<td>Severe hypertension</td>
<td>Weakness, fatigue, sedation, anorexia, dry mouth, glossitis, nausea, orthostatic hypotension</td>
<td>5—25 mg/d PO in 2 or 3 doses</td>
</tr>
<tr>
<td>prazosin</td>
<td>Minipress, generic</td>
<td>Hypertension</td>
<td>Dizziness, headache, drowsiness, lethargy, weakness, nausea, palpitations</td>
<td>1—20 mg/d PO in divided doses</td>
</tr>
<tr>
<td>terazosin</td>
<td>Hytrin</td>
<td>Hypertension, BPH</td>
<td>Dizziness, headache, drowsiness, lack of energy, weakness, somnolence, nausea, palpitations, edema, dyspnea, nasal congestion, sinusitis</td>
<td>1—20 mg/d PO at HS</td>
</tr>
<tr>
<td><strong>Angiotensin-Converting Enzyme Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>benazepril HCl</td>
<td>Lotensin</td>
<td>Hypertension</td>
<td>Nausea, cough, vomiting, constipation, hypertension, palpitations, rash</td>
<td>10—40 mg/d PO in single or two divided doses</td>
</tr>
<tr>
<td>captopril</td>
<td>Capoten, generic</td>
<td>Hypertension, HF, left ventricular dysfunction (LVD) after MI, diabetic nephropathy</td>
<td>Tachycardia, gastric irritation, peptic ulcer, proteinuria, rash, pruritus, cough</td>
<td>Hypertension: 50—450 mg/d PO in divided doses; CHF: 25—450 mg/d in divided doses; LVD: 6.25—150 mg/d PO TID; diabetic nephropathy: 25 mg PO TID</td>
</tr>
<tr>
<td>GENERIC NAME</td>
<td>TRADE NAME*</td>
<td>USES</td>
<td>ADVERSE REACTIONS</td>
<td>DOSAGE RANGES</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>------</td>
<td>------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>enalapril</td>
<td>Vasotec, Vasotec IV</td>
<td>Hypertension, HF, asymptomatic LVD</td>
<td>Headache, dizziness, fatigue, nausea, diarrhea, decreased hematocrit and hemoglobin, cough</td>
<td>Hypertension: 5–40 mg/d PO as a single dose or in two divided doses; 0.625–1.25 mg q6h IV; HF: 2.5–40 mg/d in two divided doses PO; LVD: 5–10 mg PO BID</td>
</tr>
<tr>
<td>fosinopril sodium</td>
<td>Monopril</td>
<td>Hypertension, HF</td>
<td>Nausea, cough, abdominal pain, vomiting, orthostatic hypotension, palpitation, rash</td>
<td>Hypertension: 10–40 mg/d PO as a single dose or two divided doses; CHF: 5–20 mg/d PO; acute MI: 5–10 mg PO</td>
</tr>
<tr>
<td>lisinopril</td>
<td>Prinivil, Zestril, generic</td>
<td>Hypertension, HF, acute MI</td>
<td>Headache, dizziness, insomnia, fatigue, gastric irritation, nausea, diabetes, orthostatic hypotension, proteinuria, angioedema, cough</td>
<td></td>
</tr>
<tr>
<td>moexipril HCl</td>
<td>Univasc</td>
<td>Hypertension</td>
<td>Tachycardia, gastric irritation, peptic ulcers, diarrhea, diabetes, proteinuria, rash, pruritus, flushing, flu-like syndrome, dizziness, cough</td>
<td></td>
</tr>
<tr>
<td>perindopril erbumine</td>
<td>Aceon</td>
<td>Essential hypertension</td>
<td>Orthostatic hypotension, headache, dizziness, insomnia, fatigue, proteinuria, gastric irritation, nausea, cough</td>
<td></td>
</tr>
<tr>
<td>quinapril HCl</td>
<td>Accupril</td>
<td>Hypertension, HF</td>
<td>Nausea, cough, abdominal pain, vomiting, orthostatic hypotension, palpitation, rash</td>
<td></td>
</tr>
<tr>
<td>ramipril</td>
<td>Altace</td>
<td>Hypertension, HF, decrease risk of cardiovascular disease, coronary artery disease (CAD)</td>
<td>Nausea, cough, abdominal pain, vomiting, orthostatic hypotension, palpitation, rash</td>
<td></td>
</tr>
</tbody>
</table>

**Angiotensin II Receptor Antagonists**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>candesartan cilexitil</td>
<td>Atacand</td>
<td>Hypertension</td>
<td>Diarrhea, abdominal pain, nausea, headache, dizziness, upper respiratory infection (URI) symptoms, hypotension, rash</td>
<td>16–32 mg/d PO in divided doses</td>
</tr>
<tr>
<td>eprosartan mesylate</td>
<td>Teveten</td>
<td>Hypertension</td>
<td>Abdominal pain, fatigue, depression, URI symptoms, hypotension</td>
<td>400–800 mg/d PO in divided doses BID</td>
</tr>
<tr>
<td>irbesartan er-bah-sar-ten</td>
<td>Avapro</td>
<td>Hypertension</td>
<td>Headache, dizziness, diarrhea, abdominal pain, nausea, hypotension, URI symptoms, cough, fatigue</td>
<td>75–300 mg PO as one dose</td>
</tr>
<tr>
<td>losartan potassium</td>
<td>Cozaar</td>
<td>Hypertension</td>
<td>Diarrhea, abdominal pain, nausea, headache, dizziness, hypotension, URI symptoms, cough</td>
<td>25–100 mg/d PO in one or two doses</td>
</tr>
<tr>
<td>telmisartan tel-mah-sar-ten</td>
<td>Micardis</td>
<td>Hypertension</td>
<td>Diarrhea, abdominal pain, nausea, headache, dizziness, light-headedness, URI symptoms, hypotension</td>
<td>40–80 mg/d PO</td>
</tr>
<tr>
<td>valsartan val-sar-ten</td>
<td>Diovan</td>
<td>Hypertension</td>
<td>Headache, dizziness, diarrhea, abdominal pain, nausea, URI symptoms, cough</td>
<td>80–320 mg/d PO</td>
</tr>
</tbody>
</table>

(continued)
because use may cause fetal and neonatal injury or death. These drugs are Pregnancy Category C during the first trimester of pregnancy and Pregnancy Category D during the second and third trimesters.

PRECAUTIONS

Antihypertensive drugs are used cautiously in patients with renal or hepatic impairment or electrolyte imbalances, during lactation and pregnancy, and in older patients. ACE inhibitors are used cautiously in patients with sodium depletion, hypovolemia, or coronary or cerebrovascular insufficiency and those receiving diuretic therapy or dialysis. The angiotensin II receptor agonists are used cautiously in patients with renal or hepatic dysfunction, hypovolemia, or volume or salt depletion, and patients receiving high doses of diuretics.

INTERACTIONS

The hypotensive effects of most antihypertensive drugs are increased when administered with diuretics and other antihypertensives. Many drugs can interact with the antihypertensive drugs and decrease their effectiveness (eg, antidepressants, monoamine oxidase inhibitors, antihistamines, and sympathomimetic bronchodilators). When the ACE inhibitors are administered with the NSAIDs, their antihypertensive effect may be decreased. Absorption of the ACE inhibitors may be decreased when administered with the antacids. Administration of potassium-sparing diuretics or potassium supplements concurrently with the ACE inhibitors may cause hyperkalemia. When the angiotensin II receptor agonists are administered with NSAIDs or phenobarbital, their antihypertensive effects may be decreased.

Herbal Therapy Alert

Various herbs and supplements, such as hawthorn extracts, garlic, onion, ginkgo biloba, vitamin E, and aspirin, may be used by herbalists for hypertension. Although these substances may lower blood pressure in some individuals, their use is not recommended because the effect is slight and usually too gentle to affect moderate to severe hypertension. However, several studies have demonstrated that hypertensive patients may benefit from daily doses of calcium (800 mg) or magnesium (300 mg). Patients should consult the primary health care provider before taking any herbal remedy.

NURSING PROCESS

The Patient Receiving an Antihypertensive Drug

ASSESSMENT

Preadministration Assessment
Before therapy with an antihypertensive drug is started, the nurse obtains the blood pressure (see Fig. 42-3) and pulse rate on both arms with the patient in standing, sitting, and lying positions. The nurse correctly identifies all readings (eg, the readings on each arm and the three positions used to obtain the readings) and records these on the patient’s chart. The nurse also obtains the patient’s weight, especially if a diuretic is part of therapy or if the primary care provider prescribes a weight-loss regimen.

Ongoing Assessment
Monitoring and recording the blood pressure is an important part of the ongoing assessment, especially
early in therapy. The primary care provider may need to adjust the dose of the drug upward or downward, try a different drug, or add another drug to the therapeutic regimen if the patient does not have an adequate response to drug therapy.

Each time the blood pressure is obtained, the nurse uses the same arm and the patient is placed in the same position (e.g., standing, sitting, or lying down). In some instances, the primary care provider may order the blood pressure taken in one or more positions, such as standing and lying down. The nurse monitors the blood pressure and pulse every 1 to 4 hours if the patient has severe hypertension, does not have the expected response to drug therapy, or is critically ill.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes for the patient may include an optimal response to therapy (blood pressure maintained in an acceptable range), management of common adverse drug reactions, and an understanding of and compliance with the prescribed therapeutic regimen.

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**

**ADMINISTERING ANTIADRENERGIC DRUGS.** Clonidine is available as an oral tablet (Catapres) and transdermal patch (Catapres-TTS). The nurse applies the transdermal patch to a hairless area of intact skin on the upper arm or torso; the patch is kept in place for 7 days. The adhesive overlay is applied directly over the system to ensure the patch remains in place for the required time. A different body area is selected for each application. If the patch loosens before the 7 days, the edges can be reinforced with nonallergenic tape. The date the patch was placed and the date the patch is to be removed can be written on the surface of the patch with a fiber-tipped pen. (See Chapter 23 for additional information concerning the antiadrenergic drugs.)

**ADMINISTERING VASODILATING DRUGS.** The nurse must carefully monitor the patient receiving minoxidil because the drug increases the heart rate. The primary care provider is notified if any of the following occur:

- Heart rate of 20 bpm or more above the normal rate
- Rapid weight gain of 5 lb or more
- Unusual swelling of the extremities, face, or abdomen
- Dyspnea, angina, severe indigestion, or fainting

**ADMINISTERING CALCIUM CHANNEL BLOCKERS.** The nurse may give these drugs without regard to meals. If gastrointestinal upset occurs, the drug may be administered...
with meals. Bepridil and verapamil are best given with meals or milk because of the tendency of these two drugs to cause gastric upset. The sustained-release capsules should not be crushed, opened, or chewed. Verapamil capsules (not sustained released) may be opened and the contents sprinkled in liquid or on soft foods. Diltiazem may be crushed and mixed with food or fluids for patients who have difficulty swallowing. Sublingual nifedipine may be administered by puncturing the capsule with a sterile needle. The contents can then be squeezed into the buccal pouch.

**ADMINISTERING ACE INHIBITORS.** The nurse administers captopril and moexipril 1 hour before or 2 hours after meals to enhance absorption. Some patients taking an ACE inhibitor experience a dry cough that does not subside until the drug therapy is discontinued. This reaction may need to be tolerated. If the cough becomes too bothersome, the primary care provider may discontinue use of the drug.

The ACE inhibitors may cause a significant drop in blood pressure after the first dose. This effect can be minimized by discontinuing the diuretic therapy (if the patient is taking a diuretic) or by increasing salt intake for at least 1 week before treatment with the ACE inhibitors is begun or beginning treatment with small doses. After the first dose of an ACE inhibitor, the nurse monitors the blood pressure every 15 to 30 minutes for at least 2 hours and afterward until the blood pressure is stable for 1 hour.

**ADMINISTERING ANGIOTENSIN II RECEPTOR ANTAGONISTS.** Women of childbearing age must use a reliable contraceptive while taking the angiotensin II receptor antagonists. The primary care provider is notified if pregnancy is suspected. The most serious consequences of these drugs occur during the second and third trimesters of pregnancy.

**ADMINISTERING DRUGS FOR HYPERTENSIVE EMERGENCIES.** Nitroprusside and diazoxide are drugs used to treat patients with a hypertensive emergency (a systolic pressure of 120 mm Hg or more). When these drugs are used, the nurse frequently monitors the blood pressure, heart rate, and electrocardiogram throughout the course of therapy. Continuous monitoring is preferred. The primary care provider will order the parameters for the blood pressure maintenance.

Nitroprusside infusion bottles are wrapped in aluminum foil or other opaque material to protect the drug from light. The administration tubing does not require a covering. If the solution is protected from light, it remains stable for up to 24 hours. The newly prepared solution normally has a very light brownish tint. The nurse should discard the solution if the mixture becomes blue, green, or dark red.

**Nursing Alert**

When diazoxide or nitroprusside is used for a hypertensive emergency, the nurse places the patient in a supine position immediately before, as well as after, administration of the drug. The rate of infusion (nitroprusside) or rate of direct IV administration (diazoxide) and the patient’s blood pressure are monitored closely during and after administration of the drug because severe hypotension can occur. The blood pressure and pulse rate may need to be monitored every 15 minutes until the blood pressure is reduced to safe levels. The systolic pressure should not drop below 60 mm Hg.

**Gerontologic Alert**

Older adults are particularly sensitive to the hypotensive effects of nitroprusside. To minimize the hypotensive effects, the drug is initially given in lower dosages. Older adults require more frequent monitoring during the administration of nitroprusside.

**Monitoring and Managing Adverse Drug Reactions**

The nurse observes the patient for adverse drug reactions because their occurrence may require a change in the dose or the drug. The nurse should notify the primary care provider if any adverse reactions occur. In some instances, the patient may have to tolerate mild adverse reactions, such as dry mouth or mild anorexia.

**Nursing Alert**

Should it be necessary to discontinue antihypertensive therapy, the nurse should never discontinue use of the drug abruptly. The dosage is gradually reduced over 2 to 4 days to avoid rebound hypertension (a rapid rise in blood pressure).

**Managing Fluid Volume Deficit.** The patient receiving a diuretic is observed for dehydration and electrolyte imbalances. A fluid volume deficit is most likely to occur if the patient fails to drink a sufficient amount of fluid. This is especially true in the elderly or confused patient. To prevent a fluid volume deficit, the nurse encourages patients to drink adequate oral fluids (up to 3000 mL/d, unless contraindicated).

Electrolyte imbalances that may be seen during therapy with a diuretic include hyponatremia (low blood sodium) and hypokalemia (low blood potassium), although other imbalances may also be seen. See Chapter 58 and Display 58–2 for the signs and symptoms of electrolyte imbalances. The primary care provider is notified if any signs or symptoms of an electrolyte imbalance occur.

**Minimizing the Risk for Injury.** Dizziness or weakness along with postural hypotension can occur with the administration of antihypertensive drugs. If postural
hypotension should occur, the nurse advises the patient to rise slowly from a sitting or lying position. The nurse explains that when rising from a lying position, sitting on the edge of the bed for 1 or 2 minutes often minimizes these symptoms. The nurse informs the patient that rising slowly from a chair and then standing for 1 to 2 minutes also minimizes the symptoms of postural hypotension. When symptoms of postural hypotension, dizziness, or weakness occur, the nurse assists the patient in getting out of bed or a chair and with ambulatory activities.

**Educating the Patient and Family**

Nurses can do much to educate others on the importance of having their blood pressure checked at periodic intervals. This includes people of all ages because hypertension is not a disease seen only in older individuals. Once hypertension is detected, patient teaching becomes an important factor in successfully returning the blood pressure to normal or near normal levels.

To ensure lifetime compliance with the prescribed therapeutic regimen, the nurse emphasizes the importance of drug therapy, as well as other treatments recommended by the primary care provider. The nurse describes the adverse reactions that may be seen with a particular antihypertensive drug and advises the patient to contact the primary care provider if any should occur.

The primary care provider may want the patient or family to monitor blood pressure during therapy. The nurse teaches the technique of taking a blood pressure and pulse rate to the patient or family member, allowing sufficient time for supervised practice. The nurse instructs the patient to keep a record of the blood pressure and to bring this record to each visit to the primary care provider’s office or clinic.

The nurse includes the following points in a teaching plan for the patient receiving an antihypertensive drug:

- Never discontinue use of this drug except on the advice of the primary care provider. These drugs control but do not cure hypertension. Skipping doses of the drug or voluntarily discontinuing the drug may cause severe, rebound hypertension.
- Avoid the use of any nonprescription drugs (some may contain drugs that are capable of increasing the blood pressure) unless approved by the primary care provider.
- Avoid alcohol unless its use has been approved by the primary care provider.
- This drug may produce dizziness or light-headedness when rising suddenly from a sitting or lying position. To avoid these effects, rise slowly from a sitting or lying position (see Home Care Checklist: Preventing Orthostatic Hypotension).
- If the drug causes drowsiness, avoid hazardous tasks such as driving or performing tasks that require alertness. Drowsiness may disappear with time.
- If unexplained weakness or fatigue occurs, contact the primary care provider.
- Contact the primary care provider if adverse drug effects occur.
- Follow the diet restrictions recommended by the primary care provider. Do not use salt substitutes unless a particular brand of salt substitute is approved by the primary care provider.
- Notify the primary care provider if the diastolic pressure suddenly increases to 130 mm Hg or higher; you may have malignant hypertension.
EVALUATION

• The therapeutic effect is achieved and blood pressure controlled.
• Adverse reactions are identified, reported to the primary care provider, and managed successfully through nursing interventions.
• Fluid volume deficit is corrected (when appropriate).
• No evidence of injury is seen.
• The patient complies with the prescribed drug regimen.
• The patient and family demonstrate an understanding of the drug regimen.
• The patient verbalizes the importance of complying with the prescribed therapeutic regimen.

Critical Thinking Exercises

1. Discuss important preadministration assessments that should be performed on a patient prescribed captopril for hypertension.

2. While working in the medical clinic of a hospital associated health care satellite, the primary care provider asks you to explain to a patient what can be done to avoid dizziness and light-headedness when rising from a sitting or lying down position. When talking to the patient, you discover that he understands little English. Discuss how you might communicate to this patient what he can do to decrease the symptoms of postural and orthostatic hypotension.

3. Mr. Bates, who has been treated for hypertension, is admitted for treatment of a kidney stone. On admission, he had severe pain and his blood pressure was 160/96 mm Hg. For the past 2 days, his blood pressure has been between 140/92 and 148/92 mm Hg. When taking his blood pressure before giving him an oral antihypertensive drug, you find that it now is 118/82 mm Hg. Analyze the situation and discuss what actions you would take.

4. Develop a teaching plan for a patient prescribed verapamil for hypertension. Discuss what information you would need from the patient before developing this plan. Identify important points to include in the plan.

5. Ms. Jones is admitted to the emergency department in hypertensive crisis. Nitroprusside therapy is begun, and you are asked to monitor this patient. Discuss important points that the nurse should keep in mind when administering this drug. Identify methods you would use to monitor the patient and prevent complications.

Review Questions

1. The nurse instructs the patient using the transdermal system (Catapres TTS) ______.

Medication Dosage Problems

1. Nadolol (Corgard) 80 mg PO is prescribed. The drug is available in 20-mg tablets. The nurse administers ______.

2. Diltiazem 180 mg is prescribed. The drug is available in 60-mg, 90-mg, and 120-mg tablets. Which tablet would you select? ______ How many tablets would you administer? ______
Hyperlipidemia is an increase (hyper) in the lipids (lipo), which are a group of fats or fatlike substances in the blood (demia). Cholesterol and the triglycerides are the two lipids in the blood. Elevation of one or both of these lipids is seen in hyperlipidemia. Serum cholesterol levels above 240 mg/dL and triglyceride levels above 150 mg/dL are associated with atherosclerosis. Atherosclerosis is a disorder in which lipid deposits accumulate on the lining of the blood vessels, eventually producing degenerative changes and obstruction of blood flow. Atherosclerosis is considered to be a major contributor in the development of heart disease.

Triglycerides and cholesterolides are insoluble in water and must be bound to a lipid-containing protein (lipoprotein) for transportation throughout the body. Although several lipoproteins are found in the blood, this chapter will focus on the low-density lipoproteins (LDL), the high-density lipoproteins (HDL), and cholesterol. Low-density lipoproteins (LDL) transport cholesterol to the peripheral cells. When the cells have all of the cholesterol they need, the excess cholesterol is discarded into the blood. This can result in an excess of cholesterol, which can penetrate the walls of the arteries, resulting in atherosclerotic plaque formation. Elevation of the LDL increases the risk for heart disease. High-density lipoproteins (HDL) take cholesterol from the peripheral cells and bring it to the liver, where it is metabolized and excreted. The higher the HDL, the lower the risk for development of atherosclerosis. Therefore, it is desirable to see an increase in the HDL (the “good” lipoprotein) because of the protective nature of its properties against the development of atherosclerosis and a decrease in the LDL. A laboratory examination of blood lipids, called a lipoprotein profile, provides valuable information on the important cholesterol levels, such as:

- Total cholesterol
- LDL (the harmful lipoprotein)
- HDL (the protective lipoprotein)
- Triglycerides

Table 43-1 provides an analysis of cholesterol levels. HDL cholesterol protects against heart disease, so the higher the numbers the better. An HDL level less than 40 mg/dL is low and considered a major risk factor for heart disease. Triglyceride levels that are borderline (150–190 mg/dL) or high (above 190 mg/dL) may need treatment in some individuals.
An increase in serum lipids is believed to contribute to or cause atherosclerosis, a disease characterized by deposits of fatty plaques on the inner walls of arteries. These deposits result in a narrowing of the lumen (inside diameter) of the artery and a decrease in blood supply to the area served by the artery. When these fatty deposits occur in the coronary arteries, the patient experiences coronary artery disease. Lowering blood cholesterol levels can arrest or reverse atherosclerosis in the vessels and can significantly decrease the incidence of heart disease.

Hyperlipidemia, particularly elevated serum cholesterol and LDL levels, is a risk factor in the development of atherosclerotic heart disease. Other risk factors, besides cholesterol levels, play a role in the development of hyperlipidemia. Additional risk factors include:

- Family history of early heart disease (father before the age of 55 years and mother before the age of 55 years)
- Cigarette smoking
- High blood pressure
- Age (men older than 45 years and women older than 55 years)
- Low HDL levels
- Obesity
- Diabetes

In general, the higher the LDL level and the more risk factors involved, the greater the risk for heart disease. The main goal of treatment in patients with hyperlipidemia is to lower the LDL to a level that will reduce the risk of heart disease.

The primary care provider may initially seek to control the cholesterol level by encouraging therapeutic lifestyle changes (TLC). This includes a cholesterol-lowering diet (TLC diet), physical activity, quitting smoking (if applicable), and weight management. The TLC diet is a low-saturated fat and low cholesterol-eating plan that includes less than 200 mg of dietary cholesterol per day. In addition, 30 minutes of physical activity each day is recommended in the TLC. Walking a brisk pace for 30 minutes a day 5 to 7 days a week can help raise the HDL and lower the LDL. Added benefits of a healthy diet and exercise program include a reduction of body weight. If TLC does not result in bringing blood lipids to therapeutic levels, the primary health care provider may add one of the antihyperlipidemic drugs to the treatment plan. The TLC is continued along with the drug regimen.

In addition to control of the dietary intake of fat, particularly saturated fatty acids, antihyperlipidemic drug therapy is used to lower serum levels of cholesterol and triglycerides. The primary health care provider may use one drug or, in some instances, more than one antihyperlipidemic drug for those with poor response to therapy with a single drug. Three types of antihyperlipidemic drugs are currently in use, as well as one miscellaneous antihyperlipidemic drug (see Summary Drug Table: Antihyperlipidemic Drugs for a complete listing of the drugs). The various types of drugs used to treat hyperlipidemia are:

- Bile acid sequestrants
- HMG-CoA reductase inhibitors
- Fibric acid derivatives
- Niacin

The target LDL level for treatment is less than 130 mg/dL. If the response to drug treatment is adequate, lipid levels are monitored every 4 months. If the response is inadequate, another drug or a combination of two drugs is used. Antihyperlipidemic drugs decrease cholesterol and triglyceride levels in several ways. Although the end result is a lower lipid blood level, each has a slightly different action.

### ACTIONS

#### Bile Acid Sequestrants

Cholestyramine (Questran) and colestipol (Colestid) are examples of bile acid sequestrants. Bile, which is manufactured and secreted by the liver and stored in the gallbladder, emulsifies fat and lipids as these products pass through the intestine. Once emulsified, fats and lipids are readily absorbed in the intestine. These drugs bind to bile acids to form an insoluble substance that cannot be absorbed by the intestine, so it is secreted in the feces. With increased loss of bile acids, the liver uses cholesterol to manufacture more bile. This is followed by a decrease in cholesterol levels.
### Bile Acid Sequestrants

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>cholestyramine</td>
<td>LoCHOLEST, Prevalite, Questran, Questran Light, generic</td>
<td>Hyperlipidemia, relief of pruritus associated with partial biliary obstruction</td>
<td>Constipation (may lead to fecal impaction), exacerbation of hemorrhoids, abdominal pain, distention and cramping, nausea, increased bleeding related to vitamin K malabsorption, vitamin A and D deficiencies</td>
<td>4 g PO 1–6 times/d; individualize dosage based on response</td>
</tr>
<tr>
<td>colestipol HCl</td>
<td>Colestid</td>
<td>Hyperlipidemia</td>
<td>Constipation (may lead to fecal impaction), exacerbation of hemorrhoids, abdominal pain, distention and cramping, nausea, increased bleeding related to vitamin K malabsorption, vitamin A and D deficiencies</td>
<td>Granules: 5–30 g/d PO in divided doses; tablets: 2–16 g/d</td>
</tr>
<tr>
<td>colestevam HCl</td>
<td>Welchol</td>
<td>Adjunctive therapy used alone or with an HMG-CoA inhibitor to decrease elevated LDL cholesterol</td>
<td>Constipation (may lead to fecal impaction), exacerbation of hemorrhoids, abdominal pain, distention and cramping, nausea, increased bleeding related to vitamin K malabsorption, vitamin A and D deficiencies</td>
<td>3–6 tablets/d PO</td>
</tr>
</tbody>
</table>

### HMG-CoA Reductase Inhibitors

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>atorvastatin</td>
<td>Lipitor</td>
<td>Hyperlipidemia, reduction of elevated total and LDL cholesterol levels; increase HDL-C in patients with hypercholesterolemia</td>
<td>(Usually mild) headache, flatulence, abdominal pain, cramps, constipation, nausea</td>
<td>10–80 mg/d PO</td>
</tr>
<tr>
<td>fluvastatin</td>
<td>Lescol, Lescol XL</td>
<td>Hyperlipidemia and mixed dyslipidemia, reduction of elevated total and LDL cholesterol levels, to slow progression of coronary artery disease (CAD), along with diet and exercise</td>
<td>(Usually mild) headache, flatulence, abdominal pain, cramps, constipation, nausea</td>
<td>20–80 mg/d PO</td>
</tr>
<tr>
<td>lovastatin</td>
<td>Mevacor</td>
<td>Hyperlipidemia, reduction of elevated total and LDL cholesterol levels, to slow progression of CAD along with diet and exercise</td>
<td>(Usually mild) headache, flatulence, abdominal pain, cramps, constipation, nausea</td>
<td>10–80 mg/d PO in single or divided doses</td>
</tr>
<tr>
<td>pravastatin</td>
<td>Pravachol</td>
<td>Hyperlipidemia, reduction of elevated total and LDL cholesterol levels, prevention of first MI, to slow progression of CAD, reduce risk of stroke, TIA, and MI</td>
<td>(Usually mild) headache, flatulence, abdominal pain, cramps, constipation, nausea</td>
<td>10–40 mg/d PO</td>
</tr>
</tbody>
</table>

(continued)
HMG-CoA Reductase Inhibitors

Another group of antihyperlipidemic drugs are called **HMG-CoA reductase inhibitors**. HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase is an enzyme that is a **catalyst** (a substance that accelerates a chemical reaction without itself undergoing a change) in the manufacture of cholesterol. These drugs appear to have one of two activities, namely, inhibiting the manufacture of cholesterol or promoting the breakdown of cholesterol. This drug activity lowers the blood levels of cholesterol and serum triglycerides and increases blood levels of HDLs. Examples of these drugs are fluvastatin (Lescol), lovastatin (Mevacor), and simvastatin (Zocor).

Fibric Acid Derivatives

Fibric acid derivatives, the third group of antihyperlipidemic drugs, work in a variety of ways. Clofibrate (Atromid-S), acts to stimulate the liver to increase breakdown of very-low-density lipoproteins (VLDL) to low-density lipoproteins (LDL), decreasing liver synthesis of VLDL and inhibiting cholesterol formation. Fenofibrate (Tricor) acts by reducing VLDL and stimulating the catabolism of triglyceride-rich lipoproteins, resulting in a decrease in plasma triglyceride and cholesterol. Gemfibrozil (Lopid) increases the excretion of cholesterol in the feces and reduces the production of triglycerides by the liver, thus lowering serum lipid levels.

Miscellaneous Antihyperlipidemic Drug: Niacin

The mechanism by which niacin (nicotinic acid) lowers blood lipids is not fully understood.
adequate response to a diet and exercise program. Cholestyramine may also be used to relieve pruritus associated with partial biliary obstruction.

**HMG-CoA Reductase Inhibitors**

These drugs, along with a diet restricted in saturated fat and cholesterol, are used to treat hyperlipidemia when diet and other nonpharmacologic treatments alone have not resulted in lowered cholesterol levels.

**Fibric Acid Derivatives**

While the fibric acid derivatives have antihyperlipidemic effects, their use varies depending on the drug. For example, Clofibrate (Atromid-S) and gemfibrozil (Lopid) are used to treat individuals with very high serum triglyceride levels who present a risk of abdominal pain and pancreatitis and who do not experience a response to diet modifications. Clofibrate is not used for the treatment of other types of hyperlipidemia and is not thought to be effective for prevention of coronary heart disease. Fenofibrate (Tricor) is used as adjunctive treatment for the reduction of LDL, total cholesterol, and triglycerides in patients with hyperlipidemia.

**Miscellaneous Antihyperlipidemic Drug: Niacin**

Niacin is used as adjunctive therapy for the treatment of very high serum triglyceride levels in patients who present a risk of pancreatitis (inflammation of the pancreas) and who do not experience an adequate response to dietary control.

**ADVERSE REACTIONS**

**Bile Acid Sequestrants**

A common problem associated with the administration of the bile acid sequestrants is constipation. Constipation may be severe and may occasionally result in fecal impaction. Hemorrhoids may be aggravated. Additional adverse reactions include vitamin A and D deficiencies, bleeding tendencies (including gastrointestinal bleeding) caused by a depletion of vitamin K, nausea, abdominal pain, and distention.

**HMG-CoA Reductase Inhibitors**

HMG-CoA reductase inhibitors are usually well tolerated. Adverse reactions, when they do occur, are often mild and transient and do not require discontinuing therapy. The more common adverse reactions include nausea, vomiting, constipation, abdominal pain or cramps, and headache. A rare, but more serious, adverse reaction is rhabdomyolysis.

**Fibric Acid Derivatives**

The adverse reactions associated with fibric acid derivatives include nausea, vomiting, gastrointestinal upset, and diarrhea. Clofibrate, fenofibrate, and gemfibrozil may increase cholesterol excretion into the bile, leading to cholelithiasis (stones in the gallbladder) or cholecystitis (inflammation of the gallbladder). If cholelithiasis is found, use of the drug is discontinued. Fenofibrate may also result in abnormal liver function tests, respiratory problems, back pain, and headache. Gemfibrozil may cause dyspepsia, skin rash, vertigo, and headache. See the Summary Drug Table: Antihyperlipidemic Drugs for additional adverse reactions.

**Miscellaneous Antihyperlipidemic Drug: Niacin**

Nicotinic acid may cause nausea, vomiting, abdominal pain, diarrhea, severe generalized flushing of the skin, a sensation of warmth, and severe itching or tingling.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Bile Acid Sequestrants**

The bile acid sequestrants are contraindicated in patients with known hypersensitivity to the drugs. Bile acid sequestrants are also contraindicated in those with complete biliary obstruction. These drugs are used cautiously in patients with a history of liver or kidney disease. Bile acid sequestrants are used cautiously during pregnancy (Pregnancy Category C) and lactation (decreased absorption of vitamins may affect the infant). The bile acids sequestrants, particularly cholestyramine, can decrease the absorption of numerous drugs. For this reason, the bile acid sequestrants should be administered alone and other drugs given at least 1 hour before or 4 hours after administration of the bile acid sequestrants. There is an increased risk of bleeding when the bile acid sequestrants are administered with oral anticoagulants. The dosage of the anticoagulant is usually decreased. The bile acid sequestrants may bind with digoxin, thiazide diuretics, penicillin, propranolol, tetracyclines, folic acid, and the thyroid hormones, resulting in decreased effects of these drugs.

**HMG-CoA Reductase Inhibitors**

The HMG-CoA reductase inhibitors are contraindicated in individuals with hypersensitivity to the drugs, serious liver disorders, and during pregnancy (Pregnancy
Category X) and lactation. The HMG-CoA reductase inhibitors are used cautiously in patients with a history of alcoholism, acute infection, hypotension, trauma, endocrine disorders, visual disturbances, and myopathy.

The HMG-CoA reductase inhibitors have an additive effect when used with the bile acid sequestrants, which may provide an added benefit in treating hypercholesterolemia that does not respond to a single-drug regimen. There is an increased risk of myopathy (disorders of the striated muscle) when the HMG-CoA reductase inhibitors are administered with erythromycin, niacin, or cyclosporine. When the HMG-CoA reductase inhibitors are administered with oral anticoagulants, there is an increased anticoagulant effect.

**Fibric Acid Derivatives**

The fibric acid derivatives are contraindicated in patients with hypersensitivity to the drugs and those with significant hepatic or renal dysfunction or primary biliary cirrhosis because these drugs may increase the already elevated cholesterol. The drugs are used cautiously during pregnancy (Pregnancy Category C) and lactation and in patients with peptic ulcer disease or diabetes. Although it rarely occurs, when the fibric acid derivatives, particularly gemfibrozil, are administered with the HMG-CoA reductase inhibitors, there is an increased risk for rhabdomyolysis (see Nursing Alert). When clofibrate, fenofibrate, or gemfibrozil is administered with the bile acid sequestrants, which are administered with oral anticoagulants, there is an increased risk for bleeding.

**Miscellaneous Antihyperlipidemic Drug: Niacin**

Niacin is contraindicated in patients with known hypersensitivity to niacin, active peptic ulcer, hepatic dysfunction, and arterial bleeding. The drug is used cautiously in patients with renal dysfunction, high alcohol consumption, unstable angina, gout, and pregnancy (Category C).

**Nursing Alert**

Sometimes a paradoxical elevation of blood lipid levels occurs. Should this happen, the primary health care provider is notified because the primary health care provider may prescribe a different antihyperlipidemic drug.

During the ongoing assessment, the nurse checks vital signs and assesses bowel functioning because an adverse reaction to these drugs is constipation. Constipation may become serious if not treated.

When administering the HMG-CoA reductase inhibitors and the fibric acid derivatives, the nurse monitors the patient's liver function by obtaining serum transaminase levels before the drug regimen is started, at 6 and 12 weeks, then periodically thereafter because of the possibility of liver dysfunction with the drugs. If aspartate aminotransferase (AST) levels increase to three times normal, the primary care provider in notified immediately because the HMG-CoA reductase inhibitor therapy may be discontinued.

Because the maximum effects of these drugs are usually seen within 4 weeks, periodic lipid profiles are performed to determine the therapeutic effect of the drug regimen. The primary health care provider may increase
the dosage, add another antihyperlipidemic drug, or discontinue the drug therapy, depending on the patient’s response to therapy.

NURSING DIAGNOSES
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING
The expected outcomes for the patient may include a therapeutic response to therapy (lowered blood lipid levels), management of common adverse drug reactions, and an understanding of the dietary measures necessary to reduce lipid and lipoprotein levels.

IMPLEMENTATION
Promoting an Optimal Response to Therapy
Because hyperlipidemia is often treated on an outpatient basis, the nurse explains the drug regimen and possible adverse reactions. If printed dietary guidelines are given to the patient, the nurse emphasizes the importance of following these recommendations. Drug therapy usually is discontinued if the antihyperlipidemic drug is not effective after 3 months of treatment.

Bile acid sequestrants may interfere with the digestion of fats and prevent the absorption of the fat-soluble vitamins (vitamins A, D, E, and K) and folic acid. When the bile acid sequestrants are used for long-term therapy, vitamins A and D may be given in a water-soluble form or administered parenterally. If bleeding tendencies occur as the result of vitamin K deficiency, parenteral vitamin K is administered for immediate treatment, and oral vitamin K is given for prevention of a deficiency in the future.

Monitoring and Managing Adverse Reactions
Bile acid sequestrants. Patients taking the antihyperlipidemic drugs, particularly the bile acid sequestrants, may experience constipation. The drugs can produce or severely worsen preexisting constipation. The nurse instructs the patient to increase fluid intake, eat foods high in dietary fiber, and exercise daily to help prevent constipation. If the problem persists or becomes severe, a stool softener or laxative may be required. Some patients require decreased dosage or discontinuation of the drug therapy.

Gerontologic Alert
Older adults are particularly prone to constipation when taking the bile acid sequestrants. The nurse should monitor older adults closely for hard dry stools, difficulty passing stools, and any complaints of constipation. An accurate record of bowel movements must be kept.

HMG-CoA REDUCTASE INHIBITORS AND FIBRIC ACID DERIVATIVES. The antihyperlipidemic drugs, particularly the HMG-CoA reductase inhibitors, have been associated with skeletal muscle effects leading to rhabdomyolysis. Rhabdomyolysis is a very rare condition in which muscle damage results in the release of muscle cell contents into the bloodstream. Rhabdomyolysis may precipitate renal dysfunction or acute renal failure. The nurse is alert for unexplained muscle pain, muscle tenderness, or weakness, especially if they are accompanied by malaise or fever. These symptoms should be reported to the primary health care provider because the drug may be discontinued.

Niacin. Patients taking nicotinic acid may experience moderate to severe generalized flushing of the skin, a sensation of warmth, and severe itching or tingling. Although these reactions are most often seen at higher dose levels, some patients may experience them even when small doses of nicotinic acid are administered. The sudden appearance of these reactions may frighten the patient.

Nursing Alert
The nurse should advise the patient taking nicotinic acid to put the call light on if discomfort is experienced. Contact the primary health care provider before the next dose is due should this adverse reaction occur. If the patient is in severe discomfort, the nurse should contact the primary health care provider immediately. The nurse advises outpatients to contact their primary health care provider if these reactions are severe or cause extreme discomfort.

Educating the Patient and Family
The nurse stresses the importance of following the diet recommended by the primary health care provider because drug therapy alone will not significantly lower cholesterol and triglyceride levels. The nurse provides a copy of the recommended diet and reviews the contents of the diet with the patient and family. If necessary, the
The nurse refers the patient or family member to a teaching dietitian, a dietary teaching session, or a lecture provided by a hospital or community agency (see Patient and Family Teaching Checklist: Using Diet and Drugs to Control High Blood Cholesterol Levels). The nurse develops a teaching plan to include the following information:

**BILE ACID SEQUESTRANTS**

- **Take the drug before meals unless the primary health care provider directs otherwise.**
- **Cholestyramine powder:** The prescribed dose must be mixed in 4 to 6 fluid ounces of water or noncarbonated beverage and shaken vigorously. The powder can also be mixed with highly fluid soups or pulpy fruits (applesauce, crushed pineapple). The powder should not be ingested in the dry form. Other drugs are taken 1 hour before or 4 to 6 hours after cholestyramine. Cholestyramine is available combined with the artificial sweetener, aspartame (Questran Light), for patients with diabetes or those who are concerned with weight gain.

- **Colestipol granules:** The prescribed dose must be mixed in liquids, soup, cereals, or pulpy fruits. Do not take dry. Mix the prescribed amount in a glassful of liquid. Carbonated beverages should be stirred slowly in a large glass. The tablets are taken twice daily without regard to meals.
- **Colesevelam:** Mix the granules in liquids, soups, cereals, or pulpy fruits. Do not take dry. Mix the prescribed amount in a glassful of liquid. Carbonated beverages should be stirred slowly in a large glass. The tablets are taken twice daily without regard to meals.

**HMG-CoA INHIBITORS**

- **Lovastatin** is taken once daily, preferably with the evening meal. Fluvastatin, pravastatin, and simvastatin are taken, without regard to meals, once daily in the evening or at bedtime.
- If fluvastatin or pravastatin is prescribed with a bile acid sequestrant, take fluvastatin 2 hours after the bile acid sequestrant and pravastatin at least 4 hours afterward.
- Contact the primary health care provider as soon as possible if nausea; vomiting; muscle pain, tenderness, or weakness; fever; upper respiratory infection; rash; itching; or extreme fatigue occurs.

**FIBRIC ACID DERIVATIVES**

- **Clofibrate:** If gastrointestinal upset occurs, take the drug with food. Notify the primary health care provider if chest pain, shortness of breath, palpitations, nausea, vomiting, fever, chills, or sore throat occurs.
- **Gemfibrozil:** Dizziness or blurred vision may occur. Observe caution when driving or performing hazardous tasks. Notify the primary health care provider if epigastric pain, diarrhea, nausea, or vomiting occurs.

**MISCELLANEOUS PREPARATION**

- **Nicotinic acid:** Take this drug with meals. This drug may cause mild to severe facial flushing, feeling of warmth, severe itching, or headache. These symptoms usually subside with continued therapy, but contact the primary health care provider as soon as possible if symptoms are severe. The primary health care provider may prescribe aspirin (325 mg) to be taken about 30 minutes before nicotinic acid to decrease the flushing reaction. If dizziness occurs, avoid sudden changes in posture.
EVALUATION

• The therapeutic effect is achieved and serum lipid levels are decreased.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully through successful nursing interventions.
• The patient and family demonstrate an understanding of the treatment regimen.

Critical Thinking Exercises

1. A patient in the medical clinic is taking cholestyramine (Questran) for hyperlipidemia. The primary health care provider has prescribed TLC for the patient. The patient is on a low-fat diet and walks daily for exercise. His major complaint at this visit is constipation, which is very bothersome to him. Discuss how you would approach this situation with the patient. What information would you give the patient concerning his constipation?

2. Discuss the important points to include in a teaching plan for a patient who is prescribed atorvastatin (Lipitor).

3. Describe the important aspects of the ongoing assessment when administering fluvastatin to a patient.

Review Questions

1. Which of the following adverse reactions is most common in a patient taking a bile acid sequestrant?
   A. Anorexia
   B. Vomiting
   C. Constipation
   D. Headache

2. Lovastatin (Mevacor) is best taken ______.
   A. once daily, preferably with the evening meal
   B. three times daily with meals

Medication Dosage Problems

1. A patient is prescribed 10 mg simvastatin (Zocor) PO daily for high cholesterol. The drug is available in 5-mg tablets. The nurse administers ______.

2. The primary care provider prescribes fenofibrate (Tricor) for the treatment of hypertriglyceridemia. The patient is now taking 200 mg/d PO. Is this an appropriate dosage? If not, what action would you take? If the dose is appropriate, how many capsules would you administer if the drug is available in 54-mg capsules?
Anticoagulants are used to prevent the formation and extension of a thrombus (blood clot). Anticoagulants have no direct effect on an existing thrombus and do not reverse any damage from the thrombus. However, once the presence of a thrombus has been established, anticoagulant therapy can prevent additional clots from forming. Although they do not thin the blood, they are sometimes called blood thinners by patients. The anticoagulants are a group of drugs that include warfarin (a coumarin derivative), anisindione (an indandione derivative), and fractionated and unfractionated heparin.

Whereas the anticoagulants prevent thrombus formation, thrombolytic drugs dissolve blood clots that have already formed within the walls of a blood vessel. These drugs reopen blood vessels after they become occluded. Another term used to identify the thrombolytic drugs is fibrolytic drugs. Each of these groups of drugs is discussed in this chapter. Before these drugs are discussed, a basic understanding of hemostasis and thrombus formation is needed.

**HEMOSTASIS**

Hemostasis is the process that stops bleeding in a blood vessel. Normal hemostasis involves a complex process of extrinsic and intrinsic factors. Figure 44-1 shows the coagulation pathway and factors involved. The coagulation cascade is so named because as each factor is activated it acts as a catalyst that enhances the next reaction, with the net result being a large collection of fibrin that forms a plug in the vessel. Fibrin is the insoluble protein that is essential to clot formation.

**THROMBOSIS**

Thrombosis is the formation of a clot. A thrombus may form in any vessel, artery, or vein when blood flow is impeded. For example, a venous thrombus can
develop as the result of venous stasis (decreased blood flow), injury to the vessel wall, or altered blood coagulation. Venous thrombosis most often occurs in the lower extremities and is associated with venous stasis. Deep vein thrombosis (DVT) occurs in the lower extremities and is the most common type of venous thrombosis. Arterial thrombosis can occur because of atherosclerosis or arrhythmias, such as atrial fibrillation. The thrombus may begin small, but fibrin, platelets, and red blood cells attach to the thrombus, increasing its size and shape. When a thrombus detaches itself from the wall of the vessel and is carried along through the bloodstream, it becomes an embolus. The embolus travels until it reaches a vessel that is too small to permit its passage. If the emboli goes to the lung and obstructs a pulmonary vessel, it is called a pulmonary embolism (PE). Similarly, if the embolus detaches and occludes a vessel supplying blood to the heart, it can cause a myocardial infarction (MI). The anticoagulant drugs are used prophylactically in patients who are at high risk for clot formation.

**COUMARIN AND INDANDIONE DERIVATIVES**

Warfarin (Coumadin), a coumarin derivative, is the oral anticoagulant most commonly prescribed. Although given by the oral route, warfarin is available for parenteral administration. Because it can be given orally, it is the drug of choice for patients requiring long-term therapy with an anticoagulant. Peak activity is reached 1.5 to 3 days after therapy is initiated. Anisindione (Miradon), an indandione derivative, is less frequently used but an effective anticoagulant. For more information on anisindione, see the Summary Drug Table: Anticoagulants.

**ACTIONS**

All anticoagulants interfere with the clotting mechanism of the blood. Warfarin and anisindione interfere with the manufacturing of vitamin K-dependent clotting factors.
### CHAPTER 44  Anticoagulant and Thrombolytic Drugs

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Coumadin and Indandione Derivatives</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>anisindione</td>
<td>Miradon</td>
<td>Prophylaxis and treatment of venous thrombosis and its extension; prevention and treatment of atrial fibrillation with embolization, prophyaxis and treatment of pulmonary embolism</td>
<td>Hemorrhage, nausea, alopecia, dermatitis, vomiting, anorexia, abdominal cramping, nausea,</td>
<td>25—300 mg/d PO; dose individualized based on PT or INR</td>
</tr>
<tr>
<td>warfarin sodium</td>
<td>Coumadin, generic</td>
<td>Venous thrombosis, atrial fibrillation with embolism, pulmonary embolism (PE), prophyaxis of systemic embolism after acute MI</td>
<td>Nausea, alopecia, hemorrhage, urticaria, dermatitis, vomiting, anorexia, abdominally cramping, priapism</td>
<td>2—10 mg/d PO; IV; individualized dose based on PT or INR</td>
</tr>
</tbody>
</table>

| **Unfractionated Heparin** | | | | |
| heparin sodium | Generic | Thrombosis/embolism, diagnosis and treatment of disseminated intravascular coagulation (DIC), prophyaxis of deep vein thrombosis (DVT), clotting prevention | Hemorrhage, chills, fever, urticaria, local irritation, erythema, mild pain, hematoma or ulceration at the injection site (IM or SC), bruising | 10,000—20,000 units SC in divided doses q8—12h; 5000—10,000 units q4—6h intermittent IV; 5000—40,000 units/d IV infusion; 5000 units SC q2h before surgery and 5000 units SC after surgery q8—12h |
| heparin sodium lock flush solution | Generic | Clearing intermittent infusion lines (heparin lock) to prevent clot formation at site | None significant | 10—100 units/mL heparin solution |

| **Fractionated Heparins: Low-Molecular-Weight Heparins (LMWHs)** | | | | |
| dalteparin sodium | Fragmin | Unstable angina/non-Q-wave MI, DVT prophylaxis | Hemorrhage, bruising, thrombocytopenia, chills, fever, pain, erythema and irritation at site of injection | Angina/MI: 120 IU/kg, SC q12h with concurrent oral aspirin; DVT: 2500 IU SC daily |
| danaparoid sodium | Orgaran | Prophylaxis of DVT, after hip replacement surgery | Hemorrhage, bruising, thrombocytopenia, hyperkalemia, hypersensitivity, fever, pain and erythema at injection site | 750 anti-Xa units BID SC |
| enoxaparin sodium | Lovenox | DVT and prophylaxis, DVT and pulmonary embolism (PE) treatment, unstable angina/non-Q-wave MI | Hemorrhage, bruising, thrombocytopenia, hyperkalemia, hypersensitivity, fever, pain and erythema at injection site | DVT prophylaxis: 30 mg q12h SC or 40 mg once daily SC; in abdominal surgery for patients at risk for thromboembolic complications: 40 mg/d SC; DVT/PE treatment: 1 mg/kg SC q12h; unstable angina; non-Q-wave MI: 1 mg/kg SC q12h |

(continued)
by the liver. This results in the depletion of clotting factors II (prothrombin), VII, IX, and X. It is the depletion of prothrombin (see Fig. 44-1), a substance that is essential for the clotting of blood, that accounts for most of the action of warfarin.

**USES**

Warfarin is used for:
- Prevention (prophylaxis) and treatment of DVT
- Prevention and treatment of atrial fibrillation with embolization
- Prevention and treatment of PE
- As part of the treatment of MI
- Prevention of thrombus formation after valve replacement

In most situations, warfarin is the drug of choice, with anisindione reserved for those who are unable to take warfarin.

**ADVERSE REACTIONS**

The principal adverse reaction associated with warfarin is bleeding, which may range from very mild to severe. Bleeding may be seen in many areas of the body, such as the bladder, bowel, stomach, uterus, and mucous membranes. Other adverse reactions are rare but may include nausea, vomiting, alopecia (loss of hair), urticaria (severe skin rash), abdominal cramping, diarrhea, rash, hepatitis (inflammation of the liver), jaundice (yellowish discoloration of the skin and mucous membranes), and blood dyscrasias (disorders).

**CONTRAINDICATIONS**

Warfarin is contraindicated in patients with known hypersensitivity to the drug, hemorrhagic disease, tuberculosis, leukemia, uncontrolled hypertension, gastrointestinal (GI) ulcers, recent surgery of the eye or
central nervous system, aneurysms, or severe renal or hepatic disease, and during pregnancy and lactation. Use during pregnancy (Pregnancy Category X) can cause fetal death.

**PRECAUTIONS**

Warfarin is used cautiously in patients with fever, heart failure, diarrhea, malignancy, hypertension, renal or hepatic disease, psychoses, or depression. Women of childbearing age must use a reliable contraceptive to prevent pregnancy.

**INTERACTIONS**

The effects of warfarin may increase when administered with acetaminophen, NSAIDs, beta blockers, disulfiram, isoniazid, chloral hydrate, loop diuretics, aminoglycosides, cimetidine, tetracyclines, and cephalosporins. Oral contraceptives, ascorbic acid, barbiturates, diuretics, and vitamin K decrease the effects of warfarin. Because the effects of warfarin are influenced by many drugs, the patient must notify the nurse or the primary health care provider when taking a new drug or discontinuing use of any drug, both prescription and over-the-counter preparations.

---

### The Patient Receiving Warfarin

**ASSESSMENT**

**Preadministration Assessment**

Before administering the first dose of warfarin, the nurse questions the patient about all drugs taken during the previous 2 to 3 weeks (if the patient was recently admitted to the hospital). If the patient took any drugs before admission, the nurse notifies the primary health care provider before the first dose is administered. Usually, the prothrombin time (PT) is ordered and the international normalized ratio (INR) determined before therapy is started. The first dose of warfarin is not given until blood for a baseline PT/INR is drawn. The dosage is individualized based on the results of the PT or the INR.

If the patient has a DVT, it usually occurs in a lower extremity. The nurse examines the extremity for color and skin temperature. The nurse also checks for a pedal pulse, noting the rate and strength of the pulse. It is important to record any difference between the affected extremity and the unaffected extremity. The nurse notes areas of redness or tenderness and asks the patient to describe current symptoms. The affected extremity may appear edematous and exhibit a positive Homans’ sign (pain in the calf when the foot is dorsiflexed). A positive Homans’ sign is suggestive of DVT.

**Ongoing Assessment**

During the course of therapy, the nurse continually assesses the patient for any signs of bleeding and hemorrhage. Areas of assessment include the gums, nose, stools, urine, or nasogastric drainage (see “Promoting an Optimal Response to Therapy”).

The nurse examines the skin temperature and color in the patient with a DVT for signs of improvement. The nurse takes and records vital signs every 4 hours or more frequently, if needed.

Patients receiving warfarin for the first time often require daily adjustment of the dose, which is based on the daily PT/INR results. The nurse withholds the drug and notifies the primary health care provider if the PT exceeds 1.2 to 1.5 times the control value or the INR ratio exceeds 3. A daily PT is performed until it stabilizes and when any other drug is added to or removed from the patient’s drug regimen. After the PT has stabilized, it is monitored every 4 to 6 weeks.

See Display 44-1 for more information on the laboratory examinations for monitoring warfarin.

---

**Herbal Alert: Warfarin Interaction**

Warfarin, a drug with a narrow therapeutic index, has the potential to interact with many herbal remedies. For example, warfarin should not be combined with any of the following herbs because they may have additive or synergistic activity and increase the risk for bleeding: celery, chamomile, clove, dong quai, feverfew, garlic, ginger, ginkgo biloba, ginseng, green tea, onion, passion flower, red clover, St. John’s wort, and tumeric. Any herbal remedy should be used with caution in patients taking warfarin.

Much of the information on drug–herb interactions is speculative. Herb–drug interactions are sporadically reported and difficult to determine. Because herbal supplements are not regulated by the Food and Drug Administration (FDA), products lack standardization, purity, and potency. In addition, multiple ingredients in products and batch-to-batch variation make it difficult to determine if reactions occur as the result of the herb. To assist with the identification of herb–drug interactions, nurses should report any potential interactions to the FDA through its MedWatch program (see Appendix A). Because the absorption, metabolism, distribution, and elimination characteristics of most herbal products are poorly understood, many herb–drug interactions are speculative. It is especially important to take special care when patients are taking any drugs with a narrow therapeutic index (the difference between the minimum therapeutic and minimum toxic drug concentrations is small—such as warfarin) and herbal supplements.
NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes for the patient may include an optimal response to therapy, management of common adverse drug reactions, and an understanding of the postdischarge drug regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

Before administering each dose of warfarin, the nurse checks the prothrombin flow sheet or the laboratory report to determine the current PT or INR (PT/INR) results (see Nursing Alerts below). The patient also is checked for any evidence of bleeding.

To hasten the onset of the therapeutic effect, a higher dosage (loading dose) may be prescribed for 2 to 4 days, followed by a maintenance dosage adjusted according to the daily PT/INR. Otherwise, the drug takes 3 to 5 days to reach therapeutic levels. When rapid anticoagulation is required, heparin is preferred as a loading dose, followed by maintenance dose of warfarin based on the PT or INR.

Nursing Diagnoses Checklist

- Risk for Injury related to adverse drug effects
- Ineffective Tissue Perfusion related to adverse drug reactions

Nursing Alert

Patients who have fluctuations in PT/INR levels should be asked about their food intake and any recent dietary changes. A careful assessment of the foods eaten during the last several days is necessary to determine the patient’s intake of vitamin K.

Although the drug is most often administered orally, warfarin injection may be used as an alternative route for patients who are unable to receive oral drugs. The intravenous dosage is the same as that for the oral drug. Intravenous warfarin is administered as a slow bolus injection during a period of 1 to 2 minutes. Warfarin is not recommended for intramuscular injection. After the drug is reconstituted, it is stable for 4 hours at room temperature. The vial is not recommended for multiple use, and any unused solution should be discarded.

Monitoring and Managing Adverse Drug Reactions

Bleeding can occur any time during therapy with warfarin, even when the PT appears to be within a safe limit (e.g., 1.2–1.5 times the control value). All nursing personnel and medical team members should be made aware of any patient receiving warfarin and the observations necessary with administration. The nurse checks the following for signs of bleeding:

- Urinal, bedpan, catheter drainage unit—Inspect the urine for a pink to red color and the stool for signs of GI bleeding (bright red to black stools). Visually check the catheter drainage every 2 to 4 hours and when the unit is emptied. Oral anticoagulants may impart a
acceptable level. or two doses of warfarin may quickly bring the PT to an

therapy for a few days or order vitamin K1 (phytona-
care provider may either discontinue the anticoagulant
control value or the INR exceeds 3, the primary health
immediately report to the primary health care provider

Shaving or bleeding from the gums after brushing the

Teeth; or excessive menstrual bleeding. The nurse must

shave; or bleeding from the gums after brushing the

Skin, mucous membranes—Inspect the patient’s skin
daily for evidence of easy bruising or bleeding. Be
alert for bleeding from minor cuts and scratches,
nosebleeds, or excessive bleeding after intramuscular
(IM), subcutaneous (SC), or intravenous (IV) injec-
tions or after a venipuncture. After oral care, check
the toothbrush and gums for signs of bleeding.

Nursing Alert

The nurse should withhold the drug and contact the primary
health care provider immediately if any of the following
occurs:
• The PT exceeds 1.5 times the control value.
• There is evidence of bleeding.
• The INR is greater than 3.

The nurse must apply prolonged pressure to needle or
catheter sites after venipuncture, removal of central or
peripheral IV lines, and IM and SC injections. Laboratory
personnel or those responsible for drawing blood for lab-

oratory tests are made aware of anticoagulant therapy
because prolonged pressure on the venipuncture site is
necessary. All laboratory requests require a notation stati-
ing the patient is receiving anticoagulant therapy.

MANAGING WARFARIN OVERDOSE. Symptoms of over-
dosage of warfarin include blood in the stool (melena);
petechiae (pinpoint-size red hemorrhagic spots on the
skin); oozing from superficial injuries, such as cuts from
shaving or bleeding from the gums after brushing the
teeth; or excessive menstrual bleeding. The nurse must
immediately report to the primary health care provider
any of these adverse reactions or evidence of bleeding.

If bleeding occurs or if the PT exceeds 1.5 times the
control value or the INR exceeds 3, the primary health

care provider may either discontinue the anticoagulant
therapy for a few days or order vitamin K1 (phytona-
dione), an oral anticoagulant antagonist, which must
always be readily available when a patient is receiving
warfarin. Because warfarin interferes with the synthe-
sis of vitamin K1-dependent clotting factors, the admin-
istration of vitamin K1 reverses the effects of warfarin
by providing the necessary ingredient to enhance clot
formation and stop bleeding. However, withholding one
or two doses of warfarin may quickly bring the PT to an
acceptable level.

The nurse must assess the patient for additional evi-
dence of bleeding until the PT is below 1.5 times the
control value or until the bleeding episodes cease. The
PT generally returns to a safe level within 6 hours of
administration of vitamin K1. Administration of whole
blood or plasma may be necessary if severe bleeding
occurs because of the delayed onset of vitamin K1.

Educating the Patient and Family
The nurse provides a full explanation of the drug regi-
men to patients taking warfarin, including an explana-
tion of the problems that can occur during therapy. A
thorough review of the dose regimen, possible adverse
drug reactions, and early signs of bleeding tendencies
help the patient cooperate with the prescribed therapy.
The nurse should include the following points in a
patient and family teaching plan:

• Follow the dosage schedule prescribed by the primary
health care provider.
• The PT or INR will be monitored periodically. Keep
all primary health care provider and laboratory
appointments because dosage changes may be
necessary during therapy.
• Do not take or stop taking other drugs except on the
advice of the primary health care provider. This
includes nonprescription drugs, as well as those
prescribed by a primary health care provider or
dentist.
• Inform the dentist or other primary health care
providers of therapy with this drug before any
treatment or procedure is started or drugs are
prescribed.
• Take the drug at the same time each day.
• Do not change brands of anticoagulants without
consulting a physician or pharmacist.
• Avoid alcohol unless use has been approved by the
primary health care provider. Advise the patient to
limit foods high in vitamin K, such as leafy green
vegetables, beans, broccoli, cabbage, cauliflower,
cheese, fish, and yogurt. Vegetables with large
amounts of vitamin K can interfere with the antico-
gulant’s effect (see Home Care Checklist: Ensuring
Appropriate Vitamin K Intake).
• If evidence of bleeding should occur, such as
unusual bleeding or bruising, bleeding gums, blood
in the urine or stool, black stool, or diarrhea, omit
the next dose of the drug and contact the primary
health care provider immediately. (Anisindione may
cause a red-orange discoloration of alkaline urine.)
• Use a soft toothbrush and consult a dentist regard-
ing routine oral hygiene, including the use of dental
floss. Use an electric razor when possible to avoid
small skin cuts.
• Women of childbearing age must use a reliable
contraceptive to prevent pregnancy.
Wear or carry identification, such as a medical alert tag, Alert, to inform medical personnel and others of therapy with this drug.

**EVALUATION**

- The therapeutic drug effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully using appropriate nursing interventions.
- The patient demonstrates an understanding of the drug regimen.
- The patient verbalizes the importance of complying with the prescribed therapeutic regimen.
- The patient lists or describes early signs of bleeding.

**FRACTIONATED AND UNFRACTIONATED HEPARIN**

Heparin preparations are available as heparin sodium and the low-molecular-weight heparins (fractionated heparins). Heparin is not a single drug, but rather a mixture of high and low-molecular-weight drugs. Fragments of heparin with low molecular weights are available as low-molecular-weight heparin (LMWH). Examples of LMWHs are dalteparin (Fragmin), enoxaparin (Lovenox), and tinzaparin (Innohep). LMWHs produce very stable responses when administered at the recommended doses. Because of this stability, frequent laboratory monitoring, as with heparin, is not necessary. In addition, bleeding is less likely to occur with LMWHs than with heparin.

**USES**

Heparin is used for:
- Prevention and treatment of venous thrombosis, PE, peripheral arterial embolism;
- Atrial fibrillation with embolus formation;

**FRACTIONATED AND UNFRACTIONATED HEPARIN**

Heparin preparations are available as heparin sodium and the low-molecular-weight heparins (fractionated heparins). Heparin is not a single drug, but rather a mixture of high and low-molecular-weight drugs. Fragments of heparin with low molecular weights are available as low-molecular-weight heparin (LMWH). Examples of LMWHs are dalteparin (Fragmin), enoxaparin (Lovenox), and tinzaparin (Innohep). LMWHs produce very stable responses when administered at the recommended doses. Because of this stability, frequent laboratory monitoring, as with heparin, is not necessary. In addition, bleeding is less likely to occur with LMWHs than with heparin.

**USES**

Heparin is used for:
- Prevention and treatment of venous thrombosis, PE, peripheral arterial embolism;
- Atrial fibrillation with embolus formation;

**FRACTIONATED AND UNFRACTIONATED HEPARIN**

Heparin preparations are available as heparin sodium and the low-molecular-weight heparins (fractionated heparins). Heparin is not a single drug, but rather a mixture of high and low-molecular-weight drugs. Fragments of heparin with low molecular weights are available as low-molecular-weight heparin (LMWH). Examples of LMWHs are dalteparin (Fragmin), enoxaparin (Lovenox), and tinzaparin (Innohep). LMWHs produce very stable responses when administered at the recommended doses. Because of this stability, frequent laboratory monitoring, as with heparin, is not necessary. In addition, bleeding is less likely to occur with LMWHs than with heparin.

**USES**

Heparin is used for:
- Prevention and treatment of venous thrombosis, PE, peripheral arterial embolism;
- Atrial fibrillation with embolus formation;
• Prevention of postoperative venous thrombosis (DVT) and PE in certain patients undergoing surgical procedures, such as major abdominal surgery;
• Prevention of clotting in arterial and heart surgery, in blood transfusions and dialysis procedures, and in blood samples for laboratory purposes;
• Prevention of a repeat cerebral thrombosis in some patients who have experienced a stroke;
• Treatment of coronary occlusion, acute MI, and peripheral arterial embolism;
• Prevention of clotting in equipment used for extracorporeal (occurring outside the body) circulation;
• Diagnosis and treatment of disseminated intravascular coagulation, a severe hemorrhagic disorder.

The LMWHs are used to prevent DVT after certain surgical procedures, such as hip or knee replacement surgery or abdominal surgery. The drugs are also used for ischemic complications of unstable angina and MI (for specific uses of each drug see the Summary Drug Table: Anticoagulants).

ADVERSE REACTIONS

Hemorrhage is the chief complication of heparin administration. Hemorrhage can range from minor local bruising to major hemorrhaging from any organ. Thrombocytopenia (low levels of platelets in the blood) may occur, causing bleeding from the small capillaries and resulting in easy bruising, petechiae, and hemorrhage into the tissues.

Other adverse reactions include local irritation when heparin is given via the SC route. Hypersensitivity reactions may also occur with any route of administration and include fever, chills, and urticaria. More serious hypersensitivity reactions include an asthma-like reaction and an anaphylactoid reaction.

The LMWHs cause fewer adverse reactions than heparin. Bleeding related to the LMWHs is possible but has generally been low. See the Summary Drug Table: Anticoagulants for additional adverse reactions associated with the LMWHs.

CONTRAINDICATIONS

Heparin preparations are contraindicated in patients with known hypersensitivity to the drug, active bleeding (except when caused by disseminated intravascular coagulation), hemorrhagic disorders, severe thrombocytopenia, or recent surgery (except for the LMWHs used after certain surgical procedures to prevent thromboembolic complications) and during pregnancy (Pregnancy Category C). The LMWHs are contraindicated in patients with a hypersensitivity to the drug, heparin, or pork products and inpatients with active bleeding or thrombocytopenia.

PRECAUTIONS

Treatment with heparin preparations is approached cautiously in the elderly, in patients with severe renal or kidney disease, diabetes, diabetic retinopathy, ulcer disease, or uncontrolled hypertension, and in all patients with a potential site for bleeding or hemorrhage. The LMWHs are used with caution in patients who are at increased risk of hemorrhage, such as those with severe uncontrolled hypertension, diabetic retinopathy, bacterial endocarditis, congenital or acquired bleeding disorders, GI disease, or hemorrhagic stroke and shortly after brain, spinal, or ophthalmological surgery.

INTERACTIONS

When heparin is administered with the NSAIDs, aspirin, penicillin, or the cephalosporins, there may be an increase in clotting times, thereby increasing the risk for bleeding. During heparin administration, serum transaminase (aspartate, alanine) levels may be falsely elevated. Careful interpretation is required because these laboratory tests may be used to help diagnose certain disorders, such as liver disease or MI. Protamine sulfate, a heparin antagonist, is incompatible with certain antibiotics such as penicillin and the cephalosporins. Use of the LMWHs with the following drugs may increase the risk of bleeding: aspirin, salicylates, NSAIDs, and thrombolytics.

NURSING PROCESS

The Patient Receiving Heparin

ASSESSMENT

Preadministration Assessment
Before administering the first dose of heparin, the nurse obtains the patient’s vital signs. The most commonly used test to monitor heparin is activated partial thromboplastin time (APTT). Blood is drawn for laboratory studies before giving the first dose of heparin to obtain baseline data. (See the discussion on preadministration assessment for the oral anticoagulants.)

Ongoing Assessment
The ongoing assessment of a patient receiving heparin requires close observation and careful monitoring. The nurse assesses vital signs every 2 to 4 hours or more frequently during administration.
The dosage of heparin is adjusted according to daily APTT monitoring. A therapeutic dosage is attained when the APTT is 1.5 to 2.5 times the normal. The LMWHs have little or no effect on the APTT values. Special monitoring of clotting times is not necessary when administering the drugs.

Periodic platelet counts, hematocrit, and tests for occult blood in the stool should be performed throughout the entire course of heparin therapy.

It is also important that the nurse monitor for any indication of hypersensitivity reaction. The nurse reports reactions, such as chills, fever, or hives, to the primary health care provider. When heparin is given to prevent the formation of a thrombus, the nurse observes the patient for signs of thrombus formation every 2 to 4 hours. Because the signs and symptoms of thrombus formation vary and depend on the area or organ involved, the nurse should evaluate and report any complaint the patient may have or any change in the patient's condition to the primary health care provider.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes for the patient may include an optimal response to drug therapy, management of common adverse drug reactions, and an understanding of the therapeutic regimen.

**IMPLEMENTATION**

Promoting an Optimal Response to Therapy

Heparin preparations, unlike warfarin, must be given by the parenteral route, preferably SC or IV. The onset of anticoagulation is almost immediate after a single dose. Maximum effects occur within 10 minutes of administration. Clotting time will return to normal within 4 hours unless subsequent doses are given.

Blood coagulation tests are usually ordered before and during heparin therapy, and the dose of heparin is adjusted to the test results. Optimal results of therapy are obtained when the APTT is 1.5 to 2.5 times the control value. The LMWHs do not require close monitoring of blood coagulation tests.

A complete blood count, platelets, and stools for occult blood may be ordered periodically throughout therapy. Thrombocytopenia may occur during heparin administration. A mild, transient thrombocytopenia may occur 2 to 3 days after heparin therapy is begun. This early development of thrombocytopenia tends to resolve itself despite continued therapy. The nurse reports a platelet count of less than 100,000 mm$^3$ immediately because the primary care provider may choose to discontinue the heparin therapy.

**ADMINISTERING HEPARIN PREPARATIONS.** The dosage of heparin is measured in units and is available in various dosage strengths as units per milliliter (U/mL), for example, 10,000 U/mL. When selecting the strength used for administration, choose the strength closest to the prescribed dose. For example, if 5000 U is ordered, and the available strengths are 1000, 5000, 7500, 20,000, and 40,000 U/mL, use 1 mL of the 5000 U/mL for administration.

Heparin may be given by intermittent IV administration, continuous IV infusion, and the SC route. Intramuscular administration is avoided because of the possibility of the development of local irritation, pain, or hematoma (a collection of blood in the tissue). A solution of dilute heparin may be used to maintain patency of an IV site used for intermittent administration of any drug given by the IV route.

Intermittent IV administration requires the use of an adapter or heparin lock to provide ready access to a vein without having to maintain a continuous infusion. A solution of dilute heparin consisting of 10 to 100 U/mL may be ordered for injection into the heparin lock before and after the administration of the intermittent dose of heparin or any other drug administered by the intermittent IV route. This is called a heparin lock flush. The lock flush solution aids in preventing small clots from obstructing the needle of the intermittent administration set. To prevent incompatibility of heparin with other drugs, the heparin lock set is flushed with sterile water or sterile normal saline before and after any drug is given through the IV line. The primary health care provider or institutional policy dictates the use and type of lock flush solution.

Each time heparin is given, the nurse inspects the needle site for signs of inflammation, pain, and tenderness along the pathway of the vein. If these should occur, the use of this site is discontinued and a new intermittent set is inserted at a different site. Coagulation tests are usually performed 30 minutes before the scheduled dose and from the extremity opposite the infusion site.

An infusion pump must be used for the safe administration of heparin by continuous IV infusion. The nurse checks the infusion pump every 1 to 2 hours to ensure that it is working properly. The needle site is inspected for signs of inflammation, pain, and tenderness along
the pathway of the vein. If these should occur, the infusion is discontinued and restarted in another vein.

**Nursing Alert**

Blood coagulation tests for those receiving heparin by continuous IV infusion are taken at periodic intervals (usually every 4 hours) determined by the primary health care provider. If the patient is receiving long-term heparin therapy, blood coagulation tests may be performed at less frequent intervals.

**Nursing Alert**

If the patient is receiving heparin by intermittent or continuous IV infusion, other drugs administered by the IV route are not given through the IV tubing or injection port or piggy-backed into the continuous IV line unless the primary health care provider orders the drug given in this manner. In addition, the nurse should never mix other drugs with heparin when heparin is given by any route.

When heparin is given by the SC route, administration sites are rotated and the site used is recorded on the patient’s chart. The recommended sites of administration are those on the abdomen, but areas within 2 inches of the umbilicus are avoided because of the increased vascularity of that area. Other areas of administration are the buttocks and lateral thighs. The nurse gives the injection at a 90-degree angle. The site is not massaged after giving the injection, but the nurse applies firm pressure to the injection site until all oozing of blood has stopped.

The “bunch” technique may be used when administering heparin SC. When using the bunch method, the nurse grasps the tissue around the selected site to form a tissue roll that is about 0.5 inch in diameter. The nurse inserts the needle into the tissue roll at a 90-degree angle and injects the drug. The nurse then releases the tissue roll. It is not necessary to aspirate before injecting the drug. The application of firm pressure after the injection helps to prevent hematoma formation. Each time heparin is given by this route, the nurse inspects all recent injection sites for signs of inflammation (redness, swelling, tenderness) and hematoma formation. When administering heparin by the SC route, an APTT test is performed 4 to 6 hours after the injection.

**ADMINISTERING THE LOW-MOLECULAR-WEIGHT HEPARIN.**

The LMWHs are administered by the SC route only. Dalteparin is given by the SC route 1 to 2 hours before surgery and once daily for 5 to 10 days after surgery. The first dose of enoxaparin is administered via the SC route within the first 12 to 24 hours after surgery and continued for 7 to 10 days. When enoxaparin is administered in patients having abdominal surgery, the first dose is via the SC route 2 hours before surgery and as long as 12 days after surgery. Tinzaparin is administered via the SC route within 12 to 24 hours after surgery with administration continuing as long as 14 days.

The nurse gives these drugs deep into the SC tissue in the abdomen (avoiding the navel) with the site rotated at the time of each injection. Alternate sites are the buttocks or upper thighs. The nurse places the patient in a supine position. To avoid the loss of the drug, the air bubble is not expelled from the syringe before injection. The drug is administered alternately between left and right anterolateral and left and right posterolateral abdominal wall. The injection site is varied daily. When the drug is administered, the skin is lifted between the thumb and forefinger (as in the bunch technique). The entire length of the needle is inserted into the skin fold at a 45- to 90-degree angle, with the skin fold held throughout the injection. To minimize bruising, the injection site is not rubbed after the drug is administered. bruising may be decreased by using an ice cube to massage the site before injection of the drug. Prefilled syringes or enoxaparin are available for patients taking the drug at home.

**Monitoring and Managing Adverse Drug Reactions**

Bleeding at virtually any site can occur during therapy with any heparin preparation, even the LMWHs. The nurse monitors the patient’s vital signs every 2 to 4 hours or as ordered by the primary health care provider.

**Nursing Alert**

The nurse should immediately report evidence of bleeding in any patient receiving heparin: bleeding gums, epistaxis (nose bleed), easy bruising, black tarry stools, hematuria (blood in the urine), oozing from wounds or IV sites, or decrease in blood pressure.

**Gerontologic Alert**

There is an increased incidence of bleeding in individuals older than 60 years (particularly older women) when heparin is administered. The nurse should carefully monitor older patients for evidence of bleeding.

**MANAGING OVERDOSAGE.** If a decided drop in blood pressure or rise in the pulse rate occurs, the nurse notifies the primary health care provider because this may indicate internal bleeding. Because hemorrhage may begin as a slight bleeding or bruising tendency, the nurse frequently observes the patient for these occurrences (see discussion of warfarin). At times, hemorrhage can occur without warning. If bleeding should occur, the primary health care provider may decrease the dose, discontinue
the heparin therapy for a time, or order the administra-
tion of protamine sulfate.

In most instances, discontinuation of the drug is suf-
ficient to correct overdosage because the duration of
action of heparin is short. However, if hemorrhaging is
severe, the primary health care provider may order pro-
tamine sulfate, the specific heparin antagonist or anti-
dote. Protamine sulfate is also used to treat overdosage
of the LMWHs. Protamine sulfate has an immediate
onset of action and a duration of 2 hours. It counteracts
the effects of heparin and brings blood coagulation tests
to within normal limits. The drug is given slowly via the
IV route during a period of 10 minutes.

Nursing Alert
Protamine sulfate can result in severe hypotension and ana-
phylactic reaction. When administering protamine sulfate, the
nurse should make sure that resuscitation equipment is read-
ily available.

If administration of this drug is necessary, the nurse
monitors the patient’s blood pressure and pulse rate every
15 to 30 minutes for 2 hours or more after administration
of the heparin antagonist. The nurse immediately reports
to the primary health care provider any sudden decrease
in blood pressure or increase in the pulse rate. The nurse
observes the patient for new evidence of bleeding until
blood coagulation tests are within normal limits. To
replace blood loss, the primary health care provider may
order blood transfusions or fresh frozen plasma.

Educating the Patient and Family
Although heparin is given in the hospital, the LMWHs
can be administered at home by a home health nurse, the
patient, or a family member. The patient or a family
member is taught how to administer the drug by the SC
route (see technique under Promoting an Optimal
Response to Therapy). Prefilled syringes are available,
making administration more convenient. The nurse
instructs the patient to apply firm pressure after the
injection to prevent hematoma formation. Each time the
drug is given, the nurse inspects all recent injection sites
for signs of inflammation (redness, swelling, tenderness)
and hematoma formation.

The nurse includes the following in a patient and
family teaching plan:
• Report any signs of active bleeding immediately.
• Regular coagulation blood tests are critical for safe
monitoring of the drug (except the LMWHs).
• Avoid IM injections while receiving anticoagulant
therapy.
• Use a soft toothbrush when cleaning the teeth and
an electric razor for shaving.
• Do not take any prescription or nonprescription
drugs without consulting the primary health care
provider. Drugs containing alcohol, aspirin, or
ibuprofen may alter the effects of heparin.
• Advise your dentist or primary health care provider
of anticoagulant therapy before any procedure or
surgery.
• Carry appropriate identification with information
concerning drug therapy or wear a medical alert tag
at all times.

EVALUATION
• The therapeutic drug effect is achieved.
• Adverse drug reactions are identified, reported to
the primary health care provider, and managed suc-
cessfully through appropriate nursing interventions.
• No evidence of bleeding is seen.
• The patient verbalizes an understanding of treat-
ment modalities.

THROMBOLYTIC DRUGS

Thrombolytics are a group of drugs used to dissolve
certain types of blood clots and reopen blood vessels
after they have been occluded. Examples of thrombolyt-
ics include alteplase* recombinant (Activase), reteplase
recombinant (Retavase), streptokinase (Streptase),
tenecteplase (TNKase), and urokinase (Abbokinase).
Before these drugs are used, their potential benefits
must be carefully weighed against the potential dangers
of bleeding.

ACTIONS

Although the exact action of the thrombolytic drugs is
slightly different, these drugs break down fibrin clots by
converting plasminogen to plasmin (fibrinolysin). Plasmin
is an enzyme that breaks down the fibrin of a
blood clot. This reopens blood vessels after their occlu-
sion and prevents tissue necrosis.

USES

These drugs are used to treat an acute MI by lysing (dis-
solving) a blood clot in a coronary artery. These drugs
are also effective in lysing clots causing PE and DVT.
Urokinase is also used to treat PE and to clear IV

*Alteplase is a tissue plasminogen activator (tPA) that is produced by
recombinant DNA. Recombinant DNA is obtained by using gene
splicing. Specific DNA segments of one organism are placed in the
DNA of another organism. The genetic material of the recipient
organism then reproduces itself and contains genetic material of its
own plus the genetic material from the donor organism.
catheter cannulas obstructed by a blood clot. See the Summary Drug Table: Thrombolytics for a more complete listing of the use of these drugs.

**ADVERSE REACTIONS**

Bleeding is the most common adverse reaction seen with the use of these drugs. Bleeding may be internal and involve areas such as the GI tract, genitourinary tract, and the brain. Bleeding may also be external (superficial) and may be seen at areas of broken skin, such as venipuncture sites and recent surgical wounds. Allergic reactions may also be seen.

**CONTRAINDICATIONS**

Thrombolytic drugs are contraindicated in patients with known hypersensitivity, active bleeding, history of stroke, aneurysm, and recent intracranial surgery.

**PRECAUTIONS**

These drugs are used cautiously in patients who have recently undergone major surgery (within 10 days or less), such as coronary artery bypass graft, or experienced stroke, trauma, vaginal or cesarean section delivery, GI bleeding, or trauma within the last 10 days; those who have hypertension, diabetic retinopathy, or any condition in which bleeding is a significant possibility; and patients currently receiving oral anticoagulants. All of the thrombolytic drugs discussed in this chapter are classified in Pregnancy Category C, with the exception of urokinase, which is a Pregnancy Category B drug.

**INTERACTIONS**

Administration of the thrombolytic drugs with aspirin, dipyridamole, or the anticoagulants may increase the risk of bleeding.
The Patient Receiving a Thrombolytic Drug

ASSESSMENT

Preadministration Assessment
During the preadministration assessment the nurse interviews the patient or family and notes any history of conditions that might contraindicate the use of a thrombolytic drug (see Contraindications). The nurse identifies any history of bleeding tendencies, heart disease, or allergic reactions to any drugs. In addition, a history of any drugs currently being taken is obtained. The nurse reports any relevant information to the primary health care provider before the drug is administered. Initial patient assessments include vital signs and a review of the diagnostic tests performed to establish a diagnosis. Most of these patients are admitted or transferred to an intensive care unit because close monitoring for 48 hours or more after therapy is necessary.

Ongoing Assessment
The most important aspect of the ongoing assessment is the possibility of bleeding. The nurse must assess the patient for bleeding every 15 minutes during the first 60 minutes of therapy, every 15 to 30 minutes for the next 8 hours, and at least every 4 hours until therapy is completed. Vital signs are taken at least every 4 hours for the duration of therapy.

The nurse must continually assess the patient for anaphylactic reactions (difficulty breathing, wheezing, fever, swelling around the eyes, hives, or itching) particularly with anistreplase or streptokinase. Resuscitation equipment is immediately available.

IMPLEMENTATION

Promoting an Optimal Response to Therapy
For optimal therapeutic effect the thrombolytic drugs are used as soon as possible after the formation of a thrombus, preferably within 4 to 6 hours or as soon as possible after the symptoms are identified. The greatest benefit in mortality is seen when the drugs are administered within 4 hours, but studies indicate that significant benefit has been reported when the agents were used within the first 24 hours. The nurse must follow the primary health care provider’s orders precisely regarding dosage and time of administration. These drugs are available in powder form and must be reconstituted according to the directions in the package insert.

Tenecteplase (TNKase) is the first thrombolytic drug that can be administered during a period of 5 seconds in a single dose. The drug is administered intravenously only and offers the fastest administration of a thrombolytic in the treatment of an acute MI. Specific instructions for reconstitution come with the drug. The drug is reconstituted immediately before use because it contains no antibacterial preservatives.

If pain is present, the primary health care provider may order a narcotic analgesic. Once the clot is dissolved and blood flows freely through the obstructed blood vessel, severe pain usually decreases.

When using urokinase to clear an occluded IV catheter, the nurse follows the manufacturer’s instructions in the packaged insert. The nurse avoids using excessive pressure when the drug is injected into the catheter. Excessive force could rupture the catheter or expel the clot into the circulation. It is important to remember that if the catheter is occluded by substances other than blood fibrin clots, such as drug precipitates, urokinase is not effective.

Monitoring and Managing Adverse Drug Reactions
Bleeding is the most common adverse reaction. Throughout administration of the thrombolytic drug, the nurse assesses for signs of bleeding and hemorrhage (see earlier discussion on warfarin). Internal bleeding may involve the GI tract, genitourinary tract, intracranial sites, or respiratory tract. Symptoms of internal bleeding may include abdominal pain, coffee-ground emesis, black tarry stools, hematuria, joint pain, and spitting or coughing up of blood. Superficial bleeding.
may occur at venous or arterial puncture sites or recent surgical incision sites. As fibrin is lysed during therapy, bleeding from recent injection sites may occur. The nurse must carefully monitor all potential bleeding sites (including catheter insertions sites, arterial and venous puncture sites, cutdown sites, and needle puncture sites). For minor bleeding at a puncture site, the nurse can usually control bleeding by applying pressure for at least 30 minutes at the site, followed by the application of a pressure dressing. The puncture site is checked frequently for evidence of further bleeding. Intramuscular injections and nonessential handling of the patient are avoided during treatment. Venipunctures are done only when absolutely necessary.

- Adverse reactions are identified, reported to the primary health care provider, and managed using appropriate nursing interventions.
- The patient and family demonstrate an understanding of treatment and techniques necessary to monitor therapy.

### Critical Thinking Exercises

1. Ms. Jackson, age 56 years, is hospitalized with a venous thrombosis. The primary health care provider orders SC heparin. In developing a care plan for Ms. Jackson, discuss the nursing interventions that would be most important to prevent complications while administering heparin. Provide a rationale for each intervention.

2. Mr. Harris, age 72 years, is a widower who has lived alone since his wife died 5 years ago. He has been prescribed warfarin to take at home after his dismissal from the hospital. Determine which questions concerning the home environment would be important to ask Mr. Harris to prepare him to care for himself and prevent any complications associated with the warfarin.

3. A patient enters the emergency department with an acute MI. Thrombolytic therapy is begun with streptokinase. Discuss ongoing assessments that are important for the nurse to perform.

4. Discuss the use of laboratory tests in monitoring heparin administration.

### Review Questions

1. The patient is receiving the first dose of warfarin. Before administering the drug, the nurse _______.
   - A. administers a loading of heparin
   - B. has the laboratory draw blood for a serum potassium level
   - C. takes the apical pulse
   - D. checks to see that blood has been drawn for a baseline prothrombin time

2. The nurse monitors the prothrombin time (PT) during therapy. Optimal PT for warfarin therapy is _______.
   - A. more than 15 seconds
   - B. less than 25 seconds
   - C. 1.8 to 2 times the control value
   - D. 1.2 to 1.5 times the control value

3. There is an increased risk for bleeding when the patient receiving heparin is also taking _______.
   - A. allopurinol
   - B. an NSAID
   - C. digoxin
   - D. furosemide
4. In which of the following situations would the nurse expect a LMWH to be prescribed?
   A. to prevent a DVT
   B. for a patient with disseminated intravascular coagulation
   C. to prevent hemorrhage
   D. for a patient with atrial fibrillation

5. If bleeding is noted while a patient is receiving a thrombolytic drug, the patient may receive ______.
   A. heparin
   B. whole blood or fresh, frozen plasma
   C. a diuretic
   D. protamine sulfate

Medication Dosage Problems

1. The patient is prescribed 5000 U heparin. The drug is available as a solution of 7500 U/mL. The nurse administers ______.
2. Warfarin 5 mg is prescribed. On hand are 2.5-mg tablets. The nurse administers ______.
Anemia is a decrease in the number of red blood cells (RBCs), a decrease in the amount of hemoglobin in RBCs, or both a decrease in the number of RBCs and hemoglobin. When there is an insufficient amount of hemoglobin to deliver oxygen to the tissues, anemia exists. There are various types and causes of anemia. For example, anemia can be the result of blood loss, excessive destruction of RBCs, inadequate production of RBCs, and deficits in various nutrients, such as in iron deficiency anemia. Once the type and cause have been identified, the primary health care provider selects a method of treatment.

The anemias discussed in this chapter include iron deficiency anemia, anemia in patients with chronic renal disease, pernicious anemia, and anemia resulting from a folic acid deficiency. Table 45-1 defines these anemias. Drugs used in treatment of anemia are summarized in the Summary Drug Table: Drugs Used in the Treatment of Anemia.

**DRUGS USED IN THE TREATMENT OF IRON DEFICIENCY ANEMIA**

Iron deficiency anemia is by far the most common type of anemia. Iron is a component of hemoglobin, which is in RBCs. It is the iron in the hemoglobin of RBCs that picks up oxygen from the lungs and carries it to all body tissues. Iron is stored in the body and is found mainly in the reticuloendothelial cells of the liver, spleen, and bone marrow. When the body does not have enough iron to supply the body’s needs, the resulting condition is iron deficiency anemia.

**ACTIONS AND USES**

Iron salts, such as ferrous sulfate or ferrous gluconate, are used in the treatment of iron deficiency anemia, which occurs when there is a loss of iron that is greater than the available iron stored in the body. Iron preparations act by elevating the serum iron concentration, which replenishes hemoglobin and depleted iron stores.

Iron dextran is a parenteral iron that is also used for the treatment of iron deficiency anemia. It is primarily used when the patient cannot take oral drugs or when the patient experiences gastrointestinal intolerance to oral iron administration. Other iron preparations, both oral and parenteral, used in the treatment of iron deficiency anemia can be found in the Summary Drug Table: Drugs Used in the Treatment of Anemia.
ADVERSE REACTIONS

Iron salts occasionally cause gastrointestinal irritation, nausea, vomiting, constipation, diarrhea, headache, backache, and allergic reactions. The stools usually appear darker (black). Iron dextran is given by the parenteral route. Hypersensitivity reactions, including fatal anaphylactic reactions, have been reported with the use of this form of iron. Additional adverse reactions include soreness, inflammation, and sterile abscesses at the intramuscular (IM) injection site. Intravenous (IV) administration may result in phlebitis at the injection site. When iron is administered via the IM route, a brownish discoloration of the skin may occur. Patients with rheumatoid arthritis may experience an acute exacerbation of joint pain, and swelling may occur when iron dextran is administered.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Drugs used to treat anemia are contraindicated in patients with known hypersensitivity to the drug or any component of the drug. Iron compounds are contraindicated in patients with any anemia except iron deficiency anemia. Iron compounds are used cautiously in patients with tartrazine or sulfite sensitivity because some iron compounds contain these substances. Oral iron preparations are Pregnancy Category B drugs; iron dextran is a Pregnancy Category C drug. The iron preparations are used cautiously during pregnancy and lactation. Iron dosages of 15 to 30 mg/d are sufficient to meet the needs of pregnancy. Iron dextran is used cautiously in patients with cardiovascular disease, a history of asthma or allergies, and rheumatoid arthritis (may exacerbate joint pain).

The absorption of oral iron is decreased when the agent is administered with antacids, tetracyclines, penicillamine, and the fluoroquinolones. When iron is administered with levothyroxine, there may be a decrease in the effectiveness of levothyroxine. When administered orally, iron decreases the absorption of levodopa. Ascorbic acid increases the absorption of oral iron. Iron dextran administered concurrently with chloramphenicol increases serum iron levels.

DRUGS USED IN THE TREATMENT OF ANEMIA ASSOCIATED WITH CHRONIC RENAL FAILURE

Anemia may occur in patients with chronic renal failure as the result of the inability of the kidney to produce erythropoietin. Erythropoietin is a glycoprotein hormone synthesized mainly in the kidneys and used to stimulate and regulate the production of erythrocytes or red blood cells (RBCs). Failure to produce the needed erythrocytes results in anemia. Two examples of drugs used to treat anemia associated with chronic renal failure are epoetin alfa (Epogen) and darbepoetin alfa (Aranesp).

ACTIONS AND USES

Epoetin alfa is a drug that is produced using recombinant DNA technology. The drug acts in a manner similar to that of natural erythropoietin. Epoetin alfa is used to treat anemia associated with chronic renal failure, anemia in patients with cancer who are receiving chemotherapy, and in patients with anemia who are undergoing elective nonvascular surgery. Darbepoetin alfa (Aranesp) is an erythropoiesis-stimulating protein produced in Chinese hamster ovary cells by recombinant DNA technology. Darbepoetin stimulates erythropoiesis by the same manner as natural erythropoietin. The drug is used to treat anemia associated with chronic renal failure in patients receiving dialysis as well as for patients who are not receiving dialysis. These drugs elevate or maintain RBC levels and decrease the need for transfusions.

ADVERSE REACTIONS

Epoetin alfa (erythropoietin; EPO) and darbepoetin alfa are usually well tolerated. The most common adverse reactions include hypertension, headache, tachycardia, nausea, vomiting, diarrhea, skin rashes, fever, myalgia, and skin reaction at the injection site. See the Summary Drug Table: Drugs Used in the Treatment of Anemia for more information on these drugs.
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>darbepoetin alfa</td>
<td>Aranesp</td>
<td>Anemia associated with chronic renal failure</td>
<td>Hypertension, hypotension, headache, diarrhea, vomiting, nausea, myalgia, infection, cardiac arrhythmias, cardiac arrest</td>
<td>0.45 mcg/kg IV, SC weekly</td>
</tr>
<tr>
<td>epoetin alfa (Erythropoietin; (EPO)</td>
<td>Epogen, Procrit</td>
<td>Anemia associated with chronic renal failure, anemia related to zidovudine therapy in HIV-infected patients, anemia in cancer patients receiving chemotherapy, anemia in patients who undergo elective nonvascular surgery</td>
<td>Hypertension, headache, tachycardia, nausea, vomiting, skin rashes, fever, skin reaction at injection site</td>
<td>Individualized dosage CRF 50—100 U/kg (3 times weekly IV or SC), maintenance based on HCT, generally 25 U/kg 3 times weekly; zidovudine-treated HIV-infected patients: 100 U/kg 3 times weekly; cancer: 150 U/kg 3 times weekly; surgery: 300 U/kg/d SC x 10 d before surgery, on day of surgery and 4 days after surgery</td>
</tr>
<tr>
<td>ferrous fumarate (33% elemental iron)</td>
<td>Feostat, generic</td>
<td>Prevention and treatment of iron deficiency anemia</td>
<td>GI irritation, nausea, vomiting, constipation, diarrhea, allergic reactions</td>
<td>Daily requirements: males, 10 mg/d PO; females, 18 mg/d PO; during pregnancy and lactation, 30–60 mg/d PO; replacement in deficiency states, 90–300 mg/d (6 mg/kg/d) PO for 6–10 months</td>
</tr>
<tr>
<td>ferrous gluconate (11.6% elemental iron)</td>
<td>Fergon, generic</td>
<td>Prevention and treatment of iron deficiency anemia</td>
<td>GI irritation, nausea, vomiting, constipation, diarrhea, allergic reactions</td>
<td>Daily requirements: males, 10 mg/d PO; females, 18 mg/d PO; during pregnancy and lactation, 30–60 mg/d PO; replacement in deficiency states, 90–300 mg/d (6 mg/kg/d) PO for 6–10 months</td>
</tr>
<tr>
<td>ferrous sulfate (20% elemental iron)</td>
<td>Feosol, Fer-In-Sol, generic</td>
<td>Prevention and treatment of iron deficiency anemia</td>
<td>GI irritation, nausea, vomiting, constipation, diarrhea, allergic reactions</td>
<td>Daily requirements: males, 10 mg/d PO; females, 18 mg/d PO; during pregnancy and lactation, 30–60 mg/d PO; replacement in deficiency states, 90–300 mg/d (6 mg/kg/d) PO for 6–10 months</td>
</tr>
<tr>
<td>folic acid</td>
<td>Folvite, generic</td>
<td>Megalooblastic anemia due to deficiency of folic acid</td>
<td>Allergic sensitization</td>
<td>Up to 1 mg/d PO, IM, IV, SC</td>
</tr>
<tr>
<td>iron dextran</td>
<td>DexFerrum, InFeD, generic</td>
<td>Iron deficiency anemia</td>
<td>Anaphylactoid reactions, soreness and inflammation at injection site, chest pain, arthralgia, backache, convulsions, pruritus, abdominal pain, nausea, vomiting, dyspnea</td>
<td>Dosage based on body weight and grams percent (g/dL) of hemoglobin IV, IM</td>
</tr>
</tbody>
</table>
CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Epoetin alfa is contraindicated in patients with uncontrolled hypertension, those needing an emergency transfusion, or those with a hypersensitivity to human albumin. Darbepoetin alfa (Aranesp) is contraindicated in patients with uncontrolled hypertension or in those allergic to the drug.

Epoetin alfa and darbepoetin alfa are used with caution in patients with hypertension, heart disease, congestive heart failure, or a history of seizures. Both of these drugs are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation.

DRUGS USED IN THE TREATMENT OF FOLIC ACID DEFICIENCY ANEMIA

Folic acid is required for the manufacture of RBCs in the bone marrow. Folic acid is found in leafy green vegetables, fish, meat, poultry, and whole grains. A deficiency of folic acid results in megaloblastic anemia. Megaloblastic anemia is characterized by the presence of large, abnormal, immature erythrocytes circulating in the blood.

ACTION AND USES

Folic acid is used in the treatment of megaloblastic anemias that are caused by a deficiency of folic acid. Although not related to anemia, studies indicate there is a decreased risk for neural tube defects if folic acid is taken before conception and during early pregnancy. Neural tube defects occur during early pregnancy, when the embryonic folds forming the spinal cord and brain join together. Defects of this type include anencephaly (congenital absence of brain and spinal cord), spina bifida (defect of the spinal cord), and meningocele (a saclike protrusion of the meninges in the spinal cord or skull). The United States Public Health Service recommends the use of folic acid for all women of childbearing age to decrease the incidence of neural tube defects. Dosages during pregnancy and lactation are as great as 0.8 mg/d.
Leucovorin is a derivative (and active reduced form) of folic acid. The oral and parenteral forms of this drug are used in the treatment of megaloblastic anemia. Leucovorin may also be used to diminish the hematologic effects of (intentional) massive doses of methotrexate, a drug used in the treatment of certain types of cancer (see Chap. 55). Leucovorin “rescues” normal cells from the destruction caused by methotrexate and allows them to survive. This technique of administering leucovorin after a large dose of methotrexate is called folinic acid rescue or leucovorin rescue. Occasionally, high doses of methotrexate are administered to select patients. Leucovorin is then used either at the time methotrexate is administered or a specific number of hours after the methotrexate has been given to decrease the toxic effects of the methotrexate. Leucovorin may be ordered to be given via the IV, IM, or oral route.

ADVERSE REACTIONS

Few adverse reactions are associated with the administration of folic acid and leucovorin. Rarely, parenteral administration may result in allergic hypersensitivity.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Folic acid and leucovorin are contraindicated for the treatment of pernicious anemia or for other anemias for which vitamin B₁₂ is deficient. Folic acid is a Pregnancy Category A drug and is generally considered safe for use during pregnancy. Pregnant women are more likely to experience folate acid deficiency because folic acid requirements are increased during pregnancy. Pregnant women with a folate deficiency are at increased risk for complications of pregnancy and fetal abnormalities. The recommended daily allowance (RDA) of folate during pregnancy is 0.4 mg/d and during lactation, 0.26 to 0.28 mg/d. Although fetal harm appears remote, the drug should be used cautiously and only within the RDAs. Use of aminosalicylic acid with folic acid may reduce serum folate levels. Folic acid utilization is decreased when folate is administered with methotrexate. Signs of folic acid deficiency may occur when sulfasalazine is administered concurrently. An increase in seizure activity may occur when folic acid is administered with the hydantoins.

Leucovorin is a Pregnancy Category C drug and is used cautiously during pregnancy.

Leucovorin decreases the effectiveness of the anti-convulsants. There is an increased risk of 5-fluorouracil toxicity when the drug is administered with leucovorin.

DRUGS USED IN THE TREATMENT OF PERNICIOUS ANEMIA

Vitamin B₁₂ is essential to growth, cell reproduction, the manufacture of myelin (which surrounds some nerve fibers), and blood cell manufacture. The intrinsic factor, which is produced by cells in the stomach, is necessary for the absorption of vitamin B₁₂ in the intestine. A deficiency of the intrinsic factor results in abnormal formation of erythrocytes because of the body’s failure to absorb vitamin B₁₂, a necessary component for blood cell formation. The resulting anemia is a type of megaloblastic anemia called pernicious anemia.

ACTIONS AND USES

Vitamin B₁₂ (cyanocobalamin) is used to treat a vitamin B₁₂ deficiency. A vitamin B₁₂ deficiency may be seen in:

- Strict vegetarians
- Persons who have had a total gastrectomy or subtotal gastric resection (when the cells producing the intrinsic factor are totally or partially removed)
- Persons who have intestinal diseases, such as ulcerative colitis or sprue
- Persons who have gastric carcinoma
- Persons who have a congenital decrease in the number of gastric cells secreting intrinsic factor

Vitamin B₁₂ is also used to perform the Schilling test, which is used to diagnose pernicious anemia.

Nursing Alert

Pernicious anemia must be diagnosed and treated as soon as possible because vitamin B₁₂ deficiency that is allowed to progress for more than 3 months may result in degenerative lesions of the spinal cord.

A deficiency of this vitamin caused by a low dietary intake of vitamin B₁₂ is rare because the vitamin is found in meats, milk, eggs, and cheese. The body is also able to store this vitamin; a deficiency, for any reason, will not occur for 5 to 6 years.

ADVERSE REACTIONS

Mild diarrhea and itching have been reported with the administration of vitamin B₁₂. Other adverse reactions that may be seen include a marked increase in RBC production, acne, peripheral vascular thrombosis, congestive heart failure, and pulmonary edema.
CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Vitamin B₁₂ is contraindicated in patients allergic to cobalt. Vitamin B₁₂ is a Pregnancy Category A drug if administered orally and a Pregnancy Category C drug if given parenterally. Vitamin B₁₂ is administered cautiously during pregnancy and in patients with pulmonary disease and anemia. Alcohol, aminosalicylic acid, neomycin, and colchicine may decrease the absorption of oral vitamin B₁₂.

NURSING PROCESS

The Patient Receiving a Drug Used in the Treatment of Anemia

ASSESSMENT

Preadministration Assessment

The nurse obtains a general health history and asks about the symptoms of the anemia. The primary health care provider may order laboratory tests to determine the type, severity, and possible cause of the anemia. At times, it may be easy to identify the cause of the anemia, but there are also instances where the cause of the anemia is obscure.

The nurse takes the vital signs to provide a baseline during therapy. Other physical assessments may include the patient’s general appearance and, in the severely anemic patient, an evaluation of the patient’s ability to carry out the activities of daily living. General symptoms of anemia include fatigue, shortness of breath, sore tongue, headache, and pallor.

If iron dextran is to be given, an allergy history is necessary because this drug is given with caution to those with significant allergies or asthma. The patient’s weight and hemoglobin level are required for calculating the dosage.

Ongoing Assessment

During the ongoing assessment, the nurse takes the vital signs daily; more frequent monitoring may be needed if the patient is moderately to acutely ill or if the patient is taking epoetin alfa (because of the increased risk of hypertension). The nurse monitors the patient for adverse reactions and reports any occurrence of adverse reactions to the primary health care provider before the next dose is due. However, the nurse immediately reports severe adverse reactions.

When the patient is receiving iron salt therapy, the nurse informs the patient that the color of the stool will become darker or black. If diarrhea or constipation occurs, the nurse notifies the primary health care provider.

If iron dextran is administered, the nurse informs the patient that soreness at the injection site may occur. Injection sites are checked daily for signs of inflammation, swelling, or abscess formation.

The nurse assesses the patient for relief of the symptoms of anemia (fatigue, shortness of breath, sore tongue, headache, pallor). Some patients may note a relief of symptoms after a few days of therapy. Periodic laboratory tests are necessary to monitor the results of therapy.

I *Nursing Alert*

When monitoring the patient taking epoetin, the nurse reports any increase in the hematocrit of 4 points within any 2-week period because an exacerbation of hypertension is associated with an excessive rise of hematocrit. Hematocrit is decreased by decreasing or withholding the epoetin alfa dose.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes for the patient may include an optimal response to therapy, management of constipation, adequate nutritional status, and an understanding of and compliance with the prescribed treatment regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

IRON. Iron salts are preferably given between meals with water but can be given with food or meals if gastrointestinal upset occurs. If the patient is receiving other drugs, the nurse checks with the hospital pharmacist regarding the simultaneous administration of iron salts with other drugs.

Oral iron solutions may cause temporary staining of the teeth. The solution is diluted with 2 to 4 oz of water or juice and drunk through a straw. The stool may appear darker or black; this is a normal occurrence and not a reason for concern.

Iron dextran is given via the IM or IV route. Before iron dextran is administered, a test dose may be done by

Nursing Diagnoses Checklist

- Altered Nutrition: Less than Body Requirements related to lack of iron, folic acid, other (specify) in the diet
- Constipation related to adverse reaction to iron therapy
administering 0.5 mL of iron dextran IV at a gradual rate during a period of 30 seconds or more. A test dose is also performed before administering the first dose of iron dextran IM by injecting 0.5 mL into the upper outer quadrant. The nurse monitors the patient for an allergic response for at least 1 hour after the test dose and before administering the remaining dose.

After the test dose, the prescribed dosage of iron is administered IM. The drug is given into the muscle mass of the upper outer quadrant (never into an arm or other area) using the Z-track method (see Fig. 45-1) to prevent leakage into the subcutaneous (SC) tissue. A large-bore needle is required. If the patient is standing, have the patient place weight on the leg not receiving the injection.

**EPOETIN ALFA.** When epoetin alfa is administered to a patient with hypertension, the nurse monitors the blood pressure closely. The nurse reports any rise in the systolic
or diastolic pressure of 20 mm Hg or more to the primary health care provider. The hematocrit is usually measured before each dose during therapy with epoetin alfa.

The drug is given three times weekly IV or SC, or if the patient is receiving dialysis, the drug is administered into the venous access line. The drug is mixed gently during preparation for administration. Shaking may denature the glycoprotein. The vial is used for only one dose; any remaining or unused portion is discarded.

**Nursing Alert**

This drug is not used for treatment of severe anemia or as a substitute for emergency transfusion. However, supplemental iron may be ordered during therapy with epoetin.

**LEUCOVORIN.** When leucovorin is administered after a large dose of methotrexate, the timing of the administration is outlined by the primary health care provider. It is essential that the leucovorin be given at the exact time ordered because the purpose of folinic acid rescue is to allow a high dose of a toxic drug to remain in the body for only a limited time.

**VITAMIN B12.** Patients with pernicious anemia are treated with vitamin B₁₂ by the parenteral route (IM) weekly stabilized. The parenteral route is used because the vitamin is ineffective orally due to the absence of the intrinsic factor in the stomach, which is necessary for utilization of vitamin B₁₂. After stabilization, maintenance (usually monthly) injections are necessary for life.

**Monitoring and Managing Adverse Reactions**

When the patient is receiving iron dextran, the nurse monitors closely for a hypersensitivity reaction. Epinephrine is kept on standby in the event of severe anaphylactic reaction.

**Nursing Alert**

Parenteral iron has resulted in fatal anaphylactic-type reactions. The nurse reports any of the following adverse reactions: dyspnea, urticaria, rashes, itching, and fever.

**MANAGING CONSTIPATION.** Constipation may be a problem when a patient is taking oral iron preparations. The nurse instructs the patient to increase fluid intake to 10 to 12 glasses of water per day (if the condition permits), eat a diet high in fiber, and increase activity. An active lifestyle and regular exercise (if condition permits) help to decrease the constipating effects of iron. If constipation persists, the primary health care provider may prescribe a stool softener.

**MAINTAINING ADEQUATE NUTRITION.** A special diet (eg, foods high in iron or foods high in folic acid) may be prescribed. If the diet is taken poorly, the nurse notes this on the patient’s chart and discusses the problem with the primary health care provider.

The nurse recommends a balanced diet with an emphasis on foods that are high in iron (eg, organ meats, lean red meats, cereals, dried beans, and leafy green vegetables), folic acid (eg, green leafy vegetables, liver, and yeast) or vitamin B₁₂ (eg, beef, pork, organ meats, eggs, milk, and milk products). The nurse monitors the amount of food eaten at meals. If appetite is poor or eating is inadequate to maintain normal nutrition, a consult with the dietitian may be necessary. Small portions of food may be more appealing than large or moderate portions. The nurse provides a pleasant atmosphere and allows ample time for eating.

**Educating the Patient and Family**

The nurse explains the medical regimen thoroughly to the patient and family and emphasizes the importance of following the prescribed treatment regimen. The nurse includes the following points in a patient and family teaching plan:

**IRON SAL T**

• Take this drug with water on an empty stomach. If gastrointestinal upset occurs, take the drug with food or meals.
• Do not take antacids, tetracyclines, penicillamine, or fluoroquinolones at the same time or 2 hours before or after taking iron without first checking with the primary health care provider.
• This drug may cause a darkening of the stools, constipation, or diarrhea. If constipation or diarrhea becomes severe, contact the primary health care provider.
• Mix the liquid iron preparation with water or juice and drink through a straw to prevent staining of the teeth.
• Avoid the indiscriminate use of advertised iron products. If a true iron deficiency occurs, the cause must be determined and therapy should be under the care of a health care provider.
• Have periodic blood tests during therapy to determine the therapeutic response.
• Patients with rheumatoid arthritis may experience an acute exacerbation of joint pain, and swelling may occur with iron dextran therapy.

**EPOETIN ALFA**

• Keep all appointments with the primary health care provider. The drug is administered three times per
week (via the SC or IV route or via a dialysis access line). Periodic blood tests are performed to determine the effects of the drug and to determine dosage.

- Strict compliance with antihypertensive drug regimen is important in patients with known hypertension during epoetin therapy.
- Report numbness, tingling of extremities, severe headache, dyspnea, or chest pain. Joint pain may occur but can be controlled with analgesics.

**FOLIC ACID**

- Avoid the use of multivitamin preparations unless such use has been approved by the primary health care provider.
- Follow the diet recommended by the primary health care provider because diet and drug are necessary to correct a folic acid deficiency.

**EPOETIN ALFA**

- The drug will be administered three times weekly and can be given only via the IV or SC route or via venous access during dialysis.
- Keep appointments for blood testing, which is necessary to determine the effects of the drug on the blood count and to determine dosage.
- The following adverse reactions may occur: dizziness, headache, fatigue, joint pain, nausea, vomiting, or diarrhea. Report any of these reactions.

**LEUCOVORIN**

- Megaloblastic anemia—Adhere to the diet prescribed by the primary health care provider. If the purchase of foods high in protein (which can be expensive) becomes a problem, discuss this with the primary health care provider.
- Folinic acid rescue—Take this drug at the exact prescribed intervals. If nausea and vomiting occur, contact the primary health care provider immediately.

**VITAMIN B12**

- Nutritional deficiency of vitamin B₁₂—Eat a balanced diet that includes seafood, eggs, meats, and dairy products.
- Pernicious anemia—Lifetime therapy is necessary. Eat a balanced diet that includes seafood, eggs, meats, and dairy products. Avoid contact with infections, and report any signs of infection to the primary health care provider immediately because an increase in dosage may be necessary.
- Adhere to the treatment regimen and keep all appointments with the clinic or primary health care provider. The drug is given at periodic intervals (usually monthly for life). In some instances, par-}

enteral self-administration or parenteral administration by a family member is allowed (instruction in administration is necessary).

**EVALUATION**

- The therapeutic effect of the drug is achieved.
- The patient has normal bowel movements.
- An adequate nutritional intake is achieved.
- The patient and family demonstrate an understanding of the drug regimen.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.

**Critical Thinking Exercises**

1. **Ms. Clepper, age 32 years, has received a diagnosis of pernicious anemia. Although the primary health care provider has explained the diagnosis and the treatment, the patient is confused and frightened. She questions you stating, “I just don’t understand what is happening in my body to cause me to feel so weak and tired. How is the treatment going to work?” Discuss ways in which you would handle this situation with Ms. Clepper. Determine what to tell her that would decrease her anxiety and increase her understanding.**

2. **Mr. Garcia, age 54 years, has chronic renal failure. He undergoes dialysis three times a week. The physician orders epoetin alfa to be administered. Discuss the preadministration and ongoing assessments for Mr. Garcia. During a discussion with you, Mr. Garcia asks why he is receiving this drug. Discuss how you would answer Mr. Garcia’s question.**

**Review Questions**

1. Which is the most common type of anemia?
   - A. Iron deficiency anemia
   - B. Folic acid anemia
   - C. Pernicious anemia
   - D. Megaloblastic anemia

2. Which of the following substances would decrease the absorption of oral iron?
   - A. Antacids
   - B. Levothyroxine
   - C. Ascorbic acid
   - D. Vitamin B₁₂

3. Folic acid and leucovorin are contraindicated in which of the following conditions?
   - A. Hypothyroidism
   - B. Hyperthyroidism
   - C. Pernicious anemia
   - D. Pregnancy
4. When monitoring a patient taking epoetin alfa, which of the following lab results would be most important for the nurse to report immediately?  
   A. Any increase in hematocrit of 4 points within a 2-week period  
   B. Any increase in hematocrit of 2 points within a 2-week period  
   C. A daily change in the hematocrit of 1 point or more  
   D. A stabilization in the hematocrit in any 2-day period  

5. When teaching a patient about the use of vitamin B₁₂ for pernicious anemia, the nurse would include which of the following statements?  
   A. Take the oral form of vitamin B₁₂ daily at bedtime on an empty stomach.  
   B. Take the oral form of vitamin B₁₂ when you begin to feel weak or experience a headache.  
   C. You will require vitamin B₁₂ injections monthly for life.  
   D. You will require vitamin B₁₂ injections every 2 weeks until remission occurs.  

---  

**Medication Dosage Problems**  

1. The physician prescribes 25 mg iron dextran IM. The drug is available in a vial with 50 mg/mL. The nurse administers _____.

2. Folvite (folic acid) 1 mg SC is prescribed. The drug is available in a vial with 5 mg/mL. The nurse administers _____.
A diuretic is a drug that increases the secretion of urine (ie, water, electrolytes, and waste products) by the kidneys. Many conditions or diseases, such as heart failure, endocrine disturbances, and kidney and liver diseases can cause retention of excess fluid (edema). When the patient shows signs of excess fluid retention, the primary health care provider may order a diuretic. There are various types of diuretic drugs, and the primary health care provider selects the one that best suits the patient's needs and effectively reduces the amount of excess fluid in body tissues.

The different types of diuretic drugs are:

- Carbonic anhydrase inhibitors
- Loop diuretics
- Osmotic diuretics
- Potassium-sparing diuretics
- Thiazides and related diuretics

The Summary Drug Table: Diuretics lists examples of the different types of diuretic drugs. Most diuretics act on the tubules of the kidney nephron (Fig. 46-1), the functional unit of the kidney. Each kidney contains about one million nephrons, which filter the bloodstream to remove waste products. During this process, water and electrolytes are also selectively removed. The filtrate (ie, the fluid removed from the blood) normally contains ions (potassium, sodium, chloride), waste products (ammonia, urea), water, and at times other substances that are being excreted from the body, such as drugs. The filtrate then passes through the proximal tubule, the loop of Henle, and the distal tubules. At these points, selective reabsorption of amino acids, glucose, some electrolytes, and water occurs. Ions and water that are required by the body to maintain fluid and electrolyte balance are returned to the bloodstream by means of the minute capillaries that surround the distal and proximal tubules and the loop of Henle. Ions and water that are not needed by the body are excreted in the urine.

Diuretics are used in a variety of medical disorders. The primary health care provider selects the type of diuretic that will most likely be effective for treatment of a specific disorder. In some instances, hypertension may be treated with the administration of an antihypertensive drug and a diuretic. The diuretics used for this combination therapy include the loop diuretics and the thiazides and related diuretics. The specific uses of each type of diuretic drug are discussed in the following sections.
# Drugs That Affect the Gastrointestinal and Urinary Systems

## SUMMARY DRUG TABLE:

### DIURETICS

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Carbonic Anhydrase Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>acetazolamide</td>
<td>Diamox, generic</td>
<td>Open-angle glaucoma, secondary glaucoma, preoperatively to lower intraocular pressure (IOP), edema due to CHF, drug-induced edema, centrencephalic epilepsy</td>
<td>Fever, rash, paresthesias, photosensitivity, crystalluria, acidosis, urticaria, pruritus, hematuria, weakness, malaise, anorexia, hematologic changes, convulsions</td>
<td>Glaucoma: up to 1 g/d PO in divided doses; acute glaucoma: 500 mg initially then 125–250 mg PO q4h; epilepsy: 8–30 mg kg/d in divided doses; CHF and edema: 250–375 mg/d PO 50–100 mg PO BID, TID</td>
</tr>
<tr>
<td>methazolamide</td>
<td>Neptaze</td>
<td>Glaucoma</td>
<td>Same as acetazolamide</td>
<td></td>
</tr>
</tbody>
</table>

| **Loop Diuretics** | | | | |
| bumetanide | Bumex, generic | Edema due to CHF, cirrhosis of the liver, renal disease, acute pulmonary edema (IV) | Electrolyte imbalances, anorexia, nausea, vomiting, dizziness, rash, photosensitivity reactions, postural or orthostatic hypotension, glycosuria | 0.5–10 mg/d PO, IV, IM |
| ethacrynic acid | Edecrin, Edecrin Sodium | Same as bumetanide plus ascites due to malignancy, idiopathic edema, lymphedema | Same as bumetanide | 50–200 mg/d PO; 0.5–1 mg/kg IV |
| furosemide | Lasix, generic | Same as bumetanide plus hypertension (PO) | Same as bumetanide | Edema: up to 600 mg/d PO in single or divided doses, 20–40 mg IM, IV; hypertension: up to 40 mg PO BID; acute pulmonary edema: 40–80 mg IV |
| torsemide | Demadex | Same as bumetanide | Headache, dizziness, diarrhea, electrolyte imbalances, ECG abnormalities, nausea, anorexia, drowsiness | CHF: 10–20 mg/d PO, IV; renal failure: 20 mg/d PO, IV; cirrhosis, hypertension: 5–10 mg/d PO, IV |

| **Osmotic Diuretics** | | | | |
| glycerin (glycerol) | Osmoglyn | Glaucoma, before and after surgery | Fluid and electrolyte imbalance, headache, nausea, vomiting, diarrhea, electrolyte abnormalities | 1–2 g/kg PO |
| isosorbide | Ismotic | Same as glycerin | Same as glycerin | 1–3 mg/kg BID-QID PRN PO |
| mannitol | Osmitrol, generic | To promote diuresis in acute renal failure, reduction of IOP, treatment of cerebral edema | Edema, fluid and electrolyte imbalance, headache, blurred vision, nausea, vomiting, diarrhea, urinary retention | 50–200 g/24 h IV; IOP: 1.5–2 g/kg IV |
| urea | Ureaphil | Reduction of IOP, reduction of intracranial pressure | Headache, nausea, vomiting, fluid and electrolyte imbalance, syncope | Up to 120 g/d IV |

| **Potassium-Sparing Diuretics** | | | | |
| amiloride hydrochloride | Midamor | CHF, hypertension, hypokalemia from other diuretics, prevention of hypokalemia in at-risk patients | Headache, nausea, anorexia, diarrhea, vomiting, weakness, hyperkalemia, dizziness, rash, hypotension | 5–20 mg/d PO |
### SUMMARY DRUG TABLE  DIURETICS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>spironolactone</td>
<td>Aldactone, generic</td>
<td>Hypertension, edema due to CHF, cirrhosis, renal disease; hypokalemia, prophylaxis of hypokalemia in those taking digitalis, hyperaldosteronism</td>
<td>Cramping, diarrhea, drowsiness, lethargy, rash, drug fever, hyperkalemia, gastritis, headache, inability to achieve an erection, gynecomastia</td>
<td>Up to 400 mg/d PO in single dose or divided doses</td>
</tr>
<tr>
<td>triamterene</td>
<td>Dyrenium</td>
<td>Prevention of hypokalemia, edema due to CHF, cirrhosis, renal disease</td>
<td>Diarrhea, nausea, vomiting, hyperkalemia, photosensitivity reactions, azotemia, thrombocytopenia</td>
<td>Up to 300 mg/d PO in divided doses</td>
</tr>
</tbody>
</table>

#### Thiazides and Related Diuretics

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>bendroflumethiazide</td>
<td>Naturetin</td>
<td>Edema associated with CHF, hypertension</td>
<td>Hypotension, dizziness, vertigo, light-headedness, anorexia, gastric distress, nausea, hematologic changes, photosensitivity reactions, weakness, hyperglycemia, fluid and electrolyte imbalances, diarrhea, constipation, rash</td>
<td>Edema: 5–20 mg/d; hypertension: 5–20 mg/d PO</td>
</tr>
<tr>
<td>benzthiazide</td>
<td>Exna</td>
<td>Edema associated with CHF, hypertension</td>
<td>Same as bendroflumethiazide</td>
<td>5–200 mg/d PO</td>
</tr>
<tr>
<td>chlorothiazide</td>
<td>Diuril, generic</td>
<td>Hypertension, edema due to CHF, cirrhosis, corticosteroid and estrogen therapy</td>
<td>Same as bendroflumethiazide</td>
<td>Hypertension: up to 2 g/d PO in divided doses; edema: 0.5–2 g PO, IV QID or BID</td>
</tr>
<tr>
<td>chlorthalidone</td>
<td>Hygroton, generic</td>
<td>Same as chlorothiazide</td>
<td>Same as chlorothiazide</td>
<td>Hypertension: 25–100 mg/d PO; edema: 50–200 mg/d PO</td>
</tr>
<tr>
<td>hydrochlorothiazide</td>
<td>HydroDiuril, generic</td>
<td>Same as chlorothiazide</td>
<td>Same as chlorothiazide</td>
<td>Hypertension: 25–50 mg/d PO; edema: 25–200 mg/d PO</td>
</tr>
<tr>
<td>hydroflumethiazide</td>
<td>Dicardin, Saluron</td>
<td>Same as chlorothiazide</td>
<td>Same as chlorothiazide</td>
<td>Hypertension: 50–200 mg/d PO; edema: 25–200 mg/d PO</td>
</tr>
<tr>
<td>indapamide</td>
<td>Lozol, generic</td>
<td>Hypertension, edema due to CHF</td>
<td>Same as chlorothiazide</td>
<td>Hypertension: 2.5–5 mg/d PO; edema: 2.5–5 mg/d PO</td>
</tr>
<tr>
<td>metolazone</td>
<td>Mykrox, Zaroxolyn</td>
<td>Edema in CHF, cirrhosis, corticosteroids, estrogen therapy, renal dysfunction</td>
<td>Same as bendroflumethiazide</td>
<td>Zaroxolyn: hypertension 2.5–5 mg/d PO; Mykrox: hypertension, 0.5–1 mg/d PO</td>
</tr>
<tr>
<td>methylochlorthiazide</td>
<td>Aquatensen, Enduron, generic</td>
<td>Same as chlorothiazide</td>
<td>Same as chlorothiazide</td>
<td>Hypertension: 2.5–5 mg/d PO; edema: 2.5–10 mg/d PO</td>
</tr>
<tr>
<td>polythiazide</td>
<td>Renese</td>
<td>Same as chlorothiazide</td>
<td>Same as chlorothiazide</td>
<td>Hypertension: 2–4 mg/d PO; edema: 1–4 mg/d PO</td>
</tr>
<tr>
<td>quinethazone</td>
<td>Hydromox</td>
<td>Same as bendroflumethiazide</td>
<td>Same as bendroflumethiazide</td>
<td>50–200 mg/d PO</td>
</tr>
<tr>
<td>trichlormethiazide</td>
<td>Diurese, Metahydrin, Naqua, generic</td>
<td>Same as bendroflumethiazide</td>
<td>Same as bendroflumethiazide</td>
<td>Edema: 2–4 mg/d PO; hypertension: 2–4 mg/d PO</td>
</tr>
</tbody>
</table>

*The term *generic* indicates the drug is available in generic form.

CHF, congestive heart failure; IOP, intraocular pressure.
distal and proximal tubules and in the loop of Henle. This mechanism of action at these three sites appears to increase their effectiveness as diuretics. Torsemide (Demadex) also increases urinary excretion of sodium, chloride, and water but acts primarily in the ascending portion of the loop of Henle. Bumetanide (Bumex) primarily increases the excretion of chloride but also has some sodium-excreting ability. This drug acts primarily on the proximal tubule of the nephron.

**Osmotic Diuretics**

Osmotic diuretics increase the density of the filtrate in the glomerulus. This prevents selective reabsorption of water, which allows the water to be excreted. Sodium and chloride excretion is also increased.

**Potassium-Sparing Diuretics**

Potassium-sparing diuretics work in either of two ways. Triamterene (Dyrenium) and amiloride (Midamor) depress the reabsorption of sodium in the kidney tubules, therefore increasing sodium and water excretion. Both drugs additionally depress the excretion of potassium and therefore are called potassium-sparing (or potassium-saving) diuretics. Spironolactone (Aldactone), also a potassium-sparing diuretic, antagonizes the action of aldosterone. Aldosterone, a hormone produced by the adrenal cortex, enhances the reabsorption of sodium in the distal convoluted tubules of the kidney. When this activity of aldosterone is blocked, sodium (but not potassium) and water are excreted.

**Thiazides and Related Diuretics**

Thiazides and related diuretics inhibit the reabsorption of sodium and chloride ions in the ascending portion of the loop of Henle and the early distal tubule of the nephron. This action results in the excretion of sodium, chloride, and water.

**USES**

**Carbonic Anhydrase Inhibitors**

Glaucoma is an increase in the IOP that, if left untreated, can result in blindness. Normally the eye is filled with aqueous humor in an amount that is carefully regulated to maintain the shape of the eyeball. In glaucoma, aqueous humor is increased, which causes the IOP to rise and can, without treatment, damage the retina.

Acetazolamide (Diamox) is used in the treatment of simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma when delay of surgery is desired to lower the IOP. These drugs
are also used in the treatment of edema caused by congestive heart failure (CHF), drug-induced edema, and control of epilepsy (absence [formerly petit mal] and non-localized seizures). Methazolamide (Neptazane) is used in the treatment of glaucoma.

**Loop Diuretics**

Loop diuretics are used in the treatment of edema associated with CHF, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. These drugs are particularly useful when a greater diuretic effect is desired. Furosemide is the drug of choice when a rapid diuresis is needed or if the patient has renal insufficiency. Furosemide and torsemide are also used to treat hypertension. Ethacrynic acid is also used for the short-term management of ascites caused by a malignancy, idiopathic edema, or lymphedema.

**Osmotic Diuretics**

Mannitol (Osmitrol) is used for the promotion of diuresis in the prevention and treatment of the oliguric phase of acute renal failure, as well as for the reduction of IOP and the treatment of cerebral edema. Urea (Ureaphil) is useful in reducing cerebral edema and in the reduction of IOP. Glycerin (Osmoglynn) and isosorbide (Ismotic) are used in the treatment of acute glaucoma and to reduce IOP before and after eye surgery.

**Potassium-Sparing Diuretics**

Amiloride (Midamor) is used in the treatment of CHF and hypertension and is often used with a thiazide diuretic. Spironolactone and triamterene are also used in the treatment of hypertension and edema caused by CHF, cirrhosis, and the nephrotic syndrome. A miloride, spironolactone, and triamterene are also available with hydrochlorothiazide, a thiazide diuretic that enhances the antihypertensive and diuretic effects of the drug combination while still conserving potassium.

**Thiazides and Related Diuretics**

Thiazides and related diuretics are used in the treatment of hypertension, edema caused by CHF, hepatic cirrhosis, corticosteroid and estrogen therapy, and renal dysfunction.

**ADVERSE REACTIONS**

**Carbonic Anhydrase Inhibitors**

Adverse reactions associated with short-term therapy with carbonic anhydrase inhibitors are rare. Long-term use of these drugs may result in fever, rash, paresthesia (numbness, tingling), photosensitivity reactions (exaggerated sunburn reaction when the skin is exposed to sunlight or ultraviolet light), anorexia, and crystalluria (crystals in the urine). On occasion, acidosis may occur, and oral sodium bicarbonate may be used to correct this imbalance.

**Loop Diuretics**

Adverse reactions seen with the loop diuretics may include anorexia, nausea, vomiting, dizziness, rash, postural hypotension (dizziness and light-headedness when rising suddenly from a sitting or lying position), orthostatic hypotension (hypotension after standing in one place for a long time), photosensitivity reactions, and glycosuria (glucose in the urine). Patients with diabetes who take these drugs may experience an elevation of the blood glucose level.

**Osmotic Diuretics**

The osmotic diuretics urea and mannitol are administered intravenously (IV), whereas glycerin and isosorbide are administered orally. Administration by the IV route may result in a rapid fluid and electrolyte imbalance, especially when these drugs are administered before surgery with the patient in a fasting state.

**Potassium-Sparing Diuretics**

Hyperkalemia (increase in potassium in the blood), a serious event, may be seen with the administration of potassium-sparing diuretics. Hyperkalemia is most likely to occur in patients with an inadequate fluid intake and urine output, those with diabetes or renal disease, the elderly, and those who are severely ill. In patients taking spironolactone, gynecomastia (breast enlargement in the male) may occur. This reaction appears to be related to both dosage and duration of therapy. The gynecomastia is usually reversible when therapy is discontinued, but in rare instances, some breast enlargement may remain.

Additional adverse reactions of these drugs are listed in the Summary Drug Table: Diuretics. When a potassium-sparing diuretic and a thiazide diuretic are given together, the adverse reactions associated with both drugs may be seen.

**Thiazides and Related Diuretics**

Administration of thiazides and related diuretics may be associated with numerous adverse reactions. However, many patients take these drugs without
experiencing adverse reactions other than excessive fluid and electrolyte loss, which often can be corrected with an adequate fluid intake, a balanced diet, supplemental oral electrolytes, or the eating of foods or fluids high in the electrolytes that are being lost. Some of the adverse reactions that may be seen, in addition to those listed in the Summary Drug Table: Diuretics, include gastric irritation, abdominal bloating, reduced libido, dizziness, vertigo, headache, photosensitivity, and weakness. The administration of a thiazide diuretic and a digitalis glycoside may result in cardiac arrhythmias.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Carbonic Anhydrase Inhibitors**

The carbonic anhydrase inhibitors are contraindicated in patients with known hypersensitivity to the drugs, electrolyte imbalances, severe kidney or liver dysfunction, or anuria, and for long-term use in chronic non-congestive angle-closure glaucoma (may mask worsening glaucoma).

Diuretics are used cautiously in patients with renal dysfunction. The diuretics are Pregnancy Category C drugs and must be used cautiously during pregnancy and lactation. The safety of these drugs for use during pregnancy and lactation has not been established, so they should be used only when the drug is clearly needed and when the potential benefits to the patient outweigh the potential hazards to the fetus.

There is an increased risk of cyclosporine toxicity when the drug is administered with acetazolamide. Decreased serum and urine concentrations of primidone occur when the drug is administered with acetazolamide.

**Loop Diuretics**

Loop diuretics are contraindicated in patients with known hypersensitivity to the drugs, electrolyte imbalances, severe kidney or liver dysfunction, hepatic coma, or anuria, and in infants (ethacrynic acid).

Loop diuretics are used cautiously in patients with renal dysfunction. The loop diuretics are Pregnancy Category B (ethacrynic acid and torsemide) and C drugs (furosemide and bumetanide) and must be used cautiously during pregnancy and lactation. Furosemide is used in children but should be used cautiously. The loop diuretics are used cautiously in patients with liver disease, diabetes, lupus erythematosus (may exacerbate or activate the disease), or diarrhea. Patients with sensitivity to the sulfonamides may show allergic reactions to furosemide, torsemide, or bumetanide. Additive hypotensive effects occur when the loop diuretics are given with alcohol, other antihypertensive drugs, or nitrates. Loop diuretics may increase the effectiveness of the anticoagulants or the thrombolytics. There is an increased risk of glycoside toxicity and digitalis-induced arrhythmias if the patient experiences hypokalemia while taking the loop diuretics. Otoxicity is more likely to occur if loop diuretics are given with the aminoglycosides. Plasma levels of propranolol may increase when the drug is administered with furosemide. There is an increased risk of lithium toxicity when lithium is administered with a loop diuretic. Hydantoins (phenytoin) may reduce the diuretic effects of furosemide. The effects of the loop diuretics may be decreased when they are administered with NSAIDs.

**Osmotic Diuretics**

The osmotic diuretics are contraindicated in patients with known hypersensitivity to the drugs, electrolyte imbalances, severe dehydration, or anuria and those who experience progressive renal damage after instituting therapy (mannitol). Mannitol is contraindicated in patients with active intracranial bleeding (except during craniotomy).

Osmotic diuretics are used cautiously in patients with renal or kidney impairment or electrolyte imbalances. The osmotic diuretics are Pregnancy Category B (isosorbide) and C (glycerin, mannitol, and urea) drugs and must be used cautiously during pregnancy and lactation. Additive hypotensive effects occur when the osmotic diuretics are given with other antihypertensive drugs or nitrates.

**Potassium-Sparing Diuretics**

The potassium-sparing diuretics are contraindicated in patients with known hypersensitivity to the drugs, serious electrolyte imbalances, significant renal impairment, or anuria, and those receiving another potassium-sparing diuretic. The potassium-sparing diuretics are contraindicated in patients with hyperkalemia and are not recommended for children. The potassium-sparing diuretics are used cautiously in patients with renal or kidney impairment. The diuretics are Pregnancy Category B (amiloride, triamterene) and D (spironolactone) drugs and must be used cautiously during pregnancy and lactation. The potassium-sparing diuretics are used cautiously in patients with liver disease, diabetes, or gout.

Additive hypotensive effects occur when the potassium-sparing diuretics are given with alcohol, other
Thiazides and Related Diuretics

The thiazide diuretics are contraindicated in patients with known hypersensitivity to the thiazides or related diuretics, electrolyte imbalances, renal decompensation, hepatic coma, or anuria. A cross-sensitivity reaction may occur with the thiazides and sulfonamides. Some of the thiazide diuretics contain tartrazine, which may cause allergic-type reactions or bronchial asthma in individuals sensitive to tartrazine.

All of the thiazide diuretics are Pregnancy Category B drugs, with the exception of bendroflumethiazide, benzthiazide, hydroflumethiazide, methylcloethiazide, which are Pregnancy Category C drugs. The thiazide diuretics must be used cautiously during pregnancy and lactation. These drugs are used in children but should be used cautiously.

The thiazide diuretics are used cautiously in patients with liver or kidney disease, lupus erythematosus (may exacerbate or activate the disease), or diabetes. Additive hypotensive effects occur when the thiazides are given with alcohol, other antihypertensive drugs, or nitrates.

Concurrent use of the thiazides with allopurinol may increase the incidence of hypersensitivity to allopurinol. The effects of anesthetics may be increased by thiazide administration. The effects of anticoagulants may be diminished when they are administered with a thiazide diuretic. Because thiazide diuretics may raise blood uric acid levels, dosage adjustments of antiguot drugs may be necessary. Thiazide diuretics may prolong antineoplastic-induced leukopenia. Hyperglycemia may occur when the thiazides area administered with the antidiabetic drugs. Synergistic effects may occur when the thiazide diuretics are administered concurrently with the loop diuretics, causing profound diuresis and serious electrolyte abnormalities. There is an increased risk of glycoside toxicity if the patient experiences hypokalemia while taking the thiazide diuretics.

The Patient Receiving a Diuretic

Assessment

Preadministration Assessment

Before administering a diuretic, the nurse takes the vital signs and weighs the patient. Current laboratory tests, especially the levels of serum electrolytes, are carefully reviewed. If the patient has peripheral edema, the nurse inspects the involved areas and records in the patient’s chart the degree and extent of edema. If the patient is receiving a carbonic anhydrase inhibitor for increased IOP, the patient’s description of pain and vital signs are obtained. The preadministration physical assessment of the patient receiving a diuretic for epilepsy includes vital signs and weight. The nurse reviews the patient’s chart for a description of the seizures and the frequency of their occurrence.

If the patient is to receive an osmotic diuretic, the focus of the assessment is on the patient’s disease or disorder and the symptoms being treated. For example, if the patient has a low urinary output and the osmotic diuretic is given to increase urinary output, the nurse reviews the intake and output ratio and symptoms the patient is experiencing. In addition, the nurse weighs the patient and takes the vital signs as part of the physical assessment before starting drug therapy.

Ongoing Assessment

During initial therapy, the nurse observes the patient for the effects of drug therapy. The type of assessment will depend on factors such as the reason for the
administration of the diuretic, the type of diuretic administered, the route of administration, and the condition of the patient. The nurse measures and records fluid intake and output and reports to the primary health care provider any marked decrease in the output. During ongoing therapy, the nurse weighs the patient at the same time daily, making certain that the patient is wearing the same amount or type of clothing. Depending on the specific diuretic, frequent serum electrolyte, uric acid, and liver and kidney function tests may be performed during the first few months of therapy and periodically thereafter.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes for the patient depend on the reason for administration of the diuretic but may include an optimal response to drug therapy, management of adverse drug reactions, correction of a fluid volume deficit, absence of injury, and an understanding of and compliance with the postdischarge drug regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy
Before the first dose of a diuretic is given, the nurse explains to the patient the purpose of the drug (ie, to rid the body of excess fluid), when diuresis may be expected to occur, and how long diuresis will last (Table 46-1). These drugs are administered early in the day to prevent any nighttime sleep disturbance caused by increased urination. Some patients may exhibit anxiety related to the fact that it will be necessary to urinate at frequent intervals. To reduce anxiety, the nurse explains the purpose and effects of the drug. The nurse tells the patient that the need to urinate frequently will probably decrease. For some patients, the need to urinate frequently decreases after a few weeks of therapy. The nurse makes sure that the patient on bed rest has a call light and, when necessary, a bedpan or urinal within easy reach. The nurse informs the patient that the drug will be given early in the day so nighttime sleep will not be interrupted. Although the duration of activity of most diuretics is about 8 hours or less, some diuretics have a longer activity, which may result in a need to urinate during nighttime hours. This is especially true early in therapy.

Diuretics are used to treat many different types of conditions. Therefore, promoting an optimal response to therapy for patients taking diuretics will often depend on the specific diuretic and the patient’s condition.

CARBONIC ANHYDRASE INHIBITORS. If a carbonic anhydrase inhibitor is given for glaucoma, the nurse evaluates the patient’s response to drug therapy (relief of eye pain) every 2 hours. The nurse notifies the primary health care provider immediately if eye pain increases or if it has not begun to decrease 3 to 4 hours after the first dose. If the patient has acute closed-angle glaucoma, the nurse checks the pupil of the affected eye every 2 hours for dilation and response to light. If the patient is ambulatory and has reduced vision because of glaucoma, the nurse may need to assist the patient with ambulatory and self-care activities.

Nursing Alert
The nurse notifies the primary health care provider immediately if eye pain increases or if it has not begun to decrease 3 to 4 hours after the first dose. If the patient has acute closed-angle glaucoma, the nurse checks the pupil of the affected eye every 2 hours for dilation and response to light.
If a carbonic anhydrase inhibitor is being given for absence or nonlocalized epileptic seizures, the nurse assesses the patient at frequent intervals for the occurrence of seizures, especially early in therapy and in patients known to experience seizures at frequent intervals. If a seizure does occur, the nurse records a description of the seizure in the patient’s chart, including time of onset and duration. Accurate descriptions of the pattern and the number of seizures occurring each day helps the primary health care provider plan future therapy and adjust drug dosages as needed.

**OSMOTIC DIURETICS.** Mannitol is administered only via the IV route. The nurse inspects the solution carefully before administration because, when exposed to low temperatures, mannitol solution may crystallize. If crystals are observed, the bottle is warmed in a hot water bath, a dry heat oven, or autoclave to dissolve the crystals. The solution must be cooled to body temperature or lower before administering. The rate of administration and concentration of the drug is individualized. The nurse must monitor the urine output hourly. The rate of administration is adjusted to maintain a urine flow of at least 30 to 50 mL/h.

When a patient is receiving the osmotic diuretic mannitol or urea for treatment of increased intracranial pressure caused by cerebral edema, the nurse monitors the blood pressure, pulse, and respiratory rate every 30 to 60 minutes or as ordered by the primary health care provider. The nurse immediately reports to the primary health care provider any increase in blood pressure, decrease in the pulse or respiratory rate, or any changes in the neurologic status. The nurse performs neurologic assessments (such as vital signs, response of the pupils to light, level of consciousness, or response to a painful stimulus) at the time intervals ordered by the primary health care provider. The nurse evaluates and records the patient’s response to the drug, that is, the signs and symptoms that may indicate a decrease in intracranial pressure.

**POTASSIUM-SPARING DIURETICS.** Patients taking the potassium-sparing diuretics are at risk for hyperkalemia. Serum potassium levels are monitored frequently, particularly during initial treatment.

**Nursing Alert**

Symptoms of hyperkalemia include paresthesia (numbness, tingling, or prickling sensation), muscular weakness, fatigue, flaccid paralysis of the extremities, bradycardia, shock, and electrocardiographic (ECG) abnormalities (see Display 46-1 for additional symptoms).

The drug is discontinued and the primary care provider is notified immediately if the patient experiences these symptoms or if the serum potassium levels exceed 5.3 mEq/mL. Treatment includes administration of IV bicarbonate (if the patient is acidotic) or oral or parenteral glucose with rapid-acting insulin. Persistent hyperkalemia may require dialysis.

**THIAZIDE AND RELATED DIURETICS.** When the thiazide diuretics are administered, renal function should be monitored periodically. These drugs may precipitate azotemia (accumulation of nitrogenous wastes in the blood). If nonprotein nitrogen (NPN) or blood urea nitrogen (BUN) rises, the primary care provider may consider withholding the drug or discontinuing its use. In addition, serum uric acid concentrations are monitored periodically during treatment with the thiazide diuretics because these drugs may precipitate an acute attack of gout. The patient also is monitored for any joint pain or discomfort. Because hyperglycemia may occur, insulin or oral antidiabetic drug dosages may require alterations. Serum glucose concentrations are monitored periodically.

**THE PATIENT WITH EDEMA.** Patients with edema caused by heart failure or other causes are weighed daily or as ordered by the primary health care provider. A daily weight is taken to monitor fluid loss. Weight loss of about 2 lb/d is desirable to prevent dehydration and electrolyte imbalances. The nurse carefully measures and records the fluid intake and output every 8 hours. The critically ill patient or the patient with renal disease may require more frequent measurements of urinary output. The nurse obtains the blood pressure, pulse, and respiratory rate every 4 hours or as ordered by the primary health care provider. An acutely ill patient may require more frequent monitoring of the vital signs. The nurse examines areas of edema daily to evaluate the effectiveness of drug therapy and records the findings in the patient’s chart. The nurse examines the patient’s general appearance and condition daily or more often if the patient is acutely ill.

**THE PATIENT WITH HYPERTENSION.** The nurse monitors the blood pressure, pulse, and respiratory rate of patients with hypertension receiving a diuretic, or a diuretic along with an antihypertensive drug, before the administration of the drug. More frequent monitoring may be necessary if the patient is critically ill or the blood pressure excessively high.

**Monitoring and Managing Adverse Reactions**

**ELECTROLYTE IMBALANCE.** The most common adverse reaction associated with the administration of a diuretic is the loss of fluid and electrolytes (see Display 46-1), especially during initial therapy with the drug. In some patients, the diuretic effect is moderate, whereas in others a large volume of fluid is lost. Regardless of the amount of fluid lost, there is always the possibility of excessive electrolyte loss, which is potentially serious.
The most common imbalances are a loss of potassium and water. Other electrolytes, namely magnesium, sodium, and chlorides, are also lost. When too much potassium is lost, hypokalemia (low blood potassium) occurs (see Home Care Checklist: Preventing Potassium Imbalances). In certain patients, such as those also receiving a digitalis glycoside or those who currently have a cardiac arrhythmia, hypokalemia has the potential to create a more serious arrhythmia. Hypokalemia is treated with potassium supplements or foods with high potassium content or by changing the diuretic to a potassium-sparing diuretic. In addition to hypokalemia, patients taking the loop diuretics are prone to magnesium deficiency (see Display 46-1). If too much water is lost, dehydration occurs, which also can be serious, especially in elderly patients.

Whether a fluid or electrolyte imbalance occurs depends on the amount of fluid and electrolytes lost and the ability of the individual to replace them. For example, if a patient receiving a diuretic eats poorly and does not drink extra fluids, an electrolyte and water imbalance is likely to occur, especially during initial therapy with the drug. However, even when a patient drinks adequate amounts of fluid and eats a balanced diet, an electrolyte imbalance may still occur and require electrolyte replacement (see Chapter 58 and Display 58-2 for additional discussion of fluid and electrolyte imbalances).

To prevent a fluid volume deficit, the nurse encourages oral fluids at frequent intervals during waking hours. A balanced diet may help prevent electrolyte imbalances. The nurse encourages patients to eat and drink all food and fluids served at mealtime. The nurse encourages all patients, especially the elderly, to eat or drink between meals and in the evening (when allowed). The nurse monitors the fluid intake and output and notifies the primary health care provider if the patient fails to drink an adequate amount of fluid, if the urinary output is low, if the urine appears concentrated, if the patient appears dehydrated, or if signs and symptoms of an electrolyte imbalance are apparent.

The nurse must closely observe patients receiving a potassium-sparing diuretic for signs of hyperkalemia (see Display 46-1), a serious and potentially fatal electrolyte imbalance. The patient is closely monitored for hypokalemia during loop or thiazide diuretic therapy. A supplemental potassium supplement may be prescribed to prevent hypokalemia. The primary health care provider may also encourage the patient to include...
Diuretics increase the excretion of water and sodium. Some of these drugs also increase the excretion of potassium, which places your patient at risk for hypokalemia, a possibly life-threatening condition. So be sure your patient knows what foods to eat to replace the potassium lost. Teach about the following potassium-rich foods:

**Meats**
- Beef
- Chicken
- Pork
- Turkey
- Veal

**Fish**
- Flounder
- Haddock
- Halibut
- Salmon
- Sardines, canned
- Scallops
- Tuna

**Fruits**
- Apricots
- Bananas
- Dates
- Plums
- Raisins
- Fresh orange juice
- Tomato juice
- Oranges
- Dried fruit
- Cantaloupe
- Peaches
- Prunes
- Avocado

**Vegetables**
- Carrots
- Lima beans
- Potatoes
- Radishes
- Spinach
- Sweet potatoes
- Tomatoes

**Other sources**
- Gingersnaps
- Graham crackers
- Molasses
- Peanuts
- Peanut butter
- Coffee
- Tea
- Nuts
Educating the Patient and Family

The patient and the family require a full explanation of the prescribed drug therapy, including when to take the drug (diuretics taken once a day are best taken early in the morning), if the drug is to be taken with food, and the importance of following the dosage schedule printed on the container label. The nurse also explains the onset and duration of the drug’s diuretic effect. The patient and family must also be made aware of the signs and symptoms of fluid and electrolyte imbalances and adverse reactions that may occur when using a diuretic.

To ensure compliance with the prescribed drug regimen, the nurse stresses the importance of diuretic therapy in treating the patient’s disorder. If the patient states that taking a diuretic at a specific time will be a problem, the nurse questions the patient in an attempt to identify the difficulty associated with drug therapy. Once a problem is identified, the nurse can identify solutions or make suggestions. The nurse includes the following points in a patient teaching plan:

- Do not stop taking the drug or omit doses, except on the advice of a primary health care provider.
- If gastrointestinal upset occurs, take the drug with food or milk.
- Take the drug early in the morning (once-a-day dosage) unless directed otherwise to minimize the effects on nighttime sleep. Twice-a-day dosing should be administered early in the morning (eg, 7:00 AM) and early afternoon (eg, 2:00 PM) or as directed by the primary care provider. These drugs will initially cause an increase in urination, which should subside after a few weeks.
- Avoid alcohol and nonprescription drugs unless their use has been approved by the primary health care provider. Hypertensive patients should be careful to avoid medications that increase blood pressure, such as over-the-counter drugs for appetite suppression and cold symptoms.
- Notify the primary health care provider if any of the following should occur: muscle cramps or weakness, dizziness, nausea, vomiting, diarrhea, restlessness, excessive thirst, general weakness, rapid pulse, increased heart rate or pulse, or gastrointestinal distress.
- If dizziness or weakness occurs, observe caution while driving or performing hazardous tasks, rise slowly from a sitting or lying position, and avoid standing in one place for an extended time.
- Weigh yourself weekly or as recommended by the primary health care provider. Keep a record of these weekly weights and contact the primary health care provider if weight loss exceeds 3 to 5 lb a week.
- If foods or fluids high in potassium are recommended by the primary health care provider, eat the amount recommended. Do not exceed this amount or eliminate these foods from the diet for more than 1 day, except when told to do so by the primary health care provider (see Home Care Checklist: Preventing Potassium Imbalances).
- After a time, the diuretic effect of the drug may be minimal because most of the body’s excess fluid has been removed. Continue therapy to prevent further accumulation of fluid.
- Thiazide and related diuretics, loop diuretics, potassium-sparing diuretics, carbonic anhydrase inhibitors, triamterene: Avoid exposure to sunlight or ultraviolet light (sunlamps, tanning beds) because exposure may cause exaggerated sunburn (photosensitivity reaction). Wear sunscreen and protective clothing until tolerance is determined.
- Loop and thiazide diuretics: patients with diabetes mellitus: Blood glucometer test results for glucose may be elevated (blood) or the urine positive for glucose. Contact the primary health care provider if results of home testing of blood glucose levels increase or if urine tests positive for glucose.
- Potassium-sparing diuretics: Avoid eating foods high in potassium and avoid the use of salt substitutes containing potassium. Read food labels carefully. Do not use a salt substitute unless a particular brand has been approved by the primary health care provider. Avoid the use of potassium supplements. Male patients taking spironolactone may experience gynecomastia. This is usually reversible when therapy is discontinued.
- Thiazide diuretics may cause gout attacks. Contact the primary care provider if significant, sudden joint pain occurs.
• Carbonic anhydrase inhibitors: During treatment for glaucoma, contact the primary health care provider immediately if eye pain is not relieved or if it increases. When a patient with epilepsy is being treated for seizures, a family member of the patient should keep a record of all seizures witnessed and bring this to the primary health care provider at the time of the next visit. Contact the primary health care provider immediately if the seizures increase in number.

EVALUATION
• The therapeutic effect is achieved.
• Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
• Fluid volume deficit (if present) is corrected.
• No evidence of injury is seen.
• The patient verbalizes the importance of complying with the prescribed treatment regimen.
• The patient and family demonstrate an understanding of the drug regimen.

Critical Thinking Exercises

1. Mr. Walsh, age 46 years, sees his primary health care provider and is prescribed a thiazide diuretic for hypertension. He tells you that it will be inconvenient for him to take his drug in the morning and he would prefer to take it at night. Other than asking him why taking the drug in the evening is more convenient, discuss what other questions you would ask Mr. Walsh. Analyze the situation to determine what explanation regarding present and future actions of this diuretic you would tell this patient.

2. Mr. Rodriguez, age 68 years, is taking amiloride for hypertension. He and his wife stopped by the clinic for a routine blood pressure check. Mrs. Rodriguez states that her husband has been confused and very irritable for the last 2 days. He complains of nausea and has had several "loose" stools. Discuss what actions you would take, giving a rationale for each action.

3. Ms. Palmer, age 88 years, is a resident in a nursing home. Her primary health care provider prescribes a thiazide diuretic for CHF. The nurse in charge advises you to evaluate Ms. Palmer for signs and symptoms of dehydration and hyponatremia. Discuss the assessment you would make. Identify which of these signs and symptoms might be difficult to evaluate considering the patient's age.

Review Questions

1. When evaluating the effectiveness of acetazolamide (Diamox) given for acute glaucoma, the nurse questions the patient about _______.

Medication Dosage Problems

1. The primary care provider prescribes spironolactone (Aldactone) 100 mg PO. The drug is available in 50-mg tablets. The nurse administers _______.

2. Furosemide (Lasix) 20 mg oral solution is prescribed. The oral solution is available in a concentration of 40 mg/5 mL. The nurse administers _______.

A. the amount of urine each time the patient voids
B. the relief of eye pain
C. the amount of fluid being taken
D. occipital headaches

2. When a patient taking mannitol for increased intracranial pressure is being assessed, which of the following findings would be most important for the nurse to report?
A. A serum potassium of 3.5 mEq/mL
B. Urine output of 20 mL for the last 2 hours
C. A blood pressure of 140/80 mm Hg
D. A heart rate of 72 bpm

3. When administering spironolactone (Aldactone), the nurse monitors the patient closely for which of the following electrolyte imbalances?
A. Hypernatremia
B. Hyponatremia
C. Hyperkalemia
D. Hypokalemia

4. When a diuretic is being administered for heart failure, which of the following would be most indicative of an effective response of diuretic therapy?
A. Output of 30 mL/h
B. Daily weight loss of 2 lb
C. An increase in blood pressure
D. Increasing edema of the lower extremities

5. Which electrolyte imbalance would the patient receiving a loop or thiazide diuretic most likely develop?
A. Hypernatremia
B. Hyponatremia
C. Hyperkalemia
D. Hypokalemia

6. Which of the following foods would the nurse most likely recommend the patient include in the daily diet to prevent hypokalemia?
A. Green beans
B. Apples
C. Bananas
D. Corn
Urinary Anti-infectives and Miscellaneous Urinary Drugs

**Key Terms**

<table>
<thead>
<tr>
<th>anti-infectives</th>
<th>overactive bladder</th>
</tr>
</thead>
<tbody>
<tr>
<td>bactericidal</td>
<td>prostatitis</td>
</tr>
<tr>
<td>bacteriostatic</td>
<td>pyelonephritis</td>
</tr>
<tr>
<td>cystitis</td>
<td>urine incontinence</td>
</tr>
<tr>
<td>dysuria</td>
<td>urinary tract infections</td>
</tr>
<tr>
<td>neurogenic bladder</td>
<td>urinary urgency</td>
</tr>
</tbody>
</table>

**Chapter Objectives**

On completion of this chapter, the student will:

- Discuss the uses, general drug actions, adverse reactions, contraindications, precautions, and interactions of the drugs used to treat infections and symptoms associated with urinary tract infections or an overactive bladder.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking a drug for a urinary tract infection or an overactive bladder.
- List some nursing diagnoses particular to a patient taking a drug for a urinary tract infection or an overactive bladder.
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating patients about the use of drugs used to treat a urinary tract infection or symptoms associated with an overactive bladder.

This chapter discusses drugs used to treat urinary tract infections (UTIs) and certain miscellaneous drugs used to relieve the symptoms associated with an overactive bladder (involuntary contractions of the detrusor or bladder muscle). Structures of the urinary system that may be affected include the bladder (cystitis), prostate gland (prostatitis), the kidney, or the urethra (see Fig. 47-1). These drugs also help control the discomfort associated with irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, and endoscopic procedures.

**Urinary tract infection (UTI)** is an infection caused by pathogenic microorganisms of one or more structures of the urinary tract. The most common structure affected is the bladder, with the urethra, prostate, and kidney also affected (see Fig. 47-1). Display 47-1 identifies the disorder most frequently associated with each of these structures within the urinary system. Clinical manifestations of a UTI of the bladder (cystitis) include urgency, frequency, burning and pain on urination, and pain caused by spasm in the region of the bladder and the suprapubic area.

Some drugs used in the treatment of UTIs do not belong to the antibiotic or sulfonamide groups of drugs. The drugs discussed in this chapter are **anti-infectives** (against infection) used in the treatment of UTIs, which have an effect on bacteria in the urinary tract. Although administered systemically, that is, by the oral or parenteral route, they do not achieve significant levels in the bloodstream and are of no value in the treatment of systemic infections. They are primarily excreted by the kidneys and exert their major antibacterial effects in the urine. (See Summary Drug Table: Urinary Anti-infectives for a listing of these and other drugs used to treat problems associated with the urinary system.)

**DISPLAY 47-1  ●  Common Disorders Associated With the Urinary System**

| Cystitis | inflammation of the bladder |
| Urethritis | inflammation of the urethra |
| Prostatitis | inflammation of the male prostate gland |
| Pyelonephritis | inflammation of the kidney and renal pelvis |
Examples of urinary anti-infectives include cinoxacin (Cinobac), fosfomycin (Monozol), methenamine mandelate (Mandelamine), nalidixic acid (NegGram), and nitrofurantoin (Furadantin).

Additional drugs can be used in the treatment of UTIs. Examples of these drugs include ampicillin (see Chap. 7), the cephalosporins (see Chap. 8), sulfonamides (see Chap. 6), and norfloxacin (see Chap. 10). Combination drugs are also available. The Summary Drug Table: Urinary Anti-infectives gives examples of the combination drugs used for UTIs.
### Generic Name | Trade Name* | Uses | Adverse Reactions | Dosage Ranges
--- | --- | --- | --- | ---
cinoxacin  
(sin-ox′-a-sin) | Cinobac, generic | Initial or recurrent UTIs | Nausea, abdominal pain, vomiting, anorexia, diarrhea, perineal burning, headache, photophobia, dizziness, rash | 1 g/d PO in 2–4 divided doses for 7–14 d
fosfomycin  
(foss-to-my′-sin) | Monurol | UTIs caused by susceptible microorganisms | Diarrhea, vaginitis, rhinitis, nausea, headache, back pain | 3-g packet PO
methenamine  
(hippurate)  
(meth-en′-a-meen) | Hiprex, Urex | Suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, or other chronic UTIs, infected residual urine | Anorexia, nausea, vomiting, stomatitis, cramps, rash, bladder irritation, headache | 1 g PO BID
methenamine  
(mandelate)  
(meth-en′-a-meen) | Mandelamine, generic | Same as methenamine hippurate | Same as methenamine hippurate | 1 g PO QID
nalidixic acid  
(nal-i-dix′-ic) | NegGram | UTIs caused by susceptible microorganisms | Abdominal pain, nausea, vomiting, anorexia, diarrhea, rash, drowsiness, dizziness, photosensitivity reactions, blurred vision, weakness, headache | 1 g QID for 1–2 wk; may reduce to 2 g/d for prolonged therapy
nitrofurantoin  
(ney-toe-fyoor-an′-toyn) | Furadantin, generic | UTIs caused by susceptible microorganisms | Nausea, vomiting, anorexia, rash, peripheral neuropathy, headache, brown discoloration of urine, hypersensitivity reactions, superinfection | 50–100 mg PO QID
nitrofurantoin  
(macrocrystals) | Macrodantin, generic | Same as nitrofurantoin | Same as nitrofurantoin | 50–100 mg PO QID; SR 100 mg BID
flavoxate HCl  
(fla-vox′-ate) | Urispas | Symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence due to cystitis, prostatitis, urethritis | Nausea, vomiting, dry mouth, nervousness, vertigo, headache, drowsiness, blurred vision, mental confusion (especially in the elderly) | 100–200 mg TID, QID PO
oxybutynin chloride  
(ox-i-byoo′-ti-nin) | Ditropan, generic | Bladder instability, treatment of overactive bladder | Dry mouth, constipation, headache, dizziness, diarrhea, nausea, blurred vision, drowsiness, decreased sweating, heat prostration | 5 mg BID, TID PO; maximum dosage, 5 mg QID; extended release: 5–30 mg once daily
phenazopyridine  
(fen-az-oh-peer′-i-deen) | Pyridate, generic | Relief of pain associated with irritation of the lower genitourinary tract | Headache, rash, pruritus, GI disturbances, red-orange discoloration of the urine, yellowish discoloration of the skin or sclera | 200 mg TID PO
tolterodine  
(tartrate)  
(toll-tear′-oh-dyne) | Detrol, Detrol LA | Overactive bladder with symptoms of urinary frequency, urgency or urge incontinence | Nausea, vomiting, constipation, dry mouth, headache, dizziness, blurred vision, dysuria | 2 mg BID PO; extended release: 2–4 mg once daily PO
ACTIONS, USES, AND ADVERSE REACTIONS

Cinoxacin

As a result of high concentration in the urine, cinoxacin appears to act by interfering with bacterial multiplication by interfering with the replication of DNA in susceptible gram-negative bacteria. Like the sulfonamides and other anti-infectives, the systemic anti-infectives, such as cinoxacin, are used for UTIs that are caused by susceptible microorganisms. Nausea, abdominal pain, vomiting, anorexia, diarrhea, perineal burning, headache, photophobia, and dizziness may be seen with the administration of cinoxacin.

Methenamine and Methenamine Salts

Methenamine and methenamine salts break down and form ammonia and formaldehyde, which are bactericidal. These drugs are used for UTIs that are caused by susceptible microorganisms. Administration of methenamine and methenamine salts may result in gastrointestinal disturbances, such as anorexia, nausea, vomiting, stomatitis, and cramps. Large doses may result in burning on urination and bladder irritation.

Nalidixic Acid

As a result of its high concentration in the urine, nalidixic acid appears to act by interfering with bacterial multiplication by interfering with the replication of DNA. Nalidixic acid is used for UTIs that are caused by susceptible microorganisms. Abdominal pain, nausea, vomiting, anorexia, diarrhea, rash, drowsiness, dizziness, photosensitivity reactions, blurred vision, weakness, and headache may occur with the administration of nalidixic acid. Visual disturbances, when they occur, are noted after each dose and often disappear after a few days of therapy.

Nitrofurantoin

Nitrofurantoin may be bacteriostatic (slows or retards the multiplication of bacteria) or bactericidal (destroys bacteria), depending on the concentration of the drug in the urine. Nitrofurantoin is used for UTIs that are caused by susceptible microorganisms. Nitrofurantoin administration may result in nausea, vomiting, anorexia, rash, peripheral neuropathy, headache, brown discoloration of the urine, and hypersensitivity reactions, which may range from mild to severe. Acute and chronic pulmonary reactions also have been seen.

Fosfomycin

Fosfomycin is bactericidal and interferes with bacterial cell wall synthesis. Fosfomycin is used for UTIs that are caused by susceptible microorganisms. Adverse reactions that may occur with fosfomycin include headache, dizziness, nausea, abdominal cramps, and vaginitis.
**Trimethoprim**

Trimethoprim (Trimpex) interferes with the ability of bacteria to metabolize folinic acid, thereby exerting bacteriostatic activity. Trimethoprim is used for UTIs that are caused by susceptible microorganisms. Trimethoprim administration may result in rash, pruritus, epigastric distress, nausea, and vomiting. When trimethoprim is combined with sulfamethoxazole (Septra), the adverse effects associated with a sulfonamide may also occur. The adverse reactions seen with other anti-infectives, such as ampicillin, the sulfonamides, and cephalosporins, are given in their appropriate chapters.

**Flavoxate**

Flavoxate (Urispas) counteracts smooth muscle spasm of the urinary tract by relaxing the detrusor and other muscles through action at the parasympathetic receptors. Flavoxate is used to relieve symptoms of dysuria (painful or difficult urination), urinary urgency (a strong and sudden desire to urinate), nocturia (excessive urination during the night), suprapubic pain and frequency, and urge incontinence (accidental loss of urine caused by a sudden and unstoppable urge to void). Flavoxate can cause blurred vision, drowsiness, nausea and vomiting, nervousness, vertigo, headache, and mental confusion (particularly in the elderly).

**Oxybutynin**

Oxybutynin (Ditropan) acts by relaxing the bladder muscle and reducing spasm. Oxybutynin is used to treat bladder instability (ie, urgency, frequency, leakage, incontinence, and painful or difficult urination) caused by a neurogenic bladder (altered bladder function caused by a nervous system abnormality). Adverse reactions observed in patients taking oxybutynin include dry mouth, constipation or diarrhea, decreased production of tears, decreased sweating, gastrointestinal disturbances, dim vision, and urinary hesitancy.

**Phenazopyridine**

Phenazopyridine (Pyridium) is a dye that exerts a topical analgesic effect on the lining of the urinary tract. It has no anti-infective activity. Phenazopyridine, a urinary analgesic, is available as a separate drug but is also included in some urinary anti-infective combination drugs. This drug is a urinary tract analgesic used to relieve the pain, burning, urgency, frequency, and irritation caused by infection, trauma, catheters, or surgical procedures of the urinary tract. Adverse reactions associated with phenazopyridine include headache, rash, and gastrointestinal upset.

**Tolterodine**

Tolterodine (Detrol) is an anticholinergic drug that is able to inhibit bladder contractions and delay the urge to void. Tolterodine tartrate is used to treat symptoms of overactive bladder, such as urinary frequency, urgency, or urge incontinence. Tolterodine is associated with anticholinergic adverse reactions such as dry mouth (the most commonly reported adverse reaction), drowsiness, decreased sweating, blurred vision, nausea, vomiting, dizziness, and abdominal pain. The adverse reactions of tolterodine, compared with other anticholinergic drugs, are less problematic because tolterodine is more specific for the bladder.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Cinoxacin**

Cinoxacin is contraindicated in patients with known hypersensitivity to the individual drug and in patients with anuria. Cinoxacin is a Pregnancy Category B drug and should be used with caution during pregnancy and lactation. Cinoxacin is used with caution in patients with hepatic impairment. When cinoxacin is administered with probenecid, there is a risk for lowered urine concentration of cinoxacin.

**Methenamine and Methenamine Salts**

Methenamine is contraindicated in patients with a hypersensitivity to the drug, those with hepatic impairment, and during pregnancy (Pregnancy Category C) and lactation. Patients who are allergic to tartrazine should not take methenamine hippurate (Hiprex). The drug is used cautiously in patients with renal or hepatic impairment or gout (may cause crystals to form in the urine). No serious interactions have been reported.

**Nalidixic Acid**

Nalidixic acid is contraindicated in patients who are hypersensitive to the drug or any of its components, those who have convulsive disorders, and during pregnancy (Pregnancy Category C) and lactation. Nalidixic acid is used cautiously in patients with renal and hepatic impairment, cerebral arteriosclerosis, and in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. When nalidixic acid is administered with the oral anticoagulants there is an increased risk of bleeding.
Nitrofurantoin

Nitrofurantoin is contraindicated in patients with renal impairment, those with hypersensitivity to the drug, and in lactating women. Nitrofurantoin is classified as a Pregnancy Category B drug and is used with caution during pregnancy. The drug is also used with caution in patients with a G6PD deficiency (see Chap. 1), anemia, or diabetes. There is a decreased absorption of nitrofurantoin when the drug is administered with magnesium trisilicate or magaldrate. When nitrofurantoin is administered with anticholinergics, there is a delay in gastric emptying, increasing the absorption of nitrofurantoin.

Fosfomycin

Fosfomycin is contraindicated in patients with a hypersensitivity to the drug. Fosfomycin is used cautiously during pregnancy (Pregnancy Category B) and lactation. There is a lowered plasma concentration and urinary tract excretion when fosfomycin is administered with metoclopramide.

Trimethoprim

Trimethoprim is contraindicated in patients with a hypersensitivity to the drug and in those with a creatine clearance of less than 15 mL/min. The drug is used cautiously in patients with hepatic or renal impairment and in patients with megaloblastic anemia caused by folate deficiency. Trimethoprim is classified as a Pregnancy Category C drug, and its use is not recommended during pregnancy and lactation.

No significant interactions have been reported.

Oxybutynin

Oxybutynin is contraindicated in patients with hypersensitivity to the drug, those with glaucoma, partial or complete blockage of the gastrointestinal tract, myasthenia gravis, or urinary tract obstruction. The drug is used cautiously in patients with kidney or liver disease, heart failure, irregular or rapid heart rate, hypertension, or enlarged prostate and during pregnancy (Pregnancy Category C) and lactation. There is a decreased effectiveness of the phenothiazines when these drugs are administered with oxybutynin. A decreased response and increased risk of tardive dyskinesia may occur when haloperidol is administered with oxybutynin.

Phenazopyridine

Phenazopyridine is contraindicated in patients with renal impairment and in undiagnosed urinary tract pain. Phenazopyridine is used cautiously during pregnancy (Pregnancy Category C) and lactation.

Phenazopyridine treats the symptom of pain but does not treat the cause of the disorder. No significant interactions have been reported.

Tolterodine

Tolterodine is contraindicated in patients with urinary retention (inability to urinate), gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the drug. Tolterodine is used with caution in patients with significant bladder outflow blockage or slow urinary stream because of the risk of urinary retention, pyloric stenosis (a narrowing of the opening where the stomach contents are emptied into the small intestine), and liver or kidney disease. This drug is classified as a Pregnancy Category C drug and should not be used during pregnancy or lactation. No significant interactions have been reported.

Miscellaneous Drugs

The miscellaneous drugs are used to relieve the symptoms associated with an overactive bladder (involuntary contractions of the detrusor or bladder muscle)
that sometimes occur due to disorders such as cystitis, prostatitis, or other affected structures such as the kidney or the urethra. Overactive bladder is estimated to affect more than 16 million individuals in the United States. Symptoms of an overactive bladder include urinary urgency, frequent urination day and night, and urge incontinence, accidental loss of urine caused by a sudden and unstoppable need to urinate. These drugs also help control the discomfort associated with irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, and endoscopic procedures. Other miscellaneous drugs are used to relieve the pain associated with irritation of the lower genitourinary tract (eg, phenazopyridine) caused by infection, trauma, surgery, and endoscopic procedures.

Ongoing Assessment
Many UTIs are treated on an outpatient basis because hospitalization usually is not required. UTIs may be seen in the hospitalized or nursing home patient with an indwelling urethral catheter or a disorder such as a stone in the urinary tract.

When caring for a hospitalized patient with a UTI, the nurse monitors the vital signs every 4 hours or as ordered by the primary health care provider. Any significant rise in temperature is reported to the primary health care provider because methods of reducing the fever or repeat culture and sensitivity tests may be necessary.

The nurse monitors the patient’s response to therapy daily. If after several days the symptoms of the UTI have not improved or if they become worse, the nurse notifies the primary health care provider as soon as possible. Periodic urinalysis and urine culture and sensitivity tests may be ordered to monitor the effects of drug therapy.

When the nurse is administering any of the miscellaneous drugs, the nurse monitors the patient for a reduction in the symptoms obtained in the preadministration assessment such as dysuria, urinary frequency, urgency, nocturia, and relief of any pain associated with irritation of the lower genitourinary tract.

NURSING DIAGNOSES
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING
The expected outcomes for the patient may include an optimal response to drug therapy, management of common adverse drug reactions, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION
Promoting an Optimal Response to Therapy

URINARY ANTI-INFECTIVES. To promote an optimal response to therapy, the nurse gives these drugs with food to prevent gastrointestinal upset. The nurse
The nurse advises the patient to drink at least 2000 mL or more of fluids each day unless the primary health care provider orders otherwise. Drinking extra fluids aids in the physical removal of bacteria from the genitourinary tract and is an important part of the treatment of UTIs (see Patient and Family Teaching Checklist: Using Fluids to Prevent and Treat UTIs). The nurse offers fluids, preferably water, to the patient at hourly intervals. Cranberry or prune juice is usually given rather than orange juice, other citrus juices, or vegetable juices.

The nurse notifies the primary health care provider if the patient fails to drink extra fluids, if the urine output is low, or if the urine appears concentrated during daytime hours. The urine of those drinking 2000 mL or more per day will appear dilute and light in color.

Elderly patients often have a decreased thirst sensation and must receive encouragement to increase fluid intake. The nurse offers fluids at regular intervals to elderly patients or those who seem unable to increase their fluid intake without supervision.

The nurse measures the fluid intake and output, especially when the primary health care provider orders an increase in fluid intake or when a kidney infection is being treated. The primary health care provider may also order daily urinary pH levels when methenamine or nitrofurantoin is administered. These drugs work best in acid urine; failure of the urine to remain acidic may require administration of a urinary acidifier, such as ascorbic acid.

**MISCELLANEOUS URINARY DRUGS.** Flavoxate is administered orally three to four times daily. The dosage may be reduced when the patient's symptoms improve. Phenazopyridine is administered after meals to prevent GI upset. This drug is not administered for more than 2 days to patients receiving antibiotics for treatment of a UTI. Continued use may mask the symptoms of a urinary tract infection that is not responding to treatment with an antibiotic. When administering these drugs, the nurse monitors the fluid intake and urinary output for volume and frequency. The patient is encouraged to drink at least 2000 mL of fluid daily (if condition permits) to dilute urine and decrease pain on voiding.

**Monitoring and Managing Adverse Drug Reactions**

**URINARY ANTI-INFECTIVES.** The nurse observes the patient for adverse drug reactions. If an adverse reaction occurs, the nurse contacts the primary health care provider before the next dose of the drug is due. However, serious drug reactions, such as a pulmonary reaction, are reported immediately.

Pulmonary reactions have been reported with the use of nitrofurantoin and may be seen within hours and up to 3 weeks after therapy with this drug is initiated. Signs and symptoms of an acute pulmonary reaction include dyspnea, chest pain, cough, fever, and chills. If these reactions occur, the nurse immediately notifies the primary health care provider and withholds the next dose of the drug until the patient is seen by a primary health care provider. Signs and symptoms of chronic pulmonary reactions, which may be seen during prolonged therapy, include dyspnea, nonproductive cough, and malaise.

**MISCELLANEOUS URINARY DRUGS.** Common adverse reactions with flavoxate, oxybutynin, and tolterodine include dry mouth, dizziness, blurred vision, and constipation.
For patients with dry mouth the nurse suggests that the patient suck on hard candy, sugarless lozenges, or small pieces of ice and perform frequent mouth care. This effect sometimes lessens with continued use of the drug. Hospitalized patients experiencing drowsiness or blurred vision may require assistance when ambulating. For patients with constipation, the nurse encourages fluids, provides a high-fiber diet, and provides times for ambulation or exercise (if the patient’s condition allows). If constipation persists, the primary health care provider may prescribe a mild laxative or stool softener.

The nurse informs the patient that phenazopyridine may cause a reddish orange discoloration of the urine and may stain fabrics or contact lenses. The nurse assures the patient that this is normal and will subside when use of the drug is discontinued.

**Educating the Patient and Family**

The nurse stresses the importance of increasing fluid intake to at least 2000 mL/d (unless contraindicated) to help remove bacteria from the genitourinary tract (see Patient and Family Teaching Checklist: Using Fluids to Prevent and Treat UTIs). In many cases, symptoms are relieved after several days of drug therapy. To ensure compliance with the prescribed drug regimen, the nurse stresses the importance of completing the full course of drug therapy even though symptoms have been relieved. A full course of therapy is necessary to ensure all bacteria have been eliminated from the urinary tract. The nurse should include the following points in a patient and family teaching plan:

- Take the drug with food or meals (nitrofurantoin must be taken with food or milk). If gastrointestinal upset occurs despite taking the drug with food, contact the primary health care provider.
- Take the drug at the prescribed intervals and complete the full course of therapy. Do not discontinue taking the drug even though the symptoms have disappeared, unless directed to do so by the primary health care provider.
- If drowsiness or dizziness occurs, avoid driving and performing tasks that require alertness.
- During therapy with this drug, avoid alcoholic beverages and do not take any nonprescription drug unless its use has been approved by the primary health care provider.
- Notify the primary health care provider immediately if symptoms do not improve after 3 or 4 days.
- Nitrofurantoin: Take this drug with food or milk to improve absorption. Continue therapy for at least 1 week or for 3 days after the urine shows no signs of infection. Notify the primary health care provider immediately if any of the following occur: fever, chills, cough, shortness of breath, chest pain, or difficulty breathing. Do not take the next dose of the drug until the primary health care provider has been contacted. The urine may appear brown during therapy with this drug; this is not abnormal.
- Nalidixic acid: Take this drug with food to prevent GI upset. Avoid prolonged exposure to sunlight or ultraviolet light (tanning beds or lamps) because an exaggerated sunburn may occur.
- Methenamine, methenamine salts: Avoid excessive intake of citrus products, milk, and milk products.
- Fosfomycin comes in dry form as a one-dose packet to be dissolved in 90 to 120 mL water (not hot water). Drink immediately after mixing and take with food to prevent gastric upset.

**MISCELLANEOUS DRUGS**

- For dry mouth, suck on hard candy, sugarless lozenges, or small pieces of ice and perform frequent mouth care.
- These drugs may cause drowsiness or blurred vision. Do not drive or operate dangerous machinery or participate in any activity that requires full mental alertness until you know how this medication affects you.
- If you experience constipation, drink plenty of fluids, eat a high-fiber diet, and exercise (if your condition allows). If constipation persists, the primary health care provider may prescribe a mild laxative or stool softener.
- Flavoxate: Take this drug three to four times daily as prescribed. This drug is used to treat symptoms; other drugs are given to treat the cause.
- Oxybutynin: Take this drug with food or without food. Oxybutynin (Ditropan XL) contains an outer coating that may not disintegrate and may be observed on occasion in the stool. This is not a cause for concern. This drug can cause heat prostration (fever and heat stroke caused by decreased sweating) in high temperatures. If you live in hot climates or will be exposed to high temperatures, take appropriate precautions.
- Phenazopyridine: This drug may cause a reddish-orange discoloration of the urine and may stain fabrics or contact lenses. This is normal. Take the drug after meals. Do not take this drug for more than 2 days if you are also taking an antibiotic for the treatment of a UTI.
- Tolterodine: If you experience difficulty voiding, take the drug immediately after voiding. If dysuria persists, notify the primary health care provider.

**EVALUATION**

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed successfully through appropriate nursing interventions.
• The patient and family demonstrate an understanding of the drug regimen.
• The patient verbalizes the importance of complying with the prescribed therapeutic regimen.

Critical Thinking Exercises

1. Mr. Elliott, age 42 years, had a UTI 8 weeks ago. He failed to see his primary health care provider for a follow-up urinesample 2 weeks after completing his course of drug therapy. Mr. Elliott is in to see his primary health care provider because his symptoms of a UTI have recurred. The primary health care provider suspects that Mr. Elliott may not have followed instructions regarding treatment for his UTI. Analyze the situation to determine what points you would stress in a teaching plan for this patient.

2. Ms. Howard, age 86 years, has Alzheimer’s disease and is a resident in a nursing home. She has a UTI and is prescribed cinoxacin (Cinobac). Discuss specific nursing tasks to include in a nursing care plan for this patient. What potential problems could be anticipated because of the Alzheimer’s disease? What drugs might the primary care provider prescribe for the Alzheimer’s disease?

Review Questions

1. The nurse correctly administers nitrofurantoin (Macrodantin) _____.
   A. with food
   B. no longer than 7 days
   C. without regard to food
   D. no longer than 2 days

2. To avoid raising the pH when taking methenamine (Mandelamine), the nurse advises the patient to _____.
   A. use an antacid before taking the drug
   B. take an antacid immediately after taking the drug
   C. avoid antacids containing sodium bicarbonate or sodium carbonate
   D. avoid the use of antacids 1 hour before or 2 hours after taking the drug

3. What instruction would be most important to give a patient prescribed fosfomycin (Monurol)?
   A. Drink one to two glasses of cranberry juice daily to promote healing of the urinary tract.
   B. You may take the drug without regard to meals.
   C. This drug comes in a one-dose packet that must be dissolved in 90 mL or more of fluids.
   D. This drug may cause mental confusion.

4. What statement(s) would be included in a teaching plan for a patient prescribed phenazopyridine (Pyridium)?
   A. There is a danger of heat prostration or heat stroke when taking phenazopyridine in a hot climate.
   B. This drug may turn the urine dark brown. This is an indication of a serious condition and should be reported immediately.
   C. This drug may cause photosensitivity. Take precautions when out in the sun by wearing sunscreen, a hat, and long-sleeved shirts for protection.
   D. This drug may turn the urine reddish-orange. This is a normal occurrence that will disappear when use of the drug is discontinued.

Medication Dosage Problems

1. Cinoxacin 500 mg is prescribed. The drug is available in 250-mg tablets. The nurse administers _____.

2. Nitrofurantoin oral suspension 50 mg is prescribed. The oral suspension contains 25 mg/5 mL. The nurse administers _____.
The gastrointestinal (GI) tract is subject to more diseases and disorders than any other system of the body. Some drugs used for GI disorders are available as nonprescription drugs, thereby creating the potential problems of misuse and overuse of the drugs and the disguising of more serious medical problems.

The drugs presented in this chapter include the antacids, anticholinergics, GI stimulants, proton pump inhibitors, histamine H₂ antagonists, antidiarrheals, antiflatulents, digestive enzymes, emetics, gallstone-solubilizing drugs, laxatives, and miscellaneous drugs. Some of the more common preparations are listed in the Summary Drug Table: Drugs Used in the Management of Gastrointestinal Disorders.

ANTACIDS

ACTIONS

Some of the cells of the stomach secrete hydrochloric acid, a substance that aids in the initial digestive process.

Antacids (against acids) are drugs that neutralize or reduce the acidity of stomach and duodenal contents by combining with hydrochloric acid and producing salt and water. Examples of antacids include aluminum hydroxide gel (Amphojel), magaldrate (Riopan), and magnesia or magnesium hydroxide (Milk of Magnesia).

USES

Antacids are used in the treatment of hyperacidity, such as heartburn, gastroesophageal reflux, sour stomach, acid indigestion, and in the medical treatment of peptic ulcer. Many antacid preparations contain more than one ingredient. An additional use for aluminum carbonate is in the treatment of hyperphosphatemia or for use with a low phosphate diet to prevent formation of phosphate urinary stones. Calcium carbonate may be used in treating calcium deficiency states such as menopausal osteoporosis. Magnesium oxide may be used in the treatment of magnesium deficiencies or magnesium depletion from malnutrition, restricted diet, or alcoholism.

(text continues on page 471)
### Proton Pump Inhibitors

- **esomeprazole magnesium**
  - **Generic Name:** esomeprazole magnesium
  - **Trade Name:** Nexium
  - **Uses:** Erosive esophagitis, gastroesophageal reflux disease (GERD), long-term treatment of pathologic hypersecretory conditions
  - **Dosage Ranges:** 20–40 mg/d PO

- **lansoprazole**
  - **Generic Name:** lan-sopra-zole
  - **Trade Name:** Prevacid
  - **Uses:** Duodenal ulcer, *H. pylori* eradication in patients with duodenal ulcer, gastric ulcer, erosive esophagitis, GERD, hypersecretory conditions
  - **Dosage Ranges:** 15–30 mg/d PO

- **omeprazole**
  - **Generic Name:** oh-me'-pra-zol
  - **Trade Name:** Prilosec
  - **Uses:** Duodenal ulcer, *H. pylori* eradication, hypersecretory conditions, gastric ulcer, erosive esophagitis, GERD, hypersecretory conditions
  - **Dosage Ranges:** 20–40 mg/d PO; 60 mg/d up to 120 mg TID

- **pantoprazole sodium**
  - **Generic Name:** pan-toe'-pray-zol
  - **Trade Name:** Protonix, Protonix IV
  - **Uses:** GERD
  - **Dosage Ranges:** 40 mg PO daily to BID up to 120 mg/d; IV, 80 mg; maximum dosage 240 mg/d

- **rabeprazole sodium**
  - **Generic Name:** rah-beh'-pray-zol
  - **Trade Name:** Aciphex
  - **Uses:** Duodenal ulcer, GERD, hypersecretory conditions
  - **Dosage Ranges:** 2–60 mg/d

### Miscellaneous Gastrointestinal Drugs

- **bismuth subsalicylate**
  - **Generic Name:** bismuth subsalicylate
  - **Trade Name:** Bismatrol, Pepto-Bismol, Pink Bismuth
  - **Uses:** Nausea, diarrhea, abdominal cramps, *H. pylori* with duodenal ulcer
  - **Dosage Ranges:** 2 tablets or 30 mL PO q 30 min–1 h up to 8 doses in 24 h

- **balsalazide disodium**
  - **Generic Name:** balsalazide
  - **Trade Name:** Colazal
  - **Uses:** Ulcerative colitis
  - **Dosage Ranges:** 3 750-mg capsules PO TID for 8 wk

- **infliximab**
  - **Generic Name:** infiximab
  - **Trade Name:** Remicade
  - **Uses:** Crohn’s disease, rheumatoid arthritis
  - **Dosage Ranges:** RA: 3 mg/kg IV; Crohn’s: 5 mg/kg IV

- **mesalamine**
  - **Generic Name:** mesalamine
  - **Trade Name:** Asacol, Rowasa, generic
  - **Uses:** Treatment of active to moderate ulcerative colitis, proctosigmoiditis, or proctitis
  - **Dosage Ranges:** Suspension enema: 4 g once daily in 60 mL; rectal suppository: 500 mg (1 suppository) BID; oral: 800 mg TID PO 100–200 µg QID PO

- **misoprostol**
  - **Generic Name:** misoprostol
  - **Trade Name:** Cytotec
  - **Uses:** Prevention of gastric ulcers caused by aspirin or NSAID use (unlabeled use)
  - **Dosage Ranges:** 1 g/d in two divided doses PO

- **olsalazine**
  - **Generic Name:** olsalazine
  - **Trade Name:** Dipentum
  - **Uses:** Maintenance of remission of ulcerative colitis in patients intolerant of sulfasalazine
  - **Dosage Ranges:** 1 g/d PO in divided doses

- **sucralfate**
  - **Generic Name:** sucralfate
  - **Trade Name:** Carafate, generic
  - **Uses:** Active duodenal ulcer
  - **Dosage Ranges:** 1 g QID PO

- **sulfasalazine**
  - **Generic Name:** sulfasalazine
  - **Trade Name:** Azulfidine, generic
  - **Uses:** Ulcerative colitis, rheumatoid arthritis
  - **Dosage Ranges:** 2 tablets or capsules or 10 mL of regular suspension (in water or fruit juice) or 5 mL of extra strength suspension as often as every 2 h, up to 12 times daily

### Antacids

- **aluminum carbonate gel, basic**
  - **Generic Name:** aluminum carbonate gel, basic
  - **Trade Name:** Basaljel
  - **Uses:**
  - **Dosage Ranges:** 2 tablets or capsules or 10 mL of regular suspension (in water or fruit juice) or 5 mL of extra strength suspension as often as every 2 h, up to 12 times daily

(continued)
## SUMMARY DRUG TABLE
**DRUGS USED IN THE MANAGEMENT OF GASTROINTESTINAL DISORDERS (Continued)**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>aluminum hydroxide gel</td>
<td>Alu-Tab, Amphojel, Dialume, generic</td>
<td>Tablets or capsules: 500–1500 mg 3–6 times daily PO between meals and HS; suspension: 5–15 mL as needed between meals and HS PO</td>
<td></td>
</tr>
<tr>
<td>calcium carbonate</td>
<td>Chooz, Tums, generic</td>
<td>0.5–12 g PO as needed</td>
<td></td>
</tr>
<tr>
<td>magaldrate (hydroxymagnesium aluminate)</td>
<td>Riopan, generic</td>
<td>980–1080 mg PO 1 and 3 hours after meals and HS</td>
<td></td>
</tr>
<tr>
<td>magnesium (magnesium hydroxide)</td>
<td>Milk of Magnesia, Phillips' Chewable</td>
<td>Liquid: 5–15 mL PO QID with water; tablets: 650 mg–1.3 g QID PO; laxative: 15–60 mL PO taken with liquid</td>
<td></td>
</tr>
<tr>
<td>magnesium oxide</td>
<td>Mag-Ox 400, Maox 420, Uro-mag, generic</td>
<td>Capsules: 280 mg–1.5 g QID PO; tablets: 400–820 mg/d PO</td>
<td></td>
</tr>
<tr>
<td>sodium bicarbonate</td>
<td>Bell/ans, generic</td>
<td>0.3–2 g 1–4 times daily PO</td>
<td></td>
</tr>
</tbody>
</table>

### Anticholinergics

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>belladonna</td>
<td>Generic</td>
<td>Tincture: 0.6–1 mL TID–QID</td>
<td></td>
</tr>
<tr>
<td>clindinium bromide</td>
<td>Quarzan</td>
<td>2.5–5 mg PO TID–QID AC and HS geriatric or debilitated patients: 2.5 mg TID AC</td>
<td></td>
</tr>
<tr>
<td>klin-din’-ee-um</td>
<td></td>
<td>Oral: 80–160 mg/d in 4 doses PO; parenteral: 80 mg/d IM</td>
<td></td>
</tr>
<tr>
<td>dicyclomine HCl</td>
<td>Bentyl, Di-Spasz, generic</td>
<td>Oral: 1 mg TID or 2 mg BID–TID PO; parenteral: 0.1–0.2 mg IM or IV TID–QID</td>
<td></td>
</tr>
<tr>
<td>dye-sye-klo’-meen</td>
<td>generic</td>
<td>Oral: 0.125–0.25 mg PO TID–QID PO or sublingually; sustained release: 0.375–0.75 mg q12h PO; parenteral: 0.25–0.5 mg SC, IM, IV BID–QID</td>
<td></td>
</tr>
<tr>
<td>glycopyrrolate</td>
<td>Robinul, Robinul Forte, generic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gly-ko-pie’-roll-ate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-hyoscyamine sulfate</td>
<td>Anaspaz, Donnamar, Levbid, Levsin</td>
<td></td>
<td></td>
</tr>
<tr>
<td>el-hi’-o-si-ah-meen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mepenzolate bromide</td>
<td>Cantil</td>
<td>25–50 mg QID with meals and HS</td>
<td></td>
</tr>
<tr>
<td>me-pin-zo’-late</td>
<td></td>
<td>Adult: 50–100 mg PO q6h</td>
<td></td>
</tr>
<tr>
<td>methantheline bromide</td>
<td>Banthis, generic</td>
<td>2.5 mg 30 min AC and 2.5–5 mg HS PO</td>
<td></td>
</tr>
<tr>
<td>meth-an’-tha-leen</td>
<td></td>
<td>15 mg PO 30 min AC and HS</td>
<td></td>
</tr>
<tr>
<td>methscopolamine bromide</td>
<td>Pamine</td>
<td>25–50 mg TID–QID AC and 50 mg HS PO</td>
<td></td>
</tr>
<tr>
<td>meth-sco-pol’-a-meen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>propantheline bromide</td>
<td>Pro-Banthine, generic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>proe-pan’-the-leen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tridihexethyl chloride</td>
<td>Pathilon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>tri-di-hex’-eth-l</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SUMMARY DRUG TABLE
DRUGS USED IN THE MANAGEMENT OF GASTROINTESTINAL DISORDERS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrointestinal Stimulants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dextropanthenol</td>
<td>Ilopan, generic</td>
<td></td>
<td>250–500 mg IM, IV</td>
</tr>
<tr>
<td>metoclopramide</td>
<td>Reglan, generic</td>
<td></td>
<td>10–15 mg PO 30 min AC and HS; 10–20 mg IM, IV</td>
</tr>
<tr>
<td><strong>Histamine H2 Antagonists</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cimetidine</td>
<td>Tagamet, Tagamet HB, generic</td>
<td></td>
<td>300–2400 mg/d PO; 300 mg q6h IM, IV; 50 mg/h continuous IV infusion</td>
</tr>
<tr>
<td>famotidine</td>
<td>Pepcid, Pepcid IV, generic</td>
<td></td>
<td>20–40 mg PO, IV as one dose or BID</td>
</tr>
<tr>
<td>nizatidine</td>
<td>Axid Pulvules</td>
<td></td>
<td>Gastric or duodenal ulcer: 300 mg/d PO HS or 150 mg BID PO; maintenance of healed ulcer: 150 mg/d PO HS; heartburn: 75 mg PO ½–1 h before food or beverages that cause the problem, taken with water</td>
</tr>
<tr>
<td>ranitidine</td>
<td>Zantac</td>
<td></td>
<td>150 mg PO BID or 300 mg PO HS; 50 mg q6–8h IM, IV (do not exceed 400 mg/d)</td>
</tr>
<tr>
<td><strong>Antidiarrheals</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>difenoxin HCl with atropine</td>
<td>Motofen</td>
<td></td>
<td>Initial dose 2 tablets PO, then 1 tablet after each loose stool (no more than 8 mg/d for no more than 2 days)</td>
</tr>
<tr>
<td>diphenoxylate HCl with atropine</td>
<td>Lomotil, Lonox, generic</td>
<td></td>
<td>Initial dose 5 mg PO TID–QID as needed</td>
</tr>
<tr>
<td>loperamide HCl</td>
<td>Imodium A-D, Kaopectate II, Maalox Anti-Diarrheal caplets, generic</td>
<td></td>
<td>Initial dose 4 mg PO then 2 mg after each loose stool (no more than 16 mg/d)</td>
</tr>
<tr>
<td><strong>Antiflatulents</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>charcoal</td>
<td>Liqui-Char, generic</td>
<td></td>
<td>520 mg PO after meals or at the first sign of discomfort (up to 4.16 g/d)</td>
</tr>
<tr>
<td>simethicone</td>
<td>Gas-X, Mylcon, generic</td>
<td></td>
<td>Capsules: 125 mg PO QID PC and HS; tablets: 40–125 mg PO QID PC and HS; drops: 40–80 mg PO QID PC and HS (up to 500 mg/d)</td>
</tr>
</tbody>
</table>

(continued)
### DIGESTIVE ENZYMES

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>pancreatin</td>
<td>Creon, Digestepsin, Donnazyme</td>
<td></td>
<td>1–2 tablets PO with meals or snacks</td>
</tr>
<tr>
<td>pancrelipase</td>
<td>Cotazym Capsules, Viokase Powder, Illozyme tablets</td>
<td></td>
<td>4000–48,000 lipase PO with meals and snacks; usually 1–3 capsules or tablets before or with meals and snacks</td>
</tr>
</tbody>
</table>

### EMETICS

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>apomorphine HCl</td>
<td>Generic</td>
<td></td>
<td>2–10 mg SC; do not repeat</td>
</tr>
<tr>
<td>ipecac syrup</td>
<td>Generic</td>
<td></td>
<td>15–30 mL PO, followed by 3–4 glasses of water; children’s dosage based on age: 5–15 mL PO followed by ½–3 glasses of water</td>
</tr>
</tbody>
</table>

### GALLSTONE-SOLUBILIZING AGENT

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>ursodiol</td>
<td>Actigall, generic</td>
<td></td>
<td>8–10 mg/kg/d PO in 2–3 divided doses</td>
</tr>
</tbody>
</table>

### LAXATIVES

#### Saline Laxatives

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>magnesium preparations</td>
<td>Epsom Salt, Milk of Magnesia</td>
<td></td>
<td>Follow directions given on the container</td>
</tr>
</tbody>
</table>
| Irritant or Stimulant Laxatives

#### Irritant or Stimulant Laxatives

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>cascara sagrada</td>
<td>Auromatic Cascara, generic</td>
<td></td>
<td>Follow directions given on the container</td>
</tr>
<tr>
<td>sennosides</td>
<td>Agoral, Ex-Lax, Senexon, Senna-Gel, Senokot</td>
<td></td>
<td>Follow directions given on the container</td>
</tr>
</tbody>
</table>

#### bulk-producing laxatives

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>psyllium</td>
<td>Fiberall Tropical Fruit Flavor, Genfiber, Hydrocil Instant, Konsyl, Metamucil, Serutan</td>
<td></td>
<td>Follow directions on the container</td>
</tr>
<tr>
<td>polycarbophil</td>
<td>Equalactin, FiberCon, Mitrolan</td>
<td></td>
<td>1250 mg one to four times daily or as needed (do not exceed 5 g in 24 h)</td>
</tr>
</tbody>
</table>

### Emollients

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>mineral oil</td>
<td>Kondremul Plain, Milkinol, generic</td>
<td></td>
<td>15–45 mL PO at HS</td>
</tr>
</tbody>
</table>

### FECAL SOFTENERS/SURFACENTS

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name</th>
<th>Use</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>docusate sodium</td>
<td>Colace, D-S-S, Ex-Lax Stool Softener, Modane Soft, generic</td>
<td></td>
<td>Follow directions on the container</td>
</tr>
<tr>
<td>docusate calcium</td>
<td>Surfak Liquigels, generic</td>
<td></td>
<td>240 mg/d until bowel movements are normal</td>
</tr>
</tbody>
</table>
ADVERSE REACTIONS

The magnesium- and sodium-containing antacids may have a laxative effect and produce diarrhea. A luminal- and calcium-containing products tend to produce constipation. Some of the less common but more serious adverse reactions include:

- A luminal-containing antacids—constipation, intestinal impaction, anorexia, weakness, tremors, and bone pain
- Magnesium-containing antacids—severe diarrhea, dehydration, and hypermagnesemia (nausea, vomiting, hypotension, decreased respirations)
- Calcium-containing antacids—rebound hyperacidity, metabolic alkalosis, hypercalcemia, vomiting, confusion, headache, renal calculi, and neurologic impairment
- Sodium bicarbonate—systemic alkalosis and rebound hypersecretion

Although the antacids have the potential for serious adverse reactions, they have a wide margin of safety, especially when used as prescribed.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The antacids are contraindicated in patients with severe abdominal pain of unknown cause and during lactation. Sodium-containing antacids are contraindicated in patients with cardiovascular problems, such as hypertension or congestive heart failure, and those on sodium-restricted diets. Calcium-containing antacids are contraindicated in patients with renal calculi or hypercalcemia.

A luminal-containing antacids are used cautiously in patients with gastric outlet obstruction. Magnesium- and aluminum-containing antacids are used cautiously in patients with decreased kidney function. The calcium-containing antacids are used cautiously in patients with respiratory insufficiency, renal impairment, or cardiac disease. Antacids are classified as Pregnancy Category C drugs and should be used with caution during pregnancy. Antacids may interfere with other drugs in three ways:

1. Increasing the gastric pH, which causes a decrease in absorption of weakly acidic drugs and results in a decreased drug effect (eg, digoxin, phenytoin, chlorpromazine, and isoniazid)
2. Absorbing or binding drugs to their surface, resulting in decreased bioavailability (eg, tetracycline)
3. Affecting the rate of drug elimination by increasing urinary pH (eg, the excretion of salicylates is increased, whereas excretion of quinidine and amphetamines is decreased)

The following drugs have a decreased pharmacologic effect when administered with an antacid: corticosteroids, digoxin, chlorpromazine, oral iron products, isoniazid, phenothiazines, ranitidine, phenytoin, valproic acid, and the tetracyclines.
UNIT VIII  Drugs That Affect the Gastrointestinal and Urinary Systems

ANTICHOLINERGICS

ACTIONS

Anticholinergics (cholinergic blocking drugs) reduce gastric motility and decrease the amount of acid secreted by the stomach (see Chap. 25). Examples of anticholinergics used for GI disorders include propantheline (Pro-Banthine) and glycopyrrolate (Robinul).

USES

Specific anticholinergic drugs are occasionally used in the medical treatment of peptic ulcer. These drugs have been largely replaced by histamine H₂ antagonists, which appear to be more effective and have fewer adverse drug reactions.

ADVERSE REACTIONS

Dry mouth, blurred vision, urinary hesitancy, urinary retention, nausea, vomiting, palpitations, and headache are some of the adverse reactions that may be seen with the use of anticholinergic drugs (see Chap. 25). Contraindications, precautions, and interactions of the anticholinergic drugs are discussed in Chapter 25.

GASTROINTESTINAL STIMULANTS

ACTIONS

Metoclopramide (Reglan) and dexpanthenol (Ilopan) increase the motility of the upper GI tract. The exact mode of action of these drugs is unclear.

USES

Oral preparations of metoclopramide are used in the treatment of symptomatic gastroesophageal reflux disease (GERD; a reflux or backup of gastric contents into the esophagus) and gastric stasis (failure to normally move food out of the stomach) in patients with diabetes. This drug is given intravenously (IV) to prevent nausea and vomiting associated with cancer chemotherapy and to prevent nausea and vomiting during the immediate postoperative period. Dexpanthenol may be given IV immediately after major abdominal surgery to reduce the risk of paralytic ileus (lack of peristalsis or movement of the intestines).

ADVERSE REACTIONS

The adverse reactions associated with metoclopramide are usually mild. Higher doses or prolonged administration may produce central nervous system (CNS) symptoms, such as drowsiness, dizziness, Parkinson-like symptoms (tremor, mask-like facial expression, muscle rigidity), depression, facial grimacing, motor restlessness, and involuntary movements of the eyes, face, or limbs. Dexpanthenol administration may cause itching, difficulty breathing, and urticaria.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The GI stimulants are contraindicated in patients with known hypersensitivity to the drugs, GI obstruction, gastric perforation or hemorrhage, or epilepsy. These drugs are secreted in breast milk and should not be used during lactation. These drugs are used cautiously in patients with diabetes and cardiovascular disease. Metoclopramide is a Pregnancy Category B drug; dexpanthenol is a Pregnancy Category C drug.

The effects of metoclopramide are antagonized by concurrent administration of anticholinergics or narcotic analgesics. Metoclopramide may decrease the absorption of digoxin and cimetidine and increase absorption of acetaminophen, tetracyclines, and levodopa. Metoclopramide may alter the body’s insulin requirements.

HISTAMINE H₂ ANTAGONISTS

ACTIONS

These drugs inhibit the action of histamine at histamine H₂ receptor cells of the stomach, which then reduces the secretion of gastric acid and reduces total pepsin output. The decrease in acid allows the ulcerated areas to heal. Examples of histamine H₂ antagonists include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid Pulvules), ranitidine (Zantac).

USES

These drugs are used for the medical treatment of a gastric or duodenal ulcer, gastric hypersecretory (excessive gastric secretion of hydrochloric acid) conditions, and GERD. These drugs may also be used as prophylaxis of stress-related ulcers and acute upper GI bleeding in critically ill patients.
ADVERSE REACTIONS

Adverse reactions of the histamine H₂ antagonists include dizziness, somnolence, headache, confusion, hallucinations, diarrhea, and impotence (that is reversible when the drug is discontinued). Adverse reactions are usually mild and transient.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The histamine H₂ antagonists are contraindicated in patients with a known hypersensitivity to the drugs. These drugs are used cautiously in patients with renal or hepatic impairment and in the severely ill or debilitated patient. Cimetidine is used cautiously in patients with diabetes. The histamine H₂ antagonists are used cautiously in the older adult (causes confusion). A dosage reduction may be required. Histamine antagonists are Pregnancy Category B (cimetidine, famotidine, and ranitidine) drugs and C (nizatidine) drugs and should be used with caution during pregnancy and lactation.

There are many drug–drug interactions with the histamine H₂ antagonists. The following discussion does not cover all drugs that may interact with the H₂ antagonists but represents some of the more common interactions. Antacids and metoclopramide may decrease absorption of the H₂ antagonists if administered concurrently. Concurrent use of cimetidine and digoxin may decrease serum digoxin levels. There may be a decrease in white blood cell count when the H₂ antagonists are administered with the alkylyating drugs or the antimetabolites. There is an increased risk of toxicity of oral anticoagulants, phenytoin, quinidine, lidocaine, or theophylline when administered with H₂ antagonists. Concurrent use of cimetidine and morphine increases the risk of respiratory depression.

ANTIDIARRHEALS

ACTIONS

Antidiarrheals decrease intestinal peristalsis, which is usually increased when the patient has diarrhea. Examples of these drugs include difenoxin with atropine (Motofen), diphenoxylate with atropine (Lomotil), and loperamide (Imodium).

USES

Antidiarrheals are used in the treatment of diarrhea.

ADVERSE REACTIONS

Diphenoxylate use may result in anorexia, nausea, vomiting, constipation, rash, dizziness, drowsiness, sedation, euphoria, and headache. This drug is a narcotic-related drug that has no analgesic activity but has sedative and euphoric effects and drug dependence potential. To discourage abuse, it is combined with atropine (an anticholinergic or cholinergic blocking drug), which causes dry mouth and other mild adverse effects. Loperamide is not a narcotic-related drug, and minimal adverse reactions are associated with its use. Occasionally, abdominal discomfort, pain, and distention have been seen, but these symptoms also occur with severe diarrhea and are difficult to distinguish from an adverse drug reaction.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

These drugs are contraindicated in patients whose diarrhea is associated with organisms that can harm the intestinal mucosa (Escherichia coli, Salmonella, Shigellosis) and in patients with pseudomembranous colitis, abdominal pain of unknown origin, and obstructive jaundice. The antidiarrheal drugs are contraindicated in children younger than 2 years.

The antidiarrheal drugs are used cautiously in patients with severe hepatic impairment or inflammatory bowel disease. Antidiarrheals are classified as Pregnancy Category B drugs and should be used cautiously during pregnancy and lactation.

The antidiarrheal drugs cause an additive CNS depression when administered with alcohol, antihistamines, narcotics, and sedatives or hypnotics. There are additive cholinergic effects when administered with other drugs having anticholinergic activity, such as antidepressants or antihistamines. Concurrent use of the antidiarrheals with a monoamine oxidase inhibitor increases the risk of a hypertensive crisis.

ANTIFLATULENTS

ACTIONS

Simethicone (Mylicon) and charcoal are used as antiflatulents (against flatus or gas in the intestinal tract). Simethicone has a defoaming action that disperses and prevents the formation of mucus-surrounded gas pockets in the intestine. Charcoal is an absorbent that reduces the amount of intestinal gas.
USES

Antiflatulents are used for the relief of painful symptoms of excess gas in the digestive tract. These drugs are useful as adjunctive treatment of any condition in which gas retention may be a problem (i.e., postoperative gaseous distention, air swallowing, dyspepsia, peptic ulcer, irritable colon, or diverticulosis). In addition to its use for the relief of intestinal gas, charcoal may be used in the prevention of nonspecific pruritus associated with kidney dialysis treatment and as an antidote in poisoning. Simethicone is in some antacid products, such as Mylanta Liquid and Di-Gel Liquid.

ADVERSE REACTIONS

No adverse reactions have been reported with the use of antiflatulents.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The antiflatulents are contraindicated in patients with known hypersensitivity to any components of the drug. The pregnancy category of simethicone is unknown; charcoal is a Pregnancy Category C drug. There may be a decreased effectiveness of other drugs because of adsorption by charcoal, which can also adsorb other drugs in the GI tract. There are no known interactions with simethicone.

DIGESTIVE ENZYMES

ACTIONS

The enzymes pancreatin and pancrelipase, which are manufactured and secreted by the pancreas, are responsible for the breakdown of fats, starches, and proteins. These enzymes are necessary for the breakdown and digestion of food. Both enzymes are available as oral supplements.

USES

These drugs are prescribed as replacement therapy for those with pancreatic enzyme insufficiency. Conditions or diseases that may cause a decrease in or absence of pancreatic digestive enzymes include cystic fibrosis, chronic pancreatitis, cancer of the pancreas, the malabsorption syndrome, surgical removal of all or part of the stomach, and surgical removal of all or part of the pancreas.

ADVERSE REACTIONS

No adverse reactions have been reported with the use of digestive enzymes; however, high doses may cause nausea and diarrhea.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The digestive enzymes are contraindicated in patients with a hypersensitivity to hog or cow proteins and in patients with acute pancreatitis. The digestive enzymes are used cautiously in patients with asthma (an acute asthmatic attack can occur), hyperuricemia, and during pregnancy and lactation. These drugs are Pregnancy Category C drugs, and safe use in pregnancy has not been established.

Calcium carbonate or magnesium hydroxide antacids may decrease the effectiveness of the digestive enzymes. When administered concurrently with an iron preparation, the digestive enzymes decrease the absorption of oral iron preparations.

EMETICS

ACTIONS

The emetic (a drug that induces vomiting) ipecac causes vomiting because of its local irritating effect on the stomach and by stimulation of the vomiting center in the medulla.

USES

Emetics are used to cause vomiting to empty the stomach rapidly when an individual has accidentally or intentionally ingested a poison or drug overdose. Not all poison ingestions or drug overdoses are treated with emetics.

ADVERSE REACTIONS

There are no apparent adverse reactions to ipecac. Although not an adverse reaction, a danger associated with any emetic is the aspiration of vomitus.
CHAPTER 48

Drugs That Affect the Gastrointestinal System

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Emetics are contraindicated in patients who are unconscious, semiconscious, or convulsing and in poisoning caused by corrosive substances, such as strong acids or petroleum products. Ipecac is a Pregnancy Category C drug, and safe use in pregnancy has not been established. Activated charcoal may absorb ipecac, negating its effects.

GALLSTONE-SOLUBILIZING DRUGS

ACTIONS

Gallstone-solubilizing (gallstone-dissolving) drugs, such as ursodiol (Actigall), suppress the manufacture of cholesterol and cholic acid by the liver. The suppression of the manufacture of cholesterol and cholic acid may ultimately result in a decrease in the size of radiolucent gallstones.

USES

These drugs are used in the nonsurgical treatment of radiolucent gallstones. They are not effective for all types of gallstones and require many months of usage to produce results. Because of the potential toxic effects associated with long-term use, these drugs are recommended for only carefully selected and closely monitored patients.

ADVERSE REACTIONS

Diarrhea, cramps, nausea, and vomiting are the more common adverse drug reactions. A reduction in the dose may reduce or eliminate these problems. Prolonged use of these drugs may result in hepatotoxicity (toxic to the liver).

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Ursodiol is used cautiously in patients with a hypersensitivity to the drug or bile salts and in patients with liver impairment, calcified stones, radiopaque stones or radiolucent bile pigment stones, severe acute cholecystitis, biliary obstruction, and gallstone pancreatitis. Ursodiol is used cautiously during pregnancy (Pregnancy Category B) and lactation. A sorption of ursodiol is decreased if the agent is taken with bile acid sequestering drugs or aluminum-containing antacids. Clofibrate, estrogens, and oral contraceptives increase hepatic cholesterol secretion and encourage cholesterol gallstone formation and may counteract the effectiveness of ursodiol.

LAXATIVES

ACTIONS

There are various types of laxatives (see the Summary Drug Table: Drugs Used in the Management of Gastrointestinal Disorders). The action of each laxative is somewhat different, yet they produce the same result—the relief of constipation (Display 48-1).

USES

A laxative is most often prescribed for the short-term relief or prevention of constipation. Certain stimulant, emollient, and saline laxatives are used to evacuate the colon for rectal and bowel examinations. Fecal softeners or mineral oil are used prophylactically in patients who should not strain during defecation, such as after anorectal surgery or a myocardial infarction. Psyllium may be used in patients with irritable bowel syndrome and diverticular disease. Polycarbophil may be prescribed for constipation or diarrhea associated with irritable bowel syndrome and diverticulosis. Mineral oil is

DISPLAY 48-1  Actions of Different Types of Laxatives

- Bulk-producing laxatives are not digested by the body and therefore add bulk and water to the contents of the intestines. The added bulk in the intestines stimulates peristalsis, moves the products of digestion through the intestine, and encourages evacuation of the stool. Examples of bulk-forming laxatives are psyllium (Metamucil) and polycarbophil (FiberCon).
- Emollient laxatives lubricate the intestinal walls and soften the stool, thereby enhancing passage of fecal material. Mineral oil is an emollient laxative.
- Fecal softeners promote water retention in the fecal mass and soften the stool. One difference between emollient laxatives and fecal softeners is that the emollient laxatives do not promote the retention of water in the stool. Examples of fecal softeners include docusate sodium (Colace) and docusate calcium (Surfak).
- Hyperosmolar drugs dehydrate local tissues, which causes irritation and increased peristalsis, with consequent evacuation of the fecal mass. Glycerin is a hyperosmolar drug.
- Irritant or stimulant laxatives increase peristalsis by direct action on the intestine. An example of an irritant laxative is cascara sagrada and senna (Senokot).
- Saline laxatives attract or pull water into the intestine, thereby increasing pressure in the intestine, followed by an increase in peristalsis. Magnesium hydroxide (Milk of Magnesia) is a saline laxative.
useful for the relief of fecal impaction. Docusate is used to prevent dry, hard stools.

Constipation may occur as an adverse drug reaction. When the patient has constipation as an adverse reaction to another drug, the primary care provider may prescribe a stool softener or another laxative to prevent constipation during the drug therapy. Display 48-2 lists the names of some drugs and drug classifications that may cause constipation.

### ADVERSE REACTIONS

Laxative use, especially high doses or use over a long time, can cause diarrhea and a loss of water and electrolytes. For some patients, this may be a serious adverse effect. Laxatives may also cause abdominal pain or discomfort, nausea, vomiting, perianal irritation, fainting, bloating, flatulence, cramps, and weakness. Prolonged use of a laxative can result in serious electrolyte imbalances, as well as the “laxative habit,” that is, a dependency on a laxative to have a bowel movement. Some of these products contain tartrazine, which may cause allergic-type reactions (including bronchial asthma) in susceptible individuals.

Obstruction of the esophagus, stomach, small intestine, and colon has occurred when bulk-forming laxatives are administered without adequate fluid intake or in patients with intestinal stenosis.

### CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Laxatives are contraindicated in patients with known hypersensitivity and those with persistent abdominal pain, nausea, or vomiting of unknown cause or signs of acute appendicitis, fecal impaction, intestinal obstruction, or acute hepatitis. These drugs are used only as directed because excessive or prolonged use may cause dependence. Magnesium hydroxide is used cautiously in patients with any degree of renal impairment. Laxatives are used cautiously in patients with rectal bleeding, in pregnant women, and during lactation. The following laxatives are Pregnancy Category C drugs: cascara, sagrada, docusate, glycerin, phenolphthalein, magnesium hydroxide, and senna. These drugs are used during pregnancy only when the benefits clearly outweigh the risks to the fetus.

Mineral oil may impair the GI absorption of fat-soluble vitamins (A, D, E, and K). Laxatives may reduce absorption of other drugs present in the GI tract, by combining with them chemically or hastening their passage through the intestinal tract. When surfactants are administered with mineral oil, surfactants may increase mineral oil absorption. Milk, antacids, H₂ antagonists, and proton pump inhibitors should not be administered 1 to 2 hours before bisacodyl tablets because the enteric coating may dissolve early (before reaching the intestinal tract), resulting in gastric lining irritation or dyspepsia and decreasing the laxative effect of the drug.

### PROTON PUMP INHIBITORS

Proton pump inhibitors, such as lansoprazole, omeprazole, pantoprazole, and rabeprazole, belong to a group of drugs with antisecretory properties. These drugs suppress gastric acid secretion by inhibition of the hydrogen-potassium adenosine triphosphatase (ATPase) enzyme system at the secretory surface of the gastric parietal cells. They block the last step of acid production.

The proton pump inhibitors are particularly important in the treatment of *Helicobacter pylori* in patients with active duodenal ulcers. *Helicobacter pylori* (*H. pylori*) has been implicated as a causative organism in a type of chronic gastritis and in a large number of cases of peptic and duodenal ulcers.

### ACTIONS

The proton pump inhibitors suppress gastric acid secretion by blocking the final step in the production of gastric acid by the gastric mucosa.

### USES

The proton pump inhibitors are used for treatment or symptomatic relief of various gastric disorders, including gastric and duodenal ulcers, GERD, or pathological hypersecretory conditions. Painful, persistent heartburn 2 or more days a week may indicate acid reflux disease, which can erode the delicate lining of the esophagus,

---

DISPLAY 48-2 - Drugs That May Cause Constipation

- Anticholinergics
- Antihistamines
- Phenothiazines
- Tricyclic antidepressants
- Opiates
- Non-potassium-sparing diuretics
- Iron preparations
- Barium sulfate
- Clonidine
- Antacids containing either calcium carbonate or aluminum hydroxide
causing erosive esophagitis. Esomeprazole (Nexium) or Omeprazole (Prilosec) may provide 24-hour relief from the heartburn associated with GERD or erosive esophagitis while healing occurs.

An important use of these drugs is combination therapy for the treatment of H. pylori in patients with duodenal ulcers. One treatment regimen used to treat infection with H. pylori is a triple-drug treatment regimen, such as one of the proton pump inhibitors (eg, omeprazole or lansoprazole) and two anti-infectives (eg, amoxicillin and clarithromycin). A newer treatment regimen includes bismuth subsalicylate plus two anti-infective drugs. Helidac, a treatment regimen of three drugs (bismuth subsalicylate, metronidazole, and tetracycline) may be given along with a histamine H₂ antagonist to treat disorders of the GI tract infected with H. pylori. Table 48-1 provides a listing of the various combinations used in the treatment of H. pylori. Additional information concerning the anti-infectives listed is found in Chapters 6 through 11. The Summary Drug Table: Drugs Used in the Management of Gastrointestinal Disorders provide information on the drugs used in the treatment of H. pylori.

### ADVERSE REACTIONS

The most common adverse reactions seen with the proton pump inhibitors include headache, diarrhea, and abdominal pain. Other less common adverse reactions include nausea, flatulence, constipation, and dry mouth.

### CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The proton pump inhibitors are contraindicated in patients who have hypersensitivity to any of the drugs. Omeprazole (Pregnancy Category C) and lansoprazole, rabeprazole, and pantoprazole (Pregnancy Category B) are contraindicated during pregnancy and lactation. The proton pump inhibitors are used cautiously in older adults and in patients with hepatic impairment. There is a decreased absorption of lansoprazole when it is administered with sucralfate. Lansoprazole may decrease the effects of ketoconazole, iron salts, and digoxin. When lansoprazole is administered with theophylline, there is an

### TABLE 48-1 Agents Used to Treat H. Pylori in Patients With Duodenal Ulcers

<table>
<thead>
<tr>
<th>DRUG</th>
<th>USE FOR ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER</th>
<th>DOSAGE RANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>amoxicillin</td>
<td>In combination with lansoprazole and clarithromycin or lansoprazole alone</td>
<td>1 g BID for 14 d (triple therapy) or 1 g TID (double therapy)</td>
</tr>
<tr>
<td>bismuth</td>
<td>In combination with other products</td>
<td>525 mg QID in combination with other products</td>
</tr>
<tr>
<td>bismuth subsalicylate (Bismatrol)</td>
<td>H. pylori eradication in patients with duodenal ulcer</td>
<td>525-mg chewable tablets QID in combination with at least two anti-infectives</td>
</tr>
<tr>
<td>clarithromycin (Biaxin)</td>
<td>In combination with amoxicillin</td>
<td>500 mg TID</td>
</tr>
<tr>
<td>lansoprazole (Prevacid)</td>
<td>In combination with clarithromycin and/or amoxicillin</td>
<td>30 mg BID for 14 d (triple therapy) or 30 mg TID for 14 d (double therapy)</td>
</tr>
<tr>
<td>metronidazole (Flagyl)</td>
<td>In combination with other products</td>
<td>250 mg QID</td>
</tr>
<tr>
<td>omeprazole (Prilosec)</td>
<td>In combination with clarithromycin</td>
<td>40 mg BID for 4 wk and 20 mg/d for 15–28 d</td>
</tr>
<tr>
<td>ranitidine bismuth citrate (Tritec)</td>
<td>In combination with other products</td>
<td>400 mg BID for 4 wk in combination with clarithromycin</td>
</tr>
<tr>
<td>tetracycline</td>
<td>In combination with other products</td>
<td>500 mg QID</td>
</tr>
</tbody>
</table>
increase in theophylline clearance requiring dosage changes of the theophylline. When omeprazole is admin-
istered with clarithromycin, there is a risk for an increase in plasma levels of both drugs. Omeprazole may
prolong the elimination of warfarin when the two drugs are administered together. Increased serum levels and the risk
for toxicity of benzodiazepines, phenytoin, and warfarin
may occur if any of these drugs are used with omeprazole.

MISCELLANEOUS DRUGS

The miscellaneous GI drugs include bismuth subsalicy-
late, mesalamine, misoprostol, olsalazine, sucralfate, and
sulfasalazine.

ACTIONS

Bismuth disrupts the integrity of the bacterial cell wall. Misoprostol (Cytotec) inhibits gastric acid secretion
and increases the protective property of the mucosal lining of the GI tract by increasing the production of mucus by the
lining of the GI tract. Sucralfate (Carafate) exerts a local action on the lining of the stomach. The drug forms a
complex with the exudate of the stomach lining. This complex forms a protective layer over a duodenal ulcer,
thus aiding in healing of the ulcer. Mesalamine (Asacol), olsalazine (Dipentum), and sulfasalazine (Azulfidine)
exert a topical anti-inflammatory effect in the bowel. The exact mechanism of action of these drugs is unknown.

USES

Bismuth subsalicylate is used in combination with other
drugs to treat gastric and duodenal ulcers caused by H. pylori bacteria. Mesalamine is used in the treatment
of chronic inflammatory bowel disease. Misoprostol is
used to prevent gastric ulcers in those taking aspirin or
nonsteroidal anti-inflammatory drugs in high doses for
a prolonged time. Olsalazine is used in the treatment of ulcerative colitis in those allergic to sulfasalazine.
Sulfasalazine is used in the treatment of Crohn’s disease
and ulcerative colitis. Sucralfate is used in the treatment
of duodenal ulcer.

ADVERSE REACTIONS

Adverse reactions of bismuth subsalicylate, include a tem-
porary and harmless darkening of the tongue and stool
and constipation. Salicylate toxicity (eg, tinnitus, rapid
respirations, see Chap. 17) may also occur, particularly
when the drug is used for an extended period of time.

Oral administration of mesalamine may cause
abdominal pain, nausea, headache, dizziness, fever, and
weakness. The adverse reactions associated with rectal
administration are less than those seen with oral admin-
istration, but headache, abdominal discomfort, flu-like
syndrome, and weakness may still occur. Olsalazine
administration may result in diarrhea, abdominal dis-
comfort, and nausea. Sulfasalazine is a sulfonamide
with adverse reactions the same as for the sulfonamide
drugs (see Chap. 6).

The adverse reactions seen with the administration
of sucralfate are usually mild, but constipation may be
seen in a small number of patients. Misoprostol admin-
istration may result in diarrhea, abdominal pain, nau-
sea, GI distress, and vomiting.

CONTRAINDICATIONS, PRECAUTIONS,
AND INTERACTIONS

The miscellaneous GI drugs are given with caution to
patients with a known hypersensitivity to the drugs. In
addition mesalamine, olsalazine, and sulfasalazine are
contraindicated in patients who have hypersensitivity
to the sulfonamides and salicylates or intestinal obstruc-
tion, and in children younger than 2 years. There is a
possible cross-sensitivity of mesalamine, olsalazine, and
sulfasalazine with furosemide, sulfonylurea antidiabetic
drugs, and carbonic anhydrase inhibitors. Misoprostol
is contraindicated in those with an allergy to the
prostaglandins and during pregnancy (Pregnancy
Category X) and lactation.

Misoprostol is used cautiously in women of child-
bearing age. Mesalamine, olsalazine, sucralfate, and sul-
fasalazine are Pregnancy Category B drugs; all are used
with caution during pregnancy (safety has not been
established) and lactation.

There is an increased risk of diarrhea in patients
taking misoprostol with the magnesium-containing
antacids. Sulfasalazine may increase the risk of toxic-
ity of oral hypoglycemic drugs, zidovudine, methotrex-
ate, and phenytoin. There is an increased risk of crys-
talluria when sulfasalazine is administered with methenamine. A decrease in the absorption of iron and
folic acid may occur when these agents are adminis-
tered with sulfasalazine. When bismuth subsalicylate
is administered with aspirin-containing drugs, there is
an increased risk of salicylate toxicity. There is an
increased risk of toxicity of valproic acid and
methotrexate and decreased effectiveness of the corti-
costeroids when these agents are administered with
bismuth subsalicylate.
The Patient Receiving a Drug for a Gastrointestinal Disorder

ASSESSMENT

Preadministration Assessment
During the preadministration assessment, the nurse reviews the patient’s chart for the medical diagnosis and reason for administration of the prescribed drug. The nurse questions the patient regarding the type and intensity of symptoms (such as pain, discomfort, diarrhea, or constipation) to provide a baseline for evaluation of the effectiveness of drug therapy.

Ongoing Assessment
The nurse assesses the patient receiving one of these drugs for relief of symptoms (such as diarrhea, pain, or constipation). The primary health care provider is notified if the drug fails to relieve symptoms. The nurse monitors vital signs daily or more frequently if the patient has a bleeding peptic ulcer, severe diarrhea, or other condition that may warrant more frequent observation. The nurse observes the patient for adverse drug reactions associated with the specific GI drug being administered and reports any adverse reactions to the primary health care provider before the next dose is due. The nurse evaluates the effectiveness of drug therapy by a daily comparison of symptoms with those experienced before the initiation of therapy. In some instances, frequent evaluation of the patient’s response to therapy may be necessary.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes for the patient depend on the reason for administration of the drug but may include an optimal response to drug therapy, management of common adverse reactions, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy
Ways in which the nurse can help promote an optimal response to therapy when administering GI drugs are listed in the following sections.

ANTACIDS. The nurse should not give antacids within 2 hours before or after administration of other oral drugs. Liquid antacid preparations must be shaken thoroughly immediately before administration. If tablets are given, the nurse instructs the patient to chew the tablets thoroughly before swallowing and then drink a full glass of water or milk. Liquid antacids are followed by a small amount of water. If the patient expresses a dislike for the taste of the antacid or has difficulty chewing the
tablet form, the nurse informs the primary health care provider. A flavored antacid may be ordered if the taste is a problem. A liquid form may be ordered if the patient has a problem chewing a tablet. The primary health care provider may order that the antacid be left at the patient’s bedside for self-administration. The nurse makes certain an adequate supply of water and cups for measuring the dose are available. The antacid may be administered hourly for the first 2 weeks when used to treat acute peptic ulcer. After the first 2 weeks, the drug is administered 1 to 2 hours after meals and at bedtime.

**Nursing Alert**

*Because of the possibility of an antacid interfering with the activity of other oral drugs, no oral drug should be administered within 1 to 2 hours of an antacid.*

**Gastrointestinal Stimulants.** The nurse carefully times the administration of oral metoclopramide for 30 minutes before each meal. Dextenphenol is administered intramuscularly or IV. The nurse tells the patient that intestinal colic may occur within 30 minutes of administration and that this is not abnormal and will pass within a short time.

**Histamine H₂ Antagonists.** The nurse administers ranitidine and oral cimetidine before or with meals and at bedtime. Nizatidine and famotidine are given at bedtime or, if twice-a-day dosing is prescribed, in the morning and at bedtime. These drugs are usually given concurrently with an antacid to relieve the pain. In certain situations or disorders, cimetidine and ranitidine may also be given by intermittent IV infusion or direct IV injection.

**Nursing Alert**

*Before an emetic is given, it is extremely important to know the chemicals or substances that have been ingested, the time they were ingested, and what symptoms were noted before seeking medical treatment. This information will probably be obtained from a family member or friend, but the adult patient may also contribute to the history. The primary healthcare provider or nurse may also contact the local poison control center to obtain information regarding treatment.*

The nurse must not give an emetic when a corrosive substance (such as lye) or a petroleum distillate (paint thinner, kerosene) has been ingested. In many cases of poisoning, it is preferable to insert a nasogastric tube to empty stomach contents. Emetics are used with great caution, if at all, when the substance ingested is unknown or in question. An emetic is never given to a patient who is unconscious or semiconscious because aspiration of vomitus may occur.

The nurse positions the patient on his or her side before or immediately after the drug is given. When emesis occurs, the nurse suctions the patient as needed and observes closely for the possible aspiration of vomitus. The nurse monitors vital signs every 5 to 10 minutes until signs are stable.

**Laxatives.** The nurse gives bulk-producing or fecal-softening laxatives with a full glass of water or juice. The administration of a bulk-producing laxative is followed by an additional full glass of water. Mineral oil is preferably given to the patient with an empty stomach in the evening. Immediately before administration, the nurse thoroughly mixes and stirs laxatives that are in powder, flake, or granule form. If the laxative has an unpleasant or salty taste, the nurse explains this to the patient. The taste of some of these preparations may be disguised by chilling, adding to juice, or pouring over cracked ice.
ANTIFLATULENTS. Activated charcoal can adsorb drugs while they are in the GI tract. The nurse administers charcoal 2 hours before or 1 hour after other medications. If diarrhea persists or lasts longer than 2 days or is accompanied by fever, the nurse notifies the primary care provider. Simethicone is administered after each meal and at bedtime.

PROTON PUMP INHIBITORS. The nurse administers omeprazole before meals. The drug should be swallowed whole and not chewed or crushed. Esomeprazole magnesium must be swallowed whole and is administered at least 1 hour before meals. For patients who have difficulty swallowing, the nurse may open the capsule and place the granules onto a small amount of applesauce. The granules are mixed lightly with the applesauce and administered immediately. The patient is instructed to swallow the mixture without chewing. Likewise, lansoprazole may be sprinkled on approximately 1 tablespoon of applesauce, cottage cheese, Ensure pudding, yogurt, or strained pears. The drug may also be administered through a nasogastric tube (NG). The granules are mixed with 40 mL of apple juice and injected through a tube. The tube is flushed with fluid afterward.

Monitoring and Managing Adverse Drug Reactions

ANTACIDS. When antacids are given, the nurse keeps a record of the patient’s bowel movements because these drugs may cause constipation or diarrhea. If the patient experiences diarrhea, the nurse keeps an accurate record of fluid intake and output along with a description of the diarrhea stool. Changing to a different antacid usually alleviates the problem. Diarrhea may be controlled by combining a magnesium antacid with an antacid containing aluminum or calcium.

ANTICHOLINERGICS. Urinary retention or hesitancy may be seen during therapy with these drugs. This can be avoided by instructing the patient to void before taking the drug. If urinary retention is suspected, the nurse monitors fluid intake and output. These drugs also may cause drowsiness, dizziness, and blurred vision, which may interfere with activities such as reading or watching television. If dizziness occurs, the patient will require assistance with ambulatory activities. If photophobia (aversion to bright light) occurs, the room may be kept semidark.

GASTROINTESTINAL STIMULANTS. If drowsiness or dizziness occurs with the administration of metoclopramide, the patient will require assistance with ambulatory activities. The nurse observes patients receiving high or prolonged doses of this drug for adverse reactions related to the CNS (extrapyramidal reactions or tardive dyskinesia, see Chap. 32). The nurse reports any sign of extrapyramidal reaction or tardive dyskinesia to the primary health care provider before the next dose of metoclopramide is administered because the drug therapy may be discontinued. These reactions are irreversible if therapy is continued.

Dexpanthenol is administered to prevent paralytic ileus (intestinal atony) during the immediate postoperative period. The drug also may be given if a paralytic ileus has occurred, in which case bowel sounds will be diminished or absent. During the administration of the drug, the abdomen is frequently auscultated for the presence or absence of bowel sounds and the primary health care provider notified of the results of these assessments. The nurse observes the patient taking dexpanthenol for adverse reactions, such as nausea, vomiting, and diarrhea. The nurse checks the blood pressure at frequent intervals because a slight drop in blood pressure may occur. A common adverse reaction is intestinal colic that may occur within 30 minutes after administration of the drug.

HISTAMINE H₂ ANTAGONISTS. During early therapy with these drugs, the patient may experience dizziness or drowsiness. The patient may require assistance with ambulation. These reactions usually must be tolerated, but the nurse reassures the patient that they will disappear after several days of therapy.

The nurse immediately reports adverse reactions, such as skin rash, sore throat, fever, unusual bleeding, or hallucinations because the primary health care provider may want to discontinue the drug therapy.

Gerontologic Alert

The older adult is particularly sensitive to the effects of the histamine H₂ antagonists. The nurse must closely monitor older adults for confusion and dizziness. Dizziness increases the risk for falls in the older adult.

Assistance is needed for ambulatory activities. The environment is made safe by removing throw rugs or small pieces of furniture and so forth. The nurse reports any change in orientation to the primary health care provider.

ANTIDIARRHEALS. The nurse notifies the primary health care provider if an elevation in temperature occurs or if severe abdominal pain or abdominal rigidity or distention occurs because this may indicate a complication of the disorder, such as infection or intestinal perforation. If diarrhea is severe, additional treatment measures, such as IV fluids and electrolyte replacement, may be necessary.

Drowsiness or dizziness may occur with these drugs. The patient may require assistance with ambulatory activities. If diarrhea is chronic, the nurse encourages the patient to drink extra fluids. Fluids
such as weak tea, water, bouillon, or a commercial electrolyte preparation may be used. The nurse closely monitors fluid intake and output. In some instances, the primary health care provider may prescribe an oral electrolyte supplement to replace electrolytes lost by frequent loose stools. For perianal irritation caused by loose stools, the nurse cleanses the area with mild soap and water after each bowel movement, dries the area with a soft cloth, and applies an emollient, such as petrolatum.

**DIGESTIVE ENZYMES.** The nurse observes the patient for nausea and diarrhea. If these occur, the nurse notifies the primary health care provider before the next dose is due because the dosage may need to be reduced. Digestive enzymes come in regular capsule form or as delayed-released capsules. The capsules are taken before or with meals. If necessary the capsules may be opened and sprinkled over soft foods (e.g., jello, applesauce, ice cream) that can be swallowed without chewing. It is particularly important that enteric-coated beads from the time-released capsules be swallowed and not chewed. If the drug is sprinkled over certain foods, it is important that the nurse check the patient’s tray after each meal to determine if the foods sprinkled with the drug are eaten. If these foods are not eaten, the nurse notifies the primary health care provider. The nurse weighs the patient weekly (or as ordered) and alerts the primary health care provider if there is any significant or steady weight loss.

The nurse notes and records the appearance of each stool. Periodic stool examinations, as well as ongoing descriptions of the appearance of the stools, help the primary health care provider determine the effectiveness of therapy.

**EMETICS.** After the administration of an emetic, the nurse closely observes the patient for signs of shock, respiratory depression, or other signs and symptoms that may be part of the clinical picture of the specific poison or drug that was accidentally or purposely taken.

**LAXATIVES.** The nurse records the results of administration on the patient’s chart. If excessive bowel movements or severe prolonged diarrhea occur or if the laxative is ineffective, the nurse notifies the primary health care provider. If a laxative is ordered for constipation, the nurse encourages a liberal fluid intake and an increase in foods high in fiber to prevent a repeat of this problem.

**PROTON PUMP INHIBITORS.** The adverse reactions of the proton pump inhibitors are usually mild. The most common adverse reactions associated with the proton pump inhibitors are headache, diarrhea, and abdominal pain. Headache may be treated with analgesics. The nurse notes the number, color, and consistency of the stools. The nurse reports any excessive diarrhea or severe headache.

**Educating the Patient and Family**

When a GI drug must be taken for a long time, there is a possibility that the patient may begin to skip doses or stop taking the drug. The nurse encourages patients to take the prescribed drug as directed by the primary health care provider and emphasizes the importance of not omitting doses or stopping the therapy unless advised to do so by the primary health care provider.

The nurse includes the following information in a patient and family teaching plan:

**ANTACIDS**

- Do not use the drug indiscriminately. Check with a primary health care provider before using an antacid if other medical problems, such as a cardiac condition (some laxatives contain sodium), exist.
- Chew tablets thoroughly before swallowing and then drink a full glass of water.
- Effervescent tablets: allow to completely dissolve in water. Allow most of the bubbling to stop before drinking.
- Adhere to the dosage schedule recommended by the primary health care provider. Do not increase the frequency of use or the dose if symptoms become worse; instead, see the primary health care provider as soon as possible.
- Antacids impair the absorption of some drugs. Do not take other drugs within 2 hours before or after taking the antacid unless use of an antacid with a drug is recommended by the primary health care provider.
- If pain or discomfort remains the same or becomes worse, if the stools turn black or coffee ground vomiting occurs, contact the primary health care provider as soon as possible.
- Antacids may change the color of the stool (white, white streaks); this is normal.
- Magnesium-containing products may produce a laxative effect and may cause diarrhea; aluminum- or calcium-containing antacids may cause constipation; magnesium-containing antacids are used to avoid bowel dysfunction.
- Taking too much antacid may cause the stomach to secrete excess stomach acid. Consult the primary care provider or pharmacist about appropriate dose. Do not use the maximum dose for more than 2 weeks, except under the supervision of a primary care provider.
ANTICHOLINERGICS

• If an aversion to light occurs, wear sunglasses when outside, keep rooms dimly lit, and schedule outdoor activities (when necessary) before the first dose of the drug is taken, such as early in the morning.

• If a dry mouth occurs, take frequent sips of cool water during the day, several sips of water before taking oral drugs, and frequent sips of water during meals.

• Constipation may be avoided by drinking plenty of fluids during the day.

• Drowsiness may occur with these drugs. Schedule tasks requiring alertness during times when drowsiness does not occur, such as early in the morning before the first dose of the drug is taken.

GASTROINTESTINAL STIMULANTS. Metoclopramide—Take 30 minutes before meals. If drowsiness or dizziness occurs, observe caution while driving or performing hazardous tasks. Immediately report any of the following signs: difficulty speaking or swallowing; mask-like face; shuffling gait; rigidity; tremors; uncontrolled movements of the mouth, face, or extremities; and uncontrolled chewing or unusual movements of the tongue.

HISTAMINE H₂ ANTAGONISTS

• Keep the primary health care provider informed of the results of therapy, that is, relief of pain or discomfort.

• Take as directed (e.g., with meals, at bedtime) on the prescription container.

• Follow the primary health care provider’s recommendations regarding additional treatment, such as eliminating certain foods, avoiding the use of alcohol, and using additional drugs, such as an antacid.

• If drowsiness occurs, avoid driving or performing other hazardous tasks.

• Notify the primary health care provider of the following adverse reactions: sore throat, rash, fever, unusual bleeding, black or tarry stools, easy bruising, or confusion.

DIGESTIVE ENZYMES

• Take the drugs as directed by the primary health care provider. Do not exceed the recommended dose.

• Do not chew tablets or capsules. Swallow the whole form of the drug quickly, while sitting upright to enhance swallowing and prevent mouth and throat irritation. Eat immediately after taking the drug.

• If capsules are difficult to swallow, they may be opened and their contents sprinkled over small quantities of food. Avoid sprinkling the drug over hot foods. All the food sprinkled with the powder must be eaten.

• Do not change brands without consulting with the primary care provider or the pharmacist.

• Do not inhale the powder dosage form or powder from capsules because it may irritate the skin or mucous membranes.

EMETICS (IPECAC SYRUP)

• Ipecac is available without a prescription for use in the home. The instructions for use and the recommended dose are printed on the label.

• Read the directions on the label after the drug is purchased and be familiar with these instructions before an emergency occurs.

• In case of accidental or intentional poisoning, contact the nearest poison control center before using or giving this drug. Not all poisoning can be treated with this drug.

• Do not give this drug to semiconscious, unconscious, or convulsing individuals.

• Vomiting should occur in 20 to 30 minutes. Seek medical attention immediately after contacting the poison control center and giving this drug.

GALLSTONE-SOLUBILIZING DRUGS

• Periodic laboratory tests (liver function studies) and ultrasound or radiologic examinations of the gallbladder may be scheduled by the primary health care provider.
• If diarrhea occurs, contact the primary health care provider. If symptoms of gallbladder disease (pain, nausea, or vomiting) occur, immediately contact the primary health care provider.
• Never take these drugs with aluminum-containing antacids. If antacids are required, take them 2 to 3 hours after ursodiol.

LAXATIVES
• Avoid long-term use of these products unless use of the product has been recommended by the primary health care provider. Long-term use may result in the “laxative habit,” which is a dependence on a laxative to have a bowel movement. Constipation may also occur with overuse of these drugs. Read and follow the directions on the label.
• Avoid long-term use of mineral oil. Daily use of this product may interfere with the absorption of some vitamins (vitamins A, D, E, K). Take with the stomach empty, preferably at bedtime.
• Do not use these products in the presence of abdominal pain, nausea, or vomiting.
• Notify the primary health care provider if constipation is not relieved or if rectal bleeding or other symptoms occur.
• To avoid constipation, drink plenty of fluids, get exercise, and eat foods high in bulk or roughage.
• Bulk-producing or fecal-softening laxatives—Drink a full glass of water or juice, followed by more glasses of fluid in the next few hours.
• Bisacodyl (Dulcolax)—Do not chew the tablets or take them within 1 hour of taking antacids or milk.
• Cascara sagrada or senna—Pink-red, red-violet, red-brown, yellow-brown, or black discoloration of urine may occur.

PROTON PUMP INHIBITORS
• Esomeprazole—Swallow whole at least 1 hour before eating. If you have difficulty swallowing, the capsule may be opened and the granules sprinkled on a small amount of applesauce.
• Omeprazole—Swallow tablets whole; do not chew them. This drug will be taken for up to 8 weeks or for a prolonged period. Regular medical check-ups are required.
• Lansoprazole—Take the drug before meals. Swallow the capsules whole. Do not chew, open, or crush. If you have difficulty swallowing the capsule, open and sprinkle granules on Jell-O or applesauce. You will need regular medical check-ups while taking this drug.

H. PYLORI COMBINATION DRUGS
• Helidac—Each dose includes four tablets: two round, chewable pink tablets (bismuth), one white tablet (metronidazole), and one pale orange and white capsule (tetracycline). Take each dose four times a day with meals and at bedtime for 14 days. Chew and swallow the bismuth subsalicylate tablets; swallow the metronidazole tablet and tetracycline capsule with a full glass of water. Take concomitantly prescribed H₂ antagonist therapy, as directed. Drink an adequate amount of fluid to reduce the risk of esophageal irritation and ulceration. Missed doses may be made up by continuing the formal dosing schedule until the medication is gone. Do not take double doses. If more than four doses are missed, contact the primary care provider.
• Bismuth subsalicylate—Immediately report any symptoms of salicylate toxicity (ringing in the ears, rapid respirations). Chew tablets thoroughly or dissolve them in the mouth. Do not swallow tablets whole. Stools may become dark. This is normal and will disappear when the drug therapy is discontinued. Do not take this drug with aspirin or aspirin products.

MISCELLANEOUS DRUGS
• Olsalazine—If diarrhea develops, contact the primary health care provider as soon as possible.
• Mesalamine—Swallow tablets whole; do not chew them. For the suppository, remove foil wrapper and immediately insert the pointed end into the rectum without using force. For the suspension form, instructions are included with the product. Shake well, remove the protective sheath from the applicator tip, and gently insert the tip into the rectum. Partially intact tablets may be found in the stool; if this occurs, notify the primary health care provider.
• Misoprostol—Take this drug four times a day with meals and at bedtime. Continue to take the NSAID during this drug therapy. Take the drug with meals to decrease the severity of diarrhea. The administration of antacids before or after misoprostol may decrease the pain. Magnesium-containing antacids are avoided because of the risk of increasing the diarrhea.

This drug may cause spontaneous abortion. Women of childbearing age must use a reliable contraceptive. If pregnancy is suspected, discontinue use of the drug and notify the primary health care provider. Report severe menstrual pain, bleeding, or spotting.
• Sucralfate—Take on an empty stomach 1 hour before meals. Antacids may be taken for pain but not within 1/2 hour before or after sucralfate. Therapy will continue for 4 to 8 weeks. Keep all follow-up appointments with the primary health care provider.
EVALUATION

• The therapeutic drug effect is achieved.
• Adverse reactions are identified and reported to the primary health care provider.
• The patient and family demonstrate an understanding of the drug regimen.
• The patient verbalizes the importance of complying with the prescribed treatment regimen.
• The patient verbalizes an understanding of treatment modalities and the importance of continued follow-up care.

Critical Thinking Exercises

1. Ms. Harris, age 76 years, tells you that she has been using various laxatives for constipation. She states that a laxative did help, but now she is more constipated than she was before she began taking a laxative. Discuss what advice or suggestions you would give this patient.

2. James is prescribed 0.7 g of powdered pancrelipase with meals. Discuss the preparation and administration of this drug.

3. Mr. Gates, your neighbor, has been given a prescription for diphenoxylate with atropine (Lomotil) to be taken if he should experience diarrhea while he is traveling in a foreign country. Describe the warnings you would give to your neighbor regarding this drug.

4. The primary health care provider has prescribed cimetidine for the treatment of a duodenal ulcer in Mr. Talley, who is 68 years old. A drug history by the nurse reveals that Mr. Talley is also taking the following drugs: Lanoxin 0.5 mg orally each day and a daily aspirin tablet. Analyze this situation. Discuss what you would tell Mr. Talley.

5. Ms. Jerkins has four children and wants to keep syrup of ipecac available in case of accidental poisoning. Discuss the information you feel that Ms. Jerkins should know before she administers this drug.

Medication Dosage Problems

1. The patient is to receive 800 mg cimetidine PO. Available for use is the cimetidine shown below. The nurse administers ______.

2. Prescribed is 15 mL of 1.5% ipecac syrup. Available is 30 mL ipec 1.5% syrup. The nurse administers ______.
Insulin, a hormone produced by the pancreas, acts to maintain blood glucose levels within normal limits (60–120 mg/dL). This is accomplished by the release of small amounts of insulin into the bloodstream throughout the day in response to changes in blood glucose levels. Insulin is essential for the utilization of glucose in cellular metabolism and for the proper metabolism of protein and fat.

Diabetes mellitus is a complicated, chronic disorder characterized by either insufficient insulin production by the beta cells of the pancreas or by cellular resistance to insulin. Insulin insufficiency results in elevated blood glucose levels, or hyperglycemia. As a result of the disease, individuals with diabetes are at greater risk for a number of disorders, including myocardial infarction, cerebrovascular accident (stroke), blindness, kidney disease, and lower limb amputations.

Insulin and the oral antidiabetic drugs, along with diet and exercise, are the cornerstones of treatment for diabetes mellitus. They are used to prevent episodes of hypoglycemia and to normalize carbohydrate metabolism.

There are two major types of diabetes mellitus:

- Type 1—Insulin-dependent diabetes mellitus (IDDM). Former names of this type of diabetes mellitus include juvenile diabetes, juvenile-onset diabetes, and brittle diabetes.
- Type 2—Noninsulin-dependent diabetes mellitus (NIDDM). Former names of this type of diabetes mellitus include maturity-onset diabetes, adult-onset diabetes, and stable diabetes.

Those with type 1 diabetes mellitus produce insulin in insufficient amounts and therefore must have insulin supplementation to survive. Type 1 diabetes usually has a rapid onset, occurs before the age of 20 years, produces more severe symptoms than type 2 diabetes, and is more difficult to control. Major symptoms of type 1 diabetes include hyperglycemia, polydipsia (increased thirst), polyphagia (increased appetite), polyuria (increased urination), and weight loss. Treatment of type 1 diabetes is particularly difficult to control because of the lack of insulin production by the pancreas. Treatment requires a strict regimen that typically includes a carefully calculated diet, planned physical activity, home glucose testing several times a day, and multiple daily insulin injections.

Type 2 diabetes mellitus affects about 90% to 95% of individuals with diabetes. Those with type 2 diabetes mellitus either have a decreased production of insulin...
by the beta cells of the pancreas or a decreased sensitivity of the cells to insulin, making the cells insulin resistant. Although type 2 diabetes mellitus may occur at any age, the disorder occurs most often after the age of 40 years. The onset of type 2 diabetes is usually insidious, symptoms are less severe than in type 1 diabetes mellitus, and because it tends to be more stable, it is easier to control than type 1 diabetes. Risk factors for type 2 diabetes include:

- Obesity
- Older age
- Family history of diabetes
- History of gestational diabetes (diabetes that develops during pregnancy but disappears when pregnancy is over)
- Impaired glucose tolerance
- Minimal or no physical activity
- Race/ethnicity (African Americans, Hispanic/Latino Americans, American Indians, and some Asian Americans)

Obesity is thought to contribute to type 2 diabetes by placing additional stress on the pancreas, which makes it less able to respond and produce adequate insulin to meet the body’s metabolic needs.

Many individuals with type 2 diabetes are able to control the disorder with diet, exercise, and oral antidiabetic drugs. However, about 40% of those with type 2 diabetes do not have a good response to the oral antidiabetic drugs and require the addition of insulin to control the diabetes.

**INSULIN**

Insulin is a hormone manufactured by the beta cells of the pancreas. It is the principal hormone required for the proper use of glucose (carbohydrate) by the body. Insulin also controls the storage and utilization of amino acids and fatty acids. Insulin lowers blood glucose levels by inhibiting glucose production by the liver.

Insulin is available as purified extracts from beef and pork pancreas and is biologically similar to human insulin. However, these animal source insulins are used less frequently today than in years past. They are being replaced by synthetic insulins, including human insulin or insulin analogs.

Human insulin is derived from a biosynthetic process using strains of *Escherichia coli* (recombinant DNA, rDNA). Human insulin appears to cause fewer allergic reactions than does insulin obtained from animal sources. Insulin analogs, insulin lispro, and insulin aspart are newer forms of human insulin made by using recombinant DNA technology and are structurally similar to human insulin.

**Figure 49-1.** Normal glucose metabolism. Once insulin binds with receptors on the cell membrane, glucose can move into the cell, promoting cellular metabolism and energy production.
**ACTIONS**

Insulin appears to activate a process that helps glucose molecules enter the cells of striated muscle and adipose tissue. Figure 49-1 depicts normal glucose metabolism. Insulin also stimulates the synthesis of glycogen by the liver. In addition, insulin promotes protein synthesis and helps the body store fat by preventing its breakdown for energy.

**Onset, Peak, and Duration of Action**

Onset, peak, and duration are three properties of insulin that are of clinical importance.

- **Onset**—when insulin first begins to act in the body
- **Peak**—when the insulin is exerting maximum action
- **Duration**—the length of time the insulin remains in effect

To meet the needs of those with diabetes mellitus, various insulin preparations have been developed to delay the onset and prolong the duration of action of insulin. When insulin is combined with protamine (a protein), the absorption of insulin from the injection site is slowed and the duration of action is prolonged. The addition of zinc also modifies the onset and duration of action of insulin. Insulin preparations are classified as rapid-acting, intermediate-acting, or long-acting. The Summary Drug Table: Insulin Preparations gives information concerning the onset, peak, and duration of various insulins.

---

### SUMMARY DRUG TABLE  INSULIN PREPARATIONS

<table>
<thead>
<tr>
<th>TYPES OF INSULIN</th>
<th>TRADE NAME</th>
<th>ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rapid-Acting Insulins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>30–60 min</td>
<td>2–4 h</td>
</tr>
<tr>
<td>insulin lispro (insulin analog)</td>
<td>Humalog, Humalog Mix 50/50, Humalog Mix 75/25</td>
<td>45 min</td>
</tr>
<tr>
<td></td>
<td>30–60 min</td>
<td>2–4 h</td>
</tr>
<tr>
<td></td>
<td>then 1–2 h</td>
<td>6–12 h</td>
</tr>
<tr>
<td>insulin aspart solution (insulin analog)</td>
<td>Novolog</td>
<td>5–10 min</td>
</tr>
<tr>
<td><strong>Intermediate-Acting Insulin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>isophane insulin suspension (NPH)</td>
<td>Humulin N, Novolin N, Novolin N PenFill, Novolin N Prefilled, NPH Iletin II</td>
<td>1–2 h</td>
</tr>
<tr>
<td>insulin zinc suspension (Lente)</td>
<td>Humulin L, Lente Iletin II, Novolin L</td>
<td>1–2.5 h</td>
</tr>
<tr>
<td><strong>Long-Acting Insulins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insulin glargine solution</td>
<td>Lantus</td>
<td>30–60 min</td>
</tr>
<tr>
<td>extended insulin zinc suspension (Ultralente)</td>
<td>Humulin U</td>
<td>4–8 h</td>
</tr>
<tr>
<td><strong>Mixed Insulins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>isophane insulin suspension and insulin injections (NPH)</td>
<td>Humulin 70/30, Novolin 70/30, Novolin 70/30 PenFill, Novolin 70/30 Prefilled</td>
<td>30–60 min then 1–2 h</td>
</tr>
<tr>
<td>isophane insulin suspension and insulin injection</td>
<td>Humulin 50/50</td>
<td>30–60 min then 1–2 h</td>
</tr>
<tr>
<td><strong>High-Potency Insulin</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>insulin injection concentrated</td>
<td>Humulin R Regular U-500</td>
<td></td>
</tr>
</tbody>
</table>
Insulin is necessary for controlling type 1 diabetes mellitus that is caused by a marked decrease in the amount of insulin produced by the pancreas. Insulin is also used to control the more severe and complicated forms of type 2 diabetes mellitus. However, many patients can control type 2 diabetes with diet and exercise alone or with diet, exercise, and an oral antidiabetic drug (see section “Oral Antidiabetic Drugs”). Insulin may also be used in the treatment of severe diabetic ketoacidosis (DKA) or diabetic coma. Insulin is also used in combination with glucose to treat hypokalemia by producing a shift of potassium from the blood and into the cells.

ADVERSE REACTIONS

The two major adverse reactions seen with insulin administration are hypoglycemia (low blood glucose or sugar) and hyperglycemia (elevated blood glucose or sugar). The symptoms of hypoglycemia and hyperglycemia are listed in Table 49-1.

Hypoglycemia may occur when there is too much insulin in the bloodstream in relation to the available glucose (hyperinsulinism). Hypoglycemia may occur:

- When the patient eats too little food
- When the insulin dose is incorrectly measured and is greater than that prescribed
- When the patient drastically increases physical activity

Hyperglycemia may occur if there is too little insulin in the bloodstream in relation to the available glucose (hypoinsulinism). Hyperglycemia may occur:

- When the patient eats too much food
- When too little or no insulin is given
- When the patient experiences emotional stress, infection, surgery, pregnancy, or an acute illness

Another potential adverse reaction may be if the patient has an allergy to the animal (pig or cow) from which the insulin is obtained or to the protein or zinc added to insulin. To minimize the possibility of an allergic reaction, some health care providers prescribe human insulin or purified insulin. However, on rare occasions, some individuals become allergic to the human and purified insulins.

An individual can also become insulin resistant because of the development of antibodies against insulin. These patients have impaired receptor function and become so unresponsive to insulin that the daily dose requirement may be in excess of 500 units per day (U/d), rather than the usual 40 to 60 U/d. High-potency insulin in a concentrated form (U500; see the Summary Drug Table: Insulin Preparations) is used for patients requiring more than 200 U/d.

CONTRAINDICATIONS

Insulin is contraindicated in patients with hypersensitivity to any ingredient of the product (eg, beef or pork) and when the patient is hypoglycemic.

PRECAUTIONS

Insulin is used cautiously in patients with renal and hepatic impairment and during pregnancy (Pregnancy Category B and Category C, insulin glargine and insulin

<table>
<thead>
<tr>
<th>TABLE 49-1 Hypoglycemia Versus Hyperglycemia</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SYMPTOMS</strong></td>
</tr>
<tr>
<td>Onset</td>
</tr>
<tr>
<td>Blood glucose</td>
</tr>
<tr>
<td>Central nervous system</td>
</tr>
<tr>
<td>Respiration</td>
</tr>
<tr>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>Skin</td>
</tr>
<tr>
<td>Pulse</td>
</tr>
<tr>
<td>Miscellaneous</td>
</tr>
</tbody>
</table>
aspart) and lactation (may inhibit milk formation with large doses of insulin). Insulin appears to inhibit milk production in lactating women and could interfere with breastfeeding. Lactating women may require adjustment in insulin dose and diet.

**INTERACTIONS**

When certain drugs are administered with insulin, a resultant decrease or increase in hypoglycemic effect can occur. Display 49-1 identifies selected drugs that decrease the hypoglycemic effect of insulin. Display 49-2 identifies select drugs which, when administered with insulin, may increase the hypoglycemic effect of insulin.

**NURSING PROCESS**

- **The Patient Receiving Insulin**

  **ASSESSMENT**

  **Preadministration Assessment**

  If the patient has recently received a diagnosis of diabetes mellitus and has not received insulin or if the patient is known to have diabetes, the initial physical assessment before administering the first dose of insulin includes taking the blood pressure, pulse, and respiratory rate, and weighing the patient. The nurse makes a general assessment of the skin, mucous membranes, and extremities, with special attention given to any sores or cuts that appear to be infected or healing poorly, as well as any ulcerations or other skin or mucous membrane changes. The nurse obtains the following information and includes it in the patient’s chart:

  - Dietary habits
  - Family history of diabetes (if any)
  - Type and duration of symptoms experienced

  The nurse reviews the patient’s chart for recent laboratory and diagnostic tests. If the patient has diabetes and has been receiving insulin, the nurse includes the type and dosage of insulin used, the type of diabetic diet, and the average results of glucose testing in the patient’s chart. The nurse evaluates the patient’s past compliance to the prescribed therapeutic regimen, such as diet, weight control, and periodic evaluation by a health care provider.

  **Ongoing Assessment**

  The number and amount of daily insulin doses, times of administration, and diet and exercise requirements require continual assessment. Dosage adjustments may be necessary when changing types of insulin, particularly when changing from the single-peak to the more pure Humulin insulins.

  The nurse must assess the patient for signs and symptoms of hypoglycemia and hyperglycemia (see Table 49-1) throughout insulin therapy. The patient is particularly prone to hypoglycemic reactions at the time of peak insulin action (see the Summary Drug Table: Insulin Preparations) or when the patient has not eaten for some time or has skipped a meal. In acute care settings, frequent blood glucose monitoring is routinely done to help detect abnormalities of blood glucose.

---

**DISPLAY 49-1 • Select Drugs That Decrease the Hypoglycemic Effect of Insulin**

- AIDS antivirals
- albuterol
- contraceptives, oral
- corticosteroids
- diltiazem
- diuretics
- dobutamine
- epinephrine
- estrogens
- lithium
- morphine sulfate
- niacin
- phenothiazines
- thyroid hormones

**DISPLAY 49-2 • Drugs That Increase the Hypoglycemic Effect of Insulin**

- alcohol
- angiotensin-converting enzyme (ACE) inhibitors
- antidiabetic drugs, oral
- beta blocking drugs
- calcium
- clonidine
- disopyramide
- lithium
- monoamine oxidase inhibitors (MAOIs)
- salicylates
- sulfonamides
- tetracycline
Testing usually occurs before meals and at bedtime (see section on "Managing Hypoglycemia").

Blood glucose levels are monitored frequently in patients with diabetes. Patients in the acute care setting are monitored closely for hyperglycemia. Insulin needs increase in times of stress or illness. The health care provider may order regular insulin as a supplement to the drug regimen to “cover” any episodes of hyperglycemia. For example, blood glucose levels are monitored every 6 hours or before meals and at bedtime, with insulin prescribed to cover any hyperglycemia detected. This coverage is sometimes referred to as a sliding scale or insulin coverage. Table 49-2 provides an example of a sliding scale by which regular insulin may be administered.

The nurse must closely observe the patient after administering any insulin, but particularly U500 insulin, because secondary hypoglycemic reactions may occur as long as 24 hours after the administration.

The nurse must notify the health care provider if the blood glucose level is greater than 400 mg/dL.

The primary care provider may prescribe use of a sliding scale at various times, such as every 4 hours, every 6 hours, or at specified times (eg, 7:00 AM, 11:00 AM, 4 PM, and 11 PM), depending on the patient’s individual needs.

Blood glucose levels are monitored frequently in patients with diabetes. Patients in the acute care setting are monitored closely for hyperglycemia. Insulin needs increase in times of stress or illness. The health care provider may order regular insulin as a supplement to the drug regimen to “cover” any episodes of hyperglycemia. For example, blood glucose levels are monitored every 6 hours or before meals and at bedtime, with insulin prescribed to cover any hyperglycemia detected. This coverage is sometimes referred to as a sliding scale or insulin coverage. Table 49-2 provides an example of a sliding scale by which regular insulin may be administered.

The nurse must notify the health care provider if the blood glucose level is greater than 400 mg/dL.

The primary care provider may prescribe use of a sliding scale at various times, such as every 4 hours, every 6 hours, or at specified times (eg, 7:00 AM, 11:00 AM, 4 PM, and 11 PM), depending on the patient’s individual needs.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

<table>
<thead>
<tr>
<th>TABLE 49-2</th>
<th>Example of Insulin Administration Using a Sliding Scale</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administer regular humulin insulin subcutaneously 30 minutes before meals and at bedtime according to the following blood glucose levels.</td>
<td></td>
</tr>
<tr>
<td><strong>BLOOD GLUCOSE LEVEL</strong></td>
<td><strong>REGULAR HUMULIN INSULIN TO BE ADMINISTERED</strong></td>
</tr>
<tr>
<td>150–200 mg/dL</td>
<td>2 U</td>
</tr>
<tr>
<td>201–250 mg/dL</td>
<td>4 U</td>
</tr>
<tr>
<td>251–300 mg/dL</td>
<td>6 U</td>
</tr>
<tr>
<td>301–350 mg/dL</td>
<td>8 U</td>
</tr>
<tr>
<td>351–400 mg/dL</td>
<td>10 U</td>
</tr>
<tr>
<td>&gt; 400 mg/dL</td>
<td>Call physician</td>
</tr>
</tbody>
</table>

Nursing Alert

Insulin requirements may change when the patient experiences any form of stress and with any illness, particularly illnesses resulting in nausea and vomiting.

PLANNING

The expected outcomes of the patient may include an optimal response to therapy, management of common adverse drug reactions, a reduction in anxiety and fear, improved ability to cope with the diagnosis, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION

Nursing management of a patient with diabetes requires diligent, skillful, and comprehensive nursing care.

Promoting an Optimal Response to Therapy

There is no standard dose of insulin as there is for most other drugs. Insulin dosage is highly individualized. Sometimes the health care provider finds that the patient achieves best control with one injection of insulin per day; sometimes the patient requires two or more injections per day. In addition, two different types of insulin may be combined, such as a rapid-acting and a long-acting preparation. The number of insulin injections, dosage, times of administration, and type of insulin are determined by the health care provider after careful evaluation of the patient’s metabolic needs and response to therapy. The dosage prescribed for the patient may require changes until the dosage is found that best meets the patient’s needs.
Insulin is ordered by the generic name (insulin zinc suspension, extended) or the trade (brand) name (Humulin U) (see the Summary Drug Table: Insulin Preparations). The nurse must never substitute one brand of insulin for another unless the substitution is approved by the health care provider because some patients may be sensitive to changes in brands of insulin. In addition, it is important never to substitute one type of insulin for another. For example, do not use insulin zinc suspension instead of the prescribed protamine zinc insulin.

Care must be taken when giving insulin to use the correct insulin. Names and packaging are similar and can easily be confused. The nurse carefully reads all drug labels before preparing any insulin preparation. For example, Humalog (insulin lispro) and Humulin R (regular human insulin) are easily confused because of the similar names.

Insulin must be administered via the parenteral route, usually the subcutaneous (SC) route. Insulin cannot be administered orally because it is a protein and readily destroyed in the gastrointestinal tract. Regular insulin is the only insulin preparation given intravenously (IV). Regular insulin is given 30 to 60 minutes before a meal to achieve optimal results.

Insulin aspart is given immediately before a meal (within 5 to 10 minutes of beginning a meal). Insulin lispro is given 15 minutes before a meal or immediately after a meal. Insulin aspart and lispro make insulin administration more convenient for many patients who find taking a drug 30 to 60 minutes before meals bothersome. In addition, insulin lispro (Humalog) appears to lower the blood sugar level 1 to 2 hours after meals better than does regular human insulin because it more closely mimics the body’s natural insulin. It also lowers the risk of low blood sugar reactions from midnight to 6 AM in patients with type 1 diabetes. The longer acting insulins are given before breakfast or at bedtime (depending on the health care provider’s instructions). Many patients are maintained on a single dose of intermediate-acting insulin administered SC in the morning.

Insulin glargine is given SC once daily at bedtime. This type of insulin is used in the treatment of adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes who need long-acting insulin for the control of hyperglycemia.

Insulin is available in concentrations of U100 and U500. The nurse must read the label of the insulin bottle carefully for the name, source of insulin (eg, human, beef, pork, beef and pork, purified beef), and the number of units per milliliter (U/mL). The dose of insulin is measured in units (U). U100 insulin has 100 units in each milliliter; U500 has 500 units in each milliliter. Most people with diabetes use the U100 concentration. Patients who are resistant to insulin and require large insulin doses require the U500 concentration.

**MIXING INSULINS.** If the patient is to receive regular insulin and NPH insulin, or regular and Lente insulin, the nurse must clarify with the health care provider whether two separate injections are to be given or if the insulins may be mixed in the same syringe. If the two insulins are to be given in the same syringe, the short-acting insulin (regular or lispro) is drawn into the syringe first (see Fig. 49-2). Even small amounts of

---

**Figure 49-2.** (A) After cleansing tops of both the Humulin R (Regular) insulin and Humulin N (intermediate acting insulin), the nurse injects air into the Humulin N insulin equal to the prescribed dosage of Humulin N. The nurse then injects the amount of air into the prescribed dosage of the regular insulin and withdraws the prescribed dosage of regular insulin into the syringe. (B) After removing any air bubbles and determining what the total combined volume of the two insulins would measure, the nurse inverts the vial with the NPH insulin and carefully withdraws the correct volume of medication. Note: The nurse must be sure to check medication and dosage again before returning or discarding vials or administering the insulin.
intermediate- or long-acting insulin, if mixed with the short-acting insulin, can bind with the short-acting insulin and delay its onset. (Hint: Regular insulin is clear, whereas intermediate- and long-acting insulins are cloudy. The clear insulin should be drawn up first.) When insulin lispro is mixed with a longer-acting insulin, the insulin lispro is drawn up first.

An unexpected response may be obtained when changing from mixed injections to separate injections or vice versa. If the patient had been using insulin mixtures before admission, the nurse asks whether the insulins were given separately or together.

Several types of premixed insulins are currently available. These insulins combine regular insulin with the longer-acting NPH insulin. The mixtures are available in ratios of 70/30 and 50/50 of NPH to regular. Although these premixed insulins are helpful for patients who have difficulty drawing up their insulin or seeing the markings on the syringe, they prohibit individualizing the dosage. For patients who have difficulty controlling their diabetes, these premixed insulins may not be effective.

**Nursing Alert**

Do not mix or dilute insulin glargine with any other insulin or solution because glucose control will be lost and the insulin will not be effective.

**PREPARING INSULIN FOR ADMINISTRATION.** The nurse always checks the expiration date printed on the label of the insulin bottle before withdrawing the insulin. An insulin syringe that matches the concentration of insulin to be given is always used. For example, a syringe labeled as U100 is used only with insulin labeled U100. U500 insulin is given only via the SC route or the intramuscular (IM) route, and may be administered using a tuberculin syringe if necessary.

When insulin is in a suspension (this can be seen when looking at a vial that has been untouched for about 1 hour), the nurse gently rotates the vial between the palms of the hands and tilts it gently end-to-end immediately before withdrawing the insulin. This ensures even distribution of the suspended particles. Care is taken not to shake the insulin vigorously.

The nurse carefully checks the health care provider’s order for the type and dosage of insulin immediately before withdrawing the insulin from the vial. All air bubbles must be eliminated from the syringe barrel and hub of the needle before withdrawing the syringe from the insulin vial.

**Nursing Alert**

Accuracy is of the utmost importance when measuring any insulin preparation because of the potential danger of administering an incorrect dosage. If possible, the nurse should check and compare with another nurse for accuracy of the insulin dosage by checking the insulin container, the syringe, and the primary health care provider’s order before administration.

When regular insulin and another insulin are mixed in the same syringe, the nurse must administer the insulin within 5 minutes of withdrawing the two insulins from the two vials.

**ROTATING INJECTION SITES.** Insulin may be injected into the arms, thighs, abdomen, or buttocks (see Home Care Checklist: Rotating Insulin Injection Sites). Sites of insulin injection are rotated to prevent lipodystrophy (atrophy of SC fat), a problem that can interfere with the absorption of insulin from the injection site. Lipodystrophy appears as a slight dimpling or pitting of the SC fat. Because absorption rates vary at the different sites, with the abdomen having the most rapid rate of absorption, followed by the upper arm, thigh, and buttocks, some health care providers recommend rotating the injection sites within one specific area, rather than rotating areas. For example, all available sites within the abdomen would be used before moving to the thigh.

The nurse carefully plans the pattern of rotation of the injection sites and writes this plan in the patient’s chart. Before each dose of insulin is given, the nurse checks the patient’s chart for the site of the previous injection and uses the next site (according to the rotation plan) for injection. After giving the injection, the nurse records the site used for injection. Each time insulin is given, previous injection sites are inspected for inflammation, which may indicate a localized allergic reaction. The nurse notes any inflammation or other skin reactions. The nurse reports localized allergic reactions, signs of inflammation, or other skin changes to the health care provider as soon as possible because a different type of insulin may be necessary.

**METHODS OF ADMINISTERING INSULIN.** Several methods can be used to administer insulin. The most common method is the use of a needle and syringe. Use of microfine needles has reduced the discomfort associated with an injection. A noether method is the jet injection system, which uses pressure to deliver a fine stream of insulin below the skin. A noether method uses a disposable needle and special syringe. The syringe uses a cartridge that is prefilled with a specific type of insulin (eg, regular human insulin, isophane [NPH] insulin, or a mixture of isophane and regular insulin).
If your patient must self-administer insulin at home, be sure he or she knows where to inject the insulin and how to rotate the site. Site rotation is crucial to prevent injury to the skin and fatty tissue. Review with the patient appropriate sites, including:

- Upper arms, outer aspect
- Stomach, except for a 2-inch margin around the umbilicus
- Back, right, and left sides just below the waist
- Upper thighs, both front and side

To rotate sites, teach the patient to do the following:

- Note the site of the last injection
- Place the side of his or her thumb at the old site and measure across its width—about 1 inch
- Select a site on the other side of the thumb for the next injection
- Repeat the procedure for each subsequent injection
- Use the same area for a total of about 10 to 15 injections and then move to another area
The desired units are selected by turning a dial and the locking ring.

Another method of insulin delivery is the insulin pump, which is intended for a select group of individuals, such as the pregnant woman with diabetes with early long-term complications and those with, or candidates for, renal transplantation. This system attempts to mimic the body’s normal pancreatic function, uses only regular insulin, is battery powered, and requires insertion of a needle into SC tissue. The needle is changed every 1 to 3 days. The amount of insulin injected can be adjusted according to blood glucose monitoring, which is usually done four to eight times per day.

The insulin dosage pattern that most closely follows normal insulin production is a multiple-dose plan sometimes called intensive insulin therapy. In this regimen, a single dose of intermediate- or long-acting insulin is taken in the morning or at bedtime. Small doses of regular insulin are taken before meals based on the patient’s blood glucose levels. This allows for greater flexibility in the patient’s life-style, but can also be an inconvenience to the patient (eg, the need to always have supplies with them, the lack of privacy, inconvenient schedules).

**BLOOD AND URINE TESTING.** Blood glucose levels are monitored often in the patient with diabetes. The health care provider may order blood glucose levels to be tested before meals, after meals, and at bedtime. Less frequent monitoring may be performed if the patient’s glucose levels are well controlled. The glucometer is a device used by the patient with diabetes or the nursing personnel to monitor blood glucose levels. Nursing personnel or the laboratory is responsible for obtaining blood glucose levels during hospitalization, but the patient must be taught to monitor blood glucose levels after dismissal from the acute care setting (see Patient and Family Teaching Checklist: Obtaining a Blood Glucose Reading Using a Glucometer).

Urine testing has been widely used to monitor glucose levels in the past, but this method has largely been replaced with blood glucose monitoring.

Urine testing can play a role in identifying ketone excretion in patients prone to ketoacidosis. If urine testing is done, it is usually recommended that the nurse use the second voided specimen (ie, fresh urine collected 30 minutes after the initial voiding) to check glucose or acetone levels, rather than the first specimen obtained.

**Glycosylated hemoglobin (HbA1c)** is a blood test used to monitor the patient’s average blood glucose level throughout a 3- to 4-month period. When blood glucose levels are high, glucose molecules attach to hemoglobin in the red blood cell. The longer hyperglycemia occurs in the blood, the more glucose binds to the red blood cell and the higher the glycosylated hemoglobin. This binding lasts for the life of the red blood cell (about 4 months). When the patient's diabetes is well controlled with normal or near normal blood glucose levels, the overall HbA1c level will not be greatly elevated. However, if blood glucose levels are consistently high, the HbA1c level will be elevated. The test result (expressed in percentage) refers to the average amount of glucose that has been in the blood throughout the last 4 months. Normal levels vary with the laboratory method used for analysis, but generally levels between 2.5% and 6% indicate good control of the diabetes. Results of 10% or greater indicate poor
blood glucose control for the last several months. HbA1c is useful in evaluating the success of treatment of diabetes, comparing new treatment regimens with past regimens used, and in individualizing treatment.

**Monitoring and Managing Adverse Reactions**

**Managing Hypoglycemic Reactions.** Close observation of the patient with diabetes is important, especially when diabetes is newly diagnosed in the patient, the insulin dosage is changed, the patient is pregnant, the patient has a medical illness or has had surgery, or the patient has failed to adhere to the prescribed diet. Episodes of hypoglycemia are corrected as soon as the symptoms are recognized.

**Nursing Alert**

The nurse should check the patient for hypoglycemia (see Table 49-1) at the peak time of action of the insulin (see Summary Drug Table: Insulin Preparations). Hypoglycemia, which can develop suddenly, may indicate a need for an adjustment in the insulin dosage or other changes in treatment, such as a change in diet. Hypoglycemic reactions can occur at any time but are most likely to occur when insulin is at its peak activity.

Methods of terminating a hypoglycemic reaction include the administration of one or more of the following:

- Orange juice or other fruit juice
- Hard candy or honey
- Commercial glucose products
- Glucagon by the SC, IM, or IV route
- Glucose 10% or 50% IV

Selection of any one or more of the above methods for terminating a hypoglycemic reaction, as well as other procedures to be followed, such as drawing blood for glucose levels, depends on the written order of the health care provider or hospital policy. The nurse should never give oral fluids or substances (such as candy) used to terminate a hypoglycemic reaction to a patient unless the swallowing and gag reflexes are present. Absence of these reflexes may result in aspiration of the oral fluid or substance into the lungs, which can result in extremely serious consequences and even death. If swallowing and gag reflexes are absent, or if the patient is unconscious, glucose or glucagon is given by the parenteral route.

**Glucagon** is a hormone produced by the alpha cells of the pancreas; it acts to increase blood sugar by stimulating the conversion of glycogen to glucose in the liver. A return of consciousness is observed within 5 to 20 minutes after parenteral administration of glucagon. Glucagon is effective in treating hypoglycemia only if liver glycogen is available.

The nurse notifies the health care provider of any hypoglycemic reaction, the substance and amount used to terminate the reaction, blood samples drawn (if any), the length of time required for the symptoms of hypoglycemia to disappear, and the current status of the patient. After termination of a hypoglycemic reaction, the nurse closely observes the patient for additional hypoglycemic reactions. The length of time close observation is required depends on the peak and duration of the insulin administered.

**Nursing Alert**

Hypoglycemic symptoms are more pronounced in patients taking animal-based products than in patients taking human insulin.

**Managing Diabetic Ketoacidosis.** Diabetic ketoacidosis (DKA) is a potentially life-threatening deficiency of insulin (hypoinsulinism), resulting in severe hyperglycemia and requiring prompt diagnosis and treatment. Because insulin is unavailable to allow glucose to enter the cell, dangerously high levels of glucose build up in the blood (hyperglycemia). The body, needing energy, begins to break down fat for energy. As fats are broken down, ketones are produced by the liver. As more and more fat is used for energy, higher levels of ketones accumulate in the blood. This increase in ketones disrupts the acid-base balance within the body, leading to DKA. DKA is treated with fluids, correction of acidosis and hypotension, and low-doses of regular insulin.

**Nursing Alert**

The nurse immediately reports any of the following symptoms of hyperglycemia: elevated blood glucose levels (>200 mg/mL); headache; increased thirst; epigastric pain; nausea; vomiting; hot, dry, flushed skin; restlessness; and diaphoresis (sweating).

**Relieving Anxiety and Fear**

The patient with newly diagnosed diabetes often has many concerns regarding the diagnosis. For some, initially coping with diabetes and the methods required for controlling the disorder creates many problems. Some of the fears and concerns of these patients may include having to give themselves an injection, having to follow a diet, weight control, the complications associated with diabetes, and changes in eating times and habits. An effective teaching program helps relieve some of this anxiety. The patient in this situation needs time to talk about the disorder, express concerns, and ask questions.
Assisting the Patient With Impaired Adjustment, Coping, and Altered Health Maintenance

The patient with newly diagnosed diabetes may have difficulty accepting the diagnosis, and the complexity of the therapeutic regimen can seem overwhelming. Before patients can be expected to carry out treatment, they must accept that they have diabetes and deal with their feelings about having the disorder. The nurse has an important role in helping these patients gradually accept the diagnosis and begin to understand their feelings. Understanding diabetes may help patients work with health care providers and other medical personnel in managing their diabetes.

Educating the Patient and Family

Noncompliance is a problem with some patients with diabetes, making patient and family teaching vital to the proper management of diabetes. Patients may occasionally lapse in their adherence to the prescribed diet, such as around holidays or other special occasions. This slip may not cause a problem if it is brief and not excessive and if the patient immediately returns to the prescribed regimen. However, some patients frequently stray from the prescribed regimen, take extra insulin to cover dietary indiscretions, fast for several days before follow-up blood glucose determinations, and engage in other dangerous behaviors. Although some patients can be convinced that failure to adhere to the prescribed therapeutic regimen is detrimental to their health, others continue to deviate from the prescribed regimen until serious complications develop.

Every effort is made to stress the importance of adherence to the prescribed treatment during the initial teaching session and during follow-up office or clinic visits.

The nurse establishes a thorough teaching plan for all patients with newly diagnosed diabetes, for those who have had any change in the management of their diabetes (eg, diet, insulin type, insulin dosage), and for those whose management has changed because of an illness or disability, such as loss of sight or disabling arthritis. The newly diagnosed patient with diabetes and the family must have an explanation of the disease and methods of treatment as soon as the health care provider has revealed the diagnosis to the patient. The nurse should always individualize the teaching plan because the needs of each patient are different.

Self-monitoring of blood glucose is an important component in the management of diabetes (see Patient and Family Teaching Checklist: Obtaining a Blood Glucose Reading Using a Glucometer). It is the preferred method for monitoring glucose by most health care providers for all patients with diabetes, with variations only in the suggested frequency of testing. If the patient is to use a blood glucose monitoring device, the nurse reviews the method of obtaining a small sample of blood from the finger and the use of the device with the patient. Printed instructions and illustrations are supplied with the device and must be reviewed with the patient. The nurse encourages the patient to purchase the brand recommended by the health care provider. Time is allowed for supervised practice. The nurse includes the following information in the teaching plan for a patient with diabetes:

- Blood glucose or urine testing—the testing material recommended by the health care provider; a review of the instructions included with the glucometer or the materials used for urine testing; the technique of collecting the specimen; interpreting test results; number of times a day or week the blood or urine is tested (as recommended by the health care provider); a record of test results.
- Insulin—types; how dosage is expressed; calculating the insulin dosage; importance of using only the type, source, and brand name recommended by the health care provider; importance of not changing brands unless the health care provider approves; keeping a spare vial on hand; prescription for insulin purchase not required.
- Storage of insulin—insulin is kept at room temperature away from heat and direct sunlight if used within 1 month (and up to 3 months if refrigerated); vials not in use are stored in the refrigerator; prefilled insulin in glass or plastic syringes is stable for 1 week under refrigeration. Keep filled syringes in a vertical or oblique position with the needle pointing upward to avoid plugging the needle. Before injection, pull back the plunger and tip the syringe back and forth slightly to agitate and remix the insulins.
- Needle and syringe—purchase the same brand and needle size each time; parts of the syringe; reading the syringe scale.
- Preparation for administration—principles of aseptic technique; how to hold the syringe; how to withdraw insulin from the vial; measurement of insulin in the syringe using the syringe scale; mixing insulin in the same syringe (when appropriate); elimination of air in the syringe and needle; what to do if the syringe or needle is contaminated.
- Administration of insulin—sites to be used; rotation of injection sites (see Home Care Checklist: Rotating Insulin Injection Sites); angle of injection; administration at the time of day prescribed by the health care provider; disposal of the needle and syringe.
- Insulin needs may change in patients who become ill, especially with vomiting or fever and during
periods of stress or emotional disturbances. Contact
the primary health care provider if these situations
occur.
• Diet—importance of following the prescribed diet;
calories allowed; food exchanges; planning daily
menus; establishing meal schedules; selecting food
from a restaurant menu; reading food labels; use of
artificial sweeteners.
• Traveling—importance of carrying an extra supply
of insulin and a prescription for needles and
syringes; storage of insulin when traveling; protect-
ing needles and syringes from theft; importance of
discussing travel plans (especially foreign travel)
with the health care provider.
• Hypoglycemia/hyperglycemia—signs and
symptoms of hypoglycemia and hyperglycemia;
food or fluid used to terminate a hypoglycemic
reaction; importance of notifying the health
care provider immediately if either reaction
occurs.
• Personal hygiene—importance of good skin and foot
care, personal cleanliness, frequent dental checkups,
and routine eye examinations.
• Exercise—importance of following the health care
provider’s recommendations regarding physical
activity.
• When to notify the health care provider—increase
in blood glucose levels; urine positive for ketones; if
pregnancy occurs; occurrence of antidiabetic or
hyperglycemic episodes; occurrence of illness, infec-
tion, or diarrhea (insulin dosage may require adjust-
ment); appearance of new problems (eg, leg ulcers,
numbness of the extremities, significant weight gain
or loss).
• Identification—wear identification, such as a
medical alert tag, to inform medical personnel
and others of the use of insulin to control the
disease.

EVALUATION
• The therapeutic effect is achieved and normal or
near-normal blood glucose levels are maintained.
• Adverse reactions are identified, reported to the
health care provider, and managed successfully
through appropriate nursing interventions.
• Anxiety and fear are reduced.
• The patient demonstrates a beginning ability
to cope with the disorder and its required
treatment.
• The patient demonstrates a positive outlook and
adjustment to the diagnosis.
• The patient verbalizes a willingness to comply with
the prescribed therapeutic regimen.
• The patient and family demonstrate an understand-
ing of the drug regimen.

• The patient is able to test blood glucose levels using
a glucometer.
• The patient administers insulin correctly.

ORAL ANTIDIABETIC DRUGS

The oral antidiabetic drugs are used to treat patients
with type 2 diabetes that is not controlled by diet and
exercise alone. These drugs are not effective for treating
type 1 diabetes. Five types of oral antidiabetic drugs are
currently in use:
• Sulfonylureas (glimepiride, glyburide)
• Biguanides (metformin)
• Alpha (α)-glucosidase inhibitors (acarbose, migli-
tol)
• Meglitinides (nateglinide, repaglinide)
• Thiazolidinediones (pioglitazone, rosiglitazone)

Additional drugs are listed in the Summary Drug
Table: Antidiabetic Drugs.

USES OF THE ANTIDIABETIC DRUGS

The oral antidiabetic drugs are of value only in the
treatment of patients with type 2 (NIDDM) diabetes
mellitus whose condition cannot be controlled by
diet alone. These drugs may also be used with
insulin in the management of some patients with
diabetes mellitus. Use of an oral antidiabetic drug
with insulin may decrease the insulin dosage in
some individuals. Two oral antidiabetic drugs (eg, a
sulfonylurea and metformin) may also be used
together when one antidiabetic drug and diet do not
control blood glucose levels in type 2 diabetes melli-
tus. Figure 49-3 is a pharmacological algorithm indi-
cating the appropriate medication regimen for type 2
diabetes mellitus.

ACTIONS

Sulfonylureas

The sulfonylureas appear to lower blood glucose by
stimulating the beta cells of the pancreas to release
insulin. The sulfonylureas are not effective if the
beta cells of the pancreas are unable to release a suf-
ficient amount of insulin to meet the individual’s
needs. The first generation sulfonylureas (eg, chlor-
propamide, tolazamide, and tolbutamide) are not
commonly used today because they have a long dura-
tion of action and a higher incidence of adverse
### Summary Drug Table: Antidiabetic Drugs

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sulfonylureas</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>acetohexamide</td>
<td>Dymelor,</td>
<td>Adjunct to diet to lower blood glucose in type 2 diabetes; adjunct to insulin therapy in certain patients with type 1 diabetes</td>
<td>Anorexia, nausea, vomiting, epigastric discomfort, heartburn, hypoglycemia</td>
<td>250 mg–1.5 g/d PO</td>
</tr>
<tr>
<td>a-setoh-hex'-a-mide</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>chlorpropamide</td>
<td>Diabinese,</td>
<td>Adjunct to diet in type 2 diabetes</td>
<td>Anorexia, nausea, vomiting, epigastric discomfort, heartburn, hypoglycemia</td>
<td>100–500 mg/d PO</td>
</tr>
<tr>
<td>klorproe'-pa-mide</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>glimepiride</td>
<td>Amaryl</td>
<td>Adjunct to diet to lower blood glucose in type 2 diabetes; adjunct to insulin therapy in certain patients with type 1 diabetes</td>
<td>Anorexia, nausea, vomiting, epigastric discomfort, heartburn, hypoglycemia</td>
<td>1–4 mg/d PO (do not exceed 8 mg/d)</td>
</tr>
<tr>
<td>glye-meh'-iper-ide</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>glipizide</td>
<td>Glucotrol,</td>
<td>Type 2 diabetes; adjunct to insulin therapy in the stabilization of certain cases of insulin-dependent diabetes</td>
<td>Anorexia, nausea, vomiting, epigastric discomfort, heartburn, diarrhea, hypoglycemia, allergic skin reactions</td>
<td>5–40 mg/d PO</td>
</tr>
<tr>
<td>glip'-i-zide</td>
<td>Glucotrol XL, generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>glyburide</td>
<td>DiaBeta,</td>
<td>Type 2 diabetes; adjunct to metformin when adequate results are not achieved with either drug alone; adjunct to insulin in stabilization of certain individuals with type 1 diabetes</td>
<td>Anorexia, nausea, vomiting, epigastric discomfort, heartburn, hypoglycemia</td>
<td>1.25–20 mg/d PO</td>
</tr>
<tr>
<td>(glibenclamide)</td>
<td>Micronase,</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>glye-byoo'-r-ide</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tolatamide</td>
<td>Tolinase,</td>
<td>Type 2 diabetes; adjunct to insulin therapy in the stabilization of certain cases of insulin-dependent diabetes (type 1)</td>
<td>Anorexia, nausea, vomiting, epigastric discomfort, heartburn, hypoglycemia</td>
<td>100–1000 mg/d PO</td>
</tr>
<tr>
<td>tole-az'-a-mide</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tolbutamide</td>
<td>Orinase,</td>
<td>Type 2 diabetes; adjunct to insulin therapy in the stabilization of certain cases of insulin-dependent diabetes (type 1)</td>
<td>Anorexia, nausea, vomiting, epigastric discomfort, heartburn, hypoglycemia</td>
<td>0.25–3 g/d PO</td>
</tr>
<tr>
<td>tole-byoo'-ta-mide</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>α-Glucosidase Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>acarbose</td>
<td>Precose</td>
<td>Type 2 diabetes; combination therapy with a sulfonylurea to enhance glycemic control</td>
<td>Flatulence, diarrhea, abdominal pain</td>
<td>25–100 mg TID PO</td>
</tr>
<tr>
<td>aye-kar'-bose</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miglitol</td>
<td>Glyset</td>
<td>Type 2 diabetes; combination therapy with a sulfonylurea to enhance glycemic control</td>
<td>Skin rash, flatulence, diarrhea, abdominal pain</td>
<td>25–100 mg TID PO</td>
</tr>
<tr>
<td>mi'-gli-tole</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Generic Name | Trade Name* | Uses | Adverse Reactions | Dosage Ranges |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biguanide</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>metformin</td>
<td>Glucophage, Glucophage XR, generic</td>
<td>Type 2 diabetes; with a sulfonylurea or insulin to improve glycemic control</td>
<td>Anorexia, nausea, vomiting, epigastric pain, heartburn, diarrhea, hypoglycemia, allergic skin reactions</td>
<td>500–3000 mg/d PO; XR (extended release): 500–2000 mg/d</td>
</tr>
<tr>
<td><strong>Meglitinides</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nateglinide</td>
<td>Starlix</td>
<td>Type 2 diabetes; in combination with metformin to improve glycemic control</td>
<td>Headache, upper respiratory tract infection, back pain, flu symptoms, bronchitis</td>
<td>60–120 mg TID before meals</td>
</tr>
<tr>
<td>repaglinide</td>
<td>Prandin</td>
<td>Type 2 diabetes; in combination with metformin to improve glycemic control</td>
<td>Hyperglycemia, hypoglycemia, nausea, diarrhea, upper respiratory tract infection, sinusitis, headache, arthralgia, back pain</td>
<td>0.5–4 mg before meals PO (maximum dose is 16 mg/d)</td>
</tr>
<tr>
<td><strong>Thiazolidinediones</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pioglitazone HCl</td>
<td>Actos</td>
<td>Type 2 diabetes; with sulfonylurea, metformin, or insulin to improve glycemic control</td>
<td>Headache, pain, myalgia, aggravated diabetes, infections, fatigue</td>
<td>15–45 mg/d PO</td>
</tr>
<tr>
<td>rosiglitazone maleate</td>
<td>Avandia</td>
<td>Type 2 diabetes; in combination with metformin to improve glycemic control</td>
<td>Headache, pain, diarrhea, hypoglycemia, hyperglycemia, fatigue, infections</td>
<td>4–8 mg/d PO</td>
</tr>
<tr>
<td><strong>Antidiabetic Combination Drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>glyburide/metformin HCl</td>
<td>Glucovance</td>
<td>Type 2 diabetes</td>
<td>See individual drugs</td>
<td>Starting dose: 1.25 mg/250 mg PO once or twice daily with meals, second-line therapy: 2.5 mg/500 mg - 5 mg/500 mg PO BID with meals; maximum daily dosage: 20 mg/2500 mg</td>
</tr>
<tr>
<td><strong>Glucose-Elevating Agents</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>diazoxide, oral die-aze-oxide</td>
<td>Proglycemin</td>
<td>Hypoglycemia due to hyperinsulinism</td>
<td>Sodium and fluid retention, hyperglycemia, glycosuria, tachycardia, congestive heart failure</td>
<td>3–8 mg/kg/d PO in 2 or 3 equal doses every 8 or 12 h</td>
</tr>
<tr>
<td>glucagon glue-kuh-gahn</td>
<td>Glucagon Emergency Kit</td>
<td>Hypoglycemia</td>
<td>Nausea, vomiting, generalized allergic reactions</td>
<td>See instructions on the product</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
**Biguanides**

Metformin (Glucophage), currently the only biguanide, acts by reducing hepatic glucose production and increasing insulin sensitivity in muscle and fat cells. The liver normally releases glucose by detecting the level of circulating insulin. When insulin levels are high, glucose is available in the blood, and the liver produces little or no glucose. When insulin levels are low, there is little circulating glucose, so the liver produces more glucose. In type 2 diabetes, the liver may not detect levels of glucose in the blood and, instead of regulating glucose production, releases glucose despite blood sugar levels.

Metformin sensitizes the liver to circulating insulin levels and reduces hepatic glucose production.

**α-Glucosidase Inhibitors**

The α-glucosidase inhibitors, acarbose (Precose) and miglitol (Glyset), lower blood sugar by delaying the digestion of carbohydrates and absorption of carbohydrates in the intestine.

**Meglitinides**

Like the sulfonylureas, the meglitinides act to lower blood glucose levels by stimulating the release of insulin from the pancreas. This action is dependent on the ability of the beta cell in the pancreas to produce some insulin. However, the action of the meglitinides is more rapid than that of the sulfonylureas and their reactions, and are more likely to react with other drugs. More commonly used sulfonylureas are the second and third generation drugs, such as glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (DiaBeta, Micronase).
duration of action much shorter. Because of this they must be taken three times a day. Examples of the meglitinides include nateglinide (Starlix) and repaglinide (Prandin).

**Thiazolidinediones**

The thiazolidinediones, also called glitazones, decrease insulin resistance and increase insulin sensitivity by modifying several processes, with the end result being decreasing hepatic glucogenesis (formation of glucose from glycogen) and increasing insulin-dependent muscle glucose uptake. Examples of the thiazolidinediones are rosiglitazone (Avandia) and pioglitazone (Actos).

**ADVERSE REACTIONS**

**Sulfonylureas**

Adverse reactions seen with the sulfonylureas include hypoglycemia, anorexia, nausea, vomiting, epigastric discomfort, weight gain, heartburn, and various vague neurologic symptoms, such as weakness and numbness of the extremities. Often, these can be eliminated by reducing the dosage or giving the drug in divided doses. If these reactions become severe, the health care provider may try another oral antidiabetic drug or discontinue the use of these drugs. If the drug therapy is discontinued, it may be necessary to control the diabetes with insulin.

**Biguanides**

Adverse reactions associated with the biguanide (metformin) include gastrointestinal upsets (such as abdominal bloating, nausea, cramping, diarrhea) and metallic taste (usually self-limiting). These adverse reactions are self-limiting and can be reduced if the patients are started on a low dose with dosage increased slowly and if the drug is taken with meals. Hypoglycemia rarely occurs when metformin is used alone.

Lactic acidosis (buildup of lactic acid in the blood) may also occur with the administration of metformin. Although lactic acidosis is a rare adverse reaction, its occurrence is serious and can be fatal. Lactic acidosis occurs mainly in patients with kidney dysfunction. Symptoms of lactic acidosis include malaise (vague feeling of bodily discomfort), abdominal pain, rapid respirations, shortness of breath, and muscular pain. In some patients vitamin B₁₂ levels are decreased. This can be reversed with vitamin B₁₂ supplements or with discontinuation of the drug therapy. Because weight loss can occur, metformin is sometimes recommended for obese patients or patients with insulin-resistant diabetes.

**α-Glucosidase Inhibitors**

Because the α-glucosidase inhibitors, acarbose or miglitol, increase the transit time of food in the digestive tract, gastrointestinal disturbances may occur. The most common adverse reactions are bloating and flatulence. Other adverse reactions, such as abdominal pain, and diarrhea can occur. While most oral antidiabetic drugs produce hypoglycemia, acarbose and miglitol, when used alone, do not cause hypoglycemia.

**Meglitinides**

Adverse reactions associated with the administration of the meglitinides include upper respiratory infection, headache, rhinitis, bronchitis, headache, back pain, and hypoglycemia.

**Thiazolidinediones**

Adverse reactions associated with the administration of the thiazolidinediones include aggravated diabetes mellitus, upper respiratory infections, sinusitis, headache, pharyngitis, myalgia, diarrhea, and back pain. When used alone, rosiglitazone and pioglitazone rarely cause hypoglycemia. However, patients receiving these drugs in combination with insulin or other oral hypoglycemics (eg, the sulfonylureas) are at greater risk for hypoglycemia. A reduction in the dosage of insulin or the sulfonylurea may be required to prevent episodes of hypoglycemia.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Sulfonylureas**

The oral antidiabetic drugs are contraindicated in patients with known hypersensitivity to the drugs, DKA, severe infection, or severe endocrine disease. The first generation sulfonylureas (chlorpropamide, tolazamide, and tolbutamide) are contraindicated in patients with coronary artery disease or liver or renal dysfunction. Other sulfonylureas are used cautiously in patients with impaired liver function because liver dysfunction can prolong the drug’s effect. In addition, the sulfonylureas are used cautiously in patients with renal
impairment and severe cardiovascular disease. There is a risk for cross-sensitivity with the sulfonylureas and the sulfonamides.

Many drugs may affect the action of the sulfonylureas; the nurse must monitor blood glucose carefully when beginning therapy, discontinuing therapy, and any time any change is made in the drug regimen with these drugs. The sulfonylureas may have an increased hypoglycemic effect when administered with the anticoagulants, chloramphenicol, clofibrate, fluconazole, histamine H2 antagonists, methylprednisolone, monoamine oxidase inhibitors (MAOIs), salicylates, sulfonamides, and tricyclic antidepressants. The hypoglycemic effect of the sulfonylureas may be decreased when the agents are administered with beta blockers, calcium channel blockers, cholestyramine, corticosteroids, estrogens, hydantoin, isoniazid, oral contraceptives, phenothiazines, thiazide diuretics, and thyroid agents.

Biguanides

Metformin is contraindicated in patients with heart failure, renal disease, hypersensitivity to metformin, and acute or chronic metabolic acidosis, including ketoacidosis. The drug is also contraindicated in patients older than 80 years and during pregnancy (Pregnancy Category B) and lactation.

The drug is used cautiously during surgery. Metformin use is temporarily discontinued for surgical procedures. The drug therapy is restarted when the patient’s oral intake has been resumed and renal function is normal.

There is a risk of acute renal failure when iodinated contrast material that is used for radiological studies is administered with metformin. Metformin therapy is stopped for 48 hours before and after radiological studies using iodinated material. Alcohol, amlodipine, doxycycline, fluorouracil, methotrexate, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin, cimetidine, and furosemide all increase the risk of hypoglycemia. There is an increased risk of lactic acidosis when metformin is administered with the glucocorticoids.

α-Glucosidase Inhibitors

The α-glucosidase inhibitors are contraindicated in patients with a hypersensitivity to the drug, diabetic ketoacidosis, cirrhosis, inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or predisposition to intestinal obstruction, or chronic intestinal diseases. A carbo and miglitol are used cautiously in patients with renal impairment or pre-existing gastrointestinal (GI) problems such as irritable bowel syndrome and Crohn’s disease. These drugs are Pregnancy Category B drugs and safety for use during pregnancy has not been established. Digestive enzymes may reduce the effect of miglitol. The effects of carbo may increase when the agent is administered with the loop or thiazide diuretics, glucocorticoids, oral contraceptives, calcium channel blockers, phenytoin, thyroid drugs, or the phenothiazines. Miglitol may decrease absorption of ranitidine and propranolol.

Meglitinides

These drugs are contraindicated in patients with hypersensitivity to the drug, type I diabetes, and diabetic ketoacidosis. Both repaglinide and nateglinide are Pregnancy Category C drugs and are not recommended for use during pregnancy and lactation. These drugs are used cautiously in patients with renal or hepatic impairment. Certain drugs, such as NSAIDs, salicylates, MAOIs, and beta adrenergic blocking drugs, may potentiate the hypoglycemic action of the meglitinides. Drugs such as the thiazides, corticosteroids, thyroid drugs, and sympathomimetics may decrease the hypoglycemic action of these drugs. The nurse must closely observe the patient receiving one or more of these drugs along with an oral antidiabetic drug.

Thiazolidinediones

The thiazolidinediones are contraindicated in patients with a hypersensitivity to the drug or any component of the drug and severe heart failure. These drugs are Pregnancy Category C drugs and should not be used during pregnancy unless the potential benefit of therapy outweighs the potential risk to the fetus. The thiazolidinediones are used cautiously in patients with edema, cardiovascular disease, and liver or kidney disease. These drugs may alter the effects of oral contraceptives.

NURSING PROCESS

PT the Patient Receiving an Oral Antidiabetic Drug

ASSESSMENT

Preadministration Assessment

If the patient has recently received a diagnosis of diabetes mellitus and has not received an oral antidiabetic drug, or if the patient is known to have diabetes and has been taking one of these drugs, the nurse should include weight, blood pressure, pulse, and
respiratory rate in the initial assessment. The nurse makes a general assessment of the skin, mucous membranes, and extremities, with special attention given to sores or cuts that appear to be healing poorly and ulcerations or other skin or mucous membrane changes. Dietary habits, a family history of diabetes (if any), and an inquiry into the type and duration of symptoms experienced are included in the history. The nurse reviews the patient’s chart for recent laboratory and diagnostic tests. If the patient has diabetes and has been receiving an oral antidiabetic drug, the nurse includes the name of the drug and the dosage, the type of diabetic diet, the results of blood glucose testing, and an inquiry into adherence to the dietary and weight control regimen prescribed by the health care provider.

**Ongoing Assessment**

The most important aspect of the ongoing assessment is observation of the patient every 2 to 4 hours for symptoms of hypoglycemia (see Table 49-1), particularly during initial therapy or after a change in dosage. If both an oral antidiabetic drug and insulin are given, the nurse observes the patient more frequently for hypoglycemic episodes during the initial period of combination therapy. If the patient is receiving only an oral antidiabetic drug and a hypoglycemic reaction occurs, it is often (but not always) less intense than one seen with insulin administration.

The nurse conducts daily ongoing assessments, including monitoring vital signs and observing for adverse drug reactions. The health care provider may also order the patient be weighed daily or weekly. The nurse notifies the health care provider if an adverse reaction occurs or if there is a significant weight gain or loss.

The best way to monitor long-term glycemic control and response to treatment is with HbA1c levels measured at 3-month intervals. If the first HbA1c indicates that glycemic control during the last 3 months was inadequate, the dosage may be increased for better control.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes of the patient may include an optimal response to therapy, management of common adverse reactions, a reduction in anxiety, improved ability in coping with the diagnosis, and an understanding of and compliance with the prescribed therapeutic regimen.

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**

There is no fixed dosage for the treatment of diabetes. The drug regimen is individualized on the basis of the effectiveness and tolerance of the drug(s) used and the maximum recommended dose of the drug(s). Glycemic control can often be improved when a second oral medication is added to the drug regimen. The choice of a second medication will vary from patient to patient and is prescribed by the health care provider. Glucovance, a combination drug, is a mixture of glyburide and metformin. The drug is useful for individuals needing dual therapy and those who are forgetful (only once-daily dosing is required) or mildly confused.

**Nursing Alert**

Exposure to stress, such as infection, fever, surgery, or trauma, may cause a loss of control of blood glucose levels in patients who have been stabilized with oral antidiabetic drugs. Should this occur, the health care provider may discontinue use of the oral drug and administer insulin.

Oral antidiabetic drugs are given as a single daily dose or in divided doses. The following sections provide specific information for each group of oral antidiabetic drugs.

**SULFONYLUREAS.** Acetohexamide (Dymelor), chlorpropamide (Diabinese), tolazamide (Tolinase), and tolbutamide (Orinase) are given with food to prevent gastrointestinal upset. However, because food delays
After the patient has been taking sulfonylureas for a period of time, a condition called secondary failure may occur. **Secondary failure** occurs when the sulfonylurea loses its effectiveness. When the nurse notes that a normally compliant patient has a gradual increase in blood sugar levels, secondary failure may be the cause. This increase in blood glucose levels can be caused by an increase in the severity of the diabetes or a decreased response to the drug. When secondary failure occurs, the health care provider may prescribe another sulfonylurea or add an oral antidiabetic drug such as metformin to the drug regimen. See the Summary Drug Table: Antidiabetic Drugs for additional drugs that can be used in combination with the sulfonylureas.

α-GLUCOSIDASE INHIBITORS. Acarbose and miglitol are given three times as day with the first bite of the meal because food increases absorption. Some patients begin therapy with a lower dose once daily to minimize gastrointestinal effects, such as abdominal discomfort, flatulence, and diarrhea. The dose is then gradually increased to three times daily. The nurse monitors the response to these drugs by periodic testing. Dosage adjustments are made at 4- to 16-week intervals based on 1-hour postprandial glucose levels.

BIGUANIDES. The nurse gives metformin two or three times a day with meals. If the patient has not experienced a response in 4 weeks using the maximum dose of metformin, the primary care giver may add an oral sulfonylurea while continuing metformin at the maximum dose. Glucophage XR (metformin extended release) is administered once daily with the evening meal.

MEGLITINIDES. The nurse usually gives repaglinide 15 minutes before meals but can give it immediately, or up to 30 minutes, before the meal. Nateglinide is taken up to 30 minutes before meals.

THIAZOLIDINEDIONES. The thiazolidinediones, pioglitazone and rosiglitazone, are given with or without meals. If the dose is missed at the usual meal, the drug is taken at the next meal. If the dose is missed on one day, do not double the dose the following day. If the drug is taken, do not delay the meal. Delay of a meal for as little as 1/2 hour can cause hypoglycemia.

**Monitoring and Managing Adverse Reactions**

**MANAGING HYPOGLYCEMIA.** The nurse must immediately terminate a hypoglycemic reaction. The method of terminating a hypoglycemic reaction is the same as for a hypoglycemic reaction occurring with insulin administration, with the following exception: The nurse notifies the health care provider as soon as possible if episodes of hypoglycemia occur because the dosage of the oral antidiabetic drug (or insulin, when both insulin and an oral antidiabetic drug are given) may need to be changed.

**Gerontologic Alert**

Older adults have an increased sensitivity to the sulfonylureas and may require a dosage reduction.

**Nursing Alert**

When hypoglycemia occurs in a patient taking an α-glucosidase inhibitor (eg, acarbose or miglitol), the nurse gives the patient an oral form of glucose, such as glucose tablets or dextrose, rather than sugar (sucrose). Absorption of sugar is blocked by acarbose or miglitol.

When oral antidiabetic drugs are combined with other antidiabetic drugs (eg, sulfonylureas) or insulin, the hypoglycemic effect may be enhanced. Elderly, debilitated, or malnourished patients are more likely to experience hypoglycemia.

**Gerontologic Alert**

Although elderly patients taking the oral antidiabetic drugs are particularly susceptible to hypoglycemic reactions, these reactions may be difficult to detect in the elderly. The nurse notifies the health care provider if blood sugar levels are elevated (consistently > 200 mg/dL) or if ketones are present in the urine.

**MANAGING HYPERGLYCEMIA AND KETOACIDOSIS.** Capillary blood specimens are obtained and tested in the same manner as for insulin (see Patient and Family Teaching Checklist, p. 497). The nurse notifies the health care provider if blood sugar levels are elevated.
(consistently > 200 mg/dL) or if ketones are present in the urine.

**MANAGING ANXIETY AND PROMOTING COPING SKILLS.** The patient with newly diagnosed diabetes often has many concerns about the management of the disease. Some patients, when learning that management of their diabetes can be achieved by diet and an oral drug, may have a tendency to discount the seriousness of the disorder. Without creating additional anxiety, the nurse emphasizes the importance of following the prescribed treatment regimen.

The nurse encourages the patient to talk about the disorder, express concerns, and ask questions. Allowing these patients time to talk may help them begin to cope with their diabetes.

The patient receiving an oral antidiabetic drug may also express concern about the possibility of having to take insulin in the future. The nurse encourages the patient to discuss this and other concerns with the health care provider.

**MANAGING LACTIC ACIDOSIS.** When taking metformin, the patient is at risk for lactic acidosis. The nurse monitors the patient for symptoms of lactic acidosis, which include unexplained hyperventilation, myalgia, malaise, gastrointestinal symptoms, or unusual somnolence. If the patient experiences these symptoms, the nurse should contact the primary care provider at once. Elevated blood lactate levels of greater than 5 mmol/L are associated with lactic acidosis and should be reported immediately. Once a patient’s diabetes is stabilized on metformin therapy, the adverse GI reactions that often occur at the beginning of such therapy are unlikely to be related to the drug therapy. A later occurrence of GI symptoms is more likely to be related to lactic acidosis or other serious disease.

**Educating the Patient and Family**

Failing to comply with the prescribed treatment regimen may be a problem with patients taking an oral antidiabetic drug because of the erroneous belief that not having to take insulin means that their disease is not serious and therefore does not require strict adherence to the recommended dietary plan. The nurse informs these patients that control of their diabetes is just as important as for patients requiring insulin and that control is achieved only when they adhere to the treatment regimen prescribed by the health care provider.

If the diagnosis of diabetes mellitus is new, the nurse discusses the disease and methods of control with the patient and family after the health care provider has revealed the diagnosis to the patient. Although taking an oral antidiabetic drug is less complicated than self-administration of insulin, the patient with diabetes taking one of these drugs needs a thorough explanation of the management of the disease. The teaching plan is individualized because the needs of each patient are different. The nurse includes the following information in a teaching plan:

- Take the drug exactly as directed on the container (eg, with food, 30 minutes before a meal).
- To control diabetes, follow the diet and drug regimen prescribed by the health care provider exactly.
- This drug is not oral insulin and cannot be substituted for insulin.
- Never stop taking this drug or increase or decrease the dose unless told to do so by the health care provider.
- Take the drug at the same time or times each day.
- Eat meals at about the same time each day. Erratic meal hours or skipped meals may result in difficulty in controlling diabetes with this drug.
- Avoid alcohol, dieting, commercial weight-loss products, and strenuous exercise programs unless use or participation has been approved by the health care provider.
- Test blood for glucose and urine for ketones as directed by the health care provider. Keep a record of test results and bring this record to each visit to the health care provider or clinic.
- Maintain good foot and skin care and routine eye and dental examinations for the early detection of the complications that may occur.
- Exercise should be moderate; avoid strenuous exercise and erratic periods of exercise.
- Wear identification, such as a medical alert tag, to inform medical personnel and others of diabetes and the drug or drugs currently being used to treat the disease.
- Notify the health care provider if any of the following occur: episodes of hypoglycemia, apparent symptoms of hyperglycemia, elevated blood glucose levels, positive results of urine tests for glucose or ketone bodies, or pregnancy. Also notify the health care provider of any serious illness not requiring hospitalization.
- Know the symptoms of hypoglycemia and hyperglycemia and the health care provider’s method for terminating a hypoglycemic reaction.
• Metformin—there is a risk of lactic acidosis when using this drug. Discontinue the drug therapy and notify the health care provider immediately if any of the following should occur: respiratory distress, muscular aches, unusual somnolence, unexplained malaise, or nonspecific abdominal distress.

• α-Glucosidase Inhibitors—these drugs do not generally cause hypoglycemia. However, if sulfonylureas or insulin are used in combination with acarbose or miglitol, blood sugar levels can be lowered enough to cause symptoms or even life-threatening hypoglycemia. Have a ready source of glucose to treat symptoms of low blood sugar when taking insulin or a sulfonylurea with these drugs. Adverse reactions generally develop during the first few weeks of therapy and usually involve the gastrointestinal tract: flatulence, diarrhea, or abdominal discomfort.

• Meglitinides—if a meal is skipped, do not take the drug. Similarly, if a meal is added, add a dose of the drug for that meal.

EVALUATION

• The therapeutic drug effect is achieved and normal or near-normal blood glucose levels are maintained.

• Hypoglycemic reactions are identified, reported to the health care provider, and managed successfully.

• Anxiety is reduced.

• The patient begins to demonstrate the ability to cope with the disorder and its required treatment.

• The patient demonstrates a positive outlook and adjustment to the diagnosis.

• The patient verbalizes a willingness to comply with the prescribed treatment regimen.

• The patient demonstrates an understanding of the drug regimen.

• The patient demonstrates an understanding of the information presented in teaching sessions.

• The patient is able to use the glucometer correctly to monitor blood sugar or test urine for glucose and ketones.

Critical Thinking Exercises

1. Ms. Baxter, age 37 years, has been taking insulin for the past 6 years for type 1 diabetes mellitus. An assessment at the outpatient clinic reveals a blood sugar of 110 mg/dL. In examining Ms. Baxter’s skin, the nurse notices several areas on the thighs that appear scarred and other areas that appear as dimples or pitting in the skin. Analyze this problem. Discuss suggestions you would make to Ms. Baxter for better care.

2. Mr. Goddard, age 78 years, recently has received a diagnosis of type 2 diabetes mellitus, and the health care provider has ordered an oral antidiabetic drug. Mr. Goddard says his friend with diabetes takes insulin and he wonders why insulin was not prescribed for him. How would you help Mr. Goddard understand why he is taking an oral drug and not insulin? What other information does Mr. Goddard, as a patient with newly diagnosed diabetes, need to have?

3. When assessing Jerry Jones, age 24 years, a patient with recently diagnosed diabetes, you note that he is confused and agitated. His skin is cool and clammy, and he is complaining of hunger. Discuss other assessments you could make and what action, if any, you feel should be taken for Jerry.

Review Questions

1. Which of the following would the nurse mostly likely choose to terminate a hypoglycemic reaction?
   A. Regular insulin
   B. NPH insulin
   C. Orange juice
   D. Crackers and milk

2. Which of the following would be the correct method of administering insulin glargine?
   A. Within 10 minutes of meals
   B. Immediately before meals
   C. Anytime within 30 minutes before or 30 minutes after a meal
   D. At bedtime

3. Which of the following symptoms would alert the nurse to a possible hyperglycemic reaction?
   A. Fatigue, weakness, confusion
   B. Pale skin, elevated temperature
   C. Thirst, abdominal pain, nausea
   D. Rapid, shallow respirations, headache, nervousness

4. A patient with diabetes received a glycosylated hemoglobin test result of 10%. This indicates _______.
   A. the diabetes is well controlled
   B. poor blood glucose control
   C. the need for an increase in the insulin dosage
   D. the patient is at increased risk for hypoglycemia
5. In patients receiving oral hypoglycemic drugs, the nurse must be aware that hypoglycemic reactions
   ______.
   A. will most likely occur 1 to 2 hours after a meal                      
   B. may be more intense than reactions seen with insulin administration
   C. may be less intense than reactions seen with insulin administration
   D. may occur more frequently in patients receiving oral hypoglycemic drugs.

   ● Medication Dosage Problems

1. A patient is prescribed 40 units NPH insulin mixed with 5 units of regular insulin. What is the total
   insulin dosage? Draw a line on the syringe below showing the total insulin dosage. Describe how you
   would prepare the insulins.

2. A patient is prescribed metformin (Glucophage) 1000 mg BID PO. The drug is available in 500-mg
   tablets. The nurse administers_____. What is the total daily dosage of metformin?_____.

3. A patient is prescribed rosiglitazone (Avandia) 8 mg PO daily. Available are 2-mg tablets. The nurse
   would administer ____.

4. A patient is prescribed insulin Humulin L 32 U. Choose the correct label for the insulin.
Pituitary and Adrenocortical Hormones

The pituitary gland lies deep within the cranial vault, connected to the brain by the infundibular stalk (a downward extension of the floor of the third ventricle) and protected by an indentation of the sphenoid bone called the sella turcica (see Fig. 50-1). The pituitary gland, a small, gray rounded structure, has two parts:

- Anterior pituitary (adenohypophysis)
- Posterior pituitary (neurohypophysis)

The gland secretes a number of pituitary hormones that regulate growth, metabolism, the reproductive cycle, electrolyte balance, and water retention or loss. Because the pituitary gland secretes so many hormones that regulate numerous vital processes, the gland is often referred to as the “master gland.” The hormones secreted by the anterior and posterior pituitary and the organs influenced by these hormones are shown in Figure 50-2.

**Anterior Pituitary Hormones**

The hormones of the anterior pituitary include:

- Follicle-stimulating hormone (FSH)
- Luteinizing hormone (LH)
- Growth hormone (GH)
- Adrenocorticotropic hormone (ACTH)
- Thyroid-stimulating hormone (TSH)
- Prolactin

This section of the chapter discusses FSH, LH, GH, and ACTH. FSH and LH are called gonadotropins because they influence the gonads (the organs of reproduction). GH, also called somatotropin, contributes to the growth of the body during childhood, especially the growth of muscles and bones. ACTH is produced by the anterior pituitary and stimulates the adrenal cortex to secrete the corticosteroids. The anterior pituitary hormone, TSH, is discussed in Chapter 51. Prolactin, which is also secreted by the anterior pituitary, stimulates the production of breast milk in the postpartum patient. Additional functions of prolactin are not well understood. Prolactin is the only anterior pituitary hormone that is not used medically.

**Gonadotropins: FSH and LH**

The gonadotropins (FSH and LH) influence the secretion of sex hormones, development of secondary sex characteristics, and the reproductive cycle in both men and women.
women. The gonadotropins discussed in this chapter include menotropins, urofollitropin, clomiphene, and chorionic gonadotropin.

**ACTION AND USES**

**Menotropins and Urofollitropin**

Menotropins (Pergonal) and urofollitropin (Metrodin) are purified preparations of the gonadotropins (FSH and LH) extracted from the urine of postmenopausal women. Menotropins are used to induce ovulation and pregnancy in anovulatory (failure to produce an ovum or failure to ovulate) women. Menotropins are also used with human chorionic gonadotropin in women to stimulate multiple follicles for in vitro fertilization. In men, menotropins are used to induce the production of sperm (spermatogenesis). Urofollitropin is used to induce ovulation in women with polycystic ovarian disease and to stimulate multiple follicular development in ovulatory women for in vitro fertilization. See the Summary Drug Table: Anterior and Posterior Pituitary Hormones for additional information on the gonadotropins.

**Clomiphene and Chorionic Gonadotropin**

Clomiphene (Clomid) is a synthetic nonsteroidal compound that binds to estrogen receptors, decreasing the amount of available estrogen receptors and causing the anterior pituitary to increase secretion of FSH and LH. It is used to induce ovulation in anovulatory (nonovulating) women.

Chorionic gonadotropin (HCG) is extracted from human placentas. The actions of HCG are identical to those of the pituitary LH. The hormone is used to induce ovulation in anovulatory women. This drug is also used for the treatment of prepubertal cryptorchism (failure of the testes to descend into the scrotum) and in men to treat selected cases of hypogonadotropic hypogonadism.

**ADVERSE REACTIONS**

**Menotropins and Urofollitropin**

The adverse reactions associated with the menotropins include ovarian enlargement, hemoperitoneum (blood in the peritoneal cavity), abdominal discomfort, and febrile reactions. Urofollitropin administration may result in mild to moderate ovarian enlargement, abdominal discomfort, nausea, vomiting, breast tenderness, and irritation at the injection site. Multiple births and birth defects have been reported with the use of both menotropins and urofollitropin.

**Clomiphene and HCG**

Administration of clomiphene may result in vasomotor flushes (which are like the hot flashes of menopause), abdominal discomfort, ovarian enlargement, blurred vision, nausea, vomiting, and nervousness. HCG administration may result in headache, irritability, restlessness, fatigue, edema, and precocious puberty (when given for cryptorchism).

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Menotropins and Urofollitropin**

These drugs are contraindicated in patients who have hypersensitivity to the drug or any component of the drug. Menotropins are contraindicated in patients with high gonadotropin levels, thyroid dysfunction, adrenal dysfunction, abnormal bleeding, ovarian cysts, or those with an organic intracranial lesion. Urofollitropin is contraindicated during pregnancy (Pregnancy Category X). Menotropins are Pregnancy Category C drugs and also are contraindicated for use during pregnancy.

**Clomiphene and HCG**

These drugs are contraindicated in patients with known hypersensitivity to the drugs. Clomiphene is contraindicated in patients with liver disease, abnormal bleeding of undetermined origin, or ovarian cysts, and during
pregnancy (Pregnancy Category C). HCG is contraindicated in patients with precocious puberty, prostatic cancer, or androgen-dependent neoplasm, and during pregnancy (Pregnancy Category X). These drugs are used cautiously in patients with epilepsy, migraine headaches, asthma, cardiac or renal dysfunction, and during lactation. There are no clinically significant known interactions when administering the gonadotropins.

**Nursing Process**

**The Patient Receiving a Gonadotropin**

**Assessment**

**Preadministration Assessment**

These drugs are almost always administered on an outpatient basis. Before prescribing any one of these drugs, the primary health care provider will take a thorough medical history and perform a physical examination. Additional laboratory and diagnostic tests for ovarian function and tubal patency may also be performed. The nurse takes and records the patient's vital signs and weight before therapy is instituted. A pelvic examination may be performed by the primary health care provider to rule out ovarian enlargement, pregnancy, or uterine problems.

**Ongoing Assessment**

At the time of each office or clinic visit, the nurse questions the patient regarding the occurrence of adverse reactions and records the patient’s vital signs and weight.

**Nursing Alert**

The patient is checked for signs of excessive ovarian enlargement (abdominal distention, pain, ascites [with serious cases]). The drug is discontinued at the first sign of ovarian stimulation or enlargement. The patient is usually admitted to the hospital for supportive measures.

**Figure 50-2.** The pituitary gland, and the hormones secreted by the anterior pituitary and the posterior pituitary.
### Anterior Pituitary Hormones

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chorionic gonadotropin (HCG)</td>
<td>A.P.L., Chorex, Gonic, Profasi, generic</td>
<td>Ovulatory failure, prepubertal cryptorchidism</td>
<td>Headache, edema, irritability, fatigue, nervousness, restlessness, precocious puberty, gynecomastia</td>
<td>Dosage frequency, length of treatment are individualized; ranges 5000–10,000 units dose IM</td>
</tr>
<tr>
<td>Clomiphene citrate</td>
<td>Clomid, Milophene, Serophene, generic</td>
<td>Ovulatory failure</td>
<td>Vasomotor flushes, breast tenderness, abdominal discomfort, blurred vision, ovarian enlargement, nausea, vomiting, nervousness</td>
<td>First course: 50 mg/d PO for 5 d; second and third course (if necessary) 100 mg/d for 5 d PO</td>
</tr>
<tr>
<td>Corticotropin (ACTH)</td>
<td>Acthar, generic</td>
<td>Diagnostic testing of adrenocortical function, nonsuppurative thyroiditis, hypercalcemia associated with cancer, acute exacerbations of multiple sclerosis (MS)</td>
<td>Same as glucocorticoids (Display 50-2)</td>
<td>20 units QID IM, SC; diagnostic: 10–25 units in 500 mL of 5% dextrose injection infused IV over 8 h; acute exacerbations of MS: 80–120 units/d IM for 2–3 wk</td>
</tr>
<tr>
<td>Menotropins</td>
<td>Humegon, Pergonal</td>
<td>Ovulatory failure, stimulation of spermatogenesis</td>
<td>Ovarian enlargement, hemoperitoneum, febrile reactions, multiple pregnancies, hypersensitivity</td>
<td>75–150 IU IM</td>
</tr>
<tr>
<td>Somatropin</td>
<td>Genotropin, Humatrope</td>
<td>Growth failure due to deficiency of pituitary growth hormone in children</td>
<td>Failure to respond to therapy due to development of antibodies, hypothyroidism, insulin resistance, swelling of the joints, joint and/or muscle pain</td>
<td>Genotropin: 0.16–0.24 mg/kg/wk SC divided into 6–7 injections; Humatrope: 0.006–0.0125 mg/kg/d SC Individualize dosage based on response. Up to 0.1 mg/ kg IM or SC 3 times a week.</td>
</tr>
<tr>
<td>Somatrem</td>
<td>Protropin</td>
<td>Growth failure</td>
<td>Same as somatropin</td>
<td>75 IU IM for 7–12 d then 5000–10,000 U; 1 day after last dose, may repeat sequence using 150 mg for 7–12 d followed by 5000–10,000 U HCG 1 day after last dose</td>
</tr>
<tr>
<td>Urofollitropin</td>
<td>Fertinex, Metrodin</td>
<td>Induction of ovulation, stimulation of multiple follicle development</td>
<td>Ovarian enlargement, nausea, vomiting, breast tenderness, ectopic pregnancy, abdominal discomfort</td>
<td></td>
</tr>
</tbody>
</table>

### Posterior Hormones

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desmopressin acetate</td>
<td>DDAVP, Stimate</td>
<td>Diabetes insipidus, hemophilia A, von Willebrand’s disease, nocturnal enuresis</td>
<td>Headache, nausea, nasal congestion, abdominal cramps</td>
<td>0.1–0.4 mL/d as a nasal solution as a single dose or in 2–3 divided doses; 0.5–1 mL/d SC, IV; 1 spray per nostril for a total of 300 mg; 0.05 mg PO BID (adjust according to water turnover)</td>
</tr>
<tr>
<td>Lypressin</td>
<td>Diapid</td>
<td>Diabetes insipidus</td>
<td>Rhinorrhea, nasal congestion, irritation of nasal passages, headache</td>
<td>1–2 sprays in one or both nostrils QID</td>
</tr>
<tr>
<td>Vasopressin</td>
<td>Pitressin Synthetic</td>
<td>Diabetes insipidus, prevention and treatment of postoperative abdominal distension, to dispel gas interfering with abdominal x-ray examination</td>
<td>Tremor, sweating, vertigo, nausea, vomiting, abdominal cramps, hypersensitivity, headache</td>
<td>Diabetes insipidus: 5–10 U SC, IM; abdominal distension: 5–10 U IM; prior to abdominal x-ray: 10 U IM, SC 2 hr and ½ h before procedure</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.*
NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to drug therapy, identification of adverse reactions, reduction in anxiety, and an understanding of the therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

CLOMIPHENE. Clomiphene is an oral tablet prescribed for 5 days and is self-administered in the outpatient setting.

Educating the Patient and Family

The nurse should instruct the patient taking the gonadotropins to keep all primary health care provider appointments. Adverse reactions should be reported to the nurse or primary health care provider. The nurse includes the following information when a gonadotropin is prescribed:

MENOTROPINS AND UROFOLLITROPIN

- Before beginning therapy, be aware of the possibility of multiple births and birth defects.
- It is a good idea to use a calendar to track the treatment schedule and ovulation.
- Report bloating, abdominal pain, flushing, breast tenderness, and pain at the injection site.

CLOMIPHENE

- Take the drug as prescribed (5 days) and do not stop taking the drug before the course of therapy is finished unless told to do so by the primary health care provider.
- Notify the primary health care provider if bloating, stomach or pelvic pain, jaundice, blurred vision, hot flashes, breast discomfort, headache, nausea, or vomiting occurs.
- If ovulation has not occurred after the first course, a second or third course of therapy may be used. If the drug is not successful after three regimens, the therapy is considered unsuccessful and use of the drug is discontinued.

EVALUATION

- The therapeutic effect is achieved.
- Adverse reactions are identified and reported to the primary health care provider.
- Anxiety is reduced.
- The patient demonstrates knowledge of treatment and dosage regimen, adverse drug reactions, risks of treatment, and importance of complying with the primary health care provider’s recommendations.

Growth Hormone

Growth hormone, also called somatotropic hormone, is secreted by the anterior pituitary. This hormone regulates the growth of the individual until somewhere around early adulthood or the time when the person no longer gains height.
ACTION AND USES

Growth hormone is available as the synthetic products somatrem (Protropin) and somatropin (Humatrope). Both are of recombinant DNA origin and are identical to human GH and produce skeletal growth in children. These drugs are administered to children who have not grown because of a deficiency of pituitary GH and must be used before closure of bone epiphyses. Bone epiphyses are the ends of bones, separated from the main bone but joined to its cartilage, that allow for growth or lengthening of the bone. GH is ineffective in patients with closed epiphyses because when the epiphyses close, growth (in height) can no longer occur.

ADVERSE REACTIONS

These hormones cause few adverse reactions when administered as directed. Antibodies to somatropin may develop in a small number of patients, resulting in a failure to experience response to therapy, namely, failure of the drug to produce growth in the child. Some patients may experience hypothyroidism or insulin resistance. Swelling, joint pain, and muscle pain may also occur.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Somatrem and somatropin are contraindicated in patients with known hypersensitivity to somatropin or sensitivity to benzyl alcohol, and those with epiphyseal closure or underlying cranial lesions. The drug is used cautiously in patients with thyroid disease or diabetes, and during pregnancy (Pregnancy Category C) and lactation. Excessive amounts of glucocorticoids may decrease response to somatropin.

NURSING PROCESs

The Patient Receiving a Growth Hormone

ASSESSMENT

Preadministration Assessment
A thorough physical examination and laboratory and diagnostic tests are performed before a child is accepted into a growth program. Before therapy is started, the nurse takes and records the patient’s vital signs, height, and weight.

Ongoing Assessment
Children may increase their growth rate from 3.5 to 4 cm/year before treatment to 8 to 10 cm/year during the first year of treatment. Each time the child visits the primary health care provider’s office or clinic (usually every 3–6 months), the nurse measures and records the child’s height and weight to evaluate the response to therapy. Bone age is monitored periodically. The bone age monitors bone growth and detects epiphyseal closure, at which time therapy must be stopped.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to drug therapy, management of common adverse drug reactions, reduction in anxiety, and an understanding of the therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy
Growth hormone is given either IM or subcutaneously (SC). The vial is not shaken but swirled to mix. The solution is clear, and the nurse should not give it if it is cloudy. These drugs are administered IM or SC. The weekly dosage is divided and given in three to seven doses throughout the week. The drug may (if possible) be given at bedtime to most closely adhere to the body’s natural release of the hormone.

Periodic testing of growth hormone levels, glucose tolerance, and thyroid functioning may be done at intervals during treatment.

Managing Anxiety and Body Image Disturbance
The parents, and sometimes the children, may be concerned about the success or possible failure of treatment with GH. The child is provided with the opportunity to share fears, concerns, or anger. The nurse acknowledges these feelings as normal and corrects any misconceptions the child or parents may have concerning treatment. Time is allowed for the parents and children to ask questions not only before therapy is started but also during the months of treatment.

Educating the Patient and Family
When the patient is receiving GH, the primary health care provider discusses in detail the therapeutic regimen
for increasing growth (height) with the child’s parents or guardians. If the drug is to be given at bedtime and not in the outpatient clinic, the nurse instructs the parents on the proper technique to administer the injections. The parents are encouraged to keep all clinic or office visits. The nurse explains that the child may experience sudden growth and increase in appetite. The nurse instructs the parents to report lack of growth, symptoms of diabetes (eg, increased hunger, increased thirst, or frequent voiding) or symptoms of hypothyroidism (eg, fatigue, dry skin, intolerance to cold).

**EVALUATION**

- The therapeutic effect is achieved and the child grows in height.
- Adverse reactions are identified and reported to the primary health care provider.
- Anxiety is reduced.
- The parents verbalize understanding of the treatment program.
- The child maintains a positive body image.

**Adrenocorticotropic Hormone: Corticotropin**

**ACTIONS AND USES**

Corticotropin (ACTH) is an anterior pituitary hormone that stimulates the adrenal cortex to produce and secrete adrenocortical hormones, primarily the glucocorticoids.

Corticotropin is used for diagnostic testing of adrenocortical function. This drug may also be used for the management of acute exacerbations of multiple sclerosis, non-suppressive thyroiditis, and hypercalcemia associated with cancer. It is also used as an anti-inflammatory and immunosuppressant drug when conventional glucocorticoid therapy has not been effective (see Display 50-1).

**ADVERSE REACTIONS**

Because ACTH stimulates the release of glucocorticoids from the adrenal gland, adverse reactions seen with the administration of this hormone are similar to those seen with the glucocorticoids (see Display 50-2) and affect many body systems. The most common adverse reactions include:

- Central nervous system—mental depression, mood swings, insomnia, psychosis, euphoria, nervousness, and headaches;
- Cardiovascular system—hypertension, edema, congestive heart failure, and thromboembolism;
- Gastrointestinal system—nausea, vomiting, increased appetite, weight gain, and peptic ulcer;
- Genitourinary system—amenorrhea and irregular menses;
- Integumentary system—petechiae, ecchymosis, decreased wound healing, hirsutism (excessive growth of body hair), and acne;
- Musculoskeletal system—weakness and osteoporosis;
- Endocrine system—menstrual irregularities, hyperglycemia, and decreased growth in children; and

**DISPLAY 50-1  Uses of Glucocorticoids**

**ENDOCRINE DISORDERS**
Primary or secondary adrenal cortical insufficiency, congenital adrenal hyperplasia, nonsuppressive thyroiditis, hypercalcemia associated with cancer

**RHEUMATIC DISORDERS**
Short-term management of acute ankylosing spondylitis, acute and subacute bursitis, acute and nonspecific tenosynovitis, acute gouty arthritis, psoriatic arthritis, rheumatoid arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, episcleritis

**COLLAGEN DISEASES**
Lupus erythematosus, acute rheumatic carditis, systemic dermatomyositis

**DERMATOLOGIC DISEASES**
Pemphigus, bullous dermatitis herpetiformis, severe erythema multi-forme (Stevens-Johnson syndrome), exfoliative dermatitis, mycosis fungoides, severe psoriasis, severe seborrheic dermatitis, angioedema, urticaria, various skin disorders, such as lichen planus or keloids

**ALLERGIC STATES**
Control of severe or incapacitating allergic conditions not controlled by other methods, bronchial asthma (including status asthmaticus), contact dermatitis, atopic dermatitis, serum sickness, drug hypersensitivity reactions

**OPHTHALMIC DISEASES**
Severe acute and chronic allergic and inflammatory processes, keratitis, allergic corneal marginal ulcer, herpes of the eye, iritis, iridocyclitis, chorioretinitis, diffuse posterior uveitis, optic neuritis, sympathetic ophthalmia, anterior segment inflammation

**RESPIRATORY DISEASES**
Sarcoidosis, berylliosis, fulminating or disseminating pulmonary tuberculosis, aspiration pneumonia

**HEMATOLOGIC DISORDERS**
Idiopathic or secondary thrombocytopenic purpura, hemolytic anemia, red blood cell anemia, congenital hypoplastic anemia

**NEOPLASTIC DISEASES**
Leukemia, lymphomas

**EDEMATOUS STATES**
To induce diuresis or remission of proteinuria in the nephrotic state

**GASTROINTESTINAL DISEASES**
During critical period of ulcerative colitis, regional enteritis, intractable sprue

**NERVOUS SYSTEM**
Acute exacerbations of multiple sclerosis
• Miscellaneous—hypersensitivity reactions, hypokalemia, hypernatremia, increased susceptibility to infection, cushingoid appearance (eg, moon face, “buffalo hump,” hirsutism), cataracts, and increased intraocular pressure.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

ACTH is contraindicated in patients with adrenocortical insufficiency or hyperfunction, allergy to pork or pork products (corticotropin is obtained from porcine pituitaries), systemic fungal infections, ocular herpes simplex, scleroderma, osteoporosis, and hypertension. Patients taking ACTH also should avoid any vaccinations with live virus.

ACTH is used cautiously in patients with diabetes, diverticulosis, renal insufficiencies, myasthenia gravis, tuberculosis (may reactivate the disease), hypothyroidism, cirrhosis, nonspecific ulcerative colitis, heart failure, seizures, or febrile infections. The drug is classified as a Pregnancy Category C drug and is used cautiously during pregnancy and lactation. ACTH is used cautiously in children because it can inhibit skeletal growth.

When amphotericin B or diuretics are administered with ACTH, the potential for hypokalemia is increased. There may be an increased need for insulin or oral antidiabetic drugs in the patient with diabetes who is taking ACTH. There is a decreased effect of ACTH when the agent is administered with the barbiturates. Profound muscular depression is possible when ACTH is administered with the anticholinesterase drugs. Live virus vaccines taken while taking ACTH may potentiate virus replication, increase vaccine adverse reaction, and decrease the patient’s antibody response to the vaccine.
UNIT IX  Drugs That Affect the Endocrine System

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to therapy, identification and management of adverse reactions (see section “Monitoring and Managing Adverse Reactions”), and an understanding of the therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

Nursing management depends on the patient’s diagnosis, physical status, and the reason for use of the drug. The nurse may need to assess vital signs every 4 hours and observe for the adverse reactions seen with glucocorticoid administration.

This drug may be given by the intravenous (IV), SC, or IM route. During parenteral administration of ACTH, the nurse observes the patient for hypersensitivity reactions. Symptoms of hypersensitivity include a rash, urticaria, hypotension, tachycardia, or difficulty breathing. If the drug is given IM or SC, the nurse observes the patient for hypersensitivity reactions immediately and for about 2 hours after the drug is given. If a hypersensitivity reaction occurs, the nurse notifies the primary health care provider immediately. Long-term use increases the risk of hypersensitivity.

Monitoring and Managing Adverse Reactions

Corticotropin may mask signs of infection, including fungal or viral eye infections.

Educating the Patient and Family

The nurse includes the following in a teaching plan for the patient receiving ACTH:

- Report any adverse reactions.
- Avoid contact with those who have an infection because resistance to infection may be decreased.
- Report any symptoms of infection immediately (e.g., sore throat, fever, cough, or sores that do not heal).
- Patients with diabetes—Monitor blood glucose (if self-monitoring is being done) or urine closely and notify the primary health care provider if glucose appears in the urine or the blood glucose level increases significantly. An increase in the dosage of the oral antidiabetic drug or insulin may be needed.
- Notify the primary health care provider of a marked weight gain, swelling in the extremities, muscle weakness, persistent headache, visual disturbances, or behavior change.

EVALUATION

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed using appropriate nursing interventions.
- The patient verbalizes an understanding of the therapeutic regimen and adverse effects requiring notification of the primary health care provider.

POSTERIOR PITUITARY HORMONES

The posterior pituitary gland produces two hormones: vasopressin (antidiuretic hormone) and oxytocin (see Chap. 53). Posterior pituitary hormones are summarized in the Summary Drug Table: Anterior and Posterior Pituitary Hormones.
Vasopressin

ACTIONS AND USES

Vasopressin (Pitressin Synthetic) and its derivatives, namely lypressin (Diapid) and desmopressin (DDAVP), regulate the reabsorption of water by the kidneys. Vasopressin is secreted by the pituitary when body fluids must be conserved. An example of this mechanism may be seen when an individual has severe vomiting and diarrhea with little or no fluid intake. When this and similar conditions are present, the posterior pituitary releases the hormone vasopressin, water in the kidneys is reabsorbed into the blood (ie, conserved), and the urine becomes concentrated. Vasopressin exhibits its greatest activity on the renal tubular epithelium, where it promotes water resorption and smooth muscle contraction throughout the vascular bed. Vasopressin has some vasopressor activity.

Vasopressin and its derivatives are used in the treatment of diabetes insipidus, a disease resulting from the failure of the pituitary to secrete vasopressin or from surgical removal of the pituitary. Diabetes insipidus is characterized by marked increase in urination (as much as 10 L in 24 hours) and excessive thirst by inadequate secretion of the antidiuretic hormone or vasopressin. Treatment with vasopressin therapy replaces the hormone in the body and restores normal urination and thirst. Vasopressin may also be used for the prevention and treatment of postoperative abdominal distention and to dispel gas interfering with abdominal roentgenography.

ADVERSE REACTIONS

Local or systemic hypersensitivity reactions may occur in some patients receiving vasopressin. Tremor, sweating, vertigo, nausea, vomiting, abdominal cramps, and water intoxication (overdosage, toxicity) may also be seen.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Vasopressin is contraindicated in patients with chronic renal failure, increased blood urea nitrogen, and those with allergy to beef or pork proteins.

Vasopressin is used cautiously in patients with a history of seizures, migraine headaches, asthma, congestive heart failure, or vascular disease (may precipitate angina or myocardial infarction) and in those with perioperative polyuria. The drug is classified as a Pregnancy Category C drug and must be used cautiously during pregnancy and lactation.

The antidiuretic effects of vasopressin may be decreased when the agent is taken with the following drugs: lithium, heparin, norepinephrine, or alcohol. Antidiuretic effect may be increased when the drug is used with carbamazepine, clofibrate, or fludrocortisone.

NURSING PROCESS

The Patient Receiving Vasopressin

ASSESSMENT

Preadministration Assessment

Before administering the first dose of vasopressin for the management of diabetes insipidus, the nurse takes the patient's blood pressure, pulse, and respiratory rate. The nurse weighs the patient to obtain a baseline weight for future comparison. Serum electrolyte levels and other laboratory tests may be ordered by the primary health care provider.

Before administering vasopressin to relieve abdominal distention, the nurse takes the patient's blood pressure, pulse, and respiratory rate. The nurse auscultates the abdomen and records the findings. The nurse measures and records the patient's abdominal girth.

Ongoing Assessment

During the ongoing assessment the nurse monitors the blood pressure, pulse, and respiratory rate every 4 hours or as ordered by the primary health care provider. The primary health care provider is notified if there are any significant changes in these vital signs because a dosage adjustment may be necessary.

The dosage of vasopressin or its derivatives may require periodic adjustments. After administration of the drug, the nurse observes the patient every 10 to 15 minutes for signs of an excessive dosage (eg, blanching of the skin, abdominal cramps, and nausea). If these occur, the nurse reassures the patient that recovery from these effects will occur in a few minutes.

Gerontologic Alert

Older adults are particularly sensitive to the effects of vasopressin and should be monitored closely during administration of the drug.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.
PLANNING
The expected outcomes of the patient may include an optimal response to therapy, identification of adverse reactions, and an understanding of the therapeutic regimen.

IMPLEMENTATION
Promoting an Optimal Response to Therapy
Vasopressin may be given IM or SC to treat diabetes insipidus. The injection solution may also be administered intranasally on cotton pledgets, by nasal spray, or dropper. When given parenterally 5 to 10 units administered two to three times daily is usually sufficient. To prevent or relieve abdominal distension, 5 units of the drug is administered initially and may increase to 10 units every 3 to 4 hours IM. When the drug is administered before abdominal roentgenography, the nurse administers 2 injections of 10 units each. The first dose is given 2 hours before x-ray examination and the second dose ½ hour before the testing. An enema may be given before the first dose.

Lypressin is administered intranasally by spraying 1 or 2 sprays in one or both nostrils usually four times per day or when the frequency of urination increases or significant thirst develops. Dosages greater than 10 sprays in each nostril every 3 to 4 hours are not recommended. Patients learn to regulate their dosage based on the frequency of urination and increase of thirst. The nurse instructs the patient to hold the bottle upright with the head in a vertical position when administering the drug.

Desmopressin may be given orally, intranasally, SC, or IV. The oral dose must be determined for each individual patient and adjusted according to the patient’s response to therapy. When the drug is administered nasally, a nasal tube is used for administration. The nasal tube delivery system comes with a flexible calibrated plastic tube called a rhinyle. The solution is drawn into the rhinyle. One end is inserted into the nostril and the patient (if condition allows) blows the other end to deposit solution deep into the nasal cavity. A nasal spray pump may also be used. Most adults require 0.2 mL daily in two divided doses to control diabetes insipidus. The drug may also be administered via the SC route or direct IV injection.

Monitoring and Managing Adverse Reactions
The adverse reactions associated with vasopressin, such as skin blanching, abdominal cramps, and nausea, may be decreased by administering the agent with one or two glasses of water. Should these adverse reactions occur, the nurse informs the patient that these reactions are not serious and should disappear within a few minutes.

Nursing Diagnoses Checklist
- **Deficient Fluid Volume** related to inadequate fluid intake, need to increase dose of drug, failure to recognize symptoms of dehydration (diabetes insipidus)
- **Excess Fluid Volume** related to adverse reactions (water intoxication)

Nursing Alert
Excessive dosage is manifested as water intoxication (fluid overload). Symptoms of water intoxication include drowsiness, listlessness, confusion, and headache (which may precede convulsions and coma). If signs of excessive dosage occur, the nurse should notify the primary health care provider before the next dose of the drug is due because a change in the dosage, the restriction of oral or IV fluids, and the administration of a diuretic may be necessary.

MANAGING FLUID VOLUME. The symptoms of diabetes insipidus include the voiding of a large volume of urine at frequent intervals during the day and throughout the night. Accompanied by frequent urination is the need to drink large volumes of fluid because these patients are continually thirsty. Patients must be supplied with large amounts of drinking water. The nurse is careful to refill the water container at frequent intervals. This is especially important when the patient has limited ambulatory activities. Until controlled by a drug, the symptoms of frequent urination and excessive thirst may cause a great deal of anxiety. The nurse reassures the patient that with the proper drug therapy, these symptoms will most likely be reduced or eliminated.

When the patient has diabetes insipidus, the nurse measures the fluid intake and output accurately and observes the patient for signs of dehydration (dry mucous membranes, concentrated urine, poor skin turgor, flushed dry skin, confusion). This is especially important early in treatment and until such time as the optimum dosage is determined and symptoms have diminished. If the patient’s output greatly exceeds intake, the nurse notifies the primary health care provider. In some instances, the primary health care provider may order specific gravity and volume measurements of each voiding or at hourly intervals. The nurse records these results in the chart to aid the primary health care provider in adjusting the dosage to the patient’s needs.

MANAGING ABDOMINAL DISTENTION. If the patient is receiving vasopressin for abdominal distention, the nurse explains in detail the method of treating this problem and the necessity of monitoring drug effectiveness (ie, auscultation of the abdomen for bowel sounds, insertion of a rectal tube, measurement of the abdomen).
After administration of vasopressin for abdominal distention, a rectal tube may be ordered. The lubricated end of the tube is inserted past the anal sphincter and taped in place. The tube is left in place for 1 hour or as prescribed by the primary health care provider. The nurse auscultates the abdomen every 15 to 30 minutes and measures the abdominal girth every hour, or as ordered by the primary health care provider.

Educating the Patient and Family
If lypressin or desmopressin is to be used in the form of a nasal spray or is to be instilled intranasally using the nasal tube delivery system, the nurse demonstrates the technique of instillation (see Patient and Family Teaching Checklist: Self-Administering Nasal Vasopressin). The nurse includes illustrated patient instructions with the drug and reviews them with the patient. If possible, the nurse has the patient demonstrate the technique of administration. The nurse should discuss the need to take the drug only as directed by the primary health care provider. The patient should not increase the dosage (ie, the number or frequency of sprays) unless advised to do so by the primary health care provider.

On occasion, a patient may need to self-administer vasopressin by the parenteral route. If so, the nurse instructs the patient or a family member in the preparation and administration of the drug and measurement of the specific gravity of the urine.

The nurse stresses the importance of adhering to the prescribed treatment program to control symptoms. In addition to instruction in administration, the nurse includes the following in a patient and family teaching plan:

- Drink one or two glasses of water immediately before taking the drug.
- Measure the amount of fluids taken each day.
- Measure the amount of urine passed at each voiding and then total the amount for each 24-hour period.
- Avoid the use of alcohol while taking these drugs.
- Rotate injection sites for parenteral administration.
- Contact the primary health care provider immediately if any of the following occur: a significant increase or decrease in urinary output, abdominal cramps, blanching of the skin, nausea, signs of inflammation or infection at the injection sites, confusion, headache, or drowsiness.
- Wear a medical alert tag identifying the disease (diabetes insipidus) and the drug regimen.

EVALUATION

- The therapeutic effect is achieved.
- Anxiety is reduced.
- Signs of a fluid volume deficit are absent (diabetes insipidus).

The nurse:

- Explains the reason for the drug and prescribed therapy, including drug name, correct dose (number of sprays), and frequency of administration.
- Describes equipment to be used for intranasal administration.
- Reviews schedule of administration and prescribed number of sprays to each nostril based on signs and symptoms of disease (diabetes insipidus), such as frequency of urination and increased thirst.
- Demonstrates step-by-step procedure for instillation and care, with patient performing a return demonstration of procedure.
- Provides written instructions for procedure.
- Reassures that symptoms of the disorder will most likely be reduced or eliminated with drug therapy.
- Instructs in signs and symptoms of fluid overload and the need to notify health care provider should any occur.
- Emphasizes importance of wearing medical alert tag identifying the disorder and drug therapy.
- Reinforces the need for continued follow-up to evaluate therapy.

Lypressin

- Instructs to hold bottle upright with head in vertical position.
- Discusses importance of taking drug exactly as prescribed (usually 1–2 sprays to one or both nostrils 4 times a day) and not to increase the number of sprays unless directed to do so by prescriber.
- Warns that dosages greater than 10 sprays in each nostril every 3 to 4 hours are not recommended.

Desmopressin

- When administering nasally, a nasal tube is used for administration. The nasal tube delivery system comes with a flexible calibrated plastic tube called a rhinyle.
- The prescribed amount of solution is drawn into the rhinyle. One end is inserted into the nostril, and the patient blows the other end to deposit solution deep into the nasal cavity.
- A nasal spray pump may also be used.

- The patient verbalizes an understanding of the treatment modalities and the importance of continued follow-up care (diabetes insipidus).
- The patient and family demonstrate an understanding of the drug regimen.
• Adverse reactions are identified and reported to the primary health care provider (diabetes insipidus).
• The patient verbalizes the importance of complying with the prescribed therapeutic regimen (diabetes insipidus).

**ADRENOCORTICAL HORMONES**

The adrenal gland lies on the superior surface of each kidney. It is a double organ composed of an outer cortex and an inner medulla. In response to ACTH secreted by the anterior pituitary, the adrenal cortex secretes several hormones (the glucocorticoids, the mineralocorticoids, and small amounts of sex hormones).

This section of the chapter discusses the hormones produced by the adrenal cortex or the adrenocortical hormones, which are the glucocorticoids and mineralocorticoids. These hormones are essential to life and influence many organs and structures of the body. The glucocorticoids and mineralocorticoids are collectively called corticosteroids.

**GLUCOCORTICOIDS**

The glucocorticoids influence or regulate functions such as the immune response system, the regulation of glucose, fat and protein metabolism, and control of the anti-inflammatory response. Table 50-1 describes the activity of the glucocorticoids within the body.

**TABLE 50-1 Activity of Glucocorticoids in the Body**

<table>
<thead>
<tr>
<th>FUNCTION WITHIN THE BODY</th>
<th>DESCRIPTION OF BODILY ACTIVITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-inflammatory</td>
<td>Stabilizes lysosomal membrane and prevents the release of proteolytic enzymes released during the inflammatory process</td>
</tr>
<tr>
<td>Regulation of blood pressure</td>
<td>Potentiates vasoconstrictor action of norepinephrine. Without glucocorticoids the vasoconstricting action is decreased, and blood pressure falls.</td>
</tr>
<tr>
<td>Metabolism of carbohydrates and protein</td>
<td>Facilitates the breakdown of protein in the muscle, leading to increased plasma amino acid levels. Increases activity of enzymes necessary for glucogenesis producing hyperglycemia, which can aggravate diabetes, precipitate latent diabetes, and cause insulin resistance</td>
</tr>
<tr>
<td>Metabolism of fat</td>
<td>A complex phenomena that promotes the use of fat for energy (a positive effect) and permits fat stores to accumulate in the body, causing buffalo hump and moon- or round-shaped face (a negative effect).</td>
</tr>
<tr>
<td>Interference with the immune response</td>
<td>Decreases the production of lymphocytes and eosinophils in the blood by causing atrophy of the thymus gland; blocks the release of cytokines, resulting in a decreased performance of T and B monocytes in the immune response. (This action, coupled with the anti-inflammatory action, makes the corticosteroids useful in delaying organ rejection in patients with transplants.)</td>
</tr>
<tr>
<td>Stress</td>
<td>As a protective mechanism, the corticosteroids are released during periods of stress (eg, injury or surgery). The release of epinephrine or norepinephrine by the adrenal medulla during stress has a synergistic effect along with the corticosteroids.</td>
</tr>
<tr>
<td>Central nervous system disturbances</td>
<td>Affects mood and possibly causes neuronal or brain excitability, causing euphoria, anxiety, depression, psychosis, and an increase in motor activity in some individuals</td>
</tr>
</tbody>
</table>

**ACTIONS AND USES**

The glucocorticoids enter target cells and bind to receptors, initiating many complex reactions in the body. Some of these actions are considered undesirable, depending on the indication for which these drugs are being used. Examples of the glucocorticoids include cortisone, hydrocortisone, prednisone, prednisolone, and triamcinolone. The Summary Drug Table: Adrenocortical Hormones: Glucocorticoids and Mineralocorticoids provides information concerning these hormones.

The glucocorticoids are used as replacement therapy for adrenocortical insufficiency, to treat allergic reactions, collagen diseases (eg, systemic lupus erythematosus), dermatologic conditions, rheumatic disorders, shock, and other conditions (see Display 50-1). The anti-inflammatory activity of these hormones make them valuable as anti-inflammatories and as immunosuppressants to suppress inflammation and modify the immune response.

**ADVERSE REACTIONS**

The adverse reactions that may be seen with the administration of the glucocorticoids are given in Display 50-2. Long- or short-term high-dose therapy may also produce many of the signs and symptoms seen with Cushing's syndrome, a disease caused by the overproduction of endogenous glucocorticoids. Some of the signs and symptoms of this Cushing-like (or cushingoid) state include a “buffalo” hump (a hump on the back of...
### Glucocorticoids

<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>betamethasone</td>
<td>Celestone</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>Individualize dosage: 0.6–7.2 mg/d PO Up to 9 mg/d IM, IV</td>
</tr>
<tr>
<td>sodium phosphate</td>
<td>Phosphate</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td></td>
</tr>
<tr>
<td>budesonide</td>
<td>Entocort EC</td>
<td>Crohn’s disease</td>
<td>See Display 50-2</td>
<td>9 mg once daily in AM for 8 wk</td>
</tr>
<tr>
<td>cortisone</td>
<td>Generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>25–300 mg/day PO</td>
</tr>
<tr>
<td>dexamethasone</td>
<td>Decadron, Dexameth, Dexone, Hexadrol, generic</td>
<td>Acute self-limited allergic disorder or acute exacerbations of chronic allergic disorders</td>
<td>See Display 50-2</td>
<td>Individualize dosage based on severity of condition and response: give daily dose before 9 AM to minimize adrenal suppression; after long-term therapy, reduce slowly to avoid adrenal insufficiency</td>
</tr>
<tr>
<td>acetate</td>
<td>Cortastat-LA, Dalalone-LA, Decadron-LA, Dexasone-LA, Dalalone DP, generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>0.5–9 mg/d 10 mg IV, then 4 mg IM q6h; intra-articular: large joints 4–16 mg; soft tissue: 0.8–1.6 mg</td>
</tr>
<tr>
<td>hydrocortisone</td>
<td>Cortef, generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>20–240 mg PO in single or divided doses</td>
</tr>
<tr>
<td>sodium phosphate</td>
<td>Generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>20–240 mg/d q12h</td>
</tr>
<tr>
<td>hydrocortisone</td>
<td>A-hydroCort, Solu-Cortef</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>Reduce dose based on condition and response but give no less than 25 mg/d</td>
</tr>
<tr>
<td>methylprednisolone</td>
<td>Medrol, generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>Initial dose: 4–48 mg/d PO; Dosepak 21 day therapy: follow manufacturer’s directions; alternate day therapy: twice the usual dose is administered every other morning</td>
</tr>
<tr>
<td>acetate</td>
<td>Depoject, DepoMedrol, Depopred, generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>40–120 mg IM; 4–80 mg intra-articular and soft tissue injections</td>
</tr>
<tr>
<td>methylprednisolone</td>
<td>A-Methapred, Solu-Medrol, generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>10–40 mg IV, IM</td>
</tr>
<tr>
<td>sodium succinate</td>
<td>Prelone, generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>5–60 mg/d PO; acute exacerbations in MS: 200 mg/d for 1 wk, followed by 80 mg every other day for 1 month PO</td>
</tr>
</tbody>
</table>

(continued)
SUMMARY DRUG TABLE  ADRENOCORTICAL HORMONES: CORTICOSTEROIDS AND MINERALOCORTICOID (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>prednisolone acetate</td>
<td>Key-Pred 50, Predcor-50, generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>4–60 mg/d IM (not for IV use); MS: 200 mg/d for 1 wk, followed by 80 mg/d every other day for 1 month IM</td>
</tr>
<tr>
<td>prednisone</td>
<td>Deltasone, Meticorten, Orasone, generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>Individualize dosage: initial dose usually between 5 and 60 mg/d PO</td>
</tr>
<tr>
<td>triamcinolone</td>
<td>Aristocort, Atolone, Kenacort generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>4–48 mg/d PO</td>
</tr>
<tr>
<td>triamcinolone acetonide</td>
<td>Kenalog-10, Tac-3, Triam-A, generic</td>
<td>See Display 50-1</td>
<td>See Display 50-2</td>
<td>Systemic: 2.5–60 mg/d IM; Intra-articular: 2.5–15 mg</td>
</tr>
</tbody>
</table>

Corticosteroid Retention Enemas

Corticosteroid intrarectal foam, hydrocortisone acetate intrarectal foam | Cortifoam | Adjunctive therapy in treatment of ulcerative proctitis of the distal portion of the rectum | Local pain or burning, rectal bleeding, apparent exacerbations or sensitivity reactions | 1 applicatorful once or twice daily for 2 wk and every second day thereafter |

Mineralocorticoid

fludrocortisone acetate | Florinef Acetate | Partial replacement therapy for Addison’s disease, salt-losing adrenogenital syndrome | See Display 50-2 | 0.1 mg 3 times a week to 0.2 mg/d PO |

*The term generic indicates the drug is available in generic form.

The glucocorticoids are contraindicated in patients with serious infections, such as tuberculosis and fungal and antibiotic-resistant infections. When a serious disease or disorder is being treated, it is often necessary to allow these effects to occur because therapy with these drugs is absolutely necessary.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The glucocorticoids are contraindicated in patients with serious infections, such as tuberculosis and fungal and antibiotic-resistant infections. The glucocorticoids are administered with caution to patients with renal or hepatic disease, hypothyroidism, ulcerative colitis, diverticulitis, peptic ulcer disease, inflammatory bowel disease, hypertension, osteoporosis, convulsive disorders, or diabetes. The glucocorticoids are classified as Pregnancy Category C drugs and should be used with caution during pregnancy and lactation. Multiple drug interactions may occur with the glucocorticoids. Table 50-2 identifies select clinically significant interactions.

MINERALOCORTICOID

ACTIONS AND USES

The mineralocorticoids consist of aldosterone and desoxycorticosterone and play an important role in conserving sodium and increasing the excretion of potassium. Because of these activities, the mineralocorticoids are important in controlling salt and water balance. Aldosterone is the more potent of these two hormones. Deficiencies of the mineralocorticoids result in a loss of sodium and water and a retention of potassium.
Fludrocortisone (Florinef) is a drug that has both glucocorticoid and mineralocorticoid activity and is the only currently available mineralocorticoid drug.

Fludrocortisone is used for replacement therapy for primary and secondary adrenocortical deficiency. Even though this drug has both mineralocorticoid and glucocorticoid activity, it is used only for its mineralocorticoid effects.

### ADVERSE REACTIONS

Adverse reactions may occur if the dosage is too high or prolonged, or if withdrawal is too rapid. A administration of fludrocortisone may cause edema, hypertension, congestive heart failure, enlargement of the heart, increased sweating, or allergic skin rash. Additional adverse reactions include hypokalemia, muscular weakness, headache, and hypersensitivity reactions. Because this drug has glucocorticoid and mineralocorticoid activity and is often given with the glucocorticoids, adverse reactions of the glucocorticoids must be closely monitored as well (see Display 50-2).

### CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Fludrocortisone is contraindicated in patients with hypersensitivity to fludrocortisone and those with systemic fungal infections. Fludrocortisone is used cautiously in patients with Addison’s disease, infection, and during pregnancy (Pregnancy Category C) and lactation. Fludrocortisone decreases the effects of the barbiturates, hydantoins, and rifampin. There is a decrease in serum levels of the salicylates when those agents are administered with fludrocortisone.

### NURSING PROCESS

#### The Patient Receiving a Glucocorticoid or Mineralocorticoid

**ASSESSMENT**

**Preadministration Assessment**

Before administering a glucocorticoid or mineralocorticoid, the nurse takes and records the patient’s blood
pressure, pulse, and respiratory rate. Additional physical assessments depend on the reason for use and the general condition of the patient. When feasible, the nurse performs an assessment of the area of disease involvement, such as the respiratory tract or skin, and records the findings in the patient’s record. These findings provide baseline data for the evaluation of the patient’s response to drug therapy. The nurse weighs patients who are acutely ill and those with a serious systemic disease before starting therapy.

Ongoing Assessment
Ongoing assessments of the patient receiving a glucocorticoid, and the frequency of these assessments, depend largely on the disease being treated. The nurse should take and record vital signs every 4 to 8 hours. The nurse weighs the patient daily to weekly, depending on the diagnosis and the primary health care provider’s orders. The patient’s response to the drug is assessed by daily evaluations. More frequent assessment may be necessary if a glucocorticoid is used for emergency situations. Because these drugs are used to treat a great many diseases and conditions, an evaluation of drug response is based on the patient’s diagnosis and the signs and symptoms of disease.

The nurse assesses for signs of adverse effects of the mineralocorticoid or glucocorticoid, particularly signs of electrolyte imbalance, such as hypocalcemia, hypokalemia, and hypernatremia (see Chap. 58). The nurse assesses the patient's mental status for any change, especially if there is a history of depression or other psychiatric problems or if high doses of the drug are being given. The nurse also monitors for signs of an infection, which may be masked by glucocorticoid therapy. The blood of the patient without diabetes is checked weekly for glucose levels because glucocorticoids may aggravate latent diabetes. Those with diabetes must be checked more frequently.

When administering fludrocortisone, the nurse monitors the patient’s blood pressure at frequent intervals. Hypotension may indicate insufficient dosage. The nurse weighs the patient daily and assesses for edema, particularly swelling of the feet and hands. The lungs are auscultated for adventitious sounds (eg, rales/crackles).

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient include an optimal response to therapy, identification and management of adverse drug effects, and an understanding of the therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

The glucocorticoids may be administered orally, IM, SC, IV, topically, or as an inhalant. The primary health care provider may also inject the drug into a joint (intra-articular), a lesion (intralesional), soft tissue, or bursa. The dosage of the drug is individualized and based on the severity of the condition and the patient’s response.

Daily oral doses are generally given before 9:00 AM to minimize adrenal suppression and to coincide with normal adrenal function. However, alternate-day therapy may be prescribed for patients receiving long-term therapy (see below). Fludrocortisone is given orally and is well tolerated in the GI tract.
The alternate-day therapy approach to glucocorticoid administration is used in the treatment of diseases and disorders requiring long-term therapy, especially the arthritic disorders. This regimen involves giving twice the daily dose of the glucocorticoid every other day. The drug is given only once on the alternate day and before 9 AM. The purpose of alternate-day administration is to provide the patient requiring long-term glucocorticoid therapy with the beneficial effects of the drug while minimizing certain undesirable reactions (see Display 50-2).

Plasma levels of the endogenous adrenocortical hormones vary throughout the day and nighttime hours. They are normally higher between 2 AM and about 8 AM, and lower between 4 PM and midnight. When plasma levels are lower, the anterior pituitary releases ACTH, which in turn stimulates the adrenal cortex to manufacture and release glucocorticoids. When plasma levels are high, the pituitary gland does not release ACTH. The response of the pituitary to high or low plasma levels of glucocorticoids and the resulting release or nonrelease of ACTH is an example of the feedback mechanism, which may also be seen in other glands of the body, such as the thyroid gland. The feedback mechanism (also called the feedback control) is the method by which the body maintains most hormones at relatively constant levels within the bloodstream. When the hormone concentration falls, the rate of production of that hormone increases. Likewise, when the hormone level becomes too high, the body decreases production of that hormone.

Administration of a short-acting glucocorticoid on alternate days and before 9 AM, when glucocorticoid plasma levels are still relatively high, does not affect the release of ACTH later in the day, yet it gives the patient the benefit of exogenous glucocorticoid therapy.

**The Patient with Diabetes.** Patients with diabetes who are receiving a glucocorticoid may require frequent adjustment of their insulin or oral hypoglycemic drug dosage. The nurse monitors blood glucose levels several times daily or as prescribed by the primary health care provider. If the blood glucose levels increase or urine is positive for glucose or ketones, the nurse notifies the primary health care provider. Some patients may have latent (hidden) diabetes. In these cases the corticosteroid may precipitate hyperglycemia. Therefore all patients, those with diabetes and those without, should have frequent checks of blood glucose levels.

**Monitoring and Managing Adverse Reactions**

**Adrenal Insufficiency.** Administration of the glucocorticoids poses the threat of adrenal gland insufficiency (particularly if the alternate-day therapy is not prescribed). Administration of glucocorticoids several times a day and during a short time (as little as 5–10 days) results in shutting off the pituitary release of ACTH because there are always high levels of the glucocorticoids in the plasma (caused by the body’s own glucocorticoid production plus the administration of a glucocorticoid drug). Ultimately, the pituitary atrophies and ceases to release ACTH. Without ACTH, the adrenals fail to manufacture and release (endogenous) glucocorticoids. When this happens, the patient has acute adrenal insufficiency, which is a life-threatening situation until corrected with the administration of an exogenous glucocorticoid.

**Adrenal insufficiency** is a critical deficiency of the mineralocorticoids and the glucocorticoids that requires immediate treatment. Symptoms of adrenal insufficiency include fever, myalgia, arthralgia, malaise, anorexia, nausea, orthostatic hypotension, dizziness, fainting, dyspnea, and hypoglycemia. Death due to circulatory collapse will result unless the condition is treated promptly. Situations producing stress (eg, trauma, surgery, severe illness) may precipitate the need for an increase in dosage of the corticosteroids until the crisis situation or stressful situation is resolved.

**Nursing Alert**

At no time must glucocorticoid therapy be discontinued suddenly. When administration of a glucocorticoid extends beyond 5 days and the drug therapy is to be discontinued, the dosage must be tapered over several days. In some instances, it may be necessary to taper the dose over 7 to 10 or more days. Abrupt discontinuation of glucocorticoid therapy usually results in acute adrenal insufficiency, which, if not recognized in time, can result in death. Tapering the dosage allows normal adrenal function to return gradually, preventing adrenal insufficiency.

**Managing Infection.** The nurse should report any slight rise in temperature, sore throat, or other signs of infection to the primary health care provider as soon as possible because of a possible decreased resistance to infection during glucocorticoid therapy. Nursing personnel and visitors with any type of infection or recent exposure to an infectious disease should avoid patient contact.

**Managing Mental and Emotional Changes.** Mental and emotional changes may occur when the glucocorticoids are administered. The nurse accurately documents mental changes and informs the primary health care provider of their occurrence. Patients who appear extremely depressed must be closely observed. The nurse evaluates mental status, memory, and impaired thinking (eg, changes in orientation, impaired judgment, thoughts of hopelessness, guilt). The nurse allows time for the patient to express feeling and concerns.

**Managing Fluid and Electrolyte Imbalances.** Fluid and electrolyte imbalances, particularly excess fluid volume, are common with corticosteroid therapy. The nurse checks the patient for visible edema, keeps
an accurate fluid intake and output record, obtains a daily weight, and restricts sodium if indicated by the primary health care provider. Edematous extremities are elevated and the patient's position is changed frequently. The nurse informs the primary health care provider if signs of electrolyte imbalance or glucocorticoid drug effects are noted. Dietary adjustments are made for the increased loss of potassium and the retention of sodium if necessary. Consultation with a dietitian may be indicated.

MANAGING ULCERS. Peptic ulcer has been associated with glucocorticoid therapy. The nurse reports to the primary care provider any patient complaints of epigastric burning or pain, bloody or coffee-ground emesis, or the passing of tarry stools. Giving oral corticosteroids with food or a full glass of water may minimize gastric irritation.

MANAGING BODY IMAGE DISTURBANCE. A body image disturbance may occur, especially if the patient experiences cushingoid appearance (buffalo hump, moon face), acne, or hirsutism. If continuation of the drug therapy is necessary, the nurse thoroughly explains the cushingoid appearance reaction and emphasizes the necessity of continuing the drug regimen. The nurse assesses the patient's emotional state and helps the patient to express feelings and concerns. The nurse offers positive reinforcement, when possible. The nurse instructs the patient with acne to keep the affected areas clean and use over-the-counter acne drugs and water-based cosmetics or creams.

Educating the Patient and Family
To prevent noncompliance, the nurse must provide the patient and family with thorough instructions and warnings about the drug regimen.

• These drugs may cause GI upset. To decrease GI effects, take the oral drug with meals or snacks.
• Take antacids between meals to help prevent peptic ulcer.

SHORT-TERM GLUCOCORTICOID THERAPY
• Take the drug exactly as directed in the prescription container. Do not increase, decrease, or omit a dose unless advised to do so by the primary health care provider.
• Take single daily doses before 9:00 AM.
• Follow the instructions for tapering the dose because they are extremely important.
• If the problem does not improve, contact the primary health care provider.

ALTERNATE-DAY GLUCOCORTICOID THERAPY (ORAL)
• Take this drug before 9 AM once every other day. Use a calendar or some other method to identify the days of each week the drug is taken.
• Do not stop taking the drug unless advised to do so by the primary health care provider.
• If the problem becomes worse, especially on the days the drug is not taken, contact the primary health care provider.

Most of the teaching points given below may also apply to alternate-day therapy, especially when higher doses are used and therapy extends over many months.

LONG-TERM OR HIGH-DOSE GLUCOCORTICOID THERAPY
• Do not omit this drug or increase or decrease the dosage except on the advice of the primary health care provider.
• Inform other primary health care providers, dentists, and all medical personnel of therapy with this drug. Wear a medical alert tag or other form of identification to alert medical personnel of long-term therapy with a glucocorticoid.
• Do not take any nonprescription drug unless its use has been approved by the primary health care provider.
• Do not take live virus vaccinations (eg, smallpox) because of the risk of a lack of antibody response. This does not include patients receiving the corticosteroids as replacement therapy.
• Whenever possible, avoid exposure to infections. Contact the primary health care provider if minor cuts or abrasions fail to heal, persistent joint swelling or tenderness is noted, or fever, sore throat, upper respiratory infection, or other signs of infection occur.
• If the drug cannot be taken orally for any reason or if diarrhea occurs, contact the primary health care provider immediately. If you are unable to contact the primary health care provider before the next dose is due, go to the nearest hospital emergency department (preferably where the original treatment was started or where the primary health care provider is on the hospital staff) because the drug has to be given by injection.
• Weigh yourself weekly. If significant weight gain or swelling of the extremities is noted, contact the primary health care provider.
• Remember that dietary recommendations made by the primary health care provider are an important part of therapy and must be followed.
• Follow the primary health care provider’s recommendations regarding periodic eye examinations and laboratory tests.

INTRA-ARTICULAR OR INTRALESIONAL ADMINISTRATION
• Do not overuse the injected joint, even if the pain is gone.
• Follow the primary care provider’s instructions concerning rest and exercise.

MINERALOCORTICOID (FLUDROCORTISONE) THERAPY
• Take the drug as directed. Do not increase or decrease the dosage except as instructed to do so by the primary health care provider.
• Do not discontinue use of the drug abruptly.
• Inform the primary health care provider if the following adverse reactions occur: edema, muscle weakness, weight gain, anorexia, swelling of the extremities, dizziness, severe headache, or shortness of breath.
• Carry patient identification, such as a medical alert tag, so that drug therapy will be known to medical personnel during an emergency situation.
• Keep follow-up appointments to determine if a dosage adjustment is necessary.

EVALUATION
• The therapeutic effect is achieved.
• Adverse reactions are identified, reported to the primary health care provider, and managed appropriately.
• The patient verbalizes an understanding of the dosage regimen.
• The patient verbalizes the importance of complying with the prescribed therapeutic regimen and importance of continued follow-up care.
• The patient and family demonstrate an understanding of the drug regimen.
• The patient demonstrates an understanding of the importance of not suddenly discontinuing therapy (long-term or high-dose therapy).

Critical Thinking Exercises

1. Judy Cowan, age 28 years, has been prescribed clomiphene to induce ovulation and pregnancy. Judy is very anxious and wants desperately to become pregnant. Her husband, Jim, has come to the clinic with her. Discuss assessments the nurse would consider important before initiating treatment with clomiphene. Discuss information the nurse would include in a teaching plan for Jim and Judy.

2. Plan a team conference to discuss the administration of ACTH (corticotropin). Identify three critical points that would be essential to discuss. Explain your rationale for choosing each point.

3. Discuss the rationale for administering oral prednisone at 7 AM every other day.

Review Questions

1. Which of the following adverse reactions would the nurse expect with the administration of clomiphene?
   A. Edema
   B. Vasomotor flushes
   C. Sedation
   D. Hypertension

2. Which of the following assessments would be most important for the nurse to make when a child receiving the growth hormone comes to the primary care provider’s office?
   A. Blood pressure, pulse, and respiration
   B. Diet history
   C. Height and weight
   D. Measurement of abdominal girth

3. Which of the following adverse reactions would lead the nurse to suspect cushingoid appearance in a patient taking a corticosteroid?
   A. Moon face, hirsutism
   B. Kyphosis, periorbital edema
   C. Pallor of the skin, acne
   D. Exophthalmos

4. Which of the following statements, if made by the patient, would indicate a possible adverse reaction seen with the administration of vasopressin?
   A. “I am unable to see well at night.”
   B. “My stomach is cramping.”
   C. “I have a sore throat.”
   D. “I am hungry all the time.”

5. Adverse reactions seen with the administration of fludrocortisone include: _______
   A. hyperactivity and headache
   B. sedation, lethargy
   C. edema, hypertension
   D. dyspnea, confusion

Medication Dosage Problems

1. Methylprednisolone 40 mg IM is prescribed. The drug is available in a suspension for injections in a solution of 20 mg/mL. The nurse prepares to administer _______.

2. Prednisolone 60 mg PO is prescribed. The drug is available as a syrup with 15 mg/5 mL. The nurse administers _______.

On completion of this chapter, the student will:

- Identify the hormones produced by the thyroid gland.
- Discuss the uses, general drug actions, adverse reactions, contraindications, precautions, and interactions of thyroid and antithyroid drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking thyroid and antithyroid drugs.
- List the signs and symptoms of iodism and iodine allergy.
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating patients about the use of thyroid and antithyroid drugs.

The thyroid gland is located in the neck in front of the trachea. This highly vascular gland manufactures and secretes two hormones: thyroxine (T\(_4\)) and triiodothyronine (T\(_3\)). Iodine is an essential element for the manufacture of both of these hormones. The activity of the thyroid gland is regulated by thyroid-stimulating hormone, produced by the anterior pituitary gland (see Fig. 50-1). When the level of circulating thyroid hormones decreases, the anterior pituitary secretes thyroid-stimulating hormone, which then activates the cells of the thyroid to release stored thyroid hormones. This is an example of the feedback mechanism (see Chap. 50).

Two diseases are related to the hormone-producing activity of the thyroid gland:

- **Hypothyroidism**—a decrease in the amount of thyroid hormones manufactured and secreted.
- **Hyperthyroidism**—an increase in the amount of thyroid hormones manufactured and secreted.

The symptoms of hypothyroidism and hyperthyroidism are given in Table 51-1. A severe form of hyperthyroidism, called thyrotoxicosis or thyroid storm, is characterized by high fever, extreme tachycardia, and altered mental status. Thyroid hormones are used to treat hypothyroidism and antithyroid drugs and radioactive iodine are used to treat hyperthyroidism.

**THYROID HORMONES**

Thyroid hormones used in medicine include both the natural and synthetic hormones. The synthetic hormones are generally preferred because they are more uniform in potency than are the natural hormones obtained from animals. Thyroid hormones are listed in the Summary Drug Table: Thyroid and Antithyroid Drugs.

**ACTIONS**

The thyroid hormones influence every organ and tissue of the body. These hormones are principally concerned with increasing the metabolic rate of tissues, which results in increases in the heart and respiratory rate, body temperature, cardiac output, oxygen consumption, and the metabolism of fats, proteins, and carbohydrates. The exact mechanisms by which the thyroid hormones exert their influence on body organs and tissues are not well understood.
Thyroid hormones are used as replacement therapy when the patient is hypothyroid. By supplementing the decreased endogenous thyroid production and secretion with exogenous thyroid hormones, an attempt is made to create a euthyroid (normal thyroid) state. Levothyroxine (Synthroid) is the drug of choice for hypothyroidism because it is relatively inexpensive, requires once-a-day dosages, and has a more uniform potency than do other thyroid hormone replacement drugs.

Myxedema is a severe hypothyroidism manifested by lethargy, apathy, memory impairment, emotional changes, slow speech, deep coarse voice, thick dry skin, cold intolerance, slow pulse, constipation, weight gain, and absence of menses.

Thyroid hormones are also used in the treatment or prevention of various types of euthyroid goiters (enlargement of the thyroid gland), including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's), and multinodular goiter and in the management of thyroid cancer. The hormone may be used with the antithyroid drugs to treat thyrotoxicosis. Thyroid hormones also may be used as a diagnostic measure to differentiate suspected hyperthyroidism from euthyroidism.

During initial therapy, the most common adverse reactions seen are signs of overdose and hyperthyroidism (see Table 51-1). Adverse reactions other than symptoms of hyperthyroidism are rare.

These drugs are contraindicated in patients with known hypersensitivity to the drug or to any constituents of the drug, after a recent myocardial infarction (heart attack), or in patients with thyrotoxicosis. When hypothyroidism is a cause or contributing factor to a myocardial infarction or heart disease, the physician may prescribe small doses of thyroid hormone.

These drugs are used cautiously in patients with Addison's disease and during lactation. The thyroid hormones are classified as Pregnancy Category A and are considered safe to use during pregnancy.

When administered with cholestyramine or colestipol there is a decreased absorption of the oral thyroid preparations. These drugs should not be administered within 4 of 6 hours of the thyroid hormones. When administered with the oral anticoagulants there is an increased risk of bleeding. It may be advantageous to decrease the dosage of the anticoagulant when a thyroid preparation is prescribed. There is a decreased effectiveness of the digitalis preparation if taken with a thyroid preparation.

**Table 51-1 Signs and Symptoms of Thyroid Dysfunction**

<table>
<thead>
<tr>
<th>BODY SYSTEM OR FUNCTION</th>
<th>HYPOTHYROIDISM</th>
<th>HYPERTHYROIDISM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolism</td>
<td>Decreased with anorexia, intolerance to cold, low body temperature, weight gain despite anorexia</td>
<td>Increased with increased appetite, intolerance to heat, elevated body temperature, weight loss despite increased appetite</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>Bradycardia, moderate hypotension</td>
<td>Tachycardia, moderate hypertension</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>Lethargy, sleepiness</td>
<td>Nervousness, anxiety, insomnia, tremors</td>
</tr>
<tr>
<td>Skin, skin structures</td>
<td>Pale, cool, dry skin; face appears puffy; hair coarse; nails thick and hard</td>
<td>Flushed, warm, moist skin</td>
</tr>
<tr>
<td>Ovarian function</td>
<td>Heavy menses, may be unable to conceive, loss of fetus possible</td>
<td>Irregular or scant menses</td>
</tr>
<tr>
<td>Testicular function</td>
<td>Low sperm count</td>
<td></td>
</tr>
</tbody>
</table>

**ADVERSE REACTIONS**

**USES**

**CONTRAINDICATIONS**

**PRECAUTIONS**

**INTERACTIONS**
### Thyroid Hormones

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>levothyroxine sodium (T\textsubscript{4})</td>
<td>Eltroxin, Levo-T, Levoxyl, Synthroid, generic</td>
<td>Hypothyroidism, thyrotoxicosis</td>
<td>Palpitations, tachycardia, headache, nervousness, insomnia, diarrhea, vomiting, weight loss, sweating, heat intolerance</td>
<td>0.025—0.3 mg/d PO; 0.05—0.1 mg IV; 0.05 mg initially, increase by 0.025 mg PO &amp; 2–3 wk; maintenance dose, 0.2 mg/d, may substitute IV IM</td>
</tr>
<tr>
<td>liothyronine sodium (T\textsubscript{3})</td>
<td>Cytomel, generic</td>
<td>Hypothyroidism, thyrotoxicosis</td>
<td>Same as levothyroxine</td>
<td>5–75 mcg/d PO, 25–50 μg IV q4–12h</td>
</tr>
<tr>
<td>liotrix (T\textsubscript{2}, T\textsubscript{4})</td>
<td>Armour Thyroid, generic</td>
<td>Hypothyroidism, thyrotoxicosis</td>
<td>Same as levothyroxine</td>
<td>15–120 mg/d PO</td>
</tr>
</tbody>
</table>

### Antithyroid Preparations

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>methimazole</td>
<td>Tapazole, generic</td>
<td>Hyperthyroidism</td>
<td>Agranulocytosis, headache, exfoliative dermatitis, granulocytopenia, thrombocytopenia, hepatitis, hypoprothrombinemia, jaundice, loss of hair, nausea, vomiting</td>
<td>15–60 mg/d</td>
</tr>
<tr>
<td>propylthiouracil (PTU)</td>
<td>PTU generic</td>
<td>Same as methimazole</td>
<td>Same as methimazole</td>
<td>300–900 mg/d PO, usually in divided doses at about 8-h intervals</td>
</tr>
</tbody>
</table>

### Iodine Products

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>strong iodine solution</td>
<td>Lugol’s Solution, Thyro-Block, generic</td>
<td>To prepare hyperthyroid patients for thyroid surgery, thyrotoxic crisis, thyroid blocking in radiation therapy</td>
<td>Rash, swelling of salivary glands, ‘iodism’ (metallic taste, burning mouth and throat, sore teeth and gums, symptoms of a head cold, diarrhea, nausea), allergic reactions (fever, joint pains, swelling of parts of face and body)</td>
<td>2–6 drops PO TID for 10 d before surgery; 130 mg/d PO</td>
</tr>
<tr>
<td>Sodium iodine (\textsuperscript{131}I)</td>
<td>Iodotope, generic</td>
<td>Thyrotoxicosis, selected cases of thyroid cancer</td>
<td>Bone marrow depression, anemia, blood dyscrasias, nausea, vomiting, tachycardia, itching, rash, hives, tenderness and swelling of the neck, sore throat, and cough</td>
<td>Measured by a radioactivity calibration system before administering PO 4–10 mCi; thyroid cancer: 50–150 mCi</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.*
CHAPTER 51
Thyroid and Antithyroid Drugs

533

The Patient Receiving a Thyroid Hormone

ASSESSMENT

Preadministration Assessment
After a patient receives a diagnosis of hypothyroidism and before therapy starts, the nurse takes vital signs and weighs the patient. A history of the patient’s signs and symptoms is obtained. The nurse performs a general physical assessment to determine outward signs of hypothyroidism.

Gerontologic Alert

The symptoms of hypothyroidism may be confused with symptoms associated with aging, such as depression, cold intolerance, weight gain, confusion, or unsteady gait. The presence of these symptoms should be thoroughly evaluated and documented in the preadministration assessment and periodically throughout therapy.

Ongoing Assessment
The full effects of thyroid hormone replacement therapy may not be apparent for several weeks or more, but early effects may be apparent in as little as 48 hours. During the ongoing assessment, the nurse monitors the vital signs daily or as ordered and observes the patient for signs of hyperthyroidism, which is a sign of excessive drug dosage. Signs of a therapeutic response include weight loss, mild diuresis, a sense of well-being, increased appetite, an increased pulse rate, an increase in mental activity, and decreased puffiness of the face, hands, and feet.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to therapy, identification of adverse reactions, and an understanding of and compliance with the prescribed therapeutic regimen.

Nursing Diagnoses Checklist

- Decreased Cardiac output related to adverse reactions
- Anxiety related to symptoms, adverse reactions, treatment regimen, other (specify)

IMPLEMENTATION

Promoting an Optimal Response to Therapy
Thyroid hormones are administered once a day, early in the morning and preferably before breakfast. An empty stomach increases the absorption of the oral preparation. Levothyroxine (Synthroid) also can be given intravenously and is prepared for administration immediately before use.

The dosage is individualized to the needs of the patient. The dose of thyroid hormones must be carefully adjusted according to the patient’s hormone requirements. At times, several upward or downward dosage adjustments must be made until the optimal therapeutic dosage is reached and the patient becomes euthyroid.

Some patients may exhibit anxiety related to the symptoms of their disorder, as well as concern about relief of their symptoms. The patient should be reassured that although relief may not be immediate, symptoms should begin to decrease or even disappear in a few weeks.

Monitoring and Managing Adverse Reactions
The nurse monitors the patient for any adverse reactions, especially during the initial stages of dosage adjustment. The nurse notifies the primary health care provider if the patient experiences these or any adverse drug reactions. If the dosage is inadequate the patient will continue to experience signs of hypothyroidism (see Table 51-1). If the dosage is excessive, the patient will exhibit signs of hyperthyroidism.

Nursing Alert

If signs of hyperthyroidism (eg, nervousness, anxiety, increased appetite, elevated body temperature, tachycardia, moderate hypertension or flushed, warm, moist skin) are apparent, the nurse reports these to the primary health care provider before the next dose is due because it may be necessary to decrease the daily dosage.

Thyroid hormone replacement therapy in patients with diabetes may increase the intensity of the symptoms or the diabetes. The nurse closely monitors the patient with diabetes during thyroid hormone replacement therapy for signs of hyperglycemia (see Chap. 49) and notifies the primary health care provider if this problem occurs.

The nurse carefully observes patients with cardiovascular disease taking the thyroid hormones. The development of chest pain or worsening of cardiovascular disease should be reported to the primary health care provider immediately because the patient may require a reduction in the dosage of the thyroid hormone.
UNIT IX  Drugs That Affect the Endocrine System

Educating the Patient and Family
Thyroid hormones are usually given on an outpatient basis. The nurse emphasizes the importance of taking the drug exactly as directed and not stopping the drug even though symptoms have improved. The nurse provides the following information to the patient and family when thyroid hormone replacement therapy is prescribed:

- Replacement therapy is for life, with the exception of transient hypothyroidism seen in those with thyroiditis.
- Do not increase, decrease, or skip a dose unless advised to do so by the primary health care provider.
- Take this drug in the morning, preferably before breakfast, unless advised by the primary health care provider to take it at a different time of day.
- Notify the primary health care provider if any of the following occur: headache, nervousness, palpitations, diarrhea, excessive sweating, heat intolerance, chest pain, increased pulse rate, or any unusual physical change or event.
- The dosage of this drug may require periodic adjustments; this is normal. Dosage changes are based on a response to therapy and thyroid function tests.
- Therapy needs to be evaluated at periodic intervals, which may vary from every 2 weeks during the beginning of therapy to every 6 to 12 months once symptoms are controlled. Periodic thyroid function tests will be needed.
- Weigh yourself weekly and report any significant weight gain or loss to the primary health care provider.
- Do not change from one brand of this drug to another without consulting the primary health care provider.

EVALUATION
- The therapeutic effect is achieved.
- Adverse reactions are identified and reported to the primary health care provider.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.
- The patient verbalizes an understanding of the treatment modalities and importance of continued follow-up care.
- The patient and family demonstrate an understanding of the drug regimen.

ANTITHYROID DRUGS
Antithyroid drugs or thyroid antagonists are used to treat hyperthyroidism. In addition to the antithyroid drugs, hyperthyroidism may be treated by the administration of strong iodine solutions, use of radioactive iodine (131I), or by surgical removal of some or almost all of the thyroid gland (subtotal thyroidectomy).

ACTIONS
Antithyroid drugs inhibit the manufacture of thyroid hormones. They do not affect existing thyroid hormones that are circulating in the blood or stored in the thyroid gland. For this reason, therapeutic effects of the antithyroid drugs may not be observed for 3 to 4 weeks. Antithyroid drugs are listed in the Summary Drug Table: Thyroid and Antithyroid Drugs.

Strong iodide solutions act by decreasing the vascularity of the thyroid gland by rapidly inhibiting the release of the thyroid hormones. Radioactive iodine is distributed within the cellular fluid and excreted. The radioactive isotope accumulates in the cells of the thyroid gland, where destruction of thyroid cells occurs without damaging other cells throughout the body.

USES
Methimazole (Tapazole) and propylthiouracil (PTU) are used for the medical management of hyperthyroidism. Not all patients respond adequately to antithyroid drugs; therefore, a thyroidectomy may be necessary. Antithyroid drugs may be administered before surgery to temporarily return the patient to a euthyroid state. When used for this reason, the vascularity of the thyroid gland is reduced and the tendency to bleed excessively during and immediately after surgery is decreased.

Strong iodine solution, also known as Lugol’s solution, may be given orally with methimazole or propylthiouracil to prepare for thyroid surgery. Iodine solutions are also used for rapid treatment of hyperthyroidism because they can decrease symptoms in 2 to 7 days. Radioactive iodine (131I) may be used for treatment of hyperthyroidism and selected cases of cancer of the thyroid. The drug is given orally either as a solution or in a gelatin capsule.
ADVERSE REACTIONS

Methimazole and Propylthiouracil
The most serious adverse reaction associated with these drugs is agranulocytosis (decrease in the number of white blood cells [eg, neutrophils, basophils, and eosinophils]). Reactions observed with agranulocytosis include hay fever, sore throat, skin rash, fever, or headache. Other major reactions include exfoliative dermatitis, granulocytopenia, aplastic anemia, hypoprothrombinemia, and hepatitis. Minor reactions, such as nausea, vomiting, and paresthesias, also may be seen.

Strong Iodine Solutions
Reactions that may be seen with strong iodine solution include symptoms of iodism (excessive amounts of iodine in the body), which are a metallic taste in the mouth, swelling and soreness of the parotid glands, burning of the mouth and throat, sore teeth and gums, symptoms of a head cold, and occasionally gastrointestinal upset. A allergy to iodine may also be seen and can be serious. Symptoms of iodine allergy include swelling of parts of the face and body, fever, joint pains, and sometimes difficulty in breathing. Difficulty breathing requires immediate medical attention.

Radioactive Iodine ($^{131}$I)
Reactions after administration of $^{131}$I include sore throat, swelling in the neck, nausea, vomiting, cough, and pain on swallowing. Other reactions include bone marrow depression, anemia, leukopenia, thrombocytopenia, and tachycardia.

CONTRAINDICATIONS
The antithyroid drugs are contraindicated in patients with hypersensitivity to the drug or any constituent of the drug. Methimazole and propylthiouracil are contraindicated during pregnancy and lactation. Radioactive iodine is contraindicated during pregnancy (Pregnancy Category X) and lactation.

PRECAUTIONS
Methimazole and propylthiouracil are used with extreme caution during pregnancy (Pregnancy Category D) because they can cause hypothyroidism in the fetus. However, if an antithyroid drug is necessary during pregnancy or lactation, propylthiouracil is the drug most often prescribed. In many pregnant women thyroid dysfunction diminishes as the pregnancy proceeds, making a dosage reduction possible. Methimazole and propylthiouracil are used cautiously in patients older than 40 years because there is an increased risk of agranulocytosis and in patients with a decrease in bone marrow reserve (eg, after radiation therapy for cancer). Strong iodine preparations (except $^{131}$I) are classified as Pregnancy Category D and are used cautiously during pregnancy.

INTERACTIONS
There is an additive bone marrow depression when methimazole or propylthiouracil is administered with other bone marrow depressants, such as the antineoplastic drugs, or with radiation therapy. When methimazole is administered with digitalis, there is an increased effectiveness of the digitalis and increased risk of toxicity. There is an additive effect of propylthiouracil when the drug is administered with lithium, potassium iodide, or sodium iodide. When iodine products are administered with lithium products, synergistic hypothyroid activity is likely to occur.

NURSING PROCESS

The Patient Receiving an Antithyroid Drug

ASSESSMENT

Preadministration Assessment
Before a patient starts therapy with an antithyroid drug, the nurse obtains a history of the symptoms of hyperthyroidism. It is important to include vital signs, weight, and a notation regarding the outward symptoms of the hyperthyroidism (see Table 51-1) in the physical assessment. If the patient is prescribed an iodine solution, it is essential that the nurse take a careful allergy history, particularly to iodine or seafood (which contains iodine).

Ongoing Assessment
During the ongoing assessment, the nurse observes the patient for adverse drug effects. During short-term therapy before surgery, adverse drug reactions are usually minimal. Long-term therapy is usually on an outpatient basis. The nurse questions the patient regarding relief of symptoms, as well as signs or symptoms indicating an adverse reaction related to the blood cells, such as fever, sore throat, easy bruising or bleeding, fever, cough, or any other signs of infection. As the patient becomes euthyroid, signs and symptoms of hyperthyroidism become less obvious. The nurse observes the patient for signs of thyroid storm (high fever, extreme tachycardia, and altered mental status), which can occur in patients whose hyperthyroidism is inadequately treated.
UNIT IX  Drugs That Affect the Endocrine System

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to therapy, identification and management of adverse reactions, and an understanding of and compliance with the prescribed drug regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

The patient with an enlarged thyroid gland may have difficulty swallowing the tablet. If this occurs, the nurse discusses the problem with the primary health care provider. Strong iodine solution is measured in drops, which are added to water or fruit juice. This drug has a strong, salty taste. The patient is allowed to experiment with various types of fruit juices to determine which one best disguises the taste of the drug. Iodine solutions should be drunk through a straw because they may cause tooth discoloration.

Radioactive iodine is given by the primary health care provider, orally as a single dose. The effects of iodides are evident within 24 hours, with maximum effects attained after 10 to 15 days of continuous therapy. If the patient is hospitalized, radiation safety precautions identified by the hospital’s department of nuclear medicine are followed.

Once a euthyroid state is achieved, the primary health care provider may add a thyroid hormone to the therapeutic regimen to prevent or treat hypothyroidism, which may develop slowly during long-term antithyroid drug therapy or after administration of 131I.

The patient with hyperthyroidism is likely to have cardiac symptoms such as tachycardia or palpitations. Propranolol, an adrenergic blocking drug (see Chap. 21), may be prescribed by the primary health care provider as adjunctive treatment for several weeks until the therapeutic effects of the antithyroid drug are obtained.

The patient with hyperthyroidism may be concerned with the results of medical treatment and with the problem of taking the drug at regular intervals around the clock (usually every 8 hours). Whereas some patients may be awake early in the morning and retire late at night, others may experience difficulty in an 8-hour dosage schedule. A further concern may be a tendency to forget the first dose early in the morning, thus causing a problem with the two following doses.

If the patient expresses a concern about the dosage schedule, the nurse may be able to offer suggestions. For example, the nurse suggests the following 8-hour interval schedule: 7 AM, 3 PM, and 11 PM. The nurse may also suggest posting a notice on a bathroom mirror to remind the individual that the first dose is due immediately after rising. After a week or more of therapy, most patients remember to take their morning dose on time. If the first or last dose interferes with sleep, the nurse should suggest the patient discuss this with the primary health care provider.

Monitoring and Managing Adverse Drug Reactions

The nurse monitors the patient throughout therapy for adverse drug reactions. The nurse monitors the patient frequently for signs of agranulocytosis. It is important that the patient be protected from individuals with infectious disease because if agranulocytosis is present, the patient is at increased risk of contracting any infection, particularly an upper respiratory infection. The nurse monitors for signs of infection, particularly upper respiratory infection in visitors and other health care personnel.

If the patient experiences a rash while taking methimazole or propylthiouracil, the nurse carefully documents the affected areas, noting size, texture, and extent of the rash, and reports the occurrence of the rash to the primary health care provider. Soothing creams or lubricants may be applied, and soap is used sparingly, if at all, until the rash subsides.

When iodine solutions are administered, the nurse observes the patient closely for symptoms of iodism and iodine allergy (see Adverse Reactions). If these occur, the nurse withholds the drug and immediately notifies the primary health care provider. This is especially important if swelling around or in the mouth or difficulty in breathing occurs.

Educating the Patient and Family

The nurse reviews with the patient and family the dosage and times the drug is to be taken. The following additional teaching points are included in a teaching plan.

---

<table>
<thead>
<tr>
<th>Nursing Diagnoses Checklist</th>
</tr>
</thead>
<tbody>
<tr>
<td>✅ Risk for Infection related to adverse drug reactions</td>
</tr>
<tr>
<td>✅ Risk for Impaired Skin Integrity related to adverse reactions</td>
</tr>
</tbody>
</table>

---

(custom notice or content not clearly readable in the image)
CHAPTER 51  Thyroid and Antithyroid Drugs

METHIMAZOLE AND PROPYLTHIOURACIL

- Take these drugs at regular intervals around the clock (e.g., every 8 hours) unless directed otherwise by the primary health care provider.
- Do not take these drugs in larger doses or more frequently than as directed on the prescription container.
- Notify the primary health care provider promptly if any of the following occur: sore throat, fever, cough, easy bleeding or bruising, headache, or a general feeling of malaise.
- Record weight twice a week and notify the primary health care provider if there is any sudden weight gain or loss. (Note: the primary health care provider may also want the patient to monitor pulse rate. If this is recommended, the patient needs instruction in the proper technique and a recommendation to record the pulse rate and bring the record to the primary health care provider’s office or clinic.)
- Avoid the use of nonprescription drugs unless the primary health care provider has approved the use of a specific drug.

STRONG IODINE SOLUTION

- Dilute the solution with water or fruit juice. Fruit juice often disguises the taste more than water does. Experiment with the types of fruit juice that best reduce the unpleasant taste of this drug.
- Discontinue the use of this drug and notify the primary health care provider if any of the following occur: skin rash, metallic taste in the mouth, swelling and soreness in front of the ears, sore teeth and gums, severe gastrointestinal distress, or symptoms of a head cold.

RADIOACTIVE IODINE

- Follow the directions of the department of nuclear medicine regarding precautions to be taken. (Note: In some instances, the dosage is small and no special precautions may be necessary.)
- Thyroid hormone replacement therapy may be necessary if hypothyroidism develops.
- Follow-up evaluations of the thyroid gland and the effectiveness of treatment with this drug are necessary.

EVALUATION

- The therapeutic effect is achieved.
- Adverse reactions are identified and reported to the primary health care provider.
- Anxiety is reduced.
- The patient verbalizes an understanding of the dosage regimen.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.
- The patient and family demonstrate an understanding of the drug regimen.

- Critical Thinking Exercises

1. Ms. Hartman, age 47 years, has been prescribed levothyroxine (Synthroid) for hypothyroidism. Develop a teaching plan for Ms. Hartman that would provide her with the knowledge she needs to maintain a therapeutic treatment regimen.

2. Mr. Conrad will receive a dose of radioactive iodine from the primary health care provider. Discuss how you would prepare Mr. Conrad before the drug is administered. In preparation for dismissal, analyze the most important points to stress to Mr. Conrad about radioactive iodine.

3. Ms. Coker, age 38 years, is prescribed methimazole for hyperthyroidism. Discuss important preadministration assessments for Ms. Coker.

- Review Questions

1. What adverse reaction is most likely to occur in the early days of therapy in a patient taking a thyroid hormone?
   A. Congestive heart failure
   B. Hyperthyroidism
   C. Hypothyroidism
   D. Euthyroidism

2. The nurse informs the patient that therapy with a thyroid hormone may not produce a therapeutic response for ______.
   A. 24 to 48 days
   B. 1 to 3 days
   C. several weeks or more
   D. 8 to 12 months

3. Which of the following symptoms best indicates that serious adverse reactions are developing in a patient receiving methimazole (Tapazole)?
   A. Fever, sore throat, bleeding from an injection site
   B. Cough, periorbital edema, constipation
   C. Constipation, anorexia, blurred vision
   D. Unsteady gait, blurred vision, insomnia

4. Which of the following statements made by a patient would indicate to the nurse that the patient is experiencing an adverse reaction to radioactive iodine?
   A. “I am sleepy most of the day.”
   B. “I am unable to sleep at night.”
   C. “My throat hurts when I swallow.”
   D. “My body aches all over.”

- Medication Dosage Problems

1. Methimazole 60 mg is prescribed. The drug is available in 10-mg tablets. The nurse administers ______.

2. Levothyroxine 0.2 mg PO is prescribed. Available are 0.1 mg tablets. The nurse administers ______.
Male and female hormones play a vital role because they aid in development and maintenance of secondary sex characteristics and are necessary for human reproduction. Although hormones are naturally produced by the body, administration of a male or female hormone may be indicated in the treatment of certain disorders, such as inoperable breast cancer, male hypogonadism, and male or female hormone deficiency. Hormones also are used as contraceptives and for treating the symptoms of menopause.

**MALE HORMONES**

Male hormones—testosterone and its derivatives—are collectively called androgens. Androgen secretion is under the influence of the anterior pituitary gland. Small amounts of male and female hormones are also produced by the adrenal cortex (see Chap. 50). The anabolic steroids are closely related to the androgen testosterone and have both androgenic and anabolic (stimulate cellular growth and repair) activity. Androgen hormone inhibitors inhibit the conversion of testosterone into a potent androgen.

**ANABOLISM**

The male hormone testosterone and its derivatives actuate the reproductive potential in the adolescent boy. From puberty onward, androgens continue to aid in the development and maintenance of secondary sex characteristics: facial hair, deep voice, body hair, body fat distribution, and muscle development. Testosterone also stimulates the growth in size of the accessory sex organs (penis, testes, vas deferens, prostate) at the time of puberty. The androgens also promote tissue-building processes (anabolism) and reverse tissue-depleting processes (catabolism). Examples of androgens are fluoxymesterone (Halotestin), methyltestosterone (Oreton Methyl), and testosterone. Additional examples of androgens are given in the Summary Drug Table: Male Hormones.

**Anabolic Steroids**

The anabolic steroids are synthetic drugs chemically related to the androgens. Like the androgens, they promote tissue-building processes. Given in normal doses,
### SUMMARY DRUG TABLE \ MALE HORMONES

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Androgens</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fluoxymesterone</td>
<td>Halotestin</td>
<td>Males: hypogonadism, Females: inoperable breast cancer</td>
<td>Males: gynecomastia, testicular atrophy, inhibition of testicular function, impotence, enlargement of the penis, nausea, jaundice, headache, anxiety, male pattern baldness, acne, depression Females: amenorrhea, virilization</td>
<td>Males: hypogonadism 5–20 mg/d PO Females: breast cancer, 10–40 mg/d PO in divided doses</td>
</tr>
<tr>
<td></td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>methyltestosterone</td>
<td>Android, Methitest, Vinlon, generic</td>
<td>Males: hypogonadism, male climacteric, impotence, androgen deficiency, postpubertal cryptorchidism Females: breast cancer, enlargement of the penis, nausea, jaundice, headache, anxiety, male pattern baldness, acne, depression</td>
<td>Same as fluoxymesterone</td>
<td>Males: 10–50 mg/d PO, 5–25 mg/d buccal tablets Females: 50–200 mg/d PO, 25–100 mg/d buccal tablets</td>
</tr>
<tr>
<td>testosterone</td>
<td>Androgel</td>
<td>Males: delayed puberty, androgen replacement theory, hypogonadism Females: palliation of inoperable breast cancer</td>
<td>Same as fluoxymesterone</td>
<td>5–10 mg/d applied to any skin</td>
</tr>
<tr>
<td>gel</td>
<td>tess-toss-ter-one</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>testosterone</td>
<td>Depo-Testosterone, generic</td>
<td>Males: hypogonadism, delayed puberty Females: palliation of inoperable breast cancer</td>
<td>Same as fluoxymesterone</td>
<td>Males: 50–400 mg/dose IM; Females: 200–400 mg/dose IM</td>
</tr>
<tr>
<td>cypionate (in oil)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>testosterone</td>
<td>Delastryl</td>
<td>Same as testosterone cypionate</td>
<td>Same as fluoxymesterone</td>
<td>50–400 mg IM q2–4 wk One system applied daily</td>
</tr>
<tr>
<td>enanthate</td>
<td>Androderm, Testoderm, Testoderm TTS</td>
<td>Males: androgen replacement therapy</td>
<td>Same as fluoxymesterone</td>
<td></td>
</tr>
<tr>
<td>testosterone</td>
<td>Androderm Transdermal System</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anabolic Steroids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nandrolone</td>
<td>Deca-Durabolin, generic</td>
<td>Management of anemia of renal insufficiency</td>
<td>Acne, nausea, vomiting, fluid and electrolyte imbalances, jaundice, anorexia, muscle cramps, malignant and benign liver tumors, increased risk of atherosclerosis, mental changes, testicular atrophy, virilization (females)</td>
<td>50–200 mg/wk IM</td>
</tr>
<tr>
<td>decanoate</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>oxymetholone</td>
<td>Anadrol-50</td>
<td>Anemia</td>
<td>Same as nandrolone decanoate</td>
<td>1–5 mg/kg/d PO</td>
</tr>
<tr>
<td>oxandrolone</td>
<td>Oxandrin</td>
<td>Promote weight gain in those with weight loss after extensive surgery, severe trauma, severe infections</td>
<td>Same as nandrolone decanoate</td>
<td>2.5 mg PO BID to QID</td>
</tr>
<tr>
<td>stanozolol</td>
<td>Winstrol</td>
<td>Hereditary angioedema</td>
<td>Same as nandrolone decanoate</td>
<td>2 mg PO TID, then reduce to 2 mg/d or to 2 mg/d every other d PO</td>
</tr>
<tr>
<td><strong>Androgen Hormone Inhibitor</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>finasteride</td>
<td>Proscar</td>
<td>Benign prostatic hypertrophy, prevention of male pattern baldness</td>
<td>Impotence, decreased libido, decreased volume of ejaculate</td>
<td>5 mg/d PO</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.*
they have a minimal effect on the accessory sex organs and secondary sex characteristics. Examples of anabolic steroids are given in the Summary Drug Table: Male Hormones.

**Androgen Hormone Inhibitor**

The androgen hormone inhibitor finasteride (Proscar) is a synthetic compound drug that inhibits the conversion of testosterone into the potent androgen 5 alpha (\(5\alpha\))-dihydrotestosterone (DHT). The development of the prostate gland is dependent on DHT. The lowering of serum levels of DHT reduces the effect of this hormone on the prostate gland, resulting in a decrease in the size of the gland and the symptoms associated with prostatic gland enlargement.

**USES**

**Androgens**

In the male patient, androgen therapy may be given as replacement therapy for testosterone deficiency. Deficiency states in male patients, such as hypogonadism (failure of the testes to develop), selected cases of delayed puberty, and the development of testosterone deficiency after puberty may be treated with androgens. The transdermal testosterone system is used as replacement therapy when endogenous testosterone is deficient or absent.

In the female patient, androgen therapy may be used as part of the treatment for inoperable metastatic breast carcinoma in women who are 1 to 5 years past menopause. In addition, some breast carcinomas in women are “hormone-dependent” tumors, that is, their growth and spread are influenced by the female hormone estrogen. Administration of an androgen to patients with this type of malignant breast tumor counters the effect of estrogen on these tumors. Androgens may also be administered to premenopausal women with metastatic breast carcinoma that is believed to be hormone dependent and whose tumor growth and spread have been slowed after an oophorectomy (removal of the ovaries). The uses of the androgens are listed in the Summary Drug Table: Male Hormones.

**Anabolic Steroids**

The uses of the various anabolic steroids include management of anemia of renal insufficiency, control of metastatic breast cancer in women, and promotion of weight gain in those with weight loss after surgery, trauma, or infections. Stanozolol is used prophylactically to decrease the frequency and severity of hereditary angioedema (a condition characterized by urticaria and edematous areas of the skin, mucous membranes, or viscera).

**Nursing Alert**

The use of anabolic steroids to promote an increase in muscle mass and strength has become a serious problem. Anabolic steroids are not intended for this use. Unfortunately, deaths in young, healthy individuals have been directly attributed to the use of these drugs. Nurses should discourage the illegal use of anabolic steroids to increase muscle mass.

**Androgen Hormone Inhibitor**

Finasteride is used in the treatment of the symptoms associated with benign prostatic hypertrophy (BPH), such as difficulty starting the urinary stream, frequent passage of small amounts of urine, and having to urinate during the night (nocturia). Several months of therapy may be required before a significant improvement is noted and symptoms of BPH decrease. Finasteride is also used for the prevention of male pattern baldness in men with early signs of hair loss.

**ADVERSE REACTIONS**

**Androgens**

In men, administration of an androgen may result in breast enlargement (gynecomastia), testicular atrophy, inhibition of testicular function, impotence, enlargement of the penis, nausea, jaundice, headache, anxiety, male pattern baldness, acne, and depression. Fluid and electrolyte imbalances, which include sodium, water, chloride, potassium, calcium, and phosphate retention, may also be seen.

In women receiving an androgen preparation for breast carcinoma, the most common adverse reactions are amenorrhea, other menstrual irregularities, and virilization (acquisition of male sexual characteristics by a woman). Virilization produces facial hair, a deepening of the voice, and enlargement of the clitoris. Male pattern baldness and acne may also be seen.

**Anabolic Steroids**

Virilization in the woman is the most common reaction associated with anabolic steroids, especially when higher doses are used. Acne occurs frequently in all age groups and both sexes. Nausea, vomiting, diarrhea, fluid and electrolyte imbalances (the same as for the androgens, discussed previously), testicular atrophy,
jaundice, anorexia, and muscle cramps may also be seen. Blood-filled cysts of the liver and sometimes the spleen, malignant and benign liver tumors, an increased risk of atherosclerosis, and mental changes are the most serious adverse reactions that may occur during prolonged use.

Many serious adverse drug reactions are being reported in healthy individuals using anabolic steroids. There is some indication that prolonged high-dose use has resulted in psychological and possibly physical addiction, and some individuals have required treatment in drug abuse centers. Severe mental changes, such as uncontrolled rage, severe depression, suicidal tendencies, malignant and benign liver tumors, aggressive behavior, increased risk of atherosclerosis, inability to concentrate, and personality changes are not uncommon. In addition, the incidence of the severe adverse reactions cited earlier appears to be increased in those using anabolic steroids for this purpose.

### Androgen Hormone Inhibitor

Adverse reactions with finasteride usually are mild and do not require discontinuing use of the drug. Adverse reactions, when they occur, are related to the sexual drive and include impotence, decreased libido, and a decreased volume of ejaculate.

### CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

#### Androgens

The androgens are contraindicated in patients with known hypersensitivity to the drugs, liver disorders, or serious cardiac disease, and in men with prostate gland disorders (eg, prostate carcinoma and prostate enlargement). The androgens are classified as Pregnancy Category X drugs and should not be administered during pregnancy and lactation. When the androgens are administered with anticoagulants, the anticoagulant effect may be increased.

#### Anabolic Steroids

The anabolic steroids are contraindicated in patients with known hypersensitivity to the drugs, liver disorders, or serious cardiac disease, and in men with prostate gland disorders (eg, prostate carcinoma and prostate enlargement). The anabolic steroids are classified as Pregnancy Category X drugs and should not be administered during pregnancy and lactation. Anabolic steroids are contraindicated when used to enhance physical appearance or athletic performance.
ANDROGEN HORMONE INHIBITOR. The nurse questions the patient at length about symptoms of BPH, such as frequency of voiding during the day and night and difficulty starting the urinary stream. The nurse records all symptoms in the patient’s chart.

Ongoing Assessment
The ongoing assessment depends on the reason the drug was prescribed and the condition of the patient. Men receiving an androgen or anabolic steroid are questioned by the primary health care provider or nurse regarding the effectiveness of drug therapy.

The nurse weighs the patient with inoperable breast carcinoma daily or as ordered by the primary health care provider. If the patient is on complete bed rest, the nurse may take weights every 3 to 4 days (or as ordered) using a bed scale. The nurse notifies the primary health care provider if there is a significant (≥5 lb) increase or decrease in the weight. The nurse checks the lower extremities daily for signs of edema.

.management of adverse reactions, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION
Promoting an Optimal Response to Therapy
If the androgen is to be administered as a buccal tablet, the nurse demonstrates the placement of the tablet and warns the patient not to swallow the tablet but to allow it to dissolve in the mouth. The nurse reminds the patient not to smoke or drink water until the tablet is dissolved. Oral and parenteral androgens are often taken or given by injection on an outpatient basis. When given by injection, the injection is administered deep intramuscularly (IM) into the gluteal muscle. Oral testosterone is given with or before meals to decrease gastric upset.

When the testosterone transdermal system Testoderm is prescribed, the nurse places the system on clean, dry scrotal skin. Optimal skin contact of the transdermal system is achieved by dry shaving scrotal hair before placing the system.

The system is worn for 22 to 24 hours, removed, and a new system applied. If the system comes off before it has been on 12 hours, it can be reapplied; however, if the system has been on more than 12 hours, the patient may wait until the next scheduled application time to apply a new patch. Before application of a new system, the skin of the scrotum is washed and dried. The nurse periodically checks the scrotum for scrotal hair and dry shaves the area if needed.

Another transdermal system is Testoderm TTS. This system is applied at about the same time each day and worn for 24 hours. The adhesive side is placed on a clean, dry area of skin on the arm, back, or upper buttocks immediately upon removal from the protective pouch. This system is not applied to the scrotum. The system is pressed firmly in place with the palm of the

NURSING DIAGNOSES
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING
The expected outcomes of the patient may include an optimal response to therapy, identification and management of adverse reactions, and an understanding of and compliance with the prescribed therapeutic regimen.
hand for about 10 seconds or until good contact is made with the skin. If the system falls off, the same system may be reapplied unless the system has been worn for 12 hours or more and it cannot be reapplied. Should this occur, the nurse applies the new system at the next scheduled application time.

Androderm, another transdermal system, is applied nightly to clean, dry skin on the abdomen, thigh, back, or upper arm. This system is not applied to the scrotum. Sites are rotated, with 7 days between application to any specific site. The system is applied immediately after opening the pouch and removing the protective covering. If the patient has not exhibited a therapeutic response after 8 weeks of therapy, another form of testosterone replacement therapy should be considered.

Testosterone gel (Androgel) is applied once daily (preferably in the morning) to clean, dry, intact skin of the shoulders and upper arms or abdomen. After the packet is opened, the contents are squeezed into the palm of the hand and immediately applied to the application sites. The application sites are allowed to dry before the patient gets dressed. The gel is not applied to the genitals.

**Monitoring and Managing Adverse Reactions**
The nurse observes the patient receiving an androgen or anabolic steroid for signs of adverse drug reactions. In women, virilization may be seen with long-term administration and in many cases must be tolerated to obtain the desired effect of the drug.

When the androgens are administered to a patient with diabetes, blood glucose measurements should be done frequently because glucose tolerance may be altered. Adjustments may need to be made in insulin dosage, oral antidiabetic drugs, or diet. The nurse monitors the patient for signs for hypoglycemia and hyperglycemia (see Chap. 49). Sodium and water retention may also occur with androgen or anabolic steroid administration, causing the patient to become edematous. In addition, other electrolyte imbalances, such as hypercalcemia, may occur. The nurse monitors the patient for fluid and electrolyte disturbances (see Chap. 58 for signs and symptoms of electrolyte disturbance).

**Gerontologic Alert**
Older adults with cardiac problems or kidney disease are at increased risk for sodium and water retention when taking the androgens or anabolic steroids.

The nurse makes a daily comparison of the patient’s preadministration weight with current weights. The nurse notes the presence of puffy eyelids and dependent swelling of the hands or feet (if the patient is ambulatory) or the sacral area (if the patient is non-ambulatory) and reports any findings to the primary health care provider. The nurse monitors the daily fluid intake and output to calculate fluid balance.

With long-term administration, the female patient may experience mild to moderate masculine changes (virilization), namely facial hair, a deepening of the voice, and enlargement of the clitoris. Male pattern baldness, patchy hair loss, skin pigmentation, and acne may also be seen. Although these adverse effects are not life threatening, they often are distressing and only add to the patient’s discomfort and anxiety. These problems may be easy to identify, but they are not always easy to solve. If hair loss occurs, the nurse can suggest the wearing of a wig. The nurse advises the patient that mild skin pigmentation may be covered with makeup, but severe and widespread pigmented areas and acne are often difficult to conceal. Each patient is different, and the emotional responses to these outward changes may range from severe depression to a positive attitude and acceptance. The nurse works with the patient as an individual, first identifying the problems, and then helping the patient, when possible, to deal with these changes.

**Educating the Patient and the Family**
The nurse explains the dosage regimen and possible adverse drug reactions to the patient and family and develops a teaching plan to include the following points.

**ANDROGENS**

- Notify the primary health care provider if any of the following occur: nausea, vomiting, swelling of the legs, or jaundice. Women should report any signs of virilization to the primary health care provider.
- Oral tablets—Take with food or a snack to avoid gastrointestinal upset.
- Buccal tablets—Place the tablet between the cheek and molars and allow it to dissolve in the mouth. Do not smoke or drink water until the tablet is dissolved.
- Testosterone transdermal system—Apply according to the directions supplied with the product. (See “Promoting an Optimal Response to T therapy.”) Be sure the skin is clean and dry and the placement area is free of hair. Do not store outside the pouch or use damaged systems. Discard systems in household trash in a safe manner to prevent ingestion by children or pets.

**ANABOLIC STEROIDS**

- These drugs may cause nausea and gastrointestinal upset. Take this drug with food or meals.
- Keep all primary health care provider or clinic visits because close monitoring of therapy is essential.
- Female patients: Notify the primary health care provider if signs of virilization occur.

**ANDROGEN HORMONE INHIBITOR**
- Take this drug without regard to meals.
- Inform the primary health care provider immediately if sexual partner is or may become pregnant because additional measures such as discontinuing the drug or use of a condom may be necessary.

**EVALUATION**
- The therapeutic response is achieved.
- Adverse reactions are identified and reported to the primary health care provider.
- The patient verbalizes the importance of complying with the prescribed treatment regimen.
- The patient and family demonstrate an understanding of the drug regimen.
- The patient verbalizes an understanding of treatment modalities and importance of continued follow-up care.

**FEMALE HORMONES**

The two endogenous (produced by the body) female hormones are the estrogens and progesterone. Like the androgens, their production is under the influence of the anterior pituitary gland. The endogenous estrogens are estradiol, estrone, and estriol. The most potent of these three estrogens is estradiol. Examples of estrogens used as drugs include estropipate (Ortho-Est) and estradiol (Estrace).

There are natural and synthetic progesterones, which are collectively called progestins. Examples of progestins used as drugs include medroxyprogesterone (Provera) and norethindrone (Aygestin). Examples of estrogens and progestins are given in the Summary Drug Table: Female Hormones.

**ACTIONS**

**Estrogens**

The estrogens are secreted by the ovarian follicle and in smaller amounts by the adrenal cortex. Estrogens are important in the development and maintenance of the female reproductive system and the primary and secondary sex characteristics. At puberty, they promote growth and development of the vagina, uterus, fallopian tubes, and breasts. They also affect the release of pituitary gonadotropins (see Chap. 50).

Other actions of estrogen include fluid retention, protein anabolism, thinning of the cervical mucus, and the inhibition or facilitation of ovulation. Estrogens contribute to the conservation of calcium and phosphorus, the growth of pubic and axillary hair, and pigmentation of the breast nipples and genitals. Estrogens also stimulate contraction of the fallopian tubes (which promotes movement of the ovum), modify the physical and chemical properties of the cervical mucus, and restore the endometrium after menstruation.

**Progestins**

Progesterone is secreted by the corpus luteum, placenta, and in small amounts by the adrenal cortex. Progesterone and its derivatives (ie, the progestins) transform the proliferative endometrium into a secretory endometrium. Progestins are necessary for the development of the placenta and inhibit the secretion of pituitary gonadotropins, which in turn prevents maturation of the ovarian follicle and ovulation. The synthetic progestins are usually preferred for medical use because of the decreased effectiveness of progesterone when administered orally.

**USES**

**Estrogens**

Estrogen is most commonly used in combination with progestogenes as contraceptives or as hormone replacement therapy in postmenopausal women. The estrogens are used to relieve moderate to severe vasomotor symptoms of menopause (flushing, sweating), female hypogonadism, atrophic vaginitis (orally and intravaginally), osteoporosis in women past menopause, palliative treatment for advanced prostatic carcinoma, and in selected cases of inoperable breast carcinoma. The estradiol transdermal system is used as estrogen replacement therapy (ERT) for moderate to severe vasomotor symptoms associated with menopause, female hypogonadism, after removal of the ovaries in premenopausal women (female castration), primary ovarian failure, and in the prevention of osteoporosis. Estrogen is given IM or intravenously (IV) to treat uterine bleeding caused by hormonal imbalance. When estrogen is used to treat menopausal symptoms in a woman with an intact uterus, concurrent use of progestin is recommended to decrease the risk of endometrial cancer. After a hysterectomy, estrogen alone may be used for ERT.

The estrogens, in combination with a progestin, are also used as oral contraceptives (Table 52-1). The uses of individual estrogens are given in the Summary Drug Table: Female Hormones. The use of estrogens in the treatment of carcinoma is discussed in Chapter 55.
# Male and Female Hormones

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>conjugated estrogens</td>
<td>Premarin, Premarin Intravenous</td>
<td>Oral: vasomotor symptoms associated with menopause, atrophic vaginitis, osteoporosis, hypogonadism, castration, primary ovarian failure, breast cancer palliation, prostate cancer palliation</td>
<td>Headache, migraine, dizziness, mental depression, chorea, insomnia, chloasma, nausea, vomiting, abdominal cramps, pain/bloating, colitis, breakthrough bleeding, spotting, dysmenorrhea, steepening of corneal curvature, intolerance to contact lenses, edema, changes in libido, breast pain and tenderness, hypertension, gallbladder disease</td>
<td>0.3—1.25 mg PO QD—TID 25 mg IV or IM</td>
</tr>
<tr>
<td>esterified estrogens</td>
<td>Estratab, Menest</td>
<td>Vasomotor symptoms, atrophic vaginitis, vulva and vaginal atrophy, hypogonadism, castration, primary ovarian failure, palliation for breast cancer, palliation for prostate cancer, osteoporosis prevention</td>
<td>Same as conjugated estrogens</td>
<td>0.3—1.25 mg/d PO</td>
</tr>
<tr>
<td>estradiol, oral</td>
<td>Estrace, generic</td>
<td>Moderate to severe vasomotor symptoms associated with menopause, atrophic vaginitis, female hypogonadism, female castration, primary ovarian failure, palliative therapy for breast and prostate cancer</td>
<td>Same as conjugated estrogens</td>
<td>1—2 mg/d PO</td>
</tr>
<tr>
<td>estradiol cypionate in oil</td>
<td>depGynogen, Depo-Estradiol, DepoGen, generic</td>
<td>Moderate to severe vasomotor symptoms associated with menopause, female hypogonadism</td>
<td>Same as conjugated estrogens; pain at injection site</td>
<td>1—5 mg IM</td>
</tr>
<tr>
<td>estradiol hemihydrate</td>
<td>Alora, Climara, Estraderm, FemPatch, Vivelle</td>
<td>Atrophic vaginitis</td>
<td>Same as conjugated estrogens</td>
<td>1 tablet inserted vaginally daily</td>
</tr>
<tr>
<td>estradiol transdermal system</td>
<td>Same as conjugated estrogens</td>
<td>Same as conjugated estrogens</td>
<td>0.025—0.1 mg; therapy may be given continuously in patients with no intact uterus; in patients with uterus, treatment regimen is on a cyclic schedule (eg, 3 weeks therapy, 1 week off)</td>
<td></td>
</tr>
</tbody>
</table>

(continued)
### SUMMARY DRUG TABLE: FEMALE HORMONES (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>estrone</td>
<td>Estrone</td>
<td>Moderate to severe vasomotor symptoms associated with menopause, atrophic vaginitis, female hypogonadism, female castration, primary ovarian failure, palliative therapy for breast and prostate cancer, treatment of abnormal uterine bleeding due to hormone imbalance</td>
<td>Same as conjugated estrogens; pain at injection site</td>
<td>0.1–0.5 mg</td>
</tr>
<tr>
<td>estropipate</td>
<td>Ogen, Ortho-Est, generic</td>
<td>Moderate to severe vasomotor symptoms associated with menopause, atrophic vaginitis, female hypogonadism, female castration, primary ovarian failure</td>
<td>Same as conjugated estrogens</td>
<td>0.625–5 mg/d PO</td>
</tr>
<tr>
<td>ethinyl estradiol</td>
<td>Estinyl</td>
<td>Same as conjugated estrogens</td>
<td>Same as conjugated estrogens</td>
<td>0.02–2 mg PO</td>
</tr>
<tr>
<td>synthetic conjugated estrogens, A</td>
<td>Cenestin</td>
<td>Moderate to severe vasomotor symptoms associated with menopause</td>
<td>Same as conjugated estrogens</td>
<td>0.0625–1.25 mg PO</td>
</tr>
<tr>
<td>vaginal estrogens, A</td>
<td>Estrin, Estrace Vaginal Cream, Ogen Vaginal Cream, Premarin Vaginal Cream</td>
<td>Atrophic vaginitis</td>
<td>Rare: minor vaginal irritation or itching</td>
<td>1–2 applicatorsful per day</td>
</tr>
</tbody>
</table>

### Progestins

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>hydroxyprogesterone caproate in oil</td>
<td>Hylutin, generic</td>
<td>Amenorrhea, abnormal uterine bleeding, production of secretory endometrium and desquamation</td>
<td>Breakthrough bleeding, spotting, change in menstrual flow, amenorrhea, breast tenderness, weight gain or loss, chloasma, melasma, mental depression</td>
<td>125–375 mg IM</td>
</tr>
<tr>
<td>medroxyprogesterone acetate</td>
<td>Amen, Cycin, Depo-Provera (parenteral), Provera, generic</td>
<td>Amenorrhea, abnormal uterine bleeding, reduction of endometrial hypoplasia in postmenopausal women</td>
<td>Same as hydroxyprogesterone caproate</td>
<td>5–10 mg/d PO; 400–1000 mg/wk IM</td>
</tr>
<tr>
<td>megestrol acetate</td>
<td>Megace, generic</td>
<td>Palliation of advanced carcinoma of breast or endometrium</td>
<td>Same as hydroxyprogesterone caproate</td>
<td>Breast cancer: 160 mg/d in 4 doses</td>
</tr>
<tr>
<td>Endometrial cancer: 40–320 mg/d PO in divided doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**SUMMARY DRUG TABLE  FEMALE HORMONES (Continued)**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>norethindrone acetate</td>
<td>Aygestin,</td>
<td>Amenorrhea, abnormal uterus bleeding</td>
<td>Same as hydroxyprogesterone caproate</td>
<td>Amenorrhea, abnormal uterus bleeding,</td>
</tr>
<tr>
<td>nor-eth-in’-drone</td>
<td>generic</td>
<td>endometriosis</td>
<td></td>
<td>endometriosis: up to 15 mg/d PO</td>
</tr>
<tr>
<td>progesterone pro-e-je-s-te-rone</td>
<td>Crinone, Prometrium, generic</td>
<td>Amenorrhea, abnormal uterus bleeding, infertility</td>
<td>Same as hydroxyprogesterone caproate; Vaginal gel (Crinone): somnolence, headache, constipation, breast enlargement</td>
<td>5–10 mg IM, 200–400 mg PO; Crinone: 90 mg vaginally QD</td>
</tr>
</tbody>
</table>

**Combination Products**

| estrogen and progestins combined | Activella, CombiPatch, Femhrt, Ortho-Prefest, Prempro | Treatment of moderate to severe vasomotor symptoms associated with menopause, treatment of vulval and vaginal atrophy, osteoporosis Combination: Menopause symptoms only | Adverse reactions of both hormones; same as synthetic conjugated estrogens and progesterone | PO and Patch system: dosage varies depending on specific drug and reason for administration; follow primary health care provider’s instructions |
| estrogen and androgen, parenteral | Depo-Testadiol | Moderate to severe vasomotor symptoms associated with menopause in patients with no response to estrogens alone | Adverse reactions of both hormones (estrogen and androgen) | Parenterally: dosage varies depending on specific drug and reason for administration; follow primary health care provider’s instructions |
| estrogen and androgen, oral     | Estratest, Estratest H.S., Syntest D. S. | Same as estrogen and androgen, parenteral | Same as estrogen and androgen, parenteral | PO dosage varies depending on reason for administration; follow primary health care provider’s instructions |

*The term generic indicates the drug is available in generic form.

**Progestins**

The progestins are used in the treatment of amenorrhea, endometriosis, and functional uterine bleeding. Progestins are also used as oral contraceptives, either alone or in combination with an estrogen (see the Summary Drug Table: Female Hormones and Table 52-1).

**Contraceptive Hormones**

Estrogens and progestins (combination oral contraceptives) are used as oral contraceptives. There are three types of estrogen and progestin combination oral contraceptives: monophasic, biphasic, and triphasic. The monophasic oral contraceptives provide a fixed dose of estrogen and progestin throughout the cycle. The biphasic and triphasic oral contraceptives deliver hormones similar to the levels naturally produced by the body (Table 52-1).

The oral contraceptives have changed a great deal since their introduction in the 1960s. Today the levels of hormones provide lower dosages of hormones compared with the older formulations, while retaining the same degree of effectiveness (>99% when used as prescribed).

Taking the contraceptive hormones provides health benefits not related to contraception, such as regulating the menstrual cycle and decreased blood loss, and incidence of iron deficiency anemia, and dysmenorrhea. Health benefits related to the inhibition of ovulation include a decrease in ovarian cysts and ectopic pregnancies. In addition, there is a decrease in fibrocyctic breast disease, acute pelvic inflammatory disease, endometrial cancer, ovarian cancer, maintenance of bone density, and symptoms related to endometriosis in women taking contraceptive hormones. Newer combination contraceptives such as norgestimate and ethinyl estradiol
### Monophasic Oral Contraceptives

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>50 mcg ethinyl estradiol acetate 1 mg norethindrone</td>
<td>Necon 1/50, Norinyl 1 + 50, Ortho-Novum 1/50</td>
</tr>
<tr>
<td>50 mcg ethinyl estradiol, 1 mg ethynodiol diacetate</td>
<td>Demulen 1/50, Zovia 1/50E</td>
</tr>
<tr>
<td>50 mcg ethinyl estradiol, 0.5 mg norgestrel</td>
<td>Orgestrel, Ovral</td>
</tr>
<tr>
<td>35 mcg ethinyl estradiol, 1 mg norethindrone</td>
<td>Necon 1/35, Norinyl 1 + 35, Ortho Novum 1/35</td>
</tr>
<tr>
<td>35 mcg ethinyl estradiol, 0.5 mg norethindrone</td>
<td>Brevicon, Modicon, Necon 0.5/35, Notrel</td>
</tr>
<tr>
<td>35 mcg ethinyl estradiol, 0.4 mg norethindrone</td>
<td>Ovcon-35</td>
</tr>
<tr>
<td>35 mcg ethinyl estradiol, 0.25 mg norgestimate</td>
<td>Ortho-Cyclen, Sprintex</td>
</tr>
<tr>
<td>35 mcg ethinyl estradiol, 1 mg ethynodiol diacetate</td>
<td>Demulen 1/50, Zovia 1/50E</td>
</tr>
<tr>
<td>30 mcg ethinyl estradiol, 1.5 mg norethindrone acetate</td>
<td>Loestrin, 1.5/30, Loestrin Fe 1.5/30, Microgestin Fe 1.5/30</td>
</tr>
<tr>
<td>30 mcg ethinyl estradiol, 0.3 mg norgestrel</td>
<td>Lo/Ovral, Low-Ogestrel, Cryselle</td>
</tr>
<tr>
<td>30 mcg ethinyl estradiol, 0.15 mg desogestrel</td>
<td>Apri, Desogen, Ortho-Cept</td>
</tr>
<tr>
<td>30 mcg ethinyl estradiol, 0.15 mg levonorgestrel</td>
<td>Levier, Levora, Nordette, Portia</td>
</tr>
<tr>
<td>20 mcg ethinyl estradiol, 1 mg norethindrone acetate</td>
<td>Loestrin 21 1/20, Loestrin Fe 1/20, Microgestin Fe 1/20</td>
</tr>
<tr>
<td>20 mcg ethinyl estradiol, 0.1 mg levonorgestrel</td>
<td>Alesse, Aviane, Levilite</td>
</tr>
</tbody>
</table>

### Biphasic Oral Contraceptives

| Phase one: 35 mcg ethinyl estradiol, 0.5 mg norethindrone | Necon 10/11, Ortho-Novum 10/11 |
| Phase two: 35 mcg ethinyl estradiol, 1 mg norethindrone | Tri-Norinyl |

### Triphasic Oral Contraceptives

| Phase one: 35 mcg ethinyl estradiol, 0.5 mg norethindrone | Ortho-Novum 7/7/7, Necon 7/7/7 |
| Phase two: 35 mcg ethinyl estradiol, 0.75 mg norethindrone | Ortho Tri-Cyclen |
| Phase three: 35 mcg ethinyl estradiol, 1 mg norethindrone | Ortho Tri-Cyclen Lo |

### Progestin Only Contraceptives

| 0.35 mg norethindrone | Camila, Errin, Nor-QD, Nora-BE, Ortho Micronor |
| 0.075 norgestrel | Ovrette |

### Implant Contraceptive Systems (Progestins)

- levonorgestrel: 6 capsules, each containing 36 mg levonorgestrel for subdermal implantation
- levonorgestrel: T-shaped unit containing 38 mg progesterone for insertion in the uterine cavity

<table>
<thead>
<tr>
<th>Implant Contraceptive Systems (Progestins)</th>
<th>Norplant System</th>
</tr>
</thead>
<tbody>
<tr>
<td>progesterone: T-shaped unit containing 38 mg progesterone for insertion in the uterine cavity</td>
<td>Progestasert</td>
</tr>
</tbody>
</table>
combinations found in Ortho Tri-Cyclen have been shown to help reduce moderate acne and maintain clear skin in women 15 years of age or older (who menstruate, want contraception, and have no response to topical anti-acne medications).

### ADVERSE REACTIONS

#### Estrogens

Administration of estrogens by any route may result in many adverse reactions, although the incidence and intensity of these reactions vary. Some of the adverse reactions seen with the administration of estrogens include:

- **Central nervous system**—headache, migraine, dizziness, mental depression
- **Dermatologic**—chloasma (pigmentation of the skin) or melasma (discoloration of the skin), which may continue when use of the drug is discontinued
- **Gastrointestinal**—nausea, vomiting, abdominal cramps, dermatitis, pruritus
- **Genitourinary**—breakthrough bleeding, withdrawal bleeding, spotting, change in menstrual flow, dysmenorrhea, premenstrual-like syndrome, amenorrhea, vaginal candidiasis, cervical erosion, vaginitis
- **Local**—pain at injection site, sterile abscess, redness and irritation at the application site with transdermal system
- **Ophthalmic**—steepening of corneal curvature, intolerance to contact lenses
- **Miscellaneous**—edema; changes in libido; breast pain, enlargement, and tenderness; reduced carbohydrate tolerance; venous thromboembolism; pulmonary embolism; increase or decrease in weight; skeletal pain

Warnings associated with the administration of estrogen include an increased risk of endometrial cancer, gallbladder disease, hypertension, hepatic adenoma (a benign tumor of the liver), cardiovascular disease, increased risk of thromboembolic disease, and hypercalcemia in those with breast cancer and bone metastases.

#### Progestins

Administration of the progestins by any route may result in many adverse reactions, although the incidence and intensity of these reactions varies. Progestin administration may result in breakthrough bleeding, spotting, change in the menstrual flow, amenorrhea, breast tenderness, edema, weight increase or decrease, acne, chloasma or melasma, and mental depression. In addition to the adverse reactions seen with progestins, the use of a levonorgestrel implant system may result in bruising after insertion, scar tissue formation at the site of insertion, and hyperpigmentation at the implant site. The use of medroxyprogesterone acetate contraceptive injection may result in the same adverse reactions as those associated with administration of any progestin.

#### Contraceptive Hormones

When estrogen/progestin combinations are used as oral contraceptives, the adverse reactions associated with the estrogens and the progestins must be considered. Because these drugs may exhibit adverse reactions that vary depending on their estrogen or progestin content, the adverse reactions of each must be considered. Table 52-2 identifies the symptoms of estrogen and progestin

---

**TABLE 52-2 Estrogen and Progestin: Excess and Deficiency**

<table>
<thead>
<tr>
<th>HORMONE*</th>
<th>SIGNS OF EXCESS</th>
<th>SIGNS OF DEFICIENCY</th>
</tr>
</thead>
<tbody>
<tr>
<td>estrogen</td>
<td>Nausea, bloating, cervical mucorrhea (increased cervical discharge), polyposis (numerous ployps), melasma (discoloration of the skin), hypertension, migraine headache, breast fullness or tenderness, edema</td>
<td>Early or midcycle breakthrough bleeding, increased spotting, hypomenorrhea</td>
</tr>
<tr>
<td>progestin</td>
<td>Increased appetite, weight gain, tiredness, fatigue, hypomenorrhea, acne, oily scalp, hair loss, hirsutism (excessive growth of hair), depression, monilial vaginitis, breast regression</td>
<td>Late breakthrough bleeding, amenorrhea, hypermenorrhea</td>
</tr>
</tbody>
</table>

*Hormonal balance is achieved by adjusting the estrogen/progestin dosage. Oral contraceptives have different amounts of progestin and estrogen varying the estrogenic and progestational activity in each product.
Excess or deficiency. The adverse effects are minimized by adjusting the estrogen progestin balance or dosage.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Estrogens

Estrogen therapy is contraindicated in patients with known hypersensitivity to the drugs, breast cancer (except for metastatic disease), estrogen-dependent neoplasms, undiagnosed abnormal genital bleeding, known or suspected pregnancy (Pregnancy Category X), and thromboembolic disorders.

The estrogens are used cautiously in patients with gallbladder disease, hypercalcemia (may lead to severe hypercalcemia in patients with breast cancer and bone metastasis), cardiovascular disease, and liver impairment.

The effects of the oral anticoagulants may be decreased when administered with the estrogens. When the estrogens are combined with the tricyclic antidepressants there is an increased risk of toxicity of the antidepressant. Barbiturates or rifampin may decrease estrogen blood levels, increasing the risk for breakthrough bleeding. When estrogens are administered concurrently with the hydantoins, breakthrough bleeding, spotting, and pregnancy have occurred. A loss of seizure control has also been reported. Cigarette smoking increases the risk for cardiovascular complications.

Progestins

The progestins are contraindicated in patients with known hypersensitivity to the drugs, thromboembolic disorders, cerebral hemorrhage, impaired liver function, and cancer of the breast or genital organs. Both the estrogens and progestins are classified as Pregnancy Category X drugs and are contraindicated during pregnancy. The progestins are used cautiously in patients with a history of migraine headaches, epilepsy, asthma, and cardiac or renal impairment.

The effects of the progestins are decreased when administered with anticonvulsants, barbiturates, or rifampin. Administration of the penicillins or tetracyclines with the oral contraceptives decreases the effects of the oral contraceptives.

Contraceptive Hormones

See the “Contraindications, Precautions, and Interactions” section regarding estrogens and progestins in this chapter for information regarding the combination oral contraceptives. The warnings associated with the use of oral contraceptives are the same as those for the estrogens and progestins and include cigarette smoking, which increases the risk of cardiovascular side effects, such as venous and arterial thromboembolism, myocardial infarction, and thrombotic and hemorrhagic stroke. Also reported with oral contraceptive use are hepatic adenomas and tumors, visual disturbances, gallbladder disease, hypertension, and fetal abnormalities.

Herbal Alert: Black Cohosh

Black cohosh, a herb reported to be beneficial in managing symptoms of menopause, is generally regarded as safe when used as directed. Black cohosh is a member of the buttercup flower family. The dosage of standardized extract is 2 tablets twice a day, or 40 drops of standardized tincture twice a day, or one 500- to 600-mg tablet or capsule three times daily. Black cohosh is not considered as effective as other forms. Boiling of the root releases only a portion of the therapeutic constituents.

The benefits of black cohosh (not to be confused with blue cohosh) include:

- Reduction in physical symptoms of menopause: hot flushes, night sweats, headaches, heart palpitations, dizziness, vaginal atrophy, and tinnitus (ringing in the ears)
- Decrease in psychological symptoms of menopause: insomnia, nervousness, irritability, and depression
- Improvement in menstrual cycles by balancing the hormones and reducing uterine spasms

Adverse reactions are rare when using the recommended dosage. The most common adverse reaction is nausea. Black cohosh is contraindicated during pregnancy. Toxic effects include dizziness, headache, nausea, impaired vision, and vomiting. This herb is purported to be an alternative to hormone alternative replacement therapy (HART). Women who choose HART may increase their risk for endometrial cancer (cancer of the membrane lining the uterus), along with gallbladder disease, breast tenderness, high blood pressure, depression, and weight gain. Patients desiring to use any herbal remedy should consult with the primary health care provider before beginning therapy. Although no specific drug interactions have been reported, it is important that women taking HART should consult with their primary health care provider. In addition to its popularity as an herb for women’s hormonal balance, black cohosh has been used for muscular and arthritic pain, headache, and eyestrain.

Herbal Alert: Saw Palmetto

Saw palmetto is used to relieve the symptoms of benign prostatic hypertrophy. The herb reduces urinary frequency, increases the flow of urine, and decreases the incidence of nocturia. Saw palmetto may delay the need for prostate surgery. The dosage of the herb is:

- 160 mg twice daily of standardized extract
- One 585-mg capsule or tablet up to three times/day
- 20 to 30 drops up to four times a day tincture (1:2 liquid extract)

It is not recommended to take saw palmetto as a tea because the active constituents are not water soluble. Improvement can be seen after 1 to 3 months of therapy. It is usually recommended that the herb be taken for 6 months, followed by evaluation by a primary health care provider.
CHAPTER 52  Male and Female Hormones

The Patient Receiving a Female Hormone

ASSESSMENT

Preadministration Assessment

Before administering an estrogen or progestin, the nurse obtains a complete patient health history, including a menstrual history, which includes the menarche (age of onset of first menstruation), menstrual pattern, and any changes in the menstrual pattern (including a menopause history when applicable). In patients prescribed an estrogen (including oral contraceptives), the nurse obtains a history of thrombophlebitis or other vascular disorders, a smoking history, and a history of liver diseases. Blood pressure, pulse, and respiratory rate are taken and recorded. The primary health care provider usually performs a breast and pelvic examination and obtains a Pap smear before starting therapy. He or she may also order hepatic function tests.

If the male or female patient is being treated for a malignancy, the nurse enters in the patient’s record a general evaluation of the patient’s physical and mental status. The primary health care provider may also order laboratory tests, such as serum electrolytes and liver function tests.

Ongoing Assessments

ASSESSMENT OF THE OUTPATIENT. At the time of each office or clinic visit, the nurse obtains the blood pressure, pulse, respiratory rate, and weight. The nurse questions the patient regarding any adverse drug effects, as well as the result of drug therapy. For example, if the patient is receiving an estrogen for the symptoms of menopause, the nurse asks her to compare her original symptoms with the symptoms she is currently experiencing, if any. The nurse weighs the patient and reports a steady weight gain or loss. A periodic (usually annual) physical examination is performed by the primary health care provider and may include a pelvic examination, breast examination, Pap smear, and laboratory tests. The patient with a prostatic or breast carcinoma usually requires more frequent evaluations of response to drug therapy.

ASSESSMENT OF THE HOSPITALIZED PATIENT. The hospitalized patient receiving a female hormone requires careful monitoring. The nurse takes the vital signs daily or more often, depending on the patient’s physical condition and the reason for drug use. The nurse observes the patient for adverse drug reactions, especially those related to the liver (the development of jaundice) or the cardiovascular system (thromboembolism). The nurse weighs the patient weekly or as ordered by the primary health care provider. The nurse reports any significant weight gain or loss to the primary health care provider.

In patients with breast carcinoma or prostatic carcinoma, the nurse observes for and evaluates signs indicating a response to therapy, for example, a relief of pain, an increase in appetite, a feeling of well-being. In prostatic carcinoma, the response to therapy may be rapid, but in breast carcinoma the response is usually slow.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to therapy, identification and management of adverse reactions, a reduction in anxiety, and an understanding of and compliance with the prescribed therapeutic regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

ESTROGENS. Estrogens may be administered orally, IM, IV, or intravaginally. Oral estrogens are administered with food or immediately after eating to reduce gastrointestinal upset. When estrogens are given vaginally for atrophic vaginitis, the nurse gives the patient instructions on proper use.

CONTRACEPTIVE HORMONES. The monophasic oral contraceptives are administered on a 21-day regimen, with the first tablet taken on the first Sunday after the menses begins or on the day the menses begin if the menses begin on Sunday. After the 21-day regimen, the next 7 days are skipped, then the cycle is begun again. With the biphasic oral contraceptives, the first phase is 10 days of a smaller dosage of progestin, and the second phase is a larger amount of progestin.

Nursing Diagnoses Checklist

- Ineffective Tissue Perfusion related to adverse reactions (thromboembolic effects)
- Excess Fluid Volume related to adverse reactions (sodium and water retention)
- Imbalanced Nutrition: More or Less than Body Requirements related to adverse reactions (weight gain or loss)
- Anxiety related to diagnosis, use of estrogen replacement therapy, other factors
The estrogen dosage remains constant for 21 days, followed by no estrogen for 7 days. Some regimens contain seven placebo tablets for easier management of the therapeutic regimen. With the triphasic oral contraceptives, the estrogen amount stays the same or may vary and the progestin amount varies throughout the 21-day cycle. Progestin-only oral contraceptives are taken daily and continuously.

**Implant Contraceptive System.** Levonorgestrel, a progestin, is available as an implant contraceptive system (Norplant System). Six capsules, each containing levonorgestrel, are implanted under local anesthesia in the subdermal (below the skin) tissues of the mid-portion of the upper arm. The capsules provide contraceptive protection for 5 years but may be removed at any time at the request of the patient. See Table 52-3 for more information on ways to promote an optimal response when taking the contraceptive hormones.

**Medroxyprogesterone Acetate Contraceptive Injection.** Medroxyprogesterone acetate (Depo-Provera), a synthetic progestin used in the treatment of abnormal uterine bleeding and secondary amenorrhea, is also used as a contraceptive. This drug is given IM every 3 months, and the initial dosage is given within the first 5 days of menstruation or within 5 days postpartum. When this drug is given IM, the solution must be shaken vigorously before use to ensure uniform suspension, and the drug is given deep IM into the gluteal or deltoid muscle.

**Nursing Alert**

If the interval is greater than 14 weeks between the IM injections, the nurse must be certain that the patient is not pregnant before administering the next injection.

**Monitoring and Managing Adverse Reactions**

The patient prescribed the female hormones usually takes them for several months or years. Throughout that time, the patient must be monitored for adverse reactions (see “Ongoing Assessment”). These drugs are self-administered at home. This makes patient education an important avenue for detecting and managing adverse reactions.

With the estrogens it is important to monitor for breakthrough bleeding. If breakthrough bleeding occurs with either the estrogens or progestin, the patient notifies the primary health care provider. A dosage change may be necessary.

Gastrointestinal upsets, such as nausea, vomiting, abdominal cramps, and bloating may also occur. Nausea usually decreases or subsides within 1 to 2 months of therapy. However, until that time the discomfort may lessen if the drug is taken with food. If nausea is continual, frequent small meals may help. If nausea and vomiting persist, an antiemetic may be prescribed. Bloating may be lessened with light to moderate exercise or by limiting fluid intake with meals.

The nurse carefully monitors the patient with diabetes who is taking female hormones. The primary health care provider is notified if blood glucose levels are elevated or the urine is positive for glucose or ketone bodies because a change in the dosage of insulin or the oral hypoglycemic drug may be required. See Chapter 49 for more information on ways to promote an optimal response when taking the contraceptive hormones.

**Managing Sodium and Water Retention.** Sodium and water retention may occur during female hormone therapy. In addition to reporting any swelling of the hands, ankles, or feet to the primary health care provider, the nurse weighs the hospitalized patient daily, keeps an accurate record of the intake and output, encourages ambulation (if not on bed rest), and helps the patient to eat a diet low in sodium (if prescribed by the primary health care provider).

**Managing Thromboembolic Effects.** The nurse monitors the patient for signs of thromboembolic effects, such as pain, swelling, tenderness in the extremities, headache, chest pain, and blurred vision. These adverse effects are reported to the primary health care provider. Patients with previous venous insufficiency, who are on bed rest for other medical reasons, or who smoke are at increased risk for thromboembolic effects. The nurse encourages the patient to elevate the lower extremities when sitting, if possible, and to exercise the lower extremities by walking.

**Nursing Alert**

There is an increased risk of post-operative thromboembolic complications in women taking oral contraceptives. If possible, use of the drug is discontinued at least 4 weeks before a surgical procedure associated with thromboembolism or during prolonged immobilization.

**Managing Alterations in Nutrition.** A iterations in nutrition can occur, resulting in significant weight gain or loss. Weight gain occurs more frequently than weight loss. The nurse encourages a daily diet that includes adequate amounts of protein and carbohydrates and that is low in fats. A variety of nutritious foods (fruits, vegetables, grains, cereals, meats, and poultry) should be included in the daily diet, with portion sizes decreased to meet individual needs. A dietitian may be consulted if necessary. An exercise program is helpful in both losing weight and maintaining weight loss.
GENERIC AND TRADE NAME*   PROMOTING AN OPTIMAL RESPONSE

emergency contraceptives (Plan B, Preven)   Used for emergency contraception after unprotected intercourse. When using Plan B take one tablet within 72 h after unprotected intercourse. When using Preven take 2 tablets within 72 h of unprotected intercourse and the last 2 tablets 12 h after the first dose. These drugs can be used anytime during the menstrual cycle. If vomiting occurs within 1 hour after taking either dose, notify the primary health care provider. Emergency contraceptives are not effective in terminating an existing pregnancy. Should not be used as a routine form of contraception.

etongestrel/ethinyl estradiol vaginal ring (Nuvaring, generic)   The woman inserts vaginal ring in the vagina, where it remains continuously for 3 weeks. Remove for 1 week, during which bleeding usually occurs (usually 2–3 days after removal). Insert new ring 1 week after the last ring removed on the same day of the week as it was inserted in the previous cycle. Do this even if bleeding is not finished. Insertion: Position for insertion by the woman may be standing with one leg up, squatting, or lying down. Compress the ring and insert into the vagina. (The exact position of the vaginal ring inside the vagina is not critical to its effectiveness.) The vaginal ring is removed after 3 weeks on the same day of the week as it was started. Removal is accomplished by hooking the index finger under the forward rim or by grasping the rim between the index finger and pulling it out. Discard the used ring in the foil pouch in a waste receptacle out of the reach of children or pets. (Do not flush the ring down the toilet.) Consider the menstrual cycle, ovulation, and the possibility of pregnancy before beginning treatment. The vaginal ring may be accidentally expelled (eg, when it was not inserted properly, during straining for defecation, removing a tampon, or with severe constipation). If this occurs, rinse the vaginal ring with lukewarm water and reinsert promptly. (If the ring has been out of the vagina for more than 3 h, contraceptive effectiveness may be reduced and an alternate contraceptive must be used for the next 7 days. The most common adverse reactions leading to discontinuation include: device-related problems (eg, foreign body sensations, coital problems, device expulsion). Other adverse reactions include vaginitis, headache, upper respiratory tract infection, leukorrhea, sinusitis, weight gain, and nausea. Intrauterine contraception device (IUD) for women who have had at least one child, are in a stable monogamous relationship, and have no history of pelvic inflammatory disease (PID). There is an increased risk of PID associated with IUD use, most often occurring within the first 4 months of use. The device prevents uterine pregnancy but it does not prevent ovulation or ectopic (implantation of the fertilized egg outside of the uterus) pregnancy. Before insertion, a complete medical and social history is performed, including Pap smear, gonorrhea, and Chlamydia culture, and tests for other sexually transmitted diseases. The patient is reexamined shortly after the first menses after insertion or within the first 3 months and at any time the patient exhibits symptoms. The device is removed for the following reasons: pelvic infection, endometritis, genital actinomycosis (a noncontagious bacterial infection), intractable pelvic pain, pregnancy, endometrial or cervical malignancy, increase in length of the threads extending from the cervix or any other indication of partial expulsion. Retrieval threads should be visible. If they are not visible, they may have retracted into the uterus or have been broken. After menstrual period, determine if the threads still protrude from the cervix. If threads are not found, the system is considered displaced and removed. Caution the patient not to pull the threads. If partial expulsion occurs, removal is indicated and a new system inserted. For the first few weeks after insertion, bleeding and cramping may occur. If symptoms continue or become severe, the health care provider is contacted.

TABLE 52-3   Contraceptive Hormones

(continued)
**TABLE 52-3 Contraceptive Hormones (Continued)**

<table>
<thead>
<tr>
<th>GENERIC AND TRADE NAME*</th>
<th>PROMOTING AN OPTIMAL RESPONSE</th>
</tr>
</thead>
<tbody>
<tr>
<td>levonorgestrel implants</td>
<td>Prophylactic antibiotics may be prescribed before IUD insertion to decrease the risk of PID. Patient package insert and instructions are available with the product. The primary health care provider should be notified if any of the following occurs: abnormal or excessive bleeding, severe cramping, abnormal or odorous vaginal discharge, fever or flu-like symptoms, pain, genital lesions, or missed periods. The device is replaced every 12 months.</td>
</tr>
<tr>
<td>lev'-oh-nor-jes-trel</td>
<td>An informed consent may be required in some institutions before this procedure. A surgical incision is required to insert six capsules.</td>
</tr>
<tr>
<td>(Norplant System)</td>
<td>Removal also requires surgical intervention. The capsules are inserted during the first 7 days of the cycle or immediately after an abortion.</td>
</tr>
<tr>
<td>levonorgestrel-releasing</td>
<td>Irregular menstrual bleeding, spotting, prolonged episodes of bleeding, and amenorrhea may occur. These symptoms diminish with continued use.</td>
</tr>
<tr>
<td>intrauterine system (LRIS)</td>
<td>Before insertion, provide the patient with the patient package insert.</td>
</tr>
<tr>
<td>lev'-oh-nor-jes-trel (Mirena)</td>
<td>LRIS is an intrauterine contraception device for use for not more than 5 years. Inserted with the provided inserter into the uterine cavity within 7 days of the onset of menstruation or immediately after the first trimester abortion.</td>
</tr>
<tr>
<td>LRIS</td>
<td>Teach the patient to check after each menstrual period to make certain that the thread still protrudes from the cervix and caution her not to pull the thread.</td>
</tr>
<tr>
<td>medroxyprogesterone acetate/estradiol cypionate (MPA/E2C) (Lunelle)</td>
<td>If pregnancy occurs with the LRIS in place, the LRIS should be removed. If the LRIS is not removed there is an increase in the risk of miscarriage, sepsis, premature labor, and premature delivery. Monitor the woman for flu-like symptoms, fever, chills, cramping, pain, bleeding, vaginal discharge, or leakage of fluid. Before insertion a complete medical and social history, including that of the partner, is obtained to determine conditions that might influence the use of an IUD. Initial insertion is done by the physician within 7 days of the onset of a menstrual period. Re-examination and evaluation is done shortly after the first menses or within the first 3 months after insertion.</td>
</tr>
<tr>
<td>me-drox'-ee-proe-jess'-te-rone</td>
<td>Menstrual flow usually decreases after the first 3–6 months of LRIS use; therefore, an increase of menstrual flow may indicate expulsion of the device. Symptoms of partial or complete expulsion include pain and bleeding. However, the LRIS can be expelled without any noticeable effects.</td>
</tr>
<tr>
<td>medroxyprogesterone contraceptive injection (Depo-Provera)</td>
<td>The first injection is given during the first 5 days of a normal menstrual period and is administered no earlier than 4 weeks after delivery if not breastfeeding or 6 weeks if breastfeeding. Second and subsequent injections given monthly (28–30 days) after the previous injection, not to exceed 33 days. Give patient a copy of the patient labeling before administration of the drug. The injection schedules are indicated according to the number of days and not bleeding episodes. If any patient misses 2 consecutive menstrual periods, the possibility of pregnancy should be considered. Another form of contraception should be used if the monthly dosage is late (more than 33 days since the last injection).</td>
</tr>
<tr>
<td>me-drox'-ee-proe-jess'-te-rone</td>
<td>Menstrual bleeding patterns are usually disrupted but should normalize. Irregular bleeding, amenorrhea, and excessive or prolonged bleeding should be reported to the health care provider.</td>
</tr>
<tr>
<td>norelgestromin/ethinyl estradiol transdermal system (Ortho Evra)</td>
<td>Long-term injectable contraceptive administered IM every 3 months. The injection is given only during the first 5 days of the normal menstrual period, within 5 days postpartum if not breastfeeding, or at 6 weeks postpartum. Bleeding irregularities may occur (ie, irregular or unpredictable bleeding or spotting, or heavy continuous bleeding). Bleeding usually decreases to amenorrhea as the treatment continues.</td>
</tr>
<tr>
<td>nor-el-jes'-tro-min</td>
<td>The drug is not readministered if there is a sudden partial or complete loss of vision or if the patient experiences ptosis, diplopia, or migraine. A 28-day cycle, with a new patch applied each week for 3 weeks. Week 4 is patch free.</td>
</tr>
<tr>
<td></td>
<td>Apply new patch on the same day each week (note patch change day on the calendar).</td>
</tr>
</tbody>
</table>
Weight loss is often as difficult to manage as weight gain. When a patient taking the female hormones has a decrease in appetite and loses weight, the nurse encourages the individual to increase protein, carbohydrates, and calories in the diet. Small feedings with several daily snacks are usually better tolerated in those with a loss of appetite than are three larger meals. Patients are encouraged to eat foods that they like. Dietary supplements may be necessary if a significant weight loss occurs. A dietitian may be consulted if necessary. Weights are usually taken on a weekly, rather than daily, basis.

Managing Anxiety
The woman taking female hormones may have many concerns about therapy with these drugs. Some concerns may be based on inaccurate knowledge; for example, the woman who hears incorrect facts about certain dangers associated with female hormones. Although there are dangers associated with long-term use of female hormones, many of these adverse reactions occur in a small number of patients. When the patient is closely followed up by the primary health care provider, the dangers associated with long-term use are often minimized.

Some women may be anxious because of a fear of experiencing uterine cancer as the result of taking ERT. The nurse explains that taking progestin, which counteracts the negative effect of estrogen, can prevent estrogen-induced cancer of the uterus. Other women may fear the development of breast cancer. Most research studies find that there is little risk for breast cancer developing and that the benefits of ERT often outweigh the risk of breast cancer.

The nurse encourages the patient to ask questions about her therapy. Information that is inaccurate is clarified before therapy is started. The nurse refers to the primary health care provider questions that cannot or should not be answered by a nurse.

The male patient with inoperable prostatic carcinoma also may have concerns about taking a female hormone. The nurse assures the patient that the dosage is carefully regulated and that feminizing effects, if they occur, are usually minimal.

Educating the Patient and Family
The instructions for starting oral contraceptive therapy vary with the product used. Each product has detailed patient instruction sheets regarding starting oral contraceptive therapy, and the nurse reviews them with the

---

**TABLE 52-3 Contraceptive Hormones (Continued)**

<table>
<thead>
<tr>
<th>GENERIC AND TRADE NAME*</th>
<th>PROMOTING AN OPTIMAL RESPONSE</th>
</tr>
</thead>
</table>
| Discard used patch (only wear one patch at a time). Patch is applied to clean, dry, intact, healthy skin on the buttock, abdomen, upper outer arm, or upper torso in a place where the patch will not be rubbed by clothing. Patch should not be placed on the breast or on areas that are red or irritated. \r
Beginning treatment: First day start (apply first patch on the first day of the menstrual cycle) or Sunday start (apply first patch on the first Sunday after the menstrual period begins). Use no creams or lotions on area where patch is to be applied. A backup contraceptive should be used for the first week of the first treatment cycle. Patch partially or completely detached for no longer that 24 hours: reapply to the same place or replace with a new patch immediately (no backup contraception needed). Patch detached for more than 24 hours: apply new patch immediately (new patch change day). Backup contraception needed for the first week (7 days). Forgets to change patch: begin again immediately with new patch change day (backup contraception needed for the first 7 days). If breakthrough bleeding continues longer than a few cycles, a cause other than the patch should be considered. Bleeding should occur during the patch-free week. If no bleeding occurs, consider the possibility of pregnancy. If pregnancy is confirmed, discontinue treatment. |

*The term generic indicates that the drug is available in generic form.
patient. The instructions for missed doses also are included in the package insert and are reviewed with the patient.

The nurse gives the patient a thorough explanation of the dose regimen and adverse reactions that may be seen with the prescribed drug. The nurse advises those taking oral contraceptives that skipping a dose could result in pregnancy. See Table 52-3 for more information to include in a teaching plan for a woman taking the contraceptive hormones.

In most instances, the primary health care provider performs periodic examinations, for example, laboratory tests, a pelvic examination, or a Pap smear. The patient is encouraged to keep all appointments for follow-up evaluation of therapy. The nurse includes several points in a teaching plan.

Estrogens and Progestins

- A patient package insert is available with the drug. Read the information carefully. If there are any questions about this information, discuss them with the primary health care provider.
- If gastrointestinal upset occurs, take the drug with food.
- Notify the primary health care provider if any of the following occurs: pain in the legs or groin area, sharp chest pain or sudden shortness of breath, lumps in the breast, sudden severe headache, dizziness or fainting, vision or speech disturbances, weakness or numbness in the arms or legs, severe abdominal pain, depression, or yellowing of the skin or eyes.
- Female patient: If pregnancy is suspected or abnormal vaginal bleeding occurs, stop taking the drug and contact the primary health care provider immediately.
- Patient with diabetes: Check the blood glucose or urine daily, or more often. Contact the primary health care provider if the blood glucose is elevated or if the urine is positive for glucose or ketones. An elevated blood glucose level or urine positive for glucose or ketones may require a change in diabetic therapy (insulin, oral hypoglycemic drug) or diet; these changes must be made by the primary health care provider.

Oral Contraceptives

- A patient package insert is available with the drug. Read the information carefully. Begin the first dose as directed in the package insert or as directed by the primary health care provider. If there are any questions about this information, discuss them with the primary health care provider.
- To obtain a maximum effect, take this drug as prescribed and at intervals not exceeding once every 24 hours. An oral contraceptive is best taken with the evening meal or at bedtime. The effectiveness of this drug depends on following the prescribed dosage schedule. Failure to comply with the dosage schedule may result in a pregnancy.
- Use an additional method of birth control (as recommended by the primary health care provider) until after the first week in the initial cycle.
- If one day’s dose is missed, take the missed dose as soon as remembered or take 2 tablets the next day. If 2 days are missed, take 2 tablets for the next 2 days and continue on with the normal dosing schedule. However, another form of birth control must be used until the cycle is completed and a new cycle is begun. If 3 days in a row or more are missed, discontinue use of the drug and use another form of birth control until a new cycle can begin. Before restarting the dosage regimen, make sure a pregnancy did not result from the break in the dosage regimen.
- If there are any questions regarding what to do about a missed dose, discuss the procedure with the primary health care provider.
- Avoid smoking or excessive exposure to second-hand smoke while taking these drugs; cigarette smoking during estrogen therapy may increase the risk of cardiovascular effects.
- Report adverse reactions such as fluid retention or edema to the extremities; weight gain; pain, swelling, or tenderness in the legs; blurred vision; chest pain; yellowed skin or eyes; dark urine; or abnormal vaginal bleeding.
- While taking these drugs, periodic examinations by the primary health care provider and laboratory tests are necessary.

Estradiol Transdermal System

- Aloria, Estraderm, Eslim, and Vivelle are applied twice a week; Climara and FemPatch are applied every 7 days.
- Apply the system immediately after opening the pouch, with the adhesive side down (Fig. 52-1). Apply to clean, dry skin of the trunk (not breast or waistline), buttocks, abdomen, upper inner thigh, or upper arm. (Do not apply to breasts or a site exposed to sunlight.) The area should not be oily or irritated.
- Press the system firmly in place with the palm of the hand for about 10 seconds. The application site is rotated with at least 1-week intervals between applications to a particular site.
- Avoid areas that may be exposed to rubbing or where clothing may rub the system off or loosen the edges.
- Remove the old system before applying a new system unless the primary health care provider directs
otherwise. Rotate application sites to prevent skin irritation.

- Follow the directions of the primary health care provider regarding application of the system (eg, continuous, 3 weeks use followed by 1 week off, changed weekly, or applied twice weekly).
- If the system falls off, reapply it or apply a new system. Continue the original treatment schedule.

**Intravaginal Application**

- Use the applicator correctly. Refer to the package insert for correct procedure. The applicator is marked with the correct dosage and accompanies the drug when purchased.
- Wash the applicator after each use in warm water with a mild soap and rinse well.
- Maintain a recumbent position for at least 30 minutes after instillation.
- Use a sanitary napkin or panty liner to protect clothing if necessary.
- Do not double the dosage if a dose is missed. Instead, skip the dose and resume treatment the next day (see Patient and Family Teaching Checklist: Self-Administering Intravaginal Estrogen).
- When using the vaginal ring, press the ring into an oval and insert into the upper third of the vaginal vault.

**EVALUATION**

- The therapeutic effect is achieved.
- Adverse reactions are identified, reported to the primary health care provider, and managed using appropriate nursing interventions.

---

**Figure 52-1.** This low-dose estrogen transdermal patch, available as the trade name Estraderm (Estradiol Transdermal System), is transparent and about the size of a silver dollar. It releases small amounts of estrogen directly into the bloodstream at a constant and controlled rate to a female requiring estrogen replacement therapy for postmenopausal symptoms.

**Patient and Family Teaching Checklist**

**Self-Administering Intravaginal Estrogen**

- The nurse:
  - Explains the reason for the drug and prescribed therapy, including drug name, correct dosage, and frequency of administration.
  - Describes the equipment to be used.
  - Reinforces the need to empty the bladder and wash hands before administration.
  - Demonstrates step-by-step procedure for filling applicator with drug and administration.
  - Recommends a supine position with knees flexed and legs spread.
  - Instructs patient to insert applicator into vagina, angling it toward the tailbone and advancing it about 2 inches.
  - Warns that drug may feel cold when inserted.
  - Urges patient to remain recumbent for about 30 minutes after inserting drug.
  - Suggests use of sanitary pad or napkin to prevent staining of clothes.
  - Advises patient to wash applicator with mild soap and warm water, rinse well, and dry with paper towel after use.
  - Cautions not to double dose if dose is missed, but to skip dose and resume treatment the next day.
  - Encourages daily inspection of perineal area for irritation or signs of allergic reaction.

---

**Critical Thinking Exercises**

1. Ms. Burton is receiving methyltestosterone (Oreton Methyl) for treatment of metastatic breast cancer. The drug has caused changes in her appearance, namely deepening of her voice, some male pattern baldness, and facial hair. Analyze the situation and decide what suggestions you could give this patient who has a limited income and may be unable to afford extensive cosmetic and wardrobe changes.

2. John, a friend of your brother, has started to use anabolic steroids to increase his strength and muscle mass...
to improve his chances of getting a football scholarship. Your brother tells you that this is acceptable because his friend wants an education. Discuss what you would tell your brother.

3. Susan Parker, a mother of three young children, calls the health clinic where you work stating that she has missed 3 days of oral contraceptives when she was ill. She wants to know if she can continue with the oral contraceptive. Discuss what information Susan needs to know to protect herself from becoming pregnant.

**Review Questions**

1. The nurse monitors the patient taking an anabolic steroid for the more severe adverse reactions, which include _____.
   A. anorexia  
   B. nausea and vomiting  
   C. severe mental changes  
   D. acne

2. The nurse must be aware that older men taking the androgens are _____.
   A. prone to urinary problems  
   B. at greater risk for hypertension  
   C. at increased risk for confusion  
   D. at increased risk for prostate cancer

3. When monitoring a patient taking an oral contraceptive, the nurse would observe the patient for signs of excess progestin. Which of the following reactions would indicate to the nurse that a patient has an excess of progestin?
   A. Increased appetite, hair loss  
   B. Virilization, constipation  
   C. Nausea, early breakthrough bleeding  
   D. Deepening of the voice, light-headedness

4. A patient calls the outpatient clinic and says that she missed one day’s dose of her “birth control pills.” Which of the following statements would be most appropriate for the nurse to make to the patient?
   A. Do not take an additional tablet but resume the regular schedule today.  
   B. Discontinue use of the drug and use another type of contraceptive until after your next menstrual period.  
   C. Take 2 tablets today; then resume the regular daily schedule.  
   D. Come into the office immediately for a pregnancy test.

5. When teaching the patient taking an oral contraceptive for the first time, the nurse emphasizes the importance of taking _____.
   A. two tablets per day at the first sign of ovulation  
   B. the drug at the same time each day  
   C. the drug early in the morning before arising  
   D. the drug each day for 20 days beginning on the first of the month

**Medication Dosage Problems**

1. Medroxyprogesterone 650 mg IM is prescribed. The drug is available in a solution of 400 mg/mL. The nurse administers _____.

2. The physician prescribes estrone 0.5 mg IM for a postmenopausal woman with vasomotor symptoms. On hand is a vial of estrone with a solution containing 0.5 mg/mL. The nurse administers _____.
Drugs Acting on the Uterus

**Key Terms**
- ergotism
- oxytocic
- oxytocin
- uterine atony
- uterine relaxants
- water intoxication

**Chapter Objectives**
On completion of this chapter, the student will:
- Discuss the actions, uses, adverse reactions, contraindications, precautions, and interactions of drugs acting on the uterus.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking an oxytocic drug or uterine relaxant.
- List some nursing diagnoses particular to a patient taking an oxytocic drug or uterine relaxant.
- Discuss ways to promote an optimal response to therapy, how to manage adverse reactions, and important points to keep in mind when educating patients about the use of an oxytocic drug or uterine relaxant.

**ACTION AND USES**

**Ergonovine and Methylergonovine**
Ergonovine and methylergonovine both increase the strength, duration, and frequency of uterine contractions and decrease the incidence of uterine bleeding. They are given after the delivery of the placenta and are used to prevent postpartum and postabortal hemorrhage caused by uterine atony (marked relaxation of the uterine muscle).

**Oxytocin**
Oxytocin is an endogenous hormone produced by the posterior pituitary gland (see Chap. 50). This hormone has uterine-stimulating properties, especially on the pregnant uterus. As pregnancy progresses, the sensitivity of the uterus to oxytocin increases, reaching peak sensitivity immediately before the birth of the infant. This sensitivity enables oxytocic drugs to exert their full therapeutic effect on the uterus and produce the desired results. Oxytocin also has antidiuretic and vasopressor effects. The exact role of oxytocin in normal labor and medically induced labor is not well understood.
Oxytocin is administered intravenously (IV) for starting or improving labor contractions to obtain an early vaginal delivery of the fetus. An early vaginal delivery may be indicated when there are fetal or maternal problems, for example, a woman with diabetes and a large fetus, Rh problems, premature rupture of the membranes, uterine inertia, and eclampsia or preeclampsia (also called pregnancy-induced hypertension). Preeclampsia is a condition of pregnancy characterized by hypertension, headaches, albuminuria, and edema of the lower extremities occurring at or near term. The condition may progressively worsen until eclampsia (a serious condition occurring between the 20th week of pregnancy and the end of the first postpartum and characterized by convulsive seizures and coma) occurs. Oxytocin may also be used in the management of inevitable or incomplete abortion. Oxytocin is given intramuscularly (IM) during the third stage of labor (period from the time the neonate is expelled until the placenta is expelled) to produce uterine contractions and control postpartum bleeding and hemorrhage. It may also be used intranasally to stimulate the milk ejection (milk letdown) reflex.

### ADVERSE REACTIONS

**Ergonovine and Methylergonovine**

The adverse reactions associated with ergonovine and methylergonovine include nausea, vomiting, elevated blood pressure, temporary chest pain, dizziness, water intoxication, and headache. Allergic reactions may also be seen. In some instances hypertension associated with seizure or headache may occur. **Ergotism** (overdosage of ergonovine) is manifested by nausea, vomiting, abdominal pain, numbness, tingling of the extremities, and an increase in blood pressure. In severe cases, these symptoms are followed by hypotension, respiratory depression, hypothermia, gangrene of the fingers and toes, convulsions, hallucinations, and coma.

---

**SUMMARY DRUG TABLE**

**DRUGS ACTING ON THE UTERUS**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGEs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Oxytocics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ergonovine</td>
<td>Ergotrate</td>
<td>Uterine atony and hemorrhage</td>
<td>Nausea, vomiting, elevated blood pressure, temporary chest pain, dizziness, headache</td>
<td>0.2 mg IM, IV q2–4h</td>
</tr>
<tr>
<td>maleate</td>
<td>generic</td>
<td>Routine management after delivery of the</td>
<td>Nausea, vomiting, elevated blood pressure, transient chest pain, dizziness, headache</td>
<td>0.2 mg IM, IV after delivery of the placenta; 0.2 mg PO TID, QID</td>
</tr>
<tr>
<td>methylergonovine</td>
<td>Methergine</td>
<td>placenta, uterine atony, and hemorrhage</td>
<td>Induction of labor: 1–2 mU/min IV infusion, gradually increase dosage by 1–2 mU/min with maximum dosage 20 mU/min; postpartum bleeding: IV infusion of 10–40 U in 1000 mL; 10 U IM</td>
<td></td>
</tr>
<tr>
<td>maleate</td>
<td></td>
<td>Antepartum: to initiate or improve uterine contractions; postpartum: to produce uterine contractions in third stage of labor, control of postpartum bleeding and hemorrhage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>oxytocin (parenteral)</td>
<td>Pitocin,</td>
<td>Nausea, vomiting, uterine hypertonicity or rupture, fetal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ox-i-toe-si'n</td>
<td>Syntocinon,</td>
<td>bradycardia, water intoxication, cardiac arrhythmias, anaphylactic reactions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>generic</td>
<td>generic</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

*The term generic indicates the drug is available in generic form.*
Oxytocin

Administration of oxytocin may result in fetal bradycardia, uterine rupture, uterine hypertonicity, nausea, vomiting, cardiac arrhythmias, and anaphylactic reactions. Serious water intoxication (fluid overload, fluid volume excess) may occur, particularly when the drug is administered by continuous infusion and the patient is receiving fluids by mouth. When used as a nasal spray, adverse reactions are rare.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Ergonovine and Methylergonovine

Ergonovine is contraindicated in those with known hypersensitivity to the drug, hypertension, and before the delivery of the placenta. Ergonovine is used cautiously in patients with heart disease, obliterative vascular disease, renal or hepatic disease, and during lactation.

Methylergonovine is contraindicated in patients with a known hypersensitivity to the drug, hypertension, and preeclampsia and should not be used to induce labor (Pregnancy Category C). Methylergonovine is used cautiously in patients with renal or hepatic impairment. When methylergonovine is administered concurrently with vasopressors or to patients who are heavy cigarette smokers, excessive vasoconstriction may occur.

Oxytocin

Oxytocin is contraindicated in patients with known hypersensitivity to the drug, cephalopelvic disproportion, unfavorable fetal position or presentation, in obstetric emergencies, situations of fetal distress when delivery is not imminent, severe toxemia (preeclampsia, eclampsia), hypertonic uterus, during pregnancy (intranasal administration), when there is total placenta previa, or to induce labor when vaginal delivery is contraindicated. Oxytocin is not expected to be a risk to the fetus when administered as indicated. When oxytocin is administered with vasopressors, severe hypertension may occur.

NURSING PROCESS

The Patient Receiving an Oxytocic Drug

ASSESSMENT

Preadministration Assessment

Before starting an IV infusion of oxytocin for the induction of labor, the nurse obtains an obstetric history (parity, gravidity, previous obstetric problems, type of labor, stillbirths, abortions, live birth infant abnormalities) and a general health history. Immediately before starting the IV infusion of oxytocin, the nurse assesses the fetal heart rate (FHR) and the patient’s blood pressure, pulse, and respiratory rate.

In addition, the nurse assesses and records the activity of the uterus (strength, duration, and frequency of contractions, if any). Monitoring of the uterine contractions for strength and length of the contractions can be done with the use of an external monitor or by an internal uterine catheter with an electronic monitor. A fetal monitor is placed to assess the FHR.

Ergonovine and methylergonovine may be given orally during the postpartum period to reduce the possibility of postpartum hemorrhage and to prevent relaxation of the uterus. When the patient is to receive either of these drugs after delivery, it is important to take the blood pressure, pulse, and respiratory rate before administration.

Ongoing Assessment

After injection of an oxytocic drug, the nurse monitors the blood pressure, pulse, and respiratory rate at the intervals ordered by the primary health care provider.

Nursing Alert

All patients receiving IV oxytocin must be under constant observation to identify complications. A one-to-one nurse–patient ratio is recommended when monitoring a patient receiving an oxytocin infusion. In addition, the primary health care provider should be immediately available at all times.

The nurse assesses the patient’s blood pressure, pulse, and respiratory rate every 30 minutes. The FHR and uterine contractions are assessed every 15 minutes or as ordered by the primary health care provider. Three to four firm uterine contractions should occur every 10 minutes, followed by a palpable relaxation of the uterus.

Nursing Alert

Hyperstimulation of the uterus during labor may lead to uterine tetany with marked impairment of the uteroplacental blood flow, uterine rupture, cervical rupture, amniotic fluid embolism, and trauma to the infant. Overstimulation of the uterus is dangerous to both the fetus and the mother and may occur even when the drug is administered properly in a uterus that is hypersensitive to oxytocin.

When monitoring uterine contractions, the nurse notifies the primary health care provider immediately if any of the following occurs:

• Any significant change in the FHR or rhythm
• Any marked change in the frequency, rate, or rhythm of uterine contractions: uterine contractions
lasting more than 60 seconds or contractions occurring more frequently than every 2 to 3 minutes or there is no palpable relaxation of the uterus
• A marked increase or decrease in the patient’s blood pressure or pulse or any significant change in the patient’s general condition

If any of these are noted, the nurse should immediately discontinue the oxytocin infusion and run the primary IV line at the rate prescribed by the primary health care provider until the primary health care provider examines the patient.

The nurse immediately reports any signs of water intoxication or fluid overload (eg, drowsiness, confusion, headache, listlessness, and wheezing, coughing, rapid breathing) to the primary health care provider.

Oxytocin may be given IM after delivery of the placenta. The nurse obtains the blood pressure, pulse, and respiratory rate every 5 to 10 minutes after the drug is administered. The nurse palpates the patient’s uterine fundus for firmness and position. The nurse immediately reports any excess bleeding to the primary health care provider.

When administering ergonovine and methylergonovine after delivery, the nurse monitors vital signs every 4 hours. In addition, the nurse notes the character and amount of vaginal bleeding. The patient may report abdominal cramping with the administration of these drugs. If cramping is moderately severe to severe, the nurse notifies the primary health care provider because it may be necessary to discontinue use of the drug.

NURSING DIAGNOSSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to drug therapy (ie, initiation of the normal labor process), adverse reactions identified and reported to the primary health care provider (eg, absence of a fluid volume excess [oxytocin administration]), and an understanding of the treatment regimen.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

OXYTOCIN. The patient receiving oxytocin to induce labor may have concern over the use of the drug to produce contractions. When given to induce or stimulate contractions, oxytocin may only be given intravenously (IV). The nurse explains the purpose of the IV infusion and the expected results to the patient. Because the patient receiving oxytocin must be closely supervised, the nurse spends time with the patient and offers encouragement and reassurance to help reduce anxiety.

When oxytocin is prescribed, the primary health care provider orders the type and amount of IV fluid, the number of units of oxytocin added to the IV solution, and the IV infusion rate. An electronic infusion device is used to control the infusion rate. The primary health care provider establishes guidelines for the administration of the oxytocin solution and for increasing or decreasing the flow rate or discontinuing the administration of oxytocin based on standards established by the Association of Women’s Health, Obstetric, and Neonatal Nurses (AWHONN). Usually, the flow rate is increased every 20 to 30 minutes, but this may vary according to the patient’s response. The strength, frequency, and duration of contractions and the FHR are monitored closely.

When administering oxytocin intranasally to facilitate the letdown of milk, the nurse places the patient in an upright position, and with the squeeze bottle held upright, administers the prescribed number of sprays to one or both nostrils. The patient then waits 2 to 3 minutes before breastfeeding the infant or pumping the breasts. If a breast pump is being used, the nurse records the amount of milk pumped from the breasts. The nurse notifies the primary health care provider if milk drips from the breast before or after breastfeeding or if milk drips from the opposite breast during breastfeeding because there would be no need to continue drug therapy. The primary health care provider is notified if nasal irritation, palpatations, or uterine cramping occurs.

ERGONOVINE AND METHYLERGONOVINE. The nurse administers ergonovine and methylergonovine at the direction of the primary health care provider. Ergonovine is usually given during the third stage of labor after the placenta has been delivered. Ergonovine is primarily administered IM, but in emergencies when quicker response is needed, the drug may be administered IV.

Methylergonovine is usually given IM at the time of the delivery of the anterior shoulder or after the delivery
Monitoring and Managing Adverse Reactions

**OXYTOCIN.** When oxytocin is administered, some adverse reactions must be tolerated or treated symptomatically until therapy is discontinued. For example, if the patient is nauseated, the nurse provides an emesis basin and perhaps a cool towel for the forehead. If vomiting occurs, the nurse notifies the primary health care provider.

If contractions are frequent, prolonged, or excessive, the infusion is stopped to prevent fetal anoxia or trauma to the uterus. Excessive stimulation of the uterus can cause uterine hypertonicity and possible uterine rupture. The nurse places the patient on her side and provides supplemental oxygen. The effects of the drug diminish rapidly because oxytocin is short acting.

When oxytocin is administered IV, there is a danger of a fluid volume excess (water intoxication) because oxytocin has an antidiuretic effect. The nurse measures the fluid intake and output. In some instances, hourly measurements of the output are necessary. The nurse observes the patient for signs of fluid overload (see Chap. 58). If any of these signs or symptoms is noted, the nurse should immediately discontinue the oxytocin infusion and run the primary IV line at the rate prescribed by the primary health care provider until the primary health care provider examines the patient.

**ERGONOVINE AND METHYLERGONOVINE.** When ergonovine or methylergonovine is administered for uterine atony and hemorrhage, abdominal cramping can occur and is usually an indication of drug effectiveness. The uterus is palpated in the lower abdomen as small, firm, and round. However, the nurse should report persistent or severe cramping to the primary health care provider.

**Educating the Patient and Family**

The treatment regimen is explained to the patient and family (when appropriate). The nurse answers any questions the patient may have regarding treatment. The patient is instructed to report any adverse reactions. The patient and family are informed of therapeutic response during administration of the drug. If nasal spray is to be used, the patient is taught proper use.

**EVALUATION**

- The therapeutic effect is achieved, and normal labor is initiated.
- Adverse reactions are managed effectively.
- No evidence of a fluid volume excess (oxytocin administration) is seen.
- The patient is knowledgeable of the therapeutic regimen.

**UTERINE RELAXANTS**

Uterine relaxants are useful in the management of preterm labor. These drugs will decrease uterine activity and prolong the pregnancy to allow the fetus to develop more fully, thereby increasing the chance of neonatal survival. Ritodrine (Yutopar) and terbutaline (Brethine) are two drugs currently used as uterine relaxants in the management of preterm (or premature) labor.

**Ritodrine**

Ritodrine has an effect on beta (β₁) adrenergic receptors, principally those that innervate the uterus. Stimulation of these β₁-adrenergic receptors inhibits uterine smooth muscle contractions. The β₁-adrenergic receptors are located in the heart and are not stimulated by ritodrine when administered as prescribed. Ritodrine is used to
manage preterm labor in pregnancies of greater than 20 weeks' gestation. Ritodrine administration requires hospitalization.

**Terbutaline**

Terbutaline (Brethine) is also classified as a β₂-adrenergic agonist (see Chap. 22) and is used primarily as a bronchodilator for patients with asthma and chronic obstructive pulmonary disease. Terbutaline is not approved by the Food and Drug Administration for treatment of preterm labor. Its use in the management of premature labor is investigational. However, many primary health care providers prefer terbutaline for the management of preterm labor, and it has proven to be highly effective for this purpose. When terbutaline is prescribed for the management of preterm labor, most agencies have the patient sign an informed consent before therapy is initiated.

**ADVERSE REACTIONS**

**Ritodrine**

Alterations in fetal and maternal heart rates and maternal blood pressure frequently occur when ritodrine is administered IV. Additional frequent adverse reactions associated with IV administration include nausea, vomiting, headache, palpitations, nervousness, restlessness, and emotional upset. A rare, but serious, adverse reaction is pulmonary edema.

**Terbutaline**

Adverse reactions observed with the administration of terbutaline include nervousness, restlessness, tremor, headache, anxiety, hypertension, hypokalemia (low serum potassium), arrhythmias, and palpitations. A serious, but rare, adverse reaction is pulmonary edema.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Ritodrine**

Ritodrine is contraindicated in patients with known hypersensitivity to the drug, antepartum hemorrhage, eclampsia or severe preeclampsia, cardiac disease, pulmonary hypertension, uncontrolled diabetes mellitus, or bronchial asthma (patients treated with betamimetics or steroids), in pregnancies of less than 20 weeks' gestation, and in the event of intrauterine fetal death. Ritodrine is classified as a Pregnancy Category B drug and is given cautiously during pregnancy. Because no adequate studies have been done in pregnant women before the 20th week of pregnancy, do not use this drug before the 20th week. Ritodrine is administered cautiously in patients with cardiac disease, migraine headaches, history of stroke, hyperthyroidism, and seizure disorders.

There is a decreased effectiveness of ritodrine when the drug is administered with a β-adrenergic blocking agent such as propranolol and an increased risk of pulmonary edema when administered with the corticosteroids. Co-administration of ritodrine with the sympathomimetics potentiates the effect of ritodrine. Cardiovascular effects (eg, arrhythmias or hypotension) of ritodrine may increase when the drug is administered with diazoxide, general anesthetics, magnesium sulfate, or meperidine.

**Terbutaline**

Terbutaline is contraindicated in patients with known hypersensitivity to the drug, severe cardiac problems (tachyarrhythmias), digitalis toxicity, or hypertension. Terbutaline is classified as a Pregnancy Category B drug and is given cautiously during pregnancy (after the 20th week of pregnancy only). Terbutaline is administered cautiously in patients with cardiac disease, history of stroke, hyperthyroidism, and seizure disorders. When terbutaline is administered with the anesthetic halothane, there is an increased risk of cardiac arrhythmias. Additional information about terbutaline can be found in Chapter 37.

**NURSING PROCESS**

- The Patient Receiving a Uterine Relaxant

**ASSESSMENT**

**Preadministration Assessment**

Before starting an IV infusion containing ritodrine or terbutaline, the nurse obtains the patient's vital signs. The nurse auscultates lung sounds to provide a baseline assessment. The nurse places the patient on a monitoring device to determine uterine contractions and the FHR before and during administration.

**Ongoing Assessment**

During the ongoing assessment of a patient receiving a uterine relaxant, the nurse performs the following tasks at 15- to 30-minute intervals:

- Obtains blood pressure, pulse, and respiratory rate.
- Monitors FHR.
- Checks the IV infusion rate.
Examines the area around the IV needle insertion for signs of extravasation.

- Monitors uterine contractions (frequency, intensity, length).

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes of the patient may include an optimal response to therapy, a reduction in anxiety, and an understanding of the treatment of preterm labor.

**IMPLEMENTATION**

Promoting an Optimal Response to Therapy

Nursing management for ritodrine and terbutaline is similar. For IV administration, the nurse prepares the solution according to the primary health care provider’s instructions. An infusion pump is used to control the rate of flow. Ritodrine or terbutaline may be piggybacked to the primary line, allowing the primary line to maintain the patency of the IV should it be necessary to temporarily discontinue infusion of the drug. The primary health care provider may prescribe terbutaline for administration by the oral or the subcutaneous route throughout the treatment, rather than via the IV route. The nurse places a cardiac monitor on the patient. To minimize hypotension, the nurse positions the patient in a left lateral position unless the primary health care provider orders a different position.

The primary health care provider is kept informed of the patient’s response to the drug because a dosage change may be necessary. The primary health care provider establishes guidelines for the regulation of the IV infusion rate, as well as the blood pressure and pulse ranges that require stopping the IV infusion.

Managing Anxiety

The patient in preterm labor may have many concerns about her pregnancy, as well as the effectiveness of drug therapy. The woman is encouraged to verbalize any fears or concerns. The nurse listens to the patient’s concerns and carefully and accurately answers any questions she may have concerning drug therapy. In addition, the nurse offers emotional support and encouragement during the time the drug is being administered. If allowed by the institution, the presence of family members may decrease anxiety in the woman experiencing preterm labor.

Educating the Patient and Family

The nurse carefully explains the treatment regimen to the patient. The primary health care provider usually discusses the expected outcome of treatment with the patient and answers any questions regarding therapy. Although the patient is monitored closely during therapy, the patient is instructed to notify the nurse immediately if any of the following occur: nausea, vomiting, palpitations, or shortness of breath. If a patient is taking ritodrine, the nurse discusses the importance of lying on the left side during IV administration.

If oral terbutaline is prescribed for preterm labor, the patient is instructed on use of the drug and adverse reactions to report (excessive tremor, nervousness, drowsiness, headache, nausea, dizziness). If contractions resume during oral therapy, the patient is instructed to notify the primary health care provider if four to six contractions per hour occur.

**EVALUATION**

- The therapeutic drug effect is achieved.
- Adverse reactions are identified and reported to the primary health care provider.
- Anxiety is reduced.
- The patient demonstrates an understanding of in-hospital treatment.
**Critical Thinking Exercises**

1. Develop a nursing care plan for Ms. Morris, a 28-year-old woman who is admitted to the obstetric unit with premature labor during her third trimester. This is her second child, and she has had two miscarriages. She is prescribed ritodrine for preterm labor. Analyze what nursing diagnoses would have the highest priority. Discuss how you would explore and plan to meet her emotional needs.

2. Judith Watson, aged 28 years, is admitted to the obstetric unit and is to receive oxytocin to induce labor. This is her first child, and she is extremely anxious. Analyze what information would be necessary for her to receive from the nurse before the administration of oxytocin. What assessments would be important for the nurse to make during treatment with oxytocin?

**Review Questions**

1. When oxytocin is administered over a prolonged time, which of the following adverse reactions would be most likely to occur?
   - A. Hyperglycemia
   - B. Renal impairment
   - C. Increased intracranial pressure
   - D. Water intoxication

2. When the patient is receiving oxytocin, the nurse would notify the primary health care provider in which of the following conditions?
   - A. Uterine contractions occur every 5 to 10 minutes.
   - B. Uterine contractions last more than 60 seconds or contractions occur more frequently than every 2 to 3 minutes.
   - C. Patient experiences pain during a uterine contraction.
   - D. Patient experiences increased thirst.

3. Which of the following adverse reactions is most indicative of ergotism?
   - A. Numbness, tingling of the extremities
   - B. Headache, blurred vision
   - C. Tachycardia and cardiac arrhythmias
   - D. Diaphoresis, increased respirations

4. During administration of ritodrine, in what position would the nurse most probably place the patient?
   - A. Supine
   - B. Prone
   - C. On the left side
   - D. On the right side

**Medication Dosage Problems**

1. Terbutaline 2.5 mg is prescribed. The drug is available in 5-mg tablets. The nurse administers _____.

2. Methylergonovine 0.2 mg IM is prescribed. The drug is available as 0.2 mg/mL. The nurse administers ______.
Immunity refers to the ability of the body to identify and resist microorganisms that are potentially harmful. This ability enables the body to fight or prevent infectious disease and inhibit tissue and organ damage. The immune system is not confined to any one part of the body. Immune stem cells, formed in the bone marrow, may remain in the bone marrow until maturation or migrate to different body sites for maturation. After maturation, most immune cells circulate into the body and exert specific effects. The immune system has two distinct, but overlapping, mechanisms with which to fight invading organisms:

- Cell-mediated defenses (cellular immunity)
- Antibody-mediated defenses (humoral immunity)

**Cell-Mediated Immunity**

Cell-mediated immunity (CMI) is the result of the activity of many leukocyte actions, reactions, and interactions that range from simple to complex. This type of immunity is dependent on the actions of the T lymphocytes, which are responsible for a delayed type of immune response. The T lymphocyte becomes sensitized by its first contact with a specific antigen. Subsequent exposure to an antigen stimulates multiple reactions aimed at destroying or inactivating the offending antigen. T lymphocytes and macrophages (large cells that surround, engulf, and digest microorganisms and cellular debris) work together in CMI to destroy the antigen. T lymphocytes attack the antigens directly, rather than produce antibodies (as is done in humoral immunity). Cellular reactions may also occur without macrophages. Several T lymphocytes (T cells) are involved in CMI:

- Helper T4 cells—function within the bloodstream identifying and destroying antigens
- Helper T1 cells—increase B lymphocyte antibody production
- Helper T2 cells—increase activity of cytotoxic (killer) T cells, which attack the cell directly by altering the cell membrane and causing cell lysis (destruction)
- Suppressor T cells—suppress the immune response
- Memory T lymphocytes—recognize previous contact with antigens and activate an immune response

The T lymphocytes defend against viral infections, fungal infections, and some bacterial infections. If CMI is lost, as in the case of acquired immunodeficiency...
syndrome, the body is unable to protect itself against many viral, bacterial, and fungal infections.

**HUMORAL IMMUNITY**

In **humoral immunity** special lymphocytes (white blood cells), called B lymphocytes, produce circulating antibodies to act against a foreign substance. This type of immunity is based on the antigen–antibody response. A **antigen** is a substance, usually a protein, that stimulates the body to produce antibodies. An **antibody** is a globulin (protein) produced by the B lymphocytes as a defense against an antigen. Humoral immunity protects the body against bacterial and viral infections.

Specific antibodies are formed for a specific antigen, that is, chickenpox antibodies are formed when the person is exposed to the chickenpox virus (the antigen). This is called an **antigen–antibody response.** Once manufactured, antibodies circulate in the bloodstream, sometimes for only a short time and, at other times, for the life of the person. When an antigen enters the body, specific antibodies neutralize the specific invading antigen; this is called immunity. Thus, the individual with specific circulating antibodies is immune (or has immunity) to a specific antigen. Immunity is the resistance that an individual has against disease.

Cell-mediated and humoral immunity are interdependent, that is, CMI influences the function of the B lymphocytes, and humoral immunity influences the function of the T lymphocytes.

**ACTIVE AND PASSIVE IMMUNITY**

Active and passive immunity involve the use of agents that stimulate antibody formation (active immunity) or the injection of ready-made antibodies found in the serum of immune individuals or animals (passive immunity). The following sections describe active and passive immunity.

**Active Immunity**

When a person is exposed to certain infectious microorganisms (antigens), the body begins to form antibodies (or build an immunity) to the invading microorganism. This is called **active immunity.** The two types of active immunity are naturally acquired active immunity and artificially acquired active immunity. The Summary Drug Table: Agents for Active Immunization identifies agents that produce active immunity.

**Naturally Acquired Active Immunity**

Naturally acquired active immunity occurs when the person is exposed to a disease, experiences the disease, and the body manufactures antibodies to provide future immunity to the disease. It is called active immunity because the antibodies were produced by the person who had the disease (Fig. 54-1). Thus, having the disease produces immunity. Display 54-1 provides an example of naturally acquired active immunity.

**ARTIFICIALLY ACQUIRED ACTIVE IMMUNITY**

Artificially acquired active immunity occurs when an individual is given a killed or weakened antigen, which stimulates the formation of antibodies against the antigen. The antigen does not cause the disease, but the individual will still manufacture specific antibodies against the disease. When a vaccine containing an **attenuated** (weakened) antigen is given, the individual may experience a few minor symptoms of the disease or even a mild form of the disease, but the symptoms are almost always milder and usually last for a short time.

The decision to use an attenuated, rather than a killed, virus as a vaccine to provide immunity is based on research. For example, many antigens, when killed, show a poor antibody response, whereas when the antigen is merely weakened, a good antibody response occurs. Immunization against a specific disease(s) provides artificially acquired active immunity. Display 54-2 gives an example of artificially acquired active immunity.

**DISPLAY 54-1 Example of Naturally Acquired Active Immunity**

An example is when the individual is exposed to chickenpox for the first time and has no immunity to the disease. The body immediately begins to manufacture antibodies against the chickenpox virus. However, the production of a sufficient quantity of antibodies takes time, and the individual gets the disease. At the time of exposure and while the individual still has chickenpox, the body continues to manufacture antibodies. These antibodies circulate in the individual's bloodstream for life. In the future, any exposure to the chickenpox virus results in the antibodies mobilizing to destroy the invading antigen.

**DISPLAY 54-2 Example of Artificially Acquired Active Immunity**

An example of the use of an attenuated virus is the administration of the measles vaccine to an individual who has not had measles. The measles (rubeola) vaccine contains the live, attenuated measles virus. The individual receiving the vaccine develops a mild or modified measles infection, which then produces immunity against the rubeola virus. The measles vaccine protects 95% of the recipients for several years or, for some individuals, for life. An example of a killed virus used for immunization is the cholera vaccine. This vaccine protects those who receive the vaccine for about 3 to 6 months.
<table>
<thead>
<tr>
<th>Generic Drug</th>
<th>Trade Name</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG vaccine</td>
<td>Tice BCG</td>
<td>Infants and children with negative tuberculin skin test who are at high risk of intimate and prolonged exposure to pulmonary tuberculosis</td>
<td>Rare; minor local reactions such as local tenderness, pain at injection site, malaise, nausea, diarrhea, headache, fever</td>
<td>0.2–0.3 mL percutaneous</td>
</tr>
<tr>
<td>Cholera vaccine</td>
<td>generic</td>
<td>Immunization against cholera in individuals traveling to or living in countries where cholera is endemic or epidemic</td>
<td>Same as for BCG vaccine</td>
<td>0.2–0.3 mL SC, IM with a booster of 0.5 mL at 10 y</td>
</tr>
<tr>
<td>Haemophilus influenzae type b conjugate and hepatitis B vaccine</td>
<td>ActHIB, Comvax, HibTITER Vaccine, PedvaxHIB</td>
<td>Routine immunization of children</td>
<td>Same as for BCG vaccine</td>
<td>0.5 mL IM</td>
</tr>
<tr>
<td>Lyme disease vaccine (recombinant OspA)</td>
<td>LYMErix</td>
<td>Active immunizations against Lyme disease in individuals 15–70 years of age who are at risk of contracting the disease</td>
<td>Same as for BCG vaccine</td>
<td>30 mcg IM, SC at 0, 1, and 12 months</td>
</tr>
<tr>
<td>Meningococcal polysaccharide vaccine</td>
<td>Menomune A/C/Y/W-135</td>
<td>Active immunization against invasive meningococcal disease</td>
<td>Same as for BCG vaccine</td>
<td>0.5 mL SC only</td>
</tr>
<tr>
<td>Pneumococcal vaccine, polyvalent new-mo-kok'-kal vak'-seen</td>
<td>Pneumovax 23, Pnu-Imune 23</td>
<td>Immunization against pneumococcal pneumonia and bacteremia caused by the types of pneumococci included in the vaccine</td>
<td>Same as for BCG vaccine</td>
<td>0.5 mL SC or IM</td>
</tr>
<tr>
<td>Pneumococcal 7-valent conjugate vaccine (diphtheria CRM197 protein) new-mo-kok'-kal-vak'-seen</td>
<td>Prevnar</td>
<td>Active immunization against Streptococcus pneumoniae for infants and toddlers</td>
<td>Rare; minor local reactions such as local tenderness, pain at injection site, decreased appetite, irritability, drowsiness, malaise, nausea, diarrhea, fever</td>
<td>0.5 mL IM</td>
</tr>
<tr>
<td>Typhoid vaccine</td>
<td>Typhim Vi, Vivotif Berna, generic</td>
<td>Immunization against typhoid</td>
<td>Same as for BCG vaccine</td>
<td>Oral: One capsule on alternate days 1h before a meal for a total of 4 capsules Parenteral: Adults and children 10 years and older, 2 doses of 0.5 mL SC; children younger than 10 years, 2 doses of 0.25 mL SC Booster: 0.1–0.5 mL intradermally</td>
</tr>
</tbody>
</table>
### SUMMARY DRUG TABLE  
**AGENTS FOR ACTIVE IMMUNIZATION** (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vaccines, Viral</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>measles virus vaccine, live, attenuated</td>
<td>Attenuvax</td>
<td>Active immunization against measles</td>
<td>Same as for BCG vaccine</td>
<td>0.5 mL SC</td>
</tr>
<tr>
<td>rubella virus vaccine, live</td>
<td>Meruvax II</td>
<td>Selective active immunization against rubella</td>
<td>Same as for BCG vaccine</td>
<td>Total volume of reconstituted vial SC</td>
</tr>
<tr>
<td>mumps virus vaccine, live</td>
<td>MumpsVax</td>
<td>Selective active immunization against mumps</td>
<td>Same as for BCG vaccine</td>
<td>0.5 mL SC (total volume of reconstituted vaccine)</td>
</tr>
<tr>
<td>rubella and mumps virus vaccine, live</td>
<td>Biavax-II</td>
<td>Active immunization against rubella and mumps</td>
<td>Same as for BCG vaccine</td>
<td>0.5 mL SC</td>
</tr>
<tr>
<td>measles (rubeola) and rubella virus vaccine, live</td>
<td>M-R-Vax II</td>
<td>Active immunization against rubeola and rubella</td>
<td>Same as for BCG vaccine</td>
<td>0.5 mL SC</td>
</tr>
<tr>
<td>poliovirus vaccine, live, oral, trivalent (OPV; TOPV; Sabin)</td>
<td>Orimune</td>
<td>Active immunization against poliovirus</td>
<td>Rare; malaise, nausea, diarrhea, fever</td>
<td>Three doses 0.5 mL PO at specified intervals</td>
</tr>
<tr>
<td>Poliovirus vaccine, inactivated (IPV)</td>
<td>IPOL</td>
<td>Active immunizations for the poliovirus</td>
<td>Same as for BCG vaccine</td>
<td>Three doses of 0.5 mL SC at 2 months, 4 months, and 12–15 months; children receive a booster dose before entering school</td>
</tr>
<tr>
<td>Influenza virus vaccine</td>
<td>FluShield, Fluvirin, Fluzone</td>
<td>Active immunization against the specific influenza virus strains contained in the formulation</td>
<td>Same as for BCG vaccine</td>
<td>One or two doses of 0.25–0.5 mL IM</td>
</tr>
<tr>
<td>Japanese encephalitis virus vaccine</td>
<td>JE-VAX</td>
<td>For active immunization against Japanese encephalitis for individuals older than 1 year</td>
<td>Same as for BCG vaccine</td>
<td>Three doses given to adults and children &gt; 3 years: 1 mL SC on days 0, 7, and 30; children 1–3 years: 0.5 mL SC on days 0, 7, and 30</td>
</tr>
<tr>
<td>rotavirus vaccine</td>
<td>RotaShield</td>
<td>Prevention of gastroenteritis caused by rotavirus serotypes contained in the vaccines</td>
<td>Fever, decreased appetite, abdominal cramping, irritability, and decreased activity</td>
<td>Three 2.5-mL doses given orally</td>
</tr>
<tr>
<td>yellow fever vaccine</td>
<td>YF-Vax</td>
<td>Active immunity against yellow fever virus, primarily among travelers to yellow fever endemic areas</td>
<td>Malaise, usually appearing 7–14 days after administration, myalgia, and headache</td>
<td>0.5 mL SC; booster dose suggested q10 years</td>
</tr>
<tr>
<td>GENERIC NAME</td>
<td>TRADE NAME*</td>
<td>USES</td>
<td>ADVERSE REACTIONS</td>
<td>DOSAGE RANGES</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>--------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>------------------</td>
</tr>
<tr>
<td>hepatitis B vaccine, recombinant</td>
<td>Engerix-B, Recombivax HB</td>
<td>Immunization against infections caused by all known subtypes of hepatitis B virus</td>
<td>Headache, light-headedness, vertigo, dizziness, paresthesia, insomnia, disturbed sleep, pruritus, rash, urticaria, erythema, nausea, vomiting, abdominal pain, dyspepsia, constipation, anorexia, diarrhea, hypersensitivity, local pain and soreness at injection site, swelling, induration, or tenderness at injection site, arthralgia, influenza-like symptoms, fatigue, tinnitus, earache</td>
<td>3–4 doses of 0.5–2 mL</td>
</tr>
<tr>
<td>hepatitis A vaccine, inactivated</td>
<td>Havrix, Vaqta</td>
<td>Active immunization of individuals 2 months of age and older against disease caused by hepatitis A virus (HAV)</td>
<td>Headache, hypertonic episode, insomnia, photophobia, vertigo, pruritus, rash, urticaria, erythema, dermatitis, anorexia, nausea, abdominal pain, diarrhea, vomiting, arthralgia, pharyngitis, cough, fatigue, fever, and malaise, soreness, pain, tenderness, induration, redness, swelling, or rash at injection site</td>
<td>Administered IM; dosage varies with product. See package insert for specific dosages.</td>
</tr>
<tr>
<td>hepatitis A, inactivated and hepatitis B, recombinant vaccine</td>
<td>Twinrix</td>
<td>Active immunization against hepatitis A and B viruses</td>
<td>Same as for hepatitis A, inactivated</td>
<td>Administered IM in single-dose vial and single-dose prefilled syringes. See package insert for recommended dose.</td>
</tr>
<tr>
<td>varicella virus vaccine</td>
<td>Varivax</td>
<td>Vaccination against varicella in people older than 1 year</td>
<td>Children: Upper respiratory illness, cough, irritability, nervousness, fatigue, disturbed sleep, diarrhea, loss of appetite, vomiting, otitis, diaper rash, headache, teething, malaise Adults: fever; injection site complaints of soreness, erythema, swelling, induration and numbness, varicellalike rash; upper respiratory illness; headache; fatigue; cough; myalgia; disturbed sleep; nausea; diarrhea; stiff neck; irritability; nervousness; constipation</td>
<td>Children 1–12 years: one dose 0.5 mL SC Adults: 0.5 mL; SC two doses</td>
</tr>
<tr>
<td>rabies vaccine</td>
<td>Imovax Rabies I.D. Vaccine (human diploid cell), Imovax Rabies Vaccine (human diploid cell), RabAvert</td>
<td>Pre-exposure: immunization of people with greater than usual risk of exposure to rabies virus by reason of occupation (eg, veterinarians laboratory workers, animal handlers, forest rangers, people staying more than</td>
<td>Transient pain, erythema, swelling or itching at the injection site, headache, nausea, abdominal pain, muscle aches, and dizziness</td>
<td>Pre-exposure prophylaxis: on days 0, 7, 21 to 28 and then q2–5 years based on antibody titers 1 mL IM (Imovax Rabies Vaccine or Rabies Vaccine Adsorbed) or (continued)</td>
</tr>
</tbody>
</table>
**SUMMARY DRUG TABLE  AGENTS FOR ACTIVE IMMUNIZATION (Continued)**

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rabies Vaccine Adsorbed</td>
<td>1 month in countries where rabies is a constant threat; post-exposure prophylaxis: bite by a carrier animal that is unprovoked and rabies is present in the area</td>
<td>0.1 mL I.D. (Imovax Rabies I.D.) Postexposure: Do not give intradermally, only IM, 20 IU/kg as soon as possible after exposure, followed by IM vaccine doses on days 0, 3, 7, 14 and 28</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus Toxoid, Adsorbed Toxoid, Fluid</td>
<td>Active immunization of children older than 6 weeks and adults against tetanus</td>
<td>Cochlear lesion, brachial plexus neuropathies, paralysis of the radial nerve, accommodation paresis, EEG disturbances, urticaria, rash, malaise, fever, chills, pain, hypotension, nausea, and local redness, warmth, edema, induration and sterile abscess at injection site</td>
<td>0.5 mL IM</td>
<td></td>
</tr>
<tr>
<td>Diphtheria and tetanus toxoids, combined (DT;Td) dip-ther’-ee-ah-tet’-ah-nus-toks’-oyds</td>
<td>Immunization against diphtheria and tetanus</td>
<td>See adverse reactions for both diphtheria and tetanus toxoids.</td>
<td>See package inserts for specific dosage.</td>
<td></td>
</tr>
<tr>
<td>Diptheria and tetanus toxoids, acellular pertussis vaccine, adsorbed (DTaP) dip-ther’-ee-ah-tet’-ah-nus-toks’-oyds-a-sell’-u-lar-per-tuss’-us</td>
<td>Active immunization against diphtheria, tetanus, and pertussis simultaneously</td>
<td>See adverse reactions for diphtheria and tetanus toxoids, and pertussis vaccine.</td>
<td>Follow package instructions for preparation and IM administration.</td>
<td></td>
</tr>
<tr>
<td>Diphtheria and tetanus toxoids, acellular pertussis and Haemophilus influenzae type B</td>
<td>Active immunization against diphtheria, tetanus, and pertussis and Haemophilus influenzae type B</td>
<td>See adverse reactions for diphtheria and tetanus toxoids, pertussis, and Haemophilus influenzae type B.</td>
<td>See package insert for specific dosages. For IM administration only, usual dose is 0.5 mL.</td>
<td></td>
</tr>
<tr>
<td>Vaccine diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus combined</td>
<td>Active immunization against diphtheria, tetanus, pertussis and all known subtypes of hepatitis B virus, and poliomyelitis immunization</td>
<td>See adverse reactions against individual vaccines.</td>
<td>Primary immunization series: 3 doses of 0.5 mL at 6- to 8-week intervals IM (first dose is 2 months of age, but may be given as early as 6 weeks of age)</td>
<td></td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
Artificially acquired immunity against some diseases may require periodic booster injections to keep an adequate antibody level (or antibody titer) circulating in the blood. A booster injection is the administration of an additional dose of the vaccine to "boost" the production of antibodies to a level that will maintain the desired immunity. The booster is given months or years after the initial vaccine and may be needed because the life of some antibodies is short.

The measles vaccine is considered an immunization. Immunization is a form of artificial active immunity and an important method of controlling some of the infectious diseases that are capable of causing serious and sometimes fatal consequences. The immunization schedule for children is given in Figure 54-2. Currently, many infectious diseases may be prevented by vaccine (artificial active immunity). Examples of some of these diseases can be found in Display 54-3.

### Passive Immunity

Passive immunity is obtained from the administration of immune globulins or antivenins. This type of immunity provides the individual with ready-made antibodies from another human or an animal (see Fig. 54-1). Passive immunity provides immediate immunity to the invading antigen, but lasts for only a short time. The Summary Drug Table: Agents for Passive Immunity identifies agents for passive immunizations. Display 54-4 provides an example of passive immunity.

#### Herbal Alert: Echinacea

Echinacea, a frequently used herb, is taken to stimulate the immune system function by increasing the number and activity of immune cells and to stimulate phagocytosis (ingestion and destruction of bacteria and other harmful substances). It appears to shorten the duration of colds and influenza. The recommended dosage is:

- 500-1000 mg three times a day
- 15-30 drops of tincture two to five times a day

Most herbalists recommend that echinacea should be taken at the initial signs of infection, when symptoms first become apparent. Small repeated doses throughout the day may be better than taking larger doses less frequently. Because it is an immunosuppressant, the herb should not be taken for more than eight consecutive weeks. Seven to fourteen days of treatment is usually sufficient.

Although rare, side effects such as nausea and other mild gastrointestinal effects may occur. Individuals with allergies to daisy-type plants are more susceptible to reactions.
This schedule indicates the recommended ages for routine administration of currently licensed childhood vaccines, as of December 1, 2001, for children through age 18 years. Any dose not given at the recommended age should be given at any subsequent visit when indicated and feasible. Indicates age groups that warrant special effort to administer those vaccines not previously given. Additional vaccines may be licensed and recommended during the year. Licensed combination vaccines may be used whenever any components of the combination are indicated and the vaccine's other components are not contraindicated. Providers should consult the manufacturer's package inserts for detailed recommendations. Approved by the Advisory Committee on Immunization Practices (www.cdc.gov/nip/acip), the American Academy of Pediatrics (www.aap.org), and the American Academy of Family Physicians (www.aafp.org).
1. **Hepatitis B vaccine (Hep B).** All infants should receive the first dose of hepatitis B vaccine soon after birth and before hospital discharge; the first dose may also be given by age 2 months if the infant's mother is HBsAg-negative. Only monovalent hepatitis B vaccine can be used for the birth dose. Monovalent or combination vaccine containing Hep B may be used to complete the series; four doses of vaccine may be administered if combination vaccine is used. The second dose should be given at least 4 weeks after the first dose, except for Hib-containing vaccine which cannot be administered before age 6 weeks. The third dose should be given at least 16 weeks after the first dose and at least 8 weeks after the second dose. The last dose in the vaccination series (third or fourth dose) should not be administered before age 6 months.

   Infants born to HBsAg-positive mothers should receive hepatitis B vaccine and 0.5 mL hepatitis B immune globulin (HBIG) within 12 hours of birth at separate sites. The second dose is recommended at age 1–2 months and the vaccination series should be completed (third or fourth dose) at age 6 months.

   Infants born to mothers whose HBsAg status is unknown should receive the first dose of the hepatitis B vaccine series within 12 hours of birth. Maternal blood should be drawn at the time of delivery to determine the mother's HBsAg status; if the HBsAg test is positive, the infant should receive HBIG as soon as possible (no later than age 1 week).

2. **Diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP).** The fourth dose of DTaP may be administered as early as age 12 months, provided 6 months have elapsed since the third dose and the child is unlikely to return at age 15–18 months. **Tetanus and diphtheria toxoids (Td)** is recommended at age 11–12 years if at least 5 years have elapsed since the last dose of tetanus and diphtheria toxoid-containing vaccine. Subsequent routine Td boosters are recommended every 10 years.

3. **Haemophilus influenzae type b (Hib) conjugate vaccine.** Three Hib conjugate vaccines are licensed for infant use. If PRP-OMP (PedvaxHIB or ComVax) is administered at ages 2 and 4 months, a dose at age 6 months is not required. DTaP/Hib combination products should not be used for primary immunization in infants at ages 2, 4 or 6 months, but can be used as boosters following any Hib vaccine.

4. **Inactivated polio vaccine (IPV).** An all-IPV schedule is recommended for routine childhood polio vaccination in the United States. All children should receive four doses of IPV at ages 2 months, 4 months, 6–18 months, and 4–6 years.

5. **Measles, mumps, and rubella vaccine (MMR).** The second dose of MMR is recommended routinely at age 4–6 years but may be administered during any visit, provided at least 4 weeks have elapsed since the first dose and that both doses are administered beginning at or after age 12 months. Those who have not previously received the second dose should complete the schedule by the 11–12-year-old visit.

6. **Varicella vaccine.** Varicella vaccine is recommended at any visit at or after age 12 months for susceptible children, i.e., those who lack a reliable history of chickenpox. Susceptible persons aged >13 years should receive two doses, given at least 4 weeks apart.

7. **Pneumococcal vaccine.** The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for all children age 2–23 months. It is also recommended for certain children age 24–59 months. **Pneumococcal polysaccharide vaccine (PPV)** is recommended in addition to PCV for certain high-risk groups. See MMWR. 2000;49(RR-9):1–35.

8. **Hepatitis A vaccine.** Hepatitis A vaccine is recommended for use in selected states and regions, and for certain high-risk groups; consult your local public health authority. See MMWR. 1999;48(RR-12):1–37.

9. **Influenza vaccine.** Influenza vaccine is recommended annually for children age >6 months with certain risk factors (including but not limited to asthma, cardiac disease, sickle cell disease, HIV, diabetes; see MMWR. 2001;50(RR-4):1–44), and can be administered to all others wishing to obtain immunity. Children aged ≤12 years should receive vaccine in a dosage appropriate for their age (0.25 mL if age 6–35 months or 0.5 mL if age ≥3 years). Children aged ≤8 years who are receiving influenza vaccine for the first time should receive two doses separated by at least 4 weeks.

For additional information about vaccines, vaccine supply, and contraindications for immunization, please visit the National Immunization Program Web site at www.cdc.gov/nip or call the National Immunization Hotline at (800) 232-2522 (English) or (800) 232-0233 (Spanish).
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune Globulins</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cytomegalovirus immune globulin intravenous, human (CMV-IGIV)</td>
<td>CytoGam</td>
<td>Prophylaxis of CMV associated with organ transplant (kidney)</td>
<td>Flushing, chills, muscle cramps, back pain, fever, nausea, vomiting, wheezing, decrease in blood pressure</td>
<td>15 mg/kg IV over 30 min, increase to 30 mg/kg for 30 min, then 60 mg/kg to a maximum of 150 mg/kg</td>
</tr>
<tr>
<td>hepatitis B immune globulin (human) (HBIG)</td>
<td>BayHep B, Nabi-HB</td>
<td>Postexposure prophylaxis to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to an HBsAg-positive person, household exposure to people with acute HBV infections</td>
<td>Local tenderness, pain, muscle stiffness at injection site, urticaria, angioedema, malaise, nausea, diarrhea, headache, chills, and fever</td>
<td>0.06 mL/kg (3–5 mL) IM</td>
</tr>
<tr>
<td>immune globulin (human) IgG; IgIM; gamma globulin; IgG</td>
<td>BayGam</td>
<td>Prophylaxis after exposure to hepatitis A, prevention or modification of measles in one who has not been vaccinated or has not had measles previously, immunoglobulin deficiency, passive immunity against varicella, and rubella</td>
<td>Same as HBIG</td>
<td>0.02 mL/kg (0.1 mL/lb)-1.2 mL/kg IM</td>
</tr>
<tr>
<td>immune globulin intravenous (IGIV) em-une'-glo-b'-u-lin</td>
<td>Gamimune N, Gammagard S/D, Gammar-P I.V., Iveegam, Polygamm S/D, Sandoglobulin, Venoglobulin</td>
<td>Immunodeficiency syndrome, idiopathic thrombocytopenic purpura, B-cell chronic lymphocytic leukemia (Gammagard S/D, Polygamm S/D), bone marrow transplantation (Gamimune N only), pediatric HIV (Gamimune N only)</td>
<td>Same as HBIG</td>
<td>100–400 mg/kg IV; dosage varies, see package insert</td>
</tr>
<tr>
<td>lymphocyte immune globulin, antithymocyte globulin (equine) lymph'-o-ste-em-une'-glo-b'-u-lin</td>
<td>Atgam</td>
<td>Renal transplantation, aplastic anemia</td>
<td>Same as HBIG</td>
<td>Adults: 10–30 mg/kg/d Children: 5–25 mg/kg/d IV</td>
</tr>
<tr>
<td>rabies immune globulin, human (RIG) ray'-bees-em-une'-glo-b'-u-lin</td>
<td>Bay Bab, Imogam</td>
<td>Immunization for those suspected of exposure to rabies</td>
<td>Same as HBIG</td>
<td>20 IU/kg IM</td>
</tr>
<tr>
<td>Rh (D) immune globulin (RH[D]) IGIM</td>
<td>Gamulin Rh, RhoGAM</td>
<td>Prevention of Rh hemolytic disease</td>
<td>Same as HBIG</td>
<td>300 mcg (1 vial) IM within 72 h of delivery</td>
</tr>
<tr>
<td>GENERIC NAME</td>
<td>TRADE NAME*</td>
<td>USES</td>
<td>ADVERSE REACTIONS</td>
<td>DOSAGE RANGES</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td>------</td>
<td>-------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Rh (D) immune globulin IV (human)</td>
<td>WinRho SDF</td>
<td>Suppression of Rh isoimmunization in nonsensitized Rh (D)-negative women, immune thrombocytopenic purpura, transfusion to suppress Rh isoimmunization in Rh (D)-negative female children and female adults in their childbearing years</td>
<td>Same as HBIG</td>
<td>300–1200 mcg IM or IV</td>
</tr>
<tr>
<td>Rh (D) immune globulin micro-dose (Rh [D] IG)</td>
<td>BayRho-D</td>
<td>Prevent isoimmunization of Rh (D)-negative women at the time of spontaneous or induced abortion</td>
<td>Local tenderness, pain, muscle stiffness at injection site, urticaria</td>
<td>50 mcg (1 vial) IM</td>
</tr>
<tr>
<td>Respiratory syncytial virus immune globulin IV (human) (RSV-IGIV)</td>
<td>RespiGam</td>
<td>Respiratory syncytial virus (RSV)</td>
<td>Same as HBIG</td>
<td>15–6 mL/kg/h IV to a total monthly infusion of 750 mg/kg</td>
</tr>
<tr>
<td>tetanus immune globulin (human) (TIG)</td>
<td>BayTet</td>
<td>Tetanus prophylaxis after injury in patients whose immunization is incomplete or uncertain</td>
<td>Same as HBIG</td>
<td>250 units IM</td>
</tr>
<tr>
<td>varicella-zoster immune globulin (human) (VZIG)</td>
<td>Generic</td>
<td>Passive immunization of exposed, susceptible individuals who are at greater risk of complications from varicella than are healthy individuals</td>
<td>Same as HBIG</td>
<td>125–625 units IM (dosage varies depending on weight). See package insert for exact dosage.</td>
</tr>
</tbody>
</table>

**Antivenins**

<table>
<thead>
<tr>
<th>FAMILY</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crotalidae polyvalent immune Fab (ovine origin)</td>
<td>CroFab</td>
<td>For treatment of mild to moderate North American rattlesnake bites</td>
<td>Same as HBIG</td>
<td>4–6 vials, depending on severity of symptoms, dilute each vial with 10 mL sterile water, then with 250 mL 0.9% sodium chloride; give each 250 mL over 60 min</td>
</tr>
<tr>
<td>Antivenin (micrurus fulvius) an-tee’-ven-in</td>
<td>Generic</td>
<td>Passive transient protection for toxic effects of venoms of coral snake in U.S.</td>
<td>Same as HBIG</td>
<td>30–50 mL slow IV injection; flush with IV fluids after antivenin has been infused; may require up to 100 mL</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.
An example of passive immunity is the administration of immune globulins (see Summary Drug Table: Agents for Passive Immunity), such as hepatitis B immune globulin. Administration of this vaccine is an attempt to prevent hepatitis B after the individual has been exposed to the virus.

### Herbal Alert: Shiitake

The shiitake mushroom is an edible variety of mushroom and is not associated with severe adverse reactions. Mild side effects such as skin rashes or gastrointestinal upsets have been reported. The recommended dosage for general health maintenance:

- 3–4 fresh shiitake mushrooms
- 1–5 capsules/day
- 1 dropper two to three times a day

Lentinan, a derivative of the shiitake mushroom, is proving to be valuable in boosting the body’s immune system and may prolong the survival time of patients with cancer by supporting immunity. In Japan, lentinan is commonly used to treat cancer. Additional possible benefits of this herb are to lower cholesterol levels by increasing the rate at which cholesterol is excreted from the body. Under no circumstances should shiitake or lentinan be used for cancer or any serious illness without consulting a primary health care provider.

### IMMUINOLOGIC AGENTS

Some immunologic agents capitalize on the body’s natural defenses by stimulating the immune response, thereby creating within the body protection to a specific disease. Other immunologic agents supply ready-made antibodies to provide passive immunity. Examples of immunologic agents include vaccines, toxoids, and immune globulins.

### ACTIONS AND USES

#### Vaccines and Toxoids

Antibody-producing tissues cannot distinguish between an antigen that is capable of causing disease (a live antigen), an attenuated antigen, or a killed antigen. Because of this phenomenon, vaccines, which contain either an attenuated or a killed antigen, have been developed to create immunity to certain diseases. The live antigens are either killed or weakened during the manufacturing process. Although the vaccine contains weakened or killed antigens, they do not have sufficient strength to cause disease. Although rare, vaccination with any vaccine may not result in a protective antibody response in all individuals given the vaccine.

A **toxin** is a poisonous substance produced by some bacteria, such as Clostridium tetani, the bacteria that cause tetanus. A toxin is capable of stimulating the body to produce antitoxins, which are substances that act in the same manner as antibodies. Toxins are powerful substances, and like other antigens, they can be attenuated. A toxin that is attenuated (or weakened) but still capable of stimulating the formation of antitoxins is called a **toxoid**.

Both vaccines and toxoids are administered to stimulate the immune response within the body to specific antigens or toxins. These agents must be administered before exposure to the pathogenic organism. The initiation of the immune response, in turn, produces resistance to a specific infectious disease. The immunity produced in this manner is active immunity. Display 54-5 gives examples of indications for use of toxoids and vaccines.

### Immune Globulins and Antivenins

**Globulins** are proteins present in blood serum or plasma, which contain antibodies. **Immune globulins** are solutions obtained from human blood containing antibodies that have been formed by the body to specific antigens. Because they contain ready-made antibodies, they are given for passive immunity against disease. The immune globulins are administered to provide passive immunization to one or more infectious diseases. Those receiving immune globulins receive antibodies only to the diseases to which the donor blood is immune. The onset of protection is rapid but of short duration (1–3 months).

**Antivenins** are used for passive, transient protection from the toxic effects of bites by spiders (black widow and similar spiders) and snakes (rattlesnakes, copperhead and cottonmouth, and coral). The most effective response is obtained when the drug is administered within 4 hours after exposure.
ADVERSE REACTIONS

Vaccines and Toxoids

Adverse reactions from the administration of vaccines or toxoids are usually mild. Chills, fever, muscular aches and pains, rash, and lethargy may be present. Pain and tenderness at the injection site may also occur. Although rare, a hypersensitivity reaction may occur. The Summary Drug Table: Agents for Active Immunization provides a listing of the more rare, but serious, adverse reactions.

Immune Globulins and Antivenins

Adverse reactions to immune globulins are rare. However, local tenderness and pain at the injection site may occur. The most common adverse reactions include urticaria, angioedema, erythema, malaise, nausea, diarrhea, headache, chills, and fever. Adverse reactions, if they occur, usually last for several hours. Systemic reactions are extremely rare.

The antivenins may cause various reactions, with hypersensitivity being the most severe. Some antivenins are prepared from horse serum, and if a patient is sensitive to horse serum, serious reactions and death may result. The immediate reactions usually occur within 30 minutes after administration of the antivenin. Symptoms include apprehension; flushing; itching; urticaria; edema of the face, tongue, and throat; cough; dyspnea; vomiting; cyanosis; and collapse. Other adverse reactions are included in the Summary Drug Table: Agents for Passive Immunity.

CONTRAINDICATIONS AND PRECAUTIONS

Vaccines and Toxoids

Immunologic agents are contraindicated in patients with known hypersensitivity to the agent or any component of it. The measles, mumps, rubella, and varicella vaccines are contraindicated in patients who have ever had an allergic reaction to gelatin, neomycin, or a previous dose of one of the vaccines. The measles, mumps, rubella, and varicella vaccines are contraindicated during pregnancy, especially during the first trimester, because of the danger of birth defects. Women are instructed to wait at least 3 months before getting pregnant after receiving these vaccines. Vaccines and toxoids are contraindicated during acute febrile illnesses, leukemia, lymphoma, immunosuppressive illness or drug therapy, and non-localized cancer. See Display 54-6 for additional information on the contraindications for immunologic agents.

The immunologic agents are used with extreme caution in individuals with a history of allergies. Sensitivity testing may be performed in individuals with a history of allergies. No adequate studies have been conducted in pregnant women, and it is not known whether these agents are excreted in breast milk. Thus, the immunologic agents (Pregnancy Category C) are used with caution in pregnant women and during lactation.

Immune Globulins and Antivenins

The immune globulins are contraindicated in patients with a history of allergic reactions after administration of human immunoglobulin preparations and individuals with isolated immunoglobulin A (IgA) deficiency (individuals could have an anaphylactic reaction to subsequent administration of blood products that contain IgA).

Nursing Alert

Human immune globulin intravenous (IGIV) products have been associated with renal impairment, acute renal failure, osmotic nephrosis, and death. Individuals with a predisposition to acute renal failure, such as those with preexisting renal disease, diabetes mellitus, individuals older than 65 years, or patients receiving nephrotoxic drugs should not be given human IGIV products.

The antivenins are contraindicated in patients with hypersensitivity to horse serum or any other component of the serum.

The immune globulins and antivenins are administered cautiously during pregnancy (Pregnancy Category C) and lactation and in children.
INTERACTIONS

Vaccines and Toxoids

Vaccinations containing live organisms are not administered within 3 months of immune globulin administration because antibodies in the globulin preparation may interfere with the immune response to the vaccination. Corticosteroids, antineoplastic drugs, and radiation therapy depress the immune system to such a degree that insufficient numbers of antibodies are produced to prevent the disease. When the salicylates are administered with the varicella vaccination, there is an increased risk of Reye's syndrome developing.

Immune Globulins and Antivenins

Antibodies in the immune globulin preparations may interfere with the immune response to live virus vaccines, particularly measles, but also others, such as mumps and rubella. It is recommended that the live virus vaccines be administered 14 to 30 days before or 6 to 12 weeks after administration of immune globulins. No known interactions have been reported with antivenins.

NURSING PROCESS

The Patient Receiving an Immunologic Agent

ASSESSMENT

Preadministration Assessment

Before the administration of any vaccine, the nurse obtains an allergy history. If the individual is known or thought to have allergies of any kind, the nurse tells the primary health care provider before the vaccine is given. Some vaccines contain antibodies obtained from animals, whereas other vaccines may contain proteins or preservatives to which the individual may be allergic. A highly allergic person may have an allergic reaction that could be serious and even fatal. If the patient has an allergy history, the primary health care provider may decide to perform skin tests for allergy to one or more of the components or proteins in the vaccine. The nurse also determines whether the patient has any conditions that contraindicate the administration of the agent (eg, cancer, leukemia, lymphoma, immunosuppressive drug therapy).

Ongoing Assessment

The patient is usually not hospitalized after administration of an immunologic agent. However, the patient may be asked to stay in the clinic or office for observation for about 30 minutes after the injection to observe for any signs of hypersensitivity (eg, laryngeal edema, hives, pruritus, angioneurotic edema, and severe dyspnea [see Chap. 2 for additional information]). Emergency resuscitation equipment is kept available to be used in the event of a severe hypersensitivity reaction.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to the immunologic agent, management of common adverse drug effects, and an understanding of and compliance with the prescribed immunization schedule.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

If a vaccine is not in liquid form and must be reconstituted, the nurse must read the directions enclosed with the vaccine. It is important to follow the enclosed directions carefully. Package inserts also contain information regarding dosage, adverse reactions, method of administration, administration sites (when appropriate), and, when needed, recommended booster schedules.

On occasion, it may be necessary to postpone the regular immunization schedule, particularly for children. This is of special concern to parents. The decision to delay immunization because of illness or for other reasons must be discussed with the primary health care provider. However, the decision to administer or delay vaccination because of febrile illness (illness causing an elevated temperature) depends on the severity of the symptoms and the specific disorder. In general, all vaccines can be administered to those with minor illness, such as a cold virus and to those with a low-grade fever. However, moderate or severe febrile illness is a contraindication. In instances of moderate or severe febrile illness, vaccination is done as soon as the acute phase of
the illness is over. Display 54-6 lists general contraindications for immunizations. Specific contraindications and precautions may be found in the package insert that comes with the drug.

The nurse documents the following information in the patient's chart or form provided by the institution:

- Date of vaccination
- Route and site, vaccine type, manufacturer
- Lot number and expiration date
- Name, address, and title of individual administering vaccine

**Monitoring and Managing Adverse Reactions**

Minor adverse reactions, such as fever, rashes, and aching of the joints, are possible with the administration of a vaccine. In most cases, these reactions subside within 48 hours.

**Nursing Alert**

In most cases, the risk of serious adverse reactions from an immunization is much smaller than the risk of contracting the disease for which the immunizing agent is given.

General interventions, such as increasing the fluids in the diet, allowing for adequate rest, and keeping the atmosphere quiet and nonstimulating, may be beneficial. The primary health care provider may prescribe acetaminophen, every 4 hours, to control these reactions. Local irritation at the injection site may be treated with warm or cool compresses, depending on the patient's preference. A lump may be palpated at the injection site after a diphtheria, pertussis, tetanus (DPT) injection or other immunization. This is not abnormal and will resolve itself within several days to several months.

**Vaccine Adverse Event Reporting System**

The Vaccine Adverse Event Reporting System (VAERS) is a national vaccine safety surveillance program co-sponsored by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA). VAERS collects and analyzes information from reports of adverse reactions after immunization. Anyone can report to VAERS, and reports are sent in by vaccine manufacturers, health care providers, and vaccine recipients and their parents or guardians. An example of the VAERS and instructions for completing the form are found in Appendix F. Any clinically significant adverse event that occurs after the administration of any vaccine should be reported. Individuals are encouraged to provide the information on the form even if the individual is uncertain if the event was related to the immunization. A copy of the form can be obtained by calling 1-800-822-7967 or by downloading it from the Internet at [http://www.vaers.org](http://www.vaers.org).

**Educating the Patient and Family**

Because of the effectiveness of various types of vaccines in the prevention of disease, nurses must inform the public about the advantages of immunization. Parents are encouraged to have infants and young children receive the immunizations suggested by the primary health care provider.

The nurse advises those traveling to a foreign country to contact their primary health care provider or local health department well in advance of their departure date for information about the immunizations that will be needed. Immunizations should be given well in advance of departure because it may take several weeks to produce adequate immunity.

When an adult or child is receiving a vaccine for immunization, the nurse explains to the patient or a family member the possible reactions that may occur, for example, soreness at the injection site or fever.

Serious viral infections of the central nervous system and fatalities have been associated with the use of vaccines. Although the number of these incidents is small, a risk factor still remains when some vaccines are given. It is also important for the parents to understand that a risk is also associated with not receiving immunization against some infectious diseases. That risk may be higher and just as serious as the risk associated with the use of vaccines. It must also be remembered that when a large segment of the population is immunized, the small number of those not immunized are less likely to be exposed to and be infected with the disease-producing microorganism. However, when large numbers of the population are not immunized, there is a great increase in the chances of exposure to the infectious disease and a significant increase in the probability that the individual will experience the disease.

The nurse encourages the parents or guardians to report any adverse reactions or serious adverse events occurring after administration of a vaccine. It may be necessary to report the event to VAERS.

The following summarizes the information to be included when educating the parents of a child receiving a vaccination.

- Discuss briefly the risks of contracting vaccine-preventable diseases and the benefits of immunization.
- Instruct the parents to bring immunization records to all visits.
- Provide the date for return for the next vaccination.
- Discuss common adverse reactions (e.g., fever, soreness at the injection site) and methods to combat these reactions (e.g., acetaminophen, warm compresses).
• Instruct the parents to report any unusual or severe adverse reactions after the administration of a vaccination.

**EVALUATION**

• The therapeutic effect is achieved and the disease for which immunization is given does not present itself.
• Adverse drug reactions are managed successfully.
• The patient or parents/guardians comply with the immunization schedule.
• The patient and family express an understanding of the need for immunizations.

**Critical Thinking Exercises**

1. Ms. Wilson has brought her 2-month-old daughter, Michelle, to the clinic for the first of the series of three DPT and oral polio vaccine (OPV) immunizations. Ms. Wilson asks you to explain how a vaccination will keep her daughter from getting sick and why she has to have three injections. Discuss how you would address these topics with Ms. Wilson.

2. Jimmy, age 4 months, has a slight cold with a “runny nose” when he comes for his regular well-baby checkup. His mother tells the nurse that because Jimmy is sick, she does not think he needs his DPT injection at this time. She says that she will bring him in next month for this immunization. Analyze the situation to determine the best response to Jimmy’s mother. Discuss any assessments that you think would be important to make before giving your response.

**Review Questions**

1. When discussing the possibility of adverse reactions after receiving a vaccine, the nurse tells the parents of a young child that ______.
   A. adverse reactions may be severe, and the child should be monitored closely for 24 hours
   B. adverse reactions are usually mild
   C. the child will likely experience a hypersensitivity reaction
   D. the most common adverse reaction is a severe headache

2. Which of the following statements made by the patient would alert the nurse to a possibility of an allergy to the measles vaccine? My daughter is allergic to ______.
   A. Jell-O
   B. peanut butter
   C. sugar
   D. corn

3. What type of immunity does an antivenin produce?
   A. Artificially acquired active immunity
   B. Naturally acquired active immunity
   C. Passive immunity
   D. Cell-mediated immunity

4. What type of immunity will be produced by the hepatitis B vaccine recombinant?
   A. Artificially acquired active immunity
   B. Naturally acquired active immunity
   C. Passive immunity
   D. Cell-mediated immunity
Chapter Objectives

On completion of this chapter, the student will:

- List the types of drugs used in the treatment of neoplastic diseases.
- Discuss the uses, general drug actions, general adverse reactions, contraindications, precautions, and interactions of the antineoplastic drugs.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on the patient taking antineoplastic drugs.
- List some nursing diagnoses particular to a patient taking antineoplastic drugs.
- Discuss ways to promote an optimal response to therapy, how to manage common adverse reactions, and important points to keep in mind when educating patients about the use of an antineoplastic drug.

Key Terms

- alopecia
- anemia
- anorexia
- antineoplastic drugs
- bone marrow suppression
- chemotherapy
- extravasation
- leukopenia
- oral mucositis
- stomatitis
- thrombocytopenia
- vesicant

Antineoplastic drugs are used in the treatment of malignant diseases (cancer). These drugs can be used for cure, control, or palliative (relief of symptoms) therapy. Although these drugs may not always lead to a complete cure of the malignancy, they often slow the rate of tumor growth and delay metastasis (spreading of the cancer to other sites). Use of these drugs is one of the tools in the treatment of cancer. The term chemotherapy is often used to refer to therapy with antineoplastic drugs.

Many antineoplastic drugs are available to treat malignancies. The antineoplastic drugs covered in this chapter include the alkylating drugs, antibiotics, antimetabolites, hormones, mitotic inhibitors, and selected miscellaneous drugs. Many antineoplastic drugs not specifically discussed in this chapter are listed in the Summary Drug Table: Antineoplastic Drugs.

**ACTIONS**

Generally, most antineoplastic drugs affect cells that rapidly proliferate (divide and reproduce). Malignant neoplasms or cancerous tumors usually consist of rapidly proliferating aberrant (abnormal) cells. Cancer cells have no biological feedback controls that stop their aberrant growth or proliferation. Cancer cells are more sensitive to antineoplastic drugs when the cells are in the process of growing and dividing. Chemotherapy is administered at the time the cell population is dividing as part of a strategy to optimize cell death.

However, the normal cells that line the oral cavity and gastrointestinal tract, and cells of the gonads, bone marrow, hair follicles, and lymph tissue are also rapidly dividing cells and are usually affected by these drugs. Thus, antineoplastic drugs may affect normal as well as malignant (cancerous) cells.

Chemotherapy is administered in a series of cycles to allow for recovery of the normal cells and to destroy more of the malignant cells (Fig. 55-1). A according to the cell kill theory, a drug regimen is intended to kill 90% of the cancer cells during the first course of treatment. The second course, according to this theory, targets the remaining cancer cells and reduces those cells by 90%. Further courses of chemotherapy continue to reduce the number of cancer cells, until all cells are killed. This theory is the rationale for using repeated doses of chemotherapy with several antineoplastic drugs. Every malignant cell must be destroyed for the cancer to be
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alkylating Drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>busulfan</td>
<td>Busulfex, Myleran</td>
<td>Chronic myelogenous leukemia</td>
<td>Leukopenia, anemia, cataracts, anxiety, skin rash, thrombocytopenia, fever, anorexia, nausea, vomiting, diarrhea, stomatitis, constipation, tachycardia, hypertension, insomnia, dizziness</td>
<td>1–12 mg/d PO; 0.8 mg/kg IV</td>
</tr>
<tr>
<td>chlorambucil</td>
<td>Leukeran</td>
<td>Chronic lymphocytic leukemia, malignant lymphomas, Hodgkin’s disease</td>
<td>Bone marrow depression, hyperuricemia, nausea, vomiting, diarrhea, hepatotoxicity, tremors</td>
<td>0.03–0.2 mg/kg/d PO</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>Cytoxan, Neosar</td>
<td>Malignant lymphomas, Hodgkin’s disease, multiple myeloma, leukemia, carcinoma of the ovary and breast, neuroblastoma, retinoblastoma</td>
<td>Leukopenia, thrombocytopenia, anemia, anorexia, nausea, vomiting, diarrhea, cystitis, alopecia</td>
<td>Initial dose: 40–50 mg/kg IV; maintenance doses: 1–5 mg/kg/d PO; 3–15 mg/kg IV</td>
</tr>
<tr>
<td>ifosfamide</td>
<td>Ifex</td>
<td>Testicular cancer</td>
<td>Hemorrhagic cystitis, mental confusion, coma, alopecia, nausea, vomiting, anorexia, diarrhea, hematuria</td>
<td>1.2 g/m²/d IV</td>
</tr>
<tr>
<td>lomustine</td>
<td>CeeNu</td>
<td>Brain tumors, Hodgkin’s disease</td>
<td>Nausea, vomiting, diarrhea, thrombocytopenia, leukopenia, alopecia, anemia, stomatitis</td>
<td>100–300 mg/m² PO</td>
</tr>
<tr>
<td>mechlorethamine</td>
<td>Mustargen</td>
<td>Hodgkin’s disease, lymphosarcoma, bronchogenic carcinoma, leukemia, mycosis fungoides</td>
<td>Nausea, vomiting, jaundice, alopecia, lymphocytopenia, granulocytopenia, thrombocytopenia, skin rash, diarrhea</td>
<td>0.4 mg/kg IV as a total dose for a course of therapy, which may be given as a single dose or divided dose</td>
</tr>
<tr>
<td>melphalan</td>
<td>Alkeran</td>
<td>Multiple myeloma, carcinoma of the ovary</td>
<td>Nausea, vomiting, bone marrow depression, skin rash, alopecia, diarrhea</td>
<td>6 mg/d PO; 16 mg/m² IV</td>
</tr>
<tr>
<td>thiopeta</td>
<td>Thioplex, generic</td>
<td>Carcinoma of the breast, ovary, bladder, Hodgkin’s disease, lymphosarcomas, intracavity effusions due to localized metastatic disease</td>
<td>Nausea, vomiting, pain at injection site, bone marrow depression, dermatitis, dysuria</td>
<td>0.3–0.4 mg/kg IV; dosage is higher for intracavity or intratumor administration; bladder instillation: 60 mg retained for 2 h</td>
</tr>
<tr>
<td><strong>Antibiotics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bleomycin</td>
<td>Blenoxane</td>
<td>Carcinoma of the head and neck, lymphomas, testicular carcinoma</td>
<td>Pneumonitis, pulmonary fibrosis, erythema, rash, fever, chills, vomiting</td>
<td>0.25–0.5 U/kg IV, IM, SC</td>
</tr>
<tr>
<td>dactinomycin</td>
<td>Cosmegen</td>
<td>Wilms’ tumor, choriocarcinoma, Ewing’s sarcoma, testicular carcinoma</td>
<td>Anorexia, alopecia, bone marrow depression, nausea, vomiting</td>
<td>Up to 15 mcg/kg/d IV; may also be given by isolation perfusion at 0.035–0.05 mg/kg</td>
</tr>
<tr>
<td>daunorubicin</td>
<td>DaunoXome</td>
<td>Kaposi’s sarcoma</td>
<td>Fatigue, headache, diarrhea, nausea, cough, fever</td>
<td>40 mg/m² IV</td>
</tr>
</tbody>
</table>
### Antineoplastic Drugs

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>daunorubicin HCl</td>
<td>Generic</td>
<td>Leukemia</td>
<td>Bone marrow depression, alopecia, acute nausea and vomiting, fever, chills</td>
<td>25–45 mg/m²/d IV</td>
</tr>
<tr>
<td>doxorubicin HCl</td>
<td>Adriamycin, Rubex</td>
<td>Acute leukemia, neuroblastoma, soft tissue and bone sarcomas, carcinomas of the breast, ovary, bladder, lymphomas, Wilms' tumor</td>
<td>Alopecia, acute nausea and vomiting, mucositis, chills, bone marrow depression, fever</td>
<td>25–75 mg/m²/d IV</td>
</tr>
<tr>
<td>epirubicin</td>
<td>Ellence</td>
<td>Breast cancer</td>
<td>Alopecia, local toxicity, rash, itching, amenorrhea, hot flashes, nausea, vomiting, mucositis, leukopenia, neutropenia, anemia, thrombocytopenia, infection, lethargy, conjunctivitis</td>
<td>100–120 mg/m² IV</td>
</tr>
<tr>
<td>idarubicin HCl</td>
<td>Idamycin</td>
<td>Leukemia</td>
<td>Congestive heart failure, arrhythmias, chest pain, myocardial infarction, nausea, vomiting, alopecia</td>
<td>12 mg/m² daily x 3 d IV</td>
</tr>
<tr>
<td>mitomycin</td>
<td>Mutamycin</td>
<td>Adenocarcinoma of the stomach, pancreas</td>
<td>Bone marrow depression, anorexia, nausea, vomiting, headache, blurred vision, fever</td>
<td>10–20 mg/m²/d IV</td>
</tr>
<tr>
<td>plicamycin</td>
<td>Mithracin</td>
<td>Malignant tumors of the testes, hypercalcemia, and hypercalciuria associated with neoplasms</td>
<td>Hemorrhagic syndrome (epistaxis, hematemesis, widespread hemorrhage in the GI tract, generalized advanced bleeding), vomiting, diarrhea, anorexia, nausea, stomatitis</td>
<td>Testicular tumors: 25–30 mcg/kg/d IV; hypercalcaemia, hypercalciuria: 25 mcg/kg/d IV for 3–4 d</td>
</tr>
<tr>
<td>valrubicin</td>
<td>ValStar</td>
<td>Bladder cancer</td>
<td>Bladder discomfort, dysuria, urinary frequency, urinary tract infection</td>
<td>800 mg intravesically weekly for 6 wk</td>
</tr>
</tbody>
</table>

### Antimetabolites

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>capecitabine</td>
<td>Xeloda</td>
<td>Breast cancer</td>
<td>Dermatitis, diarrhea, nausea, vomiting, leukopenia, granulocytopenia, thrombocytopenia, hand and foot syndrome, stomatitis, abdominal pain, constipation, dyspnea, anemia, hyperbilirubinemia, fatigue, weakness, anorexia</td>
<td>2500 mg/m²/d PO</td>
</tr>
<tr>
<td>cladribine</td>
<td>Leustatin</td>
<td>Hairy cell leukemia</td>
<td>Neutropenia, fever, infection, fatigue, nausea, headache, rash, injection site reactions, nephrotoxicity, neurotoxicity</td>
<td>0.09 mg/kg/d IV</td>
</tr>
<tr>
<td>cytarabine</td>
<td>Cytosar-U, Fludara</td>
<td>Acute myelocytic or lymphocytic leukemia</td>
<td>Bone marrow depression, nausea, vomiting, diarrhea, anorexia</td>
<td>100–200 mg/m²/d IV, SC</td>
</tr>
<tr>
<td>fludarabine</td>
<td></td>
<td>Chronic lymphocytic leukemia</td>
<td>Bone marrow depression, fever, chills, infection, nausea, vomiting, rash, diarrhea</td>
<td>25 mg/m² IV</td>
</tr>
<tr>
<td>fluorouracil (5-FU)</td>
<td>Adrucil, generic</td>
<td>Carcinoma of the breast, stomach, pancreas, colon, and rectum</td>
<td>Diarrhea, anorexia, nausea, vomiting, alopecia, bone marrow depression, angina, stomatitis</td>
<td>3–12 mg/kg/d IV</td>
</tr>
</tbody>
</table>

(continued)
## SUMMARY DRUG TABLE  ANTINEOPLASTIC DRUGS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>gemcitabine</td>
<td>Gemzar</td>
<td>Pancreatic cancer, non–small-cell lung cancer</td>
<td>Anemia, proteinuria, nausea, vomiting, fever, rash, leukopenia, neutropenia, thrombocytopenia, diarrhea, constipation, alopecia</td>
<td>1000–1250 mg/m² IV</td>
</tr>
<tr>
<td>mercaptopurine (6-mercaptopurine, 6-MP)</td>
<td>Purinethol</td>
<td>Acute lymphatic leukemia, acute or chronic myelogenous leukemia</td>
<td>Bone marrow depression, hyperuricemia, hepatotoxicity, skin rash</td>
<td>2.5–5 mg/kg/d PO; do not exceed 5 mg/kg/d</td>
</tr>
<tr>
<td>methotrexate</td>
<td>Rheumatrex, generic, Dose Pack</td>
<td>Lymphosarcoma, severe psoriasis, cancer of the head, neck, breast, lung, rheumatoid arthritis (RA)</td>
<td>Ulcerative stomatitis, nausea, rash, pruritus, renal failure, bone marrow depression, fatigue, fever, chills</td>
<td>Antineoplastic dosages vary widely depending on type of tumor; psoriasis: 10–50 mg/wk IV, IM, PO; RA: dose pack directed</td>
</tr>
<tr>
<td>pentostatin</td>
<td>Nipent</td>
<td>Alpha-interferon-refractory hairy cell leukemia</td>
<td>Bone marrow depression, anemia, nausea, vomiting, diarrhea, rash, fever</td>
<td>4 mg/m² IV every other week</td>
</tr>
<tr>
<td>thioguanine (TG)</td>
<td>generic</td>
<td>Acute leukemias</td>
<td>Bone marrow depression, hepatic toxicity, nausea, vomiting, stomatitis, hyperuricemia</td>
<td>2–3 mg/kg/d PO</td>
</tr>
</tbody>
</table>

### Mitotic Inhibitors (Antimitotic Agents)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>docetaxel</td>
<td>Taxotere</td>
<td>Breast cancer, non–small-cell lung cancer</td>
<td>Nausea, skin rash, pruritus, stomatitis, vomiting, anemia, leukopenia, neutropenia, arthralgia, alopecia, asthenia, fever, infections</td>
<td>60–100 mg/m² IV</td>
</tr>
<tr>
<td>paclitaxel</td>
<td>Taxol</td>
<td>Ovarian cancer, breast cancer, AIDS-related Kaposi’s sarcoma</td>
<td>Diarrhea, nausea, vomiting, flushing, myalgia, arthralgia, fever, peripheral neuropathy, opportunistic infections</td>
<td>135–175 mg/m² IV</td>
</tr>
<tr>
<td>vinblastine sulfate (VLB; LCR)</td>
<td>Velban, generic</td>
<td>Hodgkin’s disease, lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides, testicular cancer, Kaposi’s sarcoma, breast cancer</td>
<td>Leukopenia, nausea, vomiting, paresthesias, malaise, weakness, mental depression, headache, hypertension, alopecia, diarrhea, constipation</td>
<td>3.7–18.4 mg/m² IV</td>
</tr>
<tr>
<td>vincristine sulfate (VCR; LRC)</td>
<td>Oncovin, Vincasar PFS, generic</td>
<td>Acute leukemia, combination therapy for various cancers</td>
<td>Same as vinblastine</td>
<td>1.4 mg/m² IV</td>
</tr>
</tbody>
</table>

### Hormones

#### Androgens

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>testolactone</td>
<td>Teslac</td>
<td>Palliative treatment of advanced disseminated metastatic breast carcinoma in postmenopausal women and premenopausal women whose ovarian function has been terminated</td>
<td>Paresthesia, glossitis, anorexia, nausea, vomiting, maculopapular erythema, aches, edema of the extremities, nail growth disturbances, increase in blood pressure, virilization</td>
<td>250 mg QID PO</td>
</tr>
<tr>
<td>GENERIC NAME</td>
<td>TRADE NAME*</td>
<td>USES</td>
<td>ADVERSE REACTIONS</td>
<td>DOSAGE RANGES</td>
</tr>
<tr>
<td>-------------------</td>
<td>---------------</td>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td><strong>Antiandrogens</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bicalutamide</td>
<td>Casodex</td>
<td>Prostate cancer</td>
<td>Hot flushes, hypertension, dizziness, paresthesia, insomnia, rash, constipation, nausea, diarrhea, nocturia, hematuria, peripheral edema, bone pain, dysnea, general pain, back pain, asthenia, injection</td>
<td>50 mg once daily PO</td>
</tr>
<tr>
<td>flutamide</td>
<td>Eulexin</td>
<td>Early stage and metastatic prostate cancer</td>
<td>Hot flushes, loss of libido, impotence, diarrhea, nausea, vomiting, gynecomastia</td>
<td>125 mg PO TID at 8-h intervals PO (up to 750 mg/d)</td>
</tr>
<tr>
<td>nilutamide</td>
<td>Nilandron</td>
<td>Metastatic prostate cancer</td>
<td>Pain, headache, asthenia, abdominal pain, chest pain, flu symptoms, fever, liver toxicity, insomnia, nausea, constipation, testicular atrophy, dysnea, pain, asthenia</td>
<td>150–300 mg/d PO</td>
</tr>
<tr>
<td><strong>Progestins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>medroxyprogesterone</td>
<td>Depo-Provera</td>
<td>Endometrial or renal cancer</td>
<td>Breakthrough bleeding, spotting, change in menstrual flow, amenorrhea, rash with or without pruritus, acne, fluid retention, edema, increase or decrease in weight, sudden, partial, or complete loss of vision, migraine, nausea</td>
<td>400–1000 mg IM per week; if disease stabilizes 400 mg/month IM</td>
</tr>
<tr>
<td>megestrol acetate</td>
<td>Megace, generic</td>
<td>Breast or endometrial cancer</td>
<td>Same as medroxyprogesterone</td>
<td>Breast cancer: 160 mg/d PO; endometrial cancer: 40–320 mg/d in divided doses PO</td>
</tr>
<tr>
<td><strong>Estrogens</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>diethylstilbestrol diphosphate</td>
<td>Stiphostrol</td>
<td>Inoperable prostatic carcinoma</td>
<td>Headache, dizziness, intolerance to contact lens, edema, thromboembolism, hypertension, nausea, weight changes, testicular atrophy, acne, breast tenderness, gynecomastia</td>
<td>Oral: 50–200 mg TID PO (not to exceed 1 g/d) Parenteral: 0.5–1 g/d IV</td>
</tr>
<tr>
<td>estramustine</td>
<td>Emcyt</td>
<td>Metastatic or progressive prostatic carcinoma</td>
<td>Same as diethylstilbestrol and diarrhea, sodium and water retention, skin rash</td>
<td>10–16 mg/kg/d PO in 3–4 divided doses</td>
</tr>
<tr>
<td>aberrant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tamoxifen citrate</td>
<td>Nolvadex, generic</td>
<td>Breast cancer in menopausal women, preventative therapy for women at high risk for breast cancer</td>
<td>Fluid retention, vaginal discharge, nausea, vomiting, hypercalcemia, ophthalmic changes, hot flushes, vaginal bleeding and discharge</td>
<td>20–40 mg/d</td>
</tr>
<tr>
<td>toremifene citrate</td>
<td>Fareston</td>
<td>Breast cancer</td>
<td>Hot flushes, nausea, vomiting, vaginal bleeding, vaginal discharge, menstrual irregularities, skin rash</td>
<td>60 mg once daily PO</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gonadotropin-Releasing Hormone Analogs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>goserelin acetate</td>
<td>Zoladex</td>
<td>Prostate cancer, endometriosis, advanced breast cancer, endometrial thinning</td>
<td>Lethargy, dizziness, insomnia, anorexia, nausea, sexual dysfunction, headache, emotional lability, depression, sweating, acne, breast atrophy, peripheral edema, lower urinary tract symptoms, hot flashes, pain, edema, upper respiratory tract infection, rash</td>
<td>3.6 mg SC q28d or 10.8 mg q3 months into the upper abdominal wall</td>
</tr>
<tr>
<td>leuprolide acetate</td>
<td>Lupron, Lupron Depot</td>
<td>Advanced prostatic carcinoma, endometriosis, central precocious puberty, uterine leiomyomata</td>
<td>Edema, headache, dizziness, bone pain, nausea, vomiting, anorexia, ECG changes, hypertension</td>
<td>1 mg SC daily; Depot: 7.5—30 mg IM; endometriosis: Depot, 3.75 IM monthly; uterine leiomyomata: 3.75 IM monthly</td>
</tr>
<tr>
<td>triptorelin pamoate</td>
<td>Trelstar Depot</td>
<td>Advanced prostate cancer</td>
<td>Hot flushes, skeletal pain, injection site pain, hypertension, headache, insomnia, dizziness, vomiting, diarrhea, impotence</td>
<td>3.75 mg IM</td>
</tr>
<tr>
<td><strong>Aromastase Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>anastrazole</td>
<td>Arimidex</td>
<td>Advanced breast cancer</td>
<td>Vasodilation, headache, dizziness, insomnia, GI disturbances, nausea, constipation, diarrhea, cough, increased dyspnea, hot flushes, asthenia, pain, back pain, peripheral edema, bone pain</td>
<td>1 mg once daily</td>
</tr>
<tr>
<td>exemestane</td>
<td>Aromasin</td>
<td>Advanced breast cancer</td>
<td>Depression, insomnia, anxiety, dizziness, nausea, vomiting, abdominal pain, anorexia, constipation, diarrhea, dyspnea, fatigue, hot flushes, pain, peripheral edema</td>
<td>25 mg/d PO</td>
</tr>
<tr>
<td>letrozole</td>
<td>Femara</td>
<td>Advanced breast cancer</td>
<td>Same as for anastrazole</td>
<td>2.5 mg once daily PO</td>
</tr>
<tr>
<td><strong>Miscellaneous Anticancer Drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Epipodophyllotoxins</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>etoposide</td>
<td>Toposar, VePesid, generic</td>
<td>Testicular cancer, small-cell lung cancer</td>
<td>Nausea, vomiting, anorexia, diarrhea, constipation, alopecia, granulocytopenia</td>
<td>Testicular cancer: 50—100 mg/m²/d IV; small-cell lung cancer: 35—50 mg/m²/d IV (oral dose is 2 times the IV dose rounded to the nearest 50 mg)</td>
</tr>
<tr>
<td>teniposide (VM-26)</td>
<td>Vumon</td>
<td>Leukemia</td>
<td>Nausea, vomiting, anorexia, diarrhea, constipation, alopecia, rash, leukopenia, thrombocytopenia, anemia</td>
<td>165—250 mg/m² IV</td>
</tr>
<tr>
<td><strong>Enzymes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>asparaginase</td>
<td>Elspar</td>
<td>Leukemia</td>
<td>Hypersensitivity reactions (rash, urticaria, arthralgia, respiratory distress, acute anaphylaxis), depression, somnolence, fatigue, coma, anorexia, nausea, vomiting</td>
<td>200—1000 IU/kg/d IV; 6000 IU/m²/d IM</td>
</tr>
</tbody>
</table>
## SUMMARY DRUG TABLE

### ANTINEOPLASTIC DRUGS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>pegaspargase (PEG-asparaginase) peg-as-par'-jase</td>
<td>Oncaspar</td>
<td>Acute lymphoblastic leukemia</td>
<td>Nausea, vomiting, fever, malaise, dyspnea, diarrhea, hypotension</td>
<td>2500 mg/m² IM or IV</td>
</tr>
<tr>
<td>Platinum Coordination Complex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>carboplatin kar'-boe-pla-tin</td>
<td>Paraplatin</td>
<td>Advanced ovarian cancer</td>
<td>Peripheral neuritis; vomiting; nausea; abdominal pain; diarrhea; constipation; decreased serum sodium, magnesium, calcium, and potassium; increased blood urea nitrogen; visual disturbances; ototoxicity</td>
<td>360 mg/m² IV</td>
</tr>
<tr>
<td>cisplatin sis'-pla-tin</td>
<td>Platinol-AQ</td>
<td>Metastatic testicular tumors, advanced bladder cancer, ovarian tumors</td>
<td>Ototoxicity, peripheral neuropathies, nausea, vomiting, anorexia, bone marrow suppression, nephrotoxicity</td>
<td>20—70 mg/m² IV</td>
</tr>
<tr>
<td>Anthracenedione</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mitoxantrone HCl mye-toe-zan'-trone</td>
<td>Novantrone</td>
<td>Acute leukemias, bone pain in advanced prostatic cancer</td>
<td>Nausea, vomiting, diarrhea, headache, seizures, abdominal pain, mucositis, congestive heart failure, bone marrow depression</td>
<td>12 mg/m² IV</td>
</tr>
<tr>
<td>Substituted Ureas</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>hydroxyurea hye-drox-ee-yoor-eel'-ah</td>
<td>Droxia, Hydrea</td>
<td>Melanoma, chronic myelocytic leukemia, ovarian cancer</td>
<td>Headache, dizziness, stomatitis, anorexia, nausea, vomiting, diarrhea, constipation, bone marrow depression, impaired renal tubular function, rash, mucositis, fever, chills, malaise</td>
<td>20—80 mg/kg PO</td>
</tr>
<tr>
<td>Methylhydrazine Derivatives</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>procarbazine HCl proe-kar'-ba-zeen</td>
<td>Matulane</td>
<td>Hodgkin’s disease</td>
<td>Leukopenia, anemia, nausea, vomiting, anorexia, thrombocytopenia</td>
<td>1—6 mg/kg PO</td>
</tr>
<tr>
<td>Cytoprotective Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amifostine am-ih-foss'-teen</td>
<td>Ethyl</td>
<td>Renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer</td>
<td>Nausea, vomiting, hypotension, fever, chills, dyspnea, skin rash, urticaria</td>
<td>910 mg/m² IV QID</td>
</tr>
<tr>
<td>dexrazoxane dex-ray-zox'-ane</td>
<td>Zinecard</td>
<td>Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer</td>
<td>Alopecia, nausea, vomiting, fatigue, malaise, anorexia, stomatitis, fever, infection, diarrhea, neurotoxicity</td>
<td>500 mg/m² IV</td>
</tr>
<tr>
<td>DNA Topoisomerase Inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>irinotecan HCl eh-rin-oh'-te-kan</td>
<td>Camptosar</td>
<td>Metastatic carcinoma of the colon or rectum</td>
<td>Dizziness, somnolence, confusion, vasodilation, hypotension, thrombophlebitis, diarrhea, nausea, vomiting, abdominal pain, anorexia, constipation, mucositis, dyspnea, asthenia, pain, fever</td>
<td>125 mg/m² IV</td>
</tr>
<tr>
<td>topotecan HCl toe-poh'-te-kan</td>
<td>Hycamtin</td>
<td>Ovarian cancer, small-cell lung cancer</td>
<td>Alopecia, rash, nausea, vomiting, diarrhea, constipation, abdominal pain, stomatitis, anorexia, dyspnea, headache, fatigue, fever, pain, asthenia, bone marrow depression</td>
<td>1.5 mg/m² IV</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Biological Response Modifiers</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aldesleukin</td>
<td>Proleukin</td>
<td>Metastatic renal-cell carcinoma</td>
<td>Nausea, diarrhea, stomatitis, hypotension, anorexia, bone marrow depression, pulmonary congestion, dyspnea, oliguria</td>
<td>600,000 IU/kg IV q8h</td>
</tr>
<tr>
<td>(interleukin-2; IL-2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCG, intravesical</td>
<td>Pacis, TheraQys, TICE BCG</td>
<td>Carcinoma in situ of the bladder</td>
<td>Dysuria, urinary frequency, cystitis, hematuria, urinary incontinence</td>
<td>120 mg instilled in the bladder once a week for 6 wk</td>
</tr>
<tr>
<td>denileukin</td>
<td>Ontak</td>
<td>Cutaneous T-cell lymphoma</td>
<td>Hypotension, vasodilation, tachycardia, dizziness, paresthesia, rash, pruritus, nausea, vomiting, anorexia, diarrhea</td>
<td>9—18 µg/kg/d IV</td>
</tr>
<tr>
<td>diffttox</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>deh-nih-loo’-kin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>diff-th-tox</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>levamisole (HCl)</td>
<td>Ergamisol</td>
<td>Combination therapy in patients with Dukes stage C colon cancer</td>
<td>Nausea, vomiting, diarrhea, stomatitis, anorexia</td>
<td>50 mg q8h PO</td>
</tr>
<tr>
<td>lev-am’-ih-sole</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Retinoids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tretinoin</td>
<td>Vesanoid</td>
<td>Acute promyelocytic leukemia</td>
<td>Headache, fever, weakness, fatigue, skin/mucous membrane dryness, increased sweating, visual disturbances, ocular disturbances, alopecia, bone pain</td>
<td>45 mg/m²/d PO</td>
</tr>
<tr>
<td>tret’-i-noyn</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rexinoids</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bexarotene</td>
<td>Targretin</td>
<td>Cutaneous T-cell lymphoma</td>
<td>Elevated blood lipids, hypothyroidism, headache, asthenia, rash, leukopenia, anemia, nausea, infection, peripheral edema, abdominal pain, dry skin</td>
<td>300 mg/m²/d PO</td>
</tr>
<tr>
<td>bex-air’-oh-teen</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Monoclonal Antibodies</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>alemtuzumab</td>
<td>Campath</td>
<td>B-cell chronic lymphocytic leukemia</td>
<td>Hypotension, headache, dizziness, rash, bone marrow suppression, fever, chills, asthenia, nausea, vomiting, diarrhea, stomatitis, fatigue</td>
<td>3—30 mg IV</td>
</tr>
<tr>
<td>ay-lem-tuh’-zoo-mab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gemtuzumab</td>
<td>Mylotarg</td>
<td>Acute myeloid leukemia</td>
<td>Chills, fever, nausea, vomiting, headache, hypotension, hypertension, hypoxia, dyspnea, bone marrow depression</td>
<td>9 mg/m² IV</td>
</tr>
<tr>
<td>ozogamicin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>gem-too’-zoo-mab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>oh-zoh-gam’-ih-sin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rituximab</td>
<td>Rituxan</td>
<td>Non-Hodgkin’s lymphoma</td>
<td>Infusion reactions, hypotension, dizziness, anxiety, night sweats, rash, pruritus, nausea, diarrhea, vomiting, bone marrow depression</td>
<td>375 mg/m² IV</td>
</tr>
<tr>
<td>rih-tuck-sih-mab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ibritumomab</td>
<td>Zevalin</td>
<td>Non-Hodgkin’s lymphoma</td>
<td>Infections, allergic reactions (bronchospasms and angioedema), bone marrow depression, hemorrhage, anemia, nausea, vomiting, abdominal pain, diarrhea, increased cough, dyspnea, dizziness, arthralgia, anorexia, ecchymosis</td>
<td>250 mg/m² IV</td>
</tr>
<tr>
<td>tiuxetan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ib-ri-tu’-moe-m-ab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tie-ux-eh’-tan</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>trastuzumab</td>
<td>Herceptin</td>
<td>Breast cancer</td>
<td>Anemia, leukopenia, diarrhea, infection, nausea, vomiting, pain, headache, dizziness, dyspnea, hypotension, rash, asthenia, infusion reactions, pulmonary adverse effects</td>
<td>2—4 mg/kg IV</td>
</tr>
<tr>
<td>trass-to-zoo’-mab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**CHAPTER 55**

**Antineoplastic Drugs**

---

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>imatinib mesylate</td>
<td>Gleevec</td>
<td>Chronic myeloid leukemia, gastrointestinal stromal tumors, acute lymphocytic leukemia</td>
<td>Gastric irritation, arthralgia, muscle cramps, hemorrhage, pyrexia, weakness, epistaxis, fatigue, ecchymosis, fluid retention, night sweats</td>
<td>400–800 mg/d PO</td>
</tr>
<tr>
<td>porfimer sodium</td>
<td>Photofrin</td>
<td>Esophageal cancer</td>
<td>Atrial fibrillation, insomnia, constipation, nausea, abdominal pain, vomiting, pleural effusion, dyspnea, pneumonia, pharyngitis, anemia, fever, chest pain, pain, photosensitivity</td>
<td>2 mg/kg IV</td>
</tr>
<tr>
<td>mitotane</td>
<td>Lysodren</td>
<td>Adrenal cortical carcinoma</td>
<td>Leukocytosis, GI symptoms (nausea, vomiting, diarrhea, abdominal pain), fatigue, edema, hyperglycemia, dyspnea, cough, rash, or itching, headaches, dizziness</td>
<td>2–16 g/d PO</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.

---

**SUMMARY DRUG TABLE**

**ANTINEOPLASTIC DRUGS (Continued)**

---

Cured. Each cycle of treatment with the antineoplastic drugs kills some, but by no means all, of the malignant cells. Therefore, repeated courses of chemotherapy are used to kill more and more of the malignant cells, until theoretically none are left.

**Alkylating Drugs**

Alkylating drugs interfere with the process of cell division of malignant and normal cells. The drug binds with DNA, causing breaks and preventing DNA replication.

---

**Figure 55-1.** Cell kill theory describing activity of repeated chemotherapy regimens.
The malignant cells appear to be more susceptible to the effects of the alkylating drugs. Examples of alkylating drugs include busulfan (Myleran, Busulfex) and chlorambucil (Leukeran).

**Antineoplastic Antibiotics**

The antineoplastic antibiotics, unlike their anti-infection antibiotic relatives, do not have anti-infective (against infection) ability. Their action is similar to the alkylating drugs. An antineoplastic antibiotic appears to interfere with DNA and RNA synthesis and therefore delay or inhibit cell division, including the reproducing ability of malignant cells. Examples of antineoplastic antibiotics include bleomycin (Blenoxane), doxorubicin (Adriamycin), and plicamycin (Mithracin).

**Antimetabolites**

The antimetabolites interfere with various metabolic functions of cells, thereby disrupting normal cell functions. They inactivate enzymes or alter the structure of DNA, changing the DNA’s ability to replicate. These drugs are most effective in the treatment of rapidly dividing neoplastic cells. Examples of the antimetabolites include methotrexate and fluorouracil (Adrucil).

**Hormones**

The exact method of antineoplastic action of hormones is unclear. These drugs also appear to counteract the effect of male or female hormones in hormone-dependent tumors (see Chap. 52). They appear to alter the hormonal environment of the cell. Examples of hormones used as neoplastic drugs include the androgen testosterone (Teslac), conjugate estrogens (see Chap. 52), and the progestin megestrol (Megace).

Gonadotropin-releasing hormone analogs, for example, goserelin (Zoladex), appear to act by inhibiting the anterior pituitary secretion of gonadotropins, thus suppressing the release of pituitary gonadotropins. These drugs primarily decrease serum testosterone levels and therefore are used in the treatment of advanced prostatic carcinomas.

**Mitotic Inhibitors**

Mitotic inhibitors (antimitotics) interfere with or stop cell division. Examples of mitotic inhibitors include paclitaxel (Taxol) and vincristine (Oncovin).

**Miscellaneous Antineoplastic Drugs**

The mechanism of action of this unrelated group of drugs is not entirely clear. Examples of miscellaneous antineoplastic drugs include cisplatin (Platinol) and hydroxyurea (Hydrea).

**USES**

Antineoplastic drugs may be given alone or in combination with other antineoplastic drugs. In many instances, a combination of these drugs produces better results than the use of a single antineoplastic drug.

Although many antineoplastic drugs share a similar activity (ie, they interfere in some way with cell division), their uses are not necessarily similar. The more common uses of specific antineoplastic drugs are given in the Summary Drug Table.

**ADVERSE REACTIONS**

Antineoplastic drugs often produce a wide variety of adverse reactions. Some of these reactions are dose dependent; that is, their occurrence is more common or their intensity is more severe when higher doses are used. Other adverse reactions occur primarily because of the effect the drug has on many cells of the body. Because the antineoplastic drugs affect both cancer cells and rapidly proliferating normal cells (ie, cells in the bone marrow, gastrointestinal tract, reproductive tract, and the hair follicles), adverse reactions occur as the result of the action on these cells. Adverse reactions common to many of the antineoplastic drugs include bone marrow suppression, nausea, vomiting, stomatitis, diarrhea, and hair loss.

Some adverse reactions are desirable, for example, the depressing effect of certain antineoplastic drugs on the bone marrow because this adverse drug reaction is essential in the treatment of the leukemias. Other adverse reactions are not desirable, for example, severe vomiting or diarrhea.

Antineoplastic drugs are potentially toxic and their administration is often associated with many serious adverse reactions. At times, some of these adverse effects are allowed because the only alternative is to stop treatment of the malignancy. A treatment plan is developed that will prevent, lessen, or treat most or all of the symptoms of a specific adverse reaction. An example of prevention is giving an antiemetic before administering an antineoplastic drug known to cause severe nausea and vomiting. A n example of treatment of the symptoms of an adverse reaction is the administration of an antiemetic and intravenous (IV) fluids and electrolytes when severe vomiting occurs.

Adverse reactions seen with the administration of these drugs may range from very mild to life threatening. Some of these reactions, such as the loss of hair (alopecia), may have little effect on the physical status of the patient but may definitely have a serious effect on the patient’s mental health. Because nursing is concerned with the whole patient, these physically altering reactions that can have a profound effect on the patient must be considered when planning nursing management.
Some of the adverse reactions seen with antineoplastic drugs are listed in the Summary Drug Table: Antineoplastic Drugs. Appropriate references should be consulted when administering these drugs because there are a variety of uses, dose ranges, and, in some instances, many adverse reactions.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The information discussed in this section is general, and the contraindications, precautions, and interactions for each antineoplastic drug vary. The nurse should consult appropriate sources before administering any antineoplastic drug.

The antineoplastic drugs are contraindicated in patients with leukopenia, thrombocytopenia, anemia, serious infections, serious renal disease, or known hypersensitivity to the drug and during pregnancy (see Display 55-1 for pregnancy classifications of selected antineoplastic drugs).

Antineoplastic drugs are used cautiously in patients with renal or hepatic impairment, active infection, or other debilitating illnesses, or in those who have recently completed treatment with other antineoplastic drugs or radiation therapy.

The following sections give selected interactions of the alkylating drugs, antimetabolites, antibiotics, hormones, miotic inhibitors, and miscellaneous antineoplastic drugs. The nurse should consult appropriate sources for a more complete listing of interactions before any antineoplastic drug is administered.

DISPLAY 55-1 - Pregnancy Classification for Selected Antineoplastic Drugs

<table>
<thead>
<tr>
<th>PREGNANCY CATEGORY C</th>
<th>PREGNANCY CATEGORY D</th>
<th>PREGNANCY CATEGORY X</th>
</tr>
</thead>
<tbody>
<tr>
<td>cyclophosphamide</td>
<td>asparaginase</td>
<td>diethylstilbestrol</td>
</tr>
<tr>
<td>levamisole</td>
<td>dacarbazine</td>
<td>methotrexate</td>
</tr>
<tr>
<td>pegaspargase</td>
<td>dactinomycin</td>
<td>flutamide</td>
</tr>
<tr>
<td>PREGNANCY CATEGORY D</td>
<td></td>
<td></td>
</tr>
<tr>
<td>busulfan</td>
<td>idarubicin</td>
<td>bicalutamide</td>
</tr>
<tr>
<td>cladribine</td>
<td>mitomycin</td>
<td>goserelin</td>
</tr>
<tr>
<td>chlorambucil</td>
<td>fluorouracil</td>
<td>methotrexate</td>
</tr>
<tr>
<td>cisplatin</td>
<td>toremifene</td>
<td>fludarabine</td>
</tr>
<tr>
<td>ifosfamide</td>
<td>hydroxyurea</td>
<td>doxorubicin</td>
</tr>
<tr>
<td>mechlorethamine</td>
<td>mercaptopurine</td>
<td>triptorelin</td>
</tr>
<tr>
<td>melphalan</td>
<td>thioguanine</td>
<td></td>
</tr>
<tr>
<td>procarbazine</td>
<td>mitoxantrone</td>
<td></td>
</tr>
<tr>
<td>thiotepa</td>
<td>flutamide</td>
<td></td>
</tr>
<tr>
<td>daunorubicin</td>
<td>megestrol</td>
<td></td>
</tr>
<tr>
<td>tamoxifen</td>
<td>etoposide</td>
<td></td>
</tr>
<tr>
<td>PREGNANCY CATEGORY X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>diethylstilbestrol</td>
<td>bicalutamide</td>
<td>goserelin</td>
</tr>
<tr>
<td>methotrexate</td>
<td>plicamycin</td>
<td>triptorelin</td>
</tr>
</tbody>
</table>

Alkylating Drugs

The alkylating drugs may antagonize the effects of antigout drugs by increasing serum uric acid levels. Dosage adjustment of the antigout drug may be needed. If cisplatin is used concurrently with aminoglycosides, there may be an increase in nephrotoxicity and ototoxicity. When cisplatin is used concurrently with loop diuretics, there is an increased risk of ototoxicity. Administering live viral vaccines with cyclophosphamide may decrease the antibody response of the vaccine.

Antimetabolites

Antimetabolite drugs may antagonize the effects of antigout drugs by increasing the serum uric acid concentration. Toxicity from methotrexate may be increased by other nephrotoxic drugs. When the antimetabolites are administered with other antineoplastic drugs, bone marrow suppression is additive. Vitamin preparations containing folic acid may decrease the effects of methotrexate. Alcohol ingestion while taking methotrexate may increase the risk of hepatotoxicity. Concurrent use of methotrexate and the nonsteroidal anti-inflammatory drugs (NSAIDs) may cause severe methotrexate toxicity. Fluorouracil is not compatible with the diazepam, doxorubicin, and methotrexate. Food decreases the absorption of fluorouracil. Live viral vaccines should not be administered if the patient is receiving fluorouracil because a decrease in antibody production may occur, causing the vaccine to be ineffective. Severe cardiomyopathy with left ventricular failure has occurred when fluorouracil and cisplatin are given together.

Antineoplastic Antibiotics

Plasma digoxin levels may decrease when the drug is administered with bleomycin. When bleomycin is used with cisplatin, there is an increased risk of bleomycin toxicity. Pulmonary toxicity may occur when bleomycin is administered with other antineoplastic drugs. Plicamycin, mitomycin, mitoxantrone, and dactinomycin have an additive bone marrow depressant effect when administered with other antineoplastic drugs. In addition, mitomycin, mitoxantrone, and dactinomycin decrease antibody response to live virus vaccines. Dactinomycin potentiates or reactivates skin or gastrointestinal reactions of radiation therapy. There is an increased risk of bleeding when plicamycin is administered with aspirin, warfarin, heparin, and the NSAIDs.

Hormones

Bicalutamide may increase the effect of oral anticoagulants. Flutamide enhances the action of leuprolide. Additive antineoplastic effects may occur when leuprolide is administered with megestrol or flutamide. Estrogens decrease the effectiveness of tamoxifen.
**Miotic Inhibitors**

Additive bone marrow depressive effects occur when the miotic inhibitor drugs are administered with other antineoplastic drugs or radiation therapy. Administration of vincristine with digoxin results in a decreased therapeutic effect of the digoxin and decreased plasma digoxin levels. There is a decrease in serum concentrations of phenytoin when administered with vinblastine.

**Miscellaneous Antineoplastic Drugs**

When asparaginase is administered to a patient with diabetes, the risk for hyperglycemia is increased; a dosage adjustment of the oral antidiabetic drug may be necessary. Glucocorticoids decrease the effectiveness of aldesleukin. When aldesleukin is administered with antihypertensive drugs, there is an additive hypotensive effect. Etoposide may decrease the immune response to live viral vaccines.

There is an increased risk for bone marrow suppression when levamisole or hydroxyurea are administered with other antineoplastic drugs. Use of levamisole with phenytoin increases the risk of phenytoin toxicity. Pegaspargase may alter drug response of the anticoagulants. When procarbazine is administered with other central nervous system (CNS) depressants, such as alcohol, antidepressants, antihistamines, opiates, or the sedatives, an additive CNS effect may be seen. Procarbazine may potentiate hypoglycemia when administered with insulin or oral antidiabetic drugs.

---

**Nursing Process**

**ASSESSMENT**

Preadministration Assessment

The extent of the preadministration assessment depends on the type of malignancy and the patient's general physical condition. The initial assessment of the patient scheduled for chemotherapy may include:

- The type and location of the neoplastic lesion (as stated on the patient's chart)
- The stage of the disease, for example, early, metastatic, terminal
- The patient's general physical condition
- The patient's emotional response to the disease
- The anxiety or fears the patient may have regarding chemotherapy treatments
- Previous or concurrent treatments (if any), such as surgery, radiation therapy, other antineoplastic drugs
- Other current nonmalignant disease or disorder, for example, congestive heart failure or peptic ulcer, that may or may not be related to the malignant disease
- The patient's knowledge or understanding of the proposed chemotherapy regimen
- Other factors, such as the patient's age, financial problems that may be associated with a long-term illness, family cooperation and interest in the patient, and the adequacy of health insurance coverage (which may be of great concern to the patient)

**Herbal Alert: Green Tea**

Green tea and black teas come from the same plant. The difference is in the processing. Green tea is simply dried tea leaves, whereas black tea is fermented, giving it the dark color, the stronger flavor, and the lowest amount of tannins and polyphenols. The beneficial effects of green tea lie in the polyphenols, or flavonoids, that have antioxidant properties. Antioxidants are thought to play a major role in preventing disease (eg, colon cancer) and reducing the effects of aging. Green tea polyphenols are powerful antioxidants. The polyphenols are thought to act by inhibiting the reactions of free radicals within the body that are thought to play a role in aging. The benefits of green tea include an overall sense of well-being, cancer prevention, dental health, and maintenance of heart and liver health. Green tea taken as directed is safe and well tolerated. It contains as much as 50 mg of caffeine per cup. Decaffeinated green tea retains all of the polyphenol content. The recommended dosage is 2 to 5 cups a day. Standardized green tea extracts vary in strength, so dosages may need to be adjusted. The recommended dosage is 250 to 400 mg/d of extract standardized to 90% polyphenols. Because green tea contains caffeine, nervousness, restlessness, insomnia, and gastrointestinal upset may occur. Green tea should be avoided during pregnancy because of its caffeine content. Patients with hypertension, cardiac conditions, anxiety, insomnia, diabetes, and ulcers should use green tea with caution.

Immediately before administering the first dose of an antineoplastic drug, the nurse takes the patient's vital signs. The nurse obtains a current weight because the dose of some antineoplastic drugs is based on the patient's weight in kilograms or pounds. The dosages of some antineoplastic drugs also may be based on body surface measurements and are stated as a specific amount of drug per square meter (m²) of body surface. Additional physical assessments may be necessary for certain antineoplastic drugs.

A few antineoplastic drugs require treatment measures before administration. An example of preadministration treatment is hydration of the patient with 1 to 2 liters of IV fluid infused before administration of cisplatin (Platinol) or administration of an antiemetic before the administration of mechlorethamine. These measures are ordered by the primary health care provider and, in some instances, may vary slightly from the manufacturer's recommendations.

When an antineoplastic drug has a depressing effect on the bone marrow, laboratory tests, such as a complete blood count, are ordered to determine the effect of
the previous drug dosage. Before the first dose of the drug is administered, pretreatment laboratory tests provide baseline data for future reference.

**Ongoing Assessment**

The patient who is acutely ill with many physical problems requires different ongoing assessment activities than does one who is ambulating and able to participate in the activities of daily living. Once the patient’s general condition is assessed and needs identified, the nurse develops a care plan to meet those needs. Patients receiving chemotherapy can be at different stages of their disease; therefore, nurses must individualize the nursing care of each patient based on the patient’s needs and not only on the type of drug administered.

In general, after the administration of an antineoplastic drug, the nurse bases the ongoing assessment on the following factors:

- The patient’s general condition
- The patient’s individual response to the drug
- Adverse reactions that may occur
- Guidelines established by the primary health care provider or hospital
- Results of periodic laboratory tests

Different types of laboratory tests may be used to monitor the patient’s response to therapy. Some of these tests, for example, a complete blood count, may be used to determine the response of the bone marrow to an antineoplastic drug. Other tests, for example, liver function tests, may be used to detect liver toxicity, which may be an adverse reaction that can be seen with the administration of some of these drugs. Abnormal laboratory tests may also require a change in the nursing care plan. For example, a significant drop in the platelet count may result in bleeding episodes and require measures, such as prolonged pressure on injection sites, to prevent bleeding or bruising episodes.

The nurse reviews the results of all laboratory tests at the time they are reported. The primary health care provider is notified of the results before the administration of successive doses of an antineoplastic drug. If these tests indicate a severe depressant effect on the bone marrow or other test abnormalities, the primary health care provider may reduce the next drug dose or temporarily stop chemotherapy to allow the affected body systems to recover.

**NURSING DIAGNOSES**

The nursing diagnoses for the patient with a malignancy are usually extensive and are based on many factors, such as the patient’s physical and emotional condition, the adverse reactions resulting from antineoplastic drug therapy, and the stage of the disease.

**Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.**

**PLANNING**

The expected outcomes of the patient may include an optimal response to therapy, management of common adverse reactions, a reduction in anxiety, and an understanding of the prescribed treatment modalities.

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**

Care of the patient receiving an antineoplastic drug depends on factors such as the drug or combination of drugs given, the dosage of the drugs, the route of administration, the patient’s physical response to therapy, the response of the tumor to chemotherapy, and the type and severity of adverse reactions. Some drugs may be administered by various routes, depending on the cancer being treated. For example, thiotepa may be administered by the intravenous route for breast cancer, intravesical route for superficial bladder cancer, intrapleural route for malignant pleural effusions, and by the intraperitoneal route for ovarian cancer.

Most hospitals and clinics require that nurses receive specialized training and standardized educational preparation before they are permitted to administer antineoplastic drugs. The Oncology Nursing Society has developed guidelines and educational tools for credentialing nurses for certification in administering chemotherapy.

In some hospitals, policies are established to provide nursing personnel with specific guidelines for the assessment and care of patients receiving a single or
combination chemotherapeutic drug regimen. If guidelines are not provided, it is important for the nurse to review the drugs being given before their administration. The nurse consults appropriate references to obtain information regarding the preparation and administration of a particular drug, the average dose ranges, all the known adverse reactions, and the warnings and precautions given by the manufacturer.

**ORAL ADMINISTRATION.** A number of antineoplastic drugs are administered orally. The oral route is convenient, economical, noninvasive, and often less toxic. Most oral drugs are well absorbed when the gastrointestinal tract is functioning normally. Antineoplastic drugs such as melphalan, busulfan, and chlorambucil are usually given orally. (Melphalan and busulfan are also available as injectable products for specific indications.) Most oral drugs are administered by the patient in a home setting. The section on “Educating the Patient and Family” provides information to include in a teaching plan.

When an antineoplastic drug is administered orally, the nurse must handle the drug safely. Gloves are considered acceptable if physical contact with the tablet or capsule is necessary.

**PARENTERAL ADMINISTRATION.** Although some of these drugs are given orally, others are given by the parenteral route. Antineoplastic drugs may be administered subcutaneously, intramuscularly, and intravenously. When giving these drugs IM, the nurse gives the injection into the large muscles using the Z-tract method (see Chap. 2) because administration can cause stinging or burning. When the SC method of administration is used, the injection should contain no more than 3 mL, and injections are given in the usual SC injection sites (see Chap. 2). If the injections are given frequently, the sites should be rotated and charted appropriately.

Goserelin (Zoladex), a hormonal antineoplastic drug used to treat breast cancer, is administered subcutaneously in an unusual way. The drug is contained in a dry pellet that is implanted in the soft tissue of the abdomen, where it is gradually absorbed during a period of 1 to 3 months. After a local anesthetic, such as lidocaine, is administered, a large needle (usually 16 gauge) is used to insert the pellet.

It is most important to follow the directions of the manufacturer or primary health care provider regarding the type of solution to be used for dilution or administration. When preparing an antineoplastic drug for parenteral administration, the nurse wears disposable plastic gloves. Some of these drugs can be absorbed through the skin of the individual preparing these drugs. Because antineoplastic drugs are highly toxic and can have an effect on many organs and systems of the body, nurses must use measures to prevent absorption of the drug through the skin. It is important for the nurse to take precautions to prevent accidental spilling or spraying of the drug into the eyes or onto unprotected areas of the skin. The nurse thoroughly washes the hands before and after preparing and administering an antineoplastic drug. This is especially important when the drug is given by the parenteral route.

Special directions for administration, stated by either the primary health care provider or manufacturer, are also important. For example, cisplatin cannot be prepared or administered with needles or IV administration sets containing aluminum because aluminum reacts with cisplatin, causing formation of a precipitate and loss of potency.

**ADMINISTERING ANTINEOPLASTIC DRUGS INTRAVENOUSLY.** The intravenous route of drug delivery is the most common and most reliable method of drug delivery. Intravenous administration may be accomplished using a vascular access device, an Angiocath, or a butterfly needle. These devices have become a common method of drug delivery and depending on the patient’s individual treatment regimen, may be inserted before therapy. Selection of the device depends on the type of therapy the patient is to receive, the condition of the veins, and how long the treatment regimen is to be continued. Instructions for monitoring the administration of intravenous antineoplastic drugs are given by the physician. Nurses who are certified in chemotherapy drug administration administer these drugs, but any nurse may be involved in monitoring patients receiving antineoplastic drugs.

Most antineoplastic drugs have specific recommended administration techniques. For example, an infusion pump is recommended for the administration of cisplatin, and plicamycin (Mithracin) is administered by slow IV infusion during a period of 4 to 6 hours. If administration guidelines are not provided by the primary health care provider or the hospital, the nurse checks with the appropriate authorities (physician, pharmacist) regarding the administration of a specific antineoplastic drug.

The nurse must read thoroughly the package insert supplied with the drug before the drug is prepared and administered. The manufacturer’s recommendations may include information such as storage of the drug, reconstitution procedures, stability of the drug after reconstitution, the rate of administration, and the technique of administration.

Antineoplastic drugs are potentially toxic drugs that can cause a variety of effects during and after their administration. Display 55-2 summarizes important points to keep in mind when administering an antineoplastic drug.
GUIDELINES ESTABILISHED BY THE PRIMARY HEALTH CARE PROVIDER OR HOSPITAL. During chemotherapy, the primary health care provider may write orders for certain nursing procedures, such as measuring fluid intake and output, monitoring the vital signs at specific intervals, and increasing the fluid intake to a certain amount. Even when orders are written, the nurse should increase the frequency of certain assessments, such as monitoring vital signs, if the patient’s condition changes. Some hospitals have written guidelines for nursing management when the patient is receiving a specific antineoplastic drug. The nurse incorporates these guidelines into the nursing care plan with nursing observations and assessments geared to the individual. The nurse adds further assessments to the nursing care plan when the patient’s condition changes.

Monitoring and Managing Adverse Drug Reactions

Not all patients have the same response to a specific antineoplastic drug. For example, an antineoplastic drug may cause vomiting, but the amount of fluid and electrolytes lost through vomiting may vary from patient to patient. One patient may require additional sips of water once nausea and vomiting have subsided, whereas another may require IV fluid and electrolyte replacement. Nursing management is geared not only to what may or what did happen, but also is based on the effects produced by a particular adverse reaction. In the example of the patient who is vomiting, it is important to accurately measure all fluid intake and all output from the gastrointestinal and urinary tracts, as well as to observe the patient for signs of dehydration and electrolyte imbalances. These measurements and observations aid the primary health care provider in determining if fluid replacement is necessary.

Knowing what adverse reactions may occur allows the nurse to prepare for any event that will happen. For example, a hemorrhagic syndrome may be seen with the administration of vincristine. Knowing this, assessments for hemorrhage are incorporated in the nursing care plan. Another example is the development of hyperuricemia (elevated blood uric acid levels), which may be seen with drugs such as melphalan (Alkeran) or mercaptopurine (Purinethol). When this adverse reaction is known to occur, fluid intake and output measurements, as well as encouragement to increase fluid intake to at least 2000 mL of oral fluid per day, are included in the nursing care plan. Other antineoplastic drugs are nephrotoxic. Therefore, blood urea nitrogen levels and serum creatinine are monitored closely during therapy.

MANAGING ALOPECIA. Alopecia (loss of hair) is a common adverse reaction associated with some of the antineoplastic drugs. Some drugs cause severe hair loss, whereas others cause gradual thinning. Examples of drugs commonly associated with severe hair loss are doxorubicin and vinblastine. Methotrexate, bleomycin, vincristine, and etoposide are associated with gradual hair loss.

If hair loss is associated with the antineoplastic drug being given, the nurse informs the patient that hair loss may occur. This problem occurs 10 to 21 days after the treatment cycle is completed. Hair loss is temporary, and hair will grow again when the drug therapy is completed. The nurse warns the patient that hair loss may occur suddenly and in large amounts. Although it is not life threatening, alopecia can lower self-esteem and serve as a reminder that the individual is undergoing treatment for cancer.

Depending on the patient, the nurse may need to make plans for the purchase of a wig or cap to disguise the hair loss until the hair grows back. Although this may seem to be a minor problem when compared with the serious reactions that may be seen during chemotherapy, the loss
MANAGING ANOREXIA. Anorexia (loss of appetite resulting in the inability to eat) is a common occurrence with the antineoplastic drugs. It is not uncommon for the patient to report alterations in the sense of taste during the course of chemotherapy. The nurse assesses the nutritional status of the patient before and during treatment. Small, frequent meals (five to six meals daily) are usually better tolerated than are three large meals. Breakfast is often the best tolerated meal of the day. The nurse stresses the importance of eating meals high in nutritive value, particularly protein (eg, eggs, milk products, tuna, beans, peas, and lentils). Some patients are able to eat high-protein finger foods such as cheese or peanut butter and crackers. Nutritional supplements may also be prescribed. The nurse monitors the patient’s body weight weekly (or more often if necessary) and reports any weight loss. If the patient continues to lose weight, a feeding tube may be used to administer a nutritionally complete liquid. While this is not ideal, the patient who is malnourished and weak may benefit from this intervention.

MANAGING BONE MARROW SUPPRESSION. Bone marrow suppression is a potentially dangerous adverse reaction resulting in decreased production of blood cells. Bone marrow suppression is manifested by abnormal laboratory test results and clinical evidence of leukopenia, thrombocytopenia, or anemia. For example, there is a decrease in the white blood cells or leukocytes (leukopenia), a decrease in the thrombocytes (thrombocytopenia), and a decrease in the red blood cells, resulting in anemia. Patients with leukopenia have a decreased resistance to infection, and the nurse must monitor them closely for any signs of infection.

Nursing Alert

The nurse should report any of the following signs of infection to the health care provider immediately: temperature of 100.4°F (38°C) or higher, cough, sore throat, chills, frequent urination, or a white blood cell count of less than 2500 mm³.

Thrombocytopenia is characterized by a decrease in the platelet count (<100,000/mm³). The nurse monitors patients with thrombocytopenia for bleeding tendencies and takes precautions to prevent bleeding. Injections are avoided but, if necessary, the nurse applies pressure to the injection site for 3 to 5 minutes to prevent bleeding into the tissue and the formation of a hematoma. The nurse informs the patient to avoid the use of electric razors, nail trimmers, dental floss, firm toothbrushes, or any sharp objects. The patient is monitored closely for easy bruising, skin lesions, and bleeding from any orifice (opening) of the body.

A nursing alert

The nurse reports any of the following to the health care provider immediately: bleeding gums, easy bruising, petechiae (pinpoint hemorrhages), increased menstrual bleeding, tarry stools, bloody urine, or coffee-ground emesis.

Aemia occurs as the result of a decreased production of red blood cells in the bone marrow and is characterized by fatigue, dizziness, shortness of breath, and palpitations. On occasion, the administration of blood transfusions may be necessary to correct the anemia.

MANAGING NAUSEA AND VOMITING. Nausea and vomiting are common adverse reactions to the antineoplastic drugs. The primary health care provider may order an antiemetic about 30 minutes before treatment with the antineoplastic drug begins and continue the antiemetic for several days after administration of the chemotherapy. The nurse provides small, frequent meals to coincide with the patient’s tolerance for food. Greasy or fatty foods and unpleasant sights, smells, and tastes are avoided. Cold foods, dry foods, and salty foods may be better tolerated. It is a good idea to provide diversional activities, such as music, television, and books. Relaxation, visualization, guided imagery, hypnosis, and other nonpharmacologic measures have been helpful to some patients.

MANAGING STOMATITIS. Because the cells in the mouth grow rapidly, they are particularly sensitive to the effects of the antineoplastic drugs. Stomatitis (inflammation of the mouth) or oral mucositis (inflammation of the oral mucous membranes) may occur 5 to 7 days after chemotherapy and continue up to 10 days after therapy. This adverse reaction is particularly uncomfortable because irritation of the oral mucous membranes affects the nutritional aspects of care. The patient must avoid any foods or products that are irritating to the mouth, such as alcoholic beverages, spices, strong mouthwashes, or toothpaste. The nurse provides soft or liquid food high in nutritive value. The oral cavity is inspected for increased irritation. The nurse reports any white patches on the tongue, throat, or gums; any burning sensation; and bleeding from the mouth or gums. Good mouth care is provided every 4 hours with normal saline or alcohol-free mouthwash. Lemon/glycerin swabs are avoided because they tend to irritate the oral mucosa and complicate stomatitis. The primary health care provider may order a topical
viscous anesthetic, such as lidocaine viscous, before meals to decrease discomfort when eating.

MANAGING DIARRHEA. Measures to manage diarrhea include a low-residue diet while the bowel rests. Electrolytes are monitored and supplemented as needed. Adequate hydration must be maintained; intravenous fluids may be necessary. If diarrhea is severe, therapy may be delayed or stopped or the dose decreased.

MAINTAINING TISSUE INTEGRITY. Some antineoplastic drugs are vesicants (i.e., they cause tissue necrosis if they infiltrate or extravasate out of the blood vessel and into the soft tissue). If extravasation occurs, underlying tissue is damaged. The damage can be severe, causing physical deformity or loss of vascularity or tendon function. Examples of vesicant drugs are daunorubicin, doxorubicin, and vinblastine.

Manufacturing Anxiety

Patients and family members are usually devastated by the diagnosis of a malignancy. The emotional impact of the disease may be forgotten or put aside by members of the medical team as they plan and institute therapy to control the disease. Patients undergoing chemotherapy require a great deal of emotional support from all members of the medical team. Kindness and gentleness in giving care and an understanding of the strain placed on the patient and the family may help reduce some of the fear and anxiety experienced during treatment.

Educating the Patient and Family

When the patient is hospitalized, the nurse explains all treatments and possible adverse effects to the patient before the initiation of therapy. The primary health care provider usually discusses the proposed treatment and possible adverse drug reactions with the patient and family members. The nurse briefly reviews these explanations immediately before parenteral administration of a drug.

Some of these drugs are taken orally at home. The areas included in a patient and family teaching plan for this type of treatment regimen are based on the drug prescribed, the primary health care provider’s explanation of the chemotherapy regimen and instructions for taking the drug, and the needs of the individual. Some hospitals or primary health care providers give printed instructions to the patient. The nurse reviews these instructions after the patient has read them and allows time for the patient or family member to ask questions. The patient has a right to know the dangers associated with these drugs and what adverse reactions may occur.

Some patients are given antineoplastic drugs in the medical office or outpatient clinic. Before the initiation of therapy, the treatment regimen is explained thoroughly to the patient and family. In some instances, a drug to prevent nausea may be prescribed to be taken before administration of the drugs in the medical office or clinic. To obtain the best possible effects, the nurse stresses to the patient that the drug must be taken at the time specified by the primary health care provider. It is important for the patient to comply with the treatment regimen to maximize a therapeutic effect. Most patients are compliant with therapy; however, some patients might decide to omit a dose in order to feel better temporarily. The nurse must stress the importance of maintaining the dosing schedule exactly as prescribed. A calendar indicating the doses to take, dates the drug is to be taken, and space to record each dose is often given to the patient. The patient is instructed to bring the treatment calendar to each appointment, and the patient is questioned about any omitted or delayed doses. One course of therapy is generally prescribed at a time to avoid inadvertent over-dosing that could be life threatening.
Critical Thinking Exercises

1. Dennis, age 10 years, has leukemia and is to begin chemotherapy with chlorambucil (Leukeran). Discuss what information would be important to discuss with Dennis and his parents before beginning the treatment regimen.

2. Ms. Thompson has cancer of the lung and will begin a treatment regimen with methotrexate. Discuss important preadministration assessments you would perform before beginning therapy with methotrexate.

3. Patients with a malignant disease need special consideration, understanding, and emotional support. On occasion, these needs are unrecognized by members of the medical profession. Suppose you recently received a diagnosis of cancer. Discuss some of the feelings you would experience at this time. Describe what you would want the nurse to do for you at this time. Analyze your thoughts about your future. Discuss what you would want to know or not know. As you think about this or discuss these questions, remember that any patient may have these same emotional responses and may need the same things you would expect from the nurse or other members of the medical profession.

Review Questions

1. Which of the following findings would be most indicative to the nurse that the patient has thrombocytopenia?
   A. Nausea
   B. Blurred vision
   C. Headaches
   D. Easy bruising

2. Which of the following is the most common symptom of extravasation?
   A. Swelling around the injection site
   B. Redness along the vein and around the injection site
   C. Pain at the injection site
   D. Tenderness along the path of the vein

3. Which of the following adverse reactions to the antineoplastic drugs is most likely to affect the patient’s mental health and self-esteem?
   A. Hematuria
   B. Alopecia
   C. Nausea
   D. Diarrhea

4. When assessing the patient for leukopenia the nurse
   A. checks the patient every 8 hours for hematuria
   B. monitors the patient for fever, sore throat, chills
C. checks female patients for increased menstrual bleeding  
D. reports a WBC count of 5000 mm$^3$

5. Which of the following interventions would be most helpful for a patient with stomatitis?  
A. Mouth care should be provided at least once daily.  
B. Swab the mouth with lemon glycerin swabs every 4 hours.  
C. Provide frequent mouth care with normal saline or alcohol-free mouthwash.  
D. Use a hard bristle toothbrush to thoroughly cleanse the mouth and teeth of debris.

---

**Medication Dosage Problems**

1. Chlorambucil (Leukeran) dosage is calculated based on the patient’s body weight. Mrs. Garcia weighs 142 pounds. The prescribed dosage of chlorambucil is 0.2 mg/kg of body weight per day. What is the correct daily dosage for Mrs. Garcia?

2. A patient weighing 120 pounds is to receive bleomycin sulfate (Blenoxane) 0.25 units per kilogram of body weight. What is the correct dosage of bleomycin?
The skin forms a barrier between the outside environment and the structures located beneath the skin. The **epidermis** is the outermost layer of the skin. Immediately below the epidermis is the **dermis**. The dermis contains small capillaries, which supply nourishment to the dermis and epidermis, sebaceous (oil-secreting) glands, sweat glands, nerve fibers, and hair follicles. Because of the skin’s proximity to the outside environment, it is subject to various types of injury and trauma, as well as changes in the skin itself. Each of the following sections discusses only select topical drugs. See the Summary Drug Table: Dermatologic Drugs for a more complete listing of the drugs and additional information.

### Key Terms

- **antipsoriatrics**
- **antiseptic**
- **bactericidal**
- **bacteriostatic**
- **dermis**
- **epidermis**
- **germicide**
- **hypersensitivity**
- **immunocompromised**
- **keratolytic**
- **necrotic**
- **proteolysis**
- **proteolytic**
- **purulent exudates**
- **superinfection**

### Chapter Objectives

On completion of this chapter, the student will:
- List the types of drugs used in the treatment of skin disorders.
- Discuss the general drug actions, uses, and reactions of and any contraindications, precautions, and interactions associated with drugs used in the treatment of skin disorders.
- Discuss important preadministration and ongoing assessment activities the nurse should perform on patients receiving a drug used to treat skin disorders.
- List some nursing diagnoses particular to a patient using a drug to treat a skin disorder.
- Discuss ways to promote an optimal response to therapy and important points to keep in mind when educating the patient about a skin disorder.

### ACTIONS AND USES

#### Topical Antibiotic Drugs

Topical antibiotics exert a direct local effect on specific microorganisms and may be bactericidal or bacteriostatic. Bacitracin (Baciguent) inhibits the cell wall synthesis. Bacitracin, gentamicin (G-myticin), erythromycin (Emgel), and neomycin are examples of topical antibiotics. These drugs are used to prevent superficial infections in minor cuts, wounds, skin abrasions, and minor burns. Erythromycin is also indicated for treatment of acne vulgaris.

#### Topical Antifungal Drugs

Antifungal drugs exert a local effect by inhibiting growth of the fungi. Examples of antifungal drugs and their uses are:
- Amphotericin B (Fungizone)—used for treatment of mycotic infections (fungal)
## SUMMARY DRUG TABLE

### DERMATOLOGIC DRUGS

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibiotic Drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>azelaic acid</td>
<td>Azelex</td>
<td>Acne vulgaris</td>
<td>Mild and transient pruritus, burning, stinging, erythema</td>
<td>Apply twice daily</td>
</tr>
<tr>
<td>bacitracin</td>
<td>Baciguent, generic</td>
<td>Relief of skin infections</td>
<td>Rare; occasionally redness, burning, pruritus, stinging</td>
<td>Apply 1–5 times daily</td>
</tr>
<tr>
<td>benzoyl peroxide</td>
<td>Acne-5, Benzac, Desquam-X 10% Wash, Dryox Wash, Exact, Laroxide Neutrogena, Acne Mask, generic</td>
<td>Mild to moderate acne vulgaris and oily skin</td>
<td>Excessive drying, stinging, peeling, erythema, possible edema, allergic dermatitis</td>
<td>Use once to three times daily</td>
</tr>
<tr>
<td>clindamycin, topical</td>
<td>Cleocin T, Clinda-Derm, Clindets, C/T/S, generic</td>
<td>Acne vulgaris</td>
<td>Dryness, erythema, burning, peeling, oiliness/oily skin, diarrhea, bloody diarrhea, abdominal pains, colitis</td>
<td>Apply a thin film twice daily to affected area</td>
</tr>
<tr>
<td>erythromycin</td>
<td>Akne-Mycin, Emgel, Erygel</td>
<td>Acne vulgaris</td>
<td>Skin irritation, tenderness, pruritus, erythema, peeling, oiliness and burning sensations</td>
<td>Clean affected area twice daily</td>
</tr>
<tr>
<td>gentamicin</td>
<td>G-myticin, generic</td>
<td>Relief of primary skin infections</td>
<td>Mild and transient pruritus, burning, stinging, erythema, photosensitivity</td>
<td>Apply 1–5 times daily to affected area</td>
</tr>
<tr>
<td>metronidazole</td>
<td>Metro-Gel, MetroLotion, Noritate</td>
<td>Rosacea</td>
<td>Watery (tearing) eyes, transient redness, mild dryness, burning, skin irritation</td>
<td>Apply a thin film twice daily to affected areas</td>
</tr>
<tr>
<td>mupirocin</td>
<td>Bactroban</td>
<td>Impetigo, infections caused by Staphylococcus aureus and S. pyogenes</td>
<td>Ointment: burning, stinging, pain, itching, rash, nausea, erythema, dry skin Cream: headache, rash, nausea, abdominal pain, burning at application site, dermatitis Nasal: headache, rhinitis, respiratory disorders, such as pharyngitis, taste perversion, burning, stinging, cough</td>
<td>Ointment: apply 3 times daily for 3–5 d Cream: apply 3 times daily for 10 d Nasal: divide the single-use tube between both nostrils and apply twice daily for 5 d</td>
</tr>
<tr>
<td>neomycin</td>
<td>Myciguent, generic</td>
<td>Relief of skin infections</td>
<td>Mild and transient pruritus, burning, stinging, erythema</td>
<td>Apply 1–3 times daily</td>
</tr>
<tr>
<td>sulfacetamide sodium</td>
<td>Sebizon</td>
<td>Seborheic dermatitis, seborrhea sicca (dandruff), bacterial infections of the skin</td>
<td>Rare: skin rash, nausea, vomiting</td>
<td>Apply 2–4 times daily</td>
</tr>
<tr>
<td><strong>Antifungal Drugs</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>amphotericin B</td>
<td>Fungizone</td>
<td>Mycotic infections</td>
<td>Rare; drying effect, local irritation, including erythema, pruritus, burning sensation</td>
<td>Apply liberally to lesions 2–4 times daily for 2–4 wk</td>
</tr>
<tr>
<td>butenafine HCl</td>
<td>Mentax</td>
<td>Dermatologic infections</td>
<td>Burning, stinging, itching, worsening of the condition, contact dermatitis, erythema, irritation</td>
<td>Apply 1 time daily for 4 wk</td>
</tr>
</tbody>
</table>
### CHAPTER 56
Topical Drugs Used in the Treatment of Skin Disorders

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>ciclopirox</td>
<td>Loprox, Penlac, Nail Lacquer</td>
<td>Loprox: tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), cutaneous candidiasis&lt;br&gt;Penlac: mild to moderate onychomycosis of fingernails and toenails</td>
<td>Pruritus, burning, worsening of clinical signs and symptoms, periungal erythema, nail disorders, irritation, ingrown toenail, burning of the skin</td>
<td>Apply to affected areas 1–2 times daily</td>
</tr>
<tr>
<td>ciclopirox</td>
<td>Loprox, Penlac, Nail Lacquer</td>
<td>Tinea cruris (jock itch), tinea corporis (ringworm), cutaneous candidiasis&lt;br&gt;Penlac: mild to moderate onychomycosis of fingernails and toenails</td>
<td></td>
<td></td>
</tr>
<tr>
<td>cloquinol</td>
<td>Generic</td>
<td>Tinea pedis, tinea cruris, and other skin infections caused by ringworm</td>
<td>Burning, itching, erythema, worsening of the condition</td>
<td>Apply thin layer to affected areas BID for 4 wk</td>
</tr>
<tr>
<td>econazole nitrate</td>
<td>Spectazole</td>
<td>Tinea pedis, tinea cruris, tinea corporis, cutaneous candidiasis, tinea versicolor</td>
<td>Local burning, itching, stinging, erythema, pruritic rash</td>
<td>Apply to affected areas 1–2 times daily</td>
</tr>
<tr>
<td>gentian violet</td>
<td>Generic</td>
<td>External treatment of abrasions, minor cuts, surface injuries, superficial fungus, infections of the skin</td>
<td>Local irritation or sensitivity reactions</td>
<td>Apply locally BID</td>
</tr>
<tr>
<td>haloprogin</td>
<td>Halotex</td>
<td>Tinea pedis, tinea cruris, tinea corporis, tinea manuum</td>
<td>Local irritation, burning sensation, vesicle formation, erythema, scaling, itching, pruritus</td>
<td>Apply twice daily for 2–4 wk</td>
</tr>
<tr>
<td>ketoconazole</td>
<td>Nizoral, generic</td>
<td>Cream: tinea cruris, tinea corporis, and tinea versicolor&lt;br&gt;Shampoo: reductions of scaling due to dandruff</td>
<td>Local burning, itching, stinging, erythema, pruritic rash</td>
<td>Cream: once daily to affected areas for 2 wk Shampoo: twice a week for 4 wk with at least 3 d between each shampoo</td>
</tr>
<tr>
<td>miconazole nitrate</td>
<td>Fungoid-HC Creme, Lotrimin, Micatin, Monistat-Derm Cream, Tetterine, generic</td>
<td>Tinea pedis, tinea cruris, tinea corporis, cutaneous candidiasis</td>
<td>Local irritation, burning, maceration, allergic contact dermatitis</td>
<td>Cover affected areas twice daily</td>
</tr>
<tr>
<td>naftifine HCl</td>
<td>Naftin</td>
<td>Topical treatment of tinea pedis, tinea cruris, tinea corporis</td>
<td>Burning, stinging, erythema, itching, local irritation, rash, tenderness</td>
<td>Apply BID for 4 wk</td>
</tr>
<tr>
<td>nystatin</td>
<td>Mycostatin, Nystex, generic</td>
<td>Mycotic infections caused by Candida albicans, and other Candida species</td>
<td>Virtually nontoxic and nonsensitizing; well tolerated by all age groups, even with prolonged administration; if irritation occurs, discontinue use</td>
<td>Apply 2–3 times daily until healing is complete</td>
</tr>
<tr>
<td>oxiconazole ox-ee-kon'-ah-zole</td>
<td>Oxistat</td>
<td>Tinea pedis, tinea cruris, tinea corporis</td>
<td>Pruritus, burning, stinging, irritation, contact dermatitis, scaling, tingling</td>
<td>Apply daily to BID 1 month</td>
</tr>
<tr>
<td>oxiconazole ox-ee-kon'-ah-zole</td>
<td>Oxistat</td>
<td>Same as oxiconazole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>suconazole nitrate</td>
<td>Exelderm</td>
<td>Same as oxiconazole</td>
<td>Pruritus, burning, stinging, irritation</td>
<td>Apply 1–2 times daily for 2 wk</td>
</tr>
<tr>
<td>suconazole nitrate</td>
<td>Exelderm</td>
<td>Same as oxiconazole</td>
<td>Same as oxiconazole</td>
<td>Apply twice daily until infection clears (1–4 wk)</td>
</tr>
<tr>
<td>terbinafine HCl ter-ben'-a-feen</td>
<td>Lamisil</td>
<td>Same as oxiconazole</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Continued*
### SUMMARY DRUG TABLE
#### DERMATOLOGIC DRUGS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>tolnaftate</td>
<td>Aftate, Genaspor, Tinactin, Ting, generic</td>
<td>Same as oxiconazole</td>
<td>Same as oxiconazole</td>
<td>Apply twice daily for 2–3 wk (4–6 wk may be needed)</td>
</tr>
</tbody>
</table>

#### Antiviral Drugs

| acyclovir     | Zovirax, generic | Herpes genitalis, herpes simplex virus infections | Mild pain with transient burning/ stinging, pruritus, rash, vulvitis, edema or pain at application site | Apply to all lesions q3h 6 times daily for 1 wk |
| penciclovir   | Denavir         | Herpes labialis (cold sores) | Irritation at application site, headache, mild erythema, rash, taste perversion | Apply q2h for 4 d |

#### Antiseptic and Germicides

| benzalkonium chloride (BAC) | Benza, Mycoside NS, Ony-Clear, Zephiran, generic | Asepsis of skin, mucous membranes, and wounds; preoperative preparation of the skin; surgeon’s hand and arm soaks; preservation of ophthalmic solutions; irrigations of the eye; vaginal douching | Well tolerated in most individuals; occasionally mild sensitivity reaction | Varies, depending on administration |
| chlorhexidine gluconate | Bacto Shield 2, Betasept, Evidine-2 Scrub, Hibiclens | Surgical scrub, skin cleanser, preoperative skin preparation, skin wound cleanser, preoperative showering and bathing | Irritation, dermatitis, photosensitivity (rare), deafness, photosensitivity reactions | Varies, depending on administration |
| povidone-iodine | Acu-Dyne, Aerodine, Betadine, generic | Microbicidal against bacteria, fungi, viruses, spores, protozoa, yeasts | Dermatitis, irritation, burning, sensitivity reactions | Varies, depending on administration |
| triclosan      | Clearasil Daily Face Wash | Skin cleanser, and skin degermer | None significant | 5 mL on hands or face and rub thoroughly for 30 seconds, rinse thoroughly, pat dry |

#### Corticosteroids, Topical

| alclometasone dipropionate | Aclovate | Treatment of various allergic/immunologic skin problems | Allergic contact dermatitis, burning, dryness, edema, irritation | Apply 1–6 times daily according to directions |
| amcinonide               | Cyclocort | Same as alclometasone | Same as alclometasone | Apply 1–6 times daily according to directions |
| augmented betamethasone dipropionate | Diprolene | Same as alclometasone | Same as alclometasone | Apply 1–4 times daily according to directions |
| betamethasone dipropionate bay-ta-meth’a-sone | Alphatrex, Diprosone, Maxivate, generic | Same as alclometasone | Same as alclometasone | Apply 1–4 times daily according to directions |
### SUMMARY DRUG TABLE

#### Topical Drugs Used in the Treatment of Skin Disorders

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>betamethasone valerate</td>
<td>Betatrex, generic</td>
<td>Same as alclometasone</td>
<td>Same as alclometasone</td>
<td>Apply 1–4 times daily according to directions</td>
</tr>
<tr>
<td>desoximetasone</td>
<td>Topicort, generic</td>
<td>Same as alclometasone</td>
<td>Same as alclometasone</td>
<td>Apply 1–4 times daily according to directions</td>
</tr>
<tr>
<td>dexamethasone sodium phosphate</td>
<td>Decadron Phosphate</td>
<td>Same as alclometasone</td>
<td>Same as alclometasone</td>
<td>Apply 1–4 times daily according to directions</td>
</tr>
<tr>
<td>diflorasone diacetate</td>
<td>Florone, Maxiflor</td>
<td>Same as alclometasone</td>
<td>Same as alclometasone</td>
<td>Apply 1–4 times daily according to directions</td>
</tr>
<tr>
<td>fluocinolone acetonide</td>
<td>Fluonid, Flurosyn, Synalar, generic</td>
<td>Same as alclometasone</td>
<td>Same as alclometasone</td>
<td>Apply 1–4 times daily according to directions</td>
</tr>
<tr>
<td>flurandrenolide</td>
<td>Cordran, generic</td>
<td>Same as alclometasone</td>
<td>Same as alclometasone</td>
<td>Apply 1–4 times daily according to directions</td>
</tr>
<tr>
<td>hydrocortisone butyrate</td>
<td>Pandel</td>
<td>Psoriasis and other deep-seated dermatoses</td>
<td>Same as alclometasone</td>
<td>Apply once or twice daily</td>
</tr>
<tr>
<td>hydrocortisone</td>
<td>Cort-Dome, Hytone, generic</td>
<td>Same as alclometasone</td>
<td>Same as alclometasone</td>
<td>Apply 2–3 times daily</td>
</tr>
<tr>
<td>triamcinolone acetonide</td>
<td>Aristocort, Flutex, Kenalog, Triacet, generic</td>
<td>Same as alclometasone</td>
<td>Same as alclometasone</td>
<td>Apply 1–4 times daily according to directions</td>
</tr>
</tbody>
</table>

#### Anti-psoriatic Drugs

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>ammoniated mercury</td>
<td>Emersal</td>
<td>Psoriasis</td>
<td>Ammoniated mercury is a potential sensitizer that can cause allergic reactions</td>
<td>Apply 1–2 times daily</td>
</tr>
<tr>
<td>anthralin</td>
<td>Anthra-Derm, Dritcho Creme, Miconal</td>
<td>Psoriasis</td>
<td>Few; transient irritation of normal skin or uninvolved skin</td>
<td>Apply once a day</td>
</tr>
<tr>
<td>calcipotriene</td>
<td>Dovonex</td>
<td>Psoriasis</td>
<td>Burning, itching, skin irritation, erythema, dry skin, peeling, rash, worsening of psoriasis, dermatitis, hyperpigmentation</td>
<td>Apply twice daily</td>
</tr>
<tr>
<td>selenium sulfide</td>
<td>Exsel Head and Shoulders Intensive Treatment Dandruff Shampoo, Selsun Blue, generic</td>
<td>Treatment of dandruff, seborrheic dermatitis of the scalp, and tinea versicolor</td>
<td>None significant. Rare, some skin irritation</td>
<td>Massage 5–10 mL into wet scalp and allow to remain on scalp for 2–3 minutes, rinse</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Enzyme Preparations</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>collagenase</strong></td>
<td>Santyl, generic</td>
<td>For debriding chronic dermal ulcers and severely burned areas</td>
<td>Well tolerated and nonirritating; transient burning sensation may occur</td>
<td>Apply once daily according to directions</td>
</tr>
<tr>
<td><strong>enzyme combinations</strong></td>
<td>Accuzyme, Granulderm, Granulex, Panafil</td>
<td>Debridement of necrotic tissue and liquefication of slough in acute and chronic lesions such as decubitus ulcers, varicose and diabetic ulcers, burns, wounds, pilonidal cyst wounds, and miscellaneous trauma of infected wounds</td>
<td>Well tolerated and nonirritating; transient burning sensation may occur</td>
<td>Apply once or twice daily</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Keratolytic Drugs</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>diclofenac sodium</strong></td>
<td>Solaraze</td>
<td>Actinic keratoses</td>
<td>Usually well tolerated; transient burning sensation, rash, dry skin, scaling, flu syndrome</td>
<td>Apply twice daily</td>
</tr>
<tr>
<td><strong>masoprocol</strong></td>
<td>Actinex</td>
<td>Actinic keratoses</td>
<td>Erythema, flaking, dryness, itching, edema, burning, soreness, bleeding, crusting, skin roughness</td>
<td>Apply twice daily</td>
</tr>
<tr>
<td><strong>salicylic acid</strong></td>
<td>DuoFilm, Wart Remover, Fostex, Fung-O, Mosco, Panscol</td>
<td>Aids in the removal of excessive keratin in hyperkeratotic skin disorders, including warts, psoriasis, calluses, and corns</td>
<td>Local irritation</td>
<td>Apply as directed in individual product labeling</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Local Anesthetics</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>benzocaine</strong></td>
<td>Lanacane</td>
<td>For topical anesthesia in local skin disorders</td>
<td>Rare; hypersensitivity, local burning, stinging, tenderness, sloughing</td>
<td>Apply to affected area</td>
</tr>
<tr>
<td><strong>dibucaine</strong></td>
<td>Nupercainal, generic</td>
<td>For topical anesthesia in local skin disorders, local anesthesia of accessible mucous membranes</td>
<td>Same as benzocaine</td>
<td>Topical: apply to affected area as needed; mucous membranes: dosage varies and depends on the area to be anesthetized</td>
</tr>
<tr>
<td><strong>lidocaine</strong></td>
<td>ELA-Max, Lidocaine Viscous, Xylocaine, generic</td>
<td>For topical anesthesia in local skin disorders, local anesthesia of accessible mucous membranes</td>
<td>Same as benzocaine</td>
<td>Topical: apply to affected area as needed; mucous membranes: dosage varies and depends on the area to be anesthetized</td>
</tr>
<tr>
<td><strong>lidocaine HCl</strong></td>
<td>Dentipatch</td>
<td>Topical anesthesia of accessible mucous membranes of the mouth before dental procedures</td>
<td>Rare; local burning, stinging, tenderness</td>
<td>Apply to affected area</td>
</tr>
<tr>
<td><strong>butamben picrate</strong></td>
<td>Generic</td>
<td>Topical anesthesia</td>
<td>Rare; local burning, stinging, tenderness</td>
<td>Apply to affected area</td>
</tr>
</tbody>
</table>

*The term *generic* indicates the drug is available in generic form.*
\textbf{Topical Antifungal Drugs}

- Miconazole (Micatin), ciclopirox (Loprox), and econazole (Spectazole)—used for treatment of tinea pedis (athlete’s foot), tinea cruris (jock itch), tinea corporis (ringworm), and superficial candidiasis
- Clioquinol—used for eczema, athlete’s foot, and other fungal infections

\textbf{Topical Antiviral Drugs}

Acyclovir (Zovirax) and penciclovir (Denavir) are the only topical antiviral drugs currently available. These drugs inhibit viral replication. Acyclovir is used in the treatment of initial episodes of genital herpes, as well as herpes simplex virus infections in immunocompromised patients (patients with an immune system incapable of fighting infection). Penciclovir is used for the treatment of recurrent herpes labialis (cold sores) in adults.

\textbf{ADVERSE REACTIONS}

Adverse reactions to topical anti-infectives are usually mild. Occasionally, the patient may experience a skin rash, itching, urticaria (hives), dermatitis, irritation, or redness, which may indicate a hypersensitivity (allergic) reaction to the drug. Prolonged use of topical antibiotic preparations may result in a superficial superinfection (an overgrowth of bacterial or fungal microorganisms not affected by the antibiotic being administered).

\textbf{CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS}

These drugs are contraindicated in patients with known hypersensitivity to the drugs or any components of the drug. Because neomycin toxicity can cause nephrotoxicity and ototoxicity, neomycin is used cautiously in patients with extensive burns or trophic ulceration when extensive absorption can occur.

The topical antibiotics are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation. Acyclovir and penciclovir are Pregnancy Category B drugs and are used cautiously during pregnancy and lactation. The pregnancy categories of the antifungals are unknown except for econazole nitrate, which is Pregnancy Category C, and ciclopirox, which is Pregnancy Category B; both are used with caution during pregnancy and lactation. There are no significant interactions for the topical anti-infectives.
ADVERSE REACTIONS

Topical antiseptics and germicides have few adverse reactions. Occasionally, an individual may be allergic to the drug, and a skin rash or itching may occur. If an allergic reaction is noted, use of the topical drug is discontinued.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

These drugs are contraindicated in patients with known hypersensitivity to the individual drug or any component of the preparation. There are no significant precautions or interactions when used as directed.

TOPICAL CORTICOSTEROIDS

Topical corticosteroids vary in potency, depending on the concentration of the drug (percentage), the vehicle in which the drug is suspended (lotion, cream, aerosol spray), and the area to which the drug is applied (open or denuded skin, unbroken skin, thickness of the skin over the treated area).

Examples of topical corticosteroids include amcinonide (Cyclocort), betamethasone dipropionate (Diprosone), fluocinolone acetonide (Flurosyn), hydrocortisone (Cort-Dome), and triamcinolone acetate (Aristocort).

ACTIONS AND USES

Topical corticosteroids exert localized anti-inflammatory activity. When applied to inflamed skin, they reduce itching, redness, and swelling. These drugs are useful in treating skin disorders, such as psoriasis, dermatitis, rashes, eczema, insect bite reactions, and first- and second-degree burns, including sunburns.

ADVERSE REACTIONS

Localized reactions may include burning, itching, irritation, redness, dryness of the skin, and secondary infection.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

The topical corticosteroids are contraindicated in patients with known hypersensitivity to the drug or any component of the drug; as monotherapy for bacterial skin infections; for use on the face, groin, or axilla (only the high-potency corticosteroids); and for ophthalmic use (may cause steroid-induced glaucoma or cataracts). The topical corticosteroids are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation. There are no significant interactions when administered as directed.

TOPICAL ANTIPSORIATICS

ACTION AND USES

Topical antipsorials are drugs used in the treatment of psoriasis (a chronic skin disease manifested by bright red patches covered with silvery scales or plaques). These drugs help remove the plaques associated with this disorder. Examples of antipsorials include anthralin (Anthra-Derm) and calcipotriene (Dovonex).

ADVERSE REACTIONS

These drugs may cause burning, itching, and skin irritation. Anthralin may cause skin irritation, as well as temporary discoloration of the hair and fingernails.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

These drugs are contraindicated in patients with known hypersensitivity to the drugs. Anthralin and calcipotriene are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation.

TOPICAL ENZYMES

ACTIONS AND USES

A topical enzyme aids in the removal of dead soft tissues by hastening the reduction of proteins into simpler substances. This is called proteolysis or a proteolytic action. The components of certain types of wounds, namely necrotic (dead) tissues and purulent exudates (pus-containing fluid), prevent proper wound healing. Removal of this type of debris by application of a topical enzyme aids in healing. Examples of conditions that may respond to application of a topical enzyme include second- and third-degree burns, pressure ulcers, and ulcers caused by peripheral vascular disease. An example of a topical enzyme is collagenase (Santyl).
**ADVERSE REACTIONS**

The application of collagenase may cause mild, transient pain. Numbness and dermatitis also may be seen. Collagenase has a low incidence of adverse reactions.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

The topical enzyme preparations are contraindicated in patients with known hypersensitivity to the drugs, in wounds in contact with major body cavities or where nerves are exposed, and in fungating neoplastic ulcers. These drugs are Pregnancy Category B drugs and are used cautiously during pregnancy and lactation. Enzymatic activity may be impaired when these agents are administered with several detergents and antiseptics (benzalkonium chloride, hexachlorophene, iodine, and nitrofurazone).

**KERATOLYTICS**

**ACTIONS AND USES**

A keratolytic is a drug that removes excess growth of the epidermis (top layer of skin) in disorders such as warts. These drugs are used to remove warts, calluses, corns, and seborrheic keratoses (benign variously colored skin growths arising from oil glands of the skin). Examples of keratolytics include salicylic acid, masoprocunol (Actinex), and diclofenac (Solaraze). Some strengths of salicylic acid are available as nonprescription products for the removal of warts on the hands and feet.

**ADVERSE REACTIONS**

These drugs are usually well tolerated. Occasionally a transient burning sensation, rash, dry skin, scaling, or flu-like syndrome may occur.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

The keratolytics are contraindicated in patients with known hypersensitivity to the drugs and for use on moles, birthmarks, or warts with hair growing from them, on genital or facial warts, on warts on mucous membranes, or on infected skin. Prolonged use of the keratolytics in infants or patients with diabetes or impaired circulation is contraindicated. Salicylic acid may cause salicylate toxicity (see Chap. 17) with prolonged use. These drugs are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation.

**TOPICAL LOCAL ANESTHETICS**

A topical anesthetic may be applied to the skin or mucous membranes.

**ACTIONS AND USES**

Topical anesthetics temporarily inhibit the conduction of impulses from sensory nerve fibers. These drugs may be used to relieve itching and pain due to skin conditions, such as minor burns, fungus infections, insect bites, rashes, sunburn, and plant poisoning, such as poison ivy. Some are applied to mucous membranes as local anesthetics. Examples of local anesthetics include benzocaine (Lanacane), dibucaine (Nupercainal), and lidocaine (Xylocaine).

**ADVERSE REACTIONS**

Occasionally, local irritation, dermatitis, rash, burning, stinging, and tenderness may be noted.

**CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

These drugs are contraindicated in those with a known hypersensitivity to any component of the preparation. The topical anesthetics are used cautiously in patients receiving Class I antiarrhythmic drugs such as tocainide and mexiletine because the toxic effects are additive and potentially synergistic.

---

**Herbal Alert: Aloe Vera**

Aloe is used to prevent infection and promote healing of minor burns (e.g., sunburn) and wounds. When used externally, the herb helps repair skin tissue and reduce inflammation. Aloe gel is naturally thick when taken from the leaf but quickly becomes watery because of the action of enzymes in the plant. Commercially available preparations have additive thickeners to make the aloe appear like the fresh gel. The herb can be applied directly from the fresh leaf by cutting the leaf in half lengthwise and gently rubbing the inner gel directly onto the skin. Commercially prepared products are applied externally as needed. Rare reports of allergy have been reported with the external use of aloe. Although available as an oral juice, its benefits have not been confirmed. Some individuals have reported the oral juice effective in healing and preventing stomach ulcers.
The Patient Receiving a Topical Drug for a Skin Disorder

ASSESSMENT

Preadministration Assessment

The preadministration assessment involves a visual inspection and palpation of the involved area(s). The nurse carefully records the areas of involvement, including the size, color, and appearance. A specific description is important so that changes can be readily identified indicating worsening or improvement of the lesions. Terms used to describe skin lesions are found in Table 56-1. The nurse notes the presence of scales, crusting, drainage, or any complaint of itching. Some agencies may provide a figure on which the lesions can be drawn, indicating the shape and distribution of the involved areas.

Ongoing Assessment

At the time of each application, the nurse inspects the affected area for changes (eg, signs of improvement or worsening of the infection) and for adverse reactions, such as redness or rash. The nurse contacts the primary health care provider, and the drug is not applied if these or other changes are noted or if the patient reports new problems, such as itching, pain, or soreness at the site. The nurse may be responsible for checking the treatment sites 1 day or more after application and should inform the primary health care provider of any signs of extreme redness or infection at the application site.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient may include an optimal response to drug therapy and an understanding of the application or the reason for use of a topical drug.

IMPLEMENTATION

Promoting an Optimal Response to Therapy

Some patients may experience anxiety about the appearance of certain skin lesions or the symptoms of a specific dermatologic disorder. This may cause a negative body image. The nurse must allow time for the patient to verbalize concerns or ask questions concerning therapy. The nurse reassures the patient that the lesions are temporary and will diminish or disappear with treatment (if that is true).

TOPICAL ANTI-INFECTIVES. Before each application, the nurse cleanses the skin with soap and warm water unless the primary health care provider orders a different method. The nurse applies the anti-infective as prescribed (eg, thin layer, applied liberally) and the area is either covered or left exposed.

NURSING ALERT

The nurse must exercise care when applying anti-infectives or any topical drug near or around the eyes.

TOPICAL ANTISEPTICS AND GERMICIDES. The nurse uses, instills, or applies antiseptics and germicides as directed by the primary health care provider or by the label on the product. Topical antiseptics and germicides are not a substitute for clean or aseptic techniques. Occlusive dressings are not to be used after application of these products unless a dressing is specifically ordered by the primary health care provider. For example, an occlusive dressing is not recommended after the use of benzalkonium. Iodine permanently stains clothing and temporarily stains the skin. The nurse should remove or protect the patient’s personal clothing when iodine solution or tincture is applied.

Antiseptic and germicidal drugs kept at the patient’s bedside must be clearly labeled with the name of the product, the strength, and when applicable, the date of preparation of the solution. The nurse replaces hard-to-read or soiled, stained labels as needed. These solutions

<table>
<thead>
<tr>
<th>LESION</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macule</td>
<td>Flat spot on the skin</td>
</tr>
<tr>
<td>Papule</td>
<td>Raised spot on the skin</td>
</tr>
<tr>
<td>Nodule</td>
<td>Small solid swelling on the skin</td>
</tr>
<tr>
<td>Pustule</td>
<td>Lesion containing pus</td>
</tr>
<tr>
<td>Petechia</td>
<td>Pinpoint hemorrhagic areas of the skin</td>
</tr>
<tr>
<td>Erythema</td>
<td>Redness</td>
</tr>
<tr>
<td>Ecchymosis</td>
<td>Bruised area</td>
</tr>
<tr>
<td>Vesicle</td>
<td>Fluid-filled swelling (blister)</td>
</tr>
</tbody>
</table>

TABLE 56-1 Terms Used to Describe Skin Lesions
are not kept at the bedside of any patient who is confused or disoriented because the solution may be mistaken for water or another beverage.

**Topical Corticosteroids.** Before drug application, the nurse washes the area with soap and warm water unless the primary health care provider directs otherwise. Topical corticosteroids are usually ordered to be applied sparingly. The primary health care provider also may order the area of application to be covered or left exposed to the air. Some corticosteroids are applied as an occlusive dressing. The nurse applies the drug while the skin is still moist after washing with soap and water, covers the area with a plastic wrap, seals it with tape or bandage, and leaves it in place for the prescribed period of time.

**Topical Enzymes.** Certain types of wounds may require special preparations before applying the topical enzyme. The nurse cleanses or prepares the area and applies the topical enzyme as directed by the primary health care provider. If bleeding occurs with the use of sutilains, the nurse discontinues the ointment and contacts the primary health care provider.

**Topical Antipsoriatrics.** The nurse may be responsible for applying the product and inspecting the areas of application. Care is exercised so that the product is applied only to the psoriatic lesions and not to surrounding skin. The nurse brings signs of excessive irritation to the attention of the primary health care provider.

**Topical Anesthetics.** The nurse applies the anesthetic as directed by the primary health care provider. Before the first application, the nurse cleanses and dries the area. For subsequent applications, the nurse removes all previous residue.

When a topical gel, such as lidocaine viscous, is used for oral anesthesia for the control of pain, the nurse instructs the patient not to eat food for 1 hour after use because local anesthesia of the mouth or throat may impair swallowing and increase the possibility of aspiration.

**Monitoring and Managing Adverse Reactions**

Most topical drugs cause few adverse reactions and, if they occur, discontinuing use of the drug may be all that is necessary to relieve the symptoms. Occasionally, an increased skin sensitivity can occur, causing increased redness, discomfort, and itching. With itching and rash the nurse may use cool, wet compresses or a bath to relieve the itching. Keeping the environment cool may also make the patient more comfortable. Dry skin increases the risk of skin breakdown from scratching. The nurse can advise the patient to keep nails short, use warm water with mild soap for cleaning the skin, and rinse and dry the skin thoroughly. Bath oils, creams, and lotions may be applied if necessary as long as the primary health care provider is consulted before use. Dry, flaky skin is subject to breakdown and infection. The nurse observes the skin for signs of infection (eg, redness, heat, pus, and elevated temperature and pulse) and immediately reports any sign of infection.

**Gerontologic Alert**

Adults older than 65 years have more skin-related adverse reactions to calcipotriene. The nurse should use calcipotriene cautiously in older adults.

**Educating the Patient and Family**

If the primary health care provider has prescribed or recommended the use of a topical drug, the nurse includes the following in a teaching plan:

- Wash the hands thoroughly before and after applying the product.
- If the enclosed directions state that the product will stain clothing, be sure clothing is moved away from the treated area. If the product stains the skin, wear disposable gloves when applying the drug.
- Follow the directions on the label or use as directed by the primary health care provider. Read any enclosed directions for use of the product carefully.
- Prepare the area to be treated as recommended by the primary health care provider or as described in the directions supplied with the product.
- Do not apply to areas other than those specified by the primary health care provider. Apply the drug as directed (eg, thin layer, apply liberally, and so on).
- Follow the directions of the primary health care provider regarding covering the treated area or leaving it exposed to air. The effectiveness of certain drugs depends on keeping the area covered or leaving it open (see Home Care Checklist: Using an Occlusive Dressing).
- Keep this product away from the eyes (unless use in or around the eye has been recommended or prescribed). Do not rub or put the fingers near the eyes unless the hands have been thoroughly washed and all remnants of the drug removed from the fingers. If the product is accidentally spilled, sprayed, or splashed in the eye, wash the eye immediately with copious amounts of running water. Contact the primary health care provider immediately if burning, pain, redness, discomfort, or blurred vision persists for more than a few minutes.
- The drug may cause momentary stinging or burning when applied.
Home Care Checklist

USING AN OCCLUSIVE DRESSING

In certain circumstances, the patient who requires a topical drug must also apply an occlusive dressing to enhance the drug’s effectiveness. Although commercial-type occlusive dressings are available, they are expensive, especially if your patient requires frequent dressing changes at home. So, if appropriate, suggest these less costly home alternatives:

- Plastic food wrap such as Saran wrap
- Plastic food storage bags

After your patient gathers the necessary supplies, instruct him or her to do the following:

- Wash hands before beginning care.
- Remove the old dressing.
- Cleanse the area as directed.
- Apply the topical drug as ordered.
- Cover the area with a dry gauze dressing.
- Apply a skin adhesive to the area around the gauze dressing.
- Cover the gauze dressing with the occlusive dressing, making sure that the occlusive dressing is approximately 1 inch larger than the gauze dressing on all sides. For example, if the gauze dressing is 4 inches × 4 inches, then the occlusive dressing should be 5 inches × 5 inches.
- Check to make sure that the occlusive dressing lies flat without wrinkles.
- Run fingers around all the edges of the occlusive dressing to ensure good adhesion.
- Tape the edges of the occlusive dressing on all sides, preferably with paper tape, to secure it.

- Discontinue use of the drug and contact the primary health care provider if rash, burning, itching, redness, pain, or other skin problems occur.
- Gentamicin may cause photosensitivity. Take measures to protect the skin from ultraviolet rays (eg, wear protective clothing and use a sunscreen when out in the sun).

EVALUATION

- The therapeutic drug response is achieved.
- The patient or family member demonstrates an understanding of the use and application of the prescribed or recommended drug.

Critical Thinking Exercises

1. A nurse tells you that she is upset because she was reprimanded about the labeling of a topical antiseptic used for cleaning a pressure ulcer and for leaving the solution at the patient's bedside. She thinks her supervisor is unfair and the entire situation is not as serious as the supervisor contends. Analyze the situation to determine what you would say to this nurse.
2. Discuss the ongoing assessment activities you would include in the daily assessment of a patient prescribed a topical drug.
3. Describe important preadministration assessments that the nurse would make before administering a topical corticosteroid.

Review Questions

1. What reaction could occur with prolonged use of the topical antibiotics?
   A. Water intoxication
   B. Superficial superinfection
   C. An outbreak of eczema
   D. Cellulitis
2. Which of the following drugs has a proteolytic action?
   A. Amcinonide (Cyclocort)
   B. Collagenase (Santyl)
   C. Bacitracin (Baciguent)
   D. Ciclopirox (Loprox)

3. A keratolytic agent would be safe to use on which of the following skin conditions?
   A. Moles
   B. Birthmarks
   C. Facial warts
   D. Calluses

4. What type of action do the corticosteroids have when used topically?
   A. Bacteriocidal activity
   B. Anti-inflammatory activity
   C. Antifungal activity
   D. Antiviral activity

5. Which of the following drugs is best suited to be used as a topical antiseptic?
   A. Amphotericin B
   B. Benzocaine
   C. Iodine
   D. Povidone-iodine
The eyes and ears are subject to various disorders, which range from mild to serious. Because the eyes and ears provide an interpretation of our outside environment, any disease or injury that has the potential for partial or total loss of function of these organs must be treated.

**OTIC PREPARATIONS**

**ACTIONS**

Various types of preparations are used for the treatment of otic (ear) disorders. Otic preparations can be divided into three categories: (1) antibiotics; (2) antibiotic and steroid combinations; and (3) miscellaneous preparations. The miscellaneous preparations usually contain one or more of the following ingredients:

- Benzocaine—a local anesthetic
- Phenylephrine—a vasoconstrictor decongestant
- Hydrocortisone, desonide—corticosteroids for anti-inflammatory and antipruritic effects
- Glycerin—an emollient and a solvent
- Antipyrine—an analgesic

- Acetic acid, boric acid, benzalkonium chloride, aluminum acetate, benzethonium chloride—provide antifungal or antibacterial action
- Carbamide peroxide—aid in removing earwax by softening and breaking up the wax

Examples of otic preparations are given in the Summary Drug Table: Otic Preparations.

**USES**

Otic preparations are instilled in the external auditory canal and may be used to relieve pain, treat infection and inflammation, and aid in the removal of earwax. When the patient has an inner ear infection, systemic antibiotic therapy is indicated.

**ADVERSE REACTIONS**

When otic drugs are applied topically, the amount of drug that enters the systemic circulation is not sufficient to produce adverse reactions. Prolonged use of otic...
### Stereo and Antibiotic Combinations, Solutions

<table>
<thead>
<tr>
<th>Generic Combinations</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>1% hydrocortisone, 5 mg neomycin sulfate, 10,000 units polymyxin B</td>
<td>Antibiotic Ear Solution, AntiBiotic, Cortisporin Otic, Drotic, Ear-Eze, Otic-Care, Oticair, Otocort, Otosporin</td>
<td>Bacterial infections of the external auditory canal</td>
<td>Few; when used for prolonged periods there is a danger of a superinfection</td>
<td>4 gtt instilled TID, QID</td>
</tr>
<tr>
<td>0.5% hydrocortisone, 10,000 units polymyxin B</td>
<td>Otobiotic Otic</td>
<td>Same as hydrocortisone, above</td>
<td>Same as hydrocortisone, above</td>
<td>4 gtt instilled TID, QID</td>
</tr>
</tbody>
</table>

### Steroid and Antibiotic Combinations, Suspensions

<table>
<thead>
<tr>
<th>Generic Combinations</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>1% hydrocortisone, 5 mg neomycin sulfate, 10,000 units polymyxin B</td>
<td>AK-Spore, Antibiotic Ear Suspension, Otocort, UAD Otic</td>
<td>Same as hydrocortisone, above</td>
<td>Same as hydrocortisone, above</td>
<td>4 gtt instilled TID, QID</td>
</tr>
<tr>
<td>1% hydrocortisone, 4.71 mg neomycin sulfate</td>
<td>Coly-Mycin S Otic</td>
<td>Same as hydrocortisone, above</td>
<td>Same as hydrocortisone, above</td>
<td>4 gtt instilled TID, QID</td>
</tr>
<tr>
<td>1% hydrocortisone, 3.3 mg neomycin sulfate</td>
<td>Cortisporin-TC Otic</td>
<td>Same as hydrocortisone, above</td>
<td>Same as hydrocortisone, above</td>
<td>4 gtt instilled TID, QID</td>
</tr>
<tr>
<td>2 mg ciprofloxacin, 10 mg hydrocortisone/mL</td>
<td>Cipro HC Otic</td>
<td>Same as hydrocortisone, above</td>
<td>Same as hydrocortisone, above</td>
<td>4 gtt instilled TID, QID</td>
</tr>
</tbody>
</table>

### Otic Antibiotics

<table>
<thead>
<tr>
<th>Generic Combinations</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chloramphenicol</td>
<td>Chloromycetin Otic</td>
<td>Treatment of superficial infections involving the external auditory canal</td>
<td>Local irritation (itching, burning, angioneurotic edema, urticaria, vesicular and maculopapular dermatitis)</td>
<td>2–3 gtt into the ear TID</td>
</tr>
</tbody>
</table>

### Select Miscellaneous Preparations

<table>
<thead>
<tr>
<th>Generic Combinations</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Adverse Reactions</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>1% hydrocortisone, 2% acetic acid, 3% propylene glycol diacetate, 0.015% sodium acetate, 0.02% benzethonium chloride</td>
<td>Acetasol HC, VoSoL HC Otic</td>
<td>Relieve pain, inflammation, and irritation in the external auditory canal</td>
<td>Local irritation, itching, burning</td>
<td>Insert wick, use 3–5 gtt q4–6h × 24 h; remove wick, instill 5 gtt TID, QID</td>
</tr>
<tr>
<td>1% hydrocortisone, 1% pramoxine HCl, 0.1% chloroxylenol, 3% propylene glycol diacetate and benzalkonium chloride</td>
<td>Cortic</td>
<td>Same as hydrocortisone, above</td>
<td>Same as hydrocortisone, above</td>
<td>Insert saturated wick into the ear; leave in for 24 h, keeping moist with 3–5 gtt q4–6h; remove wick and instill 5 gtt TID, QID</td>
</tr>
</tbody>
</table>
preparations containing an antibiotic may result in a **superinfection** (an overgrowth of bacterial or fungal microorganisms not affected by the antibiotic being administered).

### CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

These drugs are contraindicated in patients with a known hypersensitivity to the drugs. The otic drugs are used with caution during pregnancy and lactation. The pregnancy category of these drugs is unknown when they are used as otic drugs. Otic drugs available in dropper bottles may be dangerous if ingested by young children. Therefore, the drugs are stored safely out of the reach of children. Drugs to remove cerumen are not used if ear drainage, discharge, pain, or irritation is present; if the eardrum is perforated; or after ear surgery. Although rare, bone marrow hypoplasia including aplastic anemia has been reported with local application of chloramphenicol. No significant interactions have been reported with use of the otic preparations.

### NURSING PROCESS

#### The Patient Receiving an Otic Preparation

**ASSESSMENT**

**Preadministration Assessment**

Before administration of an otic preparation, the primary health care provider examines the ear and external structures surrounding the ear and prescribes the drug indicated to treat the disorder. The nurse may be responsible for examining the outer structures of the ear, namely the earlobe and the skin around the ear. The nurse documents a description of any drainage or the presence of impacted cerumen.

### SUMMARY DRUG TABLE

<table>
<thead>
<tr>
<th>GENERIC COMBINATIONS</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>1% hydrocortisone, 2% acetic acid glacial, 3% propylene glycol diacetate, 0.02% benzethonium Cl, 0.015% sodium acetate, 0.2% citric acid</td>
<td>AA-HC Otic</td>
<td>Same as hydrocortisone, above</td>
<td>Same as hydrocortisone, above</td>
<td>Insert saturated wick into the ear; leave in for 24 h, keeping moist with 3–5 gtt q4–6h; remove wick and instill 5 gtt TID, QID</td>
</tr>
<tr>
<td>1.4% benzocaine, 5.4% antipyrine glycerin</td>
<td>Allergen Ear Drops, Auralgan Otic, Auroto Otic, Ear Drops, Otoacalm Ear Drops</td>
<td>Same as hydrocortisone, above</td>
<td>Same as hydrocortisone, above</td>
<td>Fill ear canal with 2–4 gtt; insert saturated cotton pledget; repeat TID, QID or q1–2h</td>
</tr>
<tr>
<td>20% benzocaine, 0.1% benzenethion chloride, 1% glycerin, PEG 300</td>
<td>Americaine Otic, Otocain</td>
<td>Same as hydrocortisone, above</td>
<td>Same as hydrocortisone, above</td>
<td>Instill 4–5 gtt; insert cotton pledget; repeat every 1–2h</td>
</tr>
<tr>
<td>10% triethanolamine polypeptide oleate-condensate, 0.5% chlorobutanol in propylene glycol</td>
<td>Cerumenex Drops</td>
<td>Aid in the removal of ear wax</td>
<td>Local irritation, itching, burning</td>
<td>Fill ear canal, insert cotton plug, allow to remain 15–30 min; flush ear</td>
</tr>
<tr>
<td>1 mg chloroxylenol, 10 mg hydrocortisone, 10 mg/mL pramoxine HCl</td>
<td>Otomar-HC</td>
<td>Relieve pain and irritation in the external auditory canal</td>
<td>Local irritation, itching, burning</td>
<td>Instill 5 gtt into affected ear TID, QID</td>
</tr>
<tr>
<td>2% acetic acid in aluminum acetate solution</td>
<td>Burow’s Otic, Otic Domeboro, generic</td>
<td>Relieve pain and irritation in the external auditory canal</td>
<td>Local irritation, itching, burning</td>
<td>Insert saturated wick; keep moist for 24 h; instill 4–6 gtt every 2–3 h</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.*
Ongoing Assessment
The nurse assesses the patient’s response to therapy. For example, a decrease in pain or inflammation should occur. The nurse examines the outer ear and ear canal for any local redness or irritation that may indicate sensitivity to the drug.

NURSING DIAGNOSES
Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING
The expected outcomes of the patient may include an optimal response to the drug, a reduction in anxiety, and an understanding of the application and use of an otic preparation.

IMPLEMENTATION
Promoting an Optimal Response to Therapy
Before instillation of otic preparations, the nurse holds the container in the hand for a few minutes to warm it to body temperature. Cold and warm (above body temperature) preparations may cause dizziness or other sensations after being instilled into the ear.

Nursing Alert
Only preparations labeled as otic are instilled in the ear. The nurse must check the label of the preparation carefully for the name of the drug and a statement indicating that the preparation is for otic use.

Special instructions for specific ear preparations are found in the Summary Drug Table: Otic Preparations. When instilling ear drops, the nurse has the patient lie on his or her side with the ear toward the ceiling. If the patient wishes to remain in an upright position, the head is tilted toward the untreated side with the ear toward the ceiling (Fig. 57-1). In the adult, the earlobe is pulled up and back. In children, the earlobe is pulled down and back. The nurse instills the prescribed number of drops into the ear canal. If the primary health care provider has not ordered a soft cotton plug to be placed in the opening of the external ear canal, the patient is kept lying on the untreated side for 2 to 3 minutes. Once the patient is upright, the solution running out of the ear may be gently removed with gauze.

Drugs that loosen cerumen work by softening the dried earwax inside the ear canal. Cerumenex is available by prescription and is not allowed to stay in the ear canal more than 30 minutes before irrigation. When Cerumenex is administered, the ear canal is filled with the solution and a cotton plug is inserted. The drug is allowed to remain in the ear for 15 to 30 minutes, and then the ear is flushed with warm water using a soft rubber bulb ear syringe.

Managing Anxiety
Ear disorders may result in symptoms such as pain, a feeling of fullness in the ear, tinnitus, dizziness, or a change in hearing. Patients with an ear disorder or injury usually have great concern over the effect the problem will have on their hearing. The nurse reassures the patient that every effort is being made to treat the disorder and relieve the symptoms. Before instilling an otic solution, the nurse informs the patient that a feeling of fullness may be felt in the ear and that hearing in the treated ear may be impaired while the solution remains in the ear canal.

Educating the Patient and Family
The nurse gives the patient or a family member instructions or a demonstration of the instillation technique of an otic preparation. The following information may be given to the patient when an ear ointment or solution is prescribed:

- Wash the hands thoroughly before cleansing the area around the ear (when necessary) and instilling ear drops or ointment.
Various types of preparations are used for the treatment of ophthalmic (eye) disorders such as glaucoma to lower the intraocular pressure (IOP), bacteria or viral infections of the eye, inflammatory conditions, and symptoms of allergy related to the eye.

**DISPLAY 57-1 • Glaucoma**

The eye's lens, iris, and cornea are continuously bathed and nourished by a fluid called aqueous humor. As aqueous humor is produced, excess fluid normally flows out through a complex network of tissue called trabecular meshwork. An angle is formed where the trabeculum and iris meet. This forms a filtration angle that maintains the normal pressure within the eye by allowing excess aqueous humor to leave the anterior chamber of the eye. In chronic or open-angle glaucoma, the angle that permits the drainage of aqueous humor appears to be normal but does not function properly. In angle-closure glaucoma, the iris blocks the trabecular meshwork and limits the flow of aqueous humor from the anterior chamber of the eye. This limitation of outflow causes an accumulation of intraocular fluid, followed by increased IOP. Some individuals have an anatomical defect that causes the angle to be more narrow than normal, but do not have any symptoms and do not develop glaucoma under normal circumstances. However, certain situations, such as medication that causes dilation of the eye, fear, or pain, that cause the eye to dilate may precipitate an attack. The aim of treatment in glaucoma is to lower the IOP. For more information on glaucoma, see Chapter 24.

Glucoma is a condition of the eye in which there is an increase in the IOP, causing progressive atrophy of the optic nerve with deterioration of vision and, if untreated, blindness. The higher the IOP, the greater the risk of optic nerve damage, visual loss, and blindness. There are two types of glaucoma: angle-closure glaucoma and open-angle, or chronic, glaucoma. Display 57-1 describes the two types of glaucoma.

Most of the drug classifications used to treat ophthalmic conditions have been discussed in previous chapters. The following sections provide a short summary of these classifications and their implications in ophthalmic use. When appropriate the student is referred to the specific chapter where additional information can be found. The Summary Drug Table: Select Ophthalmic Preparations provides examples of the drugs used to treat ophthalmic problems.

The incidence of adverse reactions associated with the ophthalmic drugs is usually small. Because small amounts of the ophthalmic preparation may be absorbed systemically, some of the adverse effects associated with systemic administration of the particular drug may be observed. Some ophthalmic preparations produce momentary stinging or burning on instillation.

**OPHTHALMIC PREPARATIONS**

Various types of preparations are used for the treatment of ophthalmic (eye) disorders such as glaucoma to lower the intraocular pressure (IOP), bacteria or viral infections of the eye, inflammatory conditions, and symptoms of allergy related to the eye.
### SUMMARY DRUG TABLE  SELECT OPHTHALMIC PREPARATIONS

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alpha2 Adrenergic Agonist</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>brimonidine tartrate</td>
<td>Alphagan</td>
<td>Lowering intraocular pressure (IOP)</td>
<td>1 gtt in affected eye(s) TID</td>
</tr>
<tr>
<td><strong>Sympathomimetics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>apraclonidine HCl app-ra-klo'-nih-deen</td>
<td>Iopidine</td>
<td>1% solution: control or prevention of postoperative elevations in IOP 5% solution: short-term therapy in patients receiving maximal medical therapy who require additional IOP reduction</td>
<td>1% solution: 1 gtt in operative eye 1 h before surgery and 1 gtt immediately after surgery 5% solution: 1–2 gtt in the affected eye(s) TID</td>
</tr>
<tr>
<td>dipivefrin HCl (dipivalyl epinephrine) die-pihv'-eh-frin</td>
<td>Propine, AKPro, generic</td>
<td>IOP</td>
<td>1 gtt into affected eye(s) every 12 h</td>
</tr>
<tr>
<td>epinephrine epp-ih-neff-rin</td>
<td>Epifrin, Glaucor Solution, generic</td>
<td>Open-angle (chronic simple glaucoma); may be used in combination with miotics, beta blockers, or carbonic anhydrase inhibitors</td>
<td>1 drop into affected eye(s) QD, BID</td>
</tr>
<tr>
<td><strong>Alpha-Adrenergic Blocking Drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dapiprazole HCl dap-ih-pray'-zole</td>
<td>Rev-Eyes</td>
<td>After ophthalmic examination to reverse the diagnostic mydriasis</td>
<td>2 gtt into the conjunctiva of each eye, followed 5 min later by an additional 2 gtt</td>
</tr>
<tr>
<td>betaxolol bay-tax'-oh-lahl</td>
<td>Betoptic, Betoptic S, generic</td>
<td>Elevated IOP</td>
<td>1–2 gtt in the affected eye(s) BID</td>
</tr>
<tr>
<td>carteolol HCl car'-tee-oh-lahl</td>
<td>Ocupress, generic</td>
<td>Elevated IOP</td>
<td>1 gtt in affected TID</td>
</tr>
<tr>
<td>levobetaxolol HCl lee'-voe-beh-tax'-oh-lahl</td>
<td>Betaxon</td>
<td>Elevated IOP</td>
<td>1 gtt in affected eye(s) BID</td>
</tr>
<tr>
<td>levobunolol HCl lee'-voe-byoo'-no-lahl</td>
<td>AKBeta, Betagan Liquifilm, generic</td>
<td>Elevated IOP</td>
<td>0.5% solution: 1–2 gtt in affected eye(s) QD 0.25% solution: 1–2 gtt in affected eye(s) BID</td>
</tr>
<tr>
<td>metipranolol HCl meh-tih-pran'-oh-lahl</td>
<td>OptiPranolol</td>
<td>Elevated IOP</td>
<td>1–2 gtt in affected eye(s) BID</td>
</tr>
<tr>
<td>timolol ti'-moe-lahl</td>
<td>Betimol, Timoptic, Timoptic-XE, generic</td>
<td>Elevated IOP</td>
<td>1 gtt in affected eye(s) QD, BID</td>
</tr>
<tr>
<td>Gel: invert the closed container and shake once before each use; administer 1 gtt/day</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Miotics, Direct Acting</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>carbachol car'-bah-kole</td>
<td>Carboptic, Isopto Carbachol</td>
<td>Glaucoma</td>
<td>1–2 gtt up to TID PRN</td>
</tr>
<tr>
<td>pilocarpine HCl pie-low-car'-peen</td>
<td>Adsorbocarpine, Akarpine, Isopto Carpine, Pilocar, Pilostat, generic</td>
<td>Glaucoma, pre- and postoperative intraocular tension</td>
<td>Solution: 1–2 gtt in affected eye(s) up to 6 times daily Gel: apply a 0.5-inch ribbon in the lower conjunctival sac of affected eye(s) once daily at HS</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>Generic Name</th>
<th>Trade Name*</th>
<th>Uses</th>
<th>Dosage Ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td>pilocarpine nitrate</td>
<td>Pilagan</td>
<td>Elevated IOP</td>
<td>1–2 gtt in affected eye(s) 2–4 times daily</td>
</tr>
<tr>
<td>pilocarpine ocular therapeutic system</td>
<td>Ocusert Pilo-20, Ocusert Pilo-40</td>
<td>Elevated IOP</td>
<td>See package insert</td>
</tr>
<tr>
<td><strong>Miotics, Cholinesterase Inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>demecarium bromide</td>
<td>Humorsol</td>
<td>Glaucoma and strabismus</td>
<td>1–2 gtt/wk, up to 1–2 gtt/d</td>
</tr>
<tr>
<td>deh-meh-care′-ee-uhm broe′-mide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>echothiophate iodide</td>
<td>Phospholine Iodide</td>
<td>Chronic open-angle glaucoma</td>
<td>2 doses/d in the morning and at HS or one dose every other day</td>
</tr>
<tr>
<td>eck-oh-thigh′-oh-fate eye-oh-dide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Carbonic Anhydrase inhibitors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>brinzolamide</td>
<td>Azopt</td>
<td>Elevated IOP</td>
<td>1 gtt in affected eye(s) TID</td>
</tr>
<tr>
<td>brin-zoe′-lah-mide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dorzolamide HCl</td>
<td>TruSopt</td>
<td>Elevated IOP</td>
<td>1 gtt in affected eye(s) TID</td>
</tr>
<tr>
<td>dore-zole-ah-mide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prostaglandin Agonist</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>latanoprost</td>
<td>Xalatan</td>
<td>Elevated IOP</td>
<td>1 gtt in affected eye(s) QD in the evening</td>
</tr>
<tr>
<td>lah-tan′-oh-prahst</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>travoprost</td>
<td>Travatan</td>
<td>Elevated IOP</td>
<td>1 gtt in affected eye(s) QD in the evening</td>
</tr>
<tr>
<td>bimatoprost</td>
<td>Lumigan</td>
<td>Elevated IOP</td>
<td>1 gtt in affected eye(s) QD in the evening</td>
</tr>
<tr>
<td>yoo-noh-prost′-ohn</td>
<td>Rescula</td>
<td>Elevated IOP</td>
<td>1 gtt in affected eye(s) BID</td>
</tr>
<tr>
<td><strong>Combinations Used, to Treat Glaucoma</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pilocarpine and epinephrine</td>
<td>E-Pilo-1, E-Pilo-2, E-Pilo-4,</td>
<td>Glaucoma</td>
<td>1–2 gtt in the affected eye(s) 1–4 times daily</td>
</tr>
<tr>
<td>dorzolamide HCl and timolol maleate</td>
<td>E-Pilo-6, P₁E₁, P₂E₂, Cosopt</td>
<td>Elevated IOP</td>
<td>1 gtt into the affected eye(s) BID</td>
</tr>
<tr>
<td>dore-zole′-ah-mide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mast Cell Stabilizer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>nedocromil sodium</td>
<td>Alocril</td>
<td>Allergic conjunctivitis</td>
<td>1–2 gtt in each eye BID</td>
</tr>
<tr>
<td>neh-doe-kroe′-mill</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pemirolast potassium</td>
<td>Alamast</td>
<td>Allergic conjunctivitis</td>
<td>1–2 gtt in each eye QID</td>
</tr>
<tr>
<td>peh-mihr-oh′-last</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nonsteroidal Anti-inflammatory Drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>diclofenac sodium</td>
<td>Voltaren, generic</td>
<td>Postoperative inflammation after cataract surgery</td>
<td>1 drop QID</td>
</tr>
<tr>
<td>di-klo′-fen-ak</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>flurbiprofen sodium</td>
<td>Ocufen, generic</td>
<td>Inhibition of intraoperative miosis</td>
<td>1 gtt q 30 min beginning 2 h before surgery (total of 4 gtt)</td>
</tr>
<tr>
<td>flure-bi′-pro-fen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ketorolac tromethamine</td>
<td>Acular</td>
<td>Relief of ocular itching due to seasonal allergies</td>
<td>1 drop QID</td>
</tr>
<tr>
<td>ke-tor′-o-lac</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SUMMARY DRUG TABLE  SELECT OPHTHALMIC PREPARATIONS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Corticosteroids</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>dexamethasone phosphate</td>
<td>AK-Dex, Maxidex, generic</td>
<td>Treatment of inflammatory conditions of the conjunctiva, lid, cornea, anterior segment of the eye</td>
<td>Solution: 1–2 gtt qh during the day and q2h at night, reduced to 1 gtt q4h when response noted, then 1 gtt TID–QID. Ointment: thin coating in lower conjunctival sac 3–4 times/d.</td>
</tr>
<tr>
<td>flurometholone flure-oh-meth'-oh-lone</td>
<td>Flarex, Fluor-Op, generic</td>
<td>Treatment of inflammatory conditions of the conjunctiva, lid, cornea, anterior segment of the eye</td>
<td>Suspension: 1–2 gtt 2–4 times/d, may increase to 2 gtt q2h; ointment: thin coating in lower conjunctival sac 1–3 times/d (up to 1 application q4h)</td>
</tr>
<tr>
<td>loteprednol etabonate low-teh'-pred'-nol ett-ab'-ohn-ate prednisolone pred-niss'-oh-lone</td>
<td>Alrex, Lotemex</td>
<td>Allergic conjunctivitis</td>
<td>1–2 gtt QID</td>
</tr>
<tr>
<td><strong>Antibiotics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>bacitracin bass-i-tray'-sin</td>
<td>AK-Tracin</td>
<td>Treatment of eye infections</td>
<td>See package insert</td>
</tr>
<tr>
<td>erythromycin er-ith-roye'-sin</td>
<td>Ilotycin, generic</td>
<td>Treatment of eye infections</td>
<td>See package insert</td>
</tr>
<tr>
<td>gentamicin jen-ta-mye'-sin</td>
<td>Garamycin, generic</td>
<td>Treatment of eye infections</td>
<td>See package insert</td>
</tr>
<tr>
<td>tobramycin toe-bra-mye'-sin</td>
<td>Tobrex, generic</td>
<td>Treatment of eye infections</td>
<td>See package insert</td>
</tr>
<tr>
<td>sodium sulfacetamide sul-fa-see'-ta-mide</td>
<td>AK-Sulf, generic</td>
<td>Treatment of conjunctivitis, corneal ulcer, other superficial eye infections</td>
<td>1–2 gtt q1–3h</td>
</tr>
<tr>
<td><strong>Silver</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>silver nitrate nye-trate</td>
<td>generic</td>
<td>Prevention of ophthalmia neonatorum</td>
<td>2 gtt of 1% solution in each eye</td>
</tr>
<tr>
<td><strong>Antiviral Drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>idoxuridine eye-dox-yoor'-i-deen</td>
<td>Herplex</td>
<td>Treatment of herpes simplex keratitis</td>
<td>1 gtt qh during the day and q2h at night</td>
</tr>
<tr>
<td>vidarabine vye-dare'-a-been</td>
<td>Vira-A</td>
<td>Treatment of herpes simplex keratitis and conjunctivitis</td>
<td>0.5 inch of ointment into lower conjunctival sac 5 times/d at 3-h intervals</td>
</tr>
<tr>
<td><strong>Antifungal Drugs</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>natamycin na-ta-mye'-sin</td>
<td>Natacyn</td>
<td>Treatment of fungal infections of the eye</td>
<td>1 gtt q1–2h (continued)</td>
</tr>
</tbody>
</table>
SUMMARY DRUG TABLE  SELECT OPHTHALMIC PREPARATIONS (Continued)

<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Vasoconstrictors/Mydriatics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>oxymetazoline hydrochloride</td>
<td>Ocuclear, Visine L. R.</td>
<td>Relief of redness of eye due to minor irritation</td>
<td>1–2 gtt q3–4h up to QID</td>
</tr>
<tr>
<td>ox-i-met-az'-oh-leen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>phenylephrine hydrochloride</td>
<td>AK-Dilate 2.5%,</td>
<td>0.12% for relief of redness of eye due to minor irritation; 2.5% and 10% treatment of uveitis, glaucoma; refraction procedures, before eye surgery</td>
<td>0.12% 1–2 gtt up to 4 times/d; 2.5% and 10%, 1 gtt</td>
</tr>
<tr>
<td>fen-ill-ef'-rin</td>
<td>Neo-Synephrine 10%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>tetrahydrozoline hydrochloride</td>
<td>Murine Plus Eye Drops,</td>
<td>Relief of redness of eye due to minor irritation</td>
<td>1–2 gtt up to 4 times/d</td>
</tr>
<tr>
<td>tet-ra-hyd-drozz'-a-leen</td>
<td>Visine, generic</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cycloplegic/Mydriatics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>atropine sulfate a'-troe-peen</td>
<td>Isopto-Atropine, generic</td>
<td>Eye refraction, treatment of acute inflammatory conditions of iris, uveal tract</td>
<td>1–2 gtt up to 4 times/d</td>
</tr>
<tr>
<td>homatropine hydrobromide</td>
<td>Isopto Homatropine</td>
<td>Eye refraction, treatment of inflammatory conditions of uveal tract</td>
<td>1–2 gtt q3–4h</td>
</tr>
<tr>
<td>hoe-ma'-troe-peen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Artificial Tears</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>benzalkonium chloride</td>
<td>Artificial Tears</td>
<td>Treatment of dry eyes</td>
<td>1–2 gtt 3–4 times/d</td>
</tr>
<tr>
<td>benz-al-koe'-nee-um</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>glycerin, sodium chloride</td>
<td>Eye-Lube-A</td>
<td>Treatment of dry eyes</td>
<td>1–2 gtt 3–4 times/d</td>
</tr>
</tbody>
</table>

*The term generic indicates the drug is available in generic form.

**Sympathomimetic Drugs**

Sympathomimetics have alpha (α) - and beta (β) -adrenergic activity (see Chap. 22 for a detailed discussion of adrenergic drugs). These drugs lower the **intraocular pressure** (IOP) (the pressure within the eye) by increasing the outflow of aqueous humor in the eye and are used to treat glaucoma. A praclonidine is used to control or prevent postoperative elevations in IOP. The Summary Drug Table: Select Ophthalmic Preparations provides additional information about these drugs.

**Alpha-Adrenergic Blocking Drugs**

Dapiprazole acts by blocking the α-adrenergic receptor in smooth muscle and produces miosis through an effect on the dilator muscle of the iris. The drug is used primarily after ophthalmic examinations to reverse the diagnostic **mydriasis** (dilation of the pupil).

**Beta-Adrenergic Blocking Drugs**

The β-adrenergic blocking drugs decrease the rate of production of aqueous humor and thereby lower the IOP. These drugs are used to treat glaucoma.

**Miotics, Direct Acting**

Miotics contract the pupil of the eye (miosis), resulting in an increase in the space through which the aqueous humor flows. This increased space and improved flow results in a decrease in the IOP. Miotics may be used in the treatment of glaucoma (see Chap. 22). The miotics were, for a number of years, the drug of choice for glaucoma. These drugs have lost that first choice treatment status to the β-adrenergic blocking drugs.

**Miotics, Cholinesterase Inhibitors**

The cholinesterase inhibitors are more potent and longer acting than the direct-acting miotics and are used
to treat open-angle glaucoma. When administered into the eye, these drugs produce intense miosis (constriction of the pupil) and muscle contractions, causing a decreased resistance to aqueous outflow.

**Carbonic Anhydrase Inhibitors**

Except for dorzolamide and brinzolamide, carbonic anhydrase inhibitors are administered systemically. Carbonic anhydrase is an enzyme found in many tissues of the body, including the eye. Inhibition of carbonic anhydrase in the eye decreases aqueous humor secretion, resulting in a decrease of IOP. These drugs are used in the treatment of elevated IOP seen in open-angle glaucoma.

**Prostaglandin Agonists**

The prostaglandin agonists are used to lower IOP in patients with open-angle glaucoma and ocular hypertension in patients who do not tolerate other IOP-lowering medications or have an insufficient response to these medications. These drugs act to lower IOP by increasing the outflow of aqueous humor through the trabecular meshwork.

**Mast Cell Stabilizers**

The mast cell stabilizers currently for ophthalmic use are nedocromil and pemirolast. These drugs are used for the prevention of eye itching caused by allergic conjunctivitis. The mast cell stabilizers act by inhibiting the antigen-induced release of inflammatory mediators (eg, histamine) from human mast cells.

**Nonsteroidal Anti-inflammatory Drugs (NSAIDs)**

The NSAIDs inhibit prostaglandin synthesis (see Chap. 18 for a discussion of the NSAIDs), thereby exerting anti-inflammatory action. These drugs are used to treat postoperative inflammation after cataract surgery (diclofenac), for the relief of itching of the eyes caused by seasonal allergies (ketorolac), and during eye surgery to prevent miosis (flurbiprofen).

**Corticosteroids**

These drugs possess anti-inflammatory activity and are used for inflammatory conditions, such as allergic conjunctivitis, keratitis, herpes zoster keratitis, and inflammation of the iris. Corticosteroids also may be used after injury to the cornea or after corneal transplants to prevent rejection.

**Antibiotics and Sulfonamides**

Antibiotics possess antibacterial activity and are used in the treatment of eye infections. Sulfonamides possess a bacteriostatic effect against a wide range of gram-positive and gram-negative microorganisms. They are used in the treatment of conjunctivitis, corneal ulcer, and other superficial infections of the eye. See the Summary Drug Table: Select Ophthalmic Preparations and Chapter 6 for additional information on the sulfonamides.

**Silver**

Silver possesses antibacterial activity against gram-positive and gram-negative microorganisms. Silver protein, mild, is occasionally used in the treatment of eye infections. Silver nitrate is occasionally used to prevent gonorrheal ophthalmia neonatorum (gonorrhea infection of the newborn’s eyes). Ophthalmic tetracycline and erythromycin have largely replaced the use of silver nitrate in newborns.

**Antiviral Drugs**

Antiviral drugs interfere with viral reproduction by altering DNA synthesis. These drugs are used in the treatment of herpes simplex infections of the eye, treatment in immunocompromised patients with cytomegalovirus (CMV) retinitis, and for the prevention of CMV retinitis in patients undergoing transplant.

**Antifungal Drugs**

Natamycin is the only ophthalmic antifungal in use. This drug possesses antifungal activity against a variety of yeast and fungi.

**Vasoconstrictors/Mydriatics**

These drugs dilate the pupil (mydriasis), constrict superficial blood vessels of the sclera, and decrease the formation of aqueous humor. Depending on the specific drug and strength, these drugs may be used before eye surgery in the treatment of glaucoma, for relief of minor eye irritation, and to dilate the pupil for examination of the eye.

**Cycloplegic Mydriatics**

Cycloplegic mydriatics cause mydriasis and cycloplegia (paralysis of the ciliary muscle, resulting in an inability to focus the eye). These drugs (see Chap. 25) are used in the treatment of inflammatory conditions of the iris and uveal tract of the eye and for examination of the eye.
Artificial Tear Solutions

These products lubricate the eyes and are used for conditions such as dry eyes and eye irritation caused by inadequate tear production.

Inactive ingredients may be found in some preparations. Examples of these drugs include preservatives, antioxidants, which prevent deterioration of the product, and drugs that slow drainage of the drug from the eye into the tear duct. Examples of the types of eye preparations are found in the Summary Drug Table: Select Ophthalmic Preparations.

ADVERSE REACTIONS

Alpha2-Adrenergic Drugs

Although side effects are usually mild, treatment with brimonidine tartrate includes oral dryness, ocular hyperemia, burning and stinging, headache, visual blurring, foreign body sensation, fatigue, drowsiness, ocular allergic reactions, and ocular pruritus.

Sympathomimetic Drugs

These drugs may cause transient local reactions such as burning and stinging, eye pain, brow ache, headache, allergic lip reactions, and ocular irritation. With prolonged use adrenochrome (a red pigment contained in epinephrine) deposits may occur in the conjunctiva and cornea. Although rare, systemic reactions may occur such as headache, palpitations, tachycardia, extrasystoles, cardiac arrhythmia, hypertension, and faintness. Dipivefrin appears to be better tolerated and has fewer adverse reactions than the other sympathomimetic drugs used to lower IOP.

Alpha-Adrenergic Blocking Drugs

The drug may cause burning in the eye, ptosis (drooping of the upper eyelid), lid edema, itching, corneal edema, browache, photophobia, dryness of the eye, tearing, and blurring of vision.

Beta-Adrenergic Blocking Drugs

Adverse reactions associated with the β-adrenergic blocking drugs include eye irritation, burning, tearing, conjunctivitis, decreased night vision, ptosis, abnormal corneal staining, and corneal sensitivity. Systemic reactions, although rare, include arrhythmias, palpitation, headache, nausea, and dizziness. (See Chap. 23 for additional systemic adverse reactions.)

Miotic, Direct Acting

The direct-acting miotics may cause stinging on instillation, transient burning, tearing, headache, browache, and decreased night vision. Systemic adverse reactions included hypotension, flushing, breathing difficulties, nausea, vomiting, diarrhea, cardiac arrhythmias, and frequent urge to urinate.

Miotics, Cholinesterase Inhibitors

Adverse reactions and systemic toxicity are more common in the cholinesterase inhibitor ophthalmic preparations than in the direct-acting miotics. Ophthalmic adverse reactions include the development of iris cysts, burning, lacrimation, lid muscle twitching, conjunctivitis and ciliary redness, browache, headache, activation of latent iritis or uveitis (an inner-eye inflammation), retinal detachment, and conjunctival thickening. Systemic adverse reactions include nausea, vomiting, abdominal cramps, diarrhea, urinary incontinence, fainting, salivation, difficulty breathing, and cardiac irregularities. Iris cysts may form, enlarge, and obstruct vision. The iris cyst usually shrinks upon discontinuation of use of the drug or after a reduction in strength of the drops or frequency of instillation.

Carbonic Anhydrase Inhibitors

Adverse reactions associated with use of the carbonic anhydrase inhibitors include ocular burning, stinging, or discomfort immediately after administration, bitter taste, ocular allergic reaction, blurred vision, tearing, dryness, dermatitis, foreign body sensation, ocular discomfort, photophobia, and headache.

Prostaglandin Agonists

Adverse reactions associated with the prostaglandin agonists include blurred vision, burning and stinging, foreign body sensation, itching, increased pigmentation of the iris, dry eye, excessive tearing, lid discomfort and pain, and photophobia.

Mast Cell Stabilizers

Although mild, the adverse reactions associated with the mast cell inhibitors include headache, rhinitis, unpleasant taste, asthma, and cold/flu symptoms. These drugs may also cause ocular burning or irritation, dry eye, eye redness, foreign body sensation, and ocular discomfort.

Nonsteroidal Anti-inflammatory Drugs

The most common adverse reactions associated with the NSAIDs include transient burning and stinging upon instillation and other minor ocular irritation.
Corticosteroids

Adverse reactions associated with administration of the corticosteroid ophthalmic preparations include elevated IOP with optic nerve damage, loss of visual acuity, cataract formation, delayed wound healing, secondary ocular infection, exacerbation of corneal infections, dry eyes, ptosis, blurred vision, discharge, ocular pain, foreign body sensation, and pruritus.

Antibiotics, Sulfonamides, and Silver

The antibiotic and sulfonamide ophthalmics are usually well tolerated, and few adverse reactions are seen. Occasional transient irritation, burning, itching, stinging, inflammation, or blurring of vision may occur. With prolonged or repeated use, a superinfection may occur.

Antiviral Drugs

The administration of the antiviral ophthalmics may cause occasional irritation, pain, pruritus, inflammation, or edema of the eyes or lids; allergic reactions; foreign body sensation; photophobia; and corneal clouding.

Antifungal Drugs

Adverse reactions are rare. Occasional local irritation to the eye may occur.

Vasoconstrictors/Mydriatics

Adverse reactions include transitory stinging on initial instillation, blurring of vision, mydriasis, increased redness, irritation, discomfort, and increased IOP. Systemic adverse reactions include headache, browache, palpitations, tachycardia, arrhythmias, hypertension, myocardial infarction, and stroke.

Cycloplegic Mydriatics

Local adverse reactions associated with administration of the cycloplegic mydriatics include increased IOP, transient stinging or burning, and irritation with prolonged use (eg, conjunctivitis, edema, exudates). Systemic adverse reactions include dryness of the mouth and skin, blurred vision, photophobia, corneal staining, tachycardia, headache, parasympathetic stimulation, and somnolence.

Artificial Tear Solutions

Adverse reactions are rare, but on occasion redness or irritation may occur.

CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS

Alpha₂-Adrenergic Drugs

The drug is contraindicated in patients with hypersensitivity to the drug or any component of the drug and in patients taking the monoamine oxidase inhibitors (MAOIs). Patients should wait at least 15 minutes after instilling brimonidine before inserting soft contact lenses because the preservative in the drug may be absorbed by soft contact lenses. The drug is used cautiously during pregnancy (Pregnancy Category B) and lactation and in patients with cardiovascular disease, depression, cerebral or coronary insufficiency, orthostatic hypotension, or Raynaud’s phenomenon. When brimonidine is used with central nervous system (CNS) depressants such as alcohol, barbiturates, opiates, sedatives, or anesthetics, there is a risk for an additive CNS depressant effect. Use the drug cautiously in combination with the beta blockers, antihypertensive drugs, and cardiac glycosides because a synergistic effect may occur.

Sympathomimetic Drugs

These drugs are contraindicated in patients with hypersensitivity to the drug or any component of the drug. Epinephrine is contraindicated in patients with narrow angle glaucoma, or patients with a narrow angle, but no glaucoma, aphakia (absence of the crystalline lens of the eye). Epinephrine should not be used while wearing soft contact lenses (discoloration of the lenses may occur).

These drugs are used cautiously during pregnancy (epinephrine and apraclonidine, Pregnancy Category C; dipivefrin, Pregnancy Category B) and lactation and in patients with hypertension, diabetes, hyperthyroidism, heart disease, cerebral arteriosclerosis, or bronchial asthma. Some of these drugs contain sulfites that may cause allergic-like reactions (hives, wheezing, anaphylaxis) in patients with sulfite sensitivity. See Chapter 22 for information on interactions.

Alpha-Adrenergic Blocking Drugs

The drug is contraindicated in patients with hypersensitivity to the drug or any component of the drug, in conditions in which pupil constriction is not desirable, such as in acute iritis (inflammation of the iris), and in the treatment of IOP in open-angle glaucoma. This drug is used cautiously during pregnancy (Pregnancy Category B) and lactation. No significant drug interactions have been reported.
Beta-Adrenergic Blocking Drugs

The β-adrenergic blocking drugs are contraindicated in patients with bronchial asthma, obstructive pulmonary disease, sinus bradycardia, heart block, cardiac failure, or cardiogenic shock and in patients with hypersensitivity to the drug or any components of the drug. These drugs are Pregnancy Category C and are used cautiously during pregnancy and lactation and in patients with cardiovascular disease, diabetes (may mask the symptoms of hypoglycemia), and hyperthyroidism (may mask symptoms of hyperthyroidism). The patient taking β-adrenergic blocking drugs for ophthalmic reasons may experience increased or additive effects when the drugs are administered with the oral beta blockers. Co-administration of timolol maleate and calcium antagonists may cause hypotension, left ventricular failure, and condition disturbances within the heart. There is a potential additive hypotensive effect when the beta-blocking ophthalmic drugs are administered with the phenothiazines.

Miotic, Direct Acting

These drugs are contraindicated in patients with hypersensitivity to the drug or any component of the drug and in conditions where constriction is undesirable (eg, iritis, uveitis, and acute inflammatory disease of the anterior chamber). The drugs are used cautiously in patients with corneal abrasion, pregnancy (Pregnancy Category C), lactation, cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, gastrointestinal spasm, urinary tract infection, Parkinson’s disease, recent myocardial infarction, hypotension, or hypertension. These drugs are also used cautiously in patients with angle closure glaucoma because miotics can, occasionally, precipitate angle closure glaucoma by increasing the resistance to aqueous flow from posterior to anterior chamber. See Chapter 24 for information on interactions.

Miotics, Cholinesterase Inhibitors

The cholinesterase inhibitors are contraindicated in patients with hypersensitivity to the drug or any components of the drug. Some of these products contain sulfites, and patients with sulfite sensitivity may experience allergic-type reactions. The drugs are also contraindicated in patients with any active inflammatory disease of the eye and during pregnancy (demecarium, Pregnancy Category X; echothiophate iodine, Pregnancy Category C) and lactation. The cholinesterase inhibitors are used cautiously in patients with myasthenia gravis (may cause additive adverse effects), before and after surgery, and in patients with chronic angle-closure (narrow angle) glaucoma or those with narrow angles (may cause papillary block and increase the angle blockage). When the cholinesterase inhibitors are administered with systemic anti-cholinesterase drugs, there is a risk for additive effects. Individuals, such as farmers, warehouse workers, or gardeners, working with carbamate/organophosphate insecticides or pesticides are at risk for systemic effects of the cholinesterase inhibitors from absorption of the pesticide or insecticide through the respiratory tract or the skin. Individuals working with pesticides or insecticides containing carbamate/organophosphate and taking a cholinesterase inhibitor should be advised to wear respiratory masks, change clothes frequently, and wash exposed clothes thoroughly.

Carbonic Anhydrase Inhibitors

Use of the carbonic anhydrase inhibitors is contraindicated in patients with hypersensitivity to the drug or any components of the drug and during pregnancy (Pregnancy Category C) and lactation. The drugs are used cautiously in patients with renal and hepatic impairment. When high doses of the salicylates are administered concurrently, toxic levels of the carbonic anhydrase inhibitors have been reported. See Chapter 46 for more information on interactions when administering the carbonic anhydrase inhibitors.

Prostaglandin Agonists

These drugs are contraindicated in patients with hypersensitivity to the drug or any component of the drug and during pregnancy (Pregnancy Category C). The drugs are used cautiously in lactating women and in patients with active intraocular inflammation, those wearing contact lenses (contact lenses must be removed and left out for at least 15 minutes after administration of the drug), and those with macular edema.

Mast Cell Stabilizers

These drugs are contraindicated in patients with a hypersensitivity to the drug or any component of the drug. The mast cell stabilizers are used cautiously in patients who wear contact lenses (preservative may be absorbed by the soft contact lenses) and during pregnancy (pemirolast, Pregnancy Category C; nedocromil, Pregnancy Category B) and lactation. There have been no significant drug-drug interactions associated with these drugs.

Nonsteroidal Anti-inflammatory Drugs

These drugs are contraindicated in individuals with known hypersensitivity to an individual drug or any components of the drug. The NSAID flurbiprofen is contraindicated in patients with herpes simplex keratitis. Diclofenac and ketorolac are contraindicated in patients who wear soft contact lenses (may cause ocular irritation).
The NSAIDs are used cautiously during pregnancy (Pregnancy Category C, flurbiprofen, ketorolac; Pregnancy Category B, diclofenac) and lactation. The NSAIDs are used cautiously in patients with bleeding tendencies. When used topically there is less risk of interactions with drugs or other substances. There is a possibility of a cross-sensitivity reaction when the NSAIDs are administered to patients allergic to the salicylates. The corticosteroids and the antibiotics are used cautiously in patients with sulfite sensitivity because an allergic-type reaction may result. Co-administration of idoxuridine with solutions containing boric acid may cause irritation. The sulfonamides are incompatible with silver nitrate.

**Corticosteroids**

The corticosteroid ophthalmic preparations are contraindicated in patients with acute superficial herpes simplex keratitis, fungal disease of the eye, or viral diseases of the eye, and after removal of a superficial corneal foreign body. The corticosteroid ophthalmic preparations are used cautiously in patients with infectious conditions of the eye. These drugs are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation. Prolonged use of the corticosteroids may result in elevated IOP and optic nerve damage.

**Antibiotics and Sulfonamides**

The antibiotic and sulfonamide ophthalmics are contraindicated in patients with a hypersensitivity to the drug or any component of the drug. These drugs are also contraindicated in patients with epithelial herpes simplex keratitis, varicella, mycobacterial infection of the eye, and fungal diseases of the eye. There are no significant precautions or interactions when the drugs are administered as directed by the primary health care provider.

**Antiviral Drugs**

These drugs are contraindicated in patients with hypersensitivity to the drug or any component of the drug. These drugs are used cautiously in immunocompromised patients and during pregnancy and lactation. Some of these solutions contain boric acid and may result in a precipitate that causes irritation.

**Antifungal Drugs**

Natamycin is contraindicated in patients with hypersensitivity to the drug or any component of the drug. The drug is a Pregnancy Category C drug and is used cautiously during pregnancy and lactation. If use of the drug for 7 to 10 days does not result in improvement, the infection may be attributable to another microorganism not susceptible to natamycin.

**Vasoconstrictors/Mydriatics**

These drugs are contraindicated in individuals with hypersensitivity to the drug or any component of the drug and in patients with narrow angle glaucoma or anatomically narrow angle and no glaucoma and in patients with a sulfite sensitivity (some of these products contain sulfite). The drugs are used cautiously in patients with hypertension, diabetes, hyperthyroidism, cardiovascular disease, and arteriosclerosis. Local anesthetics can increase absorption of topical drugs. Systemic adverse reactions may occur more frequently when these drugs are administered with the β-adrenergic blocking drugs. When the mydriatics (drugs that dilate the pupil) are administered with the MAOIs or as long as 21 days after MAOI administration, exaggerated adrenergic effects may occur.

**Cycloplegic Mydriatics**

These drugs are contraindicated in patients with a hypersensitivity to the drug or any component of the drug and in patients with glaucoma. Some of these preparations contain sulfite, and individuals who are allergic to sulfites may exhibit allergic-like symptoms. The cycloplegic mydriatics are used cautiously in elderly patients and during pregnancy (Pregnancy Category C) and lactation. No significant interactions have been reported when the drugs are given topically.

**Artificial Tear Solutions**

Artificial tears are contraindicated in patients who are allergic to any component of the solution. No precautions or interactions have been reported.

---

**Herbal Alert: Bilberry**

Bilberry, also known as whortleberry, blueberry, trackleberry, and huckleberry, is a shrub with bluish flowers that appear in early spring and ripen in July and August. Although bilberry is given to improve capillary strength and flexibility and as an antioxidant, the most beneficial use appears to be in promoting healthy eyes. Bilberry is thought to increase production of the enzymes responsible for energy production in the eye and promote capillary blood flow in the eyes, hands, and feet. Bilberry extract has been shown to increase the flexibility of the cell walls of both red blood cells and endothelial cells, making the cells better able to stretch and squeeze through tighter spaces. By increasing the flexibility of the red blood cells, more oxygen reaches the tissues, including the retina of the eye. A component of bilberry also speeds the regeneration of rhodopsin (visual purple), which is a critical protein found in the rods of the eye.

Bilberry fruit is a safe food herb with no known adverse reactions or toxicity. There are no known contraindications to its use as directed. The dosage of standard extract is 160 to 320 mg a day.
The Patient Receiving an Ophthalmic Preparation

ASSESSMENT

Preadministration Assessment
The primary health care provider examines the eye and external structures surrounding the eye and prescribes the drug indicated to treat the disorder. The nurse examines the eye for irritation, redness, and the presence of any exudate and carefully documents the findings in the patient's record. A purulent discharge is often found with infection of the eye. Pruritus (itching) is often present with allergic conditions of the eye. It is also important to determine if any visual impairment is present because this would indicate the need for assistance with ambulation and possibly activities of daily living.

Ongoing Assessment
During the ongoing assessment the nurse observes for a therapeutic drug effect and reports any increase in symptoms and the presence of any redness, irritation, or pain in the eye. Patients admitted for treatment of acute glaucoma should be assessed every 2 hours for relief of pain. Pain in the eye may indicate increased IOP.

NURSING DIAGNOSES

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

PLANNING

The expected outcomes of the patient depend on the reason for administration but may include an optimal response to therapy, management of adverse reactions, minimized anxiety, and an understanding of the application and use of an ophthalmic preparation.

IMPLEMENTATION

Promoting an Optimal Response to Therapy
Before instillation, ophthalmic solutions and ointments can be warmed in the hand for a few minutes. Ophthalmic ointments are applied to the eyelids or dropped into the lower conjunctival sac; ophthalmic solutions are dropped into the middle of the lower conjunctival sac (Fig. 57-2). When eye solutions are instilled, the nurse applies gentle pressure on the inner canthus to delay drainage of the drug down the tear duct. The primary health care provider is consulted regarding use of this technique before the first dose is instilled because this technique can be potentially dangerous in some eye conditions, such as recent eye surgery. When two eye drops are prescribed for use at the same time, the nurse waits at least 5 minutes before instilling the second drug. This helps prevent dilution of the drug and loss of some therapeutic effect from tearing.

Some ophthalmic drugs produce blurring of vision, which can result in falls and other injuries. The nurse warns patients to exercise care when getting out of bed when the vision is impaired by these drugs. Patients using the pilocarpine ocular therapeutic system must have the system replaced every 7 days (see Chap. 24). The system is inserted at bedtime because myopia (nearsightedness) occurs for several hours after insertion.

When a patient is scheduled for eye surgery, it is most important that the eye drops ordered by the primary health care provider are instilled at the correct time. This is especially important when the purpose of the drug is to change the size of the pupil.
Monitoring and Managing Adverse Reactions
Although adverse reactions are rare, these drugs can cause visual impairment such as blurring of vision and local irritation and burning. These reactions are most often self-limiting and will resolve if the patient waits a few minutes. However, if visual impairment does not resolve itself or occurs as a consequence of an eye disorder, the nurse provides assistance with ambulation to prevent injury from falls. In addition, assistance with activities of daily living may also be needed. Visual impairment that does not clear within 30 minutes after therapy is reported to the primary health care provider.

PROSTAGLANDIN AGONISTS
• Remove contact lenses before administration and leave out at least 15 minutes before reinserting them.
• The color of the iris may change because of an increase of the brown pigment and cause different eye coloration. This may be more noticeable in patients with blue, green, or gray brown or other light-colored eyes.

EVALUATION
• The therapeutic effect is achieved.
• Adverse reactions are managed.
• Anxiety is reduced.
• The patient demonstrates the ability to instill an ophthalmic preparation in eye.
• The patient and family demonstrate an understanding of the drug regimen.
• The patient verbalizes knowledge of and the importance of the treatment regimen.

Critical Thinking Exercises
1. Prepare a teaching plan for a patient prescribed Cerumenex for removal of earwax.
2. Ms. Stone, age 76 years, has glaucoma and is prescribed timolol (Timoptic) eye drops. Your initial assessment reveals that she has severe arthritis and appears to have difficulty following instructions. Discuss any further investigations you feel are important to make before developing a teaching plan for this patient.
3. Mr. Caravel, age 38 years, is prescribed tobramycin ophthalmic (Tobrex) for bacterial conjunctivitis. Discuss preadministration assessments the nurse would perform before instilling the drug.

Review Questions
1. What is the rationale for warming an otic solution that has been refrigerated before instilling the drops into the patient’s ear?
   A. The drug becomes thick when refrigerated, and warming liquefies the solution.
   B. It helps to prevent dizziness on instillation.
   C. A cold solution can significantly increase the patient’s blood pressure.
Home Care Checklist

INSTILLING AN OPHTHALMIC PREPARATION

Because of shortened hospital stays and increases in the number of ambulatory surgeries for many eye problems, the patient may be required to instill eye drops or ointment at home. If the patient is unable to do so, a family member or friend may have to instill the preparation. The nurse uses the following guide to evaluate that the patient or caregiver can properly instill the eye drops or ointment:

- Washes hands thoroughly before beginning.
- Holds bottle (drops) or tube (ointment) in hand for a few minutes before using.
- Cleanses the area around the eye of any secretions.
- Squeezes the eye dropper bulb to release and then refill the dropper, squeezes the bottle to fill the drop chamber, or squeezes ointment to tip of the tube.
- Tilts head slightly backward and toward the eye to be treated.
- Pulls affected lower lid down.
- Positions dropper, bottle, or tube over lower conjunctival sac.
- Steadies hand by resting fingers against cheek or by resting base of hand on cheek.
- Looks up at ceiling and squeezes dropper, bottle, or tube.
- Drops ordered number of drops into the middle of lower conjunctival sac; instills prescribed amount of ointment to eyelid or lower conjunctival sac.
- Closes eye briefly and gently and releases lower lid (does not squeeze eyes shut after instilling the drug).
- Places finger on inner canthus to avoid absorption via the tear duct (when instilling drops and only if ordered).
- Repeats procedure with other eye (if ordered).
- If more than one type of ophthalmic preparation is being instilled, waits the recommended time interval before instilling the second drug (usually 5 minutes for drops and 10–15 minutes for ointment).
- Replaces the cap of the eye preparation immediately after instilling the eye drops or ointment. Does not touch the tip of the dropper, bottle, or tube.

D. A cold solution could damage the tympanic membrane.

2. Which of the following adverse reactions would the nurse suspect in a patient receiving prolonged treatment with an antibiotic otic drug?
   A. Congestive heart failure
   B. Superinfection
   C. Anemia
   D. Hypersensitivity reactions

3. When administering an ophthalmic solution the drug is instilled into the ___.
   A. inner canthus
   B. upper conjunctival sac

4. Which of the following instructions would be included in a teaching plan for the patient prescribed an ophthalmic solution?
   A. Squeeze the eyes tightly after the solution is instilled.
   B. Immediately wipe the eye using pressure to squeeze out excess medication.
   C. After the drug is instilled, remain upright with the head bent slightly forward for about 2 minutes.
   D. A temporary stinging or burning may be felt at the time the drug is instilled.
**Solutions Used in the Management of Body Fluids**

Parenteral nutrients are used to correct nutritional or fluid deficiencies, as well as to treat certain diseases and conditions.

**Action and Uses**

**Blood Plasma**

Blood plasma is the liquid part of blood, containing water, sugar, electrolytes, fats, gases, proteins, bile pigment, and clotting factors. Human plasma, also called
human pooled plasma, is obtained from donated blood. Although whole blood must be typed and crossmatched because it contains red blood cells carrying blood type and Rh factors, human plasma does not require this procedure. Because of this, plasma can be given in acute emergencies. Plasma administered intravenously (IV) is used to increase blood volume when severe hemorrhage has occurred and it is necessary to partially restore blood volume while waiting for whole blood to be typed and crossmatched. Another use of plasma is in treating conditions when plasma alone has been lost, as may be seen in severe burns.

Plasma Protein Fractions

Plasma protein fractions include human plasma protein fraction 5% and normal serum albumin 5% (Albuminar-5, Buminate 5%) and 25% (Albuminar-25, Buminate 25%). Plasma protein fraction 5% is an IV solution containing 5% human plasma proteins. Serum albumin is obtained from donated whole blood and is a protein found in plasma. The albumin fraction of human blood acts to maintain plasma colloid osmotic pressure and as a carrier of intermediate metabolites in the transport and exchange of tissue products. It is critical in regulating the volume of circulating blood. When blood is lost from shock, such as in hemorrhage, there is a reduced plasma volume. When blood volume is reduced, albumin quickly restores the volume in most situations.

Plasma protein fractions are used to treat hypovolemic (low blood volume) shock that occurs as the result of burns, trauma, surgery, and infections, or in conditions where shock is not currently present but likely to occur. Plasma protein fractions are also used to treat hypoproteinemia (a deficiency of protein in the blood), as might be seen in patients with nephrotic syndrome and hepatic cirrhosis, as well as other diseases or disorders. As with human pooled plasma, blood type and crossmatch is not needed when plasma protein fractions are given.

Energy Substrates

Energy substrates include dextrose solutions and fat emulsion. Solutions used to supply energy and fluid include dextrose (glucose) in water or sodium chloride, alcohol in dextrose, and IV fat emulsion. Dextrose is a carbohydrate used to provide a source of calories and fluid. Alcohol (as alcohol in dextrose) also provides calories. Dextrose is available in various strengths (or percent of the carbohydrate) in a fluid, which may be water or sodium chloride (saline). Dextrose and dextrose in alcohol are available in various strengths (or percent of the carbohydrate and percent of the alcohol) in water. Dextrose solutions also are available with electrolytes, for example, Plasma-Lyte 56 and 5% Dextrose. Calories provided by dextrose and dextrose in alcohol solutions are listed in Table 58-1.

An IV fat emulsion contains soybean or safflower oil and a mixture of natural triglycerides, predominately unsaturated fatty acids. It is used in the prevention and treatment of essential fatty acid deficiency. It also provides nonprotein calories for those receiving TPN when calorie requirements cannot be met by glucose. Examples of intravenous fat emulsion include Intralipid 10% and 20%, Liposyn II 10% and 20%, and Liposyn III 10% and 20%. Fat emulsion is used as a source of calories and essential fatty acids for

<table>
<thead>
<tr>
<th>CARBOHYDRATE</th>
<th>PERCENTAGE</th>
<th>CALORIES/1,000 ML</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dextrose</td>
<td>2.5%</td>
<td>85</td>
</tr>
<tr>
<td>Dextrose</td>
<td>5%</td>
<td>170</td>
</tr>
<tr>
<td>Dextrose</td>
<td>10%</td>
<td>340</td>
</tr>
<tr>
<td>Dextrose</td>
<td>20%</td>
<td>680</td>
</tr>
<tr>
<td>Dextrose</td>
<td>50%</td>
<td>1,700</td>
</tr>
<tr>
<td>Dextrose</td>
<td>70%</td>
<td>2,380</td>
</tr>
<tr>
<td>Alcohol in dextrose</td>
<td>5% alcohol and 5% dextrose</td>
<td>450</td>
</tr>
<tr>
<td></td>
<td>10% alcohol and 5% dextrose</td>
<td>720</td>
</tr>
</tbody>
</table>
patients requiring parenteral nutrition for extended periods (usually more than 5 days). No more than 60% of the patient's total caloric intake should come from fat emulsion, with carbohydrates and amino acids comprising the remaining 40% or more of caloric intake.

**Plasma Expanders**

The IV solutions of plasma expanders include hetastarch (Hespan), low–molecular-weight dextran (Dextran 40), and high–molecular-weight dextran (Dextran 70, Dextran 75). Plasma expanders are used to expand plasma volume when shock is caused by burns, hemorrhage, surgery, and other trauma and for prophylaxis of venous thrombosis and thromboembolism. When used in the treatment of shock, plasma expanders are not a substitute for whole blood or plasma, but they are of value as emergency measures until the latter substances can be used.

**Intravenous Replacement Solutions**

Intravenous replacement solutions are a source of electrolytes and water for hydration (Normosol M Ringer’s Injection, Lactated Ringer’s, Plasma-Lyte R), and used to facilitate amino acid utilization and maintain electrolyte balance (Lypholyte, M ultilyte, TPN Electrolytes). Dextrose and electrolyte solutions such as Plasma-Lyte R and 5% dextrose are used as a parenteral source of electrolytes, calories, or water for hydration. Invert sugar-electrolyte solutions, such as M ultiple Electrolytes and Travert 5% and 10%, contain equal parts of dextrose and fructose and are used as a source of calories and hydration.

**ADVERSE REACTIONS, CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Blood Plasma**

Solutions used in the management of body fluids are contraindicated in patients with hypersensitivity to any component of the solution. All solutions used to manage body fluids discussed in this chapter are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation. No interactions have been reported.

**Plasma Protein Fractions**

Adverse reactions are rare when plasma protein fractions are administered, but nausea, chills, fever, urticaria, and hypotensive episodes may occasionally be seen.

Plasma proteins are contraindicated in those with a history of allergic reactions to albumin, severe anemia, or cardiac failure; in the presence of normal or increased intravascular volume; and in patients on cardiopulmonary bypass. Plasma protein fractions are used cautiously in patients who are in shock or dehydrated and in those with congestive cardiac failure or hepatic or renal failure. These solutions are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation.

Most IV solutions should not be combined with any other solutions or drugs but should be administered alone. The nurse should consult the drug insert or other appropriate sources before combining any drug with any plasma protein fraction.

**Protein Substrates**

Administration of protein substrates (amino acids) may result in nausea, fever, flushing of the skin, metabolic acidosis or alkalosis, and decreased phosphorus and calcium blood levels.

Solutions used in the management of body fluids are contraindicated in patients with hypersensitivity to any component of the solution. Plasma expanders are used cautiously in patients with renal disease, congestive heart failure, pulmonary edema, and severe bleeding disorders. These solutions are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation. Protein substrates should not be combined with any other solutions or drugs without consulting the drug insert or other appropriate sources.

**Energy Substrates**

Low– or high–molecular-weight dextran administration may result in allergic reactions, which are evidenced by urticaria, hypotension, nausea, vomiting, headache, dyspnea, fever, tightness of the chest, and wheezing. Hyperglycemia and phlebitis may be seen with administration of glucose.

The energy substrates are contraindicated in patients with hypersensitivity to any component of the solution. Dextrose solutions are contraindicated in patients with diabetic coma with excessively high blood sugar. Concentrated dextrose solutions are contraindicated in patients with increased intracranial pressure, delirium tremens (if patient is dehydrated), hepatic coma, or glucose–galactose malabsorption syndrome. Alcohol dextrose solutions are contraindicated in patients with epilepsy, urinary tract infections, alcoholism, and diabetic coma.

Alcohol dextrose solutions are used cautiously in patients with hepatic and renal impairment, vitamin deficiency (may cause or potentiate vitamin deficiency),
diabetes, or shock; during postpartum hemorrhage; and after cranial surgery. The nurse should consult the drug insert or other appropriate sources before combining any drug with an IV solution. Dextrose solutions are used cautiously in patients receiving a corticosteroid or corticotropin. Dextrose and alcohol dextrose solutions are incompatible with blood (may cause hemolysis).

The most common adverse reaction associated with the administration of fat emulsion is sepsis caused by administration equipment and thrombophlebitis caused by vein irritations from concurrently administering hypertonic solutions. Less frequently occurring adverse reactions include dyspnea, cyanosis, hyperlipidemia, hypercoagulability, nausea, vomiting, headache, flushing, increase in temperature, sweating, sleepiness, chest and back pain, slight pressure over the eyes, and dizziness.

IV fat emulsions are contraindicated in conditions that interfere with normal fat metabolism (eg, acute pancreatitis) and in patients allergic to eggs. IV fat emulsions are used with caution in those with severe liver impairment, pulmonary disease, anemia, and blood coagulation disorders. These solutions are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation. In general, fat emulsions should not be combined with any other solutions or drugs, except when combined in TPN. The nurse should consult appropriate sources before combining any drug with a fat emulsion.

Plasma Expanders

Administration of hetastarch, a plasma expander, may be accompanied by vomiting, a mild temperature elevation, itching, and allergic reactions. Allergic reactions are evidenced by wheezing, edema around the eyes (periorbital edema), and urticaria. Other plasma expanders may result in mild cutaneous eruptions, generalized urticaria, hypotension, nausea, vomiting, headache, dyspnea, fever, tightness of the chest, bronchospasm, wheezing, and rarely, anaphylactic shock.

Plasma expanders are contraindicated in patients with hypersensitivity to any component of the solution and those with severe bleeding disorders, severe cardiac failure, renal failure with oliguria, or anuria. Plasma expanders are used cautiously in patients with renal disease, congestive heart failure, pulmonary edema, and severe bleeding disorders. Plasma expanders are Pregnancy Category C drugs and are used cautiously during pregnancy and lactation. The nurse should consult the drug insert or other appropriate sources before combining a plasma expander with another drug for IV administration.

Fluid Overload

One adverse reaction common to all solutions administered by the parenteral route is fluid overload, that is, the administration of more fluid than the body is able to handle. The term fluid overload (circulatory overload) is not a specific amount of fluid that is given. It describes a condition when the body’s fluid requirements are met and the administration of fluid occurs at a rate that is greater than the rate at which the body can use or eliminate the fluid. Thus, the amount of fluid and the rate of administration of fluid that will cause fluid overload depend on several factors, such as the patient’s cardiac status and adequacy of renal function. The signs and symptoms of fluid overload are listed in Display 58-1.

---

**DISPLAY 58-1 • Signs and Symptoms of Fluid Overload**

- Headache
- Weakness
- Blurred vision
- Behavioral changes (confusion, disorientation, delirium, drowsiness)
- Weight gain
- Isolated muscle twitching
- Hypotension
- Rapid breathing
- Wheezing
- Coughing
- Rise in blood pressure
- Distended neck veins
- Elevated central venous pressure
- Convulsions

---

**NURSING PROCESS**

**The Patient Receiving a Solution for Management of Body Fluids**

**ASSESSMENT**

**Preadministration Assessment**

Solutions used to manage body fluids are often administered IV. Before administering an IV solution, the nurse assesses the patient’s general status, reviews recent laboratory test results (when appropriate), weighs the patient (when appropriate), and takes the vital signs. Blood pressure, pulse, and respiratory rate provide a baseline, which is especially important when the patient is receiving blood plasma, plasma expanders, or plasma protein fractions for shock or other serious disorders.

**Ongoing Assessment**

During the ongoing assessment, the nurse checks the needle site every 15 to 30 minutes or more frequently if the patient is restless or confused. When one of these preparations is given with a regular IV infusion set, the nurse checks the infusion rate every 15 minutes. The needle site is inspected for signs of extravasation (escape of fluid from a blood vessel into surrounding tissues) or infiltration (the collection of fluid into tissues).
If signs of extravasation or infiltration are apparent, the nurse restarts the infusion in another vein.

When these solutions are given, a central venous pressure line may be inserted to monitor the patient’s response to therapy. Central venous pressure readings are taken as ordered. During administration, the nurse takes the blood pressure, pulse, and respiratory rate as ordered or at intervals determined by the patient’s clinical condition. For example, a patient in shock and receiving a plasma expander may require monitoring of the blood pressure and pulse rate every 5 to 15 minutes, whereas the patient receiving dextrose 3 days after surgery may require monitoring every 30 to 60 minutes.

The nurse observes patients receiving IV solutions at frequent intervals for signs of fluid overload. If signs of fluid overload (see Display 58-1) are observed, the nurse slows the IV infusion rate and immediately notifies the primary health care provider.

**PLANNING**

The expected outcomes of the patient may include an optimal response to therapy, prevention of fluid overload, correction of the fluid volume deficit (where appropriate), improved oral nutrition (where appropriate), and an understanding of the administration procedure.

**IMPLEMENTATION**

Promoting an Optimal Response to Therapy

Patients receiving an IV fluid should be made as comfortable as possible, although under some circumstances this may be difficult. The extremity used for administration should be made comfortable and supported as needed by a small pillow or other device. An IV infusion pump may be ordered for the administration of these solutions. The nurse sets the alarm of the infusion pump and checks the functioning of the unit at frequent intervals.

**Nursing Diagnoses**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**Gerontologic Alert**

Older adults are at increased risk for fluid overload because of the increased incidence of cardiac disease and decreased renal function that may accompany old age. Careful monitoring for signs and symptoms of fluid overload (see Table 58-2) is extremely important when administering fluids to older adults.

**FAT EMULSIONS.** When a fat emulsion is administered, the nurse must monitor the patient’s ability to eliminate the infused fat from the circulation. The lipidemia must clear between daily infusions. The nurse monitors for lipidemia through assessing the result of the following laboratory exams: hemogram, blood coagulation, liver function tests, plasma lipid profile, and platelet count. The nurse reports an increase in any of these laboratory examinations as abnormal.

**LIPID SOLUTIONS.** Fat solutions (emulsions) should be handled with care to decrease the risk of separation or “breaking out of the oil.” Separation can be identified by yellowish streaking or the accumulation of yellowish droplets in the emulsion. Fat solutions are administered to adults at a rate no greater than 1 to 2 mL/min.
AMINO ACIDS. A microscopic filter is attached to the IV line when amino acid solutions are administered. The filter prevents microscopic aggregates (particles that may form in the IV bag) from entering the bloodstream where they could cause massive emboli.

Managing Fluid Volume Deficit and Nutritional Imbalances
Many times the solutions used in the management of body fluids are given to correct a fluid volume deficit and to supply carbohydrates (nutrition). The nurse reviews the patient’s chart for a full understanding of the rationale for administration of the specific solution.

When appropriate, nursing measures that may be instituted to correct a fluid volume and carbohydrate deficit may be included in a plan of care. Examples of these measures include offering oral fluids at frequent intervals and encouraging the patient to take small amounts of nourishment between meals and to eat as much as possible at mealtime.

Educating the Patient and Family
The nurse gives the patient or family a brief explanation of the reason for and the method of administration of an IV solution. Sometimes, patients and families tamper with or adjust the rate of flow of IV administration sets. The nurse emphasizes the importance of not touching the IV administration set or the equipment used to administer IV fluids.

EVALUATION
• The therapeutic effect of the drug is achieved.
• The fluid volume deficit is corrected.
• The nutrition deficit is corrected.
• The patient and family demonstrate an understanding of the procedure.

ELECTROLYTES
Along with a disturbance in fluid volume (eg, loss of plasma, blood, or water) or a need for providing parenteral nutrition with the previously discussed solutions, an electrolyte imbalance may exist. An electrolyte is an electrically charged substance essential to the normal functioning of all cells. Electrolytes circulate in the blood at specific levels where they are available for use when needed by the cells. An electrolyte imbalance occurs when the concentration of an electrolyte in the blood is either too high or too low. In some instances, an electrolyte imbalance may be present without an appreciable disturbance in fluid balance. For example, a patient taking a diuretic is able to maintain fluid balance by an adequate oral intake of water, which replaces the water lost through diuresis. However, the patient is likely to be unable to replace the potassium that is also lost during diuresis. When the potassium concentration in the blood is too low, as may occur with the administration of a diuretic, an imbalance may occur that requires the addition of potassium. Commonly used electrolytes are listed in the Summary Drug Table: Electrolytes.

ACTIONS AND USES

Bicarbonate (HCO₃⁻)
This electrolyte plays a vital role in the acid-base balance of the body. Bicarbonate may be given IV as sodium bicarbonate (NaHCO₃) in the treatment of metabolic acidosis, a state of imbalance that may be seen in diseases or situations such as severe shock, diabetic acidosis, severe diarrhea, extracorporeal circulation of blood, severe renal disease, and cardiac arrest. Oral sodium bicarbonate is used as a gastric and urinary alkalinizer. It may be used as a single drug or may be found as one of the ingredients in some antacid preparations. It is also useful in treating severe diarrhea accompanied by bicarbonate loss.

Bicarbonate is no longer used as the first line treatment during cardiopulmonary resuscitation following cardiac arrest. Recent evidence suggests little benefit, and the drug may actually be detrimental to resuscitation. According to the American Heart Association, bicarbonate is used when all other treatment options have failed.

Calcium (Ca²⁺)
Calcium is necessary for the functioning of nerves and muscles, the clotting of blood (see Chap. 44), the building of bones and teeth, and other physiologic processes. Examples of calcium salts are calcium gluconate and calcium carbonate. Calcium may be given for the treatment of hypocalcemia (low blood calcium), which may be seen in those with parathyroid disease or after accidental removal of the parathyroid glands during surgery of the thyroid gland. Calcium may also be given during cardiopulmonary resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. Calcium may be used as adjunct therapy of insect bites or stings to reduce muscle cramping, such as occurs with black widow spider bites. Calcium may also be recommended for those eating a diet low in calcium or as a dietary supplement when there is an increased need for calcium, such as during pregnancy.
<table>
<thead>
<tr>
<th>GENERIC NAME</th>
<th>TRADE NAME*</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>DOSAGE RANGES</th>
</tr>
</thead>
<tbody>
<tr>
<td>calcium acetate</td>
<td>PhosLo</td>
<td>Control of hyperphosphatemia in end-stage renal disease</td>
<td>See Display 58-2</td>
<td>3–4 tablets PO with each meal</td>
</tr>
<tr>
<td>calcium carbonate</td>
<td>Calcium-600, Caltrate, Oyster Shell Calcium Tums, Tums E-X, Tums Ultra, generic</td>
<td>Dietary supplement for prevention or treatment of calcium deficiency, osteoporosis, osteomalacia, rickets, latent tetany</td>
<td>Rare; see Display 58-2 for signs of hypercalcemia</td>
<td>500–2000 mg/d PO</td>
</tr>
<tr>
<td>calcium citrate</td>
<td>Citracal, Citracal Liquitab, generic</td>
<td>Same as calcium carbonate; premenstrual syndrome</td>
<td>Same as calcium carbonate</td>
<td>500–2000 mg/d PO</td>
</tr>
<tr>
<td>calcium gluconate</td>
<td>Generic</td>
<td>Same as calcium carbonate; premenstrual syndrome</td>
<td>Same as calcium carbonate</td>
<td>500–2000 mg/d PO</td>
</tr>
<tr>
<td>calcium lactate</td>
<td>Generic</td>
<td>Same as calcium carbonate</td>
<td>Same as calcium carbonate</td>
<td>500–2000 mg/d PO</td>
</tr>
<tr>
<td>oral electrolyte mixtures</td>
<td>Infalyte Oral Solution, Naturalyte, Pedialyte, Pedialyte Electrolyte, Pedialyte Freezer Pops, Rehydralyte, Resol</td>
<td>Maintenance of water and electrolytes after corrective parenteral therapy of severe diarrhea; maintenance to replace mild to moderate fluid losses when food and liquid intake are discontinued, to restore fluid and minerals lost in diarrhea and vomiting in infants and children</td>
<td>Rare; Individualize dosage following the guidelines on the product labeling</td>
<td>54–483 mg/d PO</td>
</tr>
<tr>
<td>magnesium</td>
<td>Almora, Magonate, Mag-Ox 400, Magtrate, Mag-200, Slow-Mag, Uro-Mag, generic</td>
<td>Dietary supplement, hypomagnesemia</td>
<td>Rare; see Display 58-2 for signs of hypermagnesemia</td>
<td>54–483 mg/d PO</td>
</tr>
<tr>
<td>potassium replacements</td>
<td>Effer K, K + 10, Kaon O, K-Dur, Klor-Con, K-Lyte, K-Tab, Micro-K, Slow-K, generic</td>
<td>Hypokalemia</td>
<td>See Display 58-2; most common: nausea, vomiting, diarrhea, flatulence, abdominal discomfort, skin rash</td>
<td>40–150 mEq/d PO</td>
</tr>
<tr>
<td>sodium chloride</td>
<td>Prevention or treatment of extracellular volume depletion, dehydration, sodium depletion, aid in the prevention of heat prostration</td>
<td>Nausea, vomiting, diarrhea, abdominal cramps, edema, irritability, restlessness, weakness, hypertension, tachycardia, fluid accumulation, pulmonary edema, respiratory arrest (see Display 58-2)</td>
<td>Individualize dosage</td>
<td></td>
</tr>
</tbody>
</table>
Magnesium (Mg\(^{2+}\))

Magnesium plays an important role in the transmission of nerve impulses. It is also important in the activity of many enzyme reactions, for example, carbohydrate metabolism. Magnesium sulfate is used as replacement therapy in hypomagnesemia. Magnesium sulfate (MgSO\(_4\)) is used in the prevention and control of seizures in obstetric patients with pregnancy-induced hypertension (PIH, also referred to as eclampsia and preeclampsia). It may also be added to TPN mixtures.

Potassium (K\(^{+}\))

Potassium is necessary for the transmission of impulses; the contraction of smooth, cardiac, and skeletal muscles; and other important physiologic processes. Potassium as a drug is available as potassium chloride (KCl) and potassium gluconate, and is measured in milliequivalents (mEq), for example, 40 mEq in 20 mL or 8 mEq controlled-release tablet. Potassium may be given for hypokalemia (low blood potassium). Examples of causes of hypokalemia are a marked loss of gastrointestinal fluids (severe vomiting, diarrhea, nasogastric suction, draining intestinal fistulas), diabetic acidosis, marked diuresis, and severe malnutrition.

Sodium (Na\(^{+}\))

Sodium is essential for the maintenance of normal heart action and in the regulation of osmotic pressure in body cells. Sodium, as sodium chloride (NaCl), may be given IV. A solution containing 0.9% NaCl is called normal saline, and a solution containing 0.45% NaCl is called half-normal saline. Sodium also is available combined with dextrose, for example, dextrose 5% and sodium chloride 0.9%.

Sodium is administered for hyponatremia (low blood sodium). Examples of causes of hyponatremia are excessive diaphoresis, severe vomiting or diarrhea, excessive diuresis, and draining intestinal fistulas.

**Combined Electrolyte Solutions**

Combined electrolyte solutions are available for oral and IV administration. The IV solutions contain various electrolytes and dextrose. The amount of electrolytes, given as milliequivalents per liter (mEq/L), also varies. The IV solutions are used to replace fluid and electrolytes that have been lost and to provide calories by means of their carbohydrate content. Examples of IV electrolyte solutions are dextrose 5% with 0.9% NaCl, lactated Ringer’s injection, Plasma-Lyte, and 10% Travert (invert sugar—a combination of equal parts of fructose and dextrose) and Electrolyte No. 2.

The primary health care provider selects the type of combined electrolyte solution that will meet the patient’s needs.

Oral electrolyte solutions contain a carbohydrate and various electrolytes. Examples of combined oral electrolyte solutions are Pedialyte and Rehydralyte. Oral electrolyte solutions are most often used to replace lost electrolytes, carbohydrates, and fluid in conditions such as severe vomiting or diarrhea.

**ADVERSE REACTIONS, CONTRAINDICATIONS, PRECAUTIONS, AND INTERACTIONS**

**Bicarbonate (HCO\(_3^-\))**

In some instances, excessive oral use may produce nausea and vomiting. Some individuals may use sodium bicarbonate (baking soda) for the relief of gastric disturbances, such as pain, discomfort, symptoms of indigestion, and gas. Prolonged use of oral sodium bicarbonate or excessive doses of IV sodium bicarbonate may result in systemic alkalosis.

Bicarbonate is contraindicated in patients losing chloride by continuous gastrointestinal suction or through vomiting, in patients with metabolic or respiratory alkalosis, hypocalcemia, renal failure, or severe abdominal pain of unknown cause, and in those on sodium-restricted diets. Bicarbonate is used cautiously in patients with congestive heart failure or renal impairment and with glucocorticoid therapy. Bicarbonate is a Pregnancy Category C drug and is used cautiously during pregnancy.

Oral administration of bicarbonate may decrease the absorption of ketoconazole. Increased blood levels of quinidine, flecainide, or sympathomimetics may occur when these agents are administered with bicarbonate. There is an increased risk of crystalluria when bicarbonate is administered with the fluoroquinolones. Possible decreased effects of lithium, methotrexate, chlorpropamide, salicylates, and tetracyclines may occur when these drugs are administered with sodium bicarbonate. Sodium bicarbonate is not administered within 2 hours of enteric-coated drugs; the protective enteric coating may disintegrate before the drug reaches the intestine.

**Calcium (Ca\(^{2+}\))**

Irritation of the vein used for administration, tingling, a metallic or chalky taste, and “heat waves” may occur when calcium is given IV. Rapid IV administration (calcium gluconate) may result in bradycardia, vasodilation, decreased blood pressure, cardiac arrhythmias, and
cardiac arrest. Oral administration may result in gastrointestinal disturbances. Administration of calcium chloride may cause peripheral vasodilation, temporary fall in blood pressure, and a local burning. Display 58-2 gives adverse reactions associated with hyper- and hypocalcemia.

**DISPLAY 58-2  Signs and Symptoms of Electrolyte Imbalances**

**CALCIUM**  
Normal laboratory values: 4.5–5.3 mEq/L or 9-11 mg/dL*

**Hypocalcemia**  
Hyperactive reflexes, carpopedal spasm, perioral paresthesias, positive Trousseau's sign, positive Chvostek's sign, muscle twitching, muscle cramps, tetany (numbness, tingling, and muscular twitching usually of the extremities), laryngospasm, cardiac arrhythmias, nausea, vomiting, anxiety, confusion, emotional lability, convulsions

**Hypercalcemia**  
Anorexia, nausea, vomiting, lethargy, bone tenderness or pain, polyuria, polypnea, constipation, dehydration, muscle weakness and atrophy, stupor, coma, cardiac arrest

**MAGNESIUM**  
Normal laboratory values: 1.5–2.5 mEq/L or 1.8-3 mg/dL*

**Hypermagnesemia**  
Leg and foot cramps, hypertension, tachycardia, neuromuscular irritability, tremor, hyperactive deep tendon reflexes, confusion, disorientation, visual or auditory hallucinations, painful paresthesias, positive Trousseau's sign, positive Chvostek's sign, convulsions

**Hypomagnesemia**  
Lethargy, drowsiness, impaired respiration, flushing, sweating, hypotension, weak to absent deep tendon reflexes

**POTASSIUM**  
Normal laboratory values: 3.5–5 mEq/L*

**Hypokalemia**  
Anorexia, nausea, vomiting, mental depression, confusion, delayed or impaired thought processes, drowsiness, abdominal distention, decreased bowel sounds, paralytic ileus, muscle weakness or fatigue, flaccid paralysis, absent or diminished deep tendon reflexes, weak irregular pulse, paresthesias, leg cramps, ECG changes

**Hyperkalemia**  
Irritability, anxiety, listlessness, mental confusion, nausea, diarrhea, abdominal distress, gastrointestinal hyperactivity, paresthesias, weakness and heaviness of the legs, flaccid paralysis, hypotension, cardiac arrhythmias, ECG changes

**SODIUM**  
Normal laboratory values: 132–145 mEq/L*

**Hyponatremia**  
Cold clammy skin, decreased skin turgor, apprehension, confusion, irritability, anxiety, hypotension, postural hypotension, tachycardia, headache, tremors, convulsions, abdominal cramps, nausea, vomiting, diarrhea

**Hypokalemia**  
Fever, hot dry skin, dry sticky mucous membranes, rough dry tongue, edema, weight gain, intense thirst, excitement, restlessness, agitation, oliguria or anuria

*These laboratory values may not concord with the normal range of values in all hospitals and laboratories. The hospital policy manual or laboratory values sheet should be consulted for the normal ranges of all laboratory tests.

Calcium is contraindicated in patients with hypercalcemia or ventricular fibrillation and in patients taking digitalis. Calcium is used cautiously in patients with cardiac disease. Hypercalcemia may occur when calcium is administered with the thiazide diuretics. When calcium is administered with atenolol there is a decrease in the effect of atenolol, possibly resulting in decreased beta blockade. There is an increased risk of digitalis toxicity when digitalis preparations are administered with calcium. The clinical effect of verapamil may be decreased when the drug is administered with calcium. Concurrent ingestion of spinach or cereal may decrease the absorption of calcium supplements.

**Magnesium (Mg++)**

Adverse reactions seen with magnesium administration are rare. If they do occur, they are most likely related to overdose and may include flushing, sweating, hypotension, depressed reflexes, muscle weakness, and circulatory collapse (see Display 58-2).

Magnesium sulfate is contraindicated in patients with heart block or myocardial damage and in women with PIH during the 2 hours before delivery. Magnesium is a Pregnancy Category A drug, and studies indicate no increased risk of fetal abnormalities if the agent is used during pregnancy. Nevertheless, caution is used when administering magnesium during pregnancy. In addition, magnesium chloride is contraindicated in patients with renal impairment or marked myocardial disease and those in a coma. Magnesium (sulfate) is used with caution in patients with renal function impairment. Prolonged respiratory depression and apnea may occur when magnesium is administered with the neuromuscular blocking agents.

**Potassium (K+)**

Nausea, vomiting, diarrhea, abdominal pain, and phlebitis have been seen with oral and IV administration of potassium. Adverse reactions related to hypo- or hyperkalemia are listed in Display 58-2.

If extravasation of the IV solution should occur, local tissue necrosis (death of tissue) may be seen. If extravasation occurs, the primary health care provider is contacted immediately and the infusion slowed to a rate that keeps the vein open.

Potassium is contraindicated in patients who are at risk for experiencing hyperkalemia, such as those with renal failure, oliguria, or azotemia (the presence of nitrogen-containing compounds in the blood), anuria, severe hemolytic reactions, untreated Addison’s disease (see Chap. 50), acute dehydration, heat cramps, and any form of hyperkalemia. Potassium is used cautiously in patients with renal impairment or adrenal insufficiency, heart disease, metabolic acidosis, or prolonged or severe diarrhea. Concurrent use of potassium with
angiotensin-converting enzyme (ACE) inhibitors may result in elevated serum potassium. Potassium-sparing diuretics and salt substitutes used with potassium can produce severe hyperkalemia. The use of digitalis with potassium increases the risk of digoxin toxicity.

**Sodium (Na⁺)**

Sodium as the salt (eg, NaCl) has no adverse reactions except those related to overdose (see Display 58-2). In some instances, excessive oral use may produce nausea and vomiting.

Sodium is contraindicated in patients with hypernatremia, fluid retention, and when the administration of sodium or chloride could be detrimental. Sodium is used cautiously in surgical patients and those with circulatory insufficiency, hypoproteinemia, urinary tract obstruction, congestive heart failure, edema, and renal impairment. Sodium is a Pregnancy Category C drug and is used cautiously during pregnancy.

**NURSING PROCESS**

- The Patient Receiving an Electrolyte

**ASSESSMENT**

**Preadministration Assessment**

Before administering any electrolyte, electrolyte salt, or a combined electrolyte solution, the nurse assesses the patient for signs of an electrolyte imbalance (see Display 58-2). All recent laboratory and diagnostic tests appropriate to the imbalance are reviewed. The nurse obtains vital signs to provide a database.

**Ongoing Assessment**

During therapy, the nurse periodically obtains (daily or more frequently) serum electrolyte or bicarbonate studies to monitor therapy.

**BICARBONATE.** When given in the treatment of metabolic acidosis, the drug may be added to the IV fluid or given as a prepared IV sodium bicarbonate solution. Frequent laboratory monitoring of the blood pH and blood gases is usually ordered because dosage and length of therapy depend on test results. The nurse frequently observes the patient for signs of clinical improvement and monitors the blood pressure, pulse, and respiratory rate every 15 to 30 minutes or as ordered by the primary health care provider. Extravasation of the drug requires selection of another needle site because the drug is irritating to the tissues.

**CALCIUM.** Before, during, and after the administration of IV calcium, the nurse monitors the blood pressure, pulse, and respiratory rate every 30 minutes until the patient’s condition has stabilized. After administration of calcium, the nurse observes the patient for signs of hypercalcemia (see Display 58-2).

**POTASSIUM.** Patients receiving oral potassium should have their blood pressure and pulse monitored every 4 hours, especially during early therapy. The nurse also observes the patient for signs of hyperkalemia (see Display 58-2), which would indicate that the dose of potassium is too high. Signs of hypokalemia may also occur during therapy and may indicate that the dose of potassium is too low and must be increased. If signs of hypokalemia or hyperkalemia are apparent or suspected, the nurse notifies the primary health care provider. In some instances, frequent laboratory monitoring of the serum potassium may be ordered.

The nurse inspects the IV needle site every 30 minutes for signs of extravasation. Potassium is irritating to the tissues. If extravasation occurs, the nurse discontinues the IV immediately and notifies the primary health care provider. The acutely ill patient and the patient with severe hypokalemia will require monitoring of the blood pressure and pulse rate during the time of the IV infusion. The nurse monitors the intake and output every 8 hours. The infusion rate is slowed to keep the vein open, and the primary health care provider is notified if an irregular pulse is noted.

**MAGNESIUM.** When magnesium sulfate is ordered to treat convulsions or severe hypomagnesemia, the patient requires constant observation. The nurse obtains the patient’s blood pressure, pulse, and respiratory rate immediately before the drug is administered, as well as every 5 to 10 minutes during the time of IV infusion or after the drug is given direct IV. The nurse continues monitoring these vital signs at frequent intervals until the patient’s condition has stabilized. Because magnesium is eliminated by the kidneys, it is used with caution.
in patients with renal impairment. The nurse monitors the urine output for at least 100 mL every 4 hours. Voiding less than 100 mL of urine every 4 hours is reported to the primary health care provider.

The nurse observes the patient for early signs of hypermagnesemia (see Display 58-2) and contacts the primary health care provider immediately if this imbalance is suspected. Frequent plasma magnesium levels are usually ordered. The nurse notifies the primary health care provider if the magnesium level is higher or lower than the normal range.

**Optimal response to therapy, compliance with the prescribed therapeutic regimen, and an understanding of the drug regimen and adverse drug effects.**

**IMPLEMENTATION**

**Promoting an Optimal Response to Therapy**

In some situations, electrolytes are administered when an electrolyte imbalance may potentially occur. For example, the patient with nasogastric suction is prescribed one or more electrolytes added to an IV solution, such as 5% dextrose or a combined electrolyte solution, to be given IV to make up for the electrolytes that are lost through nasogastric suction. In other instances, electrolytes are given to replace those already lost, such as the patient admitted to the hospital with severe vomiting and diarrhea of several days’ duration.

When electrolytes are administered parenterally, the dosage is expressed in milliequivalents (mEq), for example, calcium gluconate 7 mEq IV. When administered orally, sodium bicarbonate, calcium, and magnesium dosages are expressed in milligrams (mg). Potassium liquids and effervescent tablet dosages are expressed in milliequivalents; capsule or tablet dosages may be expressed as milliequivalents or milligrams.

Electrolyte disturbances can cause varying degrees of confusion, muscular weakness, nausea, vomiting, and cardiac irregularities (see Display 58-2 for specific symptoms). Serum electrolyte blood levels have a very narrow therapeutic range. Careful monitoring is needed to determine if blood levels fall above or below normal. Normal values may vary with the laboratory, but a general range of normal values for each electrolyte is found in Display 58-2. Adverse reactions are usually controlled by maintaining blood levels of the various electrolytes within the normal range.

**ADMINISTERING BICARBONATE.** The nurse gives oral sodium bicarbonate tablets with a full glass of water; the powdered form is dissolved in a full glass of water. If oral sodium bicarbonate is used to alkalinize the urine, the nurse checks the urine pH two or three times a day or as ordered by the primary health care provider. If the urine remains acidic, the nurse notifies the primary health care provider because an increase in the

---

**SODIUM.** When NaCl is administered by IV infusion, the nurse observes the patient during and after administration for signs of hypernatremia (see Display 58-2). The nurse checks the rate of IV infusion as ordered by the primary health care provider, usually every 15 to 30 minutes. More frequent monitoring of the infusion rate may be necessary when the patient is restless or confused. To minimize venous irritation during administration of sodium or any electrolyte solution, the nurse uses a small bore needle placed well within the lumen of a large vein.

Patients receiving a 3% or 5% NaCl solution by IV infusion are observed closely for signs of pulmonary edema (dyspnea, cough, restlessness, bradycardia). If any one or more of these symptoms should occur, the IV infusion is slowed to keep the vein open, and the primary health care provider is contacted immediately. Patients receiving NaCl by the IV route have their intake and output measured every 8 hours. The nurse observes the patient for signs of hypernatremia every 3 to 4 hours and contacts the primary health care provider if this condition is suspected.

**NURSING DIAGNOSES**

Drug-specific nursing diagnoses are highlighted in the Nursing Diagnoses Checklist. Other nursing diagnoses applicable to these drugs are discussed in depth in Chapter 4.

**PLANNING**

The expected outcomes of the patient depend on the specific drug, dose, route of administration, and reason for administration of an electrolyte but may include an

---

**Nursing Diagnoses Checklist**

- **Imbalanced Nutrition: Less than Body Requirements**
  - related to adverse drug reaction (nausea, vomiting)
- **Risk for Injury**
  - related to adverse drug effects (muscular weakness)
- **Disturbed Thought Processes**
  - related to adverse drug effects
- **Risk for Decreased Cardiac Output**
  - related to adverse drug effects (cardiac arrhythmias)
dose of the drug may be necessary. IV sodium bicarbonate is given in emergency situations, such as metabolic acidosis or certain types of drug overdose when alkalization of the urine is necessary to hasten drug elimination.

ADMINISTERING CALCIUM. When calcium is administered IV, the solution is warmed to body temperature immediately before administration, and the drug is administered slowly. In some clinical situations, the primary health care provider may order the patient to have a cardiac monitor because additional drug administration may be determined by electrocardiographic changes.

ADMINISTERING POTASSIUM. When given orally, potassium may cause gastrointestinal distress. Therefore, it is given immediately after meals or with food and a full glass of water. Oral potassium must not be crushed or chewed. If the patient has difficulty swallowing, the nurse consults the primary health care provider regarding the use of a solution or an effervescent tablet, which effervesces (fizzes) and dissolves on contact with water. Potassium in the form of effervescent tablets, powder, or liquid must be thoroughly mixed with 4 to 8 oz of cold water, juice, or other beverage. Effervescent tablets must stop fizzing before the solution is sipped slowly during a period of 5 to 15 minutes. Oral liquids and soluble powders that have been mixed and dissolved in cold water or juice are also sipped slowly during a period of 5 to 15 minutes. The nurse advises patients that liquid potassium solutions have a salty taste. Some of these products have a flavoring added, which makes the solution more palatable.

The primary health care provider orders the dose of the potassium salt (in mEq) and the amount and type of IV solution, as well as the time interval during which the solution is to be infused. After the drug is added to the IV container, the container is gently rotated to ensure mixture of the solution. A large vein is used for administration; the veins on the back of the hand should be avoided. An IV containing potassium should infuse in no less than 3 to 4 hours. This necessitates frequent monitoring of the IV infusion rate, even when an IV infusion pump is used.

ADMINISTERING MAGNESIUM. Magnesium sulfate may be ordered intramuscularly, IV, or by IV infusion diluted in a specified type and amount of IV solution. When ordered to be given intramuscularly, this drug is given undiluted as a 50% solution for adults and a 20% solution for children. Magnesium sulfate is given deep intramuscularly in a large muscle mass, such as the gluteus muscle.

Monitoring and Managing Adverse Reactions
When electrolyte solutions are administered, adverse reactions are most often related to overdose. Correcting the imbalance by decreasing the dosage or discontinuing the solution usually works, and the adverse reactions subside within a short period of time. Frequent serum electrolyte levels are used to monitor blood levels.

If gastrointestinal disturbances occur from oral administration, taking the drug with meals may decrease the nausea. Should the patient become disoriented or confused, the nurse gently reorients the individual. Frequent observation and quickly answering the call light helps to maintain the patient’s safety. If weakness or muscular cramping occurs, the nurse assists the patient when ambulating to prevent falls or other injury.

Some electrolytes may cause cardiac irregularities. The nurse checks the pulse rate at regular intervals, usually every 4 hours or more often if an irregularity in the heart rate is observed. Depending on the patient’s condition, cardiac monitoring may be indicated when administering the electrolytes (particularly when administering potassium or calcium). For example, if potassium is administered to a patient with cardiac disease, a cardiac monitor is needed to continuously monitor the heart rate and rhythm during therapy.

Concentrated potassium solutions are for IV mixtures only and should never be used undiluted. Direct IV injection of potassium could result in sudden death. When potassium is given IV, it is always diluted in 500 to 1000 mL of an IV solution. The maximum recommended concentration of potassium is 80 mEq in 1000 mL of IV solution (although in acute emergency situations a higher concentration of potassium may be required).

Gerontologic Alert
Older adults may need a reduced dosage of magnesium because of decreased renal function. The nurse should closely monitor serum magnesium levels when magnesium is administered to older adults.

Nursing Alert
Mild (5.5–6.5 mEq/L) to moderate (6.5–8 mEq/L) potassium blood level increases may be asymptomatic and manifested only by increased serum potassium concentrations and characteristic ECG changes, such as disappearance of P waves or spreading (widening) of the QRS complex.

Educating the Patient and Family
To ensure accurate compliance with the prescribed drug regimen, the nurse carefully explains the dose and time intervals to the patient or a family member. Because
overdose (which can be serious) may occur if the patient does not adhere to the prescribed dosage and schedule, it is most important that the patient completely understands how much and when to take the drug. The nurse stresses the importance of adhering to the prescribed dosage schedule during patient teaching.

The primary health care provider may order periodic laboratory and diagnostic tests for some patients receiving oral electrolytes. The nurse encourages the patient to keep all appointments for these tests, as well as primary health care provider or clinic visits. Persons with a history of using sodium bicarbonate (baking soda) as an antacid are warned that overuse can result in alkalosis and could disguise a more serious problem. Those with a history of using salt tablets (sodium chloride) are advised not to do so during hot weather unless it is recommended by a primary health care provider. Excessive use of salt tablets can result in a serious electrolyte imbalance.

The nurse includes the following points for specific electrolytes in a patient teaching plan.

**CALCIUM**
- Contact the primary health care provider if the following occur: nausea, vomiting, anorexia, constipation, abdominal pain, dry mouth, thirst, or polyuria (symptoms of hypercalcemia).
- Do not exceed the dosage recommendations.

**POTASSIUM**
- Take the drug exactly as directed on the prescription container. Do not increase, decrease, or omit doses of the drug unless advised to do so by the primary health care provider. Take the drug immediately after meals or with food and a full glass of water. Avoid the use of nonprescription drugs and salt substitutes (many contain potassium) unless use of a specific drug or product has been approved by the primary health care provider.
- Contact the primary health care provider if tingling of the hands or feet, a feeling of heaviness in the legs, vomiting, nausea, abdominal pain, or black stools should occur.
- If the tablet has a coating (enteric-coated tablets), swallow it whole. Do not chew or crush the tablet.
- If effervescent tablets are prescribed, place the tablet in 4 to 8 oz of cold water or juice. Wait until the fizzing stops before drinking. Sip the liquid during a period of 5 to 10 minutes.
- If an oral liquid or a powder is prescribed, add the dose to 4 to 8 oz of cold water or juice and sip slowly during a period of 5 to 10 minutes. Measure the dose accurately.

**MAGNESIUM**
- Do not take oral magnesium sulfate when abdominal pain, nausea, or vomiting is present. If diarrhea and abdominal cramping occur, discontinue the drug.

**EVALUATION**
- The therapeutic effect of the drug is achieved.
- The patient complies with the prescribed drug regimen.
- The patient and family demonstrate an understanding of the drug regimen.
- The patient verbalizes the importance of complying with the prescribed therapeutic regimen.

**TOTAL PARENTERAL NUTRITION**

When normal enteral feeding is not possible or is inadequate to meet an individual’s nutritional needs, intravenous (IV) nutritional therapy or total parenteral nutrition (TPN) is required. Products used to meet the IV nutritional requirements of the patient include protein substrates (amino acids), energy substrates (dextrose and fat emulsions), fluids, electrolytes, and trace minerals (see the Summary Drug Table: Electrolytes). TPN is used to prevent nitrogen and weight loss or to treat negative nitrogen (mineral component in protein and amino acids) balance (a situation in which more nitrogen is used by the body than is taken in) in the following situations:

- When the oral, gastrostomy, or jejunostomy route cannot or should not be used
- Gastrointestinal (GI) absorption of protein is impaired by obstruction
- Inflammatory disease or antineoplastic therapy prevents normal GI functioning
- Bowel rest is needed (eg, after bowel surgery)
- Metabolic requirements for protein are significantly increased (eg, in hypermetabolic states such as serious burns, infections, or trauma)
- Morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown (eg, renal failure)
- When tube feeding alone cannot provide adequate nutrition

TPN may be administered through a peripheral vein or through a central venous catheter. Peripheral TPN is used for patients requiring parenteral nutrition for relatively short periods of time (no more than 5-14 days) and when the central venous route is not possible or necessary. Peripheral TPN is used when the patient’s caloric needs are minimal and can be partially met by normal
means (through the alimentary tract). Peripheral TPN prevents protein catabolism (breakdown of cells) in patients who have adequate body fat and no clinically significant protein malnutrition. An example of a solution used in TPN is amino acids with electrolytes. These solutions may be used alone or combined with dextrose (5% or 10%) solutions.

TPN through a central vein is indicated in patients to promote protein synthesis in those who are severely hypercatabolic, severely depleted of nutrients, or require long-term nutritional parenteral nutrition. For example, amino acids combined with hypertonic dextrose and IV fat emulsions are infused through a central venous catheter to promote protein synthesis. Vitamins, trace minerals, and electrolytes may be added to the TPN mixture to meet the patient's individual needs. The daily dose depends on the patient's daily protein requirement and the patient's metabolic state and clinical responses. Various laboratory studies and assessments are required before and during administration of TPN. For example, baseline studies done before beginning treatment include complete blood count, prothrombin time, body weight, electrolytes, blood urea nitrogen, glucose, creatinine, cholesterol, triglycerides (if on fat emulsion), uric acid, and various other tests. Daily assessments during stabilization of the therapy (3–5 days) include urine glucose, acetone and ketones, intake/output, electrolytes, CO₂ levels, creatinine, and blood urea nitrogen. Thereafter baseline laboratory assessments are made every 2 to 3 days or weekly as the patient’s condition indicates.

To prevent a rebound hypoglycemic reaction from the sudden withdrawal of TPN containing a concentrated dose of dextrose, the rate of administration is slowly reduced or the concentration of dextrose gradually decreased. If TPN must be abruptly withdrawn, a solution of 5% or 10% dextrose is begun to gradually reduce the amount of dextrose administered.

Discuss preadministration and ongoing assessments you would make while her IV is infusing.

2. Mr. Kendall is prescribed an oral potassium chloride liquid. Discuss the instructions you should give to Mr. Kendall regarding preparing and taking the drug.

3. Ms. Hartsel is to receive an IV fat emulsion. Discuss special precautions the nurse should take when administering the solution.

Review Questions

1. Which of the following is a symptom of fluid overload?
   A. Tinnitus
   B. Hypotension
   C. Decreased body temperature
   D. Behavioral changes

2. Which of the following symptoms would indicate hypocalcemia?
   A. Tetany
   B. Constipation
   C. Muscle weakness
   D. Hypertension

3. Which of the following potassium plasma concentration laboratory results would the nurse report immediately to the physician?
   A. 3.5 mEq/L
   B. 4.0 mEq/L
   C. 4.5 mEq/L
   D. 5.5 mEq/mL

4. Which of the following symptoms would most likely indicate hypernatremia?
   A. Fever, increased thirst
   B. Cold, clammy skin
   C. Decreased skin turgor
   D. Hypotension

5. Which of the following is the most common metabolic complication of TPN?
   A. Hypomagnesemia
   B. Hypermagnesemia
   C. Hypoglycemia
   D. Hyperglycemia

Medication Dosage Problems

1. Mr. Parker is to receive 1000 mL of 5% dextrose and water during a period of 10 hours. Calculate how many milliliters should infuse each hour (see Chap. 3 for additional information on calculation).

2. The patient is prescribed potassium 40 mEq orally. The drug is available from the pharmacy in a solution of 20 mEq/15 mL. The nurse administers _____.

Critical Thinking Exercises

1. Ms. Land is receiving 20 mEq of potassium chloride (KCl) added to 1000 mL of 5% dextrose and water.
Abbreviations

A
aa of each
abd abdomen, abdominal
ABG arterial blood gas
ac before meals
ADH antidiuretic hormone
ADL activities of daily living
ad lib as much as desired
ADT alternate-day therapy
AIDS acquired immunodeficiency syndrome
ALT alanine aminotransferase
AMA against medical advice
AMI acute myocardial infarction
AODM adult-onset diabetes mellitus
ARC AIDS-related complex
A SAP as soon as possible
ASHD arteriosclerotic heart disease
AST aspartate aminotransferase

B
BE barium enema; base excess
bid twice a day
bili bilirubin
BM bowel movement
BM R basal metabolic rate
B&O belladonna and opium
BP blood pressure
BPH benign prostatic hypertrophy
BRP bathroom privileges
BUN blood urea nitrogen

C
c with
Ca cancer; calcium
C&A clinitest and acetest
CAD coronary artery disease
caps capsules
CBC complete blood count
CC chief complaint
CCU Coronary Care Unit
CHF congestive heart failure
CHO carbohydrate
chol cholesterol

CLL chronic lymphocytic leukemia
CNS central nervous system
C/O complains of
COPD chronic obstructive pulmonary disease
CPK creatine phosphokinase
CRF chronic renal failure
C&S culture and sensitivity
CTZ chemoreceptor trigger zone
CVA cerebrovascular accident
CVP central venous pressure
CXR chest x-ray

D
/d per day
d daily
DC (D/C) discontinue
Diff differential blood count
DJD degenerative joint disease
DM diabetes mellitus
DOE dyspnea on exertion
DT delirium tremens
Dx diagnosis

E
ECG electrocardiogram
ECT electroconvulsive therapy
EENT eyes, ears, nose, and throat
EKG electrocardiogram
ENT eyes, nose, and throat
ER emergency room
ESR erythrocyte sedimentation rate (sed rate)
et and

F
F Fahrenheit
FBS fasting blood sugar
fl fluid
fx fracture; fraction

G
g gram
GB gallbladder
<table>
<thead>
<tr>
<th>Abbreviations</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>GERD</td>
<td>gastroesophageal reflux disease</td>
</tr>
<tr>
<td>GFR</td>
<td>glomerular filtration rate</td>
</tr>
<tr>
<td>GI</td>
<td>gastrointestinal</td>
</tr>
<tr>
<td>gtt</td>
<td>drop</td>
</tr>
<tr>
<td>GU</td>
<td>genitourinary</td>
</tr>
<tr>
<td>H</td>
<td>hour</td>
</tr>
<tr>
<td>HA</td>
<td>headache</td>
</tr>
<tr>
<td>Hct</td>
<td>hematocrit</td>
</tr>
<tr>
<td>Hgb</td>
<td>hemoglobin</td>
</tr>
<tr>
<td>hs</td>
<td>hour of sleep</td>
</tr>
<tr>
<td>HNT</td>
<td>hypertension</td>
</tr>
<tr>
<td>Hx</td>
<td>history</td>
</tr>
<tr>
<td>ICU</td>
<td>intensive care unit</td>
</tr>
<tr>
<td>IM</td>
<td>intramuscular</td>
</tr>
<tr>
<td>I&amp;O</td>
<td>intake and output</td>
</tr>
<tr>
<td>IOP</td>
<td>intraocular pressure</td>
</tr>
<tr>
<td>IPPB</td>
<td>intermittent positive pressure breathing</td>
</tr>
<tr>
<td>IU</td>
<td>international units</td>
</tr>
<tr>
<td>IV</td>
<td>intravenous</td>
</tr>
<tr>
<td>IVP</td>
<td>intravenous pyelogram</td>
</tr>
<tr>
<td>IVPB</td>
<td>intravenous piggyback</td>
</tr>
<tr>
<td>JRA</td>
<td>juvenile rheumatoid arthritis</td>
</tr>
<tr>
<td>K</td>
<td>potassium</td>
</tr>
<tr>
<td>KUB</td>
<td>kidney, ureters, and bladder</td>
</tr>
<tr>
<td>KVO</td>
<td>keep vein open</td>
</tr>
<tr>
<td>LDH</td>
<td>lactic dehydrogenase</td>
</tr>
<tr>
<td>LDL</td>
<td>low-density lipoproteins</td>
</tr>
<tr>
<td>LOC</td>
<td>level of consciousness</td>
</tr>
<tr>
<td>LP</td>
<td>lumbar puncture</td>
</tr>
<tr>
<td>lytes</td>
<td>electrolytes</td>
</tr>
<tr>
<td>mcg</td>
<td>microgram</td>
</tr>
<tr>
<td>MI</td>
<td>myocardial infarction (heart attack)</td>
</tr>
<tr>
<td>mL</td>
<td>milliliter</td>
</tr>
<tr>
<td>MOM</td>
<td>milk of magnesia</td>
</tr>
<tr>
<td>MS</td>
<td>morphine sulfate; multiple sclerosis; mitral stenosis</td>
</tr>
<tr>
<td>N</td>
<td>normal</td>
</tr>
<tr>
<td>NG</td>
<td>nasogastric</td>
</tr>
<tr>
<td>NPO</td>
<td>nothing by mouth</td>
</tr>
<tr>
<td>NS</td>
<td>normal saline</td>
</tr>
<tr>
<td>NGT</td>
<td>nitroglycerin</td>
</tr>
<tr>
<td>NVD</td>
<td>nausea, vomiting, diarrhea; neck vein distension</td>
</tr>
<tr>
<td>O</td>
<td>oxygen</td>
</tr>
<tr>
<td>OD</td>
<td>right eye</td>
</tr>
<tr>
<td>OOB</td>
<td>out of bed</td>
</tr>
<tr>
<td>OR</td>
<td>operating room</td>
</tr>
<tr>
<td>OU</td>
<td>both eyes</td>
</tr>
<tr>
<td>OTC</td>
<td>over the counter (nonprescription)</td>
</tr>
<tr>
<td>OS</td>
<td>left eye</td>
</tr>
<tr>
<td>PAT</td>
<td>paroxysmal atrial tachycardia</td>
</tr>
<tr>
<td>PBI</td>
<td>protein-bound iodine</td>
</tr>
<tr>
<td>PC</td>
<td>after meals</td>
</tr>
<tr>
<td>PERRLA</td>
<td>pupils equal, round, react to light and accommodation</td>
</tr>
<tr>
<td>PERL</td>
<td>pupils equal and react to light</td>
</tr>
<tr>
<td>PID</td>
<td>pelvic inflammatory disease</td>
</tr>
<tr>
<td>PKU</td>
<td>phenylketonuria</td>
</tr>
<tr>
<td>PND</td>
<td>paroxymal nocturnal dyspnea</td>
</tr>
<tr>
<td>PO</td>
<td>by mouth</td>
</tr>
<tr>
<td>postop</td>
<td>after surgery</td>
</tr>
<tr>
<td>preop</td>
<td>before surgery</td>
</tr>
<tr>
<td>prn</td>
<td>as needed</td>
</tr>
<tr>
<td>PT</td>
<td>physical therapy; prothrombin time</td>
</tr>
<tr>
<td>PZI</td>
<td>protamine zinc insulin</td>
</tr>
<tr>
<td>Qd</td>
<td>every day</td>
</tr>
<tr>
<td>Qh</td>
<td>every hour (q2h, q3h, etc.—every 2 hours, every 3 hours, etc.)</td>
</tr>
<tr>
<td>Qid</td>
<td>four times a day</td>
</tr>
<tr>
<td>Qod</td>
<td>every other day</td>
</tr>
<tr>
<td>RA</td>
<td>rheumatoid arthritis; right atrium</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cell</td>
</tr>
<tr>
<td>REM</td>
<td>rapid eye movement</td>
</tr>
<tr>
<td>RF</td>
<td>rheumatoid factor</td>
</tr>
<tr>
<td>RHD</td>
<td>rheumatic heart disease; renal hypertensive disease</td>
</tr>
<tr>
<td>ROM</td>
<td>range of motion</td>
</tr>
<tr>
<td>RR</td>
<td>recovery room</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>S</td>
<td>without</td>
</tr>
<tr>
<td>SC</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>sed rate</td>
<td>erythrocyte sedimentation rate (ESR)</td>
</tr>
<tr>
<td>SGOT</td>
<td>serum glutamic oxaloacetic transaminase</td>
</tr>
<tr>
<td>SGPT</td>
<td>serum glutamic pyruvic transaminase</td>
</tr>
<tr>
<td>SL</td>
<td>sublingual</td>
</tr>
<tr>
<td>SOB</td>
<td>shortness of breath</td>
</tr>
<tr>
<td>SR</td>
<td>sedimentation rate (ESR)</td>
</tr>
<tr>
<td>STAT</td>
<td>as soon as possible</td>
</tr>
<tr>
<td>T</td>
<td>temperature</td>
</tr>
<tr>
<td>t</td>
<td>temperature</td>
</tr>
<tr>
<td>T₃</td>
<td>triiodothyronine</td>
</tr>
<tr>
<td>T₄</td>
<td>thyroxine</td>
</tr>
<tr>
<td>T&amp;A</td>
<td>tonsillectomy and adenoidectomy</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>TEDS</td>
<td>elastic stockings</td>
</tr>
<tr>
<td>TIA</td>
<td>transient ischemic attack</td>
</tr>
<tr>
<td>tid</td>
<td>three times a day</td>
</tr>
<tr>
<td>TKO</td>
<td>to keep open</td>
</tr>
<tr>
<td>TLC</td>
<td>tender loving care</td>
</tr>
<tr>
<td>TM</td>
<td>tympanic membrane</td>
</tr>
<tr>
<td>TPN</td>
<td>total parenteral nutrition</td>
</tr>
<tr>
<td>TPR</td>
<td>temperature, pulse, respiration</td>
</tr>
<tr>
<td>TSH</td>
<td>thyroid-stimulating hormone</td>
</tr>
<tr>
<td>U</td>
<td>upper gastrointestinal</td>
</tr>
<tr>
<td>UGI</td>
<td>upper gastrointestinal</td>
</tr>
<tr>
<td>ung</td>
<td>ointment</td>
</tr>
<tr>
<td>URI</td>
<td>upper respiratory infection</td>
</tr>
<tr>
<td>UTI</td>
<td>urinary tract infection</td>
</tr>
<tr>
<td>VS</td>
<td>vital signs</td>
</tr>
<tr>
<td>W</td>
<td>within normal limits</td>
</tr>
<tr>
<td>Wt</td>
<td>weight</td>
</tr>
</tbody>
</table>
Glossary

A

abstinence syndrome: symptoms that occur if a drug causing physical or psychological dependence is suddenly discontinued

achalasia: failure to relax; usually referring to the smooth muscle fibers of the gastrointestinal tract, especially failure of the lower esophagus to relax when swallowing causing difficulty swallowing and a feeling of fullness in the sternal region

active immunity: type of immunity that occurs when the person is exposed to a disease and develops the disease, and the body makes antibodies to provide future protection against the disease

addiction: a compulsive desire or craving to use a drug or chemical with a resultant physical dependence

adrenergic drug: a drug that acts like or mimics the actions of the sympathetic nervous system

aerobic: organisms that require oxygen to live

afferent nerve fiber: a sensory nerve that carries an impulse toward the brain

agonist: drug that binds with a receptor to produce a therapeutic response

agonist-antagonist: drug with both agonist and antagonist properties

agranulocytosis: a decrease or lack of granulocytes (a type of white blood cell)

akathisia: extreme restlessness and increased motor activity

aldosterone: hormone secreted by the adrenal cortex and contributing to a rise in blood pressure

alopecia: abnormal loss of hair; baldness

amenorrhea: absence or suppression of menstruation

anabolism: tissue-building process

anaerobic: organisms that do not require oxygen to live

analgesic: a drug that relieves pain

anaphylactic reaction: a sudden, severe hypersensitivity reaction with symptoms that progress rapidly and may result in death if not treated

anemia: a decrease in the number of red blood cells and hemoglobin value below normal

androgens: testosterone and its derivatives

angina pectoris (angina): acute pain in the chest resulting from decreased blood supply to the heart muscle

angioedema: localized wheals or swellings in subcutaneous tissues or mucous membranes, which may be due to an allergic response; also called angioneurotic edema

anorexia: loss of appetite

anorexiant: a drug used to suppress the appetite

antagonist: drugs that join with a receptor to prevent the action of an agonist

anthelmintic: a drug used to treat helminthiasis (worms)

antibacterial: active against bacteria

antibody: molecule with the ability to bind with a specific antigen responsible for the immune response

antiemetic: drug that is used to treat or prevent nausea

antiflatulent: drug that works against flatus (gas)

antigen: substance that is capable of inducing a specific immune response

anti-infective: a drug used to treat infection

antipsoriatics: drugs used to treat psoriasis

antipyretic: a drug that lowers an elevated body temperature

antiseptic: an agent that stops or slows, or prevents the growth of microorganisms

anxiolytics: term used to describe the antianxiety drugs

aplastic anemia: a blood disorder caused by damage to the bone marrow resulting in a marked reduction in the number of red blood cells and some white blood cells

arrhythmia: abnormal heart rate or rhythm; also called dysrhythmia

assessment: the collection of subjective and objective data

asthenia: weakness; loss of strength

ataxia: unsteady gait; muscular incoordination

atherosclerosis: a disease characterized by deposits of fatty plaques on the inner walls of arteries

atrial fibrillation: quivering of the atria of the heart

attenuate: weaken

aura: sense preceding a sudden attack, as in the aura that occurs before a convulsion

auscultation: the process of listening for sounds within the body

autonomic nervous system: a division of the peripheral nervous system concerned with functions essential to the life of the organism and not consciously controlled (ie, blood pressure, heart rate, gastrointestinal activity)

azotemia: retention of excessive amounts of nitrogenous compounds in the blood caused by failure of the kidney to remove urea from the blood

B

diocidical: a drug or agent that destroys or kills bacteria

diostatic: a drug or agent that slows or retards the multiplication of bacteria

bigeminy: an irregular pulse rate consisting of two beats followed by a pause before the next two paired beats

biliary colic: pain caused by the pressure of passing gallstones

blepharospasm: a twitching or spasm of the eyelid
blood-brain barrier: ability of the nervous system to prohibit large and potentially harmful molecules from crossing into the brain
bone marrow suppression: a decreased production of all blood cells
booster: an immunogen injected following a specified interval; often after the primary immunization to stimulate and sustain the immune response
brachial plexus: a network of spinal nerves affecting the arm, forearm, and the hand
bradycardia: slow heart rate, usually at a rate below 60 beats per minute
bronchospasm: spasm or constriction of the bronchi resulting in difficulty breathing
bulla: blister or skin vesicle filled with fluid
bursa: pad-like sac found in connecting tissue usually located in the joint area

candidiasis: infection of the skin or mucous membrane with the species Candida
cardiac output: amount of blood discharged from the left or right ventricle per minute
catabolism: tissue-depleting process
catalyst: substance that accelerates a chemical reaction without itself undergoing a change
central nervous system: one of two main divisions of the nervous system consisting of the brain and spinal cord
cervical mucorrhea: increased cervical discharge
chelating agent: a substance that selectively and chemically binds the ion of a metal to itself, thus aiding in the elimination of the metallic ion from the body
cheilosia: cracking of the edges of the lips
chemoreceptor trigger zone: a group of nerve fibers located on the surface of the fourth ventricle of the brain that, when stimulated, results in vomiting
chemotherapy: drug therapy with a chemical, often used when referring to treatment with an antineoplastic drug
cholesterol: a fat-like substance produced mostly in the liver of animals
chorea: continuous rapid, jerky, involuntary movements
choreiform movements: involuntary muscular twitching of the limbs or facial muscles
chylomicrons: small particles of fat in the blood
chinonism: quinine toxicity or poisoning
conjunctivitis: inflammation of the conjunctiva (mucous membrane lining the inner surfaces of the eye)
convulsions: paroxysm (occurring suddenly) of involuntary muscular contractions and relaxations
Crohn’s disease: inflammation of the terminal portion of the ileum
cross-allergenicity: allergy to drugs in the same or related groups
cross-sensitivity: see cross allergenicity
crystalluria: formation of crystals in the urine
cumulative drug effect: occurs when the body is unable to metabolize and excrete one dose of a drug before the next dose is given
Cushing’s syndrome: a disease caused by the overproduction of endogenous glucocorticoids
cyanosis: bluish, grayish, or dark purple discoloration of the skin due to abnormal amounts of reduced hemoglobin in the blood
cycloplegia: paralysis of the ciliary muscle resulting in an inability to focus the eye
cytomegalovirus (CMV): any of a group of herpes viruses infecting man, monkeys, or rodents; the human CMV is found in the salivary glands and causes cytomegalic inclusion disease
cystinuria: the presence of cystine, an amino acid, in the urine

deciduous: removal of all foreign material and dead or damaged tissue from a wound or infected lesion
decaliter: 10 liters or 10,000 mL
delirium tremens: signs and symptoms of withdrawal from a drug or chemical including tremors, weakness, anxiety, restlessness, excessive perspiration, nausea, and vomiting
dermis: a layer of skin immediately below the epidermis
diabetes insipidus: a disease resulting in the failure of the pituitary to secrete vasopressin or from the surgical removal of the pituitary gland
diaphoresis: increased sweating or perspiration
digitalization: administration of digitalis at intervals to produce and maintain a therapeutic blood level
diluent: a fluid that dilutes
dioplopia: double vision
diuretic drug: drug that produces urine secretion
dyskinesia: impairment of voluntary movement
dyspnea: labored or difficult breathing
dystonia: prolonged muscle contractions that may cause twisting and repetitive movements of abnormal posture
dysuria: painful or difficult urination

edema: accumulation of excess water in the body
emetic: drug that induces vomiting
endogenous: normally occurring within the organism or in the community
endorphins: naturally occurring analgesic produced by the body in response to certain stimuli (ie, exercise)
enkephalins: neurotransmitter within the brain involved with pain perception, mood, movement, and behavior
epidermis: outermost layer of the skin
epidural: outside or above the dura mater
epilepsy: a permanent, recurring seizure disorder
epiphysis: a center of ossification (conversion of tissue to bone) at each extremity of long bone
epistaxis: nosebleed
erythrocytes: red blood cells; one of several formed elements in the blood
Escherichia coli: a nonpathogenic colon bacillus; when found outside of the colon may cause infection
estrogens: female hormones
euthyroid: normal thyroid function
evaluation: a decision-making process determining the effectiveness of nursing action or intervention
exacerbation: increase in severity
exfoliative dermatitis: reddish rash in which scaling occurs following the erythema
exogenous: normally occurring outside of the organism or community
expectorant: drug that aids in raising thick, tenacious mucus from the respiratory tract
extrapulmonary: occurring outside of the respiratory systems (ie, lungs)
extrapyramidal effects: a group of adverse reactions occurring on the extrapyramidal portion of the nervous system causing abnormal muscle movements, especially akathisia and dystonia
extravasation: escape of fluid from a blood vessel into surrounding tissue

F
fat soluble: dissolves in fat
febrile: related to fever (elevated body temperature)
fibrolytic: term used to describe a drug that dissolves clots already formed within the vessel walls

G
germinicide: an agent that kills bacteria
gingival hyperplasia: overgrowth of gum tissue
gingivitis: inflammation of the gums
glaucoma: a group of diseases of the eye characterized by increased intraocular pressure; results in changes within the eye, visual field defects, and eventually blindness (if left untreated)
globulin: proteins that are insoluble in water and present in the plasma
glossitis: inflammation of the tongue
glucagon: hormone secreted by the alpha cells of the pancreas that increase the concentration of glucose in the blood
goiter: enlargement of the thyroid gland causing a swelling in the front part of the neck, usually caused by a lack of iodine in the diet
gonadotropin: hormone that stimulates the sex glands (gonads)
gonad: glands responsible for sexual activity and characteristics
granulocytopenia: a reduction or decrease in the number of granulocytes (a type of white blood cell)
gynecomastia: breast enlargement in the male

H
habituation: a desire to continually use a drug or chemical for the desired effect with no physical dependence but some psychological dependence
hallucinogen: drug capable of producing a state of delirium characterized by visual or sensory disturbances
helminthiasis: invasion by helminths (worms)
hemolytic anemia: disorder characterized by chronic premature destruction of red blood cells
herb: plant used in medicine or as seasoning
high-density lipoproteins (HDL): macromolecules that carry cholesterol from the body cells to the liver to be excreted
hirsutism: excessive growth of hair or hair growth in unusual places, usually in women
histamine: a substance found in various parts of the body (ie, liver, lungs, intestines, skin) and produced in excess in response to a substance to which the body is sensitive
humoral immunity: antibody-mediated immune response of the body
hyperglycemia: high blood glucose (sugar) level
hyperinsulinism: elevated levels of insulin in the body
hyperkalemia: increase in potassium levels in the blood
hyperlipidemia: an increase in the lipids in the blood
hypersensitivity reaction: allergic reaction to a drug or other substance
hypertension: high blood pressure
hypnotic: drug that induces sleep
hypoglycemia: low blood glucose (sugar) level
hypoinsulinism: low levels of insulin in the body
hypokalemia: low blood potassium level
hyponatremia: low blood sodium level
hypertension, orthostatic: a decrease in blood pressure occurring after standing in one place for an extended period
hypertension, postural: a decrease in blood pressure after a sudden change in body position
hypoxia: inadequate oxygen at the cellular level

I
idiosyncrasy: unusual or abnormal drug response
immunocompromised: having a immune system incapable of fighting an infection
implementation: the carrying out of a plan of action
infiltration: the collection of fluid into tissue
inotropic: affecting the force of muscular contractions
intraocular pressure: the pressure within the eye
intrinsic factor: substance produced by the cells in the stomach and necessary for the absorption of vitamin B₁₂
iritis: inflammation of the iris of the eye

J
jaundice: yellow discoloration of the skin

K
keratolyte: an agent that removes excessive growth of the epidermis (top layer of skin)
ketoacidosis: a type of metabolic acidosis caused by an accumulation of ketone bodies in the blood
ketonuria: presence of ketones in the blood

L
laryngospasm: spasm of the larynx resulting in dyspnea and noisy respirations
lethargic: sluggish, difficult to rouse
leukopenia: a decrease in the number of leukocytes (white blood cells)
lipids: a group of fats or fat-like substances
lipodystrophy: atrophy of subcutaneous fat
lipoproteins: a macromolecule consisting of a lipid (fat) and protein; the method by which fats are transported in the blood
low-density lipoproteins (LDL): macromolecules that carry cholesterol from the liver to the body cells
lumen: inside diameter, the space or opening within an artery
lupus erythematosus: A chronic inflammatory connective tissue disease affecting the skin, joints, kidneys, nervous system, and mucous membranes. A butterfly rash or erythema may be seen on the face, particularly across the nose

M
malaise: discomfort, uneasiness
megacolon: dilatation and hypertrophy of the colon
megaloblastic anemia: anemia characterized by the presence of large, abnormal, immature erythrocytes circulating in the blood
melasma: discoloration of the skin
melena: blood in the stools
merozoites: cells formed as the result of asexual reproduction
methemoglobinemia: clinical condition in which more than 1% of hemoglobin in the blood has been oxidized to the ferric form
micturition: voiding of urine
miosis: constriction of the pupils
mucolytic: drug that loosens and thins respiratory secretions (lessens the viscosity of the secretions)
myasthenia gravis: condition characterized by weakness and fatigability of the muscles
myotic: pertaining to a fungus or fungal infection
mydriasis: dilation of the pupil
myocardial infarction: heart attack
myopia: nearsightedness
myxedema: condition caused by hypothyroidism or deficiency of thyroxine and characterized by swelling of the face, periorbital tissues, hands, and feet.

N
narcolepsy: a chronic disorder that results in recurrent attacks of drowsiness and sleep during daytime
necrosis: death of tissue (as adjective, necrotic)
nephrotoxic: harmful to the kidney
nephrotoxicity: damage to the kidneys by a toxic substance
neurohypophysis: posterior lobe of the pituitary gland
neuroleptic: drug that causes an altered state of consciousness (ie, antipsychotic)
neuromuscular blockade: acute muscle paralysis and apnea
neurotoxicity: damage to the nervous system of a toxic substance
neurotransmitter: chemical substances released at the nerve ending that facilitate the transmission of nerve impulses
neutropenia: abnormally small number of neutrophil cells (type of white blood cell)
nonsteroidal: not a steroid
nursing process: a framework for nursing action, consisting of a series of problem-solving steps, that helps members of the health care team provide effective and consistent patient care
nystagmus: an involuntary and constant movement of the eyeball

O
objective data: information obtained by means of a physical assessment or physical examination
oliguria: a decrease in urinary output
ophthalmic: pertaining to the eye
opportunistic infection: infection resulting from microorganisms commonly found in the environment, which normally do not cause an infection unless there is an impaired immune system
orthostatic hypotension: see hypotension, orthostatic
osteomalacia: a softening of the bones
osteoporosis: a loss of calcium from the bones, resulting in a decrease in bone density
otic: pertaining to the ear
ototoxic: harmful to the ear
ototoxicity: damage to the organs of hearing by a toxic substance
overt: not hidden, clearly evident
oxytocic: agent that stimulates contractions of the uterus resulting in labor

P
palliative: therapy designed to treat symptoms, not to produce a cure
pancytopenia: a reduction in all cellular elements of the blood
paralytic ileus: paralysis of the bowel resulting in lack of movement of the bowel contents
parasite: an organism living in or on another organism (the host) without contributing to the survival or well-being of the host
parasympathetic nervous system: part of the autonomic nervous system concerned with conserving body energy (ie, slowing the heart rate, digesting food, and eliminating waste)
parenteral: administration of a substance, such as a drug, by any route other than the oral route
paresthesia: an abnormal sensation such as numbness, tingling, prickling, or heightened sensitivity
parkinsonism: referring to the symptoms of Parkinson's disease (ie, fine tremors, slowing of the voluntary movements, and muscular weakness)
passive immunity: a type of immunity occurring from the administration of ready-made antibodies from another individual or animal
pathogenic: disease producing
peripheral: pertaining to the outward surface; away from the center
petechiae: fine purple or red spots that appear on the skin as a result of pinpoint hemorrhages within the outer layers of the skin
phenochromocytoma: tumor of the adrenal medulla characterized by hypersecretion of epinephrine and norepinephrine
phlebitis: inflammation of a vein
phenylketonuria (PKU): a congenital disease due to a defect in the metabolism of phenylalanine (an amino acid); results from the lack of an enzyme necessary for the conversion of phenylalanine into tyrosine; untreated, the condition leads to mental retardation
photophobia: an aversion to or intolerance of light
photosensitivity: exaggerated sunburn reaction when the skin is exposed to sunlight or ultraviolet light
physical dependence: compulsive need to use a substance repeatedly to avoid withdrawal symptoms
plasma expanders: intravenous solutions used to expand plasma volume with shock due to burns, hemorrhage, or other trauma
polydipsia: excessive thirst
polyphagia: eating large amounts of food
polypharmacy: taking a large number of drugs (may be prescribed or over-the-counter drugs)
polyposis: numerous polyps
postural hypotension: see hypotension, postural
prepubertal: before puberty
progesterone: a female hormone produced by the corpus luteum that works in the uterus (along with estrogen) to prepare the uterus for possible conception
progestins: natural and synthetic progestones
prophylaxis: prevention
prostaglandins: a fatty acid derivative found in almost every tissue of the body and body fluid that affects the uterus and other smooth muscles; also thought to increase the sensation of peripheral pain receptors to painful stimuli
prostatic hypertrophy: abnormal enlargement of the prostate gland
protein substrates: amino acids essential to life
pruritus: itching
pseudomembranous colitis: a severe, life-threatening form of diarrhea
psychological dependence: compulsion to use a substance to obtain a pleasurable experience
ptosis: drooping of the upper eyelid
purpura: condition characterized by various degrees of hemorrhage into the skin and/or mucous membranes producing ecchymoses (bruises) and petechiae (small red patches) on the skin
rheumatoid arthritis: a type of arthritis marked by inflammation, degeneration, and derangement of the joints and related structures resulting in contractures and deformities of the joints
rhinitis: inflammation of the nasal passages resulting in increased nasal secretions

S
sedative: a drug producing a relaxing, calming effect
somatotrophic hormone: growth hormone produced by the anterior pituitary gland
somnolence: prolonged drowsiness; sleepiness
soporific: substance or procedure that causes sleep
sprue: a disease characterized by weakness, anemia, weight loss, and malabsorption of essential nutrients
Standard Precautions: see Universal Precautions
status epilepticus: an emergency situation characterized by continual seizure activity
Stevens-Johnson syndrome: fever, cough, muscular aches and pains, headache, and lesions of the skin, mucous membranes, and eyes. The lesions appear as red wheals or blisters, often starting on the face, in the mouth, or on the lips, neck, and extremities.
stomatitis: inflammation of the mouth
striae: lines or bands elevated above or depressed below surrounding tissue, or differing in color or texture
subjective data: information supplied by the patient or family
sublingual: under the tongue
sulfonylurea: a type of drug used to lower blood sugar in persons with non-insulin-dependent diabetes
superinfection: an overgrowth of bacterial or fungal microorganism not affected by the antibiotic being administered
sympathomimetic: acting like the sympathetic nervous system
synergistic: a drug interaction occurring when two drugs interact to produce an effect that is greater than the sum of their separate actions

T
tachycardia: heart rate above 100 beats/minute
tardive dyskinesia: rhythmic, involuntary movements of the tongue, face, mouth, jaw, and sometimes the extremities
testosterone: the most prominent male sex hormone that acts to stimulate development of the male reproductive organ and the secondary sex characteristics
tetany: nervous condition characterized by sharp flexion of the wrist and ankle joints, muscle twitching, cramps, and possible convulsions, usually caused by abnormal levels of calcium, vitamin D, and alkalosis
thrombocytopenia: low platelet count
thrombus: a blood clot (pl. thrombi)
thyroid storm: see thyrotoxicosis
thrombocytopenia: low number of the platelets in the blood
thyrotoxicosis: severe hyperthyroidism that is characterized by symptoms such as high fever, extreme tachycardia, and altered mental status (also called thyroid storm)
tinnitus: ringing in the ears
tolerance: decreased response to a drug, usually requiring an increase in the dosage to give the desired effect

tonic-clonic seizure: generalized seizure activity consisting of alternate contraction (tonic) and relaxation of muscles (clonic)

toxicity: poisonous or harmful

toxoid: an attenuated toxin that is capable of stimulating the formation of antitoxins

transient ischemic attack (TIA): temporary interference with blood supply to the brain causing symptoms related to the portion of the brain affected (ie, temporary blindness, aphasia, dizziness, numbness, difficulty swallowing or paresthesias); may last from a few moments to several hours, after which no residual neurologic damage is evident

trigeminy: an irregular pulse rate consisting of three beats followed by a pause before the next three beats

tyramine: substance found in most cheeses and in beer, bean pods, yeast, wine, and chicken liver; individuals taking the antidepressant MAOIs and eating foods containing tyramine may experience severe hypertension

urticaria: hives; itchy wheals on the skin resulting from contact with or ingestion of an allergic substance or food

uveitis: a nonspecific term for any intraocular inflammatory disorder

vaccine: substance with either weakened or killed antigens developed for the purpose of creating resistance to disease

vasodilatation: an increase in the size of the blood vessels, which when widespread results in a rise in blood pressure

venous: pertaining to the veins

vertigo: a feeling of a spinning or rotation-type motion

vitamin: organic substance needed by the body in small amounts for normal growth and nutrition

von Willebrand's disease: a congenital bleeding disorder manifested at an early age by epistaxis and easy bruising; symptoms usually decrease in severity with age

Universal Precautions: guidelines set forth by the Centers for Disease Control (CDC) to control the spread of disease

water soluble: dissolves in water
ADVICE ABOUT VOLUNTARY REPORTING

Report adverse experiences with:
- medications (drugs or biologics)
- medical devices (including in-vitro diagnostics)
- special nutritional products (dietary supplements, medical foods, infant formulas)
- cosmetics
- medication errors

Report product problems — quality, performance or safety concerns such as:
- suspected contamination
- questionable stability
- defective components
- poor packaging or labeling
- therapeutic failures

Report SERIOUS adverse events. An event is serious when the patient outcome is:
- death
- life-threatening (real risk of dying)
- hospitalization (initial or prolonged)
- disability (significant, persistent or permanent)
- congenital anomaly
- required intervention to prevent permanent impairment or damage

Report even if:
- you're not certain the product caused the event
- you don't have all the details

How to report:
- just fill in the sections that apply to your report
- use section C for all products except medical devices
- attach additional blank pages if needed
- use a separate form for each patient
- report either to FDA or the manufacturer (or both)

Confidentiality: The patient's identity is held in strict confidence by FDA and protected to the fullest extent of the law. FDA will not disclose the reporter's identity in response to a request from the public, pursuant to the Freedom of Information Act. The reporter's identity, including the identity of a self-reporter, may be shared with the manufacturer unless requested otherwise.

If your report involves a serious adverse event with a device and it occurred in a facility outside a doctor's office, that facility may be legally required to report to FDA and/or the manufacturer. Please notify the person in that facility who would handle such reporting.

Important numbers:
- 1-800-FDA-0178 to FAX report
- 1-800-FDA-1088 to report by phone or for more information
- 1-800-822-7967 for a VAERS form for vaccines

To Report via the Internet:
https://www.accessdata.fda.gov/scripts/medwatch/

---

The public reporting burden for this collection of information has been estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Deemed Reports Clearance Office
Office of the Secretary
5600 Fishers Lane
Rockville, MD 20857

The public reporting burden for this collection of information has been estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Deemed Reports Clearance Office
Office of the Secretary
5600 Fishers Lane
Rockville, MD 20857

---

MEDWATCH
The FDA Safety Information and Adverse Event Reporting Program
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20852-9787
<table>
<thead>
<tr>
<th>COMMON NAME (S)</th>
<th>SCIENTIFIC NAME</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>SIGNIFICANT CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aloe vera</td>
<td>Aloe vera</td>
<td>Inhibits infection and promotes healing of minor burns and wounds</td>
<td>None significant if used as directed; may cause burning sensation in wound</td>
<td>Rare reports of delayed healing when used in the gel form on a wound. Taken internally, aloe gel may have laxative effect.</td>
</tr>
<tr>
<td>Billberry</td>
<td>Vaccinium myrtillus</td>
<td>Vision enhancement and eye health, microcirculation, spider veins and varicose veins, capillary strengthening before surgery</td>
<td>No adverse effects have been reported in clinical studies.</td>
<td>None significant.</td>
</tr>
<tr>
<td>Black Cohosh, (black snakeroot, squawroot)</td>
<td>Cimicifuga racemosa</td>
<td>Management of some symptoms of menopause and as an alternative to hormone replacement therapy; may be beneficial for hypercholesterolemia or peripheral vascular disease</td>
<td>Overdose causes nausea, dizziness, nervous system and visual disturbances, decreased pulse rate and increased perspiration</td>
<td>Should not be used during pregnancy. Possible interactions with hormone therapy.</td>
</tr>
<tr>
<td>Chamomile</td>
<td>Matricaria chamomilla</td>
<td>As a tea for gastrointestinal disturbances, as a sedative, and as an anti-inflammatory agent</td>
<td>Possible contact dermatitis and, in rare instances, anaphylaxis</td>
<td>Chamomile is a member of the ragweed family and those allergic to ragweed should not take the herb.</td>
</tr>
<tr>
<td>Chondroitin</td>
<td>Chondroitin sulfate, chondroitin sulfuric acid, chonsurid</td>
<td>Arthritis</td>
<td>None significant if used as directed</td>
<td>Because chondroitin is concentrated in cartilage, theoretically it produces no toxic or teratogenic effects.</td>
</tr>
<tr>
<td>Cranberry</td>
<td>Vaccinium macrocarpon</td>
<td>Urinary tract infection (UTI)</td>
<td>Large doses can produce gastrointestinal symptoms (ie, diarrhea)</td>
<td>None significant.</td>
</tr>
<tr>
<td>Echinacea (American coneflower, black susans)</td>
<td>Echinacea angustifolia</td>
<td>Prevents and shortens symptoms and duration of upper respiratory Infections (URIs) including colds</td>
<td>Rare. Nausea and mild gastrointestinal (GI) upsets</td>
<td>Should not be used by individuals with autoimmune diseases such as tuberculosis, collagenosis, multiple sclerosis, AIDS, and HIV infection.</td>
</tr>
</tbody>
</table>

(continued)
<table>
<thead>
<tr>
<th>COMMON NAME (S)</th>
<th>SCIENTIFIC NAME</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>SIGNIFICANT CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ephedra (sea grape, mah-huang, yellow horse)</td>
<td>ephedra sinica</td>
<td>Relieves colds, improves respiratory function, headaches, diuretic effects</td>
<td>Skin eruptions, hypertension, irregular heart rate, psychosis</td>
<td>Ephedra should only be used after consulting with the physician. Many restrictions apply and the herb can cause serious reactions. Do not use with cardiac glycosides, monoamine oxidase inhibitor halothane, guanethidine, (MAOIs) or oxytocin. Do not use with St. John’s wort or in weight loss formulas.</td>
</tr>
<tr>
<td>Garlic</td>
<td>Allium sativum</td>
<td>Lowers blood sugar, cholesterol, and lipids</td>
<td>May cause abnormal blood glucose levels</td>
<td>Increased risk of bleeding in patients taking the coumarins, salicylates, or antiplatelet drugs.</td>
</tr>
<tr>
<td>Ginger (ginger root, black ginger)</td>
<td>Zingiber officinale</td>
<td>Antiemetic, cardiotonic, antioxidant, anti-inflammatory, GI disturbances, lower cholesterol, prophylaxis for nausea and vomiting, colic, bronchitis</td>
<td>Excessive doses may cause CNS depression and interfere with cardiac functioning or antiplatelet activity.</td>
<td>Theoretically, ginger could enhance the effects of the antiplatelet drugs, such as coumarin.</td>
</tr>
<tr>
<td>Ginkgo (maiden hair tree, kew tree)</td>
<td>Ginkgo biloba</td>
<td>Raynauds disease, cerebral insufficiency, anxiety, stress, tinnitus, dementias, circulatory problems, asthma</td>
<td>Rare if used as directed; possible effects include headache, dizziness, heart palpitations, GI effects, rash, allergic dermatitis</td>
<td>Do not take with antidepressant drugs, such as the MAOIs, or the antiplatelet drugs such as coumarin, unless advised to do so by the primary care provider.</td>
</tr>
<tr>
<td>Ginseng</td>
<td>Panax quinquefolius, Panax ginseng</td>
<td>Popular but un-proven uses: Anti-neoplastic, enhances immune function, improves cardiovascular or CNS function</td>
<td>Most common: nervousness, excitation, hypoglycemia; rare: diffuse mammary nodularity, vaginal bleeding</td>
<td>Taking ginseng in combination with stimulants such as caffeine is not advised. Do not use for longer than 3 months. (Some herbalists recommend use for 1 month followed by nonuse for 2 months.)</td>
</tr>
<tr>
<td>Goldenseal</td>
<td>Hydrastis canadensis</td>
<td>Antiseptic for skin (topical), astringent for mucous membranes (mouthwash), wash for inflamed eyes, sinus infections, peptic ulcers, colitis, gastritis</td>
<td>Large doses may cause dry or irritated mucous membranes and injury to the gastrointestinal system; may reduce the beneficial bacteria in the intestines.</td>
<td>Should not be taken for more than 3-7 days.</td>
</tr>
<tr>
<td>Glucosamine (chitosamine) Green tea</td>
<td>2-Amino-2-deoxyglucose, Camellia sinensis</td>
<td>Antiarthritic in osteoarthritis, reduces cancer, lowers lipid levels, helps prevent dental caries, antimicrobial and antioxidative effects</td>
<td>Well-tolerated</td>
<td>Contains caffeine (may cause mild stimulant effects such as anxiety, nervousness, heart irregularities, restlessness, insomnia, and digestive irritation).</td>
</tr>
</tbody>
</table>

Select Herbs and Natural Products Used for Medicinal Purposes (Continued)
## Select Herbs and Natural Products Used for Medicinal Purposes (Continued)

<table>
<thead>
<tr>
<th>COMMON NAME (S)</th>
<th>SCIENTIFIC NAME</th>
<th>USES</th>
<th>ADVERSE REACTIONS</th>
<th>SIGNIFICANT CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kava (kava, kava-kava, awa yangona)</td>
<td>Piper methysticum</td>
<td>Mild to moderate anxiety and as a sedative</td>
<td>Scaly skin rash, disturbances in visual accommodation, habituation</td>
<td>Limit use to no more than 3 months.</td>
</tr>
<tr>
<td>Lemon balm (balm, melissa, sweet balm)</td>
<td>Melissa officinalis</td>
<td>Graves’ disease, sedative, antisPasmodic, cold sores (topical)</td>
<td>None significant.</td>
<td>None significant.</td>
</tr>
<tr>
<td>Melatonin</td>
<td>Passiflora incarnata</td>
<td>Promotes sleep, treatment for pain and nervous exhaustion</td>
<td>None if used as directed. Excessively large doses may cause CNS depression.</td>
<td>May interact with anticoagulants and MAOIs.</td>
</tr>
<tr>
<td>Passion Flower (passion fruit, granadilla, water lemon, apricot vine)</td>
<td>Serenoa repens</td>
<td>Symptoms of benign prostatic hyperplasia</td>
<td>Generally well-tolerated; occasional gastrointestinal effects</td>
<td>May interact with hormones such as oral contraceptive drugs and hormone replacement therapy.</td>
</tr>
<tr>
<td>Saw palmetto (cabbage palm, fan palm, scrub palm)</td>
<td>Hypericum perforatum</td>
<td>Antidepressant and antiviral</td>
<td>Usually mild. May cause dry mouth, dizziness, constipation, other GI symptoms, photosensitivity</td>
<td>May decrease efficacy of theophylline, warfarin, and digoxin; use with other prescriptions is not recommended.</td>
</tr>
<tr>
<td>St. John’s wort (Klamath weed, goatweed, rosin rose)</td>
<td>Melaleuca alternifolia</td>
<td>Topical antimicrobial</td>
<td>Contact dermatitis</td>
<td>For topical use only; do not take orally.</td>
</tr>
<tr>
<td>Tea tree oil</td>
<td>Valeriana officinalis</td>
<td>Restlessness, sleep disorders</td>
<td>Rare if used as directed.</td>
<td>May interact with the barbiturates (eg, phenobarbital), the benzodiazepines (eg, diazepam) and the opiates, (eg, morphine).</td>
</tr>
<tr>
<td>Willow bark (weidenrinde, white willow, purple osier willow, crack willow)</td>
<td>Salix alba, S. purpurea, S. fragilis</td>
<td>Analgesic</td>
<td>Adverse reactions are those associated with the salicylates</td>
<td>Do not use with aspirin or other NSAIDs. Do not use in patients with peptic ulcers and other medical conditions in which the salicylates are contraindicated.</td>
</tr>
</tbody>
</table>
# USP Medication Errors Reporting Program

Presented in cooperation with the Institute for Safe Medication Practices

The USP Practitioners' Reporting Network™ is an FDA MEDWATCH partner

<table>
<thead>
<tr>
<th>ACTUAL ERROR</th>
<th>POTENTIAL ERROR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Please describe the error: Include sequence of events, personnel involved, and work environment (e.g., code situation, change of shift, short staffing, no 24-hr pharmacy, floor stock). If more space is needed, please attach separate page.</td>
<td></td>
</tr>
</tbody>
</table>

Was the medication administered to or used by the patient? □ No □ Yes  
Date and time of event: ____________________________

What type of staff or health care practitioner made the initial error? ____________________________

Describe outcome (e.g., death, type of injury, adverse reaction): ____________________________

If the medication did not reach the patient, describe the intervention: ____________________________

Who discovered the error? ____________________________

When and how was error discovered? ____________________________

Where did the error occur (e.g., hospital, outpatient or retail pharmacy, nursing home, patient's home)? ____________________________

Was another practitioner involved in the error? □ No □ Yes  
If yes, what type of practitioner? ____________________________

Was patient counseling provider? □ No □ Yes  
If yes, before or after error was discovered? ____________________________

If a product was involved, please complete the following:

<table>
<thead>
<tr>
<th>Product #1</th>
<th>Product #2</th>
</tr>
</thead>
</table>

| Brand name of product involved | | |
| Generic name | | |
| Manufacturer | | |
| Labeler (if different from mfr.) | | |
| Dosage form | | |
| Strength/concentration | | |
| Type and size of container | | |
| NDC number | | |

If available, please provide relevant patient information: [age, gender, diagnosis, etc.]. Patient identification not required.

Reports are most useful when relevant materials such as product label, copy of prescription/order, etc. can be reviewed.

Can these materials be provided? □ No □ Yes  
If yes, please specify: ____________________________

Suggest any recommendations you have to prevent recurrence of this error or describe policies or procedures you have instituted to prevent future similar errors.

A copy of this report is routinely sent to the Institute for Safe Medication Practices (ISMP), to the manufacturer/labeler, and to the Food and Drug Administration (FDA). USP may release my identity to: (check boxes that apply)

□ ISMP □ The manufacturer and/or labeler as listed above □ FDA □ Other persons requesting a copy of this report □ Anonymous to all

Your name and title: ____________________________

Your facility name, address, and ZIP: ____________________________

Telephone number (include area code): ____________________________

Signature: ____________________________

Date: ____________________________

Return to the attention of:  
Diane D. Coumas, R.Ph.  
USP PRN  
12601 Twinbrook Parkway  
Rockville, MD 20852-1790  

Call Toll Free: 800-23-ERROR (800-233-7767) or FAX 301-816-8532  
USP home page: http://www.usp.org/prn  
Electronic reporting forms are available. Please call for additional information and/or your EPZ diskette.

Date Received by USP: ____________________________

File Access Number: ____________________________

Additional forms can be found in the USP DI Vol. 1 and Vol. 2B and in all monthly Updates.
MEDICATION ERRORS REPORTING PROGRAM

Medication Errors Do Occur

Medication errors can occur anywhere, any time along the drug therapy course, from prescribing through transcribing, dispensing, administering, and monitoring. An error can cause confusion, alarm, and frustration for the health care provider and for the patient. And YES, an error can even cause a death or injury to your patient. The causes of errors are many; for example, lack of product knowledge or training; poor communication; ambiguities in product names, directions for use, medical abbreviations, handwriting, or labeling; job stress; poor procedures or techniques; or patient misuse. Along this continuum, any health care professional may be the cause of or contribute to an actual or potential error.

A Safer Environment for Your Patients

It is important to recognize that health care providers learn from medication errors. By sharing your experience through the nationwide USP Medication Errors Reporting (MER) Program you help your colleagues to gain an understanding of why errors occur and how to prevent them. You can also have a positive impact on the quality of patient care and influence drug standards and information. When others are informed about an error, the chance of recurrence may be lessened. Education regarding medication errors assists health care professionals to avoid errors by recognizing the circumstances and causes of actual and potential errors.

Easy Access

Just call 800-233-7767 to reach a USP health care professional, who will take your report and respond to your concerns. Reports may also be submitted in writing or faxed. All reports are forwarded to the Food and Drug Administration, the product manufacturer/labeler when appropriate, the ISMP, and the USP Divisions of Standards and Information Development. If you wish to remain anonymous to any of these sources, the USP will act as your intermediary in all correspondence. While including your identity is optional, it does allow for appropriate follow up with you to discuss your observations or provide feedback.

USP: A Partner in MedWatch

The USP Practitioners' Reporting Network is a partner in MedWatch, the FDA's medical products reporting program. As a partner, USP PRN contributes to the FDA's efforts to protect the public health by helping to identify serious adverse events for the agency. This means that your reported information is shared with the FDA on a daily basis, or immediately if necessary.

The USP PRN® is designed to collect experiences and observations from health care providers through four separate reporting programs:

- The USP Drug Product Problem Reporting Program
- The USP Medication Errors Reporting Program
- The USP Drug Product Problem Reporting Program for Radiopharmaceuticals
- The USP Veterinary Practitioners' Reporting Program

The Institute for Safe Medication Practices, the Society of Nuclear Medicine, and the American Veterinary Medical Association cooperate in presenting the USP PRN.

Your Input Could Make the Difference!

USP PRN...CALL US WHEN YOU NEED US.

U.S. Pharmacopeia
12601 Twinbrook Parkway,
Rockville, MD 20852-1790

BUSINESS REPLY MAIL
FIRST-CLASS MAIL PERMIT NO 39 ROCKVILLE MD
POSTAGE WILL BE PAID BY ADDRESSEE:
DIANE D COUSINS RPh
THE USP PRACTITIONERS' REPORTING NETWORK
12601 TWINBROOK PARKWAY
ROCKVILLE MD 20897-5211

NO POSTAGE NECESSARY IF MAILED IN THE UNITED STATES
### Metric–Apothecary Equivalents and Conversions

#### Liquid Measurements

<table>
<thead>
<tr>
<th>METRIC</th>
<th>APPROXIMATE APOTHECARY EQUIVALENTS</th>
<th>APPROXIMATE HOUSEHOLD EQUIVALENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>1000 mL</td>
<td>32 fluid ounces (1 quart)</td>
<td>1 quart</td>
</tr>
<tr>
<td>500 mL</td>
<td>16 fluid ounces (1 pint)</td>
<td>1 pint</td>
</tr>
<tr>
<td>250 mL</td>
<td>8 fluid ounces</td>
<td>1 measuring cup</td>
</tr>
<tr>
<td>30 mL</td>
<td>1 fluid ounce</td>
<td>2 tablespoonfuls</td>
</tr>
<tr>
<td>15 mL</td>
<td>4 fluid drams</td>
<td>1 tablespoonful</td>
</tr>
<tr>
<td>4 or 5 mL</td>
<td>1 fluid dram</td>
<td>1 teaspoonful</td>
</tr>
<tr>
<td>1 mL*</td>
<td>15 or 16 minims</td>
<td>1 drop</td>
</tr>
<tr>
<td>0.06 mL</td>
<td>1 minim</td>
<td></td>
</tr>
</tbody>
</table>

*1 milliliter (mL) is the approximate equivalent of 1 cubic centimeter (cc).

#### Weights

<table>
<thead>
<tr>
<th>METRIC</th>
<th>APPROXIMATE APOTHECARY EQUIVALENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 g</td>
<td>1 ounce</td>
</tr>
<tr>
<td>15 g</td>
<td>4 drams</td>
</tr>
<tr>
<td>4 g</td>
<td>60 grams (1 dram)</td>
</tr>
<tr>
<td>1 g</td>
<td>15 or 16 grains</td>
</tr>
<tr>
<td>300 mg</td>
<td>5 grains</td>
</tr>
<tr>
<td>60 mg</td>
<td>1 grain</td>
</tr>
<tr>
<td>30 mg</td>
<td>½ grain</td>
</tr>
<tr>
<td>10 mg</td>
<td>½ grain</td>
</tr>
<tr>
<td>6 mg</td>
<td>¼ grain</td>
</tr>
<tr>
<td>1 mg</td>
<td>¹/₁₀ grain</td>
</tr>
<tr>
<td>0.6 mg</td>
<td>¹/₂₀₀ grain</td>
</tr>
<tr>
<td>0.5 mg</td>
<td>¹/₂₅₀ grain</td>
</tr>
<tr>
<td>0.4 mg</td>
<td>¹/₃₀₀ grain</td>
</tr>
<tr>
<td>0.3 mg</td>
<td>¹/₄₀₀ grain</td>
</tr>
<tr>
<td>0.2 mg</td>
<td></td>
</tr>
<tr>
<td>0.1 mg</td>
<td></td>
</tr>
</tbody>
</table>
**Other Equivalents and Conversions**

**METRIC**
- 1 kg = 1000 g
- 1 g = 1000 mg
- 1 mg = 0.001 g
- 1 g = 0.001 mg
- 1 liter = 1000 mL

**WEIGHT**
- 1 kg = 2.2 pounds (lb)
- 1 lb = 453.6 g (0.454 kg)

**LENGTH**
- 1 cm = 0.39 in
- 1 inch = 2.54 cm

---

**Celsius (Centigrade) and Fahrenheit Temperatures**

<table>
<thead>
<tr>
<th>CELSIUS (CENTIGRADE)</th>
<th>FAHRENHEIT</th>
</tr>
</thead>
<tbody>
<tr>
<td>36.0</td>
<td>96.8</td>
</tr>
<tr>
<td>36.5</td>
<td>97.7</td>
</tr>
<tr>
<td>37.0</td>
<td>98.6</td>
</tr>
<tr>
<td>37.5</td>
<td>99.5</td>
</tr>
<tr>
<td>38.0</td>
<td>100.4</td>
</tr>
<tr>
<td>38.5</td>
<td>101.3</td>
</tr>
<tr>
<td>39.0</td>
<td>102.2</td>
</tr>
<tr>
<td>39.5</td>
<td>103.1</td>
</tr>
<tr>
<td>40.0</td>
<td>104.0</td>
</tr>
<tr>
<td>40.5</td>
<td>104.9</td>
</tr>
<tr>
<td>41.0</td>
<td>105.8</td>
</tr>
<tr>
<td>41.5</td>
<td>106.7</td>
</tr>
<tr>
<td>42.0</td>
<td>107.6</td>
</tr>
</tbody>
</table>

To convert degrees F to degrees C:
Subtract 32, then multiply by 5/9

To convert degrees C to degrees F:
Multiply by 9/5, then add 32
*2.5 cm = 1 inch; 1 kg = 2.2 lb.
Nomogram for Estimating Body Surface Area of Infants and Young Children

<table>
<thead>
<tr>
<th>HEIGHT</th>
<th>SURFACE AREA</th>
<th>WEIGHT</th>
</tr>
</thead>
<tbody>
<tr>
<td>feet</td>
<td>centimeters</td>
<td>in square meters</td>
</tr>
</tbody>
</table>

To determine the surface area of the patient, draw a straight line between the point representing his height on the left vertical scale to the point representing his weight on the right vertical scale. The point at which this line intersects the middle vertical scale represents the patient’s surface area in square meters. (Courtesy of Abbott Laboratories)
### Nomogram for Estimating Body Surface Area of Older Children and Adults

<table>
<thead>
<tr>
<th>HEIGHT</th>
<th>SURFACE AREA</th>
<th>WEIGHT</th>
</tr>
</thead>
<tbody>
<tr>
<td>feet</td>
<td>centimeters</td>
<td>in square meters</td>
</tr>
<tr>
<td>4'</td>
<td>120</td>
<td>.125</td>
</tr>
<tr>
<td>5'</td>
<td>145</td>
<td>.150</td>
</tr>
<tr>
<td>6'</td>
<td>160</td>
<td>.175</td>
</tr>
<tr>
<td>7'</td>
<td>175</td>
<td>.200</td>
</tr>
<tr>
<td>8'</td>
<td>180</td>
<td>.225</td>
</tr>
<tr>
<td>9'</td>
<td>190</td>
<td>.250</td>
</tr>
<tr>
<td>10'</td>
<td>195</td>
<td>.275</td>
</tr>
<tr>
<td>11'</td>
<td>200</td>
<td>.300</td>
</tr>
<tr>
<td>12'</td>
<td>210</td>
<td>.325</td>
</tr>
<tr>
<td>13'</td>
<td>220</td>
<td>.350</td>
</tr>
<tr>
<td>14'</td>
<td>230</td>
<td>.375</td>
</tr>
<tr>
<td>15'</td>
<td>240</td>
<td>.400</td>
</tr>
<tr>
<td>16'</td>
<td>250</td>
<td>.425</td>
</tr>
<tr>
<td>17'</td>
<td>260</td>
<td>.450</td>
</tr>
<tr>
<td>18'</td>
<td>270</td>
<td>.475</td>
</tr>
<tr>
<td>19'</td>
<td>280</td>
<td>.500</td>
</tr>
<tr>
<td>20'</td>
<td>290</td>
<td>.525</td>
</tr>
<tr>
<td>21'</td>
<td>300</td>
<td>.550</td>
</tr>
<tr>
<td>22'</td>
<td>310</td>
<td>.575</td>
</tr>
<tr>
<td>23'</td>
<td>320</td>
<td>.600</td>
</tr>
<tr>
<td>24'</td>
<td>330</td>
<td>.625</td>
</tr>
<tr>
<td>25'</td>
<td>340</td>
<td>.650</td>
</tr>
<tr>
<td>26'</td>
<td>350</td>
<td>.675</td>
</tr>
<tr>
<td>27'</td>
<td>360</td>
<td>.700</td>
</tr>
<tr>
<td>28'</td>
<td>370</td>
<td>.725</td>
</tr>
<tr>
<td>29'</td>
<td>380</td>
<td>.750</td>
</tr>
<tr>
<td>30'</td>
<td>390</td>
<td>.775</td>
</tr>
<tr>
<td>31'</td>
<td>400</td>
<td>.800</td>
</tr>
<tr>
<td>32'</td>
<td>410</td>
<td>.825</td>
</tr>
<tr>
<td>33'</td>
<td>420</td>
<td>.850</td>
</tr>
<tr>
<td>34'</td>
<td>430</td>
<td>.875</td>
</tr>
<tr>
<td>35'</td>
<td>440</td>
<td>.900</td>
</tr>
</tbody>
</table>

(Courtesy of Abbott Laboratories)
### Vaccine Adverse Event Reporting System (VAERS)

#### Patient Identity Kept Confidential

**Patient Name:**
- Last
- First
- M.I.
- Address
- City
- State
- Zip
- Telephone no. (___)

**Vaccine administered by (Name):**
- Responsible Physician
- Facility Name/Address
- City
- State
- Zip
- Telephone no. (___)

**Form completed by (Name):**
- Relation
  - Vaccine Provider
  - Patient/Provider to Patient
  - Manufacturer
  - Other
- Address (if different from patient or provider)
- City
- State
- Zip
- Telephone no. (___)

**Date Received:**

#### 1. State

#### 2. County where administered

#### 3. Date of birth

#### 4. Patient age

#### 5. Sex

#### 6. Date of completed form

#### 7. Describe adverse event(s) (symptoms, signs, time course) and treatment, if any

#### 8. Check all appropriate:
- Patient death (date)
- Life-threatening illness
- Required emergency room/doctor visit
- Required hospitalization
- Resulted in prolongation of hospitalization
- Resulted in permanent disability
- None of the above

#### 9. Patient recovered

#### 10. Patient's age

#### 11. Date of vaccination

#### 12. Relevant diagnostic tests/laboratory data

#### 13. Enter all vaccines given on date listed in no. 10

<table>
<thead>
<tr>
<th>Vaccine (type)</th>
<th>Manufacturer</th>
<th>Lot number</th>
<th>Route/Site</th>
<th>No. Previous Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 14. Any other vaccinations within 4 weeks prior to the date listed in no. 10

<table>
<thead>
<tr>
<th>Vaccine (type)</th>
<th>Manufacturer</th>
<th>Lot number</th>
<th>Route/Site</th>
<th>No. Previous Doses</th>
<th>Date given</th>
</tr>
</thead>
<tbody>
<tr>
<td>a.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 15. Vaccinated at:
- Private doctor's office/hospital
- Military hospital
- Public health clinic
- Other/Unknown

#### 16. Vaccine purchased with:
- Private funds
- Military funds
- Public funds
- Other/Unknown

#### 17. Other medications

#### 18. Illness at time of vaccination (specify)

#### 19. Pre-existing physician-diagnosed allergies, birth defects, medical conditions (specify)

#### 20. Have you reported this adverse event previously?
- Yes
- No
- To health department
- To doctor
- To manufacturer

#### 21. Adverse event following prior vaccination (check all applicable, specify)

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>Onset</th>
<th>Type</th>
<th>Dose no.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### 22. Birth weight

#### 23. No. of brother and sisters

#### 24. Initial, Immunization project

#### 25. Date received by manufacturer

#### 26. 15 day report

#### 27. Report type

Healthcare providers and manufacturers are required by law (42 USC 300a-25) to report reactions to vaccines listed in the Table of Reportable Events. Following immunization, reports for reactions to other vaccines are voluntary except when required as a condition of immunization grant awards.

Form VAERS-1(Fax)

---

669
APPENDIX F

"Fold in thirds, tape & mail - DO NOT STAPLE FORM"

BUSINESS REPLY MAIL
FIRST-CLASS MAIL, PERMIT NO. 1895, ROCKVILLE, MD
POSTAGE WILL BE PAID BY ADDRESSEE

VAERS
P.O. Box 1100
Rockville MD 20849-1100

DIRECTIONS FOR COMPLETING FORM
(Additional pages may be attached if more space is needed)

GENERAL

Use a separate form for each patient. Complete the form to the best of your abilities. Items 3, 4, 7, 8, 10, 11, and 13 are considered essential and should be completed whenever possible. Parents/Guardians may need to consult the facility where the vaccine was administered for some of the information (such as manufacturer, lot number or laboratory data.) Refer to the Reportable Events Table (RET) for events mandated for reporting by law. Reporting for other serious events felt to be related but not on the RET is encouraged. Health care providers other than the vaccine administrator (VA) treating a patient for a suspected adverse event should notify the VA and provide the information about the adverse event to allow the VA to complete the form to meet the VA’s legal responsibility. These data will be used to increase understanding of adverse events following vaccination and will become part of CDC Privacy Act System 09-20-0136, "Epidemiologic Studies and Surveillance of Disease Problems". Information identifying the person who received the vaccine or that person’s legal representative will not be made available to the public, but may be available to the vaccinee or legal representative. Postage will be paid by addressee. Forms may be photocopies (must be front & back on same sheet).

SPECIFIC INSTRUCTIONS

Form Completed By: To be used by parents/guardians, vaccine manufacturers/distributors, vaccine administrators, and/or the person completing the form on behalf of the patient or the health professional who administered the vaccine.

Item 7: Describe the suspected adverse event. Such things as temperature, local and general signs and symptoms, time course, duration of symptoms diagnosis, treatment and recovery should be noted.

Item 8: Check "YES" if the patient's health condition is the same as it was prior to the vaccine, "NO" if the patient has not returned to the pre-vaccination state of health, or "UNKNOWN" if the patient's condition is not known.

Item 10: Give dates and times as specifically as you can remember. If you do not know the exact time, please

Item 11: Indicate "AM" or "PM" when possible if this information is known. If more than one adverse event, give the onset date and time for the most serious event.

Item 12: Include "negative" or "normal" results of any relevant tests performed as well as abnormal findings.

Item 13: List ONLY those vaccines given on the day listed in Item 10.

Item 14: List any other vaccines that the patient received within 4 weeks prior to the date listed in Item 10.

Item 15: This section refers to how the person who gave the vaccine purchased it, not to the patient's insurance.

Item 16: List any prescription or non-prescription medications the patient was taking when the vaccine(s) was given.

Item 18: List any short term illnesses the patient had on the date the vaccine(s) was given (i.e., cold, flu, ear infection).

Item 19: List any pre-existing physician-diagnosed allergies, birth defects, medical conditions (including developmental and/or neurologic disorders) for the patient.

Item 21: List any suspected adverse events the patient, or the patient's brothers or sisters, may have had to previous vaccinations. If more than one brother or sister, or if the patient has reacted to more than one prior vaccine, use additional pages to explain completely. For the onset age of a patient, provide the age in months if less than two years old.

Item 26: This space is for manufacturers' use only.
UNIT I FOUNDATIONS OF CLINICAL PHARMACOLOGY

Chapter 1 General Principles of Pharmacology
Review Questions
1. a
2. b
3. b
4. d
5. d
6. a

Chapter 2 The Administration of Drugs
Review Questions
1. c
2. c
3. d
4. b
5. b

Chapter 3 Review of Arithmetic and Calculation of Drug Dosages

Answers are in the chapter.

Chapter 4 The Nursing Process
Review Questions
1. d
2. c
3. a

UNIT II ANTI-INFECTIVES

Chapter 5 Patient and Family Teaching
Review Questions
1. d
2. a
3. b
4. c

Chapter 6 Sulfonamides
Review Questions
1. b
2. d
3. c
4. b

Medication Dosage Problems
1. 10 mL or 2 teaspoons
2. 2 tablets

Chapter 7 Penicillins
Review Questions
1. b
2. b
3. b
4. d

Medication Dosage Problems
1. 1 teaspoon (t) = 250 mg of Amoxil (1 t = 5 mL)
   The nurse will administer 2 teaspoons (t) or 10 mL of Amoxil.
2. Ninety (90 mL) milliters of water needed for reconstitution.
Directions for reconstitution: Tap bottle until all powder flows freely. Add approximately 2/3 of the 90 mL of water; shake vigorously to wet powder. Add remaining water and shake vigorously again. Strength of reconstituted solution is 125 mg/5 mL.
The nurse would administer 20 mL.

Chapter 8 Cephalosporins and Related Antibiotics

Review Questions
1. b
2. a
3. d
4. c

Medication Dosage Problems
1. 2 tablets
2. 4 mL

Chapter 9 Tetracyclines, Macrolides, and Lincosamides

Review Questions
1. c
2. b
3. d
4. a

Medication Dosage Problems
1. 2 tablets, 1 tablet
2. 2 mL
3. 20 mL

Chapter 10 Fluoroquinolones and Aminoglycosides

Review Questions
1. c
2. c
3. b
4. a
5. c

Medication Dosage Problems
1. 1 mL
2. 2 tablets

Chapter 11 Miscellaneous Anti-Infectives

Review Questions
1. b
2. c
3. a
4. b

Medication Dosage Problems
1. 1 tablet
2. 1 mL
3. 20 mL

Chapter 12 Antitubercular Drugs

Review Questions
1. a
2. d
3. c
4. b
5. d

Medication Dosage Problems
1. 6 mL
2. 4 tablets

Chapter 13 Leprostatic Drugs

Review Questions
1. d
2. c
3. a
4. b

Medication Dosage Problems
1. 6 tablets
2. ½ tablet

Chapter 14 Antiviral Drugs

Review Questions
1. a
2. a
3. a
4. b

Medication Dosage Problems
1. 2 tablets
2. 10 mg
3. 10 mL
Chapter 15 Antifungal Drugs

Review Questions
1. a
2. c
3. a
4. d

Medication Dosage Problems
1. 63.6 kg, 95.4 mg or 95 if rounded to the nearest whole number
2. 2 tablets

Chapter 16 Antiparasitic Drugs

Review Questions
1. b
2. b
3. c
4. a

Medication Dosage Problems
1. 2 tablets
2. 2 tablets

UNIT III DRUGS USED TO MANAGE PAIN

Chapter 17 Nonnarcotic Analgesics: Salicylates and Nonsalicylates

Review Questions
1. c
2. a
3. c
4. c
5. c
6. b

Medication Dosage Problems
1. 1.5 or 1 1/2 mL
2. 2 tablets

Chapter 18 Nonnarcotic Analgesics: Nonsteroidal Anti-Inflammatory Drugs

Review Questions
1. a
2. a
3. d
4. b

Chapter 19 Narcotic Analgesics

Review Questions
1. d
2. c
3. b
4. c
5. a

Medication Dosage Problems
1. 1.2 mL
2. 1 mL

Chapter 20 Narcotic Antagonists

Review Questions
1. b
2. c
3. d

Medication Dosage Problems
1. 0.8 mL
2. 1/2 tablet

UNIT IV DRUGS THAT AFFECT THE NEUROMUSCULAR SYSTEM

Chapter 21 Drugs That Affect the Musculoskeletal System

Review Questions
1. c
2. a
3. c
4. d
5. d

Medication Dosage Problems
1. 3 tablets
2. 3 tablets

Chapter 22 Adrenergic Drugs

Review Questions
1. b
2. a
3. d
4. d
5. b

Medication Dosage Problems
1. ½ tablet
2. ½ mL

Chapter 23 Adrenergic Blocking Drugs
Review Questions
1. d
2. d
3. a
4. b

Medication Dosage Problems
1. 15 mL
2. 4 tablets

Chapter 24 Cholinergic Drugs
Review Questions
1. a
2. b
3. b

Medication Dosage Problems
1. 68.2 kg (weight), 1.5 mg (dosage)
2. ½ mL

Chapter 25 Cholinergic Blocking Drugs
Review Questions
1. b
2. b
3. d
4. b

Medication Dosage Problems
1. ½ mL
2. 10 mL

Chapter 26 Sedatives and Hypnotics
Review Questions
1. a
2. c
3. a
4. d
5. c

Medication Dosage Problems
1. ½ tablet
2. 2 tablets

Chapter 27 Central Nervous System Stimulants
Review Questions
1. c
2. a
3. d
4. d

Medication Dosage Problems
1. 24 mg, yes
2. 2 tablets

Chapter 28 Anticonvulsants
Review Questions
1. d
2. b
3. a
4. c
5. b

Medication Dosage Problems
1. 3.3 mL
2. 2 tablets
3. 10 mL

Chapter 29 Antiparkinsonism Drugs
Review Questions
1. a
2. b
3. d
4. b

Medication Dosage Problems
1. one 500-mg tablet and one 250-mg tablet
2. 3 tablets

Chapter 30 Antianxiety Drugs
Review Questions
1. a
2. d
3. b
4. c
Medication Dosage Problems

1. 1 mL
2. 2 tablets

Chapter 31 Antidepressant Drugs
Review Questions
1. d
2. c
3. c
4. b

Medication Dosage Problems
1. 3 tablets
2. 25 mL

Chapter 32 Antipsychotic Drugs
Review Questions
1. c
2. b
3. c
4. b

Medication Dosage Problems
1. 1.5 mL
2. 2 tablets
3. 2 tablets

Chapter 33 Cholinesterase Inhibitors
Review Questions
1. b
2. c
3. a
4. d

Medication Dosage Problems
1. 3 mL
2. ½ tablet

Chapter 34 Antiemetic and Antivertigo Drugs
Review Questions
1. b
2. c
3. b
4. d

Medication Dosage Problems
1. 2 mL

Chapter 35 Anesthetic Drugs
Review Questions
1. b
2. c
3. a
4. b

Medication Dosage Problems
1. 1 mL
2. 0.3 mg

UNIT V DRUGS THAT AFFECT THE RESPIRATORY SYSTEM

Chapter 36 Antihistamines and Decongestants
Review Questions
1. a
2. c
3. b
4. c

Medication Dosage Problems
1. 10 mL
2. 2 tablets

Chapter 37 Bronchodilators and Antiasthma Drugs
Review Questions
1. d
2. d
3. d
4. a
5. a

Medication Dosage Problems
1. 0.25 mL
2. 2 tablets

Chapter 38 Antitussives, Mucolytics, and Expectorants
Review Questions
1. a
2. a
UNIT VI DRUGS THAT AFFECT THE CARDIOVASCULAR SYSTEM

Chapter 39 Cardiotonics and Miscellaneous Inotropic Drugs

Review Questions
1. b
2. d
3. a
4. a
5. c

Medication Dosage Problems
1. one 0.5-mg tablet and one 0.25-mg tablet
2. ½ mL

Chapter 40 Antiarrhythmic Drugs

Review Questions
1. a
2. a
3. a
4. d
5. c

Medication Dosage Problems
1. 1.5 mL
2. 2 tablets

Chapter 41 Antianginal and Peripheral Dilating Drugs

Review Questions
1. b
2. b
3. c
4. b
5. a
6. d

Medication Dosage Problems
1. 3 tablets
2. 2 tablets

Chapter 42 Antihypertensives

Review Questions
1. c
2. c
3. d
4. b
5. b

Medication Dosage Problems
1. 4 tablets
2. 90-mg tablets and give 2 tablets

Chapter 43 Antihyperlipidemic Drugs

Review Questions
1. c
2. a
3. a
4. b
5. c

Medication Dosage Problems
1. 2 tablets
2. No, notify the primary health care provider

UNIT VII DRUGS THAT AFFECT THE HEMATOLOGICAL SYSTEM

Chapter 44 Anticoagulant and Thrombolytic Drugs

Review Questions
1. d
2. d
3. b
4. a
5. b

Medication Dosage Problems
1. 0.67 mL or 0.7 mL
2. 2 tablets

Chapter 45 Agents Used in the Treatment of Anemia

Review Questions
1. a
2. a
3. c
4. a
5. c
UNIT IX DRUGS THAT AFFECT THE ENDOCRINE SYSTEM

Chapter 49 Antidiabetic Drugs
Review Questions
1. c
2. d
3. c
4. b
5. c

Medication Dosage Problems
1. Draw an arrow to the number 45.
2. 2 tablets at each dose; total daily dose 2000 mg
3. 4 tablets
4. Label B

Chapter 50 Pituitary and Adrenocortical Hormones
Review Questions
1. b
2. c
3. a
4. b
5. c

Medication Dosage Problems
1. 2 mL
2. 20 mL

Chapter 51 Thyroid and Antithyroid Drugs
Review Questions
1. b
2. c
3. a
4. c

Medication Dosage Problems
1. 6 tablets
2. 2 tablets

Chapter 52 Male and Female Hormones
Review Questions
1. c
2. d
3. c
4. a
5. b

Medication Dosage Problems

1. 1.6 mL
2. 1 mL

Chapter 53 Drugs Acting on the Uterus

Review Questions

1. d
2. b
3. a
4. c

Medication Dosage Problems

1. 1/2 tablet
2. 1 mL

UNIT X DRUGS THAT AFFECT THE IMMUNE SYSTEM

Chapter 54 Immunologic Agents

Review Questions

1. b
2. a
3. c
4. a

UNIT XI DRUGS THAT AFFECT OTHER BODY SYSTEMS

Chapter 56 Topical Drugs Used in the Treatment of Skin Disorders

Review Questions

1. b
2. b
3. d
4. b
5. d

Chapter 57 Otic and Ophthalmic Preparations

Review Questions

1. b
2. b
3. c
4. d

Chapter 58 Fluids and Electrolytes

Review Questions

1. d
2. a
3. d
4. a
5. d

Medication Dosage Problems

1. 13.7 mg/d
2. 1.375 or 1.4 U

Medication Dosage Problems

1. 100 mL/hr
2. 30 mL
Examples of Combination Drugs

**Antacid Combinations**

Acid-X—calcium carbonate, acetaminophen
Advanced Formula Di-Gel—magnesium hydroxide, calcium carbonate, simethicone, sucrose
Alamag Plus—aluminum hydroxide, magnesium hydroxide, simethicone, parabens, sorbitol, saccharin
Alamag Suspension—aluminum hydroxide, magnesium hydroxide, sorbitol, sucrose, parabens
Alenic Alka—aluminum hydroxide, magnesium trisilicate, sodium bicarbonate, calcium stearate, sugar
Almacone—aluminum hydroxide, magnesium hydroxide, simethicone
Bromo-Seltzer Effervescent Granules—sodium bicarbonate, acetalaminophen, citric acid, sugar
Calcium Rich Rolaids—magnesium hydroxide, calcium carbonate
Citrocarbonate Effervescent Granules—sodium bicarbonate, sodium citrate anhydrous
Di-Gel Liquid—aluminum hydroxide, simethicone, saccharin, sorbitol, parabens
Extra Strength Maalox Suspension—aluminum hydroxide, magnesium hydroxide, simethicone, parabens, sorbitol, saccharin
Gas-Ban—simethicone, calcium carbonate
Gas-Ban DS Liquid—aluminum hydroxide, magnesium hydroxide, simethicone
Gaviscon Extra Strength Reliever Formula Liquid—aluminum hydroxide, magnesium carbonate, parabens, EDTA, saccharin, sorbitol, simethicone, sodium alginate
Gaviscon Liquid—magnesium carbonate, parabens, EDTA, saccharin, sorbitol, sodium alginate
Gelusil—aluminum hydroxide, magnesium hydroxide, simethicone, dextrose, saccharin, sorbitol, sugar
Lowslum Plus Liquid—magaldrate, simethicone
Maalox—aluminum, magnesium hydroxide
Maalox Plus—aluminum hydroxide, magnesium hydroxide, simethicone, sugar
Maalox Suspension—aluminum hydroxide, magnesium hydroxide, saccharin, sorbitol, parabens
Marblen—magnesium carbonate, calcium carbonate
Marblen Liquid—calcium carbonate, magnesium carbonate
Mintox—aluminum hydroxide, magnesium hydroxide
Mintox Plus—aluminum hydroxide, magnesium hydroxide, simethicone, saccharin, sorbitol, sugar
Mintox Suspension—aluminum hydroxide, magnesium hydroxide, parabens, sorbitol, saccharin
Mylagen Liquid—simethicone, parabens, sorbitol, sucrose
Mylanta—aluminum hydroxide, magnesium hydroxide, simethicone, sorbitol
Mylanta Gelcaps—calcium carbonate, magnesium carbonate, parabens
Mylanta Liquid—simethicone, sorbitol
Nephrox Liquid—aluminum hydroxide, mineral oil
Original Alka-Seltzer Effervescent Tablets—sodium bicarbonate, aspirin, citric acid, phenylalanine
Riopan Plus—magaldrate, simethicone, sorbitol, sucrose
Riopan Plus Suspension—magaldrate, simethicone, saccharin, sorbitol
Rulox #2—aluminum, magnesium hydroxide, simethicone
Rulox Plus—aluminum hydroxide, magnesium hydroxide, simethicone, sugar, saccharin, dextrose
Rulox Suspension—aluminum hydroxide, magnesium hydroxide, parabens, sorbitol, saccharin
Simaal Gel 2 Liquid—aluminum hydroxide, magnesium hydroxide, simethicone
Tempo—aluminum hydroxide, magnesium hydroxide, calcium carbonate, simethicone, sorbitol, corn syrup

**Antiasthmatic Combinations**

Bronchial Capsules—theophylline, guaifenesin
Brondelate Elixir—theophylline, oxtriphylline, guaifenesin
Dilor-G Tablets—dyphylline, guaifenesin
Dyflex-G Tablets—dyphylline, guaifenesin
Glyceryl-T Liquid—theophylline, guaifenesin
Hydrophed Tablets—theophylline, hydroxyzine, ephedrine sulfate
Lufyllin-EPG Tablets—dyphylline, ephedrine HCl, guaifenesin, phenobarbital
Marax Tablets—theophylline, hydroxyzine, ephedrine sulfate
Mundrane GG Tablets—theophylline, guaifenesin, aminophylline anhydrous, ephedrine HCl, phenobarbital
Primatene Dual Action Tablets—theophylline, ephedrine, guaifenesin
Primatene Tablets—theophylline, phenobarbital, ephedrine HCl
Quadrinal Tablets—theophylline, theophylline calcium salicylate, ephedrine HCl, potassium iodide, phenobarbital
Quibron Capsules—theophylline, guaifenesin
Slo-Phyllin GG Capsules—theophylline, guaifenesin
Slo-Phyllin GG Syrup—theophylline, guaifenesin
Tedrigen Tablets—theophylline, Phenobarbital, ephedrine HCl
Theodrine Tablets—theophylline, ephedrine HCl
Theolate Liquid—theophylline, guaifenesin

Antidiarrheal Combinations
Diasorb—activated attapulgite, sorbitol
Donnagel—attapulgite, saccharin
Kaodene Non-Narcotic—kaolin, pectin, bismuth subsalicylate, sucrose
Kaolin w/ Pectin—kaolin, pectin
Kaopectate Maximum Strength—attapulgite, sucrose
Kaopectolin—kaolin, pectin
K-C—kaolin, pectin, bismuth subcarbonate, peppermint flavor

Antihistamine and Analgesic Combinations
Aceta-Gesic Tablets—phenyltoloxamine citrate, acetaminophen
Coricidin HBP Cold and Flu Tablets—chlorpheniramine maleate, acetaminophen
Ed-Flex Capsules—phenyltoloxamine citrate, acetaminophen, salicylamide
Major-Gesic Tablets—phenyltoloxamine citrate, acetaminophen
Percogesic—phenyltoloxamine citrate, acetaminophen
Percogesic Extra Strength Tablets—diphenhydramine HCl, acetaminophen
Phenylgesic Tablets—phenyltoloxamine citrate, acetaminophen
Tylenol PM Extra Strength Tablets—diphenhydramine HCl, acetaminophen
Tylenol Severe Allergy Tablets—diphenhydramine HCl, acetaminophen

Antihypertensive Combinations
Aldoclor—chlorothiazide, methyl dopa
Aldoril—hydrochlorothiazide, methyl dopa
A presazide—hydrochlorothiazide, hydralazine
Avalide—hydrochlorothiazide, irbesartan
Capozide—hydrochlorothiazide, captopril
Chloroserpine—chlorothiazide, reserpine
Combipres—clonidine, chlorthalidone
Corzide—bendroflumethiazide, nadolol
Demi-Regroton Tablets—chlorthalidone, reserpine
Diovan HCT—hydrochlorothiazide, valsartan
Diutensin-R Tablets—methyclothiazide, reserpine
Enduronyl—methylcloathiazide, desperidine
Esimil—hydrochlorothiazide, guanethidine monosulfate
Hydrap-ES—hydrochlorothiazide, reserpine, hydralazine HCl
Hydropres-50—hydrochlorothiazide, reserpine
Hydro-Serp—hydrochlorothiazide, reserpine
Hydroserpine #1 Tablets—hydrochlorothiazide, reserpine
Hydroserpine #2 Tablets—hydrochlorothiazide, reserpine
Hyzaar—hydrochlorothiazide, losartan potassium
Inderide—hydrochlorothiazide, propranolol HCl
Inderide LA—hydrochlorothiazide, propranolol HCl
Lexxel Extended-Release—enalapril maleate, felodipine
Lopressor—hydrochlorothiazide, metoprolol
Lotensin HCT—hydrochlorothiazide, benazepril
Lotrel—amlodipine, benazepril
Marpres—hydrochlorothiazide, reserpine, hydralazine HCl
Metatensin Tablets—trichlormethazide, reserpine
Minizide—polythiazide, prazosin
Prinzide—hydrochlorothiazide, lisinopril
Rauzide Tablets—rauwolfia, bendroflumethiazide
Regroton—chlorthalidone, reserpine
Salutensin Tablets—hydroflumethiazide, reserpine
Salutensin-Demi—hydrochlorothiazide, reserpine
Ser-Ap-Es—hydrochlorothiazide, reserpine, hydralazine HCl
Tarka—trandolapril, verapamil
Teczem Extended-Release—diltiazem maleate, enalapril maleate
Tenoretic—chlorthalidone, atenolol
Timolide—hydrochlorothiazide, timolol maleate
Tri-Hydroserpine—hydrochlorothiazide, reserpine, hydralazine HCl
Uniretic—hydrochlorothiazide, moexipril HCl
Vaseretic—hydrochlorothiazide, enalapril maleate
Zestoretic—hydrochlorothiazide, lisinopril
Ziac—hydrochlorothiazide, bisoprolol fumarate

Antitussive Combinations
Alka-Seltzer Plus Cold and Flu Liqui-Gels—dextromethorphan HBr, pseudoephedrine HCl, acetaminophen
Bromatane DX—dextromethorphan HBr, brompheniramine maleate, pseudoephedrine HCl
Cardec DM—dextromethorphan HBr, carboxamine maleate, pseudoephedrine HCl
Coricidin HBP Cough & Cold Tablets—dextromethorphan HBr, chlorpheniramine, acetaminophen
Dimetane-DX Cough—dextromethorphan HBr, brompheniramine maleate, pseudoephedrine HCl
HycoDan Tablets or Syrup—hydrocodone bitartrate, homatropine M Br
Hydromide Syrup—hydrocodone bitartrate, homatropine M Br
Nucofed Capsules—codeine phosphate, pseudoephedrine HCl
Promethazine HCl/w Codeine Cough Syrup—codeine phosphate, promethazine HCl
Quad Tann Tablets—carbetapentane tannate, chlorpheniramine tannate, phencylephrine tannate, ephedrine tannate
Robitussin Maximum Strength—dextromethorphan HBr, pseudoephedrine HCl
Rynatus Tablets—carbetapentane tannate, chlorpheniramine tannate, phencylephrine tannate, ephedrine tannate
Sudafed Non-Drowsy Severe Cold Formula Maximum Strength Tablets—dextromethorphan HBr, pseudoephedrine HCl
Tannic-12 Tablets—carbetapentane tannate, chlorpheniramine tannate
Tricodine Cough & Cold Liquid—codeine phosphate, pyrilamine maleate
Trionate Tablets—carbetapentane tannate, chlorpheniramine tannate
Tussafed Syrup—dextromethorphan HBr, carbinoxamine maleate
Tussend Tablets—hydrocodone bitartrate, chlorpheniramine, pseudoephedrine HCl
Vanex HD Liquid—hydrocodone bitartrate, chlorpheniramine, phenylephrine HCl

Decongestant and Expectorant Combinations
Allegra-D Tablets—pseudoephedrine HCl, fexofenadine HCl
Allerfrim Syrup—pseudoephedrine HCl, tripolidine HCl
Aprodine Tablets—pseudoephedrine HCl, tripolidine HCl
Benadryl Allergy & Sinus Tablets—pseudoephedrine HCl, diphenhydramine citrate, diphenhydramine HCl
Bromfed Capsules—pseudoephedrine HCl, brompheniramine maleate
Bromfed Syrup—pseudoephedrine HCl, brompheniramine maleate
Claritin D—pseudoephedrine HCl, loratadine
Deconamine Syrup—pseudoephedrine HCl, chlorpheniramine maleate
Dynex Tablets—pseudoephedrine, guaifenesin
Ed A Hist Tablets—phenylephrine HCl, chlorpheniramine maleate
Genac Tablets—pseudoephedrine HCl, tripolidine HCl
Guaifed Capsules—pseudoephedrine, guaifenesin
Guiattuss PE Liquid—pseudoephedrine, guaifenesin
Histade Capsules—pseudoephedrine HCl, chlorpheniramine maleate
Histatab Plus Tablets—phenylephrine HCl, chlorpheniramine maleate
Histex PE Liquid—pseudoephedrine HCl, chlorpheniramine maleate
Lodrane Liquid—pseudoephedrine HCl, brompheniramine maleate
Phenergan VC Syrup—phenylephrine HCl, promethazine
Profen II Tablets—pseudoephedrine, guaifenesin
Pseudovent Capsules—pseudoephedrine, guaifenesin
Respahist Capsules—pseudoephedrine HCl, brompheniramine maleate
Respaire-60 SR Capsules—pseudoephedrine, guaifenesin
Rinade B.I.D. Capsules—pseudoephedrine HCl, chlorpheniramine maleate
Robafen PE Liquid—pseudoephedrine, guaifenesin
Robitussin Cold Sinus and Congestion—pseudoephedrine, guaifenesin, acetaminophen
Robitussin PE Liquid—pseudoephedrine, guaifenesin
Rondec Tablets—pseudoephedrine HCl, carbinoxamine maleate
Ryna Liquid—pseudoephedrine HCl, chlorpheniramine maleate
Rynatan Tablets—phenylephrine tannate, chlorpheniramine tannate
Severe Congestion Tussin Softgels—pseudoephedrine, guaifenesin
Sinutab Nondrying Liquid Caps—pseudoephedrine, guaifenesin
Sudafed Cold and Allergy Caps—pseudoephedrine HCl, chlorpheniramine maleate
Tanafed Suspension—pseudoephedrine, chlorpheniramine tannate
Versacaps Capsules—pseudoephedrine, guaifenesin

Decongestant, Antihistamine, and Analgesic Combinations
Alka-Seltzer Plus Cold Medicine—phenylephrine HCl, chlorpheniramine maleate, acetaminophen
Decodult Tablets—pseudoephedrine HCl, chlorpheniramine maleate, acetaminophen
Kolephrin Tablets—pseudoephedrine HCl, chlorpheniramine maleate, acetaminophen
Simplet Tablets—pseudoephedrine HCl, chlorpheniramine, acetaminophen
Sinutab Sinus Allergy, Maximum Strength—pseudoephedrine HCl, chlorpheniramine maleate
Tavist Allergy/Sinus/Headache Tablets—pseudoephedrine HCl, clemastine fumarate, acetaminophen
TheraFlu Flu and Cold Medicine Original Formula Powder—pseudoephedrine HCl, chlorpheniramine maleate, acetaminophen
Triaminic Cold, Allergy, Sinus Medicine—pseudoephedrine HCl, chlorpheniramine maleate, acetaminophen
Tylenol Sinus NightTime Maximum Strength Tablets—pseudoephedrine HCl, diphenhydramine HCl, acetaminophen

Decongestant, Antihistamine, and Anticholinergic Combinations
A H-Chew Tablets—phenylephrine HCl, chlorpheniramine maleate, methscopolamine nitrate
D.A. Chewable Tablets—phenylephrine HCl, chlorpheniramine maleate, methscopolamine nitrate
Dallergy Syrup or Tablets—phenylephrine HCl, chlorpheniramine maleate, methscopolamine nitrate
Dehistine Syrup—phenylephrine HCl, chlorpheniramine maleate, methscopolamine nitrate
Extendryl Syrup—phenylephrine HCl, chlorpheniramine maleate, methscopolamine nitrate
Pannaz Tablets or Syrup—phenylephrine HCl, chlorpheniramine maleate, methscopolamine nitrate
Rescon-MX Tablets—phenylephrine HCl, chlorpheniramine maleate, methscopolamine nitrate

Diuretic Combinations
Aldactazide—spironolactone, hydrochlorothiazide
Amiloride-hydrochlorothiazide—generic
Dyazide—triamterene, hydrochlorothiazide
Maxzide—triamterene, hydrochlorothiazide
Maxzide-25MG—triamterene, hydrochlorothiazide
Modiuretic—amiloride, hydrochlorothiazide
Spironolactone-hydrochlorothiazide—generic
Triamterene-hydrochlorothiazide—generic

Estrogen and Progesterin Combinations
Activella—estradiol, norethindrone acetate
CombiPatch—estradiol, norethindrone
Femhrt—atropine, scopolamine HBr, hyoscyamine sulfate, phenobarbital
Ortho-Prefest—estradiol, norgestimate
Prempack—heparin, conjugated estrogens, medroxyprogesterone acetate
Prempak—conjugated estrogens, medroxyprogesterone acetate

Estrogen and Androgen Combinations, Oral and Parenteral
Depo-Testadiol—estradiol cypionate, testosterone cypionate
Depotestogen—estradiol cypionate, testosterone cypionate
Duo-Cyp—estradiol cypionate, testosterone cypionate
Estratest—esterified estrogens, methyltestosterone
Estratest H.S.—esterified estrogens, methyltestosterone
Valertest No. 1—estradiol valerate, testosterone enanthate

Glaucoma Combinations
E-Pilo—pilocarpine, epinephrine
E-Pilo-2—pilocarpine, epinephrine
E-Pilo-4—pilocarpine, epinephrine
P6E1—pilocarpine, epinephrine

Gastrointestinal Anticholinergic Combinations
Antrocol Elixir—atropine sulfate, phenobarbital, alcohol
Barbidonna—atropine, scopolamine HBr, hyoscyamine sulfate, phenobarbital
Bellacane Elixir—atropine, scopolamine HBr, hyoscyamine HBr or sulfate, phenobarbital, alcohol, tartrazine
Bellacane SR Tablets—l-alkaloids of belladonna, phenobarbital, ergotamine tartrate
Bellarial-S Tablets—l-alkaloids of belladonna, phenobarbital, ergotamine tartrate
Butibell Elixir—belladonna extract, butabarbitral sodium, alcohol, saccharin
Butibell Tablets—belladonna extract, butabarbital
Chardonna-2 Tablets—belladonna extract, phenobarbital
Donnatal Elixir—atropine, scopolamine HBr, hyoscyamine HBr or sulfate, phenobarbital, alcohol, sucrose, saccharin
Donnatal Capsules and Tablets—atropine, scopolamine HBr, hyoscyamine sulfate, phenobarbital
Folergot-D F Tablets—l-alkaloids of belladonna, phenobarbital, ergotamine tartrate
Hysosphen Tablets—atropine, scopolamine HBr, hyoscyamine sulfate, phenobarbital
Librax Capsules—clindinium, chloridiazepoxide HCl
Phenerbel-S Tablets—l-alkaloids of belladonna, phenobarbital, ergotamine tartrate
Spasmolin Tablets—atropine, scopolamine HBr, hyoscyamine sulfate, phenobarbital

Isoniazid Combinations
Rifamate—rifampin, isoniazid
Rifater—rifampin, isoniazid, pyrazinamide

Laxative Combinations
DDS 100 Plus Capsules—docusate, casanthranol
Doxidan Capsules—docusate, casanthranol, sorbitol
Nature’s Remedy—cascara sagrada, aloe, lactose
Peri-Colace—docusate, casanthranol, sorbitol, parabens
Senokot-S tablets—docusate, senna concentrate, lactose

Ophthalmic Decongestant and Antihistamine Combinations
Naphcon-A Solution—naphazoline HCl, pheniramine maleate
Vasocon-A Solution—naphazoline HCl, antazoline phosphate
Ophthalmic Antibiotic Combinations
A K-Poly-Bac Ophthalmic Ointment—polymyxin B sulfate, bacitracin zinc
A K-Spore—polymyxin B Sulfate, neomycin, bacitracin zinc
Neosporin Ophthalmic Ointment—polymyxin B sulfate, neomycin, bacitracin zinc
Polysporin Ophthalmic Ointment—polymyxin B sulfate, bacitracin zinc
Polytrim Ophthalmic Solution—polymyxin B sulfate, trimethoprim sulfate

Peripheral Vasodilator Combinations
Lipo-Nicin—niacin, niacinamide, vitamins C, B1, B2, B6

Sedative and Hypnotic Combinations
Tuinal—amobarbital, secobarbital

Skeletal Muscle Relaxant Combinations
Carisoprodol Compound—carisoprodol, aspirin
Flexaphen—chlorzoxazone, acetaminophen
Lobac—salicylamide, phenyltoloxamine, acetaminophen
Norgesic Forte—orphenadrine citrate, aspirin, caffeine
Norgesic—orphenadrine citrate, aspirin, caffeine
Robaxisal—methocarbamol, aspirin
Sodol Compound—carisoprodol, aspirin
Soma Compound—carisoprodol, aspirin